<SEC-DOCUMENT>0001571049-17-007701.txt : 20170829
<SEC-HEADER>0001571049-17-007701.hdr.sgml : 20170829
<ACCEPTANCE-DATETIME>20170829170842
ACCESSION NUMBER:		0001571049-17-007701
CONFORMED SUBMISSION TYPE:	F-1
PUBLIC DOCUMENT COUNT:		31
FILED AS OF DATE:		20170829
DATE AS OF CHANGE:		20170829

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Sol-Gel Technologies Ltd.
		CENTRAL INDEX KEY:			0001684693
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		F-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-220234
		FILM NUMBER:		171058650

	BUSINESS ADDRESS:	
		STREET 1:		7 GOLDA MEIR ST.
		STREET 2:		WEIZMANN SCIENCE PARK
		CITY:			NESS ZIONA
		STATE:			L3
		ZIP:			7403648
		BUSINESS PHONE:		97289313433

	MAIL ADDRESS:	
		STREET 1:		7 GOLDA MEIR ST.
		STREET 2:		WEIZMANN SCIENCE PARK
		CITY:			NESS ZIONA
		STATE:			L3
		ZIP:			7403648
</SEC-HEADER>
<DOCUMENT>
<TYPE>F-1
<SEQUENCE>1
<FILENAME>t1702381-f1.htm
<DESCRIPTION>FORM F-1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
  <head>
    <title>t1702381-f1 - none - 6.3560385s</title>
  </head>
  <body style="width:595.31pt;">
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:19pt;margin-bottom:21.71pt;margin-left:27pt;width:541pt;">
        <div style="margin-top:12pt; text-align:center; width:541pt; line-height:11pt;font-size:10pt;">As filed with the Securities and Exchange Commission on August&#160;29, 2017 </div>
        <div style="margin-top:1.8pt; text-align:right; width:541pt; line-height:11pt;font-weight:normal;font-size:9pt;">Registration No. 333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8203;</div>
        <div style="margin-top:4.29pt; width:541pt;">
          <div style="margin-left: 0pt; width: 541pt; margin-top: 0pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:3pt; width:541pt;">
          <div style="margin-left: 0pt; width: 541pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:6pt; text-align:center; width:541pt; line-height:12pt;font-size:12pt;">UNITED STATES <br >SECURITIES AND EXCHANGE COMMISSION <br ><font style="font-size:10pt;">Washington, D.C. 20549 </font></div>
        <div style="margin-top:5.3pt; text-align:center; width:541pt;">
          <div style="margin-left: 40.018%; margin-right: 40.018%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:6pt; text-align:center; width:541pt; line-height:14pt;font-size:13pt;">Form F-1 </div>
        <div style="margin-top:1pt; text-align:center; width:541pt; line-height:10pt;font-size:9pt;">REGISTRATION STATEMENT <br >UNDER <br >THE SECURITIES ACT OF 1933 </div>
        <div style="margin-top:6.29pt; text-align:center; width:541pt;">
          <div style="margin-left: 40.018%; margin-right: 40.018%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:6pt; text-align:center; width:541pt; line-height:19pt;font-size:18pt;">Sol-Gel Technologies Ltd. </div>
        <div style="margin-top:0.8pt; text-align:center; width:541pt; line-height:10pt;font-style:italic;font-weight:normal;">(Exact Name of Registrant as Specified in its Charter)</div>
        <div style="margin-top:5.29pt; text-align:center; width:541pt;">
          <div style="margin-left: 40.018%; margin-right: 40.018%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <table style="width:541pt;height:23pt;margin-top:4.5pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:174.34pt;">
              <div style="text-align:center;">State of Israel </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:168.33pt;">
              <div style="text-align:center;">2834 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:174.33pt;">
              <div style="text-align:center;">Not Applicable </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:italic;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; width:174.34pt;">
              <div style="text-align:center;">(State or Other Jurisdiction of <br >Incorporation or Organization) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; width:168.33pt;">
              <div style="text-align:center;">(Primary Standard Industrial <br >Classification Code Number) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0.5pt 0pt 0.5pt 0pt; width:174.33pt;">
              <div style="text-align:center;">(I.R.S. Employer Identification No.)</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:9pt; text-align:center; width:541pt; line-height:9pt;">Sol-Gel Technologies Ltd. <br >7 Golda Meir St., Weizmann Science Park <br >Ness Ziona, 7403650, Israel <br >Tel: +972-8-931-3433 </div>
        <div style="margin-top:1.8pt; text-align:center; width:541pt; line-height:10pt;font-style:italic;font-weight:normal;">(Address, including zip code, and telephone number, including area code, of Registrant&#8217;s principal executive offices)</div>
        <div style="margin-top:6.29pt; text-align:center; width:541pt;">
          <div style="margin-left: 40.018%; margin-right: 40.018%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:3pt; text-align:center; width:541pt; line-height:8pt;"><font style="font-weight:normal;font-size:10pt;"></font>Cogency Global Inc. <br >10 E. 40th Street, 10th floor <br >New York, NY 10016 <br >Telephone No.: +1 800 221-0102</div>
        <div style="margin-top:1.05pt; text-align:center; width:541pt; line-height:10pt;font-style:italic;font-weight:normal;">(Name, address, including zip code, and telephone number, including area code, of agent for service)</div>
        <div style="margin-top:5.29pt; text-align:center; width:541pt;">
          <div style="margin-left: 40.018%; margin-right: 40.018%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:4pt; text-align:center; width:541pt; line-height:9pt;font-style:italic;">Copies to:</div>
        <table style="width:541pt;margin-top:-1pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:129.25pt;">
              <div style="text-align:center;">Joshua G. Kiernan<br >Nathan Ajiashvili<br >Latham &amp; Watkins LLP <br >885 Third Avenue<br >New York, NY 10022<br >Tel: +1 212 906 1200<br >Fax: +1 212 751 4864 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:123.25pt;">
              <div style="text-align:center;">Gene Kleinhendler<br >Perry Wildes<br >Gross, Kleinhendler,<br >Hodak, Halevy,<br >Greenberg &amp; Co.<br >One Azrieli Center<br >Tel Aviv 670201, Israel<br >Tel: +972 3 607 4444<br >Fax: +972 3 607 4470 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:123.25pt;">
              <div style="text-align:center;">Eric W. Blanchard<br >Brian K. Rosenzweig<br >Matthew T. Gehl<br >Covington &amp; Burling LLP<br >The New York Times Building<br >620 Eighth Avenue<br >New York, NY 10018-1405<br >Tel: +1 212 841 1000<br >Fax: +1 212 841 1010</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:129.25pt;">
              <div style="text-align:center;">Chaim Friedland<br >Ari Fried<br >Gornitzky &amp; Co.<br >Zion House<br >45 Rothschild Blvd.<br >Tel Aviv 6578403, Israel<br >Tel: +972 3 710 9191<br >Fax: +972 3 560 6555</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:14.8pt; width:541pt; line-height:10pt;">Approximate date of commencement of proposed sale to the public:<font style="font-weight:normal;"> As soon as practicable after effectiveness of this registration statement. </font></div>
        <div style="text-indent:20pt; margin-top:4pt; width:541pt; line-height:8.5pt;font-weight:normal;">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box.&#8194;&#9744;</div>
        <div style="text-indent:20pt; margin-top:4pt; width:541pt; line-height:8.5pt;font-weight:normal;">If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744;</div>
        <div style="text-indent:20pt; margin-top:4pt; width:541pt; line-height:8.5pt;font-weight:normal;">If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744;</div>
        <div style="text-indent:20pt; margin-top:4pt; width:541pt; line-height:8.5pt;font-weight:normal;">If this Form is a post-effective amendment filed pursuant to Rule 462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&#8194;&#9744;</div>
        <div style="text-indent:20pt; margin-top:4pt; width:541pt; line-height:8.5pt;font-weight:normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933. Emerging growth company&#8194;&#9746;</div>
        <div style="text-indent:20pt; margin-top:4pt; width:541pt; line-height:8.5pt;font-weight:normal;">If an emerging growth company that prepares its financial statements in accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;7(a)(2)(B) of the Securities Act.&#8194;&#9744;</div>
        <div style="margin-top:0.99pt; text-align:center; width:541pt;">
          <div style="margin-left: 40.018%; margin-right: 40.018%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:7pt; text-align:center; width:541pt; line-height:11pt;font-size:10pt;">CALCULATION OF REGISTRATION FEE </div>
        <table style="width:541pt;height:29.5pt;margin-top:-7pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;">
            <td style="border-bottom:3px double #000000;padding:0pt 0pt 1pt 0pt; width:0pt;" colspan="13">&#8203;</td>
            <td style="padding:0pt;border-bottom:3px double #000000; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0.75pt 0pt 1pt 0pt; width:331.74pt;text-align:left;">
              <div style="white-space:nowrap;">Title of each Class of Securities to be Registered </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0.75pt 0pt 1pt 0pt;" colspan="4">
              <div style="text-align:center;">Proposed Maximum <br >Aggregate Offering Price (1)(2) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0.75pt 0pt 1pt 0pt;" colspan="4">
              <div style="text-align:center;">Amount of <br >Registration Fee (3) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:9pt;">
            <td style="border-bottom:3px double #000000;padding:1.25pt 0pt 2pt 0pt; width:331.74pt;text-align:left;">
              <div style="white-space:nowrap;font-size:8pt;">Ordinary shares, par value NIS 0.1 per share </div>
            </td>
            <td style="padding:0pt;border-bottom:3px double #000000; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:3px double #000000; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:31.41pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:1.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:1.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:34.5pt; text-align:right; white-space:nowrap;">86,250,000</td>
            <td style="padding:0pt;padding-left:31.41pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:3px double #000000; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:3px double #000000; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:22.45pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:1.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:1.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:18pt; text-align:right; white-space:nowrap;">9,996</td>
            <td style="padding:0pt;padding-left:22.45pt;width:0pt;border-bottom:3px double #000000;">&#8203;</td>
            <td style="padding:0pt;border-bottom:3px double #000000; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:6pt;line-height:6pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
        <div style=" float:left; line-height:10pt; margin-top:7.98pt; margin-bottom:0pt; text-align:left; width:15pt;white-space:nowrap;font-weight:normal;">(1)<br ></div>
        <div style=" float:left; margin-top:7.98pt; margin-bottom:0pt; line-height:10pt; text-align:left; width:525.5pt;font-weight:normal;">Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457(o) under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:10pt; margin-top:3.98pt; margin-bottom:0pt; text-align:left; width:15pt;white-space:nowrap;font-weight:normal;">(2)<br ></div>
        <div style=" float:left; margin-top:3.98pt; margin-bottom:0pt; line-height:10pt; text-align:left; width:525.5pt;font-weight:normal;">Includes ordinary shares that the underwriters may purchase pursuant to their option to purchase additional ordinary shares. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:10pt; margin-top:3.98pt; margin-bottom:0pt; text-align:left; width:15pt;white-space:nowrap;font-weight:normal;">(3)<br ></div>
        <div style=" float:left; margin-top:3.98pt; margin-bottom:0pt; line-height:10pt; text-align:left; width:525.5pt;font-weight:normal;">Calculated pursuant to Rule 457(o) under the Securities Act based on an estimate of the proposed maximum aggregate offering price. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:6.49pt; text-align:center; width:541pt;">
          <div style="margin-left: 40.018%; margin-right: 40.018%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:541pt; line-height:9pt;">The registrant hereby amends this registration statement on such date or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933 or until the registration statement shall become effective on such date as the Commission acting pursuant to said Section 8(a), may determine.</div>
        <div style="margin-top:3.49pt; width:541pt;">
          <div style="margin-left: 0pt; width: 541pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:3pt; width:541pt;">
          <div style="margin-left: 0pt; width: 541pt; margin-top: 0pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:28pt;margin-bottom:21.71pt;margin-left:88pt;width:456pt;">
        <div style="text-align:justify; width:456pt; line-height:9.5pt;color:#FC0014;font-family:Helvetica, Arial, sans-serif;font-size:8pt;">The information in this preliminary prospectus is not complete and may be changed. We may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and we are not soliciting offers to buy these securities in any jurisdiction where the offer or sale is not permitted.</div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;color:#FC0014;">Subject to Completion, dated August&#160;29, 2017</div>
        <div style="width:456pt;">
          <div style="margin-top:12pt; line-height:11pt;">Preliminary Prospectus </div>
        </div>
        <div style="margin-top:1pt; text-align:center; width:456pt; line-height:15pt;font-size:14pt;">&#8199;&#8201;&#8199;&#8199;&#8199;&#8201;&#8199;&#8199;&#8199; Ordinary Shares </div>
        <div style="position:relative;z-index:-1;margin-top:-2pt; text-align:center; width:456pt;">
          <img src="lg_solgel.jpg" alt="[MISSING IMAGE: lg_solgel.jpg]" height="146" width="305" >
        </div>
        <div style="margin-top:2pt; text-align:center; width:456pt; line-height:15pt;font-size:14pt;">Sol-Gel Technologies Ltd.</div>
        <div style="margin-top:4pt; text-align:center; width:456pt; line-height:15pt;font-size:14pt;">Ordinary Shares </div>
        <div style="margin-top:11.557pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-left:20pt; margin-top:7.4pt; width:436pt; line-height:12pt;font-weight:normal;">This is the initial public offering of our ordinary shares. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:normal;">No public market currently exists for our ordinary shares. The initial public offering price is expected to be between $&#8199;&#8199;&#8199;&#8199; and $&#8199;&#8199;&#8199;&#8199; per ordinary share. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:normal;">We have applied to list our ordinary shares on The NASDAQ Global Market under the symbol &#8220;SLGL&#8221;. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:normal;">We are an &#8220;emerging growth company,&#8221; as defined in the Jumpstart Our Business Startups Act of 2012 and will be subject to reduced public company reporting requirements. See &#8220;Prospectus Summary &#8212; Implications of Being an Emerging Growth Company and a Foreign Private Issuer.&#8221; </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:normal;">Upon the closing of this offering, we will be a &#8220;controlled company&#8221; within the meaning of NASDAQ&#8217;s corporate governance listing standards. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Investing in our ordinary shares involves a high degree of risk. See &#8220;Risk Factors&#8221; beginning on page <a href="#tRF">12</a> of this prospectus for a discussion of information that should be considered in connection with an investment in our ordinary shares. </div>
        <div style="margin-top:12.09pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="text-indent:20pt; margin-top:7.6pt; width:456pt; line-height:12pt;">Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </div>
        <div style="margin-top:12.1pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <table style="width:456pt;height:57pt;margin-top:7.5pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:331.98pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.75pt 0pt;" colspan="4">
              <div style="text-align:center;">Per <br >share </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.75pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Total </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.75pt 0pt; width:331.98pt;text-align:left;">
              <div style="white-space:nowrap;">Initial public offering price </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.75pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.75pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8199;&#8201;&#8199;&#8199;&#8199;&#8201;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.75pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.75pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8199;&#8201;&#8199;&#8199;&#8199;&#8201;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.75pt 0pt; width:331.98pt;text-align:left;">
              <div style="white-space:nowrap;">Underwriting discounts and commission (1) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.75pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 0.75pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.75pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 0.75pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 0.75pt 0pt; width:331.98pt;text-align:left;">
              <div style="white-space:nowrap;">Proceeds to us (before expenses) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.75pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 0.75pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 0.75pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 0.75pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:14.49pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:11.97pt; margin-bottom:0pt; text-align:left; width:15pt;white-space:nowrap;font-weight:normal;font-size:8pt;">(1)<br ></div>
        <div style=" float:left; margin-top:11.97pt; margin-bottom:0pt; line-height:10pt; text-align:left; width:440.5pt;font-weight:normal;font-size:8pt;">We have agreed to reimburse the underwriters for certain expenses. See &#8220;Underwriting.&#8221; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-weight:normal;">Delivery of the ordinary shares is expected to be made on or about &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2017. We have granted the underwriters an option for a period of 30 days to purchase up to an additional &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares. If the underwriters exercise the option in full, the total underwriting discounts and commissions payable by us will be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, and the total proceeds to us, before expenses, will be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </div>
        <table style="width:456pt;height:33pt;margin-top:10pt;border-collapse: collapse;">
          <tr style="line-height:16pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:16pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:222pt;">Jefferies </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0.5pt 0.5pt 0pt; width:222pt;text-align:right;">
              <div style="text-align:right;">BMO Capital Markets&#8203;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:13pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:13pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:222pt;">JMP Securities</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0.5pt 0.5pt 0pt; width:222pt;text-align:right;">
              <div style="text-align:right;">Raymond James&#8203;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:16.6pt; text-align:center; width:456pt; line-height:12pt;font-weight:normal;">The date of this prospectus is &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2017 </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC">&#8203;</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;"><font style="text-transform:uppercase;">Table of Contents</font></div>
        <table style="width:456pt;height:370pt;margin-top:9pt;border-collapse: collapse;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;"><a href="#tPSUM">Prospectus Summary </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;"><a href="#tPSUM">1</a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;"><a href="#tRF">Risk Factors </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;"><a href="#tRF">12</a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;"><a href="#tSNRFLS">Special Note Regarding Forward-Looking Statements </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;"><a href="#tSNRFLS">57</a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;"><a href="#tTSMT">Trademarks, Service Marks and Trade Names </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;"><a href="#tTSMT">58</a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;"><a href="#tMID">Market and Industry Data </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;"><a href="#tMID">59</a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;"><a href="#tUOP">Use of Proceeds </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;"><a href="#tUOP">60</a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;"><a href="#tDP">Dividend Policy </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;"><a href="#tDP">61</a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;"><a href="#tCAP">Capitalization </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;"><a href="#tCAP">62</a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;"><a href="#tDIL">Dilution </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;"><a href="#tDIL">63</a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;"><a href="#tSELFOD">Selected Financial Data </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;"><a href="#tSELFOD">65</a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;"><a href="#tMDA">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;"><a href="#tMDA">66</a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;"><a href="#tBUS">Business </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;"><a href="#tBUS">80</a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;"><a href="#tMAN">Management </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;"><a href="#tMAN">116</a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;"><a href="#tPS">Principal Shareholders </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;"><a href="#tPS">138</a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;"><a href="#tCRRPT">Certain Relationships and Related Party Transactions </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;"><a href="#tCRRPT">140</a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;"><a href="#tDSC">Description of Share Capital </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;"><a href="#tDSC">142</a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;"><a href="#tSEFS">Shares Eligible for Future Sale </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;"><a href="#tSEFS">150</a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;"><a href="#tMTC">Material Tax Considerations </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;"><a href="#tMTC">153</a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;"><a href="#tUNDER">Underwriting </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;"><a href="#tUNDER">165</a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;"><a href="#tEO">Expenses Related to Offering </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;"><a href="#tEO">174</a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;"><a href="#tLM">Legal Matters </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;"><a href="#tLM">175</a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;"><a href="#tEXP">Experts </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;"><a href="#tEXP">175</a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;"><a href="#tECL">Enforceability of Civil Liabilities </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;"><a href="#tECL">175</a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;"><a href="#tWYCFAI">Where You Can Find Additional Information </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;"><a href="#tWYCFAI">177</a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;"><a href="#tIFS">Index to Financial Statements</a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;"><a href="#tIFS">F-1</a></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:16.48pt; text-align:center; width:456pt;">
          <div style="margin-left: 38.158%; margin-right: 38.158%; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="text-indent:20pt; margin-top:9.99pt; width:456pt; line-height:12pt;">Neither we nor any of the underwriters have authorized anyone to provide information different from that contained in this prospectus, any amendment or supplement to this prospectus or in any free writing prospectus prepared by us or on our behalf. When you make a decision about whether to invest in our ordinary shares, you should not rely upon any information other than the information in this prospectus, any amendment or supplement to this prospectus and any free writing prospectus prepared by us or on our behalf. Neither the delivery of this prospectus nor the sale of our ordinary shares means that information contained in this prospectus is correct after the date of this prospectus. This prospectus is not an offer to sell or solicitation of an offer to buy these ordinary shares in any circumstances under which the offer or solicitation is unlawful. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">For investors outside of the United States: Neither we nor any of the underwriters have done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. You are required to inform yourselves about and to observe any restrictions relating to this offering and the distribution of this prospectus. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">i</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tPSUM">&#8203;</a></div>
      <div style="border:1pt #000 solid;margin-top:15.3pt;min-height:703.41pt;margin-left:56pt;width:486pt;">
        <div style="margin-top:22.7pt;margin-left:14pt;width:456pt;">
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">PROSPECTUS SUMMARY </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11pt;font-style:italic;">This summary does not contain all of the information you should consider before investing in our ordinary shares. You should read this summary together with the more detailed information appearing in this prospectus, including &#8220;Risk Factors,&#8221; &#8220;Selected Historical Financial Data,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; &#8220;Business&#8221; and our financial statements and the related notes included at the end of this prospectus, before making an investment in our ordinary shares. All references to &#8220;Sol-Gel,&#8221; &#8220;Sol-Gel Technologies,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; &#8220;our,&#8221; &#8220;the Company&#8221; and similar designations refer to Sol-Gel Technologies Ltd. The terms &#8220;shekels,&#8221; &#8220;Israeli shekels&#8221; and &#8220;NIS&#8221; refer to New Israeli Shekels, the lawful currency of the State of Israel, the terms &#8220;dollar,&#8221; &#8220;US$&#8221; or &#8220;$&#8221; refer to U.S. dollars, the lawful currency of the United States. Unless derived from our financial statements or otherwise indicated, U.S. dollar translations of NIS amounts presented in this prospectus are translated using the rate of NIS 3.845 and NIS 3.902 to $1.00, based on the exchange rates reported by the Bank of Israel on December&#160;31, 2016 and 2015, respectively. </div>
          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Overview </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We are a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Our current product candidate pipeline consists of late-stage branded product candidates that leverage our proprietary, silica-based microencapsulation technology platform, and several generic product candidates across multiple indications. Our lead product candidate, TWIN, is a novel, once-daily, non-antibiotic topical cream that we are developing for the treatment of acne vulgaris, or acne. We recently completed a 726 subject, double-blind, placebo-controlled, six-arm, multi-center Phase II clinical trial designed to assess the safety and efficacy of TWIN in subjects with facial acne. In this trial, TWIN demonstrated statistically significant improvements in all pre-defined co-primary and secondary efficacy endpoints, as compared to vehicle. Subject to an End of Phase II meeting to be scheduled with the FDA, we plan to initiate a pivotal Phase III program for TWIN in the United States in 2018 and expect to report top-line data from this program in 2019. Our other branded product candidates are: SIRS-T, a topical cream containing encapsulated tretinoin for the potential treatment of acne; and VERED, a potential treatment for subtype II rosacea. </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We designed our proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Our technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin. The resulting microcapsules are designed to allow the entrapped active ingredients to gradually migrate through the pores of the shell and deliver active ingredient doses onto the skin in a controlled manner, resulting in improved tolerability and stability without sacrificing efficacy. By separately encapsulating active ingredients within protective silica shells, our technology platform also enables the production of novel fixed-dose active ingredient combinations that otherwise would not be stable. We believe that our microencapsulation technology has the potential to be used for topical drug products to treat a variety of skin diseases. As a result of the FDA having already approved silica as a safe excipient for topical drug products, we expect the review process for each of our current branded product candidates to be conducted according to the FDA&#8217;s 505(b)(2) regulatory pathway, which may provide for a more efficient regulatory process by permitting us to rely, in part, upon the FDA&#8217;s previous findings of safety and efficacy of an approved product.</div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Each of our branded product candidates leverages our proprietary, silica-based microencapsulation technology platform. We maintain exclusive, worldwide commercial rights for all of our branded product candidates, which consist of: </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:11.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">TWIN, a novel, once-daily, non-antibiotic topical cream, which we are developing for the treatment of acne, containing a fixed-dose combination of encapsulated benzoyl peroxide, or E-BPO, and encapsulated tretinoin. Acne is one of the three most prevalent skin </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:3.29000000000003pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">1</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="border:1pt #000 solid;margin-top:15.3pt;min-height:703.41pt;margin-left:56pt;width:486pt;">
        <div style="margin-top:22.7pt;margin-left:14pt;width:456pt;">
          <div style="margin-left:40pt; width:416pt; line-height:12pt;">diseases in the world and is the most commonly treated skin disease in the United States, representing a $3.7 billion market in 2016, according to Quintiles IMS Holdings, Inc., or IMS. According to IMS, dermatological drugs sales in the United States have grown at an annual rate of 10% since 2012. In July&#160;2017, we reported positive top-line results from a double-blind, dose-ranging active- and placebo-controlled, six-arm, multi-center Phase II clinical trial of TWIN in the United States in 726 subjects, 128 of which subjects across six treatment groups did not complete the study. The clinical trial evaluated the efficacy, tolerability and safety of two TWIN concentrations, TWIN Low and TWIN High, each containing a lower or higher concentration, respectively, of encapsulated tretinoin and an identical concentration of E-BPO. In this trial, TWIN showed statistically significant improvements in all pre-defined co-primary and secondary efficacy endpoints, as compared to vehicle. The Investigator Global Assessment, or IGA, success rate, defined as achieving at least two-grade reduction in the IGA score and either &#8220;clear&#8221; or almost &#8220;clear&#8221; at week 12, was 39.68% for TWIN High (p-value of&#8201; &lt;0.001), 27.43% for TWIN Low (p-value = 0.006) and 12.27% for vehicle. In addition, TWIN was well tolerated with no treatment-related serious adverse events. Based on the efficacy data we observed in the Phase II trial, we believe TWIN, if approved, has the potential to become a preferred treatment for acne. In 2018, subject to an End of Phase II meeting to be scheduled with the FDA, we plan to initiate a pivotal Phase III program for TWIN in the United States and expect to report top-line data from this program in 2019. </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">SIRS-T, a topical cream containing encapsulated tretinoin, which we are developing as a potential treatment for acne. Based on the results of the encapsulated tretinoin treatment groups in our recent Phase II TWIN study, we believe that microencapsulation of tretinoin using our technology platform will reduce the irritation typically associated with topical application of tretinoin. According to IMS, the overall sales of tretinoin products, including Retin-A Micro, Atralin and Retin-A, in the twelve months ending June&#160;30, 2017 were $561 million. By leveraging our microencapsulation technology, we believe SIRS-T has the potential to become a leading tretinoin drug product and an attractive option for physicians who prefer a single active ingredient drug for the treatment of mild acne. We intend to utilize the data from the TWIN Phase II study in the development of SIRS-T. Subject to an End of Phase II meeting to be scheduled with the FDA with regard to the Phase II TWIN trial, we plan to commence a pivotal Phase III program for SIRS-T in the United States in 2019 and expect to report top-line data from this program in 2020. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:11.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">VERED, a topical cream containing 5% E-BPO, which we are developing for the treatment of subtype II (papulopustular) rosacea. Rosacea is a chronic skin disease characterized by facial redness, inflammatory lesions, burning and stinging. According to the U.S. National Rosacea Society, approximately 16 million people in the United States are affected by rosacea. According to a study we commissioned, approximately 4.8 million people in the United States experience subtype II symptoms. Subtype II rosacea resembles acne, except that comedones are absent, and patients may report associated burning and stinging sensations. We evaluated VERED in a double blind, randomized, dose-ranging Phase II clinical trial involving 92 adult subjects at ten centers in the United States. In this trial, VERED showed statistically significant improvements in the IGA pre-defined co-primary efficacy endpoint and in the percent change in inflammatory lesion count at week 12, as compared to vehicle. VERED also had a favorable safety profile and was well tolerated in the trial. If approved, we expect VERED to be the first product containing BPO that is marketed for the treatment of subtype II rosacea. Subject to an End of Phase II meeting to be scheduled with the FDA, we expect to commence a pivotal Phase III program for VERED in the United States in 2018 and expect to report top-line data from this program in 2019. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:3.29000000000003pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">2</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="border:1pt #000 solid;margin-top:15.3pt;min-height:703.41pt;margin-left:56pt;width:486pt;">
        <div style="margin-top:22.7pt;margin-left:14pt;width:456pt;">
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In addition to our late-stage branded product candidates, we are currently developing a portfolio of six generic topical dermatological products. Three of our generic product candidates are being developed in collaboration with Perrigo UK Finco Limited Partnership, or Perrigo, which has significant experience in the development of generic drugs. </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Our most advanced generic product candidate is ivermectin cream, 1%, for the treatment of inflammatory lesions associated with rosacea, which is being developed in collaboration with Perrigo. In March&#160;2017, Perrigo submitted an abbreviated new drug application, or ANDA, with a Paragraph IV certification for ivermectin cream, 1% to the FDA. This ANDA is currently on file with the FDA and is subject to a 30-month stay of approval, under the Hatch-Waxman amendments to the Federal Food, Drug, and Cosmetic Act. Ivermectin cream, 1% is the active molecule in Soolantra, which is currently marketed in the United States by Galderma Laboratories LP. For the twelve months ended June&#160;30, 2017, Soolantra achieved sales of&#8201; $87.3 million according to IMS. </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Our leadership team has considerable expertise in the identification and development of generic dermatological drug products and our intellectual property and formulation teams continue to seek to identify new opportunities to expand our pipeline of generic product candidates. </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The following chart represents our current branded and generic product candidate pipeline: </div>
          <div style="position:relative;z-index:-1;margin-top:8pt; text-align:center; width:456pt;">
            <img src="t1701829_chrt-flow.jpg" alt="[MISSING IMAGE: t1701829_chrt-flow.jpg]" height="242" width="562" >
          </div>
          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Our Strengths </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We believe we are well positioned to become a leading, pure-play dermatology company based on the following key characteristics: </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;"><font style="font-style:italic;font-weight:bold;">Diverse late-stage branded product pipeline with observed clinical benefits and favorable tolerability profiles.</font>&nbsp;&nbsp;&nbsp;We have leveraged our knowledge of the dermatology market to establish a pipeline of diversified late-stage branded product candidates with the potential to address the need for improved drug therapies. We have observed favorable clinical results for our branded product candidates that have completed Phase II trials. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;"><font style="font-style:italic;font-weight:bold;">Proprietary, silica-based microencapsulation drug delivery technology platform with broad applicability.</font>&nbsp;&nbsp;&nbsp;We leverage our innovative silica-based microencapsulation drug delivery technology platform in the development of each of our branded product candidates. In addition, we believe our technology platform provides us with the potential to develop additional product candidates that can overcome the limitations of currently approved products for multiple skin diseases.</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:3.29000000000003pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">3</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="border:1pt #000 solid;margin-top:15.3pt;min-height:703.41pt;margin-left:56pt;width:486pt;">
        <div style="margin-top:22.7pt;margin-left:14pt;width:456pt;">
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;"><font style="font-style:italic;font-weight:bold;">Efficient FDA regulatory pathway for our current branded product pipeline.</font>&nbsp;&nbsp;&nbsp;We expect the review process for TWIN, SIRS-T and VERED to be conducted according to the FDA&#8217;s 505(b)(2) regulatory pathway, which permits us to rely, in part, upon the FDA&#8217;s previous findings of safety and efficacy of an approved product. Silica, which forms the basis of our proprietary microencapsulation technology platform, is an inorganic inert excipient that is contained in other topical drug products approved by the FDA. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.82pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:4.82pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;"><font style="font-style:italic;font-weight:bold;">Diversified pipeline of generic drug product candidates and established strategic collaborations.</font>&nbsp;&nbsp;&nbsp;Our product pipeline includes six topical generic product candidates across multiple indications. We have established collaborations, including with Perrigo, to efficiently develop four of our generic product candidates. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.82pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:4.82pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;"><font style="font-style:italic;font-weight:bold;">Comprehensive and broad intellectual property portfolio.</font>&nbsp;&nbsp;&nbsp;We maintain exclusive, worldwide commercial rights for all of our branded product candidates. If patents issue from our patent applications, our branded product candidates, TWIN, SIRS-T and VERED, will have patent coverage until 2032, 2030 and 2032, respectively. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:4.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;"><font style="font-style:italic;font-weight:bold;">Experienced leadership team with proven track record.</font>&nbsp;&nbsp;&nbsp;Our leadership team has extensive experience in the development and commercialization of dermatology drug products. We believe that our leadership team is well-positioned to lead us through clinical development, regulatory approval and commercialization for our product candidates. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Our Strategy </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Our strategy is to become a leading, pure-play dermatology company focused on identifying, developing and commercializing treatments for skin diseases in areas with the need for improved drug therapies. To achieve this objective, we intend to pursue the following: </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.82pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:4.82pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;"><font style="font-style:italic;font-weight:bold;">Complete clinical development of our late-stage branded product candidates and obtain regulatory approvals.</font>&nbsp;&nbsp;&nbsp;We plan to advance our late-stage branded product candidates through clinical development and obtain regulatory approvals. Subject to End of Phase II meetings to be scheduled with the FDA, we plan to commence pivotal Phase III programs in 2018 for TWIN for the treatment of acne and for VERED for the treatment of subtype II rosacea. Subject to an End of Phase II meeting to be scheduled with the FDA, we plan to commence a pivotal Phase III program for SIRS-T in 2019. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.62pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:4.62pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;"><font style="font-style:italic;font-weight:bold;">Maximize commercial potential of our late-stage branded product candidates.</font>&nbsp;&nbsp;&nbsp;We intend to commercialize our late-stage branded product candidates in the United States, if approved, by building a specialized sales and marketing organization focused solely on dermatologists and their patients. Because the U.S. market is served by a relatively small number of practicing dermatologists, we believe a small and dedicated sales force can efficiently cover a significant portion of the target patient population. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.62pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:4.62pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;"><font style="font-style:italic;font-weight:bold;">Selectively expand our branded product candidate pipeline.</font>&nbsp;&nbsp;&nbsp;We continuously evaluate opportunities to leverage our proprietary silica-based microencapsulation technology platform to efficiently develop additional branded product candidates for the treatment of skin diseases in areas where we believe there is a need for improved drug therapies. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.62pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:4.62pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;"><font style="font-style:italic;font-weight:bold;">Opportunistically broaden our generic pipeline.</font>&nbsp;&nbsp;&nbsp;We intend to continue to develop and opportunistically broaden our generic pipeline with product candidates that we believe have the potential to capture significant share of attractive markets and geographies. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Dermatology Market Overview </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We focus on medical dermatology, which includes many common skin diseases such as acne, rosacea, psoriasis, atopic dermatitis and actinic keratosis. These diseases can have significant, multidimensional negative effects on patients&#8217; quality of life, including their physical and emotional well-being and social acceptance. </div>
        </div>
      </div>
      <div style="margin-top:3.29000000000003pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">4</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="border:1pt #000 solid;margin-top:15.3pt;min-height:703.41pt;margin-left:56pt;width:486pt;">
        <div style="margin-top:22.7pt;margin-left:14pt;width:456pt;">
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The dermatology and skin care market has experienced significant growth in the last several years. Based on IMS data, the U.S. medical dermatology market (excluding biologics) was valued at over $11 billion in prescription pharmaceutical sales in 2016, of which $9.8 billion represented sales of topical drugs. According to IMS, dermatological drugs sales in the United States have grown at an annual rate of 10% since 2012, while total prescriptions volume grew at an annual rate of 2% over the same period. We believe many factors are continuing to drive growth in the medical dermatological market, including population growth for prevalent age groups and growth in the number of physicians dispensing products. We believe patients&#8217; willingness to pay for dermatology treatments out-of-pocket is a result of often visible symptoms from dermatological diseases, which further supports demand and pricing. </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We believe dermatology offers a low cost commercialization opportunity compared to many other medical specialties due to the relatively small number of specialists. According to IMS, there are approximately 14,000 active dermatologists in the United States. Because the U.S. market is served by a relatively small number of practicing dermatologists, we believe a small and dedicated sales force can efficiently cover a significant portion of the targeted patient population. </div>
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Risks Associated with our Business </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Investing in our ordinary shares involves risks. You should carefully consider the risks described in &#8220;Risk Factors&#8221; beginning on page <a href="#tRF">12</a> before making a decision to invest in our ordinary shares. The following is a summary of some of the principal risks we face: </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:9.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">we have incurred significant losses since our inception and we expect to incur losses and negative cash flows over the next several years and may never achieve or maintain profitability; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:9.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">our recurring operating losses have raised substantial doubt regarding our ability to continue as a going concern;</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:9.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">even if this offering is successful, we will need substantial additional funding to meet our financial obligations and to pursue our business objectives and if we are unable to raise capital when needed, we could be forced to curtail our planned operations and the pursuit of our growth strategy; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:9.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">our ability to complete the development of our product candidates and to meet our development timelines; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:9.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">we rely, and expect to continue to rely, on third parties to conduct our clinical trials and manufacture our product candidates for clinical testing, and those third parties may not perform satisfactorily, which could delay our product development activities; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:9.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">our ability to obtain and maintain regulatory approvals for our product candidates in our target markets and the possibility of adverse regulatory or legal actions relating to our product candidates even if regulatory approval is obtained; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:9.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">our ability to commercialize our product candidates; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:9.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">our ability to obtain and maintain adequate protection of our intellectual property; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:9.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the possibility that we may face third-party claims of intellectual property infringement; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:9.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">acceptance of our product candidates by healthcare professionals and patients; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:9.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">we will face substantial competition, which may result in others discovering, developing or commercializing drugs before or more successfully than we do; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:9.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">loss or retirement of key executives and research scientists; and </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:3.29000000000003pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">5</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="border:1pt #000 solid;margin-top:15.3pt;min-height:703.41pt;margin-left:56pt;width:486pt;">
        <div style="margin-top:22.7pt;margin-left:14pt;width:456pt;">
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">we expect to be treated as a PFIC for our current taxable year and possibly thereafter, which may result in adverse tax consequences for our U.S. securityholders. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Our Controlling Shareholder </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">As of the date of this prospectus, M.Arkin Dermatology Ltd., or Arkin Dermatology, owns 100% of our ordinary shares. Mr. Moshe Arkin, the chairman of our board of directors, owns 100% of the share capital of Arkin Dermatology. Upon completion of this offering, Arkin Dermatology will own approximately &#8199;&#8199;&#8199;&#8199;% of our ordinary shares, assuming the automatic conversion of our outstanding promissory note between us and Mr.&#160; Arkin  into an aggregate of&#8201; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares immediately prior to the closing of this offering, and assuming an initial public offering price of&#8201; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share, which is the midpoint of the price range set forth on the cover page of this prospectus. The actual number of shares to be issued upon conversion of the promissory note will be determined by dividing the principal amount of the promissory note at the time of conversion by the initial public offering price per ordinary share in this offering. For more information see &#8220;Principal Shareholders&#8221; and &#8220;Certain Relationships and Related Party Transactions&#160;&#8212; Loan Agreements with Our Controlling Shareholder.&#8221;</div>
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Corporate Information </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We were incorporated under the laws of the State of Israel on October&#160;28, 1997. Our principal&#160;executive offices are located at Weizmann Science Park, 7 Golda Meir St., Ness Ziona, Israel 7403650, and our telephone number is +972 (8) 931-3433. Our website address is http://www.sol-gel.com. The information contained therein, or that can be accessed therefrom, is not and shall not be deemed to be incorporated into this prospectus or the registration statement of which it forms a part. </div>
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Implications of Being an Emerging Growth Company and a Foreign Private Issuer </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We are an &#8220;emerging growth company&#8221; as defined in the Jumpstart Our Business Startups Act, or JOBS Act. As such, we are eligible to take advantage of certain exemptions from various reporting requirements that are applicable to other publicly traded entities that are not emerging growth companies. These exemptions include: </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:10.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:10.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the option to present only two years of audited financial statements and only two years of related Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations in this prospectus; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:10.38pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:10.38pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">we are not required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:10.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:10.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">we are not required to comply with any requirement that may be adopted by the Public Company Accounting Oversight Board, or PCAOB, regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements; and </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:10.58pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:10.58pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">we are not required to submit certain executive compensation matters to shareholder advisory votes, such as &#8220;say-on-pay,&#8221; &#8220;say-on-frequency&#8221; and &#8220;say-on-golden parachutes;&#8221; and we are not required to disclose certain executive compensation related items such as the correlation between executive compensation and performance and comparisons of the chief executive officer&#8217;s compensation to median employee compensation. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We may take advantage of these provisions until the last day of our fiscal year following the fifth anniversary of the closing of this offering or such earlier time that we no longer qualify as an emerging growth company. As a result, the information we provide to our shareholders may be different than you might receive from other public reporting companies in which you hold equity interests. </div>
        </div>
      </div>
      <div style="margin-top:3.29000000000003pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">6</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="border:1pt #000 solid;margin-top:15.3pt;min-height:703.41pt;margin-left:56pt;width:486pt;">
        <div style="margin-top:22.7pt;margin-left:14pt;width:456pt;">
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Section 107 of the JOBS Act also provides that an emerging growth company can take advantage of the extended transition period provided in Section 13(a) of the Exchange Act, for complying with new or revised accounting standards. Accordingly, as an emerging growth company, we have elected to utilize this exemption and delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We will remain an emerging growth company until the earliest of: (i) the last day of the first fiscal year in which our annual gross revenues exceed $1.07 billion; (ii) the last day of the fiscal year following the fifth anniversary of the date of this offering; (iii) the date that we become a &#8220;large accelerated filer&#8221; as defined in Rule 12b-2 under the Exchange Act, which would occur if the aggregate market value of our ordinary shares that is held by non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal quarter; or (iv) the date on which we have issued more than $1.0 billion in non-convertible debt securities during any three-year period. </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Upon the closing of this offering, we will report under the Exchange Act as a non-U.S. company with foreign private issuer status. Even after we no longer qualify as an emerging growth company, for as long as we qualify as a foreign private issuer under the Exchange Act, we will be exempt from certain provisions of the Exchange Act that are applicable to U.S. domestic public companies, including: </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:11.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the sections of the Exchange Act regulating the solicitation of proxies, consents or authorizations in respect of a security registered under the Exchange Act; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the sections of the Exchange Act requiring insiders to file public reports of their share ownership and trading activities and liability for insiders who profit from trades made in a short period of time; and </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the rules under the Exchange Act requiring the filing with the SEC of quarterly reports on Form 10-Q containing unaudited financial and other specific information, or current reports on Form 8-K, upon the occurrence of specified significant events. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Both foreign private issuers and emerging growth companies are also exempt from certain more stringent executive compensation disclosure rules. Thus, even if we no longer qualify as an emerging growth company, but remain a foreign private issuer, we will continue to be exempt from the more stringent compensation disclosures required of companies that are neither an emerging growth company nor a foreign private issuer.</div>
        </div>
      </div>
      <div style="margin-top:3.29000000000003pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">7</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="border:1pt #000 solid;margin-top:15.3pt;min-height:703.41pt;margin-left:56pt;width:486pt;">
        <div style="margin-top:22.7pt;margin-left:14pt;width:456pt;">
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">The Offering </div>
          <div style="width:168pt;">
            <div style="margin-top:8pt; line-height:12pt;">Ordinary shares offered by us </div>
          </div>
          <div style="margin-left:192pt; margin-top:-12pt; width:264pt; line-height:12pt;">&#8199;&#8201;&#8199;&#8199;&#8199; ordinary shares (or &#8199;&#8201;&#8199;&#8199;&#8199; ordinary shares if the underwriters exercise their option to purchase additional ordinary shares in full). </div>
          <div style="width:168pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:8pt; line-height:12pt;">Ordinary shares to be outstanding after this offering </div>
          </div>
          <div style="margin-left:192pt; margin-top:-12pt; width:264pt; line-height:12pt;">&#8199;&#8201;&#8199;&#8199;&#8199; ordinary shares (or &#8199;&#8201;&#8199;&#8199;&#8199; ordinary shares if the underwriters exercise their option to purchase additional ordinary shares in full). </div>
          <div style="width:168pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:8pt; line-height:12pt;">Option to purchase additional ordinary shares </div>
          </div>
          <div style="margin-left:192pt; margin-top:-12pt; width:264pt; line-height:12pt;">We have granted the underwriters an option to purchase up to &#8199;&#8201;&#8199;&#8199;&#8199; additional ordinary shares from us within 30 days of the date of this prospectus. </div>
          <div style="width:168pt;">
            <div style="margin-top:8pt; line-height:12pt;">Use of proceeds </div>
          </div>
          <div style="margin-left:192pt; margin-top:-12pt; width:264pt; line-height:12pt;">We estimate that we will receive net proceeds from this offering of approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, or approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million if the underwriters exercise their option to purchase additional ordinary shares in full, based on an assumed initial public offering price of&#8201; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. </div>
          <div style="margin-left:192pt; margin-top:8pt; width:264pt; line-height:12pt;">We intend to use the net proceeds from this offering to fund our planned clinical trials of our branded product candidates, TWIN, SIRS-T and VERED, as well as the development of our generic product candidates. The remaining proceeds will be used for other research and development activities, as well as for working capital and general corporate purposes. See &#8220;Use of Proceeds&#8221; for additional information. </div>
          <div style="width:168pt;">
            <div style="margin-top:8pt; line-height:12pt;">Risk factors </div>
          </div>
          <div style="margin-left:192pt; margin-top:-12pt; width:264pt; line-height:12pt;">See &#8220;Risk Factors&#8221; and other information included in this prospectus for a discussion of factors you should carefully consider before deciding to invest in our ordinary shares. </div>
          <div style="width:168pt;">
            <div style="margin-top:8pt; line-height:12pt;">Controlled company </div>
          </div>
          <div style="margin-left:192pt; margin-top:-12pt; width:264pt; line-height:12pt;">Because Arkin Dermatology will own more than 50% of the voting power of our outstanding voting share capital following the completion of this offering, we intend to avail ourselves of the &#8220;controlled company&#8221; exemptions under the rules of the NASDAQ. </div>
          <div style="width:168pt;">
            <div style="white-space:nowrap; margin-left:10pt; text-indent:-10pt; margin-top:8pt; line-height:12pt;">Passive foreign investment <br >company</div>
          </div>
          <div style="margin-left:192pt; margin-top:-12pt; width:264pt; line-height:12pt;">Based on our anticipated income and the composition of our income and assets, we expect to be a passive foreign investment company (&#8220;PFIC&#8221;) for U.S. federal income tax purposes at least until we start generating a substantial amount of active revenue. If we are considered a PFIC, material adverse U.S. federal income tax consequences could apply to U.S. Holders (as defined in the section headed &#8220;Material Tax Considerations&#8201;&#8212;&#8201;U.S. Federal Income Tax Consequences&#8221;) of our ordinary shares with </div>
        </div>
      </div>
      <div style="margin-top:3.29000000000003pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">8</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="border:1pt #000 solid;margin-top:15.3pt;min-height:703.41pt;margin-left:56pt;width:486pt;">
        <div style="margin-top:22.7pt;margin-left:14pt;width:456pt;">
          <div style="margin-left:192pt; width:264pt; line-height:12pt;">respect to any &#8220;excess distribution&#8221; received from us and any gain from a sale or other disposition of our ordinary shares. Please see &#8220;Material Tax Considerations&#8201;&#8212;&#8201;U.S. Federal Income Tax Consequences.&#8221; </div>
          <div style="width:168pt;">
            <div style="margin-left:10pt; text-indent:-10pt; margin-top:8pt; line-height:12pt;">Proposed NASDAQ Global Market symbol </div>
          </div>
          <div style="margin-left:192pt; margin-top:-12pt; width:264pt; line-height:12pt;">&#8220;SLGL&#8221; </div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Unless otherwise stated, the number of ordinary shares to be outstanding after this offering is based on &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares outstanding as of June&#160;30, 2017, and excludes the following as of such date: </div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">253,768 ordinary shares issuable upon the exercise of options to purchase ordinary shares outstanding under our 2014 Share Incentive Plan, at a weighted average exercise price of $2.86 per share; and </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">an additional &#8199;&#8199;&#8201;&#8199;&#8199;&#8199; ordinary shares reserved for future issuance under our amended and restated 2014 Share Incentive Plan, which will become effective upon the pricing of this offering. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">Unless otherwise indicated, all information in this prospectus assumes or gives effect to:</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the automatic conversion of our outstanding promissory note between us and our controlling shareholder into an aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares   immediately prior to the closing of this offering, and assuming an initial public offering price of&#8201; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share, which is the midpoint of the price range set forth on the cover page of this prospectus;</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">an assumed initial public offering price of&#8201; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share, which is the midpoint of the price range set forth on the cover page of this prospectus; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">no exercise by the underwriters of their option to purchase up to &#8199;&#8199;&#8199;&#8199; additional ordinary shares from us; </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the adoption and effectiveness of our amended and restated articles of association; and </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
          <div style=" float:left; margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; for &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; share split of our ordinary shares by means of a bonus share issuance of&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares for each ordinary share outstanding, which was effected on &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2017.</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:3.29000000000003pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">9</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tSFOD">&#8203;</a></div>
      <div style="border:1pt #000 solid;margin-top:15.3pt;min-height:703.41pt;margin-left:56pt;width:486pt;">
        <div style="margin-top:22.7pt;margin-left:14pt;width:456pt;">
          <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;"><font style="text-transform:uppercase;">Summary Financial Data</font></div>
          <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The following tables present our summary statement of operations for the years ended December&#160;31, 2015 and 2016 and the six months ended June&#160;30, 2016 and 2017, and our summary balance sheet data as of June&#160;30, 2017. Our summary statement of operations for the years ended December&#160;31, 2015 and 2016 has been derived from our audited financial statements included elsewhere in this prospectus. The statement of operations data for the six months ended June 30, 2016 and 2017 and the summary balance sheet data as of June 30, 2017 have been derived from our unaudited financial statements included elsewhere in this prospectus and have been prepared on the same basis as the audited financial statements. In the opinion of management, the unaudited data reflects all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the financial information in those statements. Our historical results are not necessarily indicative of the results that should be expected in the future, and results for the six months ended June 30, 2017 are not necessarily indicative of the results to be expected for the full year ending December 31, 2017 or any other future period. We prepare our financial statements in accordance with U.S. Generally Accepted Accounting Principles, or U.S. GAAP. You should read this summary financial data together with &#8220;Selected Financial Data,&#8221; &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and our audited financial statements and related notes included elsewhere in this prospectus. </div>
          <table style="width:456pt;height:242.5pt;margin-top:10pt;border-collapse: collapse;">
            <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:216.76pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.9pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;" colspan="10">
                <div style="white-space:nowrap; text-align:center;">Year Ended December&#160;31,</div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.9pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;" colspan="10">
                <div style="white-space:nowrap; text-align:center;">Six Months Ended June&#160;30,</div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:216.76pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.9pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">2015 </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.9pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">2016</div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.9pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">2016</div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.9pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">2017</div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
              <td style="padding:0pt 0pt 0.5pt 0pt; width:216.76pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 1pt 0pt; width:0pt;" colspan="10">
                <div style="white-space:nowrap; text-align:center;">(Unaudited)</div>
              </td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:216.76pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.9pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:3pt 0pt 2pt 0pt; width:0pt;text-align:center;" colspan="22">
                <div style="white-space:nowrap; text-align:center;">(in thousands, except share and  per share data )</div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
              <td style="padding:2.75pt 0pt 1pt 0pt; width:216.76pt;text-align:left;">Statement of Operations Data:</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="6">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
              <td style="padding:3pt 0pt 1pt 0pt; width:216.76pt;text-align:left;">
                <div style="white-space:nowrap;">Research and development expenses </div>
              </td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">7,184</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">17,023</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">6,797</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">9,376</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
              <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2pt 0pt; width:216.76pt;text-align:left;">
                <div style="white-space:nowrap;">General and administrative expenses </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">2,463</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">3,733</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">1,721</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">2,460</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
              <td style="padding:2.75pt 0pt 1pt 0pt; width:216.76pt;text-align:left;">
                <div style="white-space:nowrap;">Total operating loss </div>
              </td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 1pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 1pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">9,647</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 1pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 1pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">20,756</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 1pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 1pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">8,518</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 1pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
              <td style="padding:2.75pt 0pt 1pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">11,836</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
              <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2pt 0pt; width:216.76pt;text-align:left;">
                <div style="white-space:nowrap;">Financial expenses, net </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">13</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">15</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">(7<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">(4<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
              <td style="padding:2.75pt 0pt 2.75pt 0pt; width:216.76pt;text-align:left;">
                <div style="white-space:nowrap;">Loss for the year </div>
              </td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">9,660</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">20,771</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">8,511</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
              <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">11,832</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
              <td style="padding:2.25pt 0pt 2.75pt 0pt; width:216.76pt;text-align:left;">
                <div style="white-space:nowrap;">Basic and diluted loss per ordinary share (1)</div>
              </td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
              <td style="padding:2.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">2.76</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
              <td style="padding:2.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">5.94</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
              <td style="padding:2.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">2.44</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:2.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
              <td style="padding:2.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">3.39</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
              <td style="padding:0.917pt 0pt 2.083pt 0pt; width:216.76pt;white-space:normal;text-align:left;">
                <div style="margin-left:10pt; text-indent:-10pt;">Weighted average number of ordinary shares outstanding&#8201;&#8211;&#8201;basic and diluted </div>
              </td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0.917pt 0pt 1.333pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
              <td style="padding:0.917pt 0pt 1.333pt 0pt;border-bottom:3px double #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">3,494,579</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0.917pt 0pt 1.333pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
              <td style="padding:0.917pt 0pt 1.333pt 0pt;border-bottom:3px double #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">3,494,579</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0.917pt 0pt 1.333pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
              <td style="padding:0.917pt 0pt 1.333pt 0pt;border-bottom:3px double #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">3,494,579</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0.917pt 0pt 1.333pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
              <td style="padding:0.917pt 0pt 1.333pt 0pt;border-bottom:3px double #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">3,494,579</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
              <td style="padding:0.917pt 0pt 2.083pt 0pt; width:216.76pt;white-space:normal;text-align:left;">
                <div style="margin-left:10pt; text-indent:-10pt;">Pro forma basic and diluted net loss per ordinary share (unaudited) (1)(2) </div>
              </td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:32.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0.917pt 0pt 1.333pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
              <td style="padding:0.917pt 0pt 1.333pt 0pt;border-bottom:3px double #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:32.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0.917pt 0pt 1.333pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
              <td style="padding:0.917pt 0pt 1.333pt 0pt;border-bottom:3px double #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:12pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
              <td style="padding:0.917pt 0pt 2.75pt 0pt; width:216.76pt;white-space:normal;text-align:left;">
                <div style="margin-left:10pt; text-indent:-10pt;">Pro forma weighted average number of ordinary shares outstanding&#8201;&#8211;&#8201;basic and diluted (unaudited) (2) </div>
              </td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:32.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:32.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt; width:4.9pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="height:4.5pt;line-height:4.5pt;">
              <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="26">&#8203;</td>
            </tr>
          </table>
          <div style="margin-top:11.99pt; width:456pt;">
            <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
          </div>
          <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:15pt;white-space:nowrap;font-size:8pt;">(1)<br ></div>
          <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:10pt; text-align:left; width:440.5pt;font-size:8pt;">Basic loss per ordinary share and diluted loss per ordinary share are the same because outstanding options would be anti-dilutive due to our net losses in these periods.</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:10pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:15pt;white-space:nowrap;font-size:8pt;">(2)<br ></div>
          <div style=" float:left; margin-top:9.97pt; margin-bottom:0pt; line-height:10pt; text-align:left; width:440.5pt;font-size:8pt;">Reflects the automatic conversion of our outstanding promissory note between us and our controlling shareholder into an aggregate of&#8201; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares immediately prior to the closing of this offering, assuming an initial public offering price of&#8201; $&#8199;&#8199;&#8199;&#8199; per ordinary share, which is the midpoint of the price range set forth on the cover page of this prospectus. The actual number of shares to be issued upon conversion of the promissory note will be determined by dividing the principal amount of the promissory note at the time of conversion by the initial public offering price per ordinary share in this offering. See &#8220;Certain Relationships and Related Party Transactions &#8212; Loan Agreements with Our Controlling Shareholder.&#8221;</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:3.29000000000003pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">10</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="border:1pt #000 solid;margin-top:15.3pt;min-height:703.41pt;margin-left:56pt;width:486pt;">
        <div style="margin-top:22.7pt;margin-left:14pt;width:456pt;">
          <table style="width:456pt;height:125.5pt;margin-top:0pt;border-collapse: collapse;">
            <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:252pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;text-align:center;" colspan="16">
                <div style="white-space:nowrap; text-align:center;">June&#160;30, 2017</div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:252pt;text-align:left;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">Actual</div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
                <div style="white-space:nowrap; text-align:center;">Pro Forma (1)</div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
                <div style="text-align:center;">Pro Forma As <br >Adjusted (2) </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
              <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:252pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
              <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt; width:0pt;text-align:center;" colspan="16">
                <div style="white-space:nowrap; text-align:center;">(Unaudited, in thousands) </div>
              </td>
              <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
              <td style="padding:2.75pt 0pt 1pt 0pt; width:252pt;">Balance Sheet Data:</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="6">&#8203;</td>
              <td colspan="6">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
              <td style="padding:3pt 0pt 1pt 0pt; width:252pt;text-align:left;">
                <div style="white-space:nowrap;">Cash and cash equivalents </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.275pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">23,295</td>
              <td style="padding:0pt;padding-left:7.275pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.22pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
              <td style="padding:0pt;padding-left:4.22pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.995pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8199;&#8201;&#8199;&#8199;&#8199;&#8201;&#8199;&#8199;&#8199;</td>
              <td style="padding:0pt;padding-left:4.995pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
              <td style="padding:3pt 0pt 1pt 0pt; width:252pt;text-align:left;">
                <div style="white-space:nowrap;">Total assets </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.275pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">28,702</td>
              <td style="padding:0pt;padding-left:7.275pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.22pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.22pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.995pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.995pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
              <td style="padding:3pt 0pt 1pt 0pt; width:252pt;text-align:left;">
                <div style="white-space:nowrap;">Total liabilities </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.275pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">71,485</td>
              <td style="padding:0pt;padding-left:7.275pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.22pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.22pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.995pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.995pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
              <td style="padding:3pt 0pt 1pt 0pt; width:252pt;text-align:left;">
                <div style="white-space:nowrap;">Accumulated deficit </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.275pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">(75,525<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:7.275pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.22pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.22pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.995pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.995pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
            <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
              <td style="padding:3pt 0pt 1pt 0pt; width:252pt;text-align:left;">
                <div style="white-space:nowrap;">Total shareholders&#8217; equity (capital deficiency) </div>
              </td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:7.275pt;width:0pt;">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
              <td style="padding:3pt 0pt 1pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">(42,783<font style="position:absolute;">)</font></td>
              <td style="padding:0pt;padding-left:7.275pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.22pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.22pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt; width:6pt;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.995pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
              <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
              <td style="padding:0pt;padding-left:4.995pt;width:0pt;">&#8203;</td>
              <td style="padding:0pt; width:0pt;">&#8203;</td>
            </tr>
          </table>
          <div style="margin-top:14.49pt; width:456pt;">
            <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
          </div>
          <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:15pt;white-space:nowrap;">(1)<br ></div>
          <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:10pt; text-align:left; width:440.5pt;">The pro forma balance sheet data give effect to the automatic conversion of our outstanding promissory note between us and our controlling shareholder into an aggregate of&#8201; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares immediately prior to the closing of this offering, assuming an initial public offering price of&#8201; $&#8199;&#8199;&#8199;&#8199; per ordinary share, which is the midpoint of the price range set forth on the cover page of this prospectus. The actual number of shares to be issued upon conversion of the promissory note will be determined by dividing the principal amount of the promissory note at the time of conversion by the initial public offering price per ordinary share in this offering. See &#8220;Certain Relationships and Related Party Transactions&#8201;&#8212;&#8201;Loan Agreements with Our Controlling Shareholder.&#8221;</div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:10pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:15pt;white-space:nowrap;">(2)<br ></div>
          <div style=" float:left; margin-top:9.97pt; margin-bottom:0pt; line-height:10pt; text-align:left; width:440.5pt;">The pro forma as adjusted balance sheet data give further effect to the issuance and sale of&#8201; &#8199;&#8199;&#8201;&#8199;&#8199; ordinary shares by us in this offering at an assumed initial public offering price of&#8201; $&#8199;&#8199;&#8199;&#8199; per ordinary share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting underwriting discounts and commissions and estimated offering expenses payable by us. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
          <div style=" float:left; line-height:10pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:15pt;white-space:nowrap;">&nbsp;&nbsp;&nbsp;<br ></div>
          <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:10pt; text-align:left; width:440.5pt;">Each $1.00 increase or decrease in the assumed initial public offering price of&#8201; $&#8199;&#8199;&#8199;&#8199;per ordinary share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase or decrease the pro forma as adjusted amount of each of cash and cash equivalents, total assets and total capital deficiency by $&#8199;&#8199;&#8199;&#8199; million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting underwriting discounts and commissions. An increase or decrease of 1.0 million in the number of ordinary shares we are offering would increase or decrease, respectively, the pro forma as adjusted amount of cash and cash equivalents, total assets and total capital deficiency by $&#8199;&#8199;&#8199; million, assuming the assumed initial public offering price per ordinary share, as set forth on the cover of this prospectus, remains the same. This pro forma as adjusted information is illustrative only and will depend on the actual initial public offering price and other terms of this offering determined at pricing. </div>
          <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        </div>
        <div style="clear:both;font-size:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:3.29000000000003pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;font-size:10pt;">11</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tRF">&#8203;</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">RISK FACTORS </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Investing in our ordinary shares involves a high degree of risk. You should carefully consider the risks described below and all other information contained in this prospectus before you decide to buy our ordinary shares. If any of the following risks actually occur, our business, financial condition and results of operations could be materially and adversely affected. In that event, the trading price of our ordinary shares would likely decline and you might lose all or part of your investment. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially adversely affect our business, financial condition, cash flows and results of operations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Risks Related to Our Business and Industry </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We are a clinical stage company and have incurred significant losses since our inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We are a clinical stage pharmaceutical company with a limited operating history. We have incurred net losses since our formation in 1997. In particular, we incurred net losses of&#8201; $9.7 million in 2015 and $20.8 million in 2016, respectively, and $8.5 million and $11.8 million for the six months ended June 30, 2016 and 2017, respectively. As of June&#160;30, 2017, we had an accumulated deficit of&#8201; $75.5 million. Our losses have resulted principally from expenses incurred in research and development of our product candidates and from general and administrative expenses that we have incurred while building our business infrastructure. We expect to continue to incur net losses for the foreseeable future as we continue to invest in research and development and seek to obtain regulatory approval and commercialization of our product candidates. The extent of our future operating losses and the timing of generating revenues and becoming profitable are highly uncertain, and we may never achieve or sustain profitability. We anticipate that our expenses will increase substantially as we: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">initiate and conduct the Phase III clinical trials and long-term safety studies for TWIN, SIRS-T and VERED, which we refer to collectively as our branded product candidates, and continue the research and development of future branded product candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">continue the development, bioequivalence and other studies required for ANDA submissions for our generic product candidate ivermectin cream, 1% and other generic product candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">seek to enhance our technology platform; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">seek regulatory approvals for any product candidate that successfully completes clinical development; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">potentially establish a sales, marketing and distribution infrastructure and commercial manufacturing capabilities to commercialize any product candidates for which we may obtain regulatory approval; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">maintain, expand and protect our intellectual property portfolio; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">add clinical, scientific, operational, financial and management information systems and personnel, including personnel to support our product development and potential future commercialization efforts and to support our transition to being a public company; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">experience any delays or encounter any issues with any of the above, including but not limited to failed studies, complex results, safety issues or other regulatory challenges. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">To date, we have financed our operations primarily through private placements of equity securities and loans from our controlling shareholder. We have devoted a significant portion of our financial resources and efforts to developing our product candidates and conducting pre-clinical </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">12</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">studies and our clinical trials for TWIN, VERED, and ivermectin cream, 1%. We have not completed development of any of our product candidates. To become and remain profitable, we must succeed in developing and eventually commercializing product candidates that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing pre-clinical studies and clinical trials for our product candidates, discovering and developing additional product candidates, obtaining regulatory approval for any product candidates that successfully complete clinical trials, establishing manufacturing and marketing capabilities and ultimately selling any product candidates for which we may obtain regulatory approval. We are only in the preliminary stages of most of these activities. We may never succeed in these activities and, even if we do, may never generate revenue that is significant enough to achieve profitability. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Because of the numerous risks and uncertainties associated with pharmaceutical products, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to achieve profitability. If we are required by the FDA or other regulatory authorities to perform studies in addition to those we currently anticipate, or if there are any delays in completing our clinical trials, our expenses could increase and revenue could be further delayed. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Even if we do generate revenue from product sales or product royalties, we may never achieve or sustain profitability on a quarterly or annual basis. Our failure to sustain profitability would depress the market price of our ordinary shares and could impair our ability to raise capital, expand our business, diversify our product offerings or continue our operations. A decline in the market price of our ordinary shares also could cause you to lose all or a part of your investment. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our recurring operating losses have raised substantial doubt regarding our ability to continue as a going concern. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We have not commercialized any products or generated any revenue from our product candidates. Our recurring operating losses raise substantial doubt about our ability to continue as a going concern. As a result, for the year ended December&#160;31, 2016, our independent registered public accounting firm has issued its report on our financial statements and has expressed substantial doubt about our ability to continue as a going concern. We have no current source of revenue to sustain our present activities and we do not expect to generate revenue until, and unless, the FDA or other regulatory authorities approve, and we successfully commercialize, our product candidates. Accordingly, our ability to continue as a going concern will require us to obtain additional financing to fund our operations, such as the proceeds from this offering. The perception that we might be unable to continue as a going concern may make it more difficult for us to obtain financing for the continuation of our operations and could result in the loss of confidence by investors, suppliers and employees. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Even if this offering is successful, we will need substantial additional funding to meet our financial obligations and to pursue our business objectives. If we are unable to raise capital when needed, we could be forced to curtail our planned operations and the pursuit of our growth strategy. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Conducting pre-clinical studies and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain regulatory approval and achieve product sales. We expect to continue to incur significant expenses and operating losses over the next several years as we commence our Phase III clinical trials for TWIN, SIRS-T and VERED, seek marketing approval for TWIN, SIRS-T and VERED and advance our other product candidates. In addition, our product candidates, if approved, may not achieve commercial success. Our revenue, if any, will be derived from sales of products that we do not expect to be commercially available for a number of years, if at all. If we obtain marketing approval for TWIN, SIRS-T or VERED or any other product candidates that we develop, we expect to incur significant commercialization expenses related to product sales, marketing, distribution and manufacturing. We also expect an increase in our expenses associated with creating additional infrastructure to support operations as a public company. We expect that </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">13</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">our existing cash, cash equivalents and investments, together with anticipated net proceeds from this offering, will enable us to fund our operating expenses and capital expenditure requirements through &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the progress and results of our pivotal Phase III clinical programs for TWIN, SIRS-T and VERED&#160;; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the scope, progress, results and costs of development, laboratory testing and clinical trials for our generic product candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the cost of manufacturing clinical supplies and exhibition batches of our product candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:10.18pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:10.18pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the costs, timing and outcome of regulatory reviews of any of our product candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:10.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:10.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the costs and timing of future commercialization activities, including manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:10.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:10.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims by third parties that we are infringing upon their intellectual property rights; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:10.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:10.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the amount of revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:10.18pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:10.18pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the extent to which we acquire or invest in businesses, product candidates and technologies, including entering into licensing or collaboration arrangements for any of our product candidates. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">If we are unable to raise sufficient additional capital, we could be forced to curtail our planned operations and the pursuit of our growth strategy. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We are largely dependent on the success of our branded product candidates for the treatment of topical dermatological conditions. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We have invested a majority of our efforts and financial resources in the research and development of TWIN and SIRS-T for the treatment of acne and VERED for the treatment of subtype II rosacea. We are currently investing a majority of our efforts and resources to bring TWIN and VERED to a position to commence Phase III clinical trials in the United States during 2018. The success of our business depends largely on our ability to fund, execute and complete the development of, obtain regulatory approval for and successfully commercialize our branded product candidates in the United States in a timely manner. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We have not obtained regulatory approval for any of our product candidates in the United States or any other country. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We currently do not have any product candidates that have obtained regulatory approval for sale in the United States or any other country, and we cannot guarantee that we will ever obtain such approvals. Our business is substantially dependent on our ability to complete the development of, obtain regulatory approval for and successfully commercialize product candidates in a timely manner. We cannot commercialize our product candidates in the United States without first obtaining regulatory approval to market each product candidate from the FDA. Similarly, we cannot commercialize product candidates outside of the United States without obtaining regulatory approval from comparable foreign regulatory authorities. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">14</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Before obtaining regulatory approvals for the commercial sale of any product candidate for a target indication, we must demonstrate in pre-clinical studies and well-controlled clinical trials that the product candidate is safe and effective for use for its target indication and that the related manufacturing facilities, processes and controls are adequate. In the United States, we are required to submit and obtain the FDA&#8217;s approval of a new drug application, or NDA, before marketing our product candidates. An NDA must include extensive preclinical and clinical data and supporting information to establish the product candidate&#39;s safety and efficacy for each desired indication. We intend to submit NDAs that are subject to the requirements of section 505(b)(2) of the Food, Drug and Cosmetic Act, or FDCA, which will allow us to rely in part on published scientific literature and/or the FDA&#39;s prior findings of safety and efficacy in its approvals of similar products. The NDA must also include significant information regarding the chemistry, manufacturing and controls for the product candidate. The FDA will also inspect our manufacturing facilities to ensure that the facilities can manufacture each product candidate that is the subject of an NDA, in compliance with the applicable regulatory requirements, and may inspect our clinical trial sites to ensure that the clinical trials conducted at the inspected site were performed in accordance with good clinical practices, or GCP, and our clinical protocol. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Obtaining approval of an NDA is a lengthy, expensive and uncertain process, and approval is never guaranteed. Upon submission of an NDA, the FDA must make an initial determination that the application is sufficiently complete to accept the submission for filing. We cannot be certain that any submissions will be accepted for filing and review by the FDA, or ultimately be approved. If the application is not accepted for review or approval, the FDA may require that we conduct additional clinical trials or pre-clinical studies, or take other actions before it will reconsider our application. If the FDA requires additional studies or data, we would incur increased costs and delays in the marketing approval process, which may require us to expend more resources than anticipated or that we have available. In addition, the FDA may not consider any additional information to be complete or sufficient to support approval. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Regulatory authorities outside of the United States also have requirements for approval of drugs for commercial sale with which we must comply prior to marketing in those countries. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our product candidates. Clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and obtaining regulatory approval in one country does not mean that regulatory approval will be obtained in any other country. However, the failure to obtain regulatory approval in one jurisdiction could have a negative impact on our ability to obtain approval in a different jurisdiction. Approval processes vary among countries and can involve additional product candidate testing, development, validation and additional administrative review periods. Seeking regulatory approval outside of the United States could require additional chemical manufacturing control data, pre-clinical studies or clinical trials, which could be costly and time consuming. Obtaining regulatory approval outside of the United States may include all of the risks associated with obtaining FDA approval. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our business will be highly dependent on market perception of us and the safety and quality of our product candidates. Our business or products could be subject to negative publicity, which could have a material adverse effect on our business. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Market perception of our business is very important, especially market perception of the safety and quality of our product candidates. If any of our product candidates, if approved, or similar products that other companies distribute, or third-party products from which our product candidates are derived, are subject to market withdrawal or recall or are proven to be, or are claimed to be, harmful to consumers, it could have a material adverse effect on our business. Negative publicity associated with product quality, illness or other adverse effects resulting from, or perceived to result from, our product candidates could have a material adverse impact on our business. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Additionally, continuing and increasingly sophisticated studies of the proper utilization, safety and efficacy of pharmaceutical products are being conducted by the industry, government </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">15</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">agencies and others which could call into question the utilization, safety and efficacy of previously marketed products. In some cases, studies have resulted, and may in the future result, in the discontinuance of product marketing or other costly risk management programs such as the need for a patient registry. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We have a limited operating history in the dermatological prescription drug space which may make it difficult to evaluate the success of our business to date and to assess our future viability. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We have a limited operating history in the dermatological prescription drug space and have focused much of our efforts, to date, on the research and development of our product candidates, rather than commercialization. As such, we cannot provide you with any assurances as to when, if ever, we will obtain approvals or generate sufficient revenues to achieve sustained profitability. Our ability to successfully commercialize our product candidates and become profitable is subject to a number of challenges, including, among others, that: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">we may not have adequate financial or other resources; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">we may not be able to manufacture our product candidates in commercial quantities, in an adequate quality or at an acceptable cost; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">we may not be able to establish adequate sales, marketing and distribution channels; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">we may not be able to find suitable marketing partners; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">healthcare professionals and patients may not accept our product candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">we may not be aware of possible complications from the continued use of our product candidates since we have limited clinical experience with respect to the actual use of our product candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">changes in the market, new alliances between existing market participants and the entrance of new market participants may interfere with our market penetration efforts; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">third-party payors may not agree to reimburse patients for any or all of the purchase price of our product candidates, which may adversely affect patients&#8217; willingness to purchase our product candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">uncertainty as to market demand may result in inefficient pricing of our product candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">we may face third-party claims of intellectual property infringement; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">we may fail to obtain and maintain regulatory approvals for our product candidates in our target markets or may face adverse regulatory or legal actions relating to our product candidates even if regulatory approval is obtained; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">we are dependent upon the results of ongoing clinical trials relating to our product candidates and the products of our competitors; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">we may become involved in lawsuits pertaining to our clinical trials. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The occurrence of any one or more of these events may limit our ability to successfully commercialize our product candidates, which in turn could have a material adverse effect on our business, financial condition and results of operations. Consequently, there can be no guaranty of the accuracy of any predictions about our future success or viability. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">16</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Raising additional capital may cause dilution to our shareholders, including purchasers of ordinary shares in this offering, restrict our operations or require us to relinquish rights to our technologies or product candidates. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Until such time, if ever, as we can generate substantial revenue, we may finance our cash needs through a combination of equity offerings, debt financings and license and collaboration agreements. We do not currently have any committed external source of funds. To the extent that we raise additional capital through the sale of equity or convertible debt securities, your ownership interest will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect your rights as an ordinary shareholder. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds through equity or debt financings when needed, we may be required to delay, limit, reduce or terminate our product development or future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Even if we are able to generate revenues from our operations in the future, our revenues and operating income could fluctuate significantly. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Even if we are able to generate future revenues, our operating income, and results may vary significantly from year-to-year and quarter-to-quarter. Variations may result from, among other factors: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the timing of FDA or any other regulatory authority approvals; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the timing of process validation for particular product candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the timing of product launches and market acceptance of such products launched; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">changes in the amount we spend to research, develop, acquire, license or promote new product candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the outcome of our research, development and clinical trial programs; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">serious or unexpected health or safety concerns related to our product candidates or the branded product candidates we have genericized; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the introduction of new products by others that render our product candidates obsolete or noncompetitive; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the ability to maintain selling prices and gross margins on our product candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the ability to comply with complex governmental regulations applicable to many aspects of our business; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">changes in coverage and reimbursement policies of health plans and other health insurers, including changes to Medicare, Medicaid and similar government healthcare programs; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">increases in the cost of raw materials used to manufacture our product candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">manufacturing and supply interruptions, including product rejections or recalls due to failure to comply with manufacturing specifications; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">timing of revenue recognition related to our collaboration agreements; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">17</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the ability to protect our intellectual property and avoid infringing the intellectual property of others; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:10.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:10.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the outcome and cost of possible litigation over patents with third parties. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our business and operations would suffer in the event of computer system failures, cyber-attacks or deficiencies in our cyber-security. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Despite the implementation of security measures, our internal computer systems, and those of third parties on which we rely, are vulnerable to damage from computer viruses, malware, natural disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions over the Internet, attachments to emails, persons inside our organization, or persons with access to systems inside our organization. The risk of a security breach or disruption, particularly through cyber-attacks or cyber intrusion, including by computer hackers, foreign governments, and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our product development programs. For example, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach was to result in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur material legal claims and liability, and damage to our reputation, and the further development of our product candidates could be delayed. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Risks Related to Development and Clinical Testing of Our Product Candidates </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Clinical drug development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and clinical trials may not be predictive of future trial results, which could result in development delays or a failure to obtain marketing approval. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Clinical testing of generic products and the submission of new drug applications under the Section 505(b)(2) regulatory pathway is expensive, time consuming and has an inherently uncertain outcome. Failure can occur at any time during the clinical trial process, even with active ingredients that have been previously approved by the FDA as safe and effective. Favorable results in pre-clinical studies and early clinical trials for one or more of our product candidates may not be predictive of similar results in future clinical trials for such product candidate. Also, interim results during a clinical trial do not necessarily predict final results. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through pre-clinical studies and initial clinical trials. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials even after achieving promising results in early-stage development. Accordingly, the results from the completed pre-clinical studies and clinical trials for our product candidates may not be predictive of the results we may obtain in later stage trials for such product candidates. Our clinical trials may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials. Clinical trial results may be inconclusive, or contradicted by other clinical trials, particularly larger clinical trials. Moreover, clinical data are often susceptible to varying interpretations and analyses, and many companies that believed their product candidates performed satisfactorily in pre-clinical studies and clinical trials have nonetheless failed to obtain FDA, or other applicable regulatory agency, approval for their products. Additionally if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:10.38pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:10.38pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">regulatory authorities may withdraw approvals of such products; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:10.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:10.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">regulatory authorities may require additional warnings on the label; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">18</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">we may be required to create a medication guide outlining the risks of such side effects for distribution to patients; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">we could be sued and held liable for harm caused to patients; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">our reputation may suffer. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Any of these events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and could significantly harm our business, results of operations and prospects. Our future clinical trial results may not be successful. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We may experience delays in our clinical trials and we do not know whether planned clinical trials will begin on time, need to be redesigned, enroll patients on time or be completed on schedule, if at all. Clinical trials can be delayed for a variety of reasons, including delays related to: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">obtaining regulatory approval to commence a trial; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">reaching agreement on acceptable terms with prospective contract research organizations, or CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">obtaining institutional review board, or IRB, approval at each site; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">recruiting suitable patients to participate in a trial; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">having patients complete a trial or return for post-treatment follow-up; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">clinical sites deviating from trial protocol or dropping out of a trial; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">adding new clinical trial sites; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">manufacturing sufficient quantities of a product candidate for use in clinical trials. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Furthermore, we rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and while we have agreements governing their committed activities, we have limited influence over their actual performance. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We may also encounter delays if a clinical trial is suspended or terminated by us, by the IRBs of the institutions in which such trials are being conducted, by the Data Safety Monitoring Board, or DSMB, for such trial or by the FDA or other regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. If we experience delays in the completion of any clinical trial for our product candidates or if any clinical trials are terminated, the commercial prospects of our product candidates will be harmed, and our ability to generate product revenues from any of these product candidates will be delayed. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Moreover, changes in regulatory requirements and guidance or unanticipated events during our clinical trials may occur, as a result of which we may need to amend clinical trial protocols. Amendments may require us to resubmit our clinical trial protocols for review and approval, which may adversely affect the cost, timing and successful completion of a clinical trial. If we experience delays in the completion of, or if we terminate, any of our clinical trials, the commercial prospects for our affected product candidates would be harmed and our ability to generate product revenue would be delayed, possibly materially. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">19</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or other regulatory authorities. The FDA or other regulatory authorities may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or other regulatory authorities may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval or rejection of our marketing applications by the FDA or other regulatory authorities, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our product candidates. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Any delays in completing our clinical trials will increase our costs, slow down our product candidates&#8217; development and regulatory review and approval process and jeopardize our ability to commence product sales and generate revenues. Any of these occurrences may harm our business, financial condition and prospects significantly. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We have not evaluated SIRS-T in any clinical trials to date, and there can be no guarantee that the data obtained in our Phase II TWIN trial will be sufficient to support advancing SIRS-T into a Phase III clinical trial. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">SIRS-T is a topical cream containing silica-encapsulated tretinoin. We have not evaluated SIRS-T in any clinical trials to date. We evaluated silica-encapsulated tretinoin in two of the arms of our Phase II TWIN trial, and we intend to use this data to support the commencement of a Phase III clinical trial in SIRS-T, subject to an End of Phase II meeting with the FDA. However, we expect that the tretinoin concentration that we select for SIRS-T will be different from the concentrations that we evaluated in the encapsulated tretinoin arms of the TWIN trial, in addition to other expected differences in the formulation. There can be no guarantee that the FDA will agree with our development plan for SIRS-T. If we are required to conduct additional clinical trials for SIRS-T, this would cause us to incur significant additional expense, delay the development of SIRS-T and may materially and adversely affect our business, financial condition and prospects. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. It is possible that none of our existing product candidates or any product candidates we may seek to develop in the future will ever obtain regulatory approval. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Our product candidates could fail to receive regulatory approval for many reasons, including the following: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">20</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from pre-clinical studies or clinical trials; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States or elsewhere; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">This lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market our product candidates, which would significantly harm our business, results of operations and prospects. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In addition, even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our product candidates, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We have limited experience using the 505(b)(2) regulatory pathway to submit an NDA or any similar drug approval filing to the FDA, and we cannot be certain that any of our product candidates will receive regulatory approval. If we do not receive regulatory approvals for our product candidates, we may not be able to continue our operations. Even if we successfully obtain regulatory approvals to market one or more of our product candidates, our revenue will be dependent, to a significant extent, upon the size of the markets in the territories for which we gain regulatory approval. If the markets for patients or indications that we are targeting are not as significant as we estimate, we may not generate significant revenue from sales of such products, if approved. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Adverse side effects or other safety risks associated with our product candidates could delay or preclude approval, cause us to suspend or discontinue clinical trials, abandon product candidates, limit the commercial profile of an approved label, or result in significant negative consequences following marketing approval, if any. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Undesirable side effects caused by our product candidates could result in the delay, suspension or termination of clinical trials by us, our collaborators, the FDA or other regulatory authorities for a number of reasons. For example, to date, patients treated with TWIN and VERED have experienced drug-related side effects including moderate local site irritation such as dryness, erythema, scaling, pruritus, itching, stinging and burning. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of these or other side effects. In such an event, our clinical trials could be suspended or terminated and the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of our product candidates for any or all targeted indications. The drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete the trial or result in potential product liability claims. If we elect or are required to delay, suspend or terminate any clinical trial for any </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">21</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">product candidates that we develop, the commercial prospects of such product candidates will be harmed and our ability to generate product revenues from any of these product candidates will be delayed or eliminated. Any of these occurrences may harm our business, prospects, financial condition and results of operations significantly. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We may find it difficult to enroll patients in our clinical trials, and patients could discontinue their participation in our clinical trials, which could delay or prevent clinical trials for our product candidates. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Identifying and qualifying patients to participate in clinical trials for our product candidates is critical to our success. The timing of our clinical trials depends on the speed at which we can recruit patients to participate in testing our product candidates. If patients are unwilling to participate in our clinical trials because of negative publicity from adverse events in the biotechnology or pharmaceutical industries or for other reasons, including competitive clinical trials for similar patient populations, the timeline for recruiting patients, conducting clinical trials and obtaining regulatory approval of potential product candidates may be delayed. These delays could result in increased costs, delays in advancing our product candidates development, delays in testing the effectiveness of our technology or termination of the clinical trials altogether. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Patient enrollment is a significant factor in the timing of clinical trials. We may not be able to recruit and enroll a sufficient number of patients, which would impact our ability to complete our clinical trials in a timely manner. Patient enrollment may be affected by numerous factors, including: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:10.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:10.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">severity of the disease under investigation; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:10.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:10.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">size and nature of the patient population; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:10.18pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:10.18pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">eligibility criteria for the trial; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:10.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:10.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">design of the trial protocol; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:10.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:10.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">perceived risks and benefits of the product candidate under study; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:10.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:10.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">physicians&#8217; and patients&#8217; perceptions as to the potential advantages of the drug being studied in relation to other available therapies, including any drugs that may be approved for the same indications we are investigating; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:10.18pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:10.18pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">proximity to and availability of clinical trial sites for prospective patients; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:10.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:10.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">availability of competing therapies and clinical trials; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:10.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:10.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">ability to monitor patients adequately during and after treatment. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We face intense competition with regard to patient enrollment in clinical trials from other dermatological companies which also seek to enroll subjects from the same patient populations. In addition, patients enrolled in our clinical trials may discontinue their participation at any time during the trial as a result of a number of factors, including withdrawing their consent or experiencing adverse clinical events, which may or may not be judged related to our product candidates under evaluation. For example, 128 patients, or 17.6% of patients enrolled in our TWIN Phase II clinical trial, did not complete the study protocol. The most common reasons for subjects not completing the study were the withdrawal of informed consent (42 subjects), loss to follow-up (56 subjects) and adverse events (18 subjects). As a result, the FDA may require that we conduct additional Phase II trials or increase enrollment in our planned Phase III clinical program for TWIN to support an NDA filing for regulatory approval of TWIN. The discontinuation of patients in any one of our trials may cause us to delay or abandon our clinical trial, or cause the results from that trial not to be positive or sufficient to support a filing for regulatory approval of the applicable product candidate. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">22</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">There is a substantial risk of product liability claims in our business. We currently do not maintain product liability insurance and a product liability claim against us would adversely affect our business. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Our business exposes us to significant potential product liability risks that are inherent in the development, manufacturing and marketing of our product candidates. Product liability claims could delay or prevent completion of our development programs. If we succeed in commercializing our product candidates, such claims could result in a recall of our product candidates or a change in the approved indications for which they may be used. While we intend to purchase and maintain product liability insurance that we believe is adequate for our operations upon commercialization of our product candidates, such coverage may not be adequate to cover any incident or all incidents. Furthermore, product liability insurance is becoming increasingly expensive. As a result, we may be unable to maintain sufficient insurance at a reasonable cost to protect us against losses that could have a material adverse effect on our business. These liabilities could prevent or interfere with our product development and commercialization efforts. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">If the FDA does not conclude that our product candidates for which we intend to seek approval under Section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act satisfy the requirements of the Section 505(b)(2) regulatory approval pathway, or if the requirements for such product candidates under Section 505(b)(2) are not as we expect, the approval pathway for those product candidates will likely take significantly longer, cost significantly more and entail significantly greater complications and risks than anticipated, and in all cases may not be successful. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We are developing product candidates for which we intend to seek FDA approval through the Section 505(b)(2) regulatory pathway. The Drug Price Competition and Patent Term Restoration Act of 1984, also known as the Hatch-Waxman Act, added Section 505(b)(2) to the FDCA. Section 505(b)(2) permits the filing of an NDA where at least some of the information required for approval comes from studies that were not conducted by or for the applicant and for which the applicant has not obtained a right of reference. Section 505(b)(2), if applicable to us under the FDCA, would allow an NDA we submit to the FDA to rely in part on data in the public domain or the FDA&#8217;s prior conclusions regarding the safety and effectiveness of approved drugs, which could expedite the development program for our product candidates by potentially decreasing the amount of clinical data that we would need to generate in order to obtain FDA approval. If the FDA does not allow us to pursue the Section 505(b)(2) regulatory pathway as anticipated, we may need to conduct additional clinical trials, provide additional data and information, and meet additional standards for regulatory approval. If this were to occur, the time and financial resources required to obtain FDA approval for these product candidates, and complications and risks associated with these product candidates, would likely substantially increase. Moreover, any inability to pursue the Section 505(b)(2) regulatory pathway may result in new competitive products reaching the market more quickly than our product candidates, which would likely materially adversely impact our competitive position and prospects. Even if we are allowed to pursue the Section 505(b)(2) regulatory pathway, our product candidates may not receive the requisite approvals for commercialization. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In addition, notwithstanding the approval of a number of products by the FDA under Section 505(b)(2) over the last few years, certain brand-name pharmaceutical companies and others have objected to the FDA&#8217;s interpretation of Section 505(b)(2). If the FDA&#8217;s interpretation of Section 505(b)(2) is successfully challenged, the FDA may change its 505(b)(2) policies and practices, which could delay or even prevent the FDA from approving any NDA that we submit under Section 505(b)(2). In addition, the pharmaceutical industry is highly competitive, and Section 505(b)(2) NDAs are subject to special requirements designed to protect the patent rights of sponsors of previously approved drugs that are referenced in a Section 505(b)(2) NDA. These requirements may give rise to patent litigation and mandatory delays in approval of our NDAs for up to 30 months or longer depending on the outcome of any litigation. It is not uncommon for a manufacturer of an approved product to file a citizen petition with the FDA seeking to delay approval of, or impose additional approval requirements for, pending competing products. If </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">23</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">successful, such petitions can significantly delay, or even prevent, the approval of the new product. However, even if the FDA ultimately denies such a petition, the FDA may substantially delay approval while it considers and responds to the petition. In addition, even if we are able to utilize the Section 505(b)(2) regulatory pathway, there is no guarantee this would ultimately lead to accelerated product development or earlier approval. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Even if our branded product candidates or our generic product candidates receive marketing approval, we may continue to face future developmental and regulatory difficulties. In addition, we will be subject to ongoing obligations and continued regulatory review. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Even if we complete clinical testing and receive approval of any of our branded or generic product candidates, the FDA may grant approval contingent on the performance of additional post-approval clinical trials, risk mitigation requirements such as the implementation of Risk Evaluation and Mitigation Strategy, or REMS, and/or surveillance requirements to monitor the safety or efficacy of the product, which could negatively impact us by reducing revenues or increasing expenses, and cause the approved product candidate not to be commercially viable. Absence of long-term safety data may further limit the approved uses of our product candidates, if any. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The FDA also may approve branded product candidates or any of our generic product candidates for a more limited indication or a narrower patient population than we initially request, or may not approve the labeling that we believe is necessary or desirable for the successful commercialization of our product candidates. Furthermore, any such approved product will remain subject to extensive regulatory requirements, including requirements relating to manufacturing, labeling, packaging, adverse event reporting, storage, advertising, promotion, distribution and recordkeeping. These requirements include registration with the FDA, listing of our product candidates, payment of annual fees, as well as continued compliance with GCP requirements for any clinical trials that we conduct post-approval. Application holders must notify the FDA, and depending on the nature of the change, obtain FDA pre-approval for product manufacturing changes. In addition, manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP requirements. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">If we fail to comply with the regulatory requirements of the FDA or previously unknown problems with any approved commercial products, manufacturers or manufacturing processes are discovered, we could be subject to administrative or judicially imposed sanctions or other setbacks, including the following: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the FDA could suspend or impose restrictions on operations, including costly new manufacturing requirements; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the FDA could refuse to approve pending applications or supplements to applications; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the FDA could suspend any ongoing clinical trials; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the FDA could suspend or withdraw marketing approval; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the FDA could seek an injunction or impose civil or criminal penalties or monetary fines; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the FDA could ban or restrict imports and exports; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the FDA could issue warning letters or untitled letters or similar enforcement actions alleging noncompliance with regulatory requirements; or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the FDA or other governmental authorities could take other actions, such as imposition of product seizures or detentions, clinical holds or terminations, refusals to allow the import or export of products, disgorgement, restitution, or exclusion from federal healthcare programs. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">24</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In addition, if our branded product candidates or any of our other product candidates are approved, our product labeling, advertising and promotional materials would be subject to regulatory requirements and continuing review by the FDA. The FDA strictly regulates the promotional claims that may be made about prescription products. In particular, a product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling, a practice known as off-label promotion. If we receive marketing approval for any of our branded product candidates or any of our generic product candidates, physicians may nevertheless prescribe the products to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability and government fines. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant sanctions. The federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees of permanent injunctions under which specified promotional conduct is changed or curtailed. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Moreover, the FDA&#8217;s policies may change and additional government regulations may be enacted that could prevent, limit or delay marketing approval, and the sale and promotion of our branded product candidates or any of our other product candidates, if approved. For example, in December 2016, the 21th century Cures Act, or Cures Act, was signed into law. The Cures Act, among other things, is intended to modernize the regulation of drugs and spur innovation, but its ultimate implementation is unclear. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability. In addition, costs arising out of any regulatory developments could be time-consuming and expensive and could divert management resources and attention and, consequently, could adversely affect our business operations and financial performance. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, certain policies of the Trump administration may impact our business and industry. The Trump administration has taken several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, the FDA&#8217;s ability to engage in routine regulatory and oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. Notably, on January 30, 2017, President Trump issued an Executive Order, applicable to all executive agencies, including the FDA, that requires that for each notice of proposed rulemaking or final regulation to be issued in fiscal year 2017, the agency shall identify at least two existing regulations to be repealed, unless prohibited by law. These requirements are referred to as the &#8220;two-for-one&#8221; provisions. This Executive Order includes a budget neutrality provision that requires the total incremental cost of all new regulations in the 2017 fiscal year, including repealed regulations, to be no greater than zero, except in limited circumstances. For fiscal years 2018 and beyond, the Executive Order requires agencies to identify regulations to offset any incremental cost of a new regulation and approximate the total costs or savings associated with each new regulation or repealed regulation. In interim guidance issued by the Office of Information and Regulatory Affairs within OMB on February 2, 2017, the administration indicates that the &#8220;two-for-one&#8221; provisions may apply not only to agency regulations, but also to significant agency guidance documents. It is difficult to predict how these requirements will be implemented, and the extent to which they will impact the FDA&#8217;s ability to exercise its regulatory authority. If these executive actions impose constraints on the FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">25</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Even if our branded product candidates or our other product candidates receive regulatory approval, they may fail to achieve the broad degree of physician adoption and market acceptance necessary for commercial success. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Even if we obtain FDA approvals for our branded product candidates or any of our generic product candidates, the commercial success of such products will depend significantly on their broad adoption by dermatologists, pediatricians and other physicians for approved indications and other therapeutic or aesthetic indications that we may seek to pursue if approved. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The degree and rate of physician and patient adoption of our branded product candidates and any of our generic product candidates, if approved, will depend on a number of factors, including: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the clinical indications for which the product is approved; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the safety and efficacy of our product as compared to existing therapies for those indications; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:10.18pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:10.18pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the prevalence and severity of adverse side effects; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:10.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:10.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">patient satisfaction with the results and administration of our product and overall treatment experience, including relative convenience, ease of use and avoidance of, or reduction in, adverse side effects; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:10.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:10.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">patient demand for the treatment of acne and rosacea or other indications;</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:10.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:10.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the cost of treatment in relation to alternative treatments, the extent to which these costs are reimbursed by third-party payors, and patients&#8217; willingness to pay for our product candidates; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:10.18pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:10.18pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the effectiveness of our sales and marketing efforts, including any head-to-head studies, if conducted, especially the success of any targeted marketing efforts directed toward dermatologists, pediatricians, other physicians, clinics and any direct-to-consumer marketing efforts we may initiate. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We expend a significant amount of resources on research and development efforts that may not lead to successful product candidate introductions or the recovery of our research and development expenditures. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We conduct research and development primarily to enable us to manufacture and market topical dermatological creams containing drugs in accordance with FDA regulations as well as other regulatory authorities. We spent approximately $7.2 million and $17.0 million on research and development activities during the years ended December&#160;31, 2015 and 2016, respectively. We are required to obtain FDA approval before marketing our product candidates in the United States. The FDA approval process is costly, time consuming and inherently risky. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We cannot be certain that any investment made in developing product candidates will be recovered, even if we are successful in commercialization. To the extent that we expend significant resources on research and development efforts and are not able to introduce successful new product candidates as a result of those efforts, we will be unable to recover those expenditures. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our clinical trials for our branded product candidates were not, and will not be, conducted head-to-head with the applicable leading products of our competitors, and the comparison of our results to those of existing drugs, and the conclusions we have drawn from such comparisons, may be inaccurate. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Our clinical trials for branded product candidates were not, and will not be, conducted head-to-head with the drugs considered the applicable standard of care for the relevant indications. This means that none of the patient groups participating in these trials were, and will not in the future be, treated with the applicable standard of care drugs alongside the groups treated </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">26</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">with our product candidates. Instead, we have compared and plan to continue comparing the results of our clinical trials with historical data from prior clinical trials conducted by third parties for the applicable standard of care drugs, and which results are presented in their respective product labels. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Direct comparison generally provides more reliable information about how two or more drugs compare, and reliance on indirect comparison for evaluating their relative efficacy or other qualities is problematic due to lack of objective or validated methods to assess trial similarity. For example, the various trials were likely conducted in different countries with different demographic features and in patients with different baseline conditions and different hygiene standards, among other relevant asymmetries. Therefore, the conclusions we have drawn from comparing the results of our clinical trials with those published in the product labels for these current standard of care drugs, including conclusions regarding the relative efficacy and expediency of our branded product candidates, may be distorted by the inaccurate methodology of the comparison. Moreover, the FDA generally requires head-to-head studies to make labeling and advertising claims regarding superiority or comparability, and our failure to collect head-to-head data may limit the types of claims we may make for our product candidates, if approved. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We may be subject to risk as a result of international manufacturing operations. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Certain of our product candidates may be manufactured at third-party facilities located in Canada and New Zealand, in addition to our facility in Israel, and therefore our operations are subject to risks inherent in doing business internationally. Such risks include the adverse effects on operations from corruption, war, international terrorism, civil disturbances, political instability, governmental activities, deprivation of contract and property rights and currency valuation changes. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">If in the future we acquire or in-license technologies or additional product candidates, we may incur various costs, may have integration difficulties and may experience other risks that could harm our business and results of operations. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In the future, we may acquire or in-license additional product candidates and technologies. Any product candidate or technologies we in-license or acquire will likely require additional development efforts prior to commercial sale, including extensive pre-clinical studies, clinical trials, or both, and approval by the FDA or other applicable foreign regulatory authorities, if any. All product candidates are prone to risks of failure inherent in pharmaceutical product development, including the possibility that the product candidate, or product developed based on in-licensed technology, will not be shown to be sufficiently safe and effective for approval by regulatory authorities. If intellectual property related to product candidates or technologies we in-license or our own know-how is not adequate, we may not be able to commercialize the affected product candidates even after expending resources on their development. In addition, we may not be able to manufacture economically or successfully commercialize any product candidate that we develop based on acquired or in-licensed technology that is granted regulatory approval, and such product candidates may not gain wide acceptance or be competitive in the marketplace. Moreover, integrating any newly acquired or in-licensed product candidates could be expensive and time-consuming. If we cannot effectively manage these aspects of our business strategy, our business may not succeed. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">The time necessary to develop generic API or drug products may adversely affect whether, and the extent to which, we receive a return on our capital. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The development process, including drug formulation where applicable, testing, and FDA review and approval for generic drug products often takes many years. This process requires that we expend considerable capital to pursue activities that do not yield an immediate or near-term return. Also, because of the significant time necessary to develop a generic product, the actual market for a generic product at the time it is available for sale may be significantly less than the originally projected market for the generic product. If this were to occur, our potential return on </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">27</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">our investment in developing the generic product, if approved for marketing by the FDA, would be adversely affected and we may never receive a return on our investment in the generic product. It is also possible for the manufacturer of the brand-name product for which we are developing a generic drug to obtain approvals from the FDA to switch the brand-name drug from the prescription market to the over-the-counter, or OTC market. If this were to occur, we would be prohibited from marketing our generic product other than as an OTC drug, in which case our revenues could be significantly impacted. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Risks Related to Regulatory Matters </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">If we do not comply with laws regulating the protection of the environment and health and human safety, our business could be adversely affected. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Our research and development and manufacturing involve the use of hazardous materials and chemicals and related equipment. If an accident occurs, we could be held liable for resulting damages, which could be substantial. We are also subject to numerous environmental, health and workplace safety laws and regulations, including those governing laboratory procedures and the handling of biohazardous materials. We do not maintain insurance for environmental liability claims that may be asserted against us. Moreover, additional foreign and local laws and regulations affecting our operations may be adopted in the future. We may incur substantial costs to comply with such regulations and pay substantial fines or penalties if we violate any of these laws or regulations. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">With respect to environmental, safety and health laws and regulations, we cannot accurately predict the outcome or timing of future expenditures that we may be required to make in order to comply with such laws as they apply to our operations and facilities. We are also subject to potential liability for the remediation of contamination associated with both present and past hazardous waste generation, handling, and disposal activities. We will be periodically subject to environmental compliance reviews by environmental, safety, and health regulatory agencies. Environmental laws are subject to change and we may become subject to stricter environmental standards in the future and face larger capital expenditures in order to comply with environmental laws which could have a material adverse effect on our business. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Healthcare reform in the United States may harm our future business. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Healthcare costs in the United States have risen significantly over the past decade. In March&#160;2010, the &#8220;Patient Protection and Affordable Care Act,&#8221; as amended by the &#8220;Health Care and Education Reconciliation Act,&#8221; collectively referred to as the Affordable Care Act, was signed into law, which, among other things, required most individuals to have health insurance, established new regulations on health plans, created insurance exchanges and imposed new requirements and changes in reimbursement or funding for healthcare providers, device manufacturers and pharmaceutical companies. The Affordable Care Act also included a number of changes which may impact our product candidates, if approved: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">revisions to the Medicaid rebate program by: (a) increasing the rebate percentage for branded drugs to 23.1% of the average manufacturer price, or AMP, with limited exceptions, (b) increasing the rebate for outpatient generic, multiple source drugs dispensed to 13% of AMP; (c) changing the definition of AMP; and (d) extending the Medicaid rebate program to Medicaid managed care plans, with limited exceptions; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the imposition of annual fees upon manufacturers or importers of branded prescription drugs, which fees will be in amounts determined by the Secretary of Treasury based upon market share and other data; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">providing a 50% discount on brand-name prescriptions filled in the Medicare Part D coverage gap beginning in 2011; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">28</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">imposing increased penalties for the violation of fraud and abuse laws and funding for anti-fraud activities; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.01pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">creating a new pathway for approval of biosimilar biological products and granting an exclusivity period of 12 years for branded drug manufacturers of biological products before biosimilar products can be approved for marketing in the United States; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.01pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">expanding the definition of&#8201; &#8220;covered entities&#8221; that purchase certain outpatient drugs in the 340B Drug Pricing Program of Section 340B of the Public Health Service Act. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">While the Affordable Care Act may have increased the number of patients who have insurance coverage for our product candidates, if approved by the FDA, the Affordable Care Act also restructured payments to Medicare managed care plans and reduced reimbursement to many institutional providers. Accordingly, the timing of the insurance mandate, the change in the Medicaid rebate levels, the additional fees imposed upon us if we market branded drugs, other compliance obligations, and the reduced reimbursement levels to institutional providers may result in a loss of revenue and could adversely affect our business. In addition, the Affordable Care Act contemplates the promulgation of significant future regulatory action which may also further affect our business. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Since its enactment, there have been judicial and Congressional challenges to certain aspects of the Affordable Care Act. The new Presidential Administration and U.S. Congress have attempted and will likely continue to seek to modify, repeal, or otherwise invalidate all, or certain provisions of, the Affordable Care Act. It is uncertain the extent to which any such changes may impact our business or financial condition. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Moreover, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. On August&#160;2, 2011, the Budget Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions was signed into law. The Joint Select Committee did not achieve a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, triggering the legislation&#8217;s automatic reduction to several government programs. This included reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April&#160;1, 2013, and will remain in effect through 2025 unless additional Congressional action is taken. On January&#160;2, 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several providers, including hospitals, imaging centers and cancer treatment centers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Recently there has also been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed bills designed to, among other things, reform government program reimbursement methodologies. Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates, if approved, or additional pricing pressure. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Risks Related to Commercialization of Our Product Candidates </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our continued growth is dependent on our ability to successfully develop and commercialize new product candidates in a timely manner. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Our financial results depend upon our ability to introduce and commercialize additional product candidates in a timely manner. Generally, revenue from new products is highest immediately following launch and then declines over time, as new competitors enter the market. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">29</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">Furthermore, the greatest revenue is generally experienced by the company that is able to bring its product to the market first. Our growth is therefore dependent upon our ability to successfully introduce and commercialize new product candidates. </div>
        <div style="text-indent:20pt; margin-top:6.02pt; width:456pt; line-height:12pt;">The FDA and other regulatory authorities may not approve our product applications at all or in a timely fashion for our product candidates under development. Additionally, we may not successfully complete our development efforts for other reasons, such as poor results in clinical trials or a lack of funding to complete the required trials. Even if the FDA approves our product candidates, we may not be able to market them successfully or profitably. Our future results of operations will depend significantly upon our ability to timely develop, receive FDA approval for, and market new pharmaceutical product candidates or otherwise develop new product candidates or acquire the rights to other products. </div>
        <div style="margin-top:10.03pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our product candidates, if approved, will face significant competition and our failure to compete effectively may prevent us from achieving significant market penetration and expansion. </div>
        <div style="text-indent:20pt; margin-top:5.02pt; width:456pt; line-height:12pt;">The facial aesthetic market in general, and the market for acne and rosacea treatments in particular, are highly competitive and dynamic, and characterized by rapid and substantial technological development and product innovations. These markets are also characterized by competitors obtaining patents to protect what they consider to be their intellectual property. We anticipate that TWIN, SIRS-T and VERED, if approved, will face significant competition from other approved products, including topical drugs, topical anti-acne drugs such as Acanya, Ziana, Epiduo, Epiduo Forte, Benzaclin, Aczone, Onexton and Differin and topical drugs for the treatment of rosacea such as Metrogel, Finacea and Soolantra, oral drugs such as Solodyn, Doryx, Dynacin and Minocin. If approved, TWIN, SIRS-T and VERED may also compete with non-prescription anti-acne products, as well as unapproved and off-label treatments. In addition, if approved, TWIN may compete with drug products utilizing other technologies that can separate two drug substances, such as dual chamber tubes, dual pouches or dual sachets. To compete successfully in the facial aesthetic market, we will have to demonstrate that our product is safe and effective for the respective treatment and has advantages over existing therapies. Competing in the facial aesthetic market could result in price-cutting, reduced profit margins and loss of market share, any of which would harm our business, financial condition and results of operations. </div>
        <div style="text-indent:20pt; margin-top:6.02pt; width:456pt; line-height:12pt;">Due to less stringent regulatory requirements in certain jurisdictions outside the United States, there are many more acne products and procedures available for use in those international markets than are approved for use in the United States. There are also fewer limitations on the claims that our competitors in international markets can make about the effectiveness of their products and the manner in which they can market them. As a result, we may face more competition in markets outside of the United States. </div>
        <div style="text-indent:20pt; margin-top:6.02pt; width:456pt; line-height:12pt;">In addition, even if we are able to commercialize our product candidates, we may not be able to price them competitively with the current standards of care or other competing products for their respective indications or their price may drop considerably due to factors outside our control. If this happens or the price of materials and the cost to manufacture our product candidates increases dramatically, our ability to continue to operate our business would be materially harmed and we may be unable to commercialize our product candidates successfully. </div>
        <div style="text-indent:20pt; margin-top:6.03pt; width:456pt; line-height:12pt;">We believe that our principal competitors are Valeant Pharmaceuticals International, Inc., Galderma S.A., Allergan plc, Bayer HealthCare AG and Mylan N.V. These competitors are large and experienced companies that enjoy significant competitive advantages over us, such as greater financial, research and development, manufacturing, personnel and marketing resources, greater brand recognition, and more experience and expertise in obtaining marketing approvals from the FDA and foreign regulatory authorities. </div>
        <div style="text-indent:20pt; margin-top:6.02pt; width:456pt; line-height:12pt;">In addition to the above listed competitors, some of our product candidates might face internal competition with other product candidates of ours, for the same markets and patient populations, due to overlap in the required treatment and/or symptoms. For example, TWIN may compete with SIRS-T for treatment of acne and VERED may compete with ivermectin cream, 1%, for treatment of rosacea. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">30</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">With respect to generic pharmaceutical products, the FDA approval process often results in the FDA granting final approval to a number of ANDAs for a given product at the time a relevant patent for a corresponding branded product or other regulatory and/or market exclusivity expires. For example, on December 30, 2016, Actavis Ltd. submitted an ANDA for ivermectin, 1%, cream, and therefore we will only be able to commercialize this product after Actavis Ltd.&#8217;s six month exclusivity period expires. Thus, we expect, in accordance with the standard practices in the industry, to face immediate competition when we introduce a generic product into the market. As competition from other manufacturers intensifies, selling prices and gross profit margins often decline. Accordingly, the level of market share, revenue and gross profit attributable to a particular generic product that we develop is generally related to the number of competitors in that product&#8217;s market and the timing of that product&#8217;s regulatory approval and launch, in relation to competing approvals and launches. Additionally, ANDA approvals often continue to be granted for a given product subsequent to the initial launch of the generic product. These circumstances generally result in significantly lower prices and reduced margins for generic products compared to brand products. New generic market entrants generally cause continued price and margin erosion over the generic product life cycle. </div>
        <div style="text-indent:20pt; margin-top:6.02pt; width:456pt; line-height:12pt;">In addition to the competition we face from other generic manufacturers, we face competition from brand-name manufacturers related to our generic product candidates. Branded pharmaceutical companies may sell their branded products as &#8220;authorized generics&#8221; (an industry term that describes instances when an approved brand name drug is marketed, either by the brand name drug company, or by another company with the brand company&#8217;s permission, as a generic product without the brand name on its label, and potentially sold at a lower price than the brand name drug). Further, branded pharmaceutical companies may seek to delay FDA approval of our ANDAs or reduce generic competition by, for example, obtaining new patents on drugs whose original patent protection is about to expire, filing patent infringement suits that could delay FDA approval of generics, developing new versions of their products to obtain FDA market exclusivity, filing &#8220;citizen petitions&#8221; contesting FDA approvals of generics such as on alleged health and safety grounds, developing &#8220;next generation&#8221; versions of products that reduce demand for generic versions we are developing, changing product claims and labeling, and seeking approval to market as OTC branded products. </div>
        <div style="text-indent:20pt; margin-top:6.03pt; width:456pt; line-height:12pt;">Moreover, competitors may, upon the approval of an NDA, or an NDA supplement, obtain a three-year period of exclusivity for a particular condition of approval, or change to a marketed product, such as a new formulation for a previously approved product, if one or more new clinical trials (other than bioavailability or bioequivalence studies) was essential to the approval of the application and was conducted/sponsored by the applicant. Such exclusivity may prevent the FDA from approving one or more of our product candidates that are being developed, and for which we would seek the FDA&#8217;s approval under the 505(b)(2) regulatory pathway, if we were to seek approval for the same conditions of approval as that protected by the three-year period of exclusivity. Recent litigation against the FDA has affirmed the FDA&#8217;s interpretation of the scope of three-year exclusivity as preventing the approval of a 505(b)(2) NDA for the same change to a previously approved drug, regardless of whether or not the 505(b)(2) applicant relies on the competitor&#8217;s product as a listed drug in its 505(b)(2) application. Exclusivity determinations are highly fact-dependent and are made by the FDA on a case-by-case basis at the end of the review period for a 505(b)(2) NDA. As such, we may not know until very late in the FDA&#8217;s review of our 505(b)(2) product candidates whether or not approval may be delayed because of a competitor&#8217;s period of three-year exclusivity. </div>
        <div style="margin-top:9.02pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Other pharmaceutical companies may develop competing products for acne, rosacea and other indications we are pursuing and enter the market ahead of us. </div>
        <div style="text-indent:20pt; margin-top:5.03pt; width:456pt; line-height:12pt;">Other pharmaceutical companies are engaged in developing, patenting, manufacturing and marketing healthcare products that compete with those that we are developing. These potential competitors include large and experienced companies that enjoy significant competitive advantages over us, such as greater financial, research and development, manufacturing, personnel and marketing resources, greater brand recognition and more experience and expertise in obtaining marketing approvals from the FDA and foreign regulatory authorities. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">31</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Several of these potential competitors are privately-owned companies that are not bound by public disclosure requirements and closely guard their development plans, marketing strategies and other trade secrets. Publicly-traded pharmaceutical companies are also able to maintain a certain degree of confidentiality over their pipeline developments and other sensitive information. As a result, we do not know whether these potential competitors are already developing, or plan to develop other topical treatments for acne, rosacea or other indications we are pursuing, and we will likely be unable to ascertain whether such activities are underway in the future. These potential competitors may therefore introduce competing products without our prior knowledge and without our ability to take preemptive measures in anticipation of their commercial launch. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Furthermore, such potential competitors may enter the market before us, and their products may be designed to circumvent our granted patents and pending patent applications. They may also challenge, narrow or invalidate our granted patents or our patent applications, and such patents and patent applications may fail to provide adequate protection for our product candidates. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We currently have limited marketing capabilities and no sales organization. If we are unable to establish sales and marketing capabilities on our own or through third parties, we will be unable to successfully commercialize TWIN, VERED or any other of our other product candidates, if approved, or generate product revenues. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We currently have limited marketing capabilities and no sales organization. To commercialize TWIN, VERED or any other of our other product candidates, if approved, in the United States and other jurisdictions we may seek to enter, we must build our marketing, sales, distribution, managerial and other non-technical capabilities or make arrangements with third parties to perform these services, and we may not be successful in doing so. For instance, if TWIN and VERED receive regulatory approval from the FDA, we intend to market them in the United States through a specialized internal sales force or a combination of our internal sales force and distributors, which will be expensive and time-consuming. Alternatively, we may choose to collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. If we are unable to enter into such arrangements on acceptable terms or at all, we may not be able to successfully commercialize TWIN, VERED or any of our other product candidates. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">There are significant risks involved in building and managing a sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of our product candidates. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">If we are not successful in establishing sufficient sales and marketing capabilities to commercialize TWIN, VERED or any of our other product candidates, either on our own or through collaborations with one or more third parties, our revenues will suffer and we will incur significant additional losses. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Third-party payor coverage and adequate reimbursement may not be available for our product candidates, if approved, which could make it difficult for us to sell them profitably. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Sales of our product candidates, if approved, will depend, in part, on the extent to which the costs of our product candidates will be covered by third-party payors, such as government health programs, private health insurers and managed care organizations. Third-party payors generally decide which drugs they will cover and establish certain reimbursement levels for such drugs. In particular, in the United States, private health insurers and other third-party payors often provide reimbursement for products and services based on the level at which the government (through the Medicare or Medicaid programs) provides reimbursement for such treatments. Patients who are </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">32</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use our product candidates unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our product candidates. Sales of our product candidates, and any future product candidates, will therefore depend substantially on the extent to which the costs of our product candidates, and any future product candidates, will be paid by third-party payors. Additionally, the market for our product candidates, and any future product candidates, will depend significantly on access to third-party payors&#8217; formularies without prior authorization, step therapy, or other limitations such as approved lists of treatments for which third-party payors provide coverage and reimbursement. Additionally, coverage and reimbursement for therapeutic products can differ significantly from payor to payor. One third-party payor&#8217;s decision to cover a particular medical product or service does not ensure that other payors will also provide coverage for the medical product or service, or will provide coverage at an adequate reimbursement rate. As a result, the coverage determination process will require us to provide scientific and clinical support for the use of our product candidates to each payor separately and will be a time-consuming process. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Third-party payors are developing increasingly sophisticated methods of controlling healthcare costs and increasingly challenging the prices charged for medical products and services. Additionally, the containment of healthcare costs has become a priority of federal and state governments and the prices of drugs have been a focus in this effort. The United States government, state legislatures and foreign governments have shown significant interest in implementing cost-containment programs, including price controls and transparency requirements, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could limit our revenue and operating results. If these third-party payors do not consider our product candidates to be cost-effective compared to other therapies, they may not cover our product candidates once approved as a benefit under their plans or, if they do, the level of reimbursement may not be sufficient to allow us to sell our product candidates on a profitable basis. Decreases in third-party reimbursement for our product candidates once approved or a decision by a third-party payor to not cover our product candidates could reduce or eliminate utilization of our product candidates and have an adverse effect on our sales, results of operations and financial condition. In addition, state and federal healthcare reform measures have been and may be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates once approved or additional pricing pressures. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our current and future relationships with investigators, health care professionals, consultants, third-party payors, and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors and customers, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our product candidates for which we obtain marketing approval. Such laws include: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the federal Anti-Kickback Statute prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or service, for which payment may be made, in whole or in part, under a federal healthcare program such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">33</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-left:40pt; width:416pt; line-height:12pt;">in order to have committed a violation; in addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act; </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the federal false claims laws, including the civil False Claims Act, impose criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, claims for payment that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government; in addition, the government may assert that a claim including items and services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the civil False Claims Act; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or making false or fraudulent statements relating to healthcare matters; similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and its implementing regulations, also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the federal Physician Payment Sunshine Act, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to the government information related to certain payments or other &#8220;transfers of value&#8221; made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, and requires applicable manufacturers and group purchasing organizations to report annually to the government ownership and investment interests held by the physicians described above and their immediate family members and payments or other &#8220;transfers of value&#8221; to such physician owners. Covered manufacturers are required to submit reports to the government by the 90<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">th</font> day of each calendar year; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to our business practices, including but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; and state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or that require the reporting of pricing information and marketing expenditures; and state and foreign laws governing the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Efforts to ensure that our current and future business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">34</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">healthcare laws. If our operations are found to be in violation of any of these or any other health regulatory laws that may apply to us, we may be subject to significant penalties, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgement, individual imprisonment, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs or similar programs in other countries or jurisdictions, contractual damages, reputational harm, diminished profits and future earnings, and curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. Defending against any such actions can be costly, time-consuming and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">The illegal distribution and sale by third parties of counterfeit versions of our product candidates or of stolen products could have a negative impact on our reputation and a material adverse effect on our business, results of operations and financial condition. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Third parties could illegally distribute and sell counterfeit versions of our product candidates, which do not meet the rigorous manufacturing and testing standards that our product candidates undergo. Counterfeit products are frequently unsafe or ineffective, and can be life-threatening. Counterfeit medicines may contain harmful substances, the wrong dose of the active pharmaceutical ingredient or no active pharmaceutical ingredient at all. However, to distributors and users, counterfeit products may be visually indistinguishable from the authentic version. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Reports of adverse reactions to counterfeit drugs similar to our product candidates or increased levels of counterfeiting such products could materially affect physician and patient confidence in our authentic product candidates. It is possible that adverse events caused by unsafe counterfeit products will mistakenly be attributed to our authentic product candidates. In addition, thefts of our inventory at warehouses, plant or while in-transit, which are not properly stored and which are sold through unauthorized channels could adversely impact patient safety, our reputation and our business. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Public loss of confidence in the integrity of our pharmaceutical products as a result of counterfeiting or theft could have a material adverse effect on our business, financial position and results of operations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Risks Related to Dependence on Third Parties </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Any collaborative arrangements that we have or may establish in the future may not be successful or we may otherwise not realize the anticipated benefits from these collaborations. We do not control third parties with whom we have or may have collaborative arrangements, and we will rely on them to achieve results which may be significant to us. In addition, any current or future collaborative arrangements may place the development and commercialization of our product candidates outside our control, may require us to relinquish important rights or may otherwise be on terms unfavorable to us. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We are currently party to collaborative arrangements with respect to the development, manufacture, study and commercialization of certain of our product candidates including arrangements with Perrigo and Douglas Pharmaceuticals. Any current or future potential collaborative arrangements may require us to rely on external consultants, advisors, and experts for assistance in several key functions, including clinical development, manufacturing, regulatory and intellectual property. We cannot and will not control these third parties, but we may rely on them to achieve results, which may be significant to us. Relying upon collaborative arrangements to develop and commercialize our product candidates subjects us to a number of risks, including: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">we may not be able to control the amount and timing of resources that our collaborators may devote to our product candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">35</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">should a collaborator fail to comply with applicable laws, rules, or regulations when performing services for us, we could be held liable for such violations; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">our current or future collaborators may experience financial difficulties or changes in business focus; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">our current or future collaborators&#8217; partners may fail to secure adequate commercial supplies of our product candidates upon marketing approval, if at all; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">our current or future collaborators&#8217; partners may have a shortage of qualified personnel; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">we may be required to relinquish important rights, such as marketing and distribution rights; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">business combinations or significant changes in a collaborator&#8217;s business strategy may adversely affect a collaborator&#8217;s willingness or ability to complete its obligations under any arrangement; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">under certain circumstances, a collaborator could move forward with a competing product developed either independently or in collaboration with others, including our competitors; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">our current or future collaborators may utilize our proprietary information in a way that could expose us to competitive harm; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">collaborative arrangements are often terminated or allowed to expire, which could delay the development and may increase the cost of developing our product candidates. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In addition, if disputes arise between us and our collaborators, it could result in the delay or termination of the development, manufacturing or commercialization of our product candidates, lead to protracted and costly legal proceedings, or cause collaborators to act in their own interest, which may not be in our interest. As a result, there can be no assurance that the collaborative arrangements that we have entered into, or may enter into in the future, will achieve their intended goals. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">If any of these scenarios materialize, they could have an adverse effect on our business, financial condition or results of operations. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We also may have other product candidates where it is desirable or essential to enter into agreements with a collaborator who has greater financial resources or different expertise than us, but for which we are unable to find an appropriate collaborator or are unable to do so on favorable terms. If we fail to enter into such collaborative agreements on favorable terms, it could materially delay or impair our ability to develop and commercialize our product candidates and increase the costs of development and commercialization of such product candidates. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We currently contract with third-party manufacturers and suppliers for certain compounds and components necessary to produce our product candidates for clinical trials and expect to continue to do so to support commercial scale production, if any, of our product candidates is approved. This increases the risk that if any of our product candidates are approved, we may not have access to sufficient quantities or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We currently rely on third parties for the manufacture and supply of certain compounds and components necessary to produce our product candidates for our clinical trials, including API&#8217;s such as benzoyl peroxide and tretinoin and other active ingredients and excipients used in the formulation of our various product candidates, as well as primary and secondary packaging and labeling materials. We lack the resources and the capability to manufacture any of our product </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">36</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">candidates on a clinical or commercial scale, and we expect to continue to rely on third parties to support our commercial requirements if any of our product candidates is approved for marketing by the FDA or other foreign regulatory authorities. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The facilities used by our contract manufacturers to manufacture our product candidates must be approved by the FDA pursuant to inspections that will be conducted after we submit our marketing applications to the FDA. We do not control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with the regulatory requirements, known as current good manufacturing practices, or cGMPs, for manufacture of both active drug substances and finished drug products. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, they will not be able to secure and/or maintain regulatory approval for their manufacturing facilities. In addition, we have no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Reliance on third-party manufacturers and suppliers entails a number of risks, including reliance on the third party for regulatory compliance and quality assurance, the possible breach of the manufacturing or supply agreement by the third party, the possibility that the supply is inadequate or delayed, the risk that the third party may enter the field and seek to compete and may no longer be willing to continue supplying, and the possible termination or nonrenewal of the agreement by the third party at a time that is costly or inconvenient for us. If any of these risks transpire, we may be unable to timely retain an alternate manufacturer or suppliers on acceptable terms and with sufficient quality standards and production capacity, which may disrupt and delay our clinical trials or the manufacture and commercial sale of our product candidates, if approved. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Our failure or the failure of our third-party manufacturers and suppliers to comply with applicable regulations could result in sanctions being imposed on us, including fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our product candidates that we may develop. Any failure or refusal to supply or any interruption in supply of the components for any of our product candidates could delay, prevent or impair our clinical development or commercialization efforts. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We rely on third parties and consultants to assist us in conducting our clinical trials. If these third parties or consultants do not successfully carry out their contractual duties or meet expected deadlines, we may be unable to obtain regulatory approval for or commercialize our product candidates and our business could be substantially harmed. </div>
        <div style="text-indent:20pt; margin-top:7.61pt; width:456pt; line-height:12pt;">We do not have the ability to independently perform all aspects of our anticipated pre-clinical studies and clinical trials. We rely on medical institutions, clinical investigators, contract laboratories, collaborative partners and other third parties to assist us in conducting our clinical trials and studies for our product candidates. The third parties with whom we contract for execution of our clinical trials play a significant role in the conduct of these trials and the subsequent collection and analysis of data. However, these third parties are not employees, and except for contractual duties and obligations, we have limited ability to control the amount or timing of resources that they devote to our programs. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In addition, the execution of pre-clinical studies and clinical trials, and the subsequent compilation and analysis of the data produced, require coordination among these various third parties. In order for these functions to be carried out effectively and efficiently, it is imperative that these parties communicate and coordinate with one another, which may prove difficult to achieve. Moreover, these third parties may also have relationships with other commercial entities, some of which may compete with us. Our agreement with these third parties may inevitably enable them to terminate such agreements upon reasonable prior written notice under certain circumstances. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">37</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Although we rely on these third parties to conduct certain aspects of our clinical trials and other studies and clinical trials, we remain responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on these third parties does not relieve us of our regulatory responsibilities. Moreover, the FDA and foreign regulatory authorities require us to comply with GCPs, which are the regulations and standards for conducting, monitoring, recording and reporting the results of clinical trials to ensure that the data and results are scientifically credible and accurate, and that the trial subjects are adequately informed of the potential risks of participating in clinical trials. We also rely on our consultants to assist us in the execution, including data collection and analysis of our clinical trials. If we or any of our third-party contractors fail to comply with applicable GCPs, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials complies with GCP regulations. In addition, our clinical trials must be conducted with product produced under cGMP regulations. Our failure to comply with these regulations may require us to repeat clinical trials, which would delay the regulatory approval process. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">If the third parties or consultants that assist us in conducting our clinical trials do not perform their contractual duties or obligations, experience work stoppages, do not meet expected deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical trial protocols, regulatory requirements or GCPs, or for any other reason, we may need to conduct additional clinical trials or enter into new arrangements with alternative third parties, which could be difficult, costly or impossible, and our clinical trials may be extended, delayed or terminated or may need to be repeated. If any of the foregoing were to occur, we may not be able to obtain, or may be delayed in obtaining, regulatory approval for the product candidates being tested in such trials, and will not be able to, or may be delayed in our efforts to, successfully commercialize these product candidates. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">The manufacture of pharmaceutical products is complex and manufacturers often encounter difficulties in production. If we or any of our third-party manufacturers encounter any difficulties, our ability to provide product candidates for clinical trials or our product candidates to patients, once approved, and the development or commercialization of our product candidates could be delayed or stopped. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The manufacture of pharmaceutical products is complex and requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. We and our contract manufacturers must comply with cGMP requirements. Manufacturers of pharmaceutical products often encounter difficulties in production, particularly in scaling up and validating initial production and contamination controls. These problems include difficulties with production costs and yields, quality control, including stability of the product, quality assurance testing, operator error, shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. Furthermore, if microbial, viral or other contaminations are discovered in our product candidates or in the manufacturing facilities in which our product candidates are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We cannot assure you that any stability or other issues relating to the manufacture of any of our product candidates will not occur in the future. Additionally, we and our third-party manufacturers may experience manufacturing difficulties due to resource constraints or as a result of labor disputes or unstable political environments. If we or our third-party manufacturers were to encounter any of these difficulties, our ability to provide any product candidates to patients in clinical trials and products to patients, once approved, would be jeopardized. Any delay or interruption in the supply of clinical trial supplies could delay the initiation or completion of clinical trials, increase the costs associated with maintaining clinical trial programs and, </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">38</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">depending upon the period of delay, require us to commence new clinical trials at additional expense or terminate clinical trials completely. Any adverse developments affecting clinical or commercial manufacturing of our product candidates may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls, or other interruptions in the supply of our product candidates. We may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives. Accordingly, failures or difficulties faced at any level of our supply chain could materially adversely affect our business and delay or impede the development and commercialization of any of our product candidates and could have a material adverse effect on our business, prospects, financial condition and results of operations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Risks Related to Our Intellectual Property </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We depend on our intellectual property, and our future success is dependent on our ability to protect our intellectual property and not infringe on the rights of others. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Our success depends, in part, on our ability to obtain patent protection for our product candidates, maintain the confidentiality of our trade secrets and know how, operate without infringing on the proprietary rights of others and prevent others from infringing our proprietary rights. We try to protect our proprietary position by, among other things, filing U.S., European, and other patent applications related to our product candidates, inventions and improvements that may be important to the continuing development of our product candidates. While we generally apply for patents in those countries where we intend to make, have made, use, or sell patented products, we may not accurately predict all of the countries where patent protection will ultimately be desirable. If we fail to timely file a patent application in any such country, we may be precluded from doing so at a later date. In addition, we cannot assure you that: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:10.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:10.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">any of our future processes or product candidates will be patentable; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:10.58pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:10.58pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">our processes or product candidates will not infringe upon the patents of third parties; or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:10.78pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:10.78pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">we will have the resources to defend against charges of patent infringement or other violation or misappropriation of intellectual property by third parties or to protect our own intellectual property rights against infringement, misappropriation or violation by third parties. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Because the patent position of pharmaceutical companies involves complex legal and factual questions, we cannot predict the validity and enforceability of patents with certainty. Changes in either the patent laws or in interpretations of patent laws may diminish the value of our intellectual property. Accordingly, we cannot predict the breadth of claims that may be allowable or enforceable in our patents (including patents owned by or licensed to us). Our issued patents may not provide us with any competitive advantages, may be held invalid or unenforceable as a result of legal challenges by third parties or could be circumvented. Our competitors may also independently develop formulations, processes and technologies or products similar to ours or design around or otherwise circumvent patents issued to, or licensed by, us. Thus, any patents that we own or license from others may not provide any protection against competitors. Our pending patent applications, those we may file in the future or those we may license from third parties may not result in patents being issued. If these patents are issued, they may not be of sufficient scope to provide us with meaningful protection. The degree of future protection to be afforded by our proprietary rights is uncertain because legal means afford relatively limited protection and may not adequately protect our rights or permit us to gain or keep our competitive advantage. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Patent rights are territorial; thus, the patent protection we do have will only extend to those countries in which we have issued patents. Even so, the laws of certain countries do not protect our intellectual property rights to the same extent as do the laws of the United States and the European Union. Therefore, we cannot assure you that the patents issued, if any, as a result of our foreign patent applications will have the same scope of coverage as our U.S. patents. Competitors </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">39</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">may successfully challenge our patents, produce similar drugs or products that do not infringe our patents, or produce drugs in countries where we have not applied for patent protection or that do not respect our patents. Furthermore, it is not possible to know the scope of claims that will be allowed in published applications and it is also not possible to know which claims of granted patents, if any, will be deemed enforceable in a court of law. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">After the completion of development and registration of our patents, third parties may still act to manufacture and/or market products in infringement of our patent protected rights, and we may not have adequate resources to enforce our patents. Any such manufacture and/or market of products in infringement of our patent protected rights is likely to cause us damage and lead to a reduction in the prices of our product candidates, thereby reducing our anticipated cash flows and profits, if any. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In addition, due to the extensive time needed to develop, test and obtain regulatory approval for our product candidates, any patents that protect our product candidates may expire early during commercialization. This may reduce or eliminate any market advantages that such patents may give us. Following patent expiration, we may face increased competition through the entry of competing products into the market and a subsequent decline in market share and profits. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We have granted, and may in the future grant, to third parties licenses to use our intellectual property. Generally, these licenses have granted rights to commercialize products outside the pharmaceutical field or to technology we no longer use or to otherwise use our intellectual property for a limited purpose outside the scope of our business interests. For example, in August 2013 we entered into an assignment agreement with Medicis Pharmaceutical Corporation (&#8220;Medicis&#8221;), according to which Medicis assigned to us its entire interest in one of the patents upon which we rely for our product candidate TWIN for the treatment of acne. As part of this assignment agreement, we granted to Medicis a non-exclusive, transferable, sub-licensable, royalty-free, perpetual, license to practice the inventions claimed under the patent. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">However, our business interests may change or our licensees may disagree with the scope of our license grant. In such cases, such licensing arrangements may result in the development, manufacturing, marketing and sale by our licensees of products substantially similar to our products, causing us to face increased competition, which could reduce our market share and significantly harm our business, results of operations and prospects. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">If we are unable to protect the confidentiality of our trade secrets or know-how, such proprietary information may be used by others to compete against us. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In addition to filing patent applications, we generally try to protect our trade secrets, know-how, technology and other proprietary information by entering into confidentiality or non-disclosure agreements with parties that have access to it, such as our development and/or commercialization partners, employees, contractors and consultants. We also enter into agreements that purport to require the disclosure and assignment to us of the rights to the ideas, developments, discoveries and inventions of our employees, advisors, research collaborators, contractors and consultants while we employ or engage them. However, we cannot assure you that these agreements will provide meaningful protection for our trade secrets, know-how or other proprietary information in the event of any unauthorized use, misappropriation or disclosure of such trade secrets, know-how or other proprietary information because these agreements can be difficult and costly to enforce or may not provide adequate remedies. Any of these parties may breach the confidentiality agreements and willfully or unintentionally disclose our confidential information, or our competitors might learn of the information in some other way. The disclosure to, or independent development by, a competitor of any trade secret, know-how or other technology not protected by a patent could materially adversely affect any competitive advantage we may have over any such competitor. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">To the extent that any of our employees, advisors, research collaborators, contractors or consultants independently develop, or use independently developed, intellectual property in connection with any of our projects, disputes may arise as to the proprietary rights to this type of </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">40</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">information. If a dispute arises with respect to any proprietary right, enforcement of our rights can be costly and unpredictable and a court may determine that the right belongs to a third party. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Legal proceedings or third-party claims of intellectual property infringement and other challenges may require us to spend substantial time and money and could prevent us from developing or commercializing our product candidates. </div>
        <div style="text-indent:20pt; margin-top:7.41pt; width:456pt; line-height:12pt;">The development, manufacture, use, offer for sale, sale or importation of our product candidates may infringe on the claims of third-party patents or other intellectual property rights. The nature of claims contained in unpublished patent filings around the world is unknown to us and it is not possible to know which countries patent holders may choose for the extension of their filings under the Patent Cooperation Treaty, or other mechanisms. Therefore, there is a risk that we could adopt a technology without knowledge of a pending patent application, which technology would infringe a third-party patent once that patent is issued. We may also be subject to claims based on the actions of employees and consultants with respect to the usage or disclosure of intellectual property learned at other employers. The cost to us of any intellectual property litigation or other infringement proceeding, even if resolved in our favor, could be substantial. Any claims of patent infringement, even those without merit, could: be expensive and time consuming to defend; cause us to cease making, licensing or using products that incorporate the challenged intellectual property; require us to redesign, reengineer or rebrand our product candidates, if feasible; cause us to stop from engaging in normal operations and activities, including developing and marketing product candidates; and divert management&#8217;s attention and resources. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively because of their substantially greater financial resources. Uncertainties resulting from the initiation and continuation or defense of intellectual property litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace. Intellectual property litigation and other proceedings may also absorb significant management time. Consequently, we are unable to guarantee that we will be able to manufacture, use, offer for sale, sell or import our product candidates in the event of an infringement action. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In the event of patent infringement claims, or to avoid potential claims, we may choose or be required to seek a license from a third party and would most likely be required to pay license fees or royalties or both. These licenses may not be available on acceptable terms, or at all. Even if we were able to obtain a license, the rights may be non-exclusive, which could potentially limit our competitive advantage. Ultimately, we could be prevented from commercializing a product or be forced to cease some aspect of our business operations if, as a result of actual or threatened patent infringement or other claims, we are unable to enter into licenses on acceptable terms. This inability to enter into licenses could harm our business significantly. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In addition, because of our developmental stage, claims that our product candidates infringe on the patent rights of others are more likely to be asserted after commencement of commercial sales incorporating our technology. </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;font-style:italic;font-weight:bold;">We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants, and independent contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants, or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of any of our employees&#8217; former employers or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">41</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Although we believe that we take reasonable steps to protect our intellectual property, including the use of agreements relating to the non-disclosure of confidential information to third parties, as well as agreements that purport to require the disclosure and assignment to us of the rights to the ideas, developments, discoveries and inventions of our employees and consultants while we employ them, the agreements can be difficult and costly to enforce. Although we seek to obtain these types of agreements from our contractors, consultants, advisors and research collaborators, to the extent that employees and consultants utilize or independently develop intellectual property in connection with any of our projects, disputes may arise as to the intellectual property rights associated with our product candidates. If a dispute arises, a court may determine that the right belongs to a third party. In addition, enforcement of our rights can be costly and unpredictable. We also rely on trade secrets and proprietary know-how that we seek to protect in part by confidentiality agreements with our employees, contractors, consultants, advisors or others. Despite the protective measures we employ, we still face the risk that: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">these agreements may be breached; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">these agreements may not provide adequate remedies for the applicable type of breach; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">our trade secrets or proprietary know-how will otherwise become known; or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">our competitors will independently develop similar technology or proprietary information. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">International patent protection is particularly uncertain, and if we are involved in opposition proceedings in foreign countries, we may have to expend substantial sums and management resources. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Patent law outside the United States may be different than in the United States. Further, the laws of some foreign countries may not protect our intellectual property rights to the same extent as the laws of the United States, if at all. A failure to obtain sufficient intellectual property protection in any foreign country could materially and adversely affect our business, results of operations and future prospects. Moreover, we may participate in opposition proceedings to determine the validity of our foreign patents or our competitors&#8217; foreign patents, which could result in substantial costs and divert management&#8217;s resources and attention. Additionally, due to uncertainty in patent protection law, we have not filed applications in many countries where significant markets exist. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">An NDA submitted under Section 505(b)(2) subjects us to the risk that we may be subject to a patent infringement lawsuit that would delay or prevent the review or approval of our product candidates. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In the United States, we expect to file NDAs for our product candidates for approval under Section 505(b)(2) of the FDCA. Section 505(b)(2) permits the submission of an NDA where at least some of the information required for approval comes from studies that were not conducted by, or for, the applicant and on which the applicant has not obtained a right of reference. The 505(b)(2) application would enable us to reference published literature and/or the FDA&#8217;s previous findings of safety and effectiveness for the branded reference drug. For NDAs submitted under Section 505(b)(2) of the FDCA, the patent certification and related provisions of the Hatch-Waxman Act apply. In accordance with the Hatch-Waxman Act, such NDAs may be required to include certifications, known as paragraph IV certifications, that certify that any patents listed in the Patent and Exclusivity Information Addendum of the FDA&#8217;s publication, Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book, with respect to any product referenced in the 505(b)(2) application, are invalid, unenforceable or will not be infringed by the manufacture, use or sale of the product that is the subject of the 505(b)(2) NDA. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Under the Hatch-Waxman Act, the holder of patents that the 505(b)(2) application references may file a patent infringement lawsuit after receiving notice of the paragraph IV certification. Filing of a patent infringement lawsuit against the filer of the 505(b)(2) applicant within 45 days of </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">42</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">the patent owner&#8217;s receipt of notice triggers a one-time, automatic, 30-month stay of the FDA&#8217;s ability to approve the 505(b)(2) NDA, unless patent litigation is resolved in the favor of the paragraph IV filer or the patent expires before that time. Accordingly, we may invest a significant amount of time and expense in the development of one or more product candidates only to be subject to significant delay and patent litigation before such product candidates may be commercialized, if at all. In addition, a 505(b)(2) application will not be approved until any non-patent exclusivity, such as exclusivity for obtaining approval of a new chemical entity, or NCE, listed in the Orange Book for the referenced product has expired. The FDA may also require us to perform one or more additional clinical trials or measurements to support the change from the branded reference drug, which could be time consuming and could substantially delay our achievement of regulatory approvals for such product candidates. The FDA may also reject our future 505(b)(2) submissions and require us to file such submissions under Section 505(b)(1) of the FDCA, which would require us to provide extensive data to establish safety and effectiveness of the drug for the proposed use and could cause delay and be considerably more expensive and time consuming. These factors, among others, may limit our ability to successfully commercialize our product candidates. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Companies that produce branded reference drugs routinely bring litigation against ANDA or 505(b)(2) applicants that seek regulatory approval to manufacture and market generic and reformulated forms of their branded products. These companies often allege patent infringement or other violations of intellectual property rights as the basis for filing suit against an ANDA or 505(b)(2) applicant. Likewise, patent holders may bring patent infringement suits against companies that are currently marketing and selling their approved generic or reformulated products. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Litigation to enforce or defend intellectual property rights is often complex and often involves significant expense and can delay or prevent introduction or sale of our product candidates. If patents are held to be valid and infringed by our product candidates in a particular jurisdiction, we would, unless we could obtain a license from the patent holder, be required to cease selling in that jurisdiction and may need to relinquish or destroy existing stock in that jurisdiction. There may also be situations where we use our business judgment and decide to market and sell our approved product candidates, notwithstanding the fact that allegations of patent infringement(s) have not been finally resolved by the courts, which is known as an &#8220;at-risk launch.&#8221; The risk involved in doing so can be substantial because the remedies available to the owner of a patent for infringement may include, among other things, damages measured by the profits lost by the patent owner and not necessarily by the profits earned by the infringer. In the case of a willful infringement, the definition of which is subjective, such damages may be increased up to three times. Moreover, because of the discount pricing typically involved with bioequivalent and, to a lesser extent, 505(b)(2), products, patented branded products generally realize a substantially higher profit margin than bioequivalent and, to a lesser extent, 505(b)(2), products, resulting in disproportionate damages compared to any profits earned by the infringer. An adverse decision in patent litigation could have a material adverse effect on our business, financial position and results of operations and could cause the market value of our ordinary shares to decline. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Risks Related to Our Operations in Israel </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our headquarters, manufacturing and other significant operations are located in Israel and, therefore, our business and operations may be adversely affected by political, economic and military conditions in Israel. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Our business and operations will be directly influenced by the political, economic and military conditions affecting Israel at any given time. A change in the security and political situation in Israel and in the economy could impede the raising of the funds required to finance our research and development plans and to create joint ventures with third parties and could otherwise have a material adverse effect on our business, operating results and financial condition. Although Israel has entered into various agreements with Egypt, Jordan and the Palestinian </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">43</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">Authority, there have been times since October&#160;2000 when Israel has experienced an increase in unrest and terrorist activity. The establishment in 2006 of a government in the Palestinian Authority by representatives of the Hamas militant group has created additional unrest and uncertainty in the region. </div>
        <div style="text-indent:20pt; margin-top:6.02pt; width:456pt; line-height:12pt;">During the Second Lebanon War of 2006, between Israel and Hezbollah, a militant Islamic movement, thousands of rockets were fired from Lebanon up to 50 miles into Israel. In January&#160;2009, Israel attacked, during three weeks, Hamas strongholds in the Gaza strip, in reaction to rockets that were fired from Gaza up to 25 miles into Israel. In November&#160;2012, Israel launched a seven-day operation against Hamas operatives in the Gaza strip in response to Palestinian groups launching over 100 rockets at Israel over a 24-hour period. In July&#160;2014, Israel launched an additional operation against Hamas operatives in the Gaza strip in response to Palestinian groups launching rockets at Israel. Major hostilities involving Israel or the interruption or curtailment of trade between Israel and its present trading partners could result in damage to our facilities and likewise have a material adverse effect on our business, operating results and financial condition. </div>
        <div style="text-indent:20pt; margin-top:6.03pt; width:456pt; line-height:12pt;">Popular uprisings in various countries in the Middle East and North Africa are affecting the political stability of those countries. Such instability may lead to deterioration in the political and trade relationships that exist between the State of Israel and these countries. Furthermore, several countries, principally in the Middle East, restrict doing business with Israel and Israeli companies, and additional countries may impose restrictions on doing business with Israel and Israeli companies if hostilities in the region continue or intensify. Such restrictions may seriously limit our ability to sell our product candidates to customers in those countries. Any hostilities involving Israel or the interruption or curtailment of trade between Israel and its present trading partners, or significant downturns in the economic or financial condition of Israel, could adversely affect our operations and product development, cause our revenues to decrease and adversely affect the share price of publicly traded companies having operations in Israel, such as us. Similarly, Israeli corporations are limited in conducting business with entities from several countries. </div>
        <div style="text-indent:20pt; margin-top:6.02pt; width:456pt; line-height:12pt;">Our commercial insurance does not cover losses that may occur as a result of an event associated with the security situation in the Middle East. Although the Israeli government is currently committed to covering the reinstatement value of direct damages that are caused by terrorist attacks or acts of war, there can be no assurance that this government coverage will be maintained, or if maintained, will be sufficient to compensate us fully for damages incurred. Any losses or damages incurred by us could have a material adverse effect on our business, financial condition and results of operations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Exchange rate fluctuations between the U.S. dollar, the New Israeli Shekel and other foreign currencies, may negatively affect our future revenues. </div>
        <div style="text-indent:20pt; margin-top:5.02pt; width:456pt; line-height:12pt;">In the future, we expect that a substantial portion of our revenues will be generated in U.S. dollars, Euros and other foreign currencies, although we currently incur a significant portion of our expenses in currencies other than U.S. dollars, and mainly in NIS. Our financial records are maintained, and will be maintained, in U.S. dollars, which is our functional currency. As a result, our financial results may be affected by fluctuations in the exchange rates of currencies in the countries in which our prospective product candidates may be sold. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our operations may be affected by negative labor conditions in Israel. </div>
        <div style="text-indent:20pt; margin-top:5.02pt; width:456pt; line-height:12pt;">Strikes and work-stoppages occur relatively frequently in Israel. If Israeli trade unions threaten additional strikes or work-stoppages and such strikes or work-stoppages occur, those may, if prolonged, have a material adverse effect on the Israeli economy and on our business, including our ability to deliver products to our customers and to receive raw materials from our suppliers in a timely manner. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our operations could be disrupted as a result of the obligation of our personnel to perform military service. </div>
        <div style="text-indent:20pt; margin-top:5.02pt; width:456pt; line-height:12pt;">All of our executive officers and key employees reside in Israel and although most of them are no longer required to perform reserve duty, some may be required to perform annual military </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">44</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">reserve duty and may be called for active duty under emergency circumstances at any time. Our operations could be disrupted by the absence for a significant period of time of one or more of these officers or key employees due to military service. Any such disruption could adversely affect our business, results of operations and financial condition. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">The termination or reduction of tax and other incentives that the Israeli Government provides to domestic companies may increase the costs involved in operating a company in Israel. </div>
        <div style="text-indent:20pt; margin-top:6.81pt; width:456pt; line-height:12pt;">The Israeli government currently provides tax and capital investment incentives to domestic companies, as well as grant and loan programs relating to research and development and marketing and export activities. In recent years, the Israeli Government has reduced the benefits available under these programs and the Israeli Governmental authorities have indicated that the government may in the future further reduce or eliminate the benefits of those programs. We may take advantage of these benefits and programs in the future, however, there is no assurance that such benefits and programs would continue to be available in the future to us. If such benefits and programs were terminated or further reduced, it could have an adverse effect on our business, operating results and financial condition. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">The Israeli government grants that we have received require us to meet several conditions and may restrict our ability to manufacture some of our product candidates and transfer relevant know-how outside of Israel and require us to satisfy specified conditions, which are at present uncertain due to the enactment of a new regulatory framework. </div>
        <div style="text-indent:20pt; margin-top:6.82pt; width:456pt; line-height:12pt;">We have received royalty-bearing grants from the government of Israel through the National Authority for Technological Innovation, or the Innovation Authority (formerly known as the Office of the Chief Scientist of the Ministry of Economy and Industry, or the OCS), for the financing of a portion of our research and development expenditures in Israel. These Innovation Authority grants relate to a peripheral line of product candidates which forms a negligible part of our activities. When know-how is developed using Innovation Authority grants, the Encouragement of Research, Development and Technological Innovation in Industry Law 5744-1984, or the Innovation Law, the Innovation Authority&#8217;s rules and guidelines as well as the terms of these grants, restrict our ability to manufacture product candidates and transfer know-how developed as a result of the Innovation Authority&#8217;s funded R&amp;D outside of Israel. Transfer of the Innovation Authority funded know-how outside of Israel where the transferring company remains an operating Israeli entity or where the transferring company ceases to exist as an Israeli entity, requires pre-approval by the Innovation Authority, which may, at its sole discretion, grant such approval and impose certain conditions, including payment of a redemption fee calculated according to the formulas provided in the Innovation Authority&#8217;s rules and guidelines, or Redemption Fee, which takes into account the consideration for such know-how paid to us in the transaction in which the know-how is transferred. The Innovation Authority&#8217;s rules and guidelines establish a maximum payment of the Redemption Fee under the formulas provided in the Innovation Authority&#8217;s rules and guidelines and differentiates between certain situations, as further detailed in such rules and guidelines. In addition, the product candidates may be manufactured outside of Israel by us or by another entity only if prior approval is received from the Innovation Authority (such approval is not required for the transfer of less than 10% of the manufacturing capacity in the aggregate). In addition to the obligation to receive prior approval to manufacture outside Israel, we will be required to pay increased royalties, as defined under the Innovation Authority&#8217;s rules and guidelines. The total amount of the increased royalties to be repaid to the Innovation Authority shall not exceed, in the aggregate, 300% of the amount of the grant received (dollar linked), plus interest at annual rate based on LIBOR, depending on the manufacturing volume that is performed outside Israel less royalties already paid to the Innovation Authority. </div>
        <div style="text-indent:20pt; margin-top:7.81pt; width:456pt; line-height:12pt;">A company also has the option of declaring in its Innovation Authority grant application its intention to exercise a portion of the manufacturing capacity abroad, thus avoiding the need to obtain additional approval following the receipt of the grant. </div>
        <div style="text-indent:20pt; margin-top:7.61pt; width:456pt; line-height:12pt;">Recently, the Innovation Authority has published new rules and guidelines with respect to the grant to a foreign entity of the right to use know-how that was developed using the Innovation </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">45</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">Authority&#8217;s grants, or Funded Know-How. According to these rules, the grant to a foreign entity of a right to use the Funded Know-How (which does not entirely prevent the Innovation Authority funded company from using the Funded Know-How) is subject to receipt of the Innovation Authority&#8217;s prior approval. This approval is subject to payment to the Innovation Authority in accordance with the formulas stipulated in these rules.</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The restrictions under the Innovation Authority&#8217;s rules and guidelines continue to apply even though we have already paid the full amount of royalties payable pursuant to the grants. In addition, the government of the State of Israel may from time to time audit sales of products which it claims incorporate Funded Know-How and this may lead to additional royalties being payable on additional product candidates. Following a recent audit, the Innovation Authority confirmed to us that our product candidates TWIN, SIRS-T and VERED, were not developed with Funded Know-How. However, there can be no guarantee that the Innovation Authority will not in the future attempt to claim royalties with respect to these products, or that future products will not be subject to royalties. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">These restrictions may impair our ability to enter into agreements for Funded Know-How product candidates or technologies without the approval of the Innovation Authority. We cannot be certain that any approval of the Innovation Authority will be obtained on terms that are acceptable to us, or at all. Furthermore, in the event that we undertake a transaction involving the transfer to a non-Israeli entity of Funded Know-How pursuant to a merger or similar transaction, or in the event we undertake a transaction involving the licensing of Funded Know-How, the consideration available to our shareholders may be reduced by the amounts we are required to pay to the Innovation Authority. Any approval, if given, will generally be subject to additional financial obligations. Failure to comply with the requirements under the Innovation Authority&#8217;s rules and guidelines and the Innovation Law may subject us to mandatory repayment of grants received by us (together with interest and penalties), as well as expose us to criminal proceedings. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In August&#160;2015, a new amendment to the Innovation Law was enacted, or Amendment No. 7, which came into effect on January&#160;1, 2016. Since Amendment No.&#160;7 has entered into force, the Innovation Authority was appointed to act as the entity which is responsible for the activity which was previously under the OCS&#8217; responsibility. The Innovation Authority was granted wide freedom of action, and among other things, the authority to amend the requirements and restrictions which were specified in the Innovation Law before Amendment No. 7 became effective with respect to the ownership of Funded Know-How (including with respect to the restrictions on transfer of the Funded Know-How and manufacturing activities outside of Israel) as well as with respect to royalty payment obligations which apply to companies that received grants from the Innovation Authority. Although the Innovation Authority recently published rules, which for the most part adopted the principal provisions and restrictions specified in the Innovation Law prior to the effectiveness of Amendment No.&#160;7, as of the date of this prospectus, we are unable to assess the effect on our business of any future rules which may be published by the Innovation Authority. See &#8220;Business &#8212; Government Regulation &#8212; <font style="font-style:italic;">Innovation Authority</font>.&#8221; </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Enforcing a U.S. judgment against us and our current executive officers and directors, or asserting U.S. securities law claims in Israel, may be difficult. </div>
        <div style="text-indent:20pt; margin-top:7.21pt; width:456pt; line-height:12pt;">We are incorporated in Israel. All of our current executive officers and directors reside in Israel (although one of our nominees to serve as an external director, Jerrold S. Gattegno, resides in the United States) and most of our assets reside outside of the United States. Therefore, a judgment obtained against us or any of these persons in the United States, including one based on the civil liability provisions of the U.S. federal securities laws, may not be collectible in the United States and may not be enforced by an Israeli court. It may also be difficult to effect service of process on these persons in the United States or to assert U.S. securities law claims in original actions instituted in Israel. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Even if an Israeli court agrees to hear such a claim, it may determine that Israeli, and not U.S., law is applicable to the claim. Under Israeli law, if U.S. law is found to be applicable to such a claim, the content of applicable U.S. law must be proved as a fact, which can be a time-consuming </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">46</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">and costly process, and certain matters of procedure would be governed by Israeli law. There is little binding case law in Israel addressing these matters. See &#8220;Enforceability of Civil Liabilities&#8221; for additional information on your ability to enforce civil claim against us and our executive officers and directors. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Provisions of our amended and restated articles of association and Israeli law and tax considerations may delay, prevent or make difficult an acquisition of us, which could prevent a change of control and negatively affect the price of our ordinary shares. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Israeli corporate law regulates mergers, requires tender offers for acquisitions of shares above specified thresholds, requires special approvals for certain transactions involving directors, officers or significant shareholders and regulates other matters that may be relevant to these types of transactions. These provisions of Israeli law may delay, prevent or make difficult an acquisition of us, which could prevent a change of control and therefore depress the price of our ordinary shares. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Our amended and restated articles of association provide that our directors (other than external directors) are elected on a staggered basis, such that a potential acquirer cannot readily replace our entire board of directors at a single annual general shareholder meeting. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Furthermore, Israeli tax considerations may make potential transactions unappealing to us or to our shareholders, especially for those shareholders whose country of residence does not have a tax treaty with Israel which exempts such shareholders from Israeli tax. For example, Israeli tax law does not recognize tax-free share exchanges to the same extent as U.S. tax law. With respect to mergers, Israeli tax law allows for tax deferral in certain circumstances but makes the deferral contingent on the fulfillment of a number of conditions, including, in some cases, a holding period of two years from the date of the transaction during which sales and dispositions of shares of the participating companies are subject to certain restrictions. Moreover, with respect to certain share swap transactions, the tax deferral is limited in time, and when such time expires, the tax becomes payable even if no disposition of the shares has occurred. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We may become subject to claims for remuneration or royalties for assigned service invention rights by our employees, which could result in litigation and adversely affect our business. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We have entered into assignment of invention agreements with our employees pursuant to which such individuals agree to assign to us all rights to any inventions created during their employment or engagement with us. A significant portion of our intellectual property has been developed by our employees in the course of their employment for us. Under the Israeli Patent Law, 5727-1967, or the Patent Law, inventions conceived by an employee during the scope of his or her employment with a company and as a result thereof are regarded as &#8220;service inventions,&#8221; which belong to the employer, absent a specific agreement between the employee and employer giving the employee service invention rights. The Patent Law also provides that if there is no agreement between an employer and an employee with respect to the employee&#8217;s right to receive compensation for such &#8220;service inventions,&#8221; the Israeli Compensation and Royalties Committee, or the Committee, a body constituted under the Patent Law, shall determine whether the employee is entitled to remuneration for his or her service inventions and the scope and conditions for such remuneration. Although our employees have agreed to assign to us service invention rights, as a result of uncertainty under Israeli law with respect to the efficacy of waivers of service invention rights, we may face claims demanding remuneration in consideration for assigned inventions. As a consequence of such claims, we could be required to pay additional remuneration or royalties to our current and/or former employees, or be forced to litigate such claims, which could negatively affect our business. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">The government tax benefits that we currently are entitled to receive require us to meet several conditions and may be terminated or reduced in the future. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Some of our operations in Israel may entitle us to certain tax benefits under the Law for the Encouragement of Capital Investments, 5719-1959, or the Investment Law, once we begin to produce revenues. If we do not meet the requirements for maintaining these benefits, they may be </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">47</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">reduced or cancelled and the relevant operations would be subject to Israeli corporate tax at the standard rate, which is set at 24% in 2017 and 23% in 2018 and thereafter. In addition to being subject to the standard corporate tax rate, we could be required to refund any tax benefits that we have already received, plus interest and penalties thereon. Even if we continue to meet the relevant requirements, the tax benefits that our current &#8220;Benefited Enterprise&#8221; is entitled to may not be continued in the future at their current levels or at all. If these tax benefits were reduced or eliminated, the amount of taxes that we pay would likely increase, as all of our operations would consequently be subject to corporate tax at the standard rate, which could adversely affect our results of operations. Additionally, if we increase our activities outside of Israel, for example, by way of acquisitions, our increased activities may not be eligible for inclusion in Israeli tax benefits programs. See &#8220;Material Tax Considerations &#8212; Israeli Tax Considerations and Government Programs &#8212; Tax Benefits Under the 2011 Amendment&#8221; for additional information concerning these tax benefits. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Your rights and responsibilities as a shareholder will be governed by Israeli law, which differs in some material respects from the rights and responsibilities of shareholders of U.S. companies. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The rights and responsibilities of the holders of our ordinary shares are governed by our amended and restated articles of association and by Israeli law. These rights and responsibilities differ in some material respects from the rights and responsibilities of shareholders in U.S. corporations. For example, a shareholder of an Israeli company has a duty to act in good faith and in a customary manner in exercising its rights and performing its obligations towards the company and other shareholders, and to refrain from abusing its power in the company, including, among other things, voting at a general meeting of shareholders on matters such as amendments to a company&#8217;s articles of association, increases in a company&#8217;s authorized share capital, mergers and acquisitions and related party transactions requiring shareholder approval. In addition, a shareholder who is aware that it possesses the power to determine the outcome of a shareholder vote or to appoint or prevent the appointment of a director or executive officer in the company has a duty of fairness toward the company. There is limited case law available to assist us in understanding the nature of these duties or the implications of these provisions. These provisions may be interpreted to impose additional obligations and liabilities on holders of our ordinary shares that are not typically imposed on shareholders of U.S. corporations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Risks Related to Employee Matters </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">If we are not able to retain our key management, or attract and retain qualified scientific, technical and business personnel, our ability to implement our business plan may be adversely affected. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Our success largely depends on the skill, experience and effort of our senior management. The loss of the service of any of these persons, including the chairman of our board of directors, Mr. Moshe Arkin, and our chief executive officer, Dr. Alon Seri-Levy, would likely result in a significant loss in the knowledge and experience that we possess and could significantly delay or prevent successful product development and other business objectives. There is intense competition from numerous pharmaceutical and biotechnology companies, universities, governmental entities and other research institutions, seeking to employ qualified individuals in the technical fields in which we operate, and we may not be able to attract and retain the qualified personnel necessary for the successful development and commercialization of our product candidates. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Under applicable employment laws, we may not be able to enforce covenants not to compete. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Our employment agreements generally include covenants not to compete. These agreements prohibit our employees, if they cease working for us, from competing directly with us or working for our competitors for a limited period. We may be unable to enforce these agreements under the laws of the jurisdictions in which our employees work. For example, Israeli courts have required </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">48</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">employers seeking to enforce covenants not to compete to demonstrate that the competitive activities of a former employee will harm one of a limited number of material interests of the employer, such as the secrecy of a company&#8217;s confidential commercial information or the protection of its intellectual property. If we cannot demonstrate that such an interest will be harmed, we may be unable to prevent our competitors from benefiting from the expertise of our former employees and our competitiveness may be diminished. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Risks Related to the Offering and Our Ordinary Shares </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">The price of our ordinary shares may be volatile and may fluctuate due to factors beyond our control. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The share price of publicly traded emerging biopharmaceutical and drug discovery and development companies has been highly volatile and is likely to remain highly volatile in the future. The market price of our ordinary shares may fluctuate significantly due to a variety of factors, including: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">positive or negative results of testing and clinical trials by us, strategic partners and competitors; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">delays in entering into strategic relationships with respect to development and/or commercialization of our product candidates or entry into strategic relationships on terms that are not deemed to be favorable to us; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">technological innovations or commercial product introductions by us or competitors; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">changes in government regulations; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">developments concerning proprietary rights, including patents and litigation matters; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">public concern relating to the commercial value or safety of any of our product candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">financing or other corporate transactions; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">publication of research reports or comments by securities or industry analysts; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">general market conditions in the pharmaceutical industry or in the economy as a whole; or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">other events and factors, many of which are beyond our control. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">These and other market and industry factors may cause the market price and demand for our ordinary shares to fluctuate substantially, regardless of our actual operating performance, which may limit or prevent investors from readily selling their ordinary shares and may otherwise negatively affect the liquidity of our ordinary shares. In addition, the stock market in general, and biopharmaceutical companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">You will experience immediate and substantial dilution in the net tangible book value of the ordinary shares you purchase in this offering. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The initial public offering price of our ordinary shares will substantially exceed the net tangible book value per share of our ordinary shares immediately after this offering. Therefore, based on the anticipated public offering price of&#8201; $&#8199;&#8199;&#8199;&#8199; per ordinary share, which is the midpoint of the price range set forth on the cover page of this prospectus, if you purchase our ordinary shares in this offering, you will suffer, as of June&#160;30, 2017, immediate dilution of&#8201; $&#8199;&#8199;&#8199;&#8199; per ordinary share, or $&#8199;&#8199;&#8199; if the underwriters exercise their option to purchase additional ordinary shares, in net tangible book value after giving effect to the sale of&#8201; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares in this </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">49</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">offering at the assumed initial public offering price of&#8201; $&#8199;&#8199;&#8199;&#8199; per ordinary share (which is the midpoint of the price range set forth on the cover page of this prospectus), after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. As a result of this dilution, as of June&#160;30, 2017, investors purchasing ordinary shares from us in this offering will have contributed &#8199;&#8199;&#8199;% of the total amount of our total gross funding to date but will own only &#8199;&#8199;&#8199;% of our equity. In addition, if outstanding options to purchase our ordinary shares are exercised in the future, you will experience additional dilution. See &#8220;Dilution.&#8221; </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">There has been no prior public market for our ordinary shares, and an active trading market may not develop. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Prior to this offering, there has been no public market for our ordinary shares. We cannot predict the extent to which an active market for our ordinary shares will develop or be sustained after this offering, or how the development of such a market might affect the market price for our ordinary shares. The initial public offering price of our ordinary shares in this offering will be agreed upon between us and the underwriters based on a number of factors, including market conditions in effect at the time of the offering, which may not be indicative of the price at which our ordinary shares will trade following completion of the offering. Investors may not be able to sell their shares at or above the initial public offering price. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">The controlling share ownership position of Arkin Dermatology will limit your ability to elect the members of our board of directors, may adversely affect our share price and will result in our non-affiliated investors having very limited, if any, influence on corporate actions. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Arkin Dermatology is currently our sole shareholder, and after this offering is completed, we will continue to be controlled by Arkin Dermatology. Upon the closing of this offering, Arkin Dermatology will beneficially own approximately &#8199;&#8199;&#8199;% of the voting power of our outstanding ordinary shares, or approximately &#8199;&#8199;&#8199;% if the underwriters exercise their option to purchase additional ordinary shares in full, assuming the automatic conversion of our outstanding promissory note between us and our controlling shareholder, into an aggregate of&#8201; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares immediately prior to the closing of this offering, and assuming an initial public offering price of&#8201; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share, which is the midpoint of the price range set forth on the cover page of this prospectus. The Promissory Note will be assigned to Arkin Dermatology immediately prior to the automatic conversion thereof, and the ordinary shares issued pursuant to the automatic conversion will be held by Arkin Dermatology. Therefore, even after this offering, Arkin Dermatology will have the ability to substantially influence us and exert significant control through this ownership position. For example, Arkin Dermatology will be able to control elections of directors, amendments of our organizational documents, and approval of any merger, amalgamation, sale of assets or other major corporate transaction. Arkin Dermatology&#8217;s interests may not always coincide with our corporate interests or the interests of other shareholders, and it may exercise its voting and other rights in a manner with which you may not agree or that may not be in the best interests of our other shareholders. So long as it continues to own a significant amount of our equity, Arkin Dermatology will continue to be able to strongly influence and significantly control our decisions. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We will be a &#8220;controlled company&#8221; within the meaning of NASDAQ listing standards and, as a result, will qualify for, and intend to rely on, exemptions from certain corporate governance requirements. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">As a result of the number of shares owned by Arkin Dermatology, after the completion of this offering, we will be a &#8220;controlled company&#8221; under the NASDAQ corporate governance rules. A &#8220;controlled company&#8221; is a company of which more than 50% of the voting power is held by an individual, group or another company. Pursuant to the &#8220;controlled company&#8221; exemption, we are not required to, and intend to not comply with the requirements that: (1) a majority of our board of directors consist of independent directors and (2) we have a nominating committee composed entirely of independent directors with a written charter addressing such committee&#8217;s purpose and </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">50</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">responsibilities. See &#8220;Management &#8212; Foreign Private Issuer and Controlled Company Status &#8212; Controlled Company.&#8221; Accordingly, you will not have the same protections afforded to shareholders of companies that are subject to all of the corporate governance requirements of the NASDAQ Global Market. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">The market price of our ordinary shares could be negatively affected by future sales of our ordinary shares. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">After this offering, there will be &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares outstanding. Sales by us or our shareholders of a substantial number of our ordinary shares in the public market following this offering, or the perception that these sales might occur, could cause the market price of our ordinary shares to decline or could impair our ability to raise capital through a future sale of, or pay for acquisitions using, our equity securities. Of our issued and outstanding shares, all of the ordinary shares sold in this offering will be freely transferable, except for any shares held by our &#8220;affiliates,&#8221; as that term is defined in Rule 144 under the Securities Act of 1933, as amended, or the Securities Act. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Upon the closing of this offering, approximately &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;of our outstanding ordinary shares will be beneficially owned by shareholders that have agreed with the underwriters that, subject to limited exceptions, for a period of 180 days after the date of this prospectus, they will not directly or indirectly offer, pledge, sell, contract to sell, sell any option or contract to purchase or otherwise dispose of any ordinary shares or any securities convertible into or exercisable or exchangeable for ordinary shares, or in any manner transfer all or a portion of the economic consequences associated with the ownership of ordinary shares, or cause a registration statement covering any ordinary shares to be filed, without the prior written consent of Jefferies LLC and BMO Capital Markets Corp., which may, at any time without notice, release all or any portion of the shares subject to the corresponding lock-up agreements. After the expiration of the lock-up period, these shares can be resold into the public markets in accordance with the requirements of Rule 144, subject to certain volume limitations. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In addition, we intend to file one or more registration statements on Form S-8 with the Securities and Exchange Commission, or the SEC, covering all of the ordinary shares issuable under our 2014 Share Incentive Plan or any other equity incentive plans that we may adopt, and such shares will be freely transferable, except for any shares held by &#8220;affiliates,&#8221; as such term is defined in Rule 144 under the Securities Act. The market price of our ordinary shares may drop significantly when the restrictions on resale by our existing shareholders lapse and these shareholders are able to sell our ordinary shares into the market. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Upon the filing of the registration statements and following the expiration of the lock-up restrictions described above, the number of ordinary shares that are potentially available for sale in the open market will increase materially, which could make it harder for the value of our ordinary shares to appreciate unless there is a corresponding increase in demand for our ordinary shares. This increase in available shares could result in the value of your investment in our ordinary shares decreasing. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In addition, a sale by us of additional ordinary shares or similar securities in order to raise capital might have a similar negative impact on the share price of our ordinary shares. A decline in the price of our ordinary shares might impede our ability to raise capital through the issuance of additional ordinary shares or other equity securities, and may cause you to lose part or all of your investment in our ordinary shares. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We have broad discretion as to the use of the net proceeds from this offering and may not use them effectively. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We intend to use the net proceeds from this offering to fund our planned clinical trials of our branded product candidates, TWIN, SIRS-T and VERED, as well as the development of our generic product candidates. The remaining proceeds will be used for other research and development </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">51</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">activities, as well as for working capital and general corporate purposes. For more information, see &#8220;Use of Proceeds.&#8221; However, our management will have broad discretion in the application of the net proceeds. Our shareholders may not agree with the manner in which our management chooses to allocate the net proceeds from this offering. The failure by our management to apply these funds effectively could have a material adverse effect on our business, financial condition and results of operation. Pending their use, we may invest the net proceeds from this offering in a manner that does not produce income. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We do not intend to pay dividends on our ordinary shares for at least the next several years following this offering. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We do not anticipate paying any cash dividends on our ordinary shares for at least the next several years following this offering. We currently intend to retain all available funds and any future earnings to fund the development and growth of our business. As a result, capital appreciation, if any, of our ordinary shares will be the investors&#8217; sole source of gain for at least the next several years. In addition, Israeli law limits our ability to declare and pay dividends, and may subject us to certain Israeli taxes. For more information, see &#8220;Dividend Policy.&#8221; </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">If equity research analysts do not publish research or reports about our business or if they issue unfavorable commentary or downgrade our ordinary shares, the price of our ordinary shares could decline. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The trading market for our ordinary shares will rely in part on the research and reports that equity research analysts publish about us and our business. The price of our ordinary shares could decline if one or more securities analysts downgrade our ordinary shares or if those analysts issue other unfavorable commentary or cease publishing reports about us or our business. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">As a foreign private issuer whose shares are listed on the NASDAQ Global Market, we intend to follow certain home country corporate governance practices instead of certain NASDAQ requirements. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">As a foreign private issuer whose shares will be listed on The NASDAQ Global Market, we are permitted to follow certain home country corporate governance practices instead of certain requirements of the rules of The NASDAQ Global Market. Pursuant to the &#8220;foreign private issuer exemption&#8221;: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">we intend to establish a quorum requirement such that the quorum for any meeting of shareholders is 33<font style=" position:relative; bottom:2.66pt;font-size:7pt;">1</font>&#8725;<font style="font-size:7pt;">3</font>% of the issued share capital, as required under NASDAQ requirements; however, if the meeting is adjourned for lack of quorum, the quorum for such adjourned meeting will be any number of shareholders, instead of 33<font style=" position:relative; bottom:2.66pt;font-size:7pt;">1</font>&#8725;<font style="font-size:7pt;">3</font>% of the issued share capital;</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">we also intend to adopt and approve material changes to equity incentive plans in accordance with Israeli Companies Law, 5759-1999, or with the Companies Law, which does not impose a requirement of shareholder approval for such actions. In addition, we intend to follow Israeli corporate governance practice in lieu of NASDAQ Marketplace Rule 5635(c), which requires shareholder approval prior to an issuance of securities in connection with equity-based compensation of officers, directors, employees or consultants;</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">as opposed to making periodic reports to shareholders in the manner specified by the NASDAQ corporate governance rules, the Companies Law does not require us to distribute periodic reports directly to shareholders, and the generally accepted business practice in Israel is not to distribute such reports to shareholders but to make such reports available through a public website. We will only mail such reports to shareholders upon request; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">52</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">we will follow Israeli corporate governance practice instead of NASDAQ requirements to obtain shareholder approval for certain dilutive events (such as issuances that will result in a change of control, certain transactions other than a public offering involving issuances of a 20% or greater interest in us and certain acquisitions of the stock or assets of another company). Accordingly, our shareholders may not be afforded the same protection as provided under NASDAQ corporate governance rules.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Otherwise, we intend to comply with the rules generally applicable to U.S. domestic companies listed on the NASDAQ Global Market. However, we may in the future decide to use the foreign private issuer exemption with respect to some or all of the other NASDAQ corporate governance rules. Following our home country governance practices as opposed to the requirements that would otherwise apply to a U.S. company listed on the NASDAQ Global Market may provide less protection than is accorded to investors of domestic issuers. See &#8220;Management&#160;&#8212; Foreign Private Issuer and Controlled Company Status.&#8221; </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In addition, as a foreign private issuer, we will be exempt from the rules and regulations under the United States Securities Exchange Act of 1934, as amended, or the Exchange Act, related to the furnishing and content of proxy statements (including disclosures with respect to executive compensation), and our officers, directors, and principal shareholders will be exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. In addition, we will not be required under the Exchange Act to file annual, quarterly and current reports and financial statements with the SEC as frequently or as promptly as domestic companies whose securities are registered under the Exchange Act. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We may lose our foreign private issuer status which would then require us to comply with the Exchange Act&#8217;s domestic reporting regime and cause us to incur significant legal, accounting and other expenses. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We are a foreign private issuer and therefore we are not required to comply with all of the periodic disclosure and current reporting requirements of the Exchange Act applicable to U.S. domestic issuers. In order to maintain our current status as a foreign private issuer, either (a) a majority of our ordinary shares must be either directly or indirectly owned of record by non-residents of the United States or (b)(i) a majority of our executive officers or directors may not be U.S. citizens or residents, (ii) more than 50 percent of our assets cannot be located in the United States and (iii) our business must be administered principally outside the United States. If we were to lose this status, we would be required to comply with the Exchange Act reporting and other requirements applicable to U.S. domestic issuers, which are more detailed and extensive than the requirements for foreign private issuers. We may also be required to make changes in our corporate governance practices in accordance with various SEC and NASDAQ rules. The regulatory and compliance costs to us under U.S. securities laws if we are required to comply with the reporting requirements applicable to a U.S. domestic issuer may be significantly higher than the cost we would incur as a foreign private issuer. As a result, we expect that a loss of foreign private issuer status would increase our legal and financial compliance costs and would make some activities highly time consuming and costly. We also expect that if we were required to comply with the rules and regulations applicable to U.S. domestic issuers, it would make it more difficult and expensive for us to obtain director and officer liability insurance, and we may be required to accept reduced coverage or incur substantially higher costs to obtain coverage. These rules and regulations could also make it more difficult for us to attract and retain qualified members of our supervisory board. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We will incur increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">As a public company whose ordinary shares are listed in the United States, and particularly after we no longer qualify as an emerging growth company, we will incur accounting, legal and other expenses that we did not incur as a private company, including costs associated with our reporting requirements under the Exchange Act. We also anticipate that we will incur costs </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">53</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">associated with corporate governance requirements, including requirements under Section 404 and other provisions of the Sarbanes-Oxley Act of 2002 (the &#8220;Sarbanes-Oxley Act&#8221;), as well as rules implemented by the SEC and the NASDAQ Global Market, and provisions of Israeli corporate law applicable to public companies. We expect that these rules and regulations will increase our legal and financial compliance costs, introduce new costs such as investor relations and stock exchange listing fees, and will make some activities more time-consuming and costly. Our board and other personnel will need to devote a substantial amount of time to these initiatives. We are currently evaluating and monitoring developments with respect to these rules, and we cannot predict or estimate the amount of additional costs we may incur or the timing of such costs. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">As an &#8220;emerging growth company,&#8221; as defined in the JOBS Act, we may take advantage of certain temporary exemptions from various reporting requirements, including, but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act (and the rules and regulations of the SEC thereunder). When these exemptions cease to apply, we expect to incur additional expenses and devote increased management effort toward ensuring compliance with them. We cannot predict or estimate the amount of additional costs we may incur as a result of becoming a public company or the timing of such costs. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">Pursuant to Section 404 of the Sarbanes-Oxley Act and the related rules adopted by the SEC and the Public Company Accounting Oversight Board, starting with the second annual report that we file with the SEC after the closing of this offering, our management will be required to report on the effectiveness of our internal control over financial reporting. In addition, once we no longer qualify as an &#8220;emerging growth company&#8221; under the JOBS Act and lose the ability to rely on the exemptions related thereto discussed above and depending on our status as per Rule 12b-2 of the Exchange Act, our independent registered public accounting firm may also need to attest to the effectiveness of our internal control over financial reporting under Section 404. We have not yet commenced the process of determining whether our existing internal controls over financial reporting systems are compliant with Section 404 and whether there are any material weaknesses or significant deficiencies in our existing internal controls. This process will require the investment of substantial time and resources, including by our chief financial officer and other members of our senior management. As a result, this process may divert internal resources and take a significant amount of time and effort to complete. In addition, we cannot predict the outcome of this determination and whether we will need to implement remedial actions in order to implement effective controls over financial reporting. The determination and any remedial actions required could result in us incurring additional costs that we did not anticipate, including the hiring of outside consultants. Irrespective of compliance with Section 404, any failure of our internal controls could have a material adverse effect on our stated results of operations and harm our reputation. As a result, we may experience higher than anticipated operating expenses, as well as higher independent auditor fees during and after the implementation of these changes. If we are unable to implement any of the required changes to our internal control over financial reporting effectively or efficiently or are required to do so earlier than anticipated, it could adversely affect our operations, financial reporting and/or results of operations and could result in an adverse opinion on internal controls from our independent auditors. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Changes in the laws and regulations affecting public companies will result in increased costs to us as we respond to their requirements. These laws and regulations could make it more difficult or more costly for us to obtain certain types of insurance, including director and officer liability insurance, and we may be forced to accept reduced policy limits and coverage or incur substantially higher costs to obtain the same or similar coverage. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers. We cannot predict or estimate the amount or timing of additional costs we may incur in order to comply with such requirements. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We are an &#8220;emerging growth company&#8221; and the reduced disclosure requirements applicable to emerging growth companies may make our ordinary shares less attractive to investors. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">We are an &#8220;emerging growth company,&#8221; as defined in the JOBS Act, and we may take advantage of certain exemptions from various requirements that are applicable to other public </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">54</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">companies that are not &#8220;emerging growth companies.&#8221; Most of such requirements relate to disclosures that we would only be required to make if we also ceased to be a foreign private issuer in the future, for example, the requirement to hold stockholder advisory votes on executive and severance compensation and executive compensation disclosure requirements for U.S. companies. However, as a foreign private issuer, we could still be required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act. We are exempt from such requirement for as long as we remain an emerging growth company, which may be up to five fiscal years after the date of this offering. We will remain an emerging growth company until the earliest of: (a) the last day of our fiscal year during which we have total annual gross revenues of at least $1.07 billion; (b) the last day of our fiscal year following the fifth anniversary of the closing of this offering; (c) the date on which we have, during the previous three-year period, issued more than $1.0 billion in non-convertible debt; or (d) the date on which we are deemed to be a &#8220;large accelerated filer&#8221; under the Exchange Act. We may choose to take advantage of some or all of the available exemptions. When we are no longer deemed to be an emerging growth company, we will not be entitled to the exemptions provided in the JOBS Act discussed above. We cannot predict if investors will find our ordinary shares less attractive as a result of our reliance on exemptions under the JOBS Act. If some investors find our ordinary shares less attractive as a result, there may be a less active trading market for our ordinary shares and our share price may be more volatile. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. As a result, shareholders could lose confidence in our financial and other public reporting, which would harm our business and the trading price of our ordinary shares. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with Section 404, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our ordinary shares. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Our management will be required to assess the effectiveness of our internal controls and procedures and disclose changes in these controls on an annual basis. However, for as long as we are an &#8220;emerging growth company&#8221; under the JOBS Act, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal controls over financial reporting pursuant to Section 404. We could be an &#8220;emerging growth company&#8221; for up to five years. An independent assessment of the effectiveness of our internal controls could detect problems that our management&#8217;s assessment might not. Undetected material weaknesses in our internal controls could lead to financial statement restatements and require us to incur the expense of remediation. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We expect to be a passive foreign investment company for U.S. federal income tax purposes for the current tax year and possibly thereafter, which could result in materially adverse U.S. federal income tax consequences to U.S. Holders of our ordinary shares. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Based on our anticipated income and the composition of our income and assets, we expect to be a passive foreign investment company, or PFIC, for U.S. federal income tax purposes at least until we start generating a substantial amount of active revenue. A non-U.S. entity treated as a corporation for U.S. federal income tax purposes will be a PFIC for any taxable year if either (i) at least 75% of its gross income for such year is passive income or (ii) at least 50% of the value of its assets (based on an average of the quarterly values of the assets) during such year is attributable to assets that produce passive income or are held for the production of passive income. A separate </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">55</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">determination has to be made after the close of each taxable year as to whether we were a PFIC for that year. Because the value of our assets for purposes of the PFIC test will generally be determined by reference to the market price of our ordinary shares, our PFIC status may depend in part on the market price of our ordinary shares, which may fluctuate significantly. In addition, there are certain ambiguities in applying the PFIC test to us. If we are considered a PFIC, material adverse U.S. federal income tax consequences could apply to U.S. Holders (as defined in the section headed Material Tax Considerations &#8212; U.S. Federal Income Tax Consequences&#8221;) of our ordinary shares with respect to any &#8220;excess distribution&#8221; received from us and any gain from a sale or other disposition of our ordinary shares. Please see &#8220;Material Tax Considerations &#8212; U.S. Federal Income Tax Consequences.&#8221; </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">56</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tSNRFLS">&#8203;</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;"><font style="text-transform:uppercase;">Special Note Regarding Forward-Looking Statements</font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">We make forward-looking statements in this prospectus that are subject to risks and uncertainties. These forward-looking statements include information about possible or assumed future results of our business, financial condition, results of operations, liquidity, plans and objectives. In some cases, you can identify forward-looking statements by terminology such as &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;should,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; or the negative of these terms or other similar expressions. Forward-looking statements are based on information we have when those statements are made or our management&#8217;s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. Important factors that could cause such differences include, but are not limited to: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the adequacy of our financial and other resources, particularly in light of our history of recurring losses and the uncertainty regarding the adequacy of our liquidity to pursue our complete business objectives; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">our ability to complete the development of our product candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">our ability to find suitable co-development partners; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">our ability to obtain and maintain regulatory approvals for our product candidates in our target markets and the possibility of adverse regulatory or legal actions relating to our product candidates even if regulatory approval is obtained; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">our ability to rely on data from our Phase II TWIN trial to advance the development of SIRS-T; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">our ability to commercialize our pharmaceutical product candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">our ability to obtain and maintain adequate protection of our intellectual property; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">our ability to manufacture our product candidates in commercial quantities, at an adequate quality or at an acceptable cost; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">our ability to establish adequate sales, marketing and distribution channels; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">acceptance of our product candidates by healthcare professionals and patients; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the possibility that we may face third-party claims of intellectual property infringement; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the timing and results of clinical trials that we may conduct or that our competitors and others may conduct relating to our or their products; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">intense competition in our industry, with competitors having substantially greater financial, technological, research and development, regulatory and clinical, manufacturing, marketing and sales, distribution and personnel resources than we do; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">potential product liability claims; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">potential adverse federal, state and local government regulation in the United States, Europe or Israel; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">loss or retirement of key executives and research scientists. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">You should review carefully the risks and uncertainties described under the heading &#8220;Risk Factors&#8221; in this prospectus for a discussion of these and other risks that relate to our business and investing in our ordinary shares. The forward-looking statements contained in this prospectus are expressly qualified in their entirety by this cautionary statement. Except as required by law, we undertake no obligation to update publicly any forward-looking statements after the date of this prospectus to conform these statements to actual results or to changes in our expectations.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">57</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tTSMT">&#8203;</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;"><font style="text-transform:uppercase;">Trademarks, Service Marks and Trade Names</font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Solely for convenience, the trademarks, service marks, and trade names referred to in this prospectus are without the <font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">&#174;</font> and &#8482; symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensors to these trademarks, service marks and trade names. This prospectus contains additional trademarks, service marks and trade names of others, which are the property of their respective owners. All trademarks, service marks and trade names appearing in this prospectus are, to our knowledge, the property of their respective owners. We do not intend our use or display of other companies&#8217; trademarks, service marks or trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">58</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tMID">&#8203;</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;"><font style="text-transform:uppercase;">Market and Industry Data</font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">This prospectus includes statistics and other data relating to markets, market sizes and other industry data pertaining to our business that we have obtained from industry publications and surveys and other information available to us. Industry publications and surveys generally state that the information contained therein has been obtained from sources believed to be reliable. Market data and statistics are inherently predictive and speculative and are not necessarily reflective of actual market conditions. Such statistics are based on market research, which itself is based on sampling and subjective judgments by both the researchers and the respondents, including judgments about what types of products and transactions should be included in the relevant market. In addition, the value of comparisons of statistics for different markets is limited by many factors, including that (i)&#160;the markets are defined differently, (ii) the underlying information was gathered by different methods, and (iii) different assumptions were applied in compiling the data. Accordingly, the market statistics included in this prospectus should be viewed with caution. We believe that information from these industry publications included in this prospectus is reliable.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">59</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tUOP">&#8203;</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;"><font style="text-transform:uppercase;">Use of Proceeds</font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We estimate that the net proceeds from this offering will be approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, or approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million if the underwriters exercise in full their option to purchase additional ordinary shares, based upon an assumed initial public offering price of&#8201; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share (which is the midpoint of the price range set forth on the cover page of this prospectus), after deducting underwriting discounts and commissions and estimated offering expenses payable by us. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Each $1.00 increase (decrease) in the assumed initial public offering price of&#8201; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share would increase (decrease) the net proceeds we receive from this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming that the number of ordinary shares offered, as set forth on the cover page of this prospectus, remains the same and after deducting underwriting discounts and commissions. We may also increase or decrease the number of ordinary shares we are offering. Each increase or decrease of 1.0 million in the number of ordinary shares we are offering would increase or decrease the net proceeds we receive from this offering by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming no change in the assumed initial public offering price and after deducting underwriting discounts and commissions. </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">We intend to use the net proceeds from this offering as follows: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to fund our planned clinical program for TWIN for the treatment of acne; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.61pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:3.61pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to fund our planned clinical program of VERED for the treatment of subtype II rosacea; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:3.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million to fund our planned clinical program for SIRS-T for the treatment of acne; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:3.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the remainder to fund other research and development activities, including the development of our generic product candidates, as well as for working capital and other general corporate purposes. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Our expected use of net proceeds from this offering represents our current intentions based upon our present plans and business condition, which could change in the future as our plans and business conditions evolve. As of the date of this prospectus, we cannot predict with certainty any or all of the particular uses for the net proceeds to be received upon the closing of this offering, or the amounts, if any, that we will actually spend on the uses set forth above. The amounts and timing of our actual use of the net proceeds will vary depending on numerous factors, including our ability to obtain additional financing, if needed, the progress, cost and results of our pre-clinical and clinical development programs, and whether we are able to enter into future product development partnerships and technology license arrangements. As a result, our management will have broad discretion in the application of the net proceeds, which may include uses not set forth above, and investors will be relying on our judgment regarding the application of the net proceeds from this offering. The timing and amount of our actual expenditures will be based on many factors, including cash flows from operations and the anticipated growth of our business. We do not plan to use any proceeds from this offering for the repayment of any indebtedness. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Pending their use, we plan to invest the net proceeds from this offering in short and intermediate-term, interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed obligations of the U.S. government or to hold such proceeds as cash. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We believe that the anticipated net proceeds from this offering, together with our existing cash and cash equivalents, will be sufficient to enable us to fund our operating expenses and capital expenditure requirements through &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We have based this estimate on assumptions that may prove to be incorrect, and we could use our available capital resources sooner than we currently expect.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">60</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDP">&#8203;</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;"><font style="text-transform:uppercase;">Dividend Policy</font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We have never declared or paid any cash dividends on our ordinary shares and we anticipate that, for the foreseeable future, we will retain any future earnings to support operations and to finance the growth and development of our business. Therefore, we do not expect to pay cash dividends for at least the next several years. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The distribution of dividends may also be limited by the Companies Law, which permits the distribution of dividends only out of retained earnings or earnings derived over the two most recent fiscal years, whichever is higher, provided that there is no reasonable concern that payment of a dividend will prevent a company from satisfying its existing and foreseeable obligations as they become due. Our amended and restated articles of association provide that dividends will be paid at the discretion of, and upon resolution by, our board of directors, subject to the provisions of the Companies Law.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">61</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tCAP">&#8203;</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;"><font style="text-transform:uppercase;">Capitalization</font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">The following table sets forth our cash and cash equivalents and capitalization as of June&#160;30, 2017, on: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:1.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">an actual basis;</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.61pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:1.61pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">on a pro forma basis to give effect to (i) the automatic conversion of our outstanding promissory note between us and our controlling shareholder into an aggregate of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares immediately prior to the closing of this offering, assuming an initial public offering price of&#8201; $&#8199;&#8199;&#8199;&#8199; per ordinary share, which is the midpoint of the price range set forth on the cover page of this prospectus and (ii) the effectiveness of our amended and restated articles of association, adopted in connection with this offering; and</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:1.61pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:1.61pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">on a pro forma as adjusted basis, to give further effect to the issuance and sale of &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares in this offering at the assumed initial public offering price of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting the underwriting discounts and commissions and estimated offering expenses payable by us. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">You should read this table in conjunction with our financial statements and related notes included elsewhere in this prospectus and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221;</div>
        <table style="width:456pt;margin-top:2pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:289.67pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">As of June&#160;30, 2017</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:289.67pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:1.75pt 0pt 1pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Actual</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:1.75pt 0pt 1pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Pro Forma</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:1.75pt 0pt 1pt 0pt;" colspan="4">
              <div style="text-align:center;">Pro Forma<br >As Adjusted </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:289.67pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:1.75pt 0pt 1pt 0pt; width:0pt;text-align:center;" colspan="16">
              <div style="text-align:center;">(Unaudited)<br >(in thousands, <br >except share and per share data) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:1.75pt 0pt 1.75pt 0pt; width:289.67pt;text-align:left;">
              <div style="white-space:nowrap;">Cash and cash equivalents </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:3px double #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">23,295</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:3px double #000000; min-width:31.5pt; text-align:right; white-space:nowrap;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.88pt;width:0pt;">&#8203;</td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:3px double #000000; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.88pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:7.25pt 0pt 0.5pt 0pt; width:289.67pt;text-align:left;">
              <div style="white-space:nowrap;">Loans from the controlling shareholder </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:7.25pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:7.25pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">65,338</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:7.25pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:7.25pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.88pt;width:0pt;">&#8203;</td>
            <td style="padding:7.25pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:7.25pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.88pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:289.67pt;">Shareholders&#8217; equity (capital deficiency):</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:0.667pt 0pt 0.5pt 0pt; width:289.67pt;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">Ordinary shares of NIS 0.1 par value per share; 8,775,783 <br >shares authorized and 3,494,579 shares issued and <br >outstanding, actual; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares authorized and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <br >issued and outstanding, pro forma; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares authorized <br >and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;issued and outstanding, pro forma as adjusted </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0.667pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:0.667pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">82</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.88pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.88pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:289.67pt;text-align:left;">
              <div style="margin-left:10pt;">Additional paid-in capital </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">32,660</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:31.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.88pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.88pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2pt 0pt 1pt 0pt; width:289.67pt;text-align:left;">
              <div style="margin-left:10pt;">Accumulated deficit </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">(75,525<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:31.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.88pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.88pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:1.75pt 0pt 1pt 0pt; width:289.67pt;text-align:left;">
              <div style="margin-left:30pt;">Total shareholders&#8217; equity (capital deficiency) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.75pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">(42,783<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:31.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.88pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.88pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:1.75pt 0pt 2.75pt 0pt; width:289.67pt;text-align:left;">
              <div style="white-space:nowrap;">Total capitalization </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:1.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">22,555</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:1.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:31.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.88pt;width:0pt;">&#8203;</td>
            <td style="padding:1.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:1.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:24pt; text-align:right; white-space:nowrap;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
            <td style="padding:0pt;padding-left:4.88pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:5.5pt;line-height:5.5pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="20">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:12.5pt; width:456pt; line-height:12pt;">Each $1.00 increase or decrease in the assumed initial public offering price of&#8201; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share (which is the midpoint of the price range set forth on the cover page of this prospectus) would increase or decrease the pro forma as adjusted amount of each of cash and cash equivalents, additional paid-in capital, total shareholders&#8217; equity and total capitalization by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting the underwriting discounts and commissions. Each increase or decrease of 1.0 million in the number of ordinary shares we are offering would increase or decrease the pro forma as adjusted amount of each of cash and cash equivalents, additional paid-in capital, total shareholders&#8217; equity and total capitalization by approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, assuming no change in the assumed initial public offering price and after deducting the underwriting discounts and commissions. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The preceding table excludes (i) 253,768 ordinary shares issuable upon the exercise of options to purchase ordinary shares outstanding under our 2014 Share Incentive Plan as of June&#160;30, 2017, at a weighted average exercise price of&#8201; $2.86 per share; and (ii) an additional &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares reserved for future issuance under our amended and restated 2014 Share Incentive Plan, which will become effective upon the pricing of this offering.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">62</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDIL">&#8203;</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;"><font style="text-transform:uppercase;">Dilution</font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">If you invest in our ordinary shares in this offering, your ownership interest will be immediately diluted to the extent of the difference between the initial public offering price per share and the net tangible book value per ordinary share after this offering. Our net tangible book value (deficit) as of June&#160;30, 2017, was $(31,337) million, or $(8.97) per ordinary share. Net tangible book value per ordinary share was calculated by: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">subtracting our liabilities from our tangible assets; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">dividing the difference by the number of ordinary shares outstanding.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Our pro forma net tangible book value as of June 30, 2017 was $&#8199;&#8199;&#8199;&#8199; million, corresponding to a pro forma net tangible book value of&#8201; $&#8199;&#8199;&#8199;&#8199; per ordinary share. Pro forma net tangible book value per ordinary share represents our pro forma net tangible book value divided by the total number of our ordinary shares outstanding as of June 30, 2017, after giving effect to the assumed automatic conversion of our outstanding promissory note between us and our controlling shareholder into an aggregate of&#8201; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares immediately prior to the closing of this offering, assuming an initial public offering price of&#8201; $&#8199;&#8199;&#8199;&#8199; per ordinary share, which is the midpoint of the price range set forth on the cover page of this prospectus.</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">After giving further effect to the issuance and sale of&#8201; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares in this offering at an assumed initial public offering price of&#8201; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, after deducting underwriting discounts and commissions and estimated offering expenses payable by us, our pro forma as adjusted net tangible book value on June&#160;30, 2017 would have been approximately $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, or $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share. This represents an immediate dilution in the pro forma as adjusted net tangible book value of&#8201; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#160;per ordinary share to investors purchasing our ordinary shares in this offering. </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">The following table illustrates the immediate dilution to new investors: </div>
        <table style="width:416pt;height:166pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;">
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:343.11pt;text-align:left;">
              <div style="white-space:nowrap;">Assumed initial public offering price per ordinary share </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:0pt 0pt 1pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:343.11pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">Historical net tangible book value (deficit) per ordinary share as of June&#160;30, 2017</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">(&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:343.11pt;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">Increase per ordinary share attributable to the conversion of promissory <br >note as of June 30, 2017 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:343.11pt;text-align:left;">
              <div style="margin-left:10pt;">Pro forma net tangible book value per ordinary share </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:2.167pt 0pt 1.833pt 0pt; width:343.11pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">Increase in pro forma net tangible book value per ordinary share attributable to the offering </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:1.917pt 0pt 1.833pt 0pt; width:343.11pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">Pro forma as adjusted net tangible book value per share after this offering </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:343.11pt;text-align:left;">
              <div style="white-space:nowrap;">Dilution per ordinary share to new investors </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2.75pt 0pt; width:343.11pt;text-align:left;">
              <div style="white-space:nowrap;">Percentage of dilution per ordinary share to new investors</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;padding-bottom:1.75pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:4pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:16.5pt; text-align:right; white-space:nowrap;"><font style="position:relative;">&#8203;</font><font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:10pt;line-height:10pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="15">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:20.79pt; width:456pt; line-height:12pt;">Each $1.00 increase or decrease in the assumed initial public offering price of&#8201; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase or decrease the pro forma as adjusted net tangible book value as of June&#160;30, 2017 by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share, assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same and after deducting underwriting discounts and commissions. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Similarly, each increase or decrease of 1.0 million shares in the number of ordinary shares we are offering would increase or decrease the pro forma as adjusted net tangible book value as of June&#160;30, 2017 by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , or $(&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ) per ordinary share, respectively, and would decrease or increase dilution to investors in this offering by $(&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ) and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share, respectively, </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">63</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">assuming the assumed initial public offering price remains the same, and after deducting underwriting discounts and commissions. The pro forma as adjusted information is illustrative only, and we will adjust this information based on the actual initial public offering price and other terms of this offering determined at pricing. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">If the underwriters&#8217; option to purchase additional shares from us is exercised in full, and based on the assumed initial public offering price of&#8201; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share (which is the midpoint of the price range set forth on the cover page of this prospectus), the pro forma as adjusted net tangible book value would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share and the dilution per ordinary share to new investors in this offering would be $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; , after deducting underwriting discounts and commissions.</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The table below summarizes, as of June&#160;30, 2017, on the pro forma as adjusted basis described above, the differences for our existing shareholder and new investors in this offering, with respect to the number of ordinary shares purchased from us, the total consideration paid and the average price per ordinary share paid before deducting fees and offering expenses. </div>
        <table style="width:456pt;height:83.5pt;margin-top:10pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:247.3pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Shares purchased </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Total consideration </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="7">
              <div style="text-align:center;">Average <br >price per <br >share </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:247.3pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Number</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">% </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Amount</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">% </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:247.3pt;text-align:left;">
              <div style="white-space:nowrap;">Existing shareholder </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.79pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.79pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.485pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.485pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.550000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.550000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:247.3pt;text-align:left;">
              <div style="white-space:nowrap;">New investors</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.79pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.79pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.795pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.795pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.485pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.485pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.550000000000001pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.550000000000001pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.75pt 0pt; width:247.3pt;text-align:left;">
              <div style="white-space:nowrap;">Total </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.79pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:5.79pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:12.75pt; text-align:right; white-space:nowrap;">100</td>
            <td style="padding:0pt;padding-left:1.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.485pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:7.485pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:12.75pt; text-align:right; white-space:nowrap;">100</td>
            <td style="padding:0pt;padding-left:3.495pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.550000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:16.5pt; text-align:right; white-space:nowrap;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</td>
            <td style="padding:0pt;padding-left:0.550000000000001pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="35">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:14.98pt; width:456pt; line-height:12pt;">Each $1.00 increase or decrease in the assumed initial public offering price of&#8201; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share, which is the midpoint of the price range set forth on the cover page of this prospectus, would increase or decrease the total consideration paid by new investors by $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, and increase or decrease the percent of total consideration paid by new investors by assuming that the number of shares offered by us, as set forth on the cover page of this prospectus, remains the same. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The table and discussion above excludes (i) 253,768 ordinary shares issuable upon the exercise of options to purchase ordinary shares outstanding under our 2014 Share Incentive Plan as of June&#160;30, 2017, at a weighted average exercise price of&#8201; $2.86 per share; and (ii) an additional &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares reserved for future issuance under our amended and restated 2014 Share Incentive Plan, which will become effective upon the pricing of this offering. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">To the extent any options are issued under our equity incentive plans, or we issue additional ordinary shares in the future, there will be further dilution to investors participating in this offering. In addition, we may choose to raise additional capital because of market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans. If we raise additional capital through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our shareholders.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">64</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tSELFOD">&#8203;</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;"><font style="text-transform:uppercase;">Selected Financial Data</font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The following table sets forth our selected historical financial data, which is derived from our audited financial statements, which have been prepared in accordance with U.S. GAAP. The selected balance sheet data as of December&#160;31, 2015 and 2016 and our selected statement of operations data for the years ended December&#160;31, 2015 and 2016 is derived from our audited financial statements included elsewhere in this prospectus. The selected balance sheet data for the six months ended June 30, 2016 and 2017 and the selected statement of operations data as of June 30, 2017 have been derived from our unaudited financial statements included elsewhere in this prospectus and have been prepared on the same basis as the audited financial statements. In the opinion of management, the unaudited data reflects all adjustments, consisting only of normal recurring adjustments, necessary for a fair statement of the financial information in those statements. Our historical results are not necessarily indicative of the results that should be expected in the future, and results for the six months ended June 30, 2017 are not necessarily indicative of the results to be expected for the full year ending December 31, 2017 or any other future period. You should read this selected financial data in conjunction with, and it is qualified in its entirety by, reference to our historical financial information and other information provided in this prospectus including &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and our audited financial statements and related notes included elsewhere in this prospectus.</div>
        <table style="width:456pt;height:205.5pt;margin-top:10pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:207.95pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Year Ended December&#160;31,</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Six Months Ended June&#160;30,</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:207.95pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2015 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:207.95pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">(Unaudited)</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:207.95pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.5pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="text-align:center;">(in thousands, <br >except share and per share data) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:207.95pt;">Statement of Operations Data:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:207.95pt;text-align:left;">
              <div style="white-space:nowrap;">Research and development expenses </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">7,184</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">17,023</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">6,797</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">9,376</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:207.95pt;text-align:left;">
              <div style="white-space:nowrap;">General and administrative expenses</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">2,463</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">3,733</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">1,721</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">2,460</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:207.95pt;text-align:left;">
              <div style="white-space:nowrap;">Total operating loss</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">9,647</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">20,756</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">8,518</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">11,836</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:207.95pt;text-align:left;">
              <div style="white-space:nowrap;">Financial expenses, net </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">13</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">15</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">(7<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">(4<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:207.95pt;text-align:left;">
              <div style="white-space:nowrap;">Loss for the year</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">9,660</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">20,771</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">8,511</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">11,832</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:1.417pt 0pt 2.583pt 0pt; width:207.95pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">Basic and diluted loss per ordinary share&#160;(1)&#160;</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3px double #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">2.76</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3px double #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">5,94</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3px double #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">2.44</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:1.417pt 0pt 1.833pt 0pt;border-bottom:3px double #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">3.39</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:1.417pt 0pt 2.75pt 0pt; width:207.95pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">Weighted average number of ordinary shares <br >outstanding&#8201;&#8211;&#8201;basic and diluted</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.417pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">3,494,579</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.417pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">3,494,579</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.417pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">3,494,579</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.417pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">3,494,579</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="26">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.49pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:15pt;white-space:nowrap;font-size:8pt;">(1)<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:10pt; text-align:left; width:440.5pt;font-size:8pt;">Basic loss per ordinary share and diluted loss per ordinary share are the same because outstanding options would be anti-dilutive due to our net losses in these periods. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <table style="width:456pt;height:133pt;margin-top:10pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:337.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">As of</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:337.5pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="text-align:center;">December&#160;31,<br >2016</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="text-align:center;">June&#160;30,<br >2017</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:337.5pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.39pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.39pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">(Unaudited)</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:337.5pt;">Balance Sheet Data:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:337.5pt;text-align:left;">
              <div style="white-space:nowrap;">Cash and cash equivalents  </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.39pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">7,001</td>
            <td style="padding:0pt;padding-left:5.39pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.41pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">23,295</td>
            <td style="padding:0pt;padding-left:2.41pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:337.5pt;text-align:left;">
              <div style="white-space:nowrap;">Total assets  </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.39pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">10,985</td>
            <td style="padding:0pt;padding-left:5.39pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.41pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">28,702</td>
            <td style="padding:0pt;padding-left:2.41pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:337.5pt;text-align:left;">
              <div style="white-space:nowrap;">Total liabilities  </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.39pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">42,322</td>
            <td style="padding:0pt;padding-left:5.39pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.41pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">71,485</td>
            <td style="padding:0pt;padding-left:2.41pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:337.5pt;text-align:left;">
              <div style="white-space:nowrap;">Accumulated deficit  </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.39pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(63,693<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.39pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.41pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(75,525<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.41pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:337.5pt;text-align:left;">
              <div style="white-space:nowrap;">Total capital deficiency   </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.39pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(31,337<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.39pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.41pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(42,783<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.41pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">65</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tMDA">&#8203;</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;"><font style="text-transform:uppercase;">Management&#8217;s Discussion and Analysis of Financial Condition</font> <br ><font style="text-transform:uppercase;">and Results of Operations</font></div>
        <div style="text-indent:20pt; margin-top:6.02pt; width:456pt; line-height:12pt;font-style:italic;">The following discussion and analysis should be read in conjunction with our financial statements and related notes included elsewhere in this prospectus. This discussion and other parts of the prospectus contain forward-looking statements based upon current expectations that involve risks and uncertainties. Our actual results and the timing of selected events could differ materially from those anticipated in these forward-looking statements as a result of several factors, including those set forth under &#8220;Risk Factors&#8221; and elsewhere in this prospectus. See &#8220;Special Note Regarding Forward-Looking Statements.&#8221;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Overview </div>
        <div style="text-indent:20pt; margin-top:6.01pt; width:456pt; line-height:12pt;">We are a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Our current product candidate pipeline consists of late-stage branded product candidates that leverage our proprietary, silica-based microencapsulation technology platform, and several generic product candidates across multiple indications. Our lead product candidate, TWIN, is a novel, once-daily, non-antibiotic topical cream that we are developing for the treatment of acne vulgaris, or acne. We recently completed a 726 subject, double-blind, placebo-controlled, six-arm, multi-center Phase II clinical trial designed to assess the safety and efficacy of TWIN in subjects with facial acne. In this trial, TWIN demonstrated statistically significant improvements in all pre-defined co-primary and secondary efficacy endpoints, as compared to vehicle. Subject to an End of Phase II meeting to be scheduled with the FDA, we plan to initiate a pivotal Phase III program for TWIN in the United States in 2018 and expect to report top-line data from this program in 2019. Our other branded product candidates are: SIRS-T, a topical cream containing encapsulated tretinoin for the potential treatment of acne; and VERED, a potential treatment for subtype II rosacea. </div>
        <div style="text-indent:20pt; margin-top:7.02pt; width:456pt; line-height:12pt;">We designed our proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Our technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin. The resulting microcapsules are designed to allow the entrapped active ingredients to gradually migrate through the pores of the shell and deliver active ingredient doses onto the skin in a controlled manner, resulting in improved tolerability and stability without sacrificing efficacy. By separately encapsulating active ingredients within protective silica shells, our technology platform also enables the production of novel fixed-dose active ingredient combinations that otherwise would not be stable. We believe that our microencapsulation technology has the potential to be used for topical drug products to treat a variety of skin diseases. As a result of the FDA having already approved silica as a safe excipient for topical drug products, we expect the review process for each of our current branded product candidates to be conducted according to the FDA&#8217;s 505(b)(2) regulatory pathway, which may provide for a more efficient regulatory process by permitting us to rely, in part, upon the FDA&#8217;s previous findings of safety and efficacy of an approved product.</div>
        <div style="text-indent:20pt; margin-top:7.02pt; width:456pt; line-height:12pt;">Since our inception, we have incurred significant operating losses. We incurred net losses of $9.7 million and $20.8 million for the years ended December&#160;31, 2015 and 2016, respectively, and $8.5 million and $11.8 million for the six months ended June 30, 2016 and 2017, respectively. As of June&#160;30, 2017, we had an accumulated deficit of&#8201; $75.5 million. We expect to incur significant expenses and operating losses for the foreseeable future as we advance our product candidates from formulation development through pre-clinical development and clinical trials, seek regulatory approval and pursue commercialization of any approved product candidate. In addition, if we obtain marketing approval for any of our product candidates, we expect to incur significant expenses related to product manufacturing, marketing, sales and distribution. In addition, we may incur expenses in connection with the in-license or acquisition of additional product candidates. Furthermore, upon closing of this offering, we expect to incur additional expenses associated with operating as a U.S. public company, including significant legal, accounting, investor relations and other expenses that we did not incur as a private company. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">66</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">On August&#160;4, 2014, our former shareholders entered into a securities purchase agreement with our current sole shareholder, Arkin Dermatology, or the Purchase Agreement. The Purchase Agreement detailed the terms and conditions for the sale of the company to Arkin Dermatology in exchange for a cash payment in the amount of approximately $10.5 million in addition to an earn-out payment of up to $17.0 million based on the achievement of certain development and revenue-related milestones. In connection with the Purchase Agreement, our executive officers and certain employees were entitled, subject to certain research and development milestones and other conditions, to a special bonus in an aggregate amount of up to $3.0 million, all of which has been paid, with $1.0 million paid in each of the years 2014, 2016 and 2017 to our executive officers and certain employees. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Collaboration Agreements</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Perrigo </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">On April 27, 2015, we entered into a development, manufacturing and commercialization agreement, as amended on October 26, 2015, with Perrigo UK to work toward the objective of obtaining all FDA approvals necessary for the commercialization of ivermectin cream, 1%, in the United States. Under the terms of the agreement, Perrigo UK will conduct all regulatory, scientific, clinical and technical activities necessary to develop ivermectin cream, 1%, prepare and file an ANDA with the FDA, and gain regulatory approval to market ivermectin cream, 1%, in the United States. We granted Perrigo UK the right, title and interest in and to ivermectin cream, 1%, and agreed on each party&#8217;s portion of the costs, including the allocation of costs related to development and litigation expenses associated with performance under the agreement. As soon as reasonably practical after final approval by the FDA of the ANDA, if approval is granted, Perrigo UK is required to use diligent efforts to commercialize ivermectin cream, 1%, in the United States. Perrigo UK has the sole and exclusive right to establish and control the prices and all other terms and conditions for the sales of ivermectin cream, 1%, in the United States and is required to do so in good faith without derogating from our right to benefit from the commercialization of ivermectin cream, 1%. We will be entitled to 50% of Perrigo UK&#8217;s gross profits related to the sale of ivermectin cream, 1%, on a quarterly basis, for a period of 20 years following the first commercial sale of ivermectin cream, 1%, in the United States. The agreement may be terminated in the event of a material breach by one of the parties, certain potential infringement claims by third parties or an uncured insolvency or bankruptcy procedure of one of the parties. In addition, the agreement may be terminated if the gross profits relating to the sale of the product do not exceed a certain threshold or if the potential market for the product has been significantly reduced due to regulatory changes. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Each party is responsible for its own costs in relation to performance under the agreement. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We are obligated to finance all out-of-pocket trial expenses (including materials), and Perrigo UK is required to reimburse us for 40% of the out-of-pocket clinical trial expenses as follows (a)&#160;if we obtain FDA approval, by financing our share of the out-of-pocket litigation expenses, or (b) if FDA approval is not obtained, by reimbursing us an amount equal to 40% of our out-of-pocket expenses. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Douglas Pharmaceuticals</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">On June 7, 2017, we entered into a Development, License, Supply and Marketing Agreement, with Douglas with respect to the development and commercialization of a generic product candidate for a drug that already has generic substitutions. Douglas will manufacture the product for non-clinical and clinical trial uses, and once approved for marketing, for commercialization by us in the countries we elect to commercialize the product. Douglas will also be responsible for completing the formulation of the product and providing chemistry, manufacturing and control support, conducting all steps for production and quality controls of the product, formulation development of the product in final finished form and supporting the ANDA or any other applicable registration application. We will be responsible for conducting the legal and regulatory </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">67</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">review process, performing bioequivalence and clinical studies to obtain marketing approval for the product in the United States and preparing and filing the regulatory filings to obtain marketing approval in the United States. We have the right to commercialize the product in all countries in North America and any other country agreed with Douglas, and Douglas has the right to commercialize the product in Australia, New Zealand, the Southeast, East and North Asia region and the Middle East and North Africa region and any other country agreed to by the US and Douglas. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Each party granted the other an exclusive royalty free license under its related intellectual property with the right to grant sublicenses, to use and commercialize the product in the countries in which the other party has the right to commercialize the product. Any new intellectual property generated in the development plan will be jointly owned. We are responsible for patent prosecution and Douglas is required to reimburse us for 50% of our patent expenses.</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Each party is required to pay the other party 50% of its net profits from the sale of the products during the term of the agreement. In addition, we or the third party commercializing the product on our behalf will pay Douglas a transfer price based on the cost of goods for the manufacture of the products. The term of the agreement is ten years, and either party may terminate the agreement (i) for breach, (ii) if the joint steering committee established by the parties determines that it is unlikely that marketing approval will be achieved or determines that the commercialization of the product becomes unfeasible or uneconomic, (iii) a patent injunction permanently prohibits the future commercialization of the product or (iv) in the case of force majeure. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Financial Operations Overview </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Revenues </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Since 2013, we have not recognized any revenue and we do not expect to generate revenue from the sale of products in the near future. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Operating expenses </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Our current operating expenses consist primarily of research and development as well as general and administrative expenses. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Research and development expenses </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">Research and development expenses consist principally of: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">salaries for research and development staff and related expenses, including employee benefits and share-based compensation expenses; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">expenses paid to suppliers of disposables and raw materials, including drug substances, and related expenses, such as, external laboratory testing and development of analytical methods; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">expenses for production of our product candidates both in-house and by contract manufacturers; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">expenses paid to contract research organizations and other third parties in connection with the performance of pre-clinical studies, clinical trials and related expenses; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">expenses incurred under agreements with other third parties, including subcontractors, suppliers and consultants that conduct formulation development, regulatory activities and pre-clinical studies; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">expenses incurred to acquire, develop and manufacture materials for use in pre-clinical and other studies; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">68</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">expenses incurred from the purchase and transfer of product candidates; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">facilities, depreciation of fixed assets used to develop our product candidates, maintenance of equipment used to develop our product candidates and other expenses, including direct and allocated expenses for rent, maintenance of facilities, insurance and other operating expenses. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Research and development activities are central to our business model. Product candidates in later stages of clinical development generally have higher development expenses than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical trials. We expect our research and development expenses to increase significantly over the next several years as we increase personnel expenses, including share-based compensation, commence Phase III clinical trials for TWIN, SIRS-T and VERED and conduct pre-clinical studies and clinical trials and prepare regulatory filings for our product candidates. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Due to the inherently unpredictable and highly uncertain nature of clinical development processes, we cannot reasonably estimate the nature, timing and expenses of the efforts that will be necessary to complete the remainder of the development of our product candidates, or when, if ever, material net cash inflows may commence from any of our product candidates. Clinical development timelines, the probability of success and development expenses can differ materially from expectations. This is due to numerous risks and uncertainties associated with developing drugs, including the uncertainty of: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the scope, rate of progress and expense of our research and development activities; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">clinical trials and early-stage results; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the terms and timing of regulatory requirements and approvals; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the expense of filing, prosecuting, defending and enforcing patent claims and other intellectual property rights; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the ability to market, commercialize and achieve market acceptance of any product candidate that we are developing or may develop in the future. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">While we are currently focused on advancing our product development, our future research and development expenses will depend on the clinical success of our product candidates, as well as ongoing assessments of the candidates&#8217; commercial potential. As we obtain results from clinical trials, we may elect to discontinue or delay clinical trials for one or more of our product candidates in certain indications in order to focus our resources on more promising product candidates. Completion of clinical trials may take several years or more, but the length of time generally varies according to the type, complexity, novelty and intended use of a product candidate. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The lengthy process of completing clinical trials and seeking regulatory approval for our product candidates requires the expenditure of substantial resources. Any failure or delay in completing clinical trials, or in obtaining regulatory approvals, could cause a delay in generating product revenue and cause our research and development expenses to increase and, in turn, have a material adverse effect on our operations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">General and administrative expenses </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Our general and administrative expenses consist primarily of salaries and related expenses, including employee benefits and share-based compensation expenses, legal and professional fees for auditors and other consulting expenses not related to research and development activities. Such expenses include the process of becoming a public company, patent registration expenses, depreciation of fixed assets related to general and administrative activities and other expenses, including rent, maintenance of facilities, insurance and office expenses. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">69</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We expect that our general and administrative expenses will increase as a result of increased personnel expenses, including share-based compensation, expanded infrastructure and higher consulting, legal and tax-related service fees associated with maintaining compliance with stock exchange listing and SEC requirements, accounting and audit fees, investor relations expenses and director and officer insurance premiums associated with being a public company. Additionally, if and when we believe a regulatory approval of a product candidate appears likely, we anticipate an increase in payroll and expense as a result of our preparation for commercial operations, especially as it relates to the sales and marketing of our product candidates. </div>
        <div style="margin-top:11.61pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Financial expenses, net </div>
        <div style="text-indent:20pt; margin-top:5.03pt; width:456pt; line-height:11.5pt;">Our financial expenses consist primarily of expenses related to bank charges and foreign currency exchange transactions. </div>
        <div style="margin-top:11.61pt; width:456pt; line-height:11pt;font-weight:bold;">Results of operations </div>
        <div style="margin-left:20pt; margin-top:5.02pt; width:436pt; line-height:12pt;">The following table summarizes our results of operations for the indicated periods:</div>
        <table style="width:456pt;height:128pt;margin-top:10pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:265.47pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.25pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">For the Year Ended <br >December&#160;31,</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.25pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">For the Six Months Ended <br >June&#160;30,</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:265.47pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3pt 0pt 2.25pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2015</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3pt 0pt 2.25pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3pt 0pt 2.25pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3pt 0pt 2.25pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:265.47pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.25pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">(Unaudited)</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:265.47pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.25pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">(in thousands)</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.99999999999997pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1.25pt 0pt; width:265.47pt;text-align:left;">
              <div style="white-space:nowrap;">Research and development expenses  </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.25pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1.25pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">7,184</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.25pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1.25pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">17,023</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.25pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1.25pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">6,797</td>
            <td style="padding:0pt;padding-left:5.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.25pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1.25pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">9,376</td>
            <td style="padding:0pt;padding-left:5.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.25pt 0pt; width:265.47pt;text-align:left;">
              <div style="white-space:nowrap;">General and administrative expenses  </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">2,463</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">3,733</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">1,721</td>
            <td style="padding:0pt;padding-left:5.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">2,460</td>
            <td style="padding:0pt;padding-left:5.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.25pt 0pt; width:265.47pt;text-align:left;">
              <div style="white-space:nowrap;">Total operating loss  </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">9,647</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">20,756</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">8,518</td>
            <td style="padding:0pt;padding-left:5.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">11,836</td>
            <td style="padding:0pt;padding-left:5.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.25pt 0pt; width:265.47pt;text-align:left;">
              <div style="white-space:nowrap;">Financial expenses (income), net  </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">13</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">15</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.295pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">(7<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.295pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.29pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">(4<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.29pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 2.75pt 0pt; width:265.47pt;text-align:left;">
              <div style="white-space:nowrap;">Loss for the period  </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">9,660</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">20,771</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">8,511</td>
            <td style="padding:0pt;padding-left:5.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.29pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">11,832</td>
            <td style="padding:0pt;padding-left:5.29pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4.25pt;line-height:4.25pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="26">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:13.87pt; width:456pt; line-height:11pt;font-weight:bold;"><font style="font-weight:normal;"></font>Six months ended June&#160;30, 2016 compared to six months ended June&#160;30, 2017 </div>
        <div style="margin-top:10.61pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Research and development expenses</div>
        <div style="text-indent:20pt; margin-top:5.02pt; width:456pt; line-height:12pt;">The following table describes the breakdown of our research and development expenses for the indicated periods:</div>
        <table style="width:456pt;height:120pt;margin-top:10pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:343.58pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.25pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Six Months Ended June&#160;30,</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:343.58pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3pt 0pt 2.25pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3pt 0pt 2.25pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:343.58pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.25pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">(Unaudited)</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:343.58pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.25pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">(in thousands)</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1.25pt 0pt; width:343.58pt;text-align:left;">
              <div style="white-space:nowrap;">Payroll and related expenses  </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.825pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.25pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1.25pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">1,900</td>
            <td style="padding:0pt;padding-left:6.825pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.825pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1.25pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1.25pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">2,412</td>
            <td style="padding:0pt;padding-left:6.825pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.25pt 0pt; width:343.58pt;text-align:left;">
              <div style="white-space:nowrap;">Clinical trial expenses  </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.825pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">2,387</td>
            <td style="padding:0pt;padding-left:6.825pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.825pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">4,093</td>
            <td style="padding:0pt;padding-left:6.825pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.25pt 0pt; width:343.58pt;text-align:left;">
              <div style="white-space:nowrap;">Professional consulting and subcontracted work  </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.825pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">1,813</td>
            <td style="padding:0pt;padding-left:6.825pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.825pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.25pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">1,809</td>
            <td style="padding:0pt;padding-left:6.825pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.25pt 0pt; width:343.58pt;text-align:left;">
              <div style="white-space:nowrap;">Other  </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.825pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">697</td>
            <td style="padding:0pt;padding-left:6.825pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.825pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.25pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">1,062</td>
            <td style="padding:0pt;padding-left:6.825pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 2.75pt 0pt; width:343.58pt;text-align:left;">
              <div style="white-space:nowrap;">Total research and development expenses  </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.825pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">6,797</td>
            <td style="padding:0pt;padding-left:6.825pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.825pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">9,376</td>
            <td style="padding:0pt;padding-left:6.825pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4.25pt;line-height:4.25pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:8.28pt; width:456pt; line-height:12pt;">Our research and development expenses were $6.8 million for the six months ended June&#160;30, 2016, compared to $9.4 million for the six months ended June&#160;30, 2017. The increase of&#8201; $2.6 million is mainly attributed to an increase of&#8201; $1.7 million in clinical trial expenses related to the Phase II clinical trial of TWIN and the clinical trials of another product candidate that is no longer in development as well as $0.6 million due to accrued bonus expense.</div>
        <div style="margin-top:11.61pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">General and administrative expenses</div>
        <div style="text-indent:20pt; margin-top:5.02pt; width:456pt; line-height:12pt;">Our general and administrative expenses were $1.7 million for the six months ended June&#160;30, 2016, compared to $2.5 million for the six months ended June&#160;30, 2017. The increase of&#8201; $0.8 million is mainly attributed to an increase of&#8201; $0.3 million in professional fees and $0.4 million due to accrued bonus expense.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">70</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Financial income, net </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Our financial income, net, were immaterial for the six months ended June&#160;30, 2016 and 2017.</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Year ended December&#160;31, 2015 compared to year ended December&#160;31, 2016</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Research and development expenses </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The following table describes the breakdown of our research and development expenses for the indicated periods: </div>
        <table style="width:456pt;height:126pt;margin-top:10pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:348.01pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Year Ended December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:348.01pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2015 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:348.01pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">(in thousands) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:348.01pt;text-align:left;">
              <div style="white-space:nowrap;">Payroll and related expenses </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">2,647</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.325pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">3,629</td>
            <td style="padding:0pt;padding-left:4.325pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:348.01pt;text-align:left;">
              <div style="white-space:nowrap;">Clinical trial expenses </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">517</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.325pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">9,686</td>
            <td style="padding:0pt;padding-left:4.325pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:348.01pt;text-align:left;">
              <div style="white-space:nowrap;">Professional consulting and subcontracted work </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">2,001</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.325pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">1,830</td>
            <td style="padding:0pt;padding-left:4.325pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:348.01pt;text-align:left;">
              <div style="white-space:nowrap;">In-process research and development acquired </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">431</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.325pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.325pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:348.01pt;text-align:left;">
              <div style="white-space:nowrap;">Other </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">1,588</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.325pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">1,878</td>
            <td style="padding:0pt;padding-left:4.325pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.75pt 0pt; width:348.01pt;text-align:left;">
              <div style="white-space:nowrap;">Total research and development expenses </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">7,184</td>
            <td style="padding:0pt;padding-left:4.33pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.325pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">17,023</td>
            <td style="padding:0pt;padding-left:4.325pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:12.99pt; width:456pt; line-height:12pt;">Our research and development expenses were $7.2 million for the year ended December&#160;31, 2015, compared to $17.0 million for the year ended December 31, 2016. The increase of $9.8&#160;million is mainly attributed to an increase of&#8201; $9.2 million in clinical trial expenses due to the Phase II clinical trials of TWIN and another product candidate no longer in development, the bioequivalence study of ivermectin cream, 1%, and to an increase of&#8201; $1.0 million in payroll and related expenses due to an increase in the number of our employees, as well as to bonuses granted and paid during 2016 and to salary increases. These increases in clinical trial expenses were partially offset by a decrease in share-based compensation expenses and a decrease of&#8201; $0.4 million as a result of the transfer of an asset to us from an affiliated company in 2015. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">General and administrative expenses </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Our general and administrative expenses were $2.5 million for the year ended December&#160;31, 2015, compared to $3.7 million for the year ended December 31, 2016. The increase of&#8201; $1.2 million is mainly attributed to an increase of&#8201; $0.7 million in professional fees due to the initial public offering process and to an increase of&#8201; $0.4 million in payroll and related expenses due to bonuses that were recognized and paid during 2016 and salary raises that were partially offset by a decrease in share-based compensation expenses. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Financial expenses, net </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Our financial expenses, net, were immaterial for the years ended December&#160;31, 2015 and 2016. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Liquidity and Capital Resources </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Overview </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Since our inception, we have devoted substantially all of our resources to developing our product candidates, building our intellectual property portfolio, developing our supply chain, business planning, raising capital and providing for general and administrative support for these operations. We do not currently have any approved products. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">From inception through June 30, 2017, we have funded our operations primarily through the issuance of equity securities and loans from our shareholder in the aggregate amount of&#8201; $65.3 million, funding received from the Innovation Authority in the aggregate amount of approximately </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">71</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">$1.4 million and from amounts received pursuant to past collaboration agreements in the aggregate amount of&#8201; $28.5 million. We have agreed to automatically convert our outstanding promissory note between us and our controlling shareholder into an aggregate of&#8201; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares immediately prior to the closing of this offering. For a description of the conversion of our shareholder loan agreement, see &#8220;Certain Relationships and Related Party Transactions &#8212; Loan Agreements with Our Controlling Shareholder.&#8221; As of June 30, 2017, our cash and cash equivalents was $23.3 million. </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">The table below summarizes our cash flow activities for the indicated periods:</div>
        <table style="width:456pt;height:110pt;margin-top:10pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:271.09pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">Year Ended <br >December&#160;31,</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">Six Months <br >Ended June&#160;30,</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:271.09pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2015</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:271.09pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">(Unaudited)</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:271.09pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3pt 0pt 2pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="white-space:nowrap; text-align:center;">(in thousands)</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:271.09pt;text-align:left;">
              <div style="white-space:nowrap;">Net cash used in operating activities  </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">(8,044<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(18,495<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(7,392<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(11,143<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:271.09pt;text-align:left;">
              <div style="white-space:nowrap;">Net cash used in investing activities  </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">(210<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(391<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(153<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(603<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2pt 0pt; width:271.09pt;text-align:left;">
              <div style="white-space:nowrap;">Net cash from financing activities  </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">13,572</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">20,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">5,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">28,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:271.09pt;text-align:left;">
              <div style="white-space:nowrap;">Increase (decrease) in cash and cash equivalents  </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">5,301</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">1,106</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">(2,545<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">16,254</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4.5pt;line-height:4.5pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="26">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:16.5pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Operating Activities</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Net cash used in operating activities was $7.4 million during the six months ended June&#160;30, 2016, compared to $11.1 million during the six months ended June&#160;30, 2017. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Net cash used in operating activities in the six months ended June&#160;30, 2017 primarily resulted from our loss for the period of&#8201; $11.8 million during the period and $0.9 million used as advance payments for long-term receivables in connection with the collaboration agreement with Perrigo for ivermectin cream, 1%, along with $0.2 million used as an advance payment for laboratory equipment. This amount was partially offset by $0.4 million of share-based compensation expenses, $0.2 million of depreciation of property and equipment and a net reduction of&#8201; $0.2 million in working capital. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Net cash used in operating activities in the six months ended June&#160;30, 2016 primarily resulted from our loss of&#8201; $8.5 million during the period, and from $0.7 million used as advance payments for long-term receivables in connection with the collaboration agreement with Perrigo for ivermectin cream, 1%. This amount was partially offset by $0.2 million of share-based compensation expenses, a net reduction of&#8201; $1.4 million in working capital and $0.2 million of depreciation of property and equipment.</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Net cash used in operating activities was $8.0 million during the year ended December&#160;31, 2015, compared to $18.5 million during the year ended December 31, 2016. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Net cash used in operating activities in the year ended December&#160;31, 2015 primarily resulted from our loss for the period of&#8201; $9.7 million and $0.6 million used as an advanced payment to our CRO in connection with the Phase II clinical trial for TWIN, partially offset by $1.1 million of share-based compensation expenses, a net reduction of&#8201; $0.4 million in working capital, $0.4 million in in-process research and development acquired due to the transfer of an asset and $0.3 million of depreciation of property and equipment. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Net cash used in operating activities in the year ended December 31, 2016 primarily resulted from our loss of&#8201; $20.8 million during the period, and from $1.4 million used as advance payments for long-term receivables in connection with the Phase II clinical trial for TWIN and the collaboration agreement with Perrigo UK for ivermectin cream, 1%. This amount was partially offset by $1.0 million of share-based compensation expenses, a net reduction of&#8201; $2.3 million in working capital and $0.4 million depreciation of property and equipment. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">72</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Investing Activities</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Net cash used in investing activities was $0.2 million during the six months ended June&#160;30, 2016, compared to net cash used in investing activities of&#8201; $0.6 million during the six months ended June&#160;30, 2017. Net cash used in investing activities during the six months ended June&#160;30, 2016 and 2017 was primarily related to investments in property and equipment.</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Net cash used in investing activities was $0.2 million during the year ended December&#160;31, 2015, compared to net cash used in investing activities of&#8201; $0.4 million during the year ended December&#160;31, 2016. Net cash used for investing activities during the years ended December&#160;31, 2015 and 2016 was primarily related to the purchase of property and equipment. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Financing Activities</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Net cash from financing activities was $5.0 million during the six months ended June&#160;30, 2016, compared to $28.0 million during the six months ended June&#160;30, 2017. Financing activities in these years consisted of loans received from our controlling shareholder.</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Net cash from financing activities was $13.6 million during the year ended December&#160;31, 2015, compared to $20.0 million during the year ended December 31, 2016. Financing activities in these years consisted of loans received from our controlling shareholder. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Funding Requirements </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Our primary uses of cash have been to fund working capital requirements and research and development. We expect to continue to incur net losses for the foreseeable future as we continue to invest in research and development and seek to obtain regulatory approval for and commercialize our product candidates. We believe that the net proceeds of this offering, together with our existing cash and cash equivalents, will enable us to fund our operating expenses and capital expenditure requirements through &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. We have based this estimate on assumptions that may prove to be wrong, and we could use our capital resources sooner than we currently expect. Our ability to continue as a going concern will depend on our ability to generate positive cash flow from operations and obtain additional financing, both of which are uncertain. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In its report accompanying our audited financial statements for the year ended December&#160;31, 2016, included elsewhere in this prospectus, our independent registered accounting firm included an explanatory paragraph stating that our recurring losses from operations and lack of sufficient working capital raise substantial doubt as to our ability to continue as a going concern. In general, a &#8220;going concern&#8221; opinion means that our independent registered public accounting firm has substantial doubt about our ability to continue our operations without an additional infusion of capital from external sources, such as the proceeds from this offering. In addition, having a going concern qualification may make it less likely that investors or commercial banks will be willing to finance our operations. If we are unable to achieve these goals, our business will be in jeopardy and we may not be able to continue operations and may have to liquidate our assets. In such case, investors might receive less than the value at which those assets are carried on our financial statements, and it is likely that investors in this offering would lose all or a part of their investment. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Developing drugs, conducting clinical trials, obtaining commercial manufacturing capabilities and commercializing products is expensive and we will need to raise substantial additional funds to achieve our strategic objectives. We will require significant additional financing in the future to fund our operations, including if and when we progress into additional clinical trials for our product candidates, obtain regulatory approval for one or more of our product candidates, obtain commercial manufacturing capabilities and commercialize one or more of our product candidates. Our future funding requirements will depend on many factors, including, but not limited to: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the progress and expenses of our pre-clinical studies, clinical trials and other research and development activities; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">73</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the scope, prioritization and number of our clinical trials and other research and development programs; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the expenses and timing of obtaining regulatory approval, if any, for our product candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the expenses of filing, prosecuting, enforcing and defending patent claims and other intellectual property rights; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the expenses of, and timing for, expanding our manufacturing agreements for production of sufficient clinical and commercial quantities of our product candidates; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:3.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:3.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the potential expenses of contracting with third parties to provide marketing and distribution services for us or for building such capacities internally. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Until we can generate significant recurring revenues, we expect to satisfy our future cash needs through the net proceeds from this offering, debt or equity financings or by entering into collaborations with third parties in connection with one or more of our product candidates. We cannot be certain that additional funding will be available to us on acceptable terms, if at all. In addition, the terms of any securities we issue in future financings may be more favorable to new investors and may include preferences, superior voting rights and the issuance of warrants or other derivative securities, which may have a further dilutive effect on the holders of any of our securities then outstanding. If we raise additional funds through collaborations with third parties, we may be required to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us. If we are unable to obtain adequate funds on reasonable terms, we will need to curtail operations significantly, including possibly postponing anticipated clinical trials or entering into financing agreements with unattractive terms. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Contractual Obligations and Commitments </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">The following table summarizes our contractual obligations as of December&#160;31, 2016: </div>
        <table style="width:456pt;height:60.5pt;margin-top:10pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:212.57pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Total </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="text-align:center;">Less than <br >1 year </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">1&#8201;&#8211;&#8201;3 years </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">3&#8201;&#8211;&#8201;5 years </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="text-align:center;">More than <br >5 years </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:212.57pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="28">
              <div style="white-space:nowrap; text-align:center;">(in thousands) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:212.57pt;text-align:left;">
              <div style="white-space:nowrap;">Operating lease obligations (1) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; white-space:nowrap;">1,706</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.43pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:12.75pt; text-align:right; white-space:nowrap;">419</td>
            <td style="padding:0pt;padding-left:6.43pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; white-space:nowrap;">1,287</td>
            <td style="padding:0pt;padding-left:4.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.545pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:11.545pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.75pt 0pt; width:212.57pt;text-align:left;">
              <div style="white-space:nowrap;">Total </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; white-space:nowrap;">1,706</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.43pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:12.75pt; text-align:right; white-space:nowrap;">419</td>
            <td style="padding:0pt;padding-left:6.43pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; white-space:nowrap;">1,287</td>
            <td style="padding:0pt;padding-left:4.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.545pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:9pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:11.545pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="32">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:10.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:7.41pt; margin-bottom:0pt; text-align:left; width:15pt;white-space:nowrap;font-size:8pt;">(1)<br ></div>
        <div style=" float:left; margin-top:7.41pt; margin-bottom:0pt; line-height:10pt; text-align:left; width:440.5pt;font-size:8pt;">Operating lease obligations consist of payments pursuant to several lease agreements that are scheduled to expire on December&#160;31, 2020. Starting from March&#160;1, 2017, our total lease payments on all of our facilities increased to approximately $36,000 per month. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Under the specific terms of the funding arrangement between us and the Innovation Authority, royalties of 3.5% to 25% are payable on the sale of products developed with funding received from the Innovation Authority, which payments shall not exceed, in the aggregate, 300% of the amount of the grant received (dollar linked), plus interest at an annual rate based on LIBOR. As of December 31, 2016, we do not have any royalty payment obligations to the Innovation Authority.</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Off-Balance Sheet Arrangements </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We do not have any, and during the periods presented we did not have any, off-balance sheet arrangements as defined in the rules and regulations of the SEC. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Quantitative and Qualitative Disclosure about Market Risk </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We are exposed to market risks in the ordinary course of our business. Market risk represents the risk of loss that may impact our financial position due to adverse changes in financial market prices and rates. Our market risk exposure is primarily a result of foreign currency exchange rates, which is discussed in detail below. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">74</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Interest Rate Risk </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We do not anticipate undertaking any significant long-term borrowings. At present, our investments consist primarily of cash and cash equivalents. We may invest in investment-grade marketable securities with maturities of up to three years, including commercial paper, money market funds, and government/non-government debt securities. The primary objective of our investment activities is to preserve principal while maximizing the income that we receive from our investments without significantly increasing risk and loss. Our investments may be exposed to market risk due to fluctuation in interest rates, which may affect our interest income and the fair market value of our investments, if any. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Foreign Currency Exchange Risk </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The U.S. dollar is our functional and reporting currency. Although a substantial portion of our expenses (mainly salaries and related costs) are denominated in NIS, accounting for almost half of our expenses in the year ended December&#160;31, 2016, all of our financing has been in U.S. dollars and the vast majority of our liquid assets are held in U.S. dollars. Furthermore, while we anticipate that a portion of our expenses, principally salaries and related personnel expenses in Israel, will continue to be denominated in NIS, we expect to incur an increasing amount of expenses in U.S. dollars as we progress in the development and the regulatory processes of our product candidates. Changes of 5% in the U.S. dollar/NIS exchange rate would have increased/decreased operating expenses by approximately 2% during the fiscal year ended on December&#160;31, 2016. We also have expenses, although to a much lesser extent, in other non-U.S. dollar currencies, in particular the Euro. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Moreover, for the next few years we expect that the substantial majority of our revenues from the sale of our products in the United States, if any, will be denominated in U.S. dollars. Since a portion of our expenses is denominated in NIS and other non-U.S. currencies, we are exposed to risk associated with exchange rate fluctuations vis-&#224;-vis the non-U.S. currencies. See &#8220;Risk Factors&#160;&#8212; Exchange rate fluctuations between the U.S. dollar, the NIS and other foreign currencies, may negatively affect our future revenues.&#8221; If the NIS fluctuates significantly against the U.S. dollar it may have a negative impact on our results of operations. As of the date of this prospectus and for the periods under review, fluctuations in the currencies exchange rates have not materially affected our results of operations or financial condition. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We do not hedge our foreign currency exchange risk. In the future, we may enter into formal currency hedging transactions to decrease the risk of financial exposure from fluctuations in the exchange rates of our principal operating currencies. These measures, however, may not adequately protect us from the material adverse effects of such fluctuations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Inflation-related risks </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We do not believe that the rate of inflation in Israel has had a material impact on our business to date, however, our costs in Israel will increase if the inflation rate in Israel exceeds the devaluation of the NIS against the U.S. dollar or if the timing of such devaluation lags behind inflation in Israel. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Significant Accounting Policies and Estimates </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We prepare our financial statements in conformity with U.S. GAAP. We describe our significant accounting policies and estimates more fully in Note 2 to our financial statements as of and for the year ended December&#160;31, 2016, included elsewhere in this prospectus. We believe that the accounting policies and estimates below are critical in order to fully understand and evaluate our financial condition and results of operations. In preparing these financial statements, our management has made estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">75</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">and the reported amounts of expenses during the reporting periods recognized in our financial statements. Actual results may differ from these estimates. As applicable to the financial statements included in this prospectus, the most significant estimates and assumptions relate to the fair value of share-based compensation. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Share-based Compensation </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Share-based compensation reflects the compensation expense of our share option programs granted to employees which compensation expense is measured at the grant date fair value of the options. The grant date fair value of share-based compensation is recognized as an expense over the requisite service period, net of estimated forfeitures. We recognize compensation expense for awards conditioned only on continued service that have a graded vesting schedule using the accelerated method based on the multiple-option award approach, and classify these amounts in our statement of operations based on the department to which the related employee reports. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Options Valuation </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We selected the Black-Scholes option pricing model as the most appropriate method for determining the estimated fair value of the shared based compensation. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">For the purpose of the evaluation of the fair value and the manner of the recognition of share-based compensation, our management is required to estimate, among others, various subjective and complex parameters that are included in the calculation of the fair value of the option as well as our results and the number of options that will vest. These parameters include the expected volatility of our share price over the expected term of the options, the risk-free interest rate assumption, the share option exercise and forfeitures behaviors and expected dividends. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;"><font style="font-style:italic;">Fair value of ordinary shares</font>. Our ordinary shares are not publicly traded, thus, the fair value of the ordinary shares, for purpose of determining the exercise price for share-based payment awards, was determined in good faith by our management and approved by our board of directors. Our management considered the fair value of our ordinary shares based on a number of objective and subjective variables, consistent with the methodologies outlined in the American Institute of Certified Public Accountants Practice Aid, Valuation of Private-Held-Company Equity Securities issued as Compensation, referred to as the AICPA Practice Aid. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;"><font style="font-style:italic;">Volatility</font>. The expected share price volatility is based on the historical volatility of comparable companies. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;"><font style="font-style:italic;">Risk-free interest rate. </font>The risk-free interest rate is based on observed interest rates appropriate for the expected term of the options granted in dollar terms. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;"><font style="font-style:italic;">Expected term</font>. The expected term of options granted represents the period of time that the options are expected to be outstanding. Since adequate historical experience is not available to provide a reasonable estimate, the expected term was computed by averaging the vesting schedule of the options and the last available exercise date (the contracted expiry date). </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;"><font style="font-style:italic;">Expected dividend yield</font>. We have never declared or paid any cash dividends and we do not plan to pay cash dividends in the foreseeable future.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">76</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">The underlying data used for computing the fair value of the options are as follows: </div>
        <table style="width:456pt;height:121pt;margin-top:10pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:182.18pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">For the Year Ended December&#160;31,</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:81.13pt;">
              <div style="text-align:center;">For the<br >Six Months Ended<br >June&#160;30,</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:182.18pt;text-align:left;">
              <div style="white-space:nowrap;"></div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:81.13pt;">
              <div style="white-space:nowrap; text-align:center;">2015 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:75.57pt;">
              <div style="white-space:nowrap; text-align:center;">2016</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:81.13pt;">
              <div style="white-space:nowrap; text-align:center;">2017</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:182.18pt;text-align:left;">
              <div style="white-space:nowrap;">Value of one ordinary share </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:81.13pt;">
              <div style="text-align:center;"><font style="border-bottom:3px double #000000;">$11.35</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:75.57pt;">
              <div style="text-align:center;"><font style="border-bottom:3px double #000000;">$21.59</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:81.13pt;">
              <div style="text-align:center;"><font style="border-bottom:3px double #000000;">$</font><font style="border-bottom:3px double #000000;">36.84</font></div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.5pt 0pt; width:182.18pt;text-align:left;">
              <div style="white-space:nowrap;">Dividend yield </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt; width:81.13pt;">
              <div style="text-align:center;"><font style="border-bottom:3px double #000000;">0%</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt; width:75.57pt;">
              <div style="text-align:center;"><font style="border-bottom:3px double #000000;">0%</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt; width:81.13pt;">
              <div style="text-align:center;"><font style="border-bottom:3px double #000000;">0%</font></div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.5pt 0pt; width:182.18pt;text-align:left;">
              <div style="white-space:nowrap;">Expected volatility </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt; width:81.13pt;">
              <div style="text-align:center;"><font style="border-bottom:3px double #000000;">62.46%&#8201;&#8211;&#8201;66.22%</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt; width:75.57pt;">
              <div style="text-align:center;"><font style="border-bottom:3px double #000000;">68.45%&#8201;&#8211;&#8201;79.1%</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt; width:81.13pt;">
              <div style="text-align:center;"><font style="border-bottom:3px double #000000;">73.74%&#8201;&#8211;&#8201;</font><font style="border-bottom:3px double #000000;">78.71%</font></div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.5pt 0pt; width:182.18pt;text-align:left;">
              <div style="white-space:nowrap;">Risk-free interest rate </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt; width:81.13pt;">
              <div style="text-align:center;"><font style="border-bottom:3px double #000000;">1.61%&#8201;&#8211;&#8201;1.81%</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt; width:75.57pt;">
              <div style="text-align:center;"><font style="border-bottom:3px double #000000;">0.95%&#8201;&#8211;&#8201;1.34%</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2.5pt 0pt; width:81.13pt;">
              <div style="text-align:center;"><font style="border-bottom:3px double #000000;">1.57%&#8201;&#8211;&#8201;2.23%</font></div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2pt 0pt; width:182.18pt;text-align:left;">
              <div style="white-space:nowrap;">Expected term </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt; width:81.13pt;">
              <div style="text-align:center;"><font style="border-bottom:3px double #000000;">5.5&#8201;&#8211;&#8201;7.5 years </font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt; width:75.57pt;">
              <div style="text-align:center;"><font style="border-bottom:3px double #000000;">5&#8201;&#8211;&#8201;6.71 years</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt; width:81.13pt;">
              <div style="white-space:nowrap; text-align:center;"><font style="border-bottom:3px double #000000;">5.47&#8201;&#8211;&#8201;6.97 years</font></div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="11">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:12pt; width:456pt; line-height:12pt;">These assumptions represent our best estimates and involve inherent uncertainties and the application of our judgment. As a result, if we use significantly different assumptions or estimates, our share-based compensation expense could be materially different. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The following table presents the grant dates, number of underlying shares and related exercise prices of options granted to employees and service providers, as well as the estimated fair value of the underlying ordinary shares on the grant date. </div>
        <table style="width:456pt;height:145.5pt;margin-top:10pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:192.63pt;text-align:left;">
              <div style="white-space:nowrap;">Date of grant </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="text-align:center;">Number of <br >shares <br >subject to <br >awards <br >granted </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="text-align:center;">Class of <br >shares <br >subject to <br >the awards <br >granted </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="text-align:center;">Type of <br >equity <br >instrument <br >awarded </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="text-align:center;">Exercise <br >price per <br >share </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="text-align:center;">Estimated <br >fair value <br >per ordinary <br >share at <br >grant date </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:192.63pt;text-align:left;">
              <div style="white-space:nowrap;">March&#160;29, 2015 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.715pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">151,299</td>
            <td style="padding:0pt;padding-left:1.715pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">Ordinary</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.215pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">options</td>
            <td style="padding:0pt;padding-left:3.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.605pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">2.86</td>
            <td style="padding:0pt;padding-left:1.605pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.49pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">11.35</td>
            <td style="padding:0pt;padding-left:8.49pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:192.63pt;text-align:left;">
              <div style="white-space:nowrap;">April&#160;12, 2015 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.715pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">22,141</td>
            <td style="padding:0pt;padding-left:1.715pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">Ordinary</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.215pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">options</td>
            <td style="padding:0pt;padding-left:3.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.605pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">2.86</td>
            <td style="padding:0pt;padding-left:1.605pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.49pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">11.35</td>
            <td style="padding:0pt;padding-left:8.49pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:192.63pt;text-align:left;">
              <div style="white-space:nowrap;">August&#160;2, 2016 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.715pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">50,422</td>
            <td style="padding:0pt;padding-left:1.715pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">Ordinary</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.215pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">options</td>
            <td style="padding:0pt;padding-left:3.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.605pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">2.86</td>
            <td style="padding:0pt;padding-left:1.605pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.49pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">21.59</td>
            <td style="padding:0pt;padding-left:8.49pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:192.63pt;text-align:left;">
              <div style="white-space:nowrap;">February 12, 2017</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.715pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">29,906</td>
            <td style="padding:0pt;padding-left:1.715pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">Ordinary</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.215pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">options</td>
            <td style="padding:0pt;padding-left:3.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.605pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">2.86</td>
            <td style="padding:0pt;padding-left:1.605pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.49pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">36.84</td>
            <td style="padding:0pt;padding-left:8.49pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:192.63pt;text-align:left;">
              <div style="white-space:nowrap;">July&#160;13, 2017 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.715pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">15,040</td>
            <td style="padding:0pt;padding-left:1.715pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">Ordinary</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.215pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">options</td>
            <td style="padding:0pt;padding-left:3.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.605pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">2.86</td>
            <td style="padding:0pt;padding-left:1.605pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.49pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:8.49pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:192.63pt;text-align:left;">
              <div style="white-space:nowrap;">July&#160;13, 2017</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.715pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">211,470</td>
            <td style="padding:0pt;padding-left:1.715pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">Ordinary</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.215pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">options</td>
            <td style="padding:0pt;padding-left:3.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.605pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">10.02</td>
            <td style="padding:0pt;padding-left:1.605pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.49pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:8.49pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:192.63pt;text-align:left;">
              <div style="white-space:nowrap;">August&#160;22, 2017 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.715pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">70,500</td>
            <td style="padding:0pt;padding-left:1.715pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">Ordinary</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.215pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27.75pt; text-align:right; white-space:nowrap;">options</td>
            <td style="padding:0pt;padding-left:3.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.605pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">10.02</td>
            <td style="padding:0pt;padding-left:1.605pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.49pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:8.49pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:13.89pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:10.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:8pt;">*<br ></div>
        <div style=" float:left; margin-top:10.99pt; margin-bottom:0pt; line-height:10pt; text-align:left; width:435.5pt;font-size:8pt;">Valuation not yet finalized.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Based on the assumed initial public offering price of&#8201; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, which is the midpoint of the price range set forth on the cover page of this prospectus, the intrinsic value of the awards outstanding as of&#8201; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017 was $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, of which $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million related to vested options and $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million related to unvested options. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;"><font style="font-style:italic;">2015 awards.</font> In March&#160;and April&#160;2015, we granted 173,440 options to our executive officers to purchase ordinary shares. Our board of directors set an exercise price of&#8201; $2.86 per share for these options. Twenty-five percent of the options vest on the first anniversary of the vesting commencement date (August&#160;4, 2014) and the rest vest quarterly over the following three years. The options expire on the tenth anniversary of the grant date. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In preparation for our initial public offering, we performed in April&#160;2016 a retrospective valuation, with the assistance of a third-party valuation firm, of our ordinary shares as of March&#160;and April 2015, which determined that their fair value at that time was $11.35 per share. For the purpose of determining our enterprise value, we used the discounted cash flow, or DCF, method. Under the DCF method, our projected after-tax cash flows available to return to holders of invested capital were discounted back to present value, using the discount rate. Since it is not possible to project our after-tax cash flows beyond a limited number of years, the DCF method relies on determining a &#8220;terminal value&#8221; representing the aggregate value of the future after-tax cash flows after the end of the period for which annual projections are possible. The discount rate, </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">77</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">known as the weighted average cost of capital, or WACC, accounts for the time value of money and the appropriate degree of risk inherent in a business. The DCF method requires significant assumptions, in particular, regarding our projected cash flows and the discount rate applicable to our business. For the purpose of that valuation we applied a discount rate of 18%, and projected after-tax cash flows based on the probabilities of the realization of the scenario in which we receive FDA approval. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Having determined our enterprise value, we allocated it among the different elements of our share capital using the option pricing method, or OPM. Under the OPM, each security&#160;&#8212; ordinary shares and options&#160;&#8212; is treated as a call option having an exercise price based on the amount and optimal conversion price. The value of the call option is determined using the Black-Scholes option pricing model. The Black-Scholes model requires significant assumptions, in particular, the time until investors in our company would experience an exit event and the volatility of our ordinary shares. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;"><font style="font-style:italic;">2016 awards.</font> In August 2016, we granted 50,422 options to our executive officers to purchase ordinary shares. Our board of directors set an exercise price of&#8201; $2.86 per share for these options. Twenty-five percent of the options vest on the first anniversary of the vesting commencement date and the rest vest quarterly over the following three years. The options expire on the tenth anniversary of the grant date. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In September 2016, we performed a retrospective valuation, with the assistance of a third-party valuation firm, of our ordinary shares as of August 2016, which determined that their fair value at that time was $21.59 per share. For the purpose of determining our enterprise value, we used the discounted cash flow, or DCF, method. Under the DCF method, our projected after-tax cash flows available to return to holders of invested capital were discounted back to present value, using the discount rate. Since it is not possible to project our after-tax cash flows beyond a limited number of years, the DCF method relies on determining a &#8220;terminal value&#8221; representing the aggregate value of the future after-tax cash flows after the end of the period for which annual projections are possible. The discount rate, known as the weighted average cost of capital, or WACC, accounts for the time value of money and the appropriate degree of risk inherent in a business. The DCF method requires significant assumptions, in particular, regarding our projected cash flows and the discount rate applicable to our business. For the purpose of that valuation we applied a discount rate of 20%, and projected after-tax cash flows based on the probabilities of the realization of the scenario in which we receive FDA approval. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Having determined our enterprise value, we allocated it among the different elements of our share capital using the OPM. Under the OPM, each security &#8212; ordinary shares and options &#8212; is treated as a call option having an exercise price based on the amount and optimal conversion price. The value of the call option is determined using the Black-Scholes option pricing model. The Black-Scholes model requires significant assumptions, in particular, the time until investors in our company would experience an exit event and the volatility of our ordinary shares. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;"><font style="font-style:italic;">2017 awards.</font> In February 2017, we granted 29,906 options to one of our executive officers to purchase ordinary shares. Our board of directors set an exercise price of&#8201; $2.86 per share for these options. Twenty-five percent of the options vest on the first anniversary of the vesting commencement date and the rest vest quarterly over the following three years. Upon the occurrence of a merger or sale (as such term is defined in the option agreement), 100% of the then unvested options shall become fully vested, provided, that the grantee is an employee at such time. The options expire on the tenth anniversary of the grant date. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In July 2017, we granted 15,040 options to certain of our employees and service providers to purchase ordinary shares. Our board of directors set an exercise price of&#8201; $2.86 per share for these options. In July and August 2017, we granted 281,970 options to certain of our executive officers, employees and service providers to purchase ordinary shares. Our board of directors set an exercise price of&#8201; $10.02 for these options. Twenty-five percent of the options vest on the first </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">78</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">anniversary of the vesting commencement date and the rest vest quarterly over the following three years. The options are subject to acceleration in the event of a change of control of our company. The options expire on the tenth anniversary of the grant date. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;"><font style="font-style:italic;">Future option awards.</font> Following the completion of our initial public offering and the listing of our ordinary shares on the NASDAQ Global Market, the determination of the fair market value of our ordinary shares for purposes of setting the exercise price of future option awards or other share-based compensation to employees and other grantees will no longer require good faith estimates by our board of directors based on various comparisons or benchmarks. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Recent Accounting Pronouncements </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We are currently evaluating the impact of the U.S. GAAP standards as issued by the FASB that are effective for the first time for the financial year beginning on or after January&#160;1, 2016 on our financial statements. See Note 2 to our annual financial statements and Note&#160;2 to our interim financial statements, both included elsewhere in this prospectus. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">JOBS Act </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">On April&#160;5, 2012, the JOBS Act was signed into law. Section 107 of the JOBS Act provides that an &#8220;emerging growth company&#8221; can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. This means that an &#8220;emerging growth company&#8221; can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to utilize this exemption and, therefore, we will not be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. In addition, as a result of this election, our future financial statements may not be comparable to those of public companies that are not emerging growth companies and are required to comply with public company effective dates for new or revised accounting standards. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Subject to certain conditions set forth in the JOBS Act, as an &#8220;emerging growth company,&#8221; we also elected or may elect to rely on other exemptions, including without limitation, not (i)&#160;providing an auditor&#8217;s attestation report on our system of internal controls over financial reporting pursuant to Section 404 and (ii) complying with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#8217;s report providing additional information about the audit and the financial statements (auditor discussion and analysis). These exemptions will apply until the earliest of&#8201; (a) the last day of our fiscal year during which we have total annual gross revenues of at least $1.07 billion; (b) the last day of our fiscal year following the fifth anniversary of the closing of this offering; (c) the date on which we have, during the previous three-year period, issued more than $1.0 billion in non-convertible debt; or (d) the date on which we are deemed to be a &#8220;large accelerated filer&#8221; under the Exchange Act. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">79</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tBUS">&#8203;</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;"><font style="text-transform:uppercase;">Business</font></div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Overview </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We are a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. Our current product candidate pipeline consists of late-stage branded product candidates that leverage our proprietary, silica-based microencapsulation technology platform, and several generic product candidates across multiple indications. Our lead product candidate, TWIN, is a novel, once-daily, non-antibiotic topical cream that we are developing for the treatment of acne vulgaris, or acne. We recently completed a 726 subject, double-blind, placebo-controlled, six-arm, multi-center Phase II clinical trial designed to assess the safety and efficacy of TWIN in subjects with facial acne. In this trial, TWIN demonstrated statistically significant improvements in all pre-defined co-primary and secondary efficacy endpoints, as compared to vehicle. Subject to an End of Phase II meeting to be scheduled with the FDA, we plan to initiate a pivotal Phase III program for TWIN in the United States in 2018 and expect to report top-line data from this program in 2019. Our other branded product candidates are: SIRS-T, a topical cream containing encapsulated tretinoin for the potential treatment of acne; and VERED, a potential treatment for subtype II rosacea. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We designed our proprietary, silica-based microencapsulation technology platform to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Our technology platform entraps active ingredients in an inert, inorganic silica shell, which creates an unnoticeable barrier between the active ingredient and the skin. The resulting microcapsules are designed to allow the entrapped active ingredients to gradually migrate through the pores of the shell and deliver active ingredient doses onto the skin in a controlled manner, resulting in improved tolerability and stability without sacrificing efficacy. By separately encapsulating active ingredients within protective silica shells, our technology platform also enables the production of novel fixed-dose active ingredient combinations that otherwise would not be stable. We believe that our microencapsulation technology has the potential to be used for topical drug products to treat a variety of skin diseases. As a result of the FDA having already approved silica as a safe excipient for topical drug products, we expect the review process for each of our current branded product candidates to be conducted according to the FDA&#8217;s 505(b)(2) regulatory pathway, which may provide for a more efficient regulatory process by permitting us to rely, in part, upon the FDA&#8217;s previous findings of safety and efficacy of an approved product.</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Each of our branded product candidates leverages our proprietary, silica-based microencapsulation technology platform. We maintain exclusive, worldwide commercial rights for all of our branded product candidates, which consist of: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">TWIN, a novel, once-daily, non-antibiotic topical cream, which we are developing for the treatment of acne, containing a fixed-dose combination of encapsulated benzoyl peroxide, or E-BPO, and encapsulated tretinoin. Acne is one of the three most prevalent skin diseases in the world and is the most commonly treated skin disease in the United States, representing a $3.7&#160;billion market in 2016, according to Quintiles IMS Holdings, Inc. or IMS. According to the American Academy of Dermatology, acne affects approximately 40 to 50 million people in the United States, of which approximately 10% are treated with prescription medications. In July 2017, we reported positive top-line results from a double-blind, dose-ranging active- and placebo-controlled, six-arm, multi-center Phase II clinical trial of TWIN in the United States in 726 subjects, 128 of which subjects across six treatment groups did not complete the study. The clinical trial evaluated the efficacy, tolerability and safety of two TWIN concentrations, TWIN Low and TWIN High, each containing a lower or higher concentration, respectively, of encapsulated tretinoin and an identical concentration of E-BPO. Tretinoin and benzoyl peroxide, the two active components in TWIN, are both widely-used therapies for the treatment of acne that historically have not been conveniently co-administered due to stability concerns. The </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">80</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-left:40pt; width:416pt; line-height:12pt;">trial also evaluated the contribution of encapsulated tretinoin and E-BPO, in the same concentrations as those in the respective TWIN treatment groups, to the efficacy of TWIN High and TWIN Low. In this trial, TWIN showed statistically significant improvements in all pre-defined co-primary and secondary efficacy endpoints, as compared to vehicle. In addition, TWIN was well tolerated with no treatment-related serious adverse events. Based on the efficacy data we observed in the Phase II trial, we believe TWIN, if approved, has the potential to become a preferred treatment for acne. In 2018, subject to an End of Phase II meeting to be scheduled with the FDA, we plan to initiate a pivotal Phase III program for TWIN in the United States and expect to report top-line data from this program in 2019. </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.62pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:4.62pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">SIRS-T, a topical cream containing encapsulated tretinoin, which we are developing as a potential treatment for acne. Based on the results of the encapsulated tretinoin treatment groups in our recent Phase II TWIN study, we believe that microencapsulation of tretinoin using our technology platform will reduce the irritation typically associated with topical application of tretinoin. According to IMS, the overall sales of tretinoin products, including Retin-A Micro, Atralin and Retin-A, in the twelve months ending June&#160;30, 2017 were $561 million. SIRS-T is designed to provide a more tolerable tretinoin treatment option in order to improve patient compliance with treatment regimens. By leveraging our microencapsulation technology, we believe SIRS-T has the potential to become a leading tretinoin drug product and an attractive option for physicians who prefer a single active ingredient drug for the treatment of mild acne. We intend to utilize the data from the TWIN Phase II study in the development of SIRS-T. Subject to an End of Phase II meeting to be scheduled with the FDA with regard to the Phase II TWIN trial, we plan to commence a pivotal Phase III program for SIRS-T in the United States in 2019 and expect to report top-line data from this program in 2020. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.42pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:4.42pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">VERED, a topical cream containing 5% E-BPO, which we are developing for the treatment of subtype II (papulopustular) rosacea. Rosacea is a chronic skin disease characterized by facial redness, inflammatory lesions, burning and stinging. According to the U.S. National Rosacea Society, approximately 16 million people in the United States are affected by rosacea. According to a study we commissioned, approximately 4.8 million people in the United States experience subtype II symptoms. Subtype II rosacea is characterized by small, dome-shaped erythematous papules, tiny surmounting pustules on the central aspects of the face, solid facial erythema and edema, and thickening/overgrowth of skin. Subtype II rosacea resembles acne, except that comedones are absent, and patients may report associated burning and stinging sensations. We evaluated VERED in a double blind, randomized, dose-ranging Phase II clinical trial involving 92 adult subjects at ten centers in the United States. In this trial, VERED showed statistically significant improvements in the Investigator Global Assessment, or IGA, pre-defined co-primary efficacy endpoint and in the percent change in inflammatory lesion count at week 12, as compared to vehicle. VERED also had a favorable safety profile and was well tolerated in this trial. Current topical therapies for subtype II rosacea are limited due to tolerability concerns. For example, BPO, a common therapy for acne, is not used for the treatment of subtype II rosacea due to side effects. As encapsulated BPO, VERED is designed to redefine the standard of care for the treatment of subtype II rosacea. If approved, we expect VERED to be the first product containing BPO that is marketed for the treatment of subtype II rosacea. Subject to an End of Phase II meeting to be scheduled with the FDA, we expect to commence a pivotal Phase III program for VERED in the United States in 2018 and expect to report top-line data from this program in 2019. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In addition to our late-stage branded product candidates, we are currently developing a portfolio of six generic topical dermatological products. Three of our generic product candidates are being developed in collaboration with Perrigo UK Finco Limited Partnership, or Perrigo. A fourth generic product candidate is being developed in collaboration with Douglas Pharmaceuticals (New Zealand), or Douglas Pharmaceuticals. Both Perrigo and Douglas Pharmaceuticals have significant experience in the development of generic drugs. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">81</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Our most advanced generic product candidate is ivermectin cream, 1%, for the treatment of inflammatory lesions associated with rosacea, which is being developed in collaboration with Perrigo. In March 2017, Perrigo submitted an abbreviated new drug application, or ANDA, with a Paragraph IV certification for ivermectin cream, 1% to the FDA. This ANDA is currently on file with the FDA. Following notification from Perrigo, Galderma Laboratories, L.P., Galderma S.A., and Nestle Skin Health S.A., filed a patent litigation suit triggering the application of a 30 month stay on approval of the ANDA, under the Hatch-Waxman amendments to the Federal Food, Drug, and Cosmetic Act, or FDCA. Ivermectin cream, 1% is the active molecule in Soolantra, which is currently marketed in the United States by Galderma Laboratories LP. For the twelve months ended June 30, 2017, Soolantra achieved sales of&#8201; $87.3&#160;million according to IMS. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Our leadership team has considerable expertise in the identification and development of generic dermatological drug products and our intellectual property and formulation teams continue to seek to identify new opportunities to expand our pipeline of generic product candidates. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The following chart represents our current branded and generic product candidate pipeline: </div>
        <div style="position:relative;z-index:-1;margin-top:8pt; text-align:center; width:456pt;">
          <img src="t1701829_chrt-flow.jpg" alt="[MISSING IMAGE: t1701829_chrt-flow.jpg]" height="245" width="568" >
        </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Our Strengths </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We believe we are well positioned to become a leading, pure-play dermatology company based on the following key characteristics: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;"><font style="font-style:italic;">Diverse late-stage branded product pipeline with observed clinical benefits and favorable tolerability profiles.</font> We have leveraged our knowledge of the dermatology market to establish a pipeline of diversified late-stage branded product candidates with the potential to address the need for improved drug therapies. We have observed favorable clinical results for our branded product candidates that have completed Phase II trials. We recently completed a Phase II clinical trial for TWIN in the United States in 726 subjects with acne, the results of which we also intend to use to support further development of SIRS-T. In the Phase II TWIN trial, we observed statistically significant improvements compared to vehicle in achieving the co-primary efficacy endpoints of&#8201; &#8216;&#8216;clear&#8217;&#8217; or &#8216;&#8216;almost clear&#8217;&#8217; with two-grade reduction in IGA and in reducing absolute inflammatory and non-inflammatory lesion count at week 12. We also completed a Phase II clinical trial of VERED in the United States in 92 subjects with subtype II rosacea in which we observed statistically significant results for the co-primary efficacy endpoint of&#8201; &#8216;&#8216;clear&#8217;&#8217; or &#8216;&#8216;almost clear&#8217;&#8217; with a two-grade reduction in IGA. Subject to the End of the Phase II meetings to be scheduled with the FDA, we plan to commence Phase III programs for each of TWIN and VERED in 2018 and for SIRS-T in 2019. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">82</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;"><font style="font-style:italic;">Proprietary, silica-based microencapsulation drug delivery technology platform with broad applicability.</font> We leverage our innovative silica-based microencapsulation drug delivery technology platform in the development of each of our branded product candidates. In addition, we believe our technology platform provides us with the potential to develop additional product candidates that can overcome the limitations of currently approved products for multiple skin diseases. Our in-depth understanding of the chemical and physical parameters affecting the release rate of active pharmaceutical ingredients from microcapsules made of silica allows us to create the desired, well-defined, controlled-release profiles, including for novel fixed-dose active ingredient combinations, that otherwise would not be stable. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;"><font style="font-style:italic;">Efficient FDA regulatory pathway for our current branded product pipeline.</font> We expect the review process for TWIN, SIRS-T and VERED to be conducted according to the FDA&#8217;s 505(b)(2) regulatory pathway, which permits us to rely, in part, upon the FDA&#8217;s previous findings of safety and efficacy of an approved product. Silica, which forms the basis of our proprietary microencapsulation technology platform, is an inorganic inert excipient that is contained in other topical drug products approved by the FDA. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;"><font style="font-style:italic;">Diversified pipeline of generic drug product candidates and established strategic collaborations.</font> Our product pipeline includes six topical generic product candidates across multiple indications. We have established collaborations with Perrigo and Douglas Pharmaceuticals to efficiently develop four of our generic product candidates. We are collaborating with Perrigo in developing three of our generic product candidates, including ivermectin cream, 1%, for the treatment of inflammatory lesions associated with rosacea for which Perrigo filed an ANDA in March 2017. We are also developing a generic product candidate for a drug that already has generic substitutions in collaboration with Douglas Pharmaceuticals. We believe our strategic collaborations can help maximize the commercial potential of these generic product candidates. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;"><font style="font-style:italic;">Comprehensive and broad intellectual property portfolio.</font> We maintain exclusive, worldwide commercial rights for all of our branded product candidates. We have granted patents covering TWIN and VERED, expiring in 2028 and 2032, respectively. If patents issue from our patent applications, TWIN, SIRS-T and VERED, will have patent coverage until 2032, 2030 and 2032, respectively. In addition, we believe our patent portfolio and considerable proprietary know-how creates a barrier to entry for generic drugs with comparable and bioequivalent release profiles. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;"><font style="font-style:italic;">Experienced leadership team with proven track record.</font> Our leadership team has extensive experience in the development and commercialization of dermatology drug products. Our chief executive officer and co-founder, Alon Seri-Levy, has experience in the field of computer-aided drug design and more than 20 years of experience in the field of drug development. Mr. Arkin, who serves as the chairman of our board of directors and is our controlling shareholder, has held leadership roles in several innovative and generic drug companies. Mr. Arkin was the chairman of Agis Industries Ltd., expanding it into a leading pharmaceutical company in the United States until its acquisition by Perrigo Company plc, where he subsequently served as Vice Chairman. We believe that our leadership team is well-positioned to lead us through clinical development, regulatory approval and commercialization for our product candidates. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Our Strategy </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Our strategy is to become a leading, pure-play dermatology company focused on identifying, developing and commercializing treatments for skin diseases in areas with the need for improved drug therapies. To achieve this objective, we intend to pursue the following: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;"><font style="font-style:italic;">Complete clinical development of our late-stage branded product candidates and obtain regulatory approvals.</font> We plan to advance our late-stage branded product candidates </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">83</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-left:40pt; width:416pt; line-height:12pt;">through clinical development and obtain regulatory approvals. Subject to End of Phase II meetings to be scheduled with the FDA, we plan to commence pivotal Phase III programs in 2018 for TWIN for the treatment of acne and for VERED for the treatment of subtype II rosacea. In addition, we intend to use TWIN&#8217;s Phase II trial results in order to select the preferred dose for SIRS-T as a potential treatment for acne. Subject to an End of Phase II meeting to be scheduled with the FDA, we plan to commence a pivotal Phase III program for SIRS-T in 2019. </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;"><font style="font-style:italic;">Maximize commercial potential of our late-stage branded product candidates.</font> We intend to commercialize our late-stage branded product candidates in the United States, if approved, by building a specialized sales and marketing organization focused solely on dermatologists and their patients. Because the U.S. market is served by a relatively small number of practicing dermatologists, we believe a small and dedicated sales force can efficiently cover a significant portion of the target patient population. In other markets, we may selectively pursue strategic collaborations with third parties in order to maximize the commercial potential of our late-stage branded product candidates, if approved. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;"><font style="font-style:italic;">Selectively expand our branded product candidate pipeline.</font> We continuously evaluate opportunities to leverage our proprietary silica-based microencapsulation technology platform to efficiently develop additional branded product candidates for the treatment of skin diseases in areas where we believe there is a need for improved drug therapies. We may also seek to in-license, acquire or develop additional branded product candidates for dermatological indications from other companies by leveraging the expertise and experience of our leadership team. We intend to focus on branded product candidates that we believe have streamlined regulatory pathways. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;"><font style="font-style:italic;">Opportunistically broaden our generic pipeline.</font> We intend to continue to develop and opportunistically broaden our generic pipeline with product candidates that we believe have the potential to capture significant share of attractive markets and geographies. In certain cases, such as ivermectin cream, 1%, which we are developing in collaboration with Perrigo, we may seek strategic collaborations with pharmaceutical companies in order to expedite the development process, obtain regulatory approvals and commercialize our generic drug product candidates. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Dermatology Market Overview </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We focus on medical dermatology, which includes many common skin diseases such as acne, rosacea, psoriasis, atopic dermatitis and actinic keratosis. These diseases can have significant, multidimensional negative effects on patients&#8217; quality of life, including their physical and emotional well-being and social acceptance. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The dermatology and skin care market has experienced significant growth in the last several years. Based on IMS data, the U.S. medical dermatology market (excluding biologics) was valued at over $11 billion in prescription pharmaceutical sales in 2016, of which $9.8 billion represented sales of topical drugs. According to IMS, dermatological drugs sales in the United States have grown at an annual rate of 10% since 2012. We believe many factors are continuing to drive growth in the medical dermatological market, including population growth for prevalent age groups and growth in the number of physicians dispensing products. We believe patients&#8217; willingness to pay for dermatology treatments out-of-pocket is a result of often visible symptoms from dermatological diseases, which further supports demand and pricing. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We believe dermatology offers a low cost commercialization opportunity compared to many other medical specialties due to the relatively small number of specialists. According to IMS, there are approximately 14,000 active dermatologists in the United States. Because the U.S. market is served by a relatively small number of practicing dermatologists, we believe a small and dedicated sales force can efficiently cover a significant portion of the targeted patient population. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">84</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Our Branded Product Candidates </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our Acne Product Candidates: TWIN and SIRS-T </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Using our proprietary, silica-based microencapsulation technology platform, we are developing TWIN and SIRS-T to become preferred treatments for acne by dermatologists and their patients. </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;font-style:italic;">TWIN Overview </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">TWIN is a novel, once-daily, non-antibiotic topical cream containing a fixed-dose combination of E-BPO and encapsulated tretinoin that we are developing for the treatment of acne. Studies have shown that benzoyl peroxide and tretinoin are effective in treating acne as monotherapies, but a drug-drug interaction that causes the degradation of tretinoin has previously prohibited the development of a combination therapy. By encapsulating the two agents separately through the use of our technology platform, TWIN is designed to be a fixed-dose combination that otherwise would not be stable. Similar to other combination drug products containing retinoids, such as tretinoin, and benzoyl peroxide, we expect TWIN to be kept refrigerated throughout the supply chain and then stored in ambient conditions upon its distribution to patients. Pre-clinical data suggests that TWIN may be more tolerable than generic tretinoin gel 0.1% and Epiduo, a branded fixed-dose combination of benzoyl peroxide and adapalene, without a corresponding loss in efficacy. In addition, Epiduo and its successor Epiduo Forte contain adapalene as opposed to tretinoin, which is widely considered to be more effective than adapalene, but generally causes greater irritation. We expect that TWIN, if approved, will compete directly with Epiduo and Epiduo Forte. Epiduo and Epiduo Forte achieved sales of&#8201; $396 million for the twelve months ended June 30, 2017. We expect to utilize the FDA&#8217;s 505(b)(2) regulatory pathway in seeking approval of TWIN in the United States. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In July 2017, we completed a 726 subject, randomized, multi-center, double-blind, placebo-controlled Phase II clinical trial of TWIN in the United States that demonstrated statistically significant improvements compared to vehicle in the co-primary efficacy endpoints of &#8216;&#8216;clear&#8217;&#8217; or &#8216;&#8216;almost clear&#8217;&#8217; with a two-grade reduction in IGA and in reducing absolute inflammatory and non-inflammatory lesion counts at week 12. Of the 726 subjects enrolled in the trial, 128 subjects across six treatment groups did not complete the study. The most common reasons for subjects not completing the study were the withdrawal of informed consent (42 subjects), loss to follow-up (56 subjects) and adverse events (18 subjects). Based on the results of this trial, we intend to schedule an End of Phase II meeting with the FDA and expect to commence a Phase III program for TWIN in 2018. </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;font-style:italic;">SIRS-T Overview </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">SIRS-T is a topical cream containing a single active pharmaceutical ingredient, encapsulated tretinoin, that we are developing for the treatment of acne. By utilizing our technology platform to encapsulate tretinoin in a silica shell, we believe SIRS-T can be a more tolerable tretinoin-based treatment of acne. The silica shell in SIRS-T is designed to create a barrier between the drug substance and the skin and to control its release rate into the skin. As a result, we expect our silica-based technology platform to reduce irritation typically associated with topical application of tretinoin. Based on our recent Phase II TWIN study, we believe our technology platform can create a more tolerable tretinoin-based drug as compared to currently available tretinoin-based treatments. We intend to leverage the data from the TWIN Phase II study in the development of SIRS-T. We believe SIRS-T has the potential to be an attractive option for physicians who prefer a single active ingredient drug for the treatment of mild acne. Subject to an End of Phase II meeting to be scheduled with the FDA, we plan to commence a pivotal Phase III clinical program for SIRS-T in 2019. We expect that SIRS-T, if approved, will compete directly with Retin-A Micro, Atralin and Retin-A, which contain tretinoin as well as with generic tretinoin. Topical tretinoin products are currently available in strengths ranging from 0.025% to 0.1%. According to IMS, the </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">85</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">majority of sales unit for these products are for the 0.05% strength. The overall sales of tretinoin products, including Retin-A Micro, Atralin and Retin-A, in the twelve months ending June&#160;2017 were $561 million. We expect to utilize the FDA&#8217;s 505(b)(2) regulatory pathway in seeking approval of SIRS-T in the United States. </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;font-style:italic;">Acne Market Opportunity </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Acne is a disease characterized by areas of scaly red skin, non-inflammatory blackheads and whiteheads, inflammatory lesions, papules and pustules and occasionally boils and scarring that occur on the face, neck, chest, back, shoulders and upper arms. The development of acne lesions is caused by genetic and environmental factors that arise from the interplay of the following pathogenic factors: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">blockage of hair follicles through abnormal keratinization in the follicle, which narrows pores; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">increase in oils, or sebum production, secreted by the sebaceous gland; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">overgrowth of naturally occurring bacteria caused by the colonization by the anaerobic lipohilic bacterium <font style="font-style:italic;">Propionibacterium acnes</font>, or <font style="font-style:italic;">P. acnes</font>; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">inflammatory response due to relapse of pro-inflammatory mediators into the skin. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Due to the frequency of recurrence and relapse, acne is characterised as a chronic inflammatory disease, which may require treatment over a prolonged period of time. Acne is one of the three most prevalent skin diseases in the world and is the most commonly treated skin disease in the United States. According to the American Academy of Dermatology, acne affects approximately 40 to 50 million people in the United States and approximately 85% of people between the ages of 12 and 24 experience some form of acne. Acne patients suffer from the appearance of lesions on areas of the body with a large concentration of oil glands, such as the face, chest, neck and back. These lesions can be inflamed (papules, pustules, nodules) or non-inflamed (comedones). Early effective treatment is recommended to lessen the overall long-term impact. For most people, acne diminishes over time and tends to disappear, or at least to decrease, by the age of 25. There is, however, no way to predict how long it will take for symptoms to disappear entirely, and some individuals continue to suffer from acne well into adulthood. </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;font-style:italic;">Acne Market Size </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">According to IMS data, the U.S. acne market was valued at $3.7 billion in pharmaceutical sales in 2016 and has grown at an annual rate of nearly 15% since 2012. In 2016, $2.5 billion in sales were attributable to branded products and $3.1 billion were attributed to either branded or generic topical therapies. The acne market represented approximately 33% of the total U.S. medical dermatology market in 2016, and approximately 16% of the total U.S. dermatology drug prescriptions market. </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;font-style:italic;">Current Treatment Landscape for Acne </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The treatment options for acne depend on the severity of the disease and consist of topical and oral drugs: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;"><font style="font-weight:bold;">Mild acne</font>: characterized by few papules or pustules (both comedonal and inflammatory); treated with an over-the-counter product or topical prescription therapies. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;"><font style="font-weight:bold;">Moderate acne</font>: characterized by multiple papules and pustules with moderate inflammation and seborrhea (scaly red skin); treated with a combination of oral antibiotics and topical therapies. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;"><font style="font-weight:bold;">Severe acne</font>: characterized by substantial papulopustular disease, many nodules and/or cysts and significant inflammation and seborrhea; treated with oral and topical combination therapies and photodynamic therapy as a third-line treatment. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">86</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Topical therapies dominate the acne market as physicians and patients often prefer therapies that act locally on the skin, while minimizing side effects. For more pronounced symptoms, patients are typically treated with a combination of topical and oral therapies. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The acne prescription treatment landscape is comprised of four classes of topical products and two classes of oral products: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;"><font style="font-weight:bold;">Topical over-the-counter monotherapies</font> such as adapalene 0.1%, benzoyl peroxide and salicylic acid, in different concentrations, are the most commonly used therapies. These are generally tolerable first-line treatments for mild acne, but less efficacious than prescription therapies. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;"><font style="font-weight:bold;">Topical prescription antibiotic monotherapies</font> such as clindamycin and erythromycin that are most commonly used as topical therapies in cases of mild-to-moderate acne. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;"><font style="font-weight:bold;">Topical prescription retinoid monotherapies</font> such as tretinoin, adapalene 0.3% and tazarotene. Physicians view retinoids as moderately efficacious, but they have high rates of skin irritation. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;"><font style="font-weight:bold;">Topical prescription combination products </font>such as combinations of BPO/adapalene, BPO/clindamycin, BPO/erythromycin and clindamycin/tretinoin. These target multiple components that contribute to the development of acne, though topical side effects are common. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;"><font style="font-weight:bold;">Oral prescription antibiotics </font>such as doxycycline and minocycline. These are typically used as step-up treatments for more severe cases of acne, with risk of systemic side effects. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;"><font style="font-weight:bold;">Oral prescription isotretinoin</font>, which is primarily used for severe cystic acne and acne that has not responded to other treatments. The use of oral prescription isotretinoin is tightly controlled due to tolerability issues. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;font-style:italic;">Our Solutions for Acne&#8201;&#8212;&#8201;TWIN and SIRS-T </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Using our proprietary, silica-based microencapsulation technology platform, we are developing TWIN and SIRS-T to become preferred treatments for acne by dermatologists and their patients. Our silica-based proprietary delivery system is designed to enhance the tolerability and stability of topical drugs while maintaining their efficacy. Topical drugs often struggle to balance achieving both high efficacy and high tolerability. Our technology platform entraps active ingredients in an inert silica shell, which creates an unnoticeable barrier between the active ingredient and the skin. The resulting microcapsules are designed to allow the entrapped active ingredients to gradually migrate through the pores of the shell and deliver active ingredient doses into the skin in a controlled manner, resulting in improved tolerability and stability without sacrificing efficacy. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We believe that TWIN, a fixed-dose combination of a cream containing E-BPO and encapsulated tretinoin, has the potential to solve the industry-wide challenge of stabilizing tretinoin in the presence of benzoyl peroxide, a combination known to be effective in acne therapy, but not previously conveniently co-administered. While benzoyl peroxide slows the proliferation of P. acnes, tretinoin regulates hyperkeratinization and abnormal desquamation of follicular epithelium. This creates a synergistic combination which has the potential to overcome the challenges faced by currently approved products. </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">We designed TWIN to protect tretinoin from oxidative decomposition, which occurs when it is combined with benzoyl peroxide, with the goal of enhancing stability without reducing efficacy. We believe this could allow for a suitable clinical and commercial shelf life. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">87</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">The silica shell creates a barrier between the two drug substances and the skin. As a result, we believe TWIN can reduce irritation typically associated with topical application of benzoyl peroxide and tretinoin, leading to greater tolerability to acne-affected skin. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">By encapsulating tretinoin in our proprietary technology platform, we believe SIRS-T has the potential to be a more tolerable tretinoin-based drug as a treatment for acne and would improve patients&#8217; compliance with treatment regimens. We believe SIRS-T has the potential to become a leading tretinoin-based drug product on the market and an attractive option for physicians who prefer to prescribe a single active ingredient drug for the treatment of mild acne. </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">We designed SIRS-T to be a more tolerable tretinoin-based acne treatment for patients with mild acne who can be treated with a single agent. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">The silica shell in SIRS-T creates a barrier between the drug substances and the skin, which we believe can reduce irritation typically associated with topical application of tretinoin. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;font-style:italic;">TWIN Phase II Trial Design </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In May 2016, we commenced a Phase II, multi-center, six-arm, randomized, double-blind, placebo-controlled study designed to assess the efficacy, tolerability and safety of two TWIN concentrations, TWIN Low and TWIN High. Each TWIN concentration contained identical concentrations of E-BPO. TWIN Low contained a lower concentration of encapsulated tretinoin, while TWIN High contained a higher concentration of encapsulated tretinoin. The trial also evaluated the contribution of each of the encapsulated forms of both the lower and higher concentrations of tretinoin, or E-ATRA High and E-ATRA Low, and of E-BPO. A total of 726 subjects were enrolled in the trial at 36 sites in the United States of which 598 subjects completed the trial. We reported topline results of the trial in July 2017. Subjects were equally randomized into six treatment groups: TWIN High, TWIN Low, E-ATRA High, E-ATRA Low, E-BPO and vehicle. The age of the subjects ranged from 10 to 59, with a mean age of 22. Gender distribution was 37% male and 63% female, with patients of a variety of skin types. Inclusion criteria required 20 to 50 inflammatory lesions and 25 to 100 non-inflammatory lesions and an IGA score of 3 or 4 (&#8216;&#8216;moderate&#8217;&#8217; or &#8216;&#8216;severe&#8217;&#8217;) on a five-point scale that ranges from a score of zero, representing &#8216;&#8216;clear&#8217;&#8217; skin, to a score of 4, representing &#8216;&#8216;severe&#8217;&#8217; disease. Subjects were also required to have two or fewer cysts or nodules. The evaluation period spanned 12 weeks after initial treatment. Subjects were instructed to apply the drug once daily before bedtime. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The primary and secondary efficacy endpoints were assessed at the end of the 12-week treatment period. Three primary efficacy endpoints were defined for this trial: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the proportion of subjects who achieve at least a two-grade reduction in the IGA score and either &#8216;&#8216;clear&#8217;&#8217; or &#8216;&#8216;almost clear&#8217;&#8217; at week 12; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the mean absolute change from baseline in the number of inflammatory acne lesions at week 12; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the mean absolute change from baseline in the number of non-inflammatory acne lesions at week 12. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The two secondary efficacy endpoints measured the percent change in inflammatory and non-inflammatory lesion count at week 12. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">All statistical analyses and data shown for TWIN are on the intent-to-treat, or ITT, population. Randomized clinical trials analyzed by the ITT approach provide unbiased comparisons among the treatment groups. In an ITT population, subjects are analyzed according to the randomization scheme. In other words, for the purposes of ITT analysis, everyone who is randomized in the trial is considered to be part of the trial regardless of whether he or she is dosed at all or completes the </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">88</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">trial per protocol for the recommended duration of treatment. The ITT population for TWIN High consisted of 116 subjects, 102 of which had moderate acne and 14 of which had severe acne. The ITT population for TWIN Low consisted of 117 subjects, 104 of which had moderate acne and 13 of which had severe acne. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Discontinuations were treated statistically with the last observation carry forward methodology for the TWIN data sets shown below. P-value is a conventional statistical method for measuring the statistical significance of clinical results. A p-value of less than 0.05 is generally considered to represent statistical significance, meaning that there is a less than five percent likelihood that the observed results occurred by chance. Unless otherwise specified, the p-values shown herein represent a comparison of each active group to the pooled vehicle treatment groups. </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;font-style:italic;">TWIN Phase II Trial Results </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">As outlined below, TWIN demonstrated statistically significant improvements relative to vehicle in all primary and secondary efficacy endpoints. The IGA success rate, defined as achieving at least a two-grade reduction in the IGA score and either &#8216;&#8216;clear&#8217;&#8217; or &#8216;&#8216;almost clear&#8217;&#8217; at week 12, was 39.68% for TWIN High (p-value of&#8201; &lt;0.001), 27.43% for TWIN Low (p-value = 0.006) and 12.27% for vehicle.</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">At baseline across all treatment groups, the mean inflammatory lesion count was 26 to 29, the mean non-inflammatory lesion count was 42 to 43, and 86% to 91% of the subjects had an IGA score of&#8201; &#8216;&#8216;moderate&#8217;&#8217;, or 3, while the remainder had an IGA score of&#8201; &#8216;&#8216;severe&#8217;&#8217;, or 4. The absolute mean change from baseline in the number of non-inflammatory lesions was <font style="white-space:nowrap;">-23.6</font> for TWIN High, -23.7 for TWIN Low and <font style="white-space:nowrap;">-13.7</font> for vehicle, with a p-value of&#8201; &lt;0.001. The absolute mean change from baseline in the number of inflammatory lesions was <font style="white-space:nowrap;">-16.9</font> for TWIN High, <font style="white-space:nowrap;">-17.0</font> for TWIN Low and <font style="white-space:nowrap;">-11.5</font> for vehicle, with a p-value of&#8201; &lt;0.001. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Percent change in lesion counts from baseline at week 12 was statistically significantly compared to vehicle for both non-inflammatory and inflammatory lesions for each TWIN treatment group. Percent change from baseline at week 12 in the number of non-inflammatory lesions was 53.30% for TWIN High, 54.90% for TWIN Low and 32.40% for vehicle, with a p-value for each TWIN treatment group of&#8201; &lt;0.001. Percent change from baseline at week 12 in the number of inflammatory lesions was 64.04% for TWIN High, 60.75% for TWIN Low and 42.17% for vehicle, with a p-value for each TWIN treatment group of&#8201; &lt;0.001. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The following chart presents the proportion of subjects in the ITT population in each treatment group who achieved a successful improvement in the severity of their disease at week 12, as assessed using the IGA. </div>
        <div style="position:relative;z-index:-1;margin-top:8pt; text-align:center; width:456pt;">
          <img src="t1701829_chrt-iga.jpg" alt="[MISSING IMAGE: t1701829_chrt-iga.jpg]" height="201" width="422" >
        </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">89</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;">The following chart presents the mean absolute change from baseline in the number of inflammatory acne lesions at week 12.</div>
        <div style="position:relative;z-index:-1;margin-top:8pt; text-align:center; width:456pt;">
          <img src="t1701829_chrt-inflam01.jpg" alt="[MISSING IMAGE: t1701829_chrt-inflam01.jpg]" height="191" width="435" >
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;">The following chart presents the mean absolute change from baseline in the number of non-inflammatory acne lesions at week 12. </div>
        <div style="position:relative;z-index:-1;margin-top:8pt; text-align:center; width:456pt;">
          <img src="t1701829_chrt-inflam01a.jpg" alt="[MISSING IMAGE: t1701829_chrt-inflam01a.jpg]" height="191" width="435" >
        </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;">90</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The following chart presents the secondary efficacy endpoint of the percent reduction in inflammatory lesion count from baseline to the end of the 12-week treatment period in the ITT population.</div>
        <div style="position:relative;z-index:-1;margin-top:8pt; text-align:center; width:456pt;">
          <img src="t1701829_chrt-inflam02.jpg" alt="[MISSING IMAGE: t1701829_chrt-inflam02.jpg]" height="366" width="391" >
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The following chart presents the secondary efficacy endpoint of the percent reduction in non-inflammatory lesion count from baseline to the end of the 12-week treatment period in the ITT population.</div>
        <div style="position:relative;z-index:-1;margin-top:8pt; text-align:center; width:456pt;">
          <img src="t1701829_chrt-inflam02a.jpg" alt="[MISSING IMAGE: t1701829_chrt-inflam02a.jpg]" height="366" width="391" >
        </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">91</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We also assessed cutaneous tolerability by recording the erythema (redness), scaling, pigmentation, itching, burning and stinging on a four-point scale from 0 to 3 at baseline and at each visit. These measurements are either measured by the physician or reported by the subject. Overall, TWIN was generally well tolerated. The majority of cutaneous adverse events were mild. The remaining treatment groups were also generally well tolerated by treated subjects, which we believe demonstrates that encapsulation of tretinoin may provide a tolerable solution.</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Of the 726 subjects who enrolled in the study, 128 subjects across the six treatment groups did not complete the study. The most common reasons for subjects not completing the study were the withdrawal of informed consent (42 subjects), loss to follow-up (56 subjects) and adverse events (18 subjects). For TWIN High and TWIN Low, five subjects (4.2%) and eight subjects (6.6%) withdrew informed consent, respectively, compared to six subjects (5.0%) for vehicle, seven subjects (5.7%) for E-ATRA High, eight subjects (6.6%) for E-ATRA Low and eight subjects (6.6%) for E-BPO. Eleven subjects (9.2%) in the TWIN High group and six subjects (5.0%) in the TWIN Low group were lost to follow-up, compared to nine subjects (7.6%) for vehicle, 17 subjects (13.9%) for E-ATRA High, six subjects (4.9%) for E-ATRA Low and seven subjects (5.7%) for E-BPO. For TWIN High and TWIN Low, five subjects (4.2%) and three subjects (2.5%) did not complete the trial due to adverse events, respectively, compared to no subjects for vehicle, four subjects (3.3%) for E-ATRA High, two subjects (1.6%) for E-ATRA Low and four subjects (3.3%) for E-BPO.</div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;font-style:italic;">Phase III Clinical Development Plan </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Subject to an End of Phase II meeting to be scheduled with the FDA, we plan to initiate a pivotal Phase III clinical program for TWIN in the United States in 2018, which we expect to include two, multi-center, placebo-controlled trials with identical endpoints to our recently reported successful Phase II trial. We expect to report top-line data from this program in 2019. We intend to design the clinical program to demonstrate the efficacy of treatment with TWIN relative to vehicle for the treatment of acne. Prior to, or in parallel with, our planned Phase III clinical program, we intend to complete a pharmacokinetics safety study and expect to commence additional safety studies. We also intend to conduct a long-term safety study. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Additionally, we intend to use TWIN&#8217;s Phase II trial results in order to select the preferred dose for SIRS-T in our planned Phase III clinical program for SIRS-T. Subject to an End of Phase II meeting to be scheduled with the FDA, we plan to commence a Phase III clinical program for SIRS-T in 2019, as well as standard safety studies, with top-line results anticipated in 2020. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">VERED for Subtype II Rosacea </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;font-style:italic;">VERED Overview </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">VERED is a once-daily topical cream containing 5% E-BPO that we are developing for the treatment of subtype II rosacea. We believe VERED has the potential to become the first product to contain E-BPO for the treatment of subtype II rosacea and, if approved, has the potential to redefine the standard of care for the treatment of inflammatory lesions associated with subtype II rosacea. Subtype II rosacea is characterized by small, dome-shaped erythematous papules, tiny surmounting pustules on the central aspects of the face, solid facial erythema and edema, and thickening/overgrowth of skin. Subtype II rosacea resembles acne, except that comedones are absent, and patients may report associated burning and stinging sensations. In 2012, we completed a 92 subject, randomized, multi-center, double-blind, vehicle-controlled Phase II trial for VERED in the United States that demonstrated statistically significant improvements compared to vehicle in achieving the IGA success co-primary efficacy endpoint and in reducing papulopustular-lesions based on the percentage change in the inflammatory lesion count from baseline at week 12. In addition, the tolerability profile of VERED was similar to that of vehicle. We expect that VERED, if approved, will compete directly with Soolantra. Soolantra was launched in 2015 and achieved U.S. sales of&#8201; $87.3 million in the twelve months ending June 30, 2017. We expect to utilize the FDA&#8217;s 505(b)(2) regulatory pathway in seeking approval of VERED in the United States. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">92</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;font-style:italic;">Subtype II Rosacea Market Opportunity </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Rosacea is a chronic skin disease characterized by persistent facial erythema (redness) and temporary inflammatory lesions (papules, pustules or both). Often misdiagnosed as acne vulgaris due to similarities between inflammatory acne lesions and rosacea lesions and the potential for disfigurement, rosacea is gradually increasing in visibility as a disease. The most prominent age group affected includes adults age 30 and above, with stronger prevalence across women and adults with fair-skin. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">According to a study we commissioned, rosacea affects approximately 16 million people in the United States alone. Studies show that approximately 30% of people suffering from rosacea in the United States, or 4.8 million people, suffer from subtype II rosacea. We estimate that 43% of the subtype II rosacea population suffers from the mild form of the disease, while 41% and 16% suffer from moderate and severe forms of the disease, respectively. According to IMS, the topical drugs approved by the FDA to treat subtype II rosacea generated aggregate revenues of approximately $392 million in the United States for the twelve months ended June 30, 2017. </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;font-style:italic;">Subtype II Rosacea Market Size </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The U.S. subtype II rosacea market is estimated at approximately $600 million in pharmaceutical sales, according to IMS. The U.S. subtype II rosacea market represented approximately 5% of the total U.S. medical dermatology market in 2016. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Though not life threatening, rosacea can have a significant adverse effect on patients. Among the prevalent patient population, approximately 70% said the disease had adversely affected their professional interactions. </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;font-style:italic;">Current Treatment Landscape for Subtype II Rosacea </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">As there is no cure for rosacea, treatment is largely focused on managing the disease. We believe that a significant market opportunity exists for a subtype II rosacea treatment option that can provide both efficacy and higher tolerability than existing treatments. There are currently five approved drugs for the treatment of subtype II rosacea: Soolantra, Metrogel, Oracea and generic metronidazole. In certain cases, dermatologists often prescribe oral antibiotics either as monotherapies or in conjunction with approved medications. </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;font-style:italic;">Our Solution for Subtype II Rosacea&#8201;&#8212;&#8201;VERED </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Benzoyl peroxide is approved by the FDA for the treatment of acne and is widely considered to be safe and effective. Currently, there is no approved benzoyl peroxide product in the rosacea treatment landscape as a result of potential tolerability issues, despite clinical studies showing that treatment with benzoyl peroxide could be efficacious. According to a published study, benzoyl peroxide was found to be an effective treatment for rosacea but caused irritation. Using our proprietary, silica-based microencapsulation technology platform, we believe our VERED candidate for the treatment of subtype II rosacea can improve on current subtype II rosacea treatments in the following ways: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.02pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:4.02pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">VERED creates a silica-based barrier between benzoyl peroxide crystals and the skin and, as a result, can reduce irritation typically associated with topical application of benzoyl peroxide, increasing the potential for more tolerable application to rosacea-affected skin. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.03pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:4.03pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">VERED&#8217;s controlled release of the drug can reduce irritation while maintaining efficacy. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">VERED is an innovative topical cream, and if approved, would be the first product containing benzoyl peroxide for the treatment of subtype II rosacea. </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;font-style:italic;">VERED Phase II Trial Design </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In August 2012, we completed a multi-center, three-arm, randomized, double-blind, placebo-controlled study designed to assess the efficacy, tolerability and safety of two VERED concentrations, VERED 1% (E-BPO 1%) and VERED 5% (E-BPO 5%). A total of 92 subjects were </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">93</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">enrolled in the trial at ten sites in the United States. Subjects were equally randomized into three separate arms: VERED 1%, VERED 5% and vehicle and each group received a once-daily dose. All subjects were 18 years of age or older, with a mean age of 51. Gender distribution was 27% male and 73% female. Inclusion criteria required facial rosacea with 12 or more inflammatory lesions at enrolment and a score of 2, 3 or 4 (&#8216;&#8216;mild&#8217;&#8217;, &#8216;&#8216;moderate&#8217;&#8217; or &#8216;&#8216;severe&#8217;&#8217;) on a five-point IGA scale that ranges from a score of 0, representing &#8216;&#8216;clear skin,&#8217;&#8217; to a score of 4, representing a &#8216;&#8216;severe&#8217;&#8217; disease. The evaluator also rated the following signs and symptoms of local skin irritation on a scale of 0 to 3 (&#8216;&#8216;none&#8217;&#8217;, &#8216;&#8216;mild&#8217;&#8217;, &#8216;&#8216;moderate&#8217;&#8217;, &#8216;&#8216;severe&#8217;&#8217;): dryness, scaling, pruritus, stinging and burning. The evaluation period spanned 12 weeks after initial treatment. At baseline across all treatment groups, the mean inflammatory lesion count was 19.9, 28.6 and 22.9 for vehicle, VERED 1% and VERED 5%, respectively. 73.9% of the subjects had an IGA score of&#8201; &#8216;&#8216;moderate&#8217;&#8217;, or 3, while the remainder had an IGA score of&#8201; &#8216;&#8216;mild&#8217;&#8217;, or 2 and &#8216;&#8216;severe&#8217;&#8217;, or 4. </div>
        <div style="margin-left:20pt; margin-top:6.42pt; width:436pt; line-height:12pt;">Two primary efficacy endpoints were defined for this trial: </div>
        <div style=" float:left; line-height:12pt; margin-top:4.02pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:4.02pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:435.5pt;">the proportion of subjects who achieve at least a two-grade reduction in the IGA score and either &#8216;&#8216;clear&#8217;&#8217; or &#8216;&#8216;almost clear&#8217;&#8217; at week 12; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:4.03pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:4.03pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:435.5pt;">the reduction in the mean inflammatory lesion count from baseline at week 12. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6.22pt; width:456pt; line-height:12pt;">All statistical analyses and data shown for VERED are on the ITT population. The ITT population for VERED 1% consisted of 32 subjects, 3 of which had mild rosacea, 24 of which had moderate rosacea and 5 of which had severe rosacea. The ITT population for VERED 5% consisted of 30 subjects, 4 of which had mild rosacea, 21 of which had moderate rosacea and 5 of which had severe rosacea. </div>
        <div style="text-indent:20pt; margin-top:6.22pt; width:456pt; line-height:12pt;">In this trial, we defined &#8216;&#8216;clear&#8217;&#8217; as no inflammatory lesions present with no or very mild erythema immediately localized to and around where inflammatory lesions were present, and &#8216;&#8216;almost clear&#8217;&#8217; as very mild erythema immediately localized to and around inflammatory lesions with very few small papules/pustules. The FDA required a modification to our definition of &#8216;&#8216;clear&#8217;&#8217; on the IGA scale such that the category of&#8201;&#8217;&#8217;clear&#8217;&#8217; represented the absence of the disease at the end of the trial. Out of the 11 subjects that were defined as &#8216;&#8216;mild&#8217;&#8217; at baseline, there was only one subject that was treated with VERED and reached &#8216;&#8216;clear&#8217;&#8217; at the end of the trial. </div>
        <div style="margin-left:20pt; margin-top:6.22pt; width:436pt; line-height:12pt;font-style:italic;">VERED Phase II Trial Results </div>
        <div style="text-indent:20pt; margin-top:6.22pt; width:456pt; line-height:12pt;">As outlined below, VERED 5% demonstrated statistically significant improvement in the IGA co-primary efficacy endpoints. The IGA success rate, defined as having at least a two-grade reduction in the IGA score and either &#8216;&#8216;clear&#8217;&#8217; or &#8216;&#8216;almost clear&#8217;&#8217; at week 12, was 53.3% for VERED 5% (p-value of 0.0013 vs. vehicle), 37.5% for VERED 1% (p-value of 0.0836 vs. vehicle) and 20.0% for vehicle, indicating a successful dose-ranging study. The mean change from baseline in the absolute number of inflammatory lesions was <font style="white-space:nowrap;">-14.1</font> for VERED 5%, <font style="white-space:nowrap;">-21.6</font> for VERED 1% and <font style="white-space:nowrap;">-7.4</font> for vehicle. The median change from baseline in the absolute number of inflammatory lesions was -15.0 for VERED 5%, <font style="white-space:nowrap;">-12.5</font> for VERED 1% and <font style="white-space:nowrap;">-10.0</font> for vehicle. </div>
        <div style="margin-left:20pt; margin-top:6.22pt; width:436pt; line-height:12pt;">The following table summarizes the efficacy results for VERED. </div>
        <table style="width:456pt;height:157.5pt;margin-top:10pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.5pt 0pt; width:270pt;text-align:left;">
              <div style="white-space:nowrap;">VERED Phase II Efficacy Results at Week 12 (ITT)</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.5pt 0pt; width:50pt;">
              <div style="text-align:center;">Vehicle <br >(N=30) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.5pt 0pt; width:50pt;">
              <div style="text-align:center;">VERED 1% <br >(N=32) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.5pt 0pt; width:50pt;">
              <div style="text-align:center;">VERED 5% <br >(N=30) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:270pt;">Dichotomized IGA &#8211; Primary Success</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
            <td colspan="3">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:270pt;text-align:left;">
              <div style="margin-left:10pt;">Success </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.5pt 0.5pt 0.5pt 0pt; width:50pt;">
              <div style="white-space:nowrap; text-align:right;">6 (20.0%)&#8203;</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.5pt 0.5pt 0.5pt 0pt; width:50pt;">
              <div style="white-space:nowrap; text-align:right;">12 (37.5%)&#8203;</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.5pt 0.5pt 0.5pt 0pt; width:50pt;">
              <div style="white-space:nowrap; text-align:right;">16 (53.3%)&#8203;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:270pt;text-align:left;">
              <div style="margin-left:10pt;">Failure </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.5pt 0.5pt 0.5pt 0pt; width:50pt;">
              <div style="white-space:nowrap; text-align:right;">24 (80.0%)&#8203;</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.5pt 0.5pt 0.5pt 0pt; width:50pt;">
              <div style="white-space:nowrap; text-align:right;">20 (62.5%)&#8203;</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.5pt 0.5pt 0.5pt 0pt; width:50pt;">
              <div style="white-space:nowrap; text-align:right;">14 (46.7%)&#8203;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:270pt;text-align:left;">
              <div style="margin-left:10pt;font-style:italic;">p<font style="font-style:normal;">-value relative to vehicle </font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0.5pt 0.5pt 0pt; width:50pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.5pt 0.5pt 0.5pt 0pt; width:50pt;">
              <div style="text-align:right;">0.0836&#8203;</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.5pt 0.5pt 0.5pt 0pt; width:50pt;">
              <div style="text-align:right;">0.0013&#8203;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:8.5pt 0pt 0.5pt 0pt; width:270pt;">Inflammatory Lesion Count&#8201;&#8211;&#8201;Change from Baseline</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
            <td colspan="3">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:270pt;text-align:left;">
              <div style="margin-left:10pt;">Mean </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.5pt 0.5pt 0.5pt 0pt; width:50pt;">
              <div style="text-align:right;">-7.4&#8203;</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.5pt 0.5pt 0.5pt 0pt; width:50pt;">
              <div style="text-align:right;">-21.6&#8203;</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.5pt 0.5pt 0.5pt 0pt; width:50pt;">
              <div style="text-align:right;">-14.1&#8203;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:270pt;text-align:left;">
              <div style="margin-left:10pt;">Median </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.5pt 0.5pt 0.5pt 0pt; width:50pt;">
              <div style="text-align:right;">-10.0&#8203;</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.5pt 0.5pt 0.5pt 0pt; width:50pt;">
              <div style="text-align:right;">-12.5&#8203;</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.5pt 0.5pt 0.5pt 0pt; width:50pt;">
              <div style="text-align:right;">-15.0&#8203;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:270pt;text-align:left;">
              <div style="margin-left:10pt;font-style:italic;">p<font style="font-style:normal;">-value relative to vehicle </font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0.5pt 0.5pt 0pt; width:50pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.5pt 0.5pt 0.5pt 0pt; width:50pt;">
              <div style="text-align:right;">0.0276&#8203;</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.5pt 0.5pt 0.5pt 0pt; width:50pt;">
              <div style="text-align:right;">0.0037&#8203;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:7.167pt 0pt 0.5pt 0pt; width:270pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">LOCF (last observation carried forward) used to impute mission observations</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0.5pt 0.5pt 0pt; width:50pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:7.167pt 0.5pt 0.5pt 0pt; width:50pt;">
              <div style="text-align:right;">0.0836&#8203;</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:7.167pt 0.5pt 0.5pt 0pt; width:50pt;">
              <div style="text-align:right;">0.0013&#8203;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">94</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;">The following chart presents results for the IGA efficacy endpoint from baseline to the end of the 12-week treatment period in the ITT population. </div>
        <div style="position:relative;z-index:-1;margin-top:8pt; text-align:center; width:456pt;">
          <img src="t1701829_chrt-iga02.jpg" alt="[MISSING IMAGE: t1701829_chrt-iga02.jpg]" height="367" width="337" >
        </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;">The following chart presents the success in the mean and median reduction in inflammatory lesion counts from baseline to the end of the 12-week treatment period in the ITT population.</div>
        <div style="position:relative;z-index:-1;margin-top:8pt; text-align:center; width:456pt;">
          <img src="t1701829_chrt-iga02a.jpg" alt="[MISSING IMAGE: t1701829_chrt-iga02a.jpg]" height="387" width="332" >
        </div>
        <div style="text-align:justify; width:456pt; line-height:12pt;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;"></div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;">95</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The high reduction in the mean absolute number of inflammatory lesions in VERED 1% is a result of no upper limit on the number of inflammatory lesions at baseline and therefore we believe only the median change from baseline in the absolute number of inflammatory lesions should be examined to assess dose-ranging efficacy. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We also assessed cutaneous tolerability by recording the dryness, scaling, pruritus, stinging and burning on a four-point scale from 0 to 3 at baseline and at each visit. These measurements are either measured by the physician or reported by the subject. Overall, both of VERED 1% and VERED 5% were well tolerated. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Of the 92 subjects that were randomized, 28 subjects in each treatment group completed the study. Two subjects in the vehicle group discontinued the study early: one subject withdrew consent and one subject was lost to follow-up. Four subjects in the VERED 1% group discontinued the study early: two subjects withdrew consent and two subjects discontinued the study due to &#8216;&#8216;application site dermatitis&#8217;&#8217;, which was moderate in severity, and &#8216;&#8216;cyst&#8217;&#8217;, which was deemed not related to the local application of VERED. Two subjects in the VERED 5% group discontinued the study early: one subject was lost to follow-up, and one subject was discontinued due to an &#8216;&#8216;application site reaction&#8217;&#8217;. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Ultimately, the Phase II trial found that both VERED 1% and VERED 5% had a favorable effect on subtype II rosacea. As a result of these findings, we selected VERED 5% for further development. </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;font-style:italic;">Phase III Clinical Development Plan.</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Subject to an End of Phase II meeting to be scheduled with the FDA, we expect to commence a pivotal Phase III clinical program in the United States in 2018 for VERED 5%. We expect to report top-line data from this program in 2019. Prior to, or in parallel with, our planned Phase III clinical program, we intend to complete a pharmacokinetics safety study and we expect to commence additional standard safety studies. We intend to design the Phase III program to demonstrate the efficacy and safety of treatment with VERED relative to vehicle for the treatment of subtype II rosacea. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Generic Drug Product Candidates </div>
        <div style="text-indent:20pt; margin-top:7.81pt; width:456pt; line-height:12pt;">In addition to our branded product candidates, we have a current portfolio of six generic topical dermatological products, with three of our generic product candidates, including ivermectin cream, 1%, being developed in collaboration with Perrigo and another being developed in collaboration with Douglas Pharmaceuticals. Both Perrigo and Douglas Pharmaceuticals have significant experience in the development of generic drugs. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Our most advanced generic product candidate is ivermectin cream, 1%, for the treatment of inflammatory lesions associated with rosacea, which we are developing in collaboration with Perrigo. In March 2017, Perrigo submitted an abbreviated new drug application, or ANDA, for ivermectin cream, 1% to the FDA and received approval for filing. This ANDA is currently on file with the FDA. Following notification from Perrigo, Galderma Laboratories, L.P., Galderma S.A., and Nestle Skin Health S.A., filed a patent litigation suit triggering the application of a 30 month stay on approval of the ANDA, under the Hatch-Waxman amendments to the Federal Food, Drug, and Cosmetic Act. Ivermectin cream, 1% is the active molecule in Soolantra which is currently marketed in the United States by Galderma Laboratories LP. For the twelve months ended June 30, 2017, Soolantra achieved sales of&#8201; $87.3 million according to IMS. In addition to the second generic product candidate, which we are developing in collaboration with Douglas Pharmaceuticals, we have four other generic product candidates in early-stage development. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Our Proprietary Silica-Based Microencapsulation Technology Platform </div>
        <div style="text-indent:20pt; margin-top:7.81pt; width:456pt; line-height:12pt;">Encapsulation of a drug substance can be made using a variety of techniques, such as solvent evaporation, coacervation, and interfacial polymerization. Most encapsulations involve organic polymers, such as poly-methyl methacrylate, chitosan and cellulose. The resultant encapsulated </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">96</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">drug substance can be an aqueous dispersion of varying payload and volume fraction or a dried powder. Control over the encapsulation process when organic polymers are used is challenging and is mainly limited to shell thickness. Other properties of the organic polymer encapsulating material are hard to control. </div>
        <div style="text-indent:20pt; margin-top:6.62pt; width:456pt; line-height:12pt;">In contrast, we use proprietary &#8216;sol-gel&#8217; processes to shape silica on site to form microcapsule shells of almost any size and release rate profile. Sol-gel is a chemical process whereby amorphous silica, or other metal oxides, are made by forming interconnections among colloidal particles (the &#8216;&#8216;sol&#8217;&#8217;) under increasing viscosity until a rigid silica shell (the &#8216;&#8216;gel&#8217;&#8217;) is formed. The drug substance that is added during the sol-gel reaction is encapsulated, using a patented technique, by which a core-shell structure is formed. The drug substance is in the core and the silica is the capsule shell. At the end of the process, the microcapsules are in the shape of small beads ranging from 1&#8201;&#8211;&#8201;40 mm in size. This process results in an aqueous suspension in which the drug substances are entrapped in silica particles. </div>
        <div style="text-indent:20pt; margin-top:6.62pt; width:456pt; line-height:12pt;">We intend to leverage our technology platform to take advantage of the fact that the FDA has already approved drugs containing silica excipients for topical administration and utilizes our expertise in micro encapsulation processes to potentially expedite the approval process of drugs that are based on our technology platform. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Collaboration Agreements </div>
        <div style="text-indent:20pt; margin-top:5.42pt; width:456pt; line-height:12pt;">On April 27, 2015, we entered into a development, manufacturing and commercialization agreement with Perrigo, as amended on October 26, 2015, to work toward the objective of obtaining all FDA approvals necessary for the commercialization of ivermectin cream, 1%, in the United States. Perrigo will conduct all regulatory, scientific, clinical and technical activities necessary to develop ivermectin cream, 1%, prepare and file an ANDA with the FDA, and gain regulatory approval to market ivermectin cream, 1%, in the United States. We granted Perrigo the right, title and interest in and to ivermectin cream, 1%, and agreed on each party&#8217;s portion of the costs associated with performance under the agreement. As soon as reasonably practical after final approval by the FDA of the ANDA, if approval is granted, Perrigo is required to use diligent efforts to commercialize ivermectin cream, 1%, in the United States. Perrigo has the sole and exclusive right to establish and control the prices and all other terms and conditions for the sales of ivermectin cream, 1%, in the United States and is required to do so in good faith without derogating from our right to benefit from the commercialization of ivermectin cream, 1%. We will be entitled to 50% of Perrigo&#8217;s gross profits related to the sale of ivermectin cream, 1%, on a quarterly basis, for a period of 20 years following the first commercial sale of the ivermectin cream, 1%, in the United States. The agreement may be terminated in the event of a material breach by one of the parties, certain potential infringement claims by third parties or an uncured insolvency or bankruptcy proceeding of one of the parties. In addition, the agreement may be terminated if the gross profits relating to the sale of the product do not exceed a certain threshold or if the potential market for the product has been significantly reduced due to regulatory changes. </div>
        <div style="text-indent:20pt; margin-top:6.42pt; width:456pt; line-height:12pt;">On June&#160;7, 2017, we entered into a Development, License, Supply and Marketing Agreement, with Douglas with respect to the development and commercialization of a generic product candidate for a drug that already has generic substitutions. Douglas will manufacture the product for non-clinical and clinical trial uses, and once approved for marketing, for commercialization by us in the countries we elect to commercialize the product. Douglas will also be responsible for completing the formulation of the product and providing chemistry, manufacturing and control support, conducting all steps for production and quality controls of the product, formulation development of the product in final finished form and supporting the ANDA or any other applicable registration application. We will be responsible for conducting the legal and regulatory review process, performing bioequivalence and clinical studies to obtain marketing approval for the product in the United States and preparing and filing the regulatory filings to obtain marketing approval in the United States. We have the right to commercialize the product in all countries in North America and any other country agreed to with Douglas, and Douglas has the right to commercialize the product in Australia, New Zealand, the Southeast, East and North Asia region and the Middle East and North Africa region and any other country agreed to by us and Douglas. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">97</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Each party granted the other an exclusive royalty free license under its related intellectual property with the right to grant sublicenses, to use and commercialize the product in the countries in which the other party has the right to commercialize the product. Any new intellectual property generated in the development plan will be jointly owned. We are responsible for patent prosecution and Douglas is required to reimburse us for 50% of our patent expenses. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Each party is required to pay the other party 50% of its net profits from the sale of the products during the term of the agreement. In addition, we or the third party commercializing the product on our behalf will pay Douglas a transfer price based on the cost of goods for the manufacture of the products. The term of the agreement is ten years, and either party may terminate the agreement (i) for breach, (ii) if the joint steering committee established by the parties determines that it is unlikely that marketing approval will be achieved or determines that the commercialization of the product becomes unfeasible or uneconomic, (iii) a patent injunction permanently prohibits the future commercialization of the product or (iv) in the case of force majeure. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Intellectual Property </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Our intellectual property and proprietary technology are directed to the development, manufacture and sale of our branded product candidates: TWIN, SIRS-T and VERED. We seek to protect our intellectual property, core technologies and other know-how, through a combination of patents, trademarks, trade secrets, non-disclosure and confidentiality agreements, assignments of invention and other contractual arrangements with our employees, consultants, partners, suppliers, customers and others. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We will be able to protect our technology from unauthorized use by third parties only to the extent it is covered by valid and enforceable patents or is effectively maintained as trade secrets. Patents and other proprietary rights are an essential element of our business. If any of the below described applications are not approved, or any of the below described patents are invalidated, deemed unenforceable or otherwise successfully challenged, such loss would have a material effect on the commercialization of our product candidates and our future prospects. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Our patent portfolio that is directed to our branded product candidates includes 51 patents and patent applications and claims processes for manufacture (including silica microencapsulation platform and other technologies), formulations, composition of matter, and methods of use. Of these 51 patents and patent applications, 27 are granted patents (2 in the United States and 25 in other countries) and 24 are pending applications (9 in the United States (2 of which are provisional applications) and 15 in other countries). </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">For our TWIN product candidate, we have obtained patent protection for the composition of matter in the United States, Canada, Japan, Mexico (with a term until 2028) and we have a pending application claiming composition of matter in the European Patent Office. There are four patent families protecting the process for the encapsulation of the active agents of our TWIN product candidate (one patent family has patents granted in Canada, India, and Japan (with a term until 2028) and applications pending in the United States, Europe and Mexico; the second patent family has a patent granted in Mexico (with a term until 2029) and pending applications in the United States and Canada; and the third patent family has patents granted in Europe (validated in France, Germany, Ireland, Italy, Spain, Switzerland, United Kingdom), China, India, Japan and Mexico (with a term until 2030) and pending applications in the United States and Canada); and the fourth patent family has patents granted in Canada, China, Israel, India and Mexico and an application pending in the United States. We own pending patents for the formulation of our TWIN product candidate in the United States, Canada, Europe, China, India and Mexico and a granted patent in Japan (with a term until 2032). We have three pending unpublished U.S. applications for the administration method and regimen of our TWIN product candidate. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">For our VERED product candidate, we have obtained a patent in the United States (with a term until 2032) covering the composition for topical treatment of rosacea. We have further pending applications for this composition in the United States, Canada, Europe, Japan, China, Mexico. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">98</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">There are two patent families directed to the process for encapsulation of the active agents of our VERED product candidate (one patent family has granted patents in Canada, India, and Japan (with a term until 2028) and pending applications in the United States, Europe and Mexico; and the second patent family has patents granted in Canada, China, Israel, India and Mexico and an application pending in the United States). </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">For our SIRS-T product candidate, we have a pending unpublished U.S. application claiming the composition and method of treatment. Furthermore, there are two patent families protecting the process for the preparation of our SIRS-T product candidate (one patent family granted in Mexico (with a term until 2029) and pending in the United States and Canada; and the second patent family granted in Europe (validated in France, Germany, Ireland, Italy, Spain, Switzerland, United Kingdom), China, India, Japan and Mexico (with a term until 2030) and pending in the United States and Canada). </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We have four accepted trademark applications in Israel, one registered trademark in the United States and four trademark applications pending in the United States and Canada. These registrations and pending applications, if approved, will cover potential brand names for our VERED product candidate in Israel, Canada and the United States. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Competition </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The pharmaceutical industry is subject to intense competition as well as rapid technological changes. Our ability to compete is based on a variety of factors, including product efficacy, safety, cost-effectiveness, patient compliance, patent position and effective product promotion. Competition is also based upon the ability of a company to offer a broad range of other product offerings, large direct sales forces and long-term customer relationships with target physicians. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">There are numerous companies that have branded or generic products or product candidates in the dermatology market. Among them are Aclaris Therapeutics, Inc., Akorn, Inc., Allergan plc, Aqua Pharmaceuticals LLC, Bayer HealthCare AG, Cassiopea SpA, Dermira, Inc., Foamix Pharmaceuticals Ltd., Galderma Pharma S.A., Glenmark Pharmaceuticals Ltd., G&amp;W Laboratories, Inc., LEO Pharma A/S, Mylan N.V., Novan, Inc., Novartis AG, Novum Pharma, LLC, Perrigo Company plc, Pfizer, Inc., Sienna Biopharmaceuticals, Inc., Spear Therapeutics, Ltd., Sun Pharmaceutical Industries Ltd., Teligent, Inc., Teva Pharmaceutical Industries Ltd., and Valeant Pharmaceuticals International, Inc. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In order for our approved product candidates, if any, to compete successfully in the dermatology market, we will have to demonstrate that their efficacy, safety and cost-effectiveness provide an attractive alternative to existing therapies, some of which are widely known and accepted by physicians and patients, as well as to future new therapies. Such competition could lead to reduced market share for our product candidates and contribute to downward pressure on the pricing of our product candidates, which could harm our business, financial condition, operating results and prospects. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Many of the companies, academic research institutions, governmental agencies and other organizations involved in the field of dermatology have substantially greater financial, technical and human resources than we do, and may be better equipped to discover, develop, test and obtain regulatory approvals for products that compete with ours. They may also be better equipped to manufacture, market and sell products. These companies, institutions, agencies and organizations may develop and introduce products and drug delivery technologies competitive with or superior to ours which could inhibit our market penetration efforts. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">TWIN, SIRS-T and VERED target the well-established acne and rosacea markets. If approved, we expect them to compete with current standard-of-care treatments, whether branded, generic or over-the-counter, as well as with new treatments to be approved in the future. The current standard-of-care for acne includes topical anti-bacterial drugs such as benzoyl peroxide that are broadly available over-the-counter, prescription drug products that are based on single retinoid </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">99</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">drug products such as Differin, Atralin, Retin-A, Retin-A Micro and Tazorac, fixed-dose combinations of benzoyl peroxide and adapalene such as Epiduo and Epiduo Forte, fixed-dose combinations of benzoyl peroxide and clindamycin such as Duac, Benzaclin, Onexton and Acanya, fixed-dose combinations of tretinoin and clindamycin such as Ziana and Veltin, and topical antibiotics such as Aczone. The current standard of care for rosacea includes Metrogel, Finacea and the recently launched Soolantra, as well as oral Oracea (doxycycline embedded in a technology platform). As a fixed-dose combination product candidate, TWIN may also compete with drug products utilizing other technologies that can separate two drug substances, such as dual chamber tubes, dual pouches or dual sachets. In addition to these products, our generic drug product candidates, including ivermectin cream, 1%, is expected to face direct competition from branded drugs and authorized generics which are prescription drugs produced by the branded pharmaceutical companies and marketed under a private label, at generic prices. On December&#160;30, 2016, Actavis Ltd. submitted an ANDA for ivermectin, 1%, cream, and therefore we will only be able to commercialize this product after Actavis Ltd.&#39;s six month exclusivity period expires.</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Marketing, Sales and Distribution </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We currently do not have any sales, marketing or distribution capabilities. In order to commercialize our product candidates, if approved for commercial sale, we must either develop a sales and marketing infrastructure or collaborate with third parties that have sales and marketing experience. We intend to commercialize our late-stage branded product candidates in the United States, if approved, by building a specialized sales and marketing organization focused solely on dermatologists and their patients. Because the U.S. market is served by a relatively small number of practicing dermatologists, we believe a small and dedicated sales force can efficiently cover a significant portion of that targeted patient population. In other markets, we may selectively pursue strategic collaborations with third parties in order to maximize the commercial potential of our product candidates. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Manufacturing </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We rely on and expect to continue to rely on third-party contract manufacturing organizations, or CMOs, for the supply of current good manufacturing practice-grade, or cGMP-grade, clinical trial materials and commercial quantities of our product candidates and products, if approved. We currently do not have any agreements for the commercial production of raw materials we use. We believe that the manufacturing process for the raw materials we purchase can be transferred to a number of other CMOs for the production of clinical and commercial supplies of our product candidates in the ordinary course of business. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Government Regulation </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Our business is subject to extensive government regulation. We have been voluntarily certified by the Israel notified body, the Standards Institution of Israel for the design, development and production of pharmaceutical products, a partner of IQNet. Regulation by governmental authorities in the United States and other jurisdictions is a significant factor in the development, manufacture and commercialization of our product candidates and in our ongoing research and development activities. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Product Approval Process in the United States </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Review and approval of drugs </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In the United States, pharmaceutical products are subject to extensive regulation by the FDA. The FDCA and other federal and state statutes and implementing regulations govern, among other things, the research, development, testing, manufacture, storage, recordkeeping, approval, labeling, promotion and marketing, distribution, post-approval monitoring and reporting, sampling, and import and export of pharmaceutical products. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">100</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">approval may subject an applicant to a variety of administrative or judicial sanctions and enforcement actions brought by the FDA, the Department of Justice or other governmental entities. Possible sanctions may include the FDA&#8217;s refusal to approve pending applications, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters or untitled letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement and civil or criminal penalties. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">FDA approval of a new drug application is required before any new unapproved drug or dosage form, can be marketed in the United States. Section 505 of the FDCA describes three types of new drug applications: (1) an application that contains full reports of investigations of safety and effectiveness (section 505(b)(1)); (2) an application that contains full reports of investigations of safety and effectiveness but where at least some of the information required for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference (section 505(b)(2)); and (3) an application that contains information to show that the proposed product is identical in active ingredient, dosage form, strength, route of administration, labeling, quality, performance characteristics, and intended use, among other things, to a previously approved product (section 505(j)). Section 505(b)(1) and 505(b)(2) new drug applications are referred to as NDAs, and section 505(j) applications are referred to as ANDAs. We believe that the applications for our late-stage branded product candidates will be section 505(b)(2) NDAs and that those for our generic product candidates will be section 505(j) ANDAs. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In general, the process required by the FDA prior to marketing and distributing a new drug, as opposed to a generic drug subject to section 505(j), in the United States usually involves the following:</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:10.78pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:10.78pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">completion of pre-clinical laboratory tests, animal studies and formulation studies in compliance with the FDA&#8217;s good laboratory practices, or GLP, requirements or other applicable regulations; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:10.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:10.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">submission to the FDA of an investigational new drug application, or IND, which must become effective before human clinical trials in the United States may begin; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:10.78pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:10.78pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">approval by an independent institutional review board, or IRB, at each clinical site before each trial may be initiated; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:10.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:10.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">performance of adequate and well-controlled human clinical trials in accordance with good clinical practice, or GCP, requirements to establish the safety and efficacy of the proposed drug for its intended use; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:10.78pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:10.78pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">preparation and submission to the FDA of an NDA; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:10.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:10.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">satisfactory completion of an FDA advisory committee review, if applicable; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:10.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:10.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the product or components thereof are produced, to assess compliance with current good manufacturing practices, or cGMPs, and to assure that the facilities, methods and controls are adequate to preserve the drug&#8217;s identity, strength, quality and purity; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:10.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:10.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">satisfactory completion of FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of the clinical data; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:10.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:10.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">payment of user fees and FDA review and approval of the NDA; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:10.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:10.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy, or REMS, and the potential requirement to conduct post-approval studies. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">101</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Pre-clinical studies </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Pre-clinical studies include laboratory evaluation or product chemistry, formulation and toxicity, as well as animal studies to assess the potential safety and efficacy of the product candidate. Pre-clinical safety tests must be conducted in compliance with the FDA regulations. The results of the pre-clinical studies, together with manufacturing information and analytical data, are submitted to the FDA as part of an IND which must become effective before clinical trials may commence. Long-term pre-clinical studies, such as animal tests of reproductive toxicity and carcinogenicity, may continue after the IND application is submitted. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Clinical trials </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Clinical trials involve the administration of an investigational product to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include, among other things, the requirement that all research subjects provide their informed consent in writing before their participation in any clinical trial. Clinical trials are conducted under written trial protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to a proposed clinical trial and places the trial on clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. In addition, information about certain clinical trials must be submitted within specific timeframes to the National Institutes of Health, or NIH, for public dissemination on the NIH-maintained website, www.clinicaltrials.gov. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">An IRB representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and the IRB must conduct continuing review at least annually. The IRB must review and approve, among other things, the trial protocol information to be provided to trial subjects. An IRB must operate in compliance with FDA regulations. Information about certain clinical trials must be submitted within specific timeframes to the NIH for public dissemination on the NIH-maintained website, www.clinicaltrials.gov. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Clinical trials are typically conducted in three sequential phases, which may overlap or be combined: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:10.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:10.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;"><font style="font-style:italic;">Phase I</font>: The drug is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness and to determine optimal dosage. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:10.38pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:10.38pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;"><font style="font-style:italic;">Phase II</font>: The drug is administered to a limited patient population to identify possible short-term adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:10.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:10.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;"><font style="font-style:italic;">Phase III</font>: The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In most cases of an ANDA, the proposed generic drug must be shown to be bioequivalent to the reference listed drug (RLD, or reference product) and in other cases, the bioequivalent study is being conducted in in-vitro and not in clinical trials. The FDCA provides that a generic drug is </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">102</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">bioequivalent to the listed drug if: the rate and extent of absorption of the drug do not show a significant difference from the rate and extent of absorption of the listed drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses. During bioequivalence studies, an applicant compares the systemic exposure profile of a test drug product to that of the RLD on the target population at the same regimen and exposure period as the RLD were the resulted efficacy outcomes are being compared to demonstrate being equivalent. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Submission of an NDA to the FDA </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The results of the pre-clinical studies and clinical trials, together with other detailed information, including information on the manufacture, control and composition of the product, are submitted to the FDA as part of an NDA requesting approval to market the product candidate for a proposed indication. Under the Prescription Drug User Fee Act, as amended, applicants are required to pay fees to the FDA for reviewing an NDA. These user fees, as well as the annual fees required for commercial manufacturing establishments and for approved products, can be substantial. The NDA review fee alone can exceed $2 million, subject to certain limited deferrals, waivers and reductions that may be available. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The FDA has 60 days from its receipt of an NDA to determine whether the application will be accepted for filing based on the agency&#8217;s threshold determination that it is sufficiently complete to permit substantive review. The FDA may request additional information rather than accept an NDA for filing. In this event, the NDA must be resubmitted with the additional information and is subject to payment of additional user fees. The resubmitted application is also subject to review before the FDA accepts it for filing. If found complete, the FDA will accept the NDA for filing. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Under the Prescription Drug User Fee Act, the FDA has agreed to certain performance goals in the review of NDAs through a two-tiered classification system, Standard Review and Priority Review. Review. Priority Review designation is given to drugs that offer major advances in treatment, or provide a treatment where no adequate therapy exists. The FDA endeavors to review applications subject to Standard Review within approximately ten to twelve months of receipt, whereas the FDA&#8217;s goal is to review Priority Review applications within approximately six to eight months of receipt, depending on whether the drug is a new molecular entity. The FDA, however, may not approve a drug within these established goals, and its review goals are subject to change from time to time. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Before approving an NDA, the FDA inspects the facilities at which the product is manufactured or facilities that are significantly involved in the product development and distribution process, and will not approve the product unless cGMP compliance is satisfactory. Additionally, the FDA will typically inspect one or more clinical sites to assure compliance with GCP requirements. The FDA may also refer applications for novel drug products or drug products which present difficult questions of safety or efficacy to an advisory committee for review, evaluation and recommendation as to whether the application should be approved and under what conditions. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">After the FDA evaluates the NDA and the manufacturing facilities, it issues either an approval letter or a complete response letter to indicate that the review cycle for an application is complete and that the application is not ready for approval. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing, or information, in order for the FDA to reconsider the application. Even with submission of this additional information, the FDA may ultimately decide that an application does not satisfy the regulatory criteria for approval. If, or when, the deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the NDA, the FDA will issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">If a product is approved, the approval will impose limitations on the indicated uses for which the product may be marketed, may require that warning statements be included in the product </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">103</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">labeling, may require that additional studies or trials be conducted following approval as a condition of the approval, may impose restrictions and conditions on product distribution, prescribing or dispensing in the form of a risk management plan, or impose other limitations. For example, as a condition of NDA approval, the FDA may require a risk evaluation and mitigation strategy, or REMS, to ensure that the benefits of the drug outweigh the potential risks. If the FDA determines a REMS is necessary during review of the application, the drug sponsor must agree to the REMS plan at the time of approval. A REMS may be required to include various elements, such as a medication guide or patient package insert, a communication plan to educate healthcare providers of the drug&#8217;s risks, limitations on who may prescribe or dispense the drug, or other elements to assure safe use, such as special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring and the use of patient registries. In addition, the REMS must include a timetable to periodically assess the strategy. The requirement for a REMS can materially affect the potential market and profitability of a drug. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Further changes to some of the conditions established in an approved application, including changes in indications, labeling, or manufacturing processes or facilities, require submission and FDA approval of a new NDA or NDA supplement before the change can be implemented, which may require us to develop additional data or conduct additional pre-clinical studies and clinical trials. An NDA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses the similar procedures in reviewing NDA supplements as it does in reviewing NDAs. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Post-Approval Requirements </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Any drug products for which we receive FDA approval will be subject to continuing regulation by the FDA. Certain requirements include, among other things, record-keeping requirements, reporting of adverse experiences with the product, providing the FDA with updated safety and efficacy information on an annual basis or more frequently for specific events, product sampling and distribution requirements, complying with certain electronic records and signature requirements and complying with FDA promotion and advertising requirements. These promotion and advertising requirements include standards for direct-to-consumer advertising, prohibitions against promoting drugs for uses or patient populations that are not described in the drug&#8217;s approved labeling, known as &#8220;off-label use,&#8221; and other promotional activities, such as those considered to be false or misleading. Failure to comply with FDA requirements can have negative consequences, including the immediate discontinuation of noncomplying materials, adverse publicity, enforcement letters from the FDA, mandated corrective advertising or communications with doctors, and civil or criminal penalties. Such enforcement may also lead to scrutiny and enforcement by other government and regulatory bodies. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Although physicians may prescribe legally available drugs for off-label uses, manufacturers may not encourage, market or promote such off-label uses. As a result, &#8220;off-label promotion&#8221; has formed the basis for litigation under the Federal False Claims Act, violations of which are subject to significant civil fines and penalties. In addition, manufacturers of prescription products are required to disclose annually to the Center for Medicaid and Medicare any payments made to physicians in the United States under the Sunshine Act of 2012. These payments could be in cash or kind, could be for any reason, and are required to be disclosed even if the payments are not related to the approved product. A failure to fully disclose or not report in time could lead to penalties of up to $1 million per year. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The manufacturing of any of our product candidates will be required to comply with applicable FDA manufacturing requirements contained in the FDA&#8217;s cGMP regulations. The FDA&#8217;s cGMP regulations require, among other things, quality control and quality assurance, as well as the corresponding maintenance of comprehensive records and documentation. Drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are also required to register their establishments and list any products they make with the FDA and to comply with related requirements in certain states. Changes to the manufacturing process are </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">104</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">strictly regulated and often require prior FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP requirements and impose reporting and documentation requirements upon the sponsor and any third-party manufacturers that the sponsor may decide to use. These entities are further subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain cGMP compliance. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Discovery of problems with a product after approval may result in serious and extensive restrictions on a product, manufacturer or holder of an approved NDA, as well as lead to potential market disruptions. These restrictions may include recalls, suspension of a product until the FDA is assured that quality standards can be met, and continuing oversight of manufacturing by the FDA under a &#8220;consent decree,&#8221; which frequently includes the imposition of costs and continuing inspections over a period of many years, as well as possible withdrawal of the product from the market. In addition, changes to the manufacturing process generally require prior FDA approval before being implemented. Other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval. There also are continuing, annual user fee requirements for any marketed products and the establishments at which such products are manufactured, as well as new application fees for supplemental applications with clinical data. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The FDA also may require post-marketing testing, or Phase IV testing, as well as risk minimization action plans and surveillance to monitor the effects of an approved product or place conditions on an approval that could otherwise restrict the distribution or use of our product candidates. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Once approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.58pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.58pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls;</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.58pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.58pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">fines, warning letters or holds on post-approval clinical trials;</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.58pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.58pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product approvals;</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.58pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.58pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">product seizure or detention, or refusal to permit the import or export of products; or</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.58pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.58pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">injunctions or the imposition of civil or criminal penalties. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Pediatric trials and exclusivity </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Even when not pursuing a pediatric indication, under the Pediatric Research Equity Act of 2003, an NDA or supplement thereto must contain data that is adequate to assess the safety and effectiveness of the drug product for the claimed indications in all relevant pediatric subpopulations, and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. With the enactment of the Food and Drug Administration Safety and Innovation Act, or the FDASIA, in 2012, sponsors must also submit pediatric trial plans prior to the assessment data. Those plans must contain an outline of the proposed pediatric trials the applicant plans to conduct, including trial objectives and design, any deferral or waiver </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">105</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">requests, and other information required by regulation. The applicant, the FDA, and the FDA&#8217;s internal review committee must then review the information submitted, consult with each other, and agree upon a final plan. The FDA or the applicant may request an amendment to the plan at any time. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The FDA may, on its own initiative or at the request of the applicant, grant deferrals for submission of some or all pediatric data until after approval of the product for use in adults, or full or partial waivers from the pediatric data requirements. Additional requirements and procedures relating to deferral requests and requests for extension of deferrals are contained in the FDASIA. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Separately, in the event the FDA makes a written request for pediatric data relating to a drug product, an NDA sponsor who submits such data may be entitled to pediatric exclusivity. Pediatric exclusivity is another type of non-patent marketing exclusivity in the United States. and, if granted, provides for the attachment of an additional six months of marketing protection to the term of any existing exclusivity. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">The Hatch-Waxman Amendments </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">ANDA Approval Process </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The Drug Price Competition and Patent Term Restoration Act of 1984 (also known as the Hatch-Waxman Amendments), established abbreviated FDA approval procedures for drugs that are shown to be equivalent to proprietary drugs previously approved by the FDA through its NDA process. Approval to market and distribute these drugs is obtained by submitting an ANDA with the FDA. An ANDA is a comprehensive submission that contains, among other things, data and information pertaining to the active pharmaceutical ingredient, drug product formulation, specifications and stability of the generic drug, as well as analytical methods, manufacturing process validation data, and quality control procedures. Premarket applications for generic drugs are termed abbreviated because they generally do not include pre-clinical and clinical data to demonstrate safety and effectiveness. Instead, a generic applicant must demonstrate that its product is bioequivalent to the innovator drug. In certain situations, an applicant may obtain ANDA approval of a generic product with a strength or dosage form that differs from a referenced innovator drug pursuant to the filing and approval of an ANDA Suitability Petition. The FDA will approve the generic product as suitable for an ANDA application if it finds that the generic product does not raise new questions of safety and effectiveness as compared to the innovator product. A product is not eligible for ANDA approval if the FDA determines that it is not bioequivalent to the referenced innovator drug, if it is intended for a different use, or if it is not subject to an approved Suitability Petition. However, such a product might be approved under an NDA, with supportive data from clinical trials. We are developing certain of our product candidates as generic drugs, for which we intend to submit ANDAs to the FDA. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">505(b)(2) NDAs </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Section 505(b)(2) was enacted as part of the Hatch-Waxman Amendment, and permits the filing of an NDA where at least some of the information required for approval comes from studies or trials not conducted by or for the applicant and for which the applicant has not obtained a right of reference. As an alternative path to FDA approval for modifications to formulations or uses of products previously approved by the FDA, an applicant may submit an NDA under Section 505(b)(2) of the FDCA. Section 505(b)(2) was enacted as part of the Hatch-Waxman Amendment, and permits the filing of an NDA where at least some of the information required for approval comes from studies or trials not conducted by or for the applicant and for which the applicant has not obtained a right of reference. If the 505(b)(2) applicant can establish that reliance on the FDA&#8217;s previous findings of safety and effectiveness is scientifically appropriate, it may eliminate the need to conduct certain pre-clinical studies or clinical trials for the new product. The FDA may also require companies to perform additional studies or measurements, including clinical trials, to support the change from the approved branded reference drug. The FDA may then approve the </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">106</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">new product candidate for all, or some, of the labeled indications for which the branded reference drug has been approved, as well as for any new indication sought by the 505(b)(2) applicant. We are developing our late-stage branded product candidates with the expectation that we will submit 505(b)(2) NDAs to FDA for these products. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Orange Book Listing </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In seeking approval for a drug through an NDA, including a 505(b)(2) NDA, applicants are required to list with the FDA certain patents whose claims cover the applicant&#8217;s product. Upon approval of an NDA, each of the patents listed in the application for the drug is then published in the FDA&#8217;s Publication of Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the &#8220;Orange Book.&#8221; Any applicant who submits an ANDA seeking approval of a generic equivalent of a drug listed in the Orange Book or a Section 505(b)(2) NDA referencing a drug listed in the Orange Book must certify to the FDA that (1) no patent information on the drug product that is the subject of the application has been submitted to the FDA; (2) such patent has expired; (3) the date on which such patent expires; or (4) such patent is invalid or will not be infringed upon by the manufacture, use, or sale of the drug product for which the application is submitted. This last certification is known as a Paragraph IV certification. The applicant may also elect to submit a &#8220;section viii&#8221; statement certifying that its proposed label does not contain (or carves out) any language regarding the patented method-of-use rather than certify to a listed method-of-use patent. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">If the applicant does not challenge one or more listed patents through a Paragraph IV certification, the FDA will not approve the ANDA or Section 505(b)(2) NDA until all the listed patents claiming the referenced product have expired. Further, the FDA will also not approve, as applicable, an ANDA or Section 505(b)(2) NDA until any non-patent exclusivity, as described in greater detail below, has expired. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">If the ANDA or Section 505(b)(2) NDA applicant has provided a Paragraph IV certification to the FDA, the applicant must also send notice of the Paragraph IV certification to the owner of the referenced NDA for the previously approved product and relevant patent holders within 20 days after the ANDA or Section 505(b)(2) NDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement suit against the ANDA or Section 505(b)(2) applicant. Under the FDCA, the filing of a patent infringement lawsuit within 45 days of receipt of the notification regarding a Paragraph IV certification automatically prevents the FDA from approving the ANDA or Section 505(b)(2) NDA until the earliest to occur of 30 months beginning on the date the patent holder receives notice, expiration of the patent, settlement of the lawsuit, or until a court deems the patent unenforceable, invalid or not infringed. Even if a patent infringement claim is not brought within the 45-day period, a patent infringement claim may be brought under traditional patent law, but it does not invoke the 30-month stay. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Moreover, in cases where an ANDA or Section 505(b)(2) application containing a Paragraph IV certification is submitted after the fourth year of a previously approved drug&#8217;s five-year NCE exclusivity period, as described more fully below, and the patent holder brings suit within 45 days of notice of the Paragraph IV certification, the 30-month period is automatically extended to prevent approval of the Section 505(b)(2) application until the date that is seven and one-half years after approval of the previously approved reference product that has the five-year NCE exclusivity. The court also has the ability to shorten or lengthen either the 30 month or the seven and one-half year period if either party is found not to be reasonably cooperating in expediting the litigation. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Notwithstanding the approval of many products by the FDA pursuant to Section 505(b)(2), over the last few years, some pharmaceutical companies and others have objected to the FDA&#8217;s interpretation of Section 505(b)(2). If the FDA changes its interpretation of Section 505(b)(2), or if the FDA&#8217;s interpretation is successfully challenged in court, this could delay or even prevent the FDA from approving any Section 505(b)(2) NDA that we submit.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">107</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Non-Patent Exclusivity </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In addition to patent exclusivity, the holder of the NDA for the listed drug may be entitled to a period of non-patent exclusivity, during which the FDA cannot approve an ANDA or 505(b)(2) application that relies on the listed drug. For example, a pharmaceutical manufacturer may obtain five years of non-patent exclusivity upon NDA approval of a new chemical entity, or NCE, which is a drug that contains an active moiety that has not been approved by FDA in any other NDA. An &#8216;&#8216;active moiety&#8217;&#8217; is defined as the molecule or ion responsible for the drug substance&#8217;s physiological or pharmacologic action. During the five year exclusivity period, the FDA cannot accept for filing any ANDA seeking approval of a generic version of that drug or any 505(b)(2) NDA for the same active moiety and that relies on the FDA&#8217;s findings regarding that drug, except that FDA may accept an application for filing after four years if the follow-on applicant makes a paragraph IV certification. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Another form of non-patent exclusivity is clinical investigation exclusivity. A drug, including one approved under Section 505(b)(2), may obtain a three-year period of exclusivity for a particular condition of approval, or change to a marketed product, such as a new formulation for a previously approved product, if one or more new clinical trials (other than bioavailability or bioequivalence studies) was essential to the approval of the application and was conducted/&#8203;sponsored by the applicant. Should this occur, the FDA would be precluded from approving any ANDA or 505(b)(2) application for the protected modification until after that three-year exclusivity period has run. However, unlike NCE exclusivity, the FDA can accept an application and begin the review process during the exclusivity period. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Patent Term Restoration and Extension </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">A patent claiming a new drug product may be eligible for a limited patent term extension under the Hatch-Waxman Act, or PTE, which permits an extended patent term of up to five years for the developed pharmaceutical to compensate for patent term lost during product development and the FDA regulatory review. The PTE period granted is typically one-half the time between the effective date of an IND and the submission date of an NDA, plus the time between the submission date of a NDA and the ultimate approval date. However, the PTE cannot be used to extend the remaining term of a patent past a total of 14 years from the product&#8217;s approval date. Only one patent applicable to an approved drug product is eligible for the extension, and the application for the extension must be submitted prior to the expiration of the patent in question. A patent that covers multiple drugs for which approval is sought can only be extended in connection with one of the approvals. The U.S. Patent and Trademark Office reviews and approves the PTE application in consultation with the FDA. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Review and Approval of Drug Products Outside the United States </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In addition to regulations in the United States, if we target non-U.S. markets, we will be subject to a variety of foreign regulations governing manufacturing, clinical trials, commercial sales and distribution of our future product candidates. Whether or not we obtain FDA approval for a product candidate, we must obtain approval of the product by the comparable regulatory authorities of foreign countries before commencing clinical trials or marketing in those countries. The approval process varies from country to country, and the time may be longer or shorter than that required for FDA approval. The requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary greatly from country to country. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Under European Union regulatory systems, marketing authorizations may be submitted either under a centralized, decentralized or mutual recognition procedure. The centralized procedure provides for the grant of a single marketing authorization that is valid for all European Union member states. The decentralized procedure includes selecting one &#8220;reference member state,&#8221; or RMS, and submitting to more than one member state at the same time. The RMS National Competent Authority conducts a detailed review and prepares an assessment report, to which concerned member states provide comment. The mutual recognition procedure provides for </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">108</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">mutual recognition of national approval decisions. Under this procedure, the holder of a national marketing authorization may submit an application to the remaining member states post-initial approval. Within 90 days of receiving the applications and assessment report, each member state must decide whether to recognize the approval. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Pharmaceutical Coverage, Pricing and Reimbursement </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval. In the United States and other markets, sales of any product candidates for which we receive regulatory approval for commercial sale will depend in part on the availability of coverage and reimbursement from third-party payors. Third-party payors include government health administrative authorities, managed care providers, private health insurers and other organizations. The process for determining whether a payor will provide coverage for a drug product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the drug product. Third-party payors may limit coverage to specific drug products on an approved list, or formulary, which might not include all of the FDA-approved drug products for a particular indication. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. We may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of VERED and TWIN, in addition to the costs required to obtain the FDA approvals. For example, VERED and TWIN may not be considered medically necessary or cost-effective. A payor&#8217;s decision to provide coverage for a drug product does not imply that an adequate reimbursement rate will be approved. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In March&#160;2010, the President of the United States signed the Affordable Care Act, one of the most significant healthcare reform measures in decades. The Affordable Care Act substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacted the pharmaceutical industry. The comprehensive $940 billion dollar overhaul is expected to extend coverage to approximately 32 million previously uninsured Americans. The Affordable Care Act contained a number of provisions, including those governing enrollment in federal healthcare programs, reimbursement changes and fraud and abuse, which impacted existing government healthcare programs and will result in the development of new programs, including Medicare payment for performance initiatives and improvements to the physician quality reporting system and feedback program. </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">Additionally, the Affordable Care Act: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">increased the minimum level of rebates payable by manufacturers of brand-name drugs from 15.1% to 23.1%; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">imposed a non-deductible annual fee on pharmaceutical manufacturers or importers who sell &#8220;branded prescription drugs&#8221; to specified federal government programs. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Since its enactment, there have been judicial and Congressional challenges to certain aspects of the Affordable Care Act. The new Presidential Administration and U.S. Congress have attempted and will likely continue to seek to modify, repeal, or otherwise invalidate all, or certain provisions of, the Affordable Care Act. It is uncertain the extent to which any such changes may impact our business or financial condition.</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In addition, other legislative changes have been proposed and adopted since the Affordable Care Act was enacted. In August&#160;2011, the President signed into law the Budget Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee did not achieve a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">109</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">triggering the legislation&#8217;s automatic reduction to several government programs. These included reductions to Medicare payments to providers of 2% per fiscal year, which went into effect on April&#160;1, 2013 and, due to subsequent legislative amendments to the statute, will stay in effect through 2025 unless additional Congressional action is taken. Additionally, in January&#160;2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Recently there has also been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several Congressional inquiries and proposed bills designed to, among other things, reform government program reimbursement methodologies. Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. We expect that additional state and federal healthcare initiatives will be adopted in the future, any of which could impact the coverage and reimbursement for drugs, including our product candidates, if approved. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In the European Union, pricing and reimbursement schemes vary widely from country to country. Some countries provide that drug products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies or trials that compare the cost-effectiveness of a particular product candidate to currently available therapies. For example, the European Union provides options for its member states to restrict the range of drug products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. European Union member states may approve a specific price for a drug product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the drug product on the market. Other member states allow companies to fix their own prices for drug products, but monitor and control company profits. The downward pressure on health care costs in general, particularly prescription drugs, has become intense. As a result, there are increasingly high barriers to entry for new products. In addition, in some countries, cross-border imports from low-priced markets exert competitive pressure that may reduce pricing within a country. Any country that has price controls or reimbursement limitations for drug products may not allow favorable reimbursement and pricing arrangements. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Healthcare Laws and Regulations </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Although we currently do not have any product candidates on the market, our current and future business operations may be subject to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which we conduct our business. Such laws include, without limitation, state and federal anti-kickback, fraud and abuse, false claims, privacy and security, price reporting and physician sunshine laws. Some of our pre-commercial activities are subject to some of these laws. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The federal Anti-Kickback Statute makes it illegal for any person or entity, including a prescription drug manufacturer or a party acting on its behalf to knowingly and willfully, directly or indirectly solicit, receive, offer, or pay any remuneration that is intended to induce the referral of business, including the purchase, order, lease of any good, facility, item or service for which payment may be made under a federal healthcare program, such as Medicare or Medicaid. The term &#8220;remuneration&#8221; has been broadly interpreted to include anything of value. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, formulary managers, and beneficiaries on the other. Although there are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, the exceptions and safe harbors are drawn narrowly. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchases or recommendations may be subject to scrutiny if they do not qualify for an exception or </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">110</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all its facts and circumstances. Several courts have interpreted the statute&#8217;s intent requirement to mean that if any one purpose of an arrangement involving remuneration is to induce referrals of federal healthcare covered business, the Anti-Kickback Statute has been violated. In addition, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. Violations of this law are punishable by up to five years in prison, and can also result in criminal fines, civil money penalties and exclusion from participation in federal healthcare programs. Moreover, a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The federal civil False Claims Act prohibits, among other things, any person or entity from knowingly presenting, or causing to be presented, for payment to, or approval by, federal programs, including Medicare and Medicaid, claims for items or services, including drugs, that are false or fraudulent or not provided as claimed. Persons and entities can be held liable under these laws if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims by, for example, providing inaccurate billing or coding information to customers or promoting a product off-label. In addition, our future activities relating to the reporting of wholesaler or estimated retail prices for our product candidates, the reporting of prices used to calculate Medicaid rebate information and other information affecting federal, state and third-party reimbursement for our product candidates, and the sale and marketing of our product candidates, are subject to scrutiny under this law. Penalties for federal civil False Claims Act violations may include up to three times the actual damages sustained by the government, plus mandatory civil penalties for each separate false claim, the potential for exclusion from participation in federal healthcare programs, and, although the federal False Claims Act is a civil statute, False Claims Act violations may also implicate various federal criminal statutes. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">HIPAA created new federal criminal statutes that prohibit among other actions, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, knowingly and willfully embezzling or stealing from a healthcare benefit program, willfully obstructing a criminal investigation of a healthcare offense, and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services. Like the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The civil monetary penalties statute imposes penalties against any person or entity that, among other things, is determined to have presented or caused to be presented a claim to a federal health program that the person knows or should know is for an item or service that was not provided as claimed or is false or fraudulent. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Also, many states have similar fraud and abuse statutes or regulations that may be broader in scope and may apply regardless of payor, in addition to items and services reimbursed under Medicaid and other state programs. Additionally, to the extent that any of our product candidates are sold in a foreign country, we may be subject to similar foreign laws. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">HIPAA, as amended by HITECH, and their implementing regulations, including the final omnibus rule published on January&#160;25, 2013, mandates, among other things, the adoption of uniform standards for the electronic exchange of information in common healthcare transactions, as well as standards relating to the privacy and security of individually identifiable health information, which require the adoption of administrative, physical and technical safeguards to protect such information. Among other things, HITECH makes HIPAA&#8217;s security standards directly applicable to business associates, defined as independent contractors or agents of covered entities that create, receive or obtain protected health information in connection with providing a service </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">111</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">for or on behalf of a covered entity. HITECH also increased the civil and criminal penalties that may be imposed against covered entities and business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. In addition, certain state laws govern the privacy and security of health information in certain circumstances, some of which are more stringent than HIPAA and many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts. Failure to comply with these laws, where applicable, can result in the imposition of significant civil and/or criminal penalties. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The Affordable Care Act imposed, among other things, new annual reporting requirements for covered manufacturers for certain payments and other transfers of value provided to physicians and teaching hospitals, as well as certain ownership and investment interests held by physicians and their immediate family members. Failure to submit timely, accurately and completely the required information for all payments, transfers of value and ownership or investment interests may result in civil monetary penalties. Certain states also mandate implementation of compliance programs, impose restrictions on drug manufacturer marketing practices, require reporting of marketing expenditures and pricing information and/or require the tracking and reporting of gifts, compensation and other remuneration to physicians. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Because we intend to commercialize products that could be covered by a federal healthcare program and other governmental healthcare programs, we intend to develop a comprehensive compliance program that establishes internal controls to facilitate adherence to the rules and program requirements to which we will or may become subject. Although the development and implementation of compliance programs designed to establish internal controls and facilitate compliance can mitigate the risk of investigation, prosecution, and penalties assessed for violations of these laws, the risks cannot be entirely eliminated. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">If our operations are found to be in violation of any of such laws or any other governmental regulations that apply to us, we may be subject to penalties, including, without limitation, administrative, civil and criminal penalties, damages, fines, disgorgement, contractual damages, reputational harm, diminished profits and future earnings, the curtailment or restructuring of our operations, exclusion from participation in federal and state healthcare programs and individual imprisonment, any of which could adversely affect our ability to operate our business and our financial results. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Innovation Authority </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We have received royalty-bearing grants from the government of Israel through the Innovation Authority, for the financing of a portion of our research and development expenditures in Israel.</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Under the Innovation Law and the Innovation Authority&#8217;s rules and guidelines, recipients of grants, or Recipient Company(ies), are subject to certain obligations including, the following: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">In general, the Recipient Company is obligated to pay the Innovation Authority royalties from the revenues generated from the sale of products (and related services) developed (in all or in part) as a result of, a research and development program funded by the Innovation Authority at rates which are determined under the Innovation Authority&#8217;s rules and guidelines (currently a yearly rate of 1.3% to 5% on sales of products or services developed under the approved programs, depending on the type of the Recipient Company&#8201;&#8212;&#8201;i.e., whether it is a &#8220;Small Company,&#8221; a &#8220;Large Company&#8221; or a &#8220;Traditional Industrial Company&#8221; as such terms are defined in the Innovation Authority&#8217;s rules and guidelines), up to the aggregate amount of the total grants received by the Innovation Authority, plus annual interest (as determined in the Innovation Authority&#8217;s rules and guidelines);</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">112</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">Products developed as a result of the Innovation Authority funded R&amp;D must, as a general matter, be manufactured in Israel. The Recipient Company is prohibited from manufacturing products developed using these Innovation Authority grants outside of the State of Israel without receiving prior approval from the Innovation Authority (except for the transfer of less than 10% of the manufacturing capacity in the aggregate which requires only a notice). If the Recipient Company receives approval to manufacture products developed with government grants outside of Israel, it will be required to pay increased royalties to the Innovation Authority, up to 300% of the grant amount plus interest, depending on the manufacturing volume that is performed outside of Israel. The Company may also be subject to an accelerated royalty repayment rates. A Recipient Company also has the option of declaring in its Innovation Authority grant application its intention to exercise a portion of the manufacturing capacity abroad, thus avoiding the need to obtain additional approval following the receipt of the grant; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">Under the Innovation Authority&#8217;s rules and guidelines, a Recipient Company is prohibited from transferring the Innovation Authority-financed know-how and related intellectual property rights outside of Israel except under limited circumstances, and only with the approval of the Research Committee and subject to certain payments to the Innovation Authority calculated according to formulas provided under the Innovation Authority&#8217;s rules and guidelines (which are capped to amounts specified under such rules and guidelines). </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We have received grants from the Innovation Authority in connection with our research and development of a peripheral line of product candidates, which forms a negligble part of our activities, and therefore, we are subject to the aforementioned restrictions with respect to such product candidates. Such restrictions continue to apply even though we have paid the full amount of royalties payable pursuant to the grants. For additional information on our royalty obligations related to Innovation Authority grants, see Note 5a to our financial statements for the year ended December 31, 2016, contained elsewhere in this prospectus.</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Even if our Innovation Authority funded know-how is transferred to another Israeli entity, the transfer would require the Innovation Authority&#8217;s approval but will not be subject to the payment of a redemption fee (we note that there will be an obligation to pay royalties to the Innovation Authority from the income of such sale transaction as part of the royalty payment obligation). In such case, the acquiring company would have to assume all of our responsibilities towards the Innovation Authority as a condition to the Innovation Authority&#8217;s approval. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The government of Israel does not own intellectual property rights in technology developed with Innovation Authority funding and there is no restriction on the export of products manufactured using technology developed with Innovation Authority funding. However, the know-how is subject to transfer of know-how and manufacturing rights restrictions as described above. The Innovation Authority&#8217;s approval is not required for the export of any products resulting from the Innovation Authority research or development grants. In addition, the Innovation Authority has recently published new rules and guidelines for the granting of licenses to use know-how developed as a result of research financed by the Innovation Authority to foreign entities. According to such rules, we will be required to receive the Innovation Authority&#8217;s prior approval for the grant of such use rights, and we will be subject to the Innovation Authority in accordance with the formula stipulated under these rules and guidelines. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Pursuant to Amendment No. 7 of the Innovation Law, the Innovation Authority is authorized to change the restrictions imposed on the recipients of grants that were stipulated under the Innovation Law prior to the effectiveness of Amendment No.&#160;7 with a new set of arrangements in connection with ownership obligations of know-how (including with respect to restrictions on transfer of know-how and manufacturing activities outside of Israel), as well as royalties obligations associated with approved programs. Amendment No. 7 also includes new provisions with respect to sanctions imposed for violations of the Innovation Law. Although the Innovation Authority recently published rules which for the most part adopted the principal provisions and </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">113</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">restrictions specified in the Innovation Law prior to the effectiveness of Amendment No. 7, as of the date of this prospectus, we are unable to assess the effect on our business of any future rules which may be published by the Innovation Authority. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We may not receive the required approvals for any actual proposed transfer and, if received, we may be required to pay the Innovation Authority a portion of the consideration that we receive upon any sale of the Innovation Authority funded know-how to a non-Israeli entity. The scope of the support received, the royalties that we have already paid to the Innovation Authority, the amount of time that has elapsed between the date on which the know-how was transferred and the date on which the Innovation Authority grants were received and the sale price and the form of transaction will be taken into account in calculating the amount of the payment to the Innovation Authority. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Employees </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">As of June&#160;30, 2017, we had 50 employees, all based in Israel. We have never experienced any employment-related work stoppages and believe our relationships with our employees are good. </div>
        <table style="width:416pt;height:70pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:338pt;">
              <div style="white-space:nowrap;">Area of Activity </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="text-align:center;">As of<br >June&#160;30, <br >2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:338pt;text-align:left;">
              <div style="white-space:nowrap;">Administrative </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:27.445pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">6</td>
            <td style="padding:0pt;padding-left:27.445pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:338pt;text-align:left;">
              <div style="white-space:nowrap;">Research, development and quality assurance </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:27.445pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:9pt; text-align:right; white-space:nowrap;">44</td>
            <td style="padding:0pt;padding-left:27.445pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.75pt 0pt; width:338pt;text-align:left;">
              <div style="margin-left:10pt;">Total </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:27.445pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:9pt; text-align:right; white-space:nowrap;">50</td>
            <td style="padding:0pt;padding-left:27.445pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="8">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:16pt; width:456pt; line-height:11pt;font-weight:bold;">Facilities </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Our principal executive offices are located in a leased facility in Weizmann Science Park, Ness Ziona 7403650, Israel. The facility houses our offices, warehouse, laboratories and production area. Our lease will expire on December&#160;31, 2020. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We intend to add new facilities or expand our existing facilities as we add employees, and we believe that suitable additional or substitute space will be available as needed to accommodate any such expansion of our operations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Environmental, Health and Safety Matters </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We are subject to extensive environmental, health and safety laws and regulations in a number of jurisdictions including Israel. These laws and regulations govern, among other things, (i) the use, storage, registration, handling, emission and disposal of chemicals, waste materials and sewage and (ii) chemical, air, water and ground contamination, air emissions and the cleanup of contaminated sites, including any contamination that results from spills due to our failure to properly dispose of chemicals, waste materials and sewage. Our operations at our Ness Ziona facility use chemicals and produce waste materials and sewage. Our activities require permits from various governmental authorities, including local municipal authorities, the Ministry of Environmental Protection and the Ministry of Health. The Ministry of Environmental Protection and the Ministry of Health, local authorities and the municipal water and sewage company conduct periodic inspections in order to review and ensure our compliance with the various regulations. As of the date of this prospectus, we hold a valid poison permit for our activity in Ness Ziona (in effect until April&#160;13, 2018), and a valid business license in effect until December&#160;31, 2019. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">These laws, regulations and permits could potentially require the expenditure by us of significant amounts for compliance or remediation. If we fail to comply with such laws, regulations or permits, we may be subject to fines and other civil, administrative or criminal sanctions, including the revocation of permits and licenses necessary to continue our business activities. In addition, we may be required to pay damages or civil judgments in respect of </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">114</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">third-party claims, including those relating to personal injury (including exposure to hazardous substances we use, store, handle, transport, manufacture or dispose of), property damage or contribution claims. Some environmental, health and safety laws allow for strict, joint and several liability for remediation costs, regardless of comparative fault. We may be identified as a responsible party under such laws. Such developments could have a material adverse effect on our business, financial condition and results of operations. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In addition, laws and regulations relating to environmental, health and safety matters are often subject to change. In the event of any changes or new laws or regulations, we could be subject to new compliance measures or to penalties for activities which were previously permitted. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The operations of our subcontractors and suppliers are also subject to various Israeli and foreign laws and regulations relating to environmental, health and safety matters, and their failure to comply with such laws and regulations could have a material adverse effect on our business and reputation, result in an interruption or delay in the development or manufacture of our product candidates, or increase the costs for the development or manufacture of our product candidates. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Legal Proceedings </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">We are not subject to any material legal proceedings. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">115</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tMAN">&#8203;</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;"><font style="text-transform:uppercase;">Management</font></div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Executive officers, directors and director nominees </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The following table sets forth information concerning our executive officers, directors and director nominees, including their ages, as of the date of this prospectus: </div>
        <table style="width:456pt;height:233.5pt;margin-top:10pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:138pt;">
              <div style="white-space:nowrap;">Name </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:24pt;text-align:center;">
              <div style="white-space:nowrap; text-align:center;">Age </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:270pt;">
              <div style="white-space:nowrap;">Position </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:138pt;">Moshe Arkin </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">64 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:270pt;">Chairman of the Board of Directors </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:138pt;">Alon Seri-Levy (1) </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">56 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:270pt;">Chief Executive Officer and Director Nominee </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:138pt;">Gilad Mamlok </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">49 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:270pt;">Chief Financial Officer </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:138pt;">Haim Barsimantov </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">42 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:270pt;">Chief Technology Officer </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:138pt;">Ofer Toledano </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">52 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:270pt;">Vice President Research and Development </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:138pt;">Ofra Levy-Hacham </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">51 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:270pt;">Vice President Quality and Regulatory Affairs </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:138pt;">Karine Neimann </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">46 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:270pt;">Vice President Projects and Planning, Chief Chemist </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:138pt;">Itzik Yosef </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">41 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:270pt;">Vice President Operations </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:138pt;">Dov Zamir </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">64 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:270pt;">Vice President Special Projects </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:138pt;">Itai Arkin (1) </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">29 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:270pt;">Director Nominee </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:138pt;">Shmuel Ben Zvi (1) </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">57 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:270pt;">Director Nominee </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:138pt;">Hani Lerman (1) </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">44 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:270pt;">Director Nominee </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:138pt;">Yael Baratz (1) </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">60 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:270pt;">Director Nominee </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:138pt;">Ran Gottfried (1)(2) </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">72 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:270pt;">External Director Nominee </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:138pt;">Jerrold S. Gattegno (1)(2) </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:24pt;text-align:center;">
              <div style="text-align:center;">65</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:270pt;">External Director Nominee</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:15pt;white-space:nowrap;font-size:8pt;">(1)<br ></div>
        <div style=" float:left; margin-top:8.2pt; margin-bottom:0pt; line-height:10pt; text-align:left; width:440.5pt;font-size:8pt;">Will be appointed to the board of directors immediately following the pricing of this offering.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:10pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:15pt;white-space:nowrap;font-size:8pt;">(2)<br ></div>
        <div style=" float:left; margin-top:6.2pt; margin-bottom:0pt; line-height:10pt; text-align:left; width:440.5pt;font-size:8pt;">Proposed to serve as an external director under the Companies Law subject to ratification of his election as an external director under the Companies Law by our shareholders within three months following this offering. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;"><font style="font-style:italic;font-weight:bold;">Mr. Moshe Arkin </font>has served as chairman of our board of directors since 2014. Mr. Arkin currently sits on the board of directors of several health care companies including Exalenz Bioscience Ltd., a developer of advanced systems for gastrointestinal and liver disorders since 2006, Quiet Therapeutics Ltd., a cancer drug discovery and development and SoniVie Ltd., a private company developing systems for the treatment of pulmonary arterial hypertension. From 2005 to 2008, Mr. Arkin served as the head of generics at Perrigo Company and from 2005 until 2011 as the vice chairman of its board of directors. Prior to joining us, Mr. Arkin served as a director of cCAM Biotherapeutics Ltd., a company focused on the discovery and development of novel immunotherapies to treat cancer from 2012 until its acquisition in 2015 by Merck &amp; Co., Inc. Mr. Arkin served as chairman of Agis Industries Ltd. from its inception in 1972 until its acquisition by Perrigo Company in 2005. Mr. Arkin holds a B.A. in psychology from the Tel&#160;Aviv University, Israel. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;"><font style="font-style:italic;font-weight:bold;">Dr. Alon Seri-Levy </font>co-founded Sol-Gel and has served as our chief executive officer since our inception in 1997 and as a member of our board of directors until 2014. Prior to founding Sol-Gel, Mr. Seri-Levy established the computer-aided drug design department at Peptor Ltd., an Israeli research and development company that specialized in the development of peptide-based drug products. Mr.&#160;Seri-Levy holds a Ph.D. in Chemistry (summa cum laude) from The Hebrew University of Jerusalem, Israel, and conducted his post-doctoral studies at Oxford University, United Kingdom. Mr. Seri-Levy will be appointed to our board of directors immediately following the pricing of this offering. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;"><font style="font-style:italic;font-weight:bold;">Mr. Gilad Mamlok</font> has served as our chief financial officer since March 2017. From August 2015 to January 2017, Mr.&#160;Mamlok served as the chief financial officer for Medigus Ltd., a medical device company dual listed on Nasdaq and the Tel Aviv Stock Exchange, or the TASE. From </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">116</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">September 2005 to March 2015, Mr.&#160;Mamlok served as senior vice president, global finance and accounting of Given Imaging Ltd., a medical device company dual listed on Nasdaq and TASE, acquired by Covidien plc in February 2014. From January 2002 to September 2005, Mr.&#160;Mamlok served as chief financial officer of two other medical device companies. Mr.&#160;Mamlok holds a Master&#8217;s degree in business economics from Tel-Aviv University and a B.A. in economics (magna cum laude) from Tel-Aviv University, Israel. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;"><font style="font-style:italic;font-weight:bold;">Mr. Haim Barsimantov</font> has served as our chief technology officer since September 2016. From 2000 until 2007, Mr. Barsimantov served as our plant manager. From 2007 and until August 2016, Mr.&#160;Barsimantov served as our chief operating officer. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;"><font style="font-style:italic;font-weight:bold;">Dr. Ofer Toledano </font>has served as our vice president of research and development since 2004. Prior to joining Sol-Gel, Dr. Toledano served as manager of the formulation department at ADAMA Agricultural Solutions Ltd. (formerly known as Makhteshim Agan Industries Ltd.), an Israeli manufacturer and distributor of crop protection products from 1998 until 2004. Dr. Toledano holds a Ph.D. in chemistry from The Hebrew University of Jerusalem, Israel. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;"><font style="font-style:italic;font-weight:bold;">Dr. Ofra Levy-Hacham</font> has served as our vice president of quality and regulatory affairs since 2011. Prior to joining Sol-Gel, Dr. Levy-Hacham served as a scientific specialist and project manager at Biotechnology General Ltd., a fully integrated biopharmaceutical services private company from 2010 until 2011. From 2008 until 2010, Dr. Levy-Hacham served as vice president chemistry, manufacturing and controls at HealOr Ltd., a private company engaging in the development of therapeutics for the treatment of various skin lesions and conditions. Dr.&#160;Levy-Hacham holds a Ph.D. in chemistry from The Technion - Israel Institute of Technology, Israel. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;"><font style="font-style:italic;font-weight:bold;">Dr. Karine Neimann</font> has served as our vice president of projects and planning and chief chemist since September 2016. Since joining us in 2008, Ms. Neimann held various positions, including as chief chemist and laboratory manager. Ms. Neimann holds a Ph.D. in chemistry from The Hebrew University of Jerusalem, Israel. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;"><font style="font-style:italic;font-weight:bold;">Dr. Itzik Yosef</font> has served as our vice president of operations since August&#160;2016. Since joining us in 2010, Mr. Yosef held various positions including as head of operations. Mr. Yosef holds a Ph.D. in chemistry from The Hebrew University of Jerusalem, Israel. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;"><font style="font-style:italic;font-weight:bold;">Dr. Dov Zamir</font> has served as our vice president special projects since August&#160;2016. Prior to joining us, Mr. Zamir lead the R&amp;D group in Cima NanoTech Ltd., a private company developing sophisticated nanotechnology based coating formulations from 2007 until 2016. From 2004 to 2007, Mr. Zamir was VP of Pharma and Analytical R&amp;D at Taro Pharmaceutical Industries in Haifa, and for three years prior to that he managed its Analytical R&amp;D lab. Mr. Zamir holds a Ph.D. in organic chemistry from Tel-Aviv University, Israel. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;"><font style="font-style:italic;font-weight:bold;">Mr. Itai Arkin </font>will become a member of our board of directors immediately following the pricing of this offering. Mr. Itai Arkin currently serves as Investment Manager at Arkin Holdings Ltd. and on the board of directors of Exalenz Bioscience Ltd. Mr. Itai Arkin is an investment committee member of both Accelmed, a leading Israeli MedTech investment firm since March&#160;2014, and of Sphera Global Healthcare, a leading healthcare hedge fund. Mr. Itai Arkin holds a B.A. in business administration (cum laude) from Interdisciplinary Center, Herzliya, Israel. Mr. Itai Arkin is the son of Mr. Moshe Arkin, the chairman of our board of directors and sole beneficial owner of Arkin Dermatology, our controlling shareholder. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;"><font style="font-style:italic;font-weight:bold;">Dr. Shmuel (Muli) Ben Zvi</font> will become a member of our board of directors immediately following pricing of this offering. Dr. Ben Zvi is currently a board member and member of the audit, risk management and strategy committees at Bank Leumi. From 2004 to 2014, Dr. Ben Zvi held various managerial positions at Teva Pharmaceuticals Industries Ltd., including Vice President of Finance and Vice President of Strategy. From 2000 to 2004, Dr. Ben Zvi was the financial advisor to the Chief of General Staff of the Israel Defense Forces and head of the Defense Ministry budget department. Dr. Ben Zvi holds a Ph.D. in economics from Tel-Aviv University, Israel and participated in the Harvard Business School Advanced Management Program (AMP).</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">117</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;"><font style="font-style:italic;font-weight:bold;">Ms. Hani Lerman</font> will become a member of our board of directors immediately following pricing of this offering. Ms. Lerman has served as chief financial officer at Arkin Holdings since 2015. From 2010 until 2014, Ms. Lerman served as chief financial officer of Sansa Security (f/k/a Discretix Technologies), and from 2006 until 2010, she served as chief financial officer of Storwize, which was acquired by IBM in 2010. She serves as a board member of Exalenz Bioscience and Medical Compression Systems. She holds a Master&#39;s degree in business administration with a major in finance from Tel-Aviv University, Israel, and a B.A. in economics and accounting from Tel-Aviv University, Israel.</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;"><font style="font-style:italic;font-weight:bold;">Ms. Yael Baratz</font> will become a member of our board of directors immediately following pricing of this offering. Ms. Baratz is a Senior Partner and Chair of the Corporate &amp; Licensing Group at the international law firm of Pearl Cohen Zedek Latzer Baratz and works out of its Tel-Aviv office. Ms. Baratz has been in private practice since 1992 and currently serves as the co-chair of the Israel Bar Association&#8217;s science and technology committee. Ms. Baratz holds an L.L B. from Tel-Aviv University, Israel. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;"><font style="font-style:italic;font-weight:bold;">Mr. Ran Gottfried</font> will become a member of our board of directors immediately following the pricing of this offering and will serve as an external director under the Companies Law subject to the ratification of his appointment at a general meeting of our shareholders to be held following the completion of this offering. Since 1975, Mr.&#160;Gottfried has served as a chief executive officer, consultant and director of private companies in Israel and Europe in the areas of retail and distribution of pharmaceuticals, consumer and household products. Mr. Gottfried served as a director of Perrigo Company from 2006 until 2015. From 2006 until 2008, Mr. Gottfried served as chairman and chief executive officer of Powerpaper Ltd., a leading developer and manufacturer of micro electrical cosmetic and pharmaceutical patches. From 2005 until 2010, Mr. Gottfried served as a director of Bezeq, Israel&#8217;s leading telecommunications provider and from 2003 until its acquisition by Perrigo Company in 2005, Mr. Gottfried served as a director of Agis Industries Ltd. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;"><font style="font-style:italic;font-weight:bold;">Mr. Jerrold S. Gattegno</font> will become a member of our board of directors immediately following the pricing of this offering and will serve as an external director under the Companies Law subject to the ratification of his appointment at a general meeting of our shareholders to be held following the completion of this offering. Mr. Gattegno worked in the New York, Washington D.C. and London offices of Deloitte Touche Tohmatsu Limited, a public accounting firm, from 1973 until 2015, where he served in various senior positions, including as the founding partner of Deloitte&#8217;s multistate tax practice and as a managing partner in Deloitte&#8217;s Washington National Tax Office. Mr.&#160;Gattegno has served as a member of the Hispanic Association of Colleges and Universities finance and audit committee from 2012 until 2015. Mr. Gattegno is a certified public accountant and holds a B.S. in accounting (cum laude) from the City University of New York and an M.B.A. in taxation (with honors) from Pace University, New York. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Compensation of Executive Officers and Directors </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The aggregate compensation paid by us to our executive officers and directors for the year ended December&#160;31, 2016 was approximately $3.0 million. This amount includes approximately $0.1 million set aside or accrued to provide pension, severance, retirement or similar benefits or expenses, but does not include business travel, relocation, professional and business association dues and expenses reimbursed to officers, and other benefits commonly reimbursed or paid by companies in Israel. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Foreign Private Issuer and Controlled Company Status </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Foreign Private Issuer </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">After the consummation of this offering, we will be a &#8220;foreign private issuer&#8221; under the U.S. securities laws and the NASDAQ corporate governance rules. As a foreign private issuer, we will be exempt from the rules under the Exchange Act related to the furnishing and content of proxy statements, and our officers, directors and principal shareholders will be exempt from the </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">118</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. Also, we are not required to comply with Regulation FD, which restricts the selective disclosure of material information. However, we intend to file with the SEC, within 120 days after the end of each fiscal year, or such applicable time as required by the SEC, an annual report on Form 20-F containing financial statements audited by an independent registered public accounting firm, and we intend to submit to the SEC from time to time, on Form 6-K, reports of information that would likely be material to an investment decision in our securities. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">As a foreign private issuer, we are permitted to follow certain Israeli corporate governance practices instead of the NASDAQ corporate governance rules, provided that we disclose which requirements we are not following and the equivalent Israeli requirement. Pursuant to the &#8220;foreign private issuer exemption&#8221;: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:10.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:10.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">we intend to establish a quorum requirement such that the quorum for any meeting of shareholders is 33<font style=" position:relative; bottom:2.66pt;font-size:7pt;">1</font>&#8725;<font style="font-size:7pt;">3</font>% of the issued share capital, as required under NASDAQ requirements, however, if the meeting is adjourned for lack of quorum, the quorum for such adjourned meeting will be any number of shareholders, instead of 33<font style=" position:relative; bottom:2.66pt;font-size:7pt;">1</font>&#8725;<font style="font-size:7pt;">3</font>% of the issued share capital; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:10.38pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:10.38pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">we intend to adopt and approve material changes to equity incentive plans in accordance with the Companies Law, which does not impose a requirement of shareholder approval for such actions. In addition, we intend to follow Israeli corporate governance practice in lieu of NASDAQ Marketplace Rule 5635(c), which requires shareholder approval prior to an issuance of securities in connection with equity based compensation of officers, directors, employees or consultants; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:10.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:10.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">as opposed to making periodic reports to shareholders and proxy solicitation materials available to shareholders in the manner specified by the NASDAQ corporate governance rules, the Companies Law does not require us to distribute periodic reports directly to shareholders, and the generally accepted business practice in Israel is not to distribute such reports to shareholders but to make such reports available through a public website. We will only mail such reports to shareholders upon request; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:10.58pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:10.58pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">we will follow Israeli corporate governance practice instead of NASDAQ requirements to obtain shareholder approval for certain dilutive events (such as issuances that will result in a change of control, certain transactions other than a public offering involving issuances of a 20% or greater interest in us and certain acquisitions of the stock or assets of another company). </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Otherwise, we intend to comply with the rules generally applicable to U.S. domestic companies listed on the NASDAQ Global Market. We may in the future decide to use the foreign private issuer exemption with respect to some or all of the other NASDAQ corporate governance rules. Following the closing of this offering, we also intend to comply with Israeli corporate governance requirements under the Companies Law applicable to public companies. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Controlled Company </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">As a result of the number of shares owned by Arkin Dermatology, after the completion of this offering, we will be a &#8220;controlled company&#8221; under the NASDAQ corporate governance rules. A &#8220;controlled company&#8221; is a company of which more than 50% of the voting power is held by an individual, group or another company. Pursuant to the &#8220;controlled company&#8221; exemption, we are not required to, and will not, comply with the requirements that: (1) a majority of our board of directors consist of independent directors; and (2) we have a nominating committee composed entirely of independent directors with a written charter addressing such committee&#8217;s purpose and responsibilities. See &#8220;Management &#8212; Board of Directors and Officers.&#8221; Accordingly, you will not have the same protections afforded to shareholders of companies that are subject to all of the corporate governance requirements of the NASDAQ Global Market. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">119</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Board of Directors and Officers </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Upon the closing of this offering, our board of directors will consist of eight directors, including two directors who are intended to qualify as external directors, and whose appointment fulfills the requirements of the Companies Law for the company to have two external directors (see &#8220;Management &#8212; External Directors&#8221;). These two directors, as well as one additional director, will qualify as independent directors under the corporate governance standards of the NASDAQ corporate governance rules and the independence requirements of Rule 10A-3 of the Exchange Act. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Under our amended and restated articles of association, the number of directors on our board of directors will be no less than five (5) and no more than nine (9), including any external directors required to be appointed under the Companies Law. The minimum and maximum number of directors may be changed, at any time and from time to time, by a special vote of at least 66<font style=" position:relative; bottom:2.66pt;font-size:7pt;">2</font>&#8725;<font style="font-size:7pt;">3</font>% of our shareholders. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Other than external directors, for whom special election requirements apply under the Companies Law, as detailed below, our directors are divided into three classes with staggered three-year terms. Each class of directors consists, as nearly as possible, of one-third of the total number of directors constituting the entire board of directors (other than the external directors). At each annual general meeting of our shareholders, the election or re-election of directors following the expiration of the term of office of the directors of that class of directors will be for a term of office that expires on the third annual general meeting following such election or re-election, such that from 2018 and after, at each annual general meeting the term of office of only one class of directors will expire. Each director holds office until the third annual general meeting of our shareholders and until his or her successor is duly appointed, unless the tenure of such director expires earlier pursuant to the Companies Law or unless removed from office as described below, except that our external directors have a term of office of three years under Israeli law. See &#8220;&#8212;&#160;External directors &#8212; Election and dismissal of external directors.&#8221;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Our directors who are not external directors will be divided among the three classes as follows:</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">Class I will consist of Ms. Baratz and Dr. Ben Zvi, who are both independent directors, and their term will expire at our annual general meeting of our shareholders to be held in 2018;</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">Class II will consist of Ms. Lerman and Dr. Seri-Levy, and their term will expire at our first annual general meeting of our shareholders to be held after our annual general meeting of our shareholders to be held in 2018; and</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">Class III will consist of Mr. Itai Arkin and Mr. Moshe Arkin, and their term will expire at our second annual general meeting of our shareholders to be held after our annual general meeting of our shareholders to be held in 2018.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Mr. Gattegno and Mr. Gottfried will serve as our external directors and will each have a term of three years.</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Under our amended and restated articles of association, our board of directors may elect new directors if the number of directors is below the maximum provided therein. External directors are elected for an initial term of three years and may be elected for up to two additional three-year terms (or more) under the circumstances described below. External directors may be removed from office only under the limited circumstances set forth in the Companies Law. See &#8220;&#8212;&#160;External Directors&#8221; for a description of the procedure for the election of external directors. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Under Israeli law, the chief executive officer of a public company may not serve as the chairman of the board of directors of the company unless approved by a special majority of our shareholders as required under the Companies Law. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">120</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In addition, under the Companies Law, our board of directors must determine the minimum number of directors who are required to have financial and accounting expertise. Under applicable regulations, a director with financial and accounting expertise is a director who, by reason of his or her education, professional experience and skill, has a high level of proficiency in and understanding of business accounting matters and financial statements. See &#8220;&#8212; External Directors&#160;&#8212; Qualifications of External Directors.&#8221; He or she must be able to thoroughly comprehend the financial statements of the company and initiate debate regarding the manner in which financial information is presented. In determining the number of directors required to have such expertise, the board of directors must consider, among other things, the type and size of the company and the scope and complexity of its operations. Our board of directors has determined that we require at least one director with the requisite financial and accounting expertise and that has such expertise. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">There are no family relationships among any of our office holders (including directors), other than Mr. Itai Arkin who is the son of Mr. Moshe Arkin. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Alternate Directors </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Our amended and restated articles of association provide, as allowed by the Companies Law, that any director may, by written notice to us, appoint another person who is qualified to serve as a director to serve as an alternate director. The alternate director will be regarded as a director. Under the Companies Law, a person who is not qualified to be appointed as a director, a person who is already serving as a director or a person who is already serving as an alternate director for another director, may not be appointed as an alternate director. Nevertheless, a director who is already serving as a director may be appointed as an alternate director for a member of a committee of the board of directors as long as he or she is not already serving as a member of such committee, and if the alternate director is to replace an external director, he or she is required to be an external director and to have either &#8220;financial and accounting expertise&#8221; or &#8220;professional expertise,&#8221; depending on the qualifications of the external director he or she is replacing. The term of appointment of an alternate director may be for one meeting of the board of directors or until notice is given of the cancellation of the appointment. A person who does not have the requisite &#8220;financial and accounting experience&#8221; or the &#8220;professional expertise,&#8221; depending on the qualifications of the external director he or she is replacing, may not be appointed as an alternate director for an external director. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">External Directors </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Qualifications of External Directors </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Under the Companies Law, companies incorporated under the laws of the State of Israel that are &#8220;public companies,&#8221; including companies with shares listed on The NASDAQ Global Market, are generally required to appoint at least two external directors who meet the qualification requirements set forth in the Companies Law. The appointment of external directors must be made by a general meeting of our shareholders no later than three months following the closing of this offering, and therefore we intend to hold a shareholders&#8217; meeting within three months of the closing of this offering for the appointment of two external directors. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">A person may not be appointed as an external director if the person is a relative of a controlling shareholder or if on the date of the person&#8217;s appointment or within the preceding two years the person or his or her relatives, partners, employers or anyone to whom that person is subordinate, whether directly or indirectly, or entities under the person&#8217;s control have or had any affiliation with any of&#8201; (each an &#8220;Affiliated Party&#8221;): (1) us; (2) any person or entity controlling us on the date of such appointment; (3) any relative of a controlling shareholder; or (4) any entity controlled, on the date of such appointment or within the preceding two years, by us or by a controlling shareholder. If there is no controlling shareholder or any shareholder holding 25% or more of voting rights in the company, a person may not be appointed as an external director if the </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">121</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">person has any affiliation to the chairman of the board of directors, the general manager (chief executive officer), any shareholder holding 5% or more of the company&#8217;s shares or voting rights or the senior financial officer as of the date of the person&#8217;s appointment. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The term &#8220;controlling shareholder&#8221; means a shareholder with the ability to direct the activities of the company, other than by virtue of being an office holder. A shareholder is presumed to have &#8220;control&#8221; of the company and thus to be a controlling shareholder of the company if the shareholder holds 50% or more of the &#8220;means of control&#8221; of the company. &#8220;Means of control&#8221; is defined as (1) the right to vote at a general meeting of a company or a corresponding body of another corporation; or (2) the right to appoint directors of the corporation or its general manager. For the purpose of approving related-party transactions, the term also includes any shareholder that holds 25% or more of the voting rights of the company if the company has no shareholder that owns more than 50% of its voting rights. For the purpose of determining the holding percentage stated above, two or more shareholders who have a personal interest in a transaction that is brought for the company&#8217;s approval are deemed as joint holders. </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">The term affiliation includes: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">an employment relationship; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a business or professional relationship maintained on a regular basis; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">control; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">service as an office holder, excluding service as a director in a private company prior to the first offering of its shares to the public if such director was appointed as a director of the private company in order to serve as an external director following the initial public offering. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The term &#8220;relative&#8221; is defined as a spouse, sibling, parent, grandparent, descendant, spouse&#8217;s descendant, sibling and parent and the spouse of each of the foregoing. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The term &#8220;office holder&#8221; is defined as a general manager, chief business manager, deputy general manager, vice general manager, director or manager directly subordinate to the general manager or any other person assuming the responsibilities of any of the foregoing positions, without regard to such person&#8217;s title. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">A person may not serve as an external director if that person or that person&#8217;s relative, partner, employer, a person to whom such person is subordinate (directly or indirectly) or any entity under the person&#8217;s control has a business or professional relationship with any entity that has an affiliation with any Affiliated Party, even if such relationship is intermittent (excluding insignificant relationships). Additionally, any person who has received compensation intermittently (excluding insignificant relationships) other than compensation permitted under the Companies Law may not continue to serve as an external director. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">No person can serve as an external director if the person&#8217;s position or other affairs create, or may create, a conflict of interest with the person&#8217;s responsibilities as a director or may otherwise interfere with the person&#8217;s ability to serve as a director or if such a person is an employee of the Israeli Securities Authority or of an Israeli stock exchange. If at the time an external director is appointed all current members of the board of directors, who are not controlling shareholders or relatives of controlling shareholders, are of the same gender, then the external director to be appointed must be of the other gender. In addition, a person who is a director of a company may not be elected as an external director of another company if, at that time, a director of the other company is acting as an external director of the first company. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The Companies Law provides that an external director must meet certain professional qualifications or have financial and accounting expertise and that at least one external director must have financial and accounting expertise. However, if at least one of our other directors (1)&#160;meets the independence requirements of the Exchange Act, (2) meets the standards of the </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">122</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">NASDAQ corporate governance rules for membership on the audit committee and (3) has financial and accounting expertise as defined in the Companies Law and applicable regulations, then neither of our external directors is required to possess financial and accounting expertise as long as both possess other requisite professional qualifications. The determination of whether a director possesses financial and accounting expertise is made by the board of directors. A director with financial and accounting expertise is a director who by virtue of his or her education, professional experience and skill, has a high level of proficiency in and understanding of business accounting matters and financial statements so that he or she is able to fully understand our financial statements and initiate debate regarding the manner in which the financial information is presented. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The regulations promulgated under the Companies Law define an external director with requisite professional qualifications as a director who satisfies one of the following requirements: (1) the director holds an academic degree in either economics, business administration, accounting, law or public administration, (2) the director either holds an academic degree in any other field or has completed another form of higher education in the company&#8217;s primary field of business or in an area which is relevant to his or her office as an external director in the company, or (3) the director has at least five years of experience serving in any one of the following, or at least five years of cumulative experience serving in two or more of the following capacities: (a) a senior business management position in a company with a substantial scope of business, (b) a senior position in the company&#8217;s primary field of business or (c) a senior position in public administration. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Until the lapse of a two-year period from the date that an external director of a company ceases to act in such capacity, the company in which such external director served, and its controlling shareholder or any entity under control of such controlling shareholder may not, directly or indirectly, grant such former external director, or his or her spouse or child, any benefit, including via (i) the appointment of such former director or his or her spouse or his child as an officer in the company or in an entity controlled by the company&#8217;s controlling shareholder, (ii) the employment of such former director, and (iii) the engagement, directly or indirectly, of such former director as a provider of professional services for compensation, directly or indirectly, including via an entity under his or her control. With respect to a relative who is not a spouse or a child, such limitations shall only apply for one year from the date such external director ceased to be engaged in such capacity. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Election and Dismissal of External Directors </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Under Israeli law, external directors are elected by a majority vote at a shareholders&#8217; meeting, provided that either: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.18pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.18pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the majority of the shares that are voted at the meeting in favor of the election of the external director, excluding abstentions, include at least a majority of the votes of shareholders who are not controlling shareholders and do not have a personal interest in the appointment (excluding a personal interest that did not result from the shareholder&#8217;s relationship with the controlling shareholder); or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.38pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.38pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the total number of shares held by non-controlling shareholders or any one on their behalf that are voted against the election of the external director does not exceed two percent of the aggregate voting rights in the company. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Under Israeli law, the initial term of an external director of an Israeli public company is three years. The external director may be re-elected, subject to certain circumstances and conditions, for up to two additional terms of three years each, and thereafter, subject to conditions set out in the regulations promulgated under the Companies Law, to further three year terms, each re-election subject to one of the following: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.38pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.38pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">his or her service for each such additional term is recommended by one or more </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">123</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-left:40pt; width:416pt; line-height:12pt;">shareholders holding at least 1% of the company&#8217;s voting rights and is approved at a shareholders meeting by a disinterested majority, where the total number of shares held by non-controlling, disinterested shareholders voting for such reelection exceeds 2% of the aggregate voting rights in the company and subject to additional restrictions set forth in the Companies Law with respect to the affiliation of the external director nominee; </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the external director proposed his or her own nomination, and such nomination was approved in accordance with the requirements described in the paragraph above; or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">his or her service for each such additional term is recommended by the board of directors and is approved at a meeting of shareholders by the same majority required for the initial election of an external director (as described above). </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">An external director may be removed by the same special majority of the shareholders required for his or her election, if he or she ceases to meet the statutory qualifications for appointment or if he or she violates his or her fiduciary duty to the company. An external director may also be removed by order of an Israeli court if the court finds that the external director is permanently unable to exercise his or her office, has ceased to meet the statutory qualifications for his or her appointment, has violated his or her fiduciary duty to the company, or has been convicted by a court outside Israel of certain offenses detailed in the Companies Law. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">If the vacancy of an external directorship causes a company to have fewer than two external directors, the company&#8217;s board of directors is required under the Companies Law to call a special general meeting of the company&#8217;s shareholders as soon as possible to appoint such number of new external directors so that the company thereafter has two external directors. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Additional Provisions </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Under the Companies Law, each committee authorized to exercise any of the powers of the board of directors is required to include at least one external director and its audit and compensation committees are required to include all of the external directors. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">An external director is entitled to compensation and reimbursement of expenses in accordance with regulations promulgated under the Companies Law and is prohibited from receiving any other compensation, directly or indirectly, in connection with serving as a director except for certain exculpation, indemnification and insurance provided by the company, as specifically allowed by the Companies Law. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Audit Committee </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Companies Law Requirements </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Under the Companies Law, the board of directors of any public company must also appoint an audit committee comprised of at least three directors, including all of the external directors. The audit committee may not include: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the chairman of the board of directors; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a controlling shareholder or a relative of a controlling shareholder; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">any director employed by us or by one of our controlling shareholders or by an entity controlled by our controlling shareholders (other than as a member of the board of directors); or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">any director who regularly provides services to us, to one of our controlling shareholders or to an entity controlled by our controlling shareholders. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">124</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">According to the Companies Law, the majority of the members of the audit committee, as well as the majority of members present at audit committee meetings, will be required to be &#8220;independent&#8221; (as defined below) and the chairman of the audit committee will be required to be an external director. Any persons disqualified from serving as a member of the audit committee may not be present at the audit committee meetings, unless the chairman of the audit committee has determined that such person is required to be present at the meeting or if such person qualifies under one of the exemptions of the Companies Law. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The term &#8220;independent director&#8221; is defined under the Companies Law as an external director or a director who meets the following conditions and who is appointed or classified as such according to the Companies Law: (1) the conditions for his or her appointment as an external director (as described above) are satisfied and the audit committee approves the director having met such conditions and (2) he or she has not served as a director of the company for over nine consecutive years with any interruption of up to two years of his or her service not being deemed a disruption to the continuity of his or her service. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">NASDAQ Listing Requirements </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Under the NASDAQ corporate governance rules, we are required to maintain an audit committee consisting of at least three independent directors, all of whom are financially literate and one of whom has accounting or related financial management expertise. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Our audit committee will consist of&#8201; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. All members of our audit committee meet the requirements for financial literacy under the applicable rules and regulations of the SEC and the NASDAQ corporate governance rules. Our board of directors has determined that &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; is an audit committee financial expert as defined by SEC rules and has the requisite financial experience as defined by the NASDAQ corporate governance rules. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Each of the members of the audit committee is &#8220;independent&#8221; as such term is defined in Rule 10A-3(b)(1) under the Exchange Act. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Approval of Transactions with Related Parties </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The approval of the audit committee is required to effect specified actions and transactions with office holders and controlling shareholders and their relatives, or in which they have a personal interest. See &#8220;Management &#8212; Fiduciary Duties and Approval of Specified Related Party Transactions and Compensation under Israeli law.&#8221; The audit committee may not approve an action or a transaction with a controlling shareholder or with an office holder unless at the time of approval the audit committee meets the composition requirements under the Companies Law. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Audit Committee Role </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;"><font style="font-style:italic;font-weight:bold;"></font>In connection with this offering, our board of directors will adopt an audit committee charter setting forth the responsibilities of the audit committee consistent with the rules of the SEC and the NASDAQ corporate governance rules, which include: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">retaining and terminating our independent auditors, subject to board of directors and shareholder ratification;</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">overseeing the independence, compensation and performance of the Company&#8217;s independent auditors;</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the appointment, compensation, retention and oversight of any accounting firm engaged for the purpose of preparing or issuing an audit report or performing other audit services; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">pre-approval of audit and non-audit services to be provided by the independent auditors; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">reviewing with management and our independent directors our financial statements prior to their submission to the SEC; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">125</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">approval of certain transactions with office holders and controlling shareholders, as described below, and other related party transactions. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Additionally, under the Companies Law, the role of the audit committee includes the identification of irregularities in our business management, among other things, by consulting with the internal auditor or our independent auditors and suggesting an appropriate course of action to the board of directors. In addition, the audit committee or the board of directors, as set forth in the articles of association of the company, is required to approve the yearly or periodic work plan proposed by the internal auditor. The audit committee is required to assess the company&#8217;s internal audit system and the performance of its internal auditor. The Companies Law also requires that the audit committee assess the scope of the work and compensation of the company&#8217;s external auditor. In addition, the audit committee is required to determine whether certain related party actions and transactions are &#8220;material&#8221; or &#8220;extraordinary&#8221; for the purpose of the requisite approval procedures under the Companies Law and whether certain transactions with a controlling shareholder will be subject to a competitive procedure. The audit committee charter states that in fulfilling its role the committee is empowered to conduct or authorize investigations into any matters within its scope of responsibilities. A company whose audit committee&#8217;s composition also meets the requirements set for the composition of a compensation committee (as further detailed below) may have one committee acting as both audit and compensation committees. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Compensation Committee </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Under the Companies Law, public companies are required to appoint a compensation committee in accordance with the guidelines set forth thereunder. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The compensation committee must consist of at least three members. All of the external directors must serve on the committee and constitute a majority of its members. The chairman of the compensation committee must be an external director. The remaining members are not required to be external directors, but must be directors who qualify to serve as members of the audit committee (as described above). </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The compensation committee, which consists of&#8201; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, will assist the board of directors in determining compensation for our directors and officers. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; will serve as Chairman of the committee. Under SEC and NASDAQ rules, there are heightened independence standards for members of the compensation committee, including a prohibition against the receipt of any compensation from us other than standard supervisory board member fees. Although foreign private issuers are not required to meet this heightened standard, our board of directors has determined that all of our expected compensation committee members meet this heightened standard. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In accordance with the Companies Law, the roles of the compensation committee are, among others, as follows: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" float:left; margin-top:8.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">to recommend to the board of directors the compensation policy for directors and officers, and to recommend to the board of directors once every three years whether the compensation policy that had been approved should be extended for a period of more than three years; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(2)<br ></div>
        <div style=" float:left; margin-top:8.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">to recommend to the board of directors updates to the compensation policy, from time to time, and examine its implementation; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(3)<br ></div>
        <div style=" float:left; margin-top:8.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">to decide whether to approve the terms of office and employment of directors and officers that require approval of the compensation committee; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(4)<br ></div>
        <div style=" float:left; margin-top:8.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">to decide whether the compensation terms of the chief executive officer, which were determined pursuant to the compensation policy, will be exempted from approval by the shareholders because such approval would harm the ability to engage the chief executive officer. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">126</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In addition to the roles mentioned above our compensation committee also makes recommendations to our board of directors regarding the awarding of employee equity grants. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In general, under the Companies Law, a public company must have a compensation policy approved by the board of directors after receiving and considering the recommendations of the compensation committee. In addition, the compensation policy requires the approval of the general meeting of the shareholders. In public companies such as our company, shareholder approval requires one of the following: (i) the majority of shareholder votes counted at a general meeting including the majority of all of the votes of those shareholders who are non-controlling shareholders and do not have a personal interest in the approval of the compensation policy, who vote at the meeting (excluding abstentions) or (ii) the total number of votes against the proposal among the shareholders mentioned in paragraph (i) does exceed two percent (2%) of the voting rights in the company. Under special circumstances, the board of directors may approve the compensation policy despite the objection of the shareholders on the condition that the compensation committee and then the board of directors decide, on the basis of detailed arguments and after discussing again the compensation policy, that approval of the compensation policy, despite the objection of the meeting of shareholders, is for the benefit of the company. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">If a company initially offer its securities to the public, like us, adopts a compensation policy in advance of its initial public offering, and describes it in its prospectus, then such compensation policy shall be deemed a validly adopted policy in accordance with the Companies Law requirements described above. Furthermore, if the compensation policy is set in accordance with the aforementioned relief, then it will remain in effect for term of five years from the date such company has become a public company. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The compensation policy must be based on certain considerations, include certain provisions and needs to reference certain matters as set forth in the Companies Law. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The compensation policy must serve as the basis for decisions concerning the financial terms of employment or engagement of office holders, including exculpation, insurance, indemnification or any monetary payment or obligation of payment in respect of employment or engagement. The compensation policy must relate to certain factors, including advancement of the company&#8217;s objectives, business plan and long-term strategy, and creation of appropriate incentives for office holders. It must also consider, among other things, the company&#8217;s risk management, size and the nature of its operations. The compensation policy must furthermore consider the following additional factors: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the education, skills, experience, expertise and accomplishments of the relevant office holder; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the office holder&#8217;s position, responsibilities and prior compensation agreements with him or her; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the ratio between the cost of the terms of employment of an office holder and the cost of the employment of other employees of the company, including employees employed through contractors who provide services to the company, in particular the ratio between such cost, the average and median salary of the employees of the company, as well as the impact of such disparities on the work relationships in the company; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">if the terms of employment include variable components &#8212; the possibility of reducing variable components at the discretion of the board of directors and the possibility of setting a limit on the value of non-cash variable equity-based components; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">if the terms of employment include severance compensation &#8212; the term of employment or office of the office holder, the terms of his or her compensation during such period, the company&#8217;s performance during the such period, his or her individual contribution to the achievement of the company goals and the maximization of its profits and the circumstances under which he or she is leaving the company.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">127</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">The compensation policy must also include, among others: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">with regards to variable components: </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:8.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8201;&#8211;&#8201;<br ></div>
        <div style=" float:left; margin-top:8.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:395.5pt;">with the exception of office holders who report directly to the chief executive officer, determining the variable components on long-term performance basis and on measurable criteria; however, the company may determine that an immaterial part of the variable components of the compensation package of an office holder&#8217;s shall be awarded based on non-measurable criteria, if such amount is not higher than three monthly salaries per annum, while taking into account such office holder contribution to the company; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:8.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8201;&#8211;&#8201;<br ></div>
        <div style=" float:left; margin-top:8.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:395.5pt;">the ratio between variable and fixed components, as well as the limit of the values of variable components at the time of their grant. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a condition under which the office holder will return to the company, according to conditions to be set forth in the compensation policy, any amounts paid as part of his or her terms of employment, if such amounts were paid based on information later to be discovered to be wrong, and such information was restated in the company&#8217;s financial statements; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the minimum holding or vesting period of variable equity-based components to be set in the terms of office or employment, as applicable, while taking into consideration long-term incentives; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a limit to retirement grants. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Our compensation policy, which will become effective immediately prior to the closing of this offering, is designed to promote retention and motivation of directors and executive officers, incentivize superior individual excellence, align the interests of our directors and executive officers with our long-term performance and provide a risk management tool. To that end, a portion of an executive officer compensation package is targeted to reflect our short and long-term goals, as well as the executive officer&#8217;s individual performance. On the other hand, our compensation policy includes measures designed to reduce the executive officer&#8217;s incentives to take excessive risks that may harm us in the long-term, such as limits on the value of cash bonuses and equity-based compensation, limitations on the ratio between the variable and the total compensation of an executive officer and minimum vesting periods for equity-based compensation. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Our compensation policy also addresses our executive officer&#8217;s individual characteristics (such as his or her respective position, education, scope of responsibilities and contribution to the attainment of our goals) as the basis for compensation variation among our executive officers, and considers the internal ratios between compensation of our executive officers and directors and other employees. Pursuant to our compensation policy, the compensation that may be granted to an executive officer may include: base salary, annual bonuses and other cash bonuses (such as a signing bonus and special bonuses with respect to any special achievements, such as outstanding personal achievement, outstanding personal effort or outstanding company performance), equity-based compensation, benefits and retirement and termination of service arrangements. All cash bonuses are limited to a maximum amount linked to the executive officer&#8217;s base salary. In addition, the total variable compensation components (cash bonuses and equity based compensation) may not exceed 85% of each executive officer&#8217;s total compensation package with respect to any given calendar year. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">An annual cash bonus may be awarded to executive officers upon the attainment of pre-set periodic objectives and individual targets. The annual cash bonus that may be granted to our executive officers other than our chief executive officer will be based on performance objectives and a discretionary evaluation of the executive officer&#8217;s overall performance by our chief executive officer and subject to minimum thresholds. The annual cash bonus that may be granted to </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">128</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">executive officers other than our chief executive officer may be based entirely on a discretionary evaluation. Furthermore, the performance objectives will be recommended by our chief executive officer and approved by our compensation committee (and, if required by law, by our board of directors). </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The performance measurable objectives of our chief executive officer will be determined annually by our compensation committee and board of directors, will include the weight to be assigned to each achievement in the overall evaluation. A less significant portion of the chief executive officer&#8217;s annual cash bonus may be based on a discretionary evaluation of the chief executive officer&#8217;s overall performance by the compensation committee and the board of directors based on quantitative and qualitative criteria. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The equity-based compensation under our compensation policy for our executive officers (including members of our board of directors) is designed in a manner consistent with the underlying objectives in determining the base salary and the annual cash bonus, with its main objectives being to enhance the alignment between the executive officers&#8217; interests with our long-term interests and those of our shareholders and to strengthen the retention and the motivation of executive officers in the long term. Our compensation policy provides for executive officer compensation in the form of share options or other equity-based awards, such as restricted shares and restricted share units, in accordance with our share incentive plan then in place. All equity-based incentives granted to executive officers shall be subject to vesting periods in order to promote long-term retention of the awarded executive officers. The equity-based compensation shall be granted from time to time and be individually determined and awarded according to the performance, educational background, prior business experience, qualifications, role and the personal responsibilities of the executive officer. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In addition, our compensation policy contains compensation recovery provisions which allows us under certain conditions to recover bonuses paid in excess, enables our chief executive officer to approve an immaterial change in the terms of employment of an executive officer (provided that the changes of the terms of employment are in accordance our compensation policy) and allows us to exculpate, indemnify and insure our executive officers and directors subject to certain limitations set forth thereto. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Our compensation policy also provides for compensation to the members of our board of directors either (i) in accordance with the amounts provided in the Companies Regulations (Rules Regarding the Compensation and Expenses of an External Director) of 2000, as amended by the Companies Regulations (Relief for Public Companies Traded in Stock Exchange Outside of Israel) of 2000, as such Regulations may be amended from time to time, or (ii) in accordance with the amounts determined in our Compensation Policy.</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Our compensation policy was approved by our board of directors and our controlling shareholder in &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2017 and is filed as an exhibit to the registration statement of which this prospectus forms a part. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Internal Auditor </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Under the Companies Law, the board of directors of a public company must appoint an internal auditor based on the recommendation of the audit committee. The role of the internal auditor is, among other things, to examine whether a company&#8217;s actions comply with applicable law and orderly business procedure. Under the Companies Law, the internal auditor may not be an interested party or an office holder or a relative of an interested party or of an office holder, nor may the internal auditor be the company&#8217;s independent auditor or the representative of the same. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">An &#8220;interested party&#8221; is defined in the Companies Law as (i) a holder of 5% or more of the issued share capital or voting power in a company, (ii) any person or entity who has the right to designate one or more directors or to designate the chief executive officer of the company, or (iii)&#160;any person who serves as a director or as a chief executive officer of the company. As of the date of this prospectus, we have not yet appointed our internal auditor. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">129</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Fiduciary Duties and Approval of Specified Related Party Transactions and Compensation under Israeli Law </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Fiduciary Duties of Office Holders </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The Companies Law imposes a duty of care and a fiduciary duty on all office holders of a company. The duty of care of an office holder is based on the duty of care set forth in connection with the tort of negligence under the Israeli Torts Ordinance (New Version) 5728-1968. This duty of care requires an office holder to act with the degree of proficiency with which a reasonable office holder in the same position would have acted under the same circumstances. The duty of care includes, among other things, a duty to use reasonable means, in light of the circumstances, to obtain: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">information on the business advisability of a given action brought for his or her approval or performed by virtue of his or her position; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">all other important information pertaining to such action. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The fiduciary duty incumbent on an office holder requires him or her to act in good faith and for the benefit of the company, and includes, among other things, the duty to: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">refrain from any act involving a conflict of interest between the performance of his or her duties in the company and his or her other duties or personal affairs; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">refrain from any activity that is competitive with the business of the company; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">refrain from exploiting any business opportunity of the company for the purpose of gaining a personal advantage for himself or herself or others; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">disclose to the company any information or documents relating to the company&#8217;s affairs which the office holder received as a result of his or her position as an office holder. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We may approve an act specified above which would otherwise constitute a breach of the office holder&#8217;s fiduciary duty, provided that the office holder acted in good faith, the act or its approval does not harm the company, and the office holder discloses his or her personal interest a sufficient time before the approval of such act. Any such approval is subject to the terms of the Companies Law, setting forth, among other things, the appropriate bodies of the company entitled to provide such approval, and the methods of obtaining such approval. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Disclosure of Personal Interests of an Office Holder and Approval of Transactions </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The Companies Law requires that an office holder promptly disclose to the company any personal interest that he or she may have and all related material information or documents relating to any existing or proposed transaction by the company. An interested office holder&#8217;s disclosure must be made promptly and in any event no later than the first meeting of the board of directors at which the transaction is considered. An office holder is not obliged to disclose such information if the personal interest of the office holder derives solely from the personal interest of his or her relative in a transaction that is not considered an extraordinary transaction. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Under the Companies Law, once an office holder has complied with the above disclosure requirement, a company may approve a transaction between the company and the office holder or a third party in which the office holder has a personal interest. However, a company may not approve a transaction or action that is not to the company&#8217;s benefit. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Under the Companies Law, unless the articles of association of a company provide otherwise, a transaction with an office holder or with a third party in which the office holder has a personal interest, which is not an extraordinary transaction, requires approval by the board of directors. Our amended and restated articles of association provide that such a transaction, which is not an extraordinary transaction, shall be approved by the board of directors or a committee of the board </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">130</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">of directors or any other body or person (which has no personal interest in the transaction) authorized by the board of directors. If the transaction considered is an extraordinary transaction with an office holder or third party in which the office holder has a personal interest, then audit committee approval is required prior to approval by the board of directors. For the approval of compensation arrangements with directors and executive officers, see &#8220;Management &#8212; Disclosure of Compensation of Directors and Executive Officers.&#8221; </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Any persons who have a personal interest in the approval of a transaction that is brought before a meeting of the board of directors or the audit committee may not be present at the meeting or vote on the matter. However, if the chairman of the board of directors or the chairman of the audit committee has determined that the presence of an office holder with a personal interest is required, such office holder may be present at the meeting for the purpose of presenting the matter. Notwithstanding the foregoing, a director who has a personal interest may be present at the meeting and vote on the matter if a majority of the directors or members of the audit committee have a personal interest in the approval of such transaction. If a majority of the directors at a board of directors meeting have a personal interest in the transaction, such transaction also requires approval of the shareholders of the company. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">A &#8220;personal interest&#8221; is defined under the Companies Law as the personal interest of a person in an action or in a transaction of the company, including the personal interest of such person&#8217;s relative or the interest of any other corporate body in which the person and/or such person&#8217;s relative is a director or general manager, a 5% shareholder or holds 5% or more of the voting rights, or has the right to appoint at least one director or the general manager, but excluding a personal interest stemming solely from the fact of holding shares in the company. A personal interest also includes (1) a personal interest of a person who votes according to a proxy of another person, including in the event that the other person has no personal interest, and (2) a personal interest of a person who gave a proxy to another person to vote on his or her behalf regardless of whether or not the discretion of how to vote lies with the person voting. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">An &#8220;extraordinary transaction&#8221; is defined under the Companies Law as any of the following: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.61pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:5.61pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a transaction other than in the ordinary course of business; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.62pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:5.62pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a transaction that is not on market terms; or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.41pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:5.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a transaction that may have a material impact on the company&#8217;s profitability, assets or liabilities. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Disclosure of Personal Interests of a Controlling Shareholder and Approval of Transactions </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The Companies Law also requires that a controlling shareholder promptly disclose to the company any personal interest that he or she may have and all related material information or documents relating to any existing or proposed transaction by the company. A controlling shareholder&#8217;s disclosure must be made promptly and in any event no later than the first meeting of the board of directors at which the transaction is considered. Extraordinary transactions with a controlling shareholder or in which a controlling shareholder has a personal interest, including a private placement in which a controlling shareholder has a personal interest, and the terms of engagement of the company, directly or indirectly, with a controlling shareholder or a controlling shareholder&#8217;s relative (including through a corporation controlled by a controlling shareholder), regarding the company&#8217;s receipt of services from the controlling shareholder, and if such controlling shareholder is also an office holder or employee of the company, regarding his or her terms of employment, require the approval of each of&#8201; (i) the audit committee or the compensation committee with respect to the terms of the engagement of the company, (ii) the board of directors and (iii) the shareholders, in that order. In addition, the shareholder approval must fulfill one of the following requirements: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.42pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:5.42pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a majority of the shares held by shareholders who have no personal interest in the transaction and are voting at the meeting must be voted in favor of approving the transaction, excluding abstentions; or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">131</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the shares voted by shareholders who have no personal interest in the transaction who vote against the transaction represent no more than two percent (2%) of the voting rights in the company. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In addition, an extraordinary transaction with a controlling shareholder or in which a controlling shareholder has a personal interest, and an engagement of the company, directly or indirectly, with a controlling shareholder or a controlling shareholder&#8217;s relative (including through a corporation controlled by a controlling shareholder), regarding the company&#8217;s receipt of services from the controlling shareholder, and if such controlling shareholder is also an office holder or employee of the company, regarding his or her terms of employment, in each case with a term of more than three years requires the abovementioned approval every three years, however, transactions not involving the receipt of services or compensation can be approved for a longer term, provided that the audit committee determines that such longer term is reasonable under the circumstances. In addition, transactions with a controlling shareholder or a controlling shareholder&#8217;s relative who serves as an officer in a company, directly or indirectly (including through a corporation under his control), involving the receipt of services by a company or their compensation can have a term of five years from the company&#39;s initial public offering under certain circumstances.</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The Companies Law requires that every shareholder that participates, in person, by proxy or by voting instrument, in a vote regarding a transaction with a controlling shareholder, must indicate in advance or in the ballot whether or not that shareholder has a personal interest in the vote in question. Failure to so indicate will result in the invalidation of that shareholder&#8217;s vote. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Disclosure of Compensation of Executive Officers </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">For so long as we qualify as a foreign private issuer, we are not required to comply with the proxy rules applicable to U.S. domestic companies, including the requirement applicable to emerging growth companies to disclose the compensation of our chief executive officer and other two most highly compensated executive officers on an individual, rather than an aggregate, basis. Nevertheless, regulations promulgated under the Companies Law will require us, after we become a public company, to disclose the annual compensation of our five most highly compensated office holders on an individual basis, rather than on an aggregate basis. This disclosure will not be as extensive as that required of a U.S. domestic issuer. We intend to commence providing such disclosure, at the latest, in the annual proxy statement for our first annual general meeting of shareholders following this offering, which will be furnished under cover of a Form 6-K and we may elect to provide such information at an earlier date. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Compensation of Directors and Executive Officers </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;"><font style="font-style:italic;">Directors</font>. Under the Companies Law, the compensation of our directors requires the approval of our compensation committee, the subsequent approval of the board of directors and, unless exempted under regulations promulgated under the Companies Law, the approval of the shareholders at a general meeting. If the compensation of our directors is inconsistent with our stated compensation policy, then, those provisions that must be included in the compensation policy according to the Companies Law must have been considered by the compensation committee and board of directors, and shareholder approval will also be required, provided that: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">at least a majority of the shares held by all shareholders who are not controlling shareholders and do not have a personal interest in such matter, present and voting at such meeting, are voted in favor of the compensation package, excluding abstentions; or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.41pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.41pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the total number of shares of non-controlling shareholders and shareholders who do not have a personal interest in such matter voting against the compensation package does not exceed two percent (2%) of the aggregate voting rights in the company. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;"><font style="font-style:italic;">Executive officers other than the chief executive officer.</font> The Companies Law requires the approval of the compensation of a public company&#8217;s executive officers (other than the chief </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">132</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">executive officer) in the following order: (i) the compensation committee, (ii) the company&#8217;s board of directors, and (iii) if such compensation arrangement is inconsistent with the company&#8217;s stated compensation policy, the company&#8217;s shareholders (by a special majority vote as discussed above with respect to the approval of director compensation). However, if the shareholders of the company do not approve a compensation arrangement with an executive officer that is inconsistent with the company&#8217;s stated compensation policy, the compensation committee and board of directors may override the shareholders&#8217; decision if each of the compensation committee and the board of directors provide detailed reasons for their decision. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;"><font style="font-style:italic;">Chief executive officer.</font> Under the Companies Law, the compensation of a public company&#8217;s chief executive officer is required to be approved by: (i) the company&#8217;s compensation committee; (ii) the company&#8217;s board of directors, and (iii) the company&#8217;s shareholders (by a special majority vote as discussed above with respect to the approval of director compensation). However, if the shareholders of the company do not approve the compensation arrangement with the chief executive officer, the compensation committee and board of directors may override the shareholders&#8217; decision if each of the compensation committee and the board of directors provide a detailed report for their decision. The approval of each of the compensation committee and the board of directors should be in accordance with the company&#8217;s stated compensation policy; however, in special circumstances, they may approve compensation terms of a chief executive officer that are inconsistent with such policy provided that they have considered those provisions that must be included in the compensation policy according to the Companies Law and that shareholder approval was obtained (by a special majority vote as discussed above with respect to the approval of director compensation). In addition, the compensation committee may waive the shareholder approval requirement with regards to the approval of the engagement terms of a candidate for the chief executive officer position, if they determine that the compensation arrangement is consistent with the company&#8217;s stated compensation policy, and that the chief executive officer did not have a prior business relationship with the company or a controlling shareholder of the company and that subjecting the approval of the engagement to a shareholder vote would impede the company&#8217;s ability to employ the chief executive officer candidate. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Duties of Shareholders </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Under the Companies Law, a shareholder has a duty to refrain from abusing its power in the company and to act in good faith and in an acceptable manner in exercising its rights and performing its obligations to the company and other shareholders, including, among other things, when voting at meetings of shareholders on the following matters: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">an amendment to the articles of association; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">an increase in the company&#8217;s authorized share capital; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a merger; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the approval of related party transactions and acts of office holders that require shareholder approval. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">A shareholder also has a general duty to refrain from discriminating against other shareholders. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The remedies generally available upon a breach of contract will also apply to a breach of the shareholder duties mentioned above, and in the event of discrimination against other shareholders, additional remedies may be available to the injured shareholder. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In addition, any controlling shareholder, any shareholder that knows that its vote can determine the outcome of a shareholder vote and any shareholder that, under a company&#8217;s articles of association, has the power to appoint or prevent the appointment of an office holder, or any other power with respect to a company, is under a duty to act with fairness towards the company. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">133</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">The Companies Law does not describe the substance of this duty except to state that the remedies generally available upon a breach of contract will also apply in the event of a breach of the duty to act with fairness, taking the shareholder&#8217;s position in the company into account. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Approval of Private Placements </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Under the Companies Law and the regulations promulgated thereunder, a private placement of securities does not require approval at a general meeting of the shareholders of a company; provided however, that in special circumstances, such as a private placement which is intended to obviate the need to conduct a special tender offer (see &#8220;Description of Share Capital &#8212; Acquisitions under Israeli law&#8221;) or a private placement which qualifies as a related party transaction (see &#8220;Management &#8212; Fiduciary Duties and Approval of Specified Related Party Transactions and Compensation under Israeli Law&#8221;), approval at a general meeting of the shareholders of a company is required. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Exculpation, Insurance and Indemnification of Directors and Officers </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Under the Companies Law, a company may not exculpate an office holder from liability for a breach of the fiduciary duty. An Israeli company may exculpate an office holder in advance from liability to the company, in whole or in part, for damages caused to the company as a result of a breach of duty of care but only if a provision authorizing such exculpation is included in its articles of association. Our amended and restated articles of association include such a provision. The company may not exculpate in advance a director from liability arising due to the breach of his or her duty of care in the event of a prohibited dividend or distribution to shareholders. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Under the Companies Law and the Israeli Securities Law, 5728-1968 (the &#8220;Securities Law&#8221;) a company may indemnify an office holder in respect of the following liabilities, payments and expenses incurred for acts performed by him or her as an office holder, either in advance of an event or following an event, provided its articles of association include a provision authorizing such indemnification: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a monetary liability incurred by or imposed on the office holder in favor of another person pursuant to a court judgment, including pursuant to a settlement confirmed as judgment or arbitrator&#8217;s decision approved by a competent court. However, if an undertaking to indemnify an office holder with respect to such liability is provided in advance, then such an undertaking must be limited to events which, in the opinion of the board of directors, can be foreseen based on the company&#8217;s activities when the undertaking to indemnify is given, and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances, and such undertaking shall detail the abovementioned foreseen events and amount or criteria; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">reasonable litigation expenses, including reasonable attorneys&#8217; fees, which were incurred by the office holder as a result of an investigation or proceeding filed against the office holder by an authority authorized to conduct such investigation or proceeding, provided that such investigation or proceeding was either (i) concluded without the filing of an indictment against such office holder and without the imposition on him of any monetary obligation in lieu of a criminal proceeding; (ii) concluded without the filing of an indictment against the office holder but with the imposition of a monetary obligation on the office holder in lieu of criminal proceedings for an offense that does not require proof of criminal intent; or (iii) in connection with a monetary sanction; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a monetary liability imposed on the office holder in favor of a payment for a breach offended at an Administrative Procedure (as defined below) as set forth in Section 52(54)(a)(1)(a) to the Securities Law; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.61pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.61pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">expenses expended by the office holder with respect to an Administrative Procedure under the Securities Law, including reasonable litigation expenses and reasonable attorneys&#8217; fees; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">134</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">reasonable litigation expenses, including attorneys&#8217; fees, incurred by the office holder or which were imposed on the office holder by a court (i) in a proceeding instituted against him or her by the company, on its behalf, or by a third party, (ii) in connection with criminal indictment of which the office holder was acquitted, or (iii) in a criminal indictment which the office holder was convicted of an offense that does not require proof of criminal intent; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">any other obligation or expense in respect of which it is permitted or will be permitted under applicable law to indemnify an office holder, including, without limitation, matters referenced in Section 56H(b)(1) of the Securities Law. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">An &#8220;Administrative Procedure&#8221; is defined as a procedure pursuant to chapters H3 (Monetary Sanction by the Israeli Securities Authority), H4 (Administrative Enforcement Procedures of the Administrative Enforcement Committee) or I1 (Arrangement to prevent Procedures or Interruption of procedures subject to conditions) to the Securities Law. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Under the Companies Law and the Securities Law, a company may insure an office holder against the following liabilities incurred for acts performed by him or her as an office holder if and to the extent provided in the company&#8217;s articles of association: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a breach of the fiduciary duty to the company, provided that the office holder acted in good faith and had a reasonable basis to believe that the act would not harm the company; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a breach of duty of care to the company or to a third party, to the extent such a breach arises out of the negligent conduct of the office holder; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a monetary liability imposed on the office holder in favor of a third party; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a monetary liability imposed on the office holder in favor of an injured party at an Administrative Procedure pursuant to Section 52(54)(a)(1)(a) of the Securities Law; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">expenses incurred by an office holder in connection with an Administrative Procedure, including reasonable litigation expenses and reasonable attorneys&#8217; fees. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Under the Companies Law, a company may not indemnify, exculpate or insure an office holder against any of the following: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a breach of the fiduciary duty, except for indemnification and insurance for a breach of the fiduciary duty to the company to the extent that the office holder acted in good faith and had a reasonable basis to believe that the act would not prejudice the company; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a breach of duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the office holder; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">an act or omission committed with intent to derive illegal personal benefit; or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a fine or forfeit levied against the office holder. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Under the Companies Law, exculpation, indemnification and insurance of office holders must be approved by the compensation committee and the board of directors and, with respect to directors or controlling shareholders, their relatives and third parties in which controlling shareholders have a personal interest, also by the shareholders. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Our amended and restated articles of association permit us to exculpate, indemnify and insure our office holders to the fullest extent permitted or to be permitted by law. Our office holders are currently covered by a directors&#8217; and officers&#8217; liability insurance policy. As of the date of this prospectus, no claims for directors&#8217; and officers&#8217; liability insurance have been filed under this policy and we are not aware of any pending or threatened litigation or proceeding involving any of our office holders, including our directors, in which indemnification is sought. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">135</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Employment and Consulting Agreements with Executive Officers </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We have entered into written employment or service agreements with each of our executive officers. See &#8220;Certain Relationships and Related Party Transactions &#8212; Employment Agreements&#8221; for additional information. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Directors&#8217; Service Contracts </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">There are no arrangements or understandings between us, on the one hand, and any of our directors, on the other hand, providing for benefits upon termination of their employment or service as directors of our company. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">2014 Share Incentive Plan </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">On December&#160;2, 2014, we adopted the 2014 Share Incentive Plan, or the Plan, and, in connection with this offering, we intend to amend and restate the Plan which will become effective upon the pricing of this offering. The Plan is intended to afford an incentive to our and any of our affiliate&#8217;s employees, directors, officers, consultants, advisors and any other person or entity who provides services to the Company, to continue as service providers, to increase their efforts on our and our affiliates behalf and to promote our success, by providing such persons with opportunities to acquire a proprietary interest in us. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Under the Plan, as amended and restated, we may issue up to &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&#8199; of our ordinary shares, subject to adjustment if particular capital changes affect our share capital or such other number as our board of directors may determine from time to time. Ordinary shares subject to outstanding awards under the Plan that subsequently expire, are cancelled, forfeited or terminated for any reason before being exercised will be automatically, and without any further action, returned to the &#8220;pool&#8221; of reserved shares and will again be available for grant under the Plan. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">A share option is the right to purchase a specified number of ordinary shares in the future at a specified exercise price and subject to the other terms and conditions specified in the option agreement and the Plan. The exercise price of each share option granted under the Plan will be determined in accordance with the limitations set forth under the Plan. The exercise price of any share options granted under the Plan may be paid in cash, through the surrender of ordinary shares by the option holder or any other method that may be approved by our compensation committee, which may include procedures for cashless exercise. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Our compensation committee may also grant, or recommend that our board of directors grant, other forms of equity incentive awards under the Plan, such as restricted shares, restricted share units, and other forms of share-based compensation. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Israeli participants in the Plan may be granted options subject to Section 102 of the Israeli Income Tax Ordinance (New Version), 1961, or the Israeli Tax Ordinance. Section 102 of the Israeli Tax Ordinance allows employees, directors and officers who are not controlling shareholders (as defined for those purposes under the Israeli Tax Ordinance) and are considered Israeli residents to receive favorable tax treatment for compensation in the form of shares or options. Our non-employee service providers and controlling shareholders may only be granted options under another section of the Israeli Tax Ordinance, which does not provide for similar tax benefits. Section 102 includes two alternatives for tax treatment involving the issuance of options or shares to a trustee for the benefit of the grantees and also includes an additional alternative for the issuance of options or shares directly to the grantee. The most favorable tax treatment for the grantees is under Section 102(b)(2) of the Israeli Tax Ordinance, the issuance to a trustee under the &#8220;capital gain track.&#8221; However, under this track we are not allowed to deduct an expense with respect to the issuance of the options or shares. Any options granted under the Plan to participants in the United States will be either &#8220;incentive stock options,&#8221; which may be eligible for special tax treatment under the Internal Revenue Code of 1986, or options other than incentive stock options (referred to as &#8220;nonqualified stock options&#8221;), as determined by our compensation committee or our board of directors and stated in the option agreement. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">136</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Our compensation committee will administer the Plan, or if determined otherwise by our board of directors, the Plan will be administered by our board of directors or other designated committee on its behalf. Even if the compensation committee or any other committee was appointed by our board of directors in order to administrate the Plan, our board of directors may, subject to any legal limitations, exercise any powers or duties of the compensation committee or any other committee concerning the Plan. The compensation committee will, among others, select which eligible persons will receive options or other awards under the Plan and will determine, or recommend to our board of directors, the number of ordinary shares covered by those options or other awards, the terms under which such options or other awards may be exercised (however, options generally may not be exercised later than ten years from the grant date of an option) or may be settled or paid, and the other terms and conditions of such options and other awards under the Plan. All awards granted under the Plan shall not be transferable other than by will or by the laws of descent and distribution, unless otherwise determined by our compensation committee. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">To the extent permitted under applicable law, our compensation committee will have the authority to accelerate the vesting of any outstanding awards at such time and under such circumstances as it, in its sole discretion, deems appropriate. In the event of a change of control, as defined in the Plan, any award then outstanding shall be assumed or an equivalent award shall be substituted by the successor corporation of the merger or sale or any parent or affiliate thereof as determined by our board of directors. In the event that the awards are not assumed or substituted, our compensation committee may, in its discretion, accelerate the vesting, exercisability of the outstanding award, or provide for the cancellation of such award and payment of cash, as determined to be fair in the circumstances. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Subject to particular limitations specified in the Plan and under applicable law, our board of directors may amend or terminate the Plan, and the compensation committee may amend awards outstanding under the Plan. In addition, an amendment to the Plan that requires shareholder approval under applicable law will not be effective unless approved by the requisite vote of shareholders. In addition, in general, no suspension, termination, modification or amendment of the Plan may adversely affect any award previously granted without the written consent of grantees holding a majority in interest of the awards so affected. The Plan will continue in effect until all ordinary shares available under the Plan are delivered and all restrictions on those shares have lapsed, unless the Plan is terminated earlier by our board of directors. No awards may be granted under the Plan on or after the tenth anniversary of the date of adoption of the plan unless our board of directors chooses to extend the term. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Any equity award to an office holder, director or controlling shareholder, whether under the Plan or otherwise, may be subject to further approvals in addition to the approval of the compensation committee as described above. As of June 30, 2017, options to purchase 253,768 ordinary shares, under our Plan, at an exercise price of&#8201; $2.86 per share were outstanding. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">137</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tPS">&#8203;</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;"><font style="text-transform:uppercase;">Principal Shareholders</font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">The following table sets forth information with respect to the beneficial ownership of our ordinary shares as of August 15, 2017 by: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">each person or entity known by us to own beneficially 5% or more of our outstanding ordinary shares; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">each of our directors, executive officers and director nominees; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">all of our executive officers, directors and director nominees as a group. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The beneficial ownership of our ordinary shares is determined in accordance with the rules of the SEC. Under these rules, a person is deemed to be a beneficial owner of a security if that person has or shares voting power, which includes the power to vote or to direct the voting of the security, or investment power, which includes the power to dispose of or to direct the disposition of the security. For purposes of the table below, we deem ordinary shares issuable pursuant to options that are currently exercisable or exercisable within 60 days as of August 15, 2017, if any, to be outstanding and to be beneficially owned by the person holding the options or warrants for the purposes of computing the percentage ownership of that person, but we do not treat them as outstanding for the purpose of computing the percentage ownership of any other person. The percentage of ordinary shares beneficially owned prior to the offering is based on &#8199;&#8201;&#8199;&#8199;&#8199;&#8201;&#8199;&#8199;&#8199; ordinary shares outstanding as of August 15, 2017, assuming the automatic conversion of our outstanding promissory note between us and our controlling shareholder into an aggregate of&#8201; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &#8199;&#8201;&#8199;&#8199;&#8199;&#8201;&#8199;&#8199;&#8199; ordinary shares immediately prior to the closing of this offering and assuming an initial public offering price of&#8201; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share, which is the midpoint of the price range set forth on the cover page of this prospectus. The percentage of ordinary shares beneficially owned after the offering is based on the number of shares outstanding prior to the offering plus the ordinary shares that we are selling in this offering.</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The percentages of ordinary shares beneficially owned after the offering assume that the underwriters will not exercise their option to purchase additional ordinary shares in the offering. Except where otherwise indicated, we believe, based on information furnished to us by such owners, that the beneficial owners of the ordinary shares listed below have sole investment and voting power with respect to such shares. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Upon the closing of this offering, none of our shareholders will have different voting rights from other shareholders. We are not aware of any arrangement that may, at a subsequent date, result in a change of control of our company. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">As of August 15, 2017, there were no U.S. persons that were holders of record of our ordinary shares. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Unless otherwise noted below, the address for each beneficial owner is c/o Sol-Gel Technologies Ltd., 7&#160;Golda Meir St., Weizmann Science Park, Ness Ziona, 7403650 Israel.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">138</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <table style="width:456pt;height:335pt;margin-top:0pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:261.01pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">Shares Beneficially <br >Owned Prior to the <br >Offering </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="text-align:center;">Shares Beneficially <br >Owned After the <br >Offering </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:261.01pt;text-align:left;">
              <div style="white-space:nowrap;">Name of Beneficial Owner </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Number </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Percentage </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Number </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Percentage </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:italic;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:261.01pt;text-align:left;">5% or greater shareholders</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.44pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.44pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:261.01pt;text-align:left;">
              <div style="white-space:nowrap;">M.Arkin Dermatology Ltd. (1) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.885pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">100<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:11.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.44pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;"><font style="position:relative;">&#8203;</font><font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:2.44pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:italic;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:261.01pt;">Directors, director nominees and executive officers</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:261.01pt;text-align:left;">
              <div style="white-space:nowrap;">Moshe Arkin (1) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.885pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">100<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:11.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.44pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.44pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:261.01pt;text-align:left;">
              <div style="white-space:nowrap;">Alon Seri-Levy (2) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">56,022</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.885pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;"><font style="position:relative;">&#8203;</font><font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:11.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">56,022</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.44pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.44pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:261.01pt;text-align:left;">
              <div style="white-space:nowrap;">Gilad Mamlok</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.885pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:11.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.44pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*</td>
            <td style="padding:0pt;padding-left:2.44pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:261.01pt;text-align:left;">
              <div style="white-space:nowrap;">Haim Barsimantov </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.885pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:11.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.44pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:2.44pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:261.01pt;text-align:left;">
              <div style="white-space:nowrap;">Ofer Toledano </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.885pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:11.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.44pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:2.44pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:261.01pt;text-align:left;">
              <div style="white-space:nowrap;">Ofra Levy-Hacham </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.885pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:11.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.44pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:2.44pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:261.01pt;text-align:left;">
              <div style="white-space:nowrap;">Karine Neimann</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.885pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:11.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.44pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:2.44pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:261.01pt;text-align:left;">
              <div style="white-space:nowrap;">Itzik Yosef</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.885pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:11.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.44pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:2.44pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:261.01pt;text-align:left;">
              <div style="white-space:nowrap;">Dov Zamir</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.885pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:11.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.44pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.44pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:261.01pt;text-align:left;">
              <div style="white-space:nowrap;">Itai Arkin</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.885pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:11.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.44pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.44pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:261.01pt;text-align:left;">
              <div style="white-space:nowrap;">Ran Gottfried</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.885pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:11.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.44pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.44pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:261.01pt;text-align:left;">
              <div style="white-space:nowrap;">Jerrold S. Gattegno</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.885pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:11.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.44pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.44pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:261.01pt;text-align:left;">
              <div style="white-space:nowrap;">Shmuel Ben Zvi </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.885pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:11.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.44pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.44pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:261.01pt;text-align:left;">
              <div style="white-space:nowrap;">Hani Lerman </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.885pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:11.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.44pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.44pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:261.01pt;text-align:left;">
              <div style="white-space:nowrap;">Yael Baratz </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.885pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:11.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.44pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.44pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 2.75pt 0pt; width:261.01pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;font-style:italic;font-weight:bold;">All directors, director nominees and executive officers <br >as a group (15 persons) <font style="font-style:normal;font-weight:normal;">(1)(3) </font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.885pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:12.75pt; text-align:right; white-space:nowrap;">100<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:11.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.44pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:27pt; text-align:right; white-space:nowrap;"><font style="position:relative;">&#8203;</font><font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:2.44pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="26">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.49pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:15pt;white-space:nowrap;font-size:8pt;">*<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:10pt; text-align:left; width:440.5pt;font-size:8pt;">Less than 1%. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:10pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:15pt;white-space:nowrap;font-size:8pt;">(1)<br ></div>
        <div style=" float:left; margin-top:9.97pt; margin-bottom:0pt; line-height:10pt; text-align:left; width:440.5pt;font-size:8pt;">Consists of (i)&#160;3,494,579 ordinary shares directly owned by Arkin Dermatology, and (ii) and &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares, to be issued immediately prior to the closing of this offering upon the automatic conversion of our outstanding promissory note between us and our controlling shareholder into an aggregate of&#8201; &#8199;&#8201;&#8199;&#8199;&#8199;&#8201;&#8199;&#8199;&#8199; ordinary shares immediately prior to the closing of this offering and assuming an initial public offering price of&#8201; $&#8199;&#8199;&#8199;&#8199; per ordinary share  which is the midpoint of the price range set forth on the cover page of this prospectus. The promissory note will be assigned to M.Arkin Dermatology Ltd. immediately prior to the conversion, and all ordinary shares will be held by M.Arkin Dermatology Ltd. The actual number of shares to be issued upon conversion of the promissory note will be determined by dividing the principal amount of the promissory note at the time of conversion by the initial public offering price per ordinary share in this offering. Mr. Moshe Arkin, the chairman of our board of directors, owns 100% of the outstanding share capital of Arkin Dermatology. As a result, Mr.&#160;Arkin has sole power to vote or to direct the vote and sole power to dispose or to direct the disposition of, all shares owned by Arkin Dermatology. Mr. Arkin disclaims beneficial ownership in the ordinary shares except to the extent of his pecuniary interest therein.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:10pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:15pt;white-space:nowrap;font-size:8pt;">(2)<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:10pt; text-align:left; width:440.5pt;font-size:8pt;">Consists of options to purchase 56,022 ordinary shares currently exercisable or exercisable within 60 days of August&#160;15, 2017. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:10pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:15pt;white-space:nowrap;font-size:8pt;">(3)<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:10pt; text-align:left; width:440.5pt;font-size:8pt;">Includes options to purchase 133,116 ordinary shares currently exercisable or exercisable within 60 days of August&#160;15, 2017.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">139</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tCRRPT">&#8203;</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;"><font style="text-transform:uppercase;">Certain Relationships and Related Party Transactions</font></div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Employment Agreements </div>
        <div style="text-indent:20pt; margin-top:5.02pt; width:456pt; line-height:12pt;">We have entered into written employment agreements with each of our executive officers. These agreements provide for notice periods of varying duration for termination of the agreement by us or by the relevant executive officer, during which time the executive officer will continue to receive base salary and benefits. These agreements also contain customary provisions regarding noncompetition, confidentiality of information and assignment of inventions. However, the enforceability of the noncompetition provisions may be limited under applicable law. See &#8220;Risk Factors &#8212; Risks Relating to Employee Matters &#8212; Under applicable employment laws, we may not be able to enforce covenants not to compete&#8221; for a further description of the enforceability of non-competition clauses. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Securities Purchase Agreement </div>
        <div style="text-indent:20pt; margin-top:5.03pt; width:456pt; line-height:12pt;">On August&#160;4, 2014, our former shareholders entered into a securities purchase agreement with our controlling shareholder, Arkin Dermatology, or the Purchase Agreement. The Purchase Agreement detailed the terms and conditions for the sale of the company to Arkin Dermatology in exchange for a cash payment in the amount of approximately $10.5 million in addition to an earn out payment of up to $17.0 million based on the achievement of certain development and revenue-related milestones. In connection with the Purchase Agreement, certain of our employees, including our chief executive officer, are entitled, subject to the achievement of certain research and development milestones and other conditions, to a special bonus in an aggregate amount of up to $3.0 million, all of which has been paid. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Project Transfers From Our Controlling Shareholder </div>
        <div style="text-indent:20pt; margin-top:5.03pt; width:456pt; line-height:12pt;">On December&#160;31, 2015, we assumed, following entering into a transfer agreement with M.&#160;Arkin (1999) Ltd., an affiliate of our controlling shareholder, an agreement with Perrigo Israel for the development, manufacturing and commercialization of a product candidate no longer in development. The consideration for the transfer of the project, in the amount of&#8201; $431,000, was paid to the related company during 2015 by utilizing a loan from our controlling shareholder.</div>
        <div style="text-indent:20pt; margin-top:6.02pt; width:456pt; line-height:12pt;">On August 22, 2017, our controlling shareholder, Arkin Dermatology, transferred an in-process research and development generic product candidate to us, in consideration of one ordinary share.</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Loan Agreements with Our Controlling Shareholder </div>
        <div style="text-indent:20pt; margin-top:5.03pt; width:456pt; line-height:12pt;">Since January&#160;1, 2014, we have received several loans in an aggregate principal amount of approximately $65.35 million from Mr. Arkin, our controlling shareholder. These loans are denominated in U.S. dollars, bear no interest and are backed by a promissory note, or the Promissory Note. The Promissory Note is an unsecured note, has no repayment date and is subject to acceleration in certain events of default.</div>
        <div style="text-indent:20pt; margin-top:6.02pt; width:456pt; line-height:12pt;">The Promissory Note will automatically convert into an aggregate of&#8201; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares immediately prior to the closing of this offering. The actual number of shares to be issued upon conversion of the promissory note will be determined by dividing the principal amount of the promissory note at the time of conversion by the initial public offering price per ordinary share in this offering. The Promissory Note will be assigned to Arkin Dermatology immediately prior to the automatic conversion thereof, and the ordinary shares issued pursuant to the automatic conversion of the Promissory Note will be held by Arkin Dermatology. Mr. Arkin, the chairman of our board of directors, owns 100% of the share capital of Arkin Dermatology.</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Directors and Officers Insurance Policy and Indemnification Agreements </div>
        <div style="text-indent:20pt; margin-top:5.03pt; width:456pt; line-height:12pt;">Our amended and restated articles of association permit us to exculpate, indemnify and insure each of our directors and officers to the fullest extent permitted by the Companies Law. We have obtained Directors and Officers insurance for each of our executive officers and directors. For further information, see &#8220;Management &#8212; Exculpation, Insurance and Indemnification of Directors and Officers.&#8221; </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">140</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We intend to enter into agreements with each of our current directors and officers exculpating them from a breach of their duty of care to us to the fullest extent permitted by law, subject to limited exceptions, and undertaking to indemnify them to the fullest extent permitted by law, subject to limited exceptions, including, with respect to liabilities resulting from this offering, to the extent that these liabilities are not covered by insurance. This indemnification is limited, with respect to any monetary liability imposed in favor of a third party, to events determined as foreseeable by the board of directors based on our activities. The maximum aggregate amount of indemnification that we may pay to our directors and officers based on such indemnification agreement is the greater of&#8201; (1) &#8199;&#8199;&#8199;&#8199;% of our shareholders&#8217; equity pursuant to our audited financial statements for the year preceding the year in which the event in connection of which indemnification is sought occurred, and (2) $&#8199;&#8199;&#8199;&#8199; million (as may be increased from time to time by shareholders&#8217; approval). Such indemnification amounts are in addition to any insurance amounts. Each director or officer who agrees to receive this letter of indemnification also gives his approval to the termination of all previous letters of indemnification that we have provided to him or her in the past, if any. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Registration Rights Agreement </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In connection with the closing of this offering, we intend to enter into a registration rights agreement, pursuant to which we intend to grant demand registration rights, short-form registration rights and piggyback registration rights to Arkin Dermatology, our controlling shareholder. All fees, costs and expenses of underwritten registrations are expected to be borne by us. No registration rights to be granted pursuant to this registration rights agreement shall be exercisable until expiration of the 180-day lock-up agreement entered into by Arkin Dermatology in connection with this offering.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">141</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tDSC">&#8203;</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;"><font style="text-transform:uppercase;">Description of Share Capital</font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The following description of our share capital and provisions of our amended and restated articles of association are summaries and do not purport to be complete. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">General </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Upon the closing of this offering, our authorized share capital will consist of&#8201; &#8199;&#8199;&#8199;&#8199;ordinary shares, par value NIS 0.1 per share, of which, effective upon closing of this offering, &#8199;&#8199;&#8199;&#8199;shares will be issued and outstanding (assuming that the underwriters do not exercise their option to purchase additional ordinary shares). </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">All of our outstanding ordinary shares will be validly issued, fully paid and non-assessable. Our ordinary shares are not redeemable and do not have any preemptive rights. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Registration Number and Purposes of the Company </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Our registration number with the Israeli Registrar of Companies is 51-254469-3. Our purpose as set forth in our amended and restated articles of association is to engage in any lawful activity. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Voting Rights and Conversion </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">All ordinary shares will have identical voting and other rights in all respects. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Transfer of Shares </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Our fully paid ordinary shares are issued in registered form and may be freely transferred under our amended and restated articles of association, unless the transfer is restricted or prohibited by another instrument, applicable law or the rules of a stock exchange on which the shares are listed for trade. The ownership or voting of our ordinary shares by non-residents of Israel is not restricted in any way by our amended and restated articles of association or the laws of the State of Israel, except for ownership by nationals of some countries that are, or have been, in a state of war with Israel. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Liability to Further Capital Calls </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Our board of directors may make, from time to time, such calls as it may deem fit upon shareholders with respect to any sum unpaid with respect to shares held by such shareholders which is not payable at a fixed time. Such shareholder shall pay the amount of every call so made upon him. Unless otherwise stipulated by the board of directors, each payment in response to a call shall be deemed to constitute a pro rata payment on account of all shares with respect to which such call was made. A shareholder shall not be entitled to his rights as shareholder, including the right to dividends, unless such shareholder has fully paid all the notices of call delivered to him, or which according to our amended and restated articles of association are deemed to have been delivered to him, together with interest, linkage and expenses, if any, unless otherwise determined by the board of directors. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Election of Directors </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Our ordinary shares do not have cumulative voting rights for the election of directors. As a result, the holders of a majority of the voting power represented at a shareholders meeting have the power to elect all of our directors, subject to the special approval requirements for external directors under the Companies Law described under &#8220;Management &#8212; External Directors.&#8221; </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Under our amended and restated articles of association, our board of directors must consist of not less than five (5) but no more than nine (9) directors, including any external directors required to be appointed by the Companies Law. Pursuant to our amended and restated articles of association, other than the external directors, for whom special election requirements apply under the Companies Law, the vote required to appoint a director is a simple majority vote of holders of </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">142</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">our voting shares participating and voting at the relevant meeting. In addition, our amended and restated articles of association allow our board of directors to appoint new directors to fill vacancies on the board of directors if the number of directors is below the maximum number provided in our amended and restated articles. Furthermore, under our amended and restated articles of association our directors other than external directors are divided into three classes with staggered three-year terms. For a more detailed description on the composition of our board of election procedures of our directors, other than our external directors, see &#8220;Management &#8212; Corporate Government Practices &#8212; Board of Directors and Officers.&#8221; External directors are elected for an initial term of three years, may be elected for additional terms of three years each under certain circumstances, and may be removed from office pursuant to the terms of the Companies Law. For further information on the election and removal of external directors, see &#8220;Management &#8212; External Directors &#8212; Election and Dismissal of External Directors.&#8221; </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Dividend and Liquidation Rights </div>
        <div style="text-indent:20pt; margin-top:7.41pt; width:456pt; line-height:12pt;">We may declare a dividend to be paid to the holders of our ordinary shares in proportion to their respective shareholdings. Under the Companies Law, dividend distributions are determined by the board of directors and do not require the approval of the shareholders of a company unless the company&#8217;s articles of association provide otherwise. Our amended and restated articles of association do not require shareholder approval of a dividend distribution and provide that dividend distributions may be determined by our board of directors. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Pursuant to the Companies Law, the distribution amount is limited to the greater of retained earnings or earnings generated over the previous two years, according to our then last reviewed or audited financial statements, provided that the date of the financial statements is not more than six months prior to the date of the distribution, or we may distribute dividends that do not meet such criteria only with court approval. In each case, we are only permitted to distribute a dividend if our board of directors and the court, if applicable, determines that there is no reasonable concern that payment of the dividend will prevent us from satisfying our existing and foreseeable obligations as they become due. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In the event of our liquidation, after satisfaction of liabilities to creditors, our assets will be distributed to the holders of our ordinary shares in proportion to their shareholdings. This right, as well as the right to receive dividends, may be affected by the grant of preferential dividend or distribution rights to the holders of a class of shares with preferential rights that may be authorized in the future. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Exchange Controls </div>
        <div style="text-indent:20pt; margin-top:7.41pt; width:456pt; line-height:12pt;">There are currently no Israeli currency control restrictions on remittances of dividends on our ordinary shares, proceeds from the sale of the shares or interest or other payments to non-residents of Israel, except for shareholders who are subjects of certain countries that are considered to be in a state of war with Israel at such time. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Shareholder Meetings </div>
        <div style="text-indent:20pt; margin-top:7.41pt; width:456pt; line-height:12pt;">Under Israeli law, we are required to hold an annual general meeting of our shareholders once every calendar year that must be held no later than 15 months after the date of the previous annual general meeting. All general meetings other than the annual meeting of shareholders are referred to in our amended and restated articles of association as special meetings. Our board of directors may call special meetings whenever it sees fit, at such time and place, within or outside of Israel, as it may determine. In addition, the Companies Law provides that our board of directors is required to convene a special meeting upon the written request of&#8201; (i) any two of our directors or one-quarter of the members of our board of directors or (ii) one or more shareholders holding, in the aggregate, either (a) 5% or more of our outstanding issued shares and 1% or more of our outstanding voting power or (b) 5% or more of our outstanding voting power. This is different from the Delaware General Corporation Law, or the DGCL, which allows such right of shareholders to be denied by a provision in a company&#8217;s certificate of incorporation. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">143</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Under Israeli law, one or more shareholders holding at least 1% of the voting rights at the general meeting may request that the board of directors include a matter in the agenda of a general meeting to be convened in the future, provided that it is appropriate to discuss such a matter at the general meeting. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Subject to the provisions of the Companies Law and the regulations promulgated thereunder, shareholders entitled to participate and vote at general meetings are the shareholders of record on a date to be decided by the board of directors, which may be between four and 40 days prior to the date of the meeting. Furthermore, the Companies Law requires that resolutions regarding the following matters must be passed at a general meeting of our shareholders: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.01pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.01pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">amendments to our amended and restated articles of association; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">appointment or termination of our auditors; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">appointment of external directors; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">approval of certain related party transactions; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">increases or reductions of our authorized share capital; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">mergers; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.81pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.81pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the exercise of our board of director&#8217;s powers by a general meeting, if our board of directors is unable to exercise its powers and the exercise of any of its powers is required for our proper management. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Under our amended and restated articles of association, we are not required to give notice to our registered shareholders pursuant to the Companies Law, unless otherwise required by law. The Companies Law requires that a notice of any annual general meeting or special general meeting be provided to shareholders at least 21 days prior to the meeting and if the agenda of the meeting includes the appointment or removal of directors, the approval of transactions with office holders or interested or related parties, or an approval of a merger, or as otherwise required under applicable law, notice must be provided at least 35 days prior to the meeting. Under the Companies Law, shareholders are not permitted to take action by written consent in lieu of a meeting. Our amended and restated articles of association provide that a notice of general meeting shall be published by us on Form 6-K at a date prior to the meeting as required by law. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Voting Rights </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Quorum Requirements </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Pursuant to our amended and restated articles of association, holders of our ordinary shares have one vote for each ordinary share held on all matters submitted to a vote before the shareholders at a general meeting. Under our amended and restated articles of association, the quorum required for general meetings of shareholders must consist of holders of at least two shareholders present in person or by proxy holding 33<font style=" position:relative; bottom:2.66pt;font-size:7pt;">1</font>&#8725;<font style="font-size:7pt;">3</font>% or more of the outstanding ordinary shares of the Company, which complies with the quorum requirements for general meetings under the NASDAQ Marketplace Rules. A meeting adjourned for lack of a quorum will generally be adjourned to the same day of the following week at the same time and place, or to such other day, time or place as indicated by our board of directors if so specified in the notice of the meeting. At the reconvened meeting, any number of shareholders present in person or by proxy shall constitute a lawful quorum, instead of 33<font style=" position:relative; bottom:2.66pt;font-size:7pt;">1</font>&#8725;<font style="font-size:7pt;">3</font>% of the outstanding ordinary shares as required under the NASDAQ Marketplace Rules. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Vote Requirements </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Our amended and restated articles of association provide that all resolutions of our shareholders require a simple majority vote, unless otherwise required by the Companies Law or by our amended and restated articles of association. Pursuant to our amended and restated articles </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">144</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">of association, an amendment to our amended and restated articles of association regarding any change of the composition or election procedures of our directors will require a special majority vote (66<font style=" position:relative; bottom:2.66pt;font-size:7pt;">2</font>&#8725;<font style="font-size:7pt;">3</font>%). Under the Companies Law, each of&#8201; (i) the approval of an extraordinary transaction with a controlling shareholder and (ii) the terms of employment or other engagement of the controlling shareholder of the company or such controlling shareholder&#8217;s relative (even if not extraordinary) requires the approval described above under &#8220;Management &#8212; Fiduciary duties and approval of specified related party transactions and compensation under Israeli law &#8212; Disclosure of personal interests of a controlling shareholder and approval of transactions.&#8221; Certain transactions with respect to remuneration of our office holders and directors require further approvals described above under &#8220;Management &#8212; Fiduciary duties and approval of specified related party transactions and compensation under Israeli law &#8212; Compensation of directors and executive officers.&#8221; Under our amended and restated articles of association, any change to the rights and privileges of the holders of any class of our shares requires a simple majority of the class so affected (or such other percentage of the relevant class that may be set forth in the governing documents relevant to such class), in addition to the ordinary majority vote of all classes of shares voting together as a single class at a shareholder meeting. Another exception to the simple majority vote requirement is a resolution for the voluntary winding up, or an approval of a scheme of arrangement or reorganization, of the company pursuant to Section 350 of the Companies Law, which requires the approval of holders of 75% of the voting rights represented at the meeting, in person, by proxy or by voting deed and voting on the resolution. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Access to Corporate Records </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Under the Companies Law, shareholders are provided access to minutes of our general meetings, our shareholders register and principal shareholders register, our amended and restated articles of association, our financial statements and any document that we are required by law to file publicly with the Israeli Companies Registrar or the Israel Securities Authority. In addition, shareholders may request to be provided with any document related to an action or transaction requiring shareholder approval under the related party transaction provisions of the Companies Law. We may deny this request if we believe it has not been made in good faith or if such denial is necessary to protect our interest or protect a trade secret or patent. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Modification of Class Rights </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Under the Companies Law and our amended and restated articles of association, the rights attached to any class of share, such as voting, liquidation and dividend rights, may be amended by adoption of a resolution by the holders of a majority of the shares of that class present at a separate class meeting, or otherwise in accordance with the rights attached to such class of shares, in addition to the ordinary majority vote of all classes of shares voting together as a single class at a shareholder meeting, as set forth in our amended and restated articles of association. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Registration Rights </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">For a discussion of registration rights we intend to grant to our controlling shareholder in connection with the closing of this offering, please see &#8220;Certain Relationships and Related Party Transactions &#8212; Registration Rights Agreement.&#8221; </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Acquisitions under Israeli Law </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Full Tender Offer </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">A person wishing to acquire shares of an Israeli public company and who would as a result hold over 90% of the target company&#8217;s issued and outstanding share capital is required by the Companies Law to make a tender offer to all of the company&#8217;s shareholders for the purchase of all of the issued and outstanding shares of the company. A person wishing to acquire shares of a public Israeli company and who would as a result hold over 90% of the issued and outstanding share capital of a certain class of shares is required to make a tender offer to all of the shareholders </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">145</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">who hold shares of the relevant class for the purchase of all of the issued and outstanding shares of that class. If the shareholders who do not accept the offer hold less than 5% of the issued and outstanding share capital of the company or of the applicable class, and more than half of the shareholders who do not have a personal interest in the offer accept the offer, all of the shares that the acquirer offered to purchase will be transferred to the acquirer by operation of law. However, a tender offer will also be accepted if the shareholders who do not accept the offer hold less than 2% of the issued and outstanding share capital of the company or of the applicable class of shares. </div>
        <div style="text-indent:20pt; margin-top:7.22pt; width:456pt; line-height:12pt;">Upon a successful completion of such a full tender offer, any shareholder that was an offeree in such tender offer, whether such shareholder accepted the tender offer or not, may, within six months from the date of acceptance of the tender offer, petition an Israeli court to determine whether the tender offer was for less than fair value and that the fair value should be paid as determined by the court. However, under certain conditions, the offeror may include in the terms of the tender offer that an offeree who accepted the offer will not be entitled to petition the Israeli court as described above. </div>
        <div style="text-indent:20pt; margin-top:7.21pt; width:456pt; line-height:12pt;">If&#8201; (a) the shareholders who did not respond or accept the tender offer hold at least 5% of the issued and outstanding share capital of the company or of the applicable class or the shareholders who accept the offer constitute less than a majority of the offerees that do not have a personal interest in the acceptance of the tender offer, or (b) the shareholders who did not accept the tender offer hold 2% or more of the issued and outstanding share capital of the company (or of the applicable class), the acquirer may not acquire shares of the company that will increase its holdings to more than 90% of the company&#8217;s issued and outstanding share capital or of the applicable class from shareholders who accepted the tender offer. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Special Tender Offer </div>
        <div style="text-indent:20pt; margin-top:6.22pt; width:456pt; line-height:12pt;">The Companies Law provides that an acquisition of shares of an Israeli public company must be made by means of a special tender offer if as a result of the acquisition the purchaser would become a holder of 25% or more of the voting rights in the company. This requirement does not apply if there is already another holder of at least 25% of the voting rights in the company. Similarly, the Companies Law provides that an acquisition of shares in a public company must be made by means of a special tender offer if as a result of the acquisition the purchaser would become a holder of more than 45% of the voting rights in the company, if there is no other shareholder of the company who holds more than 45% of the voting rights in the company, subject to certain exceptions. </div>
        <div style="text-indent:20pt; margin-top:7.21pt; width:456pt; line-height:12pt;">A special tender offer must be extended to all shareholders of a company but the offeror is not required to purchase shares representing more than 5% of the voting power attached to the company&#8217;s outstanding shares, regardless of how many shares are tendered by shareholders. A special tender offer may be consummated only if&#8201; (i) at least 5% of the voting power attached to the company&#8217;s outstanding shares will be acquired by the offeror and (ii) the number of shares tendered in the offer exceeds the number of shares whose holders objected to the offer (excluding the purchaser and its controlling shareholder, holders of 25% or more of the voting rights in the company or any person having a personal interest in the acceptance of the tender offer or any other person acting on their behalf, including relatives and entities under such person&#8217;s control). If a special tender offer is accepted, then the purchaser or any person or entity controlling it or under common control with the purchaser or such controlling person or entity may not make a subsequent tender offer for the purchase of shares of the target company and may not enter into a merger with the target company for a period of one year from the date of the offer, unless the purchaser or such person or entity undertook to effect such an offer or merger in the initial special tender offer. </div>
        <div style="margin-left:20pt; margin-top:7.22pt; width:436pt; line-height:12pt;">Under the DGCL there are no provisions relating to mandatory tender offers. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Merger </div>
        <div style="text-indent:20pt; margin-top:6.02pt; width:456pt; line-height:12pt;">The Companies Law permits merger transactions if approved by each party&#8217;s board of directors and, unless certain requirements described under the Companies Law are met, by a majority vote </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">146</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">of each party&#8217;s shares, and, in the case of the target company, a majority vote of each class of its shares voted on the proposed merger at a shareholders meeting. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">For purposes of the shareholder vote, unless a court rules otherwise, the merger will not be deemed approved if a majority of the votes of the shares represented at the shareholders meeting that are held by parties other than the other party to the merger, or by any person (or group of persons acting in concert) who holds (or hold, as the case may be) 25% or more of the voting rights or the right to appoint 25% or more of the directors of the other party, vote against the merger. If, however, the merger involves a merger with a company&#8217;s own controlling shareholder or if the controlling shareholder has a personal interest in the merger, then the merger is instead subject to the same special majority approval that governs all extraordinary transactions with controlling shareholders (as described under &#8220;Management &#8212; Fiduciary duties and approval of specified related party transactions and compensation under Israeli Law &#8212; Disclosure of personal interests of a controlling shareholder and approval of transactions&#8221;). </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">If the transaction would have been approved by the shareholders of a merging company but for the separate approval of each class or the exclusion of the votes of certain shareholders as provided above, a court may still approve the merger upon the request of holders of at least 25% of the voting rights of a company, if the court holds that the merger is fair and reasonable, taking into account the value to the parties to the merger and the consideration offered to the shareholders of the company. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Upon the request of a creditor of either party to the proposed merger, the court may delay or prevent the merger if it concludes that there exists a reasonable concern that, as a result of the merger, the surviving company will be unable to satisfy the obligations of the merging entities, and may further give instructions to secure the rights of creditors. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In addition, a merger may not be consummated unless at least 50 days have passed from the date on which a proposal for approval of the merger was filed by each party with the Israeli Registrar of Companies and at least 30 days have passed from the date on which the merger was approved by the shareholders of each party. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Anti-Takeover Measures under Israeli Law </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The Companies Law allows us to create and issue shares having rights different from those attached to our ordinary shares, including shares providing certain preferred rights with respect to voting, distributions or other matters and shares having preemptive rights. As of the closing of this offering, no preferred shares will be authorized under our amended and restated articles of association. In the future, if we do authorize, create and issue a specific class of preferred shares, such class of shares, depending on the specific rights that may be attached to it, may have the ability to frustrate or prevent a takeover or otherwise prevent our shareholders from realizing a potential premium over the market value of their ordinary shares. The authorization and designation of a class of preferred shares will require an amendment to our amended and restated articles of association, which requires the prior approval of the holders of a majority of the voting power attaching to our issued and outstanding shares at a general meeting. The convening of the meeting, the shareholders entitled to participate and the majority vote required to be obtained at such a meeting will be subject to the requirements set forth in the Companies Law as described above in &#8220;&#8212; Voting Rights.&#8221; </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">As an Israeli company we are not subject to the provisions of Section 203 of the DGCL, which in general prohibits a publicly held Delaware corporation from engaging in a &#8220;business combination&#8221; with an &#8220;interested stockholder&#8221; for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. For purposes of Section 203, a &#8220;business combination&#8221; includes a merger, asset sale or other transaction resulting in a financial benefit to the interested stockholder, and an &#8220;interested stockholder&#8221; is a person who, together with affiliates and associates, owns, or within three years prior did own, 15% or more of the voting stock of a corporation. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">147</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Borrowing Powers </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Pursuant to the Companies Law and our amended and restated articles of association, our board of directors may exercise all powers and take all actions that are not required under law or under our amended and restated articles of association to be exercised or taken by our shareholders, including the power to borrow money for company purposes. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Changes in Capital </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Our amended and restated articles of association enable us to increase or reduce our share capital. Any such changes are subject to the provisions of the Companies Law and must be approved by a resolution duly adopted by our shareholders at a general meeting. In addition, transactions that have the effect of reducing capital, such as the declaration and payment of dividends in the absence of sufficient retained earnings or profits, require the approval of both our board of directors and an Israeli court. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Establishment </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We were incorporated under the laws of the State of Israel on October&#160;28, 1997. We are registered with the Israeli Registrar of Companies in Jerusalem. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Transfer Agent and Registrar </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The transfer agent and registrar for our ordinary shares is American Stock Transfer &amp; Trust Company, LLC. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Listing </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We have applied to list our ordinary shares on The NASDAQ Global Market under the symbol &#8220;SLGL.&#8221;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Home Country Practices </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">As a foreign private issuer whose shares will be listed on The NASDAQ Global Market, we are permitted to follow certain home country corporate governance practices instead of certain requirements of the rules of The NASDAQ Global Market. Pursuant to the &#8220;foreign private issuer exemption&#8221;: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">we intend to establish a quorum requirement such that the quorum for any meeting of shareholders is 33 and 1&#8725;3% of the issued share capital, as required under NASDAQ requirements; however, if the meeting is adjourned for lack of quorum, the quorum for such adjourned meeting will be any number of shareholders, instead of 33<font style=" position:relative; bottom:2.66pt;font-size:7pt;">1</font>&#8725;<font style="font-size:7pt;">3</font>% of the issued share capital; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">we intend to adopt and approve material changes to equity incentive plans in accordance with the Israeli Companies Law, 5759-1999, or Companies Law, which does not impose a requirement of shareholder approval for such actions. In addition, we intend to follow Israeli corporate governance practice in lieu of NASDAQ Marketplace Rule 5635(c), which requires shareholder approval prior to an issuance of securities in connection with equity based compensation of officers, directors, employees or consultants; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">as opposed to making periodic reports to shareholders and proxy solicitation materials available to shareholders in the manner specified by the NASDAQ corporate governance rules, the Companies Law does not require us to distribute periodic reports directly to shareholders, and the generally accepted business practice in Israel is not to distribute such reports to shareholders but to make such reports available through a public website. We will only mail such reports to shareholders upon request; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">148</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">we will follow Israeli corporate governance practice instead of NASDAQ requirements to obtain shareholder approval for certain dilutive events (such as issuances that will result in a change of control, certain transactions other than a public offering involving issuances of a 20% or greater interest in us and certain acquisitions of the stock or assets of another company). Accordingly, our shareholders may not be afforded the same protection as provided under NASDAQ corporate governance rules.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Otherwise, we intend to comply with the rules generally applicable to U.S. domestic companies listed on the NASDAQ Global Market. However, we may in the future decide to use the foreign private issuer exemption with respect to some or all of the other NASDAQ corporate governance rules.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">149</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tSEFS">&#8203;</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;"><font style="text-transform:uppercase;">Shares Eligible for Future Sale</font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Prior to this offering, no public market existed for our ordinary shares. Sales of substantial amounts of our ordinary shares following this offering, or the perception that these sales could occur, could adversely affect prevailing market prices of our ordinary shares and could impair our future ability to obtain capital, especially through an offering of equity securities. Assuming that the underwriters do not exercise their option to purchase additional ordinary shares in this offering and assuming no exercise of options outstanding following this offering and assuming the automatic conversion of our outstanding promissory note between us and our controlling shareholder into an aggregate of&#8201; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares immediately prior to the closing of this offering, and further assuming an initial public offering price of&#8201; $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per ordinary share, which is the midpoint of the price range set forth on the cover page of this prospectus, we will have an aggregate of&#8201; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares outstanding upon the closing of this offering. Of these shares, the &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares sold in this offering will be freely tradable without restriction or further registration under the Securities Act, unless purchased by &#8220;affiliates&#8221; (as that term is defined under Rule 144 of the Securities Act), who may sell only the volume of shares described below and whose sales would be subject to additional restrictions described below. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The remaining &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares will be held by our existing shareholders and will be deemed to be &#8220;restricted securities&#8221; under Rule 144. Restricted securities may only be sold in the public market pursuant to an effective registration statement under the Securities Act or pursuant to an exemption from registration such as under Rule 144 under the Securities Act. These rules are summarized below. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Eligibility of Restricted Shares for Sale in the Public Market </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">As a result of contractual restrictions described below and the provisions of Rules 144 and 701, the ordinary shares sold in this offering and the restricted securities will be available for sale in the public market as follows: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">all the ordinary shares sold in this offering will be eligible for immediate sale upon the closing of this offering; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ordinary shares will be eligible for sale in the public market upon expiration of lock-up agreements 180 days after the date of this prospectus, subject in certain circumstances to the volume, manner of sale and other limitations under Rule 144 and Rule 701. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Lock-up Agreements </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">All of our directors, executive officers and shareholders have signed lock-up agreements pursuant to which, subject to certain exceptions, such persons have agreed not to sell or otherwise dispose of ordinary shares or any securities convertible into or exchangeable for ordinary shares for a period of 180 days after the date of this prospectus without the prior written consent of Jefferies LLC and BMO Capital Markets Corp., who may, at any time upon requisite notice, release all or any portion of the ordinary shares from the restrictions in any such agreement. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Rule 144 </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Shares Held For Six Months </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In general, under Rule 144 as currently in effect, and subject to the terms of any lock-up agreement, commencing 90 days following the closing of this offering, a person, including an affiliate, who has beneficially owned our ordinary shares for six months or more, including the holding period of any prior owner other than one of our affiliates (i.e., commencing when the shares were acquired from us or from an affiliate of us as restricted securities), is entitled to sell our ordinary shares, subject to the availability of current public information about us (which information will be deemed to be available as long as we continue to file required reports with the </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">150</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">SEC). In the case of an affiliate shareholder, the right to sell is also subject to the fulfillment of certain additional conditions, including manner of sale provisions, notice requirements, and a volume limitation that limits the number of shares that may be sold thereby, within any three-month period, to the greater of:</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">1% of the number of ordinary shares then outstanding; or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the average weekly trading volume of our ordinary shares on the NASDAQ Global Market during the four calendar weeks preceding the filing of a notice on Form 144 with respect to the sale. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Rule 144 also provides that affiliates that sell our ordinary shares that are not restricted securities must nonetheless comply with the same restrictions applicable to restricted securities, other than the holding period requirement. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Shares Held by Non-Affiliates for One Year </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Under Rule 144 as currently in effect, a person who is not considered to have been one of our affiliates at any time during the three months preceding a sale and who has beneficially owned the shares proposed to be sold for at least one year, including the holding period of any prior owner other than one of our affiliates, is entitled to sell his, her or its shares under Rule 144 without complying with the provisions relating to the availability of current public information or with any other conditions under Rule 144. Therefore, unless subject to a lock-up agreement or otherwise restricted, such shares may be sold immediately upon the closing of this offering. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Rule 701 </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In general, under Rule 701 as currently in effect, each of our employees, consultants or advisors who purchases our ordinary shares from us in connection with a compensatory stock plan or other written agreement executed prior to the closing of this offering is eligible to resell such ordinary shares in reliance on Rule 144, but without compliance with some of the restrictions, as described below. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Rule 701 will apply to the options granted under our 2014 Share Incentive Plan prior to the closing of this offering, along with the shares acquired upon exercise of these options, including exercises following the closing of this offering. Securities issued in reliance on Rule 701 are restricted securities and may be sold beginning 90 days following the closing of this offering in reliance on Rule 144 by: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">persons other than affiliates, without restriction; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">affiliates, subject to the manner-of-sale, current public information and filing requirements of Rule 144, </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">in each case, without compliance with the six-month holding period requirement of Rule 144. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Form S-8 Registration Statements </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Following the closing of this offering, we intend to file one or more registration statements on Form S-8 under the Securities Act to register, in the aggregate, ordinary shares, issued or reserved for issuance under our 2014 Share Incentive Plan. The registration statement on Form S-8 will become effective automatically upon filing. Ordinary shares issued upon exercise of a share option or other award and registered pursuant to the Form S-8 registration statement will, subject to vesting provisions and Rule 144 volume limitations applicable to our affiliates, be available for sale in the open market immediately unless they are subject to the 180-day lock-up or, if subject to the lock-up, immediately after the 180-day lock-up period expires. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">151</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Registration Rights </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In connection with the closing of this offering, we intend to enter into a registration rights agreement, pursuant to which we intend to grant demand registration rights, short-form registration rights and piggyback registration rights to Arkin Dermatology, our controlling shareholder. For more information on these registration rights, see &#8220;Certain Relationships and Related Party Transactions&#8201;&#8212;&#8201;Registration Rights Agreement.&#8221; No registration rights to be granted pursuant to this registration rights agreement shall be exercisable until expiration of the 180-day lock-up agreement entered into by Arkin Dermatology in connection with this offering.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">152</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tMTC">&#8203;</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;"><font style="text-transform:uppercase;">Material Tax Considerations</font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">The following description is not intended to constitute a complete analysis of all tax consequences relating to the acquisition, ownership and disposition of our ordinary shares. You should consult your own tax advisor concerning the tax consequences of your particular situation, as well as any tax consequences that may arise under the laws of any state, local, foreign or other taxing jurisdiction. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Israeli Tax Considerations and Government Programs </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">The following is a summary of the material Israeli tax laws applicable to us, and some Israeli Government programs benefiting us. This section also contains a discussion of some Israeli tax consequences to persons owning our ordinary shares. This summary does not discuss all the aspects of Israeli tax law that may be relevant to a particular investor in light of his or her personal investment circumstances or to some types of investors subject to special treatment under Israeli law. Examples of this kind of investor include traders in securities or persons that own, directly or indirectly, 10% or more of our outstanding voting capital, all of whom are subject to special tax regimes not covered in this discussion. Some parts of this discussion are based on a new tax legislation which has not been subject to judicial or administrative interpretation. The discussion should not be construed as legal or professional tax advice and does not cover all possible tax considerations. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">SHAREHOLDERS ARE URGED TO CONSULT THEIR OWN TAX ADVISORS AS TO THE ISRAELI OR OTHER TAX CONSEQUENCES OF THE PURCHASE, OWNERSHIP AND DISPOSITION OF OUR ORDINARY SHARES, INCLUDING, IN PARTICULAR, THE EFFECT OF ANY FOREIGN, STATE OR LOCAL TAXES. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">General Corporate Tax Structure in Israel </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">Israeli resident companies are generally subject to corporate tax at the rate of 24% of a company&#8217;s taxable income in 2017, which is expected to decrease to 23% in 2018 and thereafter. However, the effective tax rate payable by a company that derives income from a Benefited Enterprise or a Preferred Enterprise (as discussed below) may be considerably less. Capital gains derived by an Israeli resident company are subject to tax at the prevailing corporate tax rate. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Under Israeli tax legislation, a corporation will be considered as an &#8220;Israeli resident company&#8221; if it meets one of the following: (i) it was incorporated in Israel; or (ii) the control and management of its business are exercised in Israel. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Law for the Encouragement of Industry (Taxes), 5729-1969 </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The Law for the Encouragement of Industry (Taxes), 5729-1969, generally referred to as the Industry Encouragement Law, provides several tax benefits for &#8220;Industrial Companies.&#8221; </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The Industry Encouragement Law defines an &#8220;Industrial Company&#8221; as a company resident in Israel and which was incorporated in Israel of which 90% or more of its income in any tax year, other than income from defense loans, is derived from an &#8220;Industrial Enterprise&#8221; owned by it and which is located in Israel. An &#8220;Industrial Enterprise&#8221; is defined as an enterprise whose principal activity in a given tax year is industrial production. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The following corporate tax benefits, among others, are available to Industrial Companies: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">amortization over an eight-year period of the cost of purchased know-how and patents and rights to use a patent and know-how which are used for the development or advancement of the Industrial Enterprise; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">under limited conditions, an election to file consolidated tax returns with related Israeli Industrial Companies; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">expenses related to a public offering are deductible in equal amounts over three years. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">153</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Although as of the date of this prospectus, we do not have industrial production activities, we may qualify as an Industrial Company in the future and may be eligible for the benefits described above. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Tax Benefits and Grants for Research and Development </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Israeli tax law allows, under certain conditions, a tax deduction for expenditures, including capital expenditures, for the year in which they are incurred. Expenditures are deemed related to scientific research and development projects, if: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">The expenditures are approved by the relevant Israeli government ministry, determined by the field of research; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">The research and development must be for the promotion of the company; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">The research and development is carried out by or on behalf of the company seeking such tax deduction. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The amount of such deductible expenses is reduced by the sum of any funds received through government grants for the financing of such scientific research and development projects. No deduction under these research and development deduction rules is allowed if such deduction is related to an expense invested in an asset depreciable under the general depreciation rules of the Israeli Tax Ordinance, 1961. Expenditures not so approved are deductible in equal amounts over three years. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">From time to time we may apply to the Innovation Authority for approval to allow a tax deduction for all research and development expenses during the year incurred. There can be no assurance that such application will be accepted. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Law for the Encouragement of Capital Investments, 5719-1959 </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The Law for the Encouragement of Capital Investments, 5719-1959, generally referred to as the Investment Law, provides certain incentives for capital investments in production facilities (or other eligible assets) by &#8220;Industrial Enterprises&#8221; (as defined under the Investment Law). </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Tax Benefits Prior to the 2005 Amendment </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">An investment program that is implemented in accordance with the provisions of the Investment Law prior to an amendment that became effective in April 2005, or the 2005 Amendment, referred to as an &#8220;Approved Enterprise,&#8221; is entitled to certain benefits. A company that wished to receive benefits as an Approved Enterprise must have received approval from the Investment Center of the Israeli Ministry of Economy and Industry, or the Investment Center. Each certificate of approval for an Approved Enterprise relates to a specific investment program in the Approved Enterprise, delineated both by the financial scope of the investment and by the physical characteristics of the facility or the asset. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In general, an Approved Enterprise is entitled to receive a grant from the Government of Israel or an alternative package of tax benefits, known as the alternative benefits track. The tax benefits from any certificate of approval relate only to taxable profits attributable to the specific Approved Enterprise. Income derived from activity that is not integral to the activity of the Approved Enterprise does not enjoy tax benefits. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In addition, a company that has an Approved Enterprise program is eligible for further tax benefits if it qualifies as a Foreign Investors&#8217; Company, or FIC, which is a company with a level of foreign investment, as defined in the Investment Law, of more than 25%. The level of foreign investment is measured as the percentage of rights in the company (in terms of shares, rights to profits, voting and appointment of directors), and of combined share and loan capital, that are owned, directly or indirectly, by persons who are not residents of Israel. The determination as to whether a company qualifies as an FIC is made on an annual basis. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">154</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">We are currently not entitled to tax benefits for Approved Enterprise. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Tax Benefits Subsequent to the 2005 Amendment </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The 2005 Amendment applies to new investment programs and investment programs commencing after 2004, but does not apply to investment programs approved prior to April&#160;1, 2005. The 2005 Amendment provides that terms and benefits included in any certificate of approval that was granted before the 2005 Amendment became effective (April&#160;1, 2005) will remain subject to the provisions of the Investment Law as in effect on the date of such approval. Pursuant to the 2005 Amendment, the Investment Center will continue to grant Approved Enterprise status to qualifying investments. The 2005 Amendment, however, limits the scope of enterprises that may be approved by the Investment Center by setting criteria for the approval of a facility as an Approved Enterprise, such as provisions generally requiring that at least 25% of the Approved Enterprise&#8217;s income be derived from exports. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The 2005 Amendment provides that Approved Enterprise status will only be necessary for receiving cash grants. As a result, it was no longer necessary for a company to obtain Approved Enterprise status in order to receive the tax benefits previously available under the alternative benefits track. Rather, a company may claim the tax benefits offered by the Investment Law directly in its tax returns, provided that its facilities meet the criteria for tax benefits set forth in the amendment. Companies are entitled to approach the Israeli Tax Authority for a pre-ruling regarding their eligibility for benefits under the Investment Law, as amended. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In order to receive the tax benefits, the 2005 Amendment states that a company must make an investment which meets all of the conditions, including exceeding a minimum investment amount specified in the Investment Law. Such investment allows a company to receive &#8220;Benefited Enterprise&#8221; status, and may be made over a period of no more than three years from the end of the year in which the company requested to have the tax benefits apply to its Benefited Enterprise. Where the company requests to apply the tax benefits to an expansion of existing facilities, only the expansion will be considered to be a Benefited Enterprise and the company&#8217;s effective tax rate will be the weighted average of the applicable rates. In this case, the minimum investment required in order to qualify as a Benefited Enterprise is required to exceed a certain percentage of the value of the company&#8217;s production assets before the expansion. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The extent of the tax benefits available under the 2005 Amendment to qualifying income of a Benefited Enterprise depend on, among other things, the geographic location in Israel of the Benefited Enterprise. The location will also determine the period for which tax benefits are available. Such tax benefits include an exemption from corporate tax on undistributed income for a period of between two to 10 years, depending on the geographic location of the Benefited Enterprise in Israel, and a reduced corporate tax rate of between 10% and the applicable corporate tax for the remainder of the benefits period, depending on the level of foreign investment in the company in each year. A company qualifying for tax benefits under the 2005 Amendment which pays a dividend out of income derived by its Benefited Enterprise during the tax exemption period will be subject to corporate tax in respect of the gross amount of the dividend at the otherwise applicable corporate tax rate or a lower rate in the case of a qualified FIC which is at least 49% owned by non-Israeli residents. Dividends paid out of income attributed to a Benefited Enterprise are generally subject to withholding tax at source at the rate of 15% or such lower rate as may be provided in an applicable tax treaty. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The benefits available to a Benefited Enterprise are subject to the fulfillment of conditions stipulated in the Investment Law and its regulations. If a company does not meet these conditions, it may be required to refund the amount of tax benefits, as adjusted by the Israeli consumer price index, and interest, or other monetary penalties. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We applied for tax benefits as a &#8220;Benefited Enterprise&#8221; with 2012 as a &#8220;Year of Election.&#8221; We may be entitled to tax benefits under this regime once we are profitable for tax purposes and subject to the fulfillment of all the relevant conditions. If we do not meet these conditions, the tax </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">155</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">benefits may not be applicable which would result in adverse tax consequences to us. Alternatively, and subject to the fulfillment of all the relevant conditions, we may elect in the future to irrevocably waive the tax benefits available for Benefited Enterprise and claim the tax benefits available to Preferred Enterprise under the 2011 Amendment (as detailed below). </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Tax Benefits Under the 2011 Amendment </div>
        <div style="text-indent:20pt; margin-top:7.61pt; width:456pt; line-height:12pt;">The Investment Law was significantly amended as of January&#160;1, 2011, or the 2011 Amendment. The 2011 Amendment introduced new benefits to replace those granted in accordance with the provisions of the Investment Law in effect prior to the 2011 Amendment. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The 2011 Amendment introduced new tax benefits for income generated by a &#8220;Preferred Company&#8221; through its &#8220;Preferred Enterprise,&#8221; in accordance with the definition of such term in the Investment Law, which generally means that a &#8220;Preferred Company&#8221; is an industrial company meeting certain conditions (including a minimum threshold of 25% export). </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">A Preferred Company is entitled to a reduced flat tax rate with respect to the income attributed to the Preferred Enterprise, at the following rates: </div>
        <table style="width:416pt;height:68.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:203.18pt;text-align:left;">
              <div style="white-space:nowrap;">Tax Year </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Development Region &#8220;A&#8221; </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Other Areas within Israel </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:203.18pt;text-align:left;">
              <div style="white-space:nowrap;">2011 &#8211; 2012 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:39.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">10<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:39.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:38.03pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">15<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:38.03pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:203.18pt;text-align:left;">
              <div style="white-space:nowrap;">2013 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:39.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">7<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:39.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:38.03pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">12.5<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:38.03pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:203.18pt;text-align:left;">2014&#8201;&#8211;&#8201;2016</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:39.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">9<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:39.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:38.03pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">16<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:38.03pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:203.18pt;text-align:left;">
              <div style="white-space:nowrap;">2017 and thereafter</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:39.71pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">7.5<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:39.71pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:38.03pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">16<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:38.03pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:14.61pt; width:456pt; line-height:12pt;">Dividends distributed from income which is attributed to a &#8220;Preferred Enterprise&#8221; will be subject to withholding tax at source at the following rates: (i) Israeli resident corporations &#8212; 0%, (ii) Israeli resident individuals &#8212; 20% in 2017 (iii) non-Israeli residents &#8212; 20% in 2017, subject to a reduced tax rate under the provisions of an applicable double tax treaty. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Under the 2011 Amendment, a company located in Development Region &#8220;A&#8221; may be entitled to cash grants and the provision of loans under certain conditions, if approved. The rates for grants and loans shall not be fixed, but up to 20% of the amount of the approved investment (may be increased with additional 4%). In addition, a company owning a Preferred Enterprise under the Grant Track may be entitled also to the tax benefits which are prescribed for a Preferred Company. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The termination or substantial reduction of any of the benefits available under the Investment Law could materially increase our tax liabilities. </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">We are currently not entitled to tax benefits for a Preferred Enterprise. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Taxation of Our Shareholders </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Capital Gains </div>
        <div style="text-indent:20pt; margin-top:7.41pt; width:456pt; line-height:12pt;">Capital gain tax is imposed on the disposition of capital assets by an Israeli resident, and on the disposition of such assets by a non-Israeli resident if those assets are either (i) located in Israel; (ii) are shares or a right to a share in an Israeli resident corporation, or (iii) represent, directly or indirectly, rights to assets located in Israel. The Israeli Tax Ordinance distinguishes between &#8220;Real Gain&#8221; and the &#8220;Inflationary Surplus.&#8221; Real Gain is the excess of the total capital gain over Inflationary Surplus computed generally on the basis of the increase in the Israeli consumer price index between the date of purchase and the date of disposition. Inflationary Surplus is not currently subject to tax in Israel. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Real Gain accrued by individuals on the sale of our ordinary shares will be taxed at the rate of 25%. However, if the individual shareholder is a &#8220;Controlling Shareholder&#8221; (i.e., a person who holds, directly or indirectly, alone or together with another, 10% or more of one of the Israeli resident company&#8217;s means of control) at the time of sale or at any time during the preceding 12-month period, such gain will be taxed at the rate of 30%. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">156</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Real Gain derived by corporations will be generally subject to the corporate tax rate of 24% in 2017 and which is expected to be reduced to 23% in 2018 and thereafter. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Individual and corporate shareholder dealing in securities in Israel are taxed at the tax rates applicable to business income &#8212; 24% for corporations in 2017, which is expected to be reduced to 23% in 2018 and thereafter, and a marginal tax rate of up to 50% in 2017 for individuals, including an excess tax. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Notwithstanding the foregoing, capital gain derived from the sale of our ordinary shares by a non-Israeli shareholder may be exempt under the Israeli Tax Ordinance from Israeli capital gain tax provided that the seller does not have a permanent establishment in Israel to which the derived capital gain is attributed. However, non-Israeli corporations will not be entitled to the foregoing exemption if more than 25% of its means of control are held, directly and indirectly, by Israeli residents, and Israeli residents are entitled to 25% or more of the revenues or profits of the corporation, directly or indirectly. In addition, such exemption would not be available to a person whose gains from selling or otherwise disposing of the securities are deemed to be business income. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In addition, the sale of shares may be exempt from Israeli capital gain tax under the provisions of an applicable tax treaty. For example, the U.S.-Israel Double Tax Treaty exempts U.S. residents from Israeli capital gain tax in connection with such sale, provided (i) the U.S. resident owned, directly or indirectly, less than 10% of an Israeli resident company&#8217;s voting power at any time within the 12-month period preceding such sale; (ii) the seller, being an individual, is present in Israel for a period or periods of less than 183 days during the taxable year; and (iii) the capital gain from the sale was not derived through a permanent establishment of the U.S. resident in Israel. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In some instances where our shareholders may be liable for Israeli tax on the sale of their ordinary shares, the payment of the consideration may be subject to the withholding of Israeli tax at source at a rate of 25% if the seller is an individual and at the corporate tax rate (24% in 2017, to be reduced to 23% in 2018 and thereafter) if the seller is a corporation. Shareholders may be required to demonstrate that they are exempt from tax on their capital gains in order to avoid withholding at source at the time of sale. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">At the sale of securities traded on a stock exchange a detailed return, including a computation of the tax due, must be filed and an advanced payment must be paid on January&#160;31 and June&#160;30 of every tax year in respect of sales of securities made within the previous six months. However, if all tax due was withheld at source according to applicable provisions of the Israeli Tax Ordinance and regulations promulgated thereunder, the aforementioned return need not be filed and no advance payment must be paid. Capital gain is also reportable on the annual income tax return. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Dividends </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We have never paid cash dividends. A distribution of a dividend by our company from income attributed to a Benefited Enterprise will generally be subject to withholding tax in Israel at a rate of 15% unless a reduced tax rate is provided under an applicable tax treaty. A distribution of a dividend by our company from income attributed to a Preferred Enterprise will generally be subject to withholding tax in Israel at the following tax rates: Israeli resident individuals &#8212; 20% with respect to dividends to be distributed as of 2017; Israeli resident companies &#8212; 0% for a Preferred Enterprise; Non-Israeli residents &#8212; 20% with respect to dividends to be distributed as of 2017, subject to a reduced rate under the provisions of any applicable double tax treaty. A distribution of dividends from income, which is not attributed to a Preferred Enterprise to an Israeli resident individual, will generally be subject to withholding tax at a rate of 25%, or 30% if the dividend recipient is a &#8220;Controlling Shareholder&#8221; (as defined above) at the time of distribution or at any time during the preceding 12-month period. If the recipient of the dividend is an Israeli resident corporation, such dividend will not be subject to Israeli tax provided the income from which such dividend is distributed was derived or accrued within Israel. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">157</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The Israeli Tax Ordinance provides that a non-Israeli resident (either individual or corporation) is generally subject to Israeli withholding tax on the receipt of dividends at the rate of 25% (30% if the dividends recipient is a &#8220;Controlling Shareholder&#8221; (as defined above), at the time of distribution or at any time during the preceding 12-month period); those rates may be subject to a reduced rate under the provisions of an applicable double tax treaty. Under the U.S.-Israel Double Tax Treaty, the following withholding rates will apply in respect of dividends distributed by an Israeli resident company to a U.S. resident: (i) if the U.S. resident is a corporation which holds during that portion of the taxable year which precedes the date of payment of the dividend and during the whole of its prior taxable year (if any), at least 10% of the outstanding shares of the voting share capital of the Israeli resident paying corporation and not more than 25% of the gross income of the Israeli resident paying corporation for such prior taxable year (if any) consists of certain type of interest or dividends &#8212; the rate is 12.5%, (ii) if both the conditions mentioned in clause (i) above are met and the dividend is paid from an Israeli resident company&#8217;s income which was entitled to a reduced tax rate applicable to an Approved Enterprise &#8212; the rate is 15% and (iii)&#160;in all other cases, the rate is 25%. The aforementioned rates under the Israel U.S. Double Tax Treaty will not apply if the dividend income was derived through a permanent establishment of the U.S. resident in Israel. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">A non-Israeli resident who receives dividends from which tax was withheld is generally exempt from the obligation to file tax returns in Israel with respect to such income, provided that (i) such income was not generated from a business conducted in Israel by the taxpayer, and (ii) the taxpayer has no other taxable sources of income in Israel with respect to which a tax return is required to be filed. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Dividends are generally subject to Israeli withholding tax at a rate of 25% so long as the shares are registered with a nominee company (whether or not the recipient is a &#8220;Controlling Shareholder,&#8221; as defined above), unless relief is provided in a treaty between Israel and the shareholder&#8217;s country of residence and provided that a certificate from the Israel Tax Authority allowing for a reduced withholding tax rate is obtained in advance. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Excess Tax </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Individuals who are subject to tax in Israel are also subject to an additional tax at a rate of 3% in 2017 and thereafter on annual income exceeding NIS 640,000 for 2017 and thereafter, linked to the annual change in the Israeli consumer price index, including, but not limited to income derived from, dividends, interest and capital gains. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Foreign Exchange Regulations </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Non-residents of Israel who hold our ordinary shares are able to receive any dividends, and any amounts payable upon the dissolution, liquidation and winding up of our affairs, repayable in non-Israeli currency at the rate of exchange prevailing at the time of conversion. However, Israeli income tax is generally required to have been paid or withheld on these amounts. In addition, the statutory framework for the potential imposition of currency exchange control has not been eliminated, and may be restored at any time by administrative action. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Estate and Gift Tax </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">Israeli law presently does not impose estate or gift taxes. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">U.S. Federal Income Tax Consequences </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The following discussion describes certain material U.S. federal income tax consequences to U.S. Holders (as defined below) under present law of an investment in our ordinary shares. This discussion applies only to U.S. Holders that hold our ordinary shares as capital assets within the meaning of Section 1221 of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;), that have acquired their ordinary shares in this offering and that have the U.S. dollar as their functional currency. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">158</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">This discussion is based on the tax laws of the United States, including the Code, as in effect on the date hereof and on U.S. Treasury regulations as in effect or, in some cases, as proposed, on the date hereof, as well as judicial and administrative interpretations thereof available on or before such date. All of the foregoing authorities are subject to change, which change could apply retroactively and could affect the tax consequences described below. This summary does not address any estate or gift tax consequences, the alternative minimum tax, the Medicare tax on net investment income or any state, local, or non-U.S. tax consequences. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The following discussion neither deals with the tax consequences to any particular investor nor describes all of the tax consequences applicable to persons in special tax situations such as: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">banks; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">certain financial institutions; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">insurance companies; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">regulated investment companies; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">real estate investment trusts; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">broker-dealers; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">traders that elect to mark to market; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">U.S. expatriates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">tax-exempt entities; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">persons holding our ordinary shares as part of a straddle, hedging, constructive sale, conversion or integrated transaction; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">persons that actually or constructively own 10% or more of the total combined voting power of all classes of our voting share capital; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">persons that are resident or ordinarily resident in or have a permanent establishment in a jurisdiction outside the United States; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">persons who acquired our ordinary shares pursuant to the exercise of any employee share option or otherwise as compensation; or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">pass-through entities, or persons holding our ordinary shares through pass-through entities. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">INVESTORS ARE URGED TO CONSULT THEIR TAX ADVISORS ABOUT THE APPLICATION OF THE U.S. FEDERAL TAX RULES TO THEIR PARTICULAR CIRCUMSTANCES AS WELL AS THE STATE, LOCAL, NON-U.S. AND OTHER TAX CONSEQUENCES TO THEM OF THE PURCHASE, OWNERSHIP AND DISPOSITION OF OUR ORDINARY SHARES. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The discussion below of the U.S. federal income tax consequences to &#8220;U.S. Holders&#8221; will apply to you if you are the beneficial owner of our ordinary shares and you are, for U.S. federal income tax purposes, </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">an individual who is a citizen or resident of the United States; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a corporation (or other entity taxable as a corporation for U.S. federal income tax purposes) created or organized in the United States or under the laws of the United States, any state thereof or the District of Columbia; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">an estate, the income of which is subject to U.S. federal income taxation regardless of its source; or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">159</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a trust that (1) is subject to the primary supervision of a court within the United States and the control of one or more U.S. persons for all substantial decisions or (2) has a valid election in effect under applicable U.S. Treasury regulations to be treated as a U.S. person. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">If an entity or other arrangement treated as a partnership for U.S. federal income tax purposes holds our ordinary shares, the tax treatment of a partner will generally depend upon the status of the partner and the activities of the partnership. A person that would be a U.S. Holder if it held our ordinary shares directly and that is a partner of a partnership holding our ordinary shares is urged to consult its own tax advisor. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Passive Foreign Investment Company </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Based on our anticipated income and the composition of our income and assets, we expect to be a passive foreign investment company (&#8220;PFIC&#8221;) for U.S. federal income tax purposes at least until we start generating a substantial amount of active revenue. A non-U.S. entity treated as a corporation for U.S. federal income tax purposes will generally be a PFIC for U.S. federal income tax purposes for any taxable year if either: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">at least 75% of its gross income for such year is passive income (such as interest income); or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">at least 50% of the value of its assets (based on an average of the quarterly values of the assets) during such year is attributable to assets that produce passive income or are held for the production of passive income. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">For this purpose, we will be treated as owning our proportionate share of the assets and earning our proportionate share of the income of any other entity treated as a corporation for U.S. federal income tax purposes in which we own, directly or indirectly, 25% or more (by value) of the stock. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">A separate determination must be made after the close of each taxable year as to whether we were a PFIC for that year. Because the value of our assets for purposes of the PFIC test will generally be determined by reference to the market price of our ordinary shares, our PFIC status may depend in part on the market price of our ordinary shares, which may fluctuate significantly. In addition, there may be certain ambiguities in applying the PFIC test to us. No rulings from the U.S. Internal Revenue Service (the &#8220;IRS&#8221;), however, have been or will be sought with respect to our status as a PFIC. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">If we are a PFIC for any taxable year during which you hold our ordinary shares, we generally will continue to be treated as a PFIC with respect to your investment in our ordinary shares for all succeeding years during which you hold our ordinary shares, unless we cease to be a PFIC and you make a &#8220;deemed sale&#8221; election with respect to our ordinary shares. If such election is made, you will be deemed to have sold our ordinary shares you hold at their fair market value on the last day of the last taxable year in which we were a PFIC, and any gain from such deemed sale would be subject to the consequences described below. After the deemed sale election, your ordinary shares with respect to which the deemed sale election was made will not be treated as shares in a PFIC unless we subsequently become a PFIC. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">For each taxable year that we are treated as a PFIC with respect to you, you will be subject to special tax rules with respect to any &#8220;excess distribution&#8221; (as defined below) you receive and any gain you realize from a sale or other disposition (including a pledge) of our ordinary shares, unless you make a valid &#8220;mark-to-market&#8221; election as discussed below. Distributions you receive in a taxable year that are greater than 125% of the average annual distributions you received during the shorter of the three preceding taxable years or your holding period for our ordinary shares will be treated as an excess distribution. Under these special tax rules: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the excess distribution or gain will be allocated ratably over your holding period for our ordinary shares; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">160</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the amount allocated to the current taxable year, and any taxable years in your holding period prior to the first taxable year in which we were a PFIC, will be treated as ordinary income; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.02pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:4.02pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the amount allocated to each other taxable year will be subject to the highest tax rate in effect for individuals or corporations, as applicable, for each such year and the interest charge generally applicable to underpayments of tax will be imposed on the resulting tax attributable to each such year. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The tax liability for amounts allocated to taxable years prior to the year of disposition or excess distribution cannot be offset by any net operating losses, and gains (but not losses) realized on the sale of our ordinary shares cannot be treated as capital gains, even if you hold our ordinary shares as capital assets. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">If we are treated as a PFIC with respect to you for any taxable year, to the extent any of our subsidiaries are also PFICs, you may be deemed to own shares in such lower-tier PFICs that are directly or indirectly owned by us in that proportion which the value of our ordinary shares you own bears to the value of all of our ordinary shares, and you may be subject to the adverse tax consequences described above with respect to the shares of such lower-tier PFICs you would be deemed to own. As a result, you may incur liability for any excess distribution described above if we receive a distribution from our lower-tier PFICs or if any shares in such lower-tier PFICs are disposed of&#8201; (or deemed disposed of). You should consult your tax advisor regarding the application of the PFIC rules to any of our subsidiaries. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">A U.S. Holder of&#8201; &#8220;marketable stock&#8221; (as defined below) in a PFIC may make a mark-to-market election for such stock to elect out of the tax treatment discussed above. If you make a valid mark-to-market election for our ordinary shares, you will include in income for each year that we are treated as a PFIC with respect to you an amount equal to the excess, if any, of the fair market value of our ordinary shares as of the close of your taxable year over your adjusted basis in such ordinary shares. You will be allowed a deduction for the excess, if any, of the adjusted basis of our ordinary shares over their fair market value as of the close of the taxable year. However, deductions will be allowable only to the extent of any net mark-to-market gains on our ordinary shares included in your income for prior taxable years. Amounts included in your income under a mark-to-market election, as well as gain on the actual sale or other disposition of our ordinary shares, will be treated as ordinary income. Ordinary loss treatment will also apply to the deductible portion of any mark-to-market loss on our ordinary shares, as well as to any loss realized on the actual sale or disposition of our ordinary shares, to the extent the amount of such loss does not exceed the net mark-to-market gains for such ordinary shares previously included in income. Your basis in our ordinary shares will be adjusted to reflect any such income or loss amounts. If you make a mark-to-market election, any distributions we make would generally be subject to the rules discussed below under &#8220;&#8212; Taxation of dividends and other distributions on our ordinary shares,&#8221; except the lower rates applicable to qualified dividend income would not apply. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The mark-to-market election is available only for &#8220;marketable stock,&#8221; which is stock that is regularly traded on a qualified exchange or other market, as defined in applicable U.S. Treasury regulations. We expect our ordinary shares will be listed on NASDAQ. Because a mark-to-market election cannot be made for equity interests in any lower-tier PFICs we own, you generally will continue to be subject to the PFIC rules with respect to your indirect interest in any investments held by us that are treated as an equity interest in a PFIC for U.S. federal income tax purposes. NASDAQ is a qualified exchange, but there can be no assurance that the trading in our ordinary shares will be sufficiently regular to qualify our ordinary shares as marketable stock. You should consult your tax advisor as to the availability and desirability of a mark-to-market election, as well as the impact of such election on interests in any lower-tier PFICs. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Alternatively, if a non-U.S. entity treated as a corporation is a PFIC, a holder of shares in that entity may avoid taxation under the PFIC rules described above regarding excess distributions and recognized gains by making a &#8220;qualified electing fund&#8221; election to include in income its share of </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">161</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">the entity&#8217;s income on a current basis. However, you may make a qualified electing fund election with respect to your ordinary shares only if we furnish you annually with certain tax information, and we currently do not intend to prepare or provide such information. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">A U.S. Holder of a PFIC may be required to file an IRS Form 8621. If we are a PFIC, you should consult your tax advisor regarding any reporting requirements that may apply to you. You are urged to consult your tax advisor regarding the application of the PFIC rules to the acquisition, ownership and disposition of our ordinary shares. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">YOU ARE STRONGLY URGED TO CONSULT YOUR TAX ADVISOR REGARDING THE IMPACT OF OUR BEING A PFIC ON YOUR INVESTMENT IN OUR ORDINARY SHARES AS WELL AS THE APPLICATION OF THE PFIC RULES AND THE POSSIBILITY OF MAKING A MARK-TO-MARKET ELECTION. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Taxation of Dividends and Other Distributions on our Ordinary Shares </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Subject to the PFIC rules discussed above, the gross amount of any distributions we make to you (including the amount of any tax withheld) with respect to our ordinary shares generally will be includible in your gross income as dividend income on the date of receipt by the holder, but only to the extent the distribution is paid out of our current or accumulated earnings and profits (as determined under U.S. federal income tax principles). The dividends will not be eligible for the dividends-received deduction allowed to corporations in respect of dividends received from other U.S. corporations. To the extent the amount of the distribution exceeds our current and accumulated earnings and profits (as determined under U.S. federal income tax principles), such excess amount will be treated first as a tax-free return of your tax basis in your ordinary shares, and then, to the extent such excess amount exceeds your tax basis in your ordinary shares, as capital gain. We currently do not, and we do not intend to, calculate our earnings and profits under U.S. federal income tax principles. Therefore, you should expect that a distribution will generally be reported as a dividend even if that distribution would otherwise be treated as a non-taxable return of capital or as capital gain under the rules described above. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">With respect to certain non-corporate U.S. Holders, including individual U.S. Holders, dividends may be taxed at the lower capital gain rates applicable to &#8220;qualified dividend income,&#8221; provided (1) our ordinary shares are readily tradable on an established securities market in the United States (such as NASDAQ), (2) we are neither a PFIC nor treated as such with respect to you (as discussed above) for either the taxable year in which the dividend was paid or the preceding taxable year, (3) certain holding period requirements are met and (4) you are not under an obligation to make related payments with respect to positions in substantially similar or related property. As discussed above under &#8220;Passive foreign investment company,&#8221; there is a significant risk that we will be a PFIC for U.S. federal income tax purposes, and, as a result, the qualified dividend rate may be unavailable with respect to dividends we pay. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The amount of any distribution paid in a currency other than U.S. dollars will be equal to the U.S. dollar value of such currency on the date such distribution is includible in your income, regardless of whether the payment is in fact converted into U.S. dollars at that time. The amount of any distribution of property other than cash will be the fair market value of such property on the date of distribution. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Any dividends will constitute foreign source income for foreign tax credit limitation purposes. If the dividends are taxed as qualified dividend income (as discussed above), the amount of the dividend taken into account for purposes of calculating the foreign tax credit limitation will in general be limited to the gross amount of the dividend, multiplied by the reduced tax rate applicable to qualified dividend income and divided by the highest tax rate normally applicable to dividends. The limitation on foreign taxes eligible for credit is calculated separately with respect to specific classes of income. For this purpose, dividends distributed by us with respect to our ordinary shares will generally constitute &#8220;passive category income&#8221; but could, in the case of certain U.S. Holders, constitute &#8220;general category income.&#8221; </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">162</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">If Israeli withholding taxes apply to any dividends paid to you with respect to our ordinary shares, subject to certain conditions and limitations, such withholding taxes may be treated as foreign taxes eligible for credit against your U.S. federal income tax liability. Instead of claiming a credit, you may elect to deduct such taxes in computing taxable income, subject to applicable limitations. If a refund of the tax withheld is available under the applicable laws of Israel or under the Israel-U.S. income tax treaty (the &#8220;Treaty&#8221;), the amount of tax withheld that is refundable will not be eligible for such credit against your U.S. federal income tax liability (and will not be eligible for the deduction against your U.S. federal taxable income). The rules relating to the determination of the foreign tax credit are complex, and you should consult your tax advisor regarding the availability of a foreign tax credit in your particular circumstances, including the effects of the Treaty. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Taxation of Disposition of Ordinary Shares </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Subject to the PFIC rules discussed above, upon a sale or other disposition of ordinary shares, you will generally recognize capital gain or loss for U.S. federal income tax purposes in an amount equal to the difference between the amount realized (including the amount of any tax withheld) and your tax basis in such ordinary shares. If the consideration you receive for our ordinary shares is not paid in U.S. dollars, the amount realized will be the U.S. dollar value of the payment received determined by reference to the spot rate of exchange on the date of the sale or other disposition. However, if our ordinary shares are treated as traded on an &#8220;established securities market&#8221; and you are either a cash basis taxpayer or an accrual basis taxpayer that has made a special election (which must be applied consistently from year to year and cannot be changed without the consent of the IRS), you will determine the U.S. dollar value of the amount realized in a non-U.S. dollar currency by translating the amount received at the spot rate of exchange on the settlement date of the sale. If you are an accrual basis taxpayer that is not eligible to or does not elect to determine the amount realized using the spot rate on the settlement date, you will recognize foreign currency gain or loss to the extent of any difference between the U.S. dollar amount realized on the date of sale or disposition and the U.S. dollar value of the currency received at the spot rate on the settlement date. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Your tax basis in our ordinary shares generally will equal the cost of such ordinary shares. Any gain or loss on the sale or other disposition of our ordinary shares will generally be treated as U.S. source income or loss, and treated as long-term capital gain or loss if your holding period in our ordinary shares at the time of the disposition exceeds one year. Accordingly, in the event any Israeli tax (including withholding tax) is imposed upon the sale or other disposition, you may not be able to utilize foreign tax credit unless you have foreign source income or gain in the same category from other sources. Long-term capital gain of non-corporate U.S. Holders generally will be subject to U.S. federal income tax at reduced tax rates. The deductibility of capital losses is subject to significant limitations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Information Reporting and Backup Withholding </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Dividend payments with respect to ordinary shares and proceeds from the sale, exchange or redemption of ordinary shares may be subject to information reporting to the IRS and possible U.S. backup withholding. Backup withholding will not apply, however, to a U.S. Holder that furnishes a correct taxpayer identification number and makes any other required certification or that is otherwise exempt from backup withholding. U.S. Holders that are required to establish their exempt status generally must provide such certification on IRS Form W-9. You should consult your tax advisor regarding the application of the U.S. information reporting and backup withholding rules.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">163</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Backup withholding is not an additional tax. Amounts withheld as backup withholding may be credited against your U.S. federal income tax liability, and you may obtain a refund of any excess amounts withheld under the backup withholding rules by filing the appropriate claim for refund with the IRS and furnishing any required information in a timely manner. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Information with respect to Foreign Financial Assets </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Certain U.S. Holders may be required to report information relating to an interest in our ordinary shares, subject to certain exceptions (including an exception for ordinary shares held in accounts maintained by certain financial institutions). Penalties can apply if U.S. Holders fail to satisfy such reporting requirements. You should consult your tax advisor regarding the effect, if any, of this requirement on your ownership and disposition of our ordinary shares. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">THE SUMMARY OF U.S. FEDERAL INCOME TAX CONSEQUENCES SET OUT ABOVE IS FOR GENERAL INFORMATIONAL PURPOSES ONLY. INVESTORS ARE URGED TO CONSULT THEIR TAX ADVISORS ABOUT THE APPLICATION OF THE U.S. FEDERAL TAX RULES TO THEIR PARTICULAR CIRCUMSTANCES AS WELL AS THE STATE, LOCAL, NON-U.S. AND OTHER TAX CONSEQUENCES TO THEM OF THE PURCHASE, OWNERSHIP AND DISPOSITION OF OUR ORDINARY SHARES. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">164</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tUNDER">&#8203;</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;"><font style="text-transform:uppercase;">Underwriting</font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Subject to the terms and conditions set forth in the underwriting agreement, dated &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2017, among us and Jefferies LLC, 520 Madison Avenue, New York, New York 10022, and BMO Capital Markets Corp, 3 Times Square, 25th Floor, New York, New York 10036, as the representatives of the underwriters named below and the joint book-running managers of the offering, we have agreed to sell to the underwriters, and each of the underwriters has agreed, severally and not jointly, to purchase from us, the respective number of ordinary shares shown opposite its name below: </div>
        <table style="width:416pt;height:92pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:338pt;">
              <div style="white-space:nowrap;">Underwriter </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="text-align:center;">Number of <br >Ordinary Shares </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:338pt;text-align:left;">
              <div style="white-space:nowrap;">Jefferies LLC </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:39pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:338pt;text-align:left;">
              <div style="white-space:nowrap;">BMO Capital Markets Corp.</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:39pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:338pt;text-align:left;">
              <div style="white-space:nowrap;">JMP Securities LLC </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:39pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:338pt;text-align:left;">
              <div style="white-space:nowrap;">Raymond James &amp; Associates, Inc.</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.215pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:39pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:5.215pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.75pt 0pt; width:338pt;text-align:left;">
              <div style="margin-left:10pt;">Total </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.215pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:39pt; text-align:right; white-space:nowrap;">&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;</td>
            <td style="padding:0pt;padding-left:5.215pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="8">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:14.99pt; width:456pt; line-height:12pt;">The underwriting agreement provides that the obligations of the several underwriters are subject to certain conditions precedent such as the receipt by the underwriters of officers&#8217; certificates and legal opinions and approval of certain legal matters by their counsel. The underwriting agreement provides that the underwriters will purchase all of the ordinary shares if any of them are purchased. If an underwriter defaults, the underwriting agreement provides that the purchase commitments of the nondefaulting underwriters may be increased or the underwriting agreement may be terminated. We have agreed to indemnify the underwriters and certain of their controlling persons against certain liabilities, including liabilities under the Securities Act, and to contribute to payments that the underwriters may be required to make in respect of those liabilities. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The underwriters have advised us that, following the completion of this offering, they currently intend to make a market in the ordinary shares as permitted by applicable laws and regulations. However, the underwriters are not obligated to do so, and the underwriters may discontinue any market-making activities at any time without notice in their sole discretion. Accordingly, no assurance can be given as to the liquidity of the trading market for the ordinary shares, that you will be able to sell any of the ordinary shares held by you at a particular time or that the prices that you receive when you sell will be favorable. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The underwriters are offering the ordinary shares subject to their acceptance of the ordinary shares from us and subject to prior sale. The underwriters reserve the right to withdraw, cancel or modify offers to the public and to reject orders in whole or in part. In addition, the underwriters have advised us that they do not intend to confirm sales to any account over which they exercise discretionary authority. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Commission and Expenses </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The underwriters have advised us that they propose to offer the ordinary shares to the public at the initial public offering price set forth on the cover page of this prospectus and to certain dealers, which may include the underwriters, at that price less a concession not in excess of&#8201; $&#8199;&#8199;&#8199; per ordinary share. The underwriters may allow, and certain dealers may reallow, a discount from the concession not in excess of&#8201; $&#8199;&#8199;&#8199; per ordinary share to certain brokers and dealers. After the offering, the initial public offering price, concession and reallowance to dealers may be reduced by the representatives. No such reduction will change the amount of proceeds to be received by us as set forth on the cover page of this prospectus.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">165</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The following table shows the initial public offering price, the underwriting discounts and commissions that we are to pay the underwriters and the proceeds, before expenses, to us in connection with this offering. Such amounts are shown assuming both no exercise and full exercise of the underwriters&#8217; option to purchase additional ordinary shares. </div>
        <table style="width:416pt;height:119pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:206.31pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Per Ordinary Share </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Total </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:206.31pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="text-align:center;">Without <br >Option to <br >Purchase <br >Additional <br >Ordinary <br >Shares </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="text-align:center;">With <br >Option to <br >Purchase <br >Additional <br >Ordinary <br >Shares </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="text-align:center;">Without <br >Option to <br >Purchase <br >Additional <br >Ordinary <br >Shares </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="text-align:center;">With <br >Option to <br >Purchase <br >Additional <br >Ordinary <br >Shares </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:206.31pt;text-align:left;">
              <div style="white-space:nowrap;">Initial public offering price</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.43pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.43pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.43pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.43pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.43pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.43pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.43pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.43pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:206.31pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">Underwriting discounts and commissions paid by us</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.43pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.43pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.43pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.43pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.43pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.43pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.43pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.43pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.833pt 0pt; width:206.31pt;text-align:left;">
              <div style="white-space:nowrap;">Proceeds to us, before expenses </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.43pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.43pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.43pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.43pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.43pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.43pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.43pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.43pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:18.98pt; width:456pt; line-height:12pt;">We estimate expenses payable by us in connection with this offering, other than the underwriting discounts and commissions referred to above, will be approximately $&#8199;&#8199;&#8199;&#8199;&#8199;. We also have agreed to reimburse the underwriters for up to $35,000 for certain expenses incurred in connection with this offering, including for their FINRA counsel fee. In accordance with FINRA Rule 5110, these reimbursed expenses are deemed underwriting compensation for this offering. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Determination of Offering Price </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Prior to this offering, there has not been a public market for our ordinary shares. Consequently, the initial public offering price for our ordinary shares will be determined by negotiations between us and the representatives. Among the factors to be considered in these negotiations will be prevailing market conditions, our financial information, market valuations of other companies that we and the underwriters believe to be comparable to us, estimates of our business potential, the present state of our development and other factors deemed relevant. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We offer no assurances that the initial public offering price will correspond to the price at which the ordinary shares will trade in the public market subsequent to the offering or that an active trading market for the ordinary shares will develop and continue after the offering. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Listing </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We have applied to have our ordinary shares listed on the NASDAQ Global Market under the trading symbol &#8220;SLGL&#8221;.</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Stamp Taxes </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">If you purchase ordinary shares offered in this prospectus, you may be required to pay stamp taxes and other charges under the laws and practices of the country of purchase, in addition to the offering price listed on the cover page of this prospectus. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Option to Purchase Additional Ordinary Shares </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We have granted to the underwriters an option, exercisable for 30 days from the date of this prospectus, to purchase, from time to time, in whole or in part, up to an aggregate of&#8201; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ordinary shares from us at the initial public offering price set forth on the cover page of this prospectus, less underwriting discounts and commissions. If the underwriters exercise this option, each underwriter will be obligated, subject to specified conditions, to purchase a number of additional ordinary shares proportionate to that underwriter&#8217;s initial purchase commitment as indicated in the table above. This option may be exercised only if the underwriters sell more ordinary shares than the total number set forth on the cover page of this prospectus. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">166</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">No Sales of Similar Securities </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We, our officers, directors and holders of all of our outstanding share capital have agreed, subject to specified exceptions, not to directly or indirectly: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">sell, offer, contract or grant any option to sell (including any short sale), pledge, transfer, establish an open &#8220;put equivalent position&#8221; within the meaning of Rule 16a-l(h) under the Securities Exchange Act of 1934, as amended, or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">otherwise dispose of any ordinary shares, options or warrants to acquire ordinary shares, or securities exchangeable or exercisable for or convertible into ordinary shares currently or hereafter owned either of record or beneficially, or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">publicly announce an intention to do any of the foregoing for a period of 180 days after the date of this prospectus without the prior written consent of Jefferies LLC and BMO Capital Markets Corp. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">This restriction terminates after the close of trading of the ordinary shares on and including the 180<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">th</font> day after the date of this prospectus. </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">The restrictions above will not apply to certain transactions, including:</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">transfers by gift, will or operation of law;</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">transfers to certain related entities;</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the exercise or conversion of options or convertible notes;</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the establishment of 10b5-1 trading plans, provided no sales can occur during the 180-day lock-up period;</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the transfer of ordinary shares acquired on the open market following this offering;</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the transfer of ordinary shares to the Company to satisfy tax withholding obligations in connection with the vesting or exercise of equity awards; and</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">transfers pursuant to a bona fide third-party tender offer for all outstanding shares of the Company, merger, consolidation or other similar transaction made to all holders of the Company&#8217;s securities involving a change of control of the Company. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Jefferies LLC and BMO Capital Markets Corp. may, in their sole discretion and at any time or from time to time before the termination of the 180-day period release all or any portion of the securities subject to lock-up agreements. There are no existing agreements between the underwriters and any of our shareholders who will execute a lock-up agreement, providing consent to the sale of ordinary shares prior to the expiration of the lock-up period. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Stabilization </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The underwriters have advised us that, pursuant to Regulation M under the Securities Exchange Act of 1934, as amended, certain persons participating in the offering may engage in short sale transactions, stabilizing transactions, syndicate covering transactions or the imposition of penalty bids in connection with this offering. These activities may have the effect of stabilizing or maintaining the market price of the ordinary shares at a level above that which might otherwise prevail in the open market. Establishing short sales positions may involve either &#8220;covered&#8221; short sales or &#8220;naked&#8221; short sales. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">&#8220;Covered&#8221; short sales are sales made in an amount not greater than the underwriters&#8217; option to purchase additional shares of our ordinary shares in this offering. The underwriters may close out any covered short position by either exercising their option to purchase additional ordinary shares or purchasing ordinary shares in the open market. In determining the source of ordinary shares to </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">167</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">close out the covered short position, the underwriters will consider, among other things, the price of ordinary shares available for purchase in the open market as compared to the price at which they may purchase ordinary shares through the option to purchase additional ordinary shares. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">&#8220;Naked&#8221; short sales are sales in excess of the option to purchase additional ordinary shares. The underwriters must close out any naked short position by purchasing ordinary shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the ordinary shares in the open market after pricing that could adversely affect investors who purchase in this offering. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">A stabilizing bid is a bid for the purchase of ordinary shares on behalf of the underwriters for the purpose of fixing or maintaining the price of the ordinary shares. A syndicate covering transaction is the bid for or the purchase of ordinary shares on behalf of the underwriters to reduce a short position incurred by the underwriters in connection with the offering. Similar to other purchase transactions, the underwriter&#8217;s purchases to cover the syndicate short sales may have the effect of raising or maintaining the market price of our ordinary shares or preventing or retarding a decline in the market price of our ordinary shares. As a result, the price of our ordinary shares may be higher than the price that might otherwise exist in the open market. A penalty bid is an arrangement permitting the underwriters to reclaim the selling concession otherwise accruing to a syndicate member in connection with the offering if the ordinary shares originally sold by such syndicate member are purchased in a syndicate covering transaction and therefore have not been effectively placed by such syndicate member. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Neither we, nor any of the underwriters make any representation or prediction as to the direction or magnitude of any effect that the transactions described above may have on the price of our ordinary shares. The underwriters are not obligated to engage in these activities and, if commenced, any of the activities may be discontinued at any time. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The underwriters may also engage in passive market making transactions in our ordinary shares on The NASDAQ Global Market in accordance with Rule 103 of Regulation M during a period before the commencement of offers or sales of our ordinary shares in this offering and extending through the completion of distribution. A passive market maker must display its bid at a price not in excess of the highest independent bid of that security. However, if all independent bids are lowered below the passive market maker&#8217;s bid, that bid must then be lowered when specified purchase limits are exceeded. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Electronic Distribution </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">A prospectus in electronic format may be made available by e-mail (or on the web sites) or through online services maintained by one or more of the underwriters or their affiliates. In those cases, prospective investors may view offering terms online and may be allowed to place orders online. The underwriters may agree with us to allocate a specific number of ordinary shares for sale to online brokerage account holders. Any such allocation for online distributions will be made by the underwriters on the same basis as other allocations. Other than the prospectus in electronic format, the information on the underwriters&#8217; web sites and any information contained in any other web site maintained by any of the underwriters is not part of this prospectus, has not been approved and/or endorsed by us or the underwriters and should not be relied upon by investors. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Other Activities and Relationships </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The underwriters and certain of their affiliates are full service financial institutions engaged in various activities, which may include securities trading, commercial and investment banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities. The underwriters and certain of their affiliates have, from time to time, performed, and may in the future perform, various commercial and investment banking and financial advisory services for us and our affiliates, for which they received or will receive customary fees and expenses. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">168</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In the ordinary course of their various business activities, the underwriters and certain of their affiliates may make or hold a broad array of investments and actively trade debt and equity securities (or related derivative securities) and financial instruments (including bank loans) for their own account and for the accounts of their customers, and such investment and securities activities may involve securities and/or instruments issued by us and our affiliates. If the underwriters or their respective affiliates have a lending relationship with us, they routinely hedge their credit exposure to us consistent with their customary risk management policies. The underwriters and their respective affiliates may hedge such exposure by entering into transactions which consist of either the purchase of credit default swaps or the creation of short positions in our securities or the securities of our affiliates, including potentially the ordinary shares offered hereby. Any such short positions could adversely affect future trading prices of the ordinary shares offered hereby. The underwriters and certain of their respective affiliates may also communicate independent investment recommendations, market color or trading ideas and/or publish or express independent research views in respect of such securities or instruments and may at any time hold, or recommend to clients that they acquire, long and/or short positions in such securities and instruments. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Disclaimers About Non-U.S. Jurisdictions </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Australia </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">This prospectus is not a disclosure document for the purposes of Australia&#8217;s Corporations Act 2001 (Cth) of Australia, or Corporations Act, has not been lodged with the Australian Securities &amp; Investments Commission and is only directed to the categories of exempt persons set out below. Accordingly, if you receive this prospectus in Australia: </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">You confirm and warrant that you are either: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a &#8220;sophisticated investor&#8221; under section 708(8)(a) or (b) of the Corporations Act; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a &#8220;sophisticated investor&#8221; under section 708(8)(c) or (d) of the Corporations Act and that you have provided an accountant&#8217;s certificate to the company which complies with the requirements of section 708(8)(c)(i) or (ii) of the Corporations Act and related regulations before the offer has been made; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a person associated with the Company under Section 708(12) of the Corporations Act; or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a &#8220;professional investor&#8221; within the meaning of section 708(11)(a) or (b) of the Corporations Act. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">To the extent that you are unable to confirm or warrant that you are an exempt sophisticated investor, associated person or professional investor under the Corporations Act any offer made to you under this prospectus is void and incapable of acceptance. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">You warrant and agree that you will not offer any of the shares issued to you pursuant to this prospectus for resale in Australia within 12 months of those securities being issued unless any such resale offer is exempt from the requirement to issue a disclosure document under section 708 of the Corporations Act. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">European Economic Area </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In relation to each member state of the European Economic Area which has implemented the Prospectus Directive, each referred to herein as a Relevant Member State, no offer of any securities which are the subject of the offering contemplated by this prospectus has been or will be made to the public in that Relevant Member State, except that with effect from and including the Relevant Implementation Date, an offer of such securities may be made to the public in that Relevant Member State: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">to any legal entity which is a &#8220;qualified investor&#8221; as defined in the Prospectus Directive; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">169</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">to fewer than 150, natural or legal persons (other than qualified investors as defined in the Prospectus Directive), as permitted under the Prospectus Directive, subject to obtaining the prior consent of the representatives of the underwriters for any such offer; or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">in any other circumstances falling within Article 3(2) of the Prospectus Directive, </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">provided that no such offer of securities shall require the company or any of the underwriters to publish a prospectus pursuant to Article 3 of the Prospectus Directive or supplement a prospectus pursuant to Article 16 of the Prospectus Directive. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">For the purposes of this provision, the expression &#8220;offer to the public&#8221; in relation to any securities in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and the securities to be offered so as to enable an investor to decide to purchase or subscribe the securities, as the same may be varied in that Relevant Member State by any measure implementing the Prospectus Directive in that Relevant Member State, and the expression &#8220;Prospectus Directive&#8221; means Directive 2003/71/EC (and amendments thereto, including Directive 2010/73/EU, the &#8220;2010 PD Amending Directive&#8221;), and includes any relevant implementing measure in the Relevant Member State, and the expression &#8220;2010 PD Amending Directive&#8221; means Directive 2010/73/EU. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Hong Kong </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">No securities have been offered or sold, and no securities may be offered or sold, in Hong Kong, by means of any document, other than to persons whose ordinary business is to buy or sell shares or debentures, whether as principal or agent; or to &#8220;professional investors&#8221; as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance; or in other circumstances which do not result in the document being a &#8220;prospectus&#8221; as defined in the Companies Ordinance (Cap. 32) of Hong Kong or which do not constitute an offer to the public within the meaning of the Companies Ordinance (Cap. 32) or the Securities and Futures Ordinance (Cap. 571) of Hong Kong. No document, invitation or advertisement relating to the securities has been issued or may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public of Hong Kong (except if permitted under the securities laws of Hong Kong) other than with respect to securities which are or are intended to be disposed of only to persons outside Hong Kong or only to &#8220;professional investors&#8221; as defined in the Securities and Futures Ordinance (Cap. 571) of Hong Kong and any rules made under that Ordinance. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">This prospectus has not been registered with the Registrar of Companies in Hong Kong. Accordingly, this prospectus may not be issued, circulated or distributed in Hong Kong, and the securities may not be offered for subscription to members of the public in Hong Kong. Each person acquiring the securities will be required, and is deemed by the acquisition of the securities, to confirm that he is aware of the restriction on offers of the securities described in this prospectus and the relevant offering documents and that he is not acquiring, and has not been offered any securities in circumstances that contravene any such restrictions. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Japan </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The offering has not been and will not be registered under the Financial Instruments and Exchange Law of Japan (Law No. 25 of 1948 of Japan, as amended), or FIEL, and the underwriters will not offer or sell any securities, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan (which term as used herein means, unless otherwise provided herein, any person resident in Japan, including any corporation or other entity organized under the laws of Japan), or to others for re-offering or resale, directly or indirectly, in Japan or to or for the benefit of a resident of Japan, except pursuant to an exemption from the registration requirements of, and otherwise in compliance with, the FIEL and any other applicable laws, regulations and ministerial guidelines of Japan. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">170</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Singapore </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">This prospectus has not been and will not be lodged or registered with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or the invitation for subscription or purchase of the securities may not be issued, circulated or distributed, nor may the securities be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i) to an institutional investor under Section 274 of the Securities and Futures Act, Chapter 289 of Singapore, or the SFA, (ii) to a relevant person as defined under Section 275(1), or any person pursuant to Section 275(1A) of the SFA, and in accordance with the conditions, specified in Section 275 of the SFA, or (iii) otherwise pursuant to, and in accordance with the conditions of any other applicable provision of the SFA. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Where the securities are subscribed or purchased under Section 275 of the SFA by a relevant person which is: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a corporation (which is not an accredited investor as defined under Section 4A of the SFA) the sole business of which is to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor; or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary is an individual who is an accredited investor, </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">securities (as defined in Section 239(1) of the SFA) of that corporation or the beneficiaries&#8217; rights and interest (howsoever described) in that trust shall not be transferred for six months after that corporation or that trust has acquired the securities pursuant to an offer made under Section 275 of the SFA except: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">to an institutional investor under Section 274 of the SFA or to a relevant person defined in Section 275(2) of the SFA, or to any person pursuant to an offer referred to in Section 275(1A) or Section 276(4)(i)(B) of the SFA; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">where no consideration is given for the transfer; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">where the transfer is by operation of law; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">as specified in Section 276(7) of the SFA; or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">as specified in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Switzerland </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The securities may not be publicly offered in Switzerland and will not be listed on the SIX Swiss Exchange, or SIX, or on any other stock exchange or regulated trading facility in Switzerland. This prospectus has been prepared without regard to the disclosure standards for issuance prospectuses under art. 652a or art. 1156 of the Swiss Code of Obligations or the disclosure standards for listing prospectuses under art. 27 ff. of the SIX Listing Rules or the listing rules of any other stock exchange or regulated trading facility in Switzerland. Neither this prospectus nor any other offering or marketing material relating to the securities or the offering may be publicly distributed or otherwise made publicly available in Switzerland. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Neither this prospectus nor any other offering or marketing material relating to the offering, the company or the securities have been or will be filed with or approved by any Swiss regulatory authority. In particular, this prospectus will not be filed with, and the offer of securities will not be supervised by, the Swiss Financial Market Supervisory Authority FINMA, or FINMA, and the offer of securities has not been and will not be authorized under the Swiss Federal Act on Collective Investment Schemes, or CISA. The investor protection afforded to acquirers of interests in collective investment schemes under the CISA does not extend to acquirers of securities. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">171</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">United Kingdom </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">This prospectus is only being distributed to, and is only directed at, persons in the United Kingdom that are qualified investors within the meaning of Article 2(1)(e) of the Prospectus Directive that are also (i) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended, referred to herein as the Order, and/or (ii) high net worth entities falling within Article 49(2)(a) to (d) of the Order and other persons to whom it may lawfully be communicated. Each such person is referred to herein as a Relevant Person. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">This prospectus and its contents are confidential and should not be distributed, published or reproduced (in whole or in part) or disclosed by recipients to any other persons in the United Kingdom. Any person in the United Kingdom that is not a Relevant Person should not act or rely on this document or any of its contents. Any investment or investment activity to which this prospectus relates is available only to Relevant Persons and will be engaged in only with Relevant Persons. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Israel </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">This document does not constitute a prospectus under the Israeli Securities Law, 5728-1968, or the Securities Law, and has not been filed with or approved by the Israel Securities Authority. In the State of Israel, this document is being distributed only to, and is directed only at, and any offer of the ordinary shares is directed only at, (i) a limited number of persons in accordance with the Securities Law and (ii) investors listed in the first addendum, or the Addendum, to the Israeli Securities Law, consisting primarily of joint investment in trust funds, provident funds, insurance companies, banks, portfolio managers, investment advisors, members of the Tel Aviv Stock Exchange, underwriters, venture capital funds, entities with equity in excess of NIS 50 million and &#8220;qualified individuals,&#8221; each as defined in the Addendum (as it may be amended from time to time), collectively referred to as qualified investors (in each case purchasing for their own account or, where permitted under the Addendum, for the accounts of their clients who are investors listed in the Addendum). Qualified investors will be required to submit written confirmation that they fall within the scope of the Addendum, are aware of the meaning of same and agree to it. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Canada </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">(A)&nbsp;&nbsp;&nbsp;Resale Restrictions </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The distribution of ordinary shares in Canada is being made only in the provinces of Ontario, Quebec, Alberta and British Columbia on a private placement basis exempt from the requirement that we prepare and file a prospectus with the securities regulatory authorities in each province where trades of these securities are made. Any resale of the ordinary shares in Canada must be made under applicable securities laws which may vary depending on the relevant jurisdiction, and which may require resales to be made under available statutory exemptions or under a discretionary exemption granted by the applicable Canadian securities regulatory authority. Purchasers are advised to seek legal advice prior to any resale of the securities. </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">(B)&nbsp;&nbsp;&nbsp;Representations of Canadian Purchasers </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">By purchasing ordinary shares in Canada and accepting delivery of a purchase confirmation, a purchaser is representing to us and the dealer from whom the purchase confirmation is received that: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the purchaser is entitled under applicable provincial securities laws to purchase the ordinary shares without the benefit of a prospectus qualified under those securities laws as it is an &#8220;accredited investor&#8221; as defined under National Instrument 45-106&#8201;&#8212;&#8201; <font style="font-style:italic;">Prospectus Exemptions</font>, </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">172</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the purchaser is a &#8220;permitted client&#8221; as defined in National Instrument 31-103&#8201;&#8212;&#8201; <font style="font-style:italic;">Registration Requirements, Exemptions and Ongoing Registrant Obligations</font>, </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">where required by law, the purchaser is purchasing as principal and not as agent, and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the purchaser has reviewed the text above under Resale Restrictions. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">(C)&nbsp;&nbsp;&nbsp;Conflicts of Interest</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Canadian purchasers are hereby notified that each of the underwriters are relying on the exemption set out in section 3A.3 or 3A.4, if applicable, of National Instrument 33-105&#8201;&#8212;&#8201; <font style="font-style:italic;">Underwriting Conflicts</font> from having to provide certain conflict of interest disclosure in this document. </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">(D)&nbsp;&nbsp;&nbsp;Statutory Rights of Action</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Securities legislation in certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if the prospectus (including any amendment thereto) such as this document contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#8217;s province or territory. The purchaser of these securities in Canada should refer to any applicable provisions of the securities legislation of the purchaser&#8217;s province or territory for particulars of these rights or consult with a legal advisor. </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">(E)&nbsp;&nbsp;&nbsp;Enforcement of Legal Rights</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">All of our directors and officers as well as the experts named herein may be located outside of Canada and, as a result, it may not be possible for Canadian purchasers to effect service of process within Canada upon us or those persons. All or a substantial portion of our assets and the assets of those persons may be located outside of Canada and, as a result, it may not be possible to satisfy a judgment against us or those persons in Canada or to enforce a judgment obtained in Canadian courts against us or those persons outside of Canada. </div>
        <div style="margin-top:8pt; width:456pt; line-height:12pt;">(F)&nbsp;&nbsp;&nbsp;Taxation and Eligibility for Investment</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Canadian purchasers of ordinary shares should consult their own legal and tax advisors with respect to the tax consequences of an investment in the ordinary shares in their particular circumstances and about the eligibility of the ordinary shares for investment by the purchaser under relevant Canadian legislation.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">173</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tEO">&#8203;</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;"><font style="text-transform:uppercase;">Expenses Related to Offering</font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The following table sets forth the costs and expenses, other than underwriting discounts and commissions, payable by us in connection with the offer and sale of ordinary shares in this offering. All amounts listed below are estimates except the SEC registration fee, NASDAQ listing fee and the Financial Industry Regulatory Authority, Inc., or FINRA, filing fee. </div>
        <table style="width:456pt;height:144pt;margin-top:10pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:378pt;">
              <div style="white-space:nowrap;">Itemized expense </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Amount </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:378pt;text-align:left;">
              <div style="white-space:nowrap;">SEC registration fee </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">9,996</td>
            <td style="padding:0pt;padding-left:14.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:378pt;text-align:left;">
              <div style="white-space:nowrap;">FINRA filing fee  </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">13,438</td>
            <td style="padding:0pt;padding-left:14.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:378pt;text-align:left;">
              <div style="white-space:nowrap;">NASDAQ Global Market listing fee  </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">25,000</td>
            <td style="padding:0pt;padding-left:14.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:378pt;text-align:left;">
              <div style="white-space:nowrap;">Printing and engraving expenses  </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:14.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:378pt;text-align:left;">
              <div style="white-space:nowrap;">Legal fees and expenses  </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:14.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:378pt;text-align:left;">
              <div style="white-space:nowrap;">Transfer agent and registrar fees  </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:14.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:378pt;text-align:left;">
              <div style="white-space:nowrap;">Accounting fees and expenses  </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:14.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:378pt;text-align:left;">
              <div style="white-space:nowrap;">Miscellaneous </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.94pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:14.94pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.75pt 0pt; width:378pt;text-align:left;">
              <div style="white-space:nowrap;">Total </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">*</td>
            <td style="padding:0pt;padding-left:14.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="8">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.49pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-size:8pt;">*<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:10pt; text-align:left; width:435.5pt;font-size:8pt;">To be filed by amendment.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">174</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tLM">&#8203;</a><a name="tEXP">&#8203;</a><a name="tECL">&#8203;</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;"><font style="text-transform:uppercase;">Legal Matters</font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The validity of the ordinary shares being offered by this prospectus and other legal matters concerning this offering relating to Israeli law will be passed upon for us by Gross, Kleinhendler, Hodak, Halevy, Greenberg &amp; Co., Tel-Aviv, Israel. Certain legal matters in connection with this offering relating to U.S. federal law will be passed upon for us by Latham &amp; Watkins LLP, New York, New York. Legal counsel to the underwriters are Gornitzky &amp; Co., Tel Aviv, Israel, with respect to Israeli law, and Covington &amp; Burling LLP, New York, New York, with respect to U.S. law. </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;"><font style="text-transform:uppercase;">Experts</font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The financial statements as of December&#160;31, 2016 and 2015 and for each of the two years in the period ended December&#160;31, 2016 included in this prospectus have been so included in reliance on the report (which contains an explanatory paragraph relating to the Company&#8217;s ability to continue as a going concern as described in Note 1 to the financial statements) of Kesselman and Kesselman, an independent registered public accounting firm and member firm of PricewaterhouseCoopers International Limited, given on the authority of said firm as experts in auditing and accounting. The offices of Kesselman and Kesselman are located at Trade Tower, 25 Hamered Street, Tel Aviv 68125, Israel. </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;"><font style="text-transform:uppercase;">Enforceability of Civil Liabilities</font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We are incorporated under the laws of the State of Israel. Service of process upon us and upon our directors and officers and the Israeli experts named in this prospectus, substantially all of whom reside outside the United States, may be difficult to obtain within the United States. Furthermore, because substantially all of our assets and substantially all of our directors and officers are located outside the United States, any judgment obtained in the United States against us or any of our directors and officers may not be collectible within the United States. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We have irrevocably appointed Cogency Global Inc. as our agent to receive service of process in any action against us in any U.S. federal or state court arising out of this offering or any purchase or sale of securities in connection with this offering. The address of our agent is 10&#160;East&#160;40<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">th</font> Street, 10<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">th</font> floor, New York, New York 10016. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We have been informed by our legal counsel in Israel, Gross, Kleinhendler, Hodak, Halevy, Greenberg &amp; Co., that it may be difficult to initiate an action with respect to U.S. securities law in Israel. Israeli courts may refuse to hear a claim based on an alleged violation of U.S. securities laws reasoning that Israel is not the most appropriate forum to hear such a claim. In addition, even if an Israeli court agrees to hear a claim, it may determine that Israeli law and not U.S. law is applicable to the claim. If U.S. law is found to be applicable, the content of applicable U.S. law must be proved as a fact by expert witnesses which can be a time-consuming and costly process. Certain matters of procedure may also be governed by Israeli law. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Subject to certain time limitations and legal procedures, Israeli courts may enforce a U.S. judgment in a civil matter which, subject to certain exceptions, is non-appealable, including judgments based upon the civil liability provisions of the Securities Act and the Exchange Act and including a monetary or compensatory judgment in a non-civil matter, provided that: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the judgment was rendered by a court which was, according to the laws of the state of the court, competent to render the judgment; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the obligation imposed by the judgment is enforceable according to the rules relating to the enforceability of judgments in Israel and the substance of the judgment is not contrary to public policy; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the judgment is executory in the state in which it was given.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">175</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Even if these conditions are met, an Israeli court will not declare a foreign civil judgment enforceable if: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the judgment was given in a state whose laws do not provide for the enforcement of judgments of Israeli courts (subject to exceptional cases); </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the enforcement of the judgment is likely to prejudice the sovereignty or security of the State of Israel; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the judgment was obtained by fraud; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the opportunity given to the defendant to bring its arguments and evidence before the court was not reasonable in the opinion of the Israeli court; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the judgment was rendered by a court not competent to render it according to the laws of private international law as they apply in Israel; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the judgment is contradictory to another judgment that was given in the same matter between the same parties and that is still valid; or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">at the time the action was brought in the foreign court, a lawsuit in the same matter and between the same parties was pending before a court or tribunal in Israel. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">If a foreign judgment is enforced by an Israeli court, it generally will be payable in Israeli currency, which can then be converted into non-Israeli currency and transferred out of Israel. The usual practice in an action before an Israeli court to recover an amount in a non-Israeli currency is for the Israeli court to issue a judgment for the equivalent amount in Israeli currency at the rate of exchange in force on the date of the judgment, but the judgment debtor may make payment in foreign currency. Pending collection, the amount of the judgment of an Israeli court stated in Israeli currency ordinarily will be linked to the Israeli consumer price index plus interest at the annual statutory rate set by Israeli regulations prevailing at the time. Judgment creditors must bear the risk of unfavorable exchange rates.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">176</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tWYCFAI">&#8203;</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;"><font style="text-transform:uppercase;">Where You Can Find Additional Information</font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We have filed with the SEC a registration statement on Form F-1 under the Securities Act relating to this offering of our ordinary shares. This prospectus does not contain all of the information contained in the registration statement. The rules and regulations of the SEC allow us to omit certain information from this prospectus that is included in the registration statement. Statements made in this prospectus concerning the contents of any contract, agreement or other document are summaries of all material information about the documents summarized, but are not complete descriptions of all terms of these documents. If we filed any of these documents as an exhibit to the registration statement, you may read the document itself for a complete description of its terms. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">You may read and copy the registration statement, including the related exhibits and schedules, and any document we file with the SEC without charge at the SEC&#8217;s public reference room at 100 F Street, N.E., Room 1580, Washington, D.C. 20549. You may also obtain copies of the documents at prescribed rates by writing to the Public Reference Section of the SEC at 100 F Street, N.E., Washington, D.C. 20549. Please call the SEC at 1-800-SEC-0330 for further information on the public reference room. The SEC also maintains an Internet site that contains reports and other information regarding issuers that file electronically with the SEC. Our filings with the SEC are also available to the public through this web site at http://www.sec.gov. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We are not currently subject to the informational requirements of the Exchange Act. As a result of this offering, we will become subject to the informational requirements of the Exchange Act applicable to foreign private issuers and will fulfill the obligations of these requirements by filing reports with the SEC. As a foreign private issuer, we will be exempt from the rules under the Exchange Act relating to the furnishing and content of proxy statements, and our officers, directors and principal shareholders will be exempt from the reporting and short-swing profit recovery provisions contained in Section 16 of the Exchange Act. In addition, we will not be required under the Exchange Act to file periodic reports and financial statements with the SEC as frequently or as promptly as U.S. companies whose securities are registered under the Exchange Act. However, we intend to file with the SEC, within 120 days after the end of our fiscal year, an annual report on Form 20-F containing financial statements which will be audited and reported on, with an opinion expressed, by an independent registered public accounting firm. We also intend to file with the SEC reports on Form 6-K containing unaudited financial information for the first three quarters of each fiscal year. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">We maintain a corporate website at www.sol-gel.com. Information contained on, or that can be accessed through, our website does not constitute a part of this prospectus. We have included our website address in this prospectus solely as an inactive textual reference. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">177</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC2">&#8203;</a><a name="tIFS">&#8203;</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Index to Financial Statements </div>
        <table style="width:456pt;height:233.5pt;margin-top:25pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:423.45pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:20.55pt;text-align:center;">
              <div style="white-space:nowrap; text-align:center;">Page </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:423.45pt;">
              <div style="white-space:nowrap;font-weight:bold;"><a href="#ftRIRPAF">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:20.55pt;text-align:center;">
              <div style="text-align:center;"><a href="#ftRIRPAF">F-2</a></div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:9.5pt 0pt 1.5pt 0pt; width:423.45pt;">AUDITED FINANCIAL STATEMENTS:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:423.45pt;">
              <div style="margin-left:10pt;"><a href="#ftBS">Balance Sheets </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:20.55pt;text-align:center;">
              <div style="text-align:center;"><a href="#ftBS">F-3</a></div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:423.45pt;">
              <div style="margin-left:10pt;"><a href="#ftSO">Statements of Operations </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:20.55pt;text-align:center;">
              <div style="text-align:center;"><a href="#ftSO">F-4</a></div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:423.45pt;">
              <div style="margin-left:10pt;"><a href="#ftSCSE">Statements of Changes in Capital Deficiency </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:20.55pt;text-align:center;">
              <div style="text-align:center;"><a href="#ftSCSE">F-5</a></div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:423.45pt;">
              <div style="margin-left:10pt;"><a href="#ftSCF">Statements of Cash Flows </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:20.55pt;text-align:center;">
              <div style="text-align:center;"><a href="#ftSCF">F-6</a></div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:423.45pt;">
              <div style="margin-left:10pt;"><a href="#ftNCFS1">Notes to the Financial Statements </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:20.55pt;text-align:center;">
              <div style="text-align:center;"><a href="#ftNCFS1">F-7</a></div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:27.5pt 0pt 1.5pt 0pt; width:423.45pt;">UNAUDITED CONDENSED FINANCIAL STATEMENTS:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:423.45pt;">
              <div style="margin-left:10pt;"><a href="#ft2BS">Balance Sheets </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:20.55pt;text-align:center;">
              <div style="text-align:center;"><a href="#ft2BS">F-22</a></div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:423.45pt;">
              <div style="margin-left:10pt;"><a href="#ft2SO">Statements of Operations </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:20.55pt;text-align:center;">
              <div style="text-align:center;"><a href="#ft2SO">F-23</a></div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:423.45pt;">
              <div style="margin-left:10pt;"><a href="#ft2SCSE">Statements of Changes in Capital Deficiency </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:20.55pt;text-align:center;">
              <div style="text-align:center;"><a href="#ft2SCSE">F-24</a></div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:423.45pt;">
              <div style="margin-left:10pt;"><a href="#ft2SCF">Statements of Cash Flows </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:20.55pt;text-align:center;">
              <div style="text-align:center;"><a href="#ft2SCF">F-25</a></div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:423.45pt;">
              <div style="margin-left:10pt;"><a href="#ft2NCFS1">Notes to the Financial Statements </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:20.55pt;text-align:center;">
              <div style="text-align:center;"><a href="#ft2NCFS1">F-26</a></div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-1</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;min-height:689.11pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="ftRIRPAF">&#8203;</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:8pt; width:456pt;">
          <img src="lg_pwc.jpg" align="middle" alt="[MISSING IMAGE: lg_pwc.jpg]" height="49" width="64" >&#8201;</div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </div>
        <div style="margin-top:8pt; text-align:center; width:456pt; line-height:12pt;">To the shareholders of </div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">SOL-GEL TECHNOLOGIES LTD. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In our opinion, the accompanying balance sheets and the related statements of operations, changes in capital deficiency and cash flows present fairly, in all material respects, the financial position of Sol-Gel Technologies Ltd. As of December&#160;31, 2016 and 2015, and the results of its operations and its cash flows for each of the two years in the period ended December&#160;31, 2016 in conformity with accounting principles generally accepted in the United States of America. These financial statements are the responsibility of the Company&#8217;s Board of Directors and management. Our responsibility is to express an opinion on these financial statements based on our audits. We conducted our audits of these financial statements in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by the Board of Directors and management, and evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, in recent years the Company has not generated any revenues and is therefore dependent on the continuing support of its controlling shareholder. The Company has an accumulated deficit of approximately $63.7 million as of December&#160;31, 2016 and does not have sufficient cash to meet its liquidity requirements for the following twelve months. Consequently, there is substantial doubt about the Company&#8217;s ability to continue as a going concern. Management&#8217;s plans in regards to these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty. </div>
        <table style="width:456pt;height:32pt;margin-top:38pt;border-collapse: collapse;">
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:138pt;">Tel-Aviv, Israel </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:306pt;">/s/ Kesselman &amp; Kesselman </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:1.5pt 0pt 0.5pt 0pt; width:138pt;">March 30, 2017 </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.5pt 0pt 0.5pt 0pt; width:306pt;">Certified Public Accountants (Isr.) </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:138pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:1.5pt 0pt 0.5pt 0pt; width:306pt;">A member firm of PricewaterhouseCoopers International Limited</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="position:relative;z-index:-1;margin-top:168pt; text-align:center; width:456pt;">
          <img src="t1502228_pwc-footer.jpg" alt="[MISSING IMAGE: t1502228_pwc-footer.jpg]" height="43" width="584" >
        </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-2</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="ftBS">&#8203;</a></div>
      <div style="margin-top:46pt;margin-bottom:0.5pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">SOL-GEL TECHNOLOGIES LTD.<br >&nbsp;&nbsp;&nbsp; <br >BALANCE SHEETS <br ><font style="font-weight:normal;">(U.S. dollars in thousands, except share and per share data) </font></div>
        <table style="width:456pt;height:556.5pt;margin-top:9pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:306pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">December&#160;31 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:306pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2015 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:306pt;">
              <div style="text-align:center;">Assets</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:9.5pt 0pt 1.5pt 0pt; width:306pt;">CURRENT ASSETS:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:10pt;">Cash and cash equivalents </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">5,895</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">7,001</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:10pt;">Prepaid expenses and other current assets </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">244</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">472</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:10pt;">Advance payment </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">823</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:306pt;text-align:left;">TOTAL CURRENT ASSETS</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">
              <div style="font-weight:normal;">&#8203;</div>
            </td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:normal;">6,139</div>
            </td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">
              <div style="font-weight:normal;">&#8203;</div>
            </td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:normal;">8,296</div>
            </td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:6.25pt 0pt 1.5pt 0pt; width:306pt;">NON-CURRENT ASSETS:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:10pt;">Advance payment </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">625</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:10pt;">Long term receivables </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">1,190</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:10pt;">Restricted long term deposits </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">92</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">107</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:10pt;">Property and equipment, net </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">785</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">798</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:10pt;">Funds in respect of employee rights upon retirement </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">603</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">594</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:306pt;text-align:left;">TOTAL NON-CURRENT ASSETS</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">
              <div style="font-weight:normal;">&#8203;</div>
            </td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:normal;">2,105</div>
            </td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">
              <div style="font-weight:normal;">&#8203;</div>
            </td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:normal;">2,689</div>
            </td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:6.25pt 0pt 3.25pt 0pt; width:306pt;text-align:left;">
              <div style="font-weight:bold;">TOTAL ASSETS</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;">&#8203;</td>
            <td style="padding:6.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:6.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">8,244</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:6.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:6.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">10,985</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:8.75pt 0pt 1.5pt 0pt; width:306pt;">
              <div style="text-align:center;">Liabilities net of capital deficiency</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:9.5pt 0pt 1.5pt 0pt; width:306pt;">CURRENT LIABILITIES:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:10pt;">Accounts payable </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">311</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">667</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:10pt;">Accrued expenses and other </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">1,487</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">3,623</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:10pt;">Loans from the controlling shareholder </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">17,338</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">37,338</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:306pt;text-align:left;">TOTAL CURRENT LIABILITIES</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">
              <div style="font-weight:normal;">&#8203;</div>
            </td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:normal;">19,136</div>
            </td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">
              <div style="font-weight:normal;">&#8203;</div>
            </td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:normal;">41,628</div>
            </td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:6.25pt 0pt 1.5pt 0pt; width:306pt;">LONG-TERM LIABILITIES &#8211;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:10pt;">Liability for employee rights upon retirement </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">626</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">694</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:306pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">TOTAL LONG-TERM LIABILITIES </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">626</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">694</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:306pt;text-align:left;">
              <div style="white-space:nowrap;">COMMITMENTS </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:306pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">TOTAL LIABILITIES </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">19,762</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">42,322</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:8.75pt 0pt 1.5pt 0pt; width:306pt;">CAPITAL DEFICIENCY:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">Ordinary shares, NIS 0.1 par value &#8211; authorized: 8,775,783 as of <br >December&#160;31, 2015 and 2016; issued and outstanding: <br >3,494,579 as of December&#160;31, 2015 and 2016 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">82</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">82</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:10pt;">Additional paid-in capital </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">31,322</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">32,274</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:10pt;">Accumulated deficit </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(42,922<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(63,693<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:306pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">TOTAL CAPITAL DEFICIENCY </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(11,518<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(31,337<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:6.25pt 0pt 2.75pt 0pt; width:306pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">TOTAL LIABILITIES NET OF CAPITAL DEFICIENCY </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;">&#8203;</td>
            <td style="padding:6.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:6.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">8,244</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:6.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:6.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">10,985</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2pt;height:12pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:8pt;font-family:Times New Roman, Times, serif;font-size:8pt;">The accompanying notes are an integral part of these financial statements.<br ></div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-3</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="ftSO">&#8203;</a></div>
      <div style="margin-top:46pt;margin-bottom:395pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">SOL-GEL TECHNOLOGIES LTD.<br >&nbsp;&nbsp;&nbsp; <br >STATEMENTS OF OPERATIONS <br ><font style="font-weight:normal;">(U.S. dollars in thousands, except share and per share data) </font></div>
        <table style="width:456pt;height:162pt;margin-top:9pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:306pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Year ended December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:306pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2015 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:306pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">RESEARCH AND DEVELOPMENT EXPENSES </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.995pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">7,184</td>
            <td style="padding:0pt;padding-left:4.995pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.995pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">17,023</td>
            <td style="padding:0pt;padding-left:7.995pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:306pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">GENERAL AND ADMINISTRATIVE EXPENSES </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.995pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">2,463</td>
            <td style="padding:0pt;padding-left:4.995pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.995pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">3,733</td>
            <td style="padding:0pt;padding-left:7.995pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:306pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">TOTAL OPERATING LOSS </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.995pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">9,647</td>
            <td style="padding:0pt;padding-left:4.995pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.995pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">20,756</td>
            <td style="padding:0pt;padding-left:7.995pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:306pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">FINANCIAL EXPENSES, NET </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.995pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">13</td>
            <td style="padding:0pt;padding-left:4.995pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.995pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">15</td>
            <td style="padding:0pt;padding-left:7.995pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:306pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">LOSS FOR THE YEAR </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.995pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">9,660</td>
            <td style="padding:0pt;padding-left:4.995pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.995pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">20,771</td>
            <td style="padding:0pt;padding-left:7.995pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:5.75pt 0pt 3.25pt 0pt; width:306pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">BASIC AND DILUTED LOSS PER ORDINARY SHARE </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.995pt;width:0pt;">&#8203;</td>
            <td style="padding:5.75pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:5.75pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">2.76</td>
            <td style="padding:0pt;padding-left:4.995pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.995pt;width:0pt;">&#8203;</td>
            <td style="padding:5.75pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:5.75pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">5.94</td>
            <td style="padding:0pt;padding-left:7.995pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:4.417pt 0pt 2.75pt 0pt; width:306pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.995pt;width:0pt;">&#8203;</td>
            <td style="padding:4.417pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">
              <div style="font-weight:normal;">&#8203;</div>
            </td>
            <td style="padding:4.417pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:normal;">3,494,579</div>
            </td>
            <td style="padding:0pt;padding-left:4.995pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.995pt;width:0pt;">&#8203;</td>
            <td style="padding:4.417pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">
              <div style="font-weight:normal;">&#8203;</div>
            </td>
            <td style="padding:4.417pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:normal;">3,494,579</div>
            </td>
            <td style="padding:0pt;padding-left:7.995pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2pt;height:12pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:8pt;font-family:Times New Roman, Times, serif;font-size:8pt;">The accompanying notes are an integral part of these financial statements.<br ></div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-4</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="ftSCSE">&#8203;</a></div>
      <div style="margin-top:46pt;margin-bottom:375pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">SOL-GEL TECHNOLOGIES LTD.<br >&nbsp;&nbsp;&nbsp; <br >STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY <br ><font style="font-weight:normal;">(U.S. dollars in thousands, except share data) </font></div>
        <table style="width:456pt;height:182pt;margin-top:9pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:203.14pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Ordinary shares </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="text-align:center;">Additional <br >paid-in <br >capital </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="text-align:center;">Accumulated <br >deficit </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Total </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:203.14pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="text-align:center;">Number <br >of shares </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Amounts </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:0pt;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">Amounts </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:203.14pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">BALANCE AS OF JANUARY 1, 2015 </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">3,494,579</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.55pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">82</td>
            <td style="padding:0pt;padding-left:8.55pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">30,193</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.155pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(33,262<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.155pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(2,987<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:203.14pt;">CHANGES DURING 2015:</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:203.14pt;text-align:left;">
              <div style="margin-left:10pt;">Loss for the year </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.55pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.55pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.155pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(9,660<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.155pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(9,660<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:203.14pt;text-align:left;">
              <div style="margin-left:10pt;">Share-based compensation </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.55pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:9pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.55pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">1,129</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.155pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.155pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">1,129</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:203.14pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">BALANCE AS OF DECEMBER 31, 2015&#160;</div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">3,494,579</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.55pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">82</td>
            <td style="padding:0pt;padding-left:8.55pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">31,322</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.155pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(42,922<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.155pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(11,518<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:203.14pt;">CHANGES DURING 2016:</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:203.14pt;text-align:left;">
              <div style="margin-left:10pt;">Loss for the year </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.55pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.55pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.155pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(20,771<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.155pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(20,771<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:203.14pt;text-align:left;">
              <div style="margin-left:10pt;">Share-based compensation </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.55pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:9pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.55pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">952</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.155pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.155pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">952</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.75pt 0pt; width:203.14pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">BALANCE AS OF DECEMBER 31, 2016&#160;</div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">3,494,579</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.55pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:9pt; text-align:right; white-space:nowrap;">82</td>
            <td style="padding:0pt;padding-left:8.55pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">32,274</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.155pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(63,693<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.155pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(31,337<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="32">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2pt;height:12pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:8pt;font-family:Times New Roman, Times, serif;font-size:8pt;">The accompanying notes are an integral part of these financial statements.<br ></div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-5</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="ftSCF">&#8203;</a></div>
      <div style="margin-top:46pt;margin-bottom:8.5pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">SOL-GEL TECHNOLOGIES LTD.<br >&nbsp;&nbsp;&nbsp; <br >STATEMENTS OF CASH FLOWS <br ><font style="font-weight:normal;">(U.S. dollars in thousands) </font></div>
        <table style="width:456pt;height:548.5pt;margin-top:9pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:306pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Year ended December&#160;31 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:306pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2015 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:306pt;">CASH FLOWS FROM OPERATING ACTIVITIES:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:10pt;">Loss </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">(9,660<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:11.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(20,771<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:normal;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:306pt;">
              <div style="margin-left:20pt; text-indent:-10pt;">Adjustments required to reconcile loss to net cash used in operating activities:</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:20pt;">Depreciation </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">300</td>
            <td style="padding:0pt;padding-left:11.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">359</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:306pt;white-space:normal;text-align:left;">
              <div style="margin-left:30pt; text-indent:-10pt;">Changes in accrued liability for employee rights upon retirement </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.94pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">(86<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:11.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">68</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:20pt;">Share-based compensation </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">1,129</td>
            <td style="padding:0pt;padding-left:11.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">952</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:20pt;">In-process research and development acquired </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">431</td>
            <td style="padding:0pt;padding-left:11.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:20pt;">Finance expenses, net </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">17</td>
            <td style="padding:0pt;padding-left:11.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">8</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:306pt;">
              <div style="margin-left:10pt;">Changes in operating asset and liabilities:</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:20pt;">Prepaid expenses and other current assets </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:11.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(228<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:20pt;">Accounts payable, accrued expenses and other </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">449</td>
            <td style="padding:0pt;padding-left:11.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">2,505</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:20pt;">Advance payment </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">(625<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:11.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(198<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:20pt;">Long term receivables </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.94pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:11.94pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(1,190<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:10pt;">Net cash used in operating activities </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.94pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">(8,044<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:11.94pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(18,495<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:306pt;">CASH FLOWS FROM INVESTING ACTIVITIES:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:10pt;">Purchase of property and equipment </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">(291<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:11.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(385<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:10pt;">Long term deposits </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">(8<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:11.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(15<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.167pt 0pt 1.833pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">Amounts funded in respect of employee rights upon retirement, <br >net </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.94pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">89</td>
            <td style="padding:0pt;padding-left:11.94pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">9</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:10pt;">Net cash used in investing activities </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.94pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">(210<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:11.94pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(391<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:306pt;">CASH FLOWS FROM FINANCING ACTIVITIES:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:10pt;">Loans received from the controlling shareholder </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.94pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">13,572</td>
            <td style="padding:0pt;padding-left:11.94pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">20,000</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:10pt;">Net cash provided by financing activities </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.94pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">13,572</td>
            <td style="padding:0pt;padding-left:11.94pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">20,000</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:306pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">EFFECT OF EXCHANGE RATE ON CASH AND CASH EQUIVALENTS </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.94pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:5.25pt; text-align:right; ">
              <div style="font-weight:normal;">&#8203;</div>
            </td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:normal;">(17<font style="position:absolute;">)</font></div>
            </td>
            <td style="padding:0pt;padding-left:11.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:5.25pt; text-align:right; ">
              <div style="font-weight:normal;">&#8203;</div>
            </td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:normal;">(8<font style="position:absolute;">)</font></div>
            </td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:306pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">INCREASE IN CASH AND CASH EQUIVALENTS </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.94pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">5,301</td>
            <td style="padding:0pt;padding-left:11.94pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">1,106</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:306pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">CASH AND CASH EQUIVALENTS AT BEGINNING OF THE YEAR </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.94pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:5.25pt; text-align:right; ">
              <div style="font-weight:normal;">&#8203;</div>
            </td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:normal;">594</div>
            </td>
            <td style="padding:0pt;padding-left:11.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:5.25pt; text-align:right; ">
              <div style="font-weight:normal;">&#8203;</div>
            </td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:normal;">5,895</div>
            </td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 3.25pt 0pt; width:306pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">CASH AND CASH EQUIVALENTS AT END OF THE YEAR </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">5,895</td>
            <td style="padding:0pt;padding-left:11.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">7,001</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:normal;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:1.417pt 0pt 0.833pt 0pt; width:306pt;">
              <div style="margin-left:10pt; text-indent:-10pt;">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 3.25pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:10pt;">Purchase of property and equipment </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.94pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">23</td>
            <td style="padding:0pt;padding-left:11.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">10</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:1.417pt 0pt 2.75pt 0pt; width:306pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">Acquisition of in-process research and development product candidate </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.94pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:1.417pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">431</td>
            <td style="padding:0pt;padding-left:11.94pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:1.417pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2pt;height:12pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:8pt;font-family:Times New Roman, Times, serif;font-size:8pt;">The accompanying notes are an integral part of these financial statements.<br ></div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-6</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="ftNCFS1">&#8203;</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">SOL-GEL TECHNOLOGIES LTD.<br >&nbsp;&nbsp;&nbsp; <br >NOTES TO THE FINANCIAL STATEMENTS <br ><font style="font-weight:normal;">(U.S. dollars in thousands, except share and per share amounts) </font></div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">NOTE 1&#8201;&#8212;&#8201;NATURE OF OPERATIONS </div>
        <div style="text-indent:20pt; margin-top:7.81pt; width:456pt; line-height:12pt;">Sol-Gel Technologies Ltd. (hereafter &#8212; the Company) is an Israeli Company incorporated in 1997. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The Company is a clinical stage specialty pharmaceutical company focused on developing and commercializing topical dermatological drug products. The Company&#8217;s lead product candidates are based upon its proprietary microencapsulation delivery system, consisting of microcapsules made of precipitated silica. In addition to these novel product candidates, the Company&#8217;s product pipeline includes generic product candidates. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In 2007, the Company granted rights to a third party for use and commercialization of a product for skin protection. Under this agreement, the Company is entitled to royalties during the years 2016 to 2024. Based on current sales, royalties are not material. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">On August&#160;4, 2014, 100% of the Company&#8217;s shares were acquired by its current controlling shareholder (the &#8220;controlling shareholder&#8221;). </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">The Company has an accumulated deficit of approximately $63.7 million and its activities have been funded mainly by its shareholders. </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">The Company has been engaged in development activities since its incorporation. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Since its acquisition by the controlling shareholder, the Company has not generated any material revenues and is therefore dependent on the continuing support of its controlling shareholder. As a result, management cannot determine with reasonable certainty if and when the Company will obtain the required funds in order to complete the clinical development of its main product candidates and continue operations. Consequently, there is no assurance that the Company&#8217;s business will generate positive cash flows and there is substantial doubt about the Company&#8217;s ability to continue as a going concern. The financial statements do not include any adjustments that may be necessary should the Company be unable to continue as a going concern. If the Company is unable to obtain the appropriate funds, the Company will need to curtail or cease operations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">NOTE 2&#8201;&#8212;&#8201;SIGNIFICANT ACCOUNTING POLICIES </div>
        <div style=" float:left; line-height:11pt; margin-top:12pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">a.<br ></div>
        <div style=" float:left; margin-top:12pt; margin-bottom:0pt; line-height:11pt; text-align:left; width:435.5pt;font-weight:bold;">Basis of presentation </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:7.61pt; width:456pt; line-height:12pt;">The Company&#8217;s financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (&#8220;U.S. GAAP&#8221;). </div>
        <div style=" float:left; line-height:11pt; margin-top:13pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">b.<br ></div>
        <div style=" float:left; margin-top:13pt; margin-bottom:0pt; line-height:11pt; text-align:left; width:435.5pt;font-weight:bold;">Use of estimates in the preparation of financial statements </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:7.6pt; width:456pt; line-height:12pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results may differ from those estimates. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">As applicable to these financial statements, the most significant estimates and assumptions relate to the fair value of share-based compensation.</div>
        <div style=" float:left; line-height:11pt; margin-top:13pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">c.<br ></div>
        <div style=" float:left; margin-top:13pt; margin-bottom:0pt; line-height:11pt; text-align:left; width:435.5pt;font-weight:bold;">Functional and presentation currency </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:7.61pt; width:456pt; line-height:12pt;">The U.S. dollar (&#8220;dollar&#8221;) is the currency of the primary economic environment in which the operations of the Company are conducted. The Company&#8217;s financing has been provided in dollars, </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-7</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">SOL-GEL TECHNOLOGIES LTD.<br >&nbsp;&nbsp;&nbsp;<br >NOTES TO THE FINANCIAL STATEMENTS&#8201;<font style="font-weight:normal;">(continued)</font><br ><font style="font-weight:normal;">(U.S. dollars in thousands, except share and per share amounts)</font><br ><font style="font-weight:normal;">&#8199;</font></div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;"><font style="font-weight:bold;">NOTE 2&#8201;&#8212;&#8201;SIGNIFICANT ACCOUNTING POLICIES&#8201;</font>(continued)<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:12pt;">revenues are expected to be primarily in dollars and a significant part of expenses are incurred in dollars. The financial statements are presented in dollars, which is the Company&#8217;s functional and presentation currency. </div>
        <div style="text-indent:20pt; margin-top:7.22pt; width:456pt; line-height:12pt;">Transactions and balances originally denominated in dollars are presented at their original amounts. Balances in non-dollar currencies are translated into dollars using historical and current exchange rates for non-monetary and monetary balances, respectively. For non-dollar transactions and other items in the statements of operations (indicated below), the following exchange rates are used: (I) for transactions &#8212; exchange rates at transaction dates or average rates; and (ii) for other items (derived from non-monetary balance sheet items such as depreciation) &#8212; historical exchange rates. Currency transaction gains and losses are presented in financial income or expenses, as appropriate. </div>
        <div style=" float:left; line-height:11pt; margin-top:13pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">d.<br ></div>
        <div style=" float:left; margin-top:13pt; margin-bottom:0pt; line-height:11pt; text-align:left; width:435.5pt;font-weight:bold;">Cash and cash equivalents </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6.21pt; width:456pt; line-height:12pt;">The Company considers as cash equivalents all short-term, highly liquid investments, which include short-term bank deposits with original maturities of three months or less from the date of purchase that are not restricted as to withdrawal or use and are readily convertible to known amounts of cash. </div>
        <div style=" float:left; line-height:11pt; margin-top:13pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">e.<br ></div>
        <div style=" float:left; margin-top:13pt; margin-bottom:0pt; line-height:11pt; text-align:left; width:435.5pt;font-weight:bold;">Property and equipment: </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4.02pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">1)<br ></div>
        <div style=" float:left; margin-top:4.02pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">Property and equipment are stated at cost, net of accumulated depreciation and amortization. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.02pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">2)<br ></div>
        <div style=" float:left; margin-top:5.02pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">The Company&#8217;s property and equipment are depreciated utilizing the straight-line method on the basis of their estimated useful life. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:7.01pt; width:436pt; line-height:12pt;">Annual rates of depreciation are as follows: </div>
        <table style="width:360pt;height:53.5pt;margin-left:60pt;margin-top:10pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:234pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:114pt;text-align:center;">
              <div style="white-space:nowrap; text-align:center;">% </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:234pt;">Laboratory equipment </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:114pt;text-align:center;">
              <div style="white-space:nowrap; text-align:center;">10 &#8211; 33 (mainly 15 &#8211; 25) </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;">Office equipment and furniture </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:114pt;text-align:center;">
              <div style="text-align:center;">7 &#8211; 15 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:234pt;">Computers and related equipment </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:114pt;text-align:center;">
              <div style="text-align:center;">33</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13.02pt; width:456pt; line-height:12pt;">Leasehold improvements are amortized utilizing the straight-line method over the shorter of the expected lease term or the estimated useful life of the improvements. </div>
        <div style=" float:left; line-height:11pt; margin-top:13pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">f.<br ></div>
        <div style=" float:left; margin-top:13pt; margin-bottom:0pt; line-height:11pt; text-align:left; width:435.5pt;font-weight:bold;">Impairment of long-lived assets </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6.02pt; width:456pt; line-height:12pt;">The Company tests long-lived assets for impairment whenever events or circumstances present an indication of impairment. If the sum of expected future cash flows (undiscounted and without interest charges) of the assets is less than the carrying amount of such assets, an impairment loss would be recognized. The assets would then be written down to their estimated fair values.</div>
        <div style="text-indent:20pt; margin-top:7.01pt; width:456pt; line-height:12pt;">For the two years ended December&#160;31, 2016, the Company did not recognize an impairment loss for its long-lived assets. </div>
        <div style=" float:left; line-height:11pt; margin-top:13pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">g.<br ></div>
        <div style=" float:left; margin-top:13pt; margin-bottom:0pt; line-height:11pt; text-align:left; width:435.5pt;font-weight:bold;">Share-based compensation </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6.02pt; width:456pt; line-height:12pt;">The Company accounts for employees&#8217; share-based payment awards classified as equity awards using the grant-date fair value method. The fair value of share-based payment transactions is recognized as an expense over the requisite service period, net of estimated forfeitures. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-8</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">SOL-GEL TECHNOLOGIES LTD.<br >&nbsp;&nbsp;&nbsp;<br >NOTES TO THE FINANCIAL STATEMENTS&#8201;<font style="font-weight:normal;">(continued)</font><br ><font style="font-weight:normal;">(U.S. dollars in thousands, except share and per share amounts)</font><br ><font style="font-weight:normal;">&#8199;</font></div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;"><font style="font-weight:bold;">NOTE 2&#8201;&#8212;&#8201;SIGNIFICANT ACCOUNTING POLICIES&#8201;</font>(continued)<br >&#8199;</div>
        <div style="text-indent:20pt; margin-top:1pt; width:456pt; line-height:12pt;">The Company elected to recognize compensation costs for awards conditioned only on continued service that have a graded vesting schedule using the accelerated method based on the multiple-option award approach. </div>
        <div style=" float:left; line-height:11pt; margin-top:13pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">h.<br ></div>
        <div style=" float:left; margin-top:13pt; margin-bottom:0pt; line-height:11pt; text-align:left; width:435.5pt;font-weight:bold;">Research and development expenses </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, share-based compensation expenses, payroll taxes and other employee benefits, lab expenses, consumable equipment and consulting fees. All costs associated with research and developments are expensed as incurred. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Grants received from the National Authority for Technological Innovation,(hereafter &#8212;&#160;&#8220;&#160;NATI&#8221;), formerly known as the Office of the Chief Scientist of the Ministry of Economy and Industry, or OCS are recognized when the grant becomes receivable, provided there is reasonable assurance that the Company will comply with the conditions attached to the grant and there is reasonable assurance the grant will be received. The grant is deducted from the research and development expenses as the applicable costs are incurred. As of December&#160;31, 2016, the Company does not have a royalty liability to the NATI (see note 5a). </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Clinical trial costs are a significant component of research and development expenses and include costs associated with third-party contractors. The Company out sources its clinical trial activities utilizing external entities such as clinical research organizations, independent clinical investigators, and other third-party service providers to assist the Company with the execution of its clinical trials. Clinical trial costs are expensed as incurred. </div>
        <div style=" float:left; line-height:11pt; margin-top:13pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">i.<br ></div>
        <div style=" float:left; margin-top:13pt; margin-bottom:0pt; line-height:11pt; text-align:left; width:435.5pt;font-weight:bold;">Income taxes: </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">1)<br ></div>
        <div style=" float:left; margin-top:9.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">Deferred taxes </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Income taxes are computed using the asset and liability method. Under the asset and liability method, deferred income tax assets and liabilities are determined based on the differences between the financial reporting and tax bases of assets and liabilities and are measured using the currently enacted tax rates and laws. A valuation allowance is recognized to the extent that it is more likely than not that the deferred taxes will not be realized in the foreseeable future. The Company has provided a full valuation allowance with respect to its deferred tax assets. </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:10.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">2)<br ></div>
        <div style=" float:left; margin-top:10.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">Uncertainty in income taxes </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The Company follows a two-step approach in recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the available evidence indicates that it is more likely than not that the position will be sustained based on technical merits. If this threshold is met, the second step is to measure the tax position as the largest amount that has more than a 50% likelihood of being realized upon ultimate settlement. </div>
        <div style=" float:left; line-height:11pt; margin-top:13pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">j.<br ></div>
        <div style=" float:left; margin-top:13pt; margin-bottom:0pt; line-height:11pt; text-align:left; width:435.5pt;font-weight:bold;">Loss per share </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Basic loss per share is computed on the basis of the net loss for the period divided by the weighted average number of ordinary shares outstanding during the period. Diluted loss per share is based upon the weighted average number of ordinary shares and of ordinary shares equivalents outstanding when dilutive. Ordinary share equivalents include outstanding stock options, which </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-9</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">SOL-GEL TECHNOLOGIES LTD.<br >&nbsp;&nbsp;&nbsp;<br >NOTES TO THE FINANCIAL STATEMENTS&#8201;<font style="font-weight:normal;">(continued)</font><br ><font style="font-weight:normal;">(U.S. dollars in thousands, except share and per share amounts)</font><br ><font style="font-weight:normal;">&#8199;</font></div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;"><font style="font-weight:bold;">NOTE 2&#8201;&#8212;&#8201;SIGNIFICANT ACCOUNTING POLICIES&#8201;</font>(continued)<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:12pt;">are included under the treasury stock method when dilutive. The calculation of diluted loss per share does not include 130,775 and 194,300 options for the years ended December&#160;31, 2015 and 2016, respectively, because the effect would be anti-dilutive. </div>
        <div style=" float:left; line-height:11pt; margin-top:13pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">k.<br ></div>
        <div style=" float:left; margin-top:13pt; margin-bottom:0pt; line-height:11pt; text-align:left; width:435.5pt;font-weight:bold;">Fair value measurement </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Fair value is based on the price that would be received from the sale of an asset or that would be paid to transfer a liability in an orderly transaction between market participants at the measurement date. In order to increase consistency and comparability in fair value measurements, the guidance establishes a fair value hierarchy that prioritizes observable and unobservable inputs used to measure fair value into three broad levels, which are described as follows: </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Level 1: Quoted prices (unadjusted) in active markets that are accessible at the measurement date for assets or liabilities. The fair value hierarchy gives the highest priority to Level 1 inputs. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Level 2: Observable prices that are based on inputs not quoted on active markets, but corroborated by market data. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Level 3: Unobservable inputs are used when little or no market data is available. The fair value hierarchy gives the lowest priority to Level 3 inputs. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible and considers counterparty credit risk in its assessment of fair value. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The carrying amount of the cash and cash equivalents and accrued expenses and other liabilities approximates their fair value. </div>
        <div style=" float:left; line-height:11pt; margin-top:13pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">l.<br ></div>
        <div style=" float:left; margin-top:13pt; margin-bottom:0pt; line-height:11pt; text-align:left; width:435.5pt;font-weight:bold;">Concentration of credit risks </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist principally of cash and cash equivalents and third party credit exposure as part of long-term receivables. The Company deposits cash and cash equivalents with highly rated financial institutions (Israeli banks). The Company has not experienced any credit losses in these accounts and does not believe it is exposed to significant credit risk on these instruments. The Company assesses risk associated with the quality of the third party credit by evaluating the third party&#8217;s financial standing and other factors. </div>
        <div style=" float:left; line-height:11pt; margin-top:13pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">m.<br ></div>
        <div style=" float:left; margin-top:13pt; margin-bottom:0pt; line-height:11pt; text-align:left; width:435.5pt;font-weight:bold;">Newly issued and recently adopted accounting pronouncements: </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">1)&nbsp;&nbsp;&nbsp;In August&#160;2014, the FASB issued ASU No. 2014-15, &#8220;Presentation of Financial Statements&#160;&#8212; Going Concern (Subtopic 205-40), Disclosure of Uncertainties about an Entity&#8217;s Ability to Continue as a Going Concern.&#8221; Continuation of a reporting entity as a going concern is presumed as the basis for preparing financial statements unless and until the entity&#8217;s liquidation becomes imminent. Preparation of financial statements under this presumption is commonly referred to as the going concern basis of accounting. Prior to this, there was no guidance under U.S. GAAP about management&#8217;s responsibility to evaluate whether there is substantial doubt about an entity&#8217;s ability to continue as a going concern or to provide related footnote disclosures. The amendments in this update provide that guidance. The amendments in this ASU are effective for the annual period ending after December&#160;15, 2016. Therefore, the Company has prospectively adopted this new standard on December&#160;15, 2016. The adoption of this standard did not have a material impact on our consolidated financial statements as of December&#160;31, 2016.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-10</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">SOL-GEL TECHNOLOGIES LTD.<br >&nbsp;&nbsp;&nbsp;<br >NOTES TO THE FINANCIAL STATEMENTS&#8201;<font style="font-weight:normal;">(continued)</font><br ><font style="font-weight:normal;">(U.S. dollars in thousands, except share and per share amounts)</font><br ><font style="font-weight:normal;">&#8199;</font></div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;"><font style="font-weight:bold;">NOTE 2&#8201;&#8212;&#8201;SIGNIFICANT ACCOUNTING POLICIES&#8201;</font>(continued)<br >&#8199;</div>
        <div style="margin-left:20pt; margin-top:1pt; width:436pt; line-height:12pt;">In doing so, the amendments reduce diversity in the timing and content of footnote </div>
        <div style="margin-top:2pt; width:456pt; line-height:12pt;">disclosures. The amendments require management to assess an entity&#8217;s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in U.S. auditing standards. Specifically, the amendments (1) provide a definition of the term substantial doubt, (2) require an evaluation every reporting period including interim periods, (3) provide principles for considering the mitigating effect of management&#8217;s plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of management&#8217;s plans, (5) require an express statement and other disclosures when substantial doubt is not alleviated, and (6) require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). For the period ended December&#160;31, 2016, management evaluated the Company&#8217;s ability to continue as a going concern and concluded that there is substantial doubt of its ability to continue as a going concern. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">2)&nbsp;&nbsp;&nbsp;In February&#160;2016, the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes the existing guidance for lease accounting, Leases (Topic 840). ASU 2016-02 requires lessees to recognize leases on their balance sheets, and leaves lessor accounting largely unchanged. The amendments in this ASU are effective for fiscal years beginning after December&#160;15, 2018 and interim periods within those fiscal years. Early application is permitted for all entities. ASU 2016-02 requires a modified retrospective approach for all leases existing at, or entered into after, the date of initial application, with an option to elect to use certain transition relief. The Company is currently evaluating the impact of this new standard on its financial statements. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;font-size:9.9pt;">3)&nbsp;&nbsp;&nbsp;In March&#160;2016, the FASB issued ASU No. 2016-09, Compensation &#8212; Stock Compensation (Topic 718). ASU No. 2016-09 identifies areas for simplification involving several aspects of accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, an option to recognize gross stock compensation expense with actual forfeitures recognized as they occur, as well as certain classifications on the statement of cash flows. The amendments are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December&#160;15, 2016. Early adoption is permitted but all of the guidance must be adopted in the same period. The adoption of this standard is not expected to have a material impact on the Company&#8217;s financial statements. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">NOTE 3&#8201;&#8212;&#8201;PROPERTY AND EQUIPMENT </div>
        <table style="width:456pt;height:138pt;margin-top:9pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:364.22pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">December&#160;31 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:364.22pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.25pt 0pt 1.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2015 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.25pt 0pt 1.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:364.22pt;">Cost:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:364.22pt;text-align:left;">
              <div style="margin-left:10pt;">Laboratory equipment </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,065</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,263</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:364.22pt;text-align:left;">
              <div style="margin-left:10pt;">Office equipment and furniture </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">182</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">234</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:364.22pt;text-align:left;">
              <div style="margin-left:10pt;">Computers and software </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">222</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">282</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.5pt 0pt 1.5pt 0pt; width:364.22pt;text-align:left;">
              <div style="margin-left:10pt;">Leasehold improvements </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">466</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">528</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:364.22pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,935</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">2,307</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:364.22pt;">Less:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.5pt 0pt 1.5pt 0pt; width:364.22pt;text-align:left;">
              <div style="margin-left:10pt;">Accumulated depreciation and amortization </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(1,150<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(1,509<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 2.75pt 0pt; width:364.22pt;text-align:left;">
              <div style="margin-left:10pt;">Property and equipment, net </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">785</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">798</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:5pt;line-height:5pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:15.98pt; width:456pt; line-height:12pt;">Depreciation and amortization expense totaled $300 and $359 for the years ended December&#160;31, 2015 and 2016, respectively. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-11</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">SOL-GEL TECHNOLOGIES LTD.<br >&nbsp;&nbsp;&nbsp;<br >NOTES TO THE FINANCIAL STATEMENTS&#8201;<font style="font-weight:normal;">(continued)</font><br ><font style="font-weight:normal;">(U.S. dollars in thousands, except share and per share amounts)</font><br ><font style="font-weight:normal;">&#8199;</font></div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-weight:bold;">NOTE 4&#8201;&#8212;&#8201;EMPLOYEE SEVERANCE BENEFITS </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The Company is required to make severance payments upon dismissal of an employee or upon termination of employment in certain circumstances. The severance payment liability to the employees (based upon length of service and the latest monthly salary &#8212; one month&#8217;s salary for each year employed) is recorded on the Company&#8217;s balance sheet under &#8220;Liability for employee rights upon retirement.&#8221; The liability is recorded as if it were payable at each balance sheet date on an undiscounted basis. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In accordance with the current employment terms starting in August&#160;2014 with all of its employees, the Company makes regular deposits with certain insurance companies for accounts controlled by each applicable employee in order to secure the employee&#8217;s retirement benefit obligation. The Company is fully relieved from any severance pay liability with respect to each such employee after it makes the payments on behalf of the employee. The liability accrued in respect of these employees and the amounts funded, as of the respective agreement dates, are not reflected in the Company balance sheet, as the amounts funded are not under the control and management of the Company and the pension or severance pay risks have been irrevocably transferred to the applicable insurance companies (the &#8220;Contribution Plan&#8221;). </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">With regard to the period before August&#160;2014, the liability is funded in part from the purchase of insurance policies or by the establishment of pension funds with dedicated deposits in the funds. The amounts used to fund these liabilities are included in the balance sheets under &#8220;Funds in respect of employee rights upon retirement.&#8221; These policies are the Company&#8217;s assets. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The amounts of severance payment expenses were $162 and $261 for the years ended December&#160;31, 2015 and 2016, respectively, of which $159 and $185 in the years ended December, 2015 and 2016, respectively, were in respect of the Contribution Plan. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The Company expects to contribute approximately $193 in the year ending December&#160;31, 2017 to insurance companies in connection with its expected severance liabilities for that year. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">NOTE 5&#8201;&#8212;&#8201;COMMITMENTS </div>
        <div style=" float:left; line-height:11pt; margin-top:14.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">a.<br ></div>
        <div style=" float:left; margin-top:14.99pt; margin-bottom:0pt; line-height:11pt; text-align:left; width:435.5pt;font-weight:bold;">Royalty Commitments </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The Company is obligated to pay royalties to the NATI on proceeds from the sale of products developed from research and development activities that were funded, partially, by grants from the NATI. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Under the terms of the funding arrangements with the NATI, royalties of 3.5% to 25% are payable on the sale of products developed from product candidates funded by the NATI, which payments shall not exceed, in the aggregate, 300% of the amount of the grant received (dollar linked), plus interest at annual rate based on LIBOR. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">As of December&#160;31, 2016, the Company had recognized and received grants from the NATI in the amount of&#8201; $1,431. Through December&#160;31, 2016, the Company recorded an accumulated royalty expense of&#8201;&#8201;$1,997, of which an amount of&#8201; $492 was paid during 2016, as royalties to the NATI with respect to revenue recognized until 2013. As of December&#160;31, 2016, the Company does not have any liabilities to the NATI.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-12</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">SOL-GEL TECHNOLOGIES LTD.<br >&nbsp;&nbsp;&nbsp;<br >NOTES TO THE FINANCIAL STATEMENTS&#8201;<font style="font-weight:normal;">(continued)</font><br ><font style="font-weight:normal;">(U.S. dollars in thousands, except share and per share amounts)</font><br ><font style="font-weight:normal;">&#8199;</font></div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;"><font style="font-weight:bold;">NOTE 5&#8201;&#8212;&#8201;COMMITMENTS&#8201;</font>(continued)<br >&#8199;</div>
        <div style="text-indent:20pt; margin-top:1pt; width:456pt; line-height:12pt;">The Company did not receive any grants from the NATI for the years ended December&#160;31, 2015 and 2016.</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">1.<br ></div>
        <div style=" float:left; margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">The Company has an agreement, that was amended several times (hereafter &#8212; the agreements) with Yissum Research Development Company (hereafter &#8212; &#8220;Yissum&#8221;), the technology-licensing arm of the Hebrew University of Jerusalem.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:40pt; margin-top:6pt; width:416pt; line-height:12pt;">According to the agreements, the Company received from Yissum an exclusive and a non-exclusive license for the commercialization of certain Yissum patents. According to the agreements the Company shall pay Yissum:</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:9pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">i.<br ></div>
        <div style=" float:left; margin-top:9pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:395.5pt;">Royalties of 1.5% of net sales related to certain patents. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">ii.<br ></div>
        <div style=" float:left; margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:395.5pt;">1.5%&#8201;&#8211;&#8201;8% of proceeds received by the Company for the sub-license or license of certain patents.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The term of the above mentioned agreements terminated on May&#160;4, 2013. According to the agreements, the Company may continue commercial use of certain Yissum&#8217;s patents in connection with the products and subject to the obligation to pay Yissum the royalties and the sub-license fees. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The Company granted rights to a third party for use and commercialization of certain Yissum patents. As of December&#160;31, 2016 and 2015, the Company does not have any liability regarding these patents. </div>
        <div style=" float:left; line-height:11pt; margin-top:13pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">b.<br ></div>
        <div style=" float:left; margin-top:13pt; margin-bottom:0pt; line-height:11pt; text-align:left; width:435.5pt;font-weight:bold;">Lease Agreements </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The Company leases office spaces and research and development facilities under several agreements. These agreements are linked to the change in the Israeli consumer price index and expire in December&#160;2020. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">On January&#160;13, 2016 (and for a term ending on February&#160;28, 2017) the Company entered into a sub-lease agreement with one of the tenants in the facility in which the offices are located for the leasing of additional office space. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The annual lease expenses for the years ended December&#160;31, 2015 and 2016 were approximately $256 and $316, respectively. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">As of December&#160;31, 2016, future minimum lease commitments under these operating lease agreements are as follows: </div>
        <table style="width:296pt;height:84pt;margin-left:80pt;margin-top:10pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:218pt;">
              <div style="white-space:nowrap;">Year </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Amount </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:218pt;text-align:left;">
              <div style="white-space:nowrap;">2017 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.72pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">419</td>
            <td style="padding:0pt;padding-left:17.72pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:218pt;text-align:left;">
              <div style="white-space:nowrap;">2018 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.72pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">429</td>
            <td style="padding:0pt;padding-left:17.72pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:218pt;text-align:left;">
              <div style="white-space:nowrap;">2019 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.72pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">429</td>
            <td style="padding:0pt;padding-left:17.72pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:218pt;text-align:left;">
              <div style="white-space:nowrap;">2020 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.72pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">429</td>
            <td style="padding:0pt;padding-left:17.72pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.5pt 0pt; width:218pt;text-align:left;">
              <div style="white-space:nowrap;">Total </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17.72pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">1,706</td>
            <td style="padding:0pt;padding-left:17.72pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:16.99pt; width:456pt; line-height:12pt;">As security for its obligation under the lease agreements the Company deposited $99 in an amount equal to four monthly lease payments, which are classified as restricted long-term deposits.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-13</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">SOL-GEL TECHNOLOGIES LTD.<br >&nbsp;&nbsp;&nbsp;<br >NOTES TO THE FINANCIAL STATEMENTS&#8201;<font style="font-weight:normal;">(continued)</font><br ><font style="font-weight:normal;">(U.S. dollars in thousands, except share and per share amounts)</font><br ><font style="font-weight:normal;">&#8199;</font></div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;"><font style="font-weight:bold;">NOTE 5&#8201;&#8212;&#8201;COMMITMENTS&#8201;</font>(continued)<br >&#8199;</div>
        <div style=" float:left; line-height:11pt; margin-top:0pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">c.<br ></div>
        <div style=" float:left; margin-top:0pt; margin-bottom:0pt; line-height:11pt; text-align:left; width:435.5pt;font-weight:bold;">Vehicle Lease Agreements </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The Company has entered into operating lease agreements for vehicles used by its employees for a period of 3 years. The annual lease expenses for the years ended December&#160;31, 2015 and 2016 were $163 and $156, respectively. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The expected annual lease payments under this agreement for the next three years are $122, $40 and $6 for the years ending December&#160;31, 2017, 2018 and 2019, respectively.</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">As security for its obligation under the lease agreements the Company deposited $20, $8 of which is classified as restricted long term deposits. </div>
        <div style="text-indent:20pt; margin-top:9pt; width:456pt; line-height:12pt;"><font style="font-weight:bold;">d.</font>&nbsp;&nbsp;&nbsp;In connection with the acquisition of the Company, as described in note 1, the Executive Officers and certain employees are entitled, subject to certain research and development milestones and other conditions, as set forth in the agreement, to a special bonus in an aggregate amount of up to $3,000, of which $873 and $127 were paid in each of the years 2014 and 2016 to Executive Officers and certain employees, respectively. As of December&#160;31, 2016 the remaining milestones were not yet achieved and the Company has not recorded a liability regarding this special bonus. </div>
        <div style="text-indent:20pt; margin-top:9pt; width:456pt; line-height:12pt;"><font style="font-weight:bold;">e.</font>&nbsp;&nbsp;&nbsp;In June&#160;2008, the Company entered into a Master Clinical Trial Services Agreement with a third party, which was later amended in April&#160;2016, to retain its services as a clinical research organization for certain product candidate subject to task work orders to be issued by the Company. As consideration for its services the Company will pay a total amount of approximately $3,919 during the term of the engagement and based on achievement of certain milestones, $1,730 of which were recognized as an expense through December&#160;31, 2016. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;"><font style="font-weight:bold;">f.&nbsp;&nbsp;&nbsp;</font>In March&#160;2015, the Company entered into a Clinical Development Master Services Agreement (which was amended during 2016) with a third party, to retain it as another clinical research organization, for its Phase II clinical trial for acne. As consideration for its services the Company will pay a total amount of approximately $7,230 during the term of the engagement and based on achievement of certain milestones, $191 and $4,707 of which were recognized as an expense through December&#160;31, 2015 and 2016, respectively. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In addition, as security for its obligation under this agreement, the Company made an advance payment in the amount of&#8201; $823, which is expected to be used by the end of the clinical trial (in 2017) and therefore it is classified as a current asset. </div>
        <div style="text-indent:20pt; margin-top:9pt; width:456pt; line-height:12pt;"><font style="font-weight:bold;">g.</font>&nbsp;&nbsp;&nbsp;In April&#160;2015, the Company entered into a development, manufacturing and commercialization agreement, as amended on October&#160;26, 2015, with a third party, to work towards the objective of obtaining all FDA approvals necessary for the commercialization of one of its product candidates in the U.S. Under this agreement, the third party is obligated to conduct all regulatory, scientific, clinical and technical activities necessary to develop the product and prepare and file an abbreviated new drug application, or ANDA, with the FDA and gain regulatory approval. As soon as reasonably practical after FDA approval, the third party has exclusive rights and is required to use diligent efforts to commercialize this product in the U.S., including all required sales, marketing and distributing activities associated with the agreement. The Company is entitled to 50% of the third party&#8217;s gross profits related to the sale of this product, as such term is defined in the agreement, on a quarterly basis, for a period of 20 years following the first commercial sale of this product in the U.S.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-14</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">SOL-GEL TECHNOLOGIES LTD.<br >&nbsp;&nbsp;&nbsp;<br >NOTES TO THE FINANCIAL STATEMENTS&#8201;<font style="font-weight:normal;">(continued)</font><br ><font style="font-weight:normal;">(U.S. dollars in thousands, except share and per share amounts)</font><br ><font style="font-weight:normal;">&#8199;</font></div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;"><font style="font-weight:bold;">NOTE 5&#8201;&#8212;&#8201;COMMITMENTS&#8201;</font>(continued)<br >&#8199;</div>
        <div style="text-indent:20pt; margin-top:1pt; width:456pt; line-height:12pt;">Each party is responsible for its own costs in relation to performance under the agreement. The Company will finance all out-of-pocket clinical trial expenses (including materials), and the third party will reimburse the Company for 40% of the out-of-pocket clinical trial expenses as follows (a) in case of success of obtaining the FDA approval, by financing the Company&#8217;s share in the out-of-pocket litigation expenses (and by a cash payment if such financing is less than the reimbursement owed to the Company), or (b) in case of failure to obtain the required FDA approval for the commercialization of the product candidate, by paying back the Company an amount equal to 40% of its out-of-pocket expenses. The Company recognized the third party&#8217;s obligation in an amount of&#8201; $1,190 as long term receivables. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The total consideration for the clinical trial is approximately $5,157 during the term of the engagement, of which the Company will recognize 60% as an expense. During the year ended December&#160;31, 2016, the Company recognized $1,785 as an expense. </div>
        <div style="text-indent:20pt; margin-top:9pt; width:456pt; line-height:12pt;"><font style="font-weight:bold;">h.</font>&nbsp;&nbsp;&nbsp;On May&#160;28, 2015, the Company entered into a Product Development, Manufacturing and Supply Agreement with a third party (hereafter &#8212; the CMO), a manufacturer of pharmaceutical drug products for consumer use, for the development, manufacture and supply of clinical materials for our Phase III trial of one of the products candidates. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">CMO will develop an acceptable, scaled-up formulation and manufacturing process for this product. Unless earlier terminated, the initial term of the agreement is set for a period of five years which automatically renews thereafter for additional two year periods except if either party provides a notice of non-renewal not less than 12 months prior to the end of the then applicable renewal term. Until the Company determines at its sole discretion that an acceptable stable, scaled-up formulation and manufacturing process has been developed for each product, either party may terminate the agreement by providing 120 days&#8217; prior written notice to the other party. The CMO will manufacture, deliver and sell to the Company pursuant to written purchase orders at the times and quantities specified by the Company, $797 and $580 of which were recognized as an expense through December&#160;31, 2015 and 2016, respectively. </div>
        <div style="text-indent:20pt; margin-top:9pt; width:456pt; line-height:12pt;"><font style="font-weight:bold;">i.</font>&nbsp;&nbsp;&nbsp;On December&#160;31, 2015, the Company assumed, following the transfer of an in-process research and development product candidate (hereafter &#8212; the product) from a related party, an agreement with a third party for the development, manufacturing and commercialization of this product. According to this agreement, the third party will conduct all regulatory, scientific, clinical and technical activities necessary to develop the product. The Company will be responsible to pay all out-of-pocket expenses incurred by the third party in performing its services under the development plan. The Company will pay the third party approximately $2,000 upon NDA submission of the product, and approximately $3,000 upon the approval of the FDA on the first NDA for the product. In addition, the Company will be required to pay royalties to the third party on the net sales of the product (as defined in the agreement) ranging from 5.5% to 6.5% depending on the net sale volume of the product. See also note 9d. As of the date of these financial statements, none of the agreed upon milestones have been met. </div>
        <div style="text-indent:20pt; margin-top:9pt; width:456pt; line-height:12pt;"><font style="font-weight:bold;">j.</font>&nbsp;&nbsp;&nbsp;In June&#160;2016, the Company entered into a development, manufacturing and commercialization agreement, with a third party, to work towards the objective of obtaining all FDA approvals necessary for the commercialization of one of its product candidates in the U.S. Under this agreement, the third party is obligated to conduct all regulatory, scientific, clinical and technical activities necessary to develop the product and prepare and file an abbreviated new drug application, or ANDA, with the FDA and gain regulatory approval. The Company is obligated for sourcing the active pharmaceutical ingredient (API) during the development phase. As soon as </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-15</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">SOL-GEL TECHNOLOGIES LTD.<br >&nbsp;&nbsp;&nbsp;<br >NOTES TO THE FINANCIAL STATEMENTS&#8201;<font style="font-weight:normal;">(continued)</font><br ><font style="font-weight:normal;">(U.S. dollars in thousands, except share and per share amounts)</font><br ><font style="font-weight:normal;">&#8199;</font></div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;"><font style="font-weight:bold;">NOTE 5&#8201;&#8212;&#8201;COMMITMENTS&#8201;</font>(continued)<br >&#8199;</div>
        <div style="margin-top:1pt; width:456pt; line-height:12pt;">reasonably practical after FDA approval, the third party has exclusive rights and is required to use diligent efforts to commercialize this product in the U.S., including all required sales, marketing and distributing activities associated with the agreement. The Company is entitled to 50% of the third party&#8217;s gross profits related to the sale of this product, as such term is defined in the agreement, on a quarterly basis, for a period of 20 years following the first commercial sale of this product in the U.S. As of the date of these financial statements, none of the agreed upon milestones have been met. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">NOTE 6&#8201;&#8212;&#8201;LOANS FROM THE CONTROLLING SHAREHOLDER </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Until December&#160;31, 2014, the Company received loans from its controlling shareholder in the amount of&#8201; $3,335. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In 2015 and 2016, the Company received additional loans from its controlling shareholder in the amounts of&#8201;$13,572 and $20,000, respectively. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In addition, the consideration for the transfer in 2015, as detailed in note 9d, was added to the loans. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The loans are classified as a current liability and denominated in US dollars, bear no interest and are backed by a promissory note. The Promissory Note is an unsecured note, has no repayment date and is subject to acceleration in certain events of default.</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">NOTE 7&#8201;&#8212;&#8201;SHARE CAPITAL </div>
        <div style=" float:left; line-height:11pt; margin-top:12pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">a.<br ></div>
        <div style=" float:left; margin-top:12pt; margin-bottom:0pt; line-height:11pt; text-align:left; width:435.5pt;font-weight:bold;">Rights of the Company&#8217;s ordinary shares </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Each ordinary share is entitled to one vote. The holder of the ordinary shares is also entitled to receive dividends whenever funds are legally available, when and if declared by the Board of Directors. Since its inception, the Company has not declared any dividends. </div>
        <div style=" float:left; line-height:11pt; margin-top:13pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">b.<br ></div>
        <div style=" float:left; margin-top:13pt; margin-bottom:0pt; line-height:11pt; text-align:left; width:435.5pt;font-weight:bold;">Share-based compensation: </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">1)<br ></div>
        <div style=" float:left; margin-top:7.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;"><font style="font-weight:bold;">Option plan</font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In December, 2014, the Company&#8217;s Board of Directors approved a Share Incentive Plan (hereafter &#8212; the Plan) and reserved a pool of 349,458 ordinary shares, par value NIS 0.1 each, or such other number as the Board may determine, subject to certain terms and conditions as defined in the Plan. According to the Plan, the Company may issue shares or restricted shares, may grant options or restricted share units and other share-based awards (hereafter &#8212; the awards) to the Company employees, consultants, directors and other service providers. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The Plan is designed to enable the Company to grant awards to purchase Ordinary Shares under various and different tax regimes including, without limitation: pursuant and subject to Section 102 of the Israeli Tax Ordinance and pursuant and subject to Section 3(i) of the Israeli Tax Ordinance. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The awards may be exercised after vesting and in accordance with vesting schedules which will be determined by the Board of Directors for each grant. The maximum term of the awards is 10 years. The fair value of each option granted under this Plan is estimated using the Black-Scholes option pricing method. Expected volatility is based on the historical volatility of comparable peer companies. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-16</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">SOL-GEL TECHNOLOGIES LTD.<br >&nbsp;&nbsp;&nbsp;<br >NOTES TO THE FINANCIAL STATEMENTS&#8201;<font style="font-weight:normal;">(continued)</font><br ><font style="font-weight:normal;">(U.S. dollars in thousands, except share and per share amounts)</font><br ><font style="font-weight:normal;">&#8199;</font></div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;"><font style="font-weight:bold;">NOTE 7&#8201;&#8212;&#8201;SHARE CAPITAL&#8201;</font>(continued)<br >&#8199;</div>
        <div style="text-indent:20pt; margin-top:1pt; width:456pt; line-height:12pt;">The risk-free interest rate assumption is based on observed interest rates appropriate for the expected term of the options granted in dollar terms. The expected term of the options is estimated based on the simplified method. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">As of December&#160;31, 2016, 125,596 ordinary shares remain available for grant under the Plan. </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:10.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">2)<br ></div>
        <div style=" float:left; margin-top:10.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;"><font style="font-weight:bold;">Options granted to employees:</font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">a.&nbsp;&nbsp;&nbsp;In March and April&#160;2015, the Company granted 173,440 options to the Executive Officers of the Company to purchase ordinary shares at an exercise price of&#8201; $2.86 per share. 25% of the options vest on the first anniversary of the vesting commencement date (August&#160;4, 2014) and the rest vest quarterly over the following three years. The options expire on the tenth anniversary of the grant date. </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">b.&nbsp;&nbsp;&nbsp;In August&#160;2016, the Company granted 50,422 options to the Executive Officers of the Company to purchase shares of NIS 0.1 par value ordinary shares of the Company at an exercise price of&#8201;&#8201; $2.86 per share. 25% of the options vest on the first anniversary of the vesting commencement date and the rest vest quarterly over the following three years. The options expire on the tenth anniversary of the grant date. </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:8pt; width:436pt; line-height:12pt;">The fair value of options granted to employees in 2015 and 2016 were $1,618 and $986, respectively. The underlying data used for computing the fair value of the options are as follows: </div>
        <table style="width:416pt;height:91.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:235.31pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:81.13pt;">
              <div style="white-space:nowrap; text-align:center;">2015 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:75.57pt;">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:235.31pt;text-align:left;">
              <div style="white-space:nowrap;">Value of one ordinary share </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:3px double #000000;padding:3.25pt 0pt 2.5pt 0pt; width:81.13pt;">
              <div style="text-align:center;">$11.35 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:3px double #000000;padding:3.25pt 0pt 2.5pt 0pt; width:75.57pt;">
              <div style="text-align:center;">$21.59 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 3.25pt 0pt; width:235.31pt;text-align:left;">
              <div style="white-space:nowrap;">Dividend yield </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:3px double #000000;padding:4pt 0pt 2.5pt 0pt; width:81.13pt;">
              <div style="text-align:center;">0% </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:3px double #000000;padding:4pt 0pt 2.5pt 0pt; width:75.57pt;">
              <div style="text-align:center;">0% </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 3.25pt 0pt; width:235.31pt;text-align:left;">
              <div style="white-space:nowrap;">Expected volatility </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:3px double #000000;padding:4pt 0pt 2.5pt 0pt; width:81.13pt;">
              <div style="text-align:center;">62.46%&#8201;&#8211;&#8201;66.22% </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:3px double #000000;padding:4pt 0pt 2.5pt 0pt; width:75.57pt;">
              <div style="text-align:center;">68.46%&#8201;&#8211;&#8201;79.1% </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 3.25pt 0pt; width:235.31pt;text-align:left;">
              <div style="white-space:nowrap;">Risk-free interest rate </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:3px double #000000;padding:4pt 0pt 2.5pt 0pt; width:81.13pt;">
              <div style="text-align:center;">1.61%&#8201;&#8211;&#8201;1.81% </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:3px double #000000;padding:4pt 0pt 2.5pt 0pt; width:75.57pt;">
              <div style="text-align:center;">0.95%&#8201;&#8211;&#8201;1.34% </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2.75pt 0pt; width:235.31pt;text-align:left;">
              <div style="white-space:nowrap;">Expected term </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:3px double #000000;padding:4pt 0pt 2pt 0pt; width:81.13pt;">
              <div style="text-align:center;">5.5&#8201;&#8211;&#8201;7.5 years </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:3px double #000000;padding:4pt 0pt 2pt 0pt; width:75.57pt;">
              <div style="text-align:center;">5&#8201;&#8211;&#8201;6.71 years</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:10pt;line-height:10pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="8">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:20.99pt; width:436pt; line-height:12pt;">The total unrecognized compensation cost of employee options at December&#160;31, 2016 is $523, which is expected to be recognized over a period of 2.8 years.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-17</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">SOL-GEL TECHNOLOGIES LTD.<br >&nbsp;&nbsp;&nbsp;<br >NOTES TO THE FINANCIAL STATEMENTS&#8201;<font style="font-weight:normal;">(continued)</font><br ><font style="font-weight:normal;">(U.S. dollars in thousands, except share and per share amounts)</font><br ><font style="font-weight:normal;">&#8199;</font></div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;"><font style="font-weight:bold;">NOTE 7&#8201;&#8212;&#8201;SHARE CAPITAL&#8201;</font>(continued)<br >&#8199;</div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:1pt; width:436pt; line-height:12pt;">c.&nbsp;&nbsp;&nbsp;The following table summarizes the number of options outstanding under the Plan for the years ended December&#160;31, 2015 and 2016, and related information: </div>
        <table style="width:416pt;height:166pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:145.41pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="34">
              <div style="white-space:nowrap; text-align:center;">Year ended December&#160;31 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:145.41pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:0pt;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">2015 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:0pt;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:145.41pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="text-align:center;">Number of <br >options </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="text-align:center;">Weighted <br >average <br >exercise <br >price </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="text-align:center;">Weighted <br >average <br >remaining <br >contractual <br >life </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="text-align:center;">Number of <br >options </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="text-align:center;">Weighted <br >average <br >exercise <br >price </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="text-align:center;">Weighted <br >average <br >remaining <br >contractual <br >life </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:145.41pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">Options outstanding at the beginning of the year </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.715pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.715pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.045pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.6pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:11.6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.715pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">173,440</td>
            <td style="padding:0pt;padding-left:1.715pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.045pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">2.86</td>
            <td style="padding:0pt;padding-left:5.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.6pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">9.25</td>
            <td style="padding:0pt;padding-left:11.6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:145.41pt;text-align:left;">
              <div style="white-space:nowrap;">Granted </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.715pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">173,440</td>
            <td style="padding:0pt;padding-left:1.715pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.045pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:15pt; text-align:right; white-space:nowrap;">2.86</td>
            <td style="padding:0pt;padding-left:5.045pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.6pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:15pt; text-align:right; white-space:nowrap;">9.25</td>
            <td style="padding:0pt;padding-left:11.6pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.715pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">50,422</td>
            <td style="padding:0pt;padding-left:1.715pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.045pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:15pt; text-align:right; white-space:nowrap;">2.86</td>
            <td style="padding:0pt;padding-left:5.045pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.6pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:15pt; text-align:right; white-space:nowrap;">9.59</td>
            <td style="padding:0pt;padding-left:11.6pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:1.917pt 0pt 2.583pt 0pt; width:145.41pt;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">Options outstanding at the end <br >of the year </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.715pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3px double #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">173,440</td>
            <td style="padding:0pt;padding-left:1.715pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.045pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3px double #000000; min-width:15pt; text-align:right; white-space:nowrap;">2.86</td>
            <td style="padding:0pt;padding-left:5.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.6pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3px double #000000; min-width:15pt; text-align:right; white-space:nowrap;">9.25</td>
            <td style="padding:0pt;padding-left:11.6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.715pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3px double #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">223,862</td>
            <td style="padding:0pt;padding-left:1.715pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.045pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3px double #000000; min-width:15pt; text-align:right; white-space:nowrap;">2.86</td>
            <td style="padding:0pt;padding-left:5.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.6pt;width:0pt;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:3px double #000000; min-width:15pt; text-align:right; white-space:nowrap;">8.55</td>
            <td style="padding:0pt;padding-left:11.6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:1.417pt 0pt 2.75pt 0pt; width:145.41pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">Options exercisable at the end of the year </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.715pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.417pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">54,200</td>
            <td style="padding:0pt;padding-left:1.715pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.045pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:1.417pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:15pt; text-align:right; white-space:nowrap;">2.86</td>
            <td style="padding:0pt;padding-left:5.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.6pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.417pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:15pt; text-align:right; white-space:nowrap;">9.25</td>
            <td style="padding:0pt;padding-left:11.6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.715pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.417pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">106,854</td>
            <td style="padding:0pt;padding-left:1.715pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.045pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:1.417pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:15pt; text-align:right; white-space:nowrap;">2.86</td>
            <td style="padding:0pt;padding-left:5.045pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.6pt;width:0pt;">&#8203;</td>
            <td style="padding:1.417pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.417pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:15pt; text-align:right; white-space:nowrap;">9.59</td>
            <td style="padding:0pt;padding-left:11.6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="38">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:9.61pt; width:436pt; line-height:12pt;">The aggregate intrinsic value of the total outstanding and of total exercisable options as of December&#160;31, 2016 is approximately $4,193 and $2,001, respectively. </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:7.42pt; width:436pt; line-height:12pt;">d.&nbsp;&nbsp;&nbsp;The following table illustrates the effect of share-based compensation on the statements of operations: </div>
        <table style="width:416pt;height:75.5pt;margin-left:20pt;margin-top:10pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:314pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="text-align:center;">Year ended <br >December&#160;31 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:314pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2015 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:314pt;text-align:left;">
              <div style="white-space:nowrap;">Research and development expenses </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.72pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:18.75pt; text-align:right; white-space:nowrap;">468</td>
            <td style="padding:0pt;padding-left:2.72pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.885pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:12.75pt; text-align:right; white-space:nowrap;">541</td>
            <td style="padding:0pt;padding-left:9.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:314pt;text-align:left;">
              <div style="white-space:nowrap;">General and administrative expenses </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.72pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">661</td>
            <td style="padding:0pt;padding-left:2.72pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.885pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:12.75pt; text-align:right; white-space:nowrap;">411</td>
            <td style="padding:0pt;padding-left:9.885pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.75pt 0pt; width:314pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.72pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:18.75pt; text-align:right; white-space:nowrap;">1,129</td>
            <td style="padding:0pt;padding-left:2.72pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.885pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:12.75pt; text-align:right; white-space:nowrap;">952</td>
            <td style="padding:0pt;padding-left:9.885pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:16pt; width:456pt; line-height:11pt;font-weight:bold;">NOTE 8&#8201;&#8212;&#8201;TAXES ON INCOME </div>
        <div style="margin-left:20pt; margin-top:6.41pt; width:436pt; line-height:12pt;">The Company is taxed under Israel tax laws: </div>
        <div style=" float:left; line-height:11pt; margin-top:13pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">a.<br ></div>
        <div style=" float:left; margin-top:13pt; margin-bottom:0pt; line-height:11pt; text-align:left; width:435.5pt;font-weight:bold;">Tax rates </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6.42pt; width:456pt; line-height:12pt;">The income of the Company and the Capital gains, other than income from Benefitted Enterprises (see b. below), are subject to the normal corporate tax rates (26.5% for 2015 and 25% for 2016). </div>
        <div style="text-indent:20pt; margin-top:7.41pt; width:456pt; line-height:12pt;">In December&#160;2016, the Economic Efficiency Law (Legislative Amendments for Implementing the Economic Policy for the 2017 and 2018 Budget Year), 2016 was published, introducing a gradual reduction in corporate tax rate from 25% to 23%. As a result, the regular tax rate will be 24% in 2017 and 23% in 2018 and thereafter. </div>
        <div style=" float:left; line-height:11pt; margin-top:13pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">b.<br ></div>
        <div style=" float:left; margin-top:13pt; margin-bottom:0pt; line-height:11pt; text-align:left; width:435.5pt;font-weight:bold;">Tax benefits under the Law for the Encouragement of Capital Investments, 1959 (the &#8220;Investment Law&#8221;) </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6.42pt; width:456pt; line-height:12pt;">Under the Investment Law, including Amendment No. 60 to the Investment Law that was published in April&#160;2005, by virtue of the Benefited Enterprise program for certain of its facilities; the Company may be entitled to various tax benefits. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-18</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">SOL-GEL TECHNOLOGIES LTD.<br >&nbsp;&nbsp;&nbsp;<br >NOTES TO THE FINANCIAL STATEMENTS&#8201;<font style="font-weight:normal;">(continued)</font><br ><font style="font-weight:normal;">(U.S. dollars in thousands, except share and per share amounts)</font><br ><font style="font-weight:normal;">&#8199;</font></div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;"><font style="font-weight:bold;">NOTE 8&#8201;&#8212;&#8201;TAXES ON INCOME&#8201;</font>(continued)<br >&#8199;</div>
        <div style="text-indent:20pt; margin-top:1pt; width:456pt; line-height:12pt;">The main benefit arising from such status is the reduction in tax rates on income derived from a Benefited Enterprise. The extent of such benefits depends on the location of the enterprise. Since the Company&#8217;s facilities are not located in &#8220;national development zone A,&#8221; income derived from Benefited Enterprises will be tax exempt for a period of two years and then have a reduced tax rate for a period of up to an additional eight years. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The period of tax benefits, as described above, is limited to 12 years from the beginning of the Benefited Enterprise election year (2012). As of December&#160;31, 2016, the period of benefits has not yet commenced. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In the event of distribution of cash dividends from income which was tax exempt as above, the amount distributed will be subject to the tax rate it was exempted from. The Company is entitled to claim accelerated depreciation in respect of equipment used by the approved enterprises during five tax years. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Entitlement to the above benefits is conditioned upon the Company fulfilling the conditions stipulated by the Investment Law and regulations published thereunder. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In the event of failure to comply with these conditions, the benefits may be canceled and the Company may be required to refund the amount of the benefits, in whole or in part, with the addition of linkage differences to the Israeli consumer price index and interest. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The Investment Law was amended as part of the Economic Policy Law for the years 2011&#160;&#8211;&#160;2012 (the &#8220;Amendment&#8221;), which became effective on January&#160;1, 2011. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The Amendment sets alternative benefit tracks to the ones currently in place under the provisions of the Investment Law, including a reduced corporate tax rate. Tax rate for &#8220;Preferred Enterprise&#8221; income of companies not located in national development zone A, is 16% for fiscal year 2014 and thereafter. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The benefits are granted to companies that qualify under criteria set forth in the Investment Law; for the most part, those criteria are similar to the criteria that have existed in the Investment Law prior to its amendment and the benefit period is unlimited in time. However, in accordance with the Amendment, the classification of licensing income as Preferred income is subject to the issuance of a pre-ruling by the Israel Tax Authority.</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Under the transitional provisions of the Investment Law, a company is allowed to continue to enjoy the tax benefits available under the Investment Law prior to its amendment until the end of the period of benefits, as defined in the Investment Law. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In each year during the period of benefits of its Benefitted Enterprise, the Company will be able to opt for application of the Amendment, thereby making available to itself the tax rate described above. The Company&#8217;s election to apply the Amendment is irrevocable. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">As of December&#160;31, 2016, the Company&#8217;s management decided not to adopt the application of the Amendment. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">There is no assurance that future taxable income of the Company will qualify as Benefited or Preferred income or that the benefits described above will be available to the Company in the future. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-19</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">SOL-GEL TECHNOLOGIES LTD.<br >&nbsp;&nbsp;&nbsp;<br >NOTES TO THE FINANCIAL STATEMENTS&#8201;<font style="font-weight:normal;">(continued)</font><br ><font style="font-weight:normal;">(U.S. dollars in thousands, except share and per share amounts)</font><br ><font style="font-weight:normal;">&#8199;</font></div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;"><font style="font-weight:bold;">NOTE 8&#8201;&#8212;&#8201;TAXES ON INCOME&#8201;</font>(continued)<br >&#8199;</div>
        <div style=" float:left; line-height:11pt; margin-top:0pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">c.<br ></div>
        <div style=" float:left; margin-top:0pt; margin-bottom:0pt; line-height:11pt; text-align:left; width:435.5pt;font-weight:bold;">Tax assessments </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">Tax assessments filed by the Company through the year 2012 are considered to be final. </div>
        <div style=" float:left; line-height:11pt; margin-top:15.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">d.<br ></div>
        <div style=" float:left; margin-top:15.59pt; margin-bottom:0pt; line-height:11pt; text-align:left; width:435.5pt;font-weight:bold;">Losses for tax purposes carried forward to future years </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">As of December&#160;31, 2016, the Company had approximately $47.4 million of net carry forward tax losses which are available to reduce future taxable income with no limited period of use. </div>
        <div style=" float:left; line-height:11pt; margin-top:15.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">e.<br ></div>
        <div style=" float:left; margin-top:15.59pt; margin-bottom:0pt; line-height:11pt; text-align:left; width:435.5pt;font-weight:bold;">Deferred income taxes: </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <table style="width:456pt;height:104.5pt;margin-top:9pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:354pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">As of December&#160;31 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:354pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.25pt 0pt 1.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2015 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.25pt 0pt 1.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:354pt;">In respect of:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:354pt;text-align:left;">
              <div style="white-space:nowrap;">Net operating loss carry forward </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">9,468</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.275pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">10,912</td>
            <td style="padding:0pt;padding-left:1.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:354pt;text-align:left;">
              <div style="white-space:nowrap;">Research and development expenses </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">1,377</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.275pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">2,935</td>
            <td style="padding:0pt;padding-left:1.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:354pt;text-align:left;">
              <div style="white-space:nowrap;">Other </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">43</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.275pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">152</td>
            <td style="padding:0pt;padding-left:1.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:8.5pt 0pt 1.5pt 0pt; width:354pt;text-align:left;">
              <div style="white-space:nowrap;">Less&#8201;&#8211;&#8201;valuation allowance </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-3.45pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:8.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:8.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(10,888<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:8.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:8.5pt 0pt 1.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(13,999<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 2.75pt 0pt; width:354pt;text-align:left;">
              <div style="white-space:nowrap;">Net deferred tax assets </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-3.45pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.275pt;width:0pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:2.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:5pt;line-height:5pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
        <div style=" float:left; line-height:11pt; margin-top:19.58pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">f.<br ></div>
        <div style=" float:left; margin-top:19.58pt; margin-bottom:0pt; line-height:11pt; text-align:left; width:435.5pt;font-weight:bold;">Reconciliation of theoretical tax expenses to actual expenses </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The primary reconciling items between the statutory tax rate of the Company and the effective rate are the full valuation allowance of deferred tax assets and nondeductible expenses. </div>
        <div style=" float:left; line-height:11pt; margin-top:15.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">g.<br ></div>
        <div style=" float:left; margin-top:15.79pt; margin-bottom:0pt; line-height:11pt; text-align:left; width:435.5pt;font-weight:bold;">Provision for uncertain tax positions </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">As of December&#160;31, 2015 and 2016, the Company does not have a provision for uncertain tax positions. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">NOTE 9&#8201;&#8212;&#8201;RELATED PARTIES </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">a.&nbsp;&nbsp;&nbsp;Related parties include the controlling shareholder and companies under his control, the Board of Directors and the Executive Officers of the Company. </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">b.&nbsp;&nbsp;&nbsp;As to bonus to Executive Officers, see note 5d. </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">c.&nbsp;&nbsp;&nbsp;As to options granted to Executive Officers, see note 7b2. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">d.&nbsp;&nbsp;&nbsp;On December&#160;31, 2015, a related company (wholly owned by the Company&#8217;s controlling shareholder) transferred an in-process research and development product candidate (hereafter &#8212; the product) to the Company, together with a collaboration agreement with third party to research, develop and manufacture the product, in consideration of&#8201; $431. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">This was considered a transaction between entities under common control and thus it was recorded on historical cost basis and therefore the Company recognized the consideration of&#8201; $431 as a research and development expense in 2015. The amount was paid to the related company during 2015 by utilizing a loan from the controlling shareholder. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-20</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">SOL-GEL TECHNOLOGIES LTD.<br >&nbsp;&nbsp;&nbsp;<br >NOTES TO THE FINANCIAL STATEMENTS&#8201;<font style="font-weight:normal;">(continued)</font><br ><font style="font-weight:normal;">(U.S. dollars in thousands, except share and per share amounts)</font><br ><font style="font-weight:normal;">&#8199;</font></div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-weight:bold;">NOTE 10&#8201;&#8212;&#8201;SUBSEQUENT EVENTS </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">On February&#160;12, 2017, the Company granted 29,906 options to one of its Executive Officers to purchase ordinary shares at an exercise price of&#8201; $2.86 per share. 25% of the options vest on the first anniversary of the vesting commencement date and the rest vest quarterly over the following three years. Upon the occurrence of a merger or sale (as such term is defined in the agreement), 100% of the then unvested options shall become fully vested, provided, that the grantee is an Employee of the Company at such time. </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">The options expire on the tenth anniversary of the grant date.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-21</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="ft2BS">&#8203;</a></div>
      <div style="margin-top:46pt;margin-bottom:11pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">SOL-GEL TECHNOLOGIES LTD. <br >&nbsp;&nbsp;&nbsp;<br >UNAUDITED BALANCE SHEETS <br ><font style="font-weight:normal;">(U.S. dollars in thousands, except share and per share data) </font></div>
        <table style="width:456pt;height:546pt;margin-top:9pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:306pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="text-align:center;">December&#160;31, <br >2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="text-align:center;">June&#160;30, <br >2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:306pt;">
              <div style="text-align:center;">Assets</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:9.5pt 0pt 1.5pt 0pt; width:306pt;">CURRENT ASSETS:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:10pt;">Cash and cash equivalents  </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">7,001</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">23,295</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:10pt;">Prepaid expenses and other current assets  </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">472</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">193</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:10pt;">Advance payment  </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">823</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">994</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:306pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">TOTAL CURRENT ASSETS  </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">8,296</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">24,482</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:6.25pt 0pt 1.5pt 0pt; width:306pt;">NON-CURRENT ASSETS:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:10pt;">Long-term receivables  </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">1,190</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">2,096</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:10pt;">Restricted long-term deposits  </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">107</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">108</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:10pt;">Property and equipment, net  </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">798</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">1,362</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:10pt;">Funds in respect of employee rights upon retirement  </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">594</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">654</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:306pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">TOTAL NON-CURRENT ASSETS  </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">2,689</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">4,220</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:6.25pt 0pt 3.25pt 0pt; width:306pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">TOTAL ASSETS  </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;">&#8203;</td>
            <td style="padding:6.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:6.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">10,985</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:6.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:6.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">28,702</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:8.75pt 0pt 1.5pt 0pt; width:306pt;">
              <div style="text-align:center;">Liabilities net of capital deficiency</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:9.5pt 0pt 1.5pt 0pt; width:306pt;">CURRENT LIABILITIES:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:10pt;">Accounts payable  </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">667</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">1,232</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:10pt;">Accrued expenses and other  </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">3,623</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">4,109</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:10pt;">Loans from the controlling shareholder  </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">37,338</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">65,338</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:306pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">TOTAL CURRENT LIABILITIES  </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">41,628</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">70,679</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:6.25pt 0pt 1.5pt 0pt; width:306pt;">LONG-TERM LIABILITIES &#8211;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:10pt;">Liability for employee rights upon retirement  </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">694</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">806</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:306pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">TOTAL LONG-TERM LIABILITIES  </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">694</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">806</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:306pt;text-align:left;">
              <div style="white-space:nowrap;">COMMITMENTS  </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:306pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">TOTAL LIABILITIES  </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">42,322</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">71,485</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:9.25pt 0pt 1.5pt 0pt; width:306pt;">CAPITAL DEFICIENCY:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">Ordinary Shares, NIS 0.1 par value &#8211; authorized: 8,775,783 as of <br >December&#160;31, 2016 and June&#160;30, 2017; issued and <br >outstanding: 3,494,579 as of December&#160;31, 2016 and June&#160;30, <br >2017  </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">82</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">82</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:10pt;">Additional paid-in capital  </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">32,274</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">32,660</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:10pt;">Accumulated deficit  </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(63,693<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">(75,525<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:306pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">TOTAL CAPITAL DEFICIENCY  </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(31,337<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">(42,783<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:6.25pt 0pt 2.75pt 0pt; width:306pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">TOTAL LIABILITIES NET OF CAPITAL DEFICIENCY </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;">&#8203;</td>
            <td style="padding:6.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:6.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">10,985</td>
            <td style="padding:0pt;padding-left:10.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:6.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:6.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">28,702</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2pt;height:12pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:8pt;font-family:Times New Roman, Times, serif;font-size:8pt;">The accompanying notes are an integral part of these unaudited condensed financial statements.<br ></div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-22</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="ft2SO">&#8203;</a></div>
      <div style="margin-top:46pt;margin-bottom:395pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">SOL-GEL TECHNOLOGIES LTD. <br >&nbsp;&nbsp;&nbsp;<br >UNAUDITED STATEMENT OF OPERATIONS <br ><font style="font-weight:normal;">(U.S. dollars in thousands, except share and per share data) </font></div>
        <table style="width:456pt;height:162pt;margin-top:9pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:306pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Six months ended June&#160;30,</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:306pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:306pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">RESEARCH AND DEVELOPMENT EXPENSES  </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.995pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">6,797</td>
            <td style="padding:0pt;padding-left:4.995pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.995pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">9,376</td>
            <td style="padding:0pt;padding-left:7.995pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:306pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">GENERAL AND ADMINISTRATIVE EXPENSES  </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.995pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">1,721</td>
            <td style="padding:0pt;padding-left:4.995pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.995pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">2,460</td>
            <td style="padding:0pt;padding-left:7.995pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:306pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">TOTAL OPERATING LOSS  </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.995pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">8,518</td>
            <td style="padding:0pt;padding-left:4.995pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.995pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">11,836</td>
            <td style="padding:0pt;padding-left:7.995pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:306pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">FINANCIAL INCOME, NET  </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.995pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">(7<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.995pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.995pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">(4<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.995pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:306pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">LOSS FOR THE PERIOD  </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.995pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">8,511</td>
            <td style="padding:0pt;padding-left:4.995pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.995pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">11,832</td>
            <td style="padding:0pt;padding-left:7.995pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:5.75pt 0pt 3.25pt 0pt; width:306pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">BASIC AND DILUTED LOSS PER ORDINARY SHARE  </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.995pt;width:0pt;">&#8203;</td>
            <td style="padding:5.75pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:5.75pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">2.44</td>
            <td style="padding:0pt;padding-left:4.995pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.995pt;width:0pt;">&#8203;</td>
            <td style="padding:5.75pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:5.75pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">3.39</td>
            <td style="padding:0pt;padding-left:7.995pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:4.417pt 0pt 2.75pt 0pt; width:306pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">WEIGHTED AVERAGE NUMBER OF SHARES OUTSTANDING USED IN COMPUTATION OF BASIC AND DILUTED LOSS PER SHARE  </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.995pt;width:0pt;">&#8203;</td>
            <td style="padding:4.417pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">
              <div style="font-weight:normal;">&#8203;</div>
            </td>
            <td style="padding:4.417pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:normal;">3,494,579</div>
            </td>
            <td style="padding:0pt;padding-left:4.995pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.995pt;width:0pt;">&#8203;</td>
            <td style="padding:4.417pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">
              <div style="font-weight:normal;">&#8203;</div>
            </td>
            <td style="padding:4.417pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:normal;">3,494,579</div>
            </td>
            <td style="padding:0pt;padding-left:7.995pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2pt;height:12pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:8pt;font-family:Times New Roman, Times, serif;font-size:8pt;">The accompanying notes are an integral part of these unaudited condensed financial statements.<br ></div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-23</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="ft2SCSE">&#8203;</a></div>
      <div style="margin-top:46pt;margin-bottom:328pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">SOL-GEL TECHNOLOGIES LTD.<br >&nbsp;&nbsp;&nbsp; <br >UNAUDITED STATEMENTS OF CHANGES IN CAPITAL DEFICIENCY <br ><font style="font-weight:normal;">(U.S. dollars in thousands, except per share data) </font></div>
        <table style="width:456pt;height:229pt;margin-top:9pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:203.14pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Ordinary shares </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="text-align:center;">Additional <br >paid-in <br >capital </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="text-align:center;">Accumulated <br >deficit </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Total </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:203.14pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="text-align:center;">Number <br >of shares </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Amounts</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt; width:0pt;" colspan="16">
              <div style="white-space:nowrap; text-align:center;">Amounts </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:203.14pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">BALANCE AS OF JANUARY 1, 2016  </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">3,494,579</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.55pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">82</td>
            <td style="padding:0pt;padding-left:8.55pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">31,322</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.155pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(42,922<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.155pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(11,518<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:normal;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:203.14pt;">
              <div style="margin-left:10pt; text-indent:-10pt;">CHANGES DURING THE SIX MONTHS ENDED JUNE 30, 2016:</div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:203.14pt;text-align:left;">
              <div style="margin-left:10pt;">Loss for the period </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.55pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.55pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.155pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(8,511<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.155pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(8,511<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:203.14pt;text-align:left;">
              <div style="margin-left:10pt;">Share-based compensation  </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.55pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:9pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.55pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">185</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.155pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.155pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">185</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:203.14pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">BALANCE AT JUNE 30, 2016  </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">3,494,579</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.55pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:9pt; text-align:right; white-space:nowrap;">82</td>
            <td style="padding:0pt;padding-left:8.55pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">31,507</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.155pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(51,433<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.155pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(19,844<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:8.75pt 0pt 1.5pt 0pt; width:203.14pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">BALANCE AS OF JANUARY 1, 2017  </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:8.75pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:8.75pt 0pt 1.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">3,494,579</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.55pt;width:0pt;">&#8203;</td>
            <td style="padding:8.75pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:8.75pt 0pt 1.5pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">82</td>
            <td style="padding:0pt;padding-left:8.55pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:8.75pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:8.75pt 0pt 1.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">32,274</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.155pt;width:0pt;">&#8203;</td>
            <td style="padding:8.75pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:8.75pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(63,693<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.155pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:8.75pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:8.75pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(31,337<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:normal;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:203.14pt;">
              <div style="margin-left:10pt; text-indent:-10pt;">CHANGES DURING THE SIX MONTHS ENDED JUNE 30, 2017:</div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:203.14pt;text-align:left;">
              <div style="margin-left:10pt;">Loss for the period </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:32.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.55pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:9pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.55pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.155pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(11,832<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.155pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(11,832<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:203.14pt;text-align:left;">
              <div style="margin-left:10pt;">Share-based compensation  </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.55pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:9pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.55pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">386</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.155pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.155pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">386</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.75pt 0pt; width:203.14pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">BALANCE AT JUNE 30, 2017  </div>
            </td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:32.25pt; text-align:right; white-space:nowrap;">3,494,579</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.55pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:9pt; text-align:right; white-space:nowrap;">82</td>
            <td style="padding:0pt;padding-left:8.55pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">32,660</td>
            <td style="padding:0pt;padding-left:2.15pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.155pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(75,525<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.155pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt; width:4.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(42,783<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="32">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2pt;height:12pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:8pt;font-family:Times New Roman, Times, serif;font-size:8pt;">The accompanying notes are an integral part of these unaudited condensed financial statements.<br ></div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-24</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="ft2SCF">&#8203;</a></div>
      <div style="margin-top:46pt;margin-bottom:68.02pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">SOL-GEL TECHNOLOGIES LTD. <br >&nbsp;&nbsp;&nbsp;<br >UNAUDITED STATEMENTS OF CASH FLOWS <br ><font style="font-weight:normal;">(U.S. dollars in thousands) </font></div>
        <table style="width:456pt;height:478pt;margin-top:9pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:306pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Six months ended June&#160;30,</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:306pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:306pt;">CASH FLOWS FROM OPERATING ACTIVITIES:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:10pt;">Loss  </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.055pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(8,511<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:13.055pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(11,832<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:normal;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:306pt;">
              <div style="margin-left:20pt; text-indent:-10pt;">Adjustments required to reconcile loss to net cash used in operating activities:</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:20pt;">Depreciation  </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.055pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">164</td>
            <td style="padding:0pt;padding-left:13.055pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">183</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:306pt;white-space:normal;text-align:left;">
              <div style="margin-left:30pt; text-indent:-10pt;">Changes in accrued liability for employee rights upon retirement, net  </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.055pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">52</td>
            <td style="padding:0pt;padding-left:13.055pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">52</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:20pt;">Share-based compensation  </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.055pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">185</td>
            <td style="padding:0pt;padding-left:13.055pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">386</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:20pt;">Financial income, net  </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.055pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(33<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:13.055pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(40<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:306pt;">
              <div style="margin-left:10pt;">Changes in operating asset and liabilities:</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:20pt;">Prepaid expenses and other current assets  </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.055pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(55<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:13.055pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">279</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:20pt;">Accounts payable, accrued expenses and other  </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.055pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,522</td>
            <td style="padding:0pt;padding-left:13.055pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">906</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:20pt;">Advance payment  </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.055pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.055pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(171<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:20pt;">Long-term receivables  </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.055pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(716<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:13.055pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(906<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:10pt;">Net cash used in operating activities  </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.055pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(7,392<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:13.055pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(11,143<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:306pt;">CASH FLOWS FROM INVESTING ACTIVITIES:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:10pt;">Purchase of property and equipment  </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.055pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(127<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:13.055pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">(602<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:10pt;">Long-term deposits  </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.055pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(26<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:13.055pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(1<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:10pt;">Net cash used in investing activities  </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.055pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(153<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:13.055pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(603<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:306pt;">CASH FLOWS FROM FINANCING ACTIVITIES:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:10pt;">Loans received from the controlling shareholder  </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.055pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">5,000</td>
            <td style="padding:0pt;padding-left:13.055pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">28,000</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:10pt;">Net cash provided by financing activities  </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.055pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">5,000</td>
            <td style="padding:0pt;padding-left:13.055pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">28,000</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:1.917pt 0pt 1.833pt 0pt; width:306pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">EFFECT OF EXCHANGE RATE ON CASH AND CASH EQUIVALENTS  </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.055pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">
              <div style="font-weight:normal;">&#8203;</div>
            </td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:normal;">33</div>
            </td>
            <td style="padding:0pt;padding-left:13.055pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">
              <div style="font-weight:normal;">&#8203;</div>
            </td>
            <td style="padding:1.917pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">
              <div style="font-weight:normal;">40</div>
            </td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:306pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS  </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.055pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(2,545<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:13.055pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">16,254</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.167pt 0pt 1.833pt 0pt; width:306pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;font-weight:bold;">CASH AND CASH EQUIVALENTS AT BEGINNING OF THE PERIOD </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.055pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">5,895</td>
            <td style="padding:0pt;padding-left:13.055pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:5.25pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">7,001</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:306pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">CASH AND CASH EQUIVALENTS AT END OF THE PERIOD  </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.055pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">3,383</td>
            <td style="padding:0pt;padding-left:13.055pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">23,295</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:normal;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:1.417pt 0pt 0.833pt 0pt; width:306pt;">
              <div style="margin-left:10pt; text-indent:-10pt;">SUPPLEMENTARY INFORMATION ON INVESTING AND FINANCING ACTIVITIES NOT INVOLVING CASH FLOWS:</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="6">&#8203;</td>
            <td colspan="6">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 2.75pt 0pt; width:306pt;text-align:left;">
              <div style="margin-left:10pt;">Purchase of property and equipment  </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.055pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">42</td>
            <td style="padding:0pt;padding-left:13.055pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:5.25pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">155</td>
            <td style="padding:0pt;padding-left:13.275pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2pt;height:12pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:8pt;font-family:Times New Roman, Times, serif;font-size:8pt;">The accompanying notes are an integral part of these unaudited condensed financial statements.<br ></div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-25</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="ft2NCFS1">&#8203;</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">SOL-GEL TECHNOLOGIES LTD. <br >&nbsp;&nbsp;&nbsp;<br >NOTES TO THE UNAUDITED CONDENSED FINANCIAL STATEMENTS <br ><font style="font-weight:normal;">(U.S. dollars in thousands, except share and per share amounts)</font></div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">NOTE 1&#8201;&#8212;&#8201;NATURE OF OPERATIONS</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Sol-Gel Technologies Ltd. (hereafter&#8201;&#8212;&#8201;the Company) is an Israeli Company incorporated in 1997.</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The Company is a clinical stage specialty pharmaceutical company focused on developing and commercializing topical dermatological drug products. The Company&#8217;s lead product candidates are based upon its proprietary microencapsulation delivery system, consisting of microcapsules made of precipitated silica. In addition to these branded product candidates, the Company&#8217;s product pipeline includes generic product candidates.</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In 2007, the Company granted rights to a third party for use and commercialization of a product for skin protection. Under this agreement, the Company is entitled to royalties during the years 2016 to 2024. Based on current sales, royalties are not material.</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">On August&#160;4, 2014, 100% of the Company&#8217;s shares were acquired by its current controlling shareholder (the &#8220;controlling shareholder&#8221;).</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">As of June&#160;30, 2017, the Company has an accumulated deficit of approximately $75.5 million and its activities have been funded mainly by the controlling shareholder. </div>
        <div style="margin-left:20pt; margin-top:8pt; width:436pt; line-height:12pt;">The Company has been engaged in development activities since its incorporation.</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Since its acquisition by the controlling shareholder, the Company has not generated any material revenues and is therefore dependent on the continuing support of its controlling shareholder. As a result, management cannot determine with reasonable certainty if and when the Company will obtain the required funds in order to complete the clinical development of its main product candidates and continue operations. Consequently, there is no assurance that the Company&#8217;s business will generate positive cash flows and there is substantial doubt about the Company&#8217;s ability to continue as a going concern. The financial statements do not include any adjustments that may be necessary should the Company be unable to continue as a going concern. If the Company is unable to obtain the appropriate funds, the Company will need to curtail or cease operations.</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">NOTE 2&#8201;&#8212;&#8201;SIGNIFICANT ACCOUNTING POLICIES:</div>
        <div style=" float:left; line-height:11pt; margin-top:12pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">a.<br ></div>
        <div style=" float:left; margin-top:12pt; margin-bottom:0pt; line-height:11pt; text-align:left; width:435.5pt;font-weight:bold;">Basis of Presentation</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The unaudited condensed financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;) for interim financial statements. Accordingly, they do not include all of the information and notes required by U.S. GAAP for annual financial statements. In the opinion of management, these unaudited condensed interim financial statements reflect all adjustments, which include normal recurring adjustments, necessary for a fair statement of the Company&#8217;s financial position as of June&#160;30, 2017, the results of operations, statements of changes in capital deficiency and cash flows for the six-month periods ended June&#160;30, 2016 and 2017.</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The results for the six-month period ended June&#160;30, 2017 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2017.</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">These unaudited condensed financial statements should be read in conjunction with the audited financial statements of the Company for the year ended December&#160;31, 2016. The comparative balance sheet at December&#160;31, 2016 has been derived from the audited financial statements at that date but does not include all disclosures required by U.S. GAAP.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-26</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">SOL-GEL TECHNOLOGIES LTD.<br >&nbsp;&nbsp;&nbsp;<br >NOTES TO THE UNAUDITED CONDENSED FINANCIAL STATEMENTS&#8201;<font style="font-weight:normal;">(continued)</font><br ><font style="font-weight:normal;">(U.S. dollars in thousands, except share and per share amounts)</font><br ><font style="font-weight:normal;">&#8199;</font></div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;"><font style="font-weight:bold;">NOTE 2&#8201;&#8212;&#8201;SIGNIFICANT ACCOUNTING POLICIES:&#8201;</font>(continued)<br >&#8199;</div>
        <div style=" float:left; line-height:11pt; margin-top:0pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">b.<br ></div>
        <div style=" float:left; margin-top:0pt; margin-bottom:0pt; line-height:11pt; text-align:left; width:435.5pt;font-weight:bold;">Loss per share</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:7.81pt; width:456pt; line-height:12pt;">Basic loss per share is computed on the basis of the net loss for the period divided by the weighted average number of ordinary shares outstanding during the period. Diluted loss per share is based upon the weighted average number of ordinary shares and of ordinary share equivalents outstanding when dilutive. Ordinary share equivalents include outstanding stock options, which are included under the treasury stock method when dilutive. The calculation of diluted loss per share does not include 173,440 and 246,790 options for the six months ended June&#160;30, 2016 and 2017, respectively, because the effect would be anti-dilutive.</div>
        <div style=" float:left; line-height:11pt; margin-top:13pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">c.<br ></div>
        <div style=" float:left; margin-top:13pt; margin-bottom:0pt; line-height:11pt; text-align:left; width:435.5pt;font-weight:bold;">Newly issued and recently adopted accounting pronouncements:</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:5.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">1)<br ></div>
        <div style=" float:left; margin-top:5.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">In February&#160;2016, the FASB issued ASU 2016-02, Leases (Topic 842), which supersedes the existing guidance for lease accounting, Leases (Topic 840). ASU 2016-02 requires lessees to recognize leases on their balance sheets, and leaves lessor accounting largely unchanged. The amendments in this ASU are effective for fiscal years beginning after December&#160;15, 2018 and interim periods within those fiscal years. Early application is permitted for all entities. ASU 2016-02 requires a modified retrospective approach for all leases existing at, or entered into after, the date of initial application, with an option to elect to use certain transition relief. The Company is currently evaluating the impact of this new standard on its financial statements.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.61pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">2)<br ></div>
        <div style=" float:left; margin-top:6.61pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">In March&#160;2016, the FASB issued ASU No. 2016-09, Compensation&#8201;&#8212;&#8201;Stock Compensation (Topic 718). ASU No. 2016-09 identifies areas for simplification involving several aspects of accounting for share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, an option to recognize gross stock compensation expense with actual forfeitures recognized as they occur, as well as certain classifications on the statement of cash flows. The amendments are effective for all entities for fiscal years, and interim periods within those fiscal years, beginning after December&#160;15, 2016. Early adoption is permitted but all of the guidance must be adopted in the same period. The adoption of this standard does not have an impact on the Company&#8217;s financial statements.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">NOTE 3&#8201;&#8212;&#8201;LOANS FROM THE CONTROLLING SHAREHOLDER</div>
        <div style="text-indent:20pt; margin-top:7.61pt; width:456pt; line-height:12pt;">Through June&#160;30, 2017, the Company has received loans from its controlling shareholder in the aggregate amount of&#8201; $65,338, including loans received during the six months ended June&#160;30, 2016 and 2017 in the amounts of&#8201;$5,000 and $28,000, respectively.</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">The loans are classified as a current liability and denominated in U.S. dollars, bear no interest and are backed by a promissory note. The promissory note is an unsecured note, has no repayment date and is subject to acceleration in certain events of default. As to the subsequent agreements relating to the promissory note after the balance sheet date, see Note 6.</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">NOTE 4&#8201;&#8212;&#8201;STOCK-BASED COMPENSATION</div>
        <div style="text-indent:20pt; margin-top:7.61pt; width:456pt; line-height:12pt;">On February&#160;12, 2017 the Company granted 29,906 options to an executive officer to purchase ordinary shares at an exercise price of&#8201; $2.86 per share. 25% of the options vest on the first anniversary of the vesting commencement date and the rest vest quarterly over the following three years. Upon the occurrence of a merger or sale (as such term is defined in the agreement), 100% of the then unvested options shall become fully vested, provided, that the grantee is an employee of the Company at such time. The options expire on the tenth anniversary of the grant date.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-27</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">SOL-GEL TECHNOLOGIES LTD.<br >&nbsp;&nbsp;&nbsp;<br >NOTES TO THE UNAUDITED CONDENSED FINANCIAL STATEMENTS&#8201;<font style="font-weight:normal;">(continued)</font><br ><font style="font-weight:normal;">(U.S. dollars in thousands, except share and per share amounts)</font><br ><font style="font-weight:normal;">&#8199;</font></div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;font-weight:bold;">NOTE 4&#8201;&#8212;&#8201;STOCK-BASED COMPENSATION<font style="font-weight:normal;">&#8201;(continued)</font><br ><font style="font-weight:normal;">&#8199;</font></div>
        <div style="text-indent:20pt; margin-top:1pt; width:456pt; line-height:12pt;">The fair value of options granted was $1,041. The underlying data used for computing the fair value of the options are as follows: </div>
        <table style="width:336pt;height:107.5pt;margin-left:60pt;margin-top:10pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:242.88pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:81.13pt;text-align:center;">
              <div style="text-align:center;">For the Six<br >Months Ended<br >June 30, 2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:242.88pt;">
              <div style="white-space:nowrap;">Value of one ordinary share  </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:3px double #000000;padding:3.25pt 0pt 2.5pt 0pt; width:81.13pt;text-align:center;">
              <div style="text-align:center;">$36.84</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 3.25pt 0pt; width:242.88pt;">
              <div style="white-space:nowrap;">Dividend yield  </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:3px double #000000;padding:4pt 0pt 2.5pt 0pt; width:81.13pt;text-align:center;">
              <div style="text-align:center;">0% </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 3.25pt 0pt; width:242.88pt;">
              <div style="white-space:nowrap;">Expected volatility  </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:3px double #000000;padding:4pt 0pt 2.5pt 0pt; width:81.13pt;text-align:center;">
              <div style="text-align:center;">73.74%&#8201;&#8211;&#8201;78.71% </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 3.25pt 0pt; width:242.88pt;">
              <div style="white-space:nowrap;">Risk-free interest rate  </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:3px double #000000;padding:4pt 0pt 2.5pt 0pt; width:81.13pt;text-align:center;">
              <div style="text-align:center;">1.57%&#8201;&#8211;&#8201;2.23% </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:4pt 0pt 2.75pt 0pt; width:242.88pt;">
              <div style="white-space:nowrap;">Expected term  </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="border-bottom:3px double #000000;padding:4pt 0pt 2pt 0pt; width:81.13pt;text-align:center;">
              <div style="white-space:nowrap; text-align:center;">5.47&#8201;&#8211;&#8201;6.97 years</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:10pt;line-height:10pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="5">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:18pt; width:456pt; line-height:12pt;">The total unrecognized compensation cost of employee options at June 30, 2017 is $1,178, which is expected to be recognized over a period of 2.8 years.</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">NOTE 5&#8201;&#8212;&#8201;RELATED PARTIES: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;"><font style="font-weight:bold;">a.</font><br >
        </div>
        <div style=" float:left; margin-top:7pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">Related parties include the controlling shareholder and companies under his control, the board of directors and the executive officers of the Company. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;"><font style="font-weight:bold;">b.</font><br >
        </div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">As to loans received from the controlling shareholder, see note 3. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;"><font style="font-weight:bold;">c.</font><br >
        </div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">As to options granted to executive officer during the six months period ended June&#160;30, 2017, see note 4. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">NOTE 6&#8201;&#8212;&#8201;SUBSEQUENT EVENTS: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;"><font style="font-weight:bold;">a.</font><br >
        </div>
        <div style=" float:left; margin-top:7pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">In connection with the acquisition of the Company, as described in note 1, the executive officers and certain employees are entitled, subject to certain research and development milestones and other conditions, as set forth in the agreement, to a special bonus in an aggregate amount of up to $3,000, out of which an aggregate of $2,000 was paid in 2014 and 2016. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">After June&#160;30, 2017, following the achievement of the remaining milestone, the executive officers and employees became entitled to the remaining amount of the special bonus. As of June&#160;30, 2017, the Company has recorded a liability of&#8201; $1,000 regarding this special bonus. </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;"><font style="font-weight:bold;">b.</font><br >
        </div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">On July&#160;13, 2017, the Company&#8217;s Board of Directors approved an increase of the ordinary shares that may be issued under the Company&#8217;s &#8220;2014 Share Incentive Plan&#8221; by reserving an additional 400,542 Ordinary Shares of the Company with a par value of NIS 0.1 per share. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;"><font style="font-weight:bold;">c.</font><br >
        </div>
        <div style=" float:left; margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">In July&#160;and August 2017, the Company&#8217;s Board of Directors approved the grant of options to employees and non-employees as follows: </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:7.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">1.<br ></div>
        <div style=" float:left; margin-top:7.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:395.5pt;">Grants of 221,890 and 60,080 options to several employees and non-employees, respectively, to purchase ordinary shares at an exercise price of&#8201; $10.018 per share. 25% of the options vest on the first anniversary of the vesting commencement date and the rest vest quarterly over the following three years. The options expire on the tenth anniversary of the grant date. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-28</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">SOL-GEL TECHNOLOGIES LTD.<br >&nbsp;&nbsp;&nbsp;<br >NOTES TO THE UNAUDITED CONDENSED FINANCIAL STATEMENTS&#8201;<font style="font-weight:normal;">(continued)</font><br ><font style="font-weight:normal;">(U.S. dollars in thousands, except share and per share amounts)</font><br ><font style="font-weight:normal;">&#8199;</font></div>
        <div style="margin-top:1pt; width:456pt; line-height:11pt;"><font style="font-weight:bold;">NOTE 6&#8201;&#8212;&#8201;SUBSEQUENT EVENTS:&#8201;</font>(continued)<br >&#8199;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:-1pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">2.<br ></div>
        <div style=" float:left; margin-top:-1pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:395.5pt;">Grants of 7,520 and 7,520 options to an employee and a non-employee, respectively, to purchase ordinary shares at an exercise price of&#8201; $2.86 per share. 25% of the options vest on the first anniversary of the vesting commencement date (October&#160;1, 2015 and July&#160;10, 2016, respectively) and the rest vest quarterly over the following three years. The options expire on the tenth anniversary of the grant date.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:40pt; margin-top:8pt; width:416pt; line-height:12pt;">Upon the occurrence of a merger or sale, 100% of the unvested options shall become fully vested, provided, that the grantee is an employee of the Company at such time or a non-employee is continuously a service provider of the Company at such time.</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:10.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;"><font style="font-weight:bold;">d.</font><br ></div>
        <div style=" float:left; margin-top:10.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">On August 22, 2017, the Company and the controlling shareholder agreed to convert the promissory note in the event of an initial public offering. Per the agreement, the principal amount will automatically convert into the Company&#8217;s shares immediately prior to the closing of an initial public offering. The number of ordinary shares to be issued upon the automatic conversion will be equal to the principal amount divided by the price per ordinary share paid by investors in the initial public offering.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:10.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;"><font style="font-weight:bold;">e.</font><br ></div>
        <div style=" float:left; margin-top:10.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">On August 22, 2017, the parent company (wholly owned by the Company&#8217;s controlling shareholder) contributed an in-process research and development product candidate to the Company. In the third quarter of 2017, the Company will recognize the fair value of the product candidate contributed as research and development expenses.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">For the issuance of the unaudited interim financial statements as of June 30, 2017, and the six months ended June&#160;30, 2016 and 2017, the Company has evaluated subsequent events through August 23, 2017, the date on which the unaudited interim financial statements were available to be issued.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">F-29</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a></div>
      <div style="margin-top:28pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:8pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 0pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:3pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:76.98pt; text-align:center; width:456pt; line-height:17pt;font-weight:bold;font-size:16pt;">&#8199;&#8199;&#8199;&#8201;&#8199;&#8199;&#8199; Ordinary Shares</div>
        <div style="position:relative;z-index:-1;margin-top:36pt; text-align:center; width:456pt;">
          <img src="lg_solgel.jpg" alt="[MISSING IMAGE: lg_solgel.jpg]" height="170" width="356" >
        </div>
        <div style="margin-top:48pt; text-align:center; width:456pt; line-height:17pt;font-weight:bold;font-size:16pt;">Sol-Gel Technologies Ltd.<br >Ordinary Shares </div>
        <div style="margin-top:48pt; text-align:center; width:456pt; line-height:15pt;font-weight:bold;font-size:16pt;">Jefferies<br >BMO Capital Markets<br ><font style="font-size:13pt;">JMP Securities</font><br ><font style="font-size:13pt;">Raymond James</font></div>
        <div style="text-indent:20pt; margin-top:120pt; width:456pt; line-height:12pt;">Until and including &#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199;&#8199; &#8199;&#8199;, 2017, 25 days after the date of this prospectus, all dealers that buy, sell or trade our ordinary shares, whether or not participating in this offering, may be required to deliver a prospectus. This is in addition to the dealer&#8217;s obligation to deliver a prospectus when acting as underwriters and with respect to unsold allotments or subscriptions. </div>
        <div style="margin-top:41.49pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:3pt; width:456pt;">
          <div style="margin-left: 0pt; width: 456pt; margin-top: 0pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;"><font style="text-transform:uppercase;">Part</font> II </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;"><font style="text-transform:uppercase;">Information Not Required in Prospectus</font></div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Item 6.&nbsp;&nbsp;&nbsp;Indemnification of Office Holders (including Directors). </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Under the Companies Law, a company may not exculpate an office holder from liability for a breach of a fiduciary duty. An Israeli company may exculpate an office holder in advance from liability to the company, in whole or in part, for damages caused to the company as a result of a breach of duty of care but only if a provision authorizing such exculpation is included in its articles of association. Our amended and restated articles of association include such a provision. The company may not exculpate in advance a director from liability arising due to the breach of his or her duty or care in the event of a prohibited dividend or distribution to shareholders. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Under the Companies Law and the Israeli Securities Law, 5728-1968, or the Securities Law, a company may indemnify an office holder in respect of the following liabilities, payments and expenses incurred for acts performed by him as an office holder, either in advance of an event or following an event, provided its articles of association include a provision authorizing such indemnification: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a monetary liability incurred by or imposed on the office holder in favor of another person pursuant to a court judgment, including pursuant to a settlement confirmed as judgment or arbitrator&#8217;s decision approved by a competent court. However, if an undertaking to indemnify an office holder with respect to such liability is provided in advance, then such an undertaking must be limited to events which, in the opinion of the board of directors, can be foreseen based on the company&#8217;s activities when the undertaking to indemnify is given, and to an amount or according to criteria determined by the board of directors as reasonable under the circumstances, and such undertaking shall detail the abovementioned foreseen events and amount or criteria; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">reasonable litigation expenses, including reasonable attorneys&#8217; fees, which were incurred by the office holder as a result of an investigation or proceeding filed against the office holder by an authority authorized to conduct such investigation or proceeding, provided that such investigation or proceeding was either (i) concluded without the filing of an indictment against such office holder and without the imposition on him of any monetary obligation in lieu of a criminal proceeding; (ii) concluded without the filing of an indictment against the office holder but with the imposition of a monetary obligation on the office holder in lieu of criminal proceedings for an offense that does not require proof of criminal intent; or (iii) in connection with a monetary sanction; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a monetary liability imposed on the office holder in favor of all the injured parties by the breach in an Administrative Procedure (as defined below) as set forth in Section 52(54)(a)(1)(a) to the Securities Law; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">expenses expended by the office holder with respect to an Administrative Procedure under the Securities Law, including reasonable litigation expenses and reasonable attorneys&#8217; fees; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">reasonable litigation expenses, including attorneys&#8217; fees, incurred by the office holder or which were imposed on the office holder by a court (i) in a proceeding instituted against him or her by the company, on its behalf, or by a third party, (ii) in connection with criminal indictment of which the office holder was acquitted, or (iii) in a criminal indictment which the office holder was convicted of an offense that does not require proof of criminal intent. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">Any other obligation or expense in respect of which it is permitted or will be permitted under applicable law to indemnify an office holder, including, without limitation, matters referenced in Section 56H(b)(1) of the Securities Law. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">II-1</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">An &#8220;Administrative Procedure&#8221; is defined as a procedure pursuant to chapters H3 (Monetary Sanction by the Israeli Securities Authority), H4 (Administrative Enforcement Procedures of the Administrative Enforcement Committee) or I1 (Arrangement to prevent Procedures or Interruption of procedures subject to conditions) to the Securities Law.</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Under the Companies Law and the Securities Law, a company may insure an office holder against the following liabilities incurred for acts performed by him or her as an office holder if and to the extent provided in the company&#8217;s articles of association: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a breach of the duty of loyalty to the company, provided that the office holder acted in good faith and had a reasonable basis to believe that the act would not harm the company; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a breach of duty of care to the company or to a third party, to the extent such a breach arises out of the negligent conduct of the office holder; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a monetary liability imposed on the office holder in favor of a third party; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a monetary liability imposed on the office holder in favor of an injured party at an Administrative Procedure pursuant to Section 52(54)(a)(1)(a) of the Securities Law; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">expenses incurred by an office holder in connection with an Administrative Procedure, including reasonable litigation expenses and reasonable attorneys&#8217; fees. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Under the Companies Law, a company may not indemnify, exculpate or insure an office holder against any of the following: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a breach of the duty of loyalty, except for indemnification and insurance for a breach of the duty of loyalty to the company to the extent that the office holder acted in good faith and had a reasonable basis to believe that the act would not prejudice the company; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a breach of duty of care committed intentionally or recklessly, excluding a breach arising out of the negligent conduct of the office holder; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">an act or omission committed with intent to derive illegal personal benefit; or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a fine or forfeit levied against the office holder. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Under the Companies Law, exculpation, indemnification and insurance of office holders in a public company must be approved by the compensation committee and the board of directors and, with respect to directors or controlling shareholders, their relatives and third parties in which controlling shareholders have a personal interest, also by the shareholders. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Our amended and restated articles of association permit us to exculpate, indemnify and insure our office holders to the fullest extent permitted or to be permitted by law. Our office holders are currently covered by a directors&#8217; and officers&#8217; liability insurance policy. As of the date of this registration statement, no claims for directors&#8217; and officers&#8217; liability insurance have been filed under this policy and we are not aware of any pending or threatened litigation or proceeding involving any of our office holders, including our directors, in which indemnification is sought. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:11.5pt;">We have entered into agreements with each of our current office holders exculpating them from a breach of their duty of care to us to the fullest extent permitted by law, subject to limited exceptions, and undertaking to indemnify them to the fullest extent permitted by law, subject to limited exceptions, including, with respect to liabilities resulting from this offering, to the extent that these liabilities are not covered by insurance. This indemnification is limited, with respect to any monetary liability imposed in favor of a third party, to events determined as foreseeable by the board of directors based on our activities. The maximum aggregate amount of indemnification that we may pay to our office holders based on such indemnification agreement is the greater of (1)&#160;&nbsp;&nbsp;&nbsp;% of our shareholders&#8217; equity pursuant to our audited financial statements for the year preceding the year in which the event in connection of which indemnification is sought occurred, and (2) $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million (as may be increased from time to time by shareholders&#8217; approval). Such </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">II-2</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11.5pt;">indemnification amounts are in addition to any insurance amounts. Each office holder who agrees to receive this letter of indemnification also gives his approval to the termination of all previous letters of indemnification that we have provided to him or her in the past, if any. However, in the opinion of the SEC, indemnification of office holders for liabilities arising under the Securities Act is against public policy and therefore unenforceable.</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Item 7.&nbsp;&nbsp;&nbsp;Recent Sales of Unregistered Securities. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">In August&#160;2014, we issued a total of 3,388,359 ordinary shares to Arkin Dermatology in connection with the conversion of outstanding preferred shares into ordinary shares following the execution of the Purchase Agreement. In connection with the foregoing conversion, the par value of the ordinary shares (in the amount of approximately $80) was paid. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">All of the foregoing issuances were made outside of the United States pursuant to Regulation&#160;S or to U.S. entities pursuant to Section 4(a)(2) of the Securities Act. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Item 8.&nbsp;&nbsp;&nbsp;Exhibits and Financial Statement Schedules. </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">(a)<br ></div>
        <div style=" float:left; margin-top:7.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;font-weight:bold;">Exhibits.<font style="font-weight:normal;"> See the Exhibit Index attached to this registration statement, which is incorporated by reference herein. </font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;"><font style="font-weight:bold;">(b)</font><br >
        </div>
        <div style=" float:left; margin-top:8.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;"><font style="font-weight:bold;">Financial Statement Schedules.</font> Schedules not listed above have been omitted because the information required to be set forth therein is not applicable or is shown in the financial statements or notes thereto. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Item 9.&nbsp;&nbsp;&nbsp;Undertakings. </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">a.<br ></div>
        <div style=" float:left; margin-top:7.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">The undersigned registrant hereby undertakes to provide to the underwriters at the closing specified in the underwriting agreements certificates in such denominations and registered in such names as required by the underwriters to permit prompt delivery to each purchaser. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">b.<br ></div>
        <div style=" float:left; margin-top:8.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the Securities and Exchange Commission such indemnification is against public policy as expressed in the Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Act and will be governed by the final adjudication of such issue. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">c.<br ></div>
        <div style=" float:left; margin-top:8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">The undersigned registrant hereby undertakes that: </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:8.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">1.<br ></div>
        <div style=" float:left; margin-top:8.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:395.5pt;">For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant to Rule 424(b)(1) or (4) or 497(h) under the Securities Act shall be deemed to be part of this registration statement as of the time it was declared effective. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:8.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">2.<br ></div>
        <div style=" float:left; margin-top:8.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:395.5pt;">For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide offering thereof.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">II-3</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">SIGNATURES </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form F-1 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Ness Ziona, State of Israel on August&#160;29, 2017. </div>
        <table style="width:456pt;height:61.5pt;margin-top:10pt;border-collapse: collapse;">
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:210pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:0pt;" colspan="4">Sol-Gel Technologies Ltd.</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:210pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #FFFFFF;padding:14.5pt 0pt 1.5pt 0pt; width:12pt;">By: </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:14.5pt 0pt 1.5pt 0pt; width:210pt;">/s/ Alon Seri-Levy</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:210pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.25pt 0pt 0.5pt 0pt; width:210pt;">Name: Alon Seri-Levy </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:210pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:210pt;">Title: Chief Executive Officer</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:22.99pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">POWER OF ATTORNEY </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Each person whose signature appears below constitutes and appoints Alon Seri-Levy and Gilad Mamlok, and each of them, as attorney-in-fact with full power of substitution, for him or her in any and all capacities, to do any and all acts and all things and to execute any and all instruments which said attorney and agent may deem necessary or desirable to enable the registrant to comply with the Securities Act, and any rules, regulations and requirements of the Securities and Exchange Commission thereunder, in connection with the registration under the Securities Act of ordinary shares of the registrant (the &#8220;Shares&#8221;), including, without limitation, the power and authority to sign the name of each of the undersigned in the capacities indicated below to the Registration Statement on Form F-1 (the &#8221;Registration Statement&#8221;) to be filed with the Securities and Exchange Commission with respect to such Shares, to any and all amendments or supplements to such Registration Statement, whether such amendments or supplements are filed before or after the effective date of such Registration Statement, to any related Registration Statement filed pursuant to Rule 462(b) under the Securities Act, and to any and all instruments or documents filed as part of or in connection with such Registration Statement or any and all amendments thereto, whether such amendments are filed before or after the effective date of such Registration Statement, and each of the undersigned hereby ratifies and confirms all that such attorney and agent shall do or cause to be done by virtue hereof. </div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated. </div>
        <table style="width:456pt;height:131.5pt;margin-top:10pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:146pt;text-align:left;">
              <div style="white-space:nowrap;">Signatures </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:140pt;">
              <div style="white-space:nowrap; text-align:center;">Title </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:146pt;">
              <div style="white-space:nowrap; text-align:center;">Date </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:13.917pt 0pt 2.833pt 0pt; width:146pt;">
              <div>/s/ Alon Seri-Levy</div>
              <div style="margin-top:2.5pt;">
                <div style="margin-left: 0pt; width: 146pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt;">Alon Seri-Levy </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:13.917pt 0pt 2.833pt 0pt; width:140pt;">Chief Executive Officer </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:13.917pt 0pt 2.833pt 0pt; width:146pt;">August&#160;29, 2017 </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:14.167pt 0pt 2.833pt 0pt; width:146pt;">
              <div>/s/ Gilad Mamlok</div>
              <div style="margin-top:2.5pt;">
                <div style="margin-left: 0pt; width: 146pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt;">Gilad Mamlok </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 2.833pt 0pt; width:140pt;">Chief Financial Officer </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 2.833pt 0pt; width:146pt;">August&#160;29, 2017 </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:14.167pt 0pt 2.833pt 0pt; width:146pt;">
              <div>/s/ Moshe Arkin</div>
              <div style="margin-top:2.5pt;">
                <div style="margin-left: 0pt; width: 146pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt;">Moshe Arkin </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 2.833pt 0pt; width:140pt;">Director </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.167pt 0pt 2.833pt 0pt; width:146pt;">August&#160;29, 2017</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">II-4</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;"><font style="text-transform:uppercase;">Signature of authorized representative in the United States</font></div>
        <div style="text-indent:20pt; margin-top:8pt; width:456pt; line-height:12pt;">Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant&#8217;s duly authorized representative has signed this registration statement on Form F-1 in on this 29 day of August, 2017. </div>
        <table style="width:456pt;height:92pt;margin-top:10pt;border-collapse: collapse;">
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:210pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:0pt;" colspan="4">By:</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:210pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:26.5pt 0pt 0.5pt 0pt; width:12pt;">By: </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:26.5pt 0pt 0.5pt 0pt; width:210pt;">
              <div>/s/ Colleen A. DeVries</div>
              <div style="margin-top:2.5pt;">
                <div style="margin-left: 0pt; width: 210pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:210pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:6.5pt 0pt 1.833pt 0pt; width:210pt;">Name: Colleen A. DeVries</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:210pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:12pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4.167pt 0pt 0.5pt 0pt; width:210pt;">Title: Senior Vice-President on behalf<br >of Cogency Global Inc.</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">II-5</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">EXHIBIT INDEX </div>
        <table style="width:456pt;height:629.5pt;margin-top:9pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:42pt;">
              <div style="white-space:nowrap;">Exhibit No. </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:402pt;text-align:center;">
              <div style="white-space:nowrap; text-align:center;">Description </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3pt 0pt; width:42pt;">1.1* </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 3pt 0pt; width:402pt;">Form of Underwriting Agreement. </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:5pt 0pt 3pt 0pt; width:42pt;">3.1*</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:5pt 0pt 3pt 0pt; width:402pt;">Amended and Restated Memorandum of Association of the Registrant.</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:5pt 0pt 3pt 0pt; width:42pt;">3.2</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:5pt 0pt 3pt 0pt; width:402pt;">Articles of Association of the Registrant (currently in effect). </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.667pt 0pt 2.333pt 0pt; width:42pt;">3.3* </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.667pt 0pt 2.333pt 0pt; width:402pt;white-space:normal;">Form of Amended and Restated Articles of Association of the Registrant to become effective in connection with this offering. </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:5pt 0pt 3pt 0pt; width:42pt;">4.1* </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:5pt 0pt 3pt 0pt; width:402pt;">Form of Specimen Share Certificate. </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.667pt 0pt 2.333pt 0pt; width:42pt;">5.1*</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.667pt 0pt 2.333pt 0pt; width:402pt;white-space:normal;">Opinion of Gross, Kleinhendler, Hodak, Halevy, Greenberg &amp; Co., Israeli counsel to the Registrant, as to the validity of the ordinary shares. </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:5pt 0pt 3pt 0pt; width:42pt;">10.1*#</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:5pt 0pt 3pt 0pt; width:402pt;">Form of Amended and Restated 2014 Share Incentive Plan.</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:5pt 0pt 3pt 0pt; width:42pt;">10.2* </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:5pt 0pt 3pt 0pt; width:402pt;">Form of Registration Rights Agreement. </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.667pt 0pt 2.333pt 0pt; width:42pt;">10.3+* </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.667pt 0pt 2.333pt 0pt; width:402pt;white-space:normal;">Development, Manufacturing and Commercialization Agreement between Perrigo UK Finco Limited Partnership and Sol-Gel Technologies Ltd., dated as of April 27, 2015.</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.667pt 0pt 2.333pt 0pt; width:42pt;">10.4+* </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.667pt 0pt 2.333pt 0pt; width:402pt;white-space:normal;">Amendment to the Development, Manufacturing and Commercialization Agreement between the Registrant and Perrigo UK Finco Limited Partnership, dated as of October 26, 2015.</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:5pt 0pt 3pt 0pt; width:42pt;">10.5* </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:5pt 0pt 3pt 0pt; width:402pt;">Form of Indemnification Agreement. </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:5pt 0pt 3pt 0pt; width:42pt;">10.6*#</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:5pt 0pt 3pt 0pt; width:402pt;">Compensation Policy. </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.667pt 0pt 2.333pt 0pt; width:42pt;">10.7&#8734; </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.667pt 0pt 2.333pt 0pt; width:402pt;white-space:normal;">Lease Agreement by and between the Registrant and Rachel Zacks, dated as of October&#160;10, 2007.</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.667pt 0pt 2.333pt 0pt; width:42pt;">10.8&#8734; </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.667pt 0pt 2.333pt 0pt; width:402pt;white-space:normal;">Lease Agreement by and between the Registrant and Rachel Zacks, dated as of September&#160;29, 2014.</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.667pt 0pt 2.333pt 0pt; width:42pt;">10.9&#8734; </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.667pt 0pt 2.333pt 0pt; width:402pt;white-space:normal;">Lease Agreement by and between the Registrant and Rachel Zacks, dated as of March&#160;30, 2016.</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.667pt 0pt 2.333pt 0pt; width:42pt;">10.10&#8734; </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.667pt 0pt 2.333pt 0pt; width:402pt;white-space:normal;">Lease Agreement by and between the Registrant and Rachel Zacks, dated as of September 20, 2016.</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.667pt 0pt 2.333pt 0pt; width:42pt;">10.11&#8734; </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.667pt 0pt 2.333pt 0pt; width:402pt;white-space:normal;">Lease Agreement by and between the Registrant and Rachel Zacks, dated as of January&#160;30, 2017.</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.667pt 0pt 2.333pt 0pt; width:42pt;">10.12</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.667pt 0pt 2.333pt 0pt; width:402pt;white-space:normal;">Promissory Note by and between the Registrant and Moshe Arkin, dated as of August&#160;2, 2016.</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.667pt 0pt 2.333pt 0pt; width:42pt;">10.13</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.667pt 0pt 2.333pt 0pt; width:402pt;white-space:normal;">Schedule A, as amended, of Promissory Note by and between the Registrant and Moshe Arkin, dated as of June 28, 2017.</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.667pt 0pt 2.333pt 0pt; width:42pt;">10.14</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.667pt 0pt 2.333pt 0pt; width:402pt;white-space:normal;">Instrument of Conversion of Promissory Note by and between the Registrant and Moshe Arkin, dated as of August&#160;22, 2017. </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.667pt 0pt 2.333pt 0pt; width:42pt;">10.15</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.667pt 0pt 2.333pt 0pt; width:402pt;white-space:normal;">Assignment Agreement between the Registrant and Medicis Pharmaceutical Corporation, dated August 16, 2013.</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.667pt 0pt 2.333pt 0pt; width:42pt;">23.1</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.667pt 0pt 2.333pt 0pt; width:402pt;white-space:normal;">Consent of Kesselman and Kesselman, Member Firm of PricewaterhouseCoopers International Limited. </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.667pt 0pt 2.333pt 0pt; width:42pt;">23.2*</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.667pt 0pt 2.333pt 0pt; width:402pt;white-space:normal;">Consent of Gross, Kleinhendler, Hodak, Halevy, Greenberg &amp; Co., Israeli counsel to the Registrant (included in Exhibit 5.1). </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:5pt 0pt 2.333pt 0pt; width:42pt;">24.1</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:5pt 0pt 2.333pt 0pt; width:402pt;">Power of Attorney (included in the signature page of the Registration Statement).</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">II-6</div>
      </div>
      <hr >
    </div>
    <div style=" width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <table style="width:456pt;height:113.5pt;margin-top:0pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:42pt;">
              <div style="white-space:nowrap;">Exhibit No. </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:402pt;text-align:center;">
              <div style="white-space:nowrap; text-align:center;">Description </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3pt 0pt; width:42pt;">99.1</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 3pt 0pt; width:402pt;">Consent of director nominee. </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:5pt 0pt 3pt 0pt; width:42pt;">99.2</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:5pt 0pt 3pt 0pt; width:402pt;">Consent of director nominee. </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:5pt 0pt 3pt 0pt; width:42pt;">99.3</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:5pt 0pt 3pt 0pt; width:402pt;">Consent of director nominee. </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:5pt 0pt 3pt 0pt; width:42pt;">99.4 </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:5pt 0pt 3pt 0pt; width:402pt;">Consent of director nominee. </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:5pt 0pt 3pt 0pt; width:42pt;">99.5 </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:5pt 0pt 3pt 0pt; width:402pt;">Consent of director nominee. </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Palatino Linotype, Book Antiqua, Palatino, serif;font-size:10pt;">
            <td style="padding:5pt 0pt 3pt 0pt; width:42pt;">99.6 </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:5pt 0pt 3pt 0pt; width:402pt;">Consent of director nominee.</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:14.49pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:15pt;white-space:nowrap;font-size:8pt;">*<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:10pt; text-align:left; width:440.5pt;font-size:8pt;">To be filed by amendment</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:10pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:15pt;white-space:nowrap;font-size:8pt;">&#8734;<br ></div>
        <div style=" float:left; margin-top:9.97pt; margin-bottom:0pt; line-height:10pt; text-align:left; width:440.5pt;font-size:8pt;">Informal English translation of the original Hebrew document</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:10pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:15pt;white-space:nowrap;font-size:8pt;">+<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:10pt; text-align:left; width:440.5pt;font-size:8pt;">Confidential treatment to be requested</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:10pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:15pt;white-space:nowrap;font-size:8pt;">#<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:10pt; text-align:left; width:440.5pt;font-size:8pt;">Indicates management contract or compensatory plan</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">II-7</div>
      </div>
      <hr >
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.2
<SEQUENCE>2
<FILENAME>t1702381_ex3-2.htm
<DESCRIPTION>EXHIBIT 3.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 3.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>The
Companies Law - 1999</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>A
Company Limited by Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Articles
of Association</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>of</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>SOL-GEL
TECHNOLOGIES LTD.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Preliminary</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in; text-align: left"><FONT STYLE="font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><B><U>Definitions</U></B></FONT>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in; text-align: left"><FONT STYLE="font-size: 10pt">1.1.</FONT></TD><TD STYLE="text-align: justify">Capitalized terms used in these Articles shall bear the
meanings ascribed to such terms as set forth in this Article, unless inconsistent with the context:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 85%; border-collapse: collapse; margin-left: 1in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><B>Term</B></FONT></TD>
    <TD STYLE="width: 3%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 67%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-variant: small-caps"><B>Definition</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Articles</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">These Articles of Association as amended from time to time by a Shareholders&rsquo; resolution; </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Auditors</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The auditors of the Company;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Board of Directors; Board</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The Board of Directors of the Company;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Chairman</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The Chairman of the Board of Directors, as may be appointed, from time to time (if appointed);</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Company</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">SOL-GEL TECHNOLOGIES LTD.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Companies Law</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The Companies Law, 1999, or any statutory re-enactment or modification thereof being in force at the time; and any reference to any section or provision of the Companies Law shall be deemed to include a reference to any statutory re-enactment or modification thereof being in force at the time;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Companies Ordinance</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The Companies Ordinance (New Version), 5743-1983, or any statutory re-enactment or modification thereof being in force at the time; and any reference to any section or provision of the Companies Ordinance shall be deemed to include a reference to any statutory re-enactment or modification thereof being in force at the time;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Director(s)</FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The member(s) of the Board of Directors appointed in accordance with these Articles holding office at any given time;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 85%; border-collapse: collapse; margin-left: 1in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 30%"><FONT STYLE="font-family: Times New Roman, Times, Serif">month</FONT></TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 67%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Calendar month;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Office</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The Registered Office of the Company at any given time;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Officer (&lsquo;<I>Nosei Misra&rsquo;</I>)</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">As defined in the Companies Law;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Register of Shareholders</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The Register of Shareholders of the Company administered in accordance to Section 127 of the Companies Law;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">RTP Law</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The Israeli Restrictive Trade Practices Law, 5758-1988, as amended from time to time, and any regulations promulgated thereunder;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Shareholders</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">The shareholders of the Company, at any given time;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">in writing</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Written, printed, photocopied, typed, sent via facsimile or produced by any visible substitute for writing, or partly one and partly another, and signed shall be construed accordingly.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif">Year</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Calendar year commencing on January 1<SUP>st</SUP> and ending on December 31<SUP>st</SUP>;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-size: 10pt">1.2.</FONT></TD><TD STYLE="text-align: justify">Unless the context shall otherwise require: words in the singular shall also include the plural, and vice versa; any pronoun
shall include the corresponding masculine, feminine and neuter forms; the words &ldquo;include&rdquo;, &ldquo;includes&rdquo; and
&ldquo;including&rdquo; shall be deemed to be followed by the phrase &ldquo;without limitation&rdquo;; the words &ldquo;herein&rdquo;,
&ldquo;hereof&rdquo; and &ldquo;hereunder&rdquo; and words of similar import refer to these Articles in its entirety and not to
any part hereof; all references herein to Articles, Sections or clauses shall be deemed references to Articles, Sections or clauses
of these Articles; any references to any agreement or other instrument or law, statute or regulation are to it as amended, supplemented
or restated, from time to time (and, in the case of any law, to any successor provisions or re-enactment or modification thereof
being in force at the time); any reference to &ldquo;law&rdquo; shall include any supranational, national, federal, state, local,
or foreign statute or law and shall be deemed also to refer to all rules and regulations promulgated thereunder; any reference
in this Agreement to a &ldquo;day&rdquo; or a number of &ldquo;days&rdquo; (without any explicit reference otherwise, such as to
business days) shall be interpreted as a reference to a calendar day or number of calendar days; reference to month<B> </B>or<B>
</B>year means according to the Gregorian calendar; reference to a &ldquo;company&rdquo;, &ldquo;corporate body&rdquo; or &ldquo;entity&rdquo;
shall include a, partnership, corporation, limited liability company, association, trust, unincorporated organization, or a government
or agency or political subdivision thereof, and reference to a &ldquo;person&rdquo; shall mean any of the foregoing or an individual.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">1.3.</FONT></TD><TD STYLE="text-align: justify">Save as aforesaid any words or expressions defined in the Companies Law or in the Companies Ordinance (to the extent still
in effect according to the provisions of the Companies Law), shall, if not inconsistent with the subject or context, bear the same
meaning in these Articles.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">1.4.</FONT></TD><TD STYLE="text-align: justify">The captions in these Articles are for convenience only and shall not be deemed a part hereof or affect the construction of
any provision hereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-size: 10pt">1.5.</FONT></TD><TD STYLE="text-align: justify">In the event that a Hebrew version of these Articles is filed with any regulatory or governmental agency, including the Israeli
Registrar of Companies, then whether or not such Hebrew version contains signatures of Shareholders, such Hebrew version shall
be considered solely a convenience translation and shall have no binding effect, as between the Shareholders of the Company and
with respect to any third party. The English version shall be the only binding version of these Articles, and in the event of any
contradiction or inconsistency between the meaning of the English version and the meaning of the Hebrew version of these Articles,
the Hebrew version shall be disregarded, shall have no binding effect and shall have no impact on the interpretation of these Articles
or any provision hereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><B><U>Private company</U></B></FONT>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">The Company is a private company, and accordingly:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">2.1.</FONT></TD><TD STYLE="text-align: justify">the right to transfer shares is restricted in the manner hereinafter prescribed;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">2.2.</FONT></TD><TD STYLE="text-align: justify">the number of Shareholders (exclusive of persons who are in the employment of the Company, or of persons who having been formerly
in the employment of the Company were, while in such employment, and have continued after the termination of such employment to
be, Shareholders of the Company) is limited to 50; provided that where two or more persons hold one or more shares in the Company
jointly they shall, for the purpose of this Article, be treated as a single shareholder;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">2.3.</FONT></TD><TD STYLE="text-align: justify">any invitation to the public to subscribe for any shares or debentures of the Company is prohibited.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Limited
Liability</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in; text-align: left"><FONT STYLE="font-size: 10pt">3.</FONT></TD><TD STYLE="text-align: justify">The Company is a Limited Liability Company and therefore
each Shareholder&rsquo;s obligations to the Company&rsquo;s obligations shall be limited to the payment of the par value of the
shares held by such Shareholder, subject to the provisions of the Companies Law.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Company&rsquo;s
Objectives</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%; text-align: left"></TD><TD STYLE="width: 0.4in; text-align: left"><FONT STYLE="font-size: 10pt">4.</FONT></TD><TD STYLE="text-align: justify">The Company&rsquo;s objectives are to carry on any business,
and do any act, which is not prohibited by law.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">5.</FONT></TD><TD STYLE="text-align: justify">The Company may donate a reasonable amount of money for
any purpose that the Board of Directors finds appropriate, even if the donation is not for business considerations for the purpose
of achieving profits to the Company.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Share
Capital</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in; text-align: left"><FONT STYLE="font-size: 10pt">6.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><B><U>Share Capital</U></B></FONT>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">The share capital of the Company is NIS 877,578.30
divided into 8,775,783 Ordinary Shares, par value of NIS 0.1 each (the &ldquo;<B>Ordinary Shares</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">The rights attached to the Ordinary Shares shall
be all the rights in the Company including, without limitation, the right to receive notices of Shareholders meetings, to attend
and vote at Shareholders&rsquo; meetings, to participate in distribution of dividends and stock dividends and to participate in
distribution of surplus assets and funds in liquidation of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">7.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><B><U>Increase of
Share Capital</U></B></FONT>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">7.1.</FONT></TD><TD STYLE="text-align: justify">The Company may, from time to time, by a Shareholders resolution, whether or not all the shares then authorized have been issued,
and whether or not all the shares theretofore issued have been called up for payment, increase its share capital by the creation
of new shares. Any such increase shall be in such amount and shall be divided into shares of such nominal amounts, and such shares
shall confer such rights and preferences, and shall be subject to such restrictions, as such resolution shall provide.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-size: 10pt">7.2.</FONT></TD><TD STYLE="text-align: justify">Except to the extent otherwise provided in such resolution, such new shares shall be subject to all the provisions applicable
to the shares of the original capital.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">8.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><B><U>Special Rights;
Modifications of Rights</U></B></FONT>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">8.1.</FONT></TD><TD STYLE="text-align: justify">Subject to the provisions of these Articles and the Companies Law, the Company may, from time to time, provide for shares with
such preferred or deferred rights or rights of redemption or other special rights and/or such restrictions, whether in regard to
dividends, voting, repayment of share capital or otherwise, as may be stipulated in such resolution.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">8.2.</FONT></TD><TD STYLE="text-align: justify">If at any time, the share capital is divided into different classes of shares, the rights attached to any class, unless otherwise
provided by these Articles, may be modified or abrogated by the Company, subject to a resolution passed at a separate General Meeting
of the holders of the shares of such class.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">8.3.</FONT></TD><TD STYLE="text-align: justify">The provisions of these Articles relating to General Meetings shall apply, in the relevant changes, to any separate General
Meeting of the holders of the shares of a particular class.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">8.4.</FONT></TD><TD STYLE="text-align: justify">Without prejudice, the increase of the authorized share capital, the creation of a new class of shares, the increase of the
authorized share capital of a class of shares, or the issuance of shares of any class out of the authorized and unissued share
capital, shall not be deemed to modify or abrogate the rights attached to any class of shares, whether previously issued shares
of such class or of any other class.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">9.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><B><U>Consolidation, Subdivision, Cancellation and Reduction of Share Capital</U></B>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">9.1.</FONT></TD><TD STYLE="text-align: justify">The Company may, by Shareholders&rsquo; resolution and subject to the Companies Law, from time to time:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">9.1.1.</FONT></TD><TD STYLE="text-align: justify">consolidate all or any of its issued or unissued share capital into shares of larger, equal to or smaller nominal value than
its existing shares;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.35pt; text-indent: -8.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">9.1.2.</FONT></TD><TD STYLE="text-align: justify">divide its shares (issued or unissued) or any of them,
into shares of smaller or the same nominal value than is fixed by these Articles (subject, however, to the provisions of the Companies
Law), and the resolution whereby any share is divided may determine that, as among the holders of the shares resulting from such
subdivision, one or more of the shares may, in contrast to others, have any such preferred or deferred rights or rights of redemption
or other special rights, or be subject to any such restrictions, as the Company may attach to unissued or new shares;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.35pt; text-indent: -8.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">9.1.3.</FONT></TD><TD STYLE="text-align: justify">cancel any shares which, at the date of the adoption of
such resolution, have not been taken or agreed to be taken by any person, and diminish the amount of its share capital by the
amount of the shares so canceled, or</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.35pt; text-indent: -8.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">9.1.4.</FONT></TD><TD STYLE="text-align: justify">reduce its authorized share capital in any manner.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.35pt; text-indent: -8.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">9.2.</FONT></TD><TD STYLE="text-align: justify">With
                                         respect to any consolidation of issued shares and with respect to any other action which
                                         may result in fractional shares, the Board of Directors may settle any difficulty which
                                         may arise with regard thereto, as it deems fit, including, <I>inter alia</I>, resort
                                         to one or more of the following actions:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">9.2.1.</FONT></TD><TD STYLE="text-align: justify">determine, as to the holder of shares so consolidated, which issued shares shall be consolidated into each share of larger,
equal or smaller nominal value;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.35pt; text-indent: -8.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">9.2.2.</FONT></TD><TD STYLE="text-align: justify">allot, in contemplation of or subsequent to such consolidation or other action, such shares or fractional shares sufficient
to preclude or remove fractional share holdings;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.35pt; text-indent: -8.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">9.2.3.</FONT></TD><TD STYLE="text-align: justify">redeem, in the case of redeemable shares, and subject to applicable law, such shares or fractional shares sufficient to preclude
or remove fractional share holdings;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.35pt; text-indent: -8.5pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">9.2.4.</FONT></TD><TD STYLE="text-align: justify">round up, round down or round to the nearest whole number, any fractional shares resulting from the consolidation or from any
other action which may result in fractional shares;</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.35pt; text-indent: -8.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-size: 10pt">9.2.5.</FONT></TD><TD STYLE="text-align: justify">cause the transfer of fractional shares by certain Shareholders to other Shareholders so as to most expediently preclude or
remove any fractional shareholdings, and cause the transferees to pay the transferors the fair value of fractional shares so transferred,
and the Board of Directors is hereby authorized to act as agent for the transferors and transferees with power of substitution
for purposes of implementing the provisions of this sub-Article 9.2.5.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.35pt; text-indent: -8.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in; text-align: left"><FONT STYLE="font-size: 10pt">10.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><B><U>Issuance of
Share Certificates; Replacement of Lost Certificates</U></B></FONT>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">10.1.</FONT></TD><TD STYLE="text-align: justify">Share certificates shall be issued under the stamp of the Company and shall bear the signatures of a Director and/or of any
other person or persons authorized thereto by the Board of Directors.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">10.2.</FONT></TD><TD STYLE="text-align: justify">Each shareholder shall be entitled to one numbered certificate for all the shares of any class registered in his name, and
if the Board of Directors so approves, to several certificates, each for one or more of such shares. Each certificate shall specify
the serial numbers of the shares represented thereby and may also specify the amount paid up thereon.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">10.3.</FONT></TD><TD STYLE="text-align: justify">A share certificate registered in the names of two or more persons shall be delivered to the person first named in the Registrar
of Shareholders in respect of such co-ownership.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">10.4.</FONT></TD><TD STYLE="text-align: justify">If a share certificate is defaced, lost or destroyed, it may be replaced, upon payment of such fee, and upon the furnishing
of such evidence of ownership and such indemnity, as the Board of Directors may think fit.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">11.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><B><U>Registered
Holder</U></B></FONT>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">Except as otherwise provided in these Articles,
the Company shall be entitled to treat the registered holder of any share as the absolute owner thereof, and, accordingly, shall
not, except as ordered by a court of competent jurisdiction, or as required by statute, be bound to recognize any equitable or
other claim to, or interest in such share on the part of any other person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">12.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><B><U>Allotment
of Shares</U></B></FONT>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">12.1.</FONT></TD><TD STYLE="text-align: justify">The
                                         shares, other than the issued and outstanding shares, shall be under the control of the
                                         Board of Directors, who shall have the power to allot shares or otherwise dispose of
                                         them to such persons, on such terms and conditions (including, <I>inter alia</I>, terms
                                         relating to calls as set forth in Article 14.6 hereof), and either at par or at a premium,
                                         or, subject to the provisions of the Companies Law, at a discount, and at such times,
                                         as the Board of Directors may think fit, and the power to give to any person the option
                                         to acquire from the Company any shares, either at par or at a premium, or, subject as
                                         aforesaid, at a discount, during such time and for such consideration as the Board of
                                         Directors may think fit. Such issuance may be made in cash, cash equivalents or for in
                                         kind consideration.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">12.2.</FONT></TD><TD STYLE="text-align: justify">Section 290(a) of the Companies Law shall not apply to the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">13.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><B><U>Payment in
Installments</U></B></FONT>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">If by the terms of allotment of any share, the whole
or any part of the price thereof shall be payable in installments, every such installment shall, when due, be paid to the Company
by the then registered holder(s) of the share of the person(s) entitled thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">14.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><B><U>Calls on Shares</U></B></FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">14.1.</FONT></TD><TD STYLE="text-align: justify">The Board of Directors may, from time to time make such calls as it may think fit upon Shareholders in respect of any sum unpaid
in respect of shares held by such Shareholders which is not, by the terms of allotment thereof or otherwise, payable at a fixed
time, and each shareholder shall pay the amount of every call so made upon him (and of each installment thereof if the
same is payable in installments), to the person(s) and at the time(s) and place(s) designated by the Board of Directors, as any
such time(s) may be thereafter extended and/or such person(s) or place(s) changed. Unless otherwise stipulated in the resolution
of the Board of Directors (and in the notice hereafter referred to), each payment in response to a call shall be deemed to constitute
a pro rata payment on account of all shares in respect of which such call was made.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-size: 10pt">14.2.</FONT></TD><TD STYLE="text-align: justify">Notice of any call shall be given in writing to the shareholder (s) in question not less than fourteen (14) days prior to the
time of payment, specifying the time and place of payment, and designating the person to whom such payment shall be made, provided,
however, that before the time for any such payment, the Board of Directors may, by notice in writing to such shareholder (s), revoke
such call in whole or in part, extend such time, or alter such person and/or place. In the event of a call payable in installments,
only one notice thereof need be given.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">14.3.</FONT></TD><TD STYLE="text-align: justify">If, by the terms of allotment of any share or otherwise, any amount is made payable at any fixed time, every such amount shall
be payable at such time as if it were a call duly made by the Board of Directors and of which due notice had been given, and all
the provisions herein contained with respect to such calls shall apply to each such amount.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">14.4.</FONT></TD><TD STYLE="text-align: justify">The joint holders of a share shall be jointly and severally liable to pay all calls in respect thereof and all interest payable
thereon.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">14.5.</FONT></TD><TD STYLE="text-align: justify">Any amount unpaid in respect of a call shall bear interest from the date on which it is payable until actual payment thereof,
at such rate (not exceeding the then prevailing debitory rate charged by leading commercial banks in Israel), and at such time(s)
as the Board of Directors may prescribe.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">14.6.</FONT></TD><TD STYLE="text-align: justify">Upon the allotment of shares, the Board of Directors may provide for differences among the allottees of such shares as to the
amount of calls and/or the times of payment thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">15.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><B><U>Prepayment</U></B></FONT>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">With the approval of the Board of Directors, any
shareholder may pay to the Company any amount not yet payable in respect of his shares, and the Board of Directors may approve
the payment of interest on any such amount until the same would be payable if it had not been paid in advance, at such rate and
time(s) as may be approved by the Board of Directors. The Board of Directors may at any time cause the Company to repay all or
any part of the money so advanced, without premium or penalty. Nothing in this Article 15 shall derogate from the right of the
Board of Directors to make any call before or after receipt by the Company of any such advance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">16.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><B><U>Forfeiture
and Surrender</U></B></FONT>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">16.1.</FONT></TD><TD STYLE="text-align: justify">If
                                         any shareholder fails to pay any amount payable in respect of a call, or interest thereon
                                         as provided for herein, on or before the day fixed for payment of the same, the Company,
                                         by resolution of the Board of Directors, and subject to the provisions of Section 181
                                         of the Companies Law, may at any time thereafter, so long as the said amount or interest
                                         remains unpaid, forfeit all or any of the shares in respect of which said call had been
                                         made. Any expense incurred by the Company in attempting to collect any such amount or
                                         interest, including, <I>inter alia</I>, attorneys&rsquo; fees and costs of suit, shall
                                         be added to, and shall, for all purposes (including the accrual of interest thereon),
                                         constitute a part of the amount payable to the Company in respect of such call.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">16.2.</FONT></TD><TD STYLE="text-align: justify">Upon the adoption of a resolution of forfeiture, the Board of Directors shall cause notice thereof to be given to such shareholder,
which notice shall state that, in the event of the failure to pay the entire amount so payable within a period stipulated in the
notice (which period shall not be less than fourteen (14) days and which may be extended by the Board of Directors), such shares
shall be ipso facto forfeited, provided, however, that, prior to the expiration of such period, the Board of Directors may nullify
such resolution of forfeiture, but no such nullification
shall stop the Board of Directors from adopting a further resolution of forfeiture in respect of the non-payment of the same amount.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-size: 10pt">16.3.</FONT></TD><TD STYLE="text-align: justify">Whenever shares are forfeited as herein provided, all dividends theretofore declared in respect thereof and not actually paid
shall be deemed to have been forfeited at the same time.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">16.4.</FONT></TD><TD STYLE="text-align: justify">The Company, by resolution of the Board of Directors, may accept the voluntary surrender of any share.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">16.5.</FONT></TD><TD STYLE="text-align: justify">Any share forfeited or surrendered as provided herein shall become dormant shares (as defined in Section 308 of the Companies
Law), and the same, subject to the provisions of these Articles, may be sold, re-allotted or otherwise disposed of as the Board
of Directors thinks fit.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">16.6.</FONT></TD><TD STYLE="text-align: justify">Any shareholder whose shares have been forfeited or surrendered shall cease to be a shareholder in respect of the forfeited
or surrendered shares, but shall, notwithstanding, be liable to pay, and shall forthwith pay, to the Company, all calls, interest
and expenses owing upon or in respect of such shares at the time of forfeiture or surrender, together with interest thereon from
the time of forfeiture or surrender until actual payment, at the rate prescribed in Article 14.5 above, unless such shares were
sold by the Company, and the Company shall have received in full the amounts specified above in addition to any additional costs
of such sale of shares, and the Board of Directors, in its discretion, may enforce the payment of such moneys, or any part thereof,
but shall not be under any obligation to do so. In the event of such forfeiture or surrender, the Company, by resolution of the
Board of Directors, may accelerate the date(s) of payment of any or all amounts then owing by the shareholder in question (but
not yet due) in respect of all shares owned by such shareholder, solely or jointly with another, and in respect of any other matter
or transaction whatsoever.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">16.7.</FONT></TD><TD STYLE="text-align: justify">The Board of Directors may at any time, before any share so forfeited or surrendered shall have been sold, re-allotted or otherwise
disposed of, nullify the forfeiture or surrender on such conditions as it thinks fit, but no such nullification shall stop the
Board of Directors from re-exercising its powers of forfeiture pursuant to this Article 16.7.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">17.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><B><U>Lien</U></B></FONT>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">17.1.</FONT></TD><TD STYLE="text-align: justify">Except to the extent the same may be waived or subordinated in writing, the Company shall have a first and paramount lien upon
all the shares registered in the name of each Shareholder (without regard to any equitable or other claim or interest in such shares
on the part of any other person), and upon the proceeds of the sale thereof, for the call on shares made by the Board of Directors,
in respect of unpaid sum relating to shares held by such Shareholder. Such lien shall extend to all dividends from time to time
declared in respect of such share. Unless otherwise provided, the registration by the Company of a transfer of shares shall not
be deemed to be a waiver on the part of the Company of the lien (if any) existing on such shares immediately prior to such transfer.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">17.2.</FONT></TD><TD STYLE="text-align: justify">The Board of Directors may cause the Company to sell any shares subject to such lien when any such debt, liability or engagement
has matured, in such manner as the Board of Directors may think fit, but no such sale shall be made unless such debt, liability
or engagement has not been satisfied within fourteen (14) days after written notice of the intention to sell shall have been served
on such shareholder, his executors or administrators.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">17.3.</FONT></TD><TD STYLE="text-align: justify">The net proceeds of any such sale, after payment of the costs thereof, shall be applied in or toward satisfaction of the debts,
liabilities or engagements of such Shareholder (whether or not the same have matured), or any specific part of the same (as the
Company may determine), and the residue (if any) shall be paid to the shareholder, his executors, administrators or assigns.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-size: 10pt">18.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><B><U>Sale after Forfeiture or Surrender or in Enforcement of Lien</U></B></FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-indent: -19.85pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">Upon any sale of shares after forfeiture or surrender
or for enforcing a lien, the Board of Directors may appoint some person to execute an instrument of transfer of the shares so sold
and cause the purchaser&rsquo;s name to be entered in the Register of Shareholders in respect of such shares, and the purchaser
shall not be bound to see to the regularity of the proceedings, or to the application of the purchase money, and after his name
has been entered in the Register of Shareholders in respect of such shares, the validity of the sale shall not be impeached by
any person, and the remedy of any person aggrieved by the sale shall be in damages only and against the Company exclusively.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">19.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><B><U>Redeemable Shares</U></B></FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">The Company may, subject to applicable law, issue
redeemable shares and redeem the same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Transfer
Of Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-size: 10pt">20.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><B><U>Effectiveness and Registration</U></B></FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">20.1.</FONT></TD><TD STYLE="text-align: justify">No transfer of shares in the Company, and no assignment of an option to acquire such shares from the Company, shall be effective
unless the transfer or assignment has been approved by the Board of Directors, such approval shall be at the sole discretion of
the Board of Directors. The Board of Directors may refuse to approve such transfer or assignment without the need to give any reasons.
Without limiting the forgoing, no transfer or other disposition of Ordinary Shares issued upon exercise of Awards (as defined and
under the Company&rsquo;s 2014 Share Incentive Plan (the &quot;<B>Plan</B>&quot;)) shall be made, except in accordance with the
provisions of these Articles and the Plan.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">20.2.</FONT></TD><TD STYLE="text-align: justify">No such transfer as described in Article 20.1 shall be registered unless a proper instrument of transfer (in form and substance
satisfactory to the Board of Directors) has been submitted to the Company, together with the share certificate(s) and such other
evidence of title as the Board of Directors may reasonably require. Until the transferee has been registered in the Register of
Shareholders in respect of the shares so transferred, the Company may continue to regard the transferor as the owner thereof. The
Board of Directors, may, from time to time, prescribe a fee for the registration of a transfer.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">21.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><B><U>Suspension
of Registration</U></B></FONT>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-indent: -19.85pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">The Board of Directors may suspend the registration
of transfers during the fourteen (14) days immediately preceding the Annual General Meeting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Transmission
of Shares</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in; text-align: left"><FONT STYLE="font-size: 10pt">22.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><B><U>Decedent&rsquo;s
Shares</U></B></FONT>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-size: 10pt">22.1.</FONT></TD><TD STYLE="text-align: justify">In case of a share registered in the names of two or more holders, the Company shall recognize the survivor(s) as the sole
owner(s) thereof unless and until the provisions of Article 22.20 have been effectively invoked.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">22.2.</FONT></TD><TD STYLE="text-align: justify">Any person becoming entitled to a share in consequence of the death of any person, upon producing evidence of the grant of
probate or letters of administration or declaration of succession shall be registered as a shareholder in respect of such share,
or may, subject to the regulations as to transfer herein contained, transfer such share.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">23.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><B><U>Receivers
and Liquidators</U></B></FONT>.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-indent: -19.85pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">23.1.</FONT></TD><TD STYLE="text-align: justify">The Company may recognize the receiver or liquidator of any corporate shareholder in winding-up or dissolution, or the receiver
or trustee in bankruptcy of any shareholder, as being entitled to the shares registered in the name of such shareholder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">23.2.</FONT></TD><TD STYLE="text-align: justify">The receiver or liquidator of a corporate shareholder in winding-up or dissolution, or the receiver or trustee in bankruptcy
of any shareholder, upon producing such evidence as the Board of Directors may deem
sufficient that he sustains the character in respect of which he proposes to act under this Article or of his title, shall with
the consent of the Board of Directors (which the Board of Directors may grant or refuse in its absolute discretion), be registered
as a shareholder in respect of such shares, or may, subject to the regulations as to transfer herein contained, transfer such shares.</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>General
Meetings</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-size: 10pt">24.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><B><U>Annual General Meeting</U></B></FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-indent: -19.85pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">An Annual General Meeting shall be held once in
every calendar year at such time (within a period of not more than fifteen (15) months after the last preceding Annual General
Meeting) and at such place either within or without the State of Israel as may be determined by the Board of Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">25.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><B><U>Extraordinary General Meetings</U></B></FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-indent: -19.85pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">All General Meetings other than the Annual General
Meetings shall be called &ldquo;<B>Extraordinary General Meetings</B>&rdquo;. The Board of Directors may, whenever it thinks fit,
convene an Extraordinary General Meeting at such time and place, within or without the State of Israel, as may be determined by
the Board of Directors, and shall be obliged to do so upon a requisition in writing in accordance with Section 63 of the Companies
Law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">26.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><B><U>Notice of General Meetings; Omission to Give Notice; Record Date</U></B></FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-indent: -19.85pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">26.1.</FONT></TD><TD STYLE="text-align: justify">Not less than seven (7) days&rsquo; prior notice shall be given of every General Meeting. Each such notice shall specify the
place and the day and hour of the meeting and the general nature of each item to be acted upon thereat. Notice shall be given to
all Shareholders who would be entitled to attend and vote at such meeting, if it were held on the date when such notice is issued.
Anything herein to the contrary notwithstanding, with the consent of all Shareholders entitled to vote thereon, a resolution may
be proposed and passed at such meeting although a lesser notice than hereinabove prescribed has been given.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">26.2.</FONT></TD><TD STYLE="text-align: justify">The accidental omission to give notice of a meeting to any shareholder or the non-receipt of notice sent to such shareholder,
shall not invalidate the proceedings at such meeting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">26.3.</FONT></TD><TD STYLE="text-align: justify">Unless otherwise specified in these Articles, the Board of Directors shall specify a record date for determining the identity
of the Shareholders entitled to receive notices of Shareholders meetings, vote in such meetings and for any other matter with regard
to the rights of the Shareholders, including without limitation, the rights with regard to distribution of dividends.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Proceedings
at General Meetings</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-size: 10pt">27.</FONT></TD><TD><FONT STYLE="font-variant: small-caps"><B><U>Quorum</U></B></FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-size: 10pt">27.1.</FONT></TD><TD STYLE="text-align: justify">Shareholder(s) (not in default in payment of any sum referred to in Article 33.1 hereof), present in person, by audio or video
conference so long as each Shareholder participating in such call can hear, and be heard by, each other Shareholders participating
in such General Meeting, or by proxy and holding shares conferring in the aggregate a majority of the voting power of the Company,
shall constitute a quorum at General Meetings. No business shall be transacted at a General Meeting, or at any adjournment thereof,
unless the requisite quorum is present when the meeting proceeds to business.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">27.2.</FONT></TD><TD STYLE="text-align: justify">Shareholders entitled to be present and vote at a General Meeting may participate in a General Meeting by means of audio or
video conference or similar communications equipment by means of which all persons participating in the meeting can hear each other,
and such participation in a meeting shall constitute attendance in person at the meeting.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">27.3.</FONT></TD><TD STYLE="text-align: justify">If within an hour from the time appointed for the meeting a quorum is not present, the meeting, if convened upon requisition
under Sections 63 or 64 of the Companies Law, shall be dissolved, but in any other case it shall stand adjourned to the same day
in the next week, at the same time and
place, or to such day and at such time and place as the Chairman may determine with the consent of the holders of a majority of
the voting power represented at the meeting in person or by proxy and voting on the question of adjournment. No business shall
be transacted at any adjourned meeting except business, which might lawfully have been transacted at the meeting as originally
called. At such adjourned meeting, any two (2) Shareholders (not in default as aforesaid) present, in person or by proxy, shall
constitute a quorum.</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-size: 10pt">28.</FONT></TD><TD><FONT STYLE="font-variant: small-caps"><B><U>Chairman</U></B></FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">The Shareholders present shall choose someone of
their number to be Chairman of the General Meeting. The office of Chairman shall not, by itself, entitle the holder thereof to
vote at any General Meeting nor shall it entitle such holder to a second or casting vote (without derogating, however, from the
rights of such Chairman to vote as a shareholder or proxy of a shareholder if, in fact, he is also a shareholder or such proxy).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">29.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><B><U>Adoption of resolutions at General Meetings</U></B></FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">29.1.</FONT></TD><TD STYLE="text-align: justify">A Shareholders resolution shall be deemed adopted if approved by the holders of a majority of the voting power represented
at the Shareholders meeting in person or by proxy and voting thereon.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">29.2.</FONT></TD><TD STYLE="text-align: justify">Every question submitted to a General Meeting shall be decided by a show of hands, but if a written ballot is demanded by any
shareholder present in person or by proxy and entitled to vote at the meeting, the same shall be decided by such ballot. A written
ballot may be demanded before the proposed resolution is voted upon or immediately after the declaration by the Chairman of the
results of the vote by a show of hands. If a vote by written ballot is taken after such declaration, the results of the vote by
a show of hands shall be of no effect, and the proposed resolution shall be decided by such written ballot. The demand for a written
ballot may be withdrawn at any time before the same is conducted, in which event another shareholder may then demand such written
ballot. The demand for a written ballot shall not prevent the continuance of the meeting for the transaction of business other
than the question on which the written ballot has been demanded.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">29.3.</FONT></TD><TD STYLE="text-align: justify">A declaration by the Chairman of the meeting that a resolution has been carried unanimously, or carried by a particular majority,
or lost, and an entry to that effect in the minute book of the Company, shall be conclusive evidence of the fact without proof
of the number or proportion of the votes recorded in favor of or against such resolution.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">30.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><B><U>resolutions in Writing</U></B></FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">A resolution in writing signed by all of the Shareholders
then entitled to attend and vote at General Meetings or to which all such Shareholders have given their written consent (by letter,
facsimile, telecopier, telegram, telex or otherwise) or their oral consent by telephone or otherwise (provided that a written summary
thereof has been approved and signed by the Chairman), shall be deemed to have been unanimously adopted by a General Meeting duly
convened and held.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">31.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><B><U>Power to Adjourn</U></B></FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">31.1.</FONT></TD><TD STYLE="text-align: justify">The Chairman of a General Meeting at which a quorum is present may, with the consent of the holders of a majority of the voting
power represented in person or by proxy and voting on the question of adjournment (and shall if so directed by the meeting), adjourn
the meeting from time to time and from place to place, but no business shall be transacted at any adjourned meeting except business
which might lawfully have been transacted at the meeting as originally called.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">31.2.</FONT></TD><TD STYLE="text-align: justify">It shall not be necessary to give any notice of an adjournment, unless the meeting is adjourned for a date which
is more than twenty-one (21) days, in which event notice thereof shall be given in the manner required for the meeting as originally
called.</TD></TR></TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-size: 10pt">32.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><B><U>Voting Power</U></B></FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">Subject to any provision hereof conferring special
rights as to voting, or restricting the right to vote, every Shareholder shall have one vote for each share held by him of record,
on every resolution, without regard to whether the vote thereon is conducted by a show of hands, by written ballot or by any other
means.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">33.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><B><U>Voting Rights</U></B></FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">33.1.</FONT></TD><TD STYLE="text-align: justify">No shareholder shall be entitled to vote at any General Meeting (or be counted as a part of the quorum thereat), unless all
calls and other sums then payable by him in respect of his shares in the Company have been paid.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">33.2.</FONT></TD><TD STYLE="text-align: justify">A company or other corporate body being a shareholder of the Company may authorize any person to be its representative at any
meeting of the Company. Any person so authorized shall be entitled to exercise on behalf of such shareholder all the power, which
the latter could have exercised if it were an individual shareholder. Upon the request of the Chairman of the meeting, written
evidence of such authorization (in form acceptable to the Chairman) shall be delivered to him.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">33.3.</FONT></TD><TD STYLE="text-align: justify">Any shareholder entitled to vote may vote either personally or by proxy (who need not be a shareholder of the Company), or,
if the shareholder is a company or other corporate body, by a representative authorized pursuant to Article 33.2.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">33.4.</FONT></TD><TD STYLE="text-align: justify">If two or more persons are registered as joint holders of any share, the vote of the senior who tenders a vote, in person or
by proxy, shall be accepted to the exclusion of the vote(s) of the other joint holder(s); and for this purpose seniority shall
be determined by the orders in which the names stand in the Register of Shareholders.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>Proxies</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-size: 10pt">34.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-variant: small-caps"><B><U>Instrument of Appointment</U></B></FONT>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">34.1.</FONT></TD><TD STYLE="text-align: justify">The instrument appointing a proxy shall be in writing and shall be substantially in the following form or in any usual or common
form or in such other form as may be approved by the Board of Directors. It shall be duly signed by the appointer or his duly authorized
attorney or, if such appointer is a company or other corporate body, under its common seal or stamp by its duly authorized agent(s)
or attorney(s):</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 85%; border-collapse: collapse; margin-left: 1in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 1%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&ldquo;I,&nbsp;</FONT></TD>
    <TD STYLE="width: 49%; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;of&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 49%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>(Name of Shareholder)</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>(Address of Shareholder)</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 85%; border-collapse: collapse; margin-left: 1in">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">being a shareholder of&nbsp;</FONT></TD>
    <TD STYLE="width: 49%; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;(the &ldquo;<B>Company</B>&rdquo;), hereby</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 85%; border-collapse: collapse; margin-left: 1in">
<TR STYLE="vertical-align: top">
    <TD NOWRAP STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif">appoint(s)&nbsp;</FONT></TD>
    <TD STYLE="width: 49%; border-bottom: Black 1pt solid">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;&nbsp;of&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 48%; border-bottom: Black 1pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>(Name of Proxy)</I></FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>(Address of Proxy)</I></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 85%; border-collapse: collapse; margin-left: 1in">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As my proxy, to
    vote for me and on my behalf at the General Meeting of the Company to be held on the ___ day of ______, 20__, and at any adjournment(s)
    thereof&rdquo;.</FONT></TD></TR>
</TABLE>
<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signed this &nbsp;___ day
of _________, 20___.</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse; margin-left: 0">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 25%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 50%; border-bottom: black 1pt solid; padding-left: 28.35pt"></TD>
    <TD STYLE="width: 25%"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-left: 28.35pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>(Signature
    of Appointer)</I></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-size: 10pt">34.2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The
                                         instrument appointing a proxy (and the power of attorney or other authority, if any,
                                         under which such instrument has been signed) shall either be delivered to the Company
                                         (at its Office, or at its principal place of business or at such place as the Board of
                                         Directors may specify) not less than forty-eight (48) hours before the time fixed for
                                         the meeting at which the person named in the instrument proposes to vote, or presented
                                         to the Chairman at such meeting.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">35.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B><U>Effect
                                         of Death of Appointer or Revocation of Appointment</U></B></FONT><FONT STYLE="font-size: 10pt">.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.4in; text-indent: -0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">A
vote cast pursuant to an instrument appointing a proxy shall be valid notwithstanding the previous death of the appointing shareholder
(or of his attorney-in-fact, if any, who signed such instrument), or the revocation of the appointment or the transfer of the
share in respect of which the vote is cast, provided no written intimation of such death, revocation or transfer shall have been
received by the Company or by the Chairman of the meeting before such vote is cast and provided, further, that the appointing
shareholder, if present in person at said meeting, may revoke the appointment by means of a writing, oral notification to the
Chairman, or otherwise.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>Board
Of Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-size: 10pt">36.</FONT></TD><TD><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B><U>Powers
                                         of Board of Directors</U></B>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-size: 10pt">36.1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><U>In
                                         General</U>. In addition to all powers and authorities of the Board of Directors as specified
                                         in the Companies Law, the determination of the Company&rsquo;s policy, and the supervision
                                         of the General Manager and the Company&rsquo;s officers shall be vested in the Board
                                         of Directors. In addition, the Board of Directors may exercise all such powers and do
                                         all such acts and things as the Company is authorized to exercise and do, and are not
                                         hereby or by law required to be exercised or done by the Company in General Meeting or
                                         by the General Manager or the Chief Executive Officer of the Company (the &ldquo;<B>General
                                         Manager</B>&rdquo;) under his express or residual authority. The authority conferred
                                         on the Board of Directors by this Article 36.1 shall be subject to the provisions of
                                         the Companies Law, these Articles and any regulation or resolution consistent with these
                                         Articles adopted from time to time by the Company in General Meeting, provided, however,
                                         that no such regulation or resolution shall invalidate any prior act done by or pursuant
                                         to a decision of the Board of Directors which would have been valid if such regulation
                                         or resolution had not been adopted.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">36.2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><U>Borrowing
                                         Power</U>. The Board of Directors may from time to time, in its discretion, cause the
                                         Company to borrow or secure the payment of any sum or sums of money for the purposes
                                         of the Company, and may secure or provide for the repayment of such sum or sums in such
                                         manner, at such times and upon such terms and conditions in all respects as it thinks
                                         fit, and, in particular, by the issuance of bonds, perpetual or redeemable debentures,
                                         debenture stock, or any mortgages, charges, or other securities on the undertaking or
                                         the whole or any part of the property of the Company, both present and future, including
                                         its uncalled or called but unpaid capital for the time being.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">36.3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><U>Reserves</U>.
                                         The Board of Directors may, from time to time, set aside any amount(s) out of the profits
                                         of the Company as a reserve or reserves for any purpose(s) which the Board of Directors,
                                         in its absolute discretion, shall think fit, and may invest any sum so set aside in any
                                         manner and from time to time deal with and vary such investments, and dispose of all
                                         or any part thereof, and employ any such reserve or any part thereof in the business
                                         of the Company without being bound to keep the same separate from other assets of the
                                         Company, and may subdivide or re-designate any reserve or cancel the same or apply the
                                         funds therein for another purpose, all as the Board of Directors may from time to time
                                         think fit.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 12; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-size: 10pt">37.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B><U>Exercise
                                         of Powers of Directors; Written resolution</U></B></FONT><FONT STYLE="font-size: 10pt">.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">37.1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">A
                                         meeting of the Board of Directors at which a quorum is present shall be competent to
                                         exercise all the authorities, powers and discretion vested in or exercisable by the Board
                                         of Directors.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">37.2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">A
                                         resolution proposed at any meeting of the Board of Directors shall be deemed adopted
                                         if approved by a majority of the Directors present when such resolution is put to a vote
                                         and voting thereon. The office of Chairman of the Board of Director shall not, by itself,
                                         entitle the holder thereof to a second or a casting vote.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">37.3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The
                                         Board of Directors may adopt resolutions, without convening a meeting of the Board of
                                         Directors, provided that all directors then in office and lawfully entitled to participate
                                         in the discussion on the proposed matter and to vote thereon (as conclusively determined
                                         by the chairman of the Board of Directors) have given their written consent not to convene
                                         a meeting on such matters. Minutes of such resolutions, including the resolution not
                                         to convene a meeting, shall be signed by the chairman of the Board of Directors.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">38.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B><U>Delegation
                                         of Powers; Committees</U></B></FONT><FONT STYLE="font-size: 10pt">.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">38.1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The
                                         Board of Directors may, subject to the provisions of the Companies Law, delegate any
                                         or all of its powers to committees, each consisting of two or more members, and it may
                                         from time to time revoke such delegation or alter the composition of any such committee.
                                         Any Committee so formed (in these Articles referred to as a &ldquo;<B>Committee of the
                                         Board of Directors</B>&rdquo;), shall, in the exercise of the powers so delegated, conform
                                         to any regulations imposed on it by the Board of Directors. The meeting and proceeding
                                         of any such Committee of the Board of Directors shall be governed, in the relevant changes,
                                         by the provisions herein contained for regulating the meetings of the Board of Directors,
                                         so far as not superseded by any regulations adopted by the Board of Directors under this
                                         Article. Unless otherwise expressly provided by the Board of Directors in delegating
                                         powers to a Committee of the Board of Directors, such Committee shall not be empowered
                                         to further delegate powers.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">38.2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The
                                         Board of Directors may, subject to the provisions of the Companies Law, from time to
                                         time appoint a Secretary to the Company, as well as officers, agents, employees and independent
                                         contractors, as the Board of Directors may think fit, and may terminate the service of
                                         any such person. The Board of Directors may, subject to the provisions of the Companies
                                         Law, determine the powers and duties, as well as the salaries and emoluments, of all
                                         such persons, and may require security in such cases and in such amounts as it thinks
                                         fit.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">38.3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The
                                         Board of Directors may from time to time, by power of attorney or otherwise, appoint
                                         any person, company, firm or body of persons to be the attorney or attorneys of the Company
                                         at law or in fact for such purpose(s) and with such powers, authorities and discretion,
                                         and for such period and subject to such conditions, as it thinks fit, and any such power
                                         of attorney or other appointment may contain such provisions for the protection and convenience
                                         of persons dealing with any such attorney as the Board of Directors may think fit, and
                                         may also authorize any such attorney to delegate all or any of the powers, authorities
                                         and discretion vested in him.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 13; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-size: 10pt">39.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B><U>Number
                                         of Directors</U></B></FONT><FONT STYLE="font-size: 10pt">.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">The
Board of Directors of the Company shall consist of such number as determined by a shareholders&rsquo; resolution of the Company,
but will not be less than one (1).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">40.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B><U>Appointment
                                         and Removal of Directors</U></B></FONT><FONT STYLE="font-size: 10pt">.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: left">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">40.1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The
                                         members of the Board of Directors shall be appointed and removed by resolution of the
                                         shareholders of the Company. Each Director shall continue to serve as a Director of the
                                         Company (subject to the provisions of Article 43 below) until such time as another Director
                                         is appointed as his successor by a Shareholders resolution.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-indent: 0in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">40.2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Notwithstanding
                                         anything to the contrary herein, the term of directorship of a Director may commence
                                         as of a date later than the date of the shareholders&rsquo; resolution electing said
                                         Director, if so specified in said shareholder resolution.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 35.45pt; text-indent: 0in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">41.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B><U>Qualification
                                         of Directors</U></B></FONT><FONT STYLE="font-size: 10pt">.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">No
person shall be disqualified as a Director by reason of his not holding shares in the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">42.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B><U>Continuing
                                         Directors in the Event of Vacancies</U></B></FONT><FONT STYLE="font-size: 10pt">.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">In
the event of one or more vacancies in the Board of Directors, the continuing Directors may continue to act in every matter, and,
pending the filling of any vacancy pursuant to the provisions of Article 43, may temporarily fill any such vacancy, provided,
however, that if their number is less than a majority of the number provided for pursuant to Article&nbsp;39 hereof, they may
only act in an emergency, and may call a General Meeting of the Company for the purpose of electing Directors to fill any or all
vacancies, so that at least a majority of the number of Directors provided for pursuant to Article&nbsp;39 hereof are in office
as a result of said meeting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">43.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B><U>Vacation
                                         of Office</U></B></FONT><FONT STYLE="font-size: 10pt">.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">43.1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The
                                         office of a Director shall be vacated, ipso facto, upon his death, if he is found to
                                         be legally incompetent, if he become bankrupt, if the Director is a company, upon its
                                         winding-up, if he is prevented by applicable law from serving as a Director, or if his
                                         directorship expires pursuant to these Articles and/or applicable law.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">43.2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The
                                         office of the Director shall be vacated by his written resignation. Such resignation
                                         shall become effective on the date fixed therein, or upon the delivery thereof to the
                                         Company, whichever is later.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">44.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B><U>Remuneration
                                         of Directors</U></B></FONT><FONT STYLE="font-size: 10pt">.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">A
Director may be paid remuneration by the Company for his services as Director, subject to the provisions of the Companies Law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">45.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B><U>Conflict
                                         of Interests</U></B></FONT><FONT STYLE="font-size: 10pt">.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">45.1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Subject
                                         to the provisions of the Companies Law and these Articles, the Company may enter into
                                         any contract or otherwise transact any business with any Director in which contract or
                                         business such Director has a personal interest, directly or indirectly; and may enter
                                         into any contract of otherwise transact any business with any third party in which contract
                                         or business a Director has a personal interest, directly or indirectly.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -14.15pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">46.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B><U>Alternate
                                         Directors</U></B></FONT><FONT STYLE="font-size: 10pt">.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">46.1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Subject
                                         to the provisions of the Companies Law, a Director may, by written notice to the Company,
                                         appoint an alternate for himself (in these Articles referred to as &ldquo;<B>Alternate
                                         Director</B>&rdquo;), remove such Alternate Director and appoint another Alternate Director
                                         in place of any Alternate Director appointed by him whose office has been vacated for
                                         any reason whatsoever. Unless the appointing Director, by the instrument appointing an
                                         Alternate Director or by written notice to the Company, limits such appointment to a
                                         specified period of time or restricts it to a specified meeting or action of the Board
                                         of Directors, or otherwise restricts its scope, the appointment shall be for an indefinite
                                         period, and for all purposes.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-size: 10pt">46.2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Any
                                         notice given to the Company pursuant to Article 46.1 shall become effective on the date
                                         fixed therein, or upon the delivery thereof to the Company, whichever is later.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">46.3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">An
                                         Alternate Director shall have all the rights and obligations of the Director who appointed
                                         him, provided, however, that he may not in turn appoint an alternate for himself (unless
                                         the instrument appointing him otherwise expressly provides), and provided further that
                                         an Alternate Director shall have no standing at any meeting of the Board of Directors
                                         or any committee thereof while the Director who appointed him is present.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">46.4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Any
                                         neutral person may act as an Alternate Director.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">46.5.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">An
                                         Alternate Director shall be responsible for his own acts and defaults, as provided in
                                         the Companies Law.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">46.6.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The
                                         office of an Alternate Director shall be vacated under the circumstances, mutatis mutandis,
                                         set forth in Article 43 and such office shall ipso facto be vacated if the Director who
                                         appointed such Alternate Director ceases to be a Director.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>Proceedings
of the Board of Directors</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-size: 10pt">47.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B><U>Meetings</U></B></FONT><FONT STYLE="font-size: 10pt">.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">47.1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The
                                         Board of Directors may meet and adjourn its meetings at such places either within or
                                         without the State of Israel and otherwise regulate such meetings and proceedings as the
                                         Directors think fit. Subject to all of the other provisions of these Articles concerning
                                         meetings of the Board of Directors, the Board of Directors may meet by audio or video
                                         conference so long as each Director participating in such call can hear, and be heard
                                         by, each other Director participating in such call.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">47.2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Any
                                         Director may at any time, and the Secretary, upon the request of such Director, shall,
                                         convene a meeting of the Board of Directors, but not less than three (3) business days&rsquo;
                                         written notice shall be given of any meeting, unless such notice is waived in writing
                                         by all of the Directors as to a particular meeting or unless the matters to be discussed
                                         at such meeting is of such urgency and importance that notice ought reasonably to be
                                         waived under the circumstances.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">48.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B><U>Quorum</U></B></FONT><FONT STYLE="font-size: 10pt">.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">48.1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Until
                                         otherwise unanimously decided by the Board of Directors, a quorum at a meeting of the
                                         Board of Directors shall be constituted by the presence (in person, via audio or video
                                         conference, or by proxy) of the majority of Directors then in office who are lawfully
                                         entitled to participate in the meeting (as conclusively determined by the Chairman of
                                         the Audit Committee (if any), and in the absence of such determination - by the Chairman
                                         of the Board of Directors).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">48.2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">If
                                         within an hour from the time appointed for the meeting a quorum is not present, the meeting
                                         shall stand adjourned to the same day in the next week, at the same time and place, or
                                         to such day and at such time and place as the Chairman may determine with the consent
                                         of the majority of the Directors present. No business shall be transacted at any adjourned
                                         meeting except business which might lawfully have been transacted at the meeting as originally
                                         called. At such adjourned meeting, any two (2)<B> </B>members present in person or represented
                                         by an Alternate Director shall constitute a quorum.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0%"></TD><TD STYLE="text-align: justify; width: 0.4in"><FONT STYLE="font-size: 10pt">49.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B><U>Chairman
                                         of the Board of Directors</U></B></FONT><FONT STYLE="font-size: 10pt">.</FONT></TD></TR>
</TABLE></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">The
Board of Directors may from time to time elect one of its members to be the Chairman of the Board of Directors, remove such Chairman
from office and appoint another in its place. The Chairman of the Board of Directors shall preside at every meeting of the Board
of Directors, but if there is no such Chairman, or if at any meeting he is not present within fifteen (15) minutes of the time
fixed for the meeting, or if he is unwilling to take the chair, the Directors present shall choose one of their number to be the
chairman of such meeting. The office of the Chairman shall not, by itself, entitle the holder thereof to a second or casting vote.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-size: 10pt">50.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B><U>Validity
                                         of Acts Despite Defects</U></B></FONT><FONT STYLE="font-size: 10pt">.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">Subject
to the provisions of the Companies Law, all acts done bona fide at any meeting of the Board of Directors, or of a Committee of
the Board of Directors, or by any person(s) acting as Director(s), shall, notwithstanding that it may afterwards be discovered
that there was some defect in the appointment of the participants in such meetings or any of them or any person(s) acting as aforesaid,
or that they or any of them were disqualified, be as valid as if there were no such defect or disqualification.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>General
Manager</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-size: 10pt">51.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B><U>General
                                         Manager</U></B></FONT><FONT STYLE="font-size: 10pt">.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">51.1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The
                                         Board of Directors may from time to time appoint one or more persons, whether or not
                                         Directors, as General Manager(s) of the Company and may confer upon such person(s), and
                                         from time to time modify or revoke, such title(s) (including Chief Executive Officer,
                                         Managing Director, General Manager(s), Director General or any similar or dissimilar
                                         title) and such duties and authorities of the Board of Directors as the Board of Directors
                                         may deem fit, subject to such limitations and restrictions as the Board of Directors
                                         may from time to time prescribe and subject to the provisions of the Companies Law. Such
                                         appointment(s) may be either for a fixed term or without any limitation of time, and
                                         the Board of Directors may from time to time (subject to the provisions of the Companies
                                         Law, and of any contract between any such person and the Company) fix his or their salaries
                                         and emoluments, remove or dismiss him or them from office and appoint another or others
                                         in his or their place or places.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">51.2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Subject
                                         to the resolutions of the Company&rsquo;s Board of Directors, the management and the
                                         operation of the Company&rsquo;s affairs and business in accordance with the policy determined
                                         by the Company&rsquo;s Board of Directors shall be vested in the General Manager, in
                                         addition to all powers and authorities of the General Manager, as specified in the Companies
                                         Law. Without derogating from the above, all powers of management and executive authorities
                                         which were not vested by the Companies Law or by these Articles in another organ of the
                                         Company shall be vested in the General Manager, subject to the resolutions of the Company&rsquo;s
                                         Board of Directors.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>Minutes</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-size: 10pt">52.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B><U>Minutes</U></B></FONT><FONT STYLE="font-size: 10pt">.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">52.1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Minutes
                                         of each General Meeting and of each meeting of the Board of Directors shall be recorded
                                         and duly entered in books provided for that purpose. Such minutes shall set forth the
                                         names of the persons present at the meeting and all resolutions adopted thereat.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">52.2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Any
                                         minutes as aforesaid, if purporting to be signed by the Chairman of the meeting or by
                                         the Chairman of the next succeeding meeting, shall constitute prima facie evidence of
                                         the matters recorded therein.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>Dividends</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-size: 10pt">53.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B><U>Declaration
                                         of Dividends</U></B></FONT><FONT STYLE="font-size: 10pt">.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">The
Board of Directors may from time to time declare and cause the Company to pay dividend, subject to the Companies Law. The Board
of Directors shall determine the time for payment of such dividends, and the record date for determining the Shareholders entitled
thereto.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-size: 10pt">54.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B><U>Funds
                                         Available for Payment of Dividends</U></B></FONT><FONT STYLE="font-size: 10pt">.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">No
dividend shall be paid other than out of the profits of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">55.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B><U>Amount
                                         Payable by way of Dividends</U></B></FONT><FONT STYLE="font-size: 10pt">.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">Subject
to the rights of the holders of shares with special rights as to dividends, any dividend paid by the Company shall be allocated
among the Shareholders entitled thereto in proportion to the respective holdings of the shares in respect of which such dividend
is being paid.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">56.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B><U>Interest</U></B></FONT><FONT STYLE="font-size: 10pt">.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">No
dividend shall carry interest as against the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">57.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B><U>Payment
                                         in Specie</U></B></FONT><FONT STYLE="font-size: 10pt">.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">Upon
the declaration of a dividend in accordance with Article 53, a dividend may be paid, wholly or partly, by the distribution of
specific assets of the Company or by distribution of paid up shares, debentures or debenture stock of the Company or of any other
companies, or in any one or more of such ways.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">58.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B><U>Capitalization
                                         of Profits, Reserves, etc</U></B></FONT><FONT STYLE="font-size: 10pt">.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">Upon
approval by the Board of Directors, the Company:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">58.1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">may
                                         cause any moneys, investments, or other assets forming part of the undivided profits
                                         of the Company, standing to the credit of a reserve fund, or to the credit of a reserve
                                         fund for the redemption of capital, or in the hands of the Company and available for
                                         dividends, or representing premiums received on the issuance of shares and standing to
                                         the credit of the share premium account, to be capitalized and distributed among such
                                         of the Shareholders as would be entitled to receive the same if distributed by way of
                                         dividend and in the same proportion, on the footing that they become entitled thereto
                                         as capital, or may cause any part of such capitalized fund to be applied on behalf of
                                         such Shareholders in paying up in full, either at par or at such premium as the resolution
                                         may provide, any unissued shares or debentures or debenture stock of the Company which
                                         shall be distributed accordingly, in payment, in full or in part, of the uncalled liability
                                         on any issued share or debentures or debenture stock; and</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">58.2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">may
                                         cause such distribution or payment to be accepted by such Shareholders in full satisfaction
                                         of their interest in the said capitalized sum.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">59.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B><U>Implementation
                                         of Powers under Articles 57 and 58</U></B></FONT><FONT STYLE="font-size: 10pt">.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">For
the purpose of giving full effect to any resolution under Articles 57 and 58, the Board of Directors may settle any difficulty
which may arise in regard to the distribution as it thinks expedient, and, in particular, may issue fractional certificates, and
may fix the value for distribution of any specific assets, and may determine that cash payments shall be made to any Shareholders
upon the footing of the value so fixed, or that fractions of less value than the nominal value of one share may be disregarded
in order to adjust the rights of all parties, and may vest any such cash, shares, debentures, debenture stock or specific assets
in trustees upon such trusts for the persons entitled to the dividend or capitalized fund as may seem expedient to the Board of
Directors. Where requisite under the Companies Law, a proper contract shall be filed, and the Board of Directors may appoint any
person to sign such contract on behalf of the persons entitled to the dividend or capitalized fund.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">60.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B><U>Deductions
                                         from Dividends</U></B></FONT><FONT STYLE="font-size: 10pt">.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">The
Board of Directors may deduct from any dividend or other moneys payable to any Shareholder in respect of a share any and all sums
of money then payable by him to the Company on account of calls or otherwise in respect of shares of the Company and/or on account
of any other matter of transaction whatsoever.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-size: 10pt">61.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B><U>Retention
                                         of Dividends</U></B></FONT><FONT STYLE="font-size: 10pt">.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">61.1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The
                                         Board of Directors may retain any dividend or other moneys payable or property distributable
                                         in respect of a share on which the Company has a lien, and may apply the same in or toward
                                         satisfaction of the debts, liabilities, or engagements in respect of which the lien exists.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">61.2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The
                                         Board of Directors may retain any dividend or other moneys payable or property distributable
                                         in respect of a share in respect of which any person is, under Articles 22 or 23, entitled
                                         to become a shareholder, or which any person is, under said Articles, entitled to transfer,
                                         until such person shall become a shareholder in respect of such share or shall transfer
                                         the same.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">62.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B><U>Unclaimed
                                         Dividends</U></B></FONT><FONT STYLE="font-size: 10pt">.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">All
unclaimed dividends or other moneys payable in respect of a share may be invested or otherwise made use of by the Board of Directors
for the benefit of the Company until claimed. The payment by the Directors of any unclaimed dividend or such other moneys into
a separate account shall not constitute the Company a trustee in respect thereof, and any dividend unclaimed after a period of
seven (7) years from the date of declaration of such dividend, and any such other moneys unclaimed after a like period from the
date the same were payable, shall be forfeited and shall revert to the Company, provided, however, that the Board of Directors
may, at its discretion, cause the Company to pay any such dividend or such other moneys, or any part thereof, to a person who
would have been entitled thereto had the same not reverted to the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">63.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B><U>Mechanics
                                         of Payment</U></B></FONT><FONT STYLE="font-size: 10pt">.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">Any
dividend or other moneys payable in cash in respect of a share may be paid by check or warrant sent through the post to, or by
transfer to a bank account specified by such person (or, if two or more persons are registered as joint holders of such share
or are entitled jointly thereto in consequence of the death or bankruptcy of the holder or otherwise, to any one of such persons
or to his bank account), or to such person and at such address as the person entitled thereto may be writing direct. Every such
check or warrant shall be made payable to the order of the person to whom it is sent, or to such person as the person entitled
thereto as aforesaid may direct, and payment of the check or warrant by the banker upon whom it is drawn shall be a good discharge
to the Company. Every such check or warrant shall be sent at the risk of the person entitled to the money represented thereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">64.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B><U>Receipt
                                         from a Joint Holder</U></B></FONT><FONT STYLE="font-size: 10pt">.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">If
two or more persons are registered as joint holders of any share, or are entitled jointly thereto in consequence of the death
or bankruptcy of the holder or otherwise, any one of them may give effectual receipts for any dividend or other moneys payable
or property distributable in respect of such share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>Accounts</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-size: 10pt">65.</FONT></TD><TD><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B><U>Books
                                         of Account</U></B></FONT><FONT STYLE="font-size: 10pt">.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">The
Board of Directors shall cause accurate books of account to be kept in accordance with the provisions of the Companies Law, and
of any other applicable law. Such books of account shall be kept at the Registered Office of the Company, or at such other place
or places as the Board of Directors may think fit, and they shall always be open to inspection by all Directors. No shareholder,
not being a Director, shall have any right to inspect any account or book or other similar document of the Company, except as
conferred by law or authorized by the Board of Directors. The Company shall make copies of its annual financial statements available
for inspection by the Shareholders at the principal offices of the Company. The Company shall not be required to send copies of
its annual financial statements to Shareholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">66.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B><U>Audit</U></B></FONT><FONT STYLE="font-size: 10pt">.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">At
least once in every fiscal year the accounts of the Company shall be audited and the correctness of the profit and loss account
and balance sheet certified by one or more duly qualified auditors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 18; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-size: 10pt">67.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B><U>Auditors</U></B></FONT><FONT STYLE="font-size: 10pt">.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">The
appointment, authorities, rights and duties of the Auditor(s) of the Company, shall be regulated by applicable law, provided,
however, that in exercising its authority to fix the remuneration of the auditor(s), the Shareholders in General Meeting may act
(and in the absence of any action in connection therewith shall be deemed to have so acted) to authorize the Board of Directors
to fix such remuneration subject to such criteria or standards, if any, as may be provided in such resolution, and if no such
criteria or standards are so provided, such remuneration shall be fixed in an amount commensurate with the volume and nature of
the services rendered by such auditor(s).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>Branch
Registers</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">68.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B><U>Branch
                                         Registers</U></B></FONT><FONT STYLE="font-size: 10pt">.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">Subject
to and in accordance with the provisions of the Companies Law and to all orders and regulations issued thereunder, the Company
may cause branch registers to be kept in any place outside Israel as the Board of Directors may think fit, and, subject to all
applicable requirements of law, the Board of Directors may from time to time adopt such rules and procedures as it may think fit
in connection with the keeping of such branch registers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>Rights
of Signature and Stamp</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">69.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B><U>Rights
                                         of Signature and Stamp</U></B></FONT><FONT STYLE="font-size: 10pt">.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">69.1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The
                                         Board of Directors shall be entitled to authorize any person or persons (who need not
                                         be Directors) to act and sign on behalf of the Company, and the acts and signature of
                                         such person(s) on behalf of the Company shall bind the Company insofar as such person(s)
                                         acted and signed within the scope of his or their authority.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">69.2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The
                                         Company shall have at least one (1) official stamp.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>Notices</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-size: 10pt">70.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B><U>Notices</U></B></FONT><FONT STYLE="font-size: 10pt">.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">70.1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Any
                                         notice or other document may be served by the Company on any shareholder, by any of the
                                         methods set forth below, to such shareholder at his address or other contact details
                                         as described in the Register of Shareholders or such other address or other contact details
                                         as he may have designated in writing for the receipt of notices and other documents.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">70.2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Any
                                         notice or other document may be served by any shareholder upon the Company by tendering
                                         the same in person to the Secretary or the General Manager of the Company at the principal
                                         office of the Company or by sending it by prepaid registered mail (airmail if posted
                                         outside Israel) to the Company at its Office.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">70.3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Any
                                         such notice or other document, shall be deemed to have been served on two (2) business
                                         days after it has been posted (seven (7) business days if sent to a place not located
                                         on the same continent as the place from where it was posted), or when actually received
                                         by the addressee if sooner than two days or seven days, as the case may be, after it
                                         has been posted; or when actually tendered in person, to such shareholder (or to the
                                         Secretary or the General Manager); or one upon transmission if it has been sent by facsimile,
                                         email or other electronic means with electronic confirmation of delivery (or, if transmitted
                                         on a non-business day, upon the first business day after such transmission) or when actually
                                         received by such shareholder (or by the Company), whichever is earlier. If a notice is,
                                         in fact, received by the addressee, it shall be deemed to have been duly served, when
                                         received, notwithstanding that it was defectively addressed or failed, in some respect,
                                         to comply with the provisions of this Article.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-size: 10pt">70.4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">All
                                         notices to be given to the Shareholders shall, with respect to any share to which persons
                                         are jointly entitled, be given to any one of the joint holders, and any notice so given
                                         shall be sufficient notice to the holders of such share.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">70.5.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Any
                                         shareholder whose address or other contact details were not provided to the Company to
                                         be specified in the Register of Shareholders, or who shall not have designated an address
                                         or other contact details for the receipt of notices, shall not be entitled to receive
                                         any notice from the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>Insurance
and Indemnity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-size: 10pt">71.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B><U>Insurance</U></B></FONT><FONT STYLE="font-size: 10pt">.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">Subject
to the provisions of the Companies Law and to the maximum extent permitted under law (including, the Israeli Securities Law and
the RTP Law), and subject further to Article 74, the Company may enter into a contract for the insurance of all or part of the
liability of any Officer imposed on him in consequence of an act which he has performed by virtue of being an Officer, including,
in respect of one of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">71.1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a
                                         breach of his duty of care to the Company or to another person;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">71.2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a
                                         breach of his fiduciary duty to the Company, provided that the Officer acted in good
                                         faith and had reasonable cause to assume that such act would not prejudice the interests
                                         of the Company;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">71.3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a
                                         financial obligation imposed on him in favor of another person.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">71.4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any
                                         other event, occurrence, matters or circumstances under any law with respect to which
                                         the Company may, or will be able to, insure an Office Holder, and to the extent such
                                         law requires the inclusion of a provision permitting such insurance in these Articles,
                                         then such provision is deemed to be included and incorporated herein by reference (including,
                                         without limitation, in accordance with Section 56h(b)(1) of the Israeli Securities Law
                                         5728-1968 (the &ldquo;<B>Israeli</B> <B>Securities Law</B>&rdquo;), if applicable, and
                                         Section 50P of the RTP Law).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">72.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B><U>Indemnity</U></B></FONT><FONT STYLE="font-size: 10pt">.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">72.1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Subject
                                         to the provisions of the Companies Law and to the maximum extent permitted under law
                                         (including, the Israeli Securities Law and the RTP Law), and subject further to Article
                                         74, the Company may indemnify an Officer, retroactively, in respect of any liability
                                         or expense for which indemnification may be provided under the Companies Law, including
                                         the following liabilities or expenses, imposed on such Officer or incurred by him in
                                         consequence of an act which he has performed by virtue of being an Officer:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; text-align: justify"></TD><TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">72.1.1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a
                                         financial liability imposed on such Officer in favor of any person pursuant to a judgment,
                                         including a judgment rendered in the context of a settlement or an arbitrator&rsquo;s
                                         award approved by a court; the term &ldquo;person&rdquo; in this Article 72 shall include,
                                         without limitation, a natural person, firm, partnership, joint venture, trust, company,
                                         corporation, limited liability entity, unincorporated organization, estate, government,
                                         municipality, or any political, governmental, regulatory or similar agency or body;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.35pt; text-indent: -8.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; text-align: justify"></TD><TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">72.1.2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">reasonable
                                         Litigation Expenses (as defined below) expended incurred by an Officer as a result of
                                         an investigation or any proceeding instituted against the Officer by an authority that
                                         is authorized to conduct an investigation or proceeding, and that was concluded without
                                         filing an indictment against the Officer and without imposing on the Officer a financial
                                         obligation in lieu of a criminal proceeding, or that was concluded without filing an
                                         indictment against the Officer but imposing a financial obligation in lieu of a criminal
                                         proceeding in an offence that does not require proof of <I>mens rea</I>, or in connection
                                         with a financial sanction. In this section &ldquo;conclusion of a proceeding without
                                         filing an indictment in a matter in which a criminal investigation has been instigated&rdquo;
                                         and &ldquo;financial liability in lieu of a criminal proceeding&rdquo; shall have the
                                         meaning assigned to such terms under the Companies Law, and the term &quot;financial
                                         sanction&quot; shall mean such term as referred to in Section 260(a)(1a) of the Companies
                                         Law. The term &ldquo;Litigation Expenses&rdquo; in this Article 72 shall include, without
                                         limitation, attorneys&rsquo; fees and all other costs, expenses and obligations paid
                                         or incurred by Indemnitee in connection with investigating, defending, being a witness
                                         in or participating in (including on appeal), or preparing to defend, be a witness in
                                         or participate in any claim relating to any matter for which indemnification hereunder
                                         may be provided.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.35pt; text-indent: -8.5pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left"><FONT STYLE="font-size: 10pt">72.1.3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">reasonable
                                         Litigation Expenses, including attorneys&rsquo; fees, incurred by an Officer or charged
                                         to him by a court, in a proceeding instituted against him by the Company or on its behalf
                                         or by another person, or in a criminal charge from which he was acquitted or in which
                                         he was convicted of an offence that does not require proof of <I>mens rea</I>.</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.35pt; text-indent: -8.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in; text-align: justify"></TD><TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">72.1.4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any
                                         other event, occurrence, matter or circumstances under any law with respect to which
                                         the Company may, or will be able to, indemnify an Office Holder, and to the extent such
                                         law requires the inclusion of a provision permitting such indemnity in these Articles,
                                         then such provision is deemed to be included and incorporated herein by reference (including,
                                         without limitation, in accordance with Section 56h(b)(1) of the Israeli Securities Law,
                                         if applicable, and Section 50P(b)(2) of the RTP Law).</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.35pt; text-indent: -8.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">72.2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Subject
                                         to the provisions of the Companies Law and to the maximum extent permitted under law
                                         (including, the Israeli Securities Law and the RTP Law), and subject further to Article
                                         74, the Company may undertake to indemnify an Officer, in advance, in respect of the
                                         following liabilities or expenses, imposed on such Officer or incurred by him in consequence
                                         of an act which he has performed by virtue of being an Officer:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in; text-align: justify"></TD><TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">72.2.1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">As
                                         set forth in Article 72.1.1, provided that:</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.35pt; text-indent: -8.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.75in; text-align: justify"></TD><TD STYLE="width: 0.75in; text-align: justify"><FONT STYLE="font-size: 10pt">72.2.1.1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the
                                         undertaking to indemnify is limited to such events which the Directors shall deem to
                                         be likely to occur in light of the operations of the Company at the time that the undertaking
                                         to indemnify is made and for such amounts or criterion which the Directors may, at the
                                         time of the giving of such undertaking to indemnify, deem to be reasonable under the
                                         circumstances; and</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-indent: -0.2in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.75in; text-align: justify"></TD><TD STYLE="width: 0.75in; text-align: justify"><FONT STYLE="font-size: 10pt">72.2.1.2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the
                                         undertaking to indemnify shall set forth such events which the Directors shall deem to
                                         be likely to occur in light of the operations of the Company at the time that the undertaking
                                         to indemnify is made, and the amounts and/or criterion which the Directors may, at the
                                         time of the giving of such undertaking to indemnify, deem to be reasonable under the
                                         circumstances.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-indent: -0.2in; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0">
<TR STYLE="vertical-align: top; text-align: justify">
    <TD STYLE="width: 0.5in; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 0.5in; text-align: justify">72.2.2.</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">As
                                         set forth in Articles 72.1.2 to 72.1.3, and to the extent permitted by law, as set forth in Article 72.1.4.</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 113.4pt; text-indent: -0.2in; text-align: justify"><FONT STYLE="font-size: 10pt"></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 72.35pt; text-indent: -8.5pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">73.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B><U>Release</U></B></FONT><FONT STYLE="font-size: 10pt">.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">Subject
to the provisions of the Companies Law and to the maximum extent permitted under law, and subject further to Article 74, the Company
may release, in advance, an Officer from all or any part of the liability due to damages arising out of the breach of duty of
care towards the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 28.35pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt">&nbsp;</DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-size: 10pt">74.</FONT></TD><TD><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B><U>General</U></B></FONT><FONT STYLE="font-size: 10pt">.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-size: 10pt">74.1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Notwithstanding
                                         anything to the contrary contained herein and subject to applicable law, these Articles
                                         are not intended, and shall not be interpreted, to restrict the Company in any manner
                                         in respect of the procurement of insurance and/or in respect of indemnification:</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.8in; text-align: justify"></TD><TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">74.1.1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">in
                                         connection with any person who is not an Officer, including, without limitation, any
                                         employee, agent, consultant or contractor of the Company who is not an Officer, and/or</FONT></TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 99.25pt; text-indent: -8.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.8in; text-align: justify"></TD><TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">74.1.2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">in
                                         connection with any Officer to the extent that such insurance and/or indemnification
                                         is not specifically prohibited under law;</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 99.25pt; text-indent: -8.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.8in; text-align: justify"></TD><TD STYLE="width: 0.5in; text-align: justify"><FONT STYLE="font-size: 10pt">74.1.3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">provided
                                         that if the Company has an Audit Committee, the procurement of any such insurance and/or
                                         the provision of any such indemnification shall be approved by the Audit Committee of
                                         the Company.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 99.25pt; text-indent: -8.55pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">74.2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Notwithstanding
                                         anything to the contrary in these Articles or any other agreement or instrument, the
                                         Company shall not insure, indemnify or release the Officer with respect to events or
                                         circumstances for which insurance, indemnification or release are not permitted under
                                         law.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">75.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Any
                                         amendment to the Companies Law or other applicable law adversely affecting the right
                                         of any Officer to be indemnified, insured or released pursuant to Articles 71 to 74 above
                                         shall be prospective in effect, and shall not affect the Company&rsquo;s obligation or
                                         ability to indemnify or insure an Officer for any act or omission occurring prior to
                                         such amendment, unless otherwise provided by applicable law.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>Winding
Up</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B>&nbsp;</B></FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0%"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-size: 10pt">76.</FONT></TD><TD><FONT STYLE="font-size: 10pt; font-variant: small-caps"><B><U>Winding
                                         Up</U></B></FONT><FONT STYLE="font-size: 10pt">.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 26.95pt; text-indent: -19.85pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in"></TD><TD STYLE="width: 0.4in"><FONT STYLE="font-size: 10pt">76.1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">If
                                         the Company be wound up, then, subject to applicable law and to the rights of the holders
                                         of shares with special rights upon winding up, the assets of the Company available for
                                         distribution among the Shareholders as such shall first be distributed to the Shareholders
                                         entitled thereto an amount equal to the paid-up capital attributable to their respective
                                         holdings of the shares in respect of which such distribution is being made, provided,
                                         however, that if such assets do not suffice to make such distribution in full, such assets
                                         shall be distributed to said Shareholders in proportion to the paid-up capital attributable
                                         to their respective holdings of such shares. The paid-up capital attributable to any
                                         share issued at a premium or at a lawful discount shall be the nominal value of such
                                         share, provided, however, that if less than the full issuance price of such share has
                                         been paid to the Company, the paid-up capital attributable thereto shall be such proportion
                                         of the nominal value as the amount paid to the Company bears to such full issuance price.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.4in; text-align: justify"></TD><TD STYLE="width: 0.4in; text-align: justify"><FONT STYLE="font-size: 10pt">76.2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The
                                         assets, if any, remaining after the distribution pursuant to Article 76.1 hereof, shall,
                                         subject to applicable law and to the rights of the holders of shares with special rights
                                         as aforesaid, be distributed to the Shareholders entitled thereto in proportion to the
                                         nominal value of their respective holdings of the shares in respect of which such distribution
                                         is being made, whether or not the issuance price, or any portion thereof, has been paid.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 56.7pt; text-indent: -11.35pt"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">***************</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">- <!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --> -</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>3
<FILENAME>t1702381_ex10-7.htm
<DESCRIPTION>EXHIBIT 10.7
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-align: right; text-indent: -127.6pt"><B><U STYLE="text-decoration: none">Exhibit
10.7</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-align: right; text-indent: -127.6pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">[Informal
English Translation]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Unprotected
Tenancy Contract</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Made and
executed this 10th day of October 2007</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-align: center; text-indent: -127.6pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-indent: -127.6pt"><B>Between:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-indent: -127.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-indent: -127.6pt"><B>Ms. Rachel Zacks</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-indent: -127.6pt"><B>Identity No. 29581 </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-indent: -127.6pt">And <B>Dr. Moshe Eliash Advocate</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-indent: -127.6pt"><B>Identity No. 1940998</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-indent: -127.6pt">(each of them severally and jointly)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-indent: -127.6pt">of 2 Hasoreg Street, P.O. Box
433, Jerusalem</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-indent: -127.6pt">(hereinafter &ndash; &ldquo;<B>the
Landlord</B>&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-indent: -127.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-align: right; text-indent: -127.6pt">of the one
part;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-align: right; text-indent: -127.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-indent: -127.6pt">And:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-indent: -127.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-indent: -127.6pt"><B>Sol<FONT STYLE="font-family: Times New Roman, Times, Serif">-</FONT>Gel
Technologies Ltd</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-indent: -127.6pt">Corporate number 51-2544693-3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-indent: -127.6pt">By its manager, <B>Mr. Alon Sari-Levi</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-indent: -127.6pt">(Identity No. 9-05709238) and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-indent: -127.6pt"><B>Mr. Chanan Mazor</B>
(Identity No. 053641312)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">who declare by signing this Agreement that
they are</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0in">authorized to sign in
the name of the Company</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">and that their signature is binding upon the
Company in all respects</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(The Company being hereinafter called: &ldquo;<B>the
Tenant</B>&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 28.35pt">of the other part</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 85.05pt"><B>WHEREAS</B></TD><TD STYLE="text-align: justify">the Landlord declares and confirms that he is the registered owner of an area of 5924 square meters
out of Parcel 18 in Block 3850 in Ness Ziona, (hereinafter: &ldquo;<B>the Land</B>&rdquo;); and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 85.05pt; text-align: justify; text-indent: -85.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 85.05pt"><B>WHEREAS</B></TD><TD STYLE="text-align: justify">the Landlord declares and confirms that he has erected on the Land a building according to a lawful
building permit pursuant to the Building Plans (as hereinafter defined) constituting of areas suitable for hi-tech industries,
underground parking and an open parking lot; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 85.05pt; text-align: justify; text-indent: -85.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 84.95pt"><B>WHEREAS</B></TD><TD STYLE="text-align: justify">the Landlord declares and warrants that no areas in the building will be leased for purposes of
sale or food processing or for clothing stores or building materials; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 84.95pt; text-align: justify; text-indent: -84.95pt">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 84.95pt"><B>WHEREAS</B></TD><TD STYLE="text-align: justify">the Landlord declares and confirms that he is desirous of granting a tenancy to and the Tenant
declares that it is desirous of taking a tenancy of, the Premises (as hereinafter defined) by an unprotected tenancy; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 84.95pt; text-align: justify; text-indent: -84.95pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 84.95pt"><B>WHEREAS</B></TD><TD STYLE="text-align: justify">the parties wish to regulate the terms pertaining to the tenancy of the Premises as more particularly
set out below in this Contract.</TD></TR>                                         <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify"><B>It is
therefore agreed and declared between the parties as follows:</B></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 84.95pt; text-indent: -84.95pt"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 84.95pt; text-indent: -84.95pt"><B><I>Preamble, appendices and
headings</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 84.95pt; text-indent: -84.95pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; text-align: justify"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="width: 6%; text-align: justify"><FONT STYLE="font-size: 10pt">a.</FONT></TD>
    <TD STYLE="width: 88%; text-align: justify"><FONT STYLE="font-size: 10pt">The preamble, declarations therein contained and the appendices to this Contract constitute an integral part hereof.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">b.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The headings of this Contract are for ease of reference only and are not to be applied in the interpretation of the Contract.&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 84.95pt; text-indent: -84.95pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-indent: -28.35pt"><B><I>Definitions</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="width: 6%"><FONT STYLE="font-size: 10pt">a.</FONT></TD>
    <TD STYLE="width: 15%"><FONT STYLE="font-size: 10pt"><B>&ldquo;the Building&rdquo;</B></FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="width: 69%; text-align: justify"><FONT STYLE="font-size: 10pt">means a multistorey building consisting of an underground floor and seven (7) four floors above ground (including an entrance lobby and mezzanine floor) having an area of approximately 6,000 square meters principal area and some 4,175 square meters ancillary areas and underground parking.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 6%"><FONT STYLE="font-size: 10pt">b.</FONT></TD>
    <TD STYLE="width: 15%"><FONT STYLE="font-size: 10pt"><B>&ldquo;the Parking Areas&rdquo;</B></FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="width: 69%; text-align: justify"><FONT STYLE="font-size: 10pt">means the underground covered parking area on the basement floor of the Building comprising 97 parking places and open parking in the boundaries of the area of the Land consisting of 107 parking places.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">c.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><B>&ldquo;Business Day&rdquo;</B></FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">any of the weekdays (Sunday &ndash; Thursday) on which banks in Israel are open to the public.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">d.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&ldquo;<B>Possession Date&rdquo;</B></FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the possession date pursuant to the tenancy agreement of the Premises provided that the provisions of clause 6(a) hereof have been fulfilled or such earlier date on which all of the conditions prescribed in clause 6(a) hereof have been fulfilled and which has been agreed upon in writing prior thereto by the parties.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">e.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt"><B>&ldquo;the Premises</B>&rdquo;</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the entire area of the fifth floor above ground, consisting of an area of 872.57 square meters for principal use, 30.72 square meters </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 15%">&nbsp;</TD>
    <TD STYLE="width: 4%">&nbsp;</TD>
    <TD STYLE="width: 69%; text-align: justify"><FONT STYLE="font-size: 10pt">bomb shelter, 4.94 square meters installations and technical systems and 78.50 square meters lobby and stairwells, as described in the Plan attached hereto and constituting an integral part hereof and 40 covered parking places, and a further option for four covered parking places to the extent these will be requested in order to make a passage from the entry lane into the exit lane, if the Tenant decides to separate the parking floors that are leased by electric gates, as marked in the Plan attached hereto and constitute an integral part of this Contract.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">f.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt"><B>&ldquo;the Specification</B>&rdquo;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the technical specification as will be planned by the Tenant, pursuant to its needs and to be submitted for the approval of the Building consultants, the architect Mr. Raffy Lehrman, the electricity consultants &ndash; B. Bloch Engineers Ltd., air conditioning &ndash; R.S.L Engineers Ltd., plumbing &ndash; S. Papish Ltd., Construction S. Engal Ltd., and Safety &ndash; Efraim Ben Ami (hereinafter: &ldquo;<B>the Consultants</B>&rdquo;). It is clarified that the purpose of the approval is in order to examine the compliance of the design with the Building systems under the building permit and the provisions of any law and for no other purpose. Contestations against the planning will only be allowed to the extent the planning contains factors that interfere with or could disrupt the proper functioning of the Building systems or that will be contrary to the building permit or the provisions of any law. To the extent there be any such contestations, the Tenant will modify the specification in a manner that will conform with the Building systems, the building permit and the provisions of any law.&nbsp;&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">g.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&ldquo;<B>Dollar Rate</B>&rdquo;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The representative rate of exchange of the US Dollar as published by the Bank of Israel, which is known on the day of the payment date. In the event of publication of such rate being suspended, it will be replaced by the mean rate between the selling rate and the buying rate (for transfers and cheques) of the US Dollar, as existing in Bank Leumi Le Israel BM.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 3; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%">&nbsp;</TD>
    <TD STYLE="width: 6%"><FONT STYLE="font-size: 10pt">h.</FONT></TD>
    <TD STYLE="width: 15%"><FONT STYLE="font-size: 10pt">&ldquo;<B>Town Building Plan</B>&rdquo;</FONT></TD>
    <TD STYLE="width: 4%"><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="width: 69%; text-align: justify"><FONT STYLE="font-size: 10pt">Outline Scheme number <B>NS/143</B> including the rules and appendices thereof and thereto, including any amendment or modification or addition thereto, as existing from time to time. </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">i.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&ldquo;<B>the Building Plans</B>&rdquo;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">-</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the plans for the construction of the Building and the parking places pursuant to building permit number 2002072, including any amendments thereto.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt"><B><I>Declarations
of the parties</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">a.</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Landlord declares and acknowledges that:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 6%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 6%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 82%; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">It is the registered owner of the Land, and there is no third party having any right in the Premises.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">He holds all the approvals that were required for constructing the Building and the Parking Areas and preparing the Premises for delivery pursuant to the provisions of this Contract, including, but without derogating from the generality of the foregoing, a building permit, and Form 4 and that the works at the Premises have been carried out pursuant to such approvals.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">It has entered into an engagement with all of the professional personnel required in order to carry out the construction of the Building and the Parking Areas and he is able to induce the preparation of the Premises for delivery pursuant to the provisions of this Contract, on the Possession Date.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">There is nothing to prevent him entering into this Contract.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">b.</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Tenant declares and acknowledges that:</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">It has examined and viewed the Building and the environment thereof, the building plans that have been presented to it by the Landlord, the Town Building Plan, and further examined the planning situation at the planning authorities and found all of the same to be suitable for its needs and purposes, all subject to the truthfulness of the Landlord&rsquo;s declarations and fulfilment of his undertakings according to this Contract.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">There is nothing to prevent it from entering into this Contract.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 85.05pt; text-align: justify; text-indent: -85.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-indent: -27pt"><B><I>Non-application of the Tenants
Protection Law to the tenancy according to this Contract</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-indent: -27pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%"><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD STYLE="width: 6%"><FONT STYLE="font-size: 10pt">a.</FONT></TD>
    <TD STYLE="width: 88%; text-align: justify"><FONT STYLE="font-size: 10pt">It is agreed that the Building is new, the construction
    and occupation of which having been completed after 26 Av. 5728 (August 20, 1968), and is a &lsquo;new building&rsquo;
    within the meaning of that term contained in the Tenants Protection (Consolidated Version) Law, 5732-1972 (hereinafter: &ldquo;<B>the
    Tenants Protection Law</B>&rdquo;).</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 6%; text-align: justify"><FONT STYLE="font-size: 10pt">b.</FONT></TD>
    <TD STYLE="width: 88%; text-align: justify"><FONT STYLE="font-size: 10pt">It is agreed that the provisions of the Tenants Protection Law do not nor shall they apply with respect to the Premises and this Tenancy Contract and the other tenants protection laws including the regulations and orders thereof, and that no statute conferring upon a tenant the status of a protected tenant including a right not to vacate the Premises in the cases in which it is bound to do so according to this Contract, shall apply with respect to the Premises.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">c.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Tenant declares that it has not paid nor will it pay to the Landlord any key money or any other payment that could be construed as key money, for the Premises. Without derogating from the generality of the foregoing the Tenant declares that all of the investments that will be made by it in the Premises, if at all, will be made for its own purposes and it will be estopped from claiming that such investments amount to any key money or substitute for key money or any consideration other than rent which is given in connection with the tenancy of the Premises or in connection with the taking of the possession thereof. This declaration of the Tenant constitutes a fundamental condition for the Landlord&rsquo;s agreement that the Tenant make any investment in the Premises. (For the avoidance of any doubt, nothing contained above shall derogate from that stated in clause 26 hereof, save that the provisions contained in clause 26 are to be read subject to the foregoing).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">d.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Tenant declares that it is aware that the tenancy is for a fixed term and that upon the expiration of the Tenancy Term (as hereinafter defined) (including, for the avoidance of any doubt, on the expiration of the Tenancy Term by reason of the conclusion, lawful rescission or termination of this Contract) it shall quit the Premises and redeliver possession thereof to the Landlord, subject and pursuant to the conditions set out in this Contract.&nbsp;&nbsp;&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-indent: -56.7pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-indent: -27pt"><B><I>Works at the Premises</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-indent: -27pt"><I>&nbsp;</I></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; text-align: justify"><FONT STYLE="font-size: 10pt">5.</FONT></TD>
    <TD STYLE="width: 6%; text-align: justify"><FONT STYLE="font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="width: 88%; text-align: justify"><FONT STYLE="font-size: 10pt">The Premises will be conveyed to the Tenant in their present condition which is &ldquo;a shell&rdquo; subject to the conditions set out in clauses 6(b) and 6(c) hereof.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Notwithstanding the foregoing it is hereby agreed that the Landlord will install at the Premises a ventilator shaft up to the roof of the Building in an aggregate area of not less than 9,600 square meters, in such location as is marked in the plan attached hereto as an integral part hereof, within 30 days of the date of the execution of this Agreement. The Landlord declares and covenants that in the environment of the roof area in which the shafts open systems can be placed and it will remain as such, throughout the entire duration of the Tenancy Term.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Tenant will carry out supplementary works at the Premises pursuant to the Specification and the Landlord will participate in the cost of such works in a shekel amount equal to US $490,820.00 (plus VAT as required by law), against receipt of a lawful invoice. The Consultants&rsquo; fee and payments of planning works, including interior design planning, inspection, construction management, the construction of clean rooms, installation of distilled water, transportation works of materials and systems for the construction purposes will, inter alia, be included in such cost.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 6%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 88%; text-align: justify"><FONT STYLE="font-size: 10pt">The Landlord will remit to the Tenant the payments on account of the Landlord&rsquo;s participation in the cost of such works within seven days of receiving the Tenant&rsquo;s written demand, backed by a copy of the VAT receipt/invoice proving the making of the payment by the Tenant for the work in question.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Tenant will be entitled to make any modification in the Specification at its exclusive discretion. Any modification which has ramifications on any of the Building systems or which is otherwise than in accord with the building permit or the provisions of any law as stated in clause 2(f) above will be submitted to the Consultants for approval, and dealt with as stated in clause 2(f) above.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Tenant may add works as an addit to the Specification (hereinafter: &ldquo;<B>the Addit to the Specification</B>&rdquo;), subject to the Tenant&rsquo;s right to effect such works pursuant to the provisions of this Contract, and subject to the provisions of this Contract with respect to the implementation of the supplementary works pursuant to the Specification. The cost of performing the Addit to the Specification, including the making of any modifications, repairs or demolition that will be required in order to carry out the same for the making of the Addit, including the cost and duration of any delay, disruption or deferral in the construction of the works at the Premises pursuant to the Specification that will be caused in consequence of the carrying out of the Addit to the Specification (hereinafter: &ldquo;<B>the Performance Cost</B>&rdquo;), will be borne by the Tenant and the Landlord shall have no liability to participate in the financing of the Performance Cost, other than the obligation to participate in the cost of the supplementary works, according to clause 5(b) above.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">The Landlord undertakes to sign and/or induce any person who is empowered on his behalf, to sign any document that will be required for the purpose of issuing permits, if required, in order to carry out the Specification and further for the purpose of performing the Addit to the Specification as stated in sub-clause (c) above, within a week of the date of the demand. The Landlord further undertakes to provide the Tenant with a copy of the plan of the fifth floor in which the Premises are situated, including an electronic copy of such plan.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Without derogating from&nbsp;&nbsp;that stated in clause 5(c) above the Landlord will enable the Tenant to effect at its exclusive expense, works at the Premises, at its discretion, and which are not included in the Specification and/or in the Addit to the Specification, and which the Tenant is entitled to carry out pursuant to the provisions of this Contract, after the completion of the performance of the works in the Specification and/or in the Addit to the Specification, or after delivery of possession of the Premises to the Tenant, provided that seven days&rsquo; prior written notice will be given to the Landlord setting out the works which it wishes to carry out; that no reasonable objection has been received on the part of the Landlord for performing the works; and that this does not affect the performance of works in the Building, on the part of the Landlord. The provisions of this Contract with respect to the performance of the works contained in the Specification shall apply to the performance of such works.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">It is clarified that none of the parties shall be responsible for the oversight and/or quality of the accessories and/or materials and/or equipment that will be supplied by the counterparty, including defects and/or malfunctions that are related thereto.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 6%; text-align: justify"><FONT STYLE="font-size: 10pt">(f)</FONT></TD>
    <TD STYLE="width: 88%; text-align: justify"><FONT STYLE="font-size: 10pt">The Tenant will bear any fine or penalty that will be imposed in respect of works that will be carried out at the Premises without any permit or in excess of the permit &ndash; by it and/or by persons on its behalf.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">For the avoidance of any doubt it
is clarified that the provisions of this clause will not be deemed to be the Landlord&rsquo;s license to the Tenant to perform
works without any permit or in excess of a permit.</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-indent: -63pt"><B><I>Delivery of possession</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-indent: -63pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 6%; text-align: justify"><FONT STYLE="font-size: 10pt">6.</FONT></TD>
    <TD STYLE="width: 6%; text-align: justify"><FONT STYLE="font-size: 10pt">a.</FONT></TD>
    <TD STYLE="width: 88%; text-align: justify"><FONT STYLE="font-size: 10pt">Delivery of possession in the Premises in order to carry out the works mentioned in clause 5 above will be effected immediately upon the execution of this Contract. The Landlord will, on the Possession Date, deliver to the Tenant exclusive possession of the Premises:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 12%">&nbsp;</TD>
    <TD STYLE="width: 6%; text-align: justify"><FONT STYLE="font-size: 10pt">1.</FONT></TD>
    <TD STYLE="width: 82%; text-align: justify"><FONT STYLE="font-size: 10pt">vacant and free of all persons and things;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">2.</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">with all the systems of the Building and the Premises (including the elevators) in proper working and operating condition;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">3.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">it being possible to connect the Premises permanently to the electricity grid, the air conditioning, water, sewerage systems, telephone lines, and all other connections that are required to use the Premises;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">4.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">absent of any constraint by law existing to the performance of the works as set out in clause 5 above;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">5.</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">the Landlord undertakes that to the extent building works will be carried out in the Building after possession has been delivered (including the installation of the shafts) in the Premises to the Tenant, they will not affect the reasonable use of the Tenant of the Premises and/or the access ways to the Building and the Premises.</FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>
<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt"></TD><TD STYLE="text-align: justify"></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">b.</TD><TD STYLE="text-align: justify">A tour will take place of the Premises on such date as will be agreed, being not later than seven
days after the Possession Date, in which the Landlord or persons on his behalf, and the Tenant will take part. The Tenant will
make a memorandum of delivery that will document the defects that the Tenant has found at the Premises, to the extent the memorandum
will be certified by the Landlord, it shall serve as final and conclusive proof of the existence of such defects in the Premises,
without prejudice to the Tenant&rsquo;s right to raise claims in the future in regard to flaws that are not visible and/or which
professional expertise is required to discover.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">c.</TD><TD STYLE="text-align: justify">The Lessor undertakes to carry out all the repairs of the defects specified in the delivery memorandum,
and which have been certified by the Landlord, by arrangement with the Tenant within twenty one (21) days of the date of the tour
mentioned above to the extent possible, at one and the same time, and in no event will the same disrupt the Tenant&rsquo;s use
of the Premises. Urgent repairs of defects that materially prejudice the enjoyment from the Premises and/or the use thereof, will
be repaired urgently and promptly. The non-performance of the repairs on due date will constitute a fundamental breach of this
Contract. Nothing contained above shall derogate from the Landlord&rsquo;s duty to
repair additional defects which fall within his responsibility under this Contract and/or as will be held by the court in accordance
with the provisions contained in clause 30 of this Contract.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>


<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">d.</TD><TD STYLE="text-align: justify">Without derogating from the Tenant&rsquo;s right to damages at a higher rate or to any other relief,
the Landlord will pay the Tenant in respect of each day of delay in delivering the possession of the Premises, fixed and agreed
compensation without proof of damage in the sum of $587.87 (five hundred and eighty seven US Dollars and 87 cents) (which is the
product of 1.2 times the monthly rent prescribed in this Contract divided by 30), in their shekel value on the payment date, according
to the representative rate of exchange. The parties declare that they consider such sum to be agreed and proper compensation for
the damage that the parties foresee as the probable result following a delay in delivery of the possession in the Premises.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt"></TD><TD STYLE="text-align: justify">For the avoidance of any doubt it is declared and agreed that the Tenant may set off against the
rent any sum that is due to it from the Landlord according to this clause. Any delay in the Possession Date exceeding 14 days will
constitute a fundamental breach of this Contract.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">e.</TD><TD STYLE="text-align: justify">Where possession of the Premises is delivered on a date later than the Possession Date pursuant
to the provisions of clause 6(d) above, then wherever in this Contract the expression: &ldquo;Possession Date&rdquo; appears (for
the avoidance of doubt with the exception of clause 6(d) above) it shall be regarded as the date of the actual delivery of possession.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">f.</TD><TD STYLE="text-align: justify">For the avoidance of any doubt it is clarified that the provisions of this clause will not be deemed
to be a license of the Tenant to the Landlord to defer the delivery date of the possession.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt"><B><I>Term
of the tenancy</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 25.2pt">7.</TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">The tenancy term according to this Contract will commence
three months after the Possession Date; to the extent that the Consultants&rsquo; approval has been received that will be dated
in excess of fife Business Days, the commencement of the term of the tenancy will be deferred by the same period as the delay
in the date of receiving such Consultants&rsquo; certificate.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 25.2pt"></TD><TD STYLE="width: 0.5in; text-align: left">(b) (1)</TD><TD STYLE="text-align: justify">The tenancy according to this Contract is for a term of
three years from the date of &#9;the commencement of the Tenancy Term (hereinafter: &ldquo;<B>the First Term</B>&rdquo;).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 25.2pt"></TD><TD STYLE="width: 0.5in">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)</TD><TD STYLE="text-align: justify">After the expiration of the First Term, this Contract will be renewed for two years and thereafter,
for five terms each of which shall be for a further year (hereinafter: &ldquo;<B>the Extended Term</B>&rdquo;) unless the Tenant
gives six (6) months&rsquo; prior written notice before the expiration of the First Term or the expiration of each year of the
tenancy within the framework of the Extended Term, until ten (10) years have elapsed from the Possession Date (the entire term
during which the Premises will be effectively leased to the Tenant pursuant to this Contract to be a term which, as stated, shall
not exceed ten years from the Possession Date, and will be hereinafter called: &ldquo;<B>the Tenancy Term</B>&rdquo;).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Rent</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">8.(a)</TD><TD STYLE="text-align: justify">The Tenant will pay the Landlord for the duration of the First Term, monthly rent in the sum of
$14,696.79 (fourteen thousand, six hundred and ninety six US Dollars and seventy nine cents) in the shekel value thereof on the
payment date according to the representative rate of exchange.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"></TD><TD STYLE="text-align: justify">The rent is set on the following basis:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"></TD><TD STYLE="text-align: justify">The principal area is 872.57 square meters and a secured shelter of 30.72 square meters.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"></TD><TD STYLE="text-align: justify">The gross/net ratio is 0.80, i.e. 80 square meters net deemed to be 100 square meters gross.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"></TD><TD STYLE="text-align: justify">The gross area on the floor is therefore 1090.71 square meters and the secured shelter is 30.72
square meters.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"></TD><TD STYLE="text-align: justify">The rent for the area of the Premises amounts to $11.50 per square meter (gross).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"></TD><TD STYLE="text-align: justify">The rent for the secured shelter is $5 per square meter (net).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"></TD><TD STYLE="text-align: justify">The calculation of the rent is thus as follows:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -31.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif; margin-left: 40pt">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify">1090.71 square meters (gross).</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right"><FONT STYLE="font-size: 10pt">12, 543.19</FONT></TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 83%; text-align: justify">30.72 square meters of the secured area.</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 14%; text-align: right">153.60</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: justify; padding-bottom: 1pt">40 covered parking spaces.</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: left; border-bottom: Black 1pt solid">$</TD><TD STYLE="text-align: right; border-bottom: Black 1pt solid">2,000.00</TD><TD STYLE="text-align: left; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: justify">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: justify; padding-bottom: 1pt">Total</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">14,696.79</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: center; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The monthly rent for the First Extended Term
(for the fourth and fifth year) will increase by 10% above the above rent and a further 5% above the rent last paid, in each of
the last five years of the Further Tenancy Term.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The above areas were set pursuant to that prescribed
in the building permit. In as much as the survey of a qualified surveyor agreed upon by the parties will show that the actual area
does not match that appearing in the building permit, the rent will be adjusted pursuant to the effective measured area.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0pt"></TD><TD STYLE="text-align: justify">Notwithstanding the foregoing, the Landlord shall have the right on the extension date of each
Term only, to determine with respect to the rent during the Extended Term that the rent commencing in the next year of the tenancy
shall be linked to the Consumer Price Index instead of the Dollar, according to the value of the rent in shekels on the date of
the giving of the notice, and pursuant to the CPI known on the date of giving the notice, provided that at least seven days&rsquo;
notice to that effect will be given to the Tenant before the commencement of the year of the tenancy. The Landlord shall be entitled,
upon giving such notice that the rent shall be linked to the Consumer Price Index as stated, may give further notice that the rent
in the tenancy year next following shall be linked to the Dollar according to that stated in this Agreement, pursuant to the representative
rate of exchange known on the date of the giving of the notice, and such process may be repeated,
provided that he gives notice to that effect to the Tenant at least seven days before the commencement of the new year of the tenancy.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: -27pt">&nbsp;</P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The rent mentioned shall be in respect of the
Premises as a whole, including the use of the common property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt; text-align: left">(b)</TD><TD STYLE="text-align: justify">The Tenant will pay the Landlord the rent, as follows:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 27pt; text-align: left">1.</TD><TD STYLE="text-align: justify">For three months of the tenancy, on the date of the
execution of this Agreement, the Landlord&rsquo;s signature to this Agreement to constitute acknowledgement of the receipt of
such rent. Such rent will be credited against the rent for the ensuing calendar quarter next following the commencement of the
Tenancy Term (the second quarter of the Tenancy Term).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 27pt; text-align: left">2.</TD><TD STYLE="text-align: justify">In respect of the term from the commencement date
of the tenancy until the expiration of the next ensuing calendar quarter (the first quarter of the tenancy term) on the date of
the commencement of the Tenancy, it being hereby agreed nonetheless that the Tenant shall be exempt from paying the rent for the
first month of the Tenancy Term.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 27pt; text-align: left">3.</TD><TD STYLE="text-align: justify">For the third calendar quarter and every quarter thereafter
until the expiration of the Tenancy Term, on the last Business Day of the preceding quarter.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt"></TD><TD STYLE="text-align: justify">&lsquo;Quarter&rsquo; for the purpose of this clause means a period of three months commencing
on 1.1, 1.4, 1.7 or 1.10 of each year during the Tenancy Term.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt; text-align: left">(c)</TD><TD STYLE="text-align: justify">VAT in respect of the rent will be borne and paid by the
Tenant contemporaneously with any payment on account of the rent, against the furnishing of a lawful VAT invoice to the Tenant.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt; text-align: left">(d)</TD><TD STYLE="text-align: justify">Payment of the rent by the Tenant will be made by way of
bank transfer to the Landlord&rsquo;s account in Bank Leumi Le Israel BM, account number 221200/43 in Branch No. 920, or any other
bank account notified by the Landlord in writing to the Tenant at least seven days before the date of payment.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt; text-align: left">(e)</TD><TD STYLE="text-align: justify">The Tenant shall be bound to pay the Landlord the full
amount of the rent even if it vacates the Premises before the expiration of the Tenancy Term according to the provisions of this
Contract, to the extent the vacation shall be otherwise than pursuant to the provisions of this Contract, or pursuant to the provisions
of any law.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -27pt"><B><I>Purpose
of the tenancy</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -27pt"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">8.A.</TD><TD STYLE="text-align: justify">The purpose of the tenancy is to carry on the Tenant&rsquo;s activity at the Premises pursuant
to its objectives, and/or any business subject to the provisions of the Town Building Plan, and/or to the receipt of the required
approvals from the local authority, and for no other purpose whatsoever.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -27pt"><B><I>Taxes</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt; text-align: left">9. (a)</TD><TD STYLE="text-align: justify">The Tenant shall fully and punctually pay throughout the
entire Tenancy Term all of the payments for the supply of water, electricity, telephone, city tax, business tax, signage tax or
any other service that is used in
the Premises and all and any levy, city tax or other compulsory payment which are payable by law or custom by the occupier of the
Premises, the same being in addition to all of the payments which expressly apply to it according to this Contract. For the avoidance
of any doubt the Tenant will bear no additional payment to the Landlord and/or to the Management Company in connection with the
management or the maintenance of the common areas in excess of that stated in this Contract.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -27pt">&nbsp;</P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">(b)</TD><TD STYLE="text-align: justify">If any payment mentioned in clause 9(a) above has been imposed upon the Tenant on account of a
period only part of which falls within the Tenancy Term, the Tenant will pay its proportionate share of such payment.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">(c)</TD><TD STYLE="text-align: justify">The Tenant may conduct negotiations with the various authorities regarding the payments mentioned
in clause 9(a) above provided that this shall not serve to prejudice in any way, the Landlord. The Tenant will advise the Landlord
of the results of any such negotiation.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">(d)</TD><TD STYLE="text-align: justify">Taxes, other compulsory payments, levies and fees including amelioration levy that apply by law
to the owner of the property, will be borne and paid by the Landlord.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">(e)</TD><TD STYLE="text-align: justify">If any payment has not been paid by the parties pursuant to this clause 9 on due date, the counterparty
shall be entitled, but not obliged, to pay such payment provided that prior thereto, the such party shall, prior to the payment,
give the party on whose such payment falls notice in writing that he/it is about to pay such sum and the amount has not been paid
within fourteen (14) days of receiving such notice. If either party pays any such payment as described in this clause the counterparty
shall be bound to reimburse such amount to the paying party immediately upon demand, with the addition of linkage differentials
and interest from the date of the actual payment until the reimbursement thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">(f)</TD><TD STYLE="text-align: justify">The Tenant shall be bound to notify the local authority in writing and the remaining entities who
charge payments for the Premises of the tenancy of the Premises and cause for that purpose all of the bills to the municipality
and/or any other account that relates to payment and/or tax pursuant to clause 9(a) above to be issued in the name of the Tenant.
The Landlord undertakes to sign at the Tenant&rsquo;s request, any document that will be required for such purpose within a week
of the date of the demand. Upon the expiration of the Tenancy Term, the Landlord shall be bound to notify the local authority and
the remaining entities charging payments in respect of the Premises in writing of the surrender of the possession in the Premises
to it, and induce all of the bills to the municipality and/or any other account relating to the payment or tax pursuant to clause
9(a) above that the Tenant is not bound to pay the same after the expiration of the Tenancy Term, and the same will be issued in
the Landlord&rsquo;s name. Nothing contained herein shall prejudice the Tenant&rsquo;s duties to pay all of the bills to which
it is subject pursuant to the provisions of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -27pt"><B><I>Transfer
of rights</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">10.</TD><TD STYLE="text-align: justify">The Tenant may transfer its rights and obligations under this Contact to an alternative tenant
provided that the following conditions will be fulfilled:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 27pt; text-align: left">(a)</TD><TD STYLE="text-align: justify">The Landlord has approved in writing and in advance
the identity of the alternative tenant. The Landlord undertakes not to unreasonably withhold his consent to the identity of the
alternative tenant for reasons that will be set out in writing.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify; text-indent: -58.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 27pt; text-align: left">(b)</TD><TD STYLE="text-align: justify">The alternative tenant will sign a tenancy contract
with the Landlord on the terms of this Contract.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify; text-indent: -58.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 27pt; text-align: left">(c)</TD><TD STYLE="text-align: justify">After the alternative tenant signs a tenancy contract
on the terms of this Contract, the Tenant will be released from all of its obligations and rights under this Contract, subject
to having fulfilled by such date all of its obligations according to this Contract.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 58.5pt; text-align: justify; text-indent: -58.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">11.</TD><TD STYLE="text-align: justify">The parties agree that each of them may pledge or charge his/its rights under this Contract in
whole or in part provided that such pledge or charge shall not prejudice the performance of the pledging or charging parties undertakings
under this Contract, or enable a transfer of his/rights or obligations otherwise than pursuant to the terms of this Contract.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">12.</TD><TD STYLE="text-align: justify">The Landlord may assign or sell or transfer his rights and obligations under this Contract in whole
or in part provided the rights of the Tenant under this Contract will not be prejudiced.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt"><B><I>Sub-tenancy</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">13.</TD><TD STYLE="text-align: justify">The Tenant may grant a sub-tenancy of the Premises or part thereof on the following conditions:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 27pt; text-align: left">(a)</TD><TD STYLE="text-align: justify">The Tenant will be responsible for the sub-tenant
fulfilling all of the Tenant&rsquo;s obligations under this Contract and any breach of this Contract by the sub-tenant will be
deemed to be a breach of this Contract by the Tenant.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 27pt; text-align: left">(b)</TD><TD STYLE="text-align: justify">The Tenant will remain indirectly liable towards the
Landlord for performing all of its obligations under this Contract.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 27pt; text-align: left">(c)</TD><TD STYLE="text-align: justify">The terms of the sub-tenancy will be consistent with
the performance of the provisions of this Contract and the appendices thereto, and with the law. No modification will be made
without the Landlord&rsquo;s consent which will not unreasonably be withheld save for reasons that will be set out in writing.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt"><B><I>Registration
of the tenancy</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt">14.</TD><TD STYLE="text-align: justify">The Tenant may, at its sole discretion, register the tenancy pursuant to this Contract in the Land
Registry, provided that all costs, taxes or fees relating to such registration will be paid solely by the Tenant.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt"></TD><TD STYLE="text-align: justify">Where the Tenant has registered in the Land Registry the tenancy, it shall be bound to delete at
its own exclusive expense the registration upon the expiration of the Tenancy Term, regardless of whether the Tenancy Term has
terminated upon the full expiration of the term according to the provisions of this Contract, or has terminated prior thereto for
any reason whatsoever.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt"><B><I>Use
of the Premises</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 28.35pt; text-align: justify; text-indent: -28.35pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 28.35pt; text-align: left">15. (a)</TD><TD STYLE="text-align: justify">For the purposes of this clause, the following terms shall
bear the meanings set out opposite them:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in"></TD><TD STYLE="text-align: justify">&ldquo;Installations&rdquo; &ndash; air conditioning, sanitary plumbing, water plumbing, sewerage,
electricity, lighting systems, communication systems and all other systems that are installed by the Landlord in the Premises or
any part thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">The Tenant covenants that the use of the Premises
will not cause any nuisance to the reasonable use of any other tenant in the Building, including, but without derogating from
the generality of the foregoing, nuisances which amount to noise and odors, and will be exclusively responsible for any such nuisance
that will be caused by it.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in"></TD><TD STYLE="text-align: justify">The Landlord undertakes to arrange for each new tenant in the Building signing a tenancy contract
that includes a clause in the above form.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">The Seller undertakes to fulfill all of the statutes,
regulations and bye-laws and requirements of any competent authority which apply now or hereafter during the Tenancy Term of the
Premises in regard to the Premises, the use thereof and the Tenant&rsquo;s business and activity of any kind at the Premises,
and will bear exclusive responsibility for any breach of this undertaking.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in"></TD><TD STYLE="text-align: justify">Without derogating from the generality of the foregoing, the Tenant undertakes to obtain at his
own expense all of the licenses and permits that are required by law for carrying on its business at the Premises.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in; text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">The Landlord undertakes to sign, on the Tenant&rsquo;s
request, any document that will be required for the purpose of obtaining such license or permit, within one week of the date of
the demand.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">Subject to the performance of the Landlord&rsquo;s
undertakings according to this Agreement, the Tenant will, during the Tenancy Term, bear all and any fine or penalty that will
be imposed in respect of carrying on its business and activity at the Premises, and/or the use of the Premises without a permit
or in deviation from the permit &ndash; by it and/or by its employees or agents/regardless of whether the same has been imposed
on the Tenant or on the Landlord.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in"></TD><TD STYLE="text-align: justify">For the avoidance of any doubt it is clarified that the provisions of this clause will not be deemed
to be a license of the Landlord to the Tenant to use the Premises without a permit or in deviation thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(e)</TD><TD STYLE="text-align: justify">The Landlord shall be responsible for fixing any defects
in the Premises, including in the construction and the Installations of the Premises, that result from reasonable wear or from
defective labor or negligence or the use of defective materials by the Landlord and/or any person on its behalf in all matters
relating to the construction of the Premises.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in"></TD><TD STYLE="text-align: justify">The Landlord, by his attorneys, employees, agents or persons on his behalf shall be entitled to
enter upon the Premises at any reasonable time during usual working hours after arrangement with the Tenant in order to review
the condition of the Premises, the performance of repairs or works that are required at the Premises, ameliorations and improvements
when the same is necessary on condition that the proper activity of the Tenant at the Premises will not be disrupted.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(f)</TD><TD STYLE="text-align: justify">Without derogating from the Tenant&rsquo;s obligations
under sub-clause (e) above, the Tenant undertakes to keep the Premises in good and proper condition and perform any repair that
is reasonably
required by an occupier in order to enable the proper operation of the Installations on a regular basis.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in"></TD><TD STYLE="text-align: justify">The Landlord undertakes to effect any capital repair that is required in order to ensure the operation
of the Installations.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(g)</TD><TD STYLE="text-align: justify">The Landlord undertakes to effect the repairs specified
in sub-clauses (e) and (f) above in a reasonable time; urgent repairs will be carried out as speedily as possible.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(h)</TD><TD STYLE="text-align: justify">The Tenant shall be entitled at its exclusive expense
to make in the Premises or in any part thereof any internal alteration, including the erection of an upper floor, subject to the
restrictions of any law, provided that such alterations shall not damage the walls of the Premises or the Installations, subject
to the Tenant reinstating the condition to what it was previously upon the expiration of the Tenancy Term.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(i)</TD><TD STYLE="text-align: justify">The Landlord shall be entitled to place on the Building
at its responsibility and expense, writing or a sign indicating that the Building is called <I>Mordecai Eliash House</I>. The
Tenant may install signage on the Premises, subject to any law, including on the external walls or in the framework of the general
signage in the entrance to the Building, provided that such signage shall not harm the other tenants of the Building and from
the standpoint of the form thereof, the signage has been approved by the architect of the Building, Mr. Raphi Lerman. The Tenant
shall be responsible for installing the above signage and will bear payment of any fee, tax, levy or any other payment in respect
thereof as stated in clause 9(a) above.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(j)</TD><TD STYLE="text-align: justify">The Landlord undertakes to enable the Tenant to make
use of an area that shall not be less than 80 square meters on the roof of the Building in order to position service systems that
are used by the Premises, without any additional payment. The roof area of which such use will be enabled will be adjacent to
the elevator shafts that have been or will be installed by the Landlord as stated in clause 5(a) above.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -40.5pt"><B><I>Liability
and indemnity</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">16. (a)</TD><TD STYLE="text-align: justify">Subject to its liability by law, the Tenant shall be responsible
for the duration of the Tenancy Term for the consequences of any harm, loss or damage to the property or person of any individual
that have been caused following or in connection with the use of the Premises or from the Tenant&rsquo;s activity or that of any
person on his behalf at the Premises or from any act or omission of the Tenant or of any person on its behalf, all on condition
that the harm or loss or damage have not been maliciously or willfully or negligently caused or are by reason of any breach of
statutory duty by the Landlord or of any person on its behalf and/or as a result of the condition of the Premises or its Installations,
to the extent the Landlord is responsible for the same.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"></TD><TD STYLE="text-align: justify">Without derogating from the generality of the foregoing it is clarified that subject to his liability
by law, the Landlord or any person on his behalf will bear all responsibility or liability for damages to any person or loss or
damage to property of any kind that will be caused to the Tenant and/or to its employees or to any person on his behalf or any
third party whatsoever that will be in the Premises, if the harm, loss or damage have been willfully caused or are as a result
of any malice or negligence or breach of statutory duty of the Landlord or of any person on his behalf or as a result
of the condition of the Premises or its Installations to the extent the Landlord is responsible for the same.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(b)</TD><TD STYLE="text-align: justify">Subject to his liability by law, the Landlord will bear all responsibility towards the professional
staff or persons on their behalf who will work on his behalf at the Premises save for any harm or damage that have been caused
maliciously or willfully or negligently or in breach of statutory duty by the Tenant or any person on its behalf.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(c)</TD><TD STYLE="text-align: justify">The Tenant undertakes to indemnify and compensate the Landlord for all damages and expenses that
have been incurred by him as a result of any loss, harm or damage that the Tenant is responsible for pursuant to the provisions
contained in clause 16(a) or (b) above, including, but without derogating from the generality of the foregoing, for any damage
or claim or liability that will be paid by the Landlord in connection with any loss, harm or damage that has occurred at the Premises
or in connection with or resulting from the possession of the Premises or relate to the use that will be made thereof, and indemnify
the Landlord for any sum that the Landlord will have paid to any person or entity in respect of such loss, harm or damage (including
his expenses including legal fees in connection with defending any claim for payment of such amount), against written evidence
in regard to the amount of the sum which the Landlord has borne or judgement the execution of which has not been stayed, and which
oblige the Landlord to pay any monies. The provisions of this clause will not be deemed to be a contract for the benefit of any
third party.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(d)</TD><TD STYLE="text-align: justify">The Landlord undertakes to indemnify and compensate the Tenant for all damages and expenses that
have been incurred by it as a result of any loss, harm or damage that the Landlord is responsible for pursuant to the provisions
contained in clause 16(a) or (b) above, including, but without derogating from the generality of the foregoing, for any damage
or claim or liability which the Tenant would have paid in connection with any loss, harm or damage that have occurred in the Premises
or in connection with the use that will be made thereof and which the Landlord is responsible for as stated and indemnify the Tenant
for any sum that the Tenant will pay to any person or entity in respect of such loss, harm or damage (including its expenses including
legal fees in connection with defending such claim for payment), against delivery of written evidence regarding the amount of the
sum borne by the Tenant or judgement the execution of which has not been stayed, which obligates the Tenant to pay any monies.
The provisions of this clause shall not be deemed to be a contract for the benefit of any third party.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(e)</TD><TD STYLE="text-align: justify">The Tenant&rsquo;s obligation to indemnify the Landlord pursuant to the provisions contained in
clause 16(c) above is conditional on the Landlord promptly notifying the Tenant after having received any claim or demand for compensation
that has been brought against him and which the Tenant is bound to indemnify the Landlord for as stated above, and enable the Tenant
to defend such claim either by joining him as a third party to such claim or by granting a power of attorney to the Tenant (or
to such lawyer as will be determined by it) to represent the Landlord in such claim or at the Landlord&rsquo;s election, or by
such other method as will be agreed upon between the parties in writing (if at all).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">(f)</TD><TD STYLE="text-align: justify">The Landlord&rsquo;s obligation to indemnify the Tenant pursuant to the provisions contained in
clause 16(d) above is conditional on the Tenant promptly notifying the Landlord after having received any claim or demand for compensation
that has been brought against him and which the Landlord is bound to indemnify the Tenant for as stated above, and enable the Landlord
to defend such claim either
by joining him as a third party to such claim or by granting a power of attorney to the Landlord (or to such lawyer as will be
determined by it) to represent the Tenant in such claim or at the Tenant&rsquo;s election, or by such other method as will be agreed
upon between the parties in writing (if at all).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -40.5pt"><B><I>Insurance</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">17.</TD><TD STYLE="text-align: justify">Without derogating from the Tenant&rsquo;s liability under
this Contract or at law, and offsetting the amount of any insurance that will exist in the framework of the management contract
of the Building, the Tenant undertakes to effect and maintain at its own expense throughout the entire duration of the Tenancy
Term, the insurances set out below with an authorised reputable insurance company:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Insurance for all the contents of the Premises that
are owned or in the responsibility of the Tenant in the full value, as well as any repair, modification, enhancement or reconditioning
that has or will be carried out by or on behalf of the Tenant, other than building addits, enhancements and additions to the structure
of the Premises that are made by or on behalf of the Landlord, against loss or damage following fire, smoke, lightning, explosion,
flood, damages due to liquids, bursting of pipes, damage by vehicles, damage by aircraft, sonic booms, damages following commission,
malicious damage, breakage of glass and burglary on the basis of first damage only. The insurance will include a condition whereby
the insurer waives any right of subrogation against the Landlord and/or any party on his behalf and against the other tenants
or occupiers of the Building whose insurances include a parallel clause regarding the waiver of the right of subrogation against
the Tenant or persons on its behalf other than against a person who has caused damage out of malicious intent.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Loss of income insurance (other than rent, management
fees and parking fees, if any), in an amount not less than the amount of the rent which is payable by the Tenant pursuant to the
provisions of this Contract, in consequence of loss or damage to the contents of the Premises or to the Premises following risks
that are insured in sub-clause (a) above for the duration of an indemnity period that will not be less than twelve months. The
insurance will include a condition whereby the insurer waives any right of subrogation against the Landlord or persons on his
behalf and against the other tenants or occupiers of the Building whose insurances include a parallel clause regarding the waiver
of subrogation against the Tenant or persons on his behalf, other than against a person causing damage out of malicious intent.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">The insurances will include an undertaking that the
policies will not be adversely affected nor cancelled for the duration of the insurance, unless 60 days&rsquo; prior written notice
is given by registered mail to the Landlord.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">18.</TD><TD STYLE="text-align: justify">Without derogating from the Landlord&rsquo;s liability
under this clause or at law, the Landlord undertakes to effect and maintain, either independently or by means of the management
company, for the entire duration of this Agreement, the insurances set out below with a duly authorised and reputable insurance
company (hereinafter: &ldquo;<B>the Landlord&rsquo;s Insurances</B>&rdquo;):</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Insurance of the Building including the appurtenances
thereto, installations and systems thereof, including any Building addits, enhancements and additions, in the full value thereof
against loss or damage following fire, smoke, lightning, explosion, earthquake, flood, storm and tempest damage,</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0">damage of
liquids and bursting of pipes, harm by vehicles, harm by aircraft, supersonic boom damage, collision damage, riots, strikes, malicious
damage, breakage of glass and burglary. The beneficiaries insured under the insurance policy shall be the Tenant and each and every
one of the remaining occupiers of the Building, the Landlord and the management company. The insurance will be extended to indemnify
all of the beneficiaries that are insured in respect of the liability by law for the acts or omissions of any of the other insured
beneficiaries, or any of their successors. The insurance will include a condition whereby the insurer waives any right of subrogation
against any of the insured beneficiaries or parties on their behalf, other than against a person who has caused damage out of malicious
intent, subject to a cross-liability clause whereby the insurance is deemed to have been made separately for each of the individuals
comprising the insured beneficiaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Third party liability insurance with a duly authorised
and reputable insurance company with a liability limit of $5,000,000 (five million US Dollars) per event and in the aggregate
and for the annual insurance term. This insurance will not be subject to any restriction regarding liability resulting from fire,
explosion, panic, contractors, sub-contractors, hoisting, loading and unloading devices, defective sanitary installations, poisoning,
any harmful thing in food or in drink, strikes and lockouts and subrogation claims on the part of the national insurance institute.
The insured beneficiaries according to the insurance policies shall be the Tenant and each and every one of the remaining occupiers
of the Building, the Landlord and the management company. The insurance will be extended to indemnify each of the insured beneficiaries
in respect of its liability by law for the acts or omissions of any of the other insured beneficiaries or of their successors.
The insurance will include a condition whereby the insurer waives any right of subrogation against any of the insured beneficiaries
or of their successors, other than against a person who has caused damage out of malicious intent, subject to a cross-liability
clause whereby the insurance is deemed to have been made separately for each of the individuals comprising the insured beneficiaries.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"></TD><TD STYLE="text-align: justify">The cost of purchasing the insurance policies mentioned in clause (a) above and in this clause
(b) will be divided between the tenants according to a formula dividing the liability for payment of the management fees between
them, and according to such ratio. It is clarified that to the extent the Building has yet to be fully let, the tenants will pay
only the proportionate share of the cost of purchasing the insurance policies that would have applied to them had the Building
been fully let, and the Landlord will bear the difference of the purchasing costs of the insurance policies. As stated in clause
32(b) hereof the Landlord undertakes to arrange for each tenant or occupier of the Building to sign the management agreement including
liability to pay the management fees covering also the cost of purchasing such policies.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">Consequential loss insurance including rent and management
fees (as well as parking fees &ndash; if any) in the full value thereof, that will be incurred by the Landlord or the management
company by reason of loss or damage to the Building consequent upon the risks set out in sub-clause (a) above for the duration
of an indemnity period that will not be less than 12 months. The insurance will include a condition whereby the insurer waives
any right of subrogation against the Tenant or persons on its behalf other than against a person who has caused damage out of
willful intent.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">Employers&rsquo; liability insurance insuring the
liability of the Landlord and the management company towards all of their employees with a liability limit of $5,000,000 (five
million US Dollars) per employee, per event and in the aggregate for the annual insurance term. This insurance will not include any
restriction regarding works at height or depth, working hours, contractors, sub-contractors and their employees (if the Landlord
or the management company shall be deemed to be their employer), bait and poison and also in regard to lawful juvenile employment.
Such insurance will be extended to indemnify the Tenant should it be deemed to be an employer of any of the Landlord&rsquo;s or
management company&rsquo;s employees or it is held that the Tenant bears vicarious responsibility with respect to the Landlord&rsquo;s
or the management company&rsquo;s liability towards their employees.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(e)</TD><TD STYLE="text-align: justify">The above insurance will include an undertaking that
the policy will not be reduced nor cancelled for the duration of the insurance unless 60 days&rsquo; prior written notice will
have been given to the Tenant by registered mail.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">19.</TD><TD STYLE="text-align: justify">If, in the Landlord&rsquo;s opinion, it will be necessary
to make additional or supplementary insurance to that stated above in clause 18, the Landlord undertakes to make and effect solely
at its own expense, such insurance. In any such additional or supplementary property insurance there will be included a clause
regarding the waiver of the right of subrogation against the Tenant or parties on its behalf and in liability insurances there
will be included an indemnity clause to the Tenant subject to a cross-liability clause.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in">20.</TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">The Landlord and the Tenant covenant that to the extent
damage will be caused to the structure or to the Premises, the insurance proceeds, to the extent they will be received, will be
applied in respect of such damage to repair the damage or for the restoration thereof.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">The parties undertake to fulfil all of the terms of
the insurances and fully and punctually pay the insurance premiums. The parties further undertake to co-operate with the counterparty
to the extent necessary in order to reserve and exercise their respective rights under their insurances including notifying the
insurer forthwith upon becoming aware of an event which could serve as a basis for any claim according to their respective insurances.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">If either of the parties to this Contract fails to
make the insurances which it is bound to effect according to clauses 18 and 17 above, in whole or in part, or will not maintain
all or any of such insurances, the counterparty may, but shall not be obliged, without derogating from his/its right under this
Contract or at law, to any remedy or other or additional relief, effect or maintain such insurances provided that prior thereto
the party intending to effect or maintain the insurance will have notified to the party to whom the obligation to effect or maintain
the insurance applies that it intends doing so and the insurance has not been made or maintained as required within fourteen (14)
days of the date of receiving such notice. If either of the parties hereto has effected or maintained insurance in lieu of the
counterparty as stated in this clause, all of the sums and expenses that he/it has borne in connection therewith will be reimbursed
to him/it according to his/its first demand, with the addition of linkage differentials and interest from the date of expending
the same until the date of actual reimbursement. The Tenant may offset any amount that it has paid in respect of making the insurance
the making of which applies to the Landlord out of the rent. The setoff shall be made after 14 days&rsquo; prior notice has been
given of the intention to setoff.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in; text-align: left">21.</TD><TD STYLE="text-align: justify">Pursuant to the demand of any of the parties in writing,
the counterparty undertakes to furnish to it within fourteen (14) days of the date of receiving the demand a certificate regarding
the making of insurance
signed by the insurer, or a copy of the insurance policy, pursuant to that stated in clauses 18 and 17 above.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">22.</TD><TD STYLE="text-align: justify">The parties undertake to update from time to time the insurance amounts in respect of the insurances
that are effected according to clauses 17 (the Tenant&rsquo;s insurances), and 18 (the Landlord&rsquo;s insurances) as well as
clause 19 (the additional Landlord&rsquo;s insurances) as appropriate, so that they will always reflect the full value of the property
that is insured thereunder.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">23.</TD><TD STYLE="text-align: justify">Each of the parties to this Contract may inspect the insurance certificates that will be furnished
to him/it by the counterparty as stated in this Contract above and each of the parties undertakes to make any modification or amendment
that will be required in order to adjust the same to their respective undertakings stated in this Contract. The parties declare
that the right of inspection by virtue of this clause in relation to the insurance certificate and their right to instruct an amendment
of the insurances as stated above does not impose upon the party requiring the amendment or any person on its behalf any duty and
any liability whatsoever in any matter relating to such insurance certificate, the quality, extent and validity of the insurances
of the counterparty or with respect to the absence thereof, nor does it detract from any liability whatsoever that is imposed upon
the counterparty under this Contract.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">24.</TD><TD STYLE="text-align: justify">The parties declare that they will have no claim or demand or cavil against the counterparty or
persons on his/its behalf in respect of any damage for which they are entitled to indemnity (or would have been entitled to indemnity
had it not been for the deductible specified in the policy or had there been no absent insurance condition or had it not been for
the breach of the terms of the policies) according to the insurances that are effected pursuant to clauses 17, 18 and clause 19,
as appropriate, provided that the foregoing in regard to the exemption of liability will not apply for the benefit of any person
who has caused willful damage.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"></TD><TD STYLE="text-align: justify">The parties may refrain from making any insurance for the breakage of glass save that the exemption
from such liability mentioned above will apply with respect to damage or breakage of glass as if such insurance had been made.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"></TD><TD STYLE="text-align: justify">The Tenant declares that it will neither have any claim or demand or cavil as mentioned above towards
other tenants or other occupiers of the Building in whose tenancy agreements or in any other agreement conferring upon them rights
in the Building, there is included a parallel exemption against the Tenant. The foregoing in regard to the exemption of liability
will not apply for the benefit of any person who has caused damage out of willful intent.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -40.5pt"><B><I>Force
majeure</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Should the Premises be damaged by reason of
<I>force majeure</I> in a manner whereby it is not possible to make any use thereof pursuant to this Contract, each of the parties
to this Contract shall have the right to rescind the Contract.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">For the purpose of this clause &ldquo;<I>force
majeure&rdquo;</I> means war, act of terror, fire, explosion, flood, earthquake, sovereign act and the like that are beyond the
control of the parties.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><B><I>Vacation of the Premises</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in">26.</TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Upon the expiration of the Tenancy Term (and in general,
for the avoidance of any doubt, upon the expiration of the Tenancy Term by reason of the lawful termination or conclusion of this
Contract) the Tenant will quit the Premises and leave the same vacant of any person and thing that is not permanently affixed
to the Building other than objects that are the property of the Landlord, and apart from the Installations (as defined in clause
15(a) above) and restore the Premises to the exclusive possession of the Landlord in a good and proper condition (fair wear and
tear excepted) and with all the Installations in a fully operating condition (fair wear and tear excepted).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify; text-indent: -49.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">If the Tenant has made any alterations or additions
to or in the Premises pursuant to the provisions of clause 15(g) above and the Landlord has waived the restoration to its former
condition or the Tenant has carried out works pursuant to the Specification or to an addit to the Specification, the same shall
become the property of the Landlord and the Tenant shall have no demands or claims in respect thereof or in respect of his investment
in the making thereof, unless it has been agreed in writing prior to the making thereof that the Landlord will compensate the
Tenant in respect of such works.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify; text-indent: -49.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">If the Tenant delays vacating the Premises, it will
pay to the Landlord in respect of each day of delay in vacating the Premises, fixed and pre-determined agreed damages in the sum
of $587.87 (five hundred and eighty seven US Dollars and eighty seven cents) during the First Tenancy Term, in the equivalent
value in new shekels according to the representative rate of exchange on the date of payment, as fixed and pre-determined agreed
damages during the Extended Term at a rate of 1.2 times the monthly rent as existing from time to time pursuant to the provisions
of this Contract divided by 30 in the equivalent value in new shekels or according to the representative rate of exchange on the
date of payment, as appropriate.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 40.5pt; text-align: justify; text-indent: -40.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0">The parties
declare that such amount constitutes agreed and proper compensation of the damage that the parties foresee as being the probable
result of such delay in vacating the Premises all without derogating from the Landlord&rsquo;s right to any other relief or compensation
at a higher rate including compensation for which it will be made liable, if at all, towards any alternative tenant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify; text-indent: -49.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">The Tenant will, as soon as possible after vacating
the Premises, furnish to the Landlord upon demand certifications of the authorities and various entities indicating that the Tenant
has paid all of the compulsory payments which were payable by it pursuant to this Contract including electricity, water, city
taxes or fees in respect of the Premises, until the date of the vacation.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify; text-indent: -49.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify; text-indent: -49.5pt"><B><I>Remedies</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify; text-indent: -49.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in">27.</TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">Without derogating from any other or additional relief,
and without derogating from the provisions of this Contract, the provisions of the Contracts (Remedies for Breach of Contract)
Law, 5731-1970 will apply to a breach of this Contract.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify; text-indent: -49.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Without derogating from the Landlord&rsquo;s right
to damages at a higher rate or to any other relief by reason of a fundamental breach of this Contract by the Tenant, the Landlord
will be entitled to fixed and agreed compensation without proof of damage in a sum equal to the rent for the Premises as provided
in this Contract for the duration of three (3) months of the Tenancy Term regardless
of whether the Landlord has elected to fulfil the Contract or terminate the same. The parties declare that they regard such sum
as agreed and proper compensation for the damage that the parties foresee to be a reasonable result of a fundamental breach of
this Contract by the Tenant.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify; text-indent: -49.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">Without derogating from the Tenant&rsquo;s right to
damages at a higher rate or to any other relief by reason of a fundamental breach of this Contract by the Landlord, the Tenant
will be entitled to fixed and agreed damages without proof of damage in a sum equal to the rent for the Premises as provided in
this Contract for the duration of three (3) months of the Tenancy Term regardless of whether the Tenant has elected to fulfil
the Contract or terminate the same. The parties declare that they regard such sum as agreed and proper compensation for the damage
that the parties foresee to be a reasonable result of a fundamental breach of this Contract by the Landlord.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify; text-indent: -49.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">Any sum that is due from either party to the other
according to or resulting from this Contract and which will not be paid by the party who is liable to the other within seven (7)
Business Days from the date of the specified date of payment, will bear interest at the maximum rate customary for the time being
and from time to time in Bank Leumi Le Israel BM with respect to unarranged overdrawings in overdraft accounts as from the date
of the specified payment thereof until the date of actual payment by the party who is liable to the other.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify; text-indent: -49.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(e)</TD><TD STYLE="text-align: justify">No waiver or extension by either party to this Contract
to the other in a particular instance will constitute any precedent for any other case; for purposes of this Contract, no waiver
or extension will be of any effect unless it has been made in writing.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify; text-indent: -49.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(f)</TD><TD STYLE="text-align: justify">A breach of clauses 3(a), 5(a), 6(a), 6(c), 6(d),
10, 13, 15(e), 32(g) will be deemed to be a fundamental breach of this Contract. A delay in the making of any payment that the
Tenant is liable to pay pursuant to this Contract in excess of fourteen (14) Business Days will be deemed to be a fundamental
breach of this Contract; the failure to effect insurances according to the provisions of this Contract or the continuing maintenance
of such insurances, such breach not having been cured within fourteen (14) Business Days, will be deemed to be a fundamental breach
of this Contract.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify; text-indent: -49.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(g)</TD><TD STYLE="text-align: justify">Notwithstanding the provisions herein contained it
is agreed that neither of the parties shall be entitled to the agreed compensation according to this Contract or to terminate
this Contract prior to having given to the party in breach a written extension to cure the breach of at least fourteen (14) days
and if the breach would have been cured within such period.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify; text-indent: -49.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">28.</TD><TD STYLE="text-align: justify">Either party to this Contract will, upon the occurrence
of any of the events specified below, without derogating from his/its right to any other relief, be entitled to terminate this
Contract despite any provision in this Contract contained in relation to the Tenancy Term by sixty (60) days&rsquo; prior written
notice. Upon such termination of the Contract the Tenant will quit the Premises and possession will be surrendered to the Landlord
as stated in clause 26 above:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify; text-indent: -49.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">A fundamental breach of this Contract has occurred;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify; text-indent: -49.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">A breach of any of the provisions of this Contract
by other than a fundamental breach and such breach will not have been rectified within thirty (30) days after written notice will
have been sent to the infringing party.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify; text-indent: -49.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">A petition will have been filed with respect to either
of the parties, as appropriate, with the Court for a winding up, or declaration to declare such party bankrupt, appoint for such
party a trustee, liquidator, receiver for a material part of his/its assets and/or to impose any attachment over a material part
of his/its assets and an order has been granted according to such petition or the petition has not been vacated or dismissed within
sixty days of the date of been filed with the Court and/or in the event of either of the parties having filed a petition for his/its
winding up or for a declaration of bankruptcy or for the making of a creditor&rsquo;s arrangement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify; text-indent: -49.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify; text-indent: -49.5pt"><B><I>Applicable
law and arbitration</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify; text-indent: -49.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 21.3pt">29.</TD><TD STYLE="text-align: justify">Subject as provided in clause 30 hereof, any action that will be brought in connection with or
in consequence of this Contract, the making, validity, breach, performance or interpretation thereof or by reason of any act or
omission relating to the tenancy that is regulated herein or by reason of any act or omission relating to the Premises and the
exercise thereof will be disposed of in accordance with the laws of Israel.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify; text-indent: -49.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 21.3pt">30.</TD><TD STYLE="text-align: justify">Any disputes or differences that have arisen in or on any matter pertaining to the compliance of
the addition to the Specification, the building permits as stated in clause 5(c) above, and regarding the schedule of defects according
to the provisions of clause 6(b) above, will be referred by the parties to the determination of an agreed arbitrator. The determination
of such agreed arbitrator will be final and binding upon the parties hereto, subject to the right of either party, after giving
the counterparty 21 days&rsquo; notice to transfer the determination on the matter to the competent Court.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify; text-indent: -49.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 21.3pt">31.</TD><TD STYLE="text-align: justify">Subject to the provisions of clause 30 above, it is hereby agreed by the parties that the competent
court in Jerusalem and it alone shall have the exclusive jurisdiction to dispose of any action that will be brought in respect
of or in connection with or pertaining to or in consequence of this Contract, the making, validity, breach, performance or interpretation
thereof or on account of any act or omission relating to the tenancy regulated herein or by reason of any act or omission relating
to the Premises and the operation thereof.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify; text-indent: -49.5pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify; text-indent: -49.5pt"><B><I>Management</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify; text-indent: -49.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in">32.</TD><TD STYLE="width: 0.25in; text-align: left">(a)</TD><TD STYLE="text-align: justify">It is hereby agreed that the management, operation and
maintenance of the building will be carried out by an experienced and skilled management company in which the Landlord shall have
no interest, according to the Landlord&rsquo;s decision (hereinafter: &ldquo;<B>the Management Company</B>&rdquo;) and the standard
and extent of the services that it will be required to provide shall not be less than the standard and extent of the services
that are provided by the management companies that manage the Weizman Science Park buildings and those in Rabin Park, and which
shall commence its operation not later than the Possession Date according to this Contract. The Landlord undertakes to induce
such Management Company to commence its activity on such date.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify; text-indent: -49.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(b)</TD><TD STYLE="text-align: justify">Without derogating from the Landlord&rsquo;s commitment
detailed above in sub-clause (a) the Tenant undertakes to sign with the Management Company a management contract that will include
the conditions contained in the sample management contract attached hereto as an integral part hereof (hereinafter: <B>&ldquo;the
Management Contract</B>&rdquo;). The Landlord undertakes to arrange for every tenant in the Building to sign the Management Contract
with the Management Company, and that no tenancy agreement will be made with any potential tenant who refuses to sign the Management
Contract with the Management Company and it will not receive any right to take possession or use the Building or any part thereof.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify; text-indent: -49.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(c)</TD><TD STYLE="text-align: justify">The Tenant undertakes to fulfil all of its obligations
pursuant to the Management Contract, including punctually and regularly paying its share of the management fees, subject to the
performance of the Management Company&rsquo;s undertakings under the Management Contract. It is hereby agreed that the non-payment
of the Tenant&rsquo;s share of the management fees will be treated for all purposes as non-payment of the rent according to this
Contract.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify; text-indent: -49.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0pt"></TD><TD STYLE="width: 0.5in"></TD><TD STYLE="text-align: justify">It is hereby agreed that the Tenant will not be bound to pay as its share of the management fees
during the period in which the Building is not yet fully occupied, any amount that exceeds the amount which it would have been
bound to pay had the Building been fully occupied.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify; text-indent: -49.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"></TD><TD STYLE="text-align: justify">It is hereby agreed that the Landlord will bear any deficit that will arise in the payments of
the management fees following the fact that the building has yet to be fully occupied.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify; text-indent: -49.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(d)</TD><TD STYLE="text-align: justify">It is agreed that in the Contract with the Management
Company it will be noted that any modification to the format of the management of the Building will require the Landlord&rsquo;s
approval and the approval of the Tenants who jointly lease most of the principal areas of the Building or the approval of the
Tenants who lease together two thirds of the principal areas that are leased in the Building. Each of the tenants shall have the
proportionate right according to its share of the principal areas that are leased in the Building as against all of the principal
areas that are leased in the Building.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify; text-indent: -49.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(e)</TD><TD STYLE="text-align: justify">It is hereby agreed that a breach of any fundamental
undertaking or of any other provision of the Management Contract shall be treated in all respects as a fundamental breach or as
any other breach of this Contract.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify; text-indent: -49.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(f)</TD><TD STYLE="text-align: justify">It is hereby agreed that in no event other than an
adjustment to the management fees as mentioned below, will the Tenant be bound directly or indirectly, to bear management fees
that exceed the sum of $2.30 (two Dollars and thirty cents) per month per square metre (gross) of the Premises, with the addition
of VAT.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify; text-indent: -49.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in"></TD><TD STYLE="text-align: justify">Any sum that will be required according to the Management Agreement in excess of such sum will
be paid by the Landlord. The management fees will be adjusted annually according to the rises that will occur, if at all, in the
official indices of the inputs that are comprised in the management fees or pursuant to the service package that will be included
in the management fees according to a decision that has been taken as stated in sub-clause (d) above.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify; text-indent: -49.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in; text-align: left">(g)</TD><TD STYLE="text-align: justify">It is hereby agreed that such payment of the management
fees will cover the costs of the services for which the Landlord is committed according to the provisions of this Contract through
the Management
Company that he will appoint, and which will include, without derogating from the provisions of the Management Agreement, cleaning
of all of the public areas including the service areas that are comprised in the Premises, elevator maintenance, landscaping and
guarding and concierge in the Building lobby, insurance, the employment of a building janitor, supply of air conditioning (cold
water only) between 07.00- 22.00 from Sundays to Thursdays on normal working days and from 07.00-14.00 on Fridays and Holiday Eves
and the Festivals. For the avoidance of any doubt it is clarified that the Landlord undertakes that the services of the Management
Company will include at least the above services, to a high standard. Supply of the air conditioning shall be at a level which
shall not be less than 1 ton cooling for every 16 square metres (net) of the Premises.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify; text-indent: -49.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify; text-indent: -49.5pt"><B><I>Guarantee</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify; text-indent: -49.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">33.</TD><TD STYLE="text-align: justify">The Tenant will pay on the execution of this Contract,
in addition to the rent detailed in clause 8(b) above, an amount equal to four months of the tenancy together with VAT as a surety
to secure the performance of all of the Tenant&rsquo;s undertakings according to this Contract. The Landlord shall be entitled
to recover out of the surety any sum that the Tenant is bound to pay to the Landlord under the provisions of this Contract and
will not have paid, provided that he gives the Tenant ten days&rsquo; prior written notice of his intention to recover any such
amount and the Tenant would have failed to pay such sum within ten days.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify; text-indent: -49.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"></TD><TD STYLE="text-align: justify">The surety will be in effect until the expiration of four months after the expiration of the Tenancy
Term, and at the end of such Term, the surety will be returned or any surplus thereof, to the Tenant, to the extent the surety
will not have been used for making any payment mentioned above.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify; text-indent: -49.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">34.</TD><TD STYLE="text-align: justify">Each of the parties hereby mutually undertakes to sign
any document which is to be signed or furnished by him/it and which are required in order to perfect the provisions of this Contract
and the performance thereof.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify; text-indent: -49.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">35.</TD><TD STYLE="text-align: justify">This Contract exhausts everything which has been agreed
between the parties on all the matters that are comprised in this Contract and no negotiation, declaration, representation, undertaking
and/or consent that has been given or made, if at all, either in writing or verbally or expressly or impliedly shall be of any
effect if made prior to the signature of this Contract.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify; text-indent: -49.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">36.</TD><TD STYLE="text-align: justify">No modification or waiver in relation to this Contract
will be of any effect unless expressly made in writing by both parties.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify; text-indent: -49.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in; text-align: left">37.</TD><TD STYLE="text-align: justify">The addresses of the parties for the purposes of this Contract
are:</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify; text-indent: -49.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"></TD><TD STYLE="text-align: justify">The Landlord &ndash; c/o Dr. Moshe Eliash Advocate, 2 Hasoreg Street,</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"></TD><TD STYLE="text-align: justify">P.O. Box 433, Jerusalem.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify; text-indent: -49.5pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"></TD><TD STYLE="text-align: justify">The Tenant &ndash; at the Premises and c/o Goldfarb, Levy, Eran, Meiri and Co. of 3 Azrieli Center,
Advocates, Triangular Tower, 43rd floor, Tel Aviv.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49.5pt; text-align: justify; text-indent: -49.5pt">&nbsp;</P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in"></TD><TD STYLE="text-align: justify">Any notice sent by either party to the other according to the above addresses will be deemed to
have reached its destination if sent by registered mail &ndash; after 72 hours from the time of dispatch, and if sent by fax &ndash;
after 24 hours of the time of dispatch, and if served personally &ndash; on the date of the service thereof on condition that to
the extent the notice that has been sent by the Landlord to theTenant, it has been sent to the address of the Tenant at the Premises
as well as to the Tenant&rsquo;s Address c/o Goldfarb, Levy, Eran, Meiri and Co., Advocates, as stated above.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 21.3pt; text-align: justify; text-indent: -21.3pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>In witness whereof the parties have set their hands after having
read the Agreement and understood the contents thereof:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 95%; border-collapse: collapse; margin-left: 0.25in">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Dr. Moshe Eliash</FONT></TD>
    <TD STYLE="width: 10%">&nbsp;</TD>
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Alon Seri-Levy</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">The Landlord</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Sol-Gel Technologies Ltd.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">in his own name</FONT></TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">The Tenant</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">and in the name of Ms. Rachel Zacks</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">by general power of attorney</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 85.05pt; text-indent: -85.05pt">&nbsp;</P>


<!-- Field: Page; Sequence: 25; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>4
<FILENAME>t1702381_ex10-8.htm
<DESCRIPTION>EXHIBIT 10.8
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-align: right; text-indent: -127.6pt"><B><U STYLE="text-decoration: none">Exhibit
10.8</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-align: right; text-indent: -127.6pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">[Informal
English Translation]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Tenancy Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Made and
executed in Jerusalem this 29th day of September 2014</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Between:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Ms. Rachel Zacks</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Identity
No. 29581</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Dr. Moshe
Eliash Advocate</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Identity
No. 1940998</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">(jointly
and severally)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">(hereinafter
&ndash; &ldquo;<B>the Landlord</B>&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-align: right; text-indent: -127.6pt">of the one
part;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-align: right; text-indent: -127.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">And:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Sol-Gel
Technologies Ltd</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Corporate
number 51-254469-3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">(hereinafter called: &ldquo;<B>the Tenant</B>&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">of the other part</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 85.05pt"><B>WHEREAS</B></TD><TD STYLE="text-align: justify">by a tenancy agreement
                                         signed between the parties on October 10, 2007, (hereinafter called: &ldquo;<B>the
                                         Tenancy Agreement</B>&rdquo;) the Tenant took a tenancy of the Premises as defined in
                                         the Agreement; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 84.95pt; text-align: justify; text-indent: -84.95pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 84.95pt"><B>WHEREAS</B></TD><TD STYLE="text-align: justify">the Tenant wishes to take and the Landlord wishes to grant a tenancy of an additional area in the
Building as defined in the Tenancy Agreement</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 84.95pt; text-align: justify; text-indent: -84.95pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 84.95pt; text-indent: -84.95pt">It is therefore declared and
agreed between the parties as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 84.95pt; text-indent: -84.95pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt; text-align: left">1.</TD><TD STYLE="text-align: justify">The preamble to this Agreement constitutes an integral
part thereof.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">2.</TD><TD STYLE="text-align: justify">The Landlord hereby grants to the Tenant a tenancy of an area of approximately 118.4 square meters
(net) being 148 square meters (gross) on the top storey of the Building, as described in the plan annexed hereto and constituting
an integral part of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">3.</TD><TD STYLE="text-align: justify">That area mentioned will be called &ldquo;the Premises&rdquo;.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">4.</TD><TD STYLE="text-align: justify">The tenancy term shall commence on October
                                         1, 2014 and expire at the end of the Tenancy Term according to the Tenancy Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-indent: -27pt"><I>&nbsp;</I></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">5.</TD><TD STYLE="text-align: justify">The monthly rent for the Premises is
                                         set at NIS 65 per square meter (gross) at the sum of NIS 9620, such sum being linked
                                         to the Consumer Price Index published on August 15, 2014 (102.4 points).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">6.</TD><TD STYLE="text-align: justify">The rent will be paid for three months in advance every calendar quarter as defined in the Tenancy
Agreement. Payment for the first three months of the tenancy will be made on the execution of this agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -27pt"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">7.</TD><TD STYLE="text-align: justify">The management fees for the Premises shall be at the rate of NIS 13 per square meter (gross), and
will be paid according to the provisions of the Tenancy Agreement. The Tenant will sign with the Management Company a management
agreement pursuant to the provisions of the Tenancy Agreement, immediately after the signature of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">8.</TD><TD STYLE="text-align: justify">The Tenant will pay on the execution of this Agreement, a surety at the rate of four months of
the tenancy together with VAT pursuant to the provisions of clause 33 of the Tenancy Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">9.</TD><TD STYLE="text-align: justify">For the avoidance of any doubt it is hereby clarified that to the extent the Tenant will terminate
the Tenancy Term according to the Tenancy Agreement according to the provisions of clause 7(b)(2) of the Tenancy Agreement, the
tenancy term according to this Agreement will likewise come to an end on the same date.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">10.</TD><TD STYLE="text-align: justify">Subject as herein provided, all the terms of the Tenancy Agreement will <I>mutatis mutandis</I>
apply to the tenancy according to this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">In witness whereof the parties have set their hands on the date
first above written</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 93%; border-collapse: collapse; margin-left: 27pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid; padding-right: -28.1pt"><FONT STYLE="font-size: 10pt">/s/ Dr. Moshe Eliash</FONT></TD>
    <TD STYLE="width: 10%; padding-right: -28.1pt">&nbsp;</TD>
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid; padding-right: -28.1pt"><FONT STYLE="font-size: 10pt">/s/ Kobbi Nir /s/ Ido Zalel</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: -28.1pt"><FONT STYLE="font-size: 10pt">The Landlord</FONT></TD>
    <TD STYLE="padding-right: -28.1pt">&nbsp;</TD>
    <TD STYLE="padding-right: -28.1pt"><FONT STYLE="font-size: 10pt">Sol-Gel Technologies Ltd.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: -28.1pt"><FONT STYLE="font-size: 10pt">in his own name</FONT></TD>
    <TD STYLE="padding-right: -28.1pt">&nbsp;</TD>
    <TD STYLE="padding-right: -28.1pt"><FONT STYLE="font-size: 10pt">The Tenant</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: -28.1pt"><FONT STYLE="font-size: 10pt">and in the name of Ms. Rachel Zacks</FONT></TD>
    <TD STYLE="padding-right: -28.1pt">&nbsp;</TD>
    <TD STYLE="padding-right: -28.1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: -28.1pt"><FONT STYLE="font-size: 10pt">by general power of attorney</FONT></TD>
    <TD STYLE="padding-right: -28.1pt">&nbsp;</TD>
    <TD STYLE="padding-right: -28.1pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.9
<SEQUENCE>5
<FILENAME>t1702381_ex10-9.htm
<DESCRIPTION>EXHIBIT 10.9
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-align: right; text-indent: -127.6pt"><B><U STYLE="text-decoration: none">Exhibit
10.9</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-align: right; text-indent: -127.6pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">[Informal
English Translation]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Second Addendum
to the Tenancy Agreement of 10.10.2007</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Made and
executed in Jerusalem this 30th day of March 2016</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Between:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Ms. Rachel
Zacks</B> Identity No. 29581</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Dr. Moshe
Eliash</B> Identity No. 1940998</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">(jointly
and severally)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">(hereinafter
called &ndash; &ldquo;<B>the Landlord</B>&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-align: right; text-indent: -127.6pt">of the one
part;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-align: center; text-indent: -127.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-align: center; text-indent: -127.6pt">And:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-align: center; text-indent: -127.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-align: center; text-indent: -127.6pt"><B>Sol-Gel
Technologies Ltd</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-align: center; text-indent: -127.6pt">Corporate
number 51-2544693</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(hereinafter called: &ldquo;<B>the Tenant</B>&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 28.35pt">of the other part</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 85.05pt"><B>WHEREAS</B></TD><TD STYLE="text-align: justify">by a tenancy agreement
                                         signed between the parties on 10th October, 2007, (hereinafter called: &ldquo;<B>the
                                         Tenancy Agreement</B>&rdquo;) the Tenant took a tenancy of an area constituting the entire
                                         fifth floor in the building situated at Parcel 18 of Block 3850 in Ness Ziona (&ldquo;<B>the
                                         Building</B>&rdquo;) as well as 43 covered parking places in the underground car park
                                         of the building (the area and the parking places being together called: &ldquo;<B>the
                                         Original Premises</B>&rdquo;); and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 84.95pt; text-align: justify; text-indent: -84.95pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 84.95pt"><B>WHEREAS</B></TD><TD STYLE="text-align: justify">On 29th September, 2014, the first addendum was signed between the parties to the Tenancy Agreement
whereby the Tenant took a tenancy of an additional area of 148 square meters (gross) on the top floor (sixth floor) in the Building
as marked in blue on the plan attached hereto as <B>Appendix &ldquo;A&rdquo;</B> (&ldquo;<B>the Additional Area</B>&rdquo;).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 84.95pt; text-align: justify; text-indent: -84.95pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 84.95pt"></TD><TD STYLE="text-align: justify">The Original Premises together with the Additional Area will be in this Addendum called: &ldquo;<B>the
Existing Premises&rdquo;; </B>and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 84.95pt; text-align: justify; text-indent: -84.95pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 84.95pt"><B>WHEREAS</B></TD><TD STYLE="text-align: justify">The Tenant wishes to take and the Landlord wishes to grant to the Tenant, a tenancy of additional
areas in the Building constituting the New Additional Areas (as hereinafter defined); and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 84.95pt; text-align: justify; text-indent: -84.95pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 84.95pt"><B>WHEREAS</B></TD><TD STYLE="text-align: justify">The parties wish to extend the Tenancy Term of the Presently Existing Premises (as hereinafter
defined).</TD></TR>                   <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">It is therefore
declared and agreed between the parties as follows:</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 84.95pt; text-indent: -84.95pt"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt; text-align: left">1.</TD><TD STYLE="text-align: justify">The preamble to this Agreement constitutes an integral
part thereof.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-indent: -27pt">&nbsp;</P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt; text-align: left">2.</TD><TD STYLE="text-align: justify">The Landlord hereby grants to the Tenant a tenancy of the
area on the top floor of the Building of 174 square meters (gross) west of the Additional Area and a further area on the top floor
of the Building of 185 square meters (gross) east of the Additional Area, as marked in yellow on the plan annexed hereto as <B>Appendix
&ldquo;A&rdquo;</B> and which constitutes an integral part of this Agreement (the Additional Areas to the west and east mentioned
will be hereinafter called: &ldquo;<B>the New Additional Areas</B>&rdquo;).</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt; text-align: left">3.</TD><TD STYLE="text-align: justify">The New Additional Areas together with the Existing Premises
will be called in this Addendum &ldquo;<B>the Presently Existing Premises</B>&rdquo;.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">4.</TD><TD>The Tenancy Term in respect of the New Additional Areas will commence on  March 1, 2017 (&ldquo;<B>the Operative
                                                         Date</B>&rdquo;) and expire at the end of the Adjusted Tenancy Term (as hereinafter defined).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-indent: -27pt"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">5.</TD><TD STYLE="text-align: justify">The Tenancy Term in respect of the Presently Existing Premises is hereby extended and will expire
on December 31, 2020 (&ldquo;<B>the Adjusted Tenancy Term</B>&rdquo;).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">6.</TD><TD STYLE="text-align: justify">The monthly rent in respect of the Premises will, as from the Operative Date until the expiration
of the Adjusted Tenancy Term, stand at NIS 121,972.75 plus VAT (&ldquo;<B>the Rent</B>&rdquo;) according to the following breakdown:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 27pt; text-align: left">5.1</TD><TD STYLE="text-align: justify">The monthly rent in respect of the area of 1090.71
square meters (gross) on the fifth floor and 507 square meters (gross) on the top floor will stand at NIS 65 per square meters,
and in the aggregate NIS 103,851.15.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63pt; text-align: justify; text-indent: -63pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 27pt; text-align: left">5.2</TD><TD STYLE="text-align: justify">The monthly rent in respect of the internal bomb shelter
having an area of 30.72 square meters will stand at NIS 30 per square meters, and in the aggregate NIS 921.6.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63pt; text-align: justify; text-indent: -63pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 27pt"></TD><TD STYLE="width: 27pt; text-align: left">5.3</TD><TD STYLE="text-align: justify">The monthly rent in respect of the parking places
will stand at the sum of NIS 400 per parking place, and in the aggregate in respect of 43 parking places, at the sum of NIS 17,200.0.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63pt; text-align: justify; text-indent: -63pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 63pt; text-align: justify; text-indent: -63pt">The rent is linked
to the Consumer Price Index that was published on August 15, 2014 (102.4 points).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -27pt"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">7.</TD><TD STYLE="text-align: justify">The rent will be paid for three months in advance every calendar quarter as defined in the Tenancy
Agreement. Payment of the rent in respect of the New Additional Areas for the first three months of the tenancy in the sum of NIS
70,005 (plus VAT) will be made on the date of the execution of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">8.</TD><TD STYLE="text-align: justify">The monthly management fees for the Presently Exisiting Premises will be at the rate of NIS 13
per square meter (gross) and in the aggregate NIS 20,770.23, and be paid according to the provisions of the Tenancy Agreement.
The Tenant will sign with the Management Company an appropriate amendment to the management agreement to the extent this will be
required pursuant to the provisions of this Addendum, immediately after the execution of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">9.</TD><TD STYLE="text-align: justify">The Tenant will pay on the execution of this Agreement, a surety of four months of the tenancy
plus VAT in respect of the New Additional Areas pursuant to the provisions of clause 33 of the Tenancy Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">10.</TD><TD STYLE="text-align: justify">Subject as herein provided, all the terms of the Tenancy Agreement will <I>mutatis mutandis</I>
apply to the tenancy according to this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">In witness whereof the parties have set their
hands on the date first above written</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;&nbsp;</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 93%; border-collapse: collapse; margin-left: 27pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid; padding-right: -28.1pt"><FONT STYLE="font-size: 10pt">/s/ Dr. Moshe Eliash</FONT></TD>
    <TD STYLE="width: 10%; padding-right: -28.1pt">&nbsp;</TD>
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid; padding-right: -28.1pt"><FONT STYLE="font-size: 10pt">/s/ Kobbi Nir /s/ Alon Seri-Levy</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: -28.1pt"><FONT STYLE="font-size: 10pt">The Landlord</FONT></TD>
    <TD STYLE="padding-right: -28.1pt">&nbsp;</TD>
    <TD STYLE="padding-right: -28.1pt"><FONT STYLE="font-size: 10pt">Sol-Gel Technologies Ltd.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: -28.1pt"><FONT STYLE="font-size: 10pt">in his own name</FONT></TD>
    <TD STYLE="padding-right: -28.1pt">&nbsp;</TD>
    <TD STYLE="padding-right: -28.1pt"><FONT STYLE="font-size: 10pt">The Tenant</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: -28.1pt"><FONT STYLE="font-size: 10pt">and in the name of Ms. Rachel Zacks</FONT></TD>
    <TD STYLE="padding-right: -28.1pt">&nbsp;</TD>
    <TD STYLE="padding-right: -28.1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: -28.1pt"><FONT STYLE="font-size: 10pt">by general power of attorney</FONT></TD>
    <TD STYLE="padding-right: -28.1pt">&nbsp;</TD>
    <TD STYLE="padding-right: -28.1pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.10
<SEQUENCE>6
<FILENAME>t1702381_ex10-10.htm
<DESCRIPTION>EXHIBIT 10.10
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-align: right; text-indent: -127.6pt"><B><U STYLE="text-decoration: none">Exhibit
10.10</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-align: right; text-indent: -127.6pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">[Informal
English Translation]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Memorandum
of Agreement </B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Made and
executed in Jerusalem this 20th day of September 2016</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-align: center; text-indent: -127.6pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-indent: -127.6pt"><B>Between:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-indent: -127.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-indent: -127.6pt"><B>Ms. Rachel Zacks</B> Identity
No. 29581</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-indent: -127.6pt"><B>Dr. Moshe Eliash</B> Identity
No. 1940998</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-indent: -127.6pt">(each of them severally and jointly)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-indent: -127.6pt">(hereinafter called &ndash; &ldquo;<B>the
Landlord</B>&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-indent: -127.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-align: right; text-indent: -127.6pt">of the one
part;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-align: right; text-indent: -127.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-indent: -127.6pt">And:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-indent: -127.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-indent: -127.6pt"><B>Sol-Gel Technologies Ltd.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-indent: -127.6pt">Corporate number 51-2544693</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">(hereinafter called: &ldquo;<B>the Tenant</B>&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">of the other part</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 85.05pt"><B>WHEREAS:</B></TD><TD STYLE="text-align: justify">A Second Addendum to the Tenancy Agreement of  October 10, 2007 was signed between the parties
                                                                         on  March 30, 2016; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 85.05pt; text-align: justify; text-indent: -85.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 85.05pt"><B>WHEREAS:</B></TD><TD STYLE="text-align: justify">The parties wish to modify the particulars of the New Additional Areas (as defined in the Addendum)
and in consequence the details of the payments described in the Addendum fall to be modified.</TD></TR>                                                                                                       <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">It is therefore
declared and agreed between the parties as follows:</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 84.95pt; text-indent: -84.95pt"><B><I>&nbsp;</I></B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt; text-align: left">1.</TD><TD STYLE="text-align: justify">The preamble to this Memorandum of Agreement constitutes
an integral part thereof.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt; text-align: left">2.</TD><TD STYLE="text-align: justify">The area that is leased to the Tenant in addition to the
&ldquo;Additional Area&rdquo; as defined in the Addendum is an area of 373 square meters as marked in the attached plan being
Appendix &ldquo;A&rdquo;, and this will replace the &ldquo;New Additional Areas&rdquo; as defined in the Addendum.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">3.</TD><TD STYLE="text-align: justify">The rent described in clause 6 of the Addendum for the area of 1090.71 square meters (gross) on
the first floor and 521 square meters (gross) on the top floor will stand at NIS 65 per square meter, and in the aggregate NIS
104,761.15.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">4.</TD><TD>The rent described in clause 7 of the Addendum will stand at NIS 72,735.00 for three months and the Tenant will pay the sum
of NIS 2,728.00 the difference of the rent in excess of the sum of NIS 70,007.00 which was paid according to the provisions of
the Amendment, (plus VAT), on the execution of this Memorandum of Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-indent: -27pt"><I>&nbsp;</I></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt"><I>&nbsp;</I></P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">5.</TD><TD STYLE="text-align: justify">The amount of the management fees owed by the Tenant pursuant to clause 8 of the Addendum will
stand at NIS 20,952.23 per month.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt; text-align: left">6.</TD><TD STYLE="text-align: justify">The amount of the collateral according to clause 9 of the
Addendum will stand at NIS 96,980.00 instead of the sum of NIS 93,340.00 that was paid according to the provisions of the Addendum,
and the Tenant will pay the difference in the sum of NIS 3,640 (plus VAT) on the execution of this Memorandum of Agreement.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -27pt"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">7.</TD><TD STYLE="text-align: justify">Subject as herein provided, all of the provisions of the Addendum shall remain in full force and
effect.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 28.35pt">In witness whereof the parties have set their
hands on the date first above written</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 93%; border-collapse: collapse; margin-left: 27pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid; padding-right: -28.1pt"><FONT STYLE="font-size: 10pt">/s/ Dr. Moshe Eliash</FONT></TD>
    <TD STYLE="width: 10%; padding-right: -28.1pt">&nbsp;</TD>
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid; padding-right: -28.1pt"><FONT STYLE="font-size: 10pt">/s/ Kobbi Nir</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: -28.1pt"><FONT STYLE="font-size: 10pt">The Landlord</FONT></TD>
    <TD STYLE="padding-right: -28.1pt">&nbsp;</TD>
    <TD STYLE="padding-right: -28.1pt"><FONT STYLE="font-size: 10pt">Sol-Gel Technologies Ltd.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: -28.1pt"><FONT STYLE="font-size: 10pt">in his own name</FONT></TD>
    <TD STYLE="padding-right: -28.1pt">&nbsp;</TD>
    <TD STYLE="padding-right: -28.1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: -28.1pt"><FONT STYLE="font-size: 10pt">and in the name of Ms. Rachel Zacks</FONT></TD>
    <TD STYLE="padding-right: -28.1pt">&nbsp;</TD>
    <TD STYLE="padding-right: -28.1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: -28.1pt"><FONT STYLE="font-size: 10pt">by general power of attorney</FONT></TD>
    <TD STYLE="padding-right: -28.1pt">&nbsp;</TD>
    <TD STYLE="padding-right: -28.1pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>



<P STYLE="margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>7
<FILENAME>t1702381_ex10-11.htm
<DESCRIPTION>EXHIBIT 10.11
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; margin-top: 0; margin-bottom: 6pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 15pt; text-align: right">&nbsp;</TD><TD STYLE="width: 5pt"></TD><TD STYLE="text-align: justify">&nbsp;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-align: right; text-indent: -127.6pt"><B><U STYLE="text-decoration: none">Exhibit
10.11</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-align: right; text-indent: -127.6pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">[Informal
English Translation]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Tenancy Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Made and
executed in Jerusalem this 30th day of January 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Between:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Ms. Rachel
Zacks</B> Identity No. 29581</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Dr. Moshe
Eliash Advocate</B> Identity No. 1940998</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">(jointly
and severally)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">(hereinafter
&ndash; &ldquo;<B>the Landlord</B>&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-align: right; text-indent: -127.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-align: right; text-indent: -127.6pt">of the one
part;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 127.6pt; text-align: right; text-indent: -127.6pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">And:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Sol-Gel
Technologies Ltd</B>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">Corporate
number 51-254469-3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">(hereinafter called: &ldquo;<B>the Tenant</B>&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right">of the other part</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 85.05pt"><B>WHEREAS:</B></TD><TD STYLE="text-align: justify">by a tenancy agreement signed between the parties on October 10, 2007, (hereinafter called:
                                                                         &ldquo;<B>the Tenancy Agreement</B>&rdquo;) the Tenant took a tenancy of the Premises as defined in the Agreement; and</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 84.95pt; text-align: justify; text-indent: -84.95pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 84.95pt"><B>WHEREAS:</B></TD><TD STYLE="text-align: justify">the Tenant wishes to take and the Landlord wishes to grant a tenancy of additional areas.</TD></TR>                                                                                                                                                                                                            <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="text-align: justify">It is therefore
declared and agreed between the parties as follows:</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 84.95pt; text-indent: -84.95pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt; text-align: left">1.</TD><TD STYLE="text-align: justify">The preamble to this Agreement constitutes an integral
part thereof.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">2.</TD><TD STYLE="text-align: justify">The Landlord hereby grants to the Tenant the area of approximately 151 square meters (net),
                                                         which are approximately 188.75 square meters (gross) on the fourth floor of the Building, as described in the plan annexed
                                                         hereto and                                                          which
                                                         constitutes an integral part of this Agreement. It is agreed                                                          that
                                                         the passage areas marked in blue on the above plan will                                                          remain
                                                         vacant and not be leased to any party for the duration of the Tenancy Agreement term.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">3.</TD><TD STYLE="text-align: justify">The Landlord hereby grants also a tenancy of the entire mezzanine floor of the Building having
a floor area of 105.76 square meters as described in the plan annexed hereto and which constitutes an integral part of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">4.</TD><TD>The foregoing areas will be hereinafter called: &ldquo;<B>the Premises</B>&rdquo;.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-indent: -27pt"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">5.</TD><TD STYLE="text-align: justify">The Tenancy Term commences on  January 1, 2017 and expires on the expiration of the Tenancy
                                                         Term according to the Tenancy Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">6.</TD><TD STYLE="text-align: justify">The monthly rent for the area described in clause 2 above has been set according to NIS 65
                                                         per square meter (gross) at the sum of NIS 12,268.75, such sum being linked to the Consumer Price Index published on
                                                         November 15, 2016 (99.3 points).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -27pt"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">7.</TD><TD STYLE="text-align: justify">The monthly rent for the mezzanine floor described in clause 3 above has been set according to
NIS 30 per square meters of the floor area, at the sum of NIS 3172.80, such sum being linked to the Consumer Price Index published
on  November 15, 2016 (99.3 points).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">8.</TD><TD STYLE="text-align: justify">The aggregate rent for the Premises will be paid for three months in advance every calendar quarter
as defined in the Tenancy Agreement. The payment for the first three months of the tenancy will be made on the date of the execution
of this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -27pt"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">9.</TD><TD STYLE="text-align: justify">The management fees for the Premises will be at the rate of NIS 13 per square meter (gross) of
the area described in clause 2 above and will be paid pursuant to the provisions of the Tenancy Agreement. The Tenant will sign
a management agreement with the Management Company pursuant to the provisions of the Tenancy Agreement, immediately after signing
this Agreement. No management fee will be paid with respect to the mezzanine floor. The management fees will be linked to the Index
as described above.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">10.</TD><TD STYLE="text-align: justify">VAT will be added to all of the above payments according to the rate thereof at the time of making
the payment, and will be paid together with each of such payments.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">11.</TD><TD STYLE="text-align: justify">The Tenant will pay on the execution of this Agreement collateral at the rate of four months of
the tenancy together with VAT pursuant to the provisions of clause 33 of the Tenancy Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">12.</TD><TD STYLE="text-align: justify">The Tenant takes the Premises in its present condition &ldquo;as is&rdquo; and all adjustments
that will be required in order to adjust the Premises to the purposes of their use by the Tenant will be carried out by the Tenant
at its own expense.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -27pt"><I>&nbsp;</I></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">13.</TD><TD STYLE="text-align: justify">Possession of the area described in clause 2 above will be conveyed to the Tenant upon the execution
of this Agreement. Possession of the area of the mezzanine floor will be conveyed to the Tenant upon vacation by the existing tenant,
on  January 1, 2017.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify; text-indent: -27pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 27pt">14.</TD><TD STYLE="text-align: justify">Subject as provided above, all of the terms of the Tenancy Agreement will <I>mutatis mutandis</I>
apply to the tenancy according to this Agreement.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 27pt; text-align: justify">In witness whereof the parties have set their
hands on the date first above written</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 93%; border-collapse: collapse; margin-left: 27pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid; padding-right: -28.1pt"><FONT STYLE="font-size: 10pt">/s/ Dr. Moshe Eliash</FONT></TD>
    <TD STYLE="width: 10%; padding-right: -28.1pt">&nbsp;</TD>
    <TD STYLE="width: 45%; border-bottom: Black 1pt solid; padding-right: -28.1pt"><FONT STYLE="font-size: 10pt">/s/ Kobbi Nir</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: -28.1pt"><FONT STYLE="font-size: 10pt">The Landlord</FONT></TD>
    <TD STYLE="padding-right: -28.1pt">&nbsp;</TD>
    <TD STYLE="padding-right: -28.1pt"><FONT STYLE="font-size: 10pt">Sol-Gel Technologies Ltd.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: -28.1pt"><FONT STYLE="font-size: 10pt">in his own name</FONT></TD>
    <TD STYLE="padding-right: -28.1pt">&nbsp;</TD>
    <TD STYLE="padding-right: -28.1pt"><FONT STYLE="font-size: 10pt">The Tenant</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: -28.1pt"><FONT STYLE="font-size: 10pt">and in the name of Ms. Rachel Zacks</FONT></TD>
    <TD STYLE="padding-right: -28.1pt">&nbsp;</TD>
    <TD STYLE="padding-right: -28.1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: -28.1pt"><FONT STYLE="font-size: 10pt">by general power of attorney</FONT></TD>
    <TD STYLE="padding-right: -28.1pt">&nbsp;</TD>
    <TD STYLE="padding-right: -28.1pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 85.05pt; text-indent: -85.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.12
<SEQUENCE>8
<FILENAME>t1702381_ex10-12.htm
<DESCRIPTION>EXHIBIT 10.12
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><U STYLE="text-decoration: none">Exhibit 10.12</U></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center">PROMISSORY NOTE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">FOR VALUABLE CONSIDERATION
RECEIVED, <B>SOL-GEL TECHNOLOGIES LTD</B>., an Israeli company (the &ldquo;<U>Company</U>&rdquo;), hereby promises to pay to <B>MOSHE
ARKIN.</B>, an Israeli individual, I.D number 05-164306-2 (&ldquo;<U>Holder</U>&rdquo;), the principal amounts specified in <U>Schedule
A</U> hereto (the &ldquo;<U>Aggregate Principal Amount</U>&rdquo;) comprised of several outstanding loans advanced prior or following
the date hereof (each, a &ldquo;<U>Loan</U>&rdquo;)<B>, </B>until this Promissory Note (&ldquo;<U>Note</U>&rdquo;) is paid in full.
<U>Schedule A</U> may be updated form time to time in order to reflect additional principal amounts advance hereunder, by confirmation
of the parties through the exchange of written instrument (including in electronic form).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">1.</TD><TD STYLE="text-align: justify; padding-right: 0.2pt"><U>No Interest Rate</U>. Each of the Loans shall bear no interest.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">2.</TD><TD STYLE="text-align: justify; padding-right: 0.2pt"><U>Unsecured Note</U>. Holder acknowledges and agrees that the indebtedness
represented by this Note is unsecured.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">3.</TD><TD STYLE="text-align: justify; padding-right: 0.2pt"><U>Right to Prepay By Company; Termination</U>. The Company may, in its sole
discretion, prepay this Note in its entirety or any portion of, without premium or penalty.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify">Following the full payment of all
amounts outstanding under this Note, this Note shall be terminated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">4.</TD><TD STYLE="text-align: justify; padding-right: 0.2pt"><U>Events of Default</U>. Each of the following events shall be an Event
of Default (&ldquo;<U>Event of Default&rdquo;</U>) for purposes of this Note:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in 0 1in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify">The Company makes an assignment
for the benefit of creditors or admits in writing its inability to pay its debts as they become due, or files a voluntary petition
in bankruptcy, or is adjudicated a &ldquo;debtor&rdquo; under the Israeli liquidation law or other similar law or insolvent, or
files any petition or answer seeking for itself any reorganization, arrangement, composition, readjustment, liquidation, dissolution
or similar relief under any present or future statute, law or regulation, or files any answer admitting the material allegations
of a petition filed against the Company for any such relief, or a trustee, receiver or liquidator shall be appointed for the Company
or all or any substantial part of the properties of the Company, or if any petition for bankruptcy, reorganization or arrangement
under bankruptcy law shall be filed by or against, consented to, or acquiesced in by the Company, or if any proceeding for the
dissolution or liquidation of the Company shall be instituted; provided, that if such appointment, petition or proceeding was involuntary
and not consented to by the Company, the same shall become an Event of Default upon the same not being discharged, stayed or dismissed
within sixty (60) days.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in 0 1in; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in 0 1in; text-align: justify">&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">5.</TD><TD STYLE="text-align: justify; padding-right: 0.2pt"><U>Remedies on Default; Acceleration</U>. Upon the occurrence of an Event
of Default, Holder shall have the right to declare any amount payable under this Note to be immediately due and payable upon written
notice from Holder to the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">6.</TD><TD STYLE="text-align: justify; padding-right: 0.2pt"><U>Notices</U>. All notices and other communications required or permitted
hereunder to be given to a party to this Note shall be in writing and shall be telecopied or mailed by registered or certified
mail, postage prepaid, or otherwise delivered by hand or by messenger, addressed to such party&rsquo;s address as set forth below
or at such other address as the party shall have furnished to each other party in writing in accordance with this provision:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">if to <FONT STYLE="font-family: Times New Roman, Times, Serif">Holder</FONT>,
to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 171pt">Moshe Arkin.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 171pt">Ha'Choshlim 6 Herzliya</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 171pt">4672406 Israel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 1.5in">if to Company, to:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 171pt">Sol-Gel Technologies Ltd.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 171pt">7 Golda Meir St., Weizmann Science Park</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 171pt">Ness Ziona, 7403648 Israel</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 171pt">Atten: CEO</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">7.</TD><TD STYLE="text-align: justify; padding-right: 0.2pt"><U>Modification and Waiver</U>. No purported amendment, modification or waiver
of any provision hereof shall be binding unless set forth in a written document signed by the Company and Holder (in the case of
amendments or modifications) or by the party to be charged thereby (in the case of waivers).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">8.</TD><TD STYLE="text-align: justify; padding-right: 0.2pt"><U>Assignment</U>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in 0 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">a.</TD><TD STYLE="text-align: justify; padding-right: 0.2pt">Holder shall have the right to assign, sell, transfer, delegate, or otherwise
dispose of any right or obligation under this Note without the prior written consent of the Company.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in 0 1in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in">b.</TD><TD STYLE="text-align: justify; padding-right: 0.2pt">This Note may not be assigned by the Company without Holder&rsquo;s written
consent.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">9.</TD><TD STYLE="text-align: justify; padding-right: 0.2pt"><U>Governing Law and Venue</U>. This Note shall be construed and interpreted
pursuant to and in accordance with the laws of the State of Israel. Any dispute arising out of or relating to this Note shall be
venued only in the courts of Tel Aviv in the State of Israel.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.5in; text-align: justify; text-indent: -0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.5in">10.</TD><TD STYLE="text-align: justify; padding-right: 0.2pt">Entire Agreement. This Note states all the terms of the agreement between
the parties in respect of its subject matter. It supersedes all prior agreements in respect of the loans specified in Schedule
A (including the certain Promissory Note dated December 6, 2015).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">IN WITNESS WHEREOF, this
Promissory Note has been executed and delivered effective as of the date first set forth above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">SOL-GEL TECHNOLOGIES LTD.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 45%; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By: </FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Kobbi Nir</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Name: Kobbi Nir</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">Title: CFO</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">Agreed and accepted this 2nd day of August, 2016.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Moshe Arkin</FONT></TD>
    <TD STYLE="width: 50%">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">MOSHE ARKIN</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B><U>Schedule A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 8pt">Loan No.</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 8pt">Date of Loan</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-size: 8pt">Loan Amount</FONT></TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 8pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 34%; text-align: center">1</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 50%; text-align: center">18/08/2014</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 12%; text-align: right">834,554</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">2</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">22/10/2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,500,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">3</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">04/02/2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,500,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">4</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">24/04/2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">5</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">08/07/2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">500,330</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">6</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">30/11/2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,500,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center">7</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">16/12/2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center">8</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD STYLE="font-weight: bold; text-align: center">31/12/2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">502,242</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt">9</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="font-weight: bold; padding-bottom: 1pt; text-align: center">3/5/2016</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">5,000,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 2.5pt">Aggregate Principle Amount:</TD><TD STYLE="padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: center">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">22,337,126</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 4; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>9
<FILENAME>t1702381_ex10-13.htm
<DESCRIPTION>EXHIBIT 10.13
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 198.5pt; text-align: right"><B>Exhibit 10.13</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 198.5pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>Schedule A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom">
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Loan No.</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Date of Loan</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD NOWRAP COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Loan Amount</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 66%; text-align: center">1</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 20%; text-align: center">18/08/2014</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 10%; text-align: right">834,554</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">2</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">22/10/2014</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">2,500,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">3</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">04/02/2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,500,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">4</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">24/04/2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">5</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">08/07/2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">500,330</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">6</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">30/11/2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">1,500,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">7</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">16/12/2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">8</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">31/12/2015</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">502,242</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">9</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">3/5/2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">10</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">22/8/2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">11</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">9/11/2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">12</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">21/12/2016</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center">13</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">06/04/2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: center">14</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: center">01/06/2017</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">5,000,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: center; padding-bottom: 1pt">15</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="text-align: center; padding-bottom: 1pt">28/06/2017</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">18,000,000</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1pt">Aggregate Principle Amount:</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="padding-bottom: 1pt">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-weight: bold; text-align: right">65,337,126</TD><TD STYLE="padding-bottom: 1pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Updated on June 28, 2017.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid; text-align: justify; text-decoration: none"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Moshe Arkin</FONT></TD>
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-decoration: none; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moshe
    Arkin</FONT></TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse; text-decoration: none">
<TR STYLE="vertical-align: top; text-decoration: none">
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid; text-decoration: none"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/
    Gilad Mamlok</FONT></TD>
    <TD STYLE="width: 50%; text-decoration: none"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-decoration: none">
    <TD STYLE="text-decoration: none"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sol-Gel Technologies
    Ltd.</FONT></TD>
    <TD STYLE="text-decoration: none"><FONT STYLE="font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>10
<FILENAME>t1702381_ex10-14.htm
<DESCRIPTION>EXHIBIT 10.14
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.14</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>INSTRUMENT OF CONVERSION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>OF</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>PROMISSORY NOTE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Instrument of Conversion (this &ldquo;<B>Instrument
of Conversion</B>&rdquo;) is made as of this 22<SUP>nd</SUP> day of August, 2017, with respect to that certain Promissory Note,
dated August 2, 2016, as updated by that certain Schedule A to Promissory Note, dated June 28, 2017 (the &ldquo;<B>Note</B>&rdquo;),
issued by <B>SOL-GEL TECHNOLOGIES LTD</B>., an Israeli company (the &ldquo;<B>Company</B>&rdquo;), to Moshe Arkin, an Israeli
individual, I.D number 05-164306-2 (the &ldquo;<B>Holder</B>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>WHEREAS</B>, the current aggregate outstanding
principal amount of the Note is $65,337,126 (the &ldquo;<B>Principal Amount</B>&rdquo;);</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>WHEREAS</B>, the Company is contemplating
an initial public offering (&ldquo;<B>IPO</B>&rdquo;) of its ordinary shares, par value NIS 0.1 each (&ldquo;<B>Ordinary Shares</B>&rdquo;),
pursuant to a registration statement on Form F-1 filed with the Securities and Exchange Commission;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>WHEREAS</B>, notwithstanding anything
to the contrary in the Note, the parties hereto hereby mutually desire that immediately prior to the closing of the IPO, the Principal
Amount will be automatically converted into Ordinary Shares in consideration for the cancellation of the Note, on the terms set
forth herein;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOW</B>, <B>THEREFORE</B>, in consideration
of the foregoing and the mutual promises made herein, and for other good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, it is agreed as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Notwithstanding
anything to the contrary contained in the Note, immediately prior to the closing of the IPO, all of the Principal Amount of the
Note shall automatically without any further action on the part of the Company or the Holder be converted into that number of Ordinary
Shares of the Company to be held by the Holder (the &ldquo;<B>Conversion Shares</B>&rdquo;) equal to (x) the Principal Amount divided
by (y) the initial public offering price per share set forth on the cover page of the final prospectus relating to the IPO (the
&ldquo;<B>Conversion</B>&rdquo;). The Company shall issue the Conversion Shares in the name of the Holder on the day of closing
of the IPO. The Holder acknowledges that the Conversion Shares will be deemed &ldquo;restricted securities&rdquo; as defined in
Rule 144(a)(3) under the Securities Act, and as such will bear a restrictive legend in such form as is customary for restricted
securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;If
the closing of the IPO does not occur by December 31st, 2017, then this Instrument of Conversion will have no force and effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any
taxes, levies, charges and other duties or other amounts that are levied on, or due by, the Holder under applicable law in connection
with the issuance of the Ordinary Shares to the Holder pursuant to this Instrument of Conversion shall be borne by the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Upon
the closing of the IPO and following the Conversion as contemplated by this Instrument of Conversion, the Note shall be deemed
fully repaid and shall no longer have any force and effect. By executing this Instrument of Conversion, (i) the parties agree to
the automatic conversion of the Principal Amount of the Note into Ordinary Shares in the manner described above and (ii) the Holder
agrees that upon the Conversion as contemplated by this Instrument of Conversion, all of the Company obligations and liabilities
with respect to the Principal Amount shall be deemed discharged and released in full.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The
Holder shall have the right to assign, sell, transfer, delegate, or otherwise dispose of any right or obligation under this Instrument
of Conversion without the prior written consent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;This
Instrument of Conversion shall be construed and interpreted pursuant to and in accordance with the laws of the State of Israel.
Any dispute arising out of or relating to this Instrument of Conversion shall be adjudicated only in the courts of Tel Aviv in
the State of Israel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">IN WITNESS WHEREOF the parties have signed
this Instrument of Conversion as of the date first hereinabove set forth.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>SOL-GEL TECHNOLOGIES LTD.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="width: 40%; border-bottom: Black 1pt solid; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ Gilad Mamlok</FONT></TD>
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Gilad Mamlok</FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 1pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; padding-bottom: 1pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="text-align: center; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">CFO</FONT></TD>
    <TD STYLE="text-align: justify; padding-bottom: 1pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>/s/ MOSHE ARKIN</B> </FONT></TD>
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MOSHE ARKIN</B></FONT></TD>
    <TD STYLE="text-align: justify">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>11
<FILENAME>t1702381_ex10-15.htm
<DESCRIPTION>EXHIBIT 10.15
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 10.15</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B><U>ASSIGNMENT</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>WHEREAS: MEDICIS PHARMACEUTICAL CORPORATION</B>,
a corporation organized under the laws of Delaware (hereinafter ASSIGNOR), is an owner of certain patent rights pursuant to that
certain Development and License Agreement between ASSIGNOR and ASSIGNEE (defined below), dated October 9, 2011 (hereinafter AGREEMENT);
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>WHEREAS: </B>ASSIGNOR desires to assign
to <B>SOL-GEL TECHNOLOGIES LTD.</B>, a corporation organized under the laws of the Country of Israel (hereinafter ASSIGNEE) ASSIGNOR'S
entire interest in and to a US patent application # 13/537,646, titled: &quot;Stabilized Topical Formulations Containing Core-Shell
Microcapsules&quot; (the &quot;<B>PATENT</B>&quot;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>NOW, THEREFORE, </B>for good and valuable
consideration provided by ASSIGNEE to ASSIGNOR, the receipt of which is hereby acknowledged, ASSIGNOR hereby sells, assigns and
transfers to ASSIGNEE, its successors, legal representatives, or assigns, ASSIGNOR'S full and exclusive rights, titles and interests
to the PATENT, and to any additional legal protections to be obtained for said PATENT or any continuations, continuations-in-part,
divisions, renewals, extensions, substitutions, replacements, or reissues thereof, and every priority right that is or may be predicated
upon or arise from the PATENT, or any legal equivalent of any thereof in any country for the full term or terms for which the same
may be granted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">SAID ASSIGNOR hereby further covenants
that ASSIGNOR has full right to convey the entire right, title, and interest herein sold, assigned, transferred, and set over herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">AND SAID ASSIGNOR further covenants that
ASSIGNOR will, at any time, when reasonably called upon to do so by the ASSIGNEE, its successors, legal representatives, or assigns,
at ASSIGNEE'S cost and expense, communicate thereto any facts known to him relating to said PATENT; execute and deliver any and
all lawful papers (including, but not limited to, granting powers of attorney and executing inventor declarations for continuations-in-part
and reissues of patent applications hereby assigned); make all rightful oaths, affidavits, or declarations; testify in any legal
proceedings, mediations, arbitrations, or other proceedings; and perform all other reasonable lawful acts that may be deemed by
ASSIGNEE necessary or desirable to obtain, secure, and/or vest the benefit of the rights herein assigned, and perfect the title
to said PATENT and all related rights thereto in the name of and for the benefit for the ASSIGNEE, its successors, legal representatives,
or assigns, and to assist or enable the ASSIGNEE, its successors, legal representatives, or assigns to enforce, protect, or otherwise
benefit from the rights in said, applications and patents hereby granted.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">ASSIGNEE hereby grants to ASSIGNOR and
ASSIGNOR'S affiliates a non-exclusive, transferable, sub-licensable, royalty-free, perpetual, license to practice those inventions
claimed under the PATENT.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This ASSIGNMENT shall be binding upon ASSIGNOR'S
heirs, executors, administrators, successors, and/or assigns.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: 8/16/13</FONT></TD>
    <TD STYLE="width: 50%; font-size: 10pt; border-bottom: Black 1pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">/s/ [ILLEGIBLE]</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MEDICIS PHARMACEUTICAL CORPORATION</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I hereby accept the above assignment for
and on behalf/of the ASSIGNEE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: August 8, 2013</FONT></TD>
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">/s/ Alon Seri-Levy</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify">&nbsp;</TD>
    <TD STYLE="text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SOL-GEL TECHNOLOGIES LTD.</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>


<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>12
<FILENAME>t1702381_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 23.1</B></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left"><IMG SRC="t1702381_ex23-1img1.jpg" ALT=""></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0; text-align: center"><U>CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING
FIRM</U></P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0">We hereby consent to the use in this Registration Statement on Form
F-1 of Sol-Gel Technologies Ltd. of our report dated March 30, 2017 relating to the financial statements, which appears in such
Registration Statement. We also consent to the reference to us under the heading &ldquo;Experts&quot; in such Registration Statement.</P>

<P STYLE="font: 10pt Georgia, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 11pt Calibri, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">Tel-Aviv, Israel</FONT></TD>
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">/s/ Kesselman &amp; Kesselman</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">August 29, 2017</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">Certified Public Accountants (Isr.)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">A member firm of PricewaterhouseCoopers International</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Georgia, Times, Serif; font-size: 10pt">Limited</FONT></TD></TR>
</TABLE>
<P STYLE="font: 9pt Georgia-Italic,sans-serif; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font: 9pt Georgia-Italic,sans-serif; margin: 0pt 0"><IMG SRC="t1702381_ex23-1img2.jpg" ALT="" STYLE="width: 671px; height: 21px"></P>

<P STYLE="font: 9pt Georgia-Italic,sans-serif; margin: 0pt 0 0pt 0.25in"><I>Kesselman &amp; Kesselman, Trade Tower, 25 Hamered Street, Tel-Aviv
6812508, Israel,</I></P>

<P STYLE="font: 9pt Georgia-Italic,sans-serif; margin: 0pt 0 0pt 0.25in"><I>P.O Box 50005 Tel-Aviv 6150001 Telephone: +972 -3- 7954555, Fax:+972
-3- 7954556, www.pwc.com/il</I></P>

<P STYLE="font: 9pt Georgia-Italic,sans-serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 9pt Georgia-Italic,sans-serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 9pt Georgia-Italic,sans-serif; margin: 0pt 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>13
<FILENAME>t1702381_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Consent of Director
Nominee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">I hereby consent, pursuant to Rule&nbsp;438
under the Securities Act of 1933, to being named in the Registration Statement on Form&nbsp;F-1 of <B>Sol-Gel Technologies Ltd.</B>
(the &ldquo;<U>Company</U>&rdquo;) as a person who will become a director of the Company in connection with the initial public
offering of the Company&rsquo;s Ordinary Shares contemplated in the Registration Statement. I also consent to the filing of this
consent as an exhibit to such Registration Statement and any amendments thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 46%">&nbsp;</TD>
    <TD STYLE="width: 20%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><I>/s/ Jerrold Gattegno </I></FONT></TD>
    <TD STYLE="width: 34%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Jerrold Gattegno</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Date: September 14, 2016</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>14
<FILENAME>t1702381_ex99-2.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Consent of Director
Nominee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">I hereby consent, pursuant to Rule&nbsp;438
under the Securities Act of 1933, to being named in the Registration Statement on Form&nbsp;F-1 of <B>Sol-Gel Technologies Ltd.</B>
(the &ldquo;<U>Company</U>&rdquo;) as a person who will become a director of the Company in connection with the initial public
offering of the Company&rsquo;s Ordinary Shares contemplated in the Registration Statement. I also consent to the filing of this
consent as an exhibit to such Registration Statement and any amendments thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 46%">&nbsp;</TD>
    <TD STYLE="width: 20%; border-bottom: Black 1pt solid; font-size: 10pt"><FONT STYLE="font-size: 10pt"><I>/s/ Itai Arkin</I></FONT></TD>
    <TD STYLE="width: 34%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Itai Arkin</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Date: September 27, 2016</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.3
<SEQUENCE>15
<FILENAME>t1702381_ex99-3.htm
<DESCRIPTION>EXHIBIT 99.3
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.3</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Consent of Director
Nominee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">I hereby consent, pursuant to Rule&nbsp;438
under the Securities Act of 1933, to being named in the Registration Statement on Form&nbsp;F-1 of <B>Sol-Gel Technologies Ltd.</B>
(the &ldquo;<U>Company</U>&rdquo;) as a person who will become a director of the Company in connection with the initial public
offering of the Company&rsquo;s Ordinary Shares contemplated in the Registration Statement. I also consent to the filing of this
consent as an exhibit to such Registration Statement and any amendments thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 46%">&nbsp;</TD>
    <TD STYLE="width: 20%; border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt"><I>/s/ Ran Gottfried</I></FONT></TD>
    <TD STYLE="width: 34%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Ran Gottfried</FONT></TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Date: September 26, 2016</FONT></TD>
    <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.4
<SEQUENCE>16
<FILENAME>t1702381_ex99-4.htm
<DESCRIPTION>EXHIBIT 99.4
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.4</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Consent of Director Nominee</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I hereby consent, pursuant to Rule 438
under the Securities Act of 1933, to being named in the Registration Statement on Form F-1 of Sol-Gel Technologies Ltd. (the &ldquo;Company&rdquo;)
as a person who will become a director of the Company in connection with the initial public offering of the Company&rsquo;s Ordinary
Shares contemplated in the Registration Statement. I also consent to the filing of this consent as an exhibit to such Registration
Statement and any amendments thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid; text-align: left;"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Dr. Shmuel Ben Zvi</FONT></TD>
    <TD STYLE="width: 50%; text-align: justify; direction: rtl; unicode-bidi: embed">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif">Dr. Shmuel Ben Zvi</FONT></TD>
    <TD STYLE="text-align: justify; direction: rtl; unicode-bidi: embed">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: justify; direction: rtl; unicode-bidi: embed">&nbsp;</TD>
    <TD STYLE="text-align: justify; direction: rtl; unicode-bidi: embed">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed"><FONT STYLE="font-family: Times New Roman, Times, Serif">Date: July 18, 2017</FONT></TD>
    <TD STYLE="text-align: justify; direction: rtl; unicode-bidi: embed">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.5
<SEQUENCE>17
<FILENAME>t1702381_ex99-5.htm
<DESCRIPTION>EXHIBIT 99.5
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.5</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Consent of Director Nominee</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I hereby consent, pursuant to Rule 438
under the Securities Act of 1933, to being named in the Registration Statement on Form F-1 of Sol-Gel Technologies Ltd. (the &ldquo;Company&rdquo;)
as a person who will become a director of the Company in connection with the initial public offering of the Company&rsquo;s Ordinary
Shares contemplated in the Registration Statement. I also consent to the filing of this consent as an exhibit to such Registration
Statement and any amendments thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid; text-align: left; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Yael Baratz</FONT></TD>
    <TD STYLE="width: 50%; text-align: justify; direction: rtl; unicode-bidi: embed; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Yael Baratz</FONT></TD>
    <TD STYLE="text-align: justify; direction: rtl; unicode-bidi: embed; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Date: July 28, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.6
<SEQUENCE>18
<FILENAME>t1702381_ex99-6.htm
<DESCRIPTION>EXHIBIT 99.6
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.6</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Consent of Director Nominee</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">I hereby consent, pursuant to Rule 438
under the Securities Act of 1933, to being named in the Registration Statement on Form F-1 of Sol-Gel Technologies Ltd. (the &ldquo;Company&rdquo;)
as a person who will become a director of the Company in connection with the initial public offering of the Company&rsquo;s Ordinary
Shares contemplated in the Registration Statement. I also consent to the filing of this consent as an exhibit to such Registration
Statement and any amendments thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; border-bottom: Black 1pt solid; text-align: left; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">/s/ Hani Lerman</FONT></TD>
    <TD STYLE="width: 50%; text-align: justify; direction: rtl; unicode-bidi: embed; font-size: 10pt">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left; direction: rtl; unicode-bidi: embed; font-size: 10pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">Hani Lerman</FONT></TD>
    <TD STYLE="text-align: justify; direction: rtl; unicode-bidi: embed; font-size: 10pt">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Date: July 30, 2017</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>


<!-- Field: Page; Sequence: 1; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="margin: 0"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>lg_pwc.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lg_pwc.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!A 'T P$1  (1 0,1 ?_$ /<  0 " P$! 0$!
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M=@F!8B,DA/_:  P# 0 "$0,1 #\ G\
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M(\N$(HMOFYKSQ?O2O<M\4HT+TL\_25*<8RQC+-R(X(QEC&6/+_)&,'W1EF,
M
M    &L>Y7BSY6^E,3_:>#$$9S7L+QAW/1\:H)ES?/;'<>OU?%ZR.F*6%M(
M           DA:G^+EB/[4V_S4[%W&;S[%,7/JZ7LYU1&7+VMW]NZ;L96PPF
M9%
M        UCW*\6?*WTIB?[3P8@C.:]A>,.YZ/C5!,N;Y[8[CU^KXO61TQ2PM
MI             $D+4_Q<L1_:FW^:G8NXS>?8IBY]72]G.J(RY>UN_MW3=C*
MV&$S(H
M           &G^_/BAYJ^D<'_;"W1"^</[&;]UBEXS13UFP^W?%W=-;Q6NBH
MBHQ=F             .H>'?P8V7])DOYU8=)XI?9NQZS#3BX^QZ^U]OW1'2@
MR6-C:FZ':7?8Q>OT^C_K>8=29O\ Z'O#=,G8.2\XOTU=NY:GRC=(= N<P
M                                                           :
M?[\^*'FKZ1P?]L+=$+YP_L9OW6*7C-%/6;#[=\7=TUO%:Z*B*C%V8
M      ZAX=_!C9?TF2_G5ATGBE]F['K,-.+C['K[7V_=$=*#)8V-J;H=I=]C
M%Z_3Z/\ K>8=29O_ *'O#=,G8.2\XOTU=NY:GRC=(= N<P
M                                                :?[\^*'FKZ1P
M?]L+=$+YP_L9OW6*7C-%/6;#[=\7=TUO%:Z*B*C%V8             ZAX=_
M!C9?TF2_G5ATGBE]F['K,-.+C['K[7V_=$=*#)8V-J;H=I=]C%Z_3Z/^MYAU
M)F_^A[PW3)V#DO.+]-7;N6I\HW2'0+G,
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ML,7MA(C6@
M   :4\Q;Q+<[_2" _MK;(A_+[[(;[UBEXQ1=$9I_WA<6=U5_%+0B "J=?(
M           -L[)^Q2"\HD^'.(>O[TQ:-<YD$+XP>F;1KG,@]2,2P[/V'?G9
M,^7D/F>HCK'7OJAK<=-'>.G?5#6XZ;,0TII8     [::]?@5QS]KR/S0X'Z*
M<U?[O.*?U5)V<ZM'*Y[2;XW9'L9691T CD
M                            &E/,6\2W._T@@/[:VR(?R^^R&^]8I>,4
M71&:?]X7%G=5?Q2T(@ JG7R             #;.R?L4@O*)/ASB'K^],6C7.
M9!"^,'IFT:YS(/4C$L.S]AWYV3/EY#YGJ(ZQU[ZH:W'31WCIWU0UN.FS$-*:
M6     .VFO7X%<<_:\C\T.!^BG-7^[SBG]52=G.K1RN>TF^-V1[&5F4= (Y
M                                                     !I3S%O$
MMSO]((#^VMLB'\OOLAOO6*7C%%T1FG_>%Q9W57\4M"( *IU\@
M  VSLG[%(+RB3X<XAZ_O3%HUSF00OC!Z9M&N<R#U(Q+#L_8=^=DSY>0^9ZB.
ML=>^J&MQTT=XZ=]4-;CILQ#2FE@    #MIKU^!7'/VO(_-#@?HIS5_N\XI_5
M4G9SJT<KGM)OC=D>QE9E'0".0
M                   :4\Q;Q+<[_2" _MK;(A_+[[(;[UBEXQ1=$9I_WA<6
M=U5_%+0B "J=?(             -L[)^Q2"\HD^'.(>O[TQ:-<YD$+XP>F;1
MKG,@]2,2P[/V'?G9,^7D/F>HCK'7OJAK<=-'>.G?5#6XZ;,0TII8     [::
M]?@5QS]KR/S0X'Z*<U?[O.*?U5)V<ZM'*Y[2;XW9'L9691T CD
M                                            &E/,6\2W._T@@/[:
MVR(?R^^R&^]8I>,471&:?]X7%G=5?Q2T(@ JG7R             #;.R?L4@
MO*)/ASB'K^],6C7.9!"^,'IFT:YS(/4C$L.S]AWYV3/EY#YGJ(ZQU[ZH:W'3
M1WCIWU0UN.FS$-*:6     .VFO7X%<<_:\C\T.!^BG-7^[SBG]52=G.K1RN>
MTF^-V1[&5F4= (Y
M         !H)S1G;EAH3L8[9K';N4;;MLR2R?"AR5-?]I$K4O&E:=TIJT_\
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M:O\ =YQ3^JI.SG5HY7/:3?&[(]C*S*.@$<@
M                             Y]\U'Q -D/M9MKU0;1$=Y6/9[>>M2?+
M4TY9MGMON#=%;Q6N@N#A!<J      #^V,^>4?Y>:?SZ8\UK[TJZW-I1?:S]\
M4_?RZ<&XH@-+X   #;.R?L4@O*)/ASB'K^],6C7.9!"^,'IFT:YS(/4C$L.S
M]AWYV3/EY#YGJ(ZQU[ZH:W'31WCIWU0UN.FS$-*:6     .VFO7X%<<_:\C\
MT.!^BG-7^[SBG]52=G.K1RN>TF^-V1[&5F4= (Y
M                                 !S[YJ/B ;(?:S;7J@VB([RL>SV\
M]:D^6IIRS;/;?<&Z*WBM=!<'""Y4      ']L9\\H_R\T_GTQYK7WI5UN;2B
M^UG[XI^_ETX-Q1 :7P   &V=D_8I!>42?#G$/7]Z8M&N<R"%\8/3-HUSF0>I
M&)8=G[#OSLF?+R'S/41UCKWU0UN.FCO'3OJAK<=-F(:4TL     =M->OP*XY
M^UY'YH<#]%.:O]WG%/ZJD[.=6CE<]I-\;LCV,K,HZ 1R
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M_N_!TN"&#!YQP8,'*P8.1@Y6!LT/@B
M                     '-OF]^]P[1?:K:OJDV6--R@_8ZW:W+\I(Z'S4/O
M"8M;JK^*6A7V#DI?"      #]VO^U-OCZ/\ .%'SK?!3>]CI/58N_:.NR=E!
MF\1XZ1    90A_G8R^,T_P!-1K-K[YG]UI=X=^U/?/I#SO&]7;W\0X^.E^$'
M@M?ZT/<8.]?A)/>QTWH1Y6*     &S=H?8S#>4R_#G%J61CV6W)N*7LID(XQ
M>F[3KD=*#T@DYA0!*U_X+_\ #!_NI&N?Q7[SFJ5_^0'^\?\ 4FSX\Z'0
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MJE?_ ) ?[Q_U)L^/.AT
M         '-OF]^]P[1?:K:OJDV6--R@_8ZW:W+\I(Z'S4/O"8M;JK^*6A7V
M#DI?"      #]VO^U-OCZ/\ .%'SK?!3>]CI/58N_:.NR=E!F\1XZ1    90
MA_G8R^,T_P!-1K-K[YG]UI=X=^U/?/I#SO&]7;W\0X^.E^$'@M?ZT/<8.]?A
M)/>QTWH1Y6*     &S=H?8S#>4R_#G%J61CV6W)N*7LID(XQ>F[3KD=*#T@D
MYA0!*U_X+_\ #!_NI&N?Q7[SFJ5_^0'^\?\ 4FSX\Z'0
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M)L^/.AT                                   !I=L9S"]/M3+WB\<[
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MX)L':.[NV]LP8.FP=K_2P=+TV#D8,/(9]'Q1D
M             A>=HO\ ':Q=[5BR?5:S>.;\L'VFH;AD^5K+@?\ Q^^QJ\_^
MYK1XC=S@6(H=S@           -^N5K[X/JE^-2/^MLF-LQ&^UM@U^&E%!><Q
M[!<:/JR;LY%AZ.NU!8
M                        (7G:+_':Q=[5BR?5:S>.;\L'VFH;AD^5K+@?
M_'[[&KS_ .YK1XC=S@6(H=S@           -^N5K[X/JE^-2/^MLF-LQ&^UM
M@U^&E%!><Q[!<:/JR;LY%AZ.NU!8
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M\B/)EDFC_@E3"=58P
M
M
M
M
M
M
M
M
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M&MAB15FR%QR:JI&R;"PKY:R<ECV\WCUTI0K-@G(MYQU2O2I'EX&H4.]P
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M>0N?&-SR!Z,;8Q9DFXGQE)&X\=W'(J),(64>*K.[>=K(M5U#0YDS1 6+
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M@]<'4<.WSYXN=5550QCJ*&J8U:UK6H#YH   ++OL2_B"[7>V_<>HQBX!,]
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M?\Q:*Y3F4/5TC-6H=E))J=%.G5O2EI2M"],X=^
M  1@>UY>\VWI[8#!/U\E %4*   ";YV(;QI]X/:_X]]45<!8^    K\^VJZ,
M0D8OK9S#[-ATV4G<4HKK3F]RT:E*67?-X>5O+#5QO3-T2U-((1$+<,4Z=.#F
MJHW0C$"5+1&E#! 3   !U^Y!697F"^<9R_;N:.U&I;EV M[#3PI2.%4W;//[
M*2PBHT<(-^ZHFHK?Y#%J>E4T52$5-PHGQH%ST  (07;>?%9T>_'_ )$]3IN
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M$5;EJ6M$M(*W8*,0J8U48^(B&"+=$G&O133I3B ]0
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MH=!T44FZ22""2:"""9$4442%32123+0B:229*%(FFF0M*%+2E*4I3A0!^@
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M&Y=^*JMTJUZZL'=N)<,242^=4,J>O6.95G)HEK0I"5(VIPXFH:H"7Z
M                           C ]KR]YMO3VP&"?KY* *H4   $WSL0WC3
M[P>U_P >^J*N L?    1Y>U-Y2C\:\D_::.<+-TY7*LYA+%MN)N:&,5S(2>9
M;)NF813(3A4SA.S+0E54ZU-2A3I4-7I='HF"HA   !W>[-/@!SL%SF=/V1FB
MCB Q'<%SY_N=RG3CX-;8DM.7N"U79Z=$U.K7R56":UX\.'?/&E>-*4J%PT
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M>KK0P6/X                                ",#VO+WFV]/; 8)^ODH
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M=&R62&)2KIK3;9!=6$QC:KTW%3SAXW3D5V[<].C63D%G3\Q4RN$F[<.W0
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M^1D'KG#>,%7+Q\]=**N7;IPJ:ICJ*&,<YJUK6M:@)EX
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M<6-#MH"S['LN$86[:]MPS2ANHCX>&BT&S%DW*8YCFH0E*G4.8YJU.8U:A[@
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MFV]/; 8)^ODH JA0   3?.Q#>-/O![7_ ![ZHJX"Q\
M                                                           1
M@>UY>\VWI[8#!/U\E %4*   ";YV(;QI]X/:_P"/?5%7 6/@
M
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M9P-0U.'ZH#+
M                          HEL^;B;7[3R1I79+9+-^<W57%7*"64<G7A
M><;'J<:U*6'AIR7>1$*W2K6O5HM$$$DZ=PI:4 :X      #T%KW9=5D3;*Y;
M+N6X+0N.-4HK'3]KS,C 3;!4IBG*JRE8IRT?-5"F+2M#$4+6E:4 63O8Y-L-
MF]F,-;J1>Q6?LO9V;8LO+!<7CQ7+M_W+D21M&+N"!R:M+1D-,79(RLNWC71X
M9K2C?KZHI$;D*F4A2TH F=@
M                                   (P/Z(;R;?ZE[ ?EVG/,L _1#>
M3;_4O8#\NTYYE@'Z(;R;?ZE[ ?EVG/,L _1#>3;_ %+V _+M.>98!^B&\FW^
MI>P'Y=ISS+ /T0WDV_U+V _+M.>98!^B&\FW^I>P'Y=ISS+ =4^7'RGM0^5A
M"Y6@-3(>_(B/S+*6G,7L6^;W>WHJN]LMI/,H,T<J\:MJQZ::%QN>L*7CUE:E
MK7]R Z5@
M
C                                           __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>lg_solgel.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 lg_solgel.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@#N0?0 P$1  (1 0,1 ?_$ /H  0 " @,! 0$
M       #"@@)!08' @0! 0$  @,  P$!             P0! @4&!P@)"A
M 0,# @($" 8+"P<(!@(3  $" P0%!A$'(1(Q$P@)\$%189&AT11Q@2*V=SBQ
MX5)B([05=;5V-\$RDJ+2%C875X<9\4)RU);6M^(S4R25U9<8@D.4)556QT@T
MI^=H8Y-4U[+31"9T-45&9B=G$0$  0,!! 8'!08"" 0$ @L  1$" P0A,1(%
M05%A<3(&@9&Q(A,S!_"A<A0(P=%"4H(CX6+QDJ)#)!46";)38W/"TH.3%Z.S
M)414PS1DA+1E)O_:  P# 0 "$0,1 #\ O\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M         'RYS6-<][FL8QJN>]RHUK6M35SG.71&M:B:JJ]!F(F9I&V98F8M
MB;KII;#\%HNUMOUKMU[L]7%7VJZT=/<+?6P*JQ5-)51-F@F9S(U[4?&]-4<B
M.:O!4145";5:;/HM1?I-5;-FIQWS;=;.^+HFDQZ_1U*VAUNEYEH\7,-#?;DT
M>;';?9=&ZZVZ*Q,=.V)W3MC=,5<B0+0
M
M
M
M
M                  !XKVA\P;A&SF<7=LB1U=7:)K#;E^5S)7W]/R5#(SE_
MSZ5E2Z9->'X/CP/+/(W*YYOYIT>FF*XK<L9+OPX_?F/32+?2\"^IW/(Y!Y&Y
MAK8FF>_!.&S\>;^W$QVVQ=-W5[NUBIV(MWTGAK-H[W5-66G]ZO&'R2R.YY('
M:SW>RQ(OR-('\U7$U-%T?-THB:>R/JYY8X;[?,^CM]V:69XB.G=9DGO\$]UG
M6]-_I^\[<>._R5S"^..WBRZ:9G;,;\N*.Z:Y+8W[;^B(IL5/1;ZA
M
M
M
M
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M'1^:N0Z;GVAV8-1CB9MWS9?&R^R>VRZ)M[:5C9,.ZG)=\
M
M
M
M
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MNM?2'Z?/.G_+N;9/*&NOIH]96_#,SLMSVQMLCHCXED?ZUD1%9N;43YS?8P
M
M
M
M
M                                           &,/:QW49MOM=<**BJ
M&1Y+FD=3CMFC1R)/%2SPI'>KFQNBN1**AGY&O33DFFC774]A?3;RY=S[S#9E
MRVS.@TDQEOGHF8FN.S^JZ*TZ;;;GJ/ZS^<;?*GE#+@P7Q'-=?%V#%'3%LQ3+
MDC\%DTB>BZZUI1U?Y$\/C/K'A? G%!J[R)X?&.$XH?NM=TN-EN5OO%KJ'T=R
MM5;2W&WU<*HDM+6T4[*FEJ(U75.>&>-KDU14U0AU&EPZK!?I=1;%^GR63;=;
M.Z;;HF)B>^)F%C2:S4:#5XM=H[YQZO#DMOLNC?;?9,76W1VQ,1+?OM+N%0[H
M[?XYF='U;);E1,9=:6/5&T%[I42"[42-<Y[TCAK&.6-7+JZ)S'+TGQAYFY'F
M\N\[S\JRUFW'?[DS_%CG;9=WS;2O;6.A^DODKS/I_.'EG2\^P4B_+CB,EL?P
M9;=F2WKI%T3PUWVS$]+T<X+RH
M
M
M
M
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M[6CYM?9H
M
M
M
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M;+XNMGMBNYW(Y3O
M
M
M
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MWXF/6>3=5=ML_P"(P1/5,Q;FMCNF;+HC?MOFE(ELJ/0+ZQ
M
M
M
M
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M]L2_43#FQ:C%;GP71?AOMBZVZ)K$VS%8F)Z8F)K$IS1(
M
M
M
M
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M:&IE<^ZX/4RXG6]8Y7224E+%%56:HU<YRNC6V5+(=5TU? [APU7Y!^JW(_\
MD_FS+FQQ33:RV,UO9=,S%\=_'$W=UT/T/^@?FC_J/R!AT^69G6<NOG37UWS;
M;$78KM\[/AW1;WV2RQ/6KW6
M
M
M
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MG7+R'-=$:;F>GF+8V4G-AKDLG_[?QK>VZZV&Y@^4GWJ
M
M
M
M
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MVWVSUVWVQ=$^J8?N(5@
M
M
M
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M/73W$
M
M
M
M                               _-65M';J6HKKA54U#14D3YZJLK)XJ
M:EIH8TU?-/43.9%#$Q.*N<J(A)BQ9<^2W#@MNOS732+;8F9F9Z(B-LSW(<^H
MP:7#=J=5?9CT]ELS===,6VVQ&^;KII$1'7,L)MUNW?M5@ZU%MPQD^X]^8U[4
M?:YFT6,TTK51NE3?)8Y9*K375$I()V.1%19&<%/;GEKZ,^9.;\.?FTQH-%/\
M\<668[,<3$1_7=;,?RR^>O.OZD_)?EWBTG((NYMS*(G;CG@T]L_YLTQ,W?\
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M.IQV_P"MBS7?_H(;3#YQ?98
M
M
M
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M,5D1US2&^0^,7Z4
M
M
M
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M/S.^L8L/,M/-WX/BVQ?_ +,RLOGY^/UV
M
M
M
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MW[7+E5>
M
M
M
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MX==GC_\ ,NH_8KZ?ZJ-;Y$Y-JHFO'RO2S7KGX-D3][TL\>>7@
M
M
M
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MAKV0
M
M
M
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M[D%MT4N_Y5I_OQQ+W$\.>QP
M
M
M
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M9OS/F/7ZC^?6YY]>2Z7[2>2=-^3\F\ITF[X?+=-;Z8PV1/WN_G$>3@
M
M
M
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M YW>7U)[ '.[R^I/8 YW>7U)[ '.[R^I/8 YW>7U)[ '.[R^I/8 YW>7U)[
M'.[R^I/8 YW>7U)[ '.[R^I/8 YW>7U)[ '.[R^I/8 YW>7U)[ '.[R^I/8
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M;--I[-/C^7CLMMCNMB(C[H?I(TP
M
M                                      '%TM\LE=,VGHKQ:ZRH>CE;
M!2W"DJ)G(Q%<Y6Q13/>J-:FJZ)P0,TF'*!@
M
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M=<>NU!>K;-JUKTZJNMM14TLFK'(O!R\%13??N5YB;9I=$Q+G P
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M*VBGBJJ2JIY6H^*>FJ8'R0SPR,5%:YKE:J<44W5IBFR=[]0
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M:[$,:K*RJG>Z2>IJJFRT4U1432.5722S2O5SG+Q55U+$;G&NV73':[>9:@
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MQS,;./473??=;/1=99ABV:;>'-U2W7GR,_0D
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MYVJ==%1O71-;)RJK%<WB2Q,3N4+\=^.:7Q27JIEH
M                  %;7O7_ *T-!]%F)_I?*2#)XO0ZNB^3_5+681K8
M %H'NR_J@8%^?,[^>%X+&/PN1J_GSZ/8S\-U8
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MHZ=9K<E=D[W.SZ2;/>Q[;>KIAM<)%(
M       5M>]?^M#0?19B?Z7RD@R>+T.KHOD_U2UF$:V     !:![LOZH&!?G
MS._GA>"QC\+D:OY\^CV,_#=6                               #&'M-
M]JW;;LPXNETRJI2[Y9=(7KBN!VVIA;?+Y(BR,;5SH[K/R38(9HU;-72L5B*B
MLC;++I&NMUT6[]Z;#AOS32WP]:M#V@>TQNKVD<F=?=P;V[\ETD\K\>P^V+)2
MXOC4#]6HRWT"O>M16.C726LJ'2U4NNBO1B-8V"ZZ;M[JXL5F**6[^MC\:I0
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M/%Z'5T7R?ZI:S"-;      M ]V7]4# OSYG?SPO!8Q^%R-7\^?1[&?ANK
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M%(C9J6LI9FNBG@D:V6"9CHWM:]JHD\3$Q6-SD76S9=-MVR8=L,M0
M                           "GEVF_K)=H/Z<-V/GY?RM=XI[W<P_*M_#
M'L>'FJ0     "Z+ME^S;;W]1\3_0- 6HW.#?XY[Y=X,M0
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M4[N1B*JOD=S22.=*][W5IF9FLNUCLMQVQ9;NAY<8;@
MV2=WAVNI=B\[BVWS>Z*S:7/[E#%+45DZMI<)RJI1E+19$QTB]536FXN;'3W/
M56,9&D=0KD2!S9)++J32=RKJL'Q+>.WQQ]\++).Y(
M                !3R[3?UDNT'].&['S\OY6N\4][N8?E6_ACV/#S5(
M !=%VR_9MM[^H^)_H&@+4;G!O\<]\N\&6H
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M!@MMLP66Q;;;;$1;;;$4B(B-D1$;(B-D1LA,:)
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M/!.[]S/$W5@                                 *VO>O_6AH/HLQ/\
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MD_#R#3<.3F=],FJS1'S<\Q'%29B)^'9X,<33W8K,<5UU<A3P=[0
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M]CD54<U45"RXDQ39.]^H                                 *VO>O\
MUH:#Z+,3_2^4D&3Q>AU=%\G^J6LPC6P     +0/=E_5 P+\^9W\\+P6,?A<C
M5_/GT>QGX;JP                           #$SMK[[N[/VP&5Y7;*E(,
MOOJ,PW!U1[6RPY'?8*EJ76+5=5?8+7!4US/DN:Z6G8QR:/U-;YX;:]*;3X_B
MY8MGPQME4W<YSW.>]SGO>Y7/>Y5<YSG+JYSG+JKG.5=55>DK.T^0
M'*VFQ7R_3+36.S76\U#=.:"TVZKN,S=622)K%1PS/35D+W='0Q5\2AB9B-[L
M$FVNXT3'RRX!FL<<;'22228K?6,C8Q%<][WNH$:UC6IJJKP1#-)8X[.N/6Z?
M-#-3RR05$4D$\3W1RPS,=%+$]JZ.9)&]&O8]J]**B*AALB         9&]D_
M>VJ[/^^N$[@>\2Q6%*YMAS6GC1SDK<-O<D-->FOB:YJSR6Y$CKH&:HBU5)%K
MP14-K9X9JBS8_BXYMZ>CO6ZX)X*J"&JI9HJFFJ8HYZ>H@D9-!/!,Q)(IH98U
M='+%+&Y'-<U51R+JG LN(E                                  !3R[
M3?UDNT'].&['S\OY6N\4][N8?E6_ACV/#S5(     !=%VR_9MM[^H^)_H&@+
M4;G!O\<]\N\&6H                                 &._:8[16)]FS;
MJJS"_=7<;[7K+;L,Q5L_4UF2WM&-=U:/1DCJ6U6Z-Z35M2K>6*+1K>::2&.3
MSCR!Y%YEY]Y[;RO1ULT=E+L^:E;<6/KZ*WW3[MEN^9K,TMMNNCU=]6OJER7Z
M4>5[^><RIEYCEF;-+IZTNSY:;JTGAQV1/%ER3%+;:6Q7)?9;=5YW%W*R_=;,
M;UG>;W22[Y#?:E9ZJH>Y6P4\2?)IZ"@IU>YE';J*)$9#"WY+&)XUU5?T-Y%R
M'EGEOE6+DW*,<8M#AMI$=,STW73_ !773MNNG?+\?O-/FGG?G/GNH\Q^8<UV
M?FFIOXKKIW1'\-EENZVRR/=MMC9$=M9=(ZYWD;_"3VG6H\>.N=Y&_P )/:*!
MUSO(W^$GM% ZYWD;_"3VB@=<[R-_A)[10.N=Y&_PD]HH'7.\C?X2>T4#KG>1
MO\)/:*!USO(W^$GM% ZYWD;_  D]HH'7.\C?X2>T4#KG>1O\)/:*!USO(W^$
MGM% ZYWD;_"3VB@=<[R-_A)[10.N=Y&_PD]HH'7.\C?X2>T4#KG>1O\ "3VB
M@=<[R-_A)[10.N=Y&_PD]HH'7.\C?X2>T4#KG>1O\)/:*!USO(W^$GM% ZYW
MD;_"3VB@=<[R-_A)[10.N=Y&_P )/:*!USO(W^$GM% ZYWD;_"3VB@=<[R-_
MA)[10.N=Y&_PD]HH'7.\C?X2>T4#KG>1O\)/:*!USO(W^$GM% ZYWD;_  D]
MHH'7.\C?X2>T4#KG>1O\)/:*!USO(W^$GM% ZYWD;_"3VB@=<[R-_A)[10.N
M=Y&_PD]HH'7.\C?X2>T4#KG>1O\ "3VB@=<[R-_A)[10.N=Y&_PD]HH'7.\C
M?X2>T4#KG>1O\)/:*!USO(W^$GM% ZYWD;_"3VB@DB6:>6.&&)TTTTC(HHHD
M626661R,CCCC9JY\CW*B(B(JJJ\#%TVV6S?=-+8BLS.Z(CIEM9;?DOC'CB;L
METQ$1&V9F=D1$=,ST0L/]@?L?OV4L#-SMP[<QFZF46Y(Z2V5,;72X+8*MK9%
MMZH[7J<AN;.5:UR:.@9_U=%3\-S_  ]]9_JA'FW6_P#3_(\DSY<T^2MU\;M1
MDMV<7;BL_@Z+I]_^2GZA_IK^A<_3_EL>;_-&*/\ K+68J68[HVZ/#=MX.S/D
MBGQ9WV6_VMG]SBV1'H9]7                        !A5W@&\4FSO9GS2
MKMU6ZDR3.>JVZQN2-W)/%4Y+!5)>*N%[?PD$M#C%+7212MT6.H2/14544TOF
MEJQIK./-%=T;55<KNP       Y"U6FZWVY45FL=LN%YN]SJ8J.VVJU4=3<;E
M<*N=R,AI:*AI(YJJKJ9GKHUD;7.<O!$#$S$16=S9SM!W4V]^<4U)=MR;[8MI
M;74L;*ENJ8795F#8W(U[%FLMNJZ*T422L=^]EN25$3N#X45-"2,<SOV*E^LQ
MV[+*W3ZH9KXYW16PM!#$N39YNED-:UJI*M!6XSC]ME54<G,E$N.7>OCY55%1
M/?%XIQU3@;_"CM03K<G1%L.SR]T[V8)(I(V73=>![XWL;-%E=C66%SFJULL:
M38E-"LD:KJG.QS=4XHJ<!\.WM:_G<W^7U?XO(,R[GK"*F*5^WV\656>9K7+#
M3YE8K1DD4KN9RLCEK;(_%'T[5;HBO2"7145>5==$Q.*.B6]NNN_BMCT?:6N#
M??L)=H382GJ[U>\:BR[#:1LLTV9X*^IO=JH::-%>Z>]T3Z2EO=BBBBT62:HI
MFTC7+RMG?TFDV76]RWCU.++LB:7=4L-C1.        68^[&WE?N9V=J7$+G5
MI49%M!<4Q"9'NYJB3%ZF)]?A]5(B+RMA@HTGMT2(B?(MNJZKJJV,<UMIU.3J
M\?!EXHW7;?WMC1NJ@                                K:]Z_\ 6AH/
MHLQ/]+Y209/%Z'5T7R?ZI:S"-;      M ]V7]4# OSYG?SPO!8Q^%R-7\^?
M1[&?ANK                            *[W>R[LORC>;&]J:&H5UKVPQ^
M.MND+9/DKE68PTMSE26-J:*M)CL5O6-7*JM6HD1$35>:#).VCIZ*RF.;^F9]
MC5&1KH      #,[LP]A_=OM,2Q7FWPQX9MO'4N@K<_OU+,^FJG0O6.HIL7M3
M7T]3DM9"]KFO5CX:.)[',DJ&2(C';VV3=W(,VHLP[)VW]3>5L]W>'9FVF@I*
MBJPZ/<K)(48^;(-Q$AOL3ID:Q7>Z8RZ./&*2%DS5=$KJ6:I9KHLS]$4EBRV'
M.OU6:_II'8S6MMJMEFHXK=9[=06FWP(J04-MHZ>AHX47BJ14M+'%!&BKY&H;
MH)F9VSO?O##HN:[8;<;D4;J#/\$Q+,J58^K:S),?M=X?"FCD:ZEGK:::>DEC
MYU5CXG,>Q5U:J+Q,3$3O;6WWV>&9AK-WZ[J3;7*J:NO6Q=WJ=NLD7K)HL8O5
M767G!ZYZ\S^HAJ)VU>0V!\LCO^<26M@8U$:RG8G$TG'$[EO'K+[=F3;'WM&6
MZ&U&X.S65UF%[D8S<,9O])J]L%6ULE+<*3G=''<;3<('2T-UML[F*C)X)'L5
M45JJCD5$AF)B:2Z-E]N2WBLFL/.S#8      !:@[O7=B7=CLOX3+<*A:F^X$
M^IVXO<CWJ^21V-14RV.:1SWOF?)+BM;0+(]ZZOF1ZEBR:VN/J;.#---T[6;I
MNK@                                 4\NTW]9+M!_3ANQ\_+^5KO%/
M>[F'Y5OX8]CP\U2      71=LOV;;>_J/B?Z!H"U&YP;_'/?+O!EJ
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M!3G=(OTFDOC;I]M;<^:V8K&HV5QV?[J)XKH^+2,6W4^9'VZ
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MP@8B\5=4Z(NJZ+)CFEU%366<6+BZ8E9))W*
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MHN;I7EIT\Y+BG?"AKK=EM_H;X"9S@
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M>)9%14C2:UU$S.945&\VJHJ<#-LTF)1Y;>+'=;V2N+EIPP
M                  5M>]?^M#0?19B?Z7RD@R>+T.KHOD_U2UF$:V     !
M:![LOZH&!?GS._GA>"QC\+D:OY\^CV,_#=6
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ME:[Q3WNYA^5;^&/8\/-4@     %T7;+]FVWOZCXG^@: M1N<&_QSWR[P9:@
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M8LFHFO<U>6E2FK(:^5$5JK^3F\55.5VF2*VUZEK27\.7AZ+MBLZ5W6
MEAFEIYHJB"1\4\$C)H98W*U\4L3D?'(QR<6O8]J*B^)4 NU6NM_*5LMUQZKJ
M??Z&DK>IY^LZKWJGCGZKK.2/K.KZS3FY6ZZ:Z(6W G9-'[@P
M                   %;7O7_K0T'T68G^E\I(,GB]#JZ+Y/]4M9A&M@
M 6@>[+^J!@7Y\SOYX7@L8_"Y&K^?/H]C/PW5@
M   ,*>\1O#K-V/-X98I4BGKJ7$K/"BOD8LS;KG>,45;$U8W-<JK;99E5%7E<
MUJHJ*BJBZ7^&5C2Q7/;Z?8JL%=V      ,T.[XP^+,NUQM+35,/745@N%XS"
MI7D<](9<7L%SNMHF71%:WDO\%(B.<J(BJFFJZ(N]D5NA!J;N'!=V[%JTL.,
M       8Y]KO$H<W[,>^./RQ),Y=NLAO=)$KFL1]SQ2E7*[2WG>J,:JW.RPZ
M*Y41%Z51.)K=%;92X+N'-;/;[=BH<5G;      R'[)-T=:.T]L%5L5Z+-NS@
M]K7JT8KN6^7^BLKT7G^3R*RX*CO&C==..AM;XH[T6:*X;OPRM[%EQ
M                           *>7:;^LEV@_IPW8^?E_*UWBGO=S#\JW\,
M>QX>:I      +HNV7[-MO?U'Q/\ 0- 6HW.#?XY[Y=X,M0
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MY-;R7RII;<&&D?$R32[-GNC^/-EI$WW;9I&RRRO#CLLMI;'KQXR\W
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M1O1'LD8]%145$5%312J[R,      %V'&/Z-8]^8[3^(4Y;<"=\][G P
M                          %;7O7_ *T-!]%F)_I?*2#)XO0ZNB^3_5+6
M81K8     %H'NR_J@8%^?,[^>%X+&/PN1J_GSZ/8S\-U8
M           # /O-/J@9[^?,$^>%G-,GA6=)\^/3[%7XKNN     !LM[J2"*
M7M25$DD;7OIML<NG@<O3%*ZXXY3+(W[Y8*A[?@<I)C\2IK/D^F%E G<H
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M[A9I;HNJA;3Q]719)<J:/JX&.<V!G+$FC$54:G#7@59WN]9-;(GLAYZ8;
M   78<8_HUCWYCM/XA3EMP)WSWN<#
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MVF_K)=H/Z<-V/GY?RM=XI[W<P_*M_#'L>'FJ0     "Z+ME^S;;W]1\3_0-
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M5D66QUS,1ONF=MUUU;KIVW3,S5V@Y[K@
M  !K2[UN>6+LMT\<<CF,J=SL1@G:G1+$VW9'4I&[[U)Z=COA:A'D\*WH_G>B
M5:\@=4     #:?W1/UDLV^@_)/GYMJ28O%Z%/6_*C\7[)6+B=RP        !
M35WS_;;O%]*>X/SMNY5G?/>[N/Y=OX8]CRPPW      NPXQ_1K'OS':?Q"G+
M;@3OGO<X&                                K:]Z_\ 6AH/HLQ/]+Y2
M09/%Z'5T7R?ZI:S"-;      M ]V7]4# OSYG?SPO!8Q^%R-7\^?1[&?ANK
M                          8!]YI]4#/?SY@GSPLYID\*SI/GQZ?8J_%=
MUP     -F?=0?6AK_HLRS]+XL28_%Z%36_)_JA9*)W*        .#R?^C60_
MF.[?B%0&8WQWJ3Q4=\     #U/8S]MNSOTI[??.VT&8WQWM,GR[OPS[%RHM.
M$            !^*X7*W6FDEK[K7T5LH84UFK+A5045)$GEEJ*F2.&-.'C5
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MJ\KZ'3Z'0Q2MN*V(FZ8V<5]^V_)=3^*^ZZ[M>C'%>1
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M[;HV=FUE*;(0          K:]Z_]:&@^BS$_TOE)!D\7H=71?)_JEK,(UL
M   "T#W9?U0,"_/F=_/"\%C'X7(U?SY]'L9^&ZL
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M^5KO%/>[F'Y5OX8]CP\U2      71=LOV;;>_J/B?Z!H"U&YP;_'/?+O!EJ
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M+<=M>F>&V(BL],SMG?,NV%!T0
M#!+O*+8ZX=CO<Z9B<SK378)<T8D2RO<U,\QR@E5BIQBZJ&O<]S^.C&N1>"JJ
M:9/"LZ2:9X]/L5;RNZX     &R'NK;C'1=JJFII.3FO&WN8VZ'GF;&[K(EM5
MV7JF*U5J']3:W_(314;J[71JHLF/Q*NLC^SZ867"=R0
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M/%Z'5T7R?ZI:S"-;      M ]V7]4# OSYG?SPO!8Q^%R-7\^?1[&?ANK
M                        8!]YI]4#/?SY@GSPLYID\*SI/GQZ?8J_%=UP
M     -F?=0?6AK_HLRS]+XL28_%Z%36_)_JA9*)W*
M        \8WPW]VR[/6(RY?N3?F6^!_616>R4B1U61Y+71M:ON%AM2RQ25<J
M*]O62N='3T[7(Z:2-JZF)F+8K*3'CORW<-D*Z7:>[>^[O:(GKK#0U,VWNV#W
MNCAPRQ5LGO5WITYD23+KY&RGJ;T^5':K2L2&@:B-_ OD9UKH+KYN[G4PZ:S%
MMWW]?[F"QHL          !Z!MMNGN#M!DU+E^V^5W;%+[3*U'5-MGTIZZ!KD
M>M%=K?*DMON]OD<FKJ>IBEA541>75$5,Q,QMAK?9;?'#?%86 >R'WC>([US6
MW -V&6S MT*AT5';*^.5U/A^;5+M&Q16^:JDD=8;]4/^2E%/(^*H?HD$KI)&
MT[)K;XG9.]S,^ENQ^]9ML^^&SPD5        "GEVF_K)=H/Z<-V/GY?RM=XI
M[W<P_*M_#'L>'FJ0     "Z+ME^S;;W]1\3_ $#0%J-S@W^.>^7>#+4
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M_P#=OXHFL76VW1\/'='1./'9/;,UEFH>MWM@
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M[%7XKNN     !LS[J#ZT-?\ 19EGZ7Q8DQ^+T*FM^3_5"R43N4
M               #%SM5]J;"^R[@GY?O:,O&7WQE72X-AL4W555^N-,R/KJJ
MKE:CW4%AM;JB-U74*BJB/;'&CI7L:NMUT6QVIL.&[-=2/#&^577=_>/<#?/-
MKEGNXU[EO%ZKW=73T[.LAM-CMS'.=36:PVYTDL=MM5(CEY8VJKGO5TDKI)7O
MD=7F9F:RZ]EEN.WALW/+S#<            #^HJM5'-545%145%T5%3BBHJ<
M45% WG=@#M^ON;['L3OG>GR7*1]-:=O-P;I.KWW%[U;!0XGE59,Y7.N#G*V.
M@KI%UJ%TAF7K>1\LUE_1+G:G34KDQ[NF/VMUQ*H       *>7:;^LEV@_IPW
M8^?E_*UWBGO=S#\JW\,>QX>:I      +HNV7[-MO?U'Q/] T!:C<X-_CGOEW
M@RU                             -+O?(WMD6';(XXDR(^MR;++W)#SZ
M+RVNUVNAAE5GC36[R(B^+CY3ZD_3%I+KN9\VUU)I;@PXZ_COONF/]B'PW^MK
M7VV\FY#RSBCBOU6HRS%>BRS'9$T_^I,-"6K?*GI0^P?>[7YZ^[V&K?*GI0>]
MVGN]AJWRIZ4'O=I[O8:M\J>E![W:>[V&K?*GI0>]VGN]AJWRIZ4'O=I[O8:M
M\J>E![W:>[V&K?*GI0>]VGN]AJWRIZ4'O=I[O8:M\J>E![W:>[V&K?*GI0>]
MVGN]AJWRIZ4'O=I[O8:M\J>E![W:>[V&K?*GI0>]VGN]AJWRIZ4'O=I[O8:M
M\J>E![W:>[V&K?*GI0>]VGN]AJWRIZ4'O=I[O8:M\J>E![W:>[V&K?*GI0>]
MVGN]AJWRIZ4'O=I[O8:M\J>E![W:>[V&K?*GI0>]VGN]AJWRIZ4'O=I[O8:M
M\J>E![W:>[V&K?*GI0>]VGN]AJWRIZ4'O=I[O8:M\J>E![W:>[V&K?*GI0>]
MVGN]AJWRIZ4'O=I[O8:M\J>E![W:>[V&K?*GI0>]VGN]AJWRIZ4'O=I[O8*Y
MJ<5<U$3QJJ#WNUG9.YQU1>+;2ZI+5QJY-?D1:S/U3Q*D2/Y5^'0TF^(WRN8>
M7:S/MQXYIUSLC[Z/5=M-DM_-ZYHXMH]F<WR^FF=U;;ZMM6T8M%(K5>UM3E-W
M=0XW2J]J:M26LB<Y.@\6Y[YY\J>6K9GG>OT^"^/X)OXLD]V*SBR3VTLE[$\K
M?2'SOYNR6V\ET&IU&.9\=F.8Q1V79\G!AMF>CBO[JMAVUO<\[\9:VEK]X]S<
M5VMMTKH99\?Q&FES3*&PZJM31U-:V>TV"VU*M1&LF@K+E&U5YE:[3E=Z5\P?
MJ3Y!I.+#Y=TF?69(K$7Y)C#CKT3$3%^2Z.N)MQST5VUCZ3\I_HZYUJ.'4>:-
M5IM%CV3-EM=3E[8FDV8;9Z(FV_+'3,32D[+=H.Z\[(^U,U)=*[")]U,CIFPN
M=>=TZMN34SZB)%UF;C744N+JUSEU1LM),K=$XZIJ>C/,7UN\_<_B[%9JHT6E
MNK[NGB<=U.KXE9R>JZ'TSY5_3S],_+$69+M'.OU5E/>U,Q?;7K^#$6X?1=9<
MV 6JTVNQ6ZDM%DMMOL]IM\+:>@M=JHZ>WVZBIVZJV"DHJ2.&FIH6JJZ-8UK4
M\AZHSY\^JS7:C4WWY,]\UNNNF;KIGKF9K,SWR]U:;3:;1X+=+H\=F+3612VR
MRV+;;8ZHMMB(B.R(<@1)P
M  '!918J;*,9R+&:Q42DR*Q7>Q52JU'HE-=[?46^=58O!Z=54+P7@HWLQ-)B
M8WQ*E9<K?5VFXU]JKXEAKK96U5OK(5Z8JNBGDIJB)>CC'-&J?$5'?B:Q6-S\
M0     34U1/1U$%72S24]52S15%-40O='-!/ ]LL,T4C51S)(I&HYJIQ14U
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MKHOD_P!4M9A&M@     6@>[+^J!@7Y\SOYX7@L8_"Y&K^?/H]C/PW5@
M                     , ^\T^J!GOY\P3YX6<TR>%9TGSX]/L5?BNZX
M  &S/NH/K0U_T699^E\6),?B]"IK?D_U0LE$[E
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M_ACV/#S5(     !=%VR_9MM[^H^)_H&@+4;G!O\ '/?+O!EJ
M                 : >^3N'-N#LI;%Z*3#<GKDT7CK<+W0TZZIXD_\ =G ^
MQ_TQ8HMY-S7/_-JL5O\ JV73_P#&_.W];&HXO,G(M+T6:'/?_KY;8_\ X;3+
MUC?/X?&?3]8?$AUC?/X?&*P'6-\_A\8K =8WS^'QBL!UC?/X?&*P'6-\_A\8
MK =8WS^'QBL!UC?/X?&*P'6-\_A\8K =8WS^'QBL!UC?/X?&*P'6-\_A\8K
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M9>/AG\$6LKD1$1$1$1$1$1$31$1."(B)P1$0\"WO9<1$12-S^@
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M/L5?BNZX     &S/NH/K0U_T699^E\6),?B]"IK?D_U0LE$[E
M             !6O[RWM*3;N;LR[7XY7O?M_M-7U=M>R&1JTM\SN/K*2_P!W
M?U:JV>.S_*MU*KM>165#V+RSKK!DNK-.B'5TF+@LXY\5WL:TB-;
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MTT:/E.GP:;21_!BLMQV[J5I;$16G3O=B*;H
M                          #1=WOVUDL-VVNWGH:95IJVBK-N<BJ&1JUD
M5912U>0XNLKVMY7S5M-57-NKE1R,I6(FJ)\F'+'2Z.AOV3C]/V^YI3(E\
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MI999Y9)II))III'RRRRO=)+++(Y7R222/57OD>]5555555752L[:,
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MLF(K7',S9$Q\2VR9HJZ76X-9;,XI]Z-\3O[^[M>XGN-;
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MK'8S:CD9*QDL3V21R,;)')&Y'LD8]$<Q['M56N8YJZHJ<%0W5WV
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M     %H'NR_J@8%^?,[^>%X+&/PN1J_GSZ/8S\-U8
M       # /O-/J@9[^?,$^>%G-,GA6=)\^/3[%7XKNN     !LS[J#ZT-?\
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MF9Z[I_9'[WE.#RW;;;$9;XBWJLCV3/\ \K&/+.T=O)F37P7+-;A0T3T5/<;
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M='19;:DDJ/R:^HD>D<55')+232<K5=%(]D*Q763;W.AAU-F;9NOZOW,%C18
M      66^ZQS63*.RW36&>5SYMOLXRC&(FO=S/2@KW467TKT737JNNR::-FJ
MKHD2HFB(B$^.?=<G66TS5ZX_P;(B15   "MKWK_UH:#Z+,3_ $OE)!D\7H=7
M1?)_JEK,(UL     "T#W9?U0,"_/F=_/"\%C'X7(U?SY]'L9^&ZL
M                  !@'WFGU0,]_/F"?/"SFF3PK.D^?'I]BK\5W7
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MBMV.=F6R.VV)FL?YK9F.ND[&61]6+@
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MD\7H=71?)_JEK,(UL     "T#W9?U0,"_/F=_/"\%C'X7(U?SY]'L9^&ZL
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M*JES?^L]5=J=)\8M+U<U)88[1CTT/- [_FZR:H71%>J%BR*6]KCZK)\3+/\
M+&QG&;JX   1RQ13Q20S1QS0S1OBEBE8V2*6*1JLDCDC>BL?&]BJBHJ*BHNB
M@5*^V9LK!L+VA<YPFUTRTN+UE1#E6&1\W-''C.1(^KI:*%559%ALM<VHM[5?
MJ]R4G,JNUYEK712ZCM8,GQ,473OW2Q:-4P     %C/NE<G==NSKD^.SR\\V)
M[G7F&FBYF+U-JO5CQ^Z4Z<O6+(WK+H^M756M:OB551VD^/PN7K8IEB>N&THD
M4P   IY=IOZR7:#^G#=CY^7\K7>*>]W,/RK?PQ['AYJD      NB[9?LVV]_
M4?$_T#0%J-S@W^.>^7>#+4                             U9=[QBB7S
MLLT>1,@DDEPG<?&;H^5B/5E-17>FNF-S23<OR6L?676G8BNX<[D3I5#WO^GG
MF'Y3SW=HYF(MU6BR6TZ[K)MR13T6W3W5?+OZM^4_G_IACYA%LS=HN98;YF*[
M+<EM^*:]]U]D;>F8Z95AN?S_ &#[AK<_,[AMZCG\_P!@5N.&WJ.?S_8%;CAM
MZCG\_P!@5N.&WJ.?S_8%;CAMZCG\_P!@5N.&WJ.?S_8%;CAMZCG\_P!@5N.&
MWJ.?S_8%;CAMZCG\_P!@5N.&WJ.?S_8%;CAMZCG\_P!@5N.&WJ=ZQ_;C-\GY
M'6O'Z]::1&N;75D2T-"K')JCV557U4<S=/\ H^=?,4\VOTV#9DR1Q=4;9]4.
MEI.3:_6TG!AOX)_BGW;?7-(GT5>SV7LX5:1>]91D$-'%&WK9Z>V1H]61-172
M+)<*SJX8>1J<5ZE[4Z=>!S,O/K=VGLF>V9_9'[WD6F\FWS''K<L6QU6[?]J=
MD>J73LGW:[(^S?R;AE%CR2]0HU%H[--_/FY]8BN5.M90/J++;JAKH^B1U.Y-
M47@BG+S<VU639??PV]4;/9M];RK0>5-%BF)PX..Z/XK]OI][W?5#%_.^\H1B
M3T.UVV\$,3&*REO&95KG(B\RHCOYNV1T*-8C>+=;ATKQ:FG'G7:FL[*S/:\G
MP\FFD1ENMMMCHMC]NR(]4L+,\[5._6XC9J>^;A7>BMLRR(MHQKJ<9M_4R+QI
MIDLL='5U].FFB)52SKY54ANS9+NFD=GVJZ&+EVDQ;>"+KNN[;]V[U0\#;'5U
MTSU8RIK*B1ROD5K9:B9[G+JY[U1'O<YSEXJO2I%V]*W?DQ8;:Y+K;+.V8B'/
MTF&9)6:*RV2PM5->:K<RET^%DSFRI_!,5AS,W/.5X-EV6VZ?\OO??&S[W8Z7
M;*YR<JU=?1TR*ORDB;+4O1/@5(&*O_I#B<O-YKTEOR<=]\]M+8_;/W.?I]L;
M8SC57&MG\T+(*9-?/SMJ5T^-#'$YV7S9JKODXL=O?,W?_*YR' \8A1.:@?.Y
M/\^:KJE5?.K8Y8X_XHK*AD\Q<VOG9DBV.J+;?VQ,_>Y>'';#3Z=59[<BMZ'.
MI(9'II]_(Q[]?C,5E2OYGS')X\^7_6F(]44<HRGIXO\ FH(8].CDB8S3^"U
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M.>*([+HWV7==MT1,/<#Z!
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M\7H5-;\G^J%DHG<H  :).^-_I+L/^8\^_'\6(<O0Z.AW7=\?M:72)?
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M%*^;5J*V&Q5UEN]IC5%=SO1S\BK531NC=.*_*36'+T2Z.AG9=;W-+1$O@
M  ;U>YQN:RV'?RS\TJI07?;NYHU4;U"+=J/,:571JCE>LKOR*G/JB)HC=%7C
MI-BZ7.UT;;9[_P!C=02J    4\NTW]9+M!_3ANQ\_+^5KO%/>[F'Y5OX8]CP
M\U2      71=LOV;;>_J/B?Z!H"U&YP;_'/?+O!EJ
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M8Z)B8I+],M)JM-KM+CUNCOMRZ3-CMOLOMFMMUET1=;=;,;)BZ)B8GIARQ$L
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M>A4UOR?ZH62B=R@ !HD[XW^DNP_YCS[\?Q8AR]#HZ'==WQ^UI=(E\
M    'J>QG[;=G?I3V^^=MH,QOCO:9/EW?AGV+E1:<(   .G;B5,U'M_G573/
MZNHI<.R:I@DY6/ZN:"R5LL3^21KF.Y7M1='(J+XT,3N;6^*.]2S*KO
M>X=F3ZR79\^G#:?Y^6 VM\4=Z/-\J[\,^Q<-++A@     :=N^&C8NW.S<JL8
MLC,UR"-DBM17M9)8H'2,:_3F:R1T35<B<%5J:]"$67="]H?'=W-!9"Z0
M &[_ +FK_P"L=_=!_P#2B38NES]=_!Z?V-WQ*YX   4\NTW]9+M!_3ANQ\_+
M^5KO%/>[F'Y5OX8]CP\U2      71=LOV;;>_J/B?Z!H"U&YP;_'/?+O!EJ
M                            ?DN%#272@K;97PLJ:&XTE30UM/(FL=12
M5<+Z>HA>GC9+#(K53R*28LN3!EMSXIFW+9=%T3'1,36)]$H=1@Q:K!?IL]L7
M8,EDVW1.Z;;HF)B>R8FBBWG^)UNW^=YK@=T?S7+"<MR/$K@YNO*ZMQR\5EGJ
MG-^2WY+IZ-RIP3@?IYRKF5G->5Z;FF"(^#J<&/+;^')9%\?=+\3^><GR\BYU
MK.2:K_\ F='JLN"_\6+)=CN^^V74>9/NE]9T.*[JAR_AV]IS)]TOK'%=U0?#
MM[3F3[I?6.*[J@^';VG,GW2^L<5W5!\.WM.9/NE]8XKNJ#X=O:_12T]375,-
M'105-95U,C8J>EI89:BHGE=P;'#!"Q\LLCEZ$:BJIK=DX8FZ[ABV.F=S-N&;
M[HLLBZ;YG9$;9GNADS@W95W!R5(JS(EBPZVOY7(VO1*J\2Q+RJJLMD,J>[.T
M54TJ)(GM5.+#AZOS)H]/[N'^[D[/#Z^GT5>4\O\ )G,]73)J/[&&?YMMW^K&
M[^J8GL>I9(WLF]F*!M1N1E%EFR)L"5$-#?Y6Y)DU0J,YXY*#$+935#Z:*65N
MD4[Z5&L<J(LR<5/'\_..9:WPS\/%_EV??OGMIZGFW+_*?*]'/NXYS9XZ;Z74
MGNV6V]E=O;TL*=U^]3F5)[9LGM]3TL3'/AAR3.U69ZPM5&1RT>-6>K@B@<K$
MU8LU9(C>'-&O%"C&/INF9G[?;H>4X]%-*7S%MO5&_P#='JEK7W-[0N\^\,T[
MMP=PLAO=#/(DGY!95K;,9A5CE=%U.-VMM'96OB1=$D6!951$YG*O$EW;MD+6
M/3X<>V+8FZ.F=L_X>BD=CSFS8Q>KZY%H:1_N^NCJR;6*E9IT_A')^$5/&C$<
MOF%5;6\TT6@C^_?_ '/Y8VW>KH]-(>G6S:^BA1K[K535CT5%6&G1:>G\[7/7
M6=Z+Y45BFO$\5U7FG4WUMTED66]=VV?5NC[W?:&R6ZV-1M!0T]+\E&J^*!$E
M<B?]),NLTB^=SE4Q6KQW4:S5ZN:ZG)??V3.ST1NCT0Y'JG>?^"HV*U).J=Y_
MX*C84DZIWG_@J-A23JG>?^"HV%).J=Y_X*C84DZIWG_@J-A23JG>?^"HV%).
MJ=Y_X*C84DZIWG_@J-A23JG>?^"HV%).J=Y_X*C84DZIWG_@J-A23JG>?^"H
MV%).J=Y_X*C84DZIWG_@J-A23JG>?^"HV%)6:.X^[851=K9=>R)GMUEGK;)!
M795LW55KII)9+*U7U6584R>21[$CM,KORC0QZ(J0RU;>;DCB8GSK]9/*=N+)
M;YJT-M++YBS/$4\6ZS)_5X+IZXMZ9F7VI^F/ZB7Y\.3Z?<UOF<F.+LNCF:S[
MF_+AK/\ +/\ <LCJG)&ZVV%BH]!OL$    '1]R\SI=O, R_-JOD='C=AN%SB
MB>Y&I55L4#FVZB1RJB(ZNN#XH6_?/0\3\]>:-/Y*\G<R\U:FDV:'1Y,L1.SC
MOBVF*SOR9)MLCMN0:K/&FT]^>[=9;,^GHCTSL5KKO=*N[W&X76OE6>ON=;57
M"MG=KS2U=;/)4U$J\57FDFD5?C/PXU6JU/,M=FYEK;IOU>?+?DONG^*^^Z;K
MI]-TS+U3GS3?=-]V^9F9[Y<!-)P7PXDN*SI<S+>XJ63IX_;.CCQ]'2Y^2]QD
MTO2='%CZ%#+>XB:3IX^=>/G.EBQ^IS<N3I<3/+Q7CYO#SG1Q8ZN9EOF9<1/+
MX>'D.EBQ^I1RWN*FET\?$OX[*['/R7U[G"SR^+X>A=?A.GBQ]2E?<_98<SR7
M$*U*_&KU6VFHU8LB4TJ^[U*,U5K*RCD1]+61M5>#96.:G3H4>>>4_+WFG1_D
M?,&DPZK!2:<=OO65WSCOBE^.>VRZ)[5[D_F;GGEO5?G.2:K+I\VRO#/NW4W1
M?9-;+X[+K9CL;!]D>\FSO"%I+5F3WUML9R0]8L=1=+5'"S5&*MNFJ%N=N1C>
M"^YU'5JJJO4KP0W\K<^^N_T?I'TPY]=S7RUCMB(Y3SB;M1BMMBE+--J.*S+@
MB(K%EEF3%CBM;^.8B7O'R_\ 73EFMX=-YTTGPLTS3\SIHV=^3#,S/?-LW3U6
MQN;<-I^VEM'N=0PS_E6GMDCFL;)4P3K<;8R=R?\ -5#H8F7&URNZ4954\6C>
MEWE^F?)'ZZ?(NHUEGE_ZP\NUOD_S'-L>_GMNSZ'+=TSBU.*R9BVNZZ^SX4;I
MS5W^Y.77\MY]I/S_ );U>#7:3I^'='';V7V32ZV>RZ(NZ:,M*"XV^ZTD-?:Z
MZDN-#4-YH*RAJ8:NEF;]U%/ ^2)Z? JGVGR;G?)O,7+L7./+^KTVNY3FBN//
MI\MF;%?'79DQW7671W3+6^R_'=-F2)MOCHF*2_8=1J
M                  8$]H7N\-BM\Y*^_P!KH7;7Y[5]9,_)<1HZ=EKN58_5
MRSY#BG-36RXODD<Y\LU.ZBK)GKS23OTT-+K(GLE9Q:K)CV3[UO;^]I+WR[ _
M:(V/=57"JQ:3.\0@=(YF78%'57NEAIF+JDMXL[(&WVR<D:HLCYJ=:5KE5K9W
MZ:D4V71W+^/4XLFRM+NJ6%AHL              ,FNRIVELH[,FYM#EEKDJJ
M[%+H^FMF>XLR5/=[_8.O1SI88I%ZB*^VCG=-0S_)<Q_-$KNIFF:_:V[AFO0B
MS8HS6<,^+HE; Q#+,?SS%[!F>*7*"[XYDUJH[S9KC3KK'4T-="V:)7-71\,\
M:.Y)8GHDD4K7,>B.:J)9B:[8<6ZV;9FV[?#L88    !3_P"U56K7]IGM 3K&
MD:LWBW%HN5'*Y%2W97=+>V3543196TO,J>)5TX])6N\4][N8=F*W\,>QX$:I
M      +HNV7[-MO?U'Q/] T!:C<X-_CGOEW@RU    !AYV_?J@;V?F.Q_/#'
M#6_PRGTWS[>_]BJ*5G9      S\[LOZW^!?F/._F?>#?'XE;5_(GOCVK0)8<
M@   *VO>O_6AH/HLQ/\ 2^4D&3Q>AU=%\G^J6LPC6P     +0/=E_5 P+\^9
MW\\+P6,?A<C5_/GT>QGX;JP       !^&YW.WV6VW"\7:K@M]KM-#5W.Y5]4
M](J:BM]!3R5595U$B\(X*:GB<][EZ&M50S$3,TC>K&=K;MX[C[^Y%=;%A]YO
M.$[04LTU':L=ME7-;;ADU(QSH_RMF%51OCGK'W!$1[;>KUI*5G*WEDE:Z9]>
MZ^;MVYUL&FLQQ6[;D]G<P#-%D      !WK;[<W<#:F_P91MSEU\P^^0.C7WR
MS5LE.VJCC<KVTURHW<]#=:%SE7FIZJ*:!^NCF*AF)F-S6ZRV^*7Q6%F3L/=K
M>'M18%<6W^GH;5N=A+Z.ER^W4#7PT%SI*Y)_R5DUHIY999(J6N6FDBJ(>=_N
M]3&O1'+#K/9=Q1VN3J,'P;MG@G<S?-U<    & ?>:?5 SW\^8)\\+.:9/"LZ
M3Y\>GV*OQ7=<     #9GW4'UH:_Z+,L_2^+$F/Q>A4UOR?ZH62B=R@ !HD[X
MW^DNP_YCS[\?Q8AR]#HZ'==WQ^UI=(E\           'J>QG[;=G?I3V^^=M
MH,QOCO:9/EW?AGV+E1:<(   /,]ZJF:CV;W:JZ9_5U%+MGGE3!)RL?U<T&+7
M66)_)(US'<KVHNCD5%\:&)W2WQ_,M[X4SBJ[H     'N'9D^LEV?/IPVG^?E
M@-K?%'>CS?*N_#/L7#2RX8     &GCOA?V;;._KQ??T"PBR[H7M#X[NYH)(7
M2      W?]S5_P#6._N@_P#I1)L72Y^N_@]/[&[XE<\   *>7:;^LEV@_IPW
M8^?E_*UWBGO=S#\JW\,>QX>:I      +HNV7[-MO?U'Q/] T!:C<X-_CGOEW
M@RU                              %2[O3=M$VX[7V95]) D%KW,L]BW
M'H6,A5D:5-TAFLV0+UG[V6:IR6PUE2]4T5%J$U\J_>'T1YW=S?Z?Z;%?=7/H
MLE^GN[K9B_'W1&.^RV/PORU_4OY;CR_]5]9FQ1PZ;F.+'J[8I2*WQ./+MZ9G
M-CR7S^)KHYW>;T'MRLO05#G=YO0*R4.=WF] K)1]QI--)'#$QTLLKVQQ11L5
M\DDCW(UD<;&HKGO>Y41$1%55,3=2*S.PB)F:1OEE]M;V1\QRQE/=\WDDPZQR
MHDC*!\2.R6KC7BW6BE3J[5&_RSZS)_T6BHIXYK_,NFTU<>E_NYNO^&/3T^C9
MVO,^4^3-=K8C/KJX-//1/CGT?P_U;>QV3<'M0=DKLBP5>/8TVGS'/8(Y*:LL
M^'R4M\O+:N%>K?3Y3EM1*M!9]*EB];2ME?-"NJI2HFB+XQGS\PYE/'JKYC'T
M1NB.ZW]L[>V7L3EO)M!RVWAT&*.*FV^=LSWW3MFO5;LB8W0U8[T]XUV@=TWU
M-OQNZQ[4XQ,V2+\FX9+)'>ZB)ZJB+6Y9*QMW9*C.'_4UHF+JNK5X:9QZ?'CW
M16>N=O\ @[-N"-^2>*>K='[Y],T[&!%145%7/-55<\U34U$CYJBHJ)7S3SS2
M.5TDLTTCG22R2.55<YRJJKTD_>FB(B*1$1#G[%B5\R)R+04CDIM51U=4(Z&C
M;HNCD256N65S5Z6L1SD\:&*Q&]S];S31Z"/[]W]S^6-MWJZ/31[78ML;/;.2
M:XHMVJTY5_#,5M'&Y-%7DID<J2IK_P!)S(J>)#6;I>'ZWS%K-36S!_:Q=GBG
M^KH]%.]Z&VF:UK6M8C6M1&M:UJM:UK4T1$1%1$1$0U>/S,S-9VR_ONZ>1?0O
MM >[IY%]"^T![NGD7T+[0'NZ>1?0OM >[IY%]"^T![NGD7T+[0'NZ>1?0OM
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MN<&_QSWR[P9:@    P\[?OU0-[/S'8_GACAK?X93Z;Y]O?\ L512L[(
M&?G=E_6_P+\QYW\S[P;X_$K:OY$]\>U:!+#D   !6U[U_P"M#0?19B?Z7RD@
MR>+T.KHOD_U2UF$:V     !:![LOZH&!?GS._GA>"QC\+D:OY\^CV,_#=6
M      ,*.\/R6MQCLA;M3VZ:6GJ[Q38WC771+II17_++';KQ#(J.:[JJRRRU
M,"HFNO6Z*BIJ:7^&5C2Q7/;7[;%5DKNP         -BW=;WZX6GM866VTDKF
M4N489F=FND:.5&RTE+;6Y'"BMZ'.9<+%"J>3B28_$JZR(G#7JF%F<G<D
M& ?>:?5 SW\^8)\\+.:9/"LZ3Y\>GV*OQ7=<     #9GW4'UH:_Z+,L_2^+$
MF/Q>A4UOR?ZH62B=R@ !HD[XW^DNP_YCS[\?Q8AR]#HZ'==WQ^UI=(E\
M       'J>QG[;=G?I3V^^=MH,QOCO:9/EW?AGV+E1:<(   /+-\_P!B6\7T
M6;@_-*[F)W3W-\?S+?Q1[5-4JNZ     ![AV9/K)=GSZ<-I_GY8#:WQ1WH\W
MRKOPS[%PTLN&     !IX[X7]FVSOZ\7W] L(LNZ%[0^.[N:"2%T@     -W_
M '-7_P!8[^Z#_P"E$FQ=+GZ[^#T_L;OB5SP   IY=IOZR7:#^G#=CY^7\K7>
M*>]W,/RK?PQ['AYJD      NB[9?LVV]_4?$_P! T!:C<X-_CGOEW@RU
M                          &E/OI=I7WW:C;K>.WT/6U6W^25&-7^JC21
M7Q8]F#(?<9I^5%C2GIL@MT,37.TT?6Z(NKM#Z,_3MSZ-+SS5^7\MU+-5AC)9
M'7DQ5K$=LV73/=9V/C[]7OE:==Y:Y?YLP65R:'43ARSMV8L].&9Z*1ELB-O3
MD[5;7G3R'U_67Y\4[#G3R"LE.QW; , RK<S(:;&<1M<EPKYOPE1,[FCM]LHV
MJB2W"Z5G(^.CHXM?WRZN>Y48QKY'-:M76:[!H,$ZC4W<-D>N9ZHCIG_3.Q?Y
M=RW5\UU,:316<66=_5;'7=/1$?X169B&?EQI^SQV&</@S?<^]TUUSBKBF;:F
ML@BK<FO-4V-J3T.$X]),WW2FB<O++72K&V-)$2:H8U[6'K[6\VU_.[YQ8JX]
M%U5V?U3TSV;NSI>X>2^6-!R2+<ET1FYE,>*FZO\ +&ZV-_O3MG;%=O"TX=I7
MO"=X]^'W#'[!5U&V>V]0DU.N-8_6/9=[U2/<B)_.;(8FPUM4R6--'TM.L%(Y
MKE;(R71'#!I,6#;&V_KG]G5[>UY'&.;MN7;V='^/I]$0P$+*5REHLMSOM6VB
MM5'+5SKHKDC32.%BKIUD\KM(X8T7_.<J)KPZ0KZG5Z?1XOBZFZ+;/OGLB-\S
MW/?\9VEM]O2.JORLNE8G*[W5JJEOA<BZZ*B\KZM4^_1&+]RIBL=;PGF'F;49
MYG'HXG'AZ_XI_P#E]&WM>KLIF1L;''$QC&-1K&,1K6,:U$1K6-;HUK6HFB(G
M UX;>N7C4Y+KIXKHK=/:^^I^]3U>T<-O7+''V?>=3]ZGJ]HX;>N3C[/O.I^]
M3U>T<-O7)Q]GWG4_>IZO:.&WKDX^S[SJ?O4]7M'#;UR<?9]YU/WJ>KVCAMZY
M./L^\ZG[U/5[1PV]<G'V?>=3]ZGJ]HX;>N3C[/O.I^]3U>T<-O7)Q]GWG4_>
MIZO:.&WKDX^S[SJ?O4]7M'#;UR<?9]YU/WJ>KVCAMZY./L^\ZG[U/5[1PV]<
MG'V?>=3]ZGJ]HX;>N3C[/O.I^]3U>T<-O7)Q]GWG4_>IZO:.&WKDX^S[SJ?O
M4]7M'#;UR<?9]YU/WJ>KVCAMZY./L^\ZG[U/5[1PV]<G'V?>=3]ZGJ]HX;>N
M3C[/O.I^]3U>T<-O6<?9]ZT=W&>]K\DV:W!V)NM7)+<-L,E;E&-0S2R/2+$,
MW622KH:2-VK(X+?E=%5U#^5>,ESU5-5U7YG^MG)8TW-]/SO%']O4X^"^?_4Q
M[IGMFR;8CLL?=?Z6?-,Z_P MZSRKJ+IG-H<_Q<<3.[#GWVQU1;EMNNGMR-Z9
MZ1?5(   :%NV]G/\\-_,DI8:A9K=AE';\/H>#4:R6@B?6W=$:W@KF7RX5+%<
MNJJD:>)$1/R4_5%YGGS/]8-;@Q7\>BY9CQZ.SJB<<3?F],9\F6VL[9BV.B(B
M/6?F75_&YE?9$^YCB+8]&V?OF?4PVFDZ>/VU/0F+'ZGBF6]QDTG3Q\/MG1Q8
M_4Y^6]Q,TO3X?$='%CZ5#+DHXF>7IX_:.EBQN7ER=3B)Y>DZ.*SI<_)?1Q,L
MFNO'SG1QV4[U#)>XJ>5..O1Q\%+^''7:H9+Z.$FDZ>/Q?8.IBLZ5*^]Q$TO2
MNOI+]EBCDOZ'%32:^/S?%X*7\5G2HY;Z;(<3/+Z/L^+7SH7L=BE?=TN(GEZ>
M/AQ^/B7L6.LJ62^FWI<--+KX>' Z6.RCGY;W$32Z:JJ^7P^$O8[*]RGDN>AX
M5OONEMOU4.+Y;7Q6V)S52R7%S;K958BZNBCH*])XZ-DFORG4ZPO7[I.!X+YM
M^COT[\]\67S#RS!=K[HG^_BKASUZ)G)CX9OF.B,G';_EI5YIY8^JOGOR7PX^
M1\PS6Z*V?D9*9<-.F(QY*Q97IG'P7=K/W9[O2<JPY8*')::]66!O*CJC&*B.
M\697(B<TDN+W^1T%,V1R+S/AE>]$Z$/7W*?IE]<?I-'Q/H7YSUF#EMLUCE^N
MF,NFI6LQ;9?9FT]9C9-T:?'=/_F1LF/H+R_^J7DVLF,'GKE<V9*4G/I)XMM-
M]V*^ZVZ(KMFF2ZG1;+:[L[WD>WNX*4E.MQQS(*B5NKX+)7_D?)VM:Y.LD=B=
M]=!62K&U5U5JQQ*J<':+J>S.4_K@^KGT\OMTOUY\E9KN6V4C)K^6UX-MWBX;
MKLFEONFVLQ9^:PS,TK%NVGO3R]YH\@^=(M_Z3YOILVJNC9@ONX,VS?\ VKXL
MRTCIG@FWJF6;F+[Z[896C64F34ELK':(M!D"MLU0CG+HV-DM6YM#4R.7H;#-
M(I]4?3W]8'Z?/J1;;BY9Y@TV@YG=3_A^8TT.6LS2+;;LTQ@RW3T6X,V6>QW]
M1RC7Z?;=CFZWKM]Z/NVQZ8AZXUS7M:]CFO8Y$<US51S7-<FJ.:Y-45%3H4^E
M\>3'ELC+BNB['=$3$Q-8F)VQ,3&R8GHF'-W;'T;@
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MQ1WH\WRKOPS[%PTLN&     !IX[X7]FVSOZ\7W] L(LNZ%[0^.[N:"2%T@
M   -W_<U?_6._N@_^E$FQ=+GZ[^#T_L;OB5SP   IY=IOZR7:#^G#=CY^7\K
M7>*>]W,/RK?PQ['AYJD      NB[9?LVV]_4?$_T#0%J-S@W^.>^7>#+4
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MOK;?CFZVZ*379,N3=9=9=PWQ,71T3LE^HZ#4
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MD:.YNH6&XO=7TD"KJFE+4TSD1>"IXO3?G']/OTD\\QDR<WY1@P\PR;]1I?\
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M@J<%/KS#FQ:C%;GP76WX;[8FVZV8FVZ)VQ,3%8F)C;$QLER9B8FD[WT2
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MN<&_QSWR[P9:@    P\[?OU0-[/S'8_GACAK?X93Z;Y]O?\ L512L[(
M&?G=E_6_P+\QYW\S[P;X_$K:OY$]\>U:!+#D   !6U[U_P"M#0?19B?Z7RD@
MR>+T.KHOD_U2UF$:V     !:![LOZH&!?GS._GA>"QC\+D:OY\^CV,_#=6
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MCP\U2      71=LOV;;>_J/B?Z!H"U&YP;_'/?+O!EJ
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M%/OBR^S)9&3',78[HB8F)K$Q.V)B8V3$QNEP]VR=[^FP
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MR>%9TGSX]/L5?BNZX     &S/NH/K0U_T699^E\6),?B]"IK?D_U0LE$[E
M      '!Y/\ T:R'\QW;\0J S&^.]2>*CO@     >I[&?MMV=^E/;[YVV@S&
M^.]ID^7=^&?8N5%IP@   \LWS_8EO%]%FX/S2NYB=T]S?'\RW\4>U35*KN@
M                    &[_N:O\ ZQW]T'_THDV+I<_7?P>G]C=\2N>   %/
M+M-_62[0?TX;L?/R_E:[Q3WNYA^5;^&/8\/-4@     %T7;+]FVWOZCXG^@:
M M1N<&_QSWR[P9:@                              !\2QLFCDBD3F9*
MQ\;T\K'M5KD^-%-K;ILNB^WQ1-?4UOLMR63CNVVW1,3W2IY]\SM!?'[;8WD\
M,,E0[9[/[S8\@:D3F.@M65+2VE+NY%54;3)>K)0P^/5:MBHO*BJ?;_EG7XM=
MI+-5B\&HPV9(Z=\5I7KCBV]TUH_.+G?+\W*>;Y>6Y_F:?-DQ3LIMMNI6G5/#
MLV],4K57 /*'.>Q;"1PR;IXVR5&JJLO*PH[319DLEQ5NG-PYD:BZ><UN\,N/
MS^O_ "K)3KM_\4-BWN7WJ?Q2.MSUSPVO[[E]ZG\45N."T]R^]3^**W'!:>Y?
M>I_%%;C@M/<OO4_BBMQP6GN7WJ?Q16XX+3W+[U/XHK<<%I[E]ZG\45N."T]R
M^]3^**W'!:>Y?>I_%%;C@M/<OO4_BBMQP6GN7WJ?Q16XX+3W+[U/XHK<<%I[
ME]ZG\45N."T]R^]3^**W'!:>Y?>I_%%;C@M/<OO4_BBMQP6GN7WJ?Q16XX+3
MW+[U/XHK<<%I[E]ZG\45N."T]R^]3^**W'!:>Y?>I_%%;C@M/<OO4_BBMQP6
MGN7WJ?Q16XX+3W+[U/XHK<<%I[E]ZG\45N."T]R^]3^**W'!:O1[<J]VWN".
MEUZQ<-Q=9->GG6R4*OU\_,?!/,J1S'44W?'O_P#%+]>>13,\CT<W>+\IAK_]
MNUW(I.J :7>\RNSI-S\ LJR*K*# 7W-(]7<K'7?(;M2/D1->5'2)9&IPXKRI
MKXC\[/UD:N[+YWY5R^ONXN5SDIVY<^6V9ZMOP8]7<]7^>\T_GL.'HC#7UW3'
M_P +61/)TH?)F*SI>NLV2CBIY=->/B]"'2Q8^MS,N3>XB:7IX^'VSHXL?2Y^
M2]Q$TFJ])T<6.FUS\N1Q,\R<4U\1T,..NU1R7T<+/+JJZKX_%]CXSIXL:EDO
M<3-+T\?#[1T,=BEDO<3/+T\?@\?@I?Q6=*ADR4BCBII.GC]M?87L=JA?<X>>
M7BJ^'P^74O8K*[%3)?L<-/+P7PX^0Z6.SJ<_)>XF:3IX^'VB[CLJI7W.'GEZ
M?#P4Z&*SI4LE[AYY>GC]G_(7\=BEDO<+43=/'XR_CL<W-D<)/+KKX? 7\=CF
MY+ZN'GEUU\-"[9913ONZ(<>]ZJOAZ2:(1Q$S/8@<OC]'M-XA;LMIM0.=X>53
M.^>Q:LMIWOS/=IQ\%7V&\)[8IME^1RJNOK]AM"6RRJ%[OB]GD-XA:MCHA^1[
MOB73T(;Q%4EL/QR\KVJQR(YKD5%:Y$<U45..J+P5%\Y)%;=L;TML;>UYS?\
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MYP;_ !SWR[P9:@    P\[?OU0-[/S'8_GACAK?X93Z;Y]O?^Q5%*SL@
M9^=V7];_  +\QYW\S[P;X_$K:OY$]\>U:!+#D   !6U[U_ZT-!]%F)_I?*2#
M)XO0ZNB^3_5+681K8     %H'NR_J@8%^?,[^>%X+&/PN1J_GSZ/8S\-U8
M                        # /O-/J@9[^?,$^>%G-,GA6=)\^/3[%7XKNN
M     !LS[J#ZT-?]%F6?I?%B3'XO0J:WY/\ 5"R43N4        <'D_]&LA_
M,=V_$*@,QOCO4GBH[X     'J>QG[;=G?I3V^^=MH,QOCO:9/EW?AGV+E1:<
M(   /+-\_P!B6\7T6;@_-*[F)W3W-\?S+?Q1[5-4JNZ
M     ;O^YJ_^L=_=!_\ 2B38NES]=_!Z?V-WQ*YX   4\NTW]9+M!_3ANQ\_
M+^5KO%/>[F'Y5OX8]CP\U2      71=LOV;;>_J/B?Z!H"U&YP;_ !SWR[P9
M:@                                UX]MCL_63/,=R"YW*S17K$LOM$
MN.;@6E8V\K8:J%M%2W=BM;SQO>BL:LR:/IZB.*1J\RZM]Z_2KS7%L1Y?U5_#
MGLF;L$S_ !1MF['Z-LQ'3$W1T17Y@^N?D:_XG_5_+[)G!?%MNIB(CW;HI&/-
MLZ)V6W3_  W1;.WBFE%OM4=F+,NS#N)5XQ?(I[ABESGK*K!<N2)4I,ALL<K5
MC9-(V..&"^6Z&:-E;3IPCD5',UC>QR_1V#/9GQ\=N_ICJE\UV73/NW>./O[8
M[/9N> XQ?:C&,BLN04K4?-:+C2UR1*JHV=D,K5FIWJBHJ,J(>9CN*<'$T[D>
MIP6ZG!?I[O#?;,?X^C>VV8_<;;DUEMM^M$K:FW72ECJJ>5O(NB.U;)%)HB\L
MU/*UT<C>EKVJB]!7F9B:3^UZRS::_!ENPY(I?;-)<S[G]YZF_P DQQ3]JHN
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M5JHO!3]N[+[,MD9,<Q=CNB)B8FL3$[8F)C9,3&V)A5W/HV
M               #CKO;8+S:;I9ZI$6ENMNK;;4HK6O18*ZFEI9D5CODO18Y
M5X+P4,Q-)JI,3P34L\U-41NBGIY9()XG\'1S1/6.2-R<?E,>U47X"H[Z(
M  .R8;7K:LOQ6Z(L+5MN26.O1U0NE.U:.YTM0BSJCXU2%%C^5\IOR=>*=)F-
M[%T5MF.Q=9+3@   !3R[3?UDNT'].&['S\OY6N\4][N8?E6_ACV/#S5(
M !=%VR_9MM[^H^)_H&@+4;G!O\<]\N\&6H    ,/.W[]4#>S\QV/YX8X:W^&
M4^F^?;W_ +%44K.R     !GYW9?UO\"_,>=_,^\&^/Q*VK^1/?'M6@2PY
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M'5T7R?ZI:S"-;      M ]V7]4# OSYG?SPO!8Q^%R-7\^?1[&?ANK
M                     8!]YI]4#/?SY@GSPLYID\*SI/GQZ?8J_%=UP
M  -F?=0?6AK_ *+,L_2^+$F/Q>A4UOR?ZH62B=R@       #@\G_ *-9#^8[
MM^(5 9C?'>I/%1WP     /4]C/VV[._2GM]\[;09C?'>TR?+N_#/L7*BTX0
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M^Z!2>J3XF/\ FM]<-RO=(8+FV%_^8'^>.'95B?Y2_JI_)W\YL>N]A_*'N?\
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MF;[+:X\D_P#J8ZQ$3,[[[*7;9FZ+]D-"O; [IG!,MJ+E?KGB=3MOE-5(LO\
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MSX]/L5?BNZX     &S/NH/K0U_T699^E\6),?B]"IK?D_P!4+)1.Y0
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M=\KT_..77\>AU6&S+CNZ[;[8NCTTG;'1-8>T<66S/BMS8YKCNMB8[I<Z=!(
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M-^_AR1EMV;K>")B-E?8GE;5SFT,Z:^:WXKMGX9VQ]]8]39$?3KR<
M 5F>]*^MA=_U'PO\3J2#)XG6T?R?3+701K0     %I[NX?J8[-_WA_\ %7.2
MQ9X8<?5?/N]'LAF^;JX         ID[QUC;CN[NI<&,=&RNW'SBL9&Y45T;:
MG)[I,UCE3@KFH_1="K.^7=Q[++8[(><&&X     %VZU42VVUVVWND25:"@HZ
M)94;R)*M+3QP+(C%5RM1ZLUTU734MN!.V:OWA@  4\NTW]9+M!_3ANQ\_+^5
MKO%/>[F'Y5OX8]CP\U2      71=LOV;;>_J/B?Z!H"U&YP;_'/?+O!EJ
M ##SM^_5 WL_,=C^>&.&M_AE/IOGV]_[%44K.R     !GYW9?UO\"_,>=_,^
M\&^/Q*VK^1/?'M6@2PY    5M>]?^M#0?19B?Z7RD@R>+T.KHOD_U2UF$:V
M    !:![LOZH&!?GS._GA>"QC\+D:OY\^CV,_#=6
M       P#[S3ZH&>_GS!/GA9S3)X5G2?/CT^Q5^*[K@     ;,^Z@^M#7_19
MEGZ7Q8DQ^+T*FM^3_5"R43N4        <'D_]&LA_,=V_$*@,QOCO4GBH[X
M    'J>QG[;=G?I3V^^=MH,QOCO:9/EW?AGV+E1:<(   /+-\_V);Q?19N#\
MTKN8G=/<WQ_,M_%'M4U2J[H     'N'9D^LEV?/IPVG^?E@-K?%'>CS?*N_#
M/L7#2RX8                   %/+M-_62[0?TX;L?/R_E:[Q3WNYA^5;^&
M/8\/-4@     %T7;+]FVWOZCXG^@: M1N<&_QSWR[P9:@
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M?R?3+701K0     %I[NX?J8[-_WA_P#%7.2Q9X8<?5?/N]'LAF^;JX
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M+8XFN<C5D>ETQF561HJHKWI'&YVB<>5JKT(I)C\2IK?D^F%DTG<H
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M>P_(_P"?[O\ $_QE?_O<?_MO_P#W+A\7L/R/^?[O\3_&5_\ O<?_ +;_ /\
M<N'Q>P_(_P"?[O\ $_QE?_O<?_MO_P#W+A\7L/R/^?[O\6;_ &->V5_YM_ZQ
M_P#_ %Q_5_\ U?\ \T/_ .[_ .=?Y7_G7_.C_P#Q?&O</</YM?\ X;K>N_S.
M3Y6UMW$KY\'P*;:UKT4W,WS=7   "GEVF_K)=H/Z<-V/GY?RM=XI[W<P_*M_
M#'L>'FJ0     "Z%M;+'/MEMS-#(R:&;!,0EBEB>V2.6.3'[>^.2.1BJU['M
M5%14545%+4;G!O\ '/?+O9EJ
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M,=;!=Z*E1%^74W"PUOO#D5-$BMJJBIQ1TN.=M%'6V5MC)'1L;]B9S0
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M0Z:H@K*>"KI9HZBEJH8JBFJ(7MDAG@G8V6&:*1JJU\<L;D<U4X*BZEIP4P
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M$@G9B=JBJJ;K%9$LCJ6IC?&KN5$56ZZ%JWPQW.'EBF6Z/\T^U[091@
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MR55GN<:=5=K%<.5&\MPL]>R2"3@C7JQ'LU8YKELQ-8K#B7V3COFR[?#TTRT
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MB2LMN76*BHX$1J:<T25V*U+M>*HYZHJZ<J$V*=E',UUM+XNZ)CV?Z6W,E4@
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MUMIU.3J[.'-7HNVMB9NJ@
M                /!MU^S?M5N_')/D5B2W9!R/]WRJP.;:[Y#*Y>9))I8F+
M37)$?QTJ8Y51/WJM5=3S3RUY^\R>5YC%HLWQ>7UVX<OOXYCLB?>L[[)M[:O7
M/G+Z6>3_ #M;.7F6G^#S.D\.HPS\/+$]=TQ'#D_^I;=V3&]K)W8[)>Z>U:5-
MTH(%W%PZ#5[KU8:5T=]MT/W5VQQ))JAT;>*NEIGSQL8W5[D<[0]_^6_J/Y:\
MR<.GR7?D>:S_ +K+=_;NG_T\U(B>RV^+;IG=6E7RAYR^C?G#R?QZO!;_ ,SY
M);M^+AMIELC_ -7!6;H[;L<WVQ$5NF*T8U0I#4,YX7MD:BJU=%5',<G!S)&.
M5'QO:O2UR(J'GEULV3PWQ27JFVZV^*VS6$WNWF]?_*-:QU,GNWF]?_*%8Z@]
MV\WK_P"4*QU![MYO7_RA6.H9=]C3;3^=NZ#<FK:9);/@4$=V>Z1%6-U]J5EB
ML42:ZM62&2*6I3[EU.GE0]8_53GL<K\O?\OPW4U6MF;-F_X<4G)/=,3%O]3W
M9]"O*_\ SSS='-M1;Q:'EUL9)KN^+=6,4=\3%U_9-D-P9\P/MX      !^&Z
M6RW7JVU]GN]%37*U72DJ*"XV^MA944E;15<3H*FEJ8)$='+!/"]6N:J*BHI%
MGP8=5AOTVHMMOP9+9MNMF*Q=;,4F)CIB81YL.+48KL&>V+\-]LQ=;,5B8F*3
M$QTQ,*PW;Y[#5Z[.=_JMP,!HJNZ[)Y!7ZTTC$DJ:K;^YU;YGMQV\.5\U1-9U
MY/\ J-?)HCD5()G=<UCY_C'ZE_3+/Y1UT\RY9;=?Y;S7>[.^<-TS,_#OVS,V
M_P E\[X]V[WHK=\??4WZ=ZGRIJ;N:<LMNO\ +V6[9.^<%T_P7[YFW^2^?PW>
M]$3=K"FEZ?.>L\=CTODO<3-+IKQ\Q>QV=*G?=UN'GE\_C])T,=BEDR.'GEZ?
M#XB]CL4<M]'"5$W3\?CX>"'0Q6.9ER5<+/+TKKZ^CSKYR]CL<_)?5P%37TL?
M-UE3!&B:JO/-&WC_ .DJ%_'BOF/=MF9[E:8ONFD1,^AP-1D-GAXOKHG<?_5)
M),NOD_!,<B%JS2:B[=;/IV)<>ESW37AGT['"U&96R-%ZF.IG7RHQL;/@UD>C
MTU_T5+-G+L\^*;8=#%H<E-M(==JLZJ%1?=J&&)?+-+)/P_T6-@T7XU+=G*[-
M]]TSW13]ZYCT5MN^Z9GU?O=:JLHO51JBUCH6K_FP,CBT3C_GM:LG\8MV:+36
M_P ->_:MV:?%;T5[WX;=;;]DM='06BW7>_W&5?P5%;:2MNM;(JJB?@Z>ECGG
M>JJOB0:W7\MY1IIU?,<V#3:2W??DOMQV1WW73%L>F74T6AU6MS1I]!AR9M1.
MZW';-UT]UML3,^IF#MQW>W:?W&2FJGX73X+9ZER<MTS^XQ616L5K7J]UCIV7
M')]%:Y.57436N=PYN"Z?.WG/]6WT2\GS?@CF5W-.861/]K08YSUFM*?&F<>F
MK6-L?&F8WTVQ7W1Y;^@'U+\P19ENT4:'2W?QZJ^,=(WU^'$79N[^W2>O?3/C
M;_NI=M,=2"Y[P[FW;)U8C)9;1C\%+AUD21&+UU-57*MGNUVN%.CEU:^%;?(N
MB:HG0?*GFK]=GG/G=UVA^G7(\.DK,Q&7/-^KS4KLNMQ8[<6+'=UQ?\>V.W>]
M]<A_2_Y=Y9;;J?-W,LFHI29LQ1;I\=>F)ONF^^^.VWX4LP,,PCLO['0MBVXV
M\L$5PI^1&W*DMKKQ>GR,YG-?+E.12U5RD3F75594/1O!$31$1/1//>9_7OZH
MY)R><N;:J-%?OQY,L8<,1LBD:731;9&R-UV.V9WS.VL^U>5<O^F'DFR+/+V@
MP?F+?X[;/B9)GKG/EF;O5?-.B-E',WG>J_U6K+/14EHC_P"ED_\ >%7PU_>N
MECCI6HOD6)RZ^,SRGZ.\CTT_$YMFRZK)_+']JSU6S-\]_''<WUGGSF.;W-'C
MLPV]<^_=]\1;_LSWO*KI?+S>I%DNMSK*YRKJC9YW.B:O3^#A14BC1/(UJ(>S
MN6<EY1R>R,?+--APVQ_+;$3/?=XI],R\-UVOU^NOXM9ER9*]<S2/1NCT1#A7
M)JGG3P]9V8GIC<H[^]"J:ZHO3Q^(DB:;FM*;D"^3QI^ZA)#68KMA&Y/&G^7I
MZ":V>A'N?'#33RKIJGH35/C-NUB4;F^-4X+T?'[#:):3'2@<SAIZ_L<.'02V
MW;:M9A O!?#BA8B:Q5I,5WOAS=>*=/2J>OTFT3U[D79*%R:IJ;Q-&O8A7@;M
M9CI; ^[4O\=G[153:I7JU,KV_P CL]/'\I6OK**LLV1-<J)P1S*.R3Z*O#15
M3QH?3'Z5>:6Z+ZFW:.^9KK.6Y\41UW6W8\_W6XKMO;VN_P"6,G!S*;/Y\<QZ
M8F)]D2W]'Z0/8(       !BAVWML7[L=F+=/':2G6IO-JLG\\[ R./K*A;KA
MTS+\M/2,T<KJJZ6ZCJ*-J)Q7WE43374UOBMLIM/?P9HGHK3UJF)6=H
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M2U#T;ST\%MJ9NKO;(GO1JS6^2K@17(BO1R\I/%T7;G*R8,F+Q1LZ^ADX;(0
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M;36^[6J2%O'3K;@B:+KPBRQLJO:*^ETV3T[6@\A=(
M#*#L;;1R;U=HS;;$9:5*JQ45YARS+$D8DE,F,8L]EVN%/5HNJI#>)88K>BHB
M_A*MNO#54VMBMU$.>_X>*;NG='I6W2RXH    *]?>\8:ZU;T;=YO'#U=-E^W
M\EHED1$TJ+IB%[JW54BKTK(VVY'1,7R-:TARQMJZ>ANKCFWJGVM2Q$N@
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M8[S;YTTDI+C;*F2DJX57H>ULT2\KDU:]NCD545%*V[8[D3%T<4;I<"89
M              !89[JC8*7"-M[YO7D-!U%_W/ZJWXND\7+4T>!VJ=TBU4:N
M1LD4>47EO6N:J*V2"AI96KH\GQVTBKF:S+Q7_#C='M_P;9"12    !K [US;
M:3+.SU:LZHX.LKMK\OH;A5R(SG>S',H:W'KFUFGRDUO,MLD<O%$9$Y53AJD>
M2*VU7-'?PY>'HF/8K@D#J         #>WW.7]&M^/SY@/XAE)-BZ7.UV^WT_
ML;HB50
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MG.JKS?*QJ.<B5=XND\M0]J*K8^LY&:,:U$LQ%(HXF2^<E\WSOEZ@9:
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MZ8>>&&P       !L7[K7ZV%H_4?-/Q.F),?B5=9\GTPLS$[D@
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M$V*BQ_,'M8BJL5;"C+?6.X-9)'3.T5997)#DM_BAT='F_P!U=Z/W-*!$O@
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M2.26@J'Q,JZ97(G6T5?"C9X)$^3)#(UR*J*BE:8I-'<MNB^V+HW2Z:8;
M    &]ON<OZ-;\?GS ?Q#*2;%TN=KM]OI_8W1$J@
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M8W-,]E'7Q\.KBKZ?EZFL@15ZBH:Y$5T:QO?7NMX9H[.++&6SBC?TL?35*
M             -B/=^]D2I[0&>Q9QF5ND3:# [C!/=>OC5L.99#3]7546)4S
MG(B2T$>K)[FYO-RTRMA^2^H;(R2RWBFL[E74Y_A6\-OS)^[M6:FM:QK6,:UC
M&-1K&-1&M:UJ:-:UJ:(UK431$3H)W)?0      -'W>Q=GBH=-8NT=C5$^2%(
M:'#]QXX(W.ZA8WNBQ7)9].;2.5)/R;4/54:U6T;415>Y2+);_$Z&BR[\4]\?
MM:0R%T        #8OW6OUL+1^H^:?B=,28_$JZSY/IA9F)W)
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MV-T1*H
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M=+++--(Y\]565=1(^:>>1SI9YI'/>Y7.55GB(B*1N<BZZ;[INNVS+MIEJ
M    Z_E>+6#.,:ON'Y3;:>\8[DEKK+/>;;5-YH:N@KH703QZHJ/BD1KN:.1B
MMDBD1'L5'-143MV,VS-LQ=&^%4;M8]F#*NS%N15XY<(ZJY87>9:JOP'+70K[
MO>K.DB+[C5S,C93QY#9FRLBK84Y?E*V5K>JEC5:UULVSV.SAS6YK:QXNF&+9
MJF       ;%^ZU^MA:/U'S3\3IB3'XE76?)],+,Q.Y(
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MMUSB31C*I&-HZW5%C5DBOIXH+K)M[G6P:BW-%)V7]7[F#QHL
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MGU$98X;OF>UKQ-%H      !O;[G+^C6_'Y\P'\0RDFQ=+G:[?;Z?V-T1*H
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MZZTW2WSOI:^VW.DJ*"X453$NDE/5T=5'%44T\:\',>UKD\:$:Y$Q,5C<_"
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M/.K&1R5UQJY72UMTN50V-O6U-3)+/+RIS/71"6(B(I#G77W7W<5TUEWDRU
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MW1$J@
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MN  -B_=:_6PM'ZCYI^)TQ)C\2KK/D^F%F8G<D
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M$-!1Y%'624_4S3(K:=]5&CM=/WZ$N.)BM5'69+,DV\$UI5M4)%,
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M-1%56:IIP5!%ML;8:WYLM\<-\UAD,;(@
M       #K-QPO#KQ)UMVQ/&;I*LDLRR7&PVNMD6:=>::7GJ:65W63.XN=TN7
MI%(9BZZ-TRXY-L]MVJCF[?80BHJ*BIBEA145.**BI0:HJ*8I#/'?USZW;*.@
MH;?$Z&WT5)0PND65T5'3PTT3I7-:QTCHX6,8LBL8U%7371$3Q&6M:[WZP
M
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M)^7Q=%-3KN/5W[*3,YIB+*]OP;,<5['G?*,/P=!9_-=[T^G=]U&6I[S=,
M
M
M
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M=M(B(A[#MMBVV+;=EL11^TL,@
M
M
M
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MQ2^ZW;_N\'%;=$Q_O[9C;#N<BTTW9KM3/AMBD=\_NCVMT!^B;RH
M
M
M
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M+;37.G@J>I?+#[Q##5(U_*YS>9%T54XDD;8JIW1PW3;.^)=B#
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M&AVZW+I:W*LBLF-T=35LQ;W6GJKY<J:V4\]3U.022^[PRU2.?RM<[E1=$5>
MC)$S1B[1Y+;9NK&R&6O:;[3>)]ES$[!EV76#(LAHLAR),;IJ;&TMJU4%4MMK
MKGU\_P"4ZZ@B]WZJ@<WY+G.YG)PTU4VNNBV*R@PX;LUTVVS$4AA1_B_;)?V9
M;I_P,2_WC-?BQVK'Y')UV_>RJ[+W;+P7M55^8V_#\6RS'9<,H[-65[\E;9T9
M5,O4UQ@@;2?DNYU[N>)UM<K^=&IHY-->.FUMT7;D.;!=AI-TQ-68)L@
M
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MKG)8L\,./JOGW>CV0S?-U<
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MT7<Y?TEWX_,> _C^4DN+I4-=NM[Y_8WMDSG
M
M #JF9YI8,#L=1?\ (:QM-2P_(@@:K75=PJE:KHJ*A@5S73U$G*JZ)P:U%<Y4
M:BJGKCZI_57R9]'?*.?SEYWU5N#EV+W<=D4G-J,TQ,VX-/CF8G)ENI,TC9;;
M%V2^;<=MUT6-+I<VKRQAPQ6[IZHCKGL:O]T]VLBW0NO7U[W4-CI9'?DFP0R*
MM+2-TY$J*A=&^^7"5JKS2N3Y.JM8C6\#^?K]0WZE/._Z@O,7YKG%]VC\HZ;)
M,Z/EV.^9Q88W?%RSL^-J;K:\66Z/=B9LQ199,VSYWH>6X=!CI9[V6=]W3/9V
M1]I>1N3T+\/P\=57B?.=T3.V-Z_2FR=R!4T7@G3Y?/K[#$75AK,5V/A4)K9K
M"*:SLZ43DU^$EMNI/8CF$2H6+9]36Z*HG-\?I)HGH1HU);9KWM)BFU$Y-%\W
MB+%MU>]H^535-":)Z6)0JGB7I);9IW,3%43VZ\4Z4Z?.36SZD4QZT"H3VST(
M;HZ4#VZ<4Z%\WQ^/H)[+HKMWM)1*FOAT>LFB6DPB5#>):3&S9N0N;XEU\NOG
M\OF)[9K%81H%;I^XOG);;NIK,50N3TIT?#[%)[9JBF/6@5/3KX>@FMFG<CF/
M6^.C@2]J.8Z7RJ:HOJ,Q-):1]R)4\I-;-6MUO1T(7-);;IZ$5/X;D9-$UW(Y
MBDT1JFAO$MHFKX5-?W#:VZD]@ATTX^/Q^CR$XB>WI7XU_<4WMGH8IU[D/B\.
MCSD\3ZT%]M)[)1.33X":VZJ*8KO1JFO EB:;81S'0A<GB)K9V-+H1.;KQ3I)
M(E&A5"6V>AI='2B<W3CXB:):2B5#>)Z6DQ3N0JFG!2>)K%6LQZD;FZ_";Q*/
M=L0JA(UF/6B<FG$VAB)Z'PJ:DELL3'3"!6Z? 31-4=.E$Y/M&\2CF*=R)?$G
M1IZ/C\YO'6TF/4C<GC1?#5./E\1+;+2G0BT_R^KS$E4=U>G>@<WCY/#HTT3R
MDD2U]J/S>"$D33N1W1TQO=IP3!L@W'S"P85B](ZLO.07"&AIFZ/6&G8Y5=4U
M]8^-KW0T%OIF/GGDT7DB8Y>.FAY-Y4\M<V\Y>8-+Y9Y)CG)S/5Y8LLC;2V)V
MW7WS$3PX\=M;[[J>[;;,]#;%AOSY(QX_%=/J[5DG:K;:P[28'CV!8ZQ/<K)1
M,CJ*Q8TBGNUTE1);G>*IB/DY:BXUCG2*WF<V-%1C?DM:B?LYY#\F<J^G_E31
M^5>41_P^FQQ%U]*79<L[<F:Z*S[V2^MU*S%L3%L>[;#S73X+--AMPV;HCUST
MSZ7H9Y>F             P4[R#.5PGLF9]##+U-?FU9C^#4+N9S>9+O<XJZ[
MQ:-T5_78Y::UFFJ)\K5=416KI?-+5C2V\6:.S:JVE=V "V3V&,Y7<#LI[-W:
M67K:RTXRF&UR.<KY63836U6+0+.YVJNEJ+?:H)E555525%7BI9LFML.+J+>'
M-=';7U[66ALA      K,]Z5];"[_ *CX7^)U)!D\3K:/Y/IEKH(UI:>[N'ZF
M.S?]X?\ Q5SDL6>&''U7S[O1[(9OFZN
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M3LK7V*ST=K?5LIW22N@94NI>=&*]RM1VFJZ:DL;(HH73Q73=UR[89:@
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M7?C\QX#^/Y22XNE0UVZWOG]C>V3.<
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M,Q=;BF)VVY<E+;\L;)MI;CF(FVZODO+-%^7L^+DC^]=]T=7IZ6=1]4NJ
M          TE]\/G7)0[,[9T\VO7U61YU=X%X<GND-+8,=F3BO-UGOMT:NJ)
MIRIIKJND66=T.AH;?%?Z&C8A=  L ]T%G7Y3VNW1V[FFYYL1S.VY+2L?P<RW
MYE:G4:Q0JJHCXHJ_$YGN1$U8Z?BORFDV*=DPYNNMI?%W7'L_TMOA*H@
M5F>]*^MA=_U'PO\ $ZD@R>)UM'\GTRUT$:TM/=W#]3'9O^\/_BKG)8L\,./J
MOGW>CV0S?-U<                                            4G\G
M_I+D/Y\NWX_4%5WXW08Q_27'OSY:?Q^G!.Z5V M.      !69[TKZV%W_4?"
M_P 3J2#)XG6T?R?3+701K2T]W</U,=F_[P_^*N<EBSPPX^J^?=Z/9#-\W5P
M                                  "MKWK_ -:&@^BS$_TOE)!D\7H=
M71?)_JEK,(UM:![LOZH&!?GS._GA>"QC\+D:OY\^CV,_#=6    !A!WCWU,=
MY/[O/^*N#&E_AE8TOS[?3[)582N[#8OW6OUL+1^H^:?B=,28_$JZSY/IA9F)
MW) -2G>_?L2VR^E-GS2R,CR[O2NZ'YD_A_:KVD#IMT7<Y?TEWX_,> _C^4DN
M+I4-=NM[Y_8WMDSG
M                                        .%R+(;5BMEN%_O=2VDMM
MM@=/42NXN<NJ-B@A9JBRU%1*Y&1L3BY[D0\2\]>=_+?TX\IZ[SKYMU%NFY!R
M_#.3)?.V9Z+,>.W??ERWS;CQ61MOONMMC>FP8,NIS6X,,5R732/MU1TM6>YV
MY%WW+R"2Z7!706VF=+#9+2CE=#;J-STZ41>5]94HQKII/\]R(B:-:U$_G/\
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M7VLJX[?0O96L2)L3Z.U5<BJB\R+&WQ*;V73<KZC!;AB*3,S+8D;JH
M                                /XJHB*JJB(B*JJJZ(B)Q555>A$,7
M76VVS==,1;$5F9W1 UM[^[K/SR^OL=HJ%7%+%4R,I5B?K%=[A&CHI;J[E7ED
MA9S.93+JOX-5?P5ZHGX$?K6_4KE^L_G.[RAY7U$S]-.3:BZW%-EU;-;J;*V7
MZR:;+L<5OQZ6:S'PINRQ2<TVQ["Y'RN-%A^-FC_BKXV_Y8_E_?V[.ACNJ*G#
MCT_!X:GP]%U';F*[)?Q?E)Q^%%\$)*]2*G6@<WQ>,TF.';&YK,1.SI1JFOP^
M' Q$M-R!4T7X_P#*9I3N;;X1N1%3X./Q::]!GLZ&LQ1 YJ].GD54X\?.G TB
ML326L[42IK\.GJ);9VHKHI/8C5"6):3%$3DT)[;J[6LQ78C5->'H)[9Z44Q1
M"J$ML^IK,5[T;DUX^/[)/;=39.Y&^"Q$L(G-TZ.@DB?6PC<B+P4FMN]:*Z*/
MSN;HNB_$3VW5VHKK8W(G)K\/Q$ML^I'V/SJG'S^3TK\'K+$3%.QK*-4\9)$M
M-^WI1.3Q^'B]!);,;I1;MK\[FZ+KX:^,GB>AB4+D3T^4GMNE%=%.Y YNFO@B
M?#J36W=**81*FG'TDT35'3HG>_G#S>?[/I,HYBG>B5-/CZ"6V[HEB8K%>E&Y
M"6)171PS6-R%4T)K;JQ3I:71TQN1JGC)(GH8B7PJ:FT33;#9$Y..GB)K9K%6
M$;FHJ:?"O#X/2I)$SO8GKC>@7@NFG'3C\/Q])+;.SL1WVU]Z-Z-R>/R?8)K;
MNB=R"8ZD*H31+28Z43DTX^+[!-;=,[.EILE$J>+RDL2BF*(531=%)(GIAK,=
M$HW-U^$FMGIZ$?9*!4)(:71ZT3F^-"6R[HEI*-4)8:3'2@<FA)$U:S"-R?:-
MHEINE&I)$]3,[81/;XTZ26V4<QT=*)4)*HYMJA<BIT+]GQ?!YC>-K6=NV&?O
M9'[(]1N-4T&XVY%NEI]OZ69)[-9:ILT$V931Z.CG>S\'(W&XY%15D1?^MJU6
M-UCYG'V-^G+].NH\ZY\7G7SMANQ^3L=W%APWQ-MVMNC;$S&R8TT3ONB?[LQ-
MEON\4K^BT/Q;OC98_M=$=?\ @W/Q11011PPQLAAA8R***)C8XHHHVHR...-B
M(UC&-1$1$1$1$/TZQX\>+';BQ6Q;BMB(B(BD1$;(B(C9$1&R(C<[[[-P
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M\KJBY7>[W*HDJJZX5U5(LD]34SR*KGO>Y?@1-$1$1$0K[W9B(MBD;(APQAD
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MCCW:N5K+JY>'JC_%LZ)%0
M&,G:0W)=C=A;A]HJ.2]9'3O]_EC<G/0V-W/%.W5.+)KFY%B;Y(D>O!>53\Z_
M^X#^H._Z>^2K?I7Y7S\'F[G^&[\S?;/O:?ET\5F2-FVV_5S7#;TQBC-,4F;)
M>3>7.6?FL_YO+']G'.SMNWQZ(W]]&OES=?A\.!^&]EU-^YYW,('-U^'PX$DQ
MTPUZ4.NBZ>3U^;B(ZVM]M=O2_CTU37PT3C]DVV4I/2B0*A'28FC281N35/#P
MX&T379+7<@7@O0/#LEFFRJ-R>/R_Y!,5BC7=+\[DTZ/#]U#$5K26)A&J>,EM
MNZ$4QT2C5->"DL33;".81*GB)[;NGH:S%81.;KT=)/$^I$B4EMGH:W1THW)I
MQ0L675V3O:/CI30FB6$2IHNA+$]+68JC<W5//XB:V[IZ$<QT/SJGI)XN]2&Z
MWUH7M\?J\.&I-;/0TWH5\?V/-[-2:V6DQ%43DZ22$<[JPA<WT+X=!-;=_K-/
M8_.Y-/C\/231/K:S'J1.;X="D]MT40W1/2@<FG@O^0FMN1S%42IHOAP]A-$M
M)BL;-XJ:Z^'0(FC3IJA5-.!/;-8[6LQT]$HW-)+90S'#-.B4*IH31-6DQ1&J
M:<3>)9B7PJ:H;Q-)JRB5/231-6$3FZHNG%4Z=?A^'S&\326)V(?*3VSLHAOM
MIM1.;IQ\I+;<BIT(U3Q$T3THYBB%R:</03VS6&ER)S=?A)(E%.Q"J>E"2V:=
MS68KWHG-\:=)-;/J:3V[T2H;PCF.E"J:? 3VW5[VLPC<FO[AO$M)BG<@5/$I
M)#281N3QF\2UB>A&J&\30F*]Z%R:=!-$U:37TMC_ &6>Q?59*ZV[B[NVZ6BQ
MQ'05U@PRLC='69 UKFS05]]A>J/H[+)HG)3/;UM6Q=7(R%6];]R?I]_2_J>>
MS@\Z_4C#=BY'6W)I]%?%+]3&RZW)GMG;9@G9PX[HXLT;;HMQS;.2_I-#Q3\7
M-%+>B.OMEMR@@@I8(:6EABIJ:FBC@IZ>"-D,$$$+$CBAABC1L<444;4:UK41
M&HFB<#](<.'%I\5N#!;;9@LMBVVVV(BVVV(I%ML12(B(BD1&R(V0[.[9&Y*2
M               !CGVNLY3;KLT;TY2DR4]3#@MWLMMGYN5T5WRMC,5L\L?!
M>:2*YWJ)S4TT56\>!K=-+9E+@MX\MMO;[-JH<5G;;B>Y\PUM=N+N]GTD.O\
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M<:.9M/!!/3M93QME5\G7-2*6RR)BLJ&IU-UEWP\>^-\O9.U#W86UK\ O^6;
M6Z[8IE^,VNIN\.'R7F[Y%9<JI;;325-9;*5]_J[I>J&_U<4:^ZO2J?3OF1(G
M1L23K8\W8XI6W>TPZN_BBW+MMGIZF@(A=)SN,?TEQ[\^6G\?IS+$[I78"TX
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M4=HJJJ:EJV*1$.%ENX\EUW7+V$RT
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MQ;IFACJ(98)F))#/&^&5BZZ/CD:K'L71471S7*A9<1BY_P"2/LG_ -A>#_\
MLM9_KIKP6]2;\QF_FEREB['W9DQF]VC([%LQAEMO=@N=!>;/<8*2I6HM]TME
M5%6V^N@ZRK>Q)Z2KA9(Q51='-11PV]3$Y\LQ2;II+),V1,<NUZB+V7=^T5$5
M/ZK<O714UXMM-0YJ\?&BIJGG-;O#*7!\ZWOA4/*SMLP^P%];_9/\^7SYGY&;
MV>*$&I^1=]NE:Z+#C*AW:\^M#OW]*>8?I>H*UWBGO=O!\FW\,,<S5*N2;!T\
M-)L5LM24[$BIZ;:;;FG@C17*D<,.'V:.)B*Y7.5&,:B<552U;NCN<++\R[\4
M^US^Z#6OVTW$8]K7L?@N6M>QR(YKFNL%P1S7-75'-<BZ*B](G<Q9XX[X4O"J
M[SW#LR?62[/GTX;3_/RP&UOBCO1YOE7?AGV+AI9<-I@[XR1Z8OL3$CWI&^_Y
MU(^-'*C'/CMV,MC>YFO*Y\;97(U5XHCETZ5(LO0OZ'?=W0T0D+HM[/<Y,:F.
M;\O1K4>Z][?L<]$3F<UE#EBL:KM-5:Q9'*B>+5?*38NESM=OM]/[&Z0E4&">
M^_=[;*]H3<6X[G9CD6YEHR"Z4%JM]938K>L7HK2]EGHHZ"EG;3WC#;Y5MJ'4
ML+&O7K^1>5%1J<==)LBZ:RL8]3DQ6\%L13M_TO'/\(GLV_\ SMOA_M)@?_YM
M3'PK>U)^=R]5OW_O; =F]JK#LCMKC&UN+W&^W6PXG#<:>VUV2U%NJ[U+#<;Q
M<;R]E946JUV:@D2FFN3HHN2FC5(6,1W,]'/=O$4BBMDOG)?-\TK*J_VOY'R=
MJ/?MTCWR.3='+8T<]RN5&172:*)B*Y55&1QL1K4Z$:B(G!"O=XI=C!\FWNAC
M@:I5RC8EC8]D-FV,:UC&;5;>,8QB(UK&MQ&T(UK6HB(UK431$3H+4;H[G"R?
M,N_%/M<QNK!%4[7[D4T\;98*C LP@FB=^]DBEQZXQR1NTT7E>QRHHG<Q9XX[
MX4ORJ[SW/LP2RP]I3L^OBDDB>N]FUD2NC>YCEBGSBQPS1JYJHJQS0R.8Y.AS
M7*B\%4VM\4=Z/-\J[\,^Q<*++AJHO;]^M_O9^?+'\S\<*]_BEV=-\BW[=+#P
MT3K=G8]@BI^RWL+'#&V-CML<6G5K>A9:FW1U,\G^E+/*YR^=2S;X8<3/\Z[O
M9(FR)29R""&EOU[IJ>-L4%/=[E!!$W]['##631QQMUU7E8QJ(GP%1WXW)L8_
MI+CWY\M/X_3F2=TKL!:<      "LSWI7UL+O^H^%_B=209/$ZVC^3Z9:Z"-:
M6GN[A^ICLW_>'_Q5SDL6>&''U7S[O1[(>I]KSZKV_?T69A^B*@S=X9[FF#YU
MOXH5#BL[;,/L!?6_V3_/E\^9^1F]GBA!J?D7?;I6NBPXS4GWOR)_4GMD[1-4
MW2:B+IQ1%Q+(E5$7I1%5J>@CR[EW0_,GN_:KW$#IMT7<Y?TEWX_,> _C^4DN
M+I4-=NM[Y_8W$;Y_L2WB^BS<'YI7<EG=/<HX_F6_BCVJ:I5=UD-V2J>"J[3N
MP<51$R:)-V,(FY'IJWK*:_4=3 ]4\:QSQ-<GG0VM\4=Z+/\ )N_#*WN67$:X
M^].@BE[*5PDDC:]]-GN&SP.7IBE=-7TRR-^^6"H>WX'*:9/"M:/YWHE6>*[K
M-I_=$_62S;Z#\D^?FVI)B\7H4];\J/Q?LE8N)W+5#NUY]:'?OZ4\P_2]05KO
M%/>[>#Y-OX88YFJ5<JV,_8EL[]%FWWS2M!:C='<X63YEWXI]K'7O&Y'Q]C+>
M5T;WQN5FW\:N8Y6JK)=TL(BE8JM5%5DD;U:Y.A6JJ+P4UO\ #*72_/M]/LE5
M?*[L-BO=;-:[M8V97-:Y683FCF*J(JL<M! Q7-5>+7*QZIJGB54\9)C\2KK/
MD^F%F@G<EBYVENR1MKVJ(<-BW"NV9VAV#R7Z2SSX=<K);YI4R-MG;<8J[\M8
M[D,4T>MCIU9R-B<U47551=$UNMB[>FQ9[\->&FWK8I_X1/9M_P#G;?#_ &DP
M/_\ -J:_"M[4WYW+U6_?^]EOV;.RO@'9;M64V? +[FUYHLMN%NN=>W,KC8K@
MZEJK;35%+&ZWK9,<QYL3:B*H_"]8DJKU;.56Z+KM;;%NY!ES79IB;HC9U.>S
MCLO[ ;E9+79AGFUF,Y1DURCHXJV\76*KEJYXJ"D@H*.-5;5LC9'3TE.QC4:U
M$X:]*JJYFVV=LL6YLMD<-LS$.I?^2/LG_P!A>#_^RUG^NF."WJ;?F,W\TLB\
M:QJPX=8+1BV+VNDLF/6&A@MMGM-"Q8Z2@H:9O)#30,5SG(QC?*JJO2JZFVY%
M,S=-9WRYP,*A':UIX:;M/;^QP,2-CMV<YJ'-17+K-5W^MJZA_P I5766HF<Y
M?$BKPT0K7>*>]V\/R;?PPQY-4JY=LC-+4;,;13SR/EFGVPP&::61RN?)++BE
MI?)(]R\7/>]RJJ^-5+4;H<+)\R[OGVM G>O_ %H:#Z+,3_2^4D.3Q>ATM%\G
M^J6LPC6UH'NR_J@8%^?,[^>%X+&/PN1J_GSZ/8S\-U8    &$'>/?4QWD_N\
M_P"*N#&E_AE8TOS[?3[)582N[#8OW6OUL+1^H^:?B=,28_$JZSY/IA9F)W)
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M45$T-K8K=$(\UW!BNN[%P LN&
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M>;!6X9LM%1WNU7"T5<E+CN<LJ8Z:Y4DU%.^G?+N--$R=D4RJQ7,>U'::M5.
M^)=V$:+%$UK=]W[FL4C6WN'9D^LEV?/IPVG^?E@-K?%'>CS?*N_#/L7#2RX:
MJ+V_?K?[V?GRQ_,_'"O?XI=G3?(M^W2P\-$ZWCV0_JO;"?19A_Z(IRS;X8[G
M$S_.N_%+(PV1*3^3_P!)<A_/EV_'Z@JN_&Z#&/Z2X]^?+3^/TX)W2NP%IP
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MZ^[W_,:QMLH7<RHJ-ZRQ4%T;IP5=?(BDF.-M5/6W4QQ;US[/M"Q.3N6
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M#AT^*W!I[+<>"RV+;;;8BVVV(V1$1%(B(C9$1LA;2D@
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MS_BK@QK?X92Z7Y]OI]DJL)7=AL7[K7ZV%H_4?-/Q.F),?B5=9\GTPLS$[D@
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M$1#Z;PX,.FQ6Z?3V6X\%D4MMMB+;;8C=$1%(B(ZH;I24
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MQK%8Z*H?QX?)XZ)Q-K8K,0CRW<&.Z[JA<3++A@
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M'75=-$33723''O54];=3%%O7*QN3N6
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MK&R(U6*^-R(NK51)L<4MV];FZRZ+LL3;,3'#^V7J/>/?4QWD_N\_XJX,9O\
M#+32_/M]/LE5A*[L,RNPOM+B&^&]E7MKF]+)46/(-OLR9[Q3.;%<+3<:>EI9
M[;>;7.]DC(;C;*MC98U<UT;]%9(U\;GL=O9$3-)0:B^['CX[=\3#\G:%[$N^
M'9^NUP=<,:N.88+%-(ZV[@8M;ZFX6>:B556%][I:9*FKQBM1BHV2.K1L76:I
M#-,U$>JZR;>XQ:C'EC9-+NK[;V(!HG9E]G/L/[U;_P!^MJ_S;N^$;?/ECFN^
M?9-:ZNW4"6]KTZYN.4M9'3U&27*5B.;$VG1:=LG_ #TL3>)O;9-W<@RZC'BC
M?6[J6@-O<#QK:_"<9V^P^B6WXUB=IIK1:J=[TEG6&!%=+55<R-9[Q7UU2]\]
M1+HBRSR/>J(JD\12*0Y%UTWW3==OEW(RU -(7?&PV!&[#U&FF42.SZ%',T^7
M8(4Q5[DJO'^#N,Z=1T?OYNGQ19>AT-#7WNK9^UH_(706(.Z0P#\@['YKG]1#
MU59N#G"T5-)R_P#V18,+H4HJ&3G5$5>2^W>Z,Y>*)RZZZJJ)/CC95S-;=7)%
MO5'M;7212                                       !K.W>G]XW*S"
M3@J)>)(->C3W6*&ETU37_H3^9O\ 5YKXYC^I;SCGB?#S:[%_]C'CP_=\-[CY
M!9P<FT\?Y*^N9G]KS14T\B_&BGSEO=:8?"H9C?MWHYBF[<A<FG'Q?8_RD\7<
M<4GQ0CI3N1*AB>N-[68]2%S=%U3H)K+INC;O13%$8F.K>P^50VMNGHWM)BG<
MB5-%T-[HK'%&\C;LG<C5OB,VS7;".ZWAGL0.;XE)?%#5 J*BF?:Q,5BG0_BI
MKTJG'H\7'[7QF\2AF*31 Y-%_=]1I?%)K#28J^%3Q&(GI:4I-$#F^;H]'^0S
MNC9N;1*)R:IXM4\/$(W=C68VH%1.GP\IKX9IT->A&J>GB26S24<Q3:C5":)1
MS'3T(7)IQ\7V":VZO>T[$:IKP)[9Z>EI,40JFG EB:;6DQ5\.37X2>RZG<CF
M$98B6$;FZ<4^,DB>AA$J)T>4FMGUH[HIW('-T^!>A2>V[J176]:)R:IIZ"6)
MZ81;MDOSN3377I\OB^#XRQ;.WL:S"-R>/S$D2CI6.U$Y$Z?-]K7X5);9G=T-
M)CI?F<W3C\:]'AQ)[9Z&LI*2AK+C50T5OI*FNK*F1(J>CHX):JJGD=^]CA@A
M8^:5Z^)&HJG1Y=H=?S35X^7\MPY=1K\MT6V8\5EV3)?=.ZVRRR)NNF>B(B91
M74CWIW,D,*[(V[N6K%47&V4^&6V1K7^\Y'+U-:K'(KM&6:FZ^Y1RIKQ;.R#1
M>&O3I]8_3[]%OUL\Z39J>:Z3'R+E5\1/Q-==PY:3%=FELXL]MT=-N:W#MZ=D
MJE^?';LC;/9^]EYA/8IVSL*4]5EE7=<TKX]'2P33.L]D5_(G!M%;WMN$B,DX
M_+JW-<B(BLTU1?MWR#^@_P"E?EV,>K\Y9]9SWF-NVZRZZ=-I*TZ,6&8S3$3M
M]_43;=2(NLI6)JW9[YV6[(966#&,<Q6C_)^,V&SX_1*Y'NI;/;J2W0R2(U&]
M;*RDBB2:56IQ>[5R^-3["\N>4_*_E#1?\N\J\NT7+=!,UG'IL./#;=-*<5T8
M[;>*ZF^ZZMT],H9F9VRYT\@8
M         #C76:T/J_R@^U6UU>CVRI6NH:5U6DK$1&2>\K$LW.Q&HB+S:IH&
M:SNZ')!@            #\]524M="ZGK::GK*=ZM5\%5#'40N5CD<U712M>Q
MRM<B*FJ<% _E+1T=#"E/0TM-1P(YSD@I8(J>%'.XN<D<+6,1SEZ5TX@WOT@
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M;1:9ZMM?-:[=-7,?%(RMEHJ:2K8^'E6%[:A\2S-?$K4Y51=6Z)H&:RY$,
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MXN6:Y<LQ79.2^^8C9$T4[K[[YK=,R[8>:-0
M
M                                   !Y9OG^Q+>+Z+-P?FE=S$[I[F^
M/YEOXH]JFJ57=9&=D/ZT.PGTIX?^EZ<VM\4=Z+/\F[\,K>)9<0
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M3CMW>[LASLNHS9O'=-.KH>GGN5
M
M                               !Y9OG^Q+>+Z+-P?FE=S$[I[F^/YEO
MXH]JFJ57=9&=D/ZT.PGTIX?^EZ<VM\4=Z+/\F[\,K>)9<0
M                                                       !A!WC
MWU,=Y/[O/^*N#&E_AE8TOS[?3[)582N[#8OW6OUL+1^H^:?B=,28_$JZSY/I
MA9F)W)   #71WI7U3[O^O&%_CE2:9/"M:/YWHE69*[K &[;NH^S?7LN%U[2&
M56YU/1,HZ[&=LF5,:MEJYZI74N3Y13M>UKF4T%,UUMIY&JJ2K-5HJ)R-5TV.
MW^*7/UN6*?"MW]/[&\<E<\
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M(B(B(W*$S,S6=Z4F8
M
M                        .@[KV2YY+M;N3CEDIO?;S?\  <QLEHH^NIZ;
MWNYW7';C0T%-[Q5RP4L'7U4[&<\KV1MUU<Y$15,3N;63$7Q,[HF%9_\ PX>V
M=_8W_P#;#VJ_WY(."[J=;\U@_F^Z?W/:>SEV#NU=@>_.T6:97M5^2L:Q?/L;
MO=]N7\^=MZ[W&V4%QAGJZGW.VYA65]3U43%7DABDD=T-:JF;;+HF)F$>74X;
ML=UMMVV8ZI_<L:D[E@
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M7+EF.O)?=+BY<^;//%FNFZ>UV@\Y1
M
M
M
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MD[
M
M
M
M                         >=;LV;\N;>Y/2(Q'RT]N?=($551>MM3FU^C
M=.E[XZ=S43H57'S?^KKR7_UW^G3S3RC';%^KT_+KM;BBLQ/'H9C5TMIONNLQ
M7V6QNF;J32)J[/E_4_E><8,D^&;^&>Z[W?VU:VE3@J>7["G\SDQ,;8W/<W8A
M5-/W/$;1NJQ+X$Q6*QO:;MD[G\5/61[9V[I9F$2IY=53[/#]PWB[9LWL4]2-
M4T73P\RF>V-S28VTE\*GB4WBZE)A%,=$H7-TX?N$TTN]ZW>TI_#*)4UX+XS2
M)I-8:S'1*!45%T4L1,71L1S%-[Y4Q.R:PQOV/E4U3[!)9=3NE',40JGB7I%T
M4FL;F?%%)WHG)KPZ%-[;J;>M%,="!S=26>N&$.G'P\GL,Q.UI=%8[7\5NJ+Y
MDX=''[!MLGN137TONDH*RXU,5'04E36U<SN2&EI(9:BHE=]S'#$U\CU^!"YR
MOD_->><PQ\JY)IL^LYEFNX<>+#CNRY+YZK;+(NNF>Z$=]UEMG'?,6VQTS-(9
M,8-V6,NO_55N75,>)6YR,>E)RQUU\G8O*[E6FCE;2V_G8J\99'2L=P="?H)]
M'O\ MV?4SSA;CYK]3-19Y;Y'=%MT8:6ZC7Y+9I-)QVWQBTU;9F*Y<EV6R[9?
MIM[Q_5\_T^&9MTT?$OZ]UO[Y]&SM9C83L_@& L8^Q6.&2X-1O/>;FJ7"ZR/:
MC?EMJ)F]72*Y6HJMIV0LUXZ'ZD?2?],GT:^C6*S)Y0Y1BOYU;$<6MU7_ !.K
MNF*>]&2^.'#6D3-NGLPV5V\-9EXSJN9:S63_ 'K_ '.J-D?X^FKTX]^J(
M
M
M
M
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M_%ENB9F9BR+HQ65F,=EENQXIJM;JM9=Q:B^9CJW1'=&[]KNA[75
M
M
M
M
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M8[:R\+U>OU>NNXM3?,QT1NB.Z-WIWNZGMM3
M
M
M
M
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M3/IV=40]6/IMR0
M
M
M
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M+;,>.RV*6V666Q%MEML1$6VVQ$1$4B*/#;KKK[INOF9NF:S,[9E*6F
M
M
M
M
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M&GT\3_#;,Y,F_+DOI;%OJ[FW.M5S3)2[W=-$[+(W=\]<_='1#U(^H'&
M
M
M
M
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M'CMLLB+8]2:_F&IYEJ)U&INK=T1T6QU1'5]\[YVNTGM%2
M
M
M
M
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MVV*S&/';9BM]RRUZ=YCS#4<SU5VJU$^].Z.BV.B(^VV:STNU'M11
M
M
M
M
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M
M
M
M
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MHM!^5Q33/GK';%L>*?36+?3/4SO/WX>J
M
M
M
M
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M9VX=/&#!.W;=CFZD<4Q'ICS%K_\ F'-<F2V:XK)X+>ZW?/IFL^EZ8?4;A@
M
M
M
M
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MB(A_4%99;9;%ED1%D12(C9$1&Z(CHB'HW?ME_38
M
M
M
M
M                          >9;L84W-<5J8*>-%O%KY[C:'(UO/)/'&O7
MT/,NBHROA3ETU1.M1CEU1NA\J?K"^A./ZZ_2'5<NY=CB[SKRGBUO+KHB.*_+
M99/Q=+6=O!J\?N4XK;?CVZ?)?6,5)[WEWFL\JYC;??/_  V3W;^Z=UW],[>Z
ML=+Q'LX6![[OD&03QN:EOI([/ DC=%]YK)FU%5HB_*9+3Q4C&KYIM/*?!O\
MVP/IWJ,GG'S+]1>88[K+.7:2SEN*+[?]_J,D9M12NVV_#9IL=EVZ>'43'7#R
MOSSK(C38-'9->.Z;Y[HBD>B9NGU,NS]G7K8
M
M
M
M
M                        </:+#:[$MS6UTS:5+M<YKO6,8J\CJZIB@BGD
M8U?^;9)[NCN5/DHY55--=#POR=]/O*?D&[FL^5-+;I+.<<UR\QU-MM>&[59L
M>+'EOMB?!;?\&V_@CW8ONOFV(BZD6=3K-1J_A_F+N+X>.++?PQ,S$??OZJ.8
M/-%8
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
7                            _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>t1502228_pwc-footer.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 t1502228_pwc-footer.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ EP?0 P$1  (1 0,1 ?_$ +D  0 ! P4! 0
M       )!P@* 0,$!08""P$! 0$! 0$! 0$           $" P0'!08($
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M^/+_ .J:7_S'_P!1\&1_4^"_Q4'EN\WXX9];:&7B^M+/G2G"G_C^^_\ 6O\
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M(F014^0RC<1.<4C@*0<_0NX]+[_[3LO5]?C9$,V 'N$CRVV5C)!$YUHY8;G
MM::DM-26D6KKV-T;ONM_4-7[=L\O&GAV)8UT<8=="^2)TS6W'XR"QK@YPM <
M* .!#EP:COKCVX;4RFK3&H6U&99.9F*:VU4C4T6\G:]%NYF6:JQ91"191B;)
MBJ"3P?D^14H>R9$1^;G#5=UZ':]F3=:Q8N2W,B?+&)S2QTL+7.D;8/DU@#'V
MR$D.I^T-(<O1N.A/8M-U1!VM-EXCL&:.&5T K>R'(<UD3KS\7/)>RZ, %MW[
MG.!:MJV;^8XJ.TT%JZ]JMI<2\O+P%9<VUN#<8V/M%I,S) 1X1GJ+QY'KGD$
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MI>+3 U>QU%.A2(M95G-&:/S.&*K5P_9OFB\890IUE&;<15;B4#)J?Q(94O\
M,>'5W:^J[0P<S+P,:?%?A2-:]LA:X%KPXL<US?N0TW-(^)I0N'*]';O36XZB
MV&%A;'+Q\R/.B<YCHPYM',+0]KFO^P+VVN!-PK4-(HNKUHW?HFS%]R!CROU2
MSUR9HWY1V5S+&8N8^8AXF5CH1P]*JU4*M'O#OY)/T;'(?REY-\GL D#AUKV_
MI^S-CLM=K<7(QWZ]S>9"TB2-[I&M<+35CJQFYAK0$4<>:>CM;I'>=4:S5;/:
MY>-DQ[-KQ;$'@Q21MC>]I+A1[:2 ->*5(-6-XKUF&]\J!F;/5FP1#U"UQ<C"
M&DB1UC>E06CI8\2W</'?W+5 @+PA/MFI_C,L<P'4]2!]3!S'J?<>E]M]]V/H
M>)BY,67@>6DKK2R3P2-BFX'+*/</'4NO;5QL/Q/3W/HW?>E]<ZOL7-S,67#V
M/AK"RX/B_(B=-!1QXDK&T^2@;XWT:+Q\A]Q.^6.I?:%_K$C5;4C+,7[V"_MB
MR: QBUCCGJS!W'A&(@J^2CQ<)@"3TQ@(<!]C$(7P8R'N/2R]I2=6_BY SV"T
M3_$QF3P#(+;?W!OC/#Z_O%MH!N2?HW?0]01=O?EXIUTAN./\A((OR'8P?>?B
M7^4<Q@?L-UQ(M7+R!O-0<=[,UG6F8J5L5EY\D<"UL0(T/$L7$RT!W%?%&I'7
ME9!DH4JB:RI2D424)_%)0@@?F=[W-H]#V/B=<Y&-D/R\GQ-,S:61R35\;;3\
MGBEI>]O#0X4N(<&Z]=Z*]A]CZMS.T,;*Q8\+%\SFP.KY)(\>GE?>/BPUN#&.
MY>6&MH<PNW-A]X*)KIE/'.+;#4K387]].A\LE!_9IHPR3QX2.9 1"1.V"7=.
M'BR8"1-5-,A#")E/8OH-]][DT?H'L^N]9V.-DRR9UA=(REL+'R>)KJ'Y2$.!
M+FMY#1\;G$-4ZXZ+]@[)]2VGMFKRL6&+7WM;%)==/)'%Y7-N'QB!:0UKGU!>
M?E:T%Z[+:G<VEZJ*T1"RU>P6=>[R16Y4H91HS&*C05!->16%_P"H.5B !O1N
M'H8YB^#'( ^>=NT^W=1U7%A2;/&R,DYCW\1EHL9&&E[C=]7?-MK.+N:N;05X
M=/\ 2>[[AESX]3EXV(,%D?,H>Z^24N$; &CXM-CKG\V\48ZIIIL9N?2-><74
M+*+^KV6TL,C(Q[VOQ;'[6+=IQSZ/CI,R\FL\,JDR<HM95'_1\&$Q_8OL'KY'
MW=E]G:[K7UZ#?YF--E#)G9%&QA:WES72$O<ZMH#&N^C7$NHW@$N'YW5'4NT[
M5]FR/7,'*@Q#BX[Y9)'AS^&O;& QK:7$O>WZN: VKN2 T\C*>Y5$QAKI7=BU
MZ[9)F$MJC!E7Z\W(U9R2LJ_:2[PK62=.%#H1S1)."<@9<"K>1 GJ0?</%]E[
M/U/KO7<?8W@GFUL\./)'%\62'\DL$8>27-92\7$74H:5X3U7J3=>S=GR]7?D
M8\&TQY\F*6;Y/B'XH>9"P -<^MAL!MK45MY79I;;4E?5YUM*E 6,U89UT)Q6
MM"FV+.@N*Z#8L;\PJ_C_ "*[D@"N!Q2 HB/U$/7F1VEIW=9GLX09']8,?R>'
MX^2[R>&RM;:>3B^M+?E2OQ6G=0[MO; ZE.1C?VIR?'Y_EXK3%YKZ4NKXN;*5
MO^-:?);6']NJ7EO7J7V&;UVRP$'7VDZM+P+QN#Z1*Y@/D(X;1KQHF#*33<K$
M J:A1(! , K%2#SXGJ7:>H]J]#R/?68^1!@XK9C+$0'/K V]PC(HUX+:6GX\
M\.MH5?=.H-WZ=V+C=<R9.+D;#,? (96DM93(?8PR U=&0ZMP^1H 6W5"ZS6;
M<NE;*8TO.2XVK66HL,>.)%.Q,I+[65.*#&.7F04C%XT04?N#1*15%$?A()%%
M 3(*OU-SGUGVKJNRM'E;G$QYL0X<Q9)&\A_%@>U[7- #@YM1;0.:YI!%I:YW
M3MCI[<=4^PX>BS,J#,&= )(I(P6"MYC<Q['$EI:ZA#JEKFN!!#@]K>!JMNU1
MMJIJ[U^NU:Q5>4IBBJQDY@[=VA)11'B3$C]-PU(0K-<ZZY/^74 3@'D0$0*/
M/-U=V_INTI-A#K,;(QI<!\=1):;XY3((G@M_:XF)]T9K;\:/=4T]?;O26]Z@
MCULVVRL;*BV+)*&*X62PB,RL(=^Y@$S+)!2_Y58V@KUVO&^..-C,IW+%U:K%
MJ@WE:(HYBI6:11%"P,D -]RJJV:@H>"<)&2-X27.;W+Z^#>XB0O/T?N/2>\^
MW[+U#"QLB'+U_D(>^A;*V&40R&@YC(>YMK227-)-000NG8'1F_Z^])U7N^?E
M8L^'LO$#''<'PNFA,\0J>) 8VNN<T -< *$$.6Y1=Z\?7S9NV:SQU5M3.8JS
MRPQ']J=@S/%R$W4Y1:'G696#11P\:,ROD1!LY.82K$ 3*%1_B!M:WN'3;+L[
M)ZR9BY#<['#@)B6F-SV1B1[;1\FM#2;7$FXBA J%G:](;W5=38O;,F7BOU^2
M6DP"X2,CDD,3'7'XN<7 7, %K34.=0@<VP;MT:N[70NJ;JIV=:?F$&9 MJ!F
M(P[:4D(<\ZS9FCSJ%D5F9F*0E.Y+]2K"4 3,F(J%QG]R:77]G1=92XN2<V6Q
MOG%OC$DD?D8VVMQ;:0"_[.-+2T7+>NZ,WVRZEF[9BS,5N!#Y'?CF_P CHXI/
M$]U]+ ^X$M9S5HK>'&U<3.&\] P7G"CX2GZI:)A];T62KN?B19 TA#2BQD(U
M,&3LZ*TJ*A_4RHIJ$!(IOI[G 2!OV[N'3>H>\ZST;+Q<B7+V+X6^5EH9&<B;
MP15#B"_Y\OI2UM"+S5HSZ3T?O?=^O=MV%A9>+#AZMD[O$\/+Y1C0?D34<T$,
M-G$8(-[J@V"CCO[1;O4C5RWX_IUBJ5DLS^\?$Y57AE&K="&BW$@K%HN_^9 P
MR;HSINIY;D^,P$* ^PB8 Y.SNXM-U?EX&)L\7)R79I<28K1XXV%H<ZCOWOJX
M6QBV[FKV\5O4O1V][<PMCFZG+Q<5N UH EN/DE>'.8RK?];*--TANMJ*,=S3
ME;3[JT?5JJX]LL[5K-:SY).X6@XZ)^T8"A%QR4(YE7<@\>F,DW>-V\^W%%MZ
MB*Y_<!.F!!/SW=H]I:WJ_5XNRS\:;*=ES^-C&%K:4;<YSG.J!0?1M/D?N "5
M^?U#U!M>W=OEZO79<&&W#Q_*]\@<^I<ZQC6M;0FKOW.K\1S0D@+M<Z[@4O"&
M!JYGES6K)9X:VNH5A!0S$B$8[%U-L'TBA^6=2'@D:W21CE"F,5-94R@E]4Q)
M[G)?<^U--Z=Z/C>\R03Y&'F"#PQ@!CW&=GD;>341TC#BZM346@$K/H?3^\]X
M[!RNOH\C'QL[!.1YY22]C1CR>)Y8&T,E9"UK:4%#<2 %O6#;VB0>KJ&TI8*R
M/:R\@XB59UD&Y&\Z=Y,.&S5&+<+F^2-;_;JN/*KGY#MQ(0?C,H82$-<SM/38
MG6C>S1!D/UKX&/;#0"2Y[Q%823: 'GE]2VT7-NJ 9@=/[W-[7=U,<C&9M69#
MXW35)B#&1F4O  N),8!#*!UQ#76T<X?="VYI%[UED-G4("QQE9B(>:?R5?<I
MM5I8'T"X.P>QS!P14C-ZD>23%))<12 0_D<A/\<WH>T--O>NY.QF0Y$>OAAF
M?)$0#('0%P<QIJ&/N+:L=4 APNM<'-;S]CZCWGKO9\?5TD^-+LIYX(XI@7")
MS<@-+'N%"]EH=1[2"06FV]I:YW UYW'H^P&&[EF)C7+%6(['Z4VM:8=]]G(N
MTDX.+7FES13ILH@A)"M&H>Q0,5 04'U'_P"NYCKWM'5=@^IY/M>-CS8T&'-+
M'+&\M<X.BB9,2QPH' LD;2H:;JBG%3T[-ZAW'6GN6)Z=EY,&5D9T,4L,C YC
M2V::2!H>UU2PB2)U0"X6T(/-!L:E;E4_;1G<5:Y5+!4WE-D4VCQI,KLWJ3MH
MZ$XLGK9XR]" HJ4@_(B8GE,WT Q@\&'S]6]LZGM*'.DUV-/BR8,K&N$A:ZYD
ME_C<"W[GQNN93X\4<X&J]/;_ $QN>H)\"+:9>-EQ;")[FNB#FEKXK/*PM=]6
MCR,L?7YBM6M(HNFU;WIQ]M3;[Y4JG5;37E:<"#QD^GOLC)3L,Z7<-T'AD6:B
MAXA\!VXB=LH*@%*8OJH8?8I?/UYW%I>Q=YL=%K\;(@FP"2'26D2L#S'=QRQU
MU/@:\']U00/3V=T=ONL/7M7[#L\O%R(-B "R.X.BD,8D#:N%)&VU^8MY%+:$
M$[^*-WZ)EG8[(NN,54[/&35"&P%3LSX61XF;4JLLUAIL@,TC_D(S_G'93-14
M*<%DBF%3X3^J9GK/<>E]G[ S^O\ &Q<F/,PC*!*ZVR0P/#)/B#<SY&K":W ?
M*PT:;[9T;OO4NM==V5EY>++@YXA)A;<)(AD,,D1N(M?\120"EKB+;VU<-E/>
M:A*;9FU.+4[2,\)EH]*W%!K^*5GVT(>PN6'XPXDD"QJ,:@J'WGD0,LGX*D*1
MBJCD=RZ3_P!1_P#+_P 7)_-/Q\_'C\HB,UMG[[+!3R?]_P#C9_(M'HO?_P#D
M1[<_+Q?P!1WX_P O)XC,(+[_ -E]YN\?_3_EY/XUMY-WLQYB_92HZVRU7M#Z
M8LRD R=6=D5N$9$2MI^+\"S!DJ .I-NN5RE\ZZ1@*W%3QX.)5/1['W+HO6^P
M\'KW*QLE^7FNA89FTLC?D.LA;:>7@N(O<" P&ORH0'J_17L/M766P[-P\K%C
MPL%D[Q Z[R21XS#).ZX?%A:T.\;2"9"*5:"TG=V2WFQ_K3D_'&+[/5K3.2%\
M0CY)U*PY&Q6-?A929>P#1[\:PF7F'82,>J*K5$"G(@4#@)C&(F9V)W+H^N=]
MK]%L\;)F?F@.<^.E(HR\QAU#S(ZX&K&T-HK4D@&=8]%^P=H^N[+V'4Y6+!'K
MR6-CDK=-*(Q(6U'$;;2 )'5%QH0 "X=AMMNG2-2&&.G=FJMDMJV1GDP$:U@E
M8]H#.)KI(,\V_<+R*I ,[3"QM0;M@*4%Q$_LJD!?)O7VEVQJ>K,?"FV6-/E/
MS97M:V,M;:V,,,CB7'ZB]MK?^7-7-ISX^H.FMSV_E9\&KR\?$9@0L<YTH>ZY
M\I>(V@,' /C?<[_CQ1KJ\=OLKMW3M;L1U?+,I7)ZU,KE*Q$7 P\<9O%NSFE8
MMU,_<2"\B'ABDVCV1_)?C44,L)2>H )CE[]@]I:GT#U;&]IR,>?)@S)(VQ1M
MHQQ\C#*"\N_: QIJ*$W4;0"I'#K/J#<]D^X9?J&-DX^)D8,4KYI'U>T>*1L1
M# S]Y+W"AJ!;5U2:-/WD;;NDX^UBB-GS5ZQ2U<L4)5):#K)2M&,VLO;R-CQ[
M"17,JZ81_P!J5P(N%BF73 $Q^/Y1$@&N^[2U&DZYB[',&1+KYX(9(X?BV0F>
MEK7&I:VVOR<"X<&VZHKGUSJ#=^P=HS=6C(QHMGCSSQRS?)T0&/=>]@HU[[J?
M!I#34BZVA(UC-O*+)ZIK[9)P%E2J+:!D)52MG29C/B^CY]6K*1A3D<&9"FI/
M)>A7'L! 0'Y1*'U)RXO:.FR^LCV>V#(&J$$DGB(;Y;HY70%GUMYE:0'5I;\B
M!]%,SJ'>X?; ZC?D8QW!R(X_,"[PVR0MR _Z7<0O!+*5OJP$_5?.%=O*5F77
MBT;$-:Y9(&"I$?<7MHK[A-M(2R)Z3#&GI5"&6040;3(.(WU%N;_0]U3>A@(8
MH^,^G]I:CV[T3)]\BQ\B#"PV3F:(@.>#CQ^5XC(H)*L(M/QJXVD @K7O'4&[
M]*[$Q>NILG&R,[.?CB"4$LC(R9/$PR @F.CP;Q\J-%P)!"XVIVX5.VOJ%PM,
M#69^H*4B7".F8R7,C)"=LX:*/X]^Q>1J?J[%PU1/\B!4_E14)Z^#E,0Y^?6/
M:NJ[-U67LL+'GQ78<MDC'T?P6ES'-<P?*H!JVES2*<@M)Z]M=.;GJ;<86JS\
MK'S&YT-\;XZL^37!KV.:\_&CB+7DVN!KP0X#I-3-X*'MM+9 AZI5+16'-&,P
M=D-/?9N$IB#E%W;9D_*M''51CGX+,S?(T4,<0*8HIJ*@"GQ^/K'N+2=H96=B
M:S&R<:3"M=_):1)&\N#75;4,=5O+"3P06N=1UON[;Z-W_46)K\S;9>+E19X<
MW^*X&.5@:YS*/ +V4<+9 !R"'-;5MVW@C>7'^><YY+P7!5:TPLSC\+ JTFY0
MC8\=8FE6GV]<FE_MVYA=PAP?O$CMDW &%5$P^XI*@"1L^E=RZ/W;W+8>F86-
MDPY>#Y2V1]+96PR"*0T'RC^3@6AU;FGFUWQ-]\Z+]A]!]%UGO>?E8L^'L/$'
M1LNOA=/$9HQ4_&46-<'EE+7 6WM-XTK6\M LVV$QJ>VJEJ;V&-4EH]M;%BM/
MPSV;@(!U9)AD=D!P?,F"4<R4*@[.)@<+%]0(4IB'/==W)I-CV=-UE'C9+<Z(
MO:)C;XW211F61MO[FM#6D->?W.%* %I+9]&;_5]30=LRY>*[73"-Y@%WD;%-
M*V*-UW[7.+G NC%"QIK<2' :6[>:@T_:FN:L/:I:',[/+0D:I;&QF Q+"<LK
M9-W"LA8&5^]<LE$5TP7<@8GP&/\ 1,Y2F,#:=R:35]F0=:2XV2[.F\;3,+;&
MR3-#XVVUN+2US;G\6DTM(!*:CHS?[CJ?([7AR\5N!!Y7" W^1\4+RR1U]+6N
M#FNM9S<!6YI("^\];QT' .;L:X2L-4L\Q)Y 1AW;B<B18@Q@&=@G'->B%Q:K
MJ ZECF?LEC.$T_C,DB0#$^4Y@(%]V[CTGI'N6N]-S\;)ER<]D;S(RVV)LLKX
M8S0FKS>QQ>!0M: 1<3:IZ#T;O^P/1=I[UKLO%AQ-:^5@BDNOE=#"R>0!P%K!
M9(P,)J'.)!L N7(VQW:I&I<KCF*M=2LUH4OZ\H<5(!2/0+#14,K&(/GA_P B
MLB60>F5EDOA;$,0IRE.)U4_! /KL[N#3=7Y6!B[/%R<EV<7FL1:/&R,L#G?(
MBYU7BU@(K0U<WBN>I>D-YVYB;++U.7BXK=>&"DH>?))('EK?@#8VC#<\@T)%
MK'?*WN=L-OJEJE3*K;YRKSUO_N$TA%1,?$*(1P$2,T/(NGKU[($$K?X620BF
MC\9E551 H@0ON<GK[/[3UG6.IQ=IFXT^6<N:QC8R&4 ;<YSG.^E&THVE7'C@
M D>'J3I_;]L[K+U&!E8^&,*#R2/D!?4EUC6M:P\U=6YU0&@5^1(!^\T;@4C#
MNO58V&<5VR3T'=HVIR-8KR2:$;+. N$:A+1R,JNH9VRBOMV*WLL<#+D]B^$Q
M4]B>VO<.U--ZEZ'C>^/@GR,+,; 88P Q[OR&>1@>341@,!+C\A4 "M0L^D=/
M;SW3L7*ZY9D8V-L,%V0)Y22]C1C2>)YC H9"9"T-'Q-"7.I:5\O=Q*$TU4;;
M8$@+.M4G<1]ZC7/M449_\F6<<5A6,4%0X-B($GFITP=^12.W %R@)3 '-97:
M>EQNLO\ U#P9#M48&/$5 );GS-@##S: )74+ZD6?,5"SA]0;[+[8_P#(_P C
M%;N1D/C,U28;8X79!>.+B3"TD,H'7_ T/*W<8;?47)FMD[LJW@;)%5ZJQUC>
M62N*(H.YIHZJ[4KR08QJWNT92X+-E4S(*D,F4_R>I@(H4Q"WU[M'3[_KN;L5
MD&1'K\:">26*@=(#CM+I&M/#7 @5:^K6T-7V4=;/9NH=YZWV?!U?)D8TNRR\
MG'BAF!+8G#)<UL;GBA>P@NHY@#G5%&7U;=\:Q;=U#9G%]GR7$5N=JB5/DGT=
M.0TJ=!^H7[5@G)).8^0:$2;/4G+8XAZB5-1-0H@8H%$ASXZ[[2U78?K63[)C
M8\^+'B2/;+&^CC\&"2K'-H' M/TH"' @BE"=]G=0;CK/VS%]5R\G'RY<V*-\
M4C Y@^;S'1[75+2'CZ@N!:00:U:WJ-3-U*1MHQR [K=4LM24Q^[8 \;SQV#L
M'\5+%DE(U\W7C554T7@IQ:GSMC>?B,8H)J+![&+YNK>V]3VE%FNUV+D8LF$]
M@<)"UUS)+[' M/!^#KFD?'BCG<D>OM_I7==02X#-IEXV9%GQR%KH@]I8^*SR
M-+7CEO\ (VQX/RYN:PT!X6NN\E!V,RUDC$5?JEH@)J@)34@C)2HL5HV=AX">
MC*U(/"_;J@XBW8RDJD*3=0J@G0$3B<I@,F'+KWN+2]A[_8Z#7XV1!-@5(?):
M6RQA_C+J#ECKJ? U^)K=4$#MV9T=ONLO6]7[+L\O%R(-E1I9'<'12&/RAM2*
M2-MJ+Q3Y"EM""=G&F]- R;LE:=;HVJ6B/F8 TNW969X+,\9+/H%JJ\EFYV29
M@=QJ*;= _P *IQ4!8Q?'@ODHC/7>XM+['V'G]>8V-DQYF$96B9UMDCH'6S"T
M&Y@#JV$W7@5(94 WV?HW?>K]9:[LW*R\63!SVPN,+;O)&S(;?";B+7DMIY&B
MWQDT!> 2-MUO=CYIM4AJPK4[2$RLZ0AC6[PU-%DL3I$'#9@$8B*KXT<J0Y"B
M\$Q0(<_DR8)E%3F9>Y-+%VF>K7XN3^>+6^?XF/R/@;D-;:/E;XW@%_V?Q;;\
MUJ'HO?3=0?\ K[,O%_KC>[\?Y"3Q1Y#\9S[S\;_*PD1_=G(?=\%R<M;RT'$&
MQ%%UYG*G;'TK<B0QU[*P2;J1L0%B=K,88Z<<459272.Z;* X%$I3I 4!3(L(
M^ >T=RZ3U;L#!] RL;)DRLP15F92R-T[W,C%I^3^0"\MX:UPMO<'-:]2Z+]@
M]OZUV'9&'EXL6'@F:D#ZWRMQV-DE=>/A'PXB,/Y<YINL86O=][/;P435VZ8[
MIEGJ=ILKB]J*J+.X#[%(D)'HN6K,RY4Y)1LG+/5%WA/1!-5,OJ!A.J00*4U[
M%[DTG6^ZU^FV>-D3.SODY\=*11WAEU#S(:U-C:&@^M2 9U?T9[!VGH=GO=3E
M8L#-?\6LDN+II;#)94<1MI0![JBXTI0.([C:[<:G:H1E-?V.K6*TK7&638MF
M<.*# 63(H"H\?N7$B4J?S((D-Z-O!5%#^"F$A?)R^GM+MG4]6XF'D['&R,IV
M9*YK6QT;:R,-,CB7?<7MM90%QK4M JO)U#TSN>W\W.Q=7EXV(S!A:YSI+G7/
MD+A&QK6<VDL=<^I#0!1KB0%\YYW+HV#<(TC-SBMV.RQ&1&%>DZO"MP:Q,D=I
M8HME,M1E3NS+IQJR#%^05">JH@<!*'GQY'T]@]H:OT#U'']LR,>?)ARY(F11
MM+6.)EC=*+RZM@$;'$T#C=1M.2X>7K3J/;]D>ZY/IF-DP8L^'%-)-*X.>T-A
MD;";&MI>3(]@%7-%I+JU :=^X[BT6I:Q1>SPUZR2-<G&38\57"$:-9<\HY7?
M,RQ[QPJJ=JT;)O8Y4AG)05 2 4Y2&]@+S6Z[/U&GZU'9G@GDUCX()&Q?%LA.
M1)'$QKN2UM'R"X@NH 2 [@'&AZDW6[[5/4_Y&-%MF9&1$^;Y.B QHI)I'-
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M:6&00B<ML_>&6'XR'ASJ$-L+7EE]';W%ZBA[<.9B.UTM'?CB[R-C,YQPZ_\
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M+:C=2EZK2U&A;'5+#9WEU<I@'X95HU2BX\[E1H+TZKL#%>+%51/_ *!?4P@
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MFD="WR--3&1(QP(!?\:.KS0?.I^Y-.VOC+>]KU5L=4=4Z2,T>,I?XI CMH8
M.V>-'D<G\1E54SE]V_CY2'\@'N7P<WDZL[9U7:>'F9.OQ<C%DPY&!S9*.#FR
M!Q8YKF\$FQUS*5;QR0X%>SN#IC<]/YN%B[/+QLR+.C>YCHP6EKHBT2-<UW(
MO;:^M'<\-+2%U&K^\=$VBN.0:96ZC:ZN^HRB2J2\\#)PE,1RKART^8YHM5TC
M$OT7#,X';J**$$HE%-501,4GGZY[DT?9&ZV&EUN-DP287R:^2A;+'?9=Q_K=
M6AL=4VFM:AP'J[1Z+]@ZLT6MWNURL7(BS_BYD=0Z&6SR6?+_ &-MJ#(V@#A2
ME"TNTQ%O+0<O[#7S7J&J=KCIBF?F1:V-\F@$;-$KKTC"8648&^&2ADBKKI?;
M_,0QU0/_ *A41+X&>K]RZ/VGW_/]!QL;)BR\/RALKZ62F!X9(+1\H^35A=PY
MH-UCBUKK[=T7[!ZAUOKNR,O+Q9L+.\)="RM\0R&&2(W'X2<"V0,Y:YPMO8'/
M;QF.]N/GNU+S5D*I:$IIN[7AT+:8&_XMS86J/S.F QI@(^18$*0X%>>QB'$G
MD">@@84/<FDF[2/5HQL@9_R:)S;XS(R!V0YMO[@WQM-'_=W%M*.,GZ,W\'4
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M.J&T:/I0DN(' JX>3J[J#;]G>TY?K&)E08DF%$]\LCP7CX/$8:QK:%U7GZU
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M<UK6N)):VVI+G5(HTV7DM:Z>N]0;SV#M&3JUN1C1;.":=DDY)=$&P-<YSF@
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M\NNUBEO"7^F)3@4!'^7GDZT[.UO97KLV_P /'FQ?QIG121O(=1S6-DJQS:7
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M^(-S/G(+*UN:"38?BL^Y]'[WTOKC6=CYN7BRX.R?"WPL#[XCD123Q?(BU_\
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MVK6*/K-I:S5;?3T*E:G227XJ2L%5<JL[!'_8$*+UBT0<-U ;.SB9)R5,3?P
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M<R(H *B?R^R9#LSM+2X?6C>S7P9)U;\=DC8K0);GO$36'FT#R&A?6VWY-NJ
M6#U#OL[M9W4S,C%&W9DOC=-<3$&QQF9T@XN)\0J(Z!U_P=;1Q&W0=OJ'>=89
M3:,(*R1-7@H6QR<S756Z+V<1=UERX9/(Y@JB=-E(%=.D !!Q[))>B@&6^'U4
M*3.C[3TNZZYD[($.1%K8(I7R1$!T@="2US6D4:ZX@6NJ&T-7V4<!KV#I_?:'
MM"+JPSXTVTR)H61S EL1;. YKW@@N9:";F4<ZHHR^K2[XUPV_I&Q>&[9F*-K
M]AJT?17L^RM,-()IR;ML: AFUB65BW3 I4I8CB'>)F*0I$U@6]DQ)X]#GGH'
M:FG]]]3RO:\>"?&@PGR-FC< ]P\<8E)86\/!8X$"@<'5:12A=KLGI[>=<>YX
MGIN3D8^5D9\<3H)&$L:?+(Z$![7<QD2-())+2VC@ZMS6\+47<JE[>1=Z>U>K
MV*IO*%*QC22CYT[1R5S'3Y912!D6SYB86XN')85R#AM]3-C$+_-0IRG'CU;V
MSJ.T\?-EUN-D8LN%*QKVR6FK);S&X.;Q4^-US/\ @0.7 @KMV_TSNNG\K AV
MN5C9<.?$]S'Q7-M?%8)6%KN:-\C+'_1X)X:6D+J]9MX*'L[D+)F/:Q5+/7WN
M/OF=MI":^S4:V"&0EOPJK[T:G$\.]!Z8@@U4%03)']@/Y*<I?-UWW%I>Q=YL
M='KL;)@EP:N#I+2)8P_QW<?L==3X&O!K6H('J[.Z.WW5_KVL]@VF7BY$.QHT
MLCN#HI#'Y VKA21MM?F*?(4MH03IB[>*@Y3V5R!K5%56T1T[15[.Q)97WV)H
MF8D*9(A%V-N5J@J9Y'I)N@.+54_N5RF01,"1C$*9ZWW'I/9>PL_KW&QLF/-P
M73-\KK;)'8[_ !RB@-S0'5L<:AX%3:2 ;[3T;O\ U7K/7=F9>7BR8&P; _PM
MN\D;,EGDA-Q%KR6T\C10L<:"\ D:H[PT%;;=74@*K:2V),HM"V\?L?PAYTE6
M&XG8?8 K^2+'A$>" [\>1=>2BD"(?.)G<>D?VB>KAC9/YX^/G^/C\@A\Y;;6
M^VSB_P#[\6V?-).C=_'U$WMTY>+_ %Q-WX_R\HB,_P".'W4LO\G)C^S.;R_^
M-?&4-Y<?XLV4H.MDK5;7)S=X5K+(UDC4VHQD/)7&5/#U]J9BN=-])I'=%*9T
MJA]$$SAZ LH!TR/8NX])ZYV'A=>9.-DR9N9X@96 61OG<6Q-M/R>*T+W-X:#
MQ<0X!ZQT9[![1UEG]FXN7B18&")G"%Y-\C,=H?*ZX?%AI4,:[EY'):"TG;V<
MWIQYJ]?<?4.UUBTS[JZE*^?OX--#X*]!F>A'E?@BX\*3;TSGV$&B E/\9!$3
M@84RGG8?<FBZZWVOT&RQLF>;. <YT8%(HR\QAU#_ +'%P/P;0AHK6I:#>LNB
M_8>S_7-G['JLK%QX->2QK)2:S2M8)',J/];0PMI(ZH+C0"@<6]QMMN;2M1V]
M&-:*O8K4^O,B\09,H,[1J5I&1(L@EY%=V]'X3KMPD$@1;!X,N8P_S(4!,'H[
M2[:T_5D>"[98V1DRYTCPUL=HM9%X_*\N=Q</*RQG%]3\F@$KR]0]+[ON"78M
MU65C8D.NBC+W2AQNDF\GB8&MY#7>*2]_-@ ^+BX!<W8_<*D:[8>J&87]=L5L
MB[Z\@&E7C(XB44X7"?AE[$@K)N)$OB*^.%:JG%,R9U15*"8E+Y,<OH["[4U'
M7_JV+[1D03Y4&;)&R)C*,)\D;I0YY?PP!C3Q0N+B!;2YS?/UGT]N^RO<,OU#
M&R<?$R,"*5\TCZO \4C82UC6<O)D<.:AH:"ZZMK7<S(FV](H.LC+9\(&Q358
MEH6MRL37DDD8Z;67M#QE',V+U1T8S1D#-Z]\.%@,J3XTS'1^;R0#]/8.T-/H
MNNX^QO!/-KIH87QQ !LA,Y:&M<22UMI=\G?(4!MNJ*\O6NH]Y[%V?)U=^1C0
M;2">>.28DOB QPYSW-  <^X-^#2&FI ?91U/J%VVH\QJV;:DL#9&]42KLO.+
MUPZ#8\\#B$?OHIY&(* L6/7^218'*DX^0J0D$#']!]BE8O:.FRNM#V:(,ANK
M;COD,5&^6YDAB+ :VFL@H'UI;\B!RT,SJ+>8G:PZF.1C.V[LED0FJX16R1MF
M#R*7BD;JEE";A:"11QX.#=PZ-F_ 5HSZQKUCK\-27,['VB">D:OI!"0K\+%3
MSQ.)<-E$T95JHPF4/B5$J!A4$Q3$*)?K/3^T=1[=Z)D>^1P3P8.(V<S1FUSP
M<=GD>&$$!]6TM/QJ>" K[QU%N_2NQ,;KJ3(QLC89K\<02MN9&1DR>*,R @F.
MCP;Q\Z#D%U5QM6=R:7M)3+S;X*L6*J!0'GQ3$;+G9OCK,5VKY['O&3MD8J*R
MSAM'*_*B( **@ 'L<# 89U?VAK.T-5D;+ QIL5^-/XWLD+7?47-<US>#5OU%
M 6GCD4)O;G4>VZCW.-JMEE09;,O'\K'QAS?H;7M<UW(H[]I!(<VAX-6CA:K[
MKT7:R9R)#56KV2MJT)= Y%9L6BY)N)<N7+5%^D# R@,'(*(![-CB<WA0!*8W
M@WKX.K^X=+VG)FQZK&R,?\,L(,MI\D<EUKA:3:[XFK#6E11QYI^EV[T?ONH(
MM?+N<K%R?SA("(KAXY([2]AN O;1PM>*5(-6MXKQ\'[Q4#.><\CX-@ZM:8:6
MH)I<B$W+$:F8SAZ])$B)Q,S5H95>&4;OQ-\/S&.1=(GD3)J"5(<>F=R:/W3W
M/8^F8.-DQ9&#Y+97TLE$,@BD-H^4?R(+ [ES?W6.^"U[WT9[#Z%Z)J_>MAE8
MLV-L1%=$RZ^$S1&:,7'XR?$$/+.&O_;Y&?-;=9WFQ]:-J9;5AE5;82=CBOFR
M%M.DU_#.Y:+A5+!(M3QQSIRC2.2CTQ*1T)3"=?Z"D5'_ %QFM[ET6S[,GZTB
MQ\EN=%>T3$"Q\L3+Y&6_N:T-#K9#PXM^@!:XZVO17L6IZGQ^UY<K%=KYO&]T
M )\C(IG^.-]_['.+BVZ,<M#AR7!S1L7#>['-,V>K.LDA6;0O,6)["0HVMNFD
M,6QL%E>IQ\''_CS%^^=M%GBI"KNRB5)N4WM_,"G]-;'N/1ZWLV#K*7&R3G3!
MC?,*6-ED9Y&,M_<YI81=(#1KC2T@.(QK.C?8-IU-/VS#E8K=?"9'" U\CHHG
MF*1]W[6N#P;8R*N:+K@2UI^\_;T4'7W+]$Q'8:I:)I[</M%'LU$_;?:P31\N
M1NV7*R4 SF85$Z@"9)(2&*4!^HCX*-]V[ATOI'N.M].SL;)FR=@&$R,MMB;+
M(Z&,T/,A+VNO MM: 1<3:IZ#T?OO?_1]K[QK\O%AQ=:9&B*2ZZ5T,39I1<.(
MP(WML)NO>2TV 7+L=J-UJ1JK-4*"LM4LMG?7ER E&$4CVZ$7%%<F9K/3J/5B
MB\=D<>/5N4" 8OD14+] 'IV?V[I^KI]=!L\7(R7;%\M/$6"QD)B$CC<1<[^9
MEK10.^57-H*\^I.E-WV[C[3(U.7C8K-8R*OE#SY'SB8QM%@-K?X'WO-2VK:,
M=4T[/:+<.F:P8^IN0)FM6&W-;S+1\?#1\.+6/6(V>1RDPL^?+R0D*W%".2,)
M$0*91182D-\91,H3T=F=J:KK33XFVS<:?*&9,&,9&6MH+;W.<YWTHWZ-H22:
M<"I'FZGZ>W':^\S-+@96/AG!A+Y'R!SZFZQK6M9]:N^KJ@-:*_(T:>;FW;>E
MX7P'"9\=P$_/Q-GCJX_K]>;E0CY1S_9D&CAFC(.5ON&4=]JF\+\QO*H?0?C!
M3Z>>GN/:6H]1]%Q_>I()Y\/+; 88A1KR9V>1H>3<UE&5+C\N105J"N7H_4.Z
M]U[#R>O(LG'Q\W#=D":8W/C QW^-Y8 &N?<^@:#8:&KJ4(7P]V_Q\SU?:;3!
M#612I2$4X?,J^*#09]5\UD9"(5BU3-7+Q@U-^0BUB_*HH!"% !4 AA$@=,KL
M_2XW6@[.=#D'5.QF2B*T"4N>\1-8>;0/(X"^I;9\Q5M*\\3J/>Y?:QZE;/BC
M<-RGQ.FN)A#8XS,]XX#B1$TD1D!]_P#&:.K3@8SW,Q_D?6^P;)$@K%"U^IFD
M&EA@%T2/))M*1Z<8L+1BY1*DA(MEDYIMX<%*0A1,<# 'QFYGUWM#3;_KN7L?
MPSPZS'Q\B66,@.D;^,'&5K.0U_[38?C=Q4--0+[1U'O?6^SX>K?/C3[;*R<:
M*&4%S8W?E%HA<^H<Z/\ >+VT=;S0N%"=[6K<&F;)XRMV1X.L66O%I*CW\W O
MB(/7AT&S1X];*1C]+[:-D%GK=BH'Q@<@HJ  *"4IBF'GUUVEJ>PO6<CV6"";
M$BQ)'LF8_P"=+&"2YCFCY@L(- T.#JMH>">O:'4&ZZS]LQ?5,C(@S)LV*-\,
MC/@'>1YBM>UY_C(D!%2XM+:.J.0W@ZH[HT3;!M>%:Q6['6%Z4_ BC:9(F]_*
M0ZXJ"RE&R\:11)%RJ0@?(S-Y5(8WA,52@8P>;JWMS4=I0YK]=BY&++AO:"V6
MUUS)+K'!S*@.^!N9S::4<X&H]?;W2NZZ@FP&;/+QLR+.C>6NB#FVOCMO:6OH
M2WYM+'\7"MS6$4/'UUW8H^QF4,I8NKU3M$!)8U7>?^LY?[11E.,8^7&#=.BI
M-CBXB%PD2_P16 WLB)1$Q5!%(O#K_N/2]@^Q['US Q<F"?!N<'R6VR,;((R:
M#F-UQ%&&O!Y(((7H[*Z,WW6GJ^L]HV69B9&/L2UI9'==%(^,RM;4_&1MH(+V
MTHX<-((<N!0MZL>7[9B>UG85:U,YV,6D&4;9W!61H>5?PT,_GY5)5H"J;^+;
M)Q\>?X%3@H*RO\1(F'J8VO7NX=-[%V+G==8V+D,S,)LO\SK;'F%S62BT&YH#
MG? FMP!)#> <>S='[WUCJ_7]GY67BR8.<Z+^!MWDC;.USXC<1:XEK?FT4L)
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M^TM/@]:-[,\&0_6/@CD;%0"2Z1XC#":V@!YH7U(M%S;J@'.NZ@WFP[6=U/\
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M38'@UFQXL[(@D 02%+T 0#P'TYJ35ZV77?U$N/ [4F(1^ QL,/C M$?C(LL
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MYY-?I7'U!7MJ=_7I%06O:+,L<C=5:U"J6U*/)_U&*=D.R&9(S)X^B0+ 0/\
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MCF-!>ZI)JXDU)_4ILO8-]N,?'Q-OG9F5BXK+(&3322LA;0"V)KW.$;:- HP
M4 XX"1E!HL+99BZ0U+J43<;"@FVG[9&5R'866<;)"B*3>8G6K-*4DT$A;I^I
M%U3E+\9? ?Q#PQ])I<38R[?$P\6+;9 I+.R*-LT@XXDD#0]XX'#G'Z#]$R=_
MOLW60Z3,S<N;38QK%COFD=#$37F.)SBQAY/+6@\G]2G]!H@6X+^%*J7]\!B,
M8%V_KD/_ &X(TP'*,<%D^S_,@Q$JI@%'YOC\&'Z?4>4:33#:?W@Q,7^[,=GY
M'B9Y[/\ IY;?);_\W4_PH=_O3IQZ\<W+_H!)Y!C>:3\?R?\ ?PW>._\ ^K:_
MY21H-$F++$W.7I52E+A IF2@[7(UR'?66%2./L=.)G7+-64CDS&^H@BJ0!'B
M?2:;*V,6XRL3%DVT#;8YW11NFC;SPR0M+V#D\-<!R?U3'W^]P]7-I,3-RXM+
MD.NEQV32-@E<* .DB:X1O(H.7-)X'Z!:6+']#M\C!R]LI-1M$M6'"CNM2EBK
M<--R->=*F2,JY@WLDR<N8EPH9 @F.W,F81(7R/T#DSM'I=ID0Y>SP\7)R\9U
MT+Y8HY'Q.X-T;GM)8:@&K2#P/T5UWL&^U&-/A:G.S,7#RFVS1PS21LF;0BV5
MK'-;(VA(H\$4)_5+=0*'D!LQ9WRDU&[-(M\G)QC6W5N&LC:.DDB'32D&*$RR
M>I-'R::ABE53 J@ 80 ?J/)M=%I-[&R+=X>+F11/O8)XHY0QWTN:)&N#74^X
MH?\ *NG]AW_KTDDV@SLS!FE98]V/-)"7L^MCC&YI<VO-IJ/\+>M5'I5ZA_Z]
M=ZA5[C "H@L,':J_$V&'%5J<JC97\9+M'C+Y&ZA"F(;T\D$ $/'CF]GI]1N\
M3\#<XN-EX-P=XYHF2QU;]#8]KFU'V-*C[+GJ=YNM!F?V.BS,K"V%I;Y8)9(9
M+7?N;?&YKJ.^XK0_=;LK3ZC.UPU/FZM7)BI&9(QIJM*PD9(5PT<V2*@W8&A'
M;5:,%D@@0"$2^+XRE     .:R=3J\W7'49F-CRZDL##"^-CH2QM+6F-P++6T
M%&VT%!0<!9Q-SM\#9C=8.7DP[D/<\3QRO9,'NK<\2M<'W.N-SKJFIJ>2C:GU
M%E6B4MG5JXTIR;(\:G4VT)&(5HD<H)C*1Y())J2+*R4$YA,D"7QB(CY#Z\TS
M5ZR+7?T\>- W4^(Q> 1L$/C(M,?C LL+2066VD&E**2;?;2[3^[ERLAVZ\PE
M_(,CS/Y00X2>4N\GD#@'!]UP(!K5*[3ZE3X-*L5*K5RK5M JQ4:]782,A(-$
MKCS]P5*)C&K9@F5?R/N )A[?\?/)@:K5ZO"&MUF-CXVN:"!%%&R.,!U2X!C
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M-TCF-!>ZI)JXD\GGE-CO][N((,7;YN7E8V*RR%DTTDK864 LB:]SA&V@ M8
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MJ^I*A4:9LD/<YBEU.5N%=341K]KDJ[#OK)!I*B854H>==,U92,34$X^Q4%2
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M-Y/Q=4<GA;EIHU)O,,%<NU.JUQKP'05"!M-?B;!# JV\?;*!%RS1VQ [?Q_
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M4/ ?0.635:N76_TTN-CNU'B$?@,;##XV@ 1^(BRP  !EMH   H$CW.WAVO\
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MB<(G")PB<(G"+X55202466431113.JJJJ<J:22291.HHHH<0*1,A0$1$1
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MJKGD[*VJF34] >N;&=X=T''N7F6**!E/:79^Q0_@TY)0K#-D#=,4XLHC!!1
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M8,<?=>N'L!L%5TY783/#%TZ^T<"FJ>MXJAEYM^U=(D.!U63V8G6'D/ @91(
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MQWC]KFJTR[4CT)ISEAY78551?PZ<TO.!I6'7!! /L07+2+&HH8YBE$ _B0?
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MTG<92L/H6H9=PXB,G3ZF#))PJN_<BW'P0J(?()Q(J3?^%LWZ_P#^B7;_ /\
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MYHI->F0'Y 4:B[_ F(0/)!,!%!\^P"  19[L1%,8*)C(2+0(UC(>.914<U3
M 3;,8]LDT:($    (BW1*4/_ "!PBP(,6U!7+G[D^49_!3)2(@<0&GIS-\G#
MH%4CG3Z$Q-'UFWIS+LK!F@BZG;-+-6YBB*JIETA+\AQ(?U(J_P!>R?=.\SOJ
MS%J[F28?R'7-U[+3TTOK@#]1A2,UWJFS+&KPL]ERM'0;C>XZ0NRJSG[%]\[=
MJS9)(D(!'+GY"+(SW_Z@-$^QG%#C'>;\(TV*M$56$ZYC+,M%KT55LIXI)&LC
MM*XC6+'#MV+AY58,?7Q7GIEX19,OJ+<# 10A%C:_IY9*SS 3_8#II9[/+WC
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M%?EW3=2.U_:%FG0%6J9)P1 Z^:VWA*_9RB;E,Y%KEOMD\M/5E236QU582BY
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M'BOO0W5I?^S^X]CU*T.PQ88X\'F6PZBSM^R+L[DJ#72^VG*MCFPVQT^QY@V
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M=8KA)6YTJ@3+A5@Z9OWARFCBD(K('*50X  @16?]OO3[V$[*=H>HO9!H]?\
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M8D4/M3.&J8.5P4743(I]$Z<SC\?EQ_6EU:FP9U#^H0+J% "KUMJA#?AHQS%
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MF7&)Z<^R%D#,&R,AG"?QX[(@:;BGE?@-<7]#IKJQ 4[1T1)W. 5D8P)K%44
MZ1%2KHIZ\NTWJSQK'ZJYH4Z^K[K.XO\ <,B2MVQ5D?8,V=XJ8M$/'MU6[>%L
MN!JK0K<S,^@F:91<.XMPV;&4$57'HDD!%D576G5W(=/M-"MT:A,56Z5Z8JUC
MBG)"J(2,)/1[B,DV:I3E,7U79N3E\^!\"/GA%C,]>77SV1]*=DSWA36O'&&-
MZ=*<LW]_DW%+*PYZ7UUS-AB<7: P/$6E"P8TOM9MS&2BVK%FNY9O#*K&8@\
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M?BIQ3<AHTF1D;!!5RS/V2#E.8J,E-QE9DIEM5;4U0?1ZCQFS.N+5/Y4B>3%
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M]C!W'-I]I7L?QT0ZLUI>??MG93L&3RQ1[<"%*!SBX,<!]4C\(H6/_&08M_\
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M@4_T_D80$"CPBR#^$3A%U4[,,:["3%@DU!2C8**D)B05  $4V,8T6>NU  1
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MKTJO9H"ZUFNW*J2K2=J]M@HBS5N;8'%1C,P$]'MY6'E62@E**C20CG::R9A
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M5Z/1K)C HR%H7=KJ*GF1**JA@$YC 8>$4_%#RKC/*>/83+6-+_3[_C"RPO\
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M8\6QS6/IF&Z#!4YDHU:D9FFI)DU*I8K4_1(8Y0E[=8EG4F\$!$!<NC^/ >
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M8 ,(&6* #PBS_'#A!HW7=.52(-FR*KAPLJ8"IHH(D,HJJH8?H4B:91$1_P"
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MLZ=+)-FS9)1=PX74(B@@@B05%5EE5!*FDDDF43&,80 H!Y'Z<(L>3)>:LO\
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M 4C!4-,H7[.5MMLE+/F+1A36](KJC)^NH;XBD?>#> $3E(JHT'O\Z0(VPU_
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M=;6T5A;U.OP&+,0:OY!B8>DP\2S8UN.A4*6\K5?KD;"-4DVB4>59XW;I-TR
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MWLZRO2\!: [BYLN<3!2S.D:V9<!)C-L6SM&>7EJL[9QU.."_H*S:V3_V34R
MG(DLH9/W\>H"!%"3^G_KT[Q'U3#E:524)(;+9POU_BE?D5^)2F4\L?C*&(5
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M$#*&2(J6:JDL<QRE**A5"@/D" (D5B=6^;?/]P*S2ZJ+:=Q[U\XC^Q27:_\
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ME%8QTN4@!*(!\*X*C[>2+]!>%5>KPT2O)$,G(K1C!5^F=/X3IO5&J1W1#(^
M^(Q5Q, E\!ZC].$6LQ,P]>BWTY/RL;!PL6V4>2<O,/FL9%QS1(/*KI](/54&
MC1LF'U,=0Y2E_P"(\(OST?V^^P'7C8YYI[J3@G87&^1(JMVRT9'S18,9W.#R
M+4*JO,#$5*I-K%(5!W)QY9VO-$99ZLQ!R+M-!P03ID]R"<BSE=+[]KE<M=<5
MP^L.5\599QKC_'])I4?+8EO-5O,%')PM9C6C5@Z>523DFD>^^W2 YFZHIJD$
M?J0/\<(L7W]S_7?*&2M+]<,]4B*DYNG:W9<M"V3VS!HI)-H:&R?#UV'@K9-L
M 360"&BYRN$9*.%B"BDI)IIF_P#3?4BDCZ_.T/I%KFF./,]8YRIHQJ$FMC>O
M%R=C)@YPOAG)U2M4=#%&>ITQC6MH0=PGY8DG'N19)Q[!Z66*3Y6(N"&*82*[
MBK;UY>R+I+N+N4\U]M6%L=4''N8L@ZIL[N25:9?RMCC'^+7\_"9,O&,7D"B]
MQH2ZVN,<.(:-<G<//P9VSAXFW.<Y (L:?]0+933C%VN&PC+*>QV#*)M#L!MJ
MDTC<:WC(U6JF5;A&O:Q4F-*BZ?4K!+L;'?6\A:9J2,FM%-7)"N%U$SB4Z9_!
M%G5<(K<=F-O-8].*$]R5L_G/&F$ZFUCI>1:.;Y:XF%E+)^$: \?QE+KKAR%@
MO%@!(Y"I1L0U>/EU%"$32,<Y0$BQS^EC<? ?:%OEM?V(WG+>/666"OW&J^C^
MKUENM?C\KXKU=JS-E<K)>D,=+6%:4?63,\\?\A,/&K=ZDS-'+-T'16_ND4BR
M4\^9/P-C/'<^?8C+6+\08^M$-.5R2L&5K]4L>5]=C(13EO+(%F;A*Q$88Z4:
MN<YP^0?0G\C!XX18"GZ>6Y&#L%YPW=U<ROF>@4IUEB:QW:<&C9++$5^N9 GJ
MQ+WBLV^-JL[.NHQI+6&5CY>!6CH]+V>/VR:ZB28@BIX(KKOVIK,2E]DG3%>\
M^(OF^F5$R3#6FXS9XI[*PC=S'9RQW,9I;N&\>"KMX?\ VU@H51=N@F9RJV ?
MA*H</4"+(BSCW2Z90E7AZ=IMEW%F^&V&54'-<UTUJUDR'5LL3UMO3AA[Q*N2
MY:D2\K$88QG7?D*^L<Y8W,:E&Q#9THF59=($3$5Q/77J1(Z2:O(5*_3J>0L]
MY#ME\V(VFR/#-'#A7)NQ>6Y9Q<,FSD6W*W2>O8QD^63AX4@HE<#$1K,ARBJ!
MA$BPYOU>-S=5$=J^TS:?;383"V&-A-E<M5E]5*WES(=7H4[/-+O><H76W1>/
MTK7(0ZUUE):VR\<U5C8PKEZFHS:E^$/G2 Y%7C]MZ8" VYZ<+=FUA*FTUJ>7
M)F9R7+L(AU+,"$#)V&)+*+%\W8 =9[)JXM@B*1[0Y05<E*Z!M["#CU(LA_,G
M==HQ7:E!0FJV9\9;S[,912&OZ]ZP:N9$JF5+_D*^O6)586-N2U/DIJ/PQ2HW
MY =S\]9SQS6&BFSM<2JJH?;F(K@>MO4>RZB:[N8C*T]%7/9;.F2;WLOMC?H,
MK@L-;MALPR2<U<@KQ77JLG3J5'H,*U!%$B0A"PK43)D.)R\(K_N$6"!JC6V/
M53^UMM@[V9/_ +=XM[%JEL(^UUR[:G)(3'5IL>=\MXOV(4B4[9*@A$)R$;;:
ME)511HHLDL29<,4P 2/&AER*>WO4[':%JCJ)DK F.) <H;M[84V=P/K5KQCI
M)2YY7G++E6&6JHW8M)KQ)*?0A*K$S:C]JHJV^.2D"-F2/N9P(E(O!=$VB%<Z
M9.MR(C=K+OCO%66LPW%SF'/$U=;G5:[6J18IV#81E4Q6:Y2K]A"/5:34*\0S
MOT<K-PF7$F+959K\:QB+&\WUW:U!W6_:&T1?2FR.)4M2=3'6,XY?,R]XBO\
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M7>H7/$^++!F*P,:#4_SU)IL-7J\HO9K4>&@X)^Z92LH\:%<K)?>**E!(RAU
M*<BJC^U%C]><S#U7=G=1>C=M5\?VZE05UO\ 4&CF>AX2$<91KF2ZU:U'K-,4
M!AK3$I.TF*HF]'*Z)2%'R<GN19;N>NP[4/734YUNAD+-U!1P4XIPVREV2/L\
M/(#DU=S&G?PE4QT@R=.5;;;9]8"MT&3(JRI%1,*H$335.0BQ[OUV]"L[6+8;
M;+N;W#HC['V5-RK!9G>#*!:(8\/<JSB^YSX6*3M\Q'_<('@_[2Q:QS%FS6:E
M.HR9_=!ZD72#A%;/CXH;S?M^Y%LQT91Y1]!\8OXAHH84W4;#7&DU)G4/B*(^
MI6X2EMN\BJ'@!,51 P"/DH<(KTOW!<T67&O56UH-=+)MT<WYUHE/LTFT25,R
M3J\$UE[:[B)%4K=1!$)F3BF?Q^ZB8F! X% P_P#5(KA]6)O5?:?I0>:)Z-;"
M8RRKD:"Z]$Z:M4,;7J!G+C4+/8L>R,>QBLAL(Y\+RCRUGNR+IDH27!HNJ8RJ
M@E,4#&X10*?JO[)]<N$J'F36[=:OZKX!W(Q'EVPR5=R%L15\2T.^3=:42:(2
M=999;OD9%2AK#2+-&.TQAQDSK(M?59 HI_("9%ELXI[)JEM7L_#X9TCKT1LG
M@^CMK"XV<V[KUD52P%CB718MAIN,\47B+BIJ SME2>>.?N'[2'<A$PT64%7$
MA]PH1J)%97W0=_V.NG;(^ ,9V+6^\YXF<RQSJX3[^&ND=CZ&IF/(^?\ Z^^D
M85_(5BU)7>[D<H+J)PA_P[<4RI&5D406*)2*>FF6J.O5/JMVATGZ$3;ZY"6>
M+0E6:T=)HQ\]&MI1FE(,%P!9F](W=%!5(WU(<!#_ (<(O2\(G"+&,[-__P#8
M!Z&O_P ?9_\ _E3<N$63GPBQW._GI,L':S1,39'P'D6$Q)MSKD[D7.-K)8UY
M:+KEP@'[ME+_ -4F+/7FDC8:?*P4\P+(0DHT;."MW:JR:R7JL1PU(J=5S-W[
M!>&M;9V;W1/UIZU8_P *X_DI;+NX,I+9#RI>24ZMQ!BN+/3<$UN=K=!LN6GA
M4B%9-7\W$Q$A+*ID(Q,!RLU2*,']4#4_+.:]@-N.X[/4G9K.]S/+WG&N([I<
M4V"4[D9U8;FC/9>R"Y:1D?%P[9%"4K\?$MC,FS=!%PG(-DDTTDP*8BRU]^]W
M<8=?>M%RV)R6UD;&O'+Q]3QCC*O>RMSS-E^U&598^Q/2&*#9\]?6&VRQ/4?@
M;.E&K-)PY^%0J!B"16C]4FDN3,2QV2MVMRQ:V3L-W57B;MF^0%1-ZPPC1D6J
M9\=ZO8Y,5P];Q--Q7#&2;O/MUUQD)0ASG<+HHM/C(H]^YG]AC'VB>QD#HM0+
M6SQIDYY!Q%ESALC8,:RN8XK7^LV6*),5V)HN&8F3@#91RU88AVW>H!*R4;78
MELX15<?D3G.S3(HC8/L^_6NMEJALH[G9$W:[&<RQ"J3MI==T*-:<B4N#<&*0
M[Z/I&O,&^J^NM-JSEZ!E2QR%75 OL(**JF$YSD65%U@=K.C79!%9#J.CT9<X
MVHZ[Q=&CYR/E\5$Q;4:\RMX6-"JP-5CTURLU"HMZD[$[=H@5)HD5/V]?E3 Q
M%*_PB<(G"*F>5,9XXV$Q+D?#>1X\+?BS+=,MV,LA04;8IR!"PU"U1LA5;C7#
M6*G2\+88LLA'.G+)P=D];.4P,<H'*;SPBPONZ'JXP9TIZP!V,=2M[S%H[FC'
M>2<;U*SUBIYER%>L>Y:IUOE58I2#LU9RS-7]Q8'T5-BUD$VKYXO"J,TWI%F*
MJAVZC<BRE>KG;"U[R=?FJNUE\KC6J7G,6+8Z;N</'-';"'_M<5(2-8L4K7V+
MY9T\9UJPS$&M(1J2BS@Z;!TB45E?'R&(K^.$3A$X10:]J6UN8KOD''?4[HC8
ME8O<C:V!?2N6,M1)572&E6HY5RQ60\]V!=HX:J1UWGVJZL336P.&CA:44^5-
MPW<A'@Z(I/\ 4W5?#6E.O.,-8\!UP*SC#%-=1@X5!<Z+B8F7JBBCV>MMHD$6
M[4DM;;=..7$C)NP23*N\<J&(1-/T3*18X_;%TA[?W7L-QGVY]6>3,<T[:VJ*
MU53(6.LIO7L%!7B0J5?"B-9V,GVS&08OT+-C8$JW/0L@,>W<Q#?V1>%5.9,Q
M%XGL[W7[H]<^O;,.7-O+=I!HDR>57_;JH,];)&_9CV4S%E^VMGL5$T[&S^]2
M#?'6)X.0;_/)/Y-(+3/Q,,Q=+M?A<)%<I$5P_P"JIUWV?2/KN-E+*,(M7LP;
MEST-F&6A':7V\K7L4QD0LPPS"3*'^I\<F]BY:2G_ %]_=%O/(H*II.$5B 13
M':Y=;^F>K%\RSEG$^$JPGF+-^4;EE_)68K>W+=\I3ENN]D>6F22:W:RED)J
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MTA%HBG#O%7BX_&((E ZI2*^S2/:RJ;PZH8+VPI-9L=-K6<*+'W-A5;8FB$Y
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M($^V4*4Z7H8I1 BD2000:H(M6J*39LV230;MT$R(H(((D!-%%%%,"II)))E
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M<6Z(:F43($4]+)0EOKN!L;L)ZO2)%3+IR%9?DKPJUI\DH8?19@+=0I?X@(%
M X17Z<(J44_ V#<>W2V9(H&&<44?(E],8UZOM/QW4*S=+H8[DSTYK9:86'93
MEC,9X851%XNMY5$3?];Z\(NRRKA_$F=:7(8XS=BW'68\>2ZS1Q*T+*M(K.0J
M7)KL%RN6*\A5[=&2\&]69.2 HD91 QDS@!BB _7A%QL382PS@.J)43!6(\8X
M6HZ"YW2--Q-0:KCFJ(NE"E*HY2KU/B8:(374*0 ,<$0,( 'D?IPBM[S9UPZ
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M*ZK63E(YDR=20E46.U!DDB_(O%?LA=;FT,SK=U\5C1RO92?:G:8S3&&R=AS
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M$5PE4J55H=;A*91ZS7Z93ZS&MH>MU2J0T=7:W7XADF"3.*A(*(;,XN*C6B0
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MW)[7,_8YVF[GFM1Q9KSB"9&U:_=6>-[0A?ZHPF3B'VMDVDR,Q!*!R)8$T4R
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M+\X?\?'"*Y_H[ULD-8^H#2K$:*7]4N,I@=IDV=6=QY73^&O.=G,ME^2_,L7
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7")PB<(G")PB<(G")PB<(G")PB<(O_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>t1701829_chrt-flow.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 t1701829_chrt-flow.jpg
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M=18P<=%28K*S)+3D"('A<D/#1'2D);6A@E-0P6-D)A=P\(-456" 949X$@
M! $'!0D-!@0%! (" P   0(#$3$2,I+2,P0AD=&3-$!!47&A(J+B$Q!A@;'A
M<K)#<Z.STQ3PP4)2XP4@,% C8H(D=!5@PE/#D&. \8-$!A,!  (! @0%!0$!
M 0$! 0$  0 1(3%!0%%A\1#P<9'1(#"!H<&Q4.%@<("0_]H # ,!  (1 Q$
M  ']_ 5&BLS9!/:>4ZC+&-*21FRWTT6B4D^3"T>8L)/:90   &NJ.PO!/4=Q
M\/*4ZB_D]@!C3) $&1K@;8I[2BT2\SIP)*FI$7FD#&F2 !4:-;Y;81,D/I]*
MN0+G2 ,:9( &E")>;)IXG69DTT1<Q<Z0    .!J\C8U-+(L,PA8R?,0A$_31
MR(D=YR+V3FR"HG21]/AEP   :'3%2(U>*Z1Y);3Q-,$,F/TOBK013=*=>YCQ
MEPQ-$(D<S-(2 _<**@  !^:DQ^>\TVI$U;,6+$U5,;+1,K-FT[RQ(%*%U@&M
M*-29C2"8DD+'3&"QRJB&S'Z Q5^DT2!2A=8 -#IBAD0XU[F,DF60W32/T.B0
M!2A=8 /QVFG*&LABICD?KM35^2$T_H<J_0Z)     U"1H;,4E,9*)]!.B 'G
ME4R+=+KB;2/SZF-K(F@)B9Q,M*=F/6>F$Z3^[45   #X#X5,B.E]I KA%CI^
MGP 'T^'T^@   ^'P^'T^'T'T'T I\N  ^ 'P ^GP'T^@%/EP  ^ 'P'PY ^@
M I\N  'P'P ^GP^GT     ^ ^ $ )494 'T^'T^   '(  %=;WD>,P
M   !E,;-F>JZ(       "GBX0       4\7"       "GBX0
M            ?A3]D_F)X+^*         !L1PGK?ZF_.'V_JCZ/XAD+&8
M   !6D39<P       *SB;,F      !-]1T<VU715 6^       >6[CR?7[F2
M8&XK;?<AF,385X6&   "L"=F4!YR-DH.P  &%,T  ?#Q7\7\:/J_\[?!?Q0
M        -B.$];_2#P3[!_(?ZB^ @      !UT9'97C@      #A1?YUV
M   !:W,]W^KOS3]U44F]P       0+=<M/=+U,0VF@ZM7O\ 6E%-2[48PR!6
MA<:>9LQ#168G"8,B0IV>AI?,;AQ.NTQ.DZ^HV&32*)8;?1.K4OTGB0 (CL]!
M^*_UM^<?@OXH  &7Q<^UN:[J.Y^HP69JY=J^@@VYYB.9^H   &Q'">M_I!X)
M]@_D/]1? 0       X47^==@       <*+_.NP      !^FOSU]H97B/5KK
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MXK_6WYQ^"_B@  #NHN<HGZDCC+HKM$$@ #8CA/6_T@\$^P?R'^HO@(
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MW6V_X\ #8CA/6_T@\$^P?R'^HO@(       <*+W.NR       .%%[G79
M   _1CP;Z\G?GGM5Q        @6ZY:>Z7J8CL]!EM9OZZ17)(3VGD-5IC=B)
MJLM(K<N!-)(GI$#UF*/49 DQ"27F!+/*H!=R9& 1'9Z#\5_K;\X_!?Q0
M     -B.$];_ $@\$^P?R'^HO@(       <*+_.NP       .%%_G78
M %AZ+K?UM^8OO6EJ;EW        @6ZY:>Z7J8CL]!F=9O_S?FG9*)BYN6D
M          1'9Z#\5_K;\X_!?Q0         -B.$];_3CYZ^T=9O0?&)+K]R
M      !7T7+!FV       *^BY8,VP     !9.@[&T.=[:AR^       #'9&'
M%MAI9UI^F@FYYB5Z;I]?D80\)MTD            0/<\Q =UR_7-
M  $CP=O;?,]W"=EHHY<L@      5?,6A$@      "KIBT8D       5=,6C$
M@      9<L+4]&(_EZR.7K'V              3$JQ\W3#UKYRZ*[0
M   %A:+K=K/-O<Z]V_,]$T@      4],7#$@      "G9BXHD       4[,7
M%$@      +EFR-'UWTB>?IO'<LD@             C)V<O\ $[Z\_-CP7\4
M        #8CA/6_TL^?_ +)@NST.?U^X^54]4T>:Y:[::P.:.">VB[V '935
MYZJ<,9B:.NJGFC@D<T<$]E-7;%?6>BFKKJI ZSJKM>**O;-/RJC[37U54>FW
M=[8K^TU?*J>L[ ?::O+=L#[7;M7G^RIDN8       Z:K<&W/+S_2=9"-OS>?
MU'24*CWD8) 90PAFSR%EIT<F+TAF20F8-<S98KH[C@94Q)BRUB"&PJ0 (3N.
M:_%_ZQ_.GP7\4         #8CA/6_P!&?!_KS.X>SD^NW8      'E/4
M   #RGJ      ! =URTPU705+:R;H       ! MURT]TO4Q'9Z#(ZS?ZUHAQ
M99!CZ51,7K$QDO<JTXE+2]AL["D27$4)F:%3&]\33\Q:L3;Q4)MZD "([/0?
MBO\ 6WYQ^"_B@  7+R?H=I\YW&=P]IC[V)K/Z%XSL+PWK.IOIGA    V(X3U
MO]&/!_KS-XFRE6MW@      'F/2       #S'I       *VWW'X;0]A<0
M    (%NN6GNEZF([/0236;_6%'N,46435/THU%K'45X3 RA"CF00\9=I"2>D
M +F3K>BS"J"[S(I^HQYG4^S9Z#\5_K;\X_!?Q0  )?J]_?7%>I0K;\YDL?+B
M&UT'FN6:QZ'BP  !L1PGK?Z,^#_7F=PMI)]?N@     (.?G3,;40S9AC6:6_
MD32R/<4X<#P2PQ"3=V&CTI:;-0RI&SF#:E(     %>;WD8UINGNBW?
M $"W7+3W2]3$=GH,]K-_^?4Q:L(/+B71"B)1-&%)HFRH3XU]EM%"O"$'<=YB
MCME#T;'1-,2N"'E-<Y>L]9LA"7$MV>A_%?ZV_./P7\4 <HGOHNCC-/**NBNU
MSBJ3:[=8#.U7Q&3Q\W%9.#YKED #8CA/6_T9\'^O,]A;23:_=      5V?D+
M-/>6*G (@1^@,3JO*](34]9^>TQN_$ZDS'Z!1-$%1%>S%X)H-&^L3\-S4@
M   >*[C4?MN>OW2=4       (%NN6GNEZF([/0276;^I49<GZ<$<"1&$/08%
M$Q3R/A7R)^D0U'PFJ8&BQ$QL@2+:34J+63WG< 1'9Z#\5_K;\X_!?Q0!/M)U
M6S/GWLT+VW.>VSDPS;<[VTU^JW>G.FZ?NIN8S(PN$TQ#:<_KSW7DP &Q'">M
M_HSX/]>2#!VTDP-P      !Y#U@       \AZP      "L.AXJ,\]VEZI
M    $"W7+3W2]3$=GH,EK-_^5,T^HQ)/T^=%%FYR:J1;*=?D;9Q.G4Q:Z:_1
MDSK/,1@V(B:SF)@FH4;MQ.D<Q)#;>)V>2!$=GH/Q7^MOSC\%_% 'V'9%?V)Z
MJJ.ZFYU56^43[K.5*M;O(3M^;X54<Z:^FNV !L1PGK?Z->#_ %[(,';2/ VX
M      'E/4       #RGJ      !B<G C6PTT2TW470       "!;KEI[I>I
MB.ST$IUF_I=$E3G42M(J%%D)RP          (CL]!^*_UM^<?@OXH
M  &Q'">M_HUX-]>]M-S,XFQXS3QFGJJHY14!]/AVTU@#G%7":?&>J:>$Q]/@
M/I\.<3RBH<XJX32 .JJCHBKOFGC-/**N,T]M-?**N45<9I '**NBNT(;MN<M
MSF.^I^*KB       ! =URL^TO50_:<_D=7O_ ,R9BX$T^C]58J
M  $0VG/_ ) ?4'P+XKN,         !?G%^I?IM\_?95(=/P/AP=PFGBCA53R
MB0/I\/M-?*8 Y1/65553:L/DQ]/@/I\/L3R3QB>PXS '&)^545E*S8?)C[$\
M9CG35R2BI-/&)Y3 15PJMCU47<OC9]/S3<$5       >O)U]@:_=9W#V=;[K
ME//A[7SGA,D=P           !]1[\K GVGZ8                   4V7(
M      "FRY        4V7(                        #\=?JK\]/'>QP
M        +QXWTW](/ _L*I]]QV0QLX      "H9BWHD       5!,6_$@
M   "H)BWXD      #JOXL[U?09?%V-<;CE_;8ROA]   !P/AV        'R7
MV[8_&/ZR_.GP7\4         #8CA/6_T@\$^P?R3^EOA5$@      =5%[MKL
M@      #JHO=M=D      ;'<-ZS^C?A/US1Q>(       (!NN5G^EZJ'[3G^
M&KZ#6)&$EAA#U2@J+.B?:7:?FS,;&IP2,\F[H:9S&Z\31LIA"FIBZ(FH9C,I
MV.A1AOHD "'[3G_Q9^M?SD\%_%   RV-G9+'S/=9RO)<Q_=9RN<50/=<N
M-B.$];_2#P3[!_(?ZB^ @      !UT9'97C@      #KHO\ 978      '93
M7^M'S)]Y1#0=C?        (%NN6GNEZF([/02S6;^C$><GQASUD(+!( 6NGQ
M(PI!C(ED)B*,8?3T&M,MH888E!)TQA%GI  B.ST'XK_6WYQ^"_B@  ;%<'ZY
M>7'^FUET/&2G6[O"Y>NGNEZ?3GU7Y[A6WYP  #8CA/6_T@\$^P?R'^HO@(
M     <*+_.NP       .%%_G78       V:\]]GVP\%^O[K       ! MURT
M]TO4Q'9Z"2:S?_G=--E1-=RGI;L/*:R3%@1/5+UPG)&Y<(=H.DCDO5#7*8W/
MB:CE)X9\FQL D "([/0?BO\ 6WYQ^"_B@  9?%S_ &V<G.8>SP&=JI%@;?OH
MN5KT''   #8CA/6_T@\$^P?R'^HO@(       <*+W.NR       .%%[G79
M     [:;GZ?_ "[]^7CI^F       $"W7+3W2]3$=GH,]K-_K8C,$3/27,4H
M=9C"PCJ)P5F6(?"M2QR"%J@A!&CK+:,BF>  $1V>@_%?ZV_./P7\42_5[_A-
M-M<QWGDNV(#N^5SV%M.BNW#MKSUR<IZ'6'1<5(,';8W(P^=-7"JG*8V;CK^)
M6W0<<!L1PGK?Z0>"?8/Y#_47P$       .%%[G79       '"B]SKL@
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MK_6WYQ^"_B@  ?3X      ;$<)ZW^D'@GV#^0_U%\!       #A1>YUV0
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M/@[@
M
M
M           #7I%*RMR&<(T=!,B#GB/"6J:W2L6$E(*>DL8^FP"0    !J,B
M,EQG4>P\9B2DI;QQ,A !A#-@  _-::=@(G/GJ/ 684D6T10IR5W0[B/EAEFI
M  &$,V  #2-&/E.(3LAYM2D                    #39%?RI!&N\LA#=!-
M!H\!M4G51%XE*D;+Q*5,F2XDY^K45     #0"8T>1;9619I2IN$G,%EPW*2
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MKZET$X],P:^W?*6#I.KAVTYZ8ZOH0             !#=KSVG/Y)>P=&)5\
M !]/@/I\/I\/I\ !YKL(6C[!KK[_ $9\GU4_*;V0         #HNQWVI
M        '1<COMR       )9W6)MS^@/'P7?<M/=+U,1V>@EVLW^F4Q1"-A(
MF 2V;AA3-$?,8=)CC''D+A(&68:3S%L1-VD:*L,:7R4.6P;,)[0"([/0::_D
MIZ]^<?O>GEVIN>VQ5FL*K ;"C%95-I\OD:M^H:^Z>+RME_-L_6;TK J#KL;>
M#Q/:P/>VHOL[>-R:<QAU8'/IQV13RA8_.W]Z-M1??Z,^3ZJ?E-[(
M !TW([K<@           #IN1W6Y        V+^O><D'TYY]/=+U,1V>@[=9O
M]<41.5A0Q!)3$$P*>+/,"2P@A4LMO84V785B5V;0&G<K;AUEK%:D*-TT\P"(
M[/0::_DIZ]I1ZUK>43+M1<L+G[U1];C8_(B1:ZO%Y5,PU%V=:.[2G:8LHU=R
MO.ALW[P693O88LIU5R(;>WY+T6%S]ZW.2R)=J;MD^QZV^_T9\GU4_*;V0
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M0       (CL]!IK^2GKWGQ*@         +(]DUM^?HQY1KY^=7JG936
M    ,-7&9HD            8:N,S1(       OWZJY^?>J8%?[OE+ TG5P_:
M<_,-7T &,,F 8T&2          (=M.>U\_/GTWJQY          FGH^'L%]:
M<Y6/0<9DK&8         (630            $+)H        =55$AP=K(\';
MP?;<YV470             /AW(E^LWX
M
M                                   %((P9FS5J8V9B8090LXH$M,\Q
M"R2GO/.>4\)<J:O1"R0D*+//AZRII69#O,H8@H>6U,-7I7Y"+'N.HM8L9(
M                                        &O:,29<J8Y$L-*YC>B)J
MTDQ$23E:2L.&-+M(66"4Z#RF*EG82@KR6<AYR=G KJ6;A>9'BG"6E>2@"-Q8
MFZT@
M                                                ?__:  @! 0 !
M!0+V3N9M?'L5AW+D>F#OJ"#P*6HU"8AT;%19CNTDDW*"+*6NC9?;R?.#H)'&
M&>L[[(B5:13>]\B-K1)XQ*KGYG-=6PA*]S..1U<S2F]X?TSBWK2[%J(U1\#D
M#DIIX[M@_)<?G99"]"J3%.3<>DL7(C4I*]"I3F.K640?R"WI>0[;K;[?:<L2
M)C/;)I BBD>AW-T8F#Q1>ANN2K$BTB8\B-L4;F23&NSBZ/I*)G;G].I8SW!
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ME=]]I=A6MOHT)P&A. T)P&A. T)P&A. T)P&A. T)P&A. T)P&A. T)P&A.
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M[Q=A?>*H7WB190TJMM#;+Z4-H9X&U,NH;<9?0TVIM#3@9WCJ74.,LKWKB_\
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M8\ZQ.2H/O4G="L]BWZSKDGS2_E]+)/M**^TI6;($A!FYD W,@&YD W,@&YD
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M4B0#U(D ]29 /4B0#U(D ]2) /4B0#U(D ]2) /4B0#U(D ]2) /4B0#U(D
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MT9N&C-PT9N&C-PT9N&C-PT9N&C-PT9N%[3:51"JS$P++O<QI: :8@&EH!I:
M:6@&EH!I: :6@&EH!I: :8@&F(!I: :6@&EH!IB :6@&EH!I: :6@&EH!I:
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M2E;3*U+KX6=VVM]P*I6EA?\ (W_.^M+*W5K6EIM1_IJ9X7W@VON*_D/?VG_
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M$U[%/<=]HKQGN\_9N?#4$\7\@VGTDIL]X?3+01X?)S=[)(%-(:23:Z19<L)
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M3U-)9\"2ESR%WS!-ME!M)0(N\09\]S_L[COM%>,]WG[-SX:@OSC\>YF?-<]
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M[=CXS87YQ^/^%+;D^:9_A*<KB(M\SD&&[(W6DOJ61DZ7.1V93E*R0B4WBRE
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M5[3AR)!EWBR)7Q+++G3*1[O;P#>5R>EQ?^%*%3B,_.41)(M_*?X3$X\/E/\
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M3T3HR0AE*&^$%@'6FWRI&I$XCR;Q1R90AO#NM)_<,DY1HBD^&"8Y 3:'6O\
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MN]/MV/C-A?G'X_Y!_P#))<4T99#0<%)/A[X9<0VX>#P^'4TF)\\YV^H_!(,
MQAR43N#<6H\N19+5&&;(87C^QQ+;G;3TS%$7 <P^ IT9-XP^MMQ;6&?4<6R/
MFP,IN7C267A#7[3-/M&WS7.WLI?R6O-7Z!C$J*4F5>(-8EXIKJT$9EP&?'_4
M2:;7V;Z'$K2K@,OMG@.:HE&60X<.X<1_NE_=W,-[!OT2W>GV['QFPOSC\?\
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M2<*\3V7?9A_>(JJ(<84ZR1*Q!_N"UJ+(4U*T)@9\"<AE'>@/W-*9LU6-PL.
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M(7"83AFXFE.^>4S,SBI1]]1F9GWS[AH:3VF!4J)$4)S9J.*BRP)2(Y2WTQA
MRA"Z=S%I%T[F+2+IW,6D73N8M(NG<Q:1=.YBTBZ=S%I%T[F+2+IW,6D73N8M
M(NG<Q:1=.YBTBZ=S%I%T[F+2+IW,6D73N8M(NG<Q:1=.YBTBZ=S%I%T[F+2+
MIW,6D73N8M(NG<Q:1=.YBTBZ=S%I%T[F+2+IW,6D73N8M(NG<Q:1=.YBM!.(
MQ13&&\J$2G.@93EF63(1G-2498GEA#_KU1%BGX3C_$8VI^L8VI^L8VI^L8VI
M^L8VI^L8VI^L8VI^L8VI^L8VI^L8VI^L8VI^L8VI^L8VI^L8VI^L8VI^L8VI
M^L8VI^L8VI^L8VI^L8VI^L8VI^L8;8Q+[JV32O(:HE1,&M61)#Z@EGA\&= B
M(NT46\I1J(R3'\I)C)%4J1M;_N[ VM_W=@;6_P"[L#:W_=V!M;_N[ VM_P!W
M8&UO^[L#:W_=V!M;_N[ VM_W=@;6_P"[L#:W_=V!M;_N[ VM_P!W8&UO^[L#
M:W_=V!M;_N[ VM_W=@;6_P"[L#:W_=V!M;_N[ VM_P!W8&UO^[L#:W_=V!M;
M_N[ VM_W=@;6_P"[L#:W_=V!M;_N[ VM_P!W8&UO^[L#:W_=V!M;_N[ VM_W
M=@;6_P"[L#:W_=V!M;_N[ VM_P!W8&UO^[L#:W_=V!M;_N[ VM_W=@;6_P"[
ML#:W_=V!M;_N[ VM_P!W8&UO^[L#:W_=V!M;_N[ VM_W=@;6_P"[L#:W_=V!
MM;_N[ VM_P!W8&UO^[L#:W_=V!M;_N[ VM_W=@;6_P"[L#:W_=V!M;_N[ VM
M_P!W8&UO^[L#:W_=V!M;_N[ [;"O&_"5MPDE.\U:23-5P1BGAA*$XEF[47A+
MA(^^1Y#[_<5],KL\(E1IG0BI1E+-CD))'DB9'$XP@1$9[0]T+(VA[H61M#W0
MLC:'NA9&T/="R-H>Z%D;0]T+(VA[H61M#W0LC:'NA9&T/="R-H>Z%D;0]T+(
MVA[H61M#W0LC:'NA9&T/="R-H>Z%D;0]T+(VA[H61M#W0LC:'NA9&T/="R-H
M>Z%D;0]T+(VA[H61M#W0LC:'NA9&T/="R-H>Z%D%A,9SDKH.<)D432HMY4",
MR,N:HHR&4 OSC\>YFO-7Z!C$>R5XA GWX>T7:&T8C6N6AM&(UKEH;1B-:Y:&
MT8C6N6AM&(UKEH;1B-:Y:&T8C6N6AM&(UKEH;1B-:Y:&T8C6N6AM&(UKEH;1
MB-:Y:&T8C6N6AM&(UKEH;1B-:Y:!_P"H?D_\B^3G#:,1K7+0VC$:URT-HQ&M
M<M#:,1K7+0VC$:URT-HQ&M<M#:,1K7+0VC$:URT-HQ&M<M#:,1K7+0VC$:UR
MT-HQ&M<M#:,1K7+0VC$:URT-HQ&M<M#:,1K7+0/_ %#^]ZQ<?2&T8C6N6AM&
M(UKEH;1B-:Y:&T8C6N6AM&(UKEH;1B-:Y:&T8C6N6AM&(UKEH;1B-:Y:&T8C
M6N6AM&(UKEH;1B-:Y:&T8C6N6AM&(UKEH?28MQ:V7\A3E&J"OPRQEDS;CQ!%
M)]4YRG$^4S/N8;V"/1+=Z#WRQ#/Q4%XC,@OSC\?\CZN8KZ6=-G;TZ6'&&S99
M6HG8S(%2FTH<6^$,/8=U+SD9I&654)8<0+ZQAQN=)$@>(Q.'=0PF51EDX/&.
MW<PSQ,\,W^2UYJ_0,8CV1[A5))N$Y-[^?.32(-XKULB_.*7/+X=Q8C_=+^[N
M8;V#?HEN]/MV/C-A?G'X_P"1COV.5:V^U;+_ !M[Q=]10+B(83]I;N\'AC1_
MG-!J6><^08+Z;ZN9%5^<<LTZ/WA?T2W7V%?N$'#<E:,CR$DN ^'P!]M/U?U,
M41R_V(3$[V;_ ###)PAN]C-:G%EF3/QQ_#(,3]-#Z?MUPA)"<<G>X/Y#7FK]
M QB/9'N$\F]N$\G!N#Z)P_[&(R?YRHYY..&XL1_NE_=W,-[!OT2W>GV['QFP
MOSC\?\@L3A%FV^F0R[^0'CVG5%C#,SG[\52YPWB'<0LWVHS#R<V,L,F^'&D.
M*)MXR-9?F,CB1GX0>&Q6(<6PJ4CAO''@X1V"\4[V4(0R?<4?Y+7FK] QB/9'
MN$\F]N$SAN EIR*(PUBU%!Q2<O&60_!P;AQ'^Z7]W<PWL&_1+=Z?;L?&;"_.
M/Q]UQQ2R;893.4<#5*9)+FIRGE/P \<E:5,$_P!EQY)T[B,AC\-BU-$ZSV/]
MPXP3..)PW\I9(;X6WB7TFQ]&IYM:8P41$>7AYIESDRAA>'4EQ.(=4VF'YB,B
MR^<2B47>,=N_BF6\-VRVIQQ.)HAE(BRS3C+O;\H>+&+)IIAPD&J"EQ4>4II)
MRGD*/>(*PKT)Q0RE(9&42,N,C'[D3:8%AT,FCO3E-DKTC#KO:(:9921J-7 9
MPWO%OA#CN)9:)Y1DU.)7/@<V=_A29Y"-0<>QCB6>S>4U"!JBM,I9)"REE,$E
ME]'U:DF9(@K>B<#7129D60C",5B'VF>UCV:51BJ;DCDHE'(1F$I[1)8U;7:)
M;@K*F!JI424:2B20267T?5J29DB"MZ)P-=%)F19"/^!KS5^@8Q'LCW"<LFX3
MEW W@V;QQ4/+Q$64PC"LW:$D1?;A.4^_N'$?[I?W=S#>P;]$MWI]NQ\9L+\X
M_'W>V4ZZRO>-!$J);Y*(Y?%PA_#XAMQK#JQ7;()N'!-F'O%&6)2&,9]0AU+&
M+[*$V$4=GQRY>0(:23G_ !J,&O#QR3^?.BY"2DJ3@&-<**F63);)GD,G53FT
M'#AFJG'P3"&'1^X&Z7^J=/F0,Z+<2,CX=X]X8A"S<8;=?)Q!H@9E!,R:HM_F
MDF3?+@!N$MQPLG.72D[W)WACS2E1?5(:)/>F&@SC5&*PJB.>^A!%WIKB5Y<P
MPR?W$GB>PL2*9"#B9QK(CC1.)F4> /8_%&X9O.*4IF!&VN-$LLD(RR\ PY_W
M4]BA25(229JS.=SS5+(<G^$MX,M8[MBQ&'2I)3(06DU&HHQHP,SCW@A1O8AE
MY#)(-*"*"II32,CWHE",>_ 8<_[J>Q0I*D)),U9G.YYJED.3_"6]_ UYJ_0,
M8CV1[A.63<)^#<"_W9TLM!'_ ''_ -M;<6(_W2_N[F&]@WZ);O3[=CXS87YQ
M^/<S7FK] QB/9'N$\N]N$RCP?ST81F]<5 OMW@C",W;:8>7PR[BQ'^Z7]W<P
MWL&_1+=Z?;L?&;"_./Q[F:\U?H&'V6BBZ;2H%PG#(7A"<2PXP;2RB64]$O#W
MQ38SGH%-C.>@4V,YZ!38SGH%-C.>@4V,YZ!38SGH%-C.>@4V,YZ!38SGH%-C
M.>@4V,YZ!38SGH%-C.>@4V,YZ 93V,O?/0*;&<] IL9ST"FQG/0*;&<] IL9
MST"FQG/0*;&<] IL9ST"FQG/0*;&<] IL9ST"FQG/0*;&<] IL9ST"FQG/0*
M;&<] ,I[&<] IL9ST"FQG/0*;&<] IL9ST"FQG/0*;&<] IL9ST"FQG/0*;&
M<] IL9ST"FQG/0*;&<] IL9ST"FQG/0%8S&FA3LV")N]&4_NS[BB<@7B2NWG
MEK3WTF?-/_,13B[QEW&VO6-)[-1<"D<T_%$N$C(]_=[6&*]6\@_ VHG%'Q03
M#C,BWP:_JD93_(=H;4BH=H;4BH=H;4BH=H;4BH=H;4BH=H;4BH=H;4BH=H;4
MBH=H;4BH=H;4BH=H;4BH=H;4BH=H;4BH=H;4BH=H;4BH=H;4BH=H;4BH=H;4
MBH=H;4BH=H;4BH=H;4BH=H(QZWTK2DE9)L)2AP]Q3V!<4R:SBI,"4A1\,TY#
M/?FFF,IY1?MZK]07[>J_4%^WJOU!?MZK]07[>J_4%^WJOU!?MZK]07[>J_4%
M^WJOU!?MZK]07[>J_4%^WJOU!?MZK]07[>J_4%^WJOU!?MZK]07[>J_4%^WJ
MOU!?MZK]07[>J_4%^WJOU!?MZK]07[>J_4%^WJOU!?MZK]07[>J_4%^WJOU!
M?MZK]07[>J_4%^WJOU!?MZK]07[>J_4%^WJOU!?MZK]07[>J_4%^WJOU!?MZ
MK]07[>J_4%^WJOU!?MZK]07[>J_4%^WJOU!?MZK]07[>J_4%^WJOU!?MZK]0
M7[>J_4%^WJOU!?MZK]07[>J_4%^WJOU!?MZK]07[>J_4%^WJOU!?MZK]07[>
MJ_4%^WJOU!?MZK]07[>J_4%^WJOU!?MZK]07[>J_4%^WJOU!?MZK]07[>J_4
M$,<\IS#_ /C(B0D_.E49=Z= ]_((%)W/J6%&WB#A&$BH23D[_'D5O1@+U%3K
MB]14ZXO45.N+U%3KB]14ZXO45.N+U%3KB]14ZXO45.N+U%3KB]14ZXO45.N+
MU%3KB]14ZXO45.N+U%3KB]14ZXO45.N+U%3KB]14ZXO45.N+U%3KB]14ZXO4
M5.N+U%3KB]14ZXO45.N+U%3KB]14ZXO4U.L#?4:G,2HH&I4L. H0(B[Q%QQ/
M+_\ #E^+[> ?B^W@'XOMX!^+[> ?B^W@'XOMX!^+[> ?B^W@'XOMX!^+[> ?
MB^W@'XOMX!^+[> ?B^W@'XOMX!^+[> ?B^W@'XOMX!^+[> ?B^W@'XOMX!^+
M[> 3DQCW.VP26T8/\*G(F:R_,22A-2?X3,XJ++-(4\-57;%/#55VQ3PU5=L4
M\-57;%/#55VQ3PU5=L4\-57;%/#55VQ3PU5=L4\-57;%/#55VQ3PU5=L4\-5
M7;%/#55VQ3PU5=L4\-57;%/#55VQ3PU5=L4\-57;%/#55VQ3PT/-7:%/#55V
MQ3PU5=L4\-57;%/#55VQ3PU5=L4\-57;%/#55VQ3PU5=L4\-57;%/#55VQ3P
MU1=L4\-57;%/#55VQ3PU5=L4\-57;%/#55VQ3PU5=L4\-57;%/#55VQ3PU5=
ML4\-57;%/#55VQ3PU5=L4\-57;%/#55VQ3PU5=L4\-#S5VA3PU5=L4\-57;%
M/#55VQ3PU5=L4\-57;%/#55VQ3PU5=L4\-57;%/#55VQ3PU5=L4\-57;%/#5
M5VQ3PU5=L4\-57;%/#55VQ3PU5=L4\-57;$Y/TSG^'GHC_FBJ&8=LB)'$R,C
ME2HLAI/OD>F3N*P^"02S1249P0D_R[YJ5OF12;YD/4=(>HZ0]1TAZCI#U'2'
MJ.D/4=(>HZ0]1TAZCI#U'2'J.D/4=(>HZ0]1TAZCI#U'2'J.D/4=(>HZ0]1T
MAZCI#U'2'J.D/4=(>HZ0]1TAZCI#U'2'J.D/I<4CL\3")99R5%OFE4"DWR,B
M44L(;G,8B&0^Q5RD"0A,$$7?$@D$@D$@D$@D$@D$@D$@D$@D$@D$@D$@D$@D
M$@D$@D$@D$@D$@D$@D$@D$@D$@D$@D$@D$@D$@D$@D$@D$@D$@D$@D$@D$@D
M&2CW,6@J)]DOPFDTGR-EW&%?B4VE1]]2BG*/PJ,SW>VZ5XA]J'^99(5G2I1;
MG,8CV1_]!0W^YB?9,_\ M[F&]@WZ);O3[=CXS?<1/_$9Y1D+?,LPG0RSH"9-
MY\(RA)S>8H2<R,)<N8&E"8I(X1"XED(^&0$A"8G-(Y02RWPI*SCD'/C$RW^'
M1 9#G#FTC. -R)JR;X*)04??WA.(BC&$HGPRSH RF<Y/?"CX4%#E'^0&,1[(
M_P#H/M"D,8GV3/\ [>YAO8-^B6[T^W8^,WW.RCE(Y0DDTD@HF425'(0[7_#
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M'SF+*[?XA'B74FK+-O''702XQH>AQ.MB.(D;0S/6_GL<HM#,N*Y\,<Z-8P9
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M1"YNUL<F:YHX;L6=3M^ L;<]3[0H#?:S'2HMCR(^SHUU?OK6V\8: =-KXY4
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MU*FE56-=.AK!*^38PI $<4@%D5=A)KC'A',"*637RWQN: BC8KA/3-$7-/M
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M-BA<XS'"52!='([EA16\7+GGB<VSE19U*8;RPGB"*,2(19#^5%T,8I"HV/\
M"<]Z]CW_ +$23+MZN].ZPW"-UG31TBUY6@W%:QQ &! QT:: (21S+I[8PG+F
MN>:_N[AD:UXWM5KV.3-KFKTHJ>YB1"U.>RLL9U?'<Y5<[J@3*Z(-5=FJ]7CD
M://LHS[$68Y$ZU:!'93"?A//-8DA6ZNE1QT)RQI^"QJ)B=9S':(E=#DSI3T3
M/1'B!><SLNSI&-<5>X[I-L5^W+2$ZS-6-'/;;TM>>$29 ?(M"3%@RI#$T)*3
MD#8W4NE>T[9R,\YQ!DJ9M]5R;&N-#CWU-7M&278TSB=M($(1AOT/0958]':,
MLU1O58^XI1)-<*XJ0 H9JGO:AV?.LZD;D9S8</+XQQ.5TMTH[F#U5I@DL;?S
MQM_]JJX5-6R9Q9&WTY:ELM*-8@A1V%17H]6O_!1%?DW'4X4F2QI*DU[73YL,
M\*MN*>(\ IUC52I",21&@DE#0BJC.!$<W4Q=6)\Z5YUK8<.CD[G >RJI,1MO
MMZ(H4DV]0UZ<R5&#UD6IJHPR(9BJS)R8O'F/,J6;?K&7LUUS!D5VN@,DE0W<
M496\XL JQ")\%#-<W)S$54S666MW)%.^9#@0*J522 VMO)L0R),(=7&559)4
ML:(4CD5[5 ,;G&Y:)A9]?SVH*5)@RXLL#HLZ!/A%4,N#-C/[8,D!$XIQ145'
M-56JBKMZ;;MVL5=Z;+O=S5(*(<\4^A+54[;5OG<$Z?/;,@NYB!YS4"B'TMR7
M7BF%,2PCV\K:,7<;WR*J5%C6X8\>&RZETJ:%?+%#G2FHK$:CE0C%8CF*CL6S
MK(=S2NJ:V/<.!;54B+(GUDN6VOB2ZT2<UTEI[ C HQ=)6D(U'-3/$*6>LW .
M;8S35T';ZU;EOY4N.!\H[10VE4/*#$&I'%4J!1OX6I43$[<],O/''K[8[ RA
M%CD%.J4E"E5\^.[0>/(B3HCPF9P5KFKBQL4KZU20O8@SVGL8O6=#K=T:>=:]
MWQR.\VZHB=GF\?A8'N2]-U. C:A))1A-(Y1;B9"KHR-"%I3O:LR<Q."*N6+2
MPGNLZKS-8U-990;"KDLLHYKX@ATQ>I 204T>R4J<MS-6>3DR1S53 VR85_UE
ME6VZM80*DDB7MZI>60%LV[&$CVQF.?$+I:-2E>@W*UJIQPB'?83Q-JX%U+EU
M$$EA#K:JV*0%1-GR!JC!"M3 >@<M2JC%<N3>VQ;5T<=P<U"U5NG!J)I15I5K
MXUF"(91L<\LR5%DYL&)I%S:J.T]KJM#V3+BG-3S:2#/KK*JD,LANW(?JU&<<
M2-UITF-9'1S1N&KEU,<BHBIEA E'=PR!M(U/<),J) 6[=GV!0 JQWI>V%%;:
M/E"Y+F.(W21KG:6KGC;;62H<9MMN6'3E27%DR721R85B9(L)8YPI&F/+&:J%
M)K&C&N16YJF5=7PGV.FVE6-=6V1ZR3'JIMM5-DDGU()A6M1\X((17]'+<@W(
MURN:K?MJZQ9VLB-8P8VI.DD6SEAKS@)_&%_64)E_'&BXD?GS?TCON:O_ #%A
M_8C8O>7\IYLE:/\ 3Y:Z?_'%=YS1R6'5 =<1^C4DC0G-U<M59GJ]SA]P"^!\
M/\+I^"[X'\K_ -WW"/X'03I^'^#\#WO=_=Y,:ME/B3T49HI&D4;7%"]'H(KD
M1?BR9?Y%R7L8!UK1UKDBZSR\^7S]"<[EYHB\OF9Y>]B(T[=N,)YPW"JMVHX;
MZ-$=N.V<WD.$UC%E*Q4ZWP\+YN?'[AN?U]8_['[%+^J:[^QAQ854M%=$LX,N
MOE-1<E6/- 2,9$7L*HR+AFR+]U"2C90S-NS-PQ"S$MK6"^I-5Q) :Y4;'K;'
MMF$.Y2&&JHY&-;FFFBC;@)111;0VQ>4E::L=)(Z[LK:C3;X[&0(HV>:X(8>M
MRQT4JJ1Z=MDSCLBP-(C/%MGV:2MERV#UZC3SR=HF20#-,NK(W;Y.GCVR8VTR
M3,A%\R^RMVQ3\I"?&6*S84GK0]2)_5=,9?Y6>/9_539H4!MKV5[@]G]N2/KY
MI9%W4[2K.MP=29<L?F$J]MQ[9N+[;[Z#:E;:R-D6>U8FYH<VSDFFR9HH<=TG
MJ4AJMJH<IL7F&&CBNU(U$7),;F.R?'A@N_9^/:L5[AN*2-: N9=L"686;6FA
M->4>IF>;D14Q42+^KVPD[;5W'M85*.PLBU]PU]1:U%L*9/08"PN:RS0L56C>
MH7B[?6CL/BMI*J@)*GR9YX%1(/+!SC((:F/,DM&25+(,+=3]+4R1$RX8%MT,
M*I#N$FT_,5E;Q8^GKDQ8#HSC/,K>>X+SNU+[N-ANAV<6',VE[.=Q[266@G%Y
M=O;0-IQH-C&"[)"1XDB@>]6NRS143$VRMH=#<'F;-_9BPJ[JWNKL=](=<5,Z
MPL)UA-U.CI91XQN6U@_B#:%=S,;<-8]0NYFWKS<,N)MNSM;,L"-M^^CC *B!
M?KJGO/4$C#($SV*W1J%HTZ<IFW@5E712)T.]8Z%6D/(KX\JW?-?S%D'1#R"/
M60CC/5$U/U9(B9)BRKTFP4),]AP_9BQV1=+;AL6>!9KN&?4=4I/Y7#"0:Y&$
MLPW7LY9'58YI0$/%WUM5W/-'"K3%B!Y6LB(J?%HO%.G%A?W+ZB#9V&YO9=,\
MWPB'DQ(])[.]PNNWHLH@A///LB392IVB-8WEMXY*[&Y;?:WF62/>-'654YMR
M20)::=4LLH\>R"T R><89(MEV\9>6NL6:/[=<2*Q1/L(>U]C["I*VKL*_>A&
M[\9M>),-&@#3:TD%+,9YP>C=-@R1RY!%S1 Y9^TGS=8,H;[?-J6]J#HKG&I"
M2=J;:J.KR"CTJV2&34%3F#^!J1S>*8L+$KH$#SC=^R6TZCYTM+HP&>S_ '59
M75FV1:6'QLN18 E(HW(T;4<N2IFBN=[2A!EPV+O/<NT;F I$(J1P4%?M"')'
M)R3Y0K]O%5F7#MTQM-\8H1)0[OK=P2>;J^-BPX=E'((6G_7.=,;EGPX8]G5<
M27#<7:&^+7<\Y[$)HD1)\;>H1ACYIGSVNW*+//AVCOM@_K:@_P"^UV)'Y\W]
M([]P6-:\DC4@R2P8L@R@CSK)G+ZM$.5O%HWHKE]_3E[V$K;C:P:3ET\XQ84<
MIG0Y!1->H)L95>[M<N'!>E,;6D_LLRY);2; -M.ZR2.^!&%9&C,E:D*QJ<L*
M>XOP/=QN9U+ @[HL(%PX$"ML);FM6G:UKNL1]+Q]9*I=3$=GT,1<^/&4<=-*
MCQ 2R*2$X4D@XC1OU$B&D:.U0;>"YKFB8A[A;M"NYTVSD5O(ZS,Y8D$(CT,U
MW-U*_-G[W[C7_F+#^Q&Q>N9\-*R4K.&?;(-=/#L\<5LBP16SC0P$E-</DJAW
M,12(HN'+75V/N 7:H[)_2O2WM7<6^ZOW"-=*+DA.V[+?@\$_TON"[F/GH^MM
M3QY (I=2O!,>B#-I*]^EHROR1K$3W/<XQ8Y*6MV\]L^_=YJJ9*3((6FW#:&9
M(&='O12V#")(*F?:%*YO8^X;G]?6/^Q^Q2_JFN_L8<%(,2F(P;WC"CD:I7M:
MJM$CG<&J]>&>+Z)O6B'M]]+M*3O;F0+9EV$U+!(\,\3G)#@.'/C%:B(W)6FU
M]JO2F'5VY]JGHYDC;,W==/&ASV7,BP@U;XK+2M<)L:'RKR"MC&S"BO:_G<'=
MJN+'<9-MSXL^+NS]C(>W9,N(DZ;=GNHE%7QRR1\R)#ZQ,FLYG$C0M1W%V7&\
MI+JI92WM M<63&!.2RAR*ZX$<E;819?5XCU:4D*0)S7#16$ [BJ8;-NIXH$<
MAF1@J1'O(>0]'.:"-'"PDB296#<[2QKETM5>A%P[DV45^FHBW[LB)VM--ZQU
M2R=[D4_5":7=G0N+:HMK.L@5D:AVE=U5D\[U\X"W(6^88SD:CFCKX;*P"J=<
MALYZ:W)FW%O$GDK8=;54-?>OL2V8T(D:6>T"8TJ(X3$B00I6]J92*A%U)DFG
M$^[!=PO-E6Y66,HSGQNI/R:Y&2126!.)Y4(WEHK<R:DTYYIBCA>>AD=?&G C
MD8(R-BD@ ><C)["#8>(]^G2UKF:LW)PR7/%%&O9:QG[@L'U\-48KVC4<&9.?
M)D9<61FI$T9IFNLC>&6:H*@==PDMC/$(<17N\(.+G@B./IZL.<<*HY@'/0KF
MJBHWBF#7<';$>^J8,;K%D9VX&5,F.JG8%@P125DULK5S$7/F,RQ#VSN7;8=O
MSK&DM+N":->,N8<@=1.K8<R+SO-U<K9+&VHB99+VF/VN@U<ISG[GA;6BT[C,
M;*DS+6XKX%29A'#1$%-K+://^#PCO[*=MBUM7[=L+ =3OU^R3QH9Q/DD;&K4
MMI5N 7*S(@(B/5(_PWJW)%XX'0PF=9CR-I0-W1+<1VNC285C//#CL$/3J76P
M/,1^>2M=B[V]1;1BV<7;QZ@%E:S-RLJU1UK !8YQH/FB<X_5XYN.9&ZG)@-)
MY^K76Q9<BO'$:9'$;81^8A8!'HBBCS5Y+M(GN:0F7:HN(-/#FP)MY(W1M*@D
MUKBO1X![BO:NKD.1[4Y3IT2'8\_D:N9HR<YNCCCKUS.# C*5@!N+J<\YR9JP
M$8 FDD23N:U7:!M<[2U5Z$7&T [:M=O%E;QLCQH=C:]=DU46%"KK2;+DG%7/
M#)>;K5:D1!ZV.&<G;IVJIC;=334([^TW+*L8\8)[=E-& VLKR6,@II3H-@JY
MB'DU$9Q7&V&V(&TD2WC;\%;,GO4LVLO]C7%)23*F,V(A$LM4RP/VPVJKQB1Z
M(B:LH-K,OX#*^SC==@R1O?)9(A:6N=-:D9AGI#&CTUE5$&S/ME3%96&N8?7K
MAD8M< ;U.L@,TG*A'U@:00@32]J%[U:TKN#55<$VZ"YAEN1.*-T%KUU*:./F
MR8PRZ>KFEQA(KB!8Y2C:BJY$R7%/0NAO.^WH]TW;9+3-8T+-L.HFDCN&K%5[
MI?GQ,G9IIY?9SX;>W(..Z(/<%'4W;(KR(5\9EK CSVQW%1K$(X*'TJ[),\L!
M_6U!_P!]KL2/SYOZ1W[@5+N/.+'>+():\Z!DQ9"/:YIFH[-A4THJ:5]W/%88
M4&:2MIZ:94QNL2&OL)"RFM:LB096JF7Q:9-[&-HQ88C#D;;F3Y!W\W(,T4V6
MXZ@T)QTN"]6.S]W$BV\W7D,[;);&)U"8,;7M=RC+",Q&HT0VRT?DK?P'(G8Q
M;$#-DP(-L8SSUH"Y1W#,%D9S")EV[B1QHCU_"Q VZ@"(>):GL'2-3>4]A1$8
M@T9EJ1V;_P#P_<:_\Q8?V(V+U[4S<RLE.1/=5HU5$Q739(N3(E1 G,)&O9RR
M$8CG,TD[=N2^[Q_=MPW4<8RGJ*.VM "-JY1#0(!Y0QET*C^6]XLERXY8]GE?
M=0]J64+VAU=Q8-9M@LQ;7:GF@'.5U^ TB2-D:4KVL:Y>7F_-$XIDL#;O_6HT
MF?92*NKL)]'9U]+8V49"H2'!LY0! DG7EN1B)P?V,2=O5;[242))L81;=M1/
M3;G7JECB6,-MXX205-%1CL^VTJJ<%7$6DJYD_FV:S&T<^74SX51N%]<USYK*
M.RD!9'L'1F,<KM*]A<>:]CVCR74?>-+0GG%II!Z26CK$(+NO@61@]0/.C@)Q
M1':D;FYN:<<2MP;DL!5M7$Y;22"(]ZN*9Z"  (AM<4QS$=DUK47[V>-R609L
MZ%^R4);*_K;:KFUEQ K^5SF3'UTH;#N 4:=JJ9_^*9KMVCLI!I[X3K&"Z373
MH42XA#=HD2*>5+"(=B*,]%1[F<."Y9Y+B7NRBB[4F;8@CK0G!9I9>>'3ITWJ
MCE'U<PXW5V\T:_QNG'LZI=]1-IO@[VOKFD//H$LFI"*RNA/H!(LTSD61/LRD
M:[AERV\../:?MJRB1HM'LFNM+2KL1\U"SHFV92UVXR%>1R@(@9WP-&634XX]
MA([:HIX[_:O^UTJR8%)B=0@5( 2Z1T%2&74Z9$E,>17YHN?#&_*Z^IZROFU-
M+NN]V64*R4B7@MJELH\^%(4A7.64!\1CU:/)W*UK[F*O>\B-&98S=H-W 2*+
MF=425YM68HFZG*7D*1,NG/+'LRG[LIML+M[VHSY555+1EGMN*V9',2,TDJ-*
M(01HCC-36YOP&K]]*G>MH]M[+WG=[>C2@4TD-/%TV)04==.L1!Z@"=+"WM$5
MRN<G;.R3C@U5</N8[8<F)#LKGS%:.V]5R9S0.BBGW75TA"4J21]#G(BO1%XK
MAVS0K;3K4$R%7SSUU-83:JJGV#$)$AVEH +HL,Q6.1>*Y-S[94PM 6;.YL:W
M3;LFY9637[<@WY]+64LR[:/J0;!Y-+-*KVKE34J9XM-V5,2'-G09-6$<>?S>
MK.;-L8\0BOY#QDS095RX].-[;!-$ALK-M4=#9Q)8^=UTQK0(2'9(U/4/+:IN
MUR1.C]V$ ,IT&7%F1YL.6W->48#^.IB.;K11N7AT:LE[&(T)M,_;ZAL+YQ*D
MEF.W( DJ^LIKI#I@BF;_ -4ZSUMH]68&G0?#3]PW/Z^L?]C]BE_5-=_8PXDF
MCQUEG#',4,5KVB=)*,;G#CM(_M!J9Z:<UX)GC?L'<U#(KMU[YVQ/KCW9Y<,M
M16(R/)91[=K0@5\EE3 /.>]SE[<Q'$([BY,J[=UIM213?LEL_<5>&M).B%E7
M.X+\]#)E!@.$]XDK(X]O(P1B*UQ'R.+6Z..^:S=6PK"1$MMU6FYHT -A ))D
MCL[R/-BI#(PX>KV=3H20UVMN3QII=GC=F\UV_:$G[HF[/H:;;DZZ?8WDP<27
M(AQI%G8EZV./)<>_D$>W-[ Q8Z9NZ<5!8E9>RY]78EGU=EMJ=#B6]+8K7RH(
MY#!SU;%EPY,::4)VOS;H=\%W8).D;?BWEQN?V1TNT)[ZV9&@5E9NBLD;@DRU
ME(1/BJJ0FX?BWA:_M@JW2B.14M!ILT%\M[[(]E;'$])T%GF^ZJ:Z]C303.L-
MS;3%):-YQF*JIR6]H[/M=U;/I[ =C:TOLG]D-;),"8@5D6&VMY[EM)-;(E,Y
MOF^7;18&GXSBU#HY45N+*YKZ/=);ANX=A7,ROWE>1)<G<4/9UJ>>ZNCJ,AXT
M=1!E/4+B+D8R#1V2-QLC=@MD21#I;V];.J'&J_.Y(=K0$KXMH4:/ZJB,G.R(
MSFN>T:(_C\'&RK6MJ%NUVQO(%U.KPNC,F'KG[>W'2DZIUI6!*04JX$16*YN;
M&+V43%YLYNW.VO/:,F\ ;PZS%ZI"JY&ZH>Z%*;MNO^>Z>,%8(!-;H<@AKK1O
M#&XJ:J$T]A/B#%&$YZ":][9<<JHKW<&]HQ<55ALQ@G;GJ9-E%BN,9 ,;7;EI
M+#;]B]SU^%U%\T$U&_A/B-3%5U".%OL^B@I-R$S,U"MW5MO;EALJ!#ZJB=N%
M]2:%(U]@L)/>QS%AC4:^W+]L5S./CM[S#U+K67\?K'#E].+YST _9D?;PJS9
MY6ESD0X,F[EW*T)0KFY TIY911UZ$B\IOX.-P[EG[ 3<:3;#:TNAO62XK"5:
MU57#CE>HC$81KH\X&M.G/+$X;:Z,DV1[=*S>J/1X>8^AC;VJ[0DU2Y(O-;4Q
MR=I\++M>SAU FUF26B]M-?[0?VH?+B)'?0DWQ!W"[DH[.8MM7P".B.$J(WD
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M;RM5XVG?I5[47)53WD7 ?.<Z/"ZQS.3SWZ>9RM',T^[HYC?OX!(G3H\4,GY
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M&/6"?^/Y1C99<[2WZI?G/U]DE0-V[G26H?.I!NE(LII>;U;0G_KY]C'K!/\
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M](,>K&&FMKFX>VI;(TV3F#J]$5%<U>W5Q.#,&-N*MDU\Z+:3X BRH+ZQ]M
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M&KGQQ4W$W=5/'J[X$R13SGRV=7L15X^;,ZJ].!' :O%OPM7#IX8JG,WI3_\
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M>YJZ8.CB%GVJ:W")#@!&I7SR!,UA.IHQN?,1-.![?H]U55E;'B==CQHQ]?6
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M)M+B?L3=VXI6Y*"OA@G7*5\^YW ^.HHRKE) YAV$Z=.3D7W\>WDE/ML\2/N
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M@6V CFHCBBU$5NIO%-6/\0:BHMYS3[S;[)R[<_:ED)VY;@=':_\ 472AP&A
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MD1?>54A*J(N.HV$?JD[0\@]+M<68(;D:\L0N>:Z%<FICLB-S153)4P3\X_\
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MNNYVZ+6-;ML4=4F45#0A!(@DK71#Z'M(\##9E=D]45?M(WYN1_0/Q<?\ ?\
MF_<W_D]_^-^]I^ZV_P"B[W?=;[VG[B=8E3MS(K (O8#GVS_WR*G#WOW\7G_
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M..!V4RCII=B'1R;"550)$\7+^3Y4PT=\D>CL9.X8=/D4]2>>\7(?.-6PBS7
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M +*X$*4[W^9WO\SO?YG>_P SO?YCLJV=<R)1:(B30K2,B_CJCPJXAX\^>\_
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M0QZ"$6F!^?>E8&@J,-5E$ (Y0S$E4IMD:+JBH4T +.89CLX+3'2B5;5_?G^
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M8)NL\RVW0)-."U++%9L!/,V\O'T<Z-<;0WH9MWW'3"F$?24<[<PX@4BCTF'
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M5)%,O2!#["06D)'73JJ0R3*6@C*"_#CDH_Q'R2V8+AJX)7,A;(2!H8T1-HJ
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M@2\P6 )0-4SNN$9\UK--B[<VG,8S,W(:B8<P0[@M=Z5I[M'*G"Z&F(%G@U%
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M3$7LGD5HYJ:F4>)D @LERT30$/V?/ -R;C?6P33$%=&HI>@"R^F*S91#T);
M <^".2 !=!0$I/BID96K4@%WEZ]N_P#<94O8$LCAVSP@0&KFE['=K),7;$%!
M+$-=Y L4^.#=&XKY76S:L,+LFC!70(@,J@T_&)3#I+K2NB[!)XPP;_ 'P0NC
MU-4XKFE2.?RE1I6E"_-3M@ PD+.&'W)_C_-:VO(-:67,Z6URMKVT_P"!Y[&<
M;YKYF>O O74?H;=?OYJIX5M)VAT;IF:G2 Z92Q&[,1BJ"1*>R74\44X1GSE0
MI?8DTIE$>Z>?H[!2%$/!1GV>J@B J73(D#"['Z*2;7_3S_'GE<#<I+"(72V
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M4$XCJHH+"S @+)3Q)0TI*D4+ MT:$'.!YIVYU0.H'4#J!U Z@=0.H'4#J!U
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M-&3<=18.T,I8&:B9?/>9I9A0_(F>_;1(JT$.K?NOB9+E/Q"E[SL:W;FW7/\
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M!10&#2VK5XXA+WCU[JT>1*KKQ=.OCQHR;#VX)*J'7%(+Z-.T-7<RP %9*6*
M(;)X_&.4$JF:Q3Q737*#1R*+TH9@L!6%K<5T--^<T3)M-@"^JVAP")D@L/F[
MH)RM4C:DOS/E$9KP2 [ZV_4 V8"A.H1B'#<I.RL^4P(D9$-F,#X%3!J!RVJ
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M6+%BQ8L6+%BQ8L6+0\C^W "Q8L6+%BQ8L6+%BQ8NBU'9<W_=(\OBR+RK7(V
M>I5+%BYTD>DCTD>DCTD>DCTD>DCTD>DCTD>DCTD>DCTD>DCTD>DCTD>DCTD>
MDCTD>DCTD>DCTD>DCTD;]/S?&_Y-Q)%=&IS$W &YDGZG_.',9<S^JBGY,1:V
MP848R3'3D"B%1!EIEA0JZ!C#F+@FZW72J:*WYRL:+NO*L*WE2;L%:-@49NF
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M*UT&EZ2@2_;([@=PI-Q/##3^6A+PY0JA*)DKQQ?_ /\ _P#_ /\ _P#_ /\
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MOOOOOOONFI81UWXAD-D<Q5;=? @%<HX;ZU9+UM=\Y9XX@
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M_3M/\F\-/L.DJ;>'IX^L9O\ 9=)7T$=8?:WE9FTV\#[S]'K]&WAO'Z=_'?\
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M@5SDEKH *NGQ3#;89G.)\4%7*\>GVGNAHJ]=$$!"5LN?L;?]')]2S3JJ:,
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M3\ "  )22+@     >.\"CIL2R2    2[E8QJU.9     JH[@   ,EK-$
M0LC     !M4I@     9'):4JG58UH   "2-R3R       "2"""   "0 0
M  "0 20    2 "2     "" " "2 ""    $DDDDDDDDDDL
M                                    #R2222222223OVVVVVVVU6VV
MVVVVVJVVVVVVWTVVVVVVVTT!]MMMM=O]MMMMMMJ>2222222222>DDDDDDDDP
MDDDDDDDDDDDDDDD[0        B#"VN#V&<XSREP  /R222X/"2223TDDDDDD
MDE$DDDDDDD@DDDDDDDD        $<0R CP#T#QN""  #^222#8Z2222>DDDD
MDDDDTDDDDDDDGDDDDDDDET        C@ZYJV1!:(8@%<  ?R222+!R.223TD
MDDDDDDE$DDDDDDD@DDDDDDDG        $>/OGMO_ )OC /<   _DDF1,)\&D
MDGI))))))).))))))))Y)))))))/        (\ $D:8ZD2$< ]C '\DFP')B
MH,DD]))))))))9)))))))/)))))))/@       !'CW[)_P"$VUF^V6X /Y))
M)))!))))Z22222223"222222202222222F        "/"L            !_
M))))))))))/7;;;;;;;1;;;;;;;:+;;;;;;>(       )A _@
M "/_ /\ _P#_ /\ _P#_ /T:VVVVVVVFVVVVVVVVVVVVVVVVVVVVVVVVD#QM
MMMMMMMMMMMMMO!))))))))))+#?_ /\ _P#_ /\ ]_\ _P#_ /\ _P#Z_P#_
M /\ _P#_ /\ 7_\ _P#_ /\ _P!P(R2222222222222$>2222222222>UCT
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MF 6QT+\DD]P               $       &P       !''-A0L[(-I*,K)X
M_DDX6BZN*DDG$       &        @      #X        (\\(%@
M  '\DDDDDDDDDD_V[>V>7_2SSV>?2_ZRWS?W7^VY@       #!-E
M     -;;;;;;;;;;>+EY)/.MIPYY//N-MQ!I/LNMA-DDDDDDDDG(\MMMMMMM
MMMMMMMMP                    @       $        @
M          #          '-2222222622222222222222222222222208;?_
M /\ _P#?_P#_ /\ _P#_ /\ F\DDDDDDDDDD]-MMMMMMM=MMMMMMMKMMMMMM
MM(@       &"&D4*SL,=<U1C0  WDDDA->0DDDGI))))))),))))))))I)))
M)))*H        (\?++;A_P"&WPVPP !_))).)N[)))/22222222022222222
M"22222230        1X4)W=,PWD%>-N  /Y))(_QW))))Z22222223R22222
M22>22222229@       "./\ 8K;\JU?E]J@  ?R&^D@42^/R3TDDDDDDDEDD
MDDDDDDLDDDDDDDS        $<;M)_P#?Z>>_;CC  _DDV9;U;L5DGI))))))
M)*))))))))!))))))),        (X\R4XZ<^"F>3^1 '\DDD,DDDDDD]))))
M))))9)))))))+)))))))C        !'F?             _DDDDDDDDDDG/D
MDDDDDDGDDDDDDDD\DDDDDDB        &@XA             '.VVVVVVVVVV
MX?\ _P#_ /\ _P#]_P#_ /\ _P#_ /\ O_\ _P#_ /\ _P#W_P#_ /\ _P#_
M /0'W_\ _P#_ /\ _P#_ /\ _P#_ /\ N
M
M
M                                         .'V_P!;A?9\     #;M
M_P   $   *?]W<?_    (   @^P                     IPHT-4JLR
M   ,T\)@ (  !FE#<DWP  !   )<T                       H $
M*H2222222222"22222"222222022222222>@+;;;;;;;;;;;;;:]MMMMMMMM
MMML(@         (                     (..              !<=MMC,
M8==MCQ?_ /\ _P#_ /\ _P#_ /W_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_
M /\ _P#_ /\ 1P#PWVWDWW5_E]P /G=[2?NRL_'8+_\ _P#_ /\ _P#_ /\
M\_\ _P#_ /\ _P#_ /\ _P#_ /G_ /\ _P#_ /\ _P#JCS1YIYKH/%ZC;M0
M?$;LNRFB'X1P7_\ _P#_ /\ _P#_ /\ ]_\ _P#_ /\ _P#_ /\ _P#_ //_
M /\ _P#_ /\ _P#\'F_?S_:[?;>>?V  ^V"<0F"@$@VPO_\ _P#_ /\ _P#_
M /\ S_\ _P#_ /\ _P#_ /\ _P#_ .__ /\ _P#_ /\ _P"X. AE&L!5\QX\
M$$ !]L]U"YB63#MA?_\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\
M_P#/_P#_ /\ _P#_ /\ ='CXO--9X        ^V;H^N'"HMVPO\ _P#_ /\
M_P#_ /\ _P __P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ _P#_ /\ ^ZC@F* U
M20        ?;;;;;;;;;;8:@         ,            #@       44, 0
M 2          #]MMMMMMMMMMB\DDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDWC
M$DDDDDDDDDDDDDE<
M
M                     -LM-Y]O]Y/--\-]CC_\@
M                       !]Y+]+8)-?93(+/S/YR\
M
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M^R+82"5N"LV3G4KEP5<P:6Q#X _.,*J$11&*I Q ''%GEXIP 8H:GLT@ ?\
MN4\J,JC!1  JU!(&O.FY8HK!H3S\$R./O)"$96X2&9BN8B *UE%_\5/:7UDF
M![1M&:X<L!IB,,;[<@=!0I89AZG(Y1$M2BHSHT\MJX08XB!];G2^#-O0MU34
M1@J^E7<^Q[:A,7*WY66ML02TA0>8/9K2;"$H-:8?PY^ ?+LB:XQ;.Z#"2I1H
M0:O +"#R HE62\F(R%6!U/,]@MFB%9?R4&<6I9*ZYI(8>VI32DZ&?@(FS4U*
MM(LF'$S9K"@!JGV6J@8F,R'H-*!8J/SAUZ6&P*8R-HDNVKN,-3)COO'IAI#M
M!+&&@CG);FA"R<TB \\[QRF&5,@LOR+K1\L2B+BQ"YE9T45Q9%O+)@$P,,=R
M0:\?JD\5?)$01C8($KRRVY8;FCN<):87R30'+O?=IF(BH@FEK!^P)K+-*RV,
M).)JR"P7B2D!-",AZ-' ,P4-Y#)0)L3K[5\+F T6HWH($%8FH XQ6RQ=&(3.
MW%[#9!C2Q++0BB3)IG?N9<B'!AQCHT%&>%KU<MI0 W%N_.?+$[T822 ;FUDO
M4?I$/ \4BV21*U4>ZG,8(EH$[X'\^B!T,8E>.K@0^B K2+C$*:(M(T3#?,)_
M:+\>8&#=I)"23Z\LT^KX6VY\QTA00C6,.RJ(&2*8[?GN.AZHC:KTL.IR6$UK
MTLB(='S8,H)CNB$,M+:\.'&=;%H@3W>*I$9UI U?H6D/A[1=K%E\^DU4#$QF
M0]!I0++JXA[M2:$0A26Z8SR03$<[$!9W\(CKV(7T''B* I0 T&Y 7=6DTZ&1
M1$;+[0TV8'FT3$NU#_85_)!$E"&Q^D[S?FK?,KZ8]C)X. ;E@NXT=DEX?8$#
M5D!\^P\_F5[E2Z7RD23?'Z$&6M *F9)REJ):)_$GO*(\AT&7ODA]I1CJ=R(1
M')3Z3H90@X5 (Z+^WF>!'N3A4PI$B[HL[8-L.I:9J@:)CT4D784(-Y+MB2-G
MO)5B-/,B^61*MM<=7I))2;TNB-BRD7*" ?!^,FJDEO#;M5*P!=C3D5!/CGJA
MBI24M A1,-S*.1M->@&]2#G@R)=8YB=ZQ$HM=$@)MD($A,E+MC5Y2)5FZA!2
MZ'-9W\5!)2!(9WE.2EY> "WUS*[]P"?CB&KP]^@K=",()G9>@/.+@YL)4SRP
M!FLBML.VO_=L!A,^S+^0$":@([Y'#F((H$2D2Q'")HB1O3J%PU-"Q5$MW&@M
M9<\D:0D09'0"K2(]TKSK UY0YV&F X'=: M:V&%O-101QTJ"QD52QO !&N$.
M@208U!3)<<T]8-&USV$@U+YF6TR;EY90(X!FG6+IHVULERK2E6*",ME0;N*I
M>D<Z3=VO:W8J[9Z:ABP"@PP#&=H>Z)!GJ !G\UMM;-G+[+04*M(-N9>C%5+H
ML0HY89(5B50-&E!34#J#D%KO9N@3 Y$B_6E,SLA1RAH)5.&.4(H8; @>=!+@
M: $I0"'(&K [:0$$-  6VT%!:_14KJ7=<IHZROT2 0")2)8CJ(X2    !0!0
M!@ TJITVUBPY854*P:!FHP '6 8(4$4TH%4YQ3)[%F0:.&4J+JJ-DA7F-9RT
MT@>AC$I541-&T=T(#8*R2\-H T"BP TTMK3E]"/>GV>0P:O?3" @34!'?(X<
MQ!% HI$$3DCA)F604J+#A%6!"(VI>0G!+L!NF/.J0YZD!8B?M4#U0%BBB660
M6V&VI9+  54 6NJUN_23>H_#D5<ER7Z8! *! 6#075J>PD&I?,RVB@;-:,FM
MB*&V9 0V*S6B5;S@XSJ@BL%(0H@((-  >@4$H *:#!R!6,M8 H!5H 48%&5/
MN4& 04&AHEZ)*#("@-&B7HDH '1(!6BJL=2+II<C(PJEJ-M(&#*U$KI1'#I'
M:D2Z[=9Q"BQJ!]ID]02V[3:+J9.M5W3!<!E#,#Q+D%^OFWA6#0,U&  ZRNQ(
MAC!JPH*&ID*%!"A8.H.H-3(RRZ%F[M*I;(OD]0N&AH88'65'_BF*-10E*C62
M:"31TBA3A2H3D4L,Q=KR$>H!9@<M913:[%4VWC J&BX;X0IF*E,:IU:TJEE?
M6HHXDYE=<(Z)PWGSY\^?/GSY\^?/GSY\^?/GSY:,>]\0#V&0N."8]B".J3NC
M5#X&9]_:<*>(BB >!@X[A%DIUJI1?_%+!M28A!("(C04M*N8W74_FQ^<X='
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MDFI0%QV-U0\U0!@0*X&TE_BSW@27CK_6ZS'1 ,8#FVFIY.5KJL%7_)[<K0X
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MB.,:LY^\C)@FWT!:Y^"C*F-4V6@0!),!-M+XMTVV6\>Y:[G*K[5(<W@C,N9
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M0*P9S$^P6VPFDYL$@.XRI%/!@6X+I0SC24:&P*CBY*$@!QD="&#"@V5<1.U
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MD.H0U]N!5@CS-N("8!# (+JY3/&\HT)<E5J!.VVJ-X9!<5-N#HSY$^X4B*T
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M;%GBZIDGTV<K0X-*911(GQK21R6INQ8C17P3)^^AP.VTI(P[N$R9\'V,C@2
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MI:>RDG":O";7#&[Y50E &S@*%^KN*U):BQZ1PL+># D*!(5<0 P#S!8H( "
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MSIK-3^M+>D<%5(0>3I.@_,]6_P"A%R&!&@VKTZ=F@HF9VX0XPH<-2J[JH-D
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M0"U !0"RU#CZ=$8M.2=[P*YU;12T7204 RZR\W+E\^+%=:\/7VH:B!A9 (
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MPPPPPPPPPPPPPPPPPPPPPPPPPPP=07F,_*)7HO2/)9;=E#19&0@B(^5\G#K
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MI.@)9<8WV!4-&X%FRQ"L0;N8D2#0-A<&\5I,3N$9.2S1!1D+692*(M:B8JN
ML,*J,]N 6@UDHVN%V<L_XM_TOS?68F.6HIT7 &5(YSC$5^U"]?-P64RKFHU(
M3;6U&,9:W9RA44T,48 7!S=Z8J-]#-((C<0FV@E9A:K.C"Q5&CV"BPN"!2!!
M06(4B)8F1R2B)Y 4@88+V;*#!X8FIBP"C7()U5*I\,2I4J5*94KPH]HE2F5X
M5_LJ4RI2RI4KPKZM*TATNQC3&I2L-,\KY.'6>?P-_J FEF<B[&A2M+!_Z",&
M(H.T9?29++L7<]O+ZS3QI88NZX:+J]]Y9M+BRY>;@RP\%MERR7-Y?^PUERX9
MF+ER_"_K=>5\GV EO"64)PH$["; HI.BW? S46YV I3&;C"B[%FZM3F:8+2M
M41*9Z&\;"PH.'<DVJUTO @X'*/,:J:\C$HLF?M+-=X&583>=L;QH!,%2$(SI
M7-G_ (.W +BI CM V':L96BWX9%U4KE*\:E8E2F4RI3 N;7*@7*E8N5 \ Y^
M%2F5*E1P^#KROD^Q9A6LJ"JI;0')6&46);%$.C>1Z%Y+F1$[(46;,0: P!E&
M'PE*N\C@*B^6L$B5O 0S2C:*Y 2KF*U)6BKSTS]E8QM&+R$BQQ20MD!;)9N8
MY??2I2$K%RF!SFLIB) '&\J]):KB:])4WJ5[Q.4IE;RFH%M2L7]YPXZHV 0V
MI9JV9:C.DHK4$U)A-0HYX6+JZTTF*J;V37$)C]S'[G7K+G2$LUAK"M])>.LO
M_(MG67BI?^2S]0Y18,O$LEC%AI'7P=>5\GTJ" "U6@#55P!NLSX:LD&I:EFY
M=ST5GO3-)DAEDF,D;':2:#5*0&XY-R#HKWA0/H-/2"C":L$LO2S4O:]=HQ2U
M7@.+J\.EB7I8FT;)6&L()3I@09+N\+$81*,J" ,HEAEE+>59GSBQ;#BFCREH
M/+\(&B,J:#7$0C5&4Y%[]55U^M8+;1<<K!<5H<NK# JQ;T^\2R%5B8J++-=X
M:RPQUEZP:;@TPB\/67GI-6+<O-P0SO,5F7!IN;?>'.Z62R@,M!7H,>F4EV!/
M4="-A<6#A(ND1J)6/K,_6X^JGPI^MUY7R?3=] T$&Y::Z(!?WEI4*M% V!:R
M72F*9AI!J?#<;!_< @4(-[&=Q31'E4%8U 3*(%0<#*#KH+8*=TA%0%SI%LW[
M1)S\$XRQE(, YHV1LPLS@CJB?PZ 4!8Z!3C,W.ZVXI3#32"A**[%3#9.0 '&
M-@@5":I:7=!PD+ H/K6*4TW'*P7^)<Q]HEV&BJ7KE?\ HY?B(IP$"40RBL/*
MBJ45.7A8NK->4YR_>7C\R]:YS>^L.:#[PB^>L9>^\M)?O4OWCO\ B8_&)><\
MXZ9@XZSXE_Y&7_DN_6HM_2Z\KY/I0" HI'(CJ)N0 7E  !EJ@"K5K2UYLS]"
MZ +YT%7UU@!0'56??6/M6BH^J OYC0H--EET\SKUCR,6D%7-)AZE,-X"62HR
M9L)97.#STR2V #+1<G,(-0-KN#JX#+1?.B])C8'0HHK2C0K;E!TAE(!')I8Z
M+]:Q9* 'DH!_#,BL^;86.6W-N?\ H-DI7NY7T %78%F#Z(:: %+0"K1R0\+%
MU3*KZ+XEUY7R<.LPY(26LB9<[%=8Q'REW%>4U1A9#:,Z8WK;VAU&7%KI0U0:
MYT@_,9;P=%J8>EE^L+VFK  >:@Z#*TBJ"-@\BB<X84;'0!KY+!U8814X$1KR
M0WZ3731RHM=K!>D,LI;!)8/5,SU"<.>\M%Z,WV6,YZ&V%>LU%V@OEIM9!ZL1
M!NLX*OQT]J+R(#R-!756=)H++Y>TMZ4=2;3+&;Z#?*O5C+>#HM3#TLOUAD!4
MX00#SHOH3331RXI=Z%.D,*-CH U\E@ZL<"-#H(U\@JZDUTT<J+7:P7I'("MP
M (7G8?1C+>#LM;+UIKTF^RQG/0VPKUFHLOE;2VM%U8O(@G T%=!;T@(-5/)=
M>.OM307:"^TF]A#J3;98SGH;Y5ZST"<.6\]5ZD<LI:!!:'4,P5>JD+$.^H=(
MX14Y$!CR25ZRYM;RPDWR CUEZ15!&Q>1%>4;VF[( >8AZ)&6\'9:V7K37I*B
MUTL;J%\K4?B&T9VQG6VI+JDPKL.@78Z"7/),;'GRF@NT%]I-["'4FD2U6B3>
MQ3K#:,C12F'I9?K'+*6@06AU#,I4 *1B'F@=!C*H0*L!'.:,B.FJ]10JK:KE
M5=5W>"8M0>M\ ]T#F(Z/@FI/ OZF:J:X.+9W0+RL2_5 ZH:L#] H@B#"<,=.
MG3ITZ=.G3ITZ=.G3ITZ=.G2#>!9!U'E%K1@+9A]@$& [("=2-&8LB7>ZPID"
M((:505*6)8(IPJF9>F^[]T6R-D'%:'*.MI0<FK0E+1=<HB@X.@(1 (D$+!3>
M EB 0-$:   &#2&N2!=J@&P  K""9@*;!"99";!+2LVW-A(3@JQ%3#C)K"Q3
ML&(*% %K%L]UQ>-"O07I;6K.>R+=O(')O-YS+5$U.P-&RT%MRA'.LHF[+7D>
MIIC2!*P4E-%%*BC!G!-=4!YK]6#0E)3,,?\ >30<U1O8FEZQUM*#DU:$I:+K
ME"^VM= H00&E+-FIL)"<%48*8,8-(:Y(%VJ ;  "L()F&^2)4JH&P4HK*JYF
MPD)P58BIAQDUA?;6NB4J +0%NQ4=;0@Y%T@+2VKYSGLBW;R!R;S><S35 >:O
M% 6+8%S$EX+ NRFQ99ASDAG24W-%*P/4TQI*5$W.PMFBE4IPK.>R+=O)'(O%
M9S/9<7C4JU%:T7H0L4[!B2E! :Q9,0 6BBK+%,&E#1 4V D2B!T""E8HJ#4"
MS<)MV!<U57 2Q (&BD("@3)K$T')T@2@%0"I: ;1UM"#D72 M+:OG*TWW?JJ
M6!HJYO5YPTJ@J0H2@%;E!<R]D]!W8;-E@7;F>8/?D?\ !B4J)N=A;-%*I3A6
M5@.P/M+AID4E.=8:D$54:O*JZ+K6B%BG8,24H(#6+(6R0HL%$ 1(0P*:,$!
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MS8[-CLV.S8[-CLV.S8[-CLV.S8[-@8C&SB]&BUSI'DFL=.L\7 E1 K&%!_\
M^>@6U$Q9*93I*93*93 YZ2I3*QF5RE,%*]Y22G[H7*Y2F4W4INMY3*96.M_=
M,)4IE.LI\*QUE,1-8F:)3*93$37[P%6RC]RF\2F)7_,P9>>D'+#8G)VA6^L4
MS++)IZH)B#C\Q=<RS]0K\RQ6"8ET5UEZ_=52R[WEZ:2P?Q,7G2660<)O+Q6]
MS)^X.#,L_<:R\XO*M(92%5GG%,Q3\L4I"66R\_B"8@TQ^\-'6#C\RS]R[N]9
MT?\ *5A#K:B!>:C/TLF3)D&W,*KX##)DRP,F3)DR9,F3)DRND-0H\['.76"R
M!$ J: W@P^,R.7#*T(=K!PH($"! @0($"! @0($"! @0($]7NC7KOO:OSQ80
M($"! @0($"% @0($"! @0($"! @0(6[S\:-;Y^/!! @0($"! @0($"! @0($
M&L0,Q=810&L#)14+EK>Z <:MPFZL@!"E130E%B8%4HE \@?R>0/Y/('\GD#^
M3R!_)Y _D\@?R>0/Y/('\GD#^3R!_)Y _D\@?R>0/Y/('\GD#^3R!_)Y _D\
M@?R>0/Y/('\GD#^3R!_)Y _D\@?R>0/Y/('\GD#^3R!_):PA.=O]47Z6>L+U
MPLYT:N!2DC)AP_BT:@Z#D40)N6%FYB,H<1<BU>=6V=)#TD/20])#TD/20])#
MTD/20])#TD/20])#TD/20])#TD/20])#TD.T]*]FM+_5K^)TD/20])#TD/20
M])#TD/20])#TD/20])#TD/20])#TD/20])#TD/20])#TD/20])#TD/20V$77
M:)6%[W4O&-YTD/20])#TD/20])#TD/20])#TD/20])#TD/20])#TD),#F684
M2 ;  4/ /FZF[T7?2J;&F,$5#C80\"M ]L''OGOE8T>^#QKI]:AET\;VW\+O
M3P$=/I"4G44JA2U3<-,TC62)[+Z+(AA&MKD:GA:\VY\-6JO71^UW^*KKQ8R_
MJ.6Z[_5<]N!1Y8N+J!,BW+404"M!(>)B@$%$1&IYER^BZ3'648F*E9S-ZE2I
M4J5*E1.4K-2HE2O\E2LU*94J!<J5];KPK0HQ32^(CL!HVA]YDE$J6#D<%!@F
M# 4PA4RC N%]WR"S??L2;](O-[F4O,;34/<HAT!F:A/)PZBDRID@Q'49RG0@
M-2;GU%?]ETO(4M]& (]B*D1D$$8\"6E%=RETNQLU<T91RE$%12'0K4QV29@4
M@=NM)H0KT#H)<*,@505%YAFL "Q I#@,\S3@;'?)K,:A+:Z2-77!*D$@-(MW
M-7*P[P=*@BF("RUT)-"3E!92JZS!U!LZ!:D9>?:B<AHHFH@Y9<* 9 B<8L_!
MM>;<^&LPL_!>GI=?FNE\6J37HKTZ+]FN>W!9W+P%M"AJI+<D*2>9<OHNK@YN
M7+EYN7B=)<O27+EW!U@R_"Y?BN7#$N7];KP@/MH <!2Z+M%5D=E?80I:$!BT
M!$OT*&3 0F(U"#!3F_/"\TUAK9_ "SR_!>XF^-X]JFJU 92V(W&WB-%-L,WM
MU(]J"19J)PV:&%$#2]/1PFDW[_1@&U=)KMRU*5=;7+K&;2K5MD0+,E35//B8
M2E=!;3) 11]L*Y&8E(!!#(6FDG"M5(#FPE 0+68 LFG"GAYE6&'?K@=,,L)*
MZ;@!&B-J.@O8B9S=!PD1@2R6@=MV%<RC#<WY"HASTT>T0/:V%T744!+30O!>
MM&U[\_"UYMSX;NKKT57YN^E<7_33RV57NCR'@C[! EOW2(X+HV* (I>^6+ %
MV&#8EM?0ZHNI7*)BY5RF!?A4K>5$J5F4RI6)52H2@](E,IE,IE1/LNO"%!>0
MS*9FLD P"D49NI1+<02BHRIB[&5= N4FL$:!7T8A0O(%_P">%187M]42C);<
MD4 N 5@MT+6N''KRA80H:UMZP1 ::M8/5@@H*&O3UY38&F^WO!$!IJU@]7Z;
M7FW/AJU?Y?VNOQ5]:XL9?U/+==>Y?+@LN66-+FN*"133MI0&.:"C1=YL; P!
M]#J\WM,$NX5+_P!EGM"8KK+Q+,RS\LO:8=9M+TC5402$L<18NLL8LLS+_P ^
MRZ\ 0JUAY]+4T8-W+BW@@T^($B@ ,@A$UF>P)D=  QN*S]T[\JP57/Q@02<
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M'YE2Y#*J=%WGGC[[QX\>/'CQX\>/'CQX.A")LAS&!K*W1P3#=M4&P:J*&5&
MOQUVM;0]6'\$[I3M#D 79V:/!RM$J]93;BT7%2-\LX/RA57+M"$JM5K0 M=
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M9MQ,HP8%Q*=2^P&5@2]00%$K$E%"@:0>8  '   !0 8 , 8#@G,%")D4E?\
MB2#D?!V[7F]3J.31CI,^V*7<+&WBR-K0;M.KG:.2+@6-IC$<181*HFB8X9*E
M2I4J5*E2I4J5*E2I4J5*E2@B'088&J +:H&6"1Q&TA6ZR-Q92]@F-&&Z& YL
M(3(#?@5+:LC0*P"58PQ2"%#5 ,J%-V!T@$@;(2@*H-U;$6%?I$80!:07(1I'
MQCJ!&2K;)5N-:\@"RK,BDR4CA8SOZ(  2"0$6 553<B/XLH'6HY9(E'90)M1
M +FC%YGG+7EIZ5>30G)KC3LC,1@, :30MF8J7VHI04*&LHHC8E%-*JFBM1=8
M:"P#!9!=J+R<N9IJ\GK0M<K-(K"HS54R@BRP;9&#54L#I ) V0E 50;JV)KP
M5."1 @0M6#J3<B/XL(/6LY98UKR +*LR*3)2.%C&/ 0HKS(),@ 8";D1_%E
MZU'+)$5X"G((@$@&K5U8'2$2!HA*"@H5=$Y-<:=D9B,!@#2:ZO)ZV+?*Q:BA
MJ&@L(P6!5:"L')F641H"RVQ=9%>@.LT+9F*%=J 65@#I.;7&G8&9G X4TGG+
M7EI[76#5B$=A FQ$(.:<7F6&OV(.05:V[L*QG?T0"( DJ)L%N[EF>B[$@-H
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M!EE1D<D14K@2U9>9383+8.):4!:L-JEG@*T;U*7,I*XN^X.R6$S4L%:+(--
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% /JG_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>t1701829_chrt-iga.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 t1701829_chrt-iga.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!VP/H P$1  (1 0,1 ?_$ 0$  0 " @(# 0$
M       ("0<*!08! P0+ @$!  $$ P$!              8$!0<( @,) 0H0
M   & @$ !04)#00%!@H'"0 " P0%!@$'"!$2$U<)%);6%Q@A%975=Y>8&5DQ
M(M/4M196-]<X6'@*DM*VMT%1,B,V<9$S)#D:88%"DU24M"5VV+%B4S1U)B>A
M4D,U1F>'B+@1  $# @(#"0@.!@8(! 0#"0 ! @,$!1$&(1(',=(3D]-5%A<(
M42*2%%0V5AA!87&AT3*R=)05=9665U)R([,TM(&1L4)3<V(SPR1V-S@)@M35
M&4-C-3F#A"7PP?&B1&2%M2;_V@ , P$  A$#$0 _ ,N>M7:'>1??/"P_&(]@
MNC>7?(*+B(MZ?F4Z<YVYXNOTN?E!ZU=H=Y%]\\+#\8AT;R[Y!1<1%O1TYSMS
MQ=?I<_*#UJ[0[R+[YX6'XQ#HWEWR"BXB+>CISG;GBZ_2Y^4'K5VAWD7WSPL/
MQB'1O+OD%%Q$6]'3G.W/%U^ES\H/6KM#O(OOGA8?C$.C>7?(*+B(MZ.G.=N>
M+K]+GY0>M7:'>1??/"P_&(=&\N^047$1;T=.<[<\77Z7/R@]:NT.\B^^>%A^
M,0Z-Y=\@HN(BWHZ<YVYXNOTN?E!ZU=H=Y%]\\+#\8AT;R[Y!1<1%O1TYSMSQ
M=?I<_*#UJ[0[R+[YX6'XQ#HWEWR"BXB+>CISG;GBZ_2Y^4'K5VAWD7WSPL/Q
MB'1O+OD%%Q$6]'3G.W/%U^ES\H/6KM#O(OOGA8?C$.C>7?(*+B(MZ.G.=N>+
MK]+GY0>M7:'>1??/"P_&(=&\N^047$1;T=.<[<\77Z7/R@]:NT.\B^^>%A^,
M0Z-Y=\@HN(BWHZ<YVYXNOTN?E!ZU=H=Y%]\\+#\8AT;R[Y!1<1%O1TYSMSQ=
M?I<_*#UJ[0[R+[YX6'XQ#HWEWR"BXB+>CISG;GBZ_2Y^4'K5VAWD7WSPL/QB
M'1O+OD%%Q$6]'3G.W/%U^ES\H/6KM#O(OOGA8?C$.C>7?(*+B(MZ.G.=N>+K
M]+GY0>M7:'>1??/"P_&(=&\N^047$1;T=.<[<\77Z7/R@]:NT.\B^^>%A^,0
MZ-Y=\@HN(BWHZ<YVYXNOTN?E!ZU=H=Y%]\\+#\8AT;R[Y!1<1%O1TYSMSQ=?
MI<_*#UJ[0[R+[YX6'XQ#HWEWR"BXB+>CISG;GBZ_2Y^4'K5VAWD7WSPL/QB'
M1O+OD%%Q$6]'3G.W/%U^ES\H/6KM#O(OOGA8?C$.C>7?(*+B(MZ.G.=N>+K]
M+GY0>M7:'>1??/"P_&(=&\N^047$1;T=.<[<\77Z7/R@]:NT.\B^^>%A^,0Z
M-Y=\@HN(BWHZ<YVYXNOTN?E!ZU=H=Y%]\\+#\8AT;R[Y!1<1%O1TYSMSQ=?I
M<_*#UJ[0[R+[YX6'XQ#HWEWR"BXB+>CISG;GBZ_2Y^4'K5VAWD7WSPL/QB'1
MO+OD%%Q$6]'3G.W/%U^ES\H/6KM#O(OOGA8?C$.C>7?(*+B(MZ.G.=N>+K]+
MGY0>M7:'>1??/"P_&(=&\N^047$1;T=.<[<\77Z7/R@]:NT.\B^^>%A^,0Z-
MY=\@HN(BWHZ<YVYXNOTN?E!ZU=H=Y%]\\+#\8AT;R[Y!1<1%O1TYSMSQ=?I<
M_*#UJ[0[R+[YX6'XQ#HWEWR"BXB+>CISG;GBZ_2Y^4'K5VAWD7WSPL/QB'1O
M+OD%%Q$6]'3G.W/%U^ES\H/6KM#O(OOGA8?C$.C>7?(*+B(MZ.G.=N>+K]+G
MY0>M7:'>1??/"P_&(=&\N^047$1;T=.<[<\77Z7/R@]:NT.\B^^>%A^,0Z-Y
M=\@HN(BWHZ<YVYXNOTN?E!ZU=H=Y%]\\+#\8AT;R[Y!1<1%O1TYSMSQ=?I<_
M*#UJ[0[R+[YX6'XQ#HWEWR"BXB+>CISG;GBZ_2Y^4'K5VAWD7WSPL/QB'1O+
MOD%%Q$6]'3G.W/%U^ES\H/6KM#O(OOGA8?C$.C>7?(*+B(MZ.G.=N>+K]+GY
M0>M7:'>1??/"P_&(=&\N^047$1;T=.<[<\77Z7/R@]:NT.\B^^>%A^,0Z-Y=
M\@HN(BWHZ<YVYXNOTN?E!ZU=H=Y%]\\+#\8AT;R[Y!1<1%O1TYSMSQ=?I<_*
M#UJ[0[R+[YX6'XQ#HWEWR"BXB+>CISG;GBZ_2Y^4'K5VAWD7WSPL/QB'1O+O
MD%%Q$6]'3G.W/%U^ES\H/6KM#O(OOGA8?C$.C>7?(*+B(MZ.G.=N>+K]+GY0
M>M7:'>1??/"P_&(=&\N^047$1;T=.<[<\77Z7/R@]:NT.\B^^>%A^,0Z-Y=\
M@HN(BWHZ<YVYXNOTN?E!ZU=H=Y%]\\+#\8AT;R[Y!1<1%O1TYSMSQ=?I<_*#
MUJ[0[R+[YX6'XQ#HWEWR"BXB+>CISG;GBZ_2Y^4'K5VAWD7WSPL/QB'1O+OD
M%%Q$6]'3G.W/%U^ES\H/6KM#O(OOGA8?C$.C>7?(*+B(MZ.G.=N>+K]+GY0>
MM7:'>1??/"P_&(=&\N^047$1;T=.<[<\77Z7/R@]:NT.\B^^>%A^,0Z-Y=\@
MHN(BWHZ<YVYXNOTN?E!ZU=H=Y%]\\+#\8AT;R[Y!1<1%O1TYSMSQ=?I<_*#U
MJ[0[R+[YX6'XQ#HWEWR"BXB+>CISG;GBZ_2Y^4'K5VAWD7WSPL/QB'1O+OD%
M%Q$6]'3G.W/%U^ES\H/6KM#O(OOGA8?C$.C>7?(*+B(MZ.G.=N>+K]+GY0>M
M7:'>1??/"P_&(=&\N^047$1;T=.<[<\77Z7/R@]:NT.\B^^>%A^,0Z-Y=\@H
MN(BWHZ<YVYXNOTN?E!ZU=H=Y%]\\+#\8AT;R[Y!1<1%O1TYSMSQ=?I<_*#UJ
M[0[R+[YX6'XQ#HWEWR"BXB+>CISG;GBZ_2Y^4'K5VAWD7WSPL/QB'1O+OD%%
MQ$6]'3G.W/%U^ES\H/6KM#O(OOGA8?C$.C>7?(*+B(MZ.G.=N>+K]+GY0>M7
M:'>1??/"P_&(=&\N^047$1;T=.<[<\77Z7/R@]:NT.\B^^>%A^,0Z-Y=\@HN
M(BWHZ<YVYXNOTN?E!ZU=H=Y%]\\+#\8AT;R[Y!1<1%O1TYSMSQ=?I<_*#UJ[
M0[R+[YX6'XQ#HWEWR"BXB+>CISG;GBZ_2Y^4'K5VAWD7WSPL/QB'1O+OD%%Q
M$6]'3G.W/%U^ES\H/6KM#O(OOGA8?C$.C>7?(*+B(MZ.G.=N>+K]+GY0>M7:
M'>1??/"P_&(=&\N^047$1;T=.<[<\77Z7/R@]:NT.\B^^>%A^,0Z-Y=\@HN(
MBWHZ<YVYXNOTN?E!ZU=H=Y%]\\+#\8AT;R[Y!1<1%O1TYSMSQ=?I<_*#UJ[0
M[R+[YX6'XQ#HWEWR"BXB+>CISG;GBZ_2Y^4'K5VAWD7WSPL/QB'1O+OD%%Q$
M6]'3G.W/%U^ES\H/6KM#O(OOGA8?C$.C>7?(*+B(MZ.G.=N>+K]+GY0>M7:'
M>1??/"P_&(=&\N^047$1;T=.<[<\77Z7/R@]:NT.\B^^>%A^,0Z-Y=\@HN(B
MWHZ<YVYXNOTN?E!ZU=H=Y%]\\+#\8AT;R[Y!1<1%O1TYSMSQ=?I<_*#UJ[0[
MR+[YX6'XQ#HWEWR"BXB+>CISG;GBZ_2Y^4'K5VAWD7WSPL/QB'1O+OD%%Q$6
M]'3G.W/%U^ES\H/6KM#O(OOGA8?C$.C>7?(*+B(MZ.G.=N>+K]+GY0>M7:'>
M1??/"P_&(=&\N^047$1;T=.<[<\77Z7/R@]:NT.\B^^>%A^,0Z-Y=\@HN(BW
MHZ<YVYXNOTN?E!ZU=H=Y%]\\+#\8AT;R[Y!1<1%O1TYSMSQ=?I<_*#UJ[0[R
M+[YX6'XQ#HWEWR"BXB+>CISG;GBZ_2Y^4'K5VAWD7WSPL/QB'1O+OD%%Q$6]
M'3G.W/%U^ES\H/6KM#O(OOGA8?C$.C>7?(*+B(MZ.G.=N>+K]+GY0>M7:'>1
M??/"P_&(=&\N^047$1;T=.<[<\77Z7/R@]:NT.\B^^>%A^,0Z-Y=\@HN(BWH
MZ<YVYXNOTN?E!ZU=H=Y%]\\+#\8AT;R[Y!1<1%O1TYSMSQ=?I<_*#UJ[0[R+
M[YX6'XQ#HWEWR"BXB+>CISG;GBZ_2Y^4'K5VAWD7WSPL/QB'1O+OD%%Q$6]'
M3G.W/%U^ES\H/6KM#O(OOGA8?C$.C>7?(*+B(MZ.G.=N>+K]+GY0>M7:'>1?
M?/"P_&(=&\N^047$1;T=.<[<\77Z7/R@]:NT.\B^^>%A^,0Z-Y=\@HN(BWHZ
M<YVYXNOTN?E!ZU=H=Y%]\\+#\8AT;R[Y!1<1%O1TYSMSQ=?I<_*#UJ[0[R+[
MYX6'XQ#HWEWR"BXB+>CISG;GBZ_2Y^4'K5VAWD7WSPL/QB'1O+OD%%Q$6]'3
MG.W/%U^ES\H/6KM#O(OOGA8?C$.C>7?(*+B(MZ.G.=N>+K]+GY0>M7:'>1??
M/"P_&(=&\N^047$1;T=.<[<\77Z7/R@]:NT.\B^^>%A^,0Z-Y=\@HN(BWHZ<
MYVYXNOTN?E!ZU=H=Y%]\\+#\8AT;R[Y!1<1%O1TYSMSQ=?I<_*#UJ[0[R+[Y
MX6'XQ#HWEWR"BXB+>CISG;GBZ_2Y^4'K5VAWD7WSPL/QB'1O+OD%%Q$6]'3G
M.W/%U^ES\H/6KM#O(OOGA8?C$.C>7?(*+B(MZ.G.=N>+K]+GY0>M7:'>1??/
M"P_&(=&\N^047$1;T=.<[<\77Z7/R@]:NT.\B^^>%A^,0Z-Y=\@HN(BWHZ<Y
MVYXNOTN?E!ZU=H=Y%]\\+#\8AT;R[Y!1<1%O1TYSMSQ=?I<_*#UJ[0[R+[YX
M6'XQ#HWEWR"BXB+>CISG;GBZ_2Y^4'K5VAWD7WSPL/QB'1O+OD%%Q$6]'3G.
MW/%U^ES\H/6KM#O(OOGA8?C$.C>7?(*+B(MZ.G.=N>+K]+GY0>M7:'>1??/"
MP_&(=&\N^047$1;T=.<[<\77Z7/R@]:NT.\B^^>%A^,0Z-Y=\@HN(BWHZ<YV
MYXNOTN?E!ZU=H=Y%]\\+#\8AT;R[Y!1<1%O1TYSMSQ=?I<_*#UJ[0[R+[YX6
M'XQ#HWEWR"BXB+>CISG;GBZ_2Y^4'K5VAWD7WSPL/QB'1O+OD%%Q$6]'3G.W
M/%U^ES\H/6KM#O(OOGA8?C$.C>7?(*+B(MZ.G.=N>+K]+GY0>M7:'>1??/"P
M_&(=&\N^047$1;T=.<[<\77Z7/R@]:NT.\B^^>%A^,0Z-Y=\@HN(BWHZ<YVY
MXNOTN?E!ZU=H=Y%]\\+#\8AT;R[Y!1<1%O1TYSMSQ=?I<_*#UJ[0[R+[YX6'
MXQ#HWEWR"BXB+>CISG;GBZ_2Y^4'K5VAWD7WSPL/QB'1O+OD%%Q$6]'3G.W/
M%U^ES\H2MX-[%V#*\MM#QTI>[E)1[N]-$G3%_9YMXS<I99/<Y3<-7#Y1!9/.
M<8SU3%SCW!C?:_8K)3;,[S/3T=+'.VC<J.;%&UR+K-THJ-147W#.?9FS=FRN
MV]97I*VZ7&:DDN;4<Q]3,]CDU'Z'-<]45/:5""@S$:Q
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MS'6?2T=34,;ANZSH8WM3#V<5T>R=(?,'T6]=1LFR=QTBQ<*M7S!^V69O6;I
M^4UVSMJX(FNW<(J%R4Y#E*8N<=&<=(O$,T-1$V>G>V2![45KFJCFN1=**BIB
MBHJ;BHN"D:JJ6IHJA]'6QR0U<3U:]CVJQ['-7!6N:Y$<UR+H5%1%1=T^0=A3
M@                                                    !+G@9^^
M%Q__ /CYG_["^&,MLW_*Z]_,G?*:9\[+G_4%E3[59\AY$89-,!@
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M<MOVWPQV9L27=EFITKE8C459UDF=$DN&E9DIEA55<F/!+"F*HB(E5 V/-&0
M                                                    ESP,_?"X
M_P#_ ,?,_P#V%\,9;9O^5U[^9.^4TSYV7/\ J"RI]JL^0\B,,FF P
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MG=+)$Z)9U>K4355%GCP3!&X+@W0W!(GC)1@@
M                             )<\#/WPN/\ _P#'S/\ ]A?#&6V;_E=>
M_F3OE-,^=ES_ *@LJ?:K/D/(C#)I@,
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MFX;T=;7:(_*>K_$5EWX]I?FC]GV^^D?3/0@.A&RKTWA^Z;AO1UM=HC\IZO\
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M^:/V?;[Z1],]" Z$;*O3>'[IN&]'6UVB/RGJ_P 167?CVE^:/V?;[Z1],]"
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M(^988G\+*D:8N5D??NPP:F)-P8L-A@
M
M
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MKM45$57;:^AHZ&)FHD<\\[T=4),KFN=A'3JDC$8K5UD76545,)SB_F&0
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MF8;C;JBOO$E0UM/2OX9(O%E8DNM.W]F]T;Y&QR)'BULFLU'NU<2P@20P0
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MI*F*NAI?J]KTFJ6RRM234G6)SHZ>5L*I,L+G.D2-6JY&*Y$+-A*C74
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MOQP<Q<6N5.[@5N6\Z6;:#L9SWGK..7,NQYBL]M@HJ2KIZ*.GQ6Z3+"C4@8G
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MPBN3"K9_Y)E/&,YR8_0EQDGS!67!TCTLUMIU8Y$5=5\N"O>N&XJL;WJHNX[
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M(FY.8?B7<JY=,K]XUW[CBA09!8V%<PU-T5'MFLTSA\]7H;1]I=.8J06(7/\
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MBY9F<Y:^]W*Y7F=%7%55CO%J:1RKI<LD$N**N.XY%W$QN($V-3@
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M>F8^6&17N=+!-22/CT-9([5<FLKF*U6M1['K<2)H:I
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MR?=;I59BN%5"CZ6>B;!!!3Q4R0HK)N'>Y[T6*)-7@VHNO(Y5141'6K"7FL8
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MXU];?I(DNEWK(V4W"0P*KHZ:CI6OD>V%VLY'OF<R3OI6JQ[7QNBMI$Q-7
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MJ#E!Z^=&]\VJ/G$J'QP'1W,'D%9Q$F]'3?)?.]K^E0<H/7SHWOFU1\XE0^.
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M?TKSJ@OQ\/JJZ>35'%O^ =(LO^7T?'1[X>LK7/Z?TKSJ@OQ\/JJZ>35'%O\
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MOQ\/JJZ>35'%O^ =(LO^7T?'1[X>LK7/Z?TKSJ@OQ\/JJZ>35'%O^ =(LO\
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M'UWYO,OP8=<VU+GRO\-/@'JN]GST3M'%+OA[#O$WN'UWYO,OP8=<VU+GRO\
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M8I..JN7'U?7$KNDA?[2O]X.O/:OSS/X$/)#U1^SKZ,4G'57+CZOKB5W20O\
M:5_O!UY[5^>9_ AY(>J/V=?1BDXZJY<?5]<2NZ2%_M*_W@Z\]J_/,_@0\D/5
M'[.OHQ2<=5<N/J^N)7=)"_VE?[P=>>U?GF?P(>2'JC]G7T8I..JN7'U?7$KN
MDA?[2O\ >#KSVK\\S^!#R0]4?LZ^C%)QU5RX^KZXE=TD+_:5_O!UY[5^>9_
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MR]34]YHIV30RMEJ56.1BZS'(CIG-545,<%14[J$KQC0SP
M
M
M
M
M
M
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MLS&.0KN/=H/6QCIYZJA"KME%4LF(;W,XZ>G&1\!]P
M
M
M                                                       (I<S[
MUP^I>BY5GSJEM41G';8%BJVO;&ANYHQ=ZQFYV;ED7]5A;.66:NH-!NXFH=-5
M)9]V;5)=$AC*%SU0!JV\Z*SX>%-YS>$PAX-YM",N;\GS?UPILB,X73-8?5B3
MX:>03+??;O?)M4NY"JXKD;'M614\2?2\3BU9'*!,XS[H$J^&6\M/\"_&R\:'
M2_*G9-,T2CRDF>-7*OCW=MMV2$U]3=FTTM%M$3L-"$MEID(>OKNZE;)\D:FW
MP?RA=9@_Z.MAMG.0.R>$I&4CF[X@OCF\Z8V!97[B)R?N?'/C)JN:F88C[7V\
MX'CSI=WJ[;DU&LYID9*STQ^Z:QZ;=R3!F;HKMPGG&3I&(F!@A33>NMOPO+7E
M7P<T'K/77!GPV:;R-V;PPUUK:@P[6G\X/$JTSK"[-V?)>6A8MI[W["UCQVMD
M3BN:_-GRM&0LAI"0;J8(@B3(&0/#,NTA4.8GAX5_3?);:G(^O\P_"]M7)'FO
M'7O?\[O1I";BC5-'R%<W,M&3U@F?5A.V>\7J<@#,V2;)FJGTMBML999RD!L-
MVOBEH^ZV*6M5BJ"+Z;G'9GLD[,IC!G#DY2$,IG&4\]'24F/](YH]R)@BZ#BK
M&KI4Q?PRBFM;=<DZC%=NE 53D%:(2OQZJZBZ4;&-HR(RFT;84-G"2.#FR;JE
MZ"X,;.<8QTC[)IP5=W ^,T8I[9-P=9S
M
M
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M $-.)_\ Q?RU_F8N'Y,AQV/_ +OZJ'%NZONDRQUG(
M
M
M
M      AIQ/\ ^+^6O\S%P_)D..Q_]W]5#BW=7W298ZSD
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M5VU3;@6O@
M
M                                            "&G$_P#XOY:_S,7#
M\F0X['_W?U4.+=U?=)ECK.0                                  !C#
M:-[UK5(V+K.P]FP&LG&U7K_7E+>R=QC*9.35HDH"7?XC*0_?O&:Z]L;1,<Y>
M-BMNNX)EODY<=)< #4HY0\?M<<$_%J\)J6T)R$V=S*Y![FY!,M17O1?*C9&>
M4]GUAQ^E6J+G8?(F@R]J]\[/I6QZZ@'*KQ!\@HUS(MTU<$R=%!UC(%MW,;A?
MK-_R*MOB,:?\1*9X$[0B=6YT7R(O]>>:9M^M+92*)*/)-JPV#6]J,)> B+S2
MGINP0=%,D[0(GA$R63=  @IX(T?!:LB/$4\7/DWR"NS[3/)_:-&I.DN0/+"5
MBZW;+?QIT&>5U_1MNS:JK&O1U<A=T7&TG)!Q*3)J1-DP9%;)F361,<"_/EYS
M-TAPOXH[*YA;6LK-356OZ22VL%H=ZT=.;\]ET4$Z/5:6KA0S65FK_+OVC.-R
M4V43&<E5.<J!5%"@0 \'OB7MFMQ&W/$0YF0Z;?GAS^DXZ_WV%<E<'-Q\T8T;
MM\:3XQUQ-_CRJ'94>KI-EYA+JIKK2ABI.\KJL2+F BER\X@\=KWSA=Z:X,:V
MC8OG#>KFAR7Y"[[R_F+5IS@7)6)FQ:XY2.=2R,BMK%7FWMN&;KH4$IF?OJF[
M,I9'F"M6J9G8%>FK-B[MT9QAUIR1XG[RNFJ:5(^+!7^#G#SALS1@I:D;JUNV
MY&/-2[6MG(A]+Q3V\;1Y![L<PMSN=CM+EZJ]8'21\G,DFADV -V<
M
M
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MK=TX[93&3XPH?!@)X
M
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MNDRQUG(
M
M
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MIN7D*[<0L(HO'.'"1$DUU&JF<EZY2EP;HZ>C'W DT8)[1\9[/ND[!UG,
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M7G,
M
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MMJ3V$\HC*BC3_>XO\QORD-ET>EY/0
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M5RTK]LI\35M6[FO%DIU2?U2J4&3,:T[3]7-CV)!Q]E69':8C7[_L"%6RDH;
M$Z>3',NO:$V'I#0]1I,WN_DCR"LB;2AZ8I\BRC7\3KR&>-\[(W=L>P/$7C*@
M:HU[#F4,I).TC9DY8S>,9$5=./\ =@3.
M
M        $-.)_P#Q?RU_F8N'Y,AQV/\ [OZJ'%NZONDRQUG(
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M6[B9D47<NJV<.%E3X VR@
M                                                        !#3B
M?_Q?RU_F8N'Y,AQV/_N_JH<6[J^Z3+'6<@
M        "!OB*_J 9_*%7/R98!@GM#^8+/M"'Y$I9[W_  :?KI_8I1D-'B)
M       !EC0OZ\],?*QKK_&$.)5D/SXLWVK2?S$94T?\7%_F-^4ALSCTM)X
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M1#%H24=-6GE6,D1QC &PL
M                                                         (:<
M3_\ B_EK_,Q</R9#CL?_ '?U4.+=U?=)ECK.0
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M"\73*Z@JE(3TL?*^>HP:.5,@6(@
M
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M&Z&TELW:EDA./9I:R5]71>M76OX.2S#;&WE(U5[$R$F94IZ] JF7[,YWB&<
M0L\*KEOQ W=XY&U\\?-:[;HFK=9\&-.<">(E97X^["IM6HU0I1+3R*W+$WQQ
M*Q;=#5+IA8*ZW;,L3O9/IYT[+E,RAE.E0#.G.?A#5=+;?7TSI/;&SM_["YI\
MP;+SKU/X:,YBLM-&K\A$K)7+?L'DER2V-%Q!MAL>(>L;PS;660KKQQY#-3J;
M2(8E577QA(#"G'SE9R+X=ZOO_*;4[+4FY-$3WB35;BANW9VU6EE<<N^?VV)G
M;4#H7:'(6 L<0]3J5%I]3O$J^C-<TM)NJRBZM7.H8J9E3]<#<8
M
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M/_N_JH<6[J^Z3+'6<@                                  "!OB*_J
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M9F']2NK>05TL$Y:U+RV181;:P6E&I66U2DA7V,DY6;Q+U\98O:'*7. +C
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M^<*R_P!#1U-<]]-+60L>W4B36:Z1K7)BD:*F**J:%1>XIMV#2DVI
M       .D[+A+?9M<7^MZ^N&->7VP4FU0E(O^8=I8L4:WRT$_85JX9K[\Q&,
M[BLS+A%[Y&MG"3KL.S/G!39 &J5S*TIR&\-_E;X64UH/Q$>8_(SDIRKYK:\T
MSN'2V]=A,[C2-S:#48*/=V[$4H,5#,8J@0>MHMBPPJ>/1*W8(2'E6,X,SQD
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MR98!@GM#^8+/M"'Y$I9[W_!I^NG]BE&0T>(D        &6-"_KSTQ\K&NO\
M&$.)5D/SXLWVK2?S$94T?\7%_F-^4ALSCTM)X
M                      5'^-+^Y]&?+)2OR%<AFS8'Y\O^82_+B,5;8O-)
MOSR/Y,AJA#<XU<        "0W$;]Z_C%_,-I;_,BM",9V\S+O]EU7[B0O^5/
M.BV_/Z?]\PWIQYV&[(              !63XIWBDZ&\*S0C';&VLGL=WODNX
MJ&DM3Q\BRB9C95T21;J+HGEY$Q8ZMU.OD?(+3$LYSY.Q163QG!E54B' K/\
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M&\=AZSO>E++QYK<XRK$#H2C<?]<(N)926BDG\K*6%NOE=55;!C ;W
M           #JS.\TF1L+RI1]PJSZUQV%,R%99V")<V%CA'!#*Y>0J+L\DVP
MD50N3==,O5QG'3]T <A/6.OU6-5F+/.PU<B$3IIK2L]*,H>-245-U4B*OI!=
MNU3.J;W"XR;&39^X /IBI>*GHYI,0<G'S,3((X<,)2*>MI&.?-S9S@J[1\S4
M6;.439+G&#$,8N>C[H Y  ?&C(1[AV\CV[YFN_CL-C2#%%RBJ[8%>D.JS,\;
M$.99KAVFF8R63E+VA2YR7IQC( ZE);/UK#7&)UY,;#HT5?YYOAW!4:2ML QN
M,TU,94A7,3674@E-2+<QT#XP=% Y<Y(;'3[F0!S\]9*[5624G9Y^%KD<O(Q<
M0C(3TJQAV2TM-OV\5"Q:3J07;H*2,O*.TFS5#!LJN'"I$TRF.;&,@<T
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MAL@6N@"&G$__ (OY:_S,7#\F0X['_P!W]5#BW=7W298ZSD
M                     0-\17]0#/Y0JY^3+ ,$]H?S!9]H0_(E+/>_X-/U
MT_L4HR&CQ$@        RQH7]>>F/E8UU_C"'$JR'Y\6;[5I/YB,J:/\ BXO\
MQORD-F<>EI/                                             "H_Q
MI?W/HSY9*5^0KD,V; _/E_S"7Y<1BK;%YI-^>1_)D-4(;G&K@        2&X
MC?O7\8OYAM+?YD5H1C.WF9=_LNJ_<2%_RIYT6WY_3_OF&]./.PW9
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M;!K=#J\)=;5VBA5E?SAL\;%MIJ7[9<N%%.W64[13&#&Z38QD 96
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MLT#"[@N/E<<HBSYL<A]/R<EB?-8IYBKEUK:O.V6<UF(4)+K$+)NBY:@7[
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M+J.4'C-3_B2>$[X1[\OO];/X,C/Q0.E.:>=+G]+J.4'C-3_B2>$[X1[\OO\
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M )4\Z+;\_I_WS#>G'G8;L@
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M'Y,AQV/_ +OZJ'%NZONDRQUG(
M@;XBOZ@&?RA5S\F6 8)[0_F"S[0A^1*6>]_P:?KI_8I1D-'B)        !EC
M0OZ\],?*QKK_ !A#B59#\^+-]JTG\Q&5-'_%Q?YC?E(;,X]+2>
M     $#?$5_4 S^4*N?DRP#!/:'\P6?:$/R)2SWO^#3]=/[%*,AH\1(
M   ,L:%_7GICY6-=?XPAQ*LA^?%F^U:3^8C*FC_BXO\ ,;\I#9G'I:3P
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MIID*1-,A<$(0A,8*0A"%Q@I2%+CHQC'N8P /Z
M               0TXG_ /%_+7^9BX?DR''8_P#N_JH<6[J^Z3+'6<@
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MX/&OY9*)^76@AVT+S&NWS";Y"DGR7YVV[YY%\I#>&'GL;H@
M                                                   $-.)__%_+
M7^9BX?DR''8_^[^JAQ;NK[I,L=9R
M   (&^(K^H!G\H5<_)E@&">T/Y@L^T(?D2EGO?\ !I^NG]BE&0T>(D
M  &6-"_KSTQ\K&NO\80XE60_/BS?:M)_,1E31_Q<7^8WY2&S./2TG@
M        ! WQ%?U ,_E"KGY,L P3VA_,%GVA#\B4L][_ (-/UT_L4HR&CQ$@
M        RQH7]>>F/E8UU_C"'$JR'Y\6;[5I/YB,J:/^+B_S&_*0V9QZ6D\
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MAP:L<4JJ[6D;H5J)ACIQT+7+_P!X#XA_HEM'X(:_A1!^NG*G^'6> SE#:_\
M]K;M#^799^E5/_DQ_P!X#XA_HEM'X(:_A0ZZ<J?X=9X#.4'_ +6W:'\NRS]*
MJ?\ R8_[P'Q#_1+:/P0U_"AUTY4_PZSP&<H/_:V[0_EV6?I53_Y,?]X#XA_H
MEM'X(:_A0ZZ<J?X=9X#.4'_M;=H?R[+/TJI_\F/^\!\0_P!$MH_!#7\*'73E
M3_#K/ 9R@_\ :V[0_EV6?I53_P"3'_> ^(?Z);1^"&OX4.NG*G^'6> SE!_[
M6W:'\NRS]*J?_)F2M.>-GQ@W7M77NHZQ6=BMK%L>VPE.A7$A%H$8HR4Z^28-
M%'9R*&,1N19;&3FQCW"^Z*^U[6<MW:XP6RFCJDJ)Y&L:KF-1,7+@F*H]5P[N
M@B.??^W3MRV=Y*NF>[Y69??9[10S54S8JF=TBQPL5[TC:ZE8U7JB+JHKFHJZ
M,2Y$9/-!@                       P-R;UQMC;NC[MK?2.[9+CCLFV?FW
M'Q&ZH2L1%PGZ+$)VZ >71Y78&?S[RK624I#:1CXYPY*HDQ>NTG64U.QZA@-=
MFQ5GD5X6_BJ>&/IG6_-?DGRQUAS_ );?%!WII#DO;(O8\U$%UG3(:WDW?0))
MA"Q#NIH0;B65</D2D*U(S9*HDPH590S<#OMH<<A?%C\4#FWQ@@^5F[^*_##P
MYX73M#EV7&N=94C8>^.0.XZI(W"3DK!?7D1+.V%;U::$78FCFY2=HLFD?.<E
M=*=0"$$_SNYU<8N(OCJ<,+KOVT[2W]X<%TXUL]/\H9IHQ0V\KQ<Y?V^GI*7:
MR>01Z$8O<M(:>F7<PI-8;]D@NX34/@R+8IC 3+TURJUOX;7)OQ%JLCO?:.]N
M#>BN*G%/<T3FU;2<[_M\7RCVS9-FTV,TIK*SNEWDI+W7D''0<,X90!W2W6D<
MIKHE;H+J9 %K/AOZ@Y(UK7U\Y"\QK+.+\F^6=EC]I7K4I;"]D]=\9ZBT9.&.
MKN/&NHQ0R<>WSKRI.RDL$DFD5>9L2[M90ZJ9&^< 3N?7^CQCM=A(VVNL7S53
M*3EHZEV2#A!3&,9RFJDHL4Z9\8S]S..D?=5>XI\Q3ND6N(;QI(V3E:^8.4'C
M)WR3MJ[9TV5(LW<(J14,8BJ*J>3$4(;&?<SC/1D<Y/8_5.+=U?=)J#K.8
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M&;-@?GR_YA+\N(Q5MB\TF_/(_DR&J$-SC5P        )#<1OWK^,7\PVEO\
M,BM",9V\S+O]EU7[B0O^5/.BV_/Z?]\PWIQYV&[(              !3=XW_
M .ZAK[^8:J?Y;[9&=NSWYYU7V7)^_IC$6VCS7I_G[/W,YJQC<0UD
M"4_!_P#?!XU_+)1/RZT$.VA>8UV^83?(4D^2_.VW?/(OE(;PP\]C=$
M         U\_ZB?]V'2/R\I?Y?7,85VW^;])\\_V;SU,_P"U%_SDS'_PRO\
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M_>OXQ?S#:6_S(K0C&=O,R[_9=5^XD+_E3SHMOS^G_?,-Z<>=ANR
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M3OB<,HZ.W.Z4B/SGB9/,8=T9HEVN4,IY4PF7!NG&, #M[/75"C*(?5\/3JY
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M0W$;]Z_C%_,-I;_,BM",9V\S+O\ 9=5^XD+_ )4\Z+;\_I_WS#>G'G8;L@
M            %-WC?_NH:^_F&JG^6^V1G;L]^>=5]ER?OZ8Q%MH\UZ?Y^S]S
M.:L8W$-9         E/P?_?!XU_+)1/RZT$.VA>8UV^83?(4D^2_.VW?/(OE
M(;PP\]C=$               U\_ZB?\ =ATC\O*7^7US&%=M_F_2?//]F\]3
M/^U%_P Y,Q_\,K_/4AJ C60]Y0        F5X>'[]/$WY>=<_P"(F8E.2/.^
MV_/(OE(8 [5G_39GG_AFO_<//T0!NX?E-
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MTQ\K&NO\80XE60_/BS?:M)_,1E31_P 7%_F-^4ALSCTM)X
M 5'^-+^Y]&?+)2OR%<AFS8'Y\O\ F$ORXC%6V+S2;\\C^3(:H0W.-7
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MCSOMOSR+Y2& .U9_TV9Y_P"&:_\ <//T0!NX?E-
M              (:<3_^+^6O\S%P_)D..Q_]W]5#BW=7W298ZSD
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M_P!\'C7\LE$_+K00[:%YC7;YA-\A23Y+\[;=\\B^4AO##SV-T0
M    #7S_ *B?]V'2/R\I?Y?7,85VW^;])\\_V;SU,_[47_.3,?\ PRO\]2&H
M"-9#WE        "97AX?OT\3?EYUS_B)F)3DCSOMOSR+Y2& .U9_TV9Y_P"&
M:_\ <//T0!NX?E-                                   (:<3_^+^6O
M\S%P_)D..Q_]W]5#BW=7W298ZSD
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M$_+K00_:&Q[<C797(J)XA-['^@I)LDR1NS;;D:Y%7QN/<5/TD-X8>>9NH
M            :^7]11G&.,.D>GW/_P!>4O\ +ZYC"NW#S?I/GG^S>>IO_:A1
M5VRYC1-*]&5_GJ0U >G&?N9QG_QC60]YE:Y%P5%Q&,XS]S.,_P#)D K7)NHJ
M#IQ]SIQT_P"KIP U7(F."X#IQ]SIQT_ZND C7*F*(N SG&/NYQC_ )<@$:Y=
MQ%4=./N]..C_ )0"-<JX(BXDR_#O]WG1Q-Z/=_\ UYUS]S_XB9B4Y(\[[;\\
MB^4AK_VK$5.S9GE%T+T9K_W#S]$ ;N'Y3                         #
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M_&+^8;2W^9%:$8SMYF7?[+JOW$A?\J>=%M^?T_[YAO3CSL-V0
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MZ=QVR/TS3W:&N&M LLX=_J: B-5N)9"6?%:E<+.VB2;?M$ULI ;%@ AIQ/\
M^+^6O\S%P_)D..Q_]W]5#BW=7W298ZSD     :P/]7E_V-MT_F T3^7)0 ?E
M"@         E_P"'M^_UP>_F_P"-/^<]* '[G(                @;XBOZ
M@&?RA5S\F6 8)[0_F"S[0A^1*6>]_P &GZZ?V*49#1XB0        98T+^O/
M3'RL:Z_QA#B59#\^+-]JTG\Q&5-'_%Q?YC?E(;,X]+2>               $
M#?$5_4 S^4*N?DRP#!/:'\P6?:$/R)2SWO\ @T_73^Q2C(:/$2        #+
M&A?UYZ8^5C77^,(<2K(?GQ9OM6D_F(RIH_XN+_,;\I#9G'I:3P
M     J/\:7]SZ,^62E?D*Y#-FP/SY?\ ,)?EQ&*ML7FDWYY'\F0U0AN<:N
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M,2G)'G?;?GD7RD, =JS_ *;,\_\ #-?^X>?H@#=P_*:
M                  0TXG_\7\M?YF+A^3(<=C_[OZJ'%NZONDRQUG(
MU@?ZO+_L;;I_,!HG\N2@ _*%         !+_ ,/;]_K@]_-_QI_SGI0 _<Y
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MG_=ATC\O*7^7US&%=M_F_2?//]F\]3/^U%_SDS'_ ,,K_/4AJ C60]Y0
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M;2W^9%:$8SMYF7?[+JOW$A?\J>=%M^?T_P"^8;TX\[#=D
MIN\;_P#=0U]_,-5/\M]LC.W9[\\ZK[+D_?TQB+;1YKT_S]G[F<U8QN(:R
M     !*?@_\ O@\:_EDHGY=:"';0O,:[?,)OD*2?)?G;;OGD7RD-X8>>QNB
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M>>F/E8UU_C"'$JR'Y\6;[5I/YB,J:/\ BXO\QORD-F<>EI/
M  "!OB*_J 9_*%7/R98!@GM#^8+/M"'Y$I9[W_!I^NG]BE&0T>(D
M&6-"_KSTQ\K&NO\ &$.)5D/SXLWVK2?S$94T?\7%_F-^4ALSCTM)X
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M(F8E.2/.^V_/(OE(8 [5G_39GG_AFO\ W#S]$ ;N'Y30
M                  "&G$__ (OY:_S,7#\F0X['_P!W]5#BW=7W298ZSD
M   :P/\ 5Y?]C;=/Y@-$_ER4 'Y0H         )?^'M^_P!<'OYO^-/^<]*
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M]1/^[#I'Y>4O\OKF,*[;_-^D^>?[-YZF?]J+_G)F/_AE?YZD-0$:R'O*
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M_!_]\'C7\LE$_+K00[:%YC7;YA-\A23Y+\[;=\\B^4AO##SV-T0
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M?H^^HP7NK[P]G;E+_&F^^9QO^TH-9GZ/OJ,%[J^\8:TY4>4FVO6IT<LY"O\
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M(B5EEIF'+*M6;?$68^7"_E9D?).GM>@G6Z?]G Y.=K8>TA\1,,3- XGT
M                      #"^I=2GUC,;=E3399?&T-FS&PR(E99:9ARRK5F
MWQ%F/EPOY69'R3I[7H)UNG_9P.3G:V'M(?$3#$S0.)]
M          PQIK4I]3^M;KS19KUE[GO.VB]5EEG[TDN7O7U84W2X<>5&8>]W
MNK?>84Z_^QCH]WDYVMA[28'Q$PQ]TS..)]
M PQIK4I]3^M;KS19KUE[GO.VB]5EEG[TDN7O7U84W2X<>5&8>]WNK?>84Z_^
MQCH]WDYVMA[28'Q$PQ]TS..)]                           POI+4I]0
M0]UBCS99S-NV;<]AX6*RRRPQ+;'39QB+R3+AQVYF78=&5>DO7Z?]G Y.=K8>
MTA\1,#- XGT                          #"^DM2GU!#W6*/-EG,V[9MS
MV'A8K+++#$ML=-G&(O),N'';F9=AT95Z2]?I_P!G Y.=K8>TA\1,#- XGT
M
M
M
M
M    #C6LS$/9&4B&<I'.Y6$\B]^8QL];KOXGWR0,ZCO?)FDH9PQ\O;$RHCVI
M2]J3&3%Z<>Z .2SG&,9SG/1C'NYSGW,8QC[N<Y   ?!*2D9"1[R7F9!E$Q4<
MW4=/Y*2=(,6#)JECK*N';MR=-NW03+[ICG-@N,?=R /L253723614(JBLF15
M)5(Q3IJIJ%P=-1,Y<Y*<ARYQG&<9Z,XR /[
M
M
M #.<8QG.<]&,>[G.?<QC&/NYSD >,9P;'27.#8S]S.,XSC/^C[N/< 'D
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M4FUK<4&X=HA7=FT2PT*UW6DW[7S^5;JL#OH^0.HT>IX3<HHX6;F6 L1
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M2RI3V./WGI1^OKO8*]G;XQ@\?-6I]!IS^6Y\8.1O+I=/W0!:,
M   #7:_J9-HW_5/!;1DG0MV[/X_8M7/#C;0KOL74NSK'J&TLM<6=M?T+@T5N
M]9DXI['1)F*!7"W:J&;%.V(HH0V$\= &8^ 7&3A+7M[H[!XV^*GRMYE6^C5N
M<<2NJKSXD4ARBH",+8&AZV>?M6LF\O(-%<1[B1)EB[<EP1L^RF<F>TP4 7A
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M@AK38&VTY)?5^T]1W2Y8?V"IMF3QA)/YEAY08KE-BJ7&%LNRY8 ;4P
M                                      -)CQ:+!NK@;SJYIZ'X_0$R
MLA_4"<=]2ZRTFO',S)058YG(;%I_%_:BOEC<ICUQL]T%M-Q9)&53*=<TXZ9=
M."]&%D@)\>.YPJG:)X)NJ]'<;X"^R]&X17?BQ;[% :K8HJ[&E=):)Q^;MOL,
M#'&;2K5U8H%J^3M#I9PW>HHJ1ZSQP10B2A\ 8CUAK[PF^4FXN#DI]>5RZYE7
MNN\D-2<BN.7'FY\EM$7V65W-K C^WU9;86I:7QN@-G4INQAO?!K+I2QH0R#-
M=RBLJ@IGI*!-#P\DCE\=7^HF5,D<I%,>$AA)0Q,X*I@O#VZX4PF?..@V"FQC
M!NC/N9^Z *P&#50O ?\ JWRE;G+E?E_SG.D4J)BY6[3358-DZ9<%QE3KG-G/
M3CIZ<YSG_2 /KW5;XGB!R _IK/$-WTTEH_B%KC@\IQ_V-M!.+DIF!T7L?;G%
MN AJ/9K2T9-W:L-'6X\T9FJ^(F7LVC!R94^<(IIG G5XI//?BWSB\(;Q6X[B
MGL@FZ(/4&@X-E:]B5*"GUM8/)ZZS#ATVJ]0V ZC6U:N]@@(^MX<S"$4N[Q%I
M2+'MS$.Y*7 %>/B#:_0H?+[P4^4V\]_\B.)?$>6X)(<:+%RJT!,P=87T1N"7
MIC*T5A"^7&U4+9=;I-6VTUDT8M5VZC$BG2CUE%'*39HY42 M1\-C2_AYO><N
MSN1G'7Q,]X^(SR7KW%IAHVZ3U[WKJ+?-,I>DK1M2/V% QI+/IK4%)K;:P$O%
M8<G:-UI9PY20=O<Y;=4^%$P-@(                :XO/M)4W]1/X!2I4U#
M))Z_\27"BA2&R1/K<8+%@O7/C'5+ULYZ,=/W<@"5_CV:$L>]_"XY(.]?E<)[
M=X\QU>Y;Z=DV#8CR6B+]QHG6>T_*85IDIE',Q(U*"E8YNFEC*RBCW!"%.8V"
M& K'X!:G2\7_ (9^-!RMGX%>"=^*I;;-IO4#:;1\DQ#ZSXSZ.B]0:%G,>5%Z
M&68G;"LP_.EDF,%7;Y64SE957!0.E_T\>S;IX@?(FQ<U-J5V;BI3A3P"XO>&
ME7E;"V<MU)C;#)24V)R9MI&+I3I93RLU!P39=8R?:*-W74(8J?6*8"7O 1)4
MO]1/X^JIDU"I*:_\-K":AB&P13J\8*[@W4/G'5-U<XZ,]'W,@"M[PQ^$LKSG
M_I\=M:HIKU:J<@*-S/Y$[XXJWQ)4D;+:^Y+:@V3^=6J;#%RCG&"0N92205AG
M3S)39;Q\JX4+C)REZ ,V_P!+[O6[\GMZ>,9R!V30Y36NPMF;SXWR.Q:3*1SJ
M,4K&RXG7NPX'8T"DS>_];:MXRXQSLJ**_0Y10RF58I%.L7 &W<
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M"4+58.,KT2FX<G[1PNG&Q#5FS(LNIGK'-@G6-GW<YSD =D
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MH[Y\=HV1;F>O52D(H\=F1(3+ETH1,N#*'ZQ\X+C&<^X /L
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M#)AY>]7DGWD35!KY;(NNIY2_=]@FGY0]<=F7M%3]*A^C'3G/0 /M
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MMH2LPT= Q#8ZQ^NL="-BFS5FB94^>DV2DQDV?=R .?
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M C':.+#,0<9AI'/+ 5=?K.,'RFGG!<9SGW )G@
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MND=,Y@) @
M
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M7H.<K;5Q=&-5IDDP416;S#YV[DV;;!W9UW3K"S,#9C
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MQ
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M-]8'YXL*I[V0<W[YW1Q^=#;R%FX\C;+=!^NY2ZN.L!:4
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M5M&TUJ*MEG9J+AY*36B*S3%GBICH$(FXE%4T\=0N !=
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M/-=U"MVR/E4*DE'P<NE*V0[N50*BV749I'ZW3E8N,9S@"TH
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MJ2DIZ [=:+KU!H-8A[!-1L5+R4/!4:E-%TR+HXRV<OW">#*=&5#@6[
M
M                                               -)CQPO5Q[<MG_
M #Y_[L_Y1[Q4SWM]N[VK/;&ZOYL0_7]='LZ?^Z_>KM.CW@]]?O\ WE[#J_>=
M( V=O#)['V&M >3>Q+Y/^;4IY/\ 5U>^'L<]C^<\YV7J<]]O_>GD79]'OIY3
M_P!8]^O*^T^_Z0!/$
M             :.?C.^K7V];Y^>W_=A/?'HK7O7[:GM9>UMV?YO0'3[1'L^?
M_E;WP[?H]ZO?G_>^\7D_1_N>D ;7WAX=G[%''3L?9!['U?M^R]@;RKV/>S]]
M)/J>H?R[_KWYG]7HZW;?[WR[RCK_ 'W2 )G
M                                                        #__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>t1701829_chrt-iga02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 t1701829_chrt-iga02.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@(?0?0 P$1  (1 0,1 ?_$ 0<  0$!  ,! 0$! 0$
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MD)[3S@WY[_X:[>^@ ZO?%_S1_%9+RDZZG1F]9?Y=JOD)[3S@WY[_ .&NWOH
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MUE_EVJ^0GM/.#?GO_AKM[Z #J]\7_-'\5DO*3KJ=&;UE_EVJ^0GM/.#?GO\
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MD)[3S@WY[_X:[>^@ ZO?%_S1_%9+RDZZG1F]9?Y=JOD)[3S@WY[_ .&NWOH
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MUE_EVJ^0GM/.#?GO_AKM[Z #J]\7_-'\5DO*3KJ=&;UE_EVJ^0GM/.#?GO\
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MD)[3S@WY[_X:[>^@ ZO?%_S1_%9+RDZZG1F]9?Y=JOD)[3S@WY[_ .&NWOH
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MUE_EVJ^0GM/.#?GO_AKM[Z #J]\7_-'\5DO*3KJ=&;UE_EVJ^0GM/.#?GO\
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M^7PX_P P]!^NLE_B;3[_ !S_ ,D]\?\ TMJW^ S"* VTO-Z
M
M
M
M
M                                   ::=)/UPH7^P6<_P#,6Q7[I,?Y
M77?EN7_WI7/Z!?W@LM]59W_<I45\J_5>Y(^@3</V>9$47X<?YAZ#]=9+_$VF
MW/CG_DGOC_Z6U;_ 9A% ;:7F]
M
M
M
M
M             --.DGZX4+_8+.?^8MBOW28_RNN_+<O_ +TKG] O[P66^JL[
M_N4J*^5?JO<D?0)N'[/,B*+\./\ ,/0?KK)?XFTVY\<_\D]\?_2VK?X#,(H#
M;2\WH
M
M
M
M                                                    !IITD_7"
MA?[!9S_S%L5^Z3'^5UWY;E_]Z5S^@7]X++?56=_W*5%?*OU7N2/H$W#]GF1%
M%^''^8>@_762_P 3:;<^.?\ DGOC_P"EM6_P&810&VEYO0
M
M
M
M
M                                 #33I)^N%"_V"SG_ )BV*_=)C_*Z
M[\MR_P#O2N?T"_O!9;ZJSO\ N4J*^5?JO<D?0)N'[/,B*+\./\P]!^NLE_B;
M3;GQS_R3WQ_]+:M_@,PB@-M+S>@
M
M
M
M
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M\)L]1D=_M+OY";TSW*Y,T7+%W9Y^Y7[55=JN8B8F:(KVZ8F-NFG%PB9<C4
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M15=I[M3,U435;HMTU13,3LSL1.S,15M3$U3U )05_
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M8T[6K48S;O4X3-,XQ%=%48T7+=6$[-RW5515A.S5.#X,^RQ<
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MHMZ[:OWLI?LS3=LVJ,IF[==7=:=JS715<O6XIV+DU51&-=%$Q@Q<+7M<P
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M%ZV[KXZG;D7'=O\ DZ^ZVU5:%V2I1ZWL[?OU4VS["ZH/+NS[EE54*?\ \?\
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MLAD<XRUN]G,BP['YR6<-HYR@BP:WOY2/=N?BK-.^ZB:=+J665ONK2G;==6M
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MO\3:;<^.?^2>^/\ Z6U;_ 9A% ;:7F]
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M5W,ZC?N131;MTU7+ERNJ>2FFFF)JKJJGFB(F9ER;_+]OGS);=_=MF7Z%,?\
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MJ?[RUEMN*KE/<JO[N;65HBKX&U<BJN)J<E6]5?AC?-)Q-N=Y)\34<T;TR*[
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ME8IY,:IJNTW;TX<^S3E[5W&K#"*IHB9B:HQDS-E;0^
M          TTZ2?KA0O]@LY_YBV*_=)C_*Z[\MR_^]*Y_0+^\%EOJK._[E*B
MOE7ZKW)'T";A^SS(BB_#C_,/0?KK)?XFTVY\<_\ )/?'_P!+:M_@,PB@-M+S
M>@                                               :T<5.JSLC3<
M9#X'N")=;7P&+318QTTD\L;[$QZ-2I2U-LF^>W?$<L9LTK>Z@@]O;N+:5I;\
M<\'98G;6CB/T;]!WJS%W6=U[M.FZU<F:JK<TXY:[7/LS33\*S55/+55;BJF>
M?N6U,U3?+@;TY]\.'F2R^Z_$&Q7KNZUB(HMWHKBG/V+<<D4Q77.QFJ*(Y**+
MTV[D1R?&-BFFB-[-!\IM(\E8I:0U3F+:4D6#9-S-8I))7Q.70*:E4[._)0;J
MM%KVEBRMJ?QMM<X97*5[MBUU?@*9;Z<.M[MP<S%C>3*U6[%=4Q;O4SMV;DQC
M^A<CDQPB9V*]FY$<LT1#:3PLXX<->,F1JS6XVHT7\W:HBJ]E;D3:S5B)PC&Y
M9JY9IB9BGNMN;EF:O@TW)ET8ZG/#3#-AZMR[?F&03"$VGK^-6R;)GL8UHVMS
MC$HM+PL]^7DFU*).)B"BK+W:#ZZRY>Y%M<W4NJG5*J,P='SBKJNA[Q97<O5;
MU=[=W.W(M6J:YQ^+WJYPM]SF>6*+E>%%5N)V8JJBNF(JVHKK+TTNCON[O;N1
MG^*>[N5M9;??2;,YG,UVZ=GXYE;48W^[Q3R57;-J)NT7IB:YHMS:KJFC8FWT
MCZ+7_7QM3T1W_P!\L8)<Z6'H;IOUG_\ D+JM?X<O^:.N?4$_XO+.S76N_P"J
M[2?]OL@_N]81_P!$OTBU?Y%;\*F?\2#T)W;^M;_@(8):I_ZT=;?V^P[^\,<7
M.WD]'<_\BO\ @JFK7<7TVT?ZURGA[:T#D!_U#[L]$>R/[FS)JCW*],M(^L\K
MX>V]%O%;_*[>3Z@U#_"7DQ/2ZQ1GE',W6RK])%=OBT=F.5VH+=M;5'D?C$DR
MC%;+:67=JS&3DD7-GPV]EZ-*]M>SNW;".D1J5W3N%.?ILS,5YFY8LXQ[%-5V
MFJN/S544U4SS\E6'Y8TL]"70LOK?2)T>O-4TU6LC9S>:V9]FNWEKE%N8Y)Y:
M+ERBY'+&$T1./)A.[/4TSR6P/AULM:$<N64CE2^.X3\<:W=Q1".R&::)SJ5U
M]+[+K4I& ;NFEW9VU[''W/\ 32G/1_T;+:SQ2T^G-TTUV,M%W,;,\TU6K<S;
MG\]-R:*X_P"BV>],[>C/[K]'O6;FFUUV\WGJLOD]NF<)BW?O4Q?C'&.2Y8IN
M6IPQY*_Z8D>-FC0B_2>3,Q(,HR-?RLD^CH1)PA#,'CYTY91"+M;XRZ1C&JRM
MZ#!)RXKX12U*VRE]_P!]7MK\)^>UE,K8NW,Q9MVZ+]Z8FNJFF(JKFF,(FN8C
M&J8CDB9QPCDA^W,:CJ&;RUG)YJ_>NY3+4U19HKKJJHM15.U5%NF9FFB*JOA5
M13$1,\L\JU[C?BC/!^/VE<48I(IHPNKL':JU0[?!N']V.QZ\H^[:V)UN4D))
M95>^O=M[UZE:]E.WLIJ7W\U*[J^^VK:E>F9JNZCF)C'GBGNM444^SR4T133'
M+/)'/+T@\'M"R^[7"G=O0LM33%O+:)DZ9V>:JN<O;JN5\T<MRY-5<SA&,U3.
M$<R0CE#GDMLOD/N;,9ARY<KR>Q,I094=7=Y1E"14LYB<?B[:=]2VQ*+A&+=O
M;2EU:4HG]VOW39]P\T;+:!N-I6E96FFFBWD;,U8<U5RNB*[E?L<M=RJJJ?SM
M 7&S>C/[Y<6]XMX=0KKKNWM7S--&U.,T6;5VJU8M\\X1:LT441$3AA2X8CYF
M8B4Y%&*E9*,2EV*D7+)1[YTR3E(Q:^Q1:.D;&RJ=KUBK>E;=<BK2Y.ZMM*UI
M\%#*K^4RN9JHJS-NW<JM5Q71-5,5317')%5.,3LU1C.%483R\Z.\IJ.H9"B]
M;R-^]9MYBU-N[%NNJB+EN9B9MW(IF-NB9B)FBK&F9B,8Y%!/11Q)BA@6[L[J
MBC=)2N78[B5J]>]<X18X_#+3%Z-E*V=U)%RXR6VZ[NW=JER5O>I]Y84FZ6FI
MWJ]9TC1L9^+V\K=O8>Q-5RN*,?RS$6N3'FQG#GEM=_#?T'+6MU]Y=Y]FF<Y?
MS^7RNU_:BBQ9F[,1R<D559B)G"?A33&,?!I=G^<W!?*N8618%(LMK1^$0>"P
MLNR;0KW&'L[5>6G'S9>2E+%D)Z,11HNSC6B7=\%6[_<]M;JTK2EL><'^,.G<
M+LCG;%W3:\YG,Y=HJFY3=IMX46Z9BBC";=<SA577...'PN;V9FKI-=&37.D%
MJ^E9O+:[9TW3-,RUVBFS7EJ[VU=O5TU7+D3%^W$8T6[5.&SC\#&:IB8B.L.E
M>DAF&H-N:VVBVW[$O*X'FN.Y,ZCFF"/F+B6C8N3;N)>%L>7Y0YL:TFHNU9K<
MI5.^EMJU:]VOW"0M[.DSI>]&[&?W=N:+=H^.Y2[:BJK,4U11771,47-GN,8]
MSKV:\,8QFGGA"O#CH$[P\/\ ?[1M]K.]67N?1>I9?,U6Z<E715=MVKE-5VS%
M<YFJ*>[6MNU-4TSA%<SA/,T2YRQS"4XA\@VTE99>W2UK.R*=+ZV4MH_A[$I>
M*OIX2VZWOV2C%&ZW_P ;O4IW:TKV5(-X/W[V6XG:)<L3,5SJ%NF?^C7C17S?
M[%56/Y.?D6WZ3.4RN=X [V6<Y$3:IT:]<C'#].U$7;4\OLQ<HHF/9QPPY<&+
M72#Y!8=K38F>ZHS6490*6V$<;<XE,2;E!E'5RK&[Y=O;CJSI;N)IO,C9SG_F
MGA+[;;W#2B%G:LNG;=;#I/[DZIK^AY+>32;==ZK39NQ>HHB:JNXW=B>ZQ$<L
MTVJK?P\(F8IKFN<*:*IC7-T >*^[VYN]VJ;B[R7[65HUZG+U96[<JIHM_&<O
M-VGXO-4X1%>8HO?W6U,1-=J+=.-R[13.P?+7A!JWEPSB'F4OIG%<WQIDXC\>
MS.!JW7528.5_C5T7-1+RVK69BDW5UZJ=E+VRZ2E]U;%K;;U+;ZN\,^+N\7#*
M[=M:=1:S.D9BN*KMBYC$35$8;=NNGEMUX81,X54S$1C1,Q$QL#X]=&K<CCWE
M\OF-;NYC([RY.U5;L9NQLU3%%56UW.]:K^#>M15C533%5NNFJ:MFY3%5453\
M<H.G#O/C7&/LQI6/V7K1C6M[S,,50<H/8)MW[$TW.5XRZJJ\B$%+[J]J[=9^
MS2IV>%73NNMMK=GAYQWW/W^S%&ESMZ?K]?Z-B],33<GGF+-V,*:YC_5JIMUS
M_9HF(F6J/C7T/^)O!S)7=X8[EK.YMKEKS>6IJBNS3C$15FLM5C7:IF?[=NN_
M:IC#;NTS,1/RO3WWICF@.3>)99F3BQAB&01TK@V1RZE:42@V60T;7LYESVV7
M5HQ8S3!K<ZNI6VJ;7PE].]W>Y=]+C=N?G]]>'V9TW2J9KU2Q71F+5$<]RJUC
MM41_M56ZJXHCV:]F.3'&/A]$[B;I'"KC1D-=WAKBUH&:M7<EF+L\UFB_L[%Z
MKDGX%%ZBW-R>39M[=7+ALS3WOS0&J>66LFV'9O>O(X^X<L\FQ;*,5E&UDA%R
M%63A!E.P,G:D_C7B#B/D%+:V*I.&JZ2G;6VMU++[=>NY>^N\G#7>"K5-(B+>
M=IIJM7K-ZB=FNG:B:K=RC&FNF8JIB<8FFNF8PQPF8G=5Q3X5;B\=]RZ-W]Y9
MJO:5771F<MF<M<IBY;KV*HHO6+F%=NNFJW<JC"JFY;KIJQV9F*:J<$.0_22W
M/JZ.E,JU1-M-RXQ')+/'$.TCU(7835FG8HLK<W@/#OV&1T:I6=E?B;JCQQ?V
M>"9_#V4N?N/TF-U-XK]O3MY+-6E:A<F*8KJJBYEIJG"(QN84U6L9_P!>C8IC
M]*[[,ZL^+70+XB[DY2_KFXN9M[Q:+9IFNJU3;FSGZ:(B9G9L;5=&8V8C#^YN
M=UKG]#+\N$9-7V7)W767VW67V7767V7VUMNLNMK6EUMUM:4K;=;6G96E?AI4
MLK$Q5&,<L2HA53515--43%43A,3SQ/M2_P"3EU<]\5/6AXW>GO3WVAXZ87Q'
M_P O->^I<[_AKJ4^!G^=FYW_ *ITG_'Y=7)RK]5[DCZ!-P_9YD1K*X<?YAZ#
M]=9+_$VF^_CG_DGOC_Z6U;_ 9A)UPO\ 6RX[^ES"?EIL;*.*_P#EKKGU9?\
M!RT2]'3_ #WW1^O\GX:E63RARR?P3CGN[,<5D%(G),<UEF$K!RJ-B2B\;)M8
M5W>S?H6+6*(U<-%NQ1/O6W6TOMI6M*T^ UK</--R6L;]:1I>I41=R%_4+%%R
MB<8BNB;D;5,X83A5').$Q.$M[O&S7M5W8X0[R[PZ'=G+ZQD]%S=VS=B(F;=R
MFS5-%=,3$QM4S\*G&)C&(QB44SUZ]DGKN1D7;J0D)!TX>OW[UPJZ>O7KI6]=
MT[=NE[U%W+IRNI=>HI?==???=6M:UK4VS6;-K+VJ;%BFFBQ13%---,1%--,1
MA%-,1A$1$1A$1R1')#S@YG,YC.9BYG,Y<KNYN[7577775-5===4S557755,U
M55553,U53,S,S,S.*Q'@).R>1\.]"24NYO=O$\,NA[5E+E+[ZL<<FI;'8I.Z
MY2]2^ZJ$7%HI_=[/O?@I2G92FK?C3D\OD.*6M6,K3%-J<WMX1_K7;=%VN>3#
MGKKJG^EZ#NBOJF=UCH][K9S/US<S$:=W+&9F9V,O>NY>U&,S,_!M6J*?Z.3"
M.1,QSN11;\P.0-B*=B5EVPI):ZVRVEMM5G+=HX<*5I3_ ,=9=6Z^ZO\ INNK
M4V \'*ZJ^%^B37,S/Q&F/Z(FJ(C^B(B(_(TQ]*"W;M=('>NFW$4TSJUR<(]N
MJFFJJ?SS5,S/MS,RZEDEH& +VC3&]2J$3*__ $IR7_I^8^47)N/TW_P[+_L*
M/]V'E_UW_P ;SGRJ[X2I^ ?M?*6[<=(5[C?'S1..R2=R4C :;UA"OTKK:V7)
MO8K"8-BZ3NLKVULNL70NI6E?N=AJ-WZS=K/[[ZSGK$XV+VJYNY3/MTUYBY5$
M_P!4O2EPBTW,Z/PGW8TC.1-.;RN[NFV:XF,)BNUD[-%43'L854SR),.;THWE
M^7/(5VUK2J:.T,EB[JTOMOI\8@W7Y%=T[;?@I6CN/OI6GW;:_!7X:&RSA%EZ
M\KPRT.U<_2G3K5?]%R.Z4_Z*H_.T.])7.VM0X^;VW[/Z%.MYBWSX_"LU=QJY
MO]JW/)['-/*LS-5+T2H[^GOBC/,N9>A8=^DBLW:Y4_RBVQ?M\'\:P?&9W-6-
MW92Q3M43?8^G=93L[*WTIVUI3X:;1^-VI7=*X5:SFK,S%=66IL\G/AF+MNQ5
M[7)--R8G\F/.\^71.T++[Q=(C=;3\U335:HSU>9PJYMK)9:]G*)YIY8KL4S'
MY8C&8CE4J<]<\EM;<0MXY5!N7+*5LQ=ECS1ZSN\&[9W9MD<)A*KMLK2].]!=
MLAD-U]JEM:7IUM[UOWU*%!N#.C9;7N)^CZ;G*::\M.8JNU4U<L5?%[5R_$3'
M+C$S:B)B>2>:>26X_I2;T9_<[@#O-KFF5UV\]&2HL4UT3A51\<S%G)S53.,3
M3---^9BJ)QIF-JGEB$<)M.>>A^DO,S#J+CX1U+23F%B%WSF*B%WSI:+C',I5
MO62<1[!16YHR7D:M$O#WIV6W+>"L[]:]VG9^>C*96WF*\W;M6Z<W=BF*ZXIB
M*ZXHQV(JJB,:HIVIV8F9BG&<,,9?MNZCJ%_)6M-OW[U>G9>JNJU:JKJFW;JN
M;/=*K=$SLT3<V:=N:8B:MFG:QPA4ITD_4]A?[>YS_P ^;&NSI,?YHW?D67_W
M9;NN@7]WW+?6N=_WZ6775^SG+);DLTP1_./EL0Q+"\=?P&/>%[D8QDIY%RXE
MI/XM9W;%I%[6RRRY:_O*423MLI6EM.PL1T7]'TW+;@5:S9LT1JF9S=VFY=P^
M'53;F(HHQ]BFGEF*8PC&9F>65)?Q -YM=S_&2WNQFLS=JW?R&G9>NQ8QPMT7
M+\557;FS')-RO"*9KG&K9IIIB8B,'Y72#GI.,Y8JQ+1S?9'Y)K7+6,LUK<IX
M%PFP7B)AFK5*E]J?QEL[8VTLONI=6VQ12VG9WZGZ.D_D\OF.&L9F[3$W\OJ%
MFJB?9B:HKHJC'GPFFKECV9BF9YH?AZ &J9W)<=JLA8KF,IG-&S5%VG&<*HHJ
MM7:)PQPVJ:J(PJF)F*:JXC]*6F_6(015XH0ZBB=E][;<.(+M[KK:5N16NQ_,
MVURB=:_[-]4'%]G;3_Q;ZT_TE?>BW753Q)NTTS,15I=^)_+'=+$X3_3$3^>%
MT/Q![=NO@5EZJXB:J-X<I-,S[$]PS=.,>U.S5,?FF8<:]%;$6333FWL\M32_
M*60;,:8BNK]U;XEA^+1,RU3KVITI8EX?.%JT[+J]ZOW:4[*5K]_I8ZG>N[U:
M7HTS/<+&GU7HCV-J_>KHF>?GPR]/L<GM\K#OPX] RUCAYK^]%,4_',WK-.5F
M?9V,IEK5ZF.;DC:SE<\_+//$81CUSZU&>2SG:FI-8_&7-D%"Z_6SRK.V[NM'
M$MD^1S>/VN5;+;_]^Y9L\1K:G6^W_=6KW]RO^\OH9WT3M&RUO=S4]X-FF<Y=
MSL9?:_M11:M6[F$>U%55[&<)Y9IC']&$0?B.;T9^]OSH.Y>W7&F9;29SNQCA
M15=S.8O6-J8QY:J*,K,4S,?!BNK9GX=3%IH[=,'39\Q<N&3UDX1=LWC191NZ
M:.FZEJS=RV<(W6*H.$%;*767VUI=;=2E:5I6A;"Y;MWK=5F]3379KIF*J9B)
MB8F,)B8GDF)CDF)Y)AKFL7[^5OT9G+5UV\S;KBJBNF9IJIJIG&FJFJ,)IJIF
M(F)B8F)C&.5<-I;+7F?Z<U-G<A6MS_-=9X'EKZZJ::-;GF28M%3+FM44;KDD
MJU6>W?>VUK;;]RE>PU#;V:9:T7>G4]&L?]CE-0S%FGEF?@VKU=$<L\L\E///
M*]+G#C7LQO5P\T'>C-\N:U+1<EFJ^2(^'F,M:NU<D8Q'+7/)')'-",S?V.LL
M0WMNK$HVQ-..Q?;>Q\=8)I)T22390F8S,8UL32I\":=J#:VEMM/@I3X#:MN7
MGKNJ;G:3J=^9F_F-,RMVJ9G&9JN6**YQGV9QGG>=KBII&6W?XG[R:#DXB,ID
MM>U#+T1$81%%G-WK=,1'L1%-,81["T+57_5?K?\ L%A_]WHXU1[R>D6?^6W_
M  M3T7[C>A.C_564\!;1 Y7_ .E.2_\ 3\Q\HN3;KIO_ (=E_P!A1_NP\U&N
M_P#C><^57?"5-ONB7B+)65W]GBR:5TC'Q^"XC&JT^%9%E+N<BF9Q.[M3^]2<
MKP<?6WNWU[:I5[U*=EM:U%Z6VIWJ<MHNC43/<*Z\Q>KCV)JHBU1;GGYXBY=]
MC^U&$\[97^&WH&6N9[>K>BY%,YRU:R65MS[,47:LQ>O1/)S556;&&$\LTSC'
M)#ZSK79Y+,L>T;K9FY<HP\_)9CETZWLN[C=\YQU& B\?M4[E_>6HU_+SZ^ZR
M^WNTNN3NIVW4^]^9T2]&RUW/:QKUVFF<U9MV+-N?9IB[-RNYA[6/<[<8QRX;
M4<W/]W\2#>C/Y?2=V=SLO773I^:O9O-7J8G"FNJQ%BW8QPGEV>[WIF)C")FF
M8QF.2?8NTU1+.>%><2VQN*NC<MG73E_,O<&8QTD_>7=]W(.\<<N\:6?NE:J*
MW+N7MT1X6]2ZO>4NOK==2E:UI35-Q8TC+:%Q'UC3,G331E:,Y55133^C33=B
M+L4Q&$813MX1'-$1A')#T4]''>;/[W\#=V=>U2NN[J%S3*+=RNOEKKKR]567
MFNJ<9VJJ^Y;4U3.-4S-4X3,PE]YXXZRQ;F!OZ*C[$TVRV>.IWN)6433M<94P
M890\I;93X*?^>3"G;V?!6OP_ ;#.#6>NZCPOT7,WYF;D9.+?+R\EFJJS3_[-
M$-*/2ATC+:)T@-ZLCE(B+-6J57L(C"(JS-%&9KY/^G=J61FK!Z&D*.=9SEFR
M\NGLZSF<>Y'E62OU9*8EY!6JB[EPIV6V)V6T[$FS-JC9:DW03ML1;H66)IVV
MV6VVTW$Z/H^FZ!IEG1]'LT6--R]$4T44QA$1'L^W-4SC555.-554S55,S,R\
MQ&\^\VN[Y:_FMY]YLS=SFN9R[-R[=KG&JJJ>:(]BFBF(BFBBF(HHHBFBB(II
MB(JMZ7\S(S/"O5/Y1<7NKXMUF\,T55NOO5MCF&;Y!1BWNOONN[;&:"E$4Z4[
M*6(IV6TI\!KAZ0V5L97BQJ7<*8IBY3EZYB.;:JR]O:G_ *TQM3[=4S/LMY?0
MHU'-ZCT<="^.5S758N9RS3,XS/<Z,Y?V*9F?8HIG8I]B**:8]AB3U5\YRS(N
M8.>8C,SCU[C.O6&&1N'PBBM;8Z$;S^ 8EDTTHU:V=U+XY)S$HHHLO=2JREEJ
M2=;JII)VVVWZ.&CZ;D>%^3U/*V:*-0SU=^J_<B/A7)MYF]:MQ,\^S111$4TQ
M\&)FJJ(QJJF=;/3FWFUW5^D#JF@:AF;MS1M)M92WE+,S_=V:;^1RN9O333')
MMW+MVJJNN<:ZHBBF9V;=$4]H>B=,R*>;;VQZUQ?^27>+8A,JM*W753I(QTM*
ML6[A.WO=RR^K:45MOK2G;=2EO;7[VA'G2URMBK2-&STTQ\9IS-^B)]G9JHHJ
MF)_IHB8]KE]M-GX;NHYNC>3>C28KGXC<R.4O33RX=TMW;M%-41S1.S<JB>3&
M>3VH<B=;=)*N-\>%ZI)U73F]DI)K5LMJJFDLPPR]9*Q2M._:FK>@G6ZVE>RZ
MMEM:_<H?#Z)%549_7*(F=B;.5F8]B9BJ_A.'MQC.'M8S[;+OQ)K=$Z1NE=FF
M.Z1F=0B)PY8B:,G,Q$\\1,TTS,>SA&/-#\3H@?\ VG?_ %+?_6R?KZ7?_P"K
MW_Q__P#!OF_AJ?\ ZZ__ $C_ /FAUO\ _P"S%_ZZ?_JF'1$__6'_ . __C#\
M2O\ _4K_ .K_ /\ *V"EEEREUMEEMU]]]UMEEEEM;KK[KJTI;;;;2E:W775K
MV4I3X:U+FS,4QC/)$-6U--5=44TQ,U3.$1'/,^U"LGIR\3+.-FGDIS*(_P #
MMK9S=A-YA\83L^-8W%VV7JP.%I7?#5*Z-0<57?4IV5O?K7V75OL01K36KQVX
MESO[O3.3TZO'=K3ZJK=C">2[7S7+\^WM3&S;]JW3$QA-=3>[T0N ]/!WA]3J
M>MVMG?S6J*+V;VHC:R]N(F;&3B?8[G%4UWO;OUU4S-5-JW,8]]4#EI=O+:M=
M6X;*7+:MU._=,?"-5Z7L<KSM+PK.;R#M3[$W+&(MK='L+JUOM[+7"R=U;'-*
M4M%T>>&D;G[M_P#$6JV\-XM2HBK"8^%9R\X56[?+S55\ERYS3^A15&-MK\Z:
MW'B>)N_/_!&[U^:MR-"NU48TU8T9K.QC1>O\G)51:Y;%B>6,(NW**MF]A';;
MHFXDQMB]]9VJDBI)+/\ "L29+U[U5VC%NWFYB32LIW*6VHR+ATTK=]]=6MS6
MWX+>S[Z,^EMJ=Z<QHVC4S,9>*+]ZJ/8JJF;=%$_GIB*\.;].>?V)Y_#<T'+1
MD=Z=Z*Z:9SE5W)Y6BK^U1133>NW(CDYKE55J9Y9QFW')&'PNYW.CA+E',-YK
MND?M)A@D)@;7(:_DIWC3R<_*4ID"L5160O4;SL6E9\6:1*::=+D[[K>^IV74
MI?6A%/![BWIW"VUGIOZ=7G,WG:K7PZ;M-O9HMQ7A3RVZYY:JYF>6(G".3D6*
MZ3G1MUOI!YC2(RFMVM+TW2Z+_P#=5Y>N]W2[?FUC<F:;UN(V:;5--,33,QC5
MA/PIAU U5T@LRUALW7VQF?(&(6<8+FF,Y9:V:X$_:K/+("89R:S"UQ?E2Z:=
MK]%M<C=WTU$ZVWUI=9=;6MM90WCZ3^E;P[OY[0KNB78HSF4NV<9S%,Q3W2BJ
MB*L.XQ,[,S%483$XQR3$\JO^XW0 WBW*WSTG>_+[UY>J[IFHY?-133DJZ9KB
MQ=HN31M3F:HC;BF:)QIJIPJF*J:HQB=0.8$<PE.*G(QM(V67MTM+;'D4Z7UL
MI;1_#XI*2\5?3PE+K>^G)L4;K?\ QN]2G9V5[*E>>%]^]E^(^A7+$S%<ZME:
M9_Z-=ZBBOF]NBJK'\G/R+K](')Y7/<#-[[.<B)M4[N:A<C'#].UE;EVU/+[,
M7**)CV<>;EP9,=$K&&=[OD%F:MEES]JWU]C#"^G_ )1%F^5RJ5E[+NVS_8<K
M1S*MO9=]U*O;3_9J66Z6^H78M:)I5,SW&JK,W:O:FJF+-%']457/8_M1A[*A
MWX;6BY>K,;V;Q7(B<U11D,M1/LQ17.9NW8GDYJIMV<,)_LSC',^JZUFPIB/Q
MC2>L6+ERWA\EE,LR_($D[_!HOUL91@XW'T%:V7=]=)O?/O%;D[Z43HI1*_LN
MNMI6SYW1,T3*W]0U?>&]335FLO;LV+<SRS3%V;E=R8]J9[G1$3'+AM1R1,X_
M<_$>WLU#*:+NWN5EJZZ-/SE_-9N_$3A%<Y:+-NQ3.'+5%,W[M4TS\':BW5RU
M1$TX.8+G.6:TRZ!SK!IQ[CF58T_2DH>7CU:IKMG"?;;>G?;7M2<LW2-]R3A!
M2V]%PA?>FI;=9==;6Y.L:/INOZ9>T?6+-%_3<Q1--=%48Q,3[/MQ5$X54U1A
M535$54S$Q$M7F[&\VN[FZ_E=Y]V<S=R>N9.[%RU=HG"JFJ.>)]BJBJ)FFNBJ
M)HKHFJBN)IJF)N/RK_T7R3_H"8^3G!J#TW_Q&Q^VH_WH>F+7?_!,Y\EN^#J0
MB&X]Y?P#OOTP_7DTA_ZROLAS\ACI"?Y0:O\ _"_XW++3="O[S.[7_P!1_P#T
M5GE!G47]2S?'_0$!_?;&2DG K_-C1OV]SP%UM>Z7?W<MZ/DMC_&99C_T7Y!L
MAR(V1&J7]UR_TW(N&M*UMI:I;'YIAM'"=M:W4NN6[KRVZEM*5[;+;J_!2TM!
MTKK%RO<;(9BF,;=&JTQ/Y-JQ?PG\WP<,?;F(]EK_ /PZ,W9M\6]8R=<X7KN[
MMRJGFY=C.93:C\_PXF(B.:*I]AHYU<81[*\0)!^TLK>AC.Q,(FY.ZE.VB3)P
MK(XVG?6O;3LI61R!O;_I^&[_ .&D$=&7-V<MQ0HLW)PKS&1S%NC\M413=G_V
M;=4_T+?=/C3<SGNC_=S5B,;62U?)WKGY**IN9>)[Y?HC^E/7Q*VEC&E>1FJM
MGYFB]6Q?$Y]PYF:1S:QX]1:OH:3B*/$&M]Z?QBY@M(6KULMKWZVIU[G;=V4+
MO\3-W=0WLW%U+=[2IHC4<S9B*-J=FF9IKHKV9GEPVHIFG'FY>7DQ:FN V^^B
M\..+VA[Z[Q4W:M%R&:JJO=SIBNN*:[5RUMTTS,;6Q-R*\(G&8IG9^%@I"PKJ
M?\5<_P RQ+!,=ELV4R#-LF@<1@DW>&O&K528R25:0T98Y<W.+K6[>]Z]LI>I
M6E:66]M?]!0[5NCUQ'T72LSK.>M92,EE,O<O7)B_3,Q1:HFNO",.6=FF<(]F
M>1N$W;Z:O W>K>+(;KZ1F-2JU74L[8RMF*LI733-W,7:;-N*JIJPIIFNN,:O
M8CE=K>0J22^@MWHKI)K(J:AV38HDK9:HFI97#9GMMOLOI6V^VO\ R5IV$;;D
M554;Z:171,Q5&J97"8Y)C^_MISXLVZ+O"O>6W<IBJW.[^H1,3&,3'Q2]SQ/)
M*(4VZ/-6L%Z>^G[=,\4=8P[AK1K/Y?'UV3E';2ZQ526S1-"09)ND[NRJ3N,Q
MFR/8J6_Z+VM?]/::O.-V]$[U\2=0S5%6UDLK7\5L^U%%B9IJF)]F*[O=+D3[
M5;T#=$[A_3P[X%Z+I]ZWL:KJ%KZ0S/L3-W.13<HBJ/8JMY>+%FJ/;ML0>;>D
MN56].3FU,[B]"[9D,:MG*8QB+E##IA9DXQG$T$H&.D(^^UO?2YG.7LE)"VO;
M\-7=:]E.WLI;KA)O=PXW/X?:;H^8UK3*,_W'NMZ)OT15%V],W*J:N7]*WM1:
MG_H>SSM:G23X;<<N)W&G7-Y\ENMKUW1HS/Q;*U4Y2]-%66RM,6+=RB=F?@7I
MHJOQ[?=9GDQPC7[ICM=M8SQUIK7;^"9A@\OKW*)9CC=F6P[^+OD\2G+Z3[2]
MG>^22N<?D^9?/D+K+:W411M1IVTI6VVE8.D%<W:U#?KZ?W7SF5SF5SV7HJN]
MQKIKV+UO^[JVMF9PVJ*;=6,X;54USSQ,SL Z%UC?S1N$7_!V_P#I>H:9J&DY
MZ[1EXS5JNW-S*WI[O3-$UQ&UW.]7>HF(QBBB+<<D3$1FQUE]/VX]M; -SQK3
MP;'8N/+8SD2R25>Y7*,,\!:Q=NUON4<2>-2#=!*W_2G%W5_T5)[Z*N]$Y[=O
M.[J9BK&]D;\7;43/_P!C?QVJ:8]JB[355/Y;L*=?B(\/XTG?G2N(N3MX9;5\
MI.7S$Q')\9RF&Q57/^M<R]RBBF/]7+3[3&$M:UT@'??IA^O)I#_UE?9#GY#'
M2$_R@U?_ .%_QN66FZ%?WF=VO_J/_P"BL\W.ZJGJ6;$_Z?U[_?:$*?=''_-C
M(_L<S_A[C9KTY/NY:O\ *LA_C+*3HV4-$BW[C_\ ]0^D_1'K?^YL,:B=]?3+
M5_K/->'N/2OPI_RNW;^H-/\ \)927\UMPYON+D=L^1S*45=(8IF.3X3BT2FH
MK2+Q_',9G'T2R91K6^^ZQ"]U1G\8=*4[+EW2MZE?NTI39;PFW7TC=;<33K&E
M6XIKS.5M9B]7,1MW+MVW37555/LX;6S1']FB(B/;G0[TC^(.\O$+B_K6<WAO
MU5VLCJ&9R>6M1,]SL9?+WJ[5%%NF9F(FK8[I<JCEKN5553SQ$?<=-O$668\S
MM,M))-)9E"2&09=<FI_M5>XKBDW-0BB-*IJ6U5;3[1JK\/=[+;*UI7O4I2OR
M./6IWM+X4ZK<L3,7;U%NSC'^K>O6[=R)Y8Y)MS7'L\LQR88LFZ'>@9;>'I%;
MNV,Y%-67RUV_FL)_U\ME;UZS,<D\M-^FU5RX<E,S$XQ"AKJ*YY+:\X=[CF()
MRY92TK&PF(MG;6[P:C=ME^2Q&/S-WAK;[%$:WP+]U9;?9VW44NM[.SX;J4>X
M%Z-EM<XI:5E<Y337EK=RY>FF>6)FQ:KN6^3FG^\IHF8GDPB?S3MGZ76]&?W2
MZ/>\.H:977;S]^S9RM-=,X333FLQ:L7N7&)C&Q7=B)CEBJ8YN>(_S:"\_JD/
MHOYQ+3.FMHX*_=.7,?@^<QTC")KW=]*/:9A%KK.V#.ZJEU4VU9.#6<U3I;;;
M19S??2M:J7=E#>E=I&6RF]6G:Q9IIIOYS)U4W)CGJJL5Q%-57)RSL7*:,<9G
M9HB.2*8;A/PZ-YL_J/#O6]V,U777E-,U.W<LQ5RQ;HS=NJ:J*.7DI[I9KN33
MA$15<JJY9JG#K5UK,=9--HZ5RM*Q.U_.X'D$$\OMLI:HHWQF?1?,JJ7T_P#*
M=V[*5J4[?AI2G_[.S/NB9GKMW=W5M-JF>XV<Y;N4^U$W;<TU8=YI0W^(_I&6
ML;[[N:Y1$1FLSI=^S7.'+-.7OQ71C/L\N9KB/::J].CU+-#_ /0$_P#WVR8K
MCQU_S8UG]O;\!:7DZ(GW<MU_DM__ !F98 =3G.<LROE]LN"GIQ[(0F"+0D!B
M$0JK6D= 1CG&(&5>I,&MO=236D))VHNX5K2JJMU;:775LL3MLNKT?-'TW3>%
M^GYS)6:*,WG(N7+U<1\*Y7%VY13-4\\Q313%-,<U,8X1C-4SJIZ:6\^O:[Q_
MUG3-5S-V[INEU6;&5M3/]W8MU9:Q=KBBF.2)N7*JJZZN6JJ<(F=FFB*>_O1&
MF9%>%Y&X\JXONB8N4U=,LFE;KJIHR,\TSUC*.+;:W5LI>Y;8XSMNK2E*UHC3
MMK7LIV0KTN,I8HS>A9ZFF/C-RWF[=4^S--NK+U41_1-VN?\ K2M5^&OJ.;NZ
M;O?I-=<SD;%_3;U%/+A%R_3GJ+E6'-C53E[43R8_!C''",/\>M5G.61[72FO
MF$X]98?D:.83^0PC56J+6;DX)UC:,*K)]SLO=HQ='RUZ*5U?!454\)6VM]B=
MUG?HFZ/IM^YJVMWK-%>J6)L6[5R8QFW1<B[-R*/]6:]FF*ICEPC9QPFJ)_G^
M(]O/KV4L;M[IY7,W;>[^<IS=^_9IG"F]<LU9>+,W,.6J+6W7-%,SLQ55MS$U
M4T33GATTYF1A^:FF/B#B]&R5=99#2*5+KZ)/(Y[A&255;KV6W6^$LL7136LI
M7MI:LE9=V5[I./'W*V,UPGU;NU,3-NFS73/LTU4YBUA,>UR3-,_[,S'LJD]#
M;4<WIW2.W<^*US33?N9JS<CEPKMUY/,8TU1'/$5137&/)%=-,^PWTZGZ22G!
MW=5ZB::EZ"FME4+K[+;KD5:[9P5"JB5UU*U34J@M?96ZG97NWUI]RM2E_1ZJ
MJIXO:3%,S$51FHG\L?$\Q.$^W&,1/YXB6T_IK6Z*^C1O'573$U43I\TS,8X3
M]*9*G&/:G"9C&/8F8YIE(^;,VA( V1Z+7_7QM3T1W_WRQ@JOTL/0W3?K/_\
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M>IW:4NI?2,BVUOWW;=W;:?Z.RE+:]%F_>O<.+]N[,[%K5KU-'Y*9LY>N</\
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MV=/L5<DQ;F8V[]R/UV8FFFJJ/[%%-NURS1-=72XE=7,
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M:;G,[LTY:W<S%<97+7ZK?=9BW%=4T4T[&U7.,?"C&>5]_H[F)R*XYJH,M>;
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MN-5Z*8YYJKRM5^BF*>6:JJ>2>:9##9VT"@'??IA^O)I#_P!97V0Y^0QTA/\
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MJJ_E(F>>;/+>LQRSW*;M,846:*7UO5>XF_6;@"?(#"HWPN=:QC+D<P:MK/\
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MLS[$*=W-RM\K-NJ]>TC4Z+-%,S55.5OQ$1$8S,S-O"(B.69GDB'PQ]AC
M                        #33I)^N%"_V"SG_F+8K]TF/\KKORW+_[TKG]
M O[P66^JL[_N4J*^5?JO<D?0)N'[/,B*+\./\P]!^NLE_B;3;GQS_P D]\?_
M $MJW^ S"* VTO-Z
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M3MZ135$U59Z;EFU3A_:JMUQ3<NU1_9PMUU8\N,1,U,1U#BIT.. \7]Y-SJ=
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M>5H'SMRS>SEV]EJ=C+UW:IIIY(V:9JF::<(Y(PC".3D?PG]GY0
M                --.DGZX4+_8+.?\ F+8K]TF/\KKORW+_ .]*Y_0+^\%E
MOJK._P"Y2HKY5^J]R1] FX?L\R(HOPX_S#T'ZZR7^)M-N?'/_)/?'_TMJW^
MS"* VTO-Z
M
M
M
M                                                         ::=
M)/UPH7^P6<_\Q;%?NDQ_E==^6Y?_ 'I7/Z!?W@LM]59W_<I45\J_5>Y(^@3<
M/V>9$47X<?YAZ#]=9+_$VFW/CG_DGOC_ .EM6_P&810&VEYO0
M
M
M
M
M                                    #33I)^N%"_V"SG_F+8K]TF/\
MKKORW+_[TKG] O[P66^JL[_N4J*^5?JO<D?0)N'[/,B*+\./\P]!^NLE_B;3
M;GQS_P D]\?_ $MJW^ S"* VTO-Z
M
M
M
M
M                ::=)/UPH7^P6<_\ ,6Q7[I,?Y77?EN7_ -Z5S^@7]X++
M?56=_P!RE17RK]5[DCZ!-P_9YD11?AQ_F'H/UUDO\3:;<^.?^2>^/_I;5O\
M 9A% ;:7F]
M
M
M
M                                                          --
M.DGZX4+_ &"SG_F+8K]TF/\ *Z[\MR_^]*Y_0+^\%EOJK._[E*BOE7ZKW)'T
M";A^SS(BB_#C_,/0?KK)?XFTVY\<_P#)/?'_ -+:M_@,PB@-M+S>@
M
M
M
M
M                                        &FG23]<*%_L%G/\ S%L5
M^Z3'^5UWY;E_]Z5S^@7]X++?56=_W*5%?*OU7N2/H$W#]GF1%%^''^8>@_76
M2_Q-IMSXY_Y)[X_^EM6_P&810&VEYO0
M
M
M
M
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MBVE?/:.U/9)\POS+@7[<L?%AUF.%WZW._-ZO?.H7T@O%M*^>T=J>R3YA?F7
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M\;.0
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MQ].Z)XYE>^V^V/G7BWZRP'EB.\9'T;J/B]_L*O>/IW1/',KWVWVQ\Z\6_66
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M7BWZRP'EB.\9'T;J/B]_L*O>/IW1/',KWVWVQ\Z\6_66 \L1WC(^C=1\7O\
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MEV9G!_<?Q?I
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M3#[=>$_GFQWN_P#NCJB=(WU7S7?\GY2>SHYI^8>?\OX3])A]NO"?SS8[W?\
MW1U1.D;ZKYKO^3\I/9T<T_,//^7\)^DP^W7A/YYL=[O_ +HZHG2-]5\UW_)^
M4GLZ.:?F'G_+^$_28?;KPG\\V.]W_P!T=43I&^J^:[_D_*3V='-/S#S_ )?P
MGZ3#[=>$_GFQWN_^Z.J)TC?5?-=_R?E)[.CFGYAY_P OX3])A]NO"?SS8[W?
M_='5$Z1OJOFN_P"3\I/9T<T_,//^7\)^DP^W7A/YYL=[O_NCJB=(WU7S7?\
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M\GY2>SHYI^8>?\OX3])A]NO"?SS8[W?_ '1U1.D;ZKYKO^3\I/9T<T_,//\
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MF'VZ\)_/-CO=_P#='5$Z1OJOFN_Y/RD]G1S3\P\_Y?PGZ3#[=>$_GFQWN_\
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MY/RD]G1S3\P\_P"7\)^DP^W7A/YYL=[O_NCJB=(WU7S7?\GY2>SHYI^8>?\
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M,/MUX3^>;'>[_P"Z.J)TC?5?-=_R?E)[.CFGYAY_R_A/TF'VZ\)_/-CO=_\
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MH6;EJFNNU7-=%-F::JHFU<N1&%7)RS$_D:HE<EX@
M
M
M
M
M
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M4583&U'([+'U4=@
M
M
M
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M2KLY*,]-&7B;>6S.4IY;\3EYY,O?L4175,6Z;<1-NY:NT35,545L$R-68
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MB=I.[-NK&QIND=TF/]6[F[U<UQWJQ8G^E1628H$
M
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M,U',Y2NJ.2*JLM>KLU51&,X1,T3,<L\_.Y*/U,=
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M,S56
M
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MU#.7LS=PQP[I?N57:\,9F<-JN>>9GVY?:G]WQP
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M+EVN]535?S%5$3/<XN=SM4448S5%%J*JIBJN:*-93,57
M
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MLT#C*;'O7*IWP.N<7Q+-\MBW%S2KO_=N)EO+6J4IX.J=BE;;ZI76WWV\:O\
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MIJILM)P:C0
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MYF[LY>U,X]PRMOX-BS&')C31RW)IPBN[5<N88URE6ZIDRQU?UO=3;'V0IX#
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MU3351535;FF-F;<TS3.Q,2COZO'.E[SXWUB,;JMG,NM Z[?3."Z==KQ[J/\
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MK<%PC,%5=90+VYP[B%L]9M46^&8_!5<ITL<P&E\9^+KWK4HE569O9K4I??\
M&[;?I;HY',[S:_=WJU*G_P!WMU_W<3S;<?HQ'Y+5.$X_ZVS/ML&Z3&]NA< .
M"^G='7<6[_\ .\[E(C.7:<*:XRU54SF+MS">2[J%[;IBGX6%B+M')'<IFG[;
M.[]1Z(B,=R#<FPL8UM Y7F$1@,#-Y=))1$0]RZ=:R3V+A[Y)QW63)1RRAW2U
M57%Z2":2%]]]]MMM:DL9S/Y+3Z*;F>NT6K==<41-4X1-4XS$8\T<D3/+R<C6
MYNON;O5OMF\QD-TLAF=1SV5RE>9NV[%$W+E-BW-%-=S8CX5415<HIV:8JJF:
MHBFF9E]=/0V'YUBK^(RB*QK,<(R.+[LI%SS&+R'%9V$<I6N.Q^RD$GD1*1;A
M'NW_ .\MO1OM[*_#3X3^URBQF+,T7HHKR]4<L3$54S'Y8G&)C_0^5D<WJVBZ
MG;S>FW<QE-9R]WX%=JJNU>MW(G#X-5$TUT5Q/)R3%43R(PN-&!Z_8]>]GC_"
MR^B.F,-V3DS^USC;]22QJ,Q.-U:Y1VPR9RB:[]NMAJ^8.Y&+C+O"WMU+'#1-
M*[[Y*I!NE9?+4\1(MZ%_^8T7:I^#.-,4Q;_O(B>7X.UM4T^QRQA[#;SQ%UO7
M;W0=KSW&",=[\WI]FG"]3%%ZN_7G8G)5543%,QF(L4VKUZ,(JB:;M54<E2JO
MESS?X\<(L6QK*M_96^@TLSEG<-B<+!PC_(LBGW,:@W<S"[&,86?>1\,W=HW.
MG*UZ2*5RZ2?>JJLE9?+VLZ_IF@V:+VHUS3%RJ8IB(FJJ<.?"(]B,8QF>3EB.
M>8:R.%?!K?[C+J>9TS<;*T7J\G:IN7[ERY3:M6HKF8MQ575_:N335%%%,553
M%-56&S15,<RZ4W+K[D)JO"MS:LF%9[ <_B:S&.R;B.?Q+E5!)VYCGB#J.DV[
M9ZT=L))DLW5MNL[/")5K9==96VZO[LAGLMJ63MY[)U;66N4XTSA,>SA/)/+$
MQ,3#$=\=T==W#WFSFZ&\UJ+&N9&[W.[1%=-<1,TQ73--=$S353515353,3S5
M1C$3C$<I'ZV- $6.9;/Q#@/U[]L[.SYPYB-;)9%L#-<J68,W2BTE'[AT2^SA
M-*-;665K(O'.=9(@E;;;VV*/4ZV5NLK2MUD%7\W8W=XB7LWF)FG*[5=56$<\
M7+4U\GMSMU1_2W!:1NWJW''H.Z7NYH=--W>&<OE<O9BJJ(BBK(:E3EIFN9_0
MIC+6:IF>>+<Q.$\T\^]++3NP.HOSCV7U+^0$1=;@N$9@JKK*!>W.'<0MGK-J
MBWPS'X*KE.ECF TOC/Q=>]:E$JJS-[-:E+[_ (W;;]+='(YG>;7[N]6I4_\
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MU513']<S$*RZ/H6N;Q9R-.W?R>;SVH5<UK+V;EZY/YJ+=-54_P!$/KC^SY0
M
M
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M15731-T!8!I8
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M6ZBR478Y9,8Z/@\=1=]JMC%D@BG??2R]>Y=5.U2F;:#NSIF[MJ:<E3-5^O\
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M]=3WVU2BBWG=2S==ZJBB9FFW%4X46Z9JY9BW1%-$3/+,4X\G,Z=\_>EOH+J
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MB>2JNS7$3R[..&%"I)*A@
M
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MFZ8FFU1A%%FQ1,X[%FU3$46Z9PC:F(VZYB*KE5=7*[''TT?
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MWF=1LUVJ;T1$UT4V9IFJG"9Y(GD:OE;%ZP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M=V)(R#FE$%[*W74NK=;:'.(
M
M
M
M
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ML5;N+0OHLLL3LM33MMLLLMMLLLLMI;999;2EMMMMMM*4MMMI3LI2GP4H!_T
M
M
M
M
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MMTW*%Z=UZ"ZEM%++K:U[:5H!]H
M
M
M
M
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M[*I<T^TW\.'8
M
M
M
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M?)_M!U><RZ4\ZEDX=P
M
M
M
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M?)_M!U><RZ4\ZEDX=P
M
M
M
M
M      !--T;/6=SOT#Y/]H.KSF72GG4LG#N
M
M
M
M
M                        )INC9ZSN=^@?)_M!U><RZ4\ZEDX=P
M
M
M
M
M                                         !--T;/6=SOT#Y/]H.KS
MF72GG4LG#N
M
M
M
M                                                           )
MINC9ZSN=^@?)_M!U><RZ4\ZEDX=P
M
M
M
M
M                !--T;/6=SOT#Y/\ :#J\YETIYU+)P[@
M
M
M
M
M                                   ":;HV>L[G?H'R?[0=7G,NE/.I
M9.'<
M
M
M
M                                                     33=&SUG
M<[] ^3_:#J\YETIYU+)P[@
M
M
M
M
M          ":;HV>L[G?H'R?[0=7G,NE/.I9.'<
M
M
M
M
M                            33=&SUG<[] ^3_:#J\YETIYU+)P[@
M
M
M
M
M                                             ":;HV>L[G?H'R?[
M0=7G,NE/.I9.'<
M
M
M
M
M   33=&SUG<[] ^3_:#J\YETIYU+)P[@
M
M
M
M
M                    ":;HV>L[G?H'R?[0=7G,NE/.I9.'<
M
M
M
M
M                                      33=&SUG<[] ^3_ &@ZO.9=
M*>=2R<.X
M
M
M
M                                                         FFZ
M-GK.YWZ!\G^T'5YS+I3SJ63AW
M
M
M
M
M              $TW1L]9W._0/D_V@ZO.9=*>=2R<.X
M
M
M
M
M                                FFZ-GK.YWZ!\G^T'5YS+I3SJ63AW
M
M
M
M
M                                                 $TW1L]9W._0
M/D_V@ZO.9=*>=2R<.X
M
M
M
M
M       FFZ-GK.YWZ!\G^T'5YS+I3SJ63AW
M
M
M
M
M                        $TW1L]9W._0/D_V@ZO.9=*>=2R<.X
M
M
M
M
M                                          FFZ-GK.YWZ!\G^T'5Y
MS+I3SJ63AW
M
M
M
M                                                           $
MTW1L]9W._0/D_P!H.KSF72GG4LG#N
M
M
M
M
M                  )INC9ZSN=^@?)_M!U><RZ4\ZEDX=P
M
M
M
M
M                                   !--T;/6=SOT#Y/]H.KSF72GG4
MLG#N
M
M
M
M                                                     )INC9ZS
MN=^@?)_M!U><RZ4\ZEDX=P
M
M
M
M
M          !--T;/6=SOT#Y/]H.KSF72GG4LG#N
M
M
M
M
M                            )INC9ZSN=^@?)_M!U><RZ4\ZEDX=P
M
M
M
M
M                                             !--T;/6=SOT#Y/]
MH.KSF72GG4LG#N
M
M
M
M
M   )INC9ZSN=^@?)_M!U><RZ4\ZEDX=P
M
M
M
M
M                    !--T;/6=SOT#Y/\ :#J\YETIYU+)P[@
M
M
M
M
M                                       ":;HV>L[G?H'R?[0=7G,N
ME/.I9.'<
M
M
M
M                                                         33=
M&SUG<[] ^3_:#J\YETIYU+)P[@
M
M
M
M
M              ":;HV>L[G?H'R?[0=7G,NE/.I9.'<
M
M
M
M
M                                33=&SUG<[] ^3_:#J\YETIYU+)P[
M@
M
M
M
M                                                 ":;HV>L[G?H
M'R?[0=7G,NE/.I9.'<
M
M
M
M
M       33=&SUG<[] ^3_:#J\YETIYU+)P[@
M
M
M
M
M                        ":;HV>L[G?H'R?[0=7G,NE/.I9.'<
M
M
M
M
M                                          33=&SUG<[] ^3_ &@Z
MO.9=*>=2R<.X
M
M
M
M
M FFZ-GK.YWZ!\G^T'5YS+I3SJ63AW
M
M
M
M
M                  $TW1L]9W._0/D_V@ZO.9=*>=2R<.X
M
M
M
M
M                                    FFZ-GK.YWZ!\G^T'5YS+I3SJ
M63AW
M
M
M
M                                                     $TW1L]9
MW._0/D_V@ZO.9=*>=2R<.X
M
M
M
M
M           FFZ-GK.YWZ!\G^T'5YS+I3SJ63AW
M
M
M
M
M                            $TW1L]9W._0/D_V@ZO.9=*>=2R<.X
M
M
M
M
M                                              FFZ-GK.YWZ!\G^
MT'5YS+I3SJ63AW
M
M
M
M
M   $TW1L]9W._0/D_P!H.KSF72GG4LG#N
M
M
M
M
M                      )INC9ZSN=^@?)_M!U><RZ4\ZEDX=P
M
M
M
M
M                                       !--T;/6=SOT#Y/]H.KSF7
M2GG4LG#N
M
M
M
M                                                         )IN
MC9ZSN=^@?)_M!U><RZ4\ZEDX=P
M
M
M
M
M              !--T;/6=SOT#Y/]H.KSF72GG4LG#N
M
M
M
M
M                                )INC9ZSN=^@?)_M!U><RZ4\ZEDX=
MP
M
M
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MK4;?&%8:1B5)Z-@\@AD%\RR2]&^V?F&WY$9UL8,EV[ +B@
M                                            ":;HV>L[G?H'R?[0
M=7G,NE/.I9.'<
M
M
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MI2@'U0
M    !--T;/6=SOT#Y/\ :#J\YETIYU+)P[@
M
M
M
M    .AG46Z=.@>I]H)AQOY(R&R([7D=L3'=FHJZORIGB4^KD6,161P\:@\?2
M$%D3)Y#U;9.XO4;J-;J56L24I=;<G;4#%B4]SWZ/DA KP[1CR<@Y!9FDV3RJ
M+W<W6GFJR?@^_((-YO"IC&+GBW<KWK58U1O3OU[J5OWO="0?DQKG>?NNO6#P
M)IH?>&69AK)_C^N-S(-W2J<:MN#CAE&9Y/C&2ZNW%C$2X1QV:E&TC@\XR1<6
MI(TL71:RS--BXJE:@'K) 34]8GH ;1ZKO)+#=Z1747S3C1BN$:CA=8PVI(G2
MDEL"';OV.3Y9DDUF"$Q&;_U4A;(9)7(FZ"]BL<LXHG'(TJYO2M120"1CJ->[
MO\P^C=C]O//#]DZ-YL:=UME4,[V([V+I6(DW\&IDV0M8B+R+8VD-H+[1P[*L
M1E,CDVC1TY0EWKUN[>V77HVH>%<V!;GT!NJS%]5;A?7-)37V)ZFV]H?((_3^
MU=?8 W4C]>M[VF.1TAA^5:[AEUG;G&\'R.%NO0:Q:RZZD:YCG+:U59%-%90-
MR@ &/?65Z6^?]5[1^L=(X?S R;B3$X+LV[9.1R&.ZY=[%LSU5MC4MCT)$R;*
M/VGJAVR1A+YMPY3NJ]<H7J7]MR'?L243"/;F5[G-S$U/@$WN;C]S!Q7F7FV
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M=J:M]:6+) 60@
M           $TW1L]9W._0/D_P!H.KSF72GG4LG#N
M
M
M
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MQ5*+P_QC6>D+M"N6M9MC1)JLLIOW8#Y1K2JBUSMHP4[G?0LOK8%YP
M                                                   !--T;/6=S
MOT#Y/]H.KSF72GG4LG#N
M
M
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MLLY4#54
M      FFZ-GK.YWZ!\G^T'5YS+I3SJ63AW
M
M
M
M
M                       $TW1L]9W._0/D_P!H.KSF72GG4LG#N
M
M
M
M
M                                          )INC9ZSN=^@?)_M!U>
M<RZ4\ZEDX=P
M
M
M
M                                                           !
M--T;/6=SOT#Y/]H.KSF72GG4LG#N
M
M
M
M
M                 )INC9ZSN=^@?)_M!U><RZ4\ZEDX=P
M
M
M
M            Z0[WZCG#+C-L!QJW=VY/F3G;2+C)IQ!?5YM7)/!QDPE>M'.?
MRGB.#3T/?\833K7N6N*J6=GWUMM3$M8WYW6T#.SI^K9KN6<BF*II[G>JY*N:
M<:+=5/+^?%8WAIT2^D%QAW7HWTX<[O\ TCNU7>N6J;WQ[3<OC<M3$7*>YYK.
M6;L;,S'+-&S/]F9<-^V=Z:O]2/\ ![??_"T^7]JFX?C_ /W&8_<L_P#^7STO
M?5'^::+_ .8GMG>FK_4C_![??_"T?:IN'X__ -QF/W)_R^>E[ZH_S31?_,3V
MSO35_J1_@]OO_A:/M4W#\?\ ^XS'[D_Y?/2]]4?YIHO_ )B>V=Z:O]2/\'M]
M_P#"T?:IN'X__P!QF/W)_P OGI>^J/\ --%_\Q/;.]-7^I'^#V^_^%H^U3</
MQ_\ [C,?N3_E\]+WU1_FFB_^8GMG>FK_ %(_P>WW_P +1]JFX?C_ /W&8_<G
M_+YZ7OJC_--%_P#,3VSO35_J1_@]OO\ X6C[5-P_'_\ N,Q^Y/\ E\]+WU1_
MFFB_^8GMG>FK_4C_  >WW_PM'VJ;A^/_ /<9C]R?\OGI>^J/\TT7_P Q/;.]
M-7^I'^#V^_\ A:/M4W#\?_[C,?N3_E\]+WU1_FFB_P#F)[9WIJ_U(_P>WW_P
MM'VJ;A^/_P#<9C]R?\OGI>^J/\TT7_S$]L[TU?ZD?X/;[_X6C[5-P_'_ /N,
MQ^Y/^7STO?5'^::+_P"8GMG>FK_4C_![??\ PM'VJ;A^/_\ <9C]R?\ +YZ7
MOJC_ #31?_,3VSO35_J1_@]OO_A:/M4W#\?_ .XS'[D_Y?/2]]4?YIHO_F)[
M9WIJ_P!2/\'M]_\ "T?:IN'X_P#]QF/W)_R^>E[ZH_S31?\ S$]L[TU?ZD?X
M/;[_ .%H^U3</Q__ +C,?N3_ )?/2]]4?YIHO_F)[9WIJ_U(_P 'M]_\+1]J
MFX?C_P#W&8_<G_+YZ7OJC_--%_\ ,3VSO35_J1_@]OO_ (6C[5-P_'_^XS'[
MD_Y?/2]]4?YIHO\ YB>V=Z:O]2/\'M]_\+1]JFX?C_\ W&8_<G_+YZ7OJC_-
M-%_\Q/;.]-7^I'^#V^_^%H^U3</Q_P#[C,?N3_E\]+WU1_FFB_\ F)[9WIJ_
MU(_P>WW_ ,+1]JFX?C__ '&8_<G_ "^>E[ZH_P TT7_S$]L[TU?ZD?X/;[_X
M6C[5-P_'_P#N,Q^Y/^7STO?5'^::+_YBYDT1U'.&7)G8#?5ND=R?/;.W<7)S
M3>"^KS:N-^$C(=*Q:1<_E/+L&@8>SXNFI2O<N<44O[?O;;JGU-'WYW6U_.QI
M^DYKNN<FF:HI[G>IY*>><:[=-/)^?%@'$OHE](+@]NO7OIQ&W?\ H[=JB];M
M57OCVFYC"Y=F8MT]SRN<O79VIB>6*-F/[4P[O&6JY
M                                    33=&SUG<[] ^3_:#J\YETIYU
M+)P[@
M
M
M                              !$1UW/7^R+T7ZT^37A4SC!Z9U_)[7N
M2]&7X:/W7LI]<ZAX2AC81:O^                       -D^A'Z_V.^B_9
M?R:S)2X/^F='R>[[D* ?B7?=>S?USI_A*UNY;-YS0
M                                   )INC9ZSN=^@?)_M!U><RZ4\ZE
MDX=P
M
M
M                              B(Z[GK_9%Z+]:?)KPJ9Q@],Z_D]KW)
M>C+\-'[KV4^N=0\)0QL(M7_                       &R?0C]?['?1?LO
MY-9DI<'_ $SH^3W?<A0#\2[[KV;^N=/\)6MW+9O.:
M                                   !--T;/6=SOT#Y/]H.KSF72GG4
MLG#N
M
M
M                              $1'7<]?[(O1?K3Y->%3.,'IG7\GM>Y
M+T9?AH_=>RGUSJ'A*&-A%J_X                       V3Z$?K_8[Z+]E
M_)K,E+@_Z9T?)[ON0H!^)=]U[-_7.G^$K6[ELWG-
M                                   FFZ-GK.YWZ!\G^T'5YS+I3SJ6
M3AW
M
M
M                             "(CKN>O]D7HOUI\FO"IG&#TSK^3VO<E
MZ,OPT?NO93ZYU#PE#&PBU?\                        &R?0C]?['?1?L
MOY-9DI<'_3.CY/=]R% /Q+ONO9OZYT_PE:W<MF\YH
M                                   $TW1L]9W._0/D_P!H.KSF72GG
M4LG#N
M
M
M                               $1'7<]?[(O1?K3Y->%3.,'IG7\GM>
MY+T9?AH_=>RGUSJ'A*&-A%J_X                       V3Z$?K_8[Z+]
ME_)K,E+@_P"F='R>[[D* ?B7?=>S?USI_A*UNY;-YS0
M                                     )INC9ZSN=^@?)_M!U><RZ4\
MZEDX=P
M
M
M                                B(Z[GK_9%Z+]:?)KPJ9Q@],Z_D]K
MW)>C+\-'[KV4^N=0\)0QL(M7_                       &R?0C]?['?1?
MLOY-9DI<'_3.CY/=]R% /Q+ONO9OZYT_PE:W<MF\YH
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M4:KV^'14I0.V(    FFZ-GK.YWZ!\G^T'5YS+I3SJ63AW
M
M
M
M           "(CKN>O\ 9%Z+]:?)KPJ9Q@],Z_D]KW)>C+\-'[KV4^N=0\)0
MQL(M7_                       &R?0C]?['?1?LOY-9DI<'_3.CY/=]R%
M /Q+ONO9OZYT_P )6MW+9O.:
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MD_V@ZO.9=*>=2R<.X
M
M
M                                           1$==SU_LB]%^M/DUX
M5,XP>F=?R>U[DO1E^&C]U[*?7.H>$H8V$6K_ (
M V3Z$?K_ &.^B_9?R:S)2X/^F='R>[[D* ?B7?=>S?USI_A*UNY;-YS0
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MWZ!\G^T'5YS+K3SJ63AW
M
M
M                                              "(CKN>O]D7HOUI
M\FO"IG&#TSK^3VO<EZ,OPT?NO93ZYU#PE#&PBU?\
M   ;)]"/U_L=]%^R_DUF2EP?],Z/D]WW(4 _$N^Z]F_KG3_"5K=RV;SF@
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M7&RZT]&SUG<[] ^3_:#J\2XIYU+)P[@
M
M
M                                                        !$1U
MW/7^R+T7ZT^37A4SC!Z9U_)[7N2]&7X:/W7LI]<ZAX2AC81:O^
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M^.51"XX    33=&SUG<[] ^3_:#J\YETIYU+)P[@
M
M
M
M     !$1UW/7^R+T7ZT^37A4SC!Z9U_)[7N2]&7X:/W7LI]<ZAX2AC81:O\
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M=)IDD!"Y U;K?&$&TW%L95NBX[EZ7ATD7Z#A--;P:EUO>I2EW=K6G;V5 _:
M    ":;HV>L[G?H'R?[0=7G,NE/.I9.'<
M
M
M                                                           (
MB.NYZ_V1>B_6GR:\*F<8/3.OY/:]R7HR_#1^Z]E/KG4/"4,;"+5_P
M               !LGT(_7^QWT7[+^369*7!_P!,Z/D]WW(4 _$N^Z]F_KG3
M_"5K=RV;SF@
M     33=&SUG<[] ^3_:#J\YETIYU+)P[@
M
M
M                                                           !
M$1UW/7^R+T7ZT^37A4SC!Z9U_)[7N2]&7X:/W7LI]<ZAX2AC81:O^
M                -D^A'Z_V.^B_9?R:S)2X/^F='R>[[D* ?B7?=>S?USI_
MA*UNY;-YS0
M    )INC9ZSN=^@?)_M!U><RZ4\ZEDX=P
M
M
M                                                           B
M(Z[GK_9%Z+]:?)KPJ9Q@],Z_D]KW)>C+\-'[KV4^N=0\)0QL(M7_
M                !LGT(_7^QWT7[+^369*7!_TSH^3W?<A0#\2[[KV;^N=/
M\)6MW+9O.:
M    !--T;/6=SOT#Y/\ :#J\YETIYU+)P[@
M
M
M
M!$1UW/7^R+T7ZT^37A4SC!Z9U_)[7N2]&7X:/W7LI]<ZAX2AC81:O^
M                 -D^A'Z_V.^B_9?R:S)2X/\ IG1\GN^Y"@'XEWW7LW]<
MZ?X2M;N6S><T
M      ":;HV>L[G?H'R?[0=7G,NE/.I9.'<
M
M
M
M (B.NYZ_V1>B_6GR:\*F<8/3.OY/:]R7HR_#1^Z]E/KG4/"4,;"+5_P
M                 !LGT(_7^QWT7[+^369*7!_TSH^3W?<A0#\2[[KV;^N=
M/\)6MW+9O.:
M     !--T;/6=SOT#Y/]H.KSF72GG4LG#N
M
M
M
M$1'7<]?[(O1?K3Y->%3.,'IG7\GM>Y+T9?AH_=>RGUSJ'A*&-A%J_P"
M                  -D^A'Z_P!COHOV7\FLR4N#_IG1\GN^Y"@'XEWW7LW]
M<Z?X2M;N6S><T
M       ":;HV>L[G?H'R?[0=7G,NE/.I9.'<
M
M
M
M  (B.NYZ_P!D7HOUI\FO"IG&#TSK^3VO<EZ,OPT?NO93ZYU#PE#&PBU?\
M                    ;)]"/U_L=]%^R_DUF2EP?],Z/D]WW(4 _$N^Z]F_
MKG3_  E:W<MF\YH
M         $TW1L]9W._0/D_V@ZO.9=*>=2R<.X
M
M
M
M    1$==SU_LB]%^M/DUX5,XP>F=?R>U[DO1E^&C]U[*?7.H>$H8V$6K_@
M                    #9/H1^O]COHOV7\FLR4N#_IG1\GN^Y"@'XEWW7LW
M]<Z?X2M;N6S><T
M        ":;HV>L[G?H'R?[0=7G,NE/.I9.'<
M
M
M
M   (B.NYZ_V1>B_6GR:\*F<8/3.OY/:]R7HR_#1^Z]E/KG4/"4,;"+5_P
M                   !LGT(_7^QWT7[+^369*7!_P!,Z/D]WW(4 _$N^Z]F
M_KG3_"5K=RV;SF@
M         33=&SUG<[] ^3_:#J\YETIYU+)P[@
M
M
M
M   !$1UW/7^R+T7ZT^37A4SC!Z9U_)[7N2]&7X:/W7LI]<ZAX2AC81:O^
M                    -D^A'Z_V.^B_9?R:S)2X/^F='R>[[D* ?B7?=>S?
MUSI_A*UNY;-YS0
M        )INC9ZSN=^@?)_M!U><RZ4\ZEDX=P
M
M
M
M   B(Z[GK_9%Z+]:?)KPJ9Q@],Z_D]KW)>C+\-'[KV4^N=0\)0QL(M7_
M                    !LGT(_7^QWT7[+^369*7!_TSH^3W?<A0#\2[[KV;
M^N=/\)6MW+9O.:
M        !--T;/6=SOT#Y/\ :#J\YETIYU+)P[@
M
M
M
M    !$1UW/7^R+T7ZT^37A4SC!Z9U_)[7N2]&7X:/W7LI]<ZAX2AC81:O^
M                     -D^A'Z_V.^B_9?R:S)2X/\ IG1\GN^Y"@'XEWW7
MLW]<Z?X2M;N6S><T
M          ":;HV>L[G?H'R?[0=7G,NE/.I9.'<
M
M
M
M     (B.NYZ_V1>B_6GR:\*F<8/3.OY/:]R7HR_#1^Z]E/KG4/"4,;"+5_P
M                     !LGT(_7^QWT7[+^369*7!_TSH^3W?<A0#\2[[KV
M;^N=/\)6MW+9O.:
M         !--T;/6=SOT#Y/]H.KSF72GG4LG#N
M
M
M
M    $1'7<]?[(O1?K3Y->%3.,'IG7\GM>Y+T9?AH_=>RGUSJ'A*&-A%J_P"
M                      -D^A'Z_P!COHOV7\FLR4N#_IG1\GN^Y"@'XEWW
M7LW]<Z?X2M;N6S><T
M           ":;HV>L[G?H'R?[0=7G,NE/.I9.'<
M
M
M
M      (B.NYZ_P!D7HOUI\FO"IG&#TSK^3VO<EZ,OPT?NO93ZYU#PE#&PBU?
M\                       ;)]"/U_L=]%^R_DUF2EP?],Z/D]WW(4 _$N^
MZ]F_KG3_  E:W<MF\YH
M             $TW1L]9W._0/D_V@ZO.9=*>=2R<.X
M
M
M
M        1$==SU_LB]%^M/DUX5,XP>F=?R>U[DO1E^&C]U[*?7.H>$H8V$6K
M_@                      #9/H1^O]COHOV7\FLR4N#_IG1\GN^Y"@'XEW
MW7LW]<Z?X2M;N6S><T
M            ":;HV>L[G?H'R?[0=7G,NE/.I9.'<
M
M
M
M       (B.NYZ_V1>B_6GR:\*F<8/3.OY/:]R7HR_#1^Z]E/KG4/"4,;"+5_
MP                      !LGT(_7^QWT7[+^369*7!_P!,Z/D]WW(4 _$N
M^Z]F_KG3_"5K=RV;SF@
M             33=&SUG<[] ^3_:#J\YETIYU+)P[@
M
M
M
M       !$1UW/7^R+T7ZT^37A4SC!Z9U_)[7N2]&7X:/W7LI]<ZAX2AC81:O
M^                       -D^A'Z_V.^B_9?R:S)2X/^F='R>[[D* ?B7?
M=>S?USI_A*UNY;-YS0
M            )INC9ZSN=^@?)_M!U><RZ4\ZEDX=P
M
M
M
M       B(Z[GK_9%Z+]:?)KPJ9Q@],Z_D]KW)>C+\-'[KV4^N=0\)0QL(M7_
M                        !LGT(_7^QWT7[+^369*7!_TSH^3W?<A0#\2[
M[KV;^N=/\)6MW+9O.:
M            !--T;/6=SOT#Y/\ :#J\YETIYU+)P[@
M
M
M
M        !$1UW/7^R+T7ZT^37A4SC!Z9U_)[7N2]&7X:/W7LI]<ZAX2AC81:
MO^                       -D^A'Z_V.^B_9?R:S)2X/\ IG1\GN^Y"@'X
MEWW7LW]<Z?X2M;N6S><T
M              ":;HV>L[G?H'R?[0=7G,NE/.I9.'<
M
M
M
M         (B.NYZ_V1>B_6GR:\*F<8/3.OY/:]R7HR_#1^Z]E/KG4/"4,;"+
M5_P                      !LGT(_7^QWT7[+^369*7!_TSH^3W?<A0#\2
M[[KV;^N=/\)6MW+9O.:
M             !--T;/6=SOT#Y/]H.KSF72GG4LG#N
M
M
M
M        $1'7<]?[(O1?K3Y->%3.,'IG7\GM>Y+T9?AH_=>RGUSJ'A*&-A%J
M_P"                       -D^A'Z_P!COHOV7\FLR4N#_IG1\GN^Y"@'
MXEWW7LW]<Z?X2M;N6S><T
M               ":;HV>L[G?H'R?[0=7G,NE/.I9.'<
M
M
M
M          (B.NYZ_P!D7HOUI\FO"IG&#TSK^3VO<EZ,OPT?NO93ZYU#PE#&
MPBU?\                       ;)]"/U_L=]%^R_DUF2EP?],Z/D]WW(4
M_$N^Z]F_KG3_  E:W<MF\YH
M                 $TW1L]9W._0/D_V@ZO.9=*>=2R<.X
M
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M<Y0I?9CR,O9C,),QV)J2Z2=7"-)=PQ[S/L<__P!O6BE0[K@
M                                                   (B.NYZ_V1
M>B_6GR:\*F<8/3.OY/:]R7HR_#1^Z]E/KG4/"4,;"+5_P
M       !LGT(_7^QWT7[+^369*7!_P!,Z/D]WW(4 _$N^Z]F_KG3_"5K=RV;
MSF@                                                      33=
M&SUG<[] ^3_:#J\YETIYU+)P[@
M
M                          #I%U'M?<LML<*=[:PX.9S$ZQY0[!A<9P[6
MVQIK)9/#F>"M<ASW%(O8.6HY3!Q<S/0$M :Q<S+I@ZCVRL@D^21JU[KCP=U
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M38
M       B(Z[GK_9%Z+]:?)KPJ9Q@],Z_D]KW)>C+\-'[KV4^N=0\)0QL(M7_
M                        !LGT(_7^QWT7[+^369*7!_TSH^3W?<A0#\2[
M[KV;^N=/\)6MW+9O.:
M            !--T;/6=SOT#Y/\ :#J\YETIYU+)P[@
M
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MHTQK.$<<229XO!I)I)X;#4MNOL_*JM+8L*[0
M                                         "(CKN>O]D7HOUI\FO"I
MG&#TSK^3VO<EZ,OPT?NO93ZYU#PE#&PBU?\                        &
MR?0C]?['?1?LOY-9DI<'_3.CY/=]R% /Q+ONO9OZYT_PE:W<MF\YH
M                                               $TW1L]9W._0/D
M_P!H.KSF72GG4LG#N
M
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M39Q\F\\"O<E6C1MX,+R
M                        $1'7<]?[(O1?K3Y->%3.,'IG7\GM>Y+T9?AH
M_=>RGUSJ'A*&-A%J_P"                       -D^A'Z_P!COHOV7\FL
MR4N#_IG1\GN^Y"@'XEWW7LW]<Z?X2M;N6S><T
M                               ":;HV>L[G?H'R?[0=7G,NE/.I9.'<
M
M
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M@JO+WV)U4426\"%S
M                     "(CKN>O]D7HOUI\FO"IG&#TSK^3VO<EZ,OPT?NO
M93ZYU#PE#&PBU?\                        &R?0C]?['?1?LOY-9DI<'
M_3.CY/=]R% /Q+ONO9OZYT_PE:W<MF\YH
M                           $TW1L]9W._0/D_P!H.KSF72GG4LG#N
M
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M6MB=EJ5J=E@=\>&_1*Z7_ W(6.<<<^)V"P^RHRZBT=M+.WN1[9V)$/*77?\
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M1<1&HMVC:U5PLHLK=2WOK+J7JJ77*7W75#[X
M                                        !$1UW/7^R+T7ZT^37A4S
MC!Z9U_)[7N2]&7X:/W7LI]<ZAX2AC81:O^                       -D^
MA'Z_V.^B_9?R:S)2X/\ IG1\GN^Y"@'XEWW7LW]<Z?X2M;N6S><T
M                                              ":;HV>L[G?H'R?
M[0=7G,NE/.I9.'<
M
M
M                                         (B.NYZ_V1>B_6GR:\*F
M<8/3.OY/:]R7HR_#1^Z]E/KG4/"4,;"+5_P                      !LG
MT(_7^QWT7[+^369*7!_TSH^3W?<A0#\2[[KV;^N=/\)6MW+9O.:
M                                             !--T;/6=SOT#Y/]
MH.KSF72GG4LG#N
M
M
M                                        $1'7<]?[(O1?K3Y->%3.
M,'IG7\GM>Y+T9?AH_=>RGUSJ'A*&-A%J_P"                       -D
M^A'Z_P!COHOV7\FLR4N#_IG1\GN^Y"@'XEWW7LW]<Z?X2M;N6S><T
M                                               ":;HV>L[G?H'R
M?[0=7G,NE/.I9.'<
M
M
M                                          (B.NYZ_P!D7HOUI\FO
M"IG&#TSK^3VO<EZ,OPT?NO93ZYU#PE#&PBU?\
M;)]"/U_L=]%^R_DUF2EP?],Z/D]WW(4 _$N^Z]F_KG3_  E:W<MF\YH
M                                                 $TW1L]9W._0
M/D_V@ZO.9=*>=2R<.X
M
M
M                                            1$==SU_LB]%^M/DU
MX5,XP>F=?R>U[DO1E^&C]U[*?7.H>$H8V$6K_@
M#9/H1^O]COHOV7\FLR4N#_IG1\GN^Y"@'XEWW7LW]<Z?X2M;N6S><T
M                                                ":;HV>L[G?H'
MR?[0=7G,NE/.I9.'<
M
M              "=7F3[P;A_$#DQM;C?(\8,ESI[JZ6B(I?+&6THN!:S-TKC
M$'DMJR,0O@\HJRHC9-41K;<X4[U4ZW=M.WLI,>[?"',[Q:)E]:HSU%JF_3,[
M$VIJF,*JJ>?;C']''FA%VN\3;&AZM>TJO)UW*K-41M1<B(G&F*N;8G#GPYW6
M3_O4& _T9Y?^^F&_X<'W/L&S?G*WWFK]X^1]L>6\0N=]CM#_ +U!@/\ 1GE_
M[Z8;_AP/L&S?G*WWFK]X?;'EO$+G?8[0_P"]08#_ $9Y?^^F&_X<#[!LWYRM
M]YJ_>'VQY;Q"YWV.T/\ O4& _P!&>7_OIAO^' ^P;-^<K?>:OWA]L>6\0N=]
MCM#_ +U!@/\ 1GE_[Z8;_AP/L&S?G*WWFK]X?;'EO$+G?8[0_P"]08#_ $9Y
M?^^F&_X<#[!LWYRM]YJ_>'VQY;Q"YWV.T/\ O4& _P!&>7_OIAO^' ^P;-^<
MK?>:OWA]L>6\0N=]CM#_ +U!@/\ 1GE_[Z8;_AP/L&S?G*WWFK]X?;'EO$+G
M?8[0_P"]08#_ $9Y?^^F&_X<#[!LWYRM]YJ_>'VQY;Q"YWV.T/\ O4& _P!&
M>7_OIAO^' ^P;-^<K?>:OWA]L>6\0N=]CM#_ +U!@/\ 1GE_[Z8;_AP/L&S?
MG*WWFK]X?;'EO$+G?8[0_P"]08#_ $9Y?^^F&_X<#[!LWYRM]YJ_>'VQY;Q"
MYWV.T/\ O4& _P!&>7_OIAO^' ^P;-^<K?>:OWA]L>6\0N=]CM#_ +U!@/\
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MPPP]GGY&3[J;_6=Z=1KT^WEJK-5%F;FU-<58X544X813'^OCCC[#;LB]((
M                                                          (B
M.NYZ_P!D7HOUI\FO"IG&#TSK^3VO<EZ,OPT?NO93ZYU#PE#&PBU?\
M                ;)]"/U_L=]%^R_DUF2EP?],Z/D]WW(4 _$N^Z]F_KG3_
M  E:W<MF\YH
M     $TW1L]9W._0/D_V@ZO.9=*>=2R<.X
M
M                               'FP]:W_-$Y;_VOP_[+,#+J<,O073_
M -G7X6XJEO\ ^E^=_:4^#H9:&=L.                       %&_NPWK[[
M<_PA9]]LV@2&N.7HGE_K&WX',)3X1>DE_P"0U^%LKLBJJQ8
M                                               (B.NYZ_V1>B_6
MGR:\*F<8/3.OY/:]R7HR_#1^Z]E/KG4/"4,;"+5_P
M   !LGT(_7^QWT7[+^369*7!_P!,Z/D]WW(4 _$N^Z]F_KG3_"5K=RV;SF@
M                                                     33=&SUG
M<[] ^3_:#J\YETIYU+)P[@
M
M                   >;#UK?\T3EO\ VOP_[+,#+J<,O073_P!G7X6XJEO_
M .E^=_:4^#H9:&=L.                       %&_NPWK[[<_PA9]]LV@2
M&N.7HGE_K&WX',)3X1>DE_Y#7X6RNR*JK%@
M                                   B(Z[GK_9%Z+]:?)KPJ9Q@],Z_
MD]KW)>C+\-'[KV4^N=0\)0QL(M7_                        !LGT(_7^
MQWT7[+^369*7!_TSH^3W?<A0#\2[[KV;^N=/\)6MW+9O.:
M                                        !--T;/6=SOT#Y/\ :#J\
MYETIYU+)P[@
M
M        >;#UK?\ -$Y;_P!K\/\ LLP,NIPR]!=/_9U^%N*I;_\ I?G?VE/@
MZ&6AG;#@                      !1O[L-Z^^W/\(6??;-H$AKCEZ)Y?ZQ
MM^!S"4^$7I)?^0U^%LKLBJJQ8
M                         (B.NYZ_V1>B_6GR:\*F<8/3.OY/:]R7HR_#
M1^Z]E/KG4/"4,;"+5_P                      !LGT(_7^QWT7[+^369*
M7!_TSH^3W?<A0#\2[[KV;^N=/\)6MW+9O.:
M                             !--T;/6=SOT#Y/]H.KSF72GG4LG#N
M
M                                                       !YL/6
MM_S1.6_]K\/^RS RZG#+T%T_]G7X6XJEO_Z7YW]I3X.AEH9VPX
M             4;^[#>OOMS_  A9]]LV@2&N.7HGE_K&WX',)3X1>DE_Y#7X
M6RNR*JK%@
M         B(Z[GK_ &1>B_6GR:\*F<8/3.OY/:]R7HR_#1^Z]E/KG4/"4,;"
M+5_P                      !LGT(_7^QWT7[+^369*7!_TSH^3W?<A0#\
M2[[KV;^N=/\ "5K=RV;SF@
M                33=&SUG<[] ^3_:#J\YETIYU+)P[@
M
M                                          >;#UK?\T3EO_:_#_LL
MP,NIPR]!=/\ V=?A;BJ6_P#Z7YW]I3X.AEH9VPX
M  4;^[#>OOMS_"%GWVS:!(:XY>B>7^L;?@<PE/A%Z27_ )#7X6RNR*JK%@
M                                                          B(
MZ[GK_9%Z+]:?)KPJ9Q@],Z_D]KW)>C+\-'[KV4^N=0\)0QL(M7_
M              &R?0C]?['?1?LOY-9DI<'_ $SH^3W?<A0#\2[[KV;^N=/\
M)6MW+9O.:
M   !--T;/6=SOT#Y/]H.KSF72GG4LG#N
M
M                             !YL/6M_S1.6_P#:_#_LLP,NIPR]!=/_
M &=?A;BJ6_\ Z7YW]I3X.AEH9VPX                       4;^[#>OOM
MS_"%GWVS:!(:XY>B>7^L;?@<PE/A%Z27_D-?A;*[(JJL6
M                                             "(CKN>O]D7HOUI\
MFO"IG&#TSK^3VO<EZ,OPT?NO93ZYU#PE#&PBU?\
M   &R?0C]?['?1?LOY-9DI<'_3.CY/=]R% /Q+ONO9OZYT_PE:W<MF\YH
M                                                   $TW1L]9W.
M_0/D_P!H.KSF72GG4LG#N
M
M                  !YL/6M_P T3EO_ &OP_P"RS RZG#+T%T_]G7X6XJEO
M_P"E^=_:4^#H9:&=L.                       %&_NPWK[[<_PA9]]LV@
M2&N.7HGE_K&WX',)3X1>DE_Y#7X6RNR*JK%@
M                                    B(Z[GK_9%Z+]:?)KPJ9Q@],Z
M_D]KW)>C+\-'[KV4^N=0\)0QL(M7_                       &R?0C]?[
M'?1?LOY-9DI<'_3.CY/=]R% /Q+ONO9OZYT_PE:W<MF\YH
M                                        $TW1L]9W._0/D_V@ZO.9
M=*>=2R<.X
M
M      'FP]:W_-$Y;_VOP_[+,#+J<,O073_V=?A;BJ6__I?G?VE/@Z&6AG;#
M@                      !1O[L-Z^^W/\ "%GWVS:!(:XY>B>7^L;?@<PE
M/A%Z27_D-?A;*[(JJL6
M                   "(CKN>O\ 9%Z+]:?)KPJ9Q@],Z_D]KW)>C+\-'[KV
M4^N=0\)0QL(M7_                       &R?0C]?['?1?LOY-9DI<'_3
M.CY/=]R% /Q+ONO9OZYT_P )6MW+9O.:
M                          !--T;/6=SOT#Y/]H.KSF72GG4LG#N
M
M                                                    !YL/6M_S
M1.6_]K\/^RS RZG#+T%T_P#9U^%N*I;_ /I?G?VE/@Z&6AG;#@
M            !1O[L-Z^^W/\(6??;-H$AKCEZ)Y?ZQM^!S"4^$7I)?\ D-?A
M;*[(JJL6
M        "(CKN>O]D7HOUI\FO"IG&#TSK^3VO<EZ,OPT?NO93ZYU#PE#&PBU
M?\                       ;)]"/U_L=]%^R_DUF2EP?\ 3.CY/=]R% /Q
M+ONO9OZYT_PE:W<MF\YH
M              $TW1L]9W._0/D_V@ZO.9=*>=2R<.X
M
M                                        'FP]:W_-$Y;_ -K\/^RS
M RZG#+T%T_\ 9U^%N*I;_P#I?G?VE/@Z&6AG;#@
M !1O[L-Z^^W/\(6??;-H$AKCEZ)Y?ZQM^!S"4^$7I)?^0U^%LKLBJJQ8
M                                                        (B.N
MYZ_V1>B_6GR:\*F<8/3.OY/:]R7HR_#1^Z]E/KG4/"4,;"+5_P
M              ;)]"/U_L=]%^R_DUF2EP?],Z/D]WW(4 _$N^Z]F_KG3_"5
MK=RV;SF@
M  33=&SUG<[] ^3_ &@ZO.9=*>=2R<.X
M
M                             'FP]:W_ #1.6_\ :_#_ ++,#+J<,O07
M3_V=?A;BJ6__ *7YW]I3X.AEH9VPX                       4;^[#>OO
MMS_"%GWVS:!(:XY>B>7^L;?@<PE/A%Z27_D-?A;*[(JJL6
M                                              "(CKN>O]D7HOUI
M\FO"IG&#TSK^3VO<EZ,OPT?NO93ZYU#PE#&PBU?\
M   ;)]"/U_L=]%^R_DUF2EP?],Z/D]WW(4 _$N^Z]F_KG3_"5K=RV;SF@
M                                                   33=&SUG<[
M] ^3_:#J\YETIYU+)P[@
M
M                 >;#UK?\T3EO_:_#_LLP,NIPR]!=/_9U^%N*I;_^E^=_
M:4^#H9:&=L.                       %&_NPWK[[<_P (6??;-H$AKCEZ
M)Y?ZQM^!S"4^$7I)?^0U^%LKLBJJQ8
M                              (B.NYZ_P!D7HOUI\FO"IG&#TSK^3VO
M<EZ,OPT?NO93ZYU#PE#&PBU?\                       ;)]"/U_L=]%^
MR_DUF2EP?],Z/D]WW(4 _$N^Z]F_KG3_  E:W<MF\YH
M                                     $TW1L]9W._0/D_V@ZO.9=*>
M=2R<.X
M
M   'FP]:W_-$Y;_VOP_[+,#+J<,O073_ -G7X6XJEO\ ^E^=_:4^#H9:&=L.
M                       %&_NPWK[[<_PA9]]LV@2&N.7HGE_K&WX',)3X
M1>DE_P"0U^%LKLBJJQ8
M                   (B.NYZ_V1>B_6GR:\*F<8/3.OY/:]R7HR_#1^Z]E/
MKG4/"4,;"+5_P                      !LGT(_7^QWT7[+^369*7!_P!,
MZ/D]WW(4 _$N^Z]F_KG3_"5K=RV;SF@
M                         33=&SUG<[] ^3_:#J\YETIYU+)P[@
M
M                                                   >;#UK?\T3
MEO\ VOP_[+,#+J<,O073_P!G7X6XJEO_ .E^=_:4^#H9:&=L.
M            %&_NPWK[[<_PA9]]LV@2&N.7HGE_K&WX',)3X1>DE_Y#7X6R
MNR*JK%@
M       B(Z[GK_9%Z+]:?)KPJ9Q@],Z_D]KW)>C+\-'[KV4^N=0\)0QL(M7_
M                        !LGT(_7^QWT7[+^369*7!_TSH^3W?<A0#\2[
M[KV;^N=/\)6MW+9O.:
M            !--T;/6=SOT#Y/\ :#J\YETIYU+)P[@
M
M                                        >;#UK?\ -$Y;_P!K\/\
MLLP,NIPR]!=/_9U^%N*I;_\ I?G?VE/@Z&6AG;#@
M  !1O[L-Z^^W/\(6??;-H$AKCEZ)Y?ZQM^!S"4^$7I)?^0U^%LKLBJJQ8
M                                                         (B.
MNYZ_V1>B_6GR:\*F<8/3.OY/:]R7HR_#1^Z]E/KG4/"4,;"+5_P
M             !LGT(_7^QWT7[+^369*7!_TSH^3W?<A0#\2[[KV;^N=/\)6
MMW+9O.:
M !--T;/6=SOT#Y/]H.KSF72GG4LG#N
M
M                           !YL/6M_S1.6_]K\/^RS RZG#+T%T_]G7X
M6XJEO_Z7YW]I3X.AEH9VPX                       4;^[#>OOMS_  A9
M]]LV@2&N.7HGE_K&WX',)3X1>DE_Y#7X6RNR*JK%@
M                                         B(Z[GK_ &1>B_6GR:\*
MF<8/3.OY/:]R7HR_#1^Z]E/KG4/"4,;"+5_P                      !L
MGT(_7^QWT7[+^369*7!_TSH^3W?<A0#\2[[KV;^N=/\ "5K=RV;SF@
M                                                33=&SUG<[] ^
M3_:#J\YETIYU+)P[@
M
M              >;#UK?\T3EO_:_#_LLP,NIPR]!=/\ V=?A;BJ6_P#Z7YW]
MI3X.AEH9VPX                       4;^[#>OOMS_"%GWVS:!(:XY>B>
M7^L;?@<PE/A%Z27_ )#7X6RNR*JK%@
M                              B(Z[GK_9%Z+]:?)KPJ9Q@],Z_D]KW)
M>C+\-'[KV4^N=0\)0QL(M7_                       &R?0C]?['?1?LO
MY-9DI<'_ $SH^3W?<A0#\2[[KV;^N=/\)6MW+9O.:
M                                   !--T;/6=SOT#Y/]H.KSF72GG4
MLG#N
M
M !YL/6M_S1.6_P#:_#_LLP,NIPR]!=/_ &=?A;BJ6_\ Z7YW]I3X.AEH9VPX
M                       4;^[#>OOMS_"%GWVS:!(:XY>B>7^L;?@<PE/A
M%Z27_D-?A;*[(JJL6
M                 "(CKN>O]D7HOUI\FO"IG&#TSK^3VO<EZ,OPT?NO93ZY
MU#PE#&PBU?\                        &R?0C]?['?1?LOY-9DI<'_3.C
MY/=]R% /Q+ONO9OZYT_PE:W<MF\YH
M                       $TW1L]9W._0/D_P!H.KSF72GG4LG#N
M
M                                                  !YL/6M_P T
M3EO_ &OP_P"RS RZG#+T%T_]G7X6XJEO_P"E^=_:4^#H9:&=L.
M             %&_NPWK[[<_PA9]]LV@2&N.7HGE_K&WX',)3X1>DE_Y#7X6
MRNR*JK%@
M        B(Z[GK_9%Z+]:?)KPJ9Q@],Z_D]KW)>C+\-'[KV4^N=0\)0QL(M7
M_                       &R?0C]?['?1?LOY-9DI<'_3.CY/=]R% /Q+O
MNO9OZYT_PE:W<MF\YH
M            $TW1L]9W._0/D_V@ZO.9=*>=2R<.X
M
M                                      'FP]:W_-$Y;_VOP_[+,#+J
M<,O073_V=?A;BJ6__I?G?VE/@Z&6AG;#@                      !1O[L
M-Z^^W/\ "%GWVS:!(:XY>B>7^L;?@<PE/A%Z27_D-?A;*[(JJL6
M                                                   "(CKN>O\
M9%Z+]:?)KPJ9Q@],Z_D]KW)>C+\-'[KV4^N=0\)0QL(M7_
M         &R?0C]?['?1?LOY-9DI<'_3.CY/=]R% /Q+ONO9OZYT_P )6MW+
M9O.:                                                      !-
M-T;/6=SOT#Y/]H.KSF72GG4LG#N
M
M                        !YL/6M_S1.6_]K\/^RS RZG#+T%T_P#9U^%N
M*I;_ /I?G?VE/@Z&6AG;#@                      !1O[L-Z^^W/\(6??
M;-H$AKCEZ)Y?ZQM^!S"4^$7I)?\ D-?A;*[(JJL6
M                                        "(CKN>O]D7HOUI\FO"IG
M&#TSK^3VO<EZ,OPT?NO93ZYU#PE#&PBU?\                       ;)]
M"/U_L=]%^R_DUF2EP?\ 3.CY/=]R% /Q+ONO9OZYT_PE:W<MF\YH
M                                              $TW1L]9W._0/D_
MV@ZO.9=*>=2R<.X
M
M            'FP]:W_-$Y;_ -K\/^RS RZG#+T%T_\ 9U^%N*I;_P#I?G?V
ME/@Z&6AG;#@                      !1O[L-Z^^W/\(6??;-H$AKCEZ)Y
M?ZQM^!S"4^$7I)?^0U^%LKLBJJQ8
M                            (B.NYZ_V1>B_6GR:\*F<8/3.OY/:]R7H
MR_#1^Z]E/KG4/"4,;"+5_P                        ;)]"/U_L=]%^R_
MDUF2EP?],Z/D]WW(4 _$N^Z]F_KG3_"5K=RV;SF@
M                                  33=&SUG<[] ^3_ &@ZO.9=*>=2
MR<.X
M
M 'FP]:W_ #1.6_\ :_#_ ++,#+J<,O073_V=?A;BJ6__ *7YW]I3X.AEH9VP
MX                       4;^[#>OOMS_"%GWVS:!(:XY>B>7^L;?@<PE/
MA%Z27_D-?A;*[(JJL6
M                  "(CKN>O]D7HOUI\FO"IG&#TSK^3VO<EZ,OPT?NO93Z
MYU#PE#&PBU?\                       ;)]"/U_L=]%^R_DUF2EP?],Z/
MD]WW(4 _$N^Z]F_KG3_"5K=RV;SF@
M                       33=&SUG<[] ^3_:#J\YETIYU+)P[@
M
M                                                 >;#UK?\T3EO
M_:_#_LLP,NIPR]!=/_9U^%N*I;_^E^=_:4^#H9:&=L.
M      %&_NPWK[[<_P (6??;-H$AKCEZ)Y?ZQM^!S"4^$7I)?^0U^%LKLBJJ
MQ8
M  (B.NYZ_P!D7HOUI\FO"IG&#TSK^3VO<EZ,OPT?NO93ZYU#PE#&PBU?\
M                    ;)]"/U_L=]%^R_DUF2EP?],Z/D]WW(4 _$N^Z]F_
MKG3_  E:W<MF\YH
M         $TW1L]9W._0/D_V@ZO.9=*>=2R<.X
M
M                                   'FP]:W_-$Y;_VOP_[+,#+J<,O
M073_ -G7X6XJEO\ ^E^=_:4^#H9:&=L.                       %&_NP
MWK[[<_PA9]]LV@2&N.7HGE_K&WX',)3X1>DE_P"0U^%LKLBJJQ8
M                                                   (B.NYZ_V1
M>B_6GR:\*F<8/3.OY/:]R7HR_#1^Z]E/KG4/"4,;"+5_P
M       !LGT(_7^QWT7[+^369*7!_P!,Z/D]WW(4 _$N^Z]F_KG3_"5K=RV;
MSF@                                                      33=
M&SUG<[] ^3_:#J\YETIYU+)P[@
M
M                       >;#UK?\T3EO\ VOP_[+,#+J<,O073_P!G7X6X
MJEO_ .E^=_:4^#H9:&=L.                       %&_NPWK[[<_PA9]]
MLV@2&N.7HGE_K&WX',)3X1>DE_Y#7X6RNR*JK%@
M                                       B(Z[GK_9%Z+]:?)KPJ9Q@
M],Z_D]KW)>C+\-'[KV4^N=0\)0QL(M7_                        !LGT
M(_7^QWT7[+^369*7!_TSH^3W?<A0#\2[[KV;^N=/\)6MW+9O.:
M                                            !--T;/6=SOT#Y/\
M:#J\YETIYU+)P[@
M
M            >;#UK?\ -$Y;_P!K\/\ LLP,NIPR]!=/_9U^%N*I;_\ I?G?
MVE/@Z&6AG;#@                      !1O[L-Z^^W/\(6??;-H$AKCEZ)
MY?ZQM^!S"4^$7I)?^0U^%LKLBJJQ8
M                             (B.NYZ_V1>B_6GR:\*F<8/3.OY/:]R7
MHR_#1^Z]E/KG4/"4,;"+5_P                      !LGT(_7^QWT7[+^
M369*7!_TSH^3W?<A0#\2[[KV;^N=/\)6MW+9O.:
M                                 !--T;/6=SOT#Y/]H.KSF72GG4LG
M#N
M                                                           !
MYL/6M_S1.6_]K\/^RS RZG#+T%T_]G7X6XJEO_Z7YW]I3X.AEH9VPX
M                 4;^[#>OOMS_  A9]]LV@2&N.7HGE_K&WX',)3X1>DE_
MY#7X6RNR*JK%@
M             B(Z[GK_ &1>B_6GR:\*F<8/3.OY/:]R7HR_#1^Z]E/KG4/"
M4,;"+5_P                      !LGT(_7^QWT7[+^369*7!_TSH^3W?<
MA0#\2[[KV;^N=/\ "5K=RV;SF@
M                    33=&SUG<[] ^3_:#J\YETIYU+)P[@
M
M                                              >;#UK?\T3EO_:_
M#_LLP,NIPR]!=/\ V=?A;BJ6_P#Z7YW]I3X.AEH9VPX
M      4;^[#>OOMS_"%GWVS:!(:XY>B>7^L;?@<PE/A%Z27_ )#7X6RNR*JK
M%@
M  B(Z[GK_9%Z+]:?)KPJ9Q@],Z_D]KW)>C+\-'[KV4^N=0\)0QL(M7_
M                  &R?0C]?['?1?LOY-9DI<'_ $SH^3W?<A0#\2[[KV;^
MN=/\)6MW+9O.:
M       !--T;/6=SOT#Y/]H.KSF72GG4LG#N
M
M                                 !YL/6M_S1.6_P#:_#_LLP,NIPR]
M!=/_ &=?A;BJ6_\ Z7YW]I3X.AEH9VPX                       4;^[#
M>OOMS_"%GWVS:!(:XY>B>7^L;?@<PE/A%Z27_D-?A;*[(JJL6
M                                                 "(CKN>O]D7H
MOUI\FO"IG&#TSK^3VO<EZ,OPT?NO93ZYU#PE#&PBU?\
M       &R?0C]?['?1?LOY-9DI<'_3.CY/=]R% /Q+ONO9OZYT_PE:W<MF\Y
MH                                                      $TW1L
M]9W._0/D_P!H.KSF72GG4LG#N
M
M                      !YL/6M_P T3EO_ &OP_P"RS RZG#+T%T_]G7X6
MXJEO_P"E^=_:4^#H9:&=L.                       %&_NPWK[[<_PA9]
M]LV@2&N.7HGE_K&WX',)3X1>DE_Y#7X6RNR*JK%@
M                                        B(Z[GK_9%Z+]:?)KPJ9Q
M@],Z_D]KW)>C+\-'[KV4^N=0\)0QL(M7_                       &R?0
MC]?['?1?LOY-9DI<'_3.CY/=]R% /Q+ONO9OZYT_PE:W<MF\YH
M                                            $TW1L]9W._0/D_V@
MZO.9=*>=2R<.X
M
M          'FP]:W_-$Y;_VOP_[+,#+J<,O073_V=?A;BJ6__I?G?VE/@Z&6
MAG;#@                      !1O[L-Z^^W/\ "%GWVS:!(:XY>B>7^L;?
M@<PE/A%Z27_D-?A;*[(JJL6
M                       "(CKN>O\ 9%Z+]:?)KPJ9Q@],Z_D]KW)>C+\-
M'[KV4^N=0\)0QL(M7_                       &R?0C]?['?1?LOY-9DI
M<'_3.CY/=]R% /Q+ONO9OZYT_P )6MW+9O.:
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MYS+I3SJ63AW
M
M         \V'K6_YHG+?^U^'_99@9=3AEZ"Z?^SK\+<52W_]+\[^TI\'0RT,
M[8<                       *-_=AO7WVY_A"S[[9M D-<<O1/+_6-OP.8
M2GPB])+_ ,AK\+979%55BP
M                      1$==SU_LB]%^M/DUX5,XP>F=?R>U[DO1E^&C]U
M[*?7.H>$H8V$6K_@                      #9/H1^O]COHOV7\FLR4N#_
M *9T?)[ON0H!^)=]U[-_7.G^$K6[ELWG-
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M-6UR:,@X:I!7>     $TW1L]9W._0/D_V@ZO.9=*>=2R<.X
M
M                                            'FP]:W_-$Y;_ -K\
M/^RS RZG#+T%T_\ 9U^%N*I;_P#I?G?VE/@Z&6AG;#@
M     !1O[L-Z^^W/\(6??;-H$AKCEZ)Y?ZQM^!S"4^$7I)?^0U^%LKLBJJQ8
M
M(B.NYZ_V1>B_6GR:\*F<8/3.OY/:]R7HR_#1^Z]E/KG4/"4,;"+5_P
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M.KQ+BGG4LG#N
M
M         !YL/6M_S1.6_P#:_#_LLP,NIPR]!=/_ &=?A;BJ6_\ Z7YW]I3X
M.AEH9VPX                       4;^[#>OOMS_"%GWVS:!(:XY>B>7^L
M;?@<PE/A%Z27_D-?A;*[(JJL6
M                         "(CKN>O]D7HOUI\FO"IG&#TSK^3VO<EZ,OP
MT?NO93ZYU#PE#&PBU?\                        &R?0C]?['?1?LOY-9
MDI<'_3.CY/=]R% /Q+ONO9OZYT_PE:W<MF\YH
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MT\ZEDX=P
M
M     /-AZUO^:)RW_M?A_P!EF!EU.&7H+I_[.OPMQ5+?_P!+\[^TI\'0RT,[
M8<                       *-_=AO7WVY_A"S[[9M D-<<O1/+_6-OP.82
MGPB])+_R&OPME=D556+
M                   !$1UW/7^R+T7ZT^37A4SC!Z9U_)[7N2]&7X:/W7LI
M]<ZAX2AC81:O^                       -D^A'Z_V.^B_9?R:S)2X/^F=
M'R>[[D* ?B7?=>S?USI_A*UNY;-YS0
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MWZ!\G^T'5YS+I3SJ63AW
M
M                  \V'K6_YHG+?^U^'_99@9=3AEZ"Z?\ LZ_"W%4M_P#T
MOSO[2GP=#+0SMAP                       HW]V&]??;G^$+/OMFT"0UQ
MR]$\O]8V_ YA*?"+TDO_ "&OPME=D556+
M                                 !$1UW/7^R+T7ZT^37A4SC!Z9U_)
M[7N2]&7X:/W7LI]<ZAX2AC81:O\ @                      #9/H1^O\
M8[Z+]E_)K,E+@_Z9T?)[ON0H!^)=]U[-_7.G^$K6[ELWG-
M                                         FFZ-GK.YWZ!\G^T'5YS
M+I3SJ63AW
M
M       \V'K6_P":)RW_ +7X?]EF!EU.&7H+I_[.OPMQ5+?_ -+\[^TI\'0R
MT,[8<                       *-_=AO7WVY_A"S[[9M D-<<O1/+_ %C;
M\#F$I\(O22_\AK\+979%55BP
M                        1$==SU_LB]%^M/DUX5,XP>F=?R>U[DO1E^&C
M]U[*?7.H>$H8V$6K_@                      #9/H1^O]COHOV7\FLR4N
M#_IG1\GN^Y"@'XEWW7LW]<Z?X2M;N6S><T
M                            ":;HV>L[G?H'R?[0=7G,NE/.I9.'<
M
M                                                      #S8>M;
M_FB<M_[7X?\ 99@9=3AEZ"Z?^SK\+<52W_\ 2_._M*?!T,M#.V'
M              "C?W8;U]]N?X0L^^V;0)#7'+T3R_UC;\#F$I\(O22_\AK\
M+979%55BP
M         1$==SU_LB]%^M/DUX5,XP>F=?R>U[DO1E^&C]U[*?7.H>$H8V$6
MK_@                      #9/H1^O]COHOV7\FLR4N#_IG1\GN^Y"@'XE
MWW7LW]<Z?X2M;N6S><T
M             ":;HV>L[G?H'R?[0=7G,NE/.I9.'<
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M#*I0$1!Y,TSEMBL7DE'TBUG9Q-M&/X^!BZ(1=ZCEX[L?U"G$
M                                                    !YL/6M_S
M1.6_]K\/^RS RZG#+T%T_P#9U^%N*I;_ /I?G?VE/@Z&6AG;#@
M            !1O[L-Z^^W/\(6??;-H$AKCEZ)Y?ZQM^!S"4^$7I)?\ D-?A
M;*[(JJL6
M        "(CKN>O]D7HOUI\FO"IG&#TSK^3VO<EZ,OPT?NO93ZYU#PE#&PBU
M?\                       ;)]"/U_L=]%^R_DUF2EP?\ 3.CY/=]R% /Q
M+ONO9OZYT_PE:W<MF\YH
M              $TW1L]9W._0/D_V@ZO.9=*>=2R<.X
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M4&X[)13=99LV5UYJO,LQF\4CG#:BBU%T63_5,5?8G??=W+T;;N]6MM.T/31
M >9QLYY,>\F^\7IZ9D,BD)3A/QPF,MBF+*$E%Z127&W1TVR99]E$*Z8=RQ*4
MY&[,<-&UDM9;8[;L)N.3NO4MC4*4#TF<!P'"-5X7C&N-:XECN!X#A4*QQS$<
M-Q*(8P.-8W!1B-K=A$PT/&HMV,>Q:HVTI:FG9;2GW?NUK4#S4/>;L6A^+'O
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M^75<KJ*+*WWW!R\
M                    \V'K6_YHG+?^U^'_ &68&74X9>@NG_LZ_"W%4M__
M $OSO[2GP=#+0SMAP                       HW]V&]??;G^$+/OMFT"0
MUQR]$\O]8V_ YA*?"+TDO_(:_"V5V1558L
M                                  $1'7<]?[(O1?K3Y->%3.,'IG7\
MGM>Y+T9?AH_=>RGUSJ'A*&-A%J_X                       V3Z$?K_8[
MZ+]E_)K,E+@_Z9T?)[ON0H!^)=]U[-_7.G^$K6[ELWG-
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M_O-;['*+57L2J&JH
M                    #S8>M;_FB<M_[7X?]EF!EU.&7H+I_P"SK\+<52W_
M /2_._M*?!T,M#.V'                       "C?W8;U]]N?X0L^^V;0)
M#7'+T3R_UC;\#F$I\(O22_\ (:_"V5V1558L
M                                    $1'7<]?[(O1?K3Y->%3.,'IG
M7\GM>Y+T9?AH_=>RGUSJ'A*&-A%J_P"                       -D^A'Z
M_P!COHOV7\FLR4N#_IG1\GN^Y"@'XEWW7LW]<Z?X2M;N6S><T
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MEF4ZG;M&R%B3&B*.&X;*6L^VRVY-"E]$Z4MK?0"\X
M                                             !YL/6M_S1.6_P#:
M_#_LLP,NIPR]!=/_ &=?A;BJ6_\ Z7YW]I3X.AEH9VPX
M       4;^[#>OOMS_"%GWVS:!(:XY>B>7^L;?@<PE/A%Z27_D-?A;*[(JJL
M6
M "(CKN>O]D7HOUI\FO"IG&#TSK^3VO<EZ,OPT?NO93ZYU#PE#&PBU?\
M                   &R?0C]?['?1?LOY-9DI<'_3.CY/=]R% /Q+ONO9OZ
MYT_PE:W<MF\YH
M       $TW1L]9W._0/D_P!H.KSF72GG4LG#N
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M<LYM1=+)IJ/).0?NK;$D5TD$0V^
M                                >;#UK?\ -$Y;_P!K\/\ LLP,NIPR
M]!=/_9U^%N*I;_\ I?G?VE/@Z&6AG;#@                      !1O[L-
MZ^^W/\(6??;-H$AKCEZ)Y?ZQM^!S"4^$7I)?^0U^%LKLBJJQ8
M                                                 (B.NYZ_V1>B
M_6GR:\*F<8/3.OY/:]R7HR_#1^Z]E/KG4/"4,;"+5_P
M     !LGT(_7^QWT7[+^369*7!_TSH^3W?<A0#\2[[KV;^N=/\)6MW+9O.:
M                                                     !--T;/6
M=SOT#Y/]H.KSF72GG4LG#N
M
M                   !YL/6M_S1.6_]K\/^RS RZG#+T%T_]G7X6XJEO_Z7
MYW]I3X.AEH9VPX                       4;^[#>OOMS_  A9]]LV@2&N
M.7HGE_K&WX',)3X1>DE_Y#7X6RNR*JK%@
M                                 B(Z[GK_ &1>B_6GR:\*F<8/3.OY
M/:]R7HR_#1^Z]E/KG4/"4,;"+5_P                      !LGT(_7^QW
MT7[+^369*7!_TSH^3W?<A0#\2[[KV;^N=/\ "5K=RV;SF@
M                                        33=&SUG<[] ^3_:#J\YE
MTIYU+)P[@
M
M      >;#UK?\T3EO_:_#_LLP,NIPR]!=/\ V=?A;BJ6_P#Z7YW]I3X.AEH9
MVPX                       4;^[#>OOMS_"%GWVS:!(:XY>B>7^L;?@<P
ME/A%Z27_ )#7X6RNR*JK%@
M                      B(Z[GK_9%Z+]:?)KPJ9Q@],Z_D]KW)>C+\-'[K
MV4^N=0\)0QL(M7_                       &R?0C]?['?1?LOY-9DI<'_
M $SH^3W?<A0#\2[[KV;^N=/\)6MW+9O.:
M                           !--T;/6=SOT#Y/]H.KSF72GG4LG#N
M
M                                                     !YL/6M_
MS1.6_P#:_#_LLP,NIPR]!=/_ &=?A;BJ6_\ Z7YW]I3X.AEH9VPX
M               4;^[#>OOMS_"%GWVS:!(:XY>B>7^L;?@<PE/A%Z27_D-?
MA;*[(JJL6
M         "(CKN>O]D7HOUI\FO"IG&#TSK^3VO<EZ,OPT?NO93ZYU#PE#&PB
MU?\                        &R?0C]?['?1?LOY-9DI<'_3.CY/=]R% /
MQ+ONO9OZYT_PE:W<MF\YH
M               $TW1L]9W._0/D_P!H.KSF72GG4LG#N
M
M                                          !YL/6M_P T3EO_ &OP
M_P"RS RZG#+T%T_]G7X6XJEO_P"E^=_:4^#H9:&=L.
M     %&_NPWK[[<_PA9]]LV@2&N.7HGE_K&WX',)3X1>DE_Y#7X6RNR*JK%@
M
MB(Z[GK_9%Z+]:?)KPJ9Q@],Z_D]KW)>C+\-'[KV4^N=0\)0QL(M7_
M                &R?0C]?['?1?LOY-9DI<'_3.CY/=]R% /Q+ONO9OZYT_
MPE:W<MF\YH
M    $TW1L]9W._0/D_V@ZO.9=*>=2R<.X
M
M                              'FP]:W_-$Y;_VOP_[+,#+J<,O073_V
M=?A;BJ6__I?G?VE/@Z&6AG;#@                      !1O[L-Z^^W/\
M"%GWVS:!(:XY>B>7^L;?@<PE/A%Z27_D-?A;*[(JJL6
M                                           "(CKN>O\ 9%Z+]:?)
MKPJ9Q@],Z_D]KW)>C+\-'[KV4^N=0\)0QL(M7_
M &R?0C]?['?1?LOY-9DI<'_3.CY/=]R% /Q+ONO9OZYT_P )6MW+9O.:
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MIJKU:8[GMT8Q\//51CM;'L8\G/ABN"XQ,=\1VCL(9<F9B.G]W(_.7Y[2T2E
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ME[V;GB+F+-^S--ON&Q%B,*L:^Z8]QM6YY8V<-K'\F'*_@@;X6Q]==.I*+,O
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MD=WOW:<=O8GDB*N3GPQAI$96@D
M              !--T;/6=SOT#Y/]H.KSF72GG4LG#N
M            >=+U%?7NY;^GS9/]Y'H'3$                        H8
M]W+]:+>/H#5^T/"@+$
M                    \V'K6_YHG+?^U^'_ &68&74X9>@NG_LZ_"W%4M__
M $OSO[2GP=#+0SMAP                       HW]V&]??;G^$+/OMFT"0
MUQR]$\O]8V_ YA*?"+TDO_(:_"V5V1558L
M                                  $1'7<]?[(O1?K3Y->%3.,'IG7\
MGM>Y+T9?AH_=>RGUSJ'A*&-A%J_X                       V3Z$?K_8[
MZ+]E_)K,E+@_Z9T?)[ON0H!^)=]U[-_7.G^$K6[ELWG-
M                                       FFZ-GK.YWZ!\G^T'5YS+I
M3SJ63AW                             /.EZBOKW<M_3YLG^\CT#IB
M                      4,>[E^M%O'T!J_:'A0%B
M                                            >;#UK?\ -$Y;_P!K
M\/\ LLP,NIPR]!=/_9U^%N*I;_\ I?G?VE/@Z&6AG;#@
M      !1O[L-Z^^W/\(6??;-H$AKCEZ)Y?ZQM^!S"4^$7I)?^0U^%LKLBJJQ
M8
M (B.NYZ_V1>B_6GR:\*F<8/3.OY/:]R7HR_#1^Z]E/KG4/"4,;"+5_P
M                 !LGT(_7^QWT7[+^369*7!_TSH^3W?<A0#\2[[KV;^N=
M/\)6MW+9O.:
M     !--T;/6=SOT#Y/]H.KSF72GG4LG#N
M   >=+U%?7NY;^GS9/\ >1Z!TQ                        *&/=R_6BWC
MZ U?M#PH"Q
M            /-AZUO\ FB<M_P"U^'_99@9=3AEZ"Z?^SK\+<52W_P#2_._M
M*?!T,M#.V'                       "C?W8;U]]N?X0L^^V;0)#7'+T3R
M_P!8V_ YA*?"+TDO_(:_"V5V1558L
M                             $1'7<]?[(O1?K3Y->%3.,'IG7\GM>Y+
MT9?AH_=>RGUSJ'A*&-A%J_X                       V3Z$?K_8[Z+]E_
M)K,E+@_Z9T?)[ON0H!^)=]U[-_7.G^$K6[ELWG-
M                                  FFZ-GK.YWZ!\G^T'5YS+I3SJ63
MAW                             /.EZBOKW<M_3YLG^\CT#IB
M                 4,>[E^M%O'T!J_:'A0%B
M                                       >;#UK?\T3EO\ VOP_[+,#
M+J<,O073_P!G7X6XJEO_ .E^=_:4^#H9:&=L.
M%&_NPWK[[<_PA9]]LV@2&N.7HGE_K&WX',)3X1>DE_Y#7X6RNR*JK%@
M                                                       B(Z[G
MK_9%Z+]:?)KPJ9Q@],Z_D]KW)>C+\-'[KV4^N=0\)0QL(M7_
M            !LGT(_7^QWT7[+^369*7!_TSH^3W?<A0#\2[[KV;^N=/\)6M
MW+9O.:
M!--T;/6=SOT#Y/\ :#J\YETIYU+)P[@                            '
MG2]17U[N6_I\V3_>1Z!TQ                        *&/=R_6BWCZ U?M
M#PH"Q
M       /-AZUO^:)RW_M?A_V68&74X9>@NG_ +.OPMQ5+?\ ]+\[^TI\'0RT
M,[8<                       *-_=AO7WVY_A"S[[9M D-<<O1/+_6-OP.
M82GPB])+_P AK\+979%55BP
M                       1$==SU_LB]%^M/DUX5,XP>F=?R>U[DO1E^&C]
MU[*?7.H>$H8V$6K_ (                       V3Z$?K_ &.^B_9?R:S)
M2X/^F='R>[[D* ?B7?=>S?USI_A*UNY;-YS0
M                              )INC9ZSN=^@?)_M!U><RZ4\ZEDX=P
M                           #SI>HKZ]W+?T^;)_O(] Z8@
M             %#'NY?K1;Q] :OVAX4!8@
M                                   'FP]:W_-$Y;_VOP_[+,#+J<,O
M073_ -G7X6XJEO\ ^E^=_:4^#H9:&=L.                       %&_NP
MWK[[<_PA9]]LV@2&N.7HGE_K&WX',)3X1>DE_P"0U^%LKLBJJQ8
M                                                   (B.NYZ_V1
M>B_6GR:\*F<8/3.OY/:]R7HR_#1^Z]E/KG4/"4,;"+5_P
M       !LGT(_7^QWT7[+^369*7!_P!,Z/D]WW(4 _$N^Z]F_KG3_"5K=RV;
MSF@                                                      33=
M&SUG<[] ^3_:#J\YETIYU+)P[@                            'G2]17
MU[N6_I\V3_>1Z!TQ                        *&/=R_6BWCZ U?M#PH"Q
M
M  /-AZUO^:)RW_M?A_V68&74X9>@NG_LZ_"W%4M__2_._M*?!T,M#.V'
M                   "C?W8;U]]N?X0L^^V;0)#7'+T3R_UC;\#F$I\(O22
M_P#(:_"V5V1558L
M               $1'7<]?[(O1?K3Y->%3.,'IG7\GM>Y+T9?AH_=>RGUSJ'
MA*&-A%J_X                       V3Z$?K_8[Z+]E_)K,E+@_P"F='R>
M[[D* ?B7?=>S?USI_A*UNY;-YS0
M                     )INC9ZSN=^@?)_M!U><RZ4\ZEDX=P
M                  #SI>HKZ]W+?T^;)_O(] Z8@
M    %#'NY?K1;Q] :OVAX4!8@
M                          'FP]:W_-$Y;_VOP_[+,#+J<,O073_V=?A;
MBJ6__I?G?VE/@Z&6AG;#@                      !1O[L-Z^^W/\ "%GW
MVS:!(:XY>B>7^L;?@<PE/A%Z27_D-?A;*[(JJL6
M                                       "(CKN>O\ 9%Z+]:?)KPJ9
MQ@],Z_D]KW)>C+\-'[KV4^N=0\)0QL(M7_                       &R?
M0C]?['?1?LOY-9DI<'_3.CY/=]R% /Q+ONO9OZYT_P )6MW+9O.:
M                                              !--T;/6=SOT#Y/
M]H.KSF72GG4LG#N                             >=+U%?7NY;^GS9/]
MY'H'3$                        H8]W+]:+>/H#5^T/"@+$
M                                                    \V'K6_YH
MG+?^U^'_ &68&74X9>@NG_LZ_"W%4M__ $OSO[2GP=#+0SMAP
M            HW]V&]??;G^$+/OMFT"0UQR]$\O]8V_ YA*?"+TDO_(:_"V5
MV1558L
M      $1'7<]?[(O1?K3Y->%3.,'IG7\GM>Y+T9?AH_=>RGUSJ'A*&-A%J_X
M                       V3Z$?K_8[Z+]E_)K,E+@_Z9T?)[ON0H!^)=]U
M[-_7.G^$K6[ELWG-
M           FFZ-GK.YWZ!\G^T'5YS+I3SJ63AW
M        /.EZBOKW<M_3YLG^\CT#IB                        4,>[E^
MM%O'T!J_:'A0%B
M                >;#UK?\ -$Y;_P!K\/\ LLP,NIPR]!=/_9U^%N*I;_\
MI?G?VE/@Z&6AG;#@                      !1O[L-Z^^W/\(6??;-H$AK
MCEZ)Y?ZQM^!S"4^$7I)?^0U^%LKLBJJQ8
M                                 (B.NYZ_V1>B_6GR:\*F<8/3.OY/
M:]R7HR_#1^Z]E/KG4/"4,;"+5_P                      !LGT(_7^QWT
M7[+^369*7!_TSH^3W?<A0#\2[[KV;^N=/\)6MW+9O.:
M                                     !--T;/6=SOT#Y/]H.KSF72G
MG4LG#N                             >=+U%?7NY;^GS9/\ >1Z!TQ
M                      *&/=R_6BWCZ U?M#PH"Q
M                                            /-AZUO\ FB<M_P"U
M^'_99@9=3AEZ"Z?^SK\+<52W_P#2_._M*?!T,M#.V'
M     "C?W8;U]]N?X0L^^V;0)#7'+T3R_P!8V_ YA*?"+TDO_(:_"V5V1558
ML
M $1'7<]?[(O1?K3Y->%3.,'IG7\GM>Y+T9?AH_=>RGUSJ'A*&-A%J_X
M                  V3Z$?K_8[Z+]E_)K,E+@_Z9T?)[ON0H!^)=]U[-_7.
MG^$K6[ELWG-
M      FFZ-GK.YWZ!\G^T'5YS+I3SJ63AW
M   /.EZBOKW<M_3YLG^\CT#IB                        4,>[E^M%O'T
M!J_:'A0%B
M           >;#UK?\T3EO\ VOP_[+,#+J<,O073_P!G7X6XJEO_ .E^=_:4
M^#H9:&=L.                       %&_NPWK[[<_PA9]]LV@2&N.7HGE_
MK&WX',)3X1>DE_Y#7X6RNR*JK%@
M                           B(Z[GK_9%Z+]:?)KPJ9Q@],Z_D]KW)>C+
M\-'[KV4^N=0\)0QL(M7_                        !LGT(_7^QWT7[+^3
M69*7!_TSH^3W?<A0#\2[[KV;^N=/\)6MW+9O.:
M                                !--T;/6=SOT#Y/\ :#J\YETIYU+)
MP[@                            'G2]17U[N6_I\V3_>1Z!TQ
M                 *&/=R_6BWCZ U?M#PH"Q
M                                       /-AZUO^:)RW_M?A_V68&7
M4X9>@NG_ +.OPMQ5+?\ ]+\[^TI\'0RT,[8<                       *
M-_=AO7WVY_A"S[[9M D-<<O1/+_6-OP.82GPB])+_P AK\+979%55BP
M                                                       1$==S
MU_LB]%^M/DUX5,XP>F=?R>U[DO1E^&C]U[*?7.H>$H8V$6K_ (
M             V3Z$?K_ &.^B_9?R:S)2X/^F='R>[[D* ?B7?=>S?USI_A*
MUNY;-YS0
M  )INC9ZSN=^@?)_M!U><RZ4\ZEDX=P                            #
MSI>HKZ]W+?T^;)_O(] Z8@                       %#'NY?K1;Q] :OV
MAX4!8@
M       'FP]:W_-$Y;_VOP_[+,#+J<,O073_ -G7X6XJEO\ ^E^=_:4^#H9:
M&=L.                       %&_NPWK[[<_PA9]]LV@2&N.7HGE_K&WX'
M,)3X1>DE_P"0U^%LKLBJJQ8
M                       (B.NYZ_V1>B_6GR:\*F<8/3.OY/:]R7HR_#1^
MZ]E/KG4/"4,;"+5_P                      !LGT(_7^QWT7[+^369*7!
M_P!,Z/D]WW(4 _$N^Z]F_KG3_"5K=RV;SF@
M                             33=&SUG<[] ^3_:#J\YETIYU+)P[@
M                          'G2]17U[N6_I\V3_>1Z!TQ
M            *&/=R_6BWCZ U?M#PH"Q
M                                  /-AZUO^:)RW_M?A_V68&74X9>@
MNG_LZ_"W%4M__2_._M*?!T,M#.V'                       "C?W8;U]]
MN?X0L^^V;0)#7'+T3R_UC;\#F$I\(O22_P#(:_"V5V1558L
M                                               $1'7<]?[(O1?K
M3Y->%3.,'IG7\GM>Y+T9?AH_=>RGUSJ'A*&-A%J_X
M    V3Z$?K_8[Z+]E_)K,E+@_P"F='R>[[D* ?B7?=>S?USI_A*UNY;-YS0
M                                                     )INC9ZS
MN=^@?)_M!U><RZ4\ZEDX=P                            #SI>HKZ]W+
M?T^;)_O(] Z8@                       %#'NY?K1;Q] :OVAX4!8@
M                                                          'F
MP]:W_-$Y;_VOP_[+,#+J<,O073_V=?A;BJ6__I?G?VE/@Z&6AG;#@
M               !1O[L-Z^^W/\ "%GWVS:!(:XY>B>7^L;?@<PE/A%Z27_D
M-?A;*[(JJL6
M           "(CKN>O\ 9%Z+]:?)KPJ9Q@],Z_D]KW)>C+\-'[KV4^N=0\)0
MQL(M7_                       &R?0C]?['?1?LOY-9DI<'_3.CY/=]R%
M /Q+ONO9OZYT_P )6MW+9O.:
M                  !--T;/6=SOT#Y/]H.KSF72GG4LG#N
M                >=+U%?7NY;^GS9/]Y'H'3$
M  H8]W+]:+>/H#5^T/"@+$
M                        \V'K6_YHG+?^U^'_ &68&74X9>@NG_LZ_"W%
M4M__ $OSO[2GP=#+0SMAP                       HW]V&]??;G^$+/OM
MFT"0UQR]$\O]8V_ YA*?"+TDO_(:_"V5V1558L
M                                      $1'7<]?[(O1?K3Y->%3.,'
MIG7\GM>Y+T9?AH_=>RGUSJ'A*&-A%J_X                       V3Z$?
MK_8[Z+]E_)K,E+@_Z9T?)[ON0H!^)=]U[-_7.G^$K6[ELWG-
M                                           FFZ-GK.YWZ!\G^T'5
MYS+I3SJ63AW                             /.EZBOKW<M_3YLG^\CT#
MIB                        4,>[E^M%O'T!J_:'A0%B
M                                                >;#UK?\ -$Y;
M_P!K\/\ LLP,NIPR]!=/_9U^%N*I;_\ I?G?VE/@Z&6AG;#@
M          !1O[L-Z^^W/\(6??;-H$AKCEZ)Y?ZQM^!S"4^$7I)?^0U^%LKL
MBJJQ8
M     (B.NYZ_V1>B_6GR:\*F<8/3.OY/:]R7HR_#1^Z]E/KG4/"4,;"+5_P
M                     !LGT(_7^QWT7[+^369*7!_TSH^3W?<A0#\2[[KV
M;^N=/\)6MW+9O.:
M         !--T;/6=SOT#Y/]H.KSF72GG4LG#N
M       >=+U%?7NY;^GS9/\ >1Z!TQ                        *&/=R_
M6BWCZ U?M#PH"Q
M                /-AZUO\ FB<M_P"U^'_99@9=3AEZ"Z?^SK\+<52W_P#2
M_._M*?!T,M#.V'                       "C?W8;U]]N?X0L^^V;0)#7'
M+T3R_P!8V_ YA*?"+TDO_(:_"V5V1558L
M                                 $1'7<]?[(O1?K3Y->%3.,'IG7\G
MM>Y+T9?AH_=>RGUSJ'A*&-A%J_X                       V3Z$?K_8[Z
M+]E_)K,E+@_Z9T?)[ON0H!^)=]U[-_7.G^$K6[ELWG-
M                                      FFZ-GK.YWZ!\G^T'5YS+I3
MSJ63AW                             /.EZBOKW<M_3YLG^\CT#IB
M                     4,>[E^M%O'T!J_:'A0%B
M                                           >;#UK?\T3EO\ VOP_
M[+,#+J<,O073_P!G7X6XJEO_ .E^=_:4^#H9:&=L.
M    %&_NPWK[[<_PA9]]LV@2&N.7HGE_K&WX',)3X1>DE_Y#7X6RNR*JK%@
M                                                           B
M(Z[GK_9%Z+]:?)KPJ9Q@],Z_D]KW)>C+\-'[KV4^N=0\)0QL(M7_
M                !LGT(_7^QWT7[+^369*7!_TSH^3W?<A0#\2[[KV;^N=/
M\)6MW+9O.:
M    !--T;/6=SOT#Y/\ :#J\YETIYU+)P[@
M   'G2]17U[N6_I\V3_>1Z!TQ                        *&/=R_6BWCZ
M U?M#PH"Q
M           /-AZUO^:)RW_M?A_V68&74X9>@NG_ +.OPMQ5+?\ ]+\[^TI\
M'0RT,[8<                       *-_=AO7WVY_A"S[[9M D-<<O1/+_6
M-OP.82GPB])+_P AK\+979%55BP
M                           1$==SU_LB]%^M/DUX5,XP>F=?R>U[DO1E
M^&C]U[*?7.H>$H8V$6K_ (                       V3Z$?K_ &.^B_9?
MR:S)2X/^F='R>[[D* ?B7?=>S?USI_A*UNY;-YS0
M                                  )INC9ZSN=^@?)_M!U><RZ4\ZED
MX=P                            #SI>HKZ]W+?T^;)_O(] Z8@
M                 %#'NY?K1;Q] :OVAX4!8@
M                                       'FP]:W_-$Y;_VOP_[+,#+
MJ<,O073_ -G7X6XJEO\ ^E^=_:4^#H9:&=L.                       %
M&_NPWK[[<_PA9]]LV@2&N.7HGE_K&WX',)3X1>DE_P"0U^%LKLBJJQ8
M                                                       (B.NY
MZ_V1>B_6GR:\*F<8/3.OY/:]R7HR_#1^Z]E/KG4/"4,;"+5_P
M           !LGT(_7^QWT7[+^369*7!_P!,Z/D]WW(4 _$N^Z]F_KG3_"5K
M=RV;SF@
M 33=&SUG<[] ^3_:#J\YETIYU+)P[@                            'G
M2]17U[N6_I\V3_>1Z!TQ                        *&/=R_6BWCZ U?M#
MPH"Q
M      /-AZUO^:)RW_M?A_V68&74X9>@NG_LZ_"W%4M__2_._M*?!T,M#.V'
M                       "C?W8;U]]N?X0L^^V;0)#7'+T3R_UC;\#F$I\
M(O22_P#(:_"V5V1558L
M                   $1'7<]?[(O1?K3Y->%3.,'IG7\GM>Y+T9?AH_=>RG
MUSJ'A*&-A%J_X                       V3Z$?K_8[Z+]E_)K,E+@_P"F
M='R>[[D* ?B7?=>S?USI_A*UNY;-YS0
M                         )INC9ZSN=^@?)_M!U><RZ4\ZEDX=P
M                      #SI>HKZ]W+?T^;)_O(] Z8@
M        %#'NY?K1;Q] :OVAX4!8@
M                              'FP]:W_-$Y;_VOP_[+,#+J<,O073_V
M=?A;BJ6__I?G?VE/@Z&6AG;#@                      !1O[L-Z^^W/\
M"%GWVS:!(:XY>B>7^L;?@<PE/A%Z27_D-?A;*[(JJL6
M                                           "(CKN>O\ 9%Z+]:?)
MKPJ9Q@],Z_D]KW)>C+\-'[KV4^N=0\)0QL(M7_
M &R?0C]?['?1?LOY-9DI<'_3.CY/=]R% /Q+ONO9OZYT_P )6MW+9O.:
M                                                  !--T;/6=SO
MT#Y/]H.KSF72GG4LG#N                             >=+U%?7NY;^G
MS9/]Y'H'3$                        H8]W+]:+>/H#5^T/"@+$
M                                                        \V'K
M6_YHG+?^U^'_ &68&74X9>@NG_LZ_"W%4M__ $OSO[2GP=#+0SMAP
M                HW]V&]??;G^$+/OMFT"0UQR]$\O]8V_ YA*?"+TDO_(:
M_"V5V1558L
M          $1'7<]?[(O1?K3Y->%3.,'IG7\GM>Y+T9?AH_=>RGUSJ'A*&-A
M%J_X                       V3Z$?K_8[Z+]E_)K,E+@_Z9T?)[ON0H!^
M)=]U[-_7.G^$K6[ELWG-
M               FFZ-GK.YWZ!\G^T'5YS+I3SJ63AW
M            /.EZBOKW<M_3YLG^\CT#IB                        4,
M>[E^M%O'T!J_:'A0%B
M                    >;#UK?\ -$Y;_P!K\/\ LLP,NIPR]!=/_9U^%N*I
M;_\ I?G?VE/@Z&6AG;#@                      !1O[L-Z^^W/\(6??;-
MH$AKCEZ)Y?ZQM^!S"4^$7I)?^0U^%LKLBJJQ8
M                                     (B.NYZ_V1>B_6GR:\*F<8/3
M.OY/:]R7HR_#1^Z]E/KG4/"4,;"+5_P                      !LGT(_7
M^QWT7[+^369*7!_TSH^3W?<A0#\2[[KV;^N=/\)6MW+9O.:
M                                         !--T;/6=SOT#Y/]H.KS
MF72GG4LG#N                             >=+U%?7NY;^GS9/\ >1Z!
MTQ                        *&/=R_6BWCZ U?M#PH"Q
M                                                /-AZUO\ FB<M
M_P"U^'_99@9=3AEZ"Z?^SK\+<52W_P#2_._M*?!T,M#.V'
M         "C?W8;U]]N?X0L^^V;0)#7'+T3R_P!8V_ YA*?"+TDO_(:_"V5V
M1558L
M     $1'7<]?[(O1?K3Y->%3.,'IG7\GM>Y+T9?AH_=>RGUSJ'A*&-A%J_X
M                      V3Z$?K_8[Z+]E_)K,E+@_Z9T?)[ON0H!^)=]U[
M-_7.G^$K6[ELWG-
M          FFZ-GK.YWZ!\G^T'5YS+I3SJ63AW
M       /.EZBOKW<M_3YLG^\CT#IB                        4,>[E^M
M%O'T!J_:'A0%B
M               >;#UK?\T3EO\ VOP_[+,#+J<,O073_P!G7X6XJEO_ .E^
M=_:4^#H9:&=L.                       %&_NPWK[[<_PA9]]LV@2&N.7
MHGE_K&WX',)3X1>DE_Y#7X6RNR*JK%@
M                               B(Z[GK_9%Z+]:?)KPJ9Q@],Z_D]KW
M)>C+\-'[KV4^N=0\)0QL(M7_                        !LGT(_7^QWT7
M[+^369*7!_TSH^3W?<A0#\2[[KV;^N=/\)6MW+9O.:
M                                    !--T;/6=SOT#Y/\ :#J\YETI
MYU+)P[@                            'G2]17U[N6_I\V3_>1Z!TQ
M                     *&/=R_6BWCZ U?M#PH"Q
M                                           /-AZUO^:)RW_M?A_V
M68&74X9>@NG_ +.OPMQ5+?\ ]+\[^TI\'0RT,[8<
M   *-_=AO7WVY_A"S[[9M D-<<O1/+_6-OP.82GPB])+_P AK\+979%55BP
M                                                           1
M$==SU_LB]%^M/DUX5,XP>F=?R>U[DO1E^&C]U[*?7.H>$H8V$6K_ (
M                 V3Z$?K_ &.^B_9?R:S)2X/^F='R>[[D* ?B7?=>S?US
MI_A*UNY;-YS0
M      )INC9ZSN=^@?)_M!U><RZ4\ZEDX=P
M   #SI>HKZ]W+?T^;)_O(] Z8@                       %#'NY?K1;Q]
M :OVAX4!8@
M           'FP]:W_-$Y;_VOP_[+,#+J<,O073_ -G7X6XJEO\ ^E^=_:4^
M#H9:&=L.                       %&_NPWK[[<_PA9]]LV@2&N.7HGE_K
M&WX',)3X1>DE_P"0U^%LKLBJJQ8
M                           (B.NYZ_V1>B_6GR:\*F<8/3.OY/:]R7HR
M_#1^Z]E/KG4/"4,;"+5_P                      !LGT(_7^QWT7[+^36
M9*7!_P!,Z/D]WW(4 _$N^Z]F_KG3_"5K=RV;SF@
M                                 33=&SUG<[] ^3_:#J\YETIYU+)P
M[@                            'G2]17U[N6_I\V3_>1Z!TQ
M                *&/=R_6BWCZ U?M#PH"Q
M                                      /-AZUO^:)RW_M?A_V68&74
MX9>@NG_LZ_"W%4M__2_._M*?!T,M#.V'                       "C?W8
M;U]]N?X0L^^V;0)#7'+T3R_UC;\#F$I\(O22_P#(:_"V5V1558L
M                                                   $1'7<]?[(
MO1?K3Y->%3.,'IG7\GM>Y+T9?AH_=>RGUSJ'A*&-A%J_X
M        V3Z$?K_8[Z+]E_)K,E+@_P"F='R>[[D* ?B7?=>S?USI_A*UNY;-
MYS0                                                      )IN
MC9ZSN=^@?)_M!U><RZ4\ZEDX=P                            #SI>HK
MZ]W+?T^;)_O(] Z8@                       %#'NY?K1;Q] :OVAX4!8
M@
M  'FP]:W_-$Y;_VOP_[+,#+J<,O073_V=?A;BJ6__I?G?VE/@Z&6AG;#@
M                   !1O[L-Z^^W/\ "%GWVS:!(:XY>B>7^L;?@<PE/A%Z
M27_D-?A;*[(JJL6
M               "(CKN>O\ 9%Z+]:?)KPJ9Q@],Z_D]KW)>C+\-'[KV4^N=
M0\)0QL(M7_                       &R?0C]?['?1?LOY-9DI<'_3.CY/
M=]R% /Q+ONO9OZYT_P )6MW+9O.:
M                      !--T;/6=SOT#Y/]H.KSF72GG4LG#N
M                    >=+U%?7NY;^GS9/]Y'H'3$
M      H8]W+]:+>/H#5^T/"@+$
M                            \V'K6_YHG+?^U^'_ &68&74X9>@NG_LZ
M_"W%4M__ $OSO[2GP=#+0SMAP                       HW]V&]??;G^$
M+/OMFT"0UQR]$\O]8V_ YA*?"+TDO_(:_"V5V1558L
M                                          $1'7<]?[(O1?K3Y->%
M3.,'IG7\GM>Y+T9?AH_=>RGUSJ'A*&-A%J_X                       V
M3Z$?K_8[Z+]E_)K,E+@_Z9T?)[ON0H!^)=]U[-_7.G^$K6[ELWG-
M                                               FFZ-GK.YWZ!\G
M^T'5YS+I3SJ63AW                             /.EZBOKW<M_3YLG^
M\CT#IB                        4,>[E^M%O'T!J_:'A0%B
M                                                    >;#UK?\
M-$Y;_P!K\/\ LLP,NIPR]!=/_9U^%N*I;_\ I?G?VE/@Z&6AG;#@
M              !1O[L-Z^^W/\(6??;-H$AKCEZ)Y?ZQM^!S"4^$7I)?^0U^
M%LKLBJJQ8
M         (B.NYZ_V1>B_6GR:\*F<8/3.OY/:]R7HR_#1^Z]E/KG4/"4,;"+
M5_P                      !LGT(_7^QWT7[+^369*7!_TSH^3W?<A0#\2
M[[KV;^N=/\)6MW+9O.:
M             !--T;/6=SOT#Y/]H.KSF72GG4LG#N
M           >=+U%?7NY;^GS9/\ >1Z!TQ                        *&
M/=R_6BWCZ U?M#PH"Q
M                    /-AZUO\ FB<M_P"U^'_99@9=3AEZ"Z?^SK\+<52W
M_P#2_._M*?!T,M#.V'                       "C?W8;U]]N?X0L^^V;0
M)#7'+T3R_P!8V_ YA*?"+TDO_(:_"V5V1558L
M                                     $1'7<]?[(O1?K3Y->%3.,'I
MG7\GM>Y+T9?AH_=>RGUSJ'A*&-A%J_X                       V3Z$?K
M_8[Z+]E_)K,E+@_Z9T?)[ON0H!^)=]U[-_7.G^$K6[ELWG-
M                                          FFZ-GK.YWZ!\G^T'5Y
MS+I3SJ63AW                             /.EZBOKW<M_3YLG^\CT#I
MB                        4,>[E^M%O'T!J_:'A0%B
M                                               >;#UK?\T3EO\
MVOP_[+,#+J<,O073_P!G7X6XJEO_ .E^=_:4^#H9:&=L.
M        %&_NPWK[[<_PA9]]LV@2&N.7HGE_K&WX',)3X1>DE_Y#7X6RNR*J
MK%@
M   B(Z[GK_9%Z+]:?)KPJ9Q@],Z_D]KW)>C+\-'[KV4^N=0\)0QL(M7_
M                    !LGT(_7^QWT7[+^369*7!_TSH^3W?<A0#\2[[KV;
M^N=/\)6MW+9O.:
M        !--T;/6=SOT#Y/\ :#J\YETIYU+)P[@
M       'G2]17U[N6_I\V3_>1Z!TQ                        *&/=R_6
MBWCZ U?M#PH"Q
M               /-AZUO^:)RW_M?A_V68&74X9>@NG_ +.OPMQ5+?\ ]+\[
M^TI\'0RT,[8<                       *-_=AO7WVY_A"S[[9M D-<<O1
M/+_6-OP.82GPB])+_P AK\+979%55BP
M                               1$==SU_LB]%^M/DUX5,XP>F=?R>U[
MDO1E^&C]U[*?7.H>$H8V$6K_ (                       V3Z$?K_ &.^
MB_9?R:S)2X/^F='R>[[D* ?B7?=>S?USI_A*UNY;-YS0
M                                      )INC9ZSN=^@?)_M!U><RZ4
M\ZEDX=P                            #SI>HKZ]W+?T^;)_O(] Z8@
M                     %#'NY?K1;Q] :OVAX4!8@
M                                           'FP]:W_-$Y;_VOP_[
M+,#+J<,O073_ -G7X6XJEO\ ^E^=_:4^#H9:&=L.
M   %&_NPWK[[<_PA9]]LV@2&N.7HGE_K&WX',)3X1>DE_P"0U^%LKLBJJQ8
M                                                           (
MB.NYZ_V1>B_6GR:\*F<8/3.OY/:]R7HR_#1^Z]E/KG4/"4,;"+5_P
M               !LGT(_7^QWT7[+^369*7!_P!,Z/D]WW(4 _$N^Z]F_KG3
M_"5K=RV;SF@
M     33=&SUG<[] ^3_:#J\YETIYU+)P[@
M  'G2]17U[N6_I\V3_>1Z!TQ                        *&/=R_6BWCZ
MU?M#PH"Q
M          /-AZUO^:)RW_M?A_V68&74X9>@NG_LZ_"W%4M__2_._M*?!T,M
M#.V'                       "C?W8;U]]N?X0L^^V;0)#7'+T3R_UC;\#
MF$I\(O22_P#(:_"V5V1558L
M                       $1'7<]?[(O1?K3Y->%3.,'IG7\GM>Y+T9?AH_
M=>RGUSJ'A*&-A%J_X                       V3Z$?K_8[Z+]E_)K,E+@
M_P"F='R>[[D* ?B7?=>S?USI_A*UNY;-YS0
M                             )INC9ZSN=^@?)_M!U><RZ4\ZEDX=P
M                          #SI>HKZ]W+?T^;)_O(] Z8@
M            %#'NY?K1;Q] :OVAX4!8@
M                                  'FP]:W_-$Y;_VOP_[+,#+J<,O0
M73_V=?A;BJ6__I?G?VE/@Z&6AG;#@                      !1O[L-Z^^
MW/\ "%GWVS:!(:XY>B>7^L;?@<PE/A%Z27_D-?A;*[(JJL6
M                                               "(CKN>O\ 9%Z+
M]:?)KPJ9Q@],Z_D]KW)>C+\-'[KV4^N=0\)0QL(M7_
M     &R?0C]?['?1?LOY-9DI<'_3.CY/=]R% /Q+ONO9OZYT_P )6MW+9O.:
M                                                      !--T;/
M6=SOT#Y/]H.KSF72GG4LG#N                             >=+U%?7N
MY;^GS9/]Y'H'3$                        H8]W+]:+>/H#5^T/"@+$
M
M\V'K6_YHG+?^U^'_ &68&74X9>@NG_LZ_"W%4M__ $OSO[2GP=#+0SMAP
M                    HW]V&]??;G^$+/OMFT"0UQR]$\O]8V_ YA*?"+TD
MO_(:_"V5V1558L
M              $1'7<]?[(O1?K3Y->%3.,'IG7\GM>Y+T9?AH_=>RGUSJ'A
M*&-A%J_X                       V3Z$?K_8[Z+]E_)K,E+@_Z9T?)[ON
M0H!^)=]U[-_7.G^$K6[ELWG-
M                   FFZ-GK.YWZ!\G^T'5YS+I3SJ63AW
M                /.EZBOKW<M_3YLG^\CT#IB
M  4,>[E^M%O'T!J_:'A0%B
M                        >;#UK?\ -$Y;_P!K\/\ LLP,NIPR]!=/_9U^
M%N*I;_\ I?G?VE/@Z&6AG;#@                      !1O[L-Z^^W/\(6
M??;-H$AKCEZ)Y?ZQM^!S"4^$7I)?^0U^%LKLBJJQ8
M                                         (B.NYZ_V1>B_6GR:\*F
M<8/3.OY/:]R7HR_#1^Z]E/KG4/"4,;"+5_P                      !LG
MT(_7^QWT7[+^369*7!_TSH^3W?<A0#\2[[KV;^N=/\)6MW+9O.:
M                                             !--T;/6=SOT#Y/]
MH.KSF72GG4LG#N                             >=+U%?7NY;^GS9/\
M>1Z!TQ                        *&/=R_6BWCZ U?M#PH"Q
M                                                    /-AZUO\
MFB<M_P"U^'_99@9=3AEZ"Z?^SK\+<52W_P#2_._M*?!T,M#.V'
M             "C?W8;U]]N?X0L^^V;0)#7'+T3R_P!8V_ YA*?"+TDO_(:_
M"V5V1558L
M         $1'7<]?[(O1?K3Y->%3.,'IG7\GM>Y+T9?AH_=>RGUSJ'A*&-A%
MJ_X                       V3Z$?K_8[Z+]E_)K,E+@_Z9T?)[ON0H!^)
M=]U[-_7.G^$K6[ELWG-
M              FFZ-GK.YWZ!\G^T'5YS+I3SJ63AW
M           /.EZBOKW<M_3YLG^\CT#IB                        4,>
M[E^M%O'T!J_:'A0%B
M                   >;#UK?\T3EO\ VOP_[+,#+J<,O073_P!G7X6XJEO_
M .E^=_:4^#H9:&=L.                       %&_NPWK[[<_PA9]]LV@2
M&N.7HGE_K&WX',)3X1>DE_Y#7X6RNR*JK%@
M                                   B(Z[GK_9%Z+]:?)KPJ9Q@],Z_
MD]KW)>C+\-'[KV4^N=0\)0QL(M7_                        !LGT(_7^
MQWT7[+^369*7!_TSH^3W?<A0#\2[[KV;^N=/\)6MW+9O.:
M                                        !--T;/6=SOT#Y/\ :#J\
MYETIYU+)P[@                            'G2]17U[N6_I\V3_>1Z!T
MQ                        *&/=R_6BWCZ U?M#PH"Q
M                                               /-AZUO^:)RW_M
M?A_V68&74X9>@NG_ +.OPMQ5+?\ ]+\[^TI\'0RT,[8<
M       *-_=AO7WVY_A"S[[9M D-<<O1/+_6-OP.82GPB])+_P AK\+979%5
M5BP
M   1$==SU_LB]%^M/DUX5,XP>F=?R>U[DO1E^&C]U[*?7.H>$H8V$6K_ (
M                     V3Z$?K_ &.^B_9?R:S)2X/^F='R>[[D* ?B7?=>
MS?USI_A*UNY;-YS0
M          )INC9ZSN=^@?)_M!U><RZ4\ZEDX=P
M       #SI>HKZ]W+?T^;)_O(] Z8@                       %#'NY?K
M1;Q] :OVAX4!8@
M               'FP]:W_-$Y;_VOP_[+,#+J<,O073_ -G7X6XJEO\ ^E^=
M_:4^#H9:&=L.                       %&_NPWK[[<_PA9]]LV@2&N.7H
MGE_K&WX',)3X1>DE_P"0U^%LKLBJJQ8
M                               (B.NYZ_V1>B_6GR:\*F<8/3.OY/:]
MR7HR_#1^Z]E/KG4/"4,;"+5_P                      !LGT(_7^QWT7[
M+^369*7!_P!,Z/D]WW(4 _$N^Z]F_KG3_"5K=RV;SF@
M                                     33=&SUG<[] ^3_:#J\YETIY
MU+)P[@                            'G2]17U[N6_I\V3_>1Z!TQ
M                    *&/=R_6BWCZ U?M#PH"Q
M                                          /-AZUO^:)RW_M?A_V6
M8&74X9>@NG_LZ_"W%4M__2_._M*?!T,M#.V'                       "
MC?W8;U]]N?X0L^^V;0)#7'+T3R_UC;\#F$I\(O22_P#(:_"V5V1558L
M                                                       $1'7<
M]?[(O1?K3Y->%3.,'IG7\GM>Y+T9?AH_=>RGUSJ'A*&-A%J_X
M            V3Z$?K_8[Z+]E_)K,E+@_P"F='R>[[D* ?B7?=>S?USI_A*U
MNY;-YS0
M )INC9ZSN=^@?)_M!U><RZ4\ZEDX=P                            #S
MI>HKZ]W+?T^;)_O(] Z8@                       %#'NY?K1;Q] :OVA
MX4!8@
M      'FP]:W_-$Y;_VOP_[+,#+J<,O073_V=?A;BJ6__I?G?VE/@Z&6AG;#
M@                      !1O[L-Z^^W/\ "%GWVS:!(:XY>B>7^L;?@<PE
M/A%Z27_D-?A;*[(JJL6
M                   "(CKN>O\ 9%Z+]:?)KPJ9Q@],Z_D]KW)>C+\-'[KV
M4^N=0\)0QL(M7_                       &R?0C]?['?1?LOY-9DI<'_3
M.CY/=]R% /Q+ONO9OZYT_P )6MW+9O.:
M                          !--T;/6=SOT#Y/]H.KSF72GG4LG#N
M                        >=+U%?7NY;^GS9/]Y'H'3$
M          H8]W+]:+>/H#5^T/"@+$
M                                \V'K6_YHG+?^U^'_ &68&74X9>@N
MG_LZ_"W%4M__ $OSO[2GP=#+0SMAP                       HW]V&]??
M;G^$+/OMFT"0UQR]$\O]8V_ YA*?"+TDO_(:_"V5V1558L
M                                              $1'7<]?[(O1?K3
MY->%3.,'IG7\GM>Y+T9?AH_=>RGUSJ'A*&-A%J_X
M   V3Z$?K_8[Z+]E_)K,E+@_Z9T?)[ON0H!^)=]U[-_7.G^$K6[ELWG-
M                                                   FFZ-GK.YW
MZ!\G^T'5YS+I3SJ63AW                             /.EZBOKW<M_3
MYLG^\CT#IB                        4,>[E^M%O'T!J_:'A0%B
M                                                        >;#U
MK?\ -$Y;_P!K\/\ LLP,NIPR]!=/_9U^%N*I;_\ I?G?VE/@Z&6AG;#@
M                  !1O[L-Z^^W/\(6??;-H$AKCEZ)Y?ZQM^!S"4^$7I)?
M^0U^%LKLBJJQ8
M             (B.NYZ_V1>B_6GR:\*F<8/3.OY/:]R7HR_#1^Z]E/KG4/"4
M,;"+5_P                      !LGT(_7^QWT7[+^369*7!_TSH^3W?<A
M0#\2[[KV;^N=/\)6MW+9O.:
M                 !--T;/6=SOT#Y/]H.KSF72GG4LG#N
M               >=+U%?7NY;^GS9/\ >1Z!TQ
M  *&/=R_6BWCZ U?M#PH"Q
M                        /-AZUO\ FB<M_P"U^'_99@9=3AEZ"Z?^SK\+
M<52W_P#2_._M*?!T,M#.V'                       "C?W8;U]]N?X0L^
M^V;0)#7'+T3R_P!8V_ YA*?"+TDO_(:_"V5V1558L
M                                         $1'7<]?[(O1?K3Y->%3
M.,'IG7\GM>Y+T9?AH_=>RGUSJ'A*&-A%J_X                       V3
MZ$?K_8[Z+]E_)K,E+@_Z9T?)[ON0H!^)=]U[-_7.G^$K6[ELWG-
M                                              FFZ-GK.YWZ!\G^
MT'5YS+I3SJ63AW                             /.EZBOKW<M_3YLG^\
MCT#IB                        4,>[E^M%O'T!J_:'A0%B
M                                                   >;#UK?\T3
MEO\ VOP_[+,#+J<,O073_P!G7X6XJEO_ .E^=_:4^#H9:&=L.
M            %&_NPWK[[<_PA9]]LV@2&N.7HGE_K&WX',)3X1>DE_Y#7X6R
MNR*JK%@
M       B(Z[GK_9%Z+]:?)KPJ9Q@],Z_D]KW)>C+\-'[KV4^N=0\)0QL(M7_
M                        !LGT(_7^QWT7[+^369*7!_TSH^3W?<A0#\2[
M[KV;^N=/\)6MW+9O.:
M            !--T;/6=SOT#Y/\ :#J\YETIYU+)P[@
M           'G2]17U[N6_I\V3_>1Z!TQ                        *&/
M=R_6BWCZ U?M#PH"Q
M                   /-AZUO^:)RW_M?A_V68&74X9>@NG_ +.OPMQ5+?\
M]+\[^TI\'0RT,[8<                       *-_=AO7WVY_A"S[[9M D-
M<<O1/+_6-OP.82GPB])+_P AK\+979%55BP
M                                   1$==SU_LB]%^M/DUX5,XP>F=?
MR>U[DO1E^&C]U[*?7.H>$H8V$6K_ (                       V3Z$?K_
M &.^B_9?R:S)2X/^F='R>[[D* ?B7?=>S?USI_A*UNY;-YS0
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M                        H8]W+]:+>/H#5^T/"@+$
M                                              \V'K6_YHG+?^U^
M'_99@9=3AEZ"Z?\ LZ_"W%4M_P#TOSO[2GP=#+0SMAP
M      HW]V&]??;G^$+/OMFT"0UQR]$\O]8V_ YA*?"+TDO_ "&OPME=D556
M+
M !$1UW/7^R+T7ZT^37A4SC!Z9U_)[7N2]&7X:/W7LI]<ZAX2AC81:O\ @
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M]U*7*5 YW     ":;HV>L[G?H'R?[0=7G,NE/.I9.'<
M            \Z7J*^O=RW]/FR?[R/0.F(                       !0Q
M[N7ZT6\?0&K]H>% 6(
M                   !YL/6M_S1.6_]K\/^RS RZG#+T%T_]G7X6XJEO_Z7
MYW]I3X.AEH9VPX                       4;^[#>OOMS_  A9]]LV@2&N
M.7HGE_K&WX',)3X1>DE_Y#7X6RNR*JK%@
M                                 B(Z[GK_ &1>B_6GR:\*F<8/3.OY
M/:]R7HR_#1^Z]E/KG4/"4,;"+5_P                      !LGT(_7^QW
MT7[+^369*7!_TSH^3W?<A0#\2[[KV;^N=/\ "5K=RV;SF@
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M(R:F'%WQE\O$-(VY^]K>Z<>%<K+JJAG=U!9#AG[LIPHE^/O3@P:86Y[\X^S
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M)ZR<Q*RK-W:O*OYEHHUHBRMJC5%*V,MK2O\ M5K=7M_T'+K,X.HOMH]G^97
M_+^0_@#!QM2SWXG\G9[B?L6:V)CV+Q&6/9K"I'"U8Z9>/&35%K(SF.3E[U-5
MC2JMSA-7'+$Z6U^]K:I=7[M* B<&A'MH]G^97 _+^0_@# VI/;1[/\RN!^7\
MA_ &!M2>VCV?YE<#\OY#^ ,#:D]M'L_S*X'Y?R'\ 8&U)[:/9_F5P/R_D/X
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M' _K/+_BC/\ UC!QM2?RQP/ZSR_XHS_UC VI/Y8X']9Y?\49_P"L8&U)_+'
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M0_@# VI/;1[/\RN!^7\A_ &!M2>VCV?YE<#\OY#^ ,#:D]M'L_S*X'Y?R'\
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M\ 8&U)[:/9_F5P/R_D/X P-J3VT>S_,K@?E_(?P!@;4GMH]G^97 _+^0_@#
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M_@# VI/;1[/\RN!^7\A_ &!M2>VCV?YE<#\OY#^ ,#:D]M'L_P RN!^7\A_
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M0_@# VI/;1[/\RN!^7\A_ &!M2>VCV?YE<#\OY#^ ,#:D]M'L_S*X'Y?R'\
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M*N\FGUVUB*\M+.**),8+%<;9+KM4I+*LOGW;:,C&URJ5BSYTE;>HG96Z^T)
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M[]# P@^H+1/F5U+^[C#OT,#"#Z@M$^974O[N,._0P,(/J"T3YE=2_NXP[]#
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M[]# P@^H+1/F5U+^[C#OT,#"#Z@M$^974O[N,._0P,(/J"T3YE=2_NXP[]#
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M[]# P@^H+1/F5U+^[C#OT,#"#Z@M$^974O[N,._0P,(/J"T3YE=2_NXP[]#
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M[]# P@^H+1/F5U+^[C#OT,#"#Z@M$^974O[N,._0P,(/J"T3YE=2_NXP[]#
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MD=7#=G%C5B.^=5ZEZ<.L9B.SG>N(M9G-_K[S_8%TI*LI20@<?0P&0UXZ3A,
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MY?@LLW;W-8F0=N4T[V,&YNJI=;2RE;*4K7MNI2O+K$3#; X=@
M
M              !B?QJX8<@=<<Z9S>&68K&,==/LKW#*MY9'*,>?.KV67V9+
M2"4K$LY!:2LN<UDDN];5.ER?>KWNSLJ<NN$XXML#AV
M
M        &)^&<,.0,-U$7G(-_BL8EJY;:V>92G-6Y1CRKRL+.QF1-HUQ6&3D
M+I6BBRT@E2J?@N_9WJUK2G94Y=<)QQ;8'#L
M
M ,3OY+^0/M$?Y@_FK&?5=]:_SJ_+7SHQ[XY^1?R9\6^,?D;\H?E7PGAO@\'X
M+O\ ^GL.77"<6V)P[
M
M
M
M
M
M
M
M
M
M
M    !_*^?,HQD\DI)XUCXZ/:N'S]^^<)-&3%DT2O<.GCQTXO30;-6R"=UZBE
M]UMEEEM:UK2E .%-(<H^,O)EODKOC?R*T3R":X8ZCV.8.=(;<U_M=OBCV6L>
M*Q3/)5L#R">3@G4FG'.+FZ;JJ5ZUJ"E;*5I9=V!SJ       !P!@7+'BQM79
MN6Z4U?R6X_[(W+@/Y7^?>I,"W)KK,-FX5\WY1&$GOG;@6/9'(Y5CGY$FG*;-
MY\<:(_%G2EJ2G=4NI;4.?P
M
M
M
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M^LT]03_V^_\ M/8J!Z/@
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MOB#I!I*W*Q<7J#(VEC.Y5Q;X&^CFMU].WMMM [M^S2]\"_\ TEF ?O\ 9O\
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MLEG73Z;R*:69,++G3YXLLZ=KUN55OO4ONNJ'UP
M
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M<FI;8JE?VV*6VWVW6T#[X
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M75;@UI
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MZO:/U6OA;%EDY&86?OK;J(N4$4 W(
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M(6]Y2U)!I8G;6EME++ H\
M                    .L'-7C+C/,SB5R'XLY;5NE$;RU/E^ I2#FV^Y.!G
MI6+6NQ/*+:)IK7U<8IE2+*22[++_ />M+?O;ON5"'3W-?DUD>E^1O-#IG;8L
M=8Y.RESS;>+8Q+*)ME(';&GI9/6.Z\6M;UK6]QD4O!.(I>^RW_R;?%E[ON4
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MV^4Q3/L,MDW+^48XCG#-H\M19/'+AVP?1SMO<LX231=+AMX
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M24;+1*SI[6/=M$U:+]QZF@@% 0
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MUP
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M? YQTX>G-QYXR9!:QNV9&0+W/-T.H^Y%9NMMS8S];*<OCDGJ%:I2C7#[WJ,
MU=V]E'3.)15[MO>[M U)  =?^67JL<E_\/\ N7[.LC B#]QC_P#SHG_L3?\
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M<DY7$Z17WOQ5W^2\6<W7?>W77MD'R7>I2B]M:A=X
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MQV]+*N8N0RVLZH7I4O:5M=8I!RE[/MO[U4+5.YVT[]:!=\
M
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M!Y[%G3!K!9.\GKYN;5F9J110<.$:I)T9H?&+;;K[Z_&*TLIX0.Q'7QZ/&?\
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M9O9<IW4DDTZ6VT#L8
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M\2I9WDJW?>TOI3M^ "VO;F#7[0U3L[6B<G;"W[$U[FF#63-[2LA9$WY;C<E
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M44FX<)L&B7WZSARJY=+AI2
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M''1<$@\E;\<P?%&SQU^2XY5\_627?O%U'"BCF_L#6L
M
M
M
M
M
M
M
M
M
M                                                        /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>t1701829_chrt-iga02a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 t1701829_chrt-iga02a.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@$C0/H P$1  (1 0,1 ?_$ 0L  0 #  ,! 0$! 0
M       ("0H&!PL%! ," 0$!  (" P$! 0            <( 08"!0D$ PH0
M   & @$# 0,%"P@$!@P 'P " P0%!@$'"!$2"1,A%!4BM19W.#&6MM87EQA8
M>#D*03(CU797MQDSY(=H0B15E58:46%QTR5U-L?7B$DZ4E-4U"8G-UF!<F.3
MA&5&F+AYD6(T9)3%9D?8B9G92A$  0,# P(" PD*"P0$# $- 0 " Q$$!1(&
M!R$Q$PA!42)A<3*R%'06-A>!0M(CD]-4E!55D:%2,W.SU)56. FQM'4W<I)#
M)-%B@L/$A;5V1X<925-C-"4U\**$.40F@[88_]H # ,!  (1 Q$ /P#?P"+.
M3Y5-X;JUYR<80% V_M&C01]7520/"T[8%LK,29^XE[0DX?&CH669,S/%TVZ9
M3JY)WF*0N,YSC&.E[?+CM#:><X^?>YK%XZ\O!D9F^)/;0ROTAD)#=4C'.T@D
MD"M!4^M>0GGDY+Y'VES1%BMJ;@S>,QAPEM(8;2^NK:(O=+<AS_#AE8S6X-:"
MZE2&@$] JUOTJ^4/ZR.^_P \.P_QB$]_9QQY^X<+^I6WYI4X^W/FS_&.Z?[V
MO_[0GZ5?*']9'??YX=A_C$'V<<>?N'"_J5M^:3[<^;/\8[I_O:__ +0GZ5?*
M']9'??YX=A_C$'V<<>?N'"_J5M^:3[<^;/\ &.Z?[VO_ .T)^E7RA_61WW^>
M'8?XQ!]G''G[APOZE;?FD^W/FS_&.Z?[VO\ ^T)^E7RA_61WW^>'8?XQ!]G'
M'G[APOZE;?FD^W/FS_&.Z?[VO_[0GZ5?*']9'??YX=A_C$'V<<>?N'"_J5M^
M:3[<^;/\8[I_O:__ +0GZ5?*']9'??YX=A_C$'V<<>?N'"_J5M^:3[<^;/\
M&.Z?[VO_ .T)^E7RA_61WW^>'8?XQ!]G''G[APOZE;?FD^W/FS_&.Z?[VO\
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M:3[<^;/\8[I_O:__ +0GZ5?*']9'??YX=A_C$'V<<>?N'"_J5M^:3[<^;/\
M&.Z?[VO_ .T)^E7RA_61WW^>'8?XQ!]G''G[APOZE;?FD^W/FS_&.Z?[VO\
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M:3[<^;/\8[I_O:__ +0GZ5?*']9'??YX=A_C$'V<<>?N'"_J5M^:3[<^;/\
M&.Z?[VO_ .T)^E7RA_61WW^>'8?XQ!]G''G[APOZE;?FD^W/FS_&.Z?[VO\
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M:3[<^;/\8[I_O:__ +0GZ5?*']9'??YX=A_C$'V<<>?N'"_J5M^:3[<^;/\
M&.Z?[VO_ .T)^E7RA_61WW^>'8?XQ!]G''G[APOZE;?FD^W/FS_&.Z?[VO\
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M:3[<^;/\8[I_O:__ +0GZ5?*']9'??YX=A_C$'V<<>?N'"_J5M^:3[<^;/\
M&.Z?[VO_ .T)^E7RA_61WW^>'8?XQ!]G''G[APOZE;?FD^W/FS_&.Z?[VO\
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M:3[<^;/\8[I_O:__ +0GZ5?*']9'??YX=A_C$'V<<>?N'"_J5M^:3[<^;/\
M&.Z?[VO_ .T)^E7RA_61WW^>'8?XQ!]G''G[APOZE;?FD^W/FS_&.Z?[VO\
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MLA8R1Q_"+9XG!M2 -1#R!U('6G4@>E;/=["WS831V]_A<M!/-7PVR6EPQSZ
MN.@.C!=1K23I!H 3V!7!WK)[&NW+"1:.F#]FL=N[9/6ZK5VU<)&R51!RV7(F
ML@LF;'0Q3%P;&?NX';Q317$39H'-?"X5:YI!:0>Q!'0@^L+6KFVN+.=]K=QO
MBNHW%KV/:6N:X="US7 %I'I! (7Y1^B_! 1 1 1 1 1 1 1 1 1 1 1 1 1
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M+KBZ>R.!O=SB&M'HZDD =>G4KZK.RO,A<LL["*6>\>:-9&USWN(!)#6M!<:
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M5'4%? YKF.+7 AP-"#W!]17^1E<4!$!$!$!$!$!$!$!$!$!$!$!$!%)KA?\
M:RX[_6Y2?GIL(^Y7_P"6N<_X9/\ U94T>73_ )[[1_X_9_US5M 'E(OZ+5EX
M\PGVLH[ZHZ=\]6T>A_E=_P"6K_\ B<_]7"O$[_4$_P">\/\ P"T_KKI56"QJ
MHV@(@(@(@(@(@(@(@(KK-+:EU9+>*O;FPY37%%DK^P4O*L?>7U4@W=QCS1\Q
M#I,L,+,NQ4FF2;9+J4A$ER%P4QL=.AS=:F;LW-N.V\QV,P=O?WD>$>+<.MVS
M2-@=J8\NU1!WAN)/4DM)Z#U"GH_QSL/9%_Y&\_NV^P^,FW7$;TLO7VL+KMAC
MEB#-%RYAF8&CH UX !<*>T:UF4WC#OC8>M9';M(US*VB@Q<^WJ[J4AWL([DC
MS[IY$1[>,854DI]+99PJ\GFB>/=6*Q>Y;[O0I^VP&5Y"V;@\_'MC+W\=OFI(
M3,&/;(UOAAKW%[IM'@L ;&\^W(T^SVZBM,MN\*\H[MV;-O[;6(GO=K073;9T
ML3X72&=SXF-C9;"3Y5*XOGB:/"A>*O[]'4[.OW +EEK.@NME6[4[QI5HQAB4
MFU&$]6)J5@8[/88SV6@X>9?2S=L@D?U'!RHGPT3*8SCTL%-G&OX7FKC3<&:;
M@,9DF.R,C]$8='+&R1W\EDCXVL))Z-!<-9H&:B0MTW3Y5N>-F;6?O'/X*2/"
M0Q>),63VTTL$?3VY88IGRM:T'4\AA$303+H#32P7P]<>;!BV3G(6T5!$]25J
M\E7];6=T]@W1<V#$\BQLB[&*(^6FX]ZT:,%&Q72C=%,R2RQ"'-W9$)>:+?%E
M^S8=CXZZ(R8N&2740;(/Q7AET0<_2(W-<YP>6!SB"UI(% K7_P"GWQ+E1G;K
MEG-X]IP+K*2#'W+GPN_'^.&7#F1!YFC>UK'1B1T;6EKY&M<=14RM0<A.7:G-
M%QHW?-4J52I=GK=VNM(C8Q*'D9$U5AY-\PKCTL[!V.9)E5SAD;WE)W@CCNQW
M>DB4Q<9BK=&R.,1Q0W>&S+FYNLM;SV\%P]Y>UOC/8UTK?#DBCZ#4-!95M.FI
MQ!5A^/\ ECGUWF,?QERC8V%AMV]L[R\LXXQ%))\FBD>RW>)H;B85=H/B-E D
MJ*Z(PX!4L\L=;7S;'.O>=+UQ59BXVB0O<@JWB(5KEPOANW81^7#QRH;)&S%B
MVP;'J+KG313ZX[C8ZX%L>-<]AMM<.X?+9ZYBM<<RS:"^0T%2YU&@=W./H:T%
MQ] 7G)SOL[=&^_,[N;;FS[&XR&;ERDA;%"W4[2UD>I[CT:QC>FI[RUC:BKA4
M+_4WXSN:4#7UK"YT\J]2:H9<NHJ$MM*G; DB4AC&]&&B;"[>2:Y>W&/19X<+
MFR;':3/0W3%IS_Q/>7HL8\H&.<:!\D,\<9/NO?$UK!_XS]+13J1TKG)>3/S&
MXO%.RTVWG2,8W4Z*&ZLYIP*$](8IW/D=Z-$0D>211IZTC7I_0NV=]VZ1H>J*
M@M:+9$PSZP24.I+0%>491,;(1T4^=+NK1*PC$AF\C+-TLI>KZV3*>PN<8-G&
M^[HWGMK9F,CS.Y;H6^,EE;&QX9)*'/<USV@"%DCNK6.-:::#OU%8=X^XNWYR
MEGYMK[$Q[K[/06[YY(C+! 611R1Q/<YUS+"P:9)8VENK75W1O0T[QI?CWY?7
MZL.;;7].RA8E$ZY&I)J:K-<DI?W555)PK#Q<],QSY\TQE+)DE\$P@Z+G&6YU
M>HU#+<W<887(-QE[E(_E) KX<<LK&5 (#WQL<UIZ]6UU,-=8:I+VYY3N?]TX
M5^>Q.WI_D#2X-$TUO;R2Z20XQ13S1O>WI5KP-$@(,3GU7R=6\$^56X6<S(T[
M4DRG'P4C)0KUW:'D33$U)N(=J1\G$,26I_$KOWD>_0507RB0Z+==(Z2IR*%[
M1]6XN8^.-KRQ093)Q&>:-LC6PM?.1&]H<Q[O!:\-:YI#FZB'.:X.:"TU7P;(
M\L/.7(-O<7>WL#<"UM9I(7ON7Q6@,T3BR2)@N7Q.>^-[7,>6 M8]KF/<UXTK
MHZ0U!LJ(VBWTM*U&2B]H.K1$4UO49$S1B]5L4\[9LH5D5TZ<I1GH2JT@AE!U
MZ_NBB2I52JY2-@XV^#<^ N=NNW9;74<FWFV[YS,VKFB*-KG2.H 7U8&NU,TZ
MPX%I;J%%&EWL#>-AO9G'-]830;U?>Q6C;632QYN)WL9"S4YPCI*7L+)-?A.:
MYKP_00Y2*A?'GS G+G.41OIV1;3-;;L'$X[?6"IHUMEB39$?L6Z=K3G5J[)O
MUFRI#&:LW+ARCA0N52)ESUQHMWSAQ?9XJ',ORL;K2X<X1M;',97:':7$PF,2
ML:"" ][&M=0Z22I<QWE,\P.3W%<[8BV],S(V;&.F<^>U%NSQ&![&BZ$YMY'E
MI!,<4DDC-0+VM'5<=C^#?*J3V=(:A;Z=L1+I$,64M*IN'$.C7F$/(J+I,99:
MXGDOHFJQ>J-%R(&2>*&74;+)IE.HDH0OW3\O\<6^WF;G?E8#B97N8P@/,KGM
M +F"#3XP<T.:758 T.:YQ#7-)ZBT\L_.5[O2;8$6WKL;CMXF2RASHA R*0N#
M)3=F3Y*6/+7AA;,XO='(Q@<^-[1U]O#CEN3CG-QT#MZF.ZLYF6RSN$>%>1TO
M#3+=L9,CK,;,P[M]'+KLS+I^NAZF%T,*$RH0N#DR;O-H;[VKONTDO-L7;;B.
M)P;(W2YCV$UIJ8]K7 .H=+J:74.DFAIJG)?$/(?$.2AQ>_\ '26,UPPNA?KC
MEBF:V@=X<L3WQN+*MULU![-32YH#FU[FUUX\N7FSX!A::[J1XRK\JS0D(N0M
M$[6JJI(LW1"*M7+6+G9=E,F;.FY\*I*F;%243S@Q39P8O75,[SCQCMZ]?CK[
M)L?>QO+7MACEF#7#H07QL='4'H1J+@>A'0J1-H^4OG[>N*BSF(P,D>*GC;)$
M^YGM[8R,< 6N;'-*R;2YI#FN,8:YM"'$$5ZFMO%[?5$V?6-.6S7$M"["NL@P
MBZC#NGD-[C8W<F\3CVGPFRI22E7=-O?%2D56P]]%OG/],9/IGILN,Y#V9F=O
M7&Z<9?Q2X.T8Y\SPU^J(,:7.UQ%@F!T@D-\/4[[T%:)GN$^4ML;ULN/<]AY[
M;=F2F9':Q.?%HN'2/#&^%<"0VSFZR&N>)M$9_G'-H5:]O#Q:.D.-.GG.E-5R
M;WD>I]!/RN1[G8L,1FAZ]$E5KUZ1[%:&E0S[E>2M4DOAZY^J9LY2]1+N/BMN
MT/,5&_?V4CW;DHV;#'RCY$X6LFHTN&"WKX4+IO:M];CXC1U'M:74"O5R7Y(9
MXN&]OS<<8.>3E\_(OVI&Z_A#&ZK*4WM#<7+;7V+WPFM\!YJTG1J95PJ#I.@]
MP['V)*:HHU"F;+?8)[*1\Y!QV61DX5>%?'C9-28F57:4#%LFL@3T,N5W2;8R
MIBE*IG)R8-9_+[TVO@<''N3,7L5OA9F,='([5602-UL#& &1[BWVM#6%P )(
M !I0';?%G(.\-W3[%VSB[B\W3:RR1S0QZ*0NA>8Y#+,7""-C9!H\1\C8RXM:
M'$N;7OC8?CQY>:QK#NX6/4CQU QK<SJ57K,_6;8\BVY">HJN[B*_,2$N9JW3
M*8RJZ2"J")"Y,H<I>F<Z;@^<>,-PY!N+L,FUMY(ZC!+'+"UY[ -?(QK*DT :
MYP<XF@!*E#=OE*Y^V7A9-P9C R/Q<+-4KK:>VNGQM J7.B@EDETM%2Y[6.8P
M ES@*$](:8X];AY"2<[#Z>IJMRDJU%IS,TV2FJY"Y9QRKC#5)8JECF(=%VJJ
MOGM*BB918WMS@G3&<C;MU[WVMLBWANMT70M8+B0QQDQRR:G 5(I$QY  ZES@
M&CUJ-..N)N0>6;VZQ_'V.=D;RS@$TS1-;PZ(R[2#6XEB#B7= QA<\^AM NT6
MO!7E*[IU&O)-7.4(38\U"0-03DK#58>6DGUD]3$ 9Q$2\VQ?1+25REG*2KPB
M!>S)3YZ)G(<VNR<Q<=192\PYR+77=A%)).6Q3/8UL5/$H]D;FO+*]0PN-:@5
M<"!N\/EBYOGV]C-S-PCVXW,7,,%H))[:*61]Q7P"Z*69CXFRT]ETH8*%KC1C
MFN/2VW=,[,T1<%*'MBK.*C:DXYC+XC5G\1*IK1DCA7W-ZTDX&0E(EZW5.@H3
M)D5S]BJ9TS=IR&+C;-L;KV_O+%C,[:N6W6-,CF:PU["'MIJ:62-8]I%0?::*
M@APJ""HXW]QWO/B_<!VMONQ?89P0LE\,OBE!CDKH>V2"26)[26N;5CS1S7-=
M1S2!R;9'&G=VHJ/2MC[&HR]9IVPTF2U1E7$Y67JTF20B23C3"T1%33Z;B%58
ML^%<D>MFYR>TIL8/C)<=?@=_[1W/E[O X*\%QE;$N$S!'*T,TO\ #=1[XVQO
M ?TK&YP/<$CJNYWAPWR5L';6-W?N_&.LMO99K#:RNFMGF021"9E8HIGS1$QG
M52:.,CX) <"%V-P,J];N?+C2U9M\!#6BN2D[,DDX"PQK.8AI)-M4K \02?QD
M@BX9/$4W39-3!%"&+W$QGI[!T7,N1O\ %<99;(8N>6WOXX6:)(GN9(TF:)I+
M7M(<TD$BH(-"MO\ *[A</N+GO;F&S]K;WV(GNI1)!/&R6&0-M9W@/CD#F/ <
MUKJ.!%0.BYMY**;4:%RYOM:HU7KU.KK6&H[AK 5:&CX"%:K/:A$.7:C6*BF[
M5BV,Y<J&44[$R]QS9-GVYSD=1P'E<GFN,K*_S%Q/=7SI;@&29[I)"&SO#07O
M)<:  "I-  .RV7SC;=P&UN?,KAMLV5ICL0RWLG-@MHHX(6E]I$YY;%$UK&ZG
M$N=1HJ22>I45-7:BV5NJT(TS5E.F+I8UDLN#,8I)+"3-H4Y$C/I62=JMHN'C
MR*J%(9P[610P<Q2Y-USC&9(W%N? ;3QQRNX[J*TL ::GDU<[OI8UH+WNH"=+
M&N=0$TH%!NR=@[RY'S;=N[(Q]QD<NYNK1$!1C:@%\LCRV.*,$@&25[& D NJ
M0N^]L\"^56E:NZNMYU:[)58]'UY::K\U7K4A"HXZY4<2[:O2D@_CV2!<=5'2
MB.&J>,X[E,9&E[:YFXXW9D6XG#Y%IR3S1D<D<L)D/H##*QK7./H8':SZ&J4=
M]^5SG+CC"/W'N;!R#!Q-U2S0307+81Z72M@ED?&P=W2.8(V^EX76.D^-F[>1
M,D^C=04*2M>(G*&)F4PXCHB!A_>>_*)9&>FWD=$H.54TCG3;X5,Y5(0V4TS]
M,C8=V[^VEL:!D^Y[V.V\6NAE'/D?3OICC:YY ) +J:6DC4X56E\;<.<D\N7D
MMGL#%S7_ (&GQI-4<4$6JM!)/,^.)KB 2UFHR.#3H8ZB^YNOBYO;C$\KKS;U
M"3AF,R\,:#?_ !.#LE>F'$=ANZ=1RZ\%)OB(J8(IC!V[CT%54\&,3!B8[A\>
MTN1-G<A13Q;8O3+-$W\8W1)%*P.J X"1C:CIT<W4 : D'HNSY(X2Y/X6N+2X
MW_BA;6MQ)^)?XD-Q!*Z/2YT;G0R/ -#U9)H<YNHM!:-2FOY/=@[PN371C7<O
M&^,T)\/:7/%:<(;!JNP75E*1.I)RS1NM6$6_T;C(;O:FPS<8.8QG.,E-_1F$
M2^7O";0Q4F8DVKGI,UK=!XH-M-;"+K,6$B4GQ7O]OVVT #34>T%9#SJ;KY+W
M%!MB#D39\&UO!CN_D[FWUM?NN*"U$K6FV#?D\<-8R(9*DF0$.]DJ+6I>!?*K
M=5:9W.CZM=FJDDCZ\5.V&:KU5;2Z.<D]-Q%-I^482<BR7*;)DW22!FI\%ST4
MSGIC,B[FYFXXVED'8K+Y%O[2C-'QQ1RS%A](>8V.8UP[%A<'BO5JA#8?E<YR
MY'PT>XMLX.0X*9NJ*:>:"V;*.E'1-GE9)(QPZMD:PQ. -'UH#TYN+0FW] SK
M>N;=HLO3)%\B=Q&J.S,W\3+(I>GA=2(GHAU(0<K[ME4F%BMW"AD,G+A3!<YQ
M@;3M;>>U]ZV;K_;%Y%=P,-'!NIKV$UH'QO#9&5H=.IH#J$MJ H^Y!XMY XKR
MC,1O[&7&.O)6ET9?H?%*!2IBGB=)#+IJ-89(XL) >&D@+LQAPCY3RS'6<G$Z
M?FY5AM^*1G:"ZC):KR"4G"N(QA,(RTKEG.K9J4<>.E&Y_6F/<$\95*3.>_Y(
MZ";ESCFVFR%O<Y2&.;%R&.Y#V3-+) ]S"QFJ,>,[4QPTP>(>A-*=5N5KY;.<
M+^VPUY8[?N9[7<$ FL71RVT@DA=&R42RZ)C\EC,<D;M=WX#?:#:ZNB^9O3B!
MR$XXQ\9,[8H*\) 3#O,>PL$?+0MAAC2.$LKXCW;V"D)#$8]52(8R2;K".5RI
MGREWX3/V_1L_E#9&^YI+7;5Z)KV)NIT;F212::TU!LC6ZV@T!+-6FHU4J*_'
MR;Y?^6.(+2'([[Q3K;%7$FAD\<L,\/B4KX;GP22>&\@$M;(&%X:XLU:74C0-
M_4,J]WB]Q8X[<?N,*7+SE=76UT=3L.PL=>J$S&(3,;'0LPX(6H1L;6'JR<59
M;-<DE4'/>_ZM6[=<A<X1(FX7/3CD/D;?.]N0CQAQM.ZTCAE=%+/&\L>Z1@_'
M/=*T%\44!#FTC]MSFD^T7,8/4#A/@_B/BGA5O/W.MFS)3W5NRX@M)HVS1QPR
MN'R6..V>1%<7%V"R2LWXN.-[01&UDLCNM+QS"X';WHVP:G;N,$;J.Q&IUH5U
MW=ZU 5Q1\C:V<0^<U=JYDZ?#0TS'9?3)4B%242>QN3G_ .,Y*CWGQW^(XNYE
MV;F+')8S<,F3L?E4(NK>624-,+GM$Q#)WOC=ICJ:@QRT'XL%U M,W+Y@O*]R
MAMG+8'/[*AP&7./N387EO!;EXNF1/=;-=):0PS1ZYM(#7-FMZG\<6QZG"NC2
M7&#>O(IP_2U#KZ3M+2)620EIH[J,A*]&+*X(?#=S/3SZ,BS/2H*85RU254=9
M2SW%3SC..LZ;NY"V=L5C';GOH[:64$LCH^25X'I$<;7OTU%-9 97H7!5%XVX
M5Y.Y<EE9L#$S7T$#@V68NCA@C)H=+IYWQQ:])#O#:YTI;U#"*+E.ZN%_)3C]
M#DLNS=:/XRKF62;GLT1)0MGA&BRQDTT4Y1W79&2S"^LNJ5),STK<JRN>U/)\
MYP.NVGROL'>UT;#;^09)D:$^$]DD4C@*DEC96L\2@%3X9<6CJZB[OD?RZ<Q\
M4X\9C>F&EAPA<&FYBDAN86DT $C[>23P:N(:TS!@>[HPN*XEKCC-O#;E#N>S
M->492Q4C7Q9 UNFRV"JQF(K$5$8GI#!(Z9G(Z6DC-HDV%LX:(+YSC."XQDV<
M%'9Y[D#:&V<S:;?SEX(,O>Z?!C\.9^O6_P -OM1QN8RK_9]MS?7VZKH=G\,<
ME[]VOD=Y[2QAN]M8D2&ZF\>VC\+PHO'DI'--'+)IB]LB)CSZ!5W1?BTIQWW'
MR)EYJ"TY3C7"4KT<C+3#?$]6*^5DP<.2LT5C.K1-0C18RC@W;A--0ZG3&<]O
M;C.<?MNW?.UMC6T5YNFZ^2V\\A8P^'+)J<!J(I#'(X4'I( ]%:KYN-^).0N7
M+^YQG'N/.0O;2$2RM\>V@#&.=H!U7,T+35W0-:XN[FE 2OUZSXT[NW#(7R*U
MQ1E['(ZR04<7AJ6<K,4I")I+R#8Y>LW-1I))?UXMP4J33+A0V4\]"YZXZ_EN
M#?\ M':T%E<YV\$$&0(%N?#E>)*AI_[.-^D4>TU?I KU/=?OLSAODKD&[REC
MM#&.O+O"M+KQOC6T1A <]I_GIHQ(=4;P&Q:W'2: ]*]OP'CQYA6:CIW^+TU+
M_!G#(TFSCW\O7(FTOH\J?J^\M:G*2[2P&,JECN21,W*Y<8Z>DF?N)W:O>\X\
M78_+G"W.5B^5-?H<YK)7PM=6E#,QCH^A[N#BUOWSA0TD#%>4KS!9G;0W58[=
MN/V<Z+Q&1OEMXKE\=*ZFVLDK)^HZM86"1XIH8[4VO)> _$J3Y%[J:(7"E2,O
MIRF/I%CMIPG.M:T]A'KZJVQ2J,3-S2<?9G"SFTQ""2Q6**QT"XSZ_ID-W#X.
M:.3+?8NTW/Q=W'%NF[8UUD/#,K9&MFA$SJZ'1 "%[BTR.:'?>:B*+N?*SP->
M\N\CQQ;@QLUQQ[CI9&91PG;;OA>^VNC:L+3)'<.+KF)C7B%CRP5\30TU7*.=
M'!>[:'NVP[Y0]>/(KC5%/*>TKEC=W" F%TUYB K[6116CG5@<W3*>;HY=H$.
MNTQC&,%S@V4\D/GKN'N8<1O+$6.&S-\V3?TC9S+$()& ADDI:0X1""O@!CB&
MO]?354#N_,YY8]R<7;DRVZ-KXF2#AN"2T;;W#KN"5P=+! V0&-T[KRGRQTK
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M6/!:,VPOHO'= 1 1 1 1 1 1 1 12:X7_:RX[_6Y2?GIL(^Y7_Y:YS_AD_\
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ME!W3GN4^$MZ;2Y%NY\GAK>-T;);N1TSVQ7-K,9&>+*2[3"Z)LL=7DQ.?5I:
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M:CKKV_Z<^3_SO:-\\O.U]NLX\Q6YFV5L-PO%T#<>&WQB/E5Q'0OIJ^  SO\
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MMS&;%OY,:<K+>ON)H:-G(L_D?A1MDH2QCG7+W2::.=I:W5H+VOZG\DLV]O\
MX^>*6R[-AN\N-FE]/S<I*)H$;=SVYZ3M4_8L-VZ."H-V[^4;)*93*7M+Z1<8
MZ8P-DX%M(<+S;N3 8_4S%V\5[&QA-?9@OX8XJD]26L)%3WJ:K1/.)DKG=7E0
MV+O+-:)-PWMQBII9 T-J^[P]S/<:6BC6M?*UKM(%!I % %G[%V%Y2K4YSFW;
MIG2^O]#N]P:!@=\-YYK)(P+2=5B4TZVO'0E:5?N$,2L)-$/F3(Z2*?!2D]B.
M.O7V=/.CA_:.ZMV9O,Q;7S4V&DA<TR.C#R90Z24-!T21_ H2*U^%THO;_P S
M7)/'?'.U-K3\@;5M=T174<@@9,8@+=T<-N7N;XL,P/B!S0: ? %:^CHKE-%T
MWFYP5CM^ZUD+/0HO3D9*RK#5+CX4SI[;%0.:'GH]Q&QK7"'O\572G-#.FRN$
M2-380R@D993".X\=7&5XCYB?LO/LM[VXRLC&.O!K=.?']N-P>XUTOEIX['#4
M7C7K<&-U1CS?9;=\R?EBAY4V;+>XJRV]#+*S&.\)EHWY(?"GC='&W3KBMZFT
MDC<&",B(Q,,C_#CQKO1?)!?CEK"W;OYL_HM:2+$-$=:P23Z0;2B\1+E=34(5
M[&UZ9HQ9AY)MCF=M$EWTB]18Y[LE2*3*9=XSF\-ALWWD<9M':7TBW=XKC=2%
MK2P/92.32^5EQH:PT8\MCBC=)TJXG48EVEQCS!+Q#A<]R5R1]".-A;L&/@#W
MMD,4H=-#KC@ELO%?(TF6)KYIYF0]:,#2P2+YO-&#CQG48WY4OR]%A[93LQ>W
M7;-RV=6E5M+6.&Q+F3?2<T]*];Q[A5@JLJZ756[#G.?.3Y&B\12S,\P%X/V=
M^Q3+;3Z[)K@1""R*315K(VZ2X"0-#&AM0 .@4N^92WM9O)EC'?MSZ4BWO[3P
M\JYCFNN2V6XA\6CY)GZVQN= YSI7N?1SG.JXK]U<N>F^>W'_ $WJBD<@YKCS
MN#7\+#1S:E1TD>(,]F(&NLH11JA"$DH(UQA2)L_7CCQ[W#AHB<^5$BGPHF7\
M;[%;JX8WKE=R9?"19S:][*]QG<W7I9)*Z0$R:9/ DJ[3*)(]+W :7$:7'ZL1
MN+CSS2\5;>V+MK=ESM+D'$VT4;;..0Q:Y8+=D):V$20F[A 9KMS!-XD3"XO8
M'![!T-Q?T'LRJ^2EG7^2LXK?[G2M=/[U5K9,2#NPI6]C&L&=2J$\V>S.2R#A
M6)066[,N"F<-W\>8W4QTRK#<^0]Z;?R7 ;KW8,(LL5=WS;>:%C6Q&%SG.FGC
M+6>R \AM=)#71R@= XL46\*<6;SP?G'CQ/,ER[*[BQN(?>VUU+(Z<73(XV6M
MK.U\OXQQB:7T,@+XYX":ES!(I WY[0*[S$>[>L_D=9U5Y3[RV;RFD5ZI-DB(
MVKQ#A)G*ZW<J%OF8GH_C2*I+/?AAO^-K9=X1RI@N!I.%BS5]Q:S;&/V&^YBN
MK,EE^)H];YG@N9= ?)]?LNH6Q^*/8:(B[352ONFXVKB/,')O_-<OQV-QC\FU
MLF&-K,(H[:)P9+CW'Y;X7MQAS7S?)S^->9Q'K 75D1>M3;*\P&IKMJ"?B;/"
M3=0L!YZ;A2*%8O+0RTSLF.=9P=1NVRLNG#M&)%#XP;J8N<9-UQG&-CNL/N7
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MH=$F2)9R4?MOS$[JW=MF#;^+V!)BYK5[#%/'+&]S6-!:YA @B<\/!!<7/-7
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M?,?YB]F<P\>;8VEMNTR=ODL,&_*'7+(&1N+;:.&D)BN)G/&IKC5[(O9H:5)
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M&HMSJQZED1@\*8?(^H<N)'."I9]AC&QVY^C(<4;@N^$8.-8Y[,9R(,K(72>
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MYI:R,]2#J!Z=BO1WRW><O8W%'%]ML3?%AF+J]Q]U.ZVDM8K:5@AF<Z6A,]U
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MI5BE:[';0@7MHUG<:M>];V&TT2^4VY0<<X,B\8/,F17;*$43PF9NLX(K"01
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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MQ=H9XW5:GEX!ZL4V9J2/_2IER7!.I4\K@13JK?O$CY89CD9(PO''D'*WZ_\
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M\@(@(@(@(@(@(@(@(@(@(MDW\/']BS9_[4-T_P *-*"T?"7U4N/^(2?U,"\
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MI4=*@&GH"H4\IWB8KV[V$QO3C[#4*D;3^*6O8F[K3>;QL_\ ^3&%C:T9P1K
MPB#:ZUQC*%6C\YP1!G%I9]F,J=,YP(=Y"XW@RS'9?"MABR.I\D[Y))?;:&=F
MMI(T'IZ&L'NKTW\EGGCRO'-U;\;<IW&3R.RO!MK'$6UG9X[_ +K-)<:2Z:9S
MK2=\='T)?+<.'6C*T56?@)>N77.)P@NKZB4;Q]V&R9%[$R^BV4M]/D3I=Q"%
M,IU>/UC]Q\F-\OIU[<%QB/.&WN=NX@]FV4@'O:V'_:2KI?ZG]O##Y<&21"CY
MMTV+WFI-7"UNHP>IZ>PQHH*#I6E22=HPM0OY[$!$!$!$!$!%"?B3I?8&J+SR
MRF[M%-HV.VKR"MM^I2K>4CI$TC6):7FG;)XX28N%U(]91!ZGG**^"*ESGIDN
M,XR"P%-@%E 1 1 1 1 1 1 1 1 1 1 1 1 1 11IYE?92Y"_5+=?F5T"P>R<
M-?LI<>OJEI7S*U!!V4E@64!$!$!$!%5KYI_W9W)7_8Y_C]JL$6"$$0$0$0$0
M$0$0$0$0$0$0$6N_PJ^0C7!=&47C#MNQU2D6F#N:>L]&1;:.M3F9V,:??KV)
M]F1=(-Y2&:OFLW:DFR9C&9)>D8O7&<X,8%BO5:*)>-2F(F4B%SJ)(2L<]C5E
M4NWU4TGS95LH=+O*8GJ$(KG)>N,XZ_=P"RL,'DG\6%RX9S;NW:QBKU=..416
M:FM-[3M\E3?6C[G8IU_"G@#1\1F(D5$"*98X(8C ^,&<Y[E,XQGMRN!%%=#X
MH/+#4MM5VO<?MZR5!UM<:VWU+J'14+!1MT<2>QR-X->MJ*2;I3X[$M9(J\6Q
M+DQE&2/>Y-GIVX^3A<@:J_Z7C4IB)E(A<ZB2$K'/8U95+M]5-)\V5;*'2[RF
M)ZA"*YR7KC..OW< LK#!Y)_%A<N&<V[MVL8J]73CE$5FIK3>T[?)4WUH^YV*
M=?PIX T?$9B)%1 BF6."&(P/C!G.>Y3.,9[<K@1170^*#RPU+;5=KW'[>LE0
M=;7&MM]2ZAT5"P4;='$GL<C>#7K:BDFZ4^.Q+62*O%L2Y,91DCWN39Z=N/DX
M7(&JO^EXU*8B92(7.HDA*QSV-652[?532?-E6RATN\IB>H0BN<EZXSCK]W +
M*PP>2?Q87+AG-N[=K&*O5TXY1%9J:TWM.WR5-]:/N=BG7\*> -'Q&8B140(I
MEC@AB,#XP9SGN4SC&>W*X$45T/BM\L%2V33*KI3D%)4'5]AAW6H]$Z!CH2-N
MCJ1V:_2BF52,C)+Y^/QS.5P^6AR=YS,6W>^SG^:7.287(&JT'@LK/]X:]*P/
M'/DWY-](5>5EYROZVN/'NN14M/Y99F'[5%INMP5>0S'-63++C)G&<9]-(A>F
M,>P$6@$$0$0$0$0$0$0$0$0$0$0$0$4$_)]^[NYH_LX[3_!9^-JV-]<<9\]B
M^,%KF[_JO?\ S63XI7F!"\JJ(@(@(@(@(@(@(@(@(@(@(M/'@K\M-!XTPDIQ
M<Y*V:E:XTFT1FK-KFUM*'M.T7V?VE<+7 ('K<JZIN+9%(0/PI1RJD8\.RP0Z
M9<'=YZ]AH.Y4X^N\W*W.X1DLV3):V1ADB;&V)C'>T _0=5: ^V[W&J7..][6
MV)8</EGQQ8\ N8X,D<]TCG-]DENH4I6GLC_I+;B*PJP2Q)^9;PMV;54S9^3_
M !?@MC[%HTO^6;=W)R>OFPM1(1^NG+J<;VM/%1@3-*#:)"',A)R9O001G7>"
M-TBY/WY_I;/<;<F07\;,%G7PPW3?!@MFQQS5D ;H]MU9&@]&]26#J>E.U?-^
M[ FLI'YC#MEEMG>++<%[XJ,ZZO9;1CB.KN@#ST'W>7^&CS25G1^O&G'GEM.Z
MXU5QRTU1%XK6][A->[=L^P)V]V6[2%D0A+.:HN[VT69J1#J86(JC!1Z)/=$B
M'7[S8*M\W)/&<^4O#F-O,FN,S<RUDC=)"V-L;6!NINL1FM0P4+W'J:"G;]]A
M;_AQUJ,7FW10XJWCI&\,E<\O<\NH[27BE-1J&-'0=:]]GHK4I\6,+S3>%NS5
M6?N/+?BQ!;'V3'6Z8Y,\C.6[VZ["U$P@-7LL/8S9B3JBP3QI0;1(0YD).RGR
MT1-8G_HQ[=/KA8Q<N;*\9\F03PQ[>SSX8'QMMK>T#(YBZ4T,5'N!D:#TCZGP
MVU<3V^# >_\ 8$T,LF;PS996O=<3W)>^(-C%1)[ (8XCK)T&MU&@=^_$/"WY
MI*SQRK,%Q4Y5SNN-7\9-7ZXV%)Z_V!&:]V[:MES6R[5MUI<T:]85J8[NL<I#
MJ1UUL*A#IUYB0A&+8AW/J=<.?IY,XSGS,[\_@&33YR>:,21F2%L;8VPEFINL
M,-:LC'61WPG$-I\'\-@;_AQ4+<-F710XB&)Y8\,E=(9'2A^EV@O%*/?]X.PZ
MU[[;!6%6#6,+S3>%NS56?N/+?BQ!;'V3'6Z8Y,\C.6[VZ["U$P@-7LL/8S9B
M3JBP3QI0;1(0YD).RGRT1-8G_HQ[=/KA8Q<N;*\9\F03PQ[>SSX8'QMMK>T#
M(YBZ4T,5'N!D:#TCZGPVU<3V^# >_P#8$T,LF;PS996O=<3W)>^(-C%1)[ (
M8XCK)T&MU&@=^_'/"EYE8/C]4F7%SE%,:XUGQ>TUJR_V*G;#C*#MBS[+D]@6
M[=D-/MH.PJ5!]<F+F'5)L>:R3+>NL_3(T;%4<=V#^\?OR;QM+E[@YW!-FGSM
MS/&U\9DB;&(V0EI<W6&$'\6SO(>[J#M3\N/]^1XR 8?,.BAP]O"]S7ADCI"]
MTH=1VDO%/QC^S!V%3Z]JD>_:2K!C*,%?78R3-L_9+^FJEZS1XB1PV5])8B:R
M?J(J8SVG*4V.O3.,9]@K*]CHWF-_1[20??'=3^US7M#V]6D5'O%9S>#]#B-<
M^?KR=5^$<R3IE(:FKM\65E5FJ[HLOM,VC-G6!LD=HS8I%C6<];W*+,F2&539
MD2(HHJH4ZIYEW1=R7O$F#FE#0X7#H^E:4B\>)IZD]2U@)]%:T '01;MZV9:\
ME9>*,DM,+7]?7)X,CNP'0.<0/<I4D]5H^$,*5$!$!$!$!$!$!$!$!$!$!$!%
M7+Y;?W=?)S^RU6_Q&IHT;DKZCY#^C9_6L5L_(O\ YK]G?/;G_<+M8#Q3-?T_
M("("("("("("("("("("*Z;Q->3-7B+8H;1.RUZ%6.,]OOEXV)L;8,A4]@63
M8$#-/-8-H:!:P9:?*2")HM]8Z5#-SDS /E2%=.#F4(3)5$)7XVWZ=M3-Q%^8
M8\#+-)++(62.D:XQ!K0W03T+HV#^;<>KC4#J//3SQ>3QG.V*N.2]GMR=YS#8
M8RSL;"Q9<V5O930LR+I9G3?*HV'Q&07=V\'Y;"TF.)H8YU6R;/*/=*ULBE4_
M8E+DOC-.OM7K]TJ<Q[F_COBM:M,2TG(*2^'RK5C*,??HM\DKZ+E!%PEW]JA"
M'QDN+36EU!?6D5]:NUVLT;7L=0BK7@.::$ BH(-" 1Z0"OY\]R;>S&T=Q7^U
M-PP_)\_C+V>TN8M;)/"N+:5T,T>N)SXWZ)&.;KC>]CJ58YS2":!?+/XF+#OB
MPS/)+C;#7W8O(38M]H\?=Z1(7C6%;U_$:_K>L'-45G(-*UMJD^)*$?5*#3.1
M2<>&.9XX.1OZ?3+>&N2.-Y\Q.[.X)LT^:GFC$D9DB;&(VQ%FINL,-:LC'61W
MPG$-I\'U \CGGCQ7&>*M^(N7;C&8GBO$XR\?9WC+/(W%[+>W&1;<B&8VSKIA
MC++J\<"VSB $4372ZJB6L7Q&>29]Q4LT3H+8!J%7>-ELN>QMH[)OTA5KY8=@
M0$BCJ+#>.2@_HG+/6YXM>6H$4D=+X"^7P5RXSZA<9(='0>-=]OV[<-PU[X+,
M%)++++(62.D:?!Z:=!(I6-@IX;CU=U[4N/YZ_*+;<V8>?D_:PR=WR[8X^PQU
MA9,N;*"RGC.4U2&;Y3$QPD;%>W+@[Y;"RL<0TDAS9-E.N]@U#:]%J6RZ!+_'
MZ3>8&-L]6FO<).+^*0<NV([CWWPV:91TLR]X;J8-Z3E!%8G7H8A<^P6AL;VV
MR-G'?V3M=I,P/8ZA%6D5!HX BH]! /N+^?[=>UL]LC<M]M#=$'R7<6-NI+>Y
MAUQR>'-$XM>SQ(7R1/TN!&J-[FGN'$*B[RS^*67Y$R$SR+X_Q5]OO(FT3U'@
MI>C.+KK2MZ_;4F!K#F%=R[$EL9UEX241-%L,9P>=5[S+*9(ADO\ HXBY(XZE
MS;W9S"MFFS<CXVNC,D38Q&UA:7#6&&O1O_:'N:#U>D_D<\[=AQ1:6_$_*,^,
MQG%%E:WDT5XVTR%Q>NO)KALS8GFV?<,,9\2:A%FV@8P.DK\.HGQ:>1F7X57I
M+2&Q"T*MZ$MVQYFQ;;NDO6;Q9[M6'K.HG@VZ5>S2IEXW5:GEH%DD8N(:2/\
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M"D01C\%44*7&,IZ#LC?62VKD#B<PV>2![XH=,TSXVVH:XM<=#VN#0 ?:;[%
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M/DSTCY'-<V-C8_#:P. ):1UZ.^]]751UOS88PH=E<4UC,,QC 07N<_6YQ:2
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MY?Z9)K,7,C6+7%-9F$>KQKM%_'K.8]XFJW549O6Y%4\YQU*<F,X]N 65BO\
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M-&*2P7HIG'JV:XVY)MK^W9M_/.AADC9;6]N )"Z<D&,ZS[3:DB.M=(J\^CM
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M$CWP"59;C!@DVB&.^"Z:4'[I"H3\P?AM<\/LR^^./4&1CQ3K%9H<;/N+5?\
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M[CW6V,[*-V[20DT$6F['&'+MLTSELBJ;+G.,X)[.F 1:"01 1 1 1 1 1 1
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M/D/Z-G]:Q6S\B_\ FOV=\]N?]PNU@/%,U_3\@(@(@(@(@(@(@(@(@(@(KO\
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MM<10K.YY9_$Q/[2L,SR1XUP5SONX-AWVCQ%FU?&NJ-"4RNTF!U@YKCJPQ!)
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M"X5TFO1OWWI/1>H7D<\[UEL&UM^)N5KBPQ_']G:WD[,C*+R:Z?<RW#960O\
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M6ZFE>X3/<T-8P1!P::T]+'4]UP6J^PP-*VO09RKSS2'NNNME5"3@9ICZZ<A
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M81V8Z,:-9-MZJ.,$RDDSSC/:-6V%R%>X6[_9&;\:6W>Z*&-ITL;![1::@@4
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M"3:(8[X+II0?ND*A/S!^&USP^S+[XX]09&/%.L5FAQL^XM5_^/78FP;+:7L
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M9.&OV4N/7U2TKYE:@@[*2P+* B B B BJU\T_P"[.Y*_['/\?M5@BP0@B B
MB B B B B B B B BV0>$[G3K&8XWTGCIL">I&N;=0[-^3?64=+V]L2P[;=6
M*3?VA=6'@WC9DKAXQ?V5%GZ"!W/=DQ#9-C)NT%A7K7JA578M?>UZV0$#/-'#
M9ZFTQ/0D=.I1KQVR<,2R+1M)(+))NT$G)NTY>PW3.<=V,9R"RL+O.[QV[E\?
MM_\ CFN93:EMU?$U2O2+[?L;5I*D0\+/VF4E(%:J*34++R+=LYSA-L3./>RG
M5]\*3).F<=<K@11:"_%CY3Z)R'IT5J#:[NDZIOM'C]4ZOUZQF]B8E+3NB2-
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M@(@(@(JY?+;^[KY.?V6JW^(U-&C<E?4?(?T;/ZUBMGY%_P#-?L[Y[<_[A=K
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MD)4J%7*!J2TEL^KZQ7I^0LM^MLTM8&9YB.RU5>)9=&:V% IBY+DV2MC=,>W
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M]4M*^96H(.RDL"R@(@(@(@(JM?-/^[.Y*_['/\?M5@BP0@B B B B B B B
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M![)PU^REQZ^J6E?,K4$'926!90$0$0$0$56OFG_=G<E?]CG^/VJP18(01 1
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MD:!7A7<HPCY6/BWBDJJ^AT,J))&=F,J]QC)\YZ9-A<@:JY>]4*J[%K[VO6R
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M_LM5O\1J:-&Y*^H^0_HV?UK%;/R+_P":_9WSVY_W"[6 \4S7]/R B B B B
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M- T/(6B@RKGOQ).#E-)(%P4N.I$[3<9\AMS\#,+E'2.S,4,DDDS_  VL>/&
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M>L=?0-+HM+@=?$>I0$^JR/6W^#X?UMWDA\-')\G<IXRI]W!==Y+XT@MH'Y_
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M?K^A2-HONS+;FG0U;N"JMUQ'L&\*E$O6:OOR$;.-$\DRQ;ER5N?/MSTR;"Y
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MRI1-([[FIYIZA0=>Z^[B>XDNL]<2R4U"Q8SIZHS%&W[NEHK[M5M2%9E/J B
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M=][ZNJFSSM>267F"6?DSC."ZO.6KRZM(I8I;NW@LQ9P6[H7.:V9L=)!X</\
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MO&S18Z!U$U4RK%35SDN3$,7!NG7&<>P5(Y@D,6^G2MIJ;!"1]P$JRW&+!)M
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MW^(U-&C<E?4?(?T;/ZUBMGY%_P#-?L[Y[<_[A=K >*9K^GY 1 1 1 1 1 1
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M5QA\1/*..XO?E<"*+2!XP?*/KWDGKV*U]M%Q3=,W>BMM5ZHIY[]N^$E;5O\
MM3B$)"/I"M15BAZC+R%@=2[1IE5FU/+N3N99$AE,G.3*N%R!JK>+IK^A;(BV
M\'L2D5"^PK602E6L/=*U#6F+;2B#=TS0DF\?.,GS1&01:/ETB+%)A0J:QRXS
MVG-C)95"OA,T?^C7R"\D^B?I/]-/R8VGCU6OI3\%^CGQOT&N[7/OOP/XM/?#
M>[WGM]/WQQT[>O=[>F"+0P"("("("("("("("("("("("*"?D^_=W<T?V<=I
M_@L_&U;&^N.,^>Q?&"US=_U7O_FLGQ2O,"%Y541 1 1 1 1 1 1 1 1 1 1:
M]/X>WR2:BH6MY;ASM^0UQIR+J>+5LJ!V_LG<M9I\?=I^V6N CT->Q%8L\9!M
M_C"#=ZHX(=&8=K+$0-T;%QU,6O'+^R\C=WK=R8X37,DFF-T,<+GEC6,<?$+F
MEQI44ZL %?A*;N,=UV-M:NP5\8H&,U2-EDE:T/<YS1H#7 =>M>CB33LM8&P=
M:ZYVW5GM'VK0*5LVE22S)Q(T_8-5@KG5G[B.=)/H]=[7[&PDHETLP?($61,H
MB8R2I"G+G!L8R(!L[V]Q\XNK":6"Z:#1\;W,<*BAHYI!%1T/7J%-%U:6M]";
M>]BCFMS2K7M#VFAJ*M<"#0]1T[K"-Y1_%7NS@9MUCR!XXRNT[I5Y^R;2W,M:
MM):4MNO8#BA'PEF9SM;CU;O1+'98ZLLX6.FCE8O\F@2-T8S)TDBEQG"5J]B;
M]QF[,<<1FFP13L9%#HGF9(Z[+FEKCHD:TN+BWVF_C*EU"?77'>.S,AMN^&3Q
M3II(7/DEU11.8VV <"T:V.<&@ ]#[% WH/5;3X:?,]6+_0X_CWRNM4#KY[J'
M7SZ2?\I>0O)6/.ZVU9Y6\N%HVMNS;(BX15&>2@997*!3V&3<'9Q!\E3PF7/H
MQ]R3QK/:79S& C?,VXF %K;VQI$T,ZN'AEWLZ@*_BVBK^]>^[;#W]#<VPQ>:
M>V)T$1)N)YQ^,<7]&GQ .NDFGMN-&]J=M*U]U[0=J5.5H6SZ/4-CT:>]Q^.4
MR^UJ%N%3F?A<DSF8SXK7;"RD8>1^'3$<W=H>LB?T7*":I.AR%-B%+2\N["X;
M=V,LD-TRNE\;G,>VH+31S2"*@D&AZ@D=BI9N;6VO8'6UY''+;.I5CVAS30@B
MK7 @T(!%1T(!6&/RR>)O;O"W;J')OC(OL>Z5>Z;'WIO<Y-$:+LU(@.&$!2+-
M7]@4PIKGK^P6..J\/5XZQKXC)/*%:18(UI1=!,A2&*VM-Q_R!CMS8XX/."&*
M>*&"#\?.U[KQSVNC?[$C6EQ<6C4VLA<9 "37VJZ[UV5?8"^&7Q!EDADEFF_$
MPN8VU:QS7L]MCG!H:''2ZD8 C) ]5CGA;\TT!:JS!<6.6]QAZC(ZVUQL*ZO>
M6_(SDRRR]VA/O]NM'D%1726S(R,7+,1]7OQD6F3V606]PKN?3;E1SDK;3.3.
M,YH)WY[;T;I&3S1L%I;VQI$T0D.>/")Z%T=3^+:-4G4U^%M>P-_Q30MPV;D:
MQT43WFYGN!61QE!#/Q@'4-?0?C''2SH*=M0%]U[0=J5.5H6SZ/4-CT:>]Q^.
M4R^UJ%N%3F?A<DSF8SXK7;"RD8>1^'3$<W=H>LB?T7*":I.AR%-B#+2\N["X
M;=V,LD-TRNE\;G,>VH+31S2"*@D&AZ@D=BI?N;6VO8'6UY''+;.I5CVAS30@
MBK7 @T(!%1T(!6&/RR>)O;O"W;J')OC(OL>Z5>Z;'WIO<Y-$:+LU(@.&$!2+
M-7]@4PIKGK^P6..J\/5XZQKXC)/*%:18(UI1=!,A2&*VM-Q_R!CMS8XX/."&
M*>*&"#\?.U[KQSVNC?[$C6EQ<6C4VLA<9 "37VJZ[UV5?8"^&7Q!EDADEFF_
M$PN8VU:QS7L]MCG!H:''2ZD8 C) ]5D7A6\ST1<*K%<7.6-JC:N]U5K+8%]E
M^7?(?DJU5=;'EY'<D;F IDD79,7'*MI)C [(*T9G5LS]7+.!P5- J9L%;:7R
M9QK);3NSNWXW2-N)XXQ:6]L:1@0G4\>&34%T=32)HK)U-?A;9L#?S)X6X?-/
M#'0PO>;F>?\ G"91I8?$ ZALE!^,=T9T%.VGJW4Z@[6I\A4;Y5:ALF@6EFT^
M*UBW0<+<:?8V!5VTFQ^(0LRUD8679E<MT7"7J)*$PH0BA?:4N<0;;W-W87(N
M+222"[C)HYCG,>T]0:.!#@:5!H?6%+T\%M>P&"Y9'+;/ JUP#FN'<5!J".Q'
M\*S@^.+2U8X^><[R2ZMI;.!BZE&:FC+178.KUF/IU=K41LN4TQLUC4X6N1*J
MD;'QM30N&(U+*&$DEB-<*E10P?T4YFWGDY\QQ9A;^Y+W7#K@M<YSB]SC&)HB
M]SCU)?HU&M2*TJ:5,5[5Q\.+Y#RUG;AK8!"'-#6AK6B0Q2!H:.@#=6D4I6E:
M"M!IM$(*6T!$!$!$!$!$!$!$!$!$!$!%7+Y;?W=?)S^RU6_Q&IHT;DKZCY#^
MC9_6L5L_(O\ YK]G?/;G_<+M8#Q3-?T_("("("("("("("("("("*_+PS^1R
ML<;WT;Q;V-%5&KZTV+LN^[(L>[K7=,5]G35\ZHC&L9$KQCF+-'.$I.8UXT:)
MK*/4<Y5D\8P3.2%P>9N+-\V^"<W;U\V*.PGN))73O?I#/Q( %"*&KHV@$N'5
MWN=?,3_4"\I>8Y;MIN:-IS7U[O#$X>RL+?$6UIX[KL?M*1TDHD;)XC3'%?2R
MN:V%PTV]2X!Q+=>#%[3MF4IG(LE8&\:_V#5V[UHMV,IVKV^G6N)(N@KZ:I'$
M?,0-@A7^,]IBG1<-UNF<&*;VV78^UO[0/9HFLIHP1V<Q['C[H<US3[Q!7A'<
MV^?V=N*2TN!=8W=.*O7,<*OAN+6ZMI2'"H+7Q303,(J"'L>WH00LQGEG\2\X
MI89GDAQEK,];I;8%]H]96X^:IU6S:P]&K<;K!S&REL9&K+K.,M7,[3&QW&,1
MS=/+J9SDQ\GZ94@+DCC>8SNSN C?+)--&SY-#" V-HB(+QI/8N8*^R.K^]>_
ML;Y'//)C6XJWXDYAO+6PL<7C+RX&<R62<Z6\N),BV2.V?\H;\)L-W(&'QWN\
M.U%&AO1G6GB1\J4Y0+)$<<M_S:DU4KS=M@WN<Y!;9VK,NW5"BHW4Z;V/KOI6
M-"02S#K3-#*5/)I! A5Y90Q4^['])\'&W(<UE.W!YE^NVFEDD=<S3.)C AJ&
M^U7V=4?\H=7GIZ]P\]'DIQNZ,1/RSQ=;"WSN-QUC90X3&8V)K;V23)%CYZP.
M8?%$5Z2ZD#R66S074/L:NX2;IFSZ8PG(-_ WBA7B!*Z8/VIF<W6K36IMGG&#
MDSG"[&4B)1BOG&<9P=)5(^<9QG&18N*6UR%J)H2R:SF94$4<U[7#^ @C[A"\
M0\CCMP[-W#+C<E%=8W<^-NM+V.U0W%M<0N['L^.6-XJ"*.:X5%"%FM\L_B:D
M)60F>1W&JMR\].V&>H]6+Q\U/JI@VBX.'9U=RQE;6U-6G*>>U1[#)*+XQ')E
MRJ\^4?.?::">2..'R/=G,#&Y\SWQL^30P@!K0P@O&D^MH)]D=7=UZ\^1SSQ6
MME:V_$O+]Y!:XVTM;RY_;F3R3W232ON&OCMG?*&GJ&2N:S\>XZ8NC0.@CIXJ
M?*59-*7!CQZY!2SB5J5WO\F_G-R[<VG-=^K8^,ION;>"3:V%O(MTXTTM7R)E
M)EZV(59YGH3NQ\KH^.^0I\3=#"YIQ=;33$NGFE=^* 9331U12K:?"'5W92QY
MV/)=B.1,#+RIQ; V#.XW%QLAQ6,QT-,C))=ZG3%T#HW&3PIRXGPI"61"KJ=M
M;L)-TS9],83D&_@;Q0KQ E=,'[4S.;K5IK4VSSC!R9SA=C*1$HQ7SC.,X.DJ
MD?.,XSC(LE%+:Y"U$T)9-9S,J"*.:]KA_ 01]PA>%V1QVX=F[AEQN2BNL;N?
M&W6E[':H;BVN(7=CV?'+&\5!%'-<*BA"S6^6?Q-2$K(3/([C56Y>>G;#/4>K
M%X^:GU4P;1<'#LZNY8RMK:FK3E//:H]ADE%\8CDRY5>?*/G/M-!/)''#Y'NS
MF!C<^9[XV?)H80 UH807C2?6T$^R.KNZ]>?(YYXK6RM;?B7E^\@M<;:6MY<_
MMS)Y)[I)I7W#7QVSOE#3U#)7-9^/<=,71H'01Z\47E!M>GKFRXZ[YD'<Y5KK
M>9R7GMQ;8VC-G5U9#P%%5[H@C2P-Y)!*)1>UCIDN7K9--1T;Y'7'RNDXYY N
M<7=#"9AQ?;RS.<Z::5WXEK8^U' BE6?R@.JE3SN^3/";^V_)ROQE%';9K'8V
M&*'%8W'0@9*6:\%)2Z!T;C(67'?PI'.;&/:H>FM6L6BD[2IL=:*G,P-YHEPB
MU%HR8C%VDU7;%#.\*ME3(+$]9G(,')<'3-CY1#XZXSUQU%D;>XM,A:MN+9S)
MK.5O1PHYKFGI[Q!7AIF<+N+9>X)L-G+>ZQNY;"8"2*1KHIX)6T<*@T>Q[>CA
MV(-"%3!0]<4S6?G$EXBAUBM4^!E>%!ITL!4Z]%5J&:/%;=$13DZ4=#-FC(RS
MKX05513TRF,8_3/7IUS%=G8VMARVZ*SCCBA=B=6EC0UH.MH/1H ZTK6B]!]S
M;MW#O#_3AM[_ '->7E_DX>1/!\>YGDN)7-%K+(T&25SGT;XI:UNH@ =*5HKS
M!+J\VT!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!%&GF5]E+D+]4M
MU^970+![)PU^REQZ^J6E?,K4$'926!90$0$0$0$56OFG_=G<E?\ 8Y_C]JL$
M6"$$0$0$0$0$0$0$0$0$0$0$4R)*D;?XI4/A]R6@+36XR:V+-7_;>HY"&3^.
MRU8<T2>JE9(M9H:T5K-<R_)-PYEDD"_$VJB&2Y4S@V<IXRN)Z+6;XG_)8QYD
M5*-T_>#7Z?Y%4"@R5PVE>YBJT*MT>QIFNGPJ/^CI*=+MSX=(1LVP3,0T''I9
M]%0V<F-T,IA9!JK-MY:(U3R2UQ+ZDW35?IGKZ==1+V5K_P <LE=]Z<P<DVEX
MM7XK4YB"FT/=9%FFIVIN2%/V]I\&+G)<EE8?.;'$K<GC!Y&T78U;L]!AOCU^
MNNQ>/QJ6^FKF^HT)2[4Q<U=K:6NQZBBP>2L8PF61.Q4TPBL=%3U55/893*X'
MHM)OB?\ )8QYD5*-T_>#7Z?Y%4"@R5PVE>YBJT*MT>QIFNGPJ/\ HZ2G2[<^
M'2$;-L$S$-!QZ6?14-G)C=#*87(&JLVWEHC5/)+7$OJ3=-5^F>OIUU$O96O_
M !RR5WWIS!R3:7BU?BM3F(*;0]UD6::G:FY(4_;VGP8N<ER65A\YL<2MR>,'
MD;1=C5NST&&^/7ZZ[%X_&I;Z:N;ZC0E+M3%S5VMI:['J*+!Y*QC"99$[%33"
M*QT5/554]AE,K@>BTF^)_P EC'F14HW3]X-?I_D50*#)7#:5[F*K0JW1[&F:
MZ?"H_P"CI*=+MSX=(1LVP3,0T''I9]%0V<F-T,IA<@:JS;>6B-4\DM<2^I-T
MU7Z9Z^G742]E:_\ '+)7?>G,')-I>+5^*U.8@IM#W619IJ=J;DA3]O:?!BYR
M7)96)OG?P]VUXT-HZBO\-8Z#%I3>\MK[2X]XI<C/6]]18W7%BUA-4I*TM]AU
M-LS>2L*5_'?T2IYANX.@IA=14N>JF5P/1:#_ !(^3E+E]7870^S5[]:.3E/H
M-YV+LC84A4M?5K7T_",MHM8:!:P1:=*1ZQ95C7+M"MSDS ,43F:.#F5.?!5%
M\+D#5?6\=_[P3R^_6EH'YLW&"RKG 1 1 1 1 1 1 1 1 1 1 1 103\GW[N[
MFC^SCM/\%GXVK8WUQQGSV+XP6N;O^J]_\UD^*5Y@0O*JB("("("("("("("(
M"("("*54EQ<VC1>+.LN;^)^E%U]==R2NJZO$-'TPXOL?<JBQ?3ZLI*P[RLDK
M!(')(<WI')).5CGR7!V^"YSG'0LSMC=9Z?:^B7Y9%;"5Q( C+'D-H"':M77K
M[('J*[>3#WEOAX=PZH_DLDYC: 3K#F@NJ06Z:=.GM$^XM<?A;\RLYR@DX+BY
MR6F-C[(Y0V^R;"L4'L-M0=3U76C37]<J#2?90<BI2WU3?$F$#P\CDN25U;O.
MND4[C)?]%7ODSC:+!,?G<(V&'!1LC:Z,R2OD,CGEI<-8>*=6_P#:#L:#US;L
M#?DF8>W#Y9TLN8>][@_1&V,,:T. .@M->COO#W'7U:(=H:SI&YM=W35&R83Z
M24#8=;E:C<(#XE+P_P 8KTVU492<?\5@7\7-1_O+94Q?5:N4%R=>I#ES[1#M
MC?76-O(LA9.T7<+P]CJ T<TU!HX%IH?001[BE&\M+>_M9+*[;KMI6%KFU(JT
MBA%6D$>^""L)GF'\4\AP::WG=VOR:XKG&'9&]M9TC46NX2X;&M.P*NJ75.PI
MB2^DZEXA7*>6;B4@)%4BA;!)JX]=(N"E)U*E:KCG?S-TNBQ=WXS\Y#:2OFD<
MR-L;OQL8&G0X=:.:/YMHZ'[M<M];,=MT29"V\)F'EN8V1,#GN>W\6\G5K':K
M7??N/4?<MO\ "WYI+-R-LT%Q4Y5SNQ]H<F]H;'V%)Z_V!&:]U%5=:0NM*KJ)
MI<T:]85J8[I4BG,)R-*L*A#IUY\<YWS8AW/I]<-H]Y,XS@PT#\_@&0P8."&,
M21F29TCI'3%FINL/%*/C'61OP7$-K\+=]@;_ )LK,W#9ETLV7FE>6/#(FQB-
ML0?I=H+#6K'_ 'A[CK3MI0V%0JGM2@WC6%]BOCU&V/4++0KG!^_247\9J=PA
M7M>L45\3AGD=,1WQ&'D5D?7:.$'*/?WI*$/@IL0K9W=Q87<5]:.T74,C9&.H
M#I>QP<TT<"#0@&A!!]((4L75M!>VTEG<MU6TL;F/%2*M<"UPJ""*@D5!!'H*
MP:>:3Q,*\);-.\BM3M]<5'B;=]CZ]UAJW6<9=-EVO9=<GW^HG<[8WEA->8B3
M0-#R%HH,ZY(IBR2"Q"/&Q"I)IY,FWM=QGR"-SP,PV0,TFX(H9)992R-D;FB8
M-:&Z".H;)&/YMHZ.-2>IK=O_ &2=OS.RMD(F8225D<<8?(Z1KC$2XNU@]"YC
MS_../4= .@M[\+?FDLW(VS07%3E7.['VAR;VAL?84GK_ &!&:]U%5=:0NM*K
MJ)I<T:]85J8[I4BG,)R-*L*A#IUY\<YWS8AW/I]<-H[Y,XS@PT#\_@&0P8."
M&,21F29TCI'3%FINL/%*/C'61OP7$-K\+>=@;_FRLS<-F72S9>:5Y8\,B;&(
MVQ!^EV@L-:L?]X>XZT[:4-A4*I[4H-XUA?8KX]1MCU"RT*YP?OTE%_&:G<(5
M[7K%%?$X9Y'3$=\1AY%9'UVCA!RCW]Z2A#X*;$*V=W<6%W%?6CM%U#(V1CJ
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MG:M?MS\W;$Q7/N$\OF3@S9WOG<4^]MYH'^'8,AC;D)"V9S+V*42D8^<#1:R
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M:29,Y%DKZS-^U;O6BW8HGZK9TD1=!7TU2)JI^HDIC/:8I38Z],XQD698]LC
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M,KI?&YS'MJ"TT<T@BH)!H>H)'8J7[FUMKV!UM>1QRVSJ58]H<TT((JUP(-"
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M"*-/,K[*7(7ZI;K\RN@6#V3AK]E+CU]4M*^96H(.RDL"R@(@(@(@(JM?-/\
MNSN2O^QS_'[58(L$((@(@(@(@(@(@(@(@(@(@(IG.:;MOB72^'/)R$L%40EM
M@SU\V]J9:/*XFW\ M0K!4ZUC-LB)V!;0WO?QN',JF@DH_;J-\ER<Q39RGC*X
MGHM:'BJ\F<9S1K3+4UQ:W5]R%HE"D+CL^WO*Q3J]K^<2S<BQ# M8Q7K"L_\
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MW]W7R<_LM5O\1J:-&Y*^H^0_HV?UK%;/R+_YK]G?/;G_ '"[6 \4S7]/R B
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MT-T-E<"*+3KXR/)E0N4^N&-/O*T?KB\Z]C]6ZV9OMB[3AI.R[NM[V"^%R,M
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M>Y6G7NHJVGCHL5R%E;&W#6P-A#FAHH&M>8I T#_Q0[3]RJT\B#5+J B B B
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M.IE1-1;C8Y?&Y)SF6,S)7M%2!Z OUW-Q_O+9T$5SN?'7%E;S/+6.D  <X"I
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M*@&I'4CJOM?EYT_^27\NWT_@?R0^Y?$?I]ZJ_P !]Q^+_ ?>?5]#U_3^,?\
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M?)N+;&?VG?C%[CM9;/(&,/$<@ =H<2 [H3T):1]Q=D#ZUT2 B B B B B B
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ME3'0_&2M'QC/7H>V[+-CK[<=>F;KG'7ID8;%&PU8UH/N !<IKR[N&Z+B61[
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MG%73;O'N=!>1DT<SV7--"#U%"#0D?=4K7],O;FWR9-S;.'P9"7M(J#V<3TJ
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MOD=S%T#0!U$8)]-2?<6S,6D7\_" B B B B B B B B B B B B B B B B
MB B B B BC3S*^RER%^J6Z_,KH%@]DX:_92X]?5+2OF5J"#LI+ LH"("("("
M("("("*BGS\\E]G:RXIZ\XE\<Y3X7RC\E&ZZ=PNU!)I+F;NJC";(=HL=K;"]
M0AD3MF=?ISOX<=V19 \:O-(O,'Q[OD$4QY_Q8<);QP7UEXYMCZC^FG%75U?H
M4-$T-.WWB@N)9_K_ "5Y'V>>L.K;+2+$_L$Q8CK2\FK[W@DC*.57"Y5%#YR"
M+)AY'?"/XN;9S%XT>*SQT<6VNO\ D[LATSWARHWNCNKDCL1'BEQ&K#M'$O++
M5N^[@ME(5V%M%ZX28PR,DQ<E2]1N4Z:&91D]1(MUFNJ%6-5:^HFKZ2Q-%TS6
M]-K%"J,8==5T>.K%/A&->@6)G*YCKN#-(J.23RH?.3GR7KG.<Y!%2'Y0^7&T
MMO;*<>+/A'>GE'W#9*&OLCG%RD@#^JRX(<2,MC+V"<Q)H+(%;;_VK"^JVJ<8
MDLG)-&IS27_%2&;/T2+HK^$RTFPU9XC*W?F$9)1B');D%O;=K)&<7]ZG,03*
MQM-*US$BY])OA4RD-I])8IB)I(K^OEPF3!5^XQ%S/PJSV6O/7^(!UE$N$3T^
MN^0F&V.Q;(+$6(C=-L4^<_*$N8R6?2*LXDZ2W*H7IWD42,4_RB@BT8 BZ#Y6
M?9=Y)?4'N'_#RQ BJ]\(G*G7]]XAT[33E5E4K-IF26H29;!8H1LO?)&R3,U;
MDEZK%J.$9!P1HE-I-CIX*HIE7IT]AL L55K.[]"ZIY!U U1VOK^G; 8,CO)&
MO-KG!,YYC!V%:+>QC:;9MWB2N&[ULB^.7"A.A\$,;&,^T%E86N3/%SDCXPMZ
M1V:EL&S8G(RFQ\^VW1K",M58BH=.XK35=<U_Z0G)@K5\N@T,FJ3UL>H1R4O3
MY7MRN'4+55XR_([1.7VN$ZS+8>5*_:PA-84J7>WZWP+B;VE:Y"O.6LI.P3;+
MA*2?K/92#455QG"BQE'1.ORLYZX7(&JGWN_0NJ>0=0-4=KZ_IVP&#([R1KS:
MYP3.>8P=A6BWL8VFV;=XDKAN];(OCEPH3H?!#&QC/M!96%KDSQ<Y(^,+>D=F
MI;!LV)R,IL?/MMT:PC+56(J'3N*TU77-?^D)R8*U?+H-#)JD];'J$<E+T^5[
M<KAU"U5>,OR.T3E]KA.LRV'E2OVL(36%*EWM^M\"XF]I6N0KSEK*3L$VRX2D
MGZSV4@U%5<9PHL91T3K\K.>N%R!JI][OT+JGD'4#5':^OZ=L!@R.\D:\VN<$
MSGF,'85HM[&-IMFW>)*X;O6R+XY<*$Z'P0QL8S[065A:Y,\7.2/C"WI'9J6P
M;-B<C*;'S[;=&L(RU5B*AT[BM-5US7_I"<F"M7RZ#0R:I/6QZA')2]/E>W*X
M=0M57C/\CM$Y<ZS0K\WAY3KQK2)UA0Y22V#;X%66VK<9&OG92<O7TCN$7\B\
M>R\5ZBI,X57,J^3QGY1O;A<@:JQ/:VE]3;TKK*I;DUU4-FUB.FF]C8P-TA&4
M_%M)YHQD8QK+MV;])9%.00CY=TB17&.[";@Y>O0V0651)X.-)RG''>7D=T;-
MS<?9)76EDX\UM].Q;=PTCY-=%ON]QERT;.\Y<HI&*YQCH?V]< BT4 B B B
MB B B B B B B B B@GY/OW=W-']G':?X+/QM6QOKCC/GL7Q@M<W?]5[_P":
MR?%*\P(7E51$!$!$!$!$!$!$!$!$!$!%L3_AWO(1JBM:LEN'&Q%:OK-6F9MN
MT8_9]YV16ZU"6M]:K7 1K:E1$-.)1AC3**;XR^,D>K'4(B;HEC'7.*Y<Q;0R
M$]^W<EF))Q+HB,3(W.<P,8XEY+:^STI\$4KW4Y\7[GLH;-V!NM$)CU2"1\C6
MAQ<YHT &G7K7N>W9:E-I:FUENZF2&N]O42K[(HLLO'NI.I7&(9SL"_<13U&2
MC5W4:^35;+*,7[9-9+.2YR10F#8]N!!-AD+[%W(O,=+)!=M! >PEK@"*&A'7
MJ#0J8;RRM,A;FUOHV2VSB*M< 6FAJ.A]1ZK!EY,_&9N[QV[NA-ZZ*F[;8("P
M6W9FX:_8-/:SM-<C.-<97+2RF*RP?V:'>S<=#$AHZ;*5JZ,:/333CS&*7!<?
M(M?LC>^+WCBW8K*MC9,R.*%S9I6N-R7-(<0TAI=J+>H]KX2K=N[:.0VMD&Y'
M'.>Z)SY)6NBC<T0!K@6@N!(% >A]GX*NW\-7F,KVZ*+':!Y)V!*KW'4^O'\W
M8N1NZ]R0+=MLZ<D;TMB-A,9M#:)52F48.9Z)%/(NE3-HP^2D[,9R2,.2>.)L
M9=.R^%9XEM<3!K;>&%U8FAG5WLD^SJ'7V0*N'7UR%L/?<60MAC,L[1/!$2Z>
M64?C"7]![5.M#_*/1JT.[,U?KO<U(F];;7I=;V'0+)\-^/T^W136;KTQ\'EV
M$]%?$(QZFJV<_#YJ+;.DNXN>Q= A\>TN!#UC?7F-NFWN/E?#=LKI>PEKA4%I
MH1U%6D@^X2I0N[.UO[=UI>QLEMGTU-< 6FA#A4'U$ CW0L)GE4\7&W>!F[(K
MD=Q^?62?J]TVGNO=M51TSJVS0D?Q0@->VVN7ND)2%D@GDU'0K.LQUE+A@^,2
M,1;D@5528P4N<)6JV%OO';LQCL+EPQD\4$,#_&E:XW;I&.C?1K@TN+BWVF^T
M3X@!]VN6\]G7VV\@W*XPO=#)-+*WPHW 6S6.:]E7 D -#NA]D#03[UMWA;\R
MT-M6LP7%_D_9_A%YUUKC85\GN3F[MS0;5ML607VZT- U'"=K;QBY9B/J]^10
M0[I-P?+2"/DJ6"?Z*/>3.-I+"=^=P3-5K--'&VV@A<3&/!.I_L5Z%T9)]D=7
MCK7ON^P-^QWL+</F'Z;F*)[S<2RCVSXHTM]JG4-> /:/1G;U:1=F:OUWN:D3
M>MMKTNM[#H%D^&_'Z?;HIK-UZ8^#R[">BOB$8]35;.?A\U%MG27<7/8N@0^/
M:7 A>QOKS&W3;W'ROANV5TO82UPJ"TT(ZBK20?<)4K7=G:W]NZTO8V2VSZ:F
MN +30APJ#ZB 1[H6$SRJ>+C;O S=D5R.X_/K)/U>Z;3W7NVJHZ9U;9H2/XH0
M&O;;7+W2$I"R03R:CH5G68ZREPP?&)&(MR0*JI,8*7.$K5;"WWCMV8QV%RX8
MR>*"&!_C2M<;MTC'1OHUP:7%Q;[3?:)\0 ^[7+>>SK[;>0;E<87NADFEE;X4
M;@+9K'->RK@2 &AW0^R!H)]ZW/PL>9",VU5HCC%R;L*D9=M8ZTV#L*S<G]U;
MCA4&E^=.=QQZ-?JRI;2UC5D)-A7MC-FC?*DFN;+>%S@B>"FQA./.3.-WX^=V
M<P;-5K//'&VUAA=6,"$ZG>R3T+HR3[(ZO[^O=]@;\9>PMQ&7=2XAA>]UQ+**
M/_&C2WVJ=0UX ]H]&=O5I#ONO]>[CH\O0]BU:M[#U[;F;1.:K-B8-)VMV!BD
M[:2K+#QDX*LS?-B/&B*Z?7!B]Y"FQ]S A>TN[S&W3;NSD?#>1DZ7-):YIH0:
M'N#0D*5[FVM;^W=;73&2VKP*M< 6N%014=CU *S?>-/1U:XY></R/ZCIK&$B
M:C":FC[#6(2N1"<%!UV V-,Z;V5$5B-BT5%46S:LL+>FPQDG:17+;*A2$P;!
M"S1O;*3YGB["Y"Y+G7#K@M<YQU.<Z,31EQ/I+BS5[E:=>ZBK:>.BQ7(65L;<
M-; V$.:&B@:UYBD#0/\ Q0[3]RJT\B#5+J B B B B B B B B B B BKE\M
MO[NODY_9:K?XC4T:-R5]1\A_1L_K6*V?D7_S7[.^>W/^X7:P'BF:_I^0$0$0
M$0$0$0$0$0$0$0$6B3PB^0*B:1RRXAWB!804?M':NP-D.=S6.\PU8J=100U%
M"^ZQ,JREV*2*JLB^UKALDL:00P9:12+@AC%[5)PXEWG9XFFVKM@8RXN9)3.Z
M1K&,_$MH"'#TF*@.H=7#IZ_*3_48\K>YN1O$YWVW<RW-UA<)8V#<3!9RW%S=
M%V4EU2QOB>2!&S(&1S1 \AD#R7 .JW5\^94[9E*>1SU*!O&O]@U=PR=H][*=
MJ]OIUKB3H+I>HD=Q'S$#8(5_G'<4QT7#=;KC)BF]MC7LM;^T+'Z)K*:,@]G,
M>QX^Z'-<T^\05XAVUQG]G;BCN[<W6-W3BKUKVFCX;BUNK:4%IH0U\4T$S :$
M!['MZ@$+)WY9_%)*ZVL,SR)X[U[XI3KW?:/3(7CUJ'5$PX<41DCK!SB:M&5*
MTO((FBWUCI2JRW;'H$PYF"8,ID_^DKER1QU)83NS>$9JM9IHV-MH87$QCPCJ
M?[->A=&2?9'5XZU[^X/D<\[EEN_%6_%'*UUX.?QF,O+N7.93)1-;>/.1;X5O
M2X##XC(+MK&5G>?#M74;I^!VIXE/+'875CA^-O)2PV*Z3-_O-]M:?(#:.T6J
M,31:M"ZK1F657?$L;0W_ !$\O2'7I'S(MTL.)?K@F38SA3L>-^1YW3MP6=>^
M66::1_RF644C8V'4&'4.VJ,T]H"K^WKTGSS>1[%0XFXY=XAM;3'X_%XVRMCA
M,=CG&6\N9<D8GW##;N^&(KR/4/ >XLM>K@""W3EG-0V/4%2$5@;K1KK N&JB
MC5PQG:U9ZU.L5&S@A'#91S'RL1*Q[DQ,Y(8Z2J1\^W.,B?/^[7UL0"R6TE81
MT(<U[7"AZBH+2#[Q"\<@,]M+/-<YMUCMR8ZZ:X!S7PW%O<0O#FDM<&OCEC>T
M'J YKAZ"%E7\L_BA<T>0F>17'.NMSU6<GJ/3XWCUJ/5$JY>0./HNY1F+20]:
M</$\LG$E"957[8\F,*/"]RG7^=7CDCCEUH]V<P;!\F>^-@MH822WV#J?[)/0
MEM3[/=W=>V'D<\[T.Y+6WXGY9NW#-VUK>74F<R>2C:R;_O#3%;$7#6G6V.8-
M96<^S$:-IV^EXHO*[9J]:8OCCR5G;-;W-[O3\S#<6T-G-XZ&U?7XBE8PC7GK
M>S,SX299DZ^<I"Y?-2%7>8QVY-CH;GQUR-<07#<'GGR2NFF-)I90&Q-:SX)#
MQVJW^4.KE\?G=\D6'RN%FY:XAMK.PAQF-9KQ6.QSI)<C/+=]9V.MW"K_  YP
M2?!D)9$36G;4MG-0V/4%2$5@;K1KK N&JBC5PQG:U9ZU.L5&S@A'#91S'RL1
M*Q[DQ,Y(8Z2J1\^W.,BPG_=KZV(!9+:2L(Z$.:]KA0]14%I!]XA>+8&>VEGF
MN<VZQVY,==-< YKX;BWN(7AS26N#7QRQO:#U <UP]!"RK^6?Q0N:/(3/(KCG
M76YZK.3U'I\;QZU'JB5<O(''T7<HS%I(>M.'B>63B2A,JK]L>3&%'A>Y3K_.
MKQR1QRZT>[.8-@^3/?&P6T,));[!U/\ 9)Z$MJ?9[N[KVP\CGG>AW):V_$_+
M-VX9NVM;RZDSF3R4;63?]X:8K8BX:TZVQS!K*SGV8C1M.WUO$]Y6+7"6N,XW
M<CYBU71Y>KM*KLMP;,V6DRB-75J!HIELP3YK9&2GHQZ3VMJ_=>M4TU'7MQUQ
MGN_3CGD6YBN6X+..DE=-*:32RT;$QL?P2'#M5I^^ %5\/G@\DN$R.$FY<XDM
M[+'6^-QT8?B\?CR^7(W$UY3QF.MWBLA9<-_[&1SFQ]Z$4U*LW]3V#5\.XR0@
M;G3;5%N42/8QZQGJ[8(=^DJS=%0>LE7,?),'2)CIFR0YR&QUQ_V181C[:]M]
M4;F2VLC3U!#FN:>AZBH(/9>+=Q;9S:V:\"\BNL?N"RF:2R1CX9X)6$.;5CPU
M\;VFCA4 @T*HZU)IC7&C/-K,5/55,K%!J$EPP6L;>LU&&:P40S>N[7"1;Y;#
M)F4B!G+Q6']4ZF"XR;NQC/W.N8DQN+L<1RPZVQT4<-L[%:M#&AK02]H/0>DZ
M:KT?WUR#NWDG_3JM\YO;(7F4ST/(0@=<74KII7L;;32,&M]3I8)=(;4TH3Z:
M*^@3$O,I 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 11IYE?92Y"_
M5+=?F5T"P>R<-?LI<>OJEI7S*U!!V4E@64!$!$!$!$!$!$!%FOYD,S;3_B6/
M$OK^?(5W6- <1N5G(>"CW;C*C,UNO+&SZU5=(,,M#D(^8*U:*>%5RJ7N49I&
M^3E'&%"*V7R1<]-6^-KB)L_E/M''Q/Z+LTH#7%$;+X1F=J;=L:;EMK_7$&4I
M%7&7$[*(Y5>+))+&CXEL\>F3.FV/@$4-O"CP3V;QRU+LCEER\RM-^0GGY9FN
M\^4<Q)HJ$?:_;/$W+C76@(9!=V^S"P.J8"1]W59)'R1L]4.S*=5JP99(137C
M^86O>3-.YET3@CMC6.TN3?&9KL#5S^ FS6)G3:'R2;05M8T.L;#DS0A<+UW%
M[KIV\DYB\/R$1:N2DR90G8"+(9N/7/FR\3OBZYY67:FOO'A.Q.ZH/8\URVY8
MK[8W;;N5FT+QR-DOR1,;@BX=Q%6I:U@JB^Q6;"K1*;=K"1N$RY*U567=F=$6
MA_PQ4_DUP]\9]#J'..#X]:DH?'[4,!)T20U1/7>:>-M/PU!2O5QO>ZW%G8M6
M<;=5)1Z_=/FL4CELAE)7IW=2=2+H#^&RJ-JM_&#E%STO<5)0MD\E'-W?O*6"
MBI+)DU8S5CZS+URAQY6JA?4212D(^85:J=>Q:.6:F3QZ?:8Y%HP!%T'RL^R[
MR2^H/</^'EB!%@?1K.W>)-8X><G8QU5R/[K9KOM[4A\&5FC-34*=J5>SFT1+
MEHS;IJ?'(@^2H$56(HATSDQ<Y[<97$]%KK\7GDNK_-6JQ^N+1B<6Y$4^C2%P
MVB_1JT= 41RABX?!F'T;6:S3UPHJ5A+,,'(=LCCN*IGK[,=<+(-5/WD=QVUM
MRHU/.Z6VTUEWE'L3V$?R2$'+*PLD=Q7I=I-QV49!%-11(A7S)/)\8Q\LN,X_
ME!9[K$3RNXM;J\6O)77>QV+NEII+;#M>P=">Z2CRW*L8&A6IBM727-K(Q,.F
M>028RK+"R93K%5/A3J?V8SG*X'HM//B\\EU?YJU6/UQ:,3BW(BGT:0N&T7Z-
M6CH"B.4,7#X,P^C:S6:>N%%2L)9A@Y#MD<=Q5,]?9CKA<@:J?O([CMK;E1J>
M=TMMIK+O*/8GL(_DD(.65A9([BO2[2;CLHR"*:BB1"OF2>3XQCY9<9Q_*"SW
M6(GE=Q:W5XM>2NN]CL7=+326V':]@Z$]TE'EN58P-"M3%:NDN;61B8=,\@DQ
ME66%DRG6*J?"G4_LQG.5P/1:>?%YY+J_S5JL?KBT8G%N1%/HTA<-HOT:M'0%
M$<H8N'P9A]&UFLT]<**E82S#!R';(X[BJ9Z^S'7"Y U4_>1W';6W*C4\[I;;
M367>4>Q/81_)(0<LK"R1W%>EVDW'91D$4U%$B%?,D\GQC'RRXSC^4%GNL4W,
MGB7N'QC[8TO?TW5.(V-OG9.T-!88RSVV+L8G5MDU=-5$MT;R,1$)J/44W$=Z
MZ13K$6R57&3X^[G*X'HM'_BO\GT/S0@(C45\^-.>35<HUUV#L>18U.-@-=N(
M&,V4VK\&2 <-IITZ/($K]MA2JIF:)%,L1P;O^3COPN0-??7X?'?^\$\OOUI:
M!^;-Q@LJYP$0$0$0$0$0$0$0$0$0$0$0$4$_)]^[NYH_LX[3_!9^-JV-]<<9
M\]B^,%KF[_JO?_-9/BE>8$+RJHB B B B B B B B B B BEDWT7LW77'#7/
M,%[2J%(ZRM6VI+753G7T_8E;,:[U9LZGET'U<BK#%MD8QNC$GR18R><*9Q@N
M>O4= <K8WF:FVXV65M]';B1[0UNG0XAO1Q:34U[+N/V==VN*BSKHXC:/G+&D
MN=JUMJ[JT.'3IW6Q_P /GF2;<P<1&A^0DX=]RLL]GODC -ZK0,P-)/KZM59E
M/M<NI-LZ59(RI/<)+.<9+W'Z)E_EP*X<C<;NVYJRV'93 ,9&':I-3_$<XM-
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MW_WA?R5_LXZ3_P .^,0ZW._\G\)\]F_K+E=AA_\ F=EOFL7Q+=:"!$2DQ 1
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M3>-6N%7"2;LJQ29*4_0BL+VUQUT-OI_KF4W9I_7.V'VH;DTV'J]?8-2A;9]
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MD^_=W<T?V<=I_@L_&U;&^N.,^>Q?&"US=_U7O_FLGQ2O,"%Y541 1 1 1 1
M1 1 1 1 1 1;V/ CKFF[/\64)6;K6Z]8V#C:NY4VA;!!14^G%NWJZ,?\38-Y
M9JZ10?H(NC=JA<%-TSG'7IG(J?RS>W-COQT]L]['BWAKI<6U ZT-".G160XW
MM8+S9S8;AC7M,TM-0#J$]*BOI6<_R0^+7='C@OQ[SI1_M^RZ-@:A5G<IR#[6
ME3^!VVX34K7'-3]^K4BW=(]Y?<T_DX_I/?>TV>T3+LO?>,WI:?)<F+9F4?(X
M"WZOU,8T.#Z.!'\K^!17NO9V0VI<_*,>9WXYL;29^C:.<2W35IKZOX5H2\/O
MF0I/(FJPNA]^RU!U7L>I-M/:AT['JV&P2MIW6_- .:^]DW&9)NN7,VL_B&F5
M.BF,&6>YZFS]T1!R+QO=8:X=EL2V:XLI#--,=+0V$:@X#I][0FGN-4G[%WY;
MY2%N-R;HH;M@BBB&IQ=*=.DGKZ:@?=*T&6>G5&[L$8JZ56N6Z+;O$Y!"-L\'
M&3[!!^DBX;)/D6<JU=MTGB3=VJF54I<'*14Y<9Z&SC,007-Q:O,EM(^.0BE6
MN+33O2H(-*@=/<4G3007#=%PQCV UHX!PKZZ&O7J5Y_/DK\3FX?'+<66QM#2
M.W[KI*KZXK5DMO(+T6%4^@UUN5YL>NU*E\0K<BV>-_>&;F(+W$QW*?&?3-GL
MSG MULGD#';SMC9986T64DF<UEOU?K8QC9-='"AH0_\ ZE>ZK+NS95]M6<76
M-,\F/9$USINC=#W/<S35IKVT_P#6HKSO#5YE*;N>HUSC9R+F:)JVXZ[K?&_1
MVD'LC8[#+6[D!97\9+4*0=/LR*#DF;(XE("'.KT4Z*.IG/<;/LR(LY)XVN<9
M</S>&;+/;3/N9YP&M#+=H(D %*>S1SZ=.S%(NP]^07\#,3E71PSQ,@AA)<XN
MF<06$FOWU6M^ZY:.+/3JC=V",5=*K7+=%MWB<@A&V>#C)]@@_21<-DGR+.5:
MNVZ3Q)N[53*J4N#E(J<N,]#9QF&(+FXM7F2VD?'(12K7%IIWI4$&E0.GN*59
MH(+ANBX8Q[ :T< X5]=#7KU*\_GR5^)S</CEN++8VAI';]UTE5]<5JR6WD%Z
M+"J?0:ZW*\V/7:E2^(5N1;/&_O#-S$%[B8[E/C/IFSV9S@6ZV3R!CMYVQLLL
M+:+*23.:RWZOUL8QLFNCA0T(?_U*]U67=FRK[:LXNL:9Y,>R)KG3=&Z'N>YF
MFK37MI_ZU%>=X:O,I3=SU&N<;.1<S1-6W'7=;XWZ.T@]D;'89:W<@+*_C):A
M2#I]F10<DS9'$I 0YU>BG11U,Y[C9]F1%G)/&USC+A^;PS99[:9]S/. UH9;
MM!$@ I3V:.?3IV8I%V'OR"_@9B<JZ.&>)D$,)+G%TSB"PDU^^JUOW7+1W9:E
M5;G'%A[A6:_;(DKE)X6+LL-&SL<5VB50B+HK*4;.FV'*1%CX*?M[BX/G&,^W
M(AB"XN+9_B6SWQR4I5KBTT]500:*59H(;AGASL:]E:T< 17UT-5@?\H/B4VS
MP,NB6W^/CK;-XU-&U56]WG<;=I&U9OK&Q3UQE*\G7D']>?M7C9$S-ZS*4Y,=
M^2O,%S\G.<"V6Q>0<?NRV_9V8%O%D'2>&R&I=XK6L#M5' @]0?X%6O>&R;W;
M=Q\NQAGDL@S6^6@;X;G.+=-6FO8C^%3*_AU=IS^Y>=F_;S:#+*SN>'FM*:^>
M.9![*O)3\F!=)ZR;34A(2"BKQS)3C.H)O'.3F-T77/C&<EQ@:WS)818W:MI:
MP4\+]HR/    \7QI2T = &E]![@6P<6WDM_N*YN9OYSY#&TFI)/A^%'4D]:D
M-J?=*V;"M:GE 1 1 1 1 1 1 1 1 1 1 15R^6W]W7R<_LM5O\1J:-&Y*^H^
M0_HV?UK%;/R+_P":_9WSVY_W"[6 \4S7]/R B B B B B B B B B BV.?P^
M#%E)<(]ILI%FU?LUN4-Q]9H];I.FROIZLTBJGZJ"Y%$E/353*8O7&>ABXSCV
MX%H>%6,DVG<,> YIR#^A%1_,P>A> _\ JG7-Q9^8O"W%I(^*X;LRUHYCBUPK
MDLN#1P((J"0:'J"0H%^5KQ36S7%HGN2W'..OMZC+1/;[WGO9PYD:9%0NGV#*
M0C+\Q6K3='Z/2QHM!O)S)DR)^_.2)1J>,=#YQZFH<B\=7-C</SV#;--'(^XN
M+BI8&P@$2#3\$TH7]M1HT>GO9OR2>=O![MPUMQ!RS-C,9>65KA</AFMCNY)L
MH][)+)XN''QXO$<Z.T#B[P8RZX>35OP/O>)CRSP&KJ]#<;N2L[3*%J#7E"O$
MO6=H23:\S=SL5VGMGMK&UKTN>///-C-<1EOE<IF*R2[4H]$N5.[KA3]N-^2(
M<? W!9Y\4.,@AD<R4B1SW2.E#@UU-0I1[Z>R.C1U]?6>>/R-Y3>F5N.7.(;;
M(9/?N5R=G%<8Z-UG#:06<..= Z>(/$+M7B6ML' S.JZ>0AE.K=7;MFSD&RK-
M^U;/6B^,%6:NT$G+98I3%.7"J"Q3I*8*<N,XZXSTSC&18MS6O:6O +3Z#U"\
M1(+B>UF;<6KWQSM[.:2UP]'0@@CITZ%93/*[XHK37K-.\E>.,7>KVYM]FV=M
M#<3 S^E1%?U?#1S=G9F[VO(XQ7Y/+)+!WV2D*=XN4C4O3&#9QW5UY&XZN(+A
M^>P;9IG2R2RS"K&MB: '@M^":?"_E'HO;;R1>=W"Y7#VW$/+4V-QD-A9X['8
MI^B[EGR,LCG6[F3G\?'K-(:DB)A,AJ:=N,^)CRNQ6G8^&XY\AYJGTS359@;Q
M86&TIA"[S=QD+9,6AM+,8%[F.5FFYF1T99Y@F<,B]I&Y,94QG^=^'&_(T>+8
MW!YM\46+C9(X2N\1SR]SP0TTU"G5WWOH'5=QYX_)%>[^NKCEGBFWO\AR!>75
MG _'1.LX;5EM%;NB?,SQ!"[6#%%6LQJ7N(:?1K0QB+L$6D<Z364B)1JW=)IN
MFY%VKMJN1-RW.=NY3R4Q#%R4^,'+UQGI[,9P+'_BYHP2 Z)P!ZCH1W'0KPV)
MO<7>N:USX;Z%[FDM<6N:YI+7 .:>A'4=#_$LJOE=\45IKUFG>2O'&+O5[<V^
MS;.VAN)@9_2HBOZOAHYNSLS=[7D<8K\GEDE@[[)2%.\7*1J7IC!LX[J[\C<=
M7$%P_/8-LTSI9)99A5C6Q- #P6_!-/A?RCT7MCY(O.[A<KA[;B'EJ;&XR&PL
M\=CL4_1=RSY&61SK=S)S^/CUFD-21$PF0U-.W&?$QY78K3L?#<<^0\U3Z9IJ
MLP-XL+#:4PA=YNXR%LF+0VEF,"]S'*S3<S(Z,L\P3.&1>TC<F,J8S_._#C?D
M:/%L;@\V^*+%QLD<)7>(YY>YX(:::A3J[[WT#JNX\\?DBO=_75QRSQ3;W^0Y
M O+JS@?CHG6<-JRVBMW1/F9X@A=K!BBK68U+W$-/HUI%S&3T8DIE-M)1,JT1
M<$(X0*LU>,W29%T3*-W"><'343,4W:<O_=P+(?BYHP>CHW"O7L0?<*\-B+S&
M7KF OAOH)"TEKJ.8]I(-'-/0@@BH*R\^6'Q/V96R3?)3C?$7B^6:[6ZPV[9U
M;2>TF'K&OJY%0"3XLI I*E@)#TB+,3?(PNZ4QTST+UZ9%?N1N.9S._.X)LTU
MQ+*Y\K*QM9&T-K5OP3Z/62O9GR0>=_#LQ%MQ#RY/C<9A\=8P6N/N"R[EN+Z>
M2<L\.8CQV5(>.NB-OK-%&+P.V.6L7.?)IAVY?N(CCIL**2=O'3EXZ6;FN]7E
MBY66=*JGSE-:5.0N,9P7!"X]G7KG.O\ #\\D^[_QI)<VQD%2233Q&'T^^IC_
M -3+$V.)\MM+"-D44^[+&0M8UK6AWR.YBZ!H ZB,$^FI/N+9F+2+^?A 1 1
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M,"$,;D[_ !%VV^QDKH;QH(#V]P"*'^$&BEJ_Q]ED[8V=_&V6U<02UW8T-1_
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MB*A7-3,YNI0D"W<-HFOU?8,[I[8]>KK1%THJMCZ/1%M19*&R;.#JH&,7/;G
MFC?.6FS?&&&R5R7.N7W!:]SNI<Z-LT;G&G\HL+O>*BK:&-BQ'(&5L( UL#(0
M6AO9K7F*1K17^2' ?<6H406I?0$0$0$0$0$0$0$0$0$0$0$5<OEM_=U\G/[+
M5;_$:FC1N2OJ/D/Z-G]:Q6S\B_\ FOV=\]N?]PNU@/%,U_3\@(@(@(@(@(@(
M@(@(@(@(M$GA%\@5$TCEEQ#O$"P@H_:.U=@;(<[FL=YAJQ4ZB@AJ*%]UB95E
M+L4D559%]K7#9)8T@A@RTBD7!#&+VJ3AQ+O.SQ--M7; QEQ<R2F=TC6,9^);
M0$.'I,5 =0ZN'3U^4G^HQY6]S<C>)SOMNYEN;K"X2QL&XF"SEN+FZ+LI+JEC
M?$\D"-F0,CFB!Y#('DN =5NKY\RIVS*4\CGJ4#>-?[!J[AD[1[V4[5[?3K7$
MG072]1([B/F(&P0K_..XICHN&ZW7&3%-[;&O9:W]H6/T364T9![.8]CQ]T.:
MYI]X@KQ#MKC/[.W%'=VYNL;NG%7K7M-'PW%K=6TH+30AKXIH)F T(#V/;U (
M63ORS^*25UM89GD3QWKWQ2G7N^T>F0O'K4.J)APXHC)'6#G$U:,J5I>01-%O
MK'2E5ENV/0)AS,$P93)_])7+DCCJ2PG=F\(S5:S31L;;0PN)C'A'4_V:]"Z,
MD^R.KQUKW]P?(YYW++=^*M^*.5KKP<_C,9>7<N<RF2B:V\><BWPK>EP&'Q&0
M7;6,K.\^':NHW3\#M3Q*>6.PNK'#\;>2EAL5TF;_ 'F^VM/D!M':+5&)HM6A
M=5HS+*KOB6-H;_B)Y>D.O2/F1;I8<2_7!,FQG"G8\;\CSNG;@LZ]\LLTTC_E
M,LHI&QL.H,.H=M49I[0%7]O7I/GF\CV*AQ-QR[Q#:VF/Q^+QME;'"8['.,MY
M<RY(Q/N&&W=\,17D>H> ]Q9:]7 $%NG+.:AL>H*D(K W6C76!<-5%&KAC.UJ
MSUJ=8J-G!".&RCF/E8B5CW)B9R0QTE4CY]N<9$^?]VOK8@%DMI*PCH0YKVN%
M#U%06D'WB%XY 9[:6>:YS;K';DQUTUP#FOAN+>XA>'-):X-?'+&]H/4!S7#T
M$+*OY9_%"YH\A,\BN.==;GJLY/4>GQO'K4>J)5R\@<?1=RC,6DAZTX>)Y9.)
M*$RJOVQY,84>%[E.O\ZO')''+K1[LY@V#Y,]\;!;0PDEOL'4_P!DGH2VI]GN
M[NO;#R.>=Z'<EK;\3\LW;AF[:UO+J3.9/)1M9-_WAIBMB+AK3K;',&LK.?9B
M-&T[?2\47E=LU>M,7QQY*SMFM[F]WI^9AN+:&SF\=#:OK\12L81KSUO9F9\)
M,LR=?.4A<OFI"KO,8[<FQT-SXZY&N(+AN#SSY)733&DTLH#8FM9\$AX[5;_*
M'5R^/SN^2+#Y7"S<M<0VUG80XS&LUXK'8YTDN1GEN^L['6[A5_AS@D^#(2R(
MFM.VI;.:AL>H*D(K W6C76!<-5%&KAC.UJSUJ=8J-G!".&RCF/E8B5CW)B9R
M0QTE4CY]N<9%A/\ NU];$ LEM)6$="'->UPH>HJ"T@^\0O%L#/;2SS7.;=8[
M<F.NFN <U\-Q;W$+PYI+7!KXY8WM!Z@.:X>@A95_+/XH7-'D)GD5QSKK<]5G
M)ZCT^-X]:CU1*N7D#CZ+N49BTD/6G#Q/+)Q)0F55^V/)C"CPO<IU_G5XY(XY
M=:/=G,&P?)GOC8+:&$DM]@ZG^R3T);4^SW=W7MAY'/.]#N2UM^)^6;MPS=M:
MWEU)G,GDHVLF_P"\-,5L1<-:=;8Y@UE9S[,1HVG;ZWB>\K%KA+7&<;N1\Q:K
MH\O5VE5V6X-F;+291&KJU T4RV8)\ULC)3T8])[6U?NO6J::CKVXZXSW?IQS
MR+<Q7+<%G'22NFE-)I9:-B8V/X)#AVJT_? "J^'SP>27"9'"3<N<26]ECK?&
MXZ,/Q>/QY?+D;B:\IXS'6[Q60LN&_P#8R.<V/O0BFI5F_J>P:OAW&2$#<Z;:
MHMRB1[&/6,]7;!#OTE6;HJ#UDJYCY)@Z1,=,V2'.0V.N/^R+",?;7MOJC<R6
MUD:>H(<US3T/45!![+Q;N+;.;6S7@7D5UC]P64S262,?#/!*PAS:L>&OC>TT
M<*@$&A5'6I-,:XT9YM9BIZJIE8H-0DN&"UC;UFHPS6"B&;UW:X2+?+89,RD0
M,Y>*P_JG4P7&3=V,9^YUS$F-Q=CB.6'6V.BCAMG8K5H8T-:"7M!Z#TG35>C^
M^N0=V\D_Z=5OG-[9"\RF>AY"$#KBZE=-*]C;::1@UOJ=+!+I#:FE"?317T"8
MEYE("("("("("("("("("("("("("("("("("("("("("*-/,K[*7(7ZI;K\
MRN@6#V3AK]E+CU]4M*^96H(.RDL"R@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(N
M@^5GV7>27U![A_P\L0(L"S. W%Q.KO$;DRP+ ,WEMM-UVWI]VJJA.)G^@DS4
M($ZT_#YPEA#TYZ)/CT#FSZJ6,&Z],C*XGH5L#\87DBJW-&CPU#LDH]?\D*K2
M9&W;539U(]>J)&Y;@>&CSPCDJZK5<_N$FPP9,F/YV3Y_DR,+(-5.[D=QVUMR
MHU/.Z6VTUEWE'L3V$?R2$'+*PLD=Q7I=I-QV49!%-11(A7S)/)\8Q\LN,X_E
M!9[K#URAXS;R\7_)BB[$0:5N)1+LBUWWC\J:8;W(WT>H5K:*UQ2TM/3;?\;3
M823'UDE,]539/US[,C*X=EJ7\87DBJW-&CPU#LDH]?\ )"JTF1MVU4V=2/7J
MB1N6X'AH\\(Y*NJU7/[A)L,&3)C^=D^?Y,C"Y U4[N1W';6W*C4\[I;;367>
M4>Q/81_)(0<LK"R1W%>EVDW'91D$4U%$B%?,D\GQC'RRXSC^4%GNL/7*'C-O
M+Q?\F*+L1!I6XE$NR+7?>/RIIAO<C?1ZA6MHK7%+2T]-M_QM-A),?624SU5-
MD_7/LR,KAV6I?QA>2*K<T:/#4.R2CU_R0JM)D;=M5-G4CUZHD;EN!X://".2
MKJM5S^X2;#!DR8_G9/G^3(PN0-5.[D=QVUMRHU/.Z6VTUEWE'L3V$?R2$'+*
MPLD=Q7I=I-QV49!%-11(A7S)/)\8Q\LN,X_E!9[K$MR\XK[J\:.V]0WP[.NQ
M31'?^R=F<?%,32%O4Q#:MLVL9FHJVIMZ;?.7"*:T=E=%3/5;/J8SG'M&5P/1
M:7_%GY,:]S-J$!J^]2KI]RC@:7=K[LM&,IYZ_2RUZ+V62O02D.]3<*LU76*_
M:83"J1,=3*Y6-G/4N1A<@:KX/CO_ '@GE]^M+0/S9N,%E7. B B B B B B
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M#'XA?)J?XCY2SH"*D4='_&5)FQ=__MMPQF7=7,RROT:649X;8P_J0:5JU_\
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M6X<.X^,76;[O;Y;-'+O&'*R12ML9ZG]O7(PN:T4 B B B B B B B B B B
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MXI!*]OX\O80XM ()J6FH[^T%6O=>ULCM+)LR%BZK'222QF-KOQ(:X%H)-0*
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M>5/].^WW%OJ_N<GN&+D%MNZXG(+W,9;32,'LAHTM;+I'2O0J_83*O,% 1 1
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MP-FA#+)>J;.5SKYQG&"]N,+D#5<7\=_[P3R^_6EH'YLW&"RKG 1 1 1 1 1
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MD+X'[Q\6/)"E;<U[9Z\V:V*_;"VKI)YK=A89M344)2[<P?U1E9%;? *1WO\
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M<V3&-VG4A_DSCQVWYW9K%B-N&FGCCCA9XCGL/@DN)J#T+HWGX1^$/N2AL#?
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MB7+E[>ZH@YG7<<ZKB#[$XV9I(12AO742314Z=I3]<X'4#+XVZRDVW0]W[19
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M#5JMXY&Q.K5A]D22.(]'563_ /MT?_4-_P#.*-Y_^+W_ *G_ /.JHG_VV/\
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M&\N<22VCR"X?R>I#1U*B7SQ>1RZOKJ\Y>XEM[J[R=S/DLEG#<WENR*&-K&W
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M (J X$5H2*]Z$CTKS[>=WC=Y-^*7;M<NFE[_ +VN=7KVN(BZO^6>L-8; TW
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M\L+'(1"&_ABGA#M0;(QKVAP!%0' BM"17O0D>E>?;SN\;O)OQ2[=KETTO?\
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M(XFM95WA!SG:0230UI5;&!9]>!* B B B B B B B B B B B B B B B B
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M')S5%KT?O"J?3?5UW^!_2>L?'+)6_B?T;LD/;H7_ ,-5&8@+"R]RL, T<?\
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MME3D74[2;BI+[DUI3=,[-NUXUE8K3;GR^L[U89)O+PU-<Q,W'K-W[&3(15S
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MXMJZ9F.FXQ&1"2*F,GP;KC(K;R%Q[=XJ[.<P39)(I9B[PH+<M%NUK00[5&2
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M;AS([:=\8$=K%#%1K)0-7AAQ-:UH"="0FM>5Z B B B B B B B B B B B
MB B B B B B B B B BC3S*^RER%^J6Z_,KH%@]DX:_92X]?5+2OF5J"#LI+
M LH"("("("("("("("("("("("("("("("("("("("("("("("("("("("("
M("("("("("("("("("("("*"?D^_=W<T?V<=I_@L_&U;&^N.,^>Q?&"US=_U
M7O\ YK)\4KS A>55$0$0$0$0$0$0$0$0$0$0$7I^^,']W=PN_9QU9^"S 4:W
MS]<<G\]E^,5;O:'U7L/FL?Q0IV#55L: B B B B B B B B B B B B B B
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MG#7[*7'KZI:5\RM00=E)8%E 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 103\GW[N[FC^SCM/\
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MC++6;!%N/37(B_BY)![%2K!?&"GP50BB9NF,^WV"=)H+:]MS!<,CFM9&]6N
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M(@(@(@(@(HT\ROLI<A?JENOS*Z!8/9.&OV4N/7U2TKYE:@@[*2P+* B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
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MP\A'R=@=.E'=UC<>L@D='H])C/3L4-CO+7"WTV'ES@MY'XN&0,?('L:UKCH
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M$0$0$0$0$0$0$4:>97V4N0OU2W7YE= L'LG#7[*7'KZI:5\RM00=E)8%E 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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MB,N,IGE9V0R=5_9+?87"1$TW=FN=C>.Y215(4B9GCM3TR)I]A"D4D01 1 1
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MIATT7*JU>-RNFR2Q.N,E[B%-C[F!--U:6F1M76MXQDUI(!5K@'-<*@BH['J
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M_<-E+JBFB<Z*:&1M15KA1S'"I'H(ZA9!?*)XQKEQROZG('0C1_+U6Z;"DI6
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M,3'NLIXWG0RC=3S%J+J"M0/15:_!9E>#: B B B B B B B B B B B B B
MB B B B B B B BC3S*^RER%^J6Z_,KH%@]DX:_92X]?5+2OF5J"#LI+ LH"
M("("("("("("("("("("("("("("("("("("("("("("("("("("("("("("
M("("("("("("("("("*"?D^_=W<T?V<=I_@L_&U;&^N.,^>Q?&"US=_U7O\
MYK)\4KS A>55$0$0$0$0$0$0$0$0$0$0$7I^^,']W=PN_9QU9^"S 4:WS]<<
MG\]E^,5;O:'U7L/FL?Q0IV#55L: B B B B B B B B B B B B B B B B
MB B B B B BKE\MO[NODY_9:K?XC4T:-R5]1\A_1L_K6*V?D7_S7[.^>W/\
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MWEOVY9=;E9OUEM)(R&*!I;%;SOC 9"UK.C)15VD$FM:TJM$ FU>4R B B B
MB B B B B B B B B B B B B B B B B BC3S*^RER%^J6Z_,KH%@]DX:_9
M2X]?5+2OF5J"#LI+ LH"("("("("("("("("("("("("("("("("("("("("
M("("("("("("("("("("("("("("("("("("("*"?D^_=W<T?V<=I_@L_&U;
M&^N.,^>Q?&"US=_U7O\ YK)\4KS A>55$0$0$0$0$0$0$0$0$0$0$7I^^,']
MW=PN_9QU9^"S 4:WS]<<G\]E^,5;O:'U7L/FL?Q0IV#55L: B B B B B B
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MQVKOO5MG_? ^PW*_IUO_ -1Z?_5DX\_PEFOUFV_\"?\ 5S=U?K':N^]6V?\
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M>RBBN^K=SE%BDC[D8^/9C/;6/?NQ+W;E^,SB-3K>6>21K88G 6[6$.;5S20
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M9SMM[6)L,3'NLIXWG0RC=3S%J+J"M0/15:_!9E>#: B B B B B B B B B
MB B B B B B B B B B B BC3S*^RER%^J6Z_,KH%@]DX:_92X]?5+2OF5J"
M#LI+ LH"("("("("("("("("("("("("("("("("("("("("("("("("("("
M("("("("("("("("("("("("("*"?D^_=W<T?V<=I_@L_&U;&^N.,^>Q?&"U
MS=_U7O\ YK)\4KS A>55$0$0$0$0$0$0$0$0$0$0$7I^^,']W=PN_9QU9^"S
M 4:WS]<<G\]E^,5;O:'U7L/FL?Q0IV#55L: B B B B B B B B B B B B
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MC5./_P!NC_ZAO_G%&U__ !>_]3_^=5</_ML?_,W_ - 5R8E)>?Z B B B B
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MJ'2:FLCFMPV.E*!OXWI0BH7HYM'SM>4G ;'M=F;AW[<YZ2&T,$]U>XO,OFO
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MV<=I_@L_&U;&^N.,^>Q?&"US=_U7O_FLGQ2O,"%Y541 1 1 1 1 1 1 1 1
M1 1>G[XP?W=W"[]G'5GX+,!1K?/UQR?SV7XQ5N]H?5>P^:Q_%"G8-56QH"("
M("("("("("("("("("("("("("("("("("("("("("("("("("("("("("("
M("("("("("("("("("("("("("("("("("("("("("("("("("("("("("("
M("("("("("("*-/,K[*7(7ZI;K\RN@6#V3AK]E+CU]4M*^96H(.RDL"R@(@(
M@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(
M@(@(@(@(@(@(@(@(H)^3[]W=S1_9QVG^"S\;5L;ZXXSY[%\8+7-W_5>_^:R?
M%*\P(7E51$!$!$!$!$!$!$!$!$!$!%Z?OC!_=W<+OV<=6?@LP%&M\_7')_/9
M?C%6[VA]5[#YK'\4*=@U5;&@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@
M(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(J(^5?(C</*+RG<?O&7QEV?:M7
M4GC[ P_,GR';/UY,NH2T)TELZ:(Z8XML)Q@Z:/(IUM^3DVLA8D4S)NCUIT@N
MV4R5)TB<B^YY8_++M7@Q2]Q1_&?B#L+D?L;36H5-P;1V;:43:^XJ:,JSE%Z>
M(/>]E2[V'<;$OTG[L15E2ZP=24?(JE[W;,QB=Y%8;P-V_MGD'PLXL;[WI#4^
MN;9W;HC6>W+K7Z#%SD+48.1V/58VXMX>'BK+8K9/,$XV-F4$54W4BZ5PN0_4
M^/84I%1/Q<YL?Q WD)UM-<H^'-8\.5:XLV[;6YZQHDW(EMS71VE8M>ZUVA:=
M>Q-GG'&LIV>I<H:24K:I#.V1FJ2[A%7.&K<O:G@BT1\>"\AR:6U_CEBMI=?D
M3F'5-M0_'AM>&FEBSYY)\=!'7Z6R7;V\GAVT09LF=61.599R553":1#%2(10
M8\G?D5G>$\5HK4>B=4)\AN;?,38#K5?%71CB9)7X&5F(MLS>W'9.R)S"J;B$
MU7K*+D4'4NNEDBA_63(99JW]Y?-"*O!SSU\OG!7EGPHUSY,*KP4V7Q]YX[K@
M^-\!=N'S7=5>L>D=Z7=0B%'@))':KUPG::?+RCY-NDIE SI1LW<+J.$%&Y$7
MQ%*;G7R+VIQW\MGAV@(C8%F9Z*Y7EY@Z"W!K8LL[-4I:TQ%!I%RTK;"5SU,L
M3V9A<EU&AI#LPJBP6.EW9*IG (KN 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M 1 1 1 1 1 1 1 11IYE?92Y"_5+=?F5T"P>R<-?LI<>OJEI7S*U!!V4E@64
M!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$!$
M!$!$!$!$!$!$!$!$!$!%!/R??N[N:/[..T_P6?C:MC?7'&?/8OC!:YN_ZKW_
M ,UD^*5Y@0O*JB("("("("("("("("("("+T_?&#^[NX7?LXZL_!9@*-;Y^N
M.3^>R_&*MWM#ZKV'S6/XH4[!JJV- 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 19I?X;WKOJL>1GR0V([>1
MNO./GOM1Q#2R:C9][KHS3>$*YI^JLY,AEUUXNKXGY5FVQZID\M$4#8ZYZF,1
M<R_B@+7,+^,IIQLJKLS6Z<X^5/&/B=4\HDRLYS)VK8S382G:W35175:KMM:&
M;+X+G&#D<>EG./4P"*]*9U:W_(?*Z4H\TZHS7\E+[5M0L;=L24>T]O\ 1%6I
MU^:09F78)R+JOI^BN5+*J)5CHX+W$QGK@BR?<E>)G/CP!^-]7>O%/RFSU^U/
MPZ1J!E>+6^^.>ELZCV'6]@;;@8B>JL59(=-/953DI6WWQ5^W.A+KR*^3F9)O
M$/5];!%K!T1LEQN71^FMONZ^ZJ;K:VJ=>;)<U5\8YWM:<7FHP]G6K[PZB+=0
M[J&4E,ME,F3(;)T\]2XS[,$5!M-:DW[_ !1NXINQ9*\A^!?C6I-1H$8N3!DX
MC8F_KFQL\K;X_P!7/1%\[U_<I*)<J)%R95 Z1#*%PGV'(O\ /ES<)\@_*]X+
MN%M<_P#"LS2^1=K\@&S&;=;)#5"E<;8M&5UU8IGT,E7;1]IM</-1S0YC%17>
M-?0-@^5,%P1?G\E2ZFZ_/1X+N.M>444=Z3C^6'+W9Q6RK3U86GEID= ZZEGN
M%&Z[EO'R]UUK(16.S&<.%7A2]4_3RJ0BTI B B B B B B B B B B B B B
M B B B B B B B B B B BC3S*^RER%^J6Z_,KH%@]DX:_92X]?5+2OF5J"#
MLI+ LH"("("("("("("("("("("("("("("("("("("("("("("("("("("(
M"("("("("("("("("("("("("*"?D^_=W<T?V<=I_@L_&U;&^N.,^>Q?&"US
M=_U7O_FLGQ2O,"%Y541 1 1 1 1 1 1 1 1 1 1>G[XP?W=W"[]G'5GX+,!1
MK?/UQR?SV7XQ5N]H?5>P^:Q_%"G8-56QH"("("("("("("("("("("("("("
M("("("("("("("("("("("("("("("("("("("("("("+/#_  PL YUQXP5-
M S)5$KCQDY:<MM!WYLN7*+EI<:?N&:DI%LZ:&QA5BX(TL+?)D5/EEZ]<^S.
M1=8\H?$IY;.7>P>-FP]O>2SB\Z?<3=ZQ7(O3$)#<'Y./KL5LVO*HK5>4GF"N
M\72ED1K2B!3,RN%.Y-3J?)LFSG((K0=I<<O(K>^(.L]?5'R#UO4G-*CWC%UM
M?)*G\8J;*:RVC%HNKVBEJZ?T5<;%8F4/3W=>LT8W7?-9(TB60A$GR?;ZJC8$
M5?$]X?N;_-ZSZ[;>73G]5]_<<=9WB'V"EP^XX:-8Z7U?M2S5[.5X5QN.[+RS
MFX6FMH.,YPM"90RB8AC&;N6JILG!%9OOGBYR1V?R_P"'V[=;\PK9I3CIQ^3O
M"NX.,-2K:I(KD(]G(TC2L(V:PHV)I&E@X)9%'&&CJ*>>[IIJF:G26<>JB10H
MYA^+SE3,\YU/(QXYN7%+XO[^N^FXG1.^J9M;4#;:VJMQ5"O2"3^M6!^4C]"4
M@K9 DCF#8BJ"!U5&[!$B;ANEEVB\(NU>#/CG=<0-A[VYU<S.3*W*CFKMNFEA
M=I<C+)6XC5.N-4Z/J7I6)/5>JJ(RD7<+1-<PBT4F]DGBJY3R"K)-THFV-Z^%
M2**'A_JDSS-Y<\T?-?>(J68U#D&LUXN\!XRQLWK"4C>&6GIDJ#_8B$9)().H
MACOK84(G-)-3E(JV6;.CERH@[24,1:+ 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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M B B B B B B B B B B B@GY/OW=W-']G':?X+/QM6QOKCC/GL7Q@M<W?\
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MYE:@@[*2P+* B B B B B B B B B B B B B B B B B B B B B B B B
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M&,DUTU<0SDV%"*D0PH53!O;C.,]>H+![+[/#7[*7'KZI:5\RM00=E)8%E 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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M?([\Y=6_]'(?;7O'^39?DW?G$^RC:_\ *NORC?P$_P"K5^.[_EOD=^<NK?\
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M&,,;4U-&B@J:"I^XNT1\"^Q 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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M'$E"RS-5J[0[_5;.$CIJ%*<IBX(N5 B B B B B B B B B B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
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MK["G]4W*E[6<ZZ<6B"GX^AVR%M9HN\U=BJY?T6</6W<LI"VANXP1)=BL0KQ
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M B B B B B B B B BC3S*^RER%^J6Z_,KH%@]DX:_92X]?5+2OF5J"#LI+
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M<A?JENOS*Z!8/9.&OV4N/7U2TKYE:@@[*2P+* B B B B B B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
MB B B B B B B B B B B B B B B B B B B B BC3S*^RER%^J6Z_,KH%@
M]DX:_92X]?5+2OF5J"#LI+ LH"("("("("("("("("("("("("("("("("("
M("("("("("("("("("("("("("("("("("("("("("("("("("("("("("("
M("("("("("("("("("("("("("("("("("("("("("("("("("("("("("("
M("("("("("("("("("("("("("("("("("("("("("("("("("("("("("("
M("("("("("("("("("("("("("("*-/,K[*7(7ZI;K\RN@6#V3AK]E+CU]4M
M*^96H(.RDL"R@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(
M@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(
M@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(
M@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(
M@(@(@(@(@(@(@(@(HT\ROLI<A?JENOS*Z!8/9.&OV4N/7U2TKYE:@@[*2P+*
M B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
M B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
M B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
M B B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
M B BC3S*^RER%^J6Z_,KH%@]DX:_92X]?5+2OF5J"#LI+ LH"("("("("("(
M"("("("("("("("("("("("("("("("("("("("("("("("("("("("("("(
M"("("("("("("("("("("("("("("("("("("("("("("("("("("("("("(
M"("("("("("("("("("("("("("("("("("("("("("("("("("("("("("(
M"("("("("("("("("("("("("("("("("("("("("("("("("("*-/,K[*7(
M7ZI;K\RN@6#V3AK]E+CU]4M*^96H(.RDL"R@(@(@(@(@(@(@(@(@(@(@(@(@
M(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@
M(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@
M(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@
M(@(@(@(@(@(@(@(@(@(@(@(@(HS<Q.6VG.#''+9'*+?4E+1^L]8L8IQ+I5V.
M3F;1-2-@GHNKURMU:%5>,"R]BL-AFFK1JAE9(N5%>XYR)E.<I%S/8G(/3.EM
M9,MO;\V/2>/E$<,8QT]F]X7"JZU8P;V58E?(U^9DK%--89"Q(X[DCM$G*QS+
M)F*GE3IUR1<>X\\N.+G+6$F;%QAY"Z;W[#UMXC'V1YJ78=7O.:V^=%5.S:6)
MM7Y)Z[@G#Y) ZB!'::.5TRY.GW$]H(O@[FYR\)^.-M0H/(7F%Q:T/>W4*SLC
M:E;FY!:EU?;7%=D7+YE'SR%<N]N@YA:%?/(MRBBZ*CE!55NJ4ILF3/C!%R_3
M?)_CER0KMDM7&O?&F>1T'4G7PVP2&A=JZ^VPRBIH['XBU@9&1I5DEXR+FGS3
M.#HMW2Z!CD-@WL)GN!%PSA?S&TWSPX_5?D?HM>Q%I5DEK;7'4#=(IO7KW3[5
M1K-*5.SU2[UIO(ROT>L49*11C&;&7/DS95%8N<IJDSDBE2"*-/,K[*7(7ZI;
MK\RN@6#V3AK]E+CU]4M*^96H(.RDL"R@(@(@(@(@(@(@(@(@(@(@(@(@(@(@
M(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@
M(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@
M(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@(@
M(@(@(@(@(@(@(@(@(@(@(LYOFGEU-P<ZO!EP26/[Y4]Q\T[1R=V/ D*55O,P
M'"^G1U_B(.P-T4G#MQ7YU>ROCG0.GEHOF/R=8R?H%4*17!\B.#7$SEM=]-W_
M ),Z,H^\YC07TY4U9%;+8*VND0#[8N*B6S2S[7<JNXHEHF,DI$?ADZE8YZM&
M9*H9H9 RRICD6='7&DM/:Y_BI8NO\#Z!5]3T/7WC\EI3GK6--5^/IVJB76WR
MMA+KV&L-<KK%G5XJ^2Z4C2YA1!NDW,]3;8=]IW!9%0Y%T3Y&Y7BIK'^(SQM_
MGMQT6WEQ69>,^M5Y4M@XISW*>C1FR'FT[4^KS]U5&5 OL='23*&B93LD#MR9
M:IY4+ZA<*9P8BT6>,C;'B\W/IZSWCQ:PW'"NZP?6A%'8T)H#3L#H=\PNK:/*
MDU)LO6[*ET&R1=@Q&$[6JTK'$,X;$SENHHCCN!%7MXGI8^C?*[YU.#2&5FM*
M:;YTSS=UI&$;90C4Y#E?K%A:=T+1I54V_8Q;V0\(V(5N4[8JZ*Y<9(8F?4(M
M& (HH<Q;%7U^+'()LA.PRSE35%T23;I2;)1=17,,Y+A,B1%\J&4R;V8QC'7J
M"P>R^SPU^REQZ^J6E?,K4$'926!90$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$
M0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$
M0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$
M0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$0$
M0$0$0$0$0$0$0$0$0$6;?RPY6U3YF?X?/D>^.9&HJ[BY5\9)A\NAA1BQM_(7
M4L)0];QQ5,J-T\/K,\L$DFG@RG<4S0IDTU<X,0$7:7GI\Q;;Q<:>UQ1-;+5=
M'E5REE):I:<L&Q&TK^2S3\!&+1,=<]Z[$680\QF5BZ K9&1FT.DBX<OW*WJ9
M;N$&RS=8BC!X5.6OANT VB>/&HN?-;Y3\\>7NQ'-VW[NF<I6W8^^\DM]6#XK
M.2"F).T45DQAJO#&=/$H6/7>)II)G464R=Z[<**D5GVXO-KXQ^.N[-L\=^0G
M)^#TCM[33B&):ZKLFF[%@<2+"P5>(ML/-TN9Q4G4'=XM['R^$BYC'+A?#E%0
MADL8],RA%5MX,H_](7R1>7?R7Z,H%BUIP5Y4V+2U3T*ZG:B_HC7?5MUS6SLM
MD;MKM9DV<3*%A9FV$D9;+UVS25</+6ND?/OK:021(NW/'9ZVUO/WYT-VQ/::
MEZTK/##C5'O2)]I)2U1.K47MW:G6(X=HKOJS9::Y05P0R64T'+?"B6%,FZ$6
MD0$5;;WQ3<1W[QV^<0]ZRX>N5W:^279Z4N5G*IUE<E+AMT*7)SYZ8_DP,U7'
M2%816:W!TZO0M4K4<VB*_78QG#PT6S2(BU8QS! C=JV023P4A$TDB8QC&,8P
M,+DON B B B B B B B B B B B B B B B B B B B B B B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
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M!$!$!$!$!%''D3S XL<1HVL2_)_D+J#0D?=7TC'4];:M]KM,/:'D.@V<S"4
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M2624+@Z:J2A,F(HFH0V,E-C.<9QGK@$7] 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
M1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
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MNR7!#$,8BT0 B B B B B B B B B B B B B B B B B B B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
MB B B B B B B B B B B B B B B B B B B B B B B B B B B B B B
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M .WW561Y&M=6'_Y3G^:+S#\V7_\ ,+\AOZ5/C;U;_P#P/^4SZ"?3#RL_V?\
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,(@(@(@(@(@(@(O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>t1701829_chrt-inflam01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 t1701829_chrt-inflam01.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!MP/H P$1  (1 0,1 ?_$ /8  0 " @(# 0$
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M<^-):3#N^TCCIH8HY9$5&JJI-*Z-CGL26U)'6)#'U_-$%Z=>C^7TC7-\2/\
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M*D<S:=9'1Q(JO5T^\:Z^U\4,,+Y%8]ZHC<Q3#7C#.T6K&5,JQO5][U/S!B5
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MN#W&:N!>*H<1DXILAK<!.V-BPP>.<EOH5+]=$42ID!Z=Q6<Y-E9AI9%RP"+
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M\[@B6*XT@,SE#NIDB]Q3EK6AZC40<#BD9[2VO!1#PTG0XQ.I3*NPL68;>PC
MB+N$5B:1YU@TISEC.6<RT=8[$L0K8(6)$UJJU\<L[45R/>Q58])T<U[+UJ)L
M:J.14R_Q)Z4U?$5I=E;/F1,4PMF!X-A574RNJ'R-1\4U/2R*C'11RHV6):1S
M)(Y+EUSE1SVJQ6KK85ON<<R\SI-/+)D_%6S&J\K6B+;)<S'/*!, PH2OQ=+V
M)5"I@M;BCKWY%35WLUFEB"&]@FF6%][>UKWT_P")6DJ\O9DR_J-AK+:BEE2-
MRV+9>@D2>!KE3L/MF147E1+-MITUX$,1PW.N1LYZ'8[(J4>(4ZS,:BI>W=5
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ML;+B6Z9!%<O+&DFZ;3JK&N=?5K('O?9<WT2*JE.*A:J5+3W$\X0EJE4:M.4
ML$H5U1QHCS#@V)L !0KFBN*W+:U@W^YPK:=D4<<20,3]$UJ-1.78B6(FWEV<
MYSTEJ)IZAU7(Y5J'O5ZN38MY5O*J66(FW;LLL[!^EK@O<C0GN*Y8O/ 78H)R
MU2<J-"4$0QA*"8>,P=B[#,%>P;7X<17O_+7R*"&G;<@8UC%6VQJ(B6\]B6;=
MA]J:NJK'I+5RR2R(EB*]RN6S:MEKE5;+55;/=4X=127% * 4!S;N+A=%9MNO
M6W;@C[0*"ZH^Z()G-<?:62\_86'SBO?CR\>-^-0MQ!O=_<9O[++UB7K.:WE)
ME:RK6G[S663O1%MN7G7+>6V[;=MMV\APJBDL* 4 H!0"@% <H:U:8E*0C5JA
MH2#!&DHQJ#1)231\W.:4GN.Y)9@N>_$5K6O?C?\ VU#2&))%F1K4F5+%=8EJ
MIS*O*J$=U34.@;2ND>M,U;48KENHJ\JHVVQ%VKM1.R<6HA .8J<%ZX*<"U<L
M5@2%]BE J4G* IBN ;=DG":,=B2^ +6Y0\+<+6_V5"C@AA5RQ,:U7+:MB(EJ
M\ZV<J^^3$U755+6-J)9)&L2QJ.<KD:FS8VU5L38FQ.9#B@&(L01@$( P"",
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0
M"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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MD8OA?*KJ3D>8IU><6R"1_ <1/6Y9.)=4X\B'/W%8H57=PJKGFKU AVN(XSF
MA%]H>F&^Z_JO:IXWT<S[E_',[A&C&2=H8EC6$SB6-L.R/,<$RW*627A@?("T
MNJ9@FCI-(ACX;44D6IE!;B99.D-L(D8@T!-WJF=0XS:?[,AE??36F>2K%DFR
M#!=:7.[MCF8/47F6,YT;MEA"#99@:641U>VOJ$YD>;N[(>,!I7?[>*][V$0H
MX" V(=87-R>]:M>7EY<%SN\.^#<2N;L[.:M0O<G-R7P%@5KG!P7*S#52U<M5
M&C,--,&(PPP5Q"O>][WH#.5 * 4 H!0"@% * 4!7)N_TU,?;V26"2::;);KX
M.40!C=6)"U:L['O^$F!])=UY#@<X2IH:VIS3/3PF&GL62IOR# 3?DOS6L'@!
MJ\]*#IP W3S=U6,>YAWYZH29ATPW[ROK3B <-W;R$RN"G'4+ELS9&<^8J%R-
MY+>I()&P$7.4D%HRACN*]B0VO:U@+.<++LBZ(_: HYJ0_P":LVY)UQW1Z=4#
MO@]#F/*TOR&<DS;J)'6V%R$8#9.O/0*IT_XLQFYR.2+42=.8Y+WJZHVW,(RU
M@("=?S?G9_"_4VUWE. IKD)GU\Z8$%P7LQNFR0N7R-DC<N9=C-EH5C0S'L^C
M3$>%%+0N4&0H;) +RCPIDSVK&1V9@A=H!;[]H6V,R)CGIPI(#K7-G2/9[W?S
MGK]JAK[*H3(G-ED7E!F"8H7A2X1=YC:DAZ(\:0F.+D8520?,79P!<-[B$ (@
M(X]3"290U\ZDOV:S L#S1EU+"'*?;"XZR.GMD*5)/GF;,?076AA95^7$R-V)
M29 <A 6+#QC= *[]NO4CMW3C+B K<^T!9+W^:.LIB=LTCSOEJ'2#7WIE-VZ+
M5A>-3B7H\<Y0=,.; 9X>,BL\CQVTNZ=@ERZ4XPC1B8U,>D4'.Y;>G;[]P8+@
M G?UJ-^S-A?LY"_>;5/)$VQB/+I.MTA:W['DU>HK,H8Z.69X>Q9!@"J3Q5:U
M.);E%9*D<&-S"48$HXY(9;[XN]N(&SAC%6J7XVQZN7*5"U<M@\35K%BLXQ2J
M5JE+"@.4*5*@X0SCU!YP[C&,=[B$*][WO>]Z [Q0"@% * 4 H!0"@-5/K=LD
M[S?U8NC'I\3L'LCA'#VP:7:U-DTC7/,TKP^_/0XM$HU(V-88O8#QH%2Y L:0
MEE&*TBJY1!QP"[ [40J M1U Z2.+]-<Q)\T1+;+J#Y@=D\;?(S:&;&[7R7+>
M-#DS\%,$YQ50Q>RMJ-4\(.];"2'C'?O<=[BL&XN%[ 6MT!KY]>#(V8\E>Q%T
MP=8,K2[#V>>H1L,0ED>2<=O+TRS7&.LN!4!>2,VSAL<XTZL[RUJB+EMEB@74
MIR79&G7HKBN$9G*!WKH";/Y%V=Z>!.)=A9#)%6U&G&0\G:5;*JW>0JED[*FV
M)'92S,KXXR TXQZ6OAT)6-Y![N<::H6/"!8<(T9MAWL!1CUU>F^#IRZB8VSA
MK]OSU0EDSEFT^',-NA60]V\A2-D#$9VBF2A[,2H6Q''E!3P QA([ ZYXP%VN
M+B6+C;@!?/#.EU"=!83LAG_&.WO4)R;,46KN;F%I:-@]L)5E.&,BDZ+"D*.5
MM$=4-+0!%,F1QC1%T#A8VXTMC#>2W,*P@@4#]-?IY2+:'HL0+J+RCJF]2O!F
MR!V.]E\BFY$3[DS/YFH@X81R[FB(,+C)8<_ /5'POR9Q\EN]D^."!G@$H$$X
ML ^SL!L=="/:[.NZ_2OU9V(V1[1;EZ5L\Y8I)*C&Q*RBR G@&2IA V2?&-2)
M*B0I%DG98X0>KNG)*3*%O;'D +)-+ $#6HSOO9M>V]029=9Z/9JR45TU-:^I
M# .F^^8F;);(2\4/F#4$)?('G+/ZZ(F/(HG)FTC)<D K:%X4-C;N*M)8)G.F
M[0@#?*).*4%%'D&EGD'E@.).)&$PHXHP-AEFE& N(!A9@!6N$5KWM>U^-J \
ME * 4 H!0"@% :J?6[9)WF_JQ=&/3XG8/9'".'M@TNUJ;)I&N>9I7A]^>AQ:
M)1J1L:PQ>P'C0*ER!8TA+*,5I%5RB#C@%V!VHA4!:CJ!TD<7Z:YB3YHB6V74
M'S [)XV^1FT,V-VODN6\:')GX*8)SBJAB]E;4:IX0=ZV$D/&._>X[W%8-Q<+
MV M;H#7SZ\&1LQY*]B+I@ZP96EV'L\]0C88A+(\DX[>7IEFN,=9<"H"\D9MG
M#8YQIU9WEK5$7+;+% NI3DNR-.O17%<(S.4#M70;V.R#MKTVUN#]BI3,+;1Z
MF3/+6C.S+J=*5@LEH9EC%:MCK1)!RH9ISX9*+0=Q0%">S3#E*E\;U:BYHS0C
MO8"D#K>]. '3TPCJ7D+ N_/5"6/V;-^\#ZTS$$_W;R%(6\K'62(EEA[D)[*G
M;4; 8BD@%D*1V3*3##BB@7,L(D=Q6N$"[]QZ:<4Z=^N>\^?<2;=]0/)4X#HY
MLFPLJ;83:V694C<1<$T%4S1KG,09CVQGLP9$87>'IPM[P49WTC3GJ0%7#VXK
MT!1OIQT^9-E?HE1#J8G=4[J4X1V9:\!9FSKY;*=Q9<MPJT/^*)!DI*@12:$O
MQ0U*J$O+1$B4SBG\; &;8X?$1A0A)C -F?HM[/9HW+Z7FG^R6PR?L\QY&Q^^
M6FCAXK3,HI4?#L@S& M$^&U(4R)N0F9&CT62/P@)""$=A.5[IRP$W+!8#5P>
M]\MJFWJ&-'6J%F_(Q?3#6=3%UZ:QN)PR]_MAD[7YOQZEQBFV9*B1CT<QBCRS
M(Z9RD=U]DH5%GA($FXB[#LG$!OI4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M@,HLIDNE#]'%64I@/GD;]&H^^NK@U0U.YV 6 2-K*2I0DIR"@EV+(*  "6E
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M'+4?IY8'S'U1=D8;&\EI,4P9TV RUDE/!L7MIF5IFU^43G"6V/1%CBD?4NS
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M3D@ V7"@&482$FP;E@64[;[[Z=:(1R/RK;G8/'^#FJ6+%2"*DRI:M4OTG4(
M$C<?)V*,"%XE+VG:PJ2N^CDJ(TE+VQ?:B!V@.8#%^M'5?Z=&XV0T.)M9=M<5
MY?R6Y1]QE**$1I4\E2(YB:"4ZAU77;GAG;#BO%Q*D CBA\IQ=KWY@6Y1< **
M^C!U<=8];.G0U/G4/W=;6#(,SVJV<;XE?,\^EN1,ENT6:LC&-Z$](U__ ,NF
MQ,):E=C4Y:PPDMJ3&V&78P(K"#0&U+C/)V.LT0&*Y3Q).(KDK&TX:2'V'SF$
MOC?)(M)&A0(8"US0]-1ZE"M)L<4,L?(.]RS0"+'8(PB#8#O5 * 4 H!0"@%
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M"]K5"*,NF&10%QE * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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MD3D?3_G&59Q#(HQ-[.J9)^JRHWP!$O0R=8X $N;D[2/'J89(DGWP['FA%_\
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MNVN4%UKEV,<O3W5WVO(:ZLQTMG>2I]G!A6IF>5JH!("TL?;6TE0D),3D]['
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M7_/2&4/JXRXSU)M[! 6$M.0 E*0004!)^@% * 4 H!0"@% * 4 H!0"@% *
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M5[]VHBJN[1>S:>41+Z^\36^;C'GY!PSS78_ :AWG<ZGJQ!\W&//R#AGFNQ^
MTO.YU%B#YN,>?D'#/-=C\!I>=SJ+$'S<8\_(.&>:['X#2\[G46(1OV[@T);=
M<LH+6Z'19 L(:FH1"M%'VE*J)$*2,H!"*4$) &EW$ 5[7O:]N-KWM6.=6ZBH
MI].L4FIWOCF;$RQS7*UR?IHTV*BHJ;"1Q+M:&16[%L3\:&OYWLF_Z<C_ (1?
M^[6@?C_'?#:O]=)W19N]E_I._"H[V3?].1_PB_\ =IX_QWPVK_72=T-[+_2=
M^%1WLF_Z<C_A%_[M/'^.^&U?ZZ3NAO9?Z3OPJ.]DW_3D?\(O_=IX_P =\-J_
MUTG=#>R_TG?A4=[)O^G(_P"$7_NT\?X[X;5_KI.Z&]E_I._"H[V3?].1_P (
MO_=IX_QWPVK_ %TG=#>R_P!)WX5'>R;_ *<C_A%_[M/'^.^&U?ZZ3NAO9?Z3
MOPJ;2?S<8\_(.&>:['X#74*\[G4R!8@^;C'GY!PSS78_ :7G<ZBQ!\W&//R#
MAGFNQ^ TO.YU%B#YN,>?D'#/-=C\!I>=SJ+$'S<8\_(.&>:['X#2\[G46(0I
MQU#(>=O#L0U'12-&M:+&^-#T;::Q-9B!(<>WMHCSDR,:6Z<@TZXKW$((;7%>
M_=J(JKNT7LVGE$2^OO$UOFXQY^0<,\UV/P&H=YW.IZL0?-QCS\@X9YKL?@-+
MSN=18@^;C'GY!PSS78_ :7G<ZBQ!\W&//R#AGFNQ^ TO.YU%B$;]NX-"6W7+
M*"UNAT60+"&IJ$0K11]I2JB1"DC* 0BE!"0!I=Q %>U[VO;C:][5CG5NHJ*?
M3K%)J=[XYFQ,L<URM<GZ:--BHJ*FPD<2[6AD5NQ;$_&AK^=[)O\ IR/^$7_N
MUH'X_P =\-J_UTG=%F[V7^D[\*CO9-_TY'_"+_W:>/\ '?#:O]=)W0WLO])W
MX5'>R;_IR/\ A%_[M/'^.^&U?ZZ3NAO9?Z3OPJ.]DW_3D?\ "+_W:>/\=\-J
M_P!=)W0WLO\ 2=^%1WLF_P"G(_X1?^[3Q_COAM7^ND[H;V7^D[\*CO9-_P!.
M1_PB_P#=IX_QWPVK_72=T-[+_2=^%1WLF_Z<C_A%_P"[3Q_COAM7^ND[H;V7
M^D[\*FTG\W&//R#AGFNQ^ UU"O.YU,@6(/FXQY^0<,\UV/P&EYW.HL0?-QCS
M\@X9YKL?@-+SN=18@^;C'GY!PSS78_ :7G<ZBQ!\W&//R#AGFNQ^ TO.YU%B
M$*M?H9#UFT6ZJ!7%(TJ0M;QA8+8B4L36>D;@JHK)S%(4*8U*(E(%086$0[%A
M#SW#:]^/"HCE6XW;SGEJ)>4FK\W&//R#AGFNQ^ U#O.YU/5B#YN,>?D'#/-=
MC\!I>=SJ+$'S<8\_(.&>:['X#2\[G46(/FXQY^0<,\UV/P&EYW.HL0@+U08?
M$F'1C.+LQQ>.LSHE^;3O5R:61L;G!-V^8,?IC^]UB-,2H)[9.<,L?**W, =P
MW[E[VK)6D,453J)AT-0ULD+M_:UR(YJV4TRI:BVHMBHB^^6+J5))!DFMEA<Y
MDJ;FQ6JJ*EL\2+8J;>38:A_C9U^$W#^NJ?Z2MW/$N#^"4WZIG<FJ/C7$_"9_
MUC_A'C9U^$W#^NJ?Z2GB7!_!*;]4SN1XUQ/PF?\ 6/\ A'C9U^$W#^NJ?Z2G
MB7!_!*;]4SN1XUQ/PF?]8_X1XV=?A-P_KJG^DIXEP?P2F_5,[D>-<3\)G_6/
M^$>-G7X3</ZZI_I*>)<'\$IOU3.Y'C7$_"9_UC_A'C9U^$W#^NJ?Z2GB7!_!
M*;]4SN1XUQ/PF?\ 6/\ A.P11T<C)3&BS'%<, W]G , U:@0!@$XI@B"((C+
MV$$5K\+VOW+VJ6K<&P=*.54I*:W=._W3/Z*_[)'I<4Q-:F-%J)[-XW_>/YT]
MTWROFXQY^0<,\UV/P&N<5YW.IO#8@^;C'GY!PSS78_ :7G<ZBQ!\W&//R#AG
MFNQ^ TO.YU%B#YN,>?D'#/-=C\!I>=SJ+$'S<8\_(.&>:['X#2\[G46(0JQ#
M#(>IW.V\;%$4C1[:W,^$1-[><Q-9J% )5 T1RH2)(-*).E$I-O<1EP!#SBOQ
MOQO41RK<;MYSRB)?4FK\W&//R#AGFNQ^ U#O.YU/5B#YN,>?D'#/-=C\!I>=
MSJ+$'S<8\_(.&>:['X#2\[G46(/FXQY^0<,\UV/P&EYW.HL0@+U08?$F'1C.
M+LQQ>.LSHE^;3O5R:61L;G!-V^8,?IC^]UB-,2H)[9.<,L?**W, =PW[E[VK
M)6D,453J)AT-0ULD+M_:UR(YJV4TRI:BVHMBHB^^6+J5))!DFMEA<YDJ;FQ6
MJJ*EL\2+8J;>38:A_C9U^$W#^NJ?Z2MW/$N#^"4WZIG<FJ/C7$_"9_UC_A'C
M9U^$W#^NJ?Z2GB7!_!*;]4SN1XUQ/PF?]8_X1XV=?A-P_KJG^DIXEP?P2F_5
M,[D>-<3\)G_6/^$>-G7X3</ZZI_I*>)<'\$IOU3.Y'C7$_"9_P!8_P"$>-G7
MX3</ZZI_I*>)<'\$IOU3.Y'C7$_"9_UC_A'C9U^$W#^NJ?Z2GB7!_!*;]4SN
M1XUQ/PF?]8_X3L$4='(R4QHLQQ7# -_9P# -6H$ 8!.*8(@B"(R]A!%:_"]K
M]R]JEJW!L'2CE5*2FMW3O]TS^BO^R1Z7%,36IC1:B>S>-_WC^=/=-\KYN,>?
MD'#/-=C\!KG%>=SJ;PV(/FXQY^0<,\UV/P&EYW.HL0?-QCS\@X9YKL?@-+SN
M=18@^;C'GY!PSS78_ :7G<ZBQ!\W&//R#AGFNQ^ TO.YU%B$*=:89#UV=MR4
MBV*1I8E;,D1,AM3*F)K4)V\DQH>1&$H23DHRTA0Q!M>X2[!M>]K<:B/5;K?>
M/+42U??)K?-QCS\@X9YKL?@-0[SN=3U8@^;C'GY!PSS78_ :7G<ZBQ!\W&//
MR#AGFNQ^ TO.YU%B#YN,>?D'#/-=C\!I>=SJ+$*J^M#&(U&.GYE-XC4>8X\[
MIY-B\LAT8VE TN)(#\A1\D\!2Y G3J2P'$CN =K"M80;WM?N7K'6JE1/3Y+J
M)8'O9*DD5BM547;(WLHJ*;L?Z>^%87C'%)@E!B]-!54+J/$5='-&R6-5;0SJ
MBJQZ.:JHJ(J6IL5+4-)KRJD_Y2/WQPX>$5JAXXQ?PJI_6O[H_1/ZN-//(."]
M2INB'E5)_P I'[XX</"*>.,7\*J?UK^Z'JXT\\@X+U*FZ(>54G_*1^^.'#PB
MGCC%_"JG]:_NAZN-//(."]2INB'E5)_RD?OCAP\(IXXQ?PJI_6O[H>KC3SR#
M@O4J;HAY52?\I'[XX</"*>.,7\*J?UK^Z'JXT\\@X+U*FZ(>54G_ "D?OCAP
M\(IXXQ?PJI_6O[H>KC3SR#@O4J;HC)F%Y'(568L3)E+\\J$RC)<$(4)SW1<:
M0>0;*6HLTDXHP\19I1I8KA$$5KV%:_"]3^%8OBKL4IFNJJA6K41VIO'_ --/
M]HL_4+3S($.0<<FAP/!V2LP>L5KDHJ9%14II%145([45%VHJ;44^C;\W&//R
M#AGFNQ^ UO+>=SJ?DPL0?-QCS\@X9YKL?@-+SN=18@^;C'GY!PSS78_ :7G<
MZBQ!\W&//R#AGFNQ^ TO.YU%B#YN,>?D'#/-=C\!I>=SJ+$(B:I(D;=G3=!"
MWI$R!$FR3$"DR-$04E2IR[,[W>Q9"<@ "B@6O?[@;6M423XK?>/+>5??)W5"
M/8H!0"@% * 4 H!0"@% * 4 H!0"@(-Q#^('EO\ 4#$_QZS5%7^J3WSPGQU]
MXG)4(]B@% * J Z_'\&WJ$_J =_QZPT!\8:@% * 4 H!0"@/O<8F_NKQI^K^
M&_HXVT!D"@% * 4!X I4P%!BH"<@"HX(0'*0DEA4&@!:U@ ,.L&QA@06MW+7
MO>UJ \] * 4 H",NX_[M.5?P2T_I,R5C36+]VN*_-1_MHB0Q3Z!)[R?C0UVJ
MYYEDB@% * 4 H!0&U_75<R** 4 H!0'@"E3 4&*@)R *C@A <I"26%0: %K6
M  PZP;&&!!:W<M>][6H#ST H!0"@(R[C_NTY5_!+3^DS)6--8OW:XK\U'^VB
M)#%/H$GO)^-#7:KGF62* 4 H!0"@% ;7]=5S(HH!0"@% > M*F)-/4$IR"CU
M5R[J3BR2P&J+E6N$JYY@0V&=<L(KV#S7OPM?N4!YZ 4 H!0%>G56_<(SQ_A?
M^V;'=9/T:_>3AO\ B/JLY8.I_P#D:N_L?K$1INUO6:BB@% * 4 H#L,1_M7&
M/SA9?QDFJ6K?H4WS3_S5)BD^E1?.-_&A] RN9QO@* 4 H!0'@ E3%GG*2TY!
M:E38NRA0 DL)Y]B@\A5CC0AL8;8L%N >:]^%NY:@//0"@% * KTZJW[A&>/\
M+_VS8[K)^C7[R<-_Q'U6<L'4_P#R-7?V/UB(TW:WK-110"@% * 4!V&(_P!J
MXQ^<++^,DU2U;]"F^:?^:I,4GTJ+YQOXT/H&5S.-\!0"@% * \!25,08>:0G
M()-4BL-2:42668H&&U[!&>, ;"-$&U[\+BO>]J \] * 4 H"I3K>_P .O+/Y
MTXI_:-'*QMJU_D>I^<A_:M-YO].7_P K\#_N6)?4)S1@K4,_26* 4 H!0"@,
MH80_OIQ#^M" ?I6TU4,)_P":TO\ >(_ST+-U'_=[CW_1JWZM*?2ZK?4_( *
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MFJAA/_-:7^\1_GH6;J/^[W'O^C5OU:4^EU6^I^0 4 H!0"@% * 4 H!0"@%
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M^\1_GH6;J/\ N]Q[_HU;]6E/I=5OJ?D % * 4 H!0"@% * 4 H!0"@% * 4
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M 4!E#"']].(?UH0#]*VFJAA/_-:7^\1_GH6;J/\ N]Q[_HU;]6E/I=5OJ?D
M% * 4 H!0"@% * 4 H!0"@% * 4!K6Y_6BF_VIS0V$/ T=VS!?3(S7FZ'%N#
M@4 1<NRM/,K8>D1C"@-37$)X,BS$78ZY1G.8B"9>]@@(%8P#-W5%Z=N[&R&[
MW3XW8TMG>K47F.DC;G2XV3: K++A&9"\95:H]'VX(6+%#<G='1M2M!+@(Z]W
MIJ-)4V3W#8\%S A XNG_ %+]R6;J%*NEUU.,+8'A.P,QP^LSOKWFS4YWG:W
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MM<5^:C_;1$ABGT"3WD_&AKM5SS+)% * 4 H!0"@-K^NJYD44 H!0"@% * 4
MH!0%>G56_<(SQ_A?^V;'=9/T:_>3AO\ B/JLY8.I_P#D:N_L?K$1INUO6:BB
M@% * 4 H#L,1_M7&/SA9?QDFJ6K?H4WS3_S5)BD^E1?.-_&A] RN9QO@* 4
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MM<5^:C_;1$ABGT"3WD_&AKM5SS+)% * 4 H!0"@-K^NJYD44 H!0"@% * 4
MH!0%>G56_<(SQ_A?^V;'=9/T:_>3AO\ B/JLY8.I_P#D:N_L?K$1INUO6:BB
M@% * 4 H#L,1_M7&/SA9?QDFJ6K?H4WS3_S5)BD^E1?.-_&A] RN9QO@* 4
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M!0$9=Q_W:<J_@EI_29DK&FL7[M<5^:C_ &T1(8I] D]Y/QH:[5<\RR10"@%
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M% * 4!&7<?\ =IRK^"6G])F2L::Q?NUQ7YJ/]M$2&*?0)/>3\:&NU7/,LD4
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M0PA_?3B']:$ _2MIJH83_P UI?[Q'^>A9NH_[O<>_P"C5OU:4^EU6^I^0 4
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MQ'^U<8_.%E_&2:I:M^A3?-/_ #5)BD^E1?.-_&A] RN9QO@* 4 H!0"@% *
M4 H"O3JK?N$9X_PO_;-CNLGZ-?O)PW_$?59RP=3_ /(U=_8_6(C3=K>LU%%
M* 4 H!0'88C_ &KC'YPLOXR35+5OT*;YI_YJDQ2?2HOG&_C0^@97,XWP% *
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M85A7.K._PFSVT8YR6MRC'(8N> +&55=8LR*.)N,G0HTB?OJ_>)*12;8RQ82
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M)]YN29T"U^VZK6O2/_9M:KE=[]CD]RP5TF2US!$_#8L4;E6UF\9++ ZK5/\
M>7)&PMA15_F7HEL_G6E9G4$1;:)]+L^#S9)-=7:'>*\<A*2XLA.2H_)K/5\V
M8QNA-,7RV?R9K$U@(L=8TNR:QHAW!<(PVL*PLD:'-QI-3L.7$'TKH+*C^K9(
MUUO>LUFUSW)9RV[+2T=<9=-GZ;5J93@QR/%-Y3VK5STLD5S?QWD1L--$^_;=
ML6]8B6VHMJ6:L K*>:_((BP>/<L(!EQ</_&]AVMQK;?%H-7W8E,[ JK+3,(5
M_P"B;/2UKYD;_P#4='5L8YUMNUK&I[AKQEZJX<V8+3-S70YVDS$D:;]U)789
M'3+):MJPLFP^65K+++$?(];;=I^S.U[G97+M]WF[0(A?_1PY1!JOYHCSO)'#
MYERX5%*BNWO?L51*BI8ES=[B:%6JBWKUY7(J6666+;:61)M+HI:GUFT^/U$"
MM9WOXKJ*2G<UUKMYOEJZ:I1R*ERXC$8J*CKRK:E@/:\E^>Y=S.[RW"$5@?<^
M]XVN*XK]W[O=IA<>=VX!.S&I<*?FA4DW+X(JAE*BW/T.]CDF?,Y$DVR7)6JY
MFQMUVT8[-I<_-M))EFGQ^/(B.A[YCJJBDDKW-21>^-Q-%31T[%=%8D*R0/1D
MEKI$>WM3\@LHYOYP1-P\+_\ D".PN/\ )W1#%;A5+R]#JBS$D=FNHP"3"+CK
M6TE/5QS7OYMCIJF5EVWXR7+5["H5W.-1H3)@KFZ?T>;8<Q;QECL0K,/FIMW;
MVZ*RFH8);ZI9<5)$1%Y44_@K*>:_((BP?Y+" 9<7_P!=[#M;[M2^,PZN.Q.5
MV7JG+C,&M3=-J*:M?,B74MWCXJN-BK>O676-2[8B[;56<RU4\/#,#IV9QHLY
MRYE1J[]U'6X9%3*Z\Z[NHY\/FE:ERZBH^1RJZ\J*B*B)^Q]KPMV5R[7_ /M<
MX17M_P#58(@WMW:KF8X\[OI($RC+A45<B_IEK(JB6-4N_P"[2&:)S5O?TG.2
M[LY=I:V2YM+HL0JEU$I\?GPI6_\ #IAU1202M=>7^N=4TU0QZ7+$L8UBWK5M
MLV'NXO9=>0L-DXTMEUWMKLC&<6<)(%1=<G[W$I+ : X9(3N%QV"((KA[EKVO
MW:EZ"/.K,MUC<RRX7)CRLEW+J:*>.G1NZ3=[QDLTDCG))>5ZMD:BLNHU$<BJ
ML;'9M,),W4#\ET^/19018.^65M122UCG;YV^W$L%-#"QJPW$B22)ZME1[GJY
MBHU-W_&Z'<4B6H#,O2?6AS@EB%UG-'C>"928Y:8INC.LVB0.,GR+(6<D@M?<
ML1]C$HQ#)L((+A%>PK<X:1N.I.BUSZ1:;;:D;)$=R;+%<]R<O+LY#?''9M+W
MX:]N6:?'X\8M;<=55%))"B7DO7FQ4T;U6[;=L>ECK%6U-AX<AH=S3I@\&8GE
M.L3= !>+_$"+(<"RJ]3 G@UH@NOCASC>2&!E4]H]64C3]BD*Y$HBP#YC B&+
MY5-QY9W+1/HTIMEU'LD5W(EMJMD:G+;98B;+.R>\$FTK;A<3<R4^8),:[;>.
MIJBCC@7MW7+C):621+([J.O/6U]Y4L141.]Y'3; '12/%XB>L.MLX >DO+%>
M1XS-7R**4UFTT*X,>;HQ+8\[HCQN_((FZE4H"%-8016$.]AVF:I,36%J4+H$
MJ-EY7M>K>3;=1KFJFWDM5=A1\"DR6S$9W9FBQ23"%1VY;2RP1S(MY+N]=+#(
MQR7+4==8VUUBI8FP8X3; $Q20EY=>L.N4X&>KO$U>.(S-6.*)DUVTH*$,A;I
M/+9"[K3P._.(ZZ94G")-<(0V".UQW4J8FD+DKG0+4;;JL:]&\FR\CG.5=O+8
MJ;!CLF2WXC [+,6*1X0B-WS:J6"295O+>W3HH8V-2Y8C;S'6.M5;4V'1,>(=
MS29@SF98E.L3C  ^,/'Z+'D"RJRS [BUK0M7B=SDF2']E3=F]73#4=LD-YTH
M3  Y3!!&&6I6X\D[5K7T:TVV\C&2([D6RQ72.3ELMM1=EO9*QC<VE;L+E;EN
MGS!'C7:[MU344<D"=NV_?9%2QR+;'>1MUZ6/NJMJ(J+YLD(=Q3Y:O,Q#)]:&
MR"7(0V;$>2()E)\EI:FR,FSD)>XQC(L>9SB#%]C!$6+2@$ FX0CN(5KBO]JV
MXZLZK0OI$IMEB2,D5W)MM5KVIR\FSD/&!3:7LPUC<S4^/R8Q:Z^ZEJ*2.%4O
M+=NMEII'HMVR]:];76JEB;#NL\3; '0.-E8P>L.M^3@'L]Y>X3R,S5X@:E,%
MF6!?PQMHCTM8Y A/.D%TXT=U2Y0$I&$P!EC#!!,#,5*8FM,Q*-T"5>R\KVO5
MG(MZZC7(Y.VLLM5=EMMJ[2E8-)DMN,3NS!%BC\OJC]RVGE@94(M]N[WKY(9(
MW(D=Y'W(VVONJVZU%:K%J;8!.ROX<UO6'7:1#/#>+GXMC,UC[*G3=Z#L(+^E
MELMDRY8?==RWM=.<0'LN-N'-]]2C3$TC=XP= Z7^;NVO:G)V4<YRKMYE38,Q
M29+?50KE.+%(Z%$_2I5RP2/5;?\ =K##$UJ7?Z37;=O)L,>P1!NL5+68S)TK
MU;<(($\^\A1P3'^66B6GIKI%%DP69RD&2WMG2GA7W*$.YZ4X-R;##:UA7L*T
MK3-Q])VK5OHUIOYR,9(CN3L*Z14Y;.5%V%;QB;2AV&RMR_39A9C%B;MU14T;
MX46\EM]L=+&]4NVV77M[:Q>2U%]IDU%MX?*33,-2;6]KA-T2.Q"3)L'R<_2F
MSC8 O& S7"*Y"C;2)$,SAV(+);&!MQYA"O7NK;CBS6T#Z1M/8FR1DCG6]G:U
M[4LYMA+Y?ETR9AR-S33X[)BU]UJTE121PW?YMC9J:5]ZSXRW[%["(14ZHA<_
M#T[Y^%X6P\V0E$8?MDL]M;'HAE7J;3^%%NHH,E5.RA<TD&3.Z4U/9><M$!K"
M:4.XCQ .#D;31F9G9PPYN79*!F8/TMCJF.5]/]&FWEK(I8Y-J6W/TFQ;+UJ6
MVXZS=+IXS#L2DS9!C4F2[4W;*2>FCK43OF+<7Y9J>6!51MF]NPI>6VY=38:A
M)?:]WM;EW^YR]F$0?_IX\PA5N_E>/.\<<WGI+A4LJJW==Y15$2(EBW]YOYIE
M<JK=NW5:B);;;:EFI^>YM+I9:;U94^/T\"-?WQXTJ*2H<YUK=WN5I*:F1J(E
M^^CT>JJK;JI8MOX#93S6YQ$7#Q[M@@,L+A_X7N.]N-4#"8-7VXE"[':K+3\(
M1_Z5L%+6LF5O_P!-TE6]C76V;7,<GN%VYAJN'-^"U+<J4.=H\Q+&NX=5UV&2
M4R26I8LS(</BE<RRVU&2,6VS:?T=E'-_-")L'A_]L([BX_R]T(PVX5/9CBU-
M?B"+E&HP*+"MVEJ5E/5RR[RU;RHZ&IB9<LNV)=O(MMJK:EE+R74:'18.K=1*
M3-<^/[YUCL.J\/@I]U8VXBLJ:*HDWB.OWG;RZJ*VQJ*BJOZOVO);EN7VG<XW
MN$5P?^/"UA6%_P#YJHUT>=UR[$S#)<*;FRQF\?+%4.I%7_>7(V3-F1%7XEZ5
MRI_.O%&PJ;2YN<IY<;I\??I\KI=S'!44C,11MOZ'>S24SZ9RHG]:K*=J.7XB
M-!?;=WM;EW^YR]F$0?\ ;QX\PA<?Y*\96CSW'O\ SUFPF6VYN>\8:B*SX^\W
MN_GFO6_H[ER[98^];:ED3/DVE,O>OJQILPT]F][Y\:5-'47OZO<[CO2EIKEG
MZ7>[R_>MCN7;KKWXM93S6YA$<G'NVL RPN'_ (7N.]N/#_PJAT$&KZ8I$[%*
MK+3L%WR;QL5+6MG6*W:C'OJW1I)=Y%<Q6V[;MFPNG%JKAS=@4[,"H<[,S,M.
MJ0OGKL,?2I/=[59(X\/9*Z*_M5K9&O5NQ'HNT][';+[R6/V;QHP*;O339,)8
M4<:0%5W^1V(CP$'$F#(L9R\U@B"*]N/"]JF<XQ:COD<[*,^"183WJM]*R"JE
MF62U]Y6.AJ(F(RY<1J*Q7(Y'*JJBHB4W3^?16*BNZBTF:)\?[[_1NPVKH(*=
M(+L=Q'LJJ.HD65)-ZKG-D1BL6-$:CD<KM[5U3; "Q2B3LCUATK.-B&^SB[NL
M9FJC%(U-EP+NHD4=22U-+RB#&SF"GL-T&(!_ 0[B!][7/=Z8GWDB1N@\8;+5
M5K]WR[;&HY'<G)VW*;CT\F2TS&]]7%BBY1M==8R6!*RR[VEZ5T*PJJ/VNLB2
MUNQ+%VG"Q$EV23*7R^>GW"#PD&0@M&@XBBD\C:DA38Q5XS$^#F4SE92L@PJY
M/863A($ 5A\]Q6N&P?-"W%45WC)U.YNR[NFO;[]MY[K>Q9981<S29$>R'S-A
MQ>*1%=O>_9J>5%39<W>X@A5%1;UZ\KK=EEEBV]$;6_=\,S0&O$LU5-QY:3I3
M'1$VX]RX1,S(99U+$M2H'15DY0QDR<;'S *4&(S$@5? 8B1%\07EF-S#WPBO
M?1]ZWTM1&27[ENU$7>67K.1;++>Q9L*Q/-I(N%/;2TV8TQOO=;CG5-$L"3W.
MU5S$I$D6+>6*K4>CU9L1R.VG;LM)-HU#TVBP5(,!M$="UV"[D9:AV0Y&]&O7
M?:B]S6U5#YS%D)#7WC<JW9FDF&]K8=^?EN$-H]:W&%D3Q<ZF;%9MWC7N6VWL
M77M2RRSL6VE-RW+IZRED3.$&,RUV\[1:.>FB8C+$V.2>GF<K[UNU'(EEB66V
MJONE";8"^(@IDKUAT.>NP36$\*(S-1XB[YM("AK!!C9<M+F=B!1;G+*MXUY@
MN%PF"O<FURKQ%3$^\;$=!XRY[K]U\;;VMZ]\7_:^-MY-A*,DR7YS7Y(L4\S;
M5[1)8._;-VMW]*L.XMWUBK^A_J[6I8[MCU>)$FS2=Q=Q9W?\$O#2)$19A*Q)
M$<@1MQ)<;'WNI&[GS&;2I,I1"3=P "2RC+&=VXKV[E>*)N+H]WC%U,YEFS=M
M>U;?=O/=L]ZPF,RR9 ?!$F3H<8BJ;Z[Q:R:FE:K;-EQ(((51UO*KE5+.1+3I
M?B_=_P L^U\K-5?F\\I^T[R^;W+GEGY&>->;O7QI\YWB/RG\1_>=\=Y]Z=]_
M?]CV?WE2]W,/?%M^C[UO\ER2_<MY]Y9>L[-EEO8L*KOM)?%5WO;,?COO?XW?
M-'N-_<Y;G>F\W6\VW;]^YLO7MIW3+:39I0XM L$/^"6=I"B/L_%9;B.0)(XG
M.-S[73#:#X=-HJF3(@INX,!Q9IES.[85K=RIBM;BZO;XN=3-99MWC7N6WW+K
MV[/?M*5EJ3(#()4SC#C$M3?3=K1S4T34;9MOI/!,JNMY%:J)9RI:>T3IM@+8
MB$F5/6'19Z[!38+PGC,U!B+OF\@-&C$*-F2TR9W(#%N0LVWC7F$X6$8&]B;V
M*M[1,3[QL5T'C+GNOW7QMG:WKWQ?]KXVWDV$N^3)?G-?CBQ3S-M3M%E@[]LW
M:7OTJ0[BW?6JGZ'^KL:MKNV/5XD2;-)W%W%G=_P2\-(D1%F$K$D1R!&W$EQL
M?>ZD;N?,9M*DRE$)-W  )+*,L9W;BO;N5XHFXNCW>,74SF6;-VU[5M]V\]VS
MWK"8S+)D!\$29.AQB*IOKO%K)J:5JMLV7$@@A5'6\JN54LY$M*E.LDDV:+T]
MS6HG#_@E7A04XB%VAJBD1R W92+:S,C-?D86Y2!WFSI$SUZ6]TWC093866HY
M3>P"3S Y<<:HIB:94JUK'0+AV\98C&O23^L2Y:YSE;L6R_8W:EMEFPW<X GY
M-?Q$Y>CRS%B<><N\ZK>/JI8)*);**3OJY%%#'.EYF\2GO3+<<K%DWB(Y%TYT
M(FBUC/&93B8+B'L>\3TQ-K6X7Y^TLH3GW%>]^'#APK5RG6B1%[[255[%Q6I[
M]MJ*?H!QYF;WOB\UY<-CCL=O.^HIY%5=EVYNIHK$Y;UZVW999M/P*[9W]:X"
MUUFWF!Q+$:GNNY.S#VEK&V)LGYKF\>'WG"P>'\O=KRJTO?%K4D[UM39:E_DV
M[;+.7DV<A'B9F?Q$K)Y*!<S776/;'*E+>O+<_1K*LMB,L1R;RU76JBHEB)Y5
MPF:Y8/%I3F6;S_SEURA(:7<OEOW !3IB16'S<.[>][<*]U"T*M3O5)4?;MOJ
MU4L]RQJ;24P*/.K*AZYFEPN2DN=HE+%/&]'VIM<LLTC5;=MV(B+;9MLV'G+%
M'N]PV-(>KJ^R^_$6J0V3W/Y?NA )&(VQ7/\ R7%QX?RU[:N&;I+[9]]9ML<R
M[;[UVVS^6TDJB+49<2<ZDGP1,(WO:M?!5+-NK>17-J$8LEWLHQ&V[;MFPXJ"
M[5;M?&9;@9_Y.P[P.3$\/_/VO:]\$'\W'[WEX<.'=X\>Y4*G6C2WOM)5Y++B
MM3GMMM1?<LL]TJ>/LS:_=>:\F'1_&WO?4<TEOQ;F[W,L5EG;WKUZVUMEEBV_
MDR[9WZ&Y):ZS=S%\X##DXEMP<+=KRFA("185[\>7B"]K?R\:^.6EWZ*Q).]K
M4M152]9V=MEGO;"+3,S.F".;624"YCNONN9'*E->M7=WHW2K*J(EE]$D156V
MZJ&5\.B9+YDP_P"+2G0L_P"=3'_/=<H2&E7*\J6SFL$)"8D=C.?EX7O?APX]
MRJI0+0+B5+WJDR2=\Q_'5JI9?3F:BVVV?_)C_-4>>&9(S N99L*DH/$-==2E
MAJ(Y-YWN^Q566>1JLNWK41J.O751;$5%^@#*T&ZQDR=#8/*]6TF/A.@!,R*5
MX_RRXS(IEXE=H4Z.;1DMK9%#I>W/P,*2%%=T/WG<OQW1F;CZSJM.^C2EMV(Y
MDBNL]U4D1+?>2P_+=ATVE#<+C;B]-F%V-[OMW0U-&V!7[=K&/I7R(SDV*]5Y
M=ID++J;8!2F8[8%>L.LZL!Z^\E%EV,S62)CTURTOBP+&"&RV*&I#RS;'=O=0
M(X(PW!R6#>PKBFJY,35&^+70-=MO;UKW>]9=<VSLVVVE$RS)DMDDWGE%BDL2
MHW==Y2P1*B[;^\W\,R.14NW;MVS;;;:EGFBR?/!>,WDB;/&(U>8Q(I#:/.D6
MC<R;\9D.(TAMHH-Y8G:5.<I5(DR_D$X (<23#B;"L2(H5["M]A3$DI')4.@6
MNL==5K7)';9VMJ*Y766_&L<EJ<EAXQ%^3G8_$_"8L3;E>_'O632P.JE;>3?7
M)&0LA1RMMW:NB<C76*Y')L/=8R)RL1%BB\RN./72;=^K+GJ\9,LC88M=NN,/
MB\!3?*GZ2.P5H"^/;#NIN6*_#E"&U>Z1*U(;*]8G5%J[8T<UMG8V.5RV\^TE
M<P.RX_$5=E9E;'A-QMB5;XI)KW\ZUT,<3+MOQ4N6IV54R%4T404 H!0"@% *
M 4 H!0"@% * 4 H!0"@% 0;B'\0/+?Z@8G^/6:HJ_P!4GOGA/CK[Q.2H1[%
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M_"_]LV.ZR?HU^\G#?\1]5G+!U/\ \C5W]C]8B--VMZS444 H!0"@% =AB/\
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MGN1J^WS'(DKDL^F;KCZ*SPF20SQS.96J<7J1%M I.N:D7?"@9J5N;4Y%@%D
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M9-T _P#:MP]>1LY]4PW_ .[C_P!O'NGZS]7O/3*__HI3U)9K\(P_]9-T _\
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M,4GTJ+YQOXT/H&5S.-\!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0&M']J,*,0:A
M:0SY42A/B^)>JQJ!D6=%NEEUVV\20-&76!59P"@+$:-"8ZR-( ZUQ%?S8K\H
MNTY B V7* U@=%/_ )G[KB_]O^D?[ <!T!=SG' F@>TV46"![(XAU*V)S%CB
M*J7J.0'-4*Q'EB?PR%SA9<!SVWPN;M[\]LT=DR^&C"!79(!.H-;C+ '<11G
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M1K*"_635&,X]SIER#+@&(7>++I@N7E-&-PR=L'<"TYF(.+N PQ,80I2&&E&
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M[L^I@&!(MJ45(BI_]&/N3,-4(JPH!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M,!Q [A0&(\IY_P #X,*:C\VYLQ'ATA],.*8SLIY(AN/BGDU,&PU!349+7EH
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M:>NMM4B1)T<8A.8\(:'XN1-11*5B8&K6&$+8CD9E:TR<DM*0C,>H^RJ2R2;
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M[DJR4T%PV(9YSFW(CQ%32;B  8R7*)&(%EKWM]U3>P;W#8-[@7Z4 H!0"@%
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MGSH_N>2T[6_D*PA6$2"-Q>0-K4N =Q-"J0CL+N\;4!<E0"@% * 4 H!0"@%
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M85=#T[DDB2S..%<;9951=*\F(SG=-'5$]C3^<R)W4YN3C4@37*">(@NX["N
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M O3 $ "Y2@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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MLQKB'! -2E?V4"@@*E.,9=S2!7M85N/&U[U$<BI$B+RVGE%17K9S%AE0CV*
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M3YPD4_QAKP)N9K8V<,^.I84$<SC,%)I!KL_23'#385H\E%<)+6O%=84*PQG
M- G?0"@% * 4 H!0"@% * KFW,T8<ME-E.G9L_#YBRQ"=Z+9ZF4W. ^M2AQ)
MEV(\MX_4P7+4+:CT? ]KD3L6@:3DAYE[I;=ZCL:'FN6( %C- * 4 H!0"@*R
M-LM!Y%N1N%I]DK+4]CZK474%T5YS9]?$[2Z#>\F;;H52IOQQ.YX[C6 938'B
M9A/NL:4)15SSW90H"J[5(;V=@+-Z 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
M H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"
M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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M153V&?\ <#635HIJ%G_-$*QHJ?"[GLS.\+CUDE=483A)C'%!%F5,YR16UDJ
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MD>H+&)Q:#QC6W2*.XW4GS@IO?Q2QP>7R"NLSR$>\KQ/:IG4((F-@5I2T:-M
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MHY7M6W9<X^P#)"H/UD=$GZ'M3%$5XL"[+/6:5S(WHVJSECMG@4G*B*J2 ;R
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M4TC*&@<QD+*=9'L1:MU_OE8VOOM[>ZY6PHI"?3QMPZR=1Z,H>F7.IH^:C.T
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MQ:>)9)K6"(@F<N=VA$CACHOEJ(2TAM8E87(UV&H2@"*UKJ4B<"JQ1IA%QDA
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M$Y"&][I'*]ZJY[EM55VJJKRJJ]E5/)7T\B@/$H3D*R#DJHDI2F4E&)U"=06
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MEQ/J+^X'GYQB>@F ?>T72CYV>I)[I^(OIB:_E>GFUH+Z2XGU%_<#S\XQ/03
M/O:+I1\[/4D]T_$7TQ-?RO3S:T%])<3ZB_N!Y^<8GH)@'WM%TI^;9ZZAW"W-
MH9'[BX6XWML;C(-KWX=V]K7<Q7M:]_Y.-Z+DS0ZW9G.>S_I=7W 35+BTLVZ7
M4EO_ /L&'=(?WY^NH9[AC!_F.QE\HT\S-#_3.?[KJ^Y'K2XL_P"%M+_W!AW2
M#Y^NH9[AC!_F.QE\HT\S-#_3.?[KJ^Y'K2XL_P"%M+_W!AW2#Y^NH9[AC!_F
M.QE\HT\S-#_3.?[KJ^Y'K2XL_P"%M+_W!AW2#Y^NH9[AC!_F.QE\HT\S-#_3
M.?[KJ^Y'K2XL_P"%M+_W!AW2#Y^NH9[AC!_F.QE\HT\S-#_3.?[KJ^Y'K2XL
M_P"%M+_W!AW2#Y^NH9[AC!_F.QE\HT\S-#_3.?[KJ^Y'K2XL_P"%M+_W!AW2
M#Y^NH9[AC!_F.QE\HT\S-#_3.?[KJ^Y'K2XL_P"%M+_W!AW2#Y^NH9[AC!_F
M.QE\HT\S-#_3.?[KJ^Y'K2XL_P"%M+_W!AW2#Y^NH9[AC!_F.QE\HT\S-#_3
M.?[KJ^Y'K2XL_P"%M+_W!AW2#Y^NH9[AC!_F.QE\HT\S-#_3.?[KJ^Y'K2XL
M_P"%M+_W!AW2#Y^NH9[AC!_F.QE\HT\S-#_3.?[KJ^Y'K2XL_P"%M+_W!AW2
M#Y^NH9[AC!_F.QE\HT\S-#_3.?[KJ^Y'K2XL_P"%M+_W!AW2#Y^NH9[AC!_F
M.QE\HT\S-#_3.?[KJ^Y'K2XL_P"%M+_W!AW2#Y^NH9[AC!_F.QE\HT\S-#_3
M.?[KJ^Y'K2XL_P"%M+_W!AW2#Y^NH9[AC!_F.QE\HT\S-#_3.?[KJ^Y'K2XL
M_P"%M+_W!AW2'\MLUO(W\4KKT]5JQ8"_,(]IV(@=T5P#M80 @$G87@H0PAO]
M]P/OW>Y>UK]RGJ^T@G_24V>&,B7L/PRHO?\ S(Q?>[7\(36?B9I?T-=I-))4
M)V8L?HKEB\EEV"5+>>QZ^\A_?:GW3_TZW_\ S$0GT,IZN=)_3J#[LGZ<>O#B
M-_A%5??U']D'M3[I_P"G6_\ ^8B$^AE/5SI/Z=0?=D_3CUX<1O\ "*J^_J/[
M(/:GW3_TZW__ #$0GT,IZN=)_3J#[LGZ<>O#B-_A%5??U']D'M3[I_Z=;_\
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>t1701829_chrt-inflam01a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 t1701829_chrt-inflam01a.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@!M0/H P$1  (1 0,1 ?_$ 0(  0 " P # 0$!
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M@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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MJ=":FEI)KO2LB>Y],^1\*I-$V5F5TL4+UP:]$=C&W!<<,4VKIFMK(Z% * 4
MH!0%B69=)XYC#3C$^S:*<O;J^9"%";KXNJ:D!#2WAES&ZNXPI%A)XE@Q(!(
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MGQ<)V5L#)9G>Y)*7Y"D+7+&EC9TP2P&ITIPRR##5KXM1([7&*P2^T]/@*X;
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MJ*BIBBI]94VH>>513STE0^EJ6N94Q/<Q[53!6N:JHYJIU%145%3KGK5R'"*
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MRS$'I9K]M.";25BO=(K7EG12418MW$2,Y&B=$\8,*=&1,X=7?H']<JO8%A#
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MK+JP)3 FQRY_IIX(_P#K\@_L3)ZB7CK_  GO/_)C_2(BR/1$_P#(W2_LJ?\
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MPA$B<N8;I*W.*1*X-[@[8B1+T"U.4J1+42K-YY"I(K2G@,(4I5)!@@&%C"(
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M58XWR*]$8U[G3OT%MEI[CR3<Q/"N,HJU(XG%LU,":6S)FCY"5F2$>;1LN73
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M*LW3]I;\D7_:GVA+T_!.QSPPK;TVX8(Y*I(97)RXNQV9D5/YV,FZ+<G0C/\
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MJ5-13,J'8-9''&Z)&MSL8Q6^<@/R^]@\7XBW!RV]3V3ML?B&1TDV9667+#1
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M:F")'>MY(D% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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MKY,[T:K8.5+Y684 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M;0Y:Q<P/"\=PB I>GI>L&*PB6L%@ =V6IOT6-:/X?\-?)U'* D!0"@% * 4
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M#8$3Q3E9B<93"MG<6-J?@20D"YNLP:7(A,F#9.W,Y#22 /2-.'8#]+&@% *
M4 H!0"@% * Y!.:%D?6C%'WD[EQS;;F2XEB6#6[0[,2>2OF;AQPO':9Q<7#/
MB&-ENPI66:RV5*7T\@M)U@;B[2('0]EPH"]+739#EF;+ RI@G178O6T4[E&-
M7UREA>H4HQBTY1C<8#8J'%Y);P11O573+H4\S9-9 XJD:I.@<5A'2 +K>@,#
M%,!\O$.GL^'L%,>9IS,<Z16 Q67KY% ]K=CX#/<)79A1]=9SD<GCS+A6%+S#
MHLB"-<E/"X%!3G$V,$$8;7#<"ACE4:Y\QW>9RW YNFOF_L=TL;N83L+*S(Q#
MI7I3"-EGUZP)K\^R#&6$E-Y7.LM1!7&"61$%R:!MJ5%U)UVP"H1H[&E%)P-O
M<LV*9NY87.[V:T=V5S@SYW3\S/$=MV<;Y98\4M^$(]+M@86^2_W6F5IQ5'Y/
M,([%)(\Q@#XYNXDZX=E2=C0'B 7<^P+ ;@Y[W_B.?=T_X_W[]*8,H"7_ -Y"
M_P#!*WW_ '?X^^6_%] 5>;DZ#1*%\F'4GF'Z.8L@>#M[](]:-8MK(UE7$D.9
MX'*,A1*,XLA[SGB(905P] V*<C1=_@BYU=UR-S[2->>B$G$8$A<M"<!DW.#V
MQ)YGVE/+!TLU<E08O).=7/L9/3VM+3WDSABW7?&Z)ER?G)Q>VEO=6,Q>XXUE
MA*$M8C$J2E.A;"ZI FAX#,+ ]?F><H7FHYIT(RC"YIS3H+G>.X*B)>:L884B
MO+JQE@Q\<IC@AB7/\(9()E"&9N>)! 'X:-":WH%*5*=;_..I&&Q1@[V OJY7
M.X:#?;0#5K:LA4E4/F3L6L_NA$I ]62W98B1BB%98;"B+@*&0E1Y#CSE9-80
M ]8DN48&UP##>X$^: 4 H!0"@% * XV<KY>TVPM]Z7V6E.\$QP/",4+^5S"F
M"/.VPQD1*A:C(:K)^#G%I;VP4T).:[R@V-M3L838NW:.R%*>C?H=.@+_ '$F
M4- MV<0YQP+H9M+C6. 5,J3SZENA<YQK&,G8O52\)S>T39F7Q]B?FI@DRTJ-
M&)TS@K;%5KA37!>U^B&U@-;0;6:/\KB&[ ;B96Y@W,3V>Q]C# &0Y!*H/MUG
MN#Y/@;.T10IOGBR1Q)A8,1P!:3D@PB)":FTVZLX)I3F>G"G,-/+$ "E3D[Z)
M<V&>ZM.>[N/^9C"]3))S'\H3O=#(V,'70K'^PCF0XY-?5H8BXE9,F^98V\GQ
MM[@B!O=&ML B(2M:=RN47TQW,-&!NKD0M.1>7QO5S%>3OG#(K;D9S1.4;WRP
M!.FJ%%8S8)[#\NHF)FS*IBN/4SW(VJ",K'+E3*G)9$2\].0L*<C";=788Z S
M7>O_ -3]R.OX?]W/D!SY0#[WE_X-LT_B P3^G'2@/B<[35F$<O.*8(YNVAN%
MX7A+*.E.9(&?L7&\$Q5BQDS9WU%G3^DBN2X'/8M"T#*R2XPAU<&SLZM:5<QL
M0GJU%C0B3)C" ,9YS<Q>>:#L-RK>63JEEQEBK7G\D',BR)ET^%)\EQ^)X/QG
M$G)ZU]DC]CY7(HVAG,2R'+3G '=2M4G3J'!*W7,'U=Q]$#2?.9Y>W->8M3"]
MRL@<S:&[42GETSZ*;FXS@#)H7C[7F0)73%KHD4RM^392A&8Y,]H6F,PLU:]+
M6X2(Y*Y6:2P#ZL8"CBP.K76#/T.VIUSP?LEC\X)L.SCBV%9.8R[&7--0)Y<P
MHG@YF67$64,#DQ*U)B)4 0 #+4D# (-A!O:P&]J 4 H!0"@% * 4 H!0"@%
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M"XW,T\;DZ$!A2*1L),C;7(MG?D99PPE+$]BU!81WL$=K7O0&PJ 4 H!0"@%
M* 4 H#2>4]:M<\YN#4[9MP#A/,3HQ(SFYD<LIXK@N07!F;U)UE*A"U+):PNZ
MAO1GJ+=8,HD0 "'[*]KW\- >MB[5S6;![ZME&%M=<%8@DKDTFL+C(L78CQ_
M'UP8E"Q$X'LJUVB<?:5ZII.7MJ8\:8PP1(CDY8[AZ0 WL!N5V:6I_:G-B?6Q
MO>F1Z;UK2\LSLB3.+4[-3BF,1N#8YMZPLY(O;UZ0X91Q)H!EFECN$5KAO>U
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MQ A8M<2(KCV)L,+C9+@Y'74N*XICC:!M:RUB]1>YAYMBK#-'?I"O>_AH#.*
M4 H!0"@% * T%DO5'5O-$B!,,Q:V8"RQ+2FU,S%RC)>',=SN1%M"(U2>C:@/
M<ICCJY@;4AZPX91%C>J+&:.X0VN(7$#[6*M==?<$&O9^#\%8;PV?)BV\F2'8
MJQC"<>&R II$L&UE/9D19&<;J6VC<%%TX3[F6)N>9<'#IBX@;!EL0B<^C3S#
M)W%X[-8?(T)K9(8I+61MD<:?FT_AUS>\L3PF6-;HA.Z-ND4>4,L7#PVH#Z#,
MS-$=:&J/Q]J;6)@8FU"S,C(S(4K8T,S0V)2D3:U-3:B*(1-S:W(B $D$$@ 4
M24 ( !L&UK4!C*C&6-EF04&6E>/8.JRJU1LV&M>35$383\@ML0/6*7 ^*H)F
M:@%(T<;.7K#CQH2U(4HCC1CN#I"%>X!UQEC9]G$6R<]X]@[SDF#(W9NA.0G6
M)L+C.(>WOZ4Y"^H8M+%: Y^CZ-Z1*3"592102!248(!EA!%>UP&0L98VRY&S
M8;E?'L'R=$#UB)Q/BN0HFPS2-G.#:=92W+C6.2(')K,6(%%K&$&W*N,H=ND&
M]K^&@/M2B+1B<1UZA\TCC#+XE)6U4S2.+RAH;Y!'7]H7%"(7-3TR.R=6V.K:
ML('<!I!Y1A1@+WL(-[4!A\9PGAJ%O[1*X=B3&,3E$?@+9BIADD9@4587]DQ<
MRGE*6;&[0\-;4E<6V M*DD!B9G), W$# $0"0WM:] 9\[-+4_M3FQ/K8WO3(
M]-ZUI>69V1)G%J=FIQ3&(W!L<V]86<D7MZ](<,HXDT RS2QW"*UPWO:@/CPN
M$0O&\79X1CN(1>!0N/)QI&"(0M@:8M%V-*:H.5F)F=@8TB%I;$YBI08:(!)0
M W,,$*]N(KWN!E% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H##4N1<?+ITZ8O13N&K,EL;
M"CE+UCM+)V11.F>,.*FR-OD;I$BEPW]O85RN]BB5AJ<"<TSV(1W%X* S*@%
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MCE4;?6%S5,LCB<N8[*5@6J1,+LC,*. 6>H3'@Z"A,>>E.)/, E;0"@% * 4
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MK"XUD*!2E !04D?XC+FA(^L#J40L)3+4O;&Q<6,1)Y11Y(KW 8  PB#8#8%
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MRA=D$F22WP:T(VK?.8."_4O"Y\W)6\25TP;8[BE'/"##@" E,<AB+$ ^XPE
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M7D+]&DS?&6DM"H;S74R-IU%VN&MB8:LA$4L,(2! ,T0;CL(#QQ7174F$[79
MWCBV#HFS[6Y2BY,-G>92#GPY_?8Z0WQ-I"C[L5.Q\9;%!K;!VL@U4C0IU9Y:
M:]C#16-.ZP"6= * 4 H!0"@% * 4 H!0"@(\?-/UY^<_\\[W,6?YSGN3^X=[
MK7;W[OGW*^_?.7S2[K[V\VNS]]?ENT]A[;P_)]=U?L* ; ZGZ\[4>Y/\X#&+
M/DKW#<L1G..*>]E[\@\S\J0[M'FW+4?<3LU=N4-O:S."97VA$;Q_*DCX6X >
M]-M8<#9'SMA+9F;8X:7_ #KKDAR$VX4R(I6O1#K D.5HZ.)Y 3MR-&YIF5<&
M1QTP24RZU,I$2 8KDW+$(0K@<M<)@>1=3]M.8I)^8ER;\]\R^8;([3RS(^ ]
MI\-8-P9M@R*-;$[0U1["V%UD?R5,6);A1KQJPHQIQI[%6-.,/$48!20B2JSP
M)B\G'ET3:),7-%D>Q&K;+JCJUS&YTWI\<<O,N0-9Z'%V&[X_F4!GQ\C9L=N8
MHM 'K-[%,""U[2TJ2#VTIL+(L!* E,46!>Y&]<\*1#7Q!JI'( UM>OK7BLS"
M:'&92MW.:"<6G1LV('1&Z]2XGOIR,Z.'C3#.&K$K$$5Q7-N9?I4!]K">%<7:
MYXH@N#L*1!# <4XS84\9@T.;5+DM0Q]C2F&FDH$ZMY6N3JI"$T\8KC4'FFB$
M*]Q"O>@-I4 H!0"@% * 4 H!0"@% 1"W!T)U#WZB<3@^WN$8[FR+P61*)7$6
MU^=)2RC8GY6VGM"M<C<(B_1USN%4WJ+EFDC.&09<(!"!<98!! T7JSR=.6II
M1E=-G'5W52(XDRLC87F,I9BTRK)3TN(8Y"604\H"TDKFK^U!"N*3@"(?4=;8
M-KV"*UKWX@8%F3D1\I?/F4Y)F?)FF4'6S^:.@GR;K(G,LLXQCDY>C5HG-4[S
MF 8PR!#L?S-T7N8QJE2AS:U1JI288<<(9A@Q" L^Q_CV"8HA48QMC"&Q?'F/
M84SHX_$(1"F)LC,4C#&@+ZI$TL3 SID;8UMZ8'@ 424 %N-[\.-[T!H#7/1K
M4S4B99QR#KCA")XGF.R4L3S?-KY'#7HP^=R5(Y2=W2+EB=U=7%$TITCG,W0X
MI(WE)$98UIG1*MQMP \>MFBNI&G\JS9-M:L'1/$LJV+EA,WS0]1XY\4*IS)$
MSC)7=&K66>79T);$:%RF+H:G1( )4) EIG5DAM>UK 2SH!0"@% * 4 H!0"@
M% * H'4?=>.16J4'J3=&"0F*#C3S I]D=NT:<(SAB,&$A(DSZ0E2DV$+V)90
M %@#P"$-K6M:@+C=<]=<.:F84@&NVOT/\P,.8N:U;+!8?YP2F5=QMJYW<7U4
MF\X)L]R24N?6NKLH-Z:Q<H,#UG1L*P A#8#T=G-8\&;DX,G>MFR<$)R7A3)9
M+"1-H2>_2F, >01B4L<U8!!?X4^1N4M9S7*8VA6%F(UR<SK$X;7%<%Q!$!5I
MC?[MMR2<52]JG$6T,A+@]LIP3T2;(63L]Y=BHS0&%F@NXP3+&5YK!GD(1E6]
MBL;CP\.-N' 5[7 LCV=TOUFW(A^-(!L?B]+D2'X>RU"LY8W8RY--88FC&4,=
MMSZTPV2$&8_DD55+B65MDJXFS<K,4-9P#^!R8SH@Z($H: B1N'H?J'O[CU!B
M[;_!4/S;#V=P-=8^4_#>F61Q9R4@)*6K8?.8@ZQV<Q!0Y$)BRU8FQR275E%A
M =TP!L&P$,]9N0SRM=4,J,.<,:ZUER++L1,2FPN>9CR+DS-KG"#4!@E#:IA[
M;D^72:.1UT:5HQJ$:],B+<$AX[C)/!?AP N#H!0"@% * 4 H!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M[%C^_(3XV?JNA]D/^\.::K8%<Q0"@% * 4!87RJ?I[X'_P"*'R,Y$J,>,O\
M#:Y?Y?\ 2H#?N&'PYH?^M^CRG9%5$RW0H!0"@% * 4 H!0"@.5'[Q[_375+]
MELL_I:!U77CI_B[;_P N;[<9[9?[2GP>UO[-MGY*M.:.H$/7\4 H!0"@% 7=
M\@/Z=+M^X;(']HH)4M<&/A>[V')]]&><W^Z%_P"-D'_R:B_(5IVGU:L_GG%
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M6U4 H"#>2OIX:W?NSRA^CG2N5/Q2_9/A?/I]@G)7$?8H!0"@(@<PGZ N\/\
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M#\+MMT]XFOF&D6;TJ5&8(*-NEN2\(N\GF:H!)@3#3'"0K)42):*YE@!/0VL
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MCOZ81UE;#^O*+V7#^4:<L/XYG]9/MG4I7J$2 * 4 H!0"@% * 4 H"F[G?\
MT4,??Q#13Y-\LU.W1[^&=5_I<GY>F(BXT?!>G]GL_(SG+'5Q"L@H!0"@% *
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M0"@% 97 OZ<PS]K([^F$=96P_KRB]EP_E&G+#^.9_63[9U*5ZA$@"@% * 4
MH!0"@% * INYW_T4,??Q#13Y-\LU.W1[^&=5_I<GY>F(BXT?!>G]GL_(SG+'
M5Q"L@H!0"@% * F1R^/II:Z?O#1?F*^M%XF_ &Z>Q5^VAM^@OAC;_9"?:4[9
M:\_RY(H!0"@% * 4 H!0"@**^>E_=1@G]X4D_LV75BNCM^N;C[%C^_(3XV?J
MNA]D/^\.::K8%<Q0"@% * 4!87RJ?I[X'_XH?(SD2HQXR_PVN7^7_2H#?N&'
MPYH?^M^CRG9%5$RW0H!0"@% * 4 H!0"@.5'[Q[_ $UU2_9;+/Z6@=5UXZ?X
MNV_\N;[<9[9?[2GP>UO[-MGY*M.:.H$/7\4 H!0"@% 7=\@/Z=+M^X;(']HH
M)4M<&/A>[V')]]&><W^Z%_XV0?\ R:B_(5IVGU:L_GG% * 4 H!0"@% * 4
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M!LM\C$UH#\,:@% * 4 H!0"@/W.>7M] 71[^$#6GY&(50$OZ 4 H!0"@% *
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ME"7'>:6'&+W:11%0U3YJ>10',>(G"4IGKI-ZWNP]02E6]ZED ["H.,,+7!(
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M"@% * 4 H!0"@% 45\]+^ZC!/[PI)_9LNK%=';]<W'V+']^0GQL_5=#[(?\
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MYSO1O@0AR"9S@-ESYC90G G>+7.>5-TP7$L!15BPA>PNG0+M:UBS>MM8-N-
M?[I^1>WWIOFV'LH@]V?,NU=#-0I5 +E>>)L-U^M&[NB;K>G=RM$DP^IOT> $
MU_#>W66Z0&8\L(_S/Y[7W@_%S,L1K(HY/FB65;@2!ZLE!+I9@UW>I0$DHI4H
M)LL5.,K,)7C%?IF*$(1=$J_2+L!TE4!H;,LGV CRE@!A3&46R E5$. I =(I
M4FC8VQ048DLW%I0'JDUU8518SKCO;CT+@M_RU]-1B^>7 _%S=0A@RR#-,@W=
MP.=FF 1Z .B> Y)*94<>D9$C)<$ F9T&H4J#R%"FR8TI1[&P;WM>]O#7*J-2
M-<JXH?&W.F):17 <@H!0"@(@<PGZ N\/\(&RWR,36@/PQJ 4 H!0"@% * _<
MYY>WT!='OX0-:?D8A5 2_H!0"@% * 4 H!0"@(][7?1TRW^R:C\Z25'_ !5_
MAW=O8B_?-.E<?\%)_5.<2O.@T<4 H!0"@% * ZOZ]5R110"@% * 4 H!0"@%
M 1/WA^B[D_\ W*^4.)5%/&[^&%S_ ,M^EP&.NWZOD_X?OD.?"O/XTL4 H!0"
M@% 97 OZ<PS]K([^F$=96P_KRB]EP_E&G+#^.9_63[9U*5ZA$@"@% * 4 H!
M0"@% * INYW_ -%#'W\0T4^3?+-3MT>_AG5?Z7)^7IB(N-'P7I_9[/R,YRQU
M<0K(* 4 H!0"@)D<OCZ:6NG[PT7YBOK1>)OP!NGL5?MH;?H+X8V_V0GVE.V6
MO/\ +DB@% * 4 H!0"@% * HKYZ7]U&"?WA23^S9=6*Z.WZYN/L6/[\A/C9^
MJZ'V0_[PYIJM@5S% * 4 H!0%A?*I^GO@?\ XH?(SD2HQXR_PVN7^7_2H#?N
M&'PYH?\ K?H\IV151,MT* 4 H!0"@% * 4 H#E1^\>_TUU2_9;+/Z6@=5UXZ
M?XNV_P#+F^W&>V7^TI\'M;^S;9^2K3FCJ!#U_% * 4 H!0%W?(#^G2[?N&R!
M_:*"5+7!CX7N]AR??1GG-_NA?^-D'_R:B_(5IVGU:L_GG% * 4 H!0"@% *
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M"@% * B?O#]%W)_^Y7RAQ*HIXW?PPN?^6_2X#'7;]7R?\/WR'/A7G\:6* 4
MH!0"@,K@7].89^UD=_3".LK8?UY1>RX?RC3EA_',_K)]LZE*]0B0!0"@% *
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MV]E_#5$.7'\4_)CCAY[8N.&&SK8KUS.:8U5[V=__ -MM5PW^3_&T^_W>3/\
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M!K]X[!'88.3#:U50\.0]9?="F#Q+_G![.P?O?N__ &7QYE?S:A[7V!K1-?\
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M$_>'Z+N3_P#<KY0XE44\;OX87/\ RWZ7 8Z[?J^3_A^^0Y\*\_C2Q0"@% *
M4!E<"_IS#/VLCOZ81UE;#^O*+V7#^4:<L/XYG]9/MG4I7J$2 * 4 H!0"@%
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M*X%_3F&?M9'?TPCK*V']>47LN'\HTY8?QS/ZR?;.I2O4(D 4 H!0"@% * 4
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M0L/:5QI\(8X:IKW[RJI((NQ=(Q,N?,N.*-5$7#I[JP!XVB@% * 4 H!0"@%
M* 4 H!0"@,%R7B_&F:(._8RS%CN"Y8QM*B4B>48^R7$F"=P>2)T#BC=T)#]$
MY0WNK"\$HG9O3JB@J$Y@2U!!9@;6& (K 9P  "P!++"$  !"   !L$  !M8(
M0A"&UK!"&UN%K6\%K4!_5 * ^:\LS1(FAUC\@:FU]8'UM7,SVR/*%*YM#RT.
M:4U$Y-3JVK2CT3BVN*(\9)Y!P!E'%#$ 8;AO>U ?'@\%A&,8A',?8VAT5Q[
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M (J_P[NWL1?OFG2N/^"D_JG.)7G0:.* 4 H!0"@% =7]>JY(HH!0"@% * 4
MH!0"@(G[P_1=R?\ [E?*'$JBGC=_#"Y_Y;]+@,==OU?)_P /WR'/A7G\:6*
M4 H!0"@,K@7].89^UD=_3".LK8?UY1>RX?RC3EA_',_K)]LZE*]0B0!0"@%
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MI5$K@W3 8^];1\RWF=;Y;F:S\O+:/'.ANL7+_DS/A_(VQ3EKY#ME\GYCV*5
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MNM_="GNZ<U0E1&K0*!7L8TW)5@2B^]128IOY+^P&/B$W;Y-G+)FM&*8.VEJ
ME*W25BV!QYD1.WH"1%BLM6*6K'JNP2ND5P#TC.EP!T1 = 4-8S8Q$(K&SSRU
M1\>C;&QG*20B 4H-:6Q*@,/* /V82SAI[B#:_AM:_AH#)* 4 H!0"@% * 4
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MRL3\2Y<VD1YE8GK/V5L\FE((T^ILAN$JE^<LJ$M3B\MYB\14L,:VM$@L>:Y
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M.1+I9+Y=*51%T3,SV>''\JV06#M@S$C R)K%M[0F.-"06&YIEQ 2JH!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% 0;R5]/#6[]V>4/T<Z5RI^*7[)\+
MY]/L$Y*XC[% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4!'O:[Z.F6_V3
M4?G22H_XJ_P[NWL1?OFG2N/^"D_JG.)7G0:.* 4 H!0"@% =7]>JY(HH!0"@
M% * 4 H!0"@(G[P_1=R?_N5\H<2J*>-W\,+G_EOTN QUV_5\G_#]\ASX5Y_&
MEB@% * 4 H#*X%_3F&?M9'?TPCK*V']>47LN'\HTY8?QS/ZR?;.I2O4(D 4
MH!0"@% * 4 H!0%-W._^BAC[^(:*?)OEFIVZ/?PSJO\ 2Y/R],1%QH^"]/[/
M9^1G.6.KB%9!0"@% * 4!,CE\?32UT_>&B_,5]:+Q-^ -T]BK]M#;]!?#&W^
MR$^TIVRUY_ER10"@% * 4 H!0"@% 42Z\X7R!AO[P-S#)XL@\H%C'<G3#5[+
MS)DPN-ORB#AF&!%23 +W #YI<-HVW30#6!*Y=S=(2P]O- K#8( F7&!N_<7D
MTZR[S3W($WSIEO<P;;DMK8F23XIA&U>3(9A UH8&%I826U)B5L67AQ"-Q"T!
M6+2[IQA5N)QR@?$9EZ WEH_RY\)Z!HI2V8;GVR4P:Y,RQ".)V?.VP61,QL4-
M8(04YIV-GQ]'Y8YGL<+0V3N75&A1)B[C)3)R[7L64$- 9-A#0/73 >S>R>XL
M19Y0][%;5*&@K*&1IU+'*6.22,1_J[,./X.G77"CA<#:BTB0L"!&6'K2V]&$
MX9MDB?JP,LW1TWP?OSKM-=7-BVJ0/6)9^LBB^0M\8D[I$G@U5"Y8RS-C$0\-
M)I9X"RGMA($86,)A9@+7]C85@B"!JW:'EF:>;>Z\8PUFS!CA=?'N#!0Q3@IV
MALKD<,R'AAUQZQD1N'O>/)^RN!,B:7)G94Q9/ XU0G4]46-04:,HL0 (\85Y
M)>I.+\O8[SODW(.VNY^4L-K@.F%)%O#LSD'8Q)AUU)$G-2NV/8O(CT$1:79O
M5)@J$BHY I/1*K!/3C*.+*& "/[YB/(W,+YSD2R7/,?S:):7\I%"Z$8K53B+
M/L=9]CMW<G-*:[Y-H>G?4C9YQP+7^-D(0HG8DHPFTD(":B4*$JHWH = % *
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MNA8RQO1]GT+7#?Z5Z9<K4PQ/Q&KCBJDT*XS[% * 4 H!0"@% * 4 H!0"@%
M* 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H
M!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
MH!0"@% <[//*CJG7_-O*ZYKR%&L%'-$]HSH#L4YMY=^E&M7MM&Q%B+(N074=
MA!N:WP14<G( 5X+"$^CZ8@%],80)%<R+DT0+F39QU]V#D>U^T.")9K:TG!Q0
MCPC)(:DCL>E*I],?[Y-9T4IB4DNT9",O9*1WHD,*-ZAN1]'HC3@'0'TM:N51
MEO7[-\"S!(^;'S*]A&6%+'96NPYFS+L5D6+9N%RCSNQDHY<RI86C4+D;<H=
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MQXAO0&T* 4 H!0"@,%R9D['N&(#*LIY8F<=QYCB#M)S[,)M+7-,RQJ-,J80
MJ'1Y=5@RTJ!"2(P/2,,%8(>/AO0&6-CFW/3:WO+0N2N;2[(4CFUN2$\M2B<&
MY>G+5(ER-24(12A*K3&A,+&&]PC *U[7X7H#WJ 4 H!0"@% * 4 H!0"@% *
M 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!
M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M-P(,:3BEY2!91G!#VAKN^.Z^]AAN*UCKF O?I!%:P'1M0"@% * 4 H!0"@%
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M * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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MX"/6>:-^_?\ %KE[T IY/?%_Q1[:HO"1Y:G1F^,ON==? 1ZSS1OW[_BUR]Z
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MU1>$CRU.C-\9?<ZZ^ CUGFC?OW_%KE[T IY/?%_Q1[:HO"1Y:G1F^,ON==?
M1ZSS1OW[_BUR]Z 4\GOB_P"*/;5%X2/+4Z,WQE]SKKX"/6>:-^_?\6N7O0"G
MD]\7_%'MJB\)'EJ=&;XR^YUU\!'K/-&_?O\ BUR]Z 4\GOB_XH]M47A(\M3H
MS?&7W.NO@(]9YHW[]_Q:Y>] *>3WQ?\ %'MJB\)'EJ=&;XR^YUU\!'K/-&_?
MO^+7+WH!3R>^+_BCVU1>$CRU.C-\9?<ZZ^ CUGFC?OW_ !:Y>] *>3WQ?\4>
MVJ+PD>6IT9OC+[G77P$>L\T;]^_XM<O>@%/)[XO^*/;5%X2/+4Z,WQE]SKKX
M"/6>:-^_?\6N7O0"GD]\7_%'MJB\)'EJ=&;XR^YUU\!'K/-&_?O^+7+WH!3R
M>^+_ (H]M47A(\M3HS?&7W.NO@(]9YHW[]_Q:Y>] *>3WQ?\4>VJ+PD>6IT9
MOC+[G77P$>L\T;]^_P"+7+WH!3R>^+_BCVU1>$CRU.C-\9?<ZZ^ CUGFC?OW
M_%KE[T IY/?%_P 4>VJ+PD>6IT9OC+[G77P$>L\T;]^_XM<O>@%/)[XO^*/;
M5%X2/+4Z,WQE]SKKX"/6>:-^_?\ %KE[T IY/?%_Q1[:HO"1Y:G1F^,ON==?
M 1ZSS1OW[_BUR]Z 4\GOB_XH]M47A(\M3HS?&7W.NO@(]9YHW[]_Q:Y>] *>
M3WQ?\4>VJ+PD>6IT9OC+[G77P$>L\T;]^_XM<O>@%/)[XO\ BCVU1>$CRU.C
M-\9?<ZZ^ CUGFC?OW_%KE[T IY/?%_Q1[:HO"1Y:G1F^,ON==? 1ZSS1OW[_
M (M<O>@%/)[XO^*/;5%X2/+4Z,WQE]SKKX"/6>:-^_?\6N7O0"GD]\7_ !1[
M:HO"1Y:G1F^,ON==? 1ZSS1OW[_BUR]Z 4\GOB_XH]M47A(\M3HS?&7W.NO@
M(]9YHW[]_P 6N7O0"GD]\7_%'MJB\)'EJ=&;XR^YUU\!'K/-&_?O^+7+WH!3
MR>^+_BCVU1>$CRU.C-\9?<ZZ^ CUGFC?OW_%KE[T IY/?%_Q1[:HO"1Y:G1F
M^,ON==? 1ZSS1OW[_BUR]Z 4\GOB_P"*/;5%X2/+4Z,WQE]SKKX"/6>:-^_?
M\6N7O0"GD]\7_%'MJB\)'EJ=&;XR^YUU\!'K/-&_?O\ BUR]Z 4\GOB_XH]M
M47A(\M3HS?&7W.NO@(]9YHW[]_Q:Y>] *>3WQ?\ %'MJB\)'EJ=&;XR^YUU\
M!'K/-&_?O^+7+WH!3R>^+_BCVU1>$CRU.C-\9?<ZZ^ CUGFC?OW_ !:Y>] *
M>3WQ?\4>VJ+PD>6IT9OC+[G77P$>L\T;]^_XM<O>@%/)[XO^*/;5%X2/+4Z,
MWQE]SKKX"/6>:-^_?\6N7O0"GD]\7_%'MJB\)'EJ=&;XR^YUU\!'K/-&_?O^
M+7+WH!3R>^+_ (H]M47A(\M3HS?&7W.NO@(]9YHW[]_Q:Y>] *>3WQ?\4>VJ
M+PD>6IT9OC+[G77P$>L\T;]^_P"+7+WH!3R>^+_BCVU1>$CRU.C-\9?<ZZ^
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M#EF>B.>YD+FO=R.DW>#55[T5SH[XGV:W^G',TQG@G+Z?'V'<;#U_FF?)E@"
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M;7;J;,YFP+J5EQIUJP7K$[)X-F#/@8(QY'G4YR^>G..=,>P1BE/08VMIB)I
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MMLC69,C7IT/U)90@4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
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MNPQ]+CMVG.UJU+G<JB6LN+&JUCGHC6QHO+D8W8BJFQ5Y53K'>UQQS=?=*2:
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M!4^RBF1BEBGC2:!S7Q.3%'-5%14^LJ;%/-7R<@H!0"@% * 4 H!0"@% * 4
MH!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@
M% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0%5FVWJQO=A6_.H_O:[
M@8NV?2"_^1]0;W+_ '<_[-?]3TO\7\M__$\/"K'<,_*#]ZS/W<_!G?29?U;^
M,Q3>?XK\+RX<O8_<E'./7D6_O!D_?C\/.U8<_P"O?Q.5=S^K_P"[\F/)V?W6
MTC+]AQ^'SO:D#Y7WU<RD,?1G?5[ZA]AQ^'SO:?*^^KF4?1G?5[ZA]AQ^'SO:
M?*^^KF4?1G?5[ZA]AQ^'SO:?*^^KF4?1G?5[ZA]AQ^'SO:?*^^KF4?1G?5[Z
MA]AQ^'SO:?*^^KF4?1G?5[ZA]AQ^'SO:?*^^KF4?1G?5[ZA]AQ^'SO:?*^^K
MF4?1G?5[ZA]AQ^'SO:?*^^KF4?1G?5[ZA]AQ^'SO:?*^^KF4?1G?5[ZA]AQ^
M'SO:?*^^KF4?1G?5[ZA]AQ^'SO:?*^^KF4?1G?5[ZA]AQ^'SO:?*^^KF4?1G
M?5[ZA]AQ^'SO:?*^^KF4?1G?5[ZA]AQ^'SO:?*^^KF4?1G?5[ZA]AQ^'SO:?
M*^^KF4?1G?5[ZA]AQ^'SO:?*^^KF4?1G?5[ZA]AQ^'SO:?*^^KF4?1G?5[ZA
M]AQ^'SO:?*^^KF4?1G?5[ZA]AQ^'SO:?*^^KF4?1G?5[ZA]AQ^'SO:?*^^KF
M4?1G?5[ZA]AQ^'SO:?*^^KF4?1G?5[ZA]AQ^'SO:?*^^KF4?1G?5[ZA]AQ^'
MSO:?*^^KF4?1G?5[ZA]AQ^'SO:?*^^KF4?1G?5[ZA]AQ^'SO:?*^^KF4?1G?
M5[ZA]AQ^'SO:?*^^KF4?1G?5[ZA]AQ^'SO:?*^^KF4?1G?5[ZA]AQ^'SO:?*
M^^KF4?1G?5[ZA]AQ^'SO:?*^^KF4?1G?5[ZA]AQ^'SO:?*^^KF4?1G?5[ZA]
MAQ^'SO:?*^^KF4?1G?5[ZA]AQ^'SO:?*^^KF4?1G?5[ZA]AQ^'SO:?*^^KF4
M?1G?5[ZA]AQ^'SO:?*^^KF4?1G?5[ZA]AQ^'SO:?*^^KF4?1G?5[ZA]AQ^'S
MO:?*^^KF4?1G?5[ZA]AQ^'SO:?*^^KF4?1G?5[ZA]AQ^'SO:?*^^KF4?1G?5
M[ZA]AQ^'SO:?*^^KF4?1G?5[ZA]AQ^'SO:?*^^KF4?1G?5[ZA]AQ^'SO:?*^
M^KF4?1G?5[ZA]AQ^'SO:?*^^KF4?1G?5[ZA]AQ^'SO:?*^^KF4?1G?5[ZA]A
MQ^'SO:?*^^KF4?1G?5[ZA]AQ^'SO:?*^^KF4?1G?5[ZA]AQ^'SO:?*^^KF4?
M1G?5[ZA]AQ^'SO:?*^^KF4?1G?5[ZA]AQ^'SO:?*^^KF4?1G?5[ZA]AQ^'SO
M:?*^^KF4?1G?5[ZA]AQ^'SO:?*^^KF4?1G?5[ZA]AQ^'SO:?*^^KF4?1G?5[
MZA]AQ^'SO:?*^^KF4?1G?5[ZA]AQ^'SO:?*^^KF4?1G?5[ZC"UOJ5.UJ>H\]
M>IZX?5=B]WCLG0Z5^CV;O'_/^IX?XO7?E.'X_#66A\K+=-S]J9\-N;F[-_+E
M[''^KLZQKE3\W#OW[KG'=YEPR<]Y</\ V[SL\.MF[+K[3U?L6?U^^.NN3Y6'
MYE[0.'Z.3]J^[ ^Q9_7[XZZ?*P_,O: ^CD_:ONP/L6?U^^.NGRL/S+V@/HY/
MVK[L#[%G]?OCKI\K#\R]H#Z.3]J^[ ^Q9_7[XZZ?*P_,O: ^CD_:ONP/L6?U
M^^.NGRL/S+V@/HY/VK[L#[%G]?OCKI\K#\R]H#Z.3]J^[ ^Q9_7[XZZ?*P_,
MO: ^CD_:ONP/L6?U^^.NGRL/S+V@/HY/VK[L#[%G]?OCKI\K#\R]H#Z.3]J^
M[ ^Q9_7[XZZ?*P_,O: ^CD_:ONP/L6?U^^.NGRL/S+V@/HY/VK[L#[%G]?OC
MKI\K#\R]H#Z.3]J^[ ^Q9_7[XZZ?*P_,O: ^CD_:ONP/L6?U^^.NGRL/S+V@
M/HY/VK[L#[%G]?OCKI\K#\R]H#Z.3]J^[ ^Q9_7[XZZ?*P_,O: ^CD_:ONP/
ML6?U^^.NGRL/S+V@/HY/VK[L#[%G]?OCKI\K#\R]H#Z.3]J^[ ^Q9_7[XZZ?
M*P_,O: ^CD_:ONP/L6?U^^.NGRL/S+V@/HY/VK[L#[%G]?OCKI\K#\R]H#Z.
M3]J^[ ^Q9_7[XZZ?*P_,O: ^CD_:ONP/L6?U^^.NGRL/S+V@/HY/VK[L#[%G
M]?OCKI\K#\R]H#Z.3]J^[ ^Q9_7[XZZ?*P_,O: ^CD_:ONP/L6?U^^.NGRL/
MS+V@/HY/VK[L#[%G]?OCKI\K#\R]H#Z.3]J^[ ^Q9_7[XZZ?*P_,O: ^CD_:
MONP/L6?U^^.NGRL/S+V@/HY/VK[L#[%G]?OCKI\K#\R]H#Z.3]J^[ ^Q9_7[
MXZZ?*P_,O: ^CD_:ONP/L6?U^^.NGRL/S+V@/HY/VK[L#[%G]?OCKI\K#\R]
MH#Z.3]J^[ ^Q9_7[XZZ?*P_,O: ^CD_:ONP/L6?U^^.NGRL/S+V@/HY/VK[L
M#[%G]?OCKI\K#\R]H#Z.3]J^[ ^Q9_7[XZZ?*P_,O: ^CD_:ONP/L6?U^^.N
MGRL/S+V@/HY/VK[L#[%G]?OCKI\K#\R]H#Z.3]J^[ ^Q9_7[XZZ?*P_,O: ^
MCD_:ONP/L6?U^^.NGRL/S+V@/HY/VK[L#[%G]?OCKI\K#\R]H#Z.3]J^[ ^Q
M9_7[XZZ?*P_,O: ^CD_:ONP/L6?U^^.NGRL/S+V@/HY/VK[L#[%G]?OCKI\K
M#\R]H#Z.3]J^[ ^Q9_7[XZZ?*P_,O: ^CD_:ONP/L6?U^^.NGRL/S+V@/HY/
MVK[L#[%G]?OCKI\K#\R]H#Z.3]J^[ ^Q9_7[XZZ?*P_,O: ^CD_:ONP/L6?U
M^^.NGRL/S+V@/HY/VK[L#[%G]?OCKI\K#\R]H#Z.3]J^[ ^Q9_7[XZZ?*P_,
MO: ^CD_:ONP/L6?U^^.NGRL/S+V@/HY/VK[L#[%G]?OCKI\K#\R]H#Z.3]J^
M[ ^Q9_7[XZZ?*P_,O: ^CD_:ONP/L6?U^^.NGRL/S+V@/HY/VK[L#[%G]?OC
MKI\K#\R]H#Z.3]J^[ ^Q9_7[XZZ?*P_,O: ^CD_:ONP/L6?U^^.NGRL/S+V@
M/HY/VK[L#[%G]?OCKI\K#\R]H#Z.3]J^[ ^Q9_7[XZZ?*P_,O: ^CD_:ONP/
ML6?U^^.NGRL/S+V@/HY/VK[L#[%G]?OCKI\K#\R]H#Z.3]J^[ ^Q9_7[XZZ?
M*P_,O: ^CD_:ONP/L6?U^^.NGRL/S+V@/HY/VK[L#[%G]?OCKI\K#\R]H#Z.
M3]J^[ ^Q9_7[XZZ?*P_,O: ^CD_:ONP2+U-]6'\X" _-X\[_ '8?]JO-#O3W
M4.P_T*D?G!U_G%_H;^B_;>CUW_3X=#V?1K1>)7E">\FM]_':OO6_ [_)VIF_
M'Q;O#==G^.W>.7J8X[,27.!'D5_O6M7[I.W_ -X/]Y[4WG.63_!U&_S=L?@?
,\-OL,_5PR]EE/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>t1701829_chrt-inflam02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 t1701829_chrt-inflam02.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@#JP/H P$1  (1 0,1 ?_$ 1$  0 " P$! 0$! 0
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M0E(C)"5V9Y>A8B:6IN%3HVB8&<&%U2>B0V.U1O'"1,3%_]H # ,!  (1 Q$
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MD(]9YSD^>_\ =KJ'X@!S>\H."/A5;Y2.>IRF?.7[.NKR$>L\YR?/?^[74/Q
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M0CUGG.3Y[_W:ZA^( <WO*#@CX56^4CGJ<IGSE^SKJ\A'K/.<GSW_ +M=0_$
M.;WE!P1\*K?*1SU.4SYR_9UU>0CUGG.3Y[_W:ZA^( <WO*#@CX56^4CGJ<IG
MSE^SKJ\A'K/.<GSW_NUU#\0 YO>4'!'PJM\I'/4Y3/G+]G75Y"/6><Y/GO\
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M>$=]1UCGNJ$C1$]S)1JQT:1L8J)(E2Y5:_65-5NG9(YQO4B&
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M[2MFEYUS3WSQ\];,(:V[,7I]@K.'KA?,DK'.LP;@Y.^L=5-)S@GA/R<9QE.
MLQL0XIR0OC$E=+9B*[J:NC2=K6M5SX:1)XI=5$U$<FV-1;&HBN;;JZ37V<61
M^"LO>5CAC UTT^M@F_*^Z)W4CWO>UD-5>*TD]/KN7;%C=M,BI:]7-;(C=?0A
MV;NJ"Z='$_?434+7HI6WV39N:V]7BRQZ$M2-85A[G]FFSUK$2\@FV=.9:6CU
MWBZ9$W+DI.^8IT\>!15U3A.LSTS)P9+>EVWPE+07?MK4?K*RHJY6_P!:K5>Q
MJJB,8YK&JJL8JV(J.ZMS9$YCW9R1,BLTH+@OW##KPOB^O<[W1;6DM'=M,_\
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M(ERY2I<JT_NZZM?55-;5;=E>C]7UTV/66Q%.V]R5;?$[2-*?8+V;JG5?']M
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M053)X,BKUTNZ4(GWLF[A#KG4,4G>-G/9C/9VY%*&""G:K8&,8U5ML:B(EO\
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M$15Z.E42U=.G2=F6MK)XF03RRO@C2QK7.<K6HB6)JHJV)8FC1T-!\(K'6
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MU[!G=C[!G,+[O]^_,V/Z<'IFRNX;HNR=W(YKG*"\U+U[!G=ER$>6!^AD
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MX^+U9R]X?M["9KG-8T;?.XPV'4X R#5NMFKTBY7>$A6Q%>\9)9DN;O'PK@P
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MJO:<_P#6M#?E&_IR!T^
M
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M1LK,<V5R];47E?U!X!O8I6&SVJ>"9/D-%JKLER]TRQ5X_)39]C&" 93N7_\
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MD4S1[>^EDE2%,W?6PT2A/83QVX(A+)X[>WMQ@"-KI;__ (P1^()_^\Q_AD_
M&K/Q">KUMT]3K\/9JMMLS:FFU[ON3F-")[0TC9(^G[8I1E8GB\M[=46S2L'9
M8^&G$O ]PBRK!T3!#FQW,]O;@#'=$Z+2Z9G7UU-2.4^R=D\TVO-[0UU@>#W,
MOEC<;'?M\Z&O6O2/W.P..C*9<R+76;2-M]7D,G]LXB A7[EQ.-F*>")O'R;D
M#(.K1OC:VY^LKP/XW:0XP;&YF5?IW5U_SQWOIW5UDHE3?K;1M2+BG<>W4S/[
M-G86IM76M)-1A.HH8R=XY:3:F$L9QA11N!HDW*/?>C.OYQ2YB;QX,;DX*ZHZ
M@6NVW ';:NU;SJ:]P]^VVBYQ+:1M3!QJVP6%*,LGMW&5FOG4DC(9)$)+&0-D
MA7)<@720          ! #^*._P BCG-_][-__.'Q] &3<$NE)"4.G\3=\)]0
M/JL6US!T'3NPRZEOG.G8-HT1*JGJ$%+?L=.:O=QJ<3)Z](9;Q?$2<^$<-"%2
M[>[@ =-\G;YU?8';LS&\1.//!K86CTXV"4K]HW=OK;5'V([E%8Q ]C0EJU5M
M8S\(Q:LYC*J;0R3Q?*S8I%#Y(<QDR 0^_B MM[EW ZZ9_38@]&R6^=M[_P!F
MTWE'RUXZZ4LT2G^T^EN,Y8NVWO7,'<=C+52OHU&Y70C[VLDIA)OE4];2,9'"
MYR-U0./^H_S"Y/ZNYQ]-GJI;7Z:V_N%-"XN[*7X_<BMI;"V)I"^UBR<=>0+Q
M&J/X20B=76BPSR;JB)34Y)1'AD"LO;)X7&3$7R@; %KSJ!K).. '-Q=!5-=!
M?AYR36161.51)9)32MT.FJDH3)B*)J$-C)38SG&<9[< #@3\-[_DE<"/H_V#
M_&_:  A XG\'+AS4ZM?XB:-HW.'F7PILE*W1Q^9Q$UQ0V7%T6(M<I=JSO=&/
MD-LPSBNO9NY,Z2O6^_%HQLQ7W*!9%]C#K!UDU$0)+_PW=GI&O-"\N>'5MUU2
M]7\L^%/*.^T7E]98A_8Y"0WW/2*[]Q5N4EML][F9ZSRSC:,= O\ &5G+X[3&
M(PR[1)HS<(MD@(ZNF[S#Y2[+Y'=1_J44#I=;]YJ:ZYU;A_PXTCL^I;!T33J>
MTXN<<5+!J>G4YE7=KV^*FO#6##(RMB*DWQ'/)%K_ /+J)J9 '6'X97:%SU!]
MN?I8;AUO<M&77B/O)[N'3.F]E2\).7FH\:>2"RMWJM:D9FJO92K3KJJOWJ+]
M^]9.3H+.;23N?T9P4"UF
M
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MBGIRX-@CM/M &0<]^!_'WJ0\:K?Q9Y)Q,X]U_:7D5-L)RHR;2$O-&MT LHM
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MTG9==G)NLNM9PL5J*HU:F5QQ2(1A3XVS1DA(15/:'?G?S$DFHOWS(IH%-@F
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M2G*09(:HK=01L6H$BJ\9KB/KBL STVS:%K96C,C4S-+P2>&O]67NE[.P"?H
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M7444*EX)1$I3%.!J>^=)OC_<^1G,GDY$['WWK&_<[.*C[B=ON*UI:J)#5!_
MN(2/JT=MVO1LSK2PRL;O2MU2.+&QLPX?/&#5JHIGVO,L?*H ZZXE<7M6\+.-
MNG>+&EF\LAK+2=-94VL*V!S'O;'*IHKN9"5L5E>Q47"1;VS6><?NI&16;LFB
M"SUTJ<B*138(4#3[[I]:7<=0F$ZE498]G5G?+'C\[XUV2MUV=K3/5.Q]>K3S
MJRL7-_KKJGO;+*6:#E56YVCIK,LDBDCVA%452HXQD#ND
M
M
M
M
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M9<BLDX2270537073(LBLB<JB2R2A<'3524)DQ%$U"&QDIL9SC.,]N !_0
M              !";T&.=V_.H7P]V9NKD6[J;V[U;E?NK4,2K3JVG5XPM-I+
M6FNH!!>/2=O"K2"!I]<JB^38,J7!.]CO8SG(#1O.[?E_ZZG-CI_V%W4S\>M%
M<4-2[>H+)I6TVUN0N5N3U.I-+RMGP[.K)1ZV;L\P1#*12IX*EV9[2FR8#J?A
M5,<L93;W.9OR,Y'\8-Y4"'Y%RL;QMIN@'39U>-!ZN*YG7+#6?(<C>O0AV&T&
MD,XB\+MUEI%;PR+A7QG*:R:20&TK!U >!M3NT]K2U<VN(U9V-55G;>ST"P<D
M=-PUVKCA@Z*Q?(3U5D;FVG8=9F]/A%4KA!,R:N<$-C!O8 $6'5.Y:W6#Y ]#
MYWQGWZZ+J;D=U!:]1[])ZCO+23HVX==JMV3-[7):6K3YY#6NLF=G<$41PJJC
MX8N>W\LF.Z!,3K?ECQ8W'?+1JS4/);C_ +4V=2$UUKIKC6^Y-=7B^5%)JZ*R
M<JVBH5BQRE@@$V[P^$5#.VZ6"*YP7/8;V !O\                   $)O0
M8YW;\ZA?#W9FZN1;NIO;O5N5^ZM0Q*M.K:=7C"TVDM::Z@$%X])V\*M((&GU
MRJ+Y-@RI<$[V.]C.<@3#7B^T;6-6E[SLJZ5/7M)K[?#N>N-XL4/4ZM"-3*$1
M*YE[#//(^)C6YEE"DP=98A<F-C';VYP -<:3Y0<:.2S*6DN.7(C1>_X^ 401
MG7^D]MT#:K*%5=96PV2EG5%L$\A&J.,MU,)E6,3)^X;L[>S/8!G]/V1KO82M
MK0H%]I=X7HELEJ%>$:?:8.S*TV\P)DR3M,M:<*^>GKMLA3JEP[CGF$7C;)L8
M43+VX '^JCL77U_6M3:AWJFW9Q1+5)T6[H5&SPED6IMWA?!9F:=:DH9\]/7K
M5$X7)XU'N\(NT.^7OIE[< !4=BZ^OZUJ;4.]4V[.*):I.BW="HV>$LBU-N\+
MX+,S3K4E#/GIZ]:HG"Y/&H]WA%VAWR]],O;@ 9D                *P>R.
M</5\W[U=N=/3\X,VO@UKF@\0*+H&YH37(_76VK!/6%IMK4>L[I))GEJ)95D5
MWS6RW5R1,OB#1(C%)(N<G5P<YP)D>#L!U'H&%V$GU$=@<3+[/.)2 /J]?BK4
MMF56/C8@C22+9T;F78[M=1\\</#,S,LM"$*F0JWA#&R8F" =BW6;<5FFVVR-
M$D7#JOUF>FVR#CO^+K.(J*=/T4E_!'34\"HHWQ@W=-@W=SGLSC( J%<+.>OX
MB[FMP4;]0O33_I?S]+*CM&6::(M^O-^5N^VA#4L]/PL] 1LM%71U7FTM-FKR
MWM7X>6;(G4.EAPX1QDYB@2[:7ZK3SDYT2-G]4O5M$C:;L"G\3N4.V$M:VM5]
M8JU!;@XZU+8YG<$^>,SU]]8Z3(6VB%71415:.5XIT0IS(.?"%3 BKU?SV_$/
M2?3XJ_5(8PO34WMHY74;S?=KX^1%3WQ0MW+:FKN9&0NRU8F\V9U4,72 @(-R
M[(@=P](LW(IANW>N\(,UP),]X]<;2^K>E)I7J8UG6MHO<MR:9T:I<?\ CFRD
M.[<+OOZ]+2\7C4>9IG%/>U.J3E8F</I%NP6,X:Q1S-6ZJZ[=NH!HDT7^*%>T
M8F\R7;IAPMTS&YM9.%*M$VH]8IM$VYI!+73W<Z=D655OJS?!6:RJ$F2$]L<Y
MR21*U[%@!W_TE^I+ =3OBXIN-2A/M/;@UQ?K)I3D3I66>&=R.L]Q4I-BI.QB
M!W2+.44@9-G)(.F9W3=%=$QUFBG?7:+'R!)Z
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M%J5'MVW])K7BZFJ$1E3+. C7[^T>+%;MR$3381[%L7&$FB)"@6A
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MUHA[7%2\6;>)=\ALF6/V =@=*?6?(747XD'J,47E'R<^U_N6,X(:A<6'>_\
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M;KK*C_MSJ';L@6$N$3?\PI6JUWF'D$DZ8YE)0[J16:2+E)=95,^"X MX@
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MS6W%*N&^6CF8N?)"12MT._=-3X\*W?)ZT3K[=P4_L^,('SV%QG!"@3<
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M4T468V!0KUB_IT NRS-OV)DEWQXO]EC72@X6]M$G!D\+^V)/%S=AO!JX[29
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MG]4@BW:,V[=HW33;MTDR@=F@
M                                            #6^U--ZAWI4W5!W=
MJO6^XZ*^4*L]I>U*/6-A5-XJ0BB1575<ML7+P[A0J:IBX,='.<%-G']&<@##
MM*<5N,'&I*50XY\<-#:!1G2I$FT=*:@U[JM*9(@H=9$LJG1:] DD"HJJ&,7"
MV#X*8V<X]G( WR
M        #^:R*3A)5!=)-=!=,Z*R*Q"J)+)*%R11)5,^#$434(;.#%SC.,XS
MV9 '(T!T^>!%4OJ.U:MPAXA5O:#:23F6^R(#C5IF'OJ$NBNBZ1E4;A'4MM84
MI))RV34*N5QA4ITRFP;M+C. .O0
M
M
M
M
M                        'X]AL$'4H"<M5GEH^ K59AY.P6&=EG2+&*A8
M.&9+R,M+2;UP8B#./CF#91994YL$33)DV<XQC( K?R?XE'6Z].G^1VO.GEU
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M<6V=,-;5FXMC1,7,&=O$)]1)PHCA'#<Y,@=X@
M
M
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MM\_V) ?&H/U?OO\ -*G\E)W(^6+J_.8/RC/Y1ZU;BQ_TM\_V) ?&H/U?OO\
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MU.]5!KIZY_D_/S5B9#**:XWX0A"F.<Y]8J%(0A<9,8QC&F,8*4N,=N<Y]C&
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M #JF_*L_E'H[S"X!OKWC4]Z'K:>(W_6MN_V=6?C<'RE=?YU3?E6?RCT=YA<
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M/QDG^;A7/Y0-->>VW@!5"         !Z'GX'3Y*^HE]('''S<V^ +W@
M XIY@Q<E)3_$X\='/GY(_E-K%^_,R:.'16+%!ZIE=Z\,@FIALT1Q_P ]0_=(
M7_3D5&?SO:J?#ME/9.UA3/L     U[MOY*=F_1[=/-N2&/XMXJWG]'U&\O*%
M3X-)[1W24K!#S(,!          +!_![T7=8?VU_B';1Z Y(_=A=GZ3\;G,TN
MGYOC_"[93K ;6+B     <4ZZBY-'G#R(E5HY\E%O-;ZT09R2K1PFP=K(1\;A
M9%L\,GANNJCDN<&*4V<ESCV147\6GLGPG7K[!VL*9]@    $>_4F^0RJ?2Q!
M>9]Z$?N4AQ'I?I6+XO5%EOWP1NZ)VKB$@0I,4        #*Z%\.:9Y65WW89
MBZW#\^47C<.^-*L/XYGMDZ9:4'J$;      ,/V$FHM0+PBBF=556GV9-)),A
ME%%%%(5Z4B:9"XR8YSFSC&,8QG.<Y'*;*>R<+L&B>$[!]%\7-1L)-D[CGS>'
MF"N&3YLLT=H&-:IY0I5F[@B:R1C)GP;&#8QVXSC/]&1]2=>IPWK4.IA\'T
M   4_P#JX>G+LKR>UQYB00G%DG]WE)NL^_/(FYJ\=:G<XMZ:1I#;!KD
M   )D>B!Z5^P?Y>;7_$C4PT3RA.)E+]*1[Q4FW<E^-%1X@_?H"TX(=DFP
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MYU_YNWL:ESGXH-\<C[60]&?W7O[2<_\ AFMW^B*6 BH?H8        #*:/\
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MT?X:T_RIK_NLT'8I/"XMT;TT+-B/B]7^)3[TX].$3]/QS@
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MBD\+BW1O30LV(^+U?XE/O3CTX1/T_'.
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MQDG^;A7/Y0-->>VW@!5"         !Z'GX'3Y*^HE]('''S<V^ +W@
M        ->[;^2G9OT>W3S;DAC^+>*MY_1]1O+RA4^#2>T=TE*P0\R# 0
M      "P?P>]%W6']M?XAVT>@.2/W879^D_&YS-+I^;X_P +ME.L!M8N(
M          1[]2;Y#*I]+$%YGWH1^Y2'$>E^E8OB]466_?!&[HG:N(2!"DQ0
M        ,KH7PYIGE97?=AF+K</SY1>-P[XTJP_CF>V3IEI0>H1L
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MTK]@_P O-K_B1J8:)Y0G$RE^E(]XJ3;N2_&BH\0?OT!:<$.R38
M   8];O@I9_)Z:]S7([5%X;#NK.V0Z]7X++N;NDIY^8],"!X         !<!
MZ1_H-:U\H=C^?<Z(.YV?>'5[E!O+"6657$JFW27?7$E@U.;&
M "$3K^>@M$_3SK_S=O8U+G/Q0;XY'VLAZ,_NO?VDY_\ #-;O]$4L!%0_0P
M      &4T?X:T_RIK_NLT'8I/"XMT;TT+-B/B]7^)3[TX].$3]/QS@
M                              89L?Y/+YY&6CW#?#EO7)[)PNP:!X,^
MBEIW]337G98!]R]>IPSK4.L13/H     \L3\9)_FX5S^4#37GMMX 50@
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MW;V-2YS\4&^.1]K(>C/[KW]I.?\ PS6[_1%+ 14/T,        !E-'^&M/\
M*FO^ZS0=BD\+BW1O30LV(^+U?XE/O3CTX1/T_'.
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MW1O30LV(^+U?XE/O3CTX1/T_'.
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MFX5S^4#37GMMX 50@         >AY^!T^2OJ)?2!QQ\W-O@"]X
M    #7NV_DIV;]'MT\VY(8_BWBK>?T?4;R\H5/@TGM'=)2L$/,@P$
M   L'\'O1=UA_;7^(=M'H#DC]V%V?I/QN<S2Z?F^/\+ME.L!M8N(
M     1[]2;Y#*I]+$%YGWH1^Y2'$>E^E8OB]466_?!&[HG:N(2!"DQ0
M   ,KH7PYIGE97?=AF+K</SY1>-P[XTJP_CF>V3IEI0>H1L
M   I_P#5P].797D]KCS$@A.+)/[O*3=9]^>1-S5XZU.YQ;TTC2&V#7(
M   3(]$#TK]@_P O-K_B1J8:)Y0G$RE^E(]XJ3;N2_&BH\0?OT!:<$.R38
M           8];O@I9_)Z:]S7([5%X;#NK.V0Z]7X++N;NDIY^8],"!X
M     !<!Z1_H-:U\H=C^?<Z(.YV?>'5[E!O+"6657$JFW27?7$E@U.;&
M         "$3K^>@M$_3SK_S=O8U+G/Q0;XY'VLAZ,_NO?VDY_\ #-;O]$4L
M!%0_0P        &4T?X:T_RIK_NLT'8I/"XMT;TT+-B/B]7^)3[TX].$3]/Q
MS@                   $+?#3E-N[EUU3>HRC#7Q]'\+^$4;KWB)4]=MXB
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M_A38N7-QT-L2Y4%#;]#>4?=.\-V4._:[O=%)9ZA(/ZS>M9I1J"3AE+,WL:5
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MX<TSRLKONPS%UN'Y\HO&X=\:58?QS/;)TRTH/4(V                4_\
MJX>G+LKR>UQYB00G%DG]WE)NL^_/(FYJ\=:G<XMZ:1I#;!KD        )D>B
M!Z5^P?Y>;7_$C4PT3RA.)E+]*1[Q4FW<E^-%1X@_?H"TX(=DFP
M   QZW?!2S^3TU[FN1VJ+PV'=6=LAUZOP67<W=)3S\QZ8$#P         "X#
MTC_0:UKY0['\^YT0=SL^\.KW*#>6$LLJN)5-NDN^N)+!J<V,
M $(G7\]!:)^GG7_F[>QJ7.?B@WQR/M9#T9_=>_M)S_X9K=_HBE@(J'Z&
M     RFC_#6G^5-?]UF@[%)X7%NC>FA9L1\7J_Q*?>G'IPB?I^.<
M            KC]#IB?C%RDZQG3GL"BS62U7S=E>6^JF\AC*:TQH7E[7(JP5
M$\,J?L+--:ABJH-)-RCC*:4F],0^$SF\$0#\'K&].;JV=4"A;,XM0FT.G11>
M)$QLBIW?7K^4KG)=GR,:M:=@KN,:7*?:2=IUFX<+R;AQX?Q&&3*=#P>"&3/@
MV<@2&U_C7S*Y9\7.47&/JKR/#Z;KV\J:ZUY6''"B!W95RPM?GH:4;3$[/GW?
M9[8LI;H">S'R$*HTP5JDLUSEPFKC."@"(5OTK>NX_P")*'2UG^='!Y#@J6HI
M:/=<AXK6FYWG-IUQK;-RUU/5>::_,WTLG&N*$3$*?'MJ:1)'_P"K^V9R]IS
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M=>60IS*,K'<(-:O;5Y"0[<R9EFQ7FO\ 8]>;-ERX/C/@9!NIV8,HH4@%CH
M!AFQ_D\OGD9:/<-\.6]<GLG"[!H'@SZ*6G?U-->=E@'W+UZG#.M0ZQ%,^@
M  #RQ/QDG^;A7/Y0-->>VW@!5"         !Z'GX'3Y*^HE]('''S<V^ +W@
M              ->[;^2G9OT>W3S;DAC^+>*MY_1]1O+RA4^#2>T=TE*P0\R
M# 0         "P?P>]%W6']M?XAVT>@.2/W879^D_&YS-+I^;X_PNV4ZP&UB
MX@            !'OU)OD,JGTL07F?>A'[E(<1Z7Z5B^+U19;]\$;NB=JXA(
M$*3%         RNA?#FF>5E=]V&8NMP_/E%XW#OC2K#^.9[9.F6E!ZA&P
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MIKSLL ^Y>O4X9UJ'6(IGT     >6)^,D_P W"N?R@::\]MO "J$
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MH.Q2>%Q;HWIH6;$?%ZO\2GWIQZ<(GZ?CG
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M#-C_ ">7SR,M'N&^'+>N3V3A=@T#P9]%+3OZFFO.RP#[EZ]3AG6H=8BF?0
M  !Y8GXR3_-PKG\H&FO/;;P JA          ]#S\#I\E?42^D#CCYN;? %[P
M              &O=M_)3LWZ/;IYMR0Q_%O%6\_H^HWEY0J?!I/:.Z2E8(>9
M!@(         !8/X/>B[K#^VO\0[:/0')'[L+L_2?C<YFET_-\?X7;*=8#:Q
M<0             CWZDWR&53Z6(+S/O0C]RD.(]+]*Q?%ZHLM^^"-W1.U<0D
M"%)B@        970OAS3/*RN^[#,76X?GRB\;AWQI5A_',]LG3+2@]0C8
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MR@::\]MO "J$         #T//P.GR5]1+Z0../FYM\ 7O
M:]VW\E.S?H]NGFW)#'\6\5;S^CZC>7E"I\&D]H[I*5@AYD& @         %@
M_@]Z+NL/[:_Q#MH] <D?NPNS])^-SF:73\WQ_A=LIU@-K%Q
M"/?J3?(95/I8@O,^]"/W*0XCTOTK%\7JBRW[X(W=$[5Q"0(4F*        !E
M="^'-,\K*[[L,Q=;A^?*+QN'?&E6'\<SVR=,M*#U"-@               %/
M_JX>G+LKR>UQYB00G%DG]WE)NL^_/(FYJ\=:G<XMZ:1I#;!KD        )D>
MB!Z5^P?Y>;7_ !(U,-$\H3B92_2D>\5)MW)?C14>(/WZ M."'9)L
M     ,>MWP4L_D]->YKD=JB\-AW5G;(=>K\%EW-W24\_,>F! \
MN ](_P!!K6OE#L?S[G1!W.S[PZO<H-Y82RRJXE4VZ2[ZXDL&IS8P
M     0B=?ST%HGZ>=?\ F[>QJ7.?B@WQR/M9#T9_=>_M)S_X9K=_HBE@(J'Z
M&         RFC_#6G^5-?]UF@[%)X7%NC>FA9L1\7J_Q*?>G'IPB?I^.<
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M-:?Y4U_W6:#L4GA<6Z-Z:%FQ'Q>K_$I]Z<>G")^GXYP
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M%)X7%NC>FA9L1\7J_P 2GWIQZ<(GZ?CG
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MGXR3_-PKG\H&FO/;;P JA          ]#S\#I\E?42^D#CCYN;? %[P
M         &O=M_)3LWZ/;IYMR0Q_%O%6\_H^HWEY0J?!I/:.Z2E8(>9!@(
M       !8/X/>B[K#^VO\0[:/0')'[L+L_2?C<YFET_-\?X7;*=8#:Q<0
M          CWZDWR&53Z6(+S/O0C]RD.(]+]*Q?%ZHLM^^"-W1.U<0D"%)B@
M        970OAS3/*RN^[#,76X?GRB\;AWQI5A_',]LG3+2@]0C8
M       !3_ZN'IR[*\GM<>8D$)Q9)_=Y2;K/OSR)N:O'6IW.+>FD:0VP:Y
M      "9'H@>E?L'^7FU_P 2-3#1/*$XF4OTI'O%2;=R7XT5'B#]^@+3@AV2
M;             #'K=\%+/Y/37N:Y':HO#8=U9VR'7J_!9=S=TE//S'I@0/
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MX<TSRLKONPS%UN'Y\HO&X=\:58?QS/;)TRTH/4(V                4_\
MJX>G+LKR>UQYB00G%DG]WE)NL^_/(FYJ\=:G<XMZ:1I#;!KD        )D>B
M!Z5^P?Y>;7_$C4PT3RA.)E+]*1[Q4FW<E^-%1X@_?H"TX(=DFP
M   QZW?!2S^3TU[FN1VJ+PV'=6=LAUZOP67<W=)3S\QZ8$#P         "X#
MTC_0:UKY0['\^YT0=SL^\.KW*#>6$LLJN)5-NDN^N)+!J<V,
M $(G7\]!:)^GG7_F[>QJ7.?B@WQR/M9#T9_=>_M)S_X9K=_HBE@(J'Z&
M     RFC_#6G^5-?]UF@[%)X7%NC>FA9L1\7J_Q*?>G'IPB?I^.<
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M%\,[=G[2XR3!@+"   ##-C_)Y?/(RT>X;X<MZY/9.%V#0/!GT4M._J::\[+
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MG^;A7/Y0-->>VW@!5"         !Z'GX'3Y*^HE]('''S<V^ +W@
M      ->[;^2G9OT>W3S;DAC^+>*MY_1]1O+RA4^#2>T=TE*P0\R# 0
M    "P?P>]%W6']M?XAVT>@.2/W879^D_&YS-+I^;X_PNV4ZP&UBX@
M      !'OU)OD,JGTL07F?>A'[E(<1Z7Z5B^+U19;]\$;NB=JXA($*3%
M     RNA?#FF>5E=]V&8NMP_/E%XW#OC2K#^.9[9.F6E!ZA&P
M    "G_U</3EV5Y/:X\Q((3BR3^[RDW6??GD3<U>.M3N<6]-(TAM@UR
M   $R/1 ]*_8/\O-K_B1J8:)Y0G$RE^E(]XJ3;N2_&BH\0?OT!:<$.R38
M          8];O@I9_)Z:]S7([5%X;#NK.V0Z]7X++N;NDIY^8],"!X
M    !<!Z1_H-:U\H=C^?<Z(.YV?>'5[E!O+"6657$JFW27?7$E@U.;&
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MB?C)/\W"N?R@::\]MO "J$         #T//P.GR5]1+Z0../FYM\ 7O
M          :]VW\E.S?H]NGFW)#'\6\5;S^CZC>7E"I\&D]H[I*5@AYD& @
M        %@_@]Z+NL/[:_P 0[:/0')'[L+L_2?C<YFET_-\?X7;*=8#:Q<0
M            CWZDWR&53Z6(+S/O0C]RD.(]+]*Q?%ZHLM^^"-W1.U<0D"%)
MB@        970OAS3/*RN^[#,76X?GRB\;AWQI5A_',]LG3+2@]0C8
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M?R@::\]MO "J$         #T//P.GR5]1+Z0../FYM\ 7O
M :]VW\E.S?H]NGFW)#'\6\5;S^CZC>7E"I\&D]H[I*5@AYD& @         %
M@_@]Z+NL/[:_Q#MH] <D?NPNS])^-SF:73\WQ_A=LIU@-K%Q
M "/?J3?(95/I8@O,^]"/W*0XCTOTK%\7JBRW[X(W=$[5Q"0(4F*        !
ME="^'-,\K*[[L,Q=;A^?*+QN'?&E6'\<SVR=,M*#U"-@               %
M/_JX>G+LKR>UQYB00G%DG]WE)NL^_/(FYJ\=:G<XMZ:1I#;!KD        )D
M>B!Z5^P?Y>;7_$C4PT3RA.)E+]*1[Q4FW<E^-%1X@_?H"TX(=DFP
M     QZW?!2S^3TU[FN1VJ+PV'=6=LAUZOP67<W=)3S\QZ8$#P         "
MX#TC_0:UKY0['\^YT0=SL^\.KW*#>6$LLJN)5-NDN^N)+!J<V,
M   $(G7\]!:)^GG7_F[>QJ7.?B@WQR/M9#T9_=>_M)S_ .&:W?Z(I8"*A^A@
M        ,IH_PUI_E37_ '6:#L4GA<6Z-Z:%FQ'Q>K_$I]Z<>G")^GXYP
M                                 ,,V/\GE\\C+1[AOARWKD]DX78-
M\&?12T[^IIKSLL ^Y>O4X9UJ'6(IGT     >6)^,D_S<*Y_*!IKSVV\ *H0
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M)!"<62?W>4FZS[\\B;FKQUJ=SBWII&D-L&N0        F1Z('I7[!_EYM?\
M$C4PT3RA.)E+]*1[Q4FW<E^-%1X@_?H"TX(=DFP             QZW?!2S^
M3TU[FN1VJ+PV'=6=LAUZOP67<W=)3S\QZ8$#P         "X#TC_ $&M:^4.
MQ_/N=$'<[/O#J]R@WEA++*KB53;I+OKB2P:G-C             !")U_/06B
M?IYU_P";M[&I<Y^*#?'(^UD/1G]U[^TG/_AFMW^B*6 BH?H8        #*:/
M\-:?Y4U_W6:#L4GA<6Z-Z:%FQ'Q>K_$I]Z<>G")^GXYP
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M>%Q;HWIH6;$?%ZO\2GWIQZ<(GZ?CG
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M8GXR3_-PKG\H&FO/;;P JA          ]#S\#I\E?42^D#CCYN;? %[P
M          &O=M_)3LWZ/;IYMR0Q_%O%6\_H^HWEY0J?!I/:.Z2E8(>9!@(
M        !8/X/>B[K#^VO\0[:/0')'[L+L_2?C<YFET_-\?X7;*=8#:Q<0
M           CWZDWR&53Z6(+S/O0C]RD.(]+]*Q?%ZHLM^^"-W1.U<0D"%)B
M@        970OAS3/*RN^[#,76X?GRB\;AWQI5A_',]LG3+2@]0C8
M        !3_ZN'IR[*\GM<>8D$)Q9)_=Y2;K/OSR)N:O'6IW.+>FD:0VP:Y
M       "9'H@>E?L'^7FU_Q(U,-$\H3B92_2D>\5)MW)?C14>(/WZ M."'9)
ML             ,>MWP4L_D]->YKD=JB\-AW5G;(=>K\%EW-W24\_,>F! \
M         N ](_T&M:^4.Q_/N=$'<[/O#J]R@WEA++*KB53;I+OKB2P:G-C
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M^P?Y>;7_ !(U,-$\H3B92_2D>\5)MW)?C14>(/WZ M."'9)L
M ,>MWP4L_D]->YKD=JB\-AW5G;(=>K\%EW-W24\_,>F! \          N ](
M_P!!K6OE#L?S[G1!W.S[PZO<H-Y82RRJXE4VZ2[ZXDL&IS8P
M 0B=?ST%HGZ>=?\ F[>QJ7.?B@WQR/M9#T9_=>_M)S_X9K=_HBE@(J'Z&
M      RFC_#6G^5-?]UF@[%)X7%NC>FA9L1\7J_Q*?>G'IPB?I^.<
M                             ##-C_)Y?/(RT>X;X<MZY/9.%V#0/!GT
M4M._J::\[+ /N7KU.&=:AUB*9]     'EB?C)/\ -PKG\H&FO/;;P JA
M      ]#S\#I\E?42^D#CCYN;? %[P              &O=M_)3LWZ/;IYMR
M0Q_%O%6\_H^HWEY0J?!I/:.Z2E8(>9!@(         !8/X/>B[K#^VO\0[:/
M0')'[L+L_2?C<YFET_-\?X7;*=8#:Q<0             CWZDWR&53Z6(+S/
MO0C]RD.(]+]*Q?%ZHLM^^"-W1.U<0D"%)B@        970OAS3/*RN^[#,76
MX?GRB\;AWQI5A_',]LG3+2@]0C8               !3_P"KAZ<NRO)[7'F)
M!"<62?W>4FZS[\\B;FKQUJ=SBWII&D-L&N0        F1Z('I7[!_EYM?\2-
M3#1/*$XF4OTI'O%2;=R7XT5'B#]^@+3@AV2;             #'K=\%+/Y/3
M7N:Y':HO#8=U9VR'7J_!9=S=TE//S'I@0/          +@/2/]!K6OE#L?S[
MG1!W.S[PZO<H-Y82RRJXE4VZ2[ZXDL&IS8P             0B=?ST%HGZ>=
M?^;M[&I<Y^*#?'(^UD/1G]U[^TG/_AFMW^B*6 BH?H8        #*:/\-:?Y
M4U_W6:#L4GA<6Z-Z:%FQ'Q>K_$I]Z<>G")^GXYP
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M^#WHNZP_MK_$.VCT!R1^["[/TGXW.9I=/S?'^%VRG6 VL7$
M(]^I-\AE4^EB"\S[T(_<I#B/2_2L7Q>J++?O@C=T3M7$) A28H        &5
MT+X<TSRLKONPS%UN'Y\HO&X=\:58?QS/;)TRTH/4(V                4_
M^KAZ<NRO)[7'F)!"<62?W>4FZS[\\B;FKQUJ=SBWII&D-L&N0        F1Z
M('I7[!_EYM?\2-3#1/*$XF4OTI'O%2;=R7XT5'B#]^@+3@AV2;
M   #'K=\%+/Y/37N:Y':HO#8=U9VR'7J_!9=S=TE//S'I@0/          +@
M/2/]!K6OE#L?S[G1!W.S[PZO<H-Y82RRJXE4VZ2[ZXDL&IS8P
M  0B=?ST%HGZ>=?^;M[&I<Y^*#?'(^UD/1G]U[^TG/\ X9K=_HBE@(J'Z&
M       RFC_#6G^5-?\ =9H.Q2>%Q;HWIH6;$?%ZO\2GWIQZ<(GZ?CG
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M;HWIH6;$?%ZO\2GWIQZ<(GZ?CG
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MN?R@::\]MO "J$         #T//P.GR5]1+Z0../FYM\ 7O
M  :]VW\E.S?H]NGFW)#'\6\5;S^CZC>7E"I\&D]H[I*5@AYD& @
M%@_@]Z+NL/[:_P 0[:/0')'[L+L_2?C<YFET_-\?X7;*=8#:Q<0
M    CWZDWR&53Z6(+S/O0C]RD.(]+]*Q?%ZHLM^^"-W1.U<0D"%)B@
M  970OAS3/*RN^[#,76X?GRB\;AWQI5A_',]LG3+2@]0C8
M !3_ .KAZ<NRO)[7'F)!"<62?W>4FZS[\\B;FKQUJ=SBWII&D-L&N0
M  F1Z('I7[!_EYM?\2-3#1/*$XF4OTI'O%2;=R7XT5'B#]^@+3@AV2;
M        #'K=\%+/Y/37N:Y':HO#8=U9VR'7J_!9=S=TE//S'I@0/
M   +@/2/]!K6OE#L?S[G1!W.S[PZO<H-Y82RRJXE4VZ2[ZXDL&IS8P
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M]!:)^GG7_F[>QJ7.?B@WQR/M9#T9_=>_M)S_ .&:W?Z(I8"*A^A@
M,IH_PUI_E37_ '6:#L4GA<6Z-Z:%FQ'Q>K_$I]Z<>G")^GXYP
M                         ,,V/\GE\\C+1[AOARWKD]DX78- \&?12T[^
MIIKSLL ^Y>O4X9UJ'6(IGT     >6)^,D_S<*Y_*!IKSVV\ *H0
M/0\_ Z?)7U$OI XX^;FWP!>\              !KW;?R4[-^CVZ>;<D,?Q;Q
M5O/Z/J-Y>4*GP:3VCNDI6"'F08"          6#^#WHNZP_MK_$.VCT!R1^[
M"[/TGXW.9I=/S?'^%VRG6 VL7$             (]^I-\AE4^EB"\S[T(_<I
M#B/2_2L7Q>J++?O@C=T3M7$) A28H        &5T+X<TSRLKONPS%UN'Y\HO
M&X=\:58?QS/;)TRTH/4(V                4_^KAZ<NRO)[7'F)!"<62?W
M>4FZS[\\B;FKQUJ=SBWII&D-L&N0        F1Z('I7[!_EYM?\ $C4PT3RA
M.)E+]*1[Q4FW<E^-%1X@_?H"TX(=DFP             QZW?!2S^3TU[FN1V
MJ+PV'=6=LAUZOP67<W=)3S\QZ8$#P         "X#TC_ $&M:^4.Q_/N=$'<
M[/O#J]R@WEA++*KB53;I+OKB2P:G-C             !")U_/06B?IYU_P";
MM[&I<Y^*#?'(^UD/1G]U[^TG/_AFMW^B*6 BH?H8        #*:/\-:?Y4U_
MW6:#L4GA<6Z-Z:%FQ'Q>K_$I]Z<>G")^GXYP
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MY8GXR3_-PKG\H&FO/;;P JA          ]#S\#I\E?42^D#CCYN;? %[P
M           &O=M_)3LWZ/;IYMR0Q_%O%6\_H^HWEY0J?!I/:.Z2E8(>9!@(
M         !8/X/>B[K#^VO\ $.VCT!R1^["[/TGXW.9I=/S?'^%VRG6 VL7$
M             (]^I-\AE4^EB"\S[T(_<I#B/2_2L7Q>J++?O@C=T3M7$) A
M28H        &5T+X<TSRLKONPS%UN'Y\HO&X=\:58?QS/;)TRTH/4(V
M           4_P#JX>G+LKR>UQYB00G%DG]WE)NL^_/(FYJ\=:G<XMZ:1I#;
M!KD        )D>B!Z5^P?Y>;7_$C4PT3RA.)E+]*1[Q4FW<E^-%1X@_?H"TX
M(=DFP             QZW?!2S^3TU[FN1VJ+PV'=6=LAUZOP67<W=)3S\QZ8
M$#P         "X#TC_0:UKY0['\^YT0=SL^\.KW*#>6$LLJN)5-NDN^N)+!J
M<V,             $(G7\]!:)^GG7_F[>QJ7.?B@WQR/M9#T9_=>_M)S_P"&
M:W?Z(I8"*A^A@        ,IH_P -:?Y4U_W6:#L4GA<6Z-Z:%FQ'Q>K_ !*?
M>G'IPB?I^.<                                    ##-C_ ">7SR,M
M'N&^'+>N3V3A=@T#P9]%+3OZFFO.RP#[EZ]3AG6H=8BF?0    !Y8GXR3_-P
MKG\H&FO/;;P JA          ]#S\#I\E?42^D#CCYN;? %[P
M  &O=M_)3LWZ/;IYMR0Q_%O%6\_H^HWEY0J?!I/:.Z2E8(>9!@(
M!8/X/>B[K#^VO\0[:/0')'[L+L_2?C<YFET_-\?X7;*=8#:Q<0
M   CWZDWR&53Z6(+S/O0C]RD.(]+]*Q?%ZHLM^^"-W1.U<0D"%)B@
M 970OAS3/*RN^[#,76X?GRB\;AWQI5A_',]LG3+2@]0C8
M!3_ZN'IR[*\GM<>8D$)Q9)_=Y2;K/OSR)N:O'6IW.+>FD:0VP:Y        "
M9'H@>E?L'^7FU_Q(U,-$\H3B92_2D>\5)MW)?C14>(/WZ M."'9)L
M      ,>MWP4L_D]->YKD=JB\-AW5G;(=>K\%EW-W24\_,>F! \
M N ](_T&M:^4.Q_/N=$'<[/O#J]R@WEA++*KB53;I+OKB2P:G-C
M    !")U_/06B?IYU_YNWL:ESGXH-\<C[60]&?W7O[2<_P#AFMW^B*6 BH?H
M8        #*:/\-:?Y4U_P!UF@[%)X7%NC>FA9L1\7J_Q*?>G'IPB?I^.<
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MC_#6G^5-?]UF@[%)X7%NC>FA9L1\7J_Q*?>G'IPB?I^.<
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M?U-->=E@',O7J&=:AUB*9]     'EB?C)/\ -PKG\H&FO/;;P JA
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MG?U-->=E@'W+UZG#.M0ZQ%,^@    #RQ/QDG^;A7/Y0-->>VW@!5"
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M_P"ZS0=BD\+BW1O30LV(^+U?XE/O3CTX1/T_'.
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MT'XE/_!5\[2MGG^)7(?C*V?>'3]K"ZQG]B6A@9IX//ALRCB[:PURZ:N\+?\
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M5S7U65D%\L8[W-'%3LEBE=J*K4ED=-&Z)%?8U5;')8U5=8JI8NW!W3&@
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M=?ST%HGZ>=?^;M[&I<Y^*#?'(^UD/1G]U[^TG/\ X9K=_HBE@(J'Z&
M   RFC_#6G^5-?\ =9H.Q2>%Q;HWIH6;$?%ZO\2GWIQZ<(GZ?CG
M                            PS8_R>7SR,M'N&^'+>N3V3A=@T#P9]%+
M3OZFFO.RP#[EZ]3AG6H=8BF?0                                 :]
MVW\E.S?H]NGFW)#'\6\5;S^CZC>7E"I\&D]H[I*5@AYD& @         %@_@
M]Z+NL/[:_P 0[:/0')'[L+L_2?C<YFET_-\?X7;*=8#:Q<0
MCWZDWR&53Z6(+S/O0C]RD.(]+]*Q?%ZHLM^^"-W1.U<0D"%)B@        97
M0OAS3/*RN^[#,76X?GRB\;AWQI5A_',]LG3+2@]0C8               !3_
M .KAZ<NRO)[7'F)!"<62?W>4FZS[\\B;FKQUJ=SBWII&D-L&N0        F1
MZ('I7[!_EYM?\2-3#1/*$XF4OTI'O%2;=R7XT5'B#]^@+3@AV2;
M    #'K=\%+/Y/37N:Y':HO#8=U9VR'7J_!9=S=TE//S'I@0/          +
M@/2/]!K6OE#L?S[G1!W.S[PZO<H-Y82RRJXE4VZ2[ZXDL&IS8P
M   0B=?ST%HGZ>=?^;M[&I<Y^*#?'(^UD/1G]U[^TG/_ (9K=_HBE@(J'Z&
M        RFC_  UI_E37_=9H.Q2>%Q;HWIH6;$?%ZO\ $I]Z<>G")^GXYP
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MYU_YNWL:ESGXH-\<C[60]&?W7O[2<_\ AFMW^B*6 BH?H8        #*:/\
M#6G^5-?]UF@[%)X7%NC>FA9L1\7J_P 2GWIQZ<(GZ?CG
M                     PS8_P GE\\C+1[AOARWKD]DX78- \&?12T[^IIK
MSLL ^Y>O4X9UJ'6(IGT !'5U<.2DQQ"Z:/-7D+69%:'N-#T+<6U"F6^,F6A=
MBW=%'7VNYI,F$U<'-$7:UL'/=-CNF\%V&R4O:; $<&@MRZ<Z$'X?7CEM#9$4
M:1D:IH6BVO\ 8MDX393.S^2O(I%;9;BEYFED%LI%5NMO=I.9)<BOM? QBBW@
MS$;$0R!6UYS;BXG.^F?O6>NO/7C-R-ZHW52WUQNK7*>YZWV36[5$\=],M-D0
M6RV.F*)EA+R;RH<>M&,-?,(Z2=D6.C*/,$,X462\5[@'H$:9VOQ^L?'RG[2T
MWLK7M@XX15%46JVS*_985;6Z-"H#=U"/I5.TI+HP+>!K:-=<)N7&5$V[;#53
MO9*4F>P"MSL9E*?B+.86H(RD1\DUZ-O [<RNQK7MF28G;1?/3DW25',)'U35
MB#WNJRNEJ @Z?,'D\FGA!ZC(22*>3*.&*S4"UX .!NH3U$]&=.O4+6^[-/)7
M79E[DBT[CWQRHG=E=S<BMHOUV<?"436]6;)/)5X525E&B<C)%;+-HQ)RGD^%
M'"S5LY XBZ,W3[W;HB0Y*<^N<"L6XY_=0:V1VP-M5B&,BYK_ !_US'%44U[Q
M^KSY-U)8>N*E'N$D)1PFZ70R5@P9%4<^UV7[T"(#D;T]MH<&M1\2^G+#<FX_
ME[K&/Y)V;:'3XZ<%?TQ'Z^VCNNZ1NQ+)N]J\Y@;]/L&QM5N*G&NPW![/VQ\V
M@8A.<1311,JR6,S(U S32'-_:? VB]0+D?J;C%'\[(SCMNPL!U3^HEL+=L=I
MK8_([D)2UXJ*V/2.,FJB:[MS'.H.)D-:$(6O1;J3A8CQ(V$XY(ZJKEXY DC_
M !#'(&JLNA+R?V+#G45:[[UGIZJZZC)%HH26FU-VW_7J3)HDP0<8R2895&4>
M2!D_"'PGXD?V%<EPF<"87BMKN3U!Q@XX:FFN][<ZOT+J#7<MW^S)_;.DZ]KU
M:?\ >R4I"][QJ,/V]F,8[?\ 0 -\@          #7NV_DIV;]'MT\VY(8_BW
MBK>?T?4;R\H5/@TGM'=)2L$/,@P$          L'\'O1=UA_;7^(=M'H#DC]
MV%V?I/QN<S2Z?F^/\+ME.L!M8N(             1[]2;Y#*I]+$%YGWH1^Y
M2'$>E^E8OB]466_?!&[HG:N(2!"DQ0        ,KH7PYIGE97?=AF+K</SY1
M>-P[XTJP_CF>V3IEI0>H1L                I_]7#TY=E>3VN/,2"$XLD_
MN\I-UGWYY$W-7CK4[G%O32-(;8-<@       !,CT0/2OV#_+S:_XD:F&B>4)
MQ,I?I2/>*DV[DOQHJ/$'[] 6G!#LDV             &/6[X*6?R>FO<UR.U
M1>&P[JSMD.O5^"R[F[I*>?F/3 @>          7 >D?Z#6M?*'8_GW.B#N=G
MWAU>Y0;RPEEE5Q*IMTEWUQ)8-3FQ@             A$Z_GH+1/T\Z_\W;V-
M2YS\4&^.1]K(>C/[KW]I.?\ PS6[_1%+ 14/T,        !E-'^&M/\ *FO^
MZS0=BD\+BW1O30LV(^+U?XE/O3CTX1/T_'.
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M>%Q;HWIH6;$?%ZO\2GWIQZ<(GZ?CG
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M1O30LV(^+U?XE/O3CTX1/T_'.
M !AFQ_D\OGD9:/<-\.6]<GLG"[!H'@SZ*6G?U-->=E@'W+UZG#.M0ZQ%,^@
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MKD]DX78- \&?12T[^IIKSLL ^Y>O4X9UJ'6(IGT
M            &O=M_)3LWZ/;IYMR0Q_%O%6\_H^HWEY0J?!I/:.Z2E8(>9!@
M(         !8/X/>B[K#^VO\0[:/0')'[L+L_2?C<YFET_-\?X7;*=8#:Q<0
M             CWZDWR&53Z6(+S/O0C]RD.(]+]*Q?%ZHLM^^"-W1.U<0D"%
M)B@        970OAS3/*RN^[#,76X?GRB\;AWQI5A_',]LG3+2@]0C8
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M27A%<=XV?8+CV152)R+;H/A7I9T3;'!GT4M._J::\[+ .)>O4Y9UJ'6(IGT
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MP[[_ /BD'HKP'^8?^/4=^'_N#<KWSN^R[E_^G#U,735^[=^^'??_ ,4@]%>
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MUR>R<+L&@>#/HI:=_4TUYV6 ?<O7J<,ZU#K$4SZ
M            #7NV_DIV;]'MT\VY(8_BWBK>?T?4;R\H5/@TGM'=)2L$/,@P
M$          L'\'O1=UA_;7^(=M'H#DC]V%V?I/QN<S2Z?F^/\+ME.L!M8N(
M             1[]2;Y#*I]+$%YGWH1^Y2'$>E^E8OB]466_?!&[HG:N(2!"
MDQ0        ,KH7PYIGE97?=AF+K</SY1>-P[XTJP_CF>V3IEI0>H1L
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MY)[FV;L9S#/;?;+YL*0*L6/PI!P\)'QU3J,.W081,>BCA%HD10Q>PRQP!VF
M  PS8_R>7SR,M'N&^'+>N3V3A=@T#P9]%+3OZFFO.RP#[EZ]3AG6H=8BF?0
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MEH]PWPY;UR>R<+L&@>#/HI:=_4TUYV6 ?<O7J<,ZU#K$4SZ
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M]<GLG"[!H'@SZ*6G?U-->=E@'W+UZG#.M0ZQ%,^@
M             U[MOY*=F_1[=/-N2&/XMXJWG]'U&\O*%3X-)[1W24K!#S(,
M!          +!_![T7=8?VU_B';1Z Y(_=A=GZ3\;G,TNGYOC_"[93K ;6+B
M             $>_4F^0RJ?2Q!>9]Z$?N4AQ'I?I6+XO5%EOWP1NZ)VKB$@0
MI,4        #*Z%\.:9Y65WW89BZW#\^47C<.^-*L/XYGMDZ9:4'J$;
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M;')R.I:U':GUZW;<B[MJV0FI"0;)ZPGKL<JR3IDL:+/EBKX'/]4?L ^C\.+
MV#:>K.<_4=M+"4C%NI'SCW!N37+*604;O$-"4F>E:?JUNJFN<ZY/:Y^K-LT<
M9SDF6C9 Y#&*?MR!8^                                  !AFQ_D\O
MGD9:/<-\.6]<GLG"[!H'@SZ*6G?U-->=E@'W+UZG#.M0ZQ%,^@
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M)[)PNP:!X,^BEIW]337G98!]R]>IPSK4.L13/H
M           ->[;^2G9OT>W3S;DAC^+>*MY_1]1O+RA4^#2>T=TE*P0\R# 0
M         "P?P>]%W6']M?XAVT>@.2/W879^D_&YS-+I^;X_PNV4ZP&UBX@
M           !'OU)OD,JGTL07F?>A'[E(<1Z7Z5B^+U19;]\$;NB=JXA($*3
M%         RNA?#FF>5E=]V&8NMP_/E%XW#OC2K#^.9[9.F6E!ZA&P
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MB$QG( LB
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M0+)P
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M@FDW122(!UB
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MO\G/Y2/0OA?\XK^SA[P/4@<4/G!Y#?WKUO\ _"8.<)C/\UNO\G/Y2/0OA?\
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MXEC7;',5$:KFN6Q&QLTVL32JKH.]AK<SD
M
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M\;AWQI5A_',]LG3+2@]0C8
M
M           0V\1.7&].6G5*ZA=4KMU3C^$G!ROZVXQ15';UFIGQLGEE.+.;
MOMS83JX+P"]\9N-3L&/[*9BDI1"'6*Y([RU5<9RJ0#!]S]2_E3N+F%MG@KTL
M./VH-S["XU,ZZ?E/R2Y+; M5'XS:4M=K:.I"O:G1;:Z@+#?]A[ ?LVBN7>(L
MO@HIPW606(<Z+G+8#K77')'DYH7BUR"WSU2*5Q^U.XX]L;?=I*Q\7;U<=@Z_
MN^JZG365D7GX&+V/ U2XP]F<RQ7D8VBGG:L\<)H^#R7PQ<9 A?=]8SK&N>+;
MGJ<0/3-T)GI^MZ^MME#7LQOJQ(<OGW')C@TBYW2;+>'-0(^#<5-(\P5#VN</
M$8__ %@J#AI@KI0"0/>_5?G+14^F? \ J5K_ &AN7JLIVVQZ <[ZGING:SUY
MK75FJF^WMPVW9Z%,0E[/(V"BP;Q%@:"CE$E5I+*Q,.N\B1)P!L_@QU(9+<.L
M.9:G,6OZWT#MSIX;<O>J^4LG3+3+V#2JD+3:DROC3<M(FIZ/:6".H]CJCE9<
ML=(85E6)V:A5ORCD)@#9W39Y.\AN9VH;9R>VQK6LZ?TIMF]2,SPSHIX.RQFX
MWG&MJ7Q&H[.WLYE[-*P1+5MLZ1IN,C8E@R;1D&X:]]=^=?PY0-!=,OEWNZ_<
MD>I/P5Y4W9.^;QX7<C&TQ0+DO7:C49*Z<2=_0W[?<?'4E$TFNU:LR-CJ,#A2
M/EGK-DE@V56GA\9<',JL!,D   PS8_R>7SR,M'N&^'+>N3V3A=@T#P9]%+3O
MZFFO.RP#[EZ]3AG6H=8BF?0                                 :]VW
M\E.S?H]NGFW)#'\6\5;S^CZC>7E"I\&D]H[I*5@AYD& @         %@_@]Z
M+NL/[:_Q#MH] <D?NPNS])^-SF:73\WQ_A=LIU@-K%Q             "/?J
M3?(95/I8@O,^]"/W*0XCTOTK%\7JBRW[X(W=$[5Q"0(4F*        !E="^'
M-,\K*[[L,Q=;A^?*+QN'?&E6'\<SVR=,M*#U"-@             !K^7VQJR
MO[#I^HY[9>OX3:^PHNP3E!UC+W*N1NP[Q"U-%)Q:9BGTM[)(V2RQ=:;K$/(.
M&39=)F0Y3+&)C.,@#8             #!]D;-UMIND3^S-O;"H^JM<51NW=V
MC8&R+9 T:D5MJ[?-8QHYG[79W\7 P[=S)/D&Z9W#A,IUUB)XSDYRXR!FQ#D4
M(51,Q3D.4IR'(;!B'(;&#%,4Q<YP8IL9[<9Q[&< #_0
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M3JO]A\*YUFP;7X,^BEIW]337G98!Q+UZG+.M0ZQ%,^@
M                U[MOY*=F_1[=/-N2&/XMXJWG]'U&\O*%3X-)[1W24K!#
MS(,!          +!_![T7=8?VU_B';1Z Y(_=A=GZ3\;G,TNGYOC_"[93K ;
M6+B             $>_4F^0RJ?2Q!>9]Z$?N4AQ'I?I6+XO5%EOWP1NZ)VKB
M$@0I,4        #*Z%\.:9Y65WW89BZW#\^47C<.^-*L/XYGMDZ9:4'J$;
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MYE==0B:F5IJ0:*.S%-WLIF6R7)SY+WS =^@
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MR>R<+L&@>#/HI:=_4TUYV6 ?<O7J<,ZU#K$4SZ
M           #7NV_DIV;]'MT\VY(8_BWBK>?T?4;R\H5/@TGM'=)2L$/,@P$
M          L'\'O1=UA_;7^(=M'H#DC]V%V?I/QN<S2Z?F^/\+ME.L!M8N(
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M3J9.;M,;.0!T2
M                             -))<<-(H<AW'+!MKZ):\AGNIBZ+D=G-
M',LTF)75"=I0NC>GR[%M()04NU969L5RW<.6BKQM^4FDL1(QB9 W:
M  #2.A>.&D>,%2G:-H?7T3KNLVB_7+:5G91KF6D7=DV)L&5--7*XV"9GI"6F
MYJ>G7^2Y57<N53%23213[B*2:9 -W   ,,V/\GE\\C+1[AOARWKD]DX78- \
M&?12T[^IIKSLL ^Y>O4X9UJ'6(IGT
M  &O=M_)3LWZ/;IYMR0Q_%O%6\_H^HWEY0J?!I/:.Z2E8(>9!@(
M!8/X/>B[K#^VO\0[:/0')'[L+L_2?C<YFET_-\?X7;*=8#:Q<0
M                             "/#JT<:[%R]Z:_-'CM3(U2:O.Q-#W N
MOX-%3"2L[L*J((W>@P:2ILE(FI,W"M,FQ3&S@F,J]IOR>T ?'JKC=KSF)TQ^
M.F@.;.BE)J$NO&3CXQW+I39,9.5::KM[K-'ISZ6AWZ4>ZA++5;)4;K$&PDX9
MN&KE!5#!DU,%S[('/&BOP]_23X^;'K6V*EQ8;VZ\4=XV>T%]N79NVMV0]&58
M*IN(LU9I^T+Q:*:U<0SI!)9BY5CUGC)=(BJ*Q%"%-@"2/D_Q=T?S*TM:^._(
MVHR%]TY>E(4]OIK&\; U^G84Z_-,+%%LI*<UK::?95XM*9BVZRK3QS#5SE(I
M5DU"?D@#:M%H]0UE2JCKC7U<B:?1*#68*FTNIP+1-A"5JJUF,;0T! Q#)'&$
MFD;$Q3-)!%,OL$33Q@ :"@>$_%VL<MKQSKA-2Q;/E?L?6\9J.X[>-.VYY(RN
MOH<T 9C!(UM]8'-)AU"EJT>FJ]8QC:0<(M$TU5SIXR7('&G(SH4]+KEKLV_[
MAY#\>+9LF_[0E&DQ>9)]R?Y;0D1-/F#6.8Q_<I]7WM!TR(9QS2(:IMVK&/;-
MD"H$\&F7NX '3O$/IZ<3.!E8OU2XFZ\GM516RW48_MBCW:^WMJ23E_!Q[Z,A
M'4?)[JO>QW<.6*;22V4F[4R33*A\G.D<WL@#8'%/B5I7AEJY75&D(2691$K;
MK3L2YV:UV"4N6PME;(N\D>7N&Q-D7B>7=3MPN5A>F+X=XZ4-DJ*22"14T$4D
MR <FV_HR].F^[\LW(FVZ)>3-LN^QX[<]YHJ^T=LDT)>=T129$F>V[GQY0NR6
MF+/?,)I%,JZ>PBR;EQWG2R2CLZBYP.;-X<>MR\]^KGHY?9FMKA2N"?2^;Q^[
MJG-6J,?1$+RGYIWV+;J4>4IS=X@D6?H?&V%;Y<YE43EPG9#JM.ZNV<&,0"=H
M
M                                  &&;'^3R^>1EH]PWPY;UR>R<+L&
M@>#/HI:=_4TUYV6 ?<O7J<,ZU#K$4SZ
M    #7NV_DIV;]'MT\VY(8_BWBK>?T?4;R\H5/@TGM'=)2L$/,@P$
M   L'\'O1=UA_;7^(=M'H#DC]V%V?I/QN<S2Z?F^/\+ME.L!M8N(
M
M
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MN[=>NY/92/'KCQ6IAO3856,U!&VRFH6O85TV0XS#X2?S#5C'^ /@WA#K%40
MU-PRZN$Q'<)>76\>>LM3Y*W<,.<>_P#@LUM&CJE(19^7UQU%(UB)U\[T;JY_
M8IUW+[$W++V/VN80D<_<-U7S954IF[8BV&X$C/!%QS,M&K9W;'-IQ7:IL'<-
MJ6O='XYU2(B4X[BUJM_'LRTW3]EN3=H29V5M9FTP9W;)==;,?B874:1J"+1L
M51P!Q)TB>1>U-B;MZN'&[;VP+-L>4XK]1'8[76TK;)9W.2E<T-N!DG;]7:^1
MDWBBRRT32S14FV9$,;)F[4Q$?^:F4 3<
M
M                                   ,,V/\GE\\C+1[AOARWKD]DX78
M- \&?12T[^IIKSLL ^Y>O4X9UJ'6(IGT
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M[:\U[)YRF1C8JMQ_CGD5&6.,2\7255:RD9>FW>7P=1(ZR9TBY\(@MG(%E
M
M
M!AFQ_D\OGD9:/<-\.6]<GLG"[!H'@SZ*6G?U-->=E@'W+UZG#.M0ZQ%,^@
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MV\>97.3IQC=LE[!4RXP!(*
M
M                         PS8_P GE\\C+1[AOARWKD]DX78- \&?12T[
M^IIKSLL ^Y>O4X9UJ'6(IGT
M                        !@\'K+6U9N]ZV96]>T>O['VBWJ;39FP(.IP,
M3=]B-:$QD(RBMKU:V#!O/6YO2XV6=MXDD@X<%CD'*J;?"9%#XR!G
M     #7]KU/JR]VC7]XO&M-?W*ZZFE)6<U7<+73:Y8K1K2:G8[$1-S&O[!+Q
MKR6ILI,1./%73B.6;*N&_P#5J&,3\D ;
M
M                                     !AFQ_D\OGD9:/<-\.6]<GLG
M"[!H'@SZ*6G?U-->=E@'W+UZG#.M0ZQ%,^@
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MK-7XYT#=>WMXPE$GY6GK;KW+);(<QZE9A9.P1+M-O Q;A),V2JHJE-EDA(R
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MRFJ!/<
M
M                                       PS8_R>7SR,M'N&^'+>N3V
M3A=@T#P9]%+3OZFFO.RP#[EZ]3AG6H=8BF?0
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M\-:J]7W)DELFP=!PACN=UQ@V0+*0
M
M
M##-C_)Y?/(RT>X;X<MZY/9.%V#0/!GT4M._J::\[+ /N7KU.&=:AUB*9]
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MPNK:>@C:[]QSAXU6,G>/VO;6RLE>2TI%W&.3;QSR79,)-PE"D69-T$L.#*D
M_+Y6].OCURFX#7KIT+PZFHM 6C7]2H-8C-6-(V%SKIKKJQ5JXZ[<UJ.7:N(T
M[>LVFGQSD[94F2O$TCIJ'QE4RF .<M0\(HOB/LS8W4BYX\SK=RGW%JGCK/Z_
M;;EV+1J!IK66A>/-9R>^7Q6I:SU\V4B&-FL3F*4=SMA=.G<D]0)AJEX%OVHG
M YYZ)&J;SN>W\O.L/N^N2E9O_4?O$.ZX^T^R(&2G]:\'-8M,5[0$<\;Y(BA&
MRFR(1HA-/BMBF;2#9".D,'RHZ5P4"P,
M
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MY/9.%V#0/!GT4M._J::\[+ /N7KU.&=:AUB*9]
M          ?&[CH]^9F=\Q9O3QSPDC'G=MD7)F,@DDL@F^9F6(?+5XF@Y4(5
M4G=/@BAL8SV&SV@?8             ^5ZQ92;-S'R3-K(,'B*C=XQ>MTG;-T
MW5+DJJ#ELN11%=%0N>PQ3%R7./Z< #^R**3=))!!)-!!!,B***)"II(I)EP1
M-)),F"D333(7&"EQC&,8QV8 ']
M
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MI\<J7;^5X,I<F]GM'PYVLZT^D2Q+#:X^3D
M
M
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MNTP%C
M
M
M                    'QYCH\T@26RQ9YE$V:L<G)9;(YD$X]=9%RLQ(\R3
MQ@K-9PW34,E@W<,<A39QVXQG 'V          ^-A'1\4U*RBV+.-9D4<+$:,
M&R+-J15VX5=NE2MVY$TBJ.7:YU5#8QVG4.8V>W.<Y 'V
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M            .0-S\Q(/2UW7H[_1?)2_.$(Z/DLV'6&LF=IJJA)%,ZA6J,LM
M9XHYWK7!.Q8G@<8(;.,=N1M#"F5M9BRZ$O>&^+@HF.D<W:JNK=#,FJMEJL2)
M_4K_ #5UM)'_ #%Y0=V9<XE=AFJPQC*]960QR;?=MW,J:54D151J2K4Q*KVV
M6/;JZ%Z*FJ/6.U;[J_-?ZCX[X\C)/01>/G'A+ZP=Y.8+SOKD\QLR/J:/RT>L
M=JWW5^:_U'QWQY#T$7CYQX2^L'>3CG?7)YC9D?4T?EH]8[5ONK\U_J/COCR'
MH(O'SCPE]8.\G'.^N3S&S(^IH_+1ZQVK?=7YK_4?'?'D/01>/G'A+ZP=Y..=
M]<GF-F1]31^6CUCM6^ZOS7^H^.^/(>@B\?./"7U@[R<<[ZY/,;,CZFC\M'K'
M:M]U?FO]1\=\>0]!%X^<>$OK!WDXYWUR>8V9'U-'Y:/6.U;[J_-?ZCX[X\AZ
M"+Q\X\)?6#O)QSOKD\QLR/J:/RT>L=JWW5^:_P!1\=\>0]!%X^<>$OK!WDXY
MWUR>8V9'U-'Y:/6.U;[J_-?ZCX[X\AZ"+Q\X\)?6#O)QSOKD\QLR/J:/RT>L
M=JWW5^:_U'QWQY#T$7CYQX2^L'>3CG?7)YC9D?4T?EH]8[5ONK\U_J/COCR'
MH(O'SCPE]8.\G'.^N3S&S(^IH_+1ZQVK?=7YK_4?'?'D/01>/G'A+ZP=Y..=
M]<GF-F1]31^6CUCM6^ZOS7^H^.^/(>@B\?./"7U@[R<<[ZY/,;,CZFC\M'K'
M:M]U?FO]1\=\>0]!%X^<>$OK!WDXYWUR>8V9'U-'Y:/6.U;[J_-?ZCX[X\AZ
M"+Q\X\)?6#O)QSOKD\QLR/J:/RT>L=JWW5^:_P!1\=\>0]!%X^<>$OK!WDXY
MWUR>8V9'U-'Y:/6.U;[J_-?ZCX[X\AZ"+Q\X\)?6#O)QSOKD\QLR/J:/RT>L
M=JWW5^:_U'QWQY#T$7CYQX2^L'>3CG?7)YC9D?4T?EH]8[5ONK\U_J/COCR'
MH(O'SCPE]8.\G'.^N3S&S(^IH_+1ZQVK?=7YK_4?'?'D/01>/G'A+ZP=Y..=
M]<GF-F1]31^6CUCM6^ZOS7^H^.^/(>@B\?./"7U@[R<<[ZY/,;,CZFC\M'K'
M:M]U?FO]1\=\>0]!%X^<>$OK!WDXYWUR>8V9'U-'Y:/6.U;[J_-?ZCX[X\AZ
M"+Q\X\)?6#O)QSOKD\QLR/J:/RT8ZEFJ4\=Q_I;E-%.R9R5>/D--Y(]:GQG.
M/!N"(6-PD4^<=F>S!S>QG';[/L N06)%TPWMAR2)=AS:[J5]BV)%_P!APG+)
MP*SJ:K#F.(*A.NCDNFQ[5]1R-J');T="J?\ ?67Z=^:;DU]3R_OX'H Q3PGA
M_P!_)WLYYY>7W .-/JE>_#UE^G?FFY-?4\O[^!Z ,4\)X?\ ?R=['/+R^X!Q
MI]4KWX>LOT[\TW)KZGE_?P/0!BGA/#_OY.]CGEY?< XT^J5[\/67Z=^:;DU]
M3R_OX'H Q3PGA_W\G>QSR\ON <:?5*]^'K+]._--R:^IY?W\#T 8IX3P_P"_
MD[V.>7E]P#C3ZI7OP]9?IWYIN37U/+^_@>@#%/">'_?R=['/+R^X!QI]4KWX
M>LOT[\TW)KZGE_?P/0!BGA/#_OY.]CGEY?< XT^J5[\/67Z=^:;DU]3R_OX'
MH Q3PGA_W\G>QSR\ON <:?5*]^'K+]._--R:^IY?W\#T 8IX3P_[^3O8YY>7
MW .-/JE>_#UE^G?FFY-?4\O[^!Z ,4\)X?\ ?R=['/+R^X!QI]4KWX>LOT[\
MTW)KZGE_?P/0!BGA/#_OY.]CGEY?< XT^J5[\/67Z=^:;DU]3R_OX'H Q3PG
MA_W\G>QSR\ON <:?5*]^'K+]._--R:^IY?W\#T 8IX3P_P"_D[V.>7E]P#C3
MZI7OP]9?IWYIN37U/+^_@>@#%/">'_?R=['/+R^X!QI]4KWX>LOT[\TW)KZG
ME_?P/0!BGA/#_OY.]CGEY?< XT^J5[\/67Z=^:;DU]3R_OX'H Q3PGA_W\G>
MQSR\ON <:?5*]^'K+]._--R:^IY?W\#T 8IX3P_[^3O8YY>7W .-/JE>_#UE
M^G?FFY-?4\O[^!Z ,4\)X?\ ?R=['/+R^X!QI]4KWX>LOT[\TW)KZGE_?P/0
M!BGA/#_OY.]CGEY?< XT^J5[\/67Z=^:;DU]3R_OX'H Q3PGA_W\G>QSR\ON
M <:?5*]^'K+]._--R:^IY?W\#T 8IX3P_P"_D[V.>7E]P#C3ZI7OP]9?IWYI
MN37U/+^_@>@#%/">'_?R=['/+R^X!QI]4KWX>LOT[\TW)KZGE_?P/0!BGA/#
M_OY.]CGEY?< XT^J5[\/67Z=^:;DU]3R_OX'H Q3PGA_W\G>QSR\ON <:?5*
M]^'K+]._--R:^IY?W\#T 8IX3P_[^3O8YY>7W .-/JE>_#UE^G?FFY-?4\O[
M^!Z ,4\)X?\ ?R=['/+R^X!QI]4KWX>LOT[\TW)KZGE_?P/0!BGA/#_OY.]C
MGEY?< XT^J5[\/67Z=^:;DU]3R_OX'H Q3PGA_W\G>QSR\ON <:?5*]^'K+]
M._--R:^IY?W\#T 8IX3P_P"_D[V.>7E]P#C3ZI7OP]9?IWYIN37U/+^_@>@#
M%/">'_?R=['/+R^X!QI]4KWX>LOT[\TW)KZGE_?P/0!BGA/#_OY.]CGEY?<
MXT^J5[\/67Z=^:;DU]3R_OX'H Q3PGA_W\G>QSR\ON <:?5*]^'K+]._--R:
M^IY?W\#T 8IX3P_[^3O8YY>7W .-/JE>_#UE^G?FFY-?4\O[^!Z ,4\)X?\
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M%/">'_?R=['/+R^X!QI]4KWX>LOT[\TW)KZGE_?P/0!BGA/#_OY.]CGEY?<
MXT^J5[\/67Z=^:;DU]3R_OX'H Q3PGA_W\G>QSR\ON <:?5*]^'K+]._--R:
M^IY?W\#T 8IX3P_[^3O8YY>7W .-/JE>_#UE^G?FFY-?4\O[^!Z ,4\)X?\
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M2W0FUZ5]0K4_+%P!4U#*=EQ8R1\CVM15NI41%<J(BJNW:$TZ5Z"$A@T>2T
M
M
M
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MM-;+JS^CL.0=WMRZ<5 N*)7WQT;>ZH;66DF9G#]9LU670PZPBE@[8XQVIQ9
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M;RKVI'3I75+7LI8**A6W58LK%_M%0ONBUBHQB-?86$1LD@<
M
M                                0$<U*;MGE!U7^.FG=';HQI"V<9>-
M%YWJ39A];P.VFM.G-B6=.BOF/[#VQ_&UU])3$*WB\%57,?"!%R*IXRJD7*>N
MK]@K+VQA2T5WS^YYJ2E?+MFHDFJKW:BIJ.5&JJIJ[.Q;:FE"<N3U[X6RVY+^
M(,68TN?Y9NO$>(J:[5HTJY:%T\=+"M2UWNB!KY6LCD6;0U$UE:YKE1KEUNQM
M+=.^7A=Y5WDSROY)W;F)NR@Q[Z.U<_LU.K>L];ZS-*D.C)S54U75'4A L[,[
M;Y*3QSPO=P8A5?!9<)-UD+W0X:?'>#;UOBJDK:^-%2-7-;&QENRK8VVHCE]7
M^&RU$5-2XPS\I*S!=1ESE?AVCPE@ZND:^L;#/-65=7J:61SULZ-E="U;5VO5
MML56ZVHZ1C\XUXYZHRM^K1=KPG 9AJ\TTAFXK:\M'(>7OR-=P<QG)*TWLE/A
M*\YFC$Q@B9G2J2!<YR?)<]G<SV*9<6K4L]V-NY*36ZK4=,K]7_=UFHVWV;$+
M-?T?)J;<=2N%YL<OQ+M*[0E5#=3*99>AMRQ3R2I';I5&-<Y=A%2W62/ _(:J
M<#>;'5PMUJ[%XRRZ\XV;LUW5?8]L+E>WU3D:8A5X=NRQARNZMNQ9\C=0Y$%#
M((%\,H;!4E#GQKY2AP]?U\SS=8Z*"5C>BYZM5NJEG])ZV;&A-*["F^VX"O3.
M[)S*NZKLT5-/7WM=]5-_-IZ9L[*A9I%=H1(*2)7(BN1'.74:EKFHFDMT:2V!
MHOI_\=>.^PI=Y#;KZEG.'6B/+&U85292#-[O&Q'LEOAEGY,N#LG,&WB(>,=)
MIE6:*>!?YQVIK9(IT*Z@J;OPY3794N5M=>MX,]T.V%197:SDMZ%EC6KLIH=Z
MNG,<(8RN+&N>M_X^N&)DV#\N\&5:W)#8KF.;=T20P2(U;-9)%?/,Q5U7IK0)
MUS+6]/\ 6:1U35^(&F>$U'KM2C+?O?;>G]2Z+I3*+:K.Z?%0=J@L2%GKK0Q%
M%H]"/34:0JKA/.7"WMYE/\OPBIBW7'"4<5RP7#3M8D]1-''$U$ZU$<EKF^I9
MH;;L]7ZZFM^2(_$]Y9KWOG'?515273<EU5]=>50Y[D;.^2&35AE=H1RN5'U#
M6+U+?<VMHU6HN;\ZH".M7+GI,<3(%KWJO";<L.]I*&+VG:QL)QHI3*0I)G_;
MCNY:+ER_:$P?\A4V,I&P;*F"Y[&((VS7S<US1I_4MF654]1(&HK;?6V4_P!A
M9LE:ZHNS*O-+-*N=_>4UU17:R3^<^2]ZAS:C5_WD_JGK9I:G5)9JJJ?LZ86_
MQ8ZSG+V[&R1RPXQ\8=.:!CCGSWR(R&T))/;;M=KC.<>"5;N&L@U4S@N<]O?Q
MVXQGLS]T*^[,<UL^RVDI(H4]F1=L7_XH=3%[/U7Y(>%+F2UL^),25]YO]=M&
MQ:%J+ZJ*CHGII]1;+=C47'G;U9WGU+^H-RSKCC]L->\3N.E8X_TV5;Y2792R
MB+V;O]U_9IWD^6BJ1+=1Y=%%PB<Q56SLJN#E3<XP;IW;6Q7ABJ\KXB77IJ.E
M;"U>@NE7NU?PF.1%]1;=A3*L>X4O'!7)UP'E=>#?<E_8HQ!->E0Q;4<Q%;'2
MT^W-ZY%VBI@<YKD14>Q6V*Z/1J_I@43GM8N/,GR%UM:.(3.;Y=W6[[5O.V-D
MU_;EYVY[:'LDO521RT;$S%:K1XNK*0:V8F+\>,Q8F6/DQ3]]0F>GA.GQ%+=J
MWE2OHD?6R/D?(]LCY+=96V6(K6V-L75;;8EOLF2\I&^\C[OQ['@+$--BM]'A
M2CIZ*FHJ26AIJ'4VF.;71[XYID?,DC=OFVM))$:VQ4L:Y)>.%G$N(X>:HFZ&
MWN4EL2UWS9%NW%M"]R$1'UPEKV3>,1J4]*Q=7BCK1U8B/$X9HB@Q155(D5+)
MN_G)LXQFEQ7,RY*-U.CUEFDE=+(]41NL]]EJHU-#4L1$1$]0BGG!FE59LXHA
MON2DCN^ZZ&[X*"CIF/=+M%)3:ZQ,?,]$?-)K2/<Z1R-5=:RS0<?=3-#%0Y ]
M+3>)C8;I5+F=&Z?=OSY0(BRCN0$&2$D#N5E#)&;M3-ZEG*A^^5(I2YR?!LX+
M@67%2;3>5T7AL(RN2-5]1)DL7M3;')S>M[8$S+P8G5.JL(/KVMTVN?=DFV-L
M1+;5MGT)9:JK8BII/BXF=O,WG#N+GD8IWNCM-P+_ (N<2GRI#E86M9G(*.MR
M[>AB'PB=5I(3"RT1'OBE,F[8KJHF[%6F<$^;F_OR_P"?$.S00-6"G7H.L7^M
MD3UE6UJ+T454V6E;-+_[19,73DBEC,9WO.V^;\:G70HYJ)04,FS8YL:-GEC6
MQ62-:].IEM70>NU]\=)38]:TUL&!HF[.&?*[E0YK=)V?#+.(K<M&V+NQWVLX
MS9L \368W9F=I$*846;%6450:J*9<I9,WC<6ZF6\,&U3*&I;'/<=96:K)$T2
ML?+L)(BZ'I8FRENA%6U-##.+_9@CE38?J,77#/6W-F[A?#*2U%'(B/H*FDN]
MO5/HY6JCJ=VM(EC7JU$<]K4C=9)4+/@2=A%9E>NIS$4I8&K!&5<P1)!H>9;Q
M;A8S="27C"K9>HL%W!#)D6,3"9CXR7&<YQV#8FV1J_:D<FV(EMEJ6V>K9LV>
MN0=6BK&TC;P=%*E YZL235=M:O1+58C[-57(BVJU%M1--A^J/LZQ5YU5O>P\
M;>*G-;B-JXBLCR1N'4(W[Q?XRU-@=).441V-^SA6MZ+E#M)$Q-.@Y&0ECOED
M4F#5;Q0JV2E4/W=34=X2W7<]?<U)IO1]Y300-39ZO5ZOUD:BJZU4L1;+=D])
ML3X)H,P\SL'9J8E5(\O:3 =V7Q>\[K58BTFVVTVGKWU$C(H$C:YTKV[:K+5:
MEN;\GN/UHIURZ673"TT?7<C7Z?!V[==NBMK&L+76.W+IJIAFSI9N<;5B.)J4
MB9:T(S\DYC,IY;KF?)E/GN)9[.Q>UVS03W1A.AVI8V-=*Y)-;:Y'1IK=4C=*
MHKM=RMV%M3U"SY;X[NV][HS,Y2&+DO".OJYH+O@?1;4M90T]:[:5]SOFLC8]
MD*TT+)K=9NUN5$M<2%/^'/)#D-MG0>QN8.T=+MZAQLV#%[8UYI[CK0K3%QTG
ML2NY(M5YZV;%V#892P+,8%VB0^(Y@P9-7),8(I[)<'SDCKDO2\JRFJK[F@2&
MED21D<+'(BO;UJN>]56Q/Z*(B+T30L&;67N L+7YA_*>[;X=>N(:!]%55]ZU
M,+WLI9=$T4%+2Q,B1TK55-MEED>Q;5;LV)S_ ,?M44ODOU:.;7(V[1;2T,>+
M!]0Z0TVRE&Z3^,A[BG3G#R[6(C==(S?,]5YM!V1BI^49MF544Q@JQ$E"VZ[:
M."]<95]YSHCVTFUQ1(NE$=JVN=[+5ML]365=FPSK'>*+XRZY+>#<O[FE=338
MF2NO&O<Q5:^2!9T;3Q6HMNU31JQ9$T(_:6M558KFKE/"EW$VOJ$]63D:Z4:1
MM5J]KU1HY"4(4C9FFZT]1'$=LUQ)'1*GAVXCY" :',LMA55,A\IE-A,N"BK<
M*LFQ)?%YK8D+'QQ6]#^K99);["HFE>D6W.**JNO(;*[+^-'27G4TM;>*LV7*
MVOJ4?1HRVW51[97HC6V-541RHKE52,YK<[?$]'W:&U6<@[JMIZEO."W^WEE<
M';HO8:J;=V.\JED*[/@_8VC'U>UU(M3E[#E\!)*')^0H4^,52>=F"I:Q%5DU
MZU[K7>HV1ZM=;ZRM8Y/8<2+ENBZJKE87;AB6-M5=F76#(-KA2U6R34-(V>+5
M3HO;+5Q/38ZJ)J.TM5"SW3M5ZKUEK6DZ5KU8K,5KRN1D55*I3W;*-4CG!8%N
M>7:IE8.4? RLSWHI6275R0[A5PDJZ/G)\'.-L04E'24L=!$QB4S41K6JB6:-
M.QT5T:R]&VU3S=O?$V)L1XBK,85]34RW_42/FGG:YZ/3;5U%761;61]6D+6V
MHUK5;$G4V-(9ZEL5ZSYH]9#F,T:XD4>*''B!U10,K)X727<4/6<UM"_0A>U1
M%)0J-YI*1U4\G+[#DF,YQ[.1@\-4YM^WY?;4M2CIDC9^!&LCT[-O^TEU>EP0
MRY09292RNVM^*+_EK:JQ;%1*FLCHZ:3854MIJAR-6Q>L70IC?3?TQSZB.)=4
MLFK+YQ&JV.2*3_=EQW9;:KM79N]9NQ['7<2RD[:&2DQ5:7+VF ;/"H()KJKL
M$3-LE436,JLJ:EA>AQ&RYF2TDE$SW5;*Z5S9))5<_3:Y+6M5R6V);:B6:46U
M5+CR@\7Y&U6:55=^)J'%52N'E;=T%WP345'=L<5(B,2.%R1S5$<,JM5SE:UL
MCD?:US$:QJ2T\-N*M3X::$K&C*E.REK2B'\]8)^V3+9JP?6:TVB47EIN6]JF
M&31\,SRLL5%JT1R8J#5%,ICJJ=]53,;CNB&X[N9=\+E>C555<NA7.<MJK8FA
M$Z"(FPB)LKI(M9N9FWIF[CBIQI>D$5*Z5D<44$:JYL,,+$9&S7=U4CK$5SWN
ML5SW.5&M;8UO4HNYK0          CLZD&G>76X]4UJ+XH;$5J[B#L*\QLR@1
M-P<:MMFY*DFV1P2CU?;K1D^7H;UWDJZ9C'\5;N?&"^&<HE1[%,9Q117U74;&
M7/+J*UULC$=M;I6_T&R(BZBKI]1%MTJEFG?O)\Q;E5A+$]14YH7>E3'- D='
M5/@2L@H)U5?[3-0N<U*EK>I5$37>S574C>K[6\U=/7>?!77%D/QUB-!.N#_*
M5THA'V+6FZX_)=B[&E7"AB^'K6Z9PR[W<+"2>(949Y,Z05>'.95JSRD;OYM>
M&KPP_2R_)C*9:"]UT.9*G5O7_=E73(BKL:45=E&V&Q,^<%YUX@N],?U=^MQG
MEHU%=%5W>[^RTC$38FN^.QM YC5LDL8YL:(C99M9+$_;XE'+:^K7U0[-.*)H
M3E"J7%C752C7.<9>HTZ:H;B=F%V'A3I+EC7<U M'BN"I&3RH^3SW\?D94^[F
M_KL97M+)^,C93L:G1U59:MGK6HBK[*'3S2:MU\EK+6[J)%=15U5?-7.].M6>
M.I2.-'66IKMCE?&VU46R-VC9U?GV.X)R2ZQ6@J?7SXEJCP'TYL#9>R7[8QS,
M(K9V](M&KUBF/ETC%P2:3@VT9-(I]N<&225+G'Y"I1Q5+\J8VIH(^JANZ![W
MKT$DE35:U?7LU7)_#ZY]X?C7+SDEWY>U>FU7KCF]Z6DI&KUSZ.[7K--4-1?_
M ,M9%FIW+T'.:J=<U3M#FQL$C#@[RUNE!EV,X[A>/^ZDF,G7Y%O(IQTLSI,\
MQ=.2NHX[I,CNNKY,LJ3.<93,AG!^[V9SB^W]4ZMP5L].Y'.;32V*BVV*C53H
M=%/_ (&H,G+B6?.?"USWY$^&*:_;O5S)6*Q7L=41.1-5]BJV5+&M7HHZU+=!
MKW@A*Z^T=TSN-5PF)V+AZ#4>+M/V9;IWO)D81*<A3D[]=W#CP*J_><L):1>E
M7+C/A#N"&QW"GSW,=;#SZ:@PK2SO<C:9E(U[EZ"6MUW_ ,2JMOKE_P [:6_L
M9\HO$5TTD,LU^5>)9Z2"/3K/5LZTU.B6HFAS&1JU=A&*BVJB6D!W[*V.;X@\
M8K]LB/4K;+J,]9*F;NO7MOWB-8_6UYGIIO 1$LDJJ@Q/$2)(M6;;G,HEX5J8
MANW*?9DFN]IEDN6DJ*I-5MYWXV5]O08]5L1>A8MFLGK>L3B^4[OH\UL27'AZ
M1*B;+_*.HNZFVOKG5=-%&LLC%1%=MC-=*=R(CM5Z*EFM;K3I=6C<!=6<'=O5
M^*P>0V%ON/1XZ:PJS/&5)BW6S<)LU)W%0S<G:HL^;55[(NRXQV=N6^"XSWSD
MQG8&,:WW)<$T;--34)M,;4V7.DZFQ/7U5<O\!"ODMX37$V<]U5U39'<-QR+>
MM9,[1'!!0?U[7R+L(U9FQ,7V]NPBG6/'+6+;CYQOTOJ5XZ;E+J345(J,U)>%
MSXJN_JU68,K!+F5.<Q2)/)%JNYSV9P0N#_DXP7&,8O%V4B7;=<%&Y4_J86-5
M?7:U$5?X5M4U=F!B23'F85\8IA:ZV];UJ)XV6:4;-,YT3+$Z+6*UGJK9IM4C
MRZ+39Q:N-^W.2$DBI[:\L>56]]VY=+$R50T4ZM&:HS8)8S[)6<?*5M_E,N>W
M)#JG+V]F,8+C6!46:ZYKT=U]962R_P &MJHGL(K5-]\L"2.[,PKJR^IU3W-A
M?#%VW=8FQKMAVYSE_P!YS)HK5Z*-:NS:JS!#-2)X           &([ C+=-4
M*[P] L;2GWR6J-DC*3;7\6G.,:M;G\,]:UNQO858Z:4PTA)E5%RHU,8I7!$L
MIYSC!A1J6324\C*9R,J',<C7*EJ-<J+JN5.C8MBV='8+K<51=5'?E'5W[3NJ
M[DBJX7U$#7K&Z:!LC72Q-D2U8W21HYB/1+6JNMT"N#K!K2N%FVV]CZL.@+KL
M+:$K-$C:OU +;89KDIH]R11V9.'8MH>2BVY=")M%'>2,F_M-A[V8,?\ JD$\
M'QK"D2"XJU)<8TTDM6KK&UCE6>+UDL5/ZFSH)JV^PB'H-B22^,X,*NN_DO7[
M1T&&XH=>;#$$4=TWBEC?ZQRR,>ORFKD;;([;]KV&]4]UB]?=3RX53;+OI>PL
M!9X"S:=VWSQTK8W5IA)1E,5.U14+XR:%BT)9BY-&23"S%G%TTNZN8IEB%,4B
MAT\8Q>L63PUBW2R-[7T4UXQ.UD5%:Y$V$M30J.M7H_QFJ.3?=-YX6BS)K*ZF
MGIL6W5@B\(FPR,='/"^2S;'JQR:['0[6U7=2BHU515:CE5=T=8':*],X57?6
M583S+;6Y.2];XZ:HJ+0V#2EIL&QYEG&S31FW+G*G@T:EX]VJYQA$KA1!(YBY
M6)V][&M6L%Q24D755E6YL,;>BY7JB*B?@V^M;8G1,/Y*&&F7OG#18CO)=JPQ
MAN*6]:V=W60Q4D;GQN<NQ:L^U]3URL1[D148IW%I2IUK3&L]0<?FD_$+RVLM
M0TBIL(LL@@67?P-%K\13\SZ46NOF44C57+ I3.#$R7PI^Z8W?R+_ $$,5#20
M7:US5?%"QJ);I5&(C;;-FS1LFF,8WI>.+\1WMCN6"5M+>5ZU$[GZJ[6V6IE?
M/M2O1-1'HCE5&HMMB6HEA&MP8.6U=2CJRW><43-9H:U<<]<Q#!;./'(>G0=$
ML35NNW(<Y5$HVRFA6KCLPD1,ZS<Q\'4,<QL8MA]=NQ3?,\GXUKX6(G11J,=_
ML=8B_P '1)$9TM6[.3QE=<U$B_)TU+>M7(Y.MDGDJ8G*B]!7P[8]O7*J-<C;
M&HB(8)M>RO=T]5EU9Z*E[?5_IN<3=H66:D6N#NF"._-RUJ<C8RC=Y B[=>16
MI*J;GN]U7P:[!RD<A5D<%'7K)75^+UEI^JCNNCD<J]#;I6JB,]G5T]'2BILH
M7K#%W0X/Y,3;MOI=HK\PL44<,;%L:Y;LH)HWOJ=-BHU*A%9;:VULD;T56/53
M<G199P%8Z9>BK I+L#XFL;9NUSL;IV@DD:47VK>O;1Y-OUW2J9%X:-CTFSE9
M93&<8:9,?N>R4O>P*V.+"M/(KDZK;'.=Z^V/M55]9$L55]0Q+E@35UY<HV^Z
M%L3TVGW%3T\36JJZB45-J-C:B(MDCW.>QK4_GV-MV5QCI1I.=M6_G/S>,V<(
MUOE3R(4BM6.G:+A%2=U!HQO+TZEV9%)?!/ HR9Y=VV4)W2G*X8*%-VE*3(I8
M/1:R:\+_ +%VJLJ;(_7CBM:UW\-JI[**7+E/NCPM=6"LFD<U;PPS<"/K4:J*
MD==>2LJ*B%5395FHQZ+:J*V5JI8JN/\ 5^_[WNMAHJLX_P!:A^)W$/8.V5LY
M_*1973;T^IK=1FH4W>)XPI6)%@Z3_H-GNY-C_P"A]H5']MQW3Q;+*.B?)[#I
M%U+.Q5%.+C_X4Y'5]WBO4U>*,5TM"GJNIZ&)*M')T;$F9(Q>AIL_G$Q(S8B8
M
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MZ*-[E55<YK+7+UUMJDKPS B^
M
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M^A+W)]-QQ@I[D:V^+K5RK8B)5P6JOJ)_6&>"S&4
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M6] Q;_N\_P!T=_YH1<?[\_S-^R2R?\)?Y!_]2#_N\_W1W_FA#^_/\S?LD?\
M"7^0?_4@_P"[S_='?^:$/[\_S-^R1_PE_D'_ -2#_N\_W1W_ )H0_OS_ #-^
MR1_PE_D'_P!2#_N\_P!T=_YH0_OS_,W[)'_"7^0?_4@_[O/]T=_YH0_OS_,W
M[)'_  E_D'_U(/\ N\_W1W_FA#^_/\S?LD?\)?Y!_P#4@_[O/]T=_P":$/[\
M_P S?LD?\)?Y!_\ 4@_[O/\ ='?^:$/[\_S-^R1_PE_D'_U(/^[S_='?^:$/
M[\_S-^R1_P )?Y!_]2#_ +O/]T=_YH0_OS_,W[)'_"7^0?\ U(/^[S_='?\
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..T]N            /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>t1701829_chrt-inflam02a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 t1701829_chrt-inflam02a.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@#J /H P$1  (1 0,1 ?_$ /0  0 # 0 # 0$! 0
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MSK6#@QYUM4?*2_\ ?"KX8><!GCY[,N?21,N_(>!63>U%LZU@X,>=;5'RDO\
MWPJ^&'G 9X^>S+GTD3+OR'@5DWM1;.M8.#'G6U1\I+_WPJ^&'G 9X^>S+GTD
M3+OR'@5DWM1;.M8.#'G6U1\I+_WPJ^&'G 9X^>S+GTD3+OR'@5DWM1;.M8.#
M'G6U1\I+_P!\*OAAYP&>/GLRY])$R[\AX%9-[46SK6#@QYUM4?*2_P#?"KX8
M><!GCY[,N?21,N_(>!63>U%LZU@X,>=;5'RDO_?"KX8><!GCY[,N?21,N_(>
M!63>U%LZU@X,>=;5'RDO_?"KX8><!GCY[,N?21,N_(>!63>U%LZU@X,>=;5'
MRDO_ 'PJ^&'G 9X^>S+GTD3+OR'@5DWM1;.M8.#'G6U1\I+_ -\*OAAYP&>/
MGLRY])$R[\AX%9-[46SK6#@QYUM4?*2_]\*OAAYP&>/GLRY])$R[\AX%9-[4
M6SK6#@QYUM4?*2_]\*OAAYP&>/GLRY])$R[\AX%9-[46SK6#@QYUM4?*2_\
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MB6"R4%WJ8((U<]^Q%'*YK&[<CG/=LHB)M/<YR^BJKNG#1>!C(
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MVX+G>WV*2MFB8VG6G;,R"65&;&RLBQ*^%\2/WY%?L.>FS[%*'A,DU>@
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M,&.>JM:DK(I)-Z;,R2)=B9C95;',W>XGPNQ5S51LF]U=B0Y"8
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M;E9JEU/<6328LK&1I'#43-=511MB6I5JK#%"]K8FOVF/<N#Z.!+XUG
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MF?4;.5?74-FL,;U9\G2+![H*9]3/MK*Q^*,9O.#6[*\\N*[J%=(SH1$
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M#<)G[%KN$4MNJ<=Q-ZJZ6WL8Y5QW&QU"02N5<4V8U]5(M)-+JTY553C<T_\
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MBDB:CM[DII(7JD#W8RM@G@EWN2)SE1'*KMU61N3U3$]TLUXX]<8Y?U0QJU9
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MJ>A^'J>GR$NN7)_<;=^*T'_#A*Z1G0B*
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M+E4J](MM9-YB:UL<,*/5K-O>H6,CVMAFUL[6PW'93D(N<Q^
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MC32"1KG4L,BS23;$F^L223>XD1N^_MW-1CGOF1'/E?ANP &:R*@
M
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M/N\P)[Z,A_5:'WK-//F5Z^)IOI8_QUZV=M,K=<U_\M-- U_&YT
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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MBZPLQR<"T'<Z4KU;CE)MA=M*W74I4"C?@MY>MD>0]^V P_NOB'&&"M@,=0O
MFP6,XQC-LF#(TSC6;8['[=-H1*^XYE-I\M<71F(=&ZYQ6$*TI%/9U(FN1D*4
MZFE0-$P
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M^.FJ1Q>XJ[N>R/SET6VF&]6VVXY:U7F&4J96^ZX#DG!#^HY^XL^_^P_\IG,
M4CZ':;3_ &*X.,F;$ZX=LW;J<>_)SL9MOJX]-Z2Y8YN[M 6O%#U/\57)2[K3
MG1IR5&F.SI;;*THYNK8WIS:U(O-MN GUK;N% ]^OW#_&GMSCHFUO8,S\([N_
M+X_W;8XG0Z8M^==H(_/X.K7%ED46*H9-VEP;+CNS*[H[EH;2RVV^E !L[
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M;'$A?14BS_: W)
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MJUK3I '5
M
M
M
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MNEYF17!VE3RQ.JAN=XD3:VU;&YIM)3&WV'6J+^J;0"V,
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M)71G1PO*:V1%21S:"8O*HBM(E"0AELHA..//2%7WW7&ICZ=%H MC
M             %;&@_(TP;VY-WTQJRXL>,<J=%MLY]JJ\.KI*$4B(R*X01]D
M#"=,VQ*D9VHR.HW)1'3+[41MZN\NPRWI.NKTTH!9.
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M<8FXI;L=K3W%U95+.X*),6]&9#)LL+)4(ZD437W5NOK=;: +)P
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MX:AE,=B&!V1G21#&#"6X$6)VYM)O56MC>IO-3*"UZ8A1<!LC
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M4M]E7")3Q_BQ\UCW43T+<US2].489DRDBPZTHRP^I=]MU3;:T U&
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M4N[B:T,3-)GY"V.+^H;([<C)7*ZIR2#W&P^\BRA%2Z #L@
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MD(UK>9*RQ1)2+0>8T<Y*MHZOZM$WU.0H+^UM)Z_:G4MK:7;=?T6U N9
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MS8N69]>G"4L+(NC+)D)GPH1%E+4RN:U.Z2<Q<H@R\N\M 4>836VRIE+;;Z7
M#K7.GJ;FS>/BNVEU<UTC[;*LR9/MPI=#F!WD+-%&]QK"-BL1Y%?[#W^0JT#.
M@N(B\17&E]N=90TRRTNVO6OMI4"//)-H1LGL?J?Q-XEQ1%V-ZF>J.\VA^;,T
MHUTM8&1&P8ZP9CF<1?)#RVN#HL3)Y H9W1^3]DD1U-5*RZW7$EW]7H %8VZ^
MO.5MW^>39F!ZS0S1K8]9A71[ 4)V-A?)=A:29*PMA9YDLG5Y.QFT81K Y$BR
M";-I7'9#1X6JDI2)L1%+511ZA2>>420!8CQK;.YCU^W:DO#CL)JEI1@J3QG6
M@O;G%TJX[4L@C6OKU"5<X0X]?$LHQC+&E')H//'5^NO5&&JCSKS:$TI>8IM.
M2K50$@>"73;/.BVCCAA#8R.M,7R&HV*SWD(IK9I*RRM)6+3B8U<XTMJZL"M:
MWT.7(+.UN)Z_:DTNI:9;;?TVT <(&FV>=(]<-A,<;"1UIC4JR!O+LEFZ,(V>
M2LLI3K,=Y$71>Z)NQRUB5K$R-4XE-!U]R0VZU21;U:&V675ZM +F0
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MI"
M                       'K\LBD:GD5DL'F;$URB'S*/O,4ED9?$9+BRR*
M-2)N4M#ZQ.[>IMO3KFMW:UAJ=029;6PTHRZVZE:5J *-4?[=K3!E8%V,8AGO
MD3@FM3D8YV+]0X=O/F=HUH5M+SVWLM'5$$JXJ'<UC<Z'5H>7<Z5--I2E+C*T
MK=T@7,83PGBC7'%$%P;@V"L.-,38T84\:A$(C2<Q.TL32G,-/NLLN/-4+5RY
M<M4&JEBQ4:>L7+#S5"@TT\TPRX#J0
M                       *K-J.'W5C:3/1FU),PV7UDV;<(NVPF39YT[V#
MG&OF1)K$F8BU&TLDQ61D]2SOI:!OLL2VJ3$=%UZ,DE/>?>2G3EE =*TMXQM6
MM%Y+D')6+T62LA9WRVA;&O*FR.PF4)9F[/<^:&?N:Y S/.0)DM5'HF6P]&2<
M:C;B$*92<01>=895.G[("PD
M
M
M
M
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M*\O^GH4W>R",AR?C+JGG6%DVDJ@+10
M
M
M                                                  !F$TO/N5_N
MC^8_V=MMJYM6INHS=!+E:>Q.JMA*G&& 7.3VM!G9%7KFFZ9GVU4&])E+55+2
MZW4ZE++0/\;I):6?ND.&U:R4+]E5&I^W*6<52GEW*ZPM)BW8 V,T=$U3*WE-
M=)>MO[GOZEO:**W4I6[J74M C=M5H!*>.+3F)8OS%L[CF8<7.JVVK3LAK?K7
M%L'R"FYN>,K/669'E#"^D%L[KD!SA+W&9'F69'6F.;=&O9TUO+.4'52(2C;4
MH'N6LV>MHM.,R;.(T^FQF^O*%DO$\1W=Y-)<ASQ$L(0O7J#2,B06:_:;X9<)
M)%<AN4V=,58U9[T[6R%]R-ZPRAJFYW,[4NTD#2AJ)M!CC=+6;"NU&)*N5N/L
MWP5KFS B>K$A3XRW*ZFI'>-OQ3>K7H"GZ+OJ-4W+;2#SB;524REE]]O1=4"1
MH CQF'*.9X(^-C=C77A?F%J6-5%J]\29"98?8V.%5BDBK5<A<V9R-5743%6'
M=K;?;;T&]7HZ:5K7DU&JFZN!Q553F)B1P,W*SZ3/4^,#-.'*V>*HQ=,D\=KF
MF/U4F1FUQ.::NM%-(;5!0FC@GO*ZE3:&]-O3U>CHJ.>PW#:VMSU#CMKCAANG
MN7G$[6_8<>?IPB?P6'YLL_2_(?NT[TAYQ.UOV''GZ<(G\%@V6?I?D&T[TAYQ
M.UOV''GZ<(G\%@V6?I?D&T[TAYQ.UOV''GZ<(G\%@V6?I?D&T[TCCV?^0C)V
MK>()MGS/FJ2O'.(L<H4+E-9JY9B:W)"PH7)X;8^A4*$,?@CN\*+5#P[IB*4(
M3&W4N-I6M*6TK6C99^E^0;3O2*HO_=F<?'_JD8]]^0_J&#99^E^0;3O2'_NS
M./C_ -4C'OOR']0P;+/TOR#:=Z0_]V9Q\?\ JD8]]^0_J&#99^E^0;3O2'_N
MS./C_P!4C'OOR']0P;+/TOR#:=Z0_P#=F<?'_JD8]]^0_J&#99^E^0;3O2'_
M +LSCX_]4C'OOR']0P;+/TOR#:=Z1[5!?W2ND.2YO#L<0:R/2":Y E4>A,/8
M4\UG*=0]RF5NZ-BC[00H78-2H2#G)V7DDVWG&EE6W7TK?=;;2M:-EGZ7Y!M.
M](N4\XG:W[#CS].$3^"P;+/TOR#:=Z0\XG:W[#CS].$3^"P;+/TOR#:=Z0\X
MG:W[#CS].$3^"P;+/TOR#:=Z0\XG:W[#CS].$3^"P;+/TOR#:=Z0\XG:W[#C
MS].$3^"P;+/TOR#:=Z1Z;"-RL^Y';G!WA6G#D_-S4^.,;<%2?-,?3V)GMHJ5
M:XH+K5T-2F7&):GV=-UMM2Z]/J75'ZL;6[BN_(?B/5>8A[EYQ.UOV''GZ<(G
M\%A^;+/TOR'[M.](><3M;]AQY^G")_!8-EGZ7Y!M.](><3M;]AQY^G")_!8-
MEGZ7Y!M.](><3M;]AQY^G")_!8-EGZ7Y!M.](Y=D3?/+N)CFI/D/4E=&3GLI
M6<UV*LR,ZJJLI#>18JOLJW0=9;90F]392O7K;6O6]3I]46OF'..5<J/BCS#6
MLIGSHY6(YDCMI&X([V#7<S:3FX<T\\]9#3*B3KLJO,YOK(<W_-0=_LXW_2T3
M]70MSSOZ9=MX?BYN#.C^+47Z:?E_T'YJ#O\ 9QO^EHGZN@\[^F7;>'XN;@Q_
M%J+]-/R_Z#\U!W^SC?\ 2T3]70>=_3+MO#\7-P8_BU%^FGY?]!^:@[_9QO\
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M@<@      ,X>UOI%Y;_NQ3ZV2C71JK]8EVXVO0M+'N/5TGMB/@Q^>(
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M:.?=./\ *:_#L]Z_6]8X>^?B)R#K.8    !2#^Y"_1*WW\7^/O+?B\ ?'%
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M/>-')?\ R2(2ST?\3&<8E_.A\YW_ &7?W0U7<6W]+>7)C*1K_
M                          @VZ?J+1S[IQ_E-?AV>]?K>L</?/Q$Y!UG,
M     I!_<A?HE;[^+_'WEOQ> /CB@         E_Q[>GUH]][_6GRSPH ?<Y
M                %1/)S_/<0>U,Q]>1X1)Y3/5UH^"J.BB+:O\ [.+U'>L5
M;"+Q;X        6/<:7RK3SQ>W^$C&)%\FSQJK^Y_P"^B*Y8NJ7^T]="Z$3,
M+I               ,X>UOI%Y;_NQ3ZV2C71JK]8EVXVO0M+'N/5TGMB/@Q^
M>(        +^=#/1IA_MM+_"9S$]M"?JUH_A:CISR\K/U WU7?G4F,,PE3
M           "/.W/HH;._=YS3Y-Y*+GR3XYVCNI2]/C*!FOQ7N7$*CI+S"P-
MB9"8        .AXC^5?&/C"A?A(VBF7OL-5\5EZ!Q4+5V4IN,1]&AOJ&M@G0
M               45\Z7R48)\84D\&RQ(KD[=F;CQ6/HS">MG8NAXP_H#-,)
M8$<P        N1X0/2OR#]WF5^4C$PP3RA/$RE[J1](J3+NB_C14<0?TZ U.
M"'9)L               P'\MOZBFSG]TQ;R<PT0SU*\>+A\(SI3#Z?N0O_:A
MD[B53_SZLKE%C$LP        V[\$7H Q[QHY+_Y)$)9Z/^)C.,2_G0^<[_LN
M_NAJNXMOZ6\N3&4C7^                                    !!MT_4
M6CGW3C_*:_#L]Z_6]8X>^?B)R#K.8    !2#^Y"_1*WW\7^/O+?B\ ?'%
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M] &/>-')?_)(A+/1_P 3&<8E_.A\YW_9=_=#5=Q;?TMY<F,I&O\
M                             @VZ?J+1S[IQ_E-?AV>]?K>L</?/Q$Y!
MUG,     I!_<A?HE;[^+_'WEOQ> /CB@         E_Q[>GUH]][_6GRSPH
M?<Y                %1/)S_/<0>U,Q]>1X1)Y3/5UH^"J.BB+:O_LXO4=Z
MQ5L(O%O@       !8]QI?*M//%[?X2,8D7R;/&JO[G_OHBN6+JE_M/70NA$S
M"Z0              #.'M;Z1>6_[L4^MDHUT:J_6)=N-KT+2Q[CU=)[8CX,?
MGB        "_G0ST:8?[;2_PF<Q/;0GZM:/X6HZ<\O*S]0-]5WYU)C#,)4P
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M?@B] &/>-')?_)(A+/1_Q,9QB7\Z'SG?]EW]T-5W%M_2WER8RD:_P
M                             (-NGZBT<^Z<?Y37X=GO7ZWK'#WS\1.0
M=9S     *0?W(7Z)6^_B_P ?>6_%X ^.*         "7_'MZ?6CWWO\ 6GRS
MPH ?<Y                %1/)S_ #W$'M3,?7D>$2>4SU=:/@JCHHBVK_[.
M+U'>L5;"+Q;X        6/<:7RK3SQ>W^$C&)%\FSQJK^Y_[Z(KEBZI?[3UT
M+H1,PND               SA[6^D7EO^[%/K9*-=&JOUB7;C:]"TL>X]72>V
M(^#'YX@        OYT,]&F'^VTO\)G,3VT)^K6C^%J.G/+RL_4#?5=^=28PS
M"5,             (\[<^BAL[]WG-/DWDHN?)/CG:.ZE+T^,H&:_%>Y<0J.D
MO,+ V)D)@        Z'B/Y5\8^,*%^$C:*9>^PU7Q67H'%0M792FXQ'T:&^H
M:V"=               !17SI?)1@GQA23P;+$BN3MV9N/%8^C,)ZV=BZ'C#^
M@,TPE@1S        "Y'A ]*_(/W>97Y2,3#!/*$\3*7NI'TBI,NZ+^-%1Q!_
M3H#4X(=DFP              # ?RV_J*;.?W3%O)S#1#/4KQXN'PC.E,/I^Y
M"_\ :AD[B53_ ,^K*Y18Q+,        -N_!%Z ,>\:.2_P#DD0EGH_XF,XQ+
M^=#YSO\ LN_NAJNXMOZ6\N3&4C7^
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M/Y;?U%-G/[IBWDYAHAGJ5X\7#X1G2F'T_<A?^U#)W$JG_GU97*+&)9@
M  !MWX(O0!CWC1R7_P DB$L]'_$QG&)?SH?.=_V7?W0U7<6W]+>7)C*1K_
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M.E,/I^Y"_P#:AD[B53_SZLKE%C$LP        V[\$7H Q[QHY+_Y)$)9Z/\
MB8SC$OYT/G._[+O[H:KN+;^EO+DQE(U_@
M         0;=/U%HY]TX_P IK\.SWK];UCA[Y^(G(.LY@    %(/[D+]$K??
MQ?X^\M^+P!\<4         $O^/;T^M'OO?ZT^6>% #[G(
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M?D'[O,K\I&)A@GE">)E+W4CZ14F7=%_&BHX@_IT!J<$.R38
M !@/Y;?U%-G/[IBWDYAHAGJ5X\7#X1G2F'T_<A?^U#)W$JG_ )]65RBQB68
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MXF,XQ+^=#YSO^R[^Z&J[BV_I;RY,92-?X
M         $&W3]1:.?=./\IK\.SWK];UCA[Y^(G(.LY@    %(/[D+]$K??Q
M?X^\M^+P!\<4         $O^/;T^M'OO?ZT^6>% #[G(
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M'\J^,?&%"_"1M%,O?8:KXK+T#BH6KLI3<8CZ-#?4-;!.@
MHKYTODHP3XPI)X-EB17)V[,W'BL?1F$];.Q=#QA_0&:82P(Y@       !<CP
M@>E?D'[O,K\I&)A@GE">)E+W4CZ14F7=%_&BHX@_IT!J<$.R38
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M     "D']R%^B5OOXO\ 'WEOQ> /CB@         E_Q[>GUH]][_ %I\L\*
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M,)8$<P        N1X0/2OR#]WF5^4C$PP3RA/$RE[J1](J3+NB_C14<0?TZ
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MYV2;"9ZCBAUP;:QYWGE\FNDLG.R):5B"BE43,S5*HAP[FO(NN)5F=3JUK2M
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MG._[+O[H:KN+;^EO+DQE(U_@
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M_44V<_NF+>3F&B&>I7CQ</A&=*8?3]R%_P"U#)W$JG_GU97*+&)9@
M!MWX(O0!CWC1R7_R2(2ST?\ $QG&)?SH?.=_V7?W0U7<6W]+>7)C*1K_
M                                  (-NGZBT<^Z<?Y37X=GO7ZWK'#W
MS\1.0=9S     *0?W(7Z)6^_B_Q]Y;\7@#XXH         )?\>WI]:/?>_UI
M\L\* 'W.0               !43R<_SW$'M3,?7D>$2>4SU=:/@JCHHBVK_[
M.+U'>L5;"+Q;X        6/<:7RK3SQ>W^$C&)%\FSQJK^Y_[Z(KEBZI?[3U
MT+H1,PND               SA[6^D7EO^[%/K9*-=&JOUB7;C:]"TL>X]72>
MV(^#'YX@        OYT,]&F'^VTO\)G,3VT)^K6C^%J.G/+RL_4#?5=^=28P
MS"5,             (\[<^BAL[]WG-/DWDHN?)/CG:.ZE+T^,H&:_%>Y<0J.
MDO,+ V)D)@        Z'B/Y5\8^,*%^$C:*9>^PU7Q67H'%0M792FXQ'T:&^
MH:V"=               !17SI?)1@GQA23P;+$BN3MV9N/%8^C,)ZV=BZ'C#
M^@,TPE@1S        "Y'A ]*_(/W>97Y2,3#!/*$\3*7NI'TBI,NZ+^-%1Q!
M_3H#4X(=DFP              # ?RV_J*;.?W3%O)S#1#/4KQXN'PC.E,/I^
MY"_]J&3N)5/_ #ZLKE%C$LP        V[\$7H Q[QHY+_P"21"6>C_B8SC$O
MYT/G._[+O[H:KN+;^EO+DQE(U_@
M   0;=/U%HY]TX_RFOP[/>OUO6.'OGXB<@ZSF     4@_N0OT2M]_%_C[RWX
MO 'QQ0         2_P"/;T^M'OO?ZT^6>% #[G(                J)Y.?
MY[B#VIF/KR/")/*9ZNM'P51T41;5_P#9Q>H[UBK81>+?        "Q[C2^5:
M>>+V_P )&,2+Y-GC57]S_P!]$5RQ=4O]IZZ%T(F872               9P]
MK?2+RW_=BGULE&NC57ZQ+MQM>A:6/<>KI/;$?!C\\0        7\Z&>C3#_;
M:7^$SF)[:$_5K1_"U'3GEY6?J!OJN_.I,89A*F             $>=N?10V=
M^[SFGR;R47/DGQSM'=2EZ?&4#-?BO<N(5'27F%@;$R$P        =#Q'\J^,
M?&%"_"1M%,O?8:KXK+T#BH6KLI3<8CZ-#?4-;!.@               HKYTO
MDHP3XPI)X-EB17)V[,W'BL?1F$];.Q=#QA_0&:82P(Y@       !<CP@>E?D
M'[O,K\I&)A@GE">)E+W4CZ14F7=%_&BHX@_IT!J<$.R38              !
M@/Y;?U%-G/[IBWDYAHAGJ5X\7#X1G2F'T_<A?^U#)W$JG_GU97*+&)9@
M   !MWX(O0!CWC1R7_R2(2ST?\3&<8E_.A\YW_9=_=#5=Q;?TMY<F,I&O\
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M)C.,2_G0^<[_ ++O[H:KN+;^EO+DQE(U_@
M          0;=/U%HY]TX_RFOP[/>OUO6.'OGXB<@ZSF     4@_N0OT2M]_
M%_C[RWXO 'QQ0         2_X]O3ZT>^]_K3Y9X4 /N<@
M"HGDY_GN(/:F8^O(\(D\IGJZT?!5'11%M7_V<7J.]8JV$7BWP        L>X
MTOE6GGB]O\)&,2+Y-GC57]S_ -]$5RQ=4O\ :>NA=")F%T@
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M'I7Y!^[S*_*1B88)Y0GB92]U(^D5)EW1?QHJ.(/Z= :G!#LDV
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M6>C_ (F,XQ+^=#YSO^R[^Z&J[BV_I;RY,92-?X
M              $&W3]1:.?=./\ *:_#L]Z_6]8X>^?B)R#K.8    !2#^Y"
M_1*WW\7^/O+?B\ ?'%         !+_CV]/K1[[W^M/EGA0 ^YR
M      *B>3G^>X@]J9CZ\CPB3RF>KK1\%4=%$6U?_9Q>H[UBK81>+?
M  "Q[C2^5:>>+V_PD8Q(ODV>-5?W/_?1%<L75+_:>NA=")F%T@
M    &</:WTB\M_W8I];)1KHU5^L2[<;7H6ECW'JZ3VQ'P8_/$        %_.
MAGHTP_VVE_A,YB>VA/U:T?PM1TYY>5GZ@;ZKOSJ3&&82I@            !'
MG;GT4-G?N\YI\F\E%SY)\<[1W4I>GQE S7XKW+B%1TEYA8&Q,A,        '
M0\1_*OC'QA0OPD;13+WV&J^*R] XJ%J[*4W&(^C0WU#6P3H
M  **^=+Y*,$^,*2>#98D5R=NS-QXK'T9A/6SL70\8?T!FF$L".8        7
M(\('I7Y!^[S*_*1B88)Y0GB92]U(^D5)EW1?QHJ.(/Z= :G!#LDV
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M$)9Z/^)C.,2_G0^<[_LN_NAJNXMOZ6\N3&4C7^
M              !!MT_46CGW3C_*:_#L]Z_6]8X>^?B)R#K.8    !2#^Y"_
M1*WW\7^/O+?B\ ?'%         !+_CV]/K1[[W^M/EGA0 ^YR
M     *B>3G^>X@]J9CZ\CPB3RF>KK1\%4=%$6U?_ &<7J.]8JV$7BWP
M   L>XTOE6GGB]O\)&,2+Y-GC57]S_WT17+%U2_VGKH70B9A=(
M    !G#VM](O+?\ =BGULE&NC57ZQ+MQM>A:6/<>KI/;$?!C\\0        7
M\Z&>C3#_ &VE_A,YB>VA/U:T?PM1TYY>5GZ@;ZKOSJ3&&82I@
M !'G;GT4-G?N\YI\F\E%SY)\<[1W4I>GQE S7XKW+B%1TEYA8&Q,A,
M  '0\1_*OC'QA0OPD;13+WV&J^*R] XJ%J[*4W&(^C0WU#6P3H
M     **^=+Y*,$^,*2>#98D5R=NS-QXK'T9A/6SL70\8?T!FF$L".8
M  7(\('I7Y!^[S*_*1B88)Y0GB92]U(^D5)EW1?QHJ.(/Z= :G!#LDV
M          8#^6W]139S^Z8MY.8:(9ZE>/%P^$9TIA]/W(7_ +4,G<2J?^?5
ME<HL8EF        &W?@B] &/>-')?_)(A+/1_P 3&<8E_.A\YW_9=_=#5=Q;
M?TMY<F,I&O\                                      @VZ?J+1S[IQ
M_E-?AV>]?K>L</?/Q$Y!UG,     I!_<A?HE;[^+_'WEOQ> /CB@
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MY]TX_P IK\.SWK];UCA[Y^(G(.LY@    %(/[D+]$K??Q?X^\M^+P!\<4
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MXT<E_P#)(A+/1_Q,9QB7\Z'SG?\ 9=_=#5=Q;?TMY<F,I&O\
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M.E,/I^Y"_P#:AD[B53_SZLKE%C$LP        V[\$7H Q[QHY+_Y)$)9Z/\
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M6$-QS7:8HML3TOJ +M     0;=/U%HY]TX_RFOP[/>OUO6.'OGXB<@ZSF
M  4@_N0OT2M]_%_C[RWXO 'QQ0         2_P"/;T^M'OO?ZT^6>% #[G(
M               J)Y.?Y[B#VIF/KR/")/*9ZNM'P51T41;5_P#9Q>H[UBK8
M1>+?        "Q[C2^5:>>+V_P )&,2+Y-GC57]S_P!]$5RQ=4O]IZZ%T(F8
M72               9P]K?2+RW_=BGULE&NC57ZQ+MQM>A:6/<>KI/;$?!C\
M\0        7\Z&>C3#_;:7^$SF)[:$_5K1_"U'3GEY6?J!OJN_.I,89A*F
M           $>=N?10V=^[SFGR;R47/DGQSM'=2EZ?&4#-?BO<N(5'27F%@;
M$R$P        =#Q'\J^,?&%"_"1M%,O?8:KXK+T#BH6KLI3<8CZ-#?4-;!.@
M               HKYTODHP3XPI)X-EB17)V[,W'BL?1F$];.Q=#QA_0&:82
MP(Y@       !<CP@>E?D'[O,K\I&)A@GE">)E+W4CZ14F7=%_&BHX@_IT!J<
M$.R38              !@/Y;?U%-G/[IBWDYAHAGJ5X\7#X1G2F'T_<A?^U#
M)W$JG_GU97*+&)9@       !MWX(O0!CWC1R7_R2(2ST?\3&<8E_.A\YW_9=
M_=#5=Q;?TMY<F,I&O\                                    "#;I^H
MM'/NG'^4U^'9[U^MZQP]\_$3D'6<P    "D']R%^B5OOXO\ 'WEOQ> /CB@
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M1>@#'O&CDO\ Y)$)9Z/^)C.,2_G0^<[_ ++O[H:KN+;^EO+DQE(U_@
M                              0;=/U%HY]TX_RFOP[/>OUO6.'OGXB<
M@ZSF     4@_N0OT2M]_%_C[RWXO 'QQ0         2_X]O3ZT>^]_K3Y9X4
M /N<@               "HGDY_GN(/:F8^O(\(D\IGJZT?!5'11%M7_V<7J.
M]8JV$7BWP        L>XTOE6GGB]O\)&,2+Y-GC57]S_ -]$5RQ=4O\ :>NA
M=")F%T@              &</:WTB\M_W8I];)1KHU5^L2[<;7H6ECW'JZ3VQ
M'P8_/$        %_.AGHTP_VVE_A,YB>VA/U:T?PM1TYY>5GZ@;ZKOSJ3&&8
M2I@            !'G;GT4-G?N\YI\F\E%SY)\<[1W4I>GQE S7XKW+B%1TE
MYA8&Q,A,        '0\1_*OC'QA0OPD;13+WV&J^*R] XJ%J[*4W&(^C0WU#
M6P3H               **^=+Y*,$^,*2>#98D5R=NS-QXK'T9A/6SL70\8?T
M!FF$L".8        7(\('I7Y!^[S*_*1B88)Y0GB92]U(^D5)EW1?QHJ.(/Z
M= :G!#LDV               8#^6W]139S^Z8MY.8:(9ZE>/%P^$9TIA]/W(
M7_M0R=Q*I_Y]65RBQB68        ;=^"+T 8]XT<E_\ )(A+/1_Q,9QB7\Z'
MSG?]EW]T-5W%M_2WER8RD:_P
M(-NGZBT<^Z<?Y37X=GO7ZWK'#WS\1.0=9S     *0?W(7Z)6^_B_Q]Y;\7@#
MXXH         )?\ 'MZ?6CWWO]:?+/"@!]SD                5$\G/\]Q
M![4S'UY'A$GE,]76CX*HZ*(MJ_\ LXO4=ZQ5L(O%O@       !8]QI?*M//%
M[?X2,8D7R;/&JO[G_OHBN6+JE_M/70NA$S"Z0              #.'M;Z1>6
M_P"[%/K9*-=&JOUB7;C:]"TL>X]72>V(^#'YX@        OYT,]&F'^VTO\
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MMOZBFSG]TQ;R<PT0SU*\>+A\(SI3#Z?N0O\ VH9.XE4_\^K*Y18Q+,
M  -N_!%Z ,>\:.2_^21"6>C_ (F,XQ+^=#YSO^R[^Z&J[BV_I;RY,92-?X
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ME_.A\YW_ &7?W0U7<6W]+>7)C*1K_
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M#]WF5^4C$PP3RA/$RE[J1](J3+NB_C14<0?TZ U."'9)L
MP'\MOZBFSG]TQ;R<PT0SU*\>+A\(SI3#Z?N0O_:AD[B53_SZLKE%C$LP
M    V[\$7H Q[QHY+_Y)$)9Z/^)C.,2_G0^<[_LN_NAJNXMOZ6\N3&4C7^
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M&<8E_.A\YW_9=_=#5=Q;?TMY<F,I&O\
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M@_=YE?E(Q,,$\H3Q,I>ZD?2*DR[HOXT5'$'].@-3@AV2;
M,!_+;^HILY_=,6\G,-$,]2O'BX?",Z4P^G[D+_VH9.XE4_\ /JRN46,2S
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MQ,9QB7\Z'SG?]EW]T-5W%M_2WER8RD:_P
M         (-NGZBT<^Z<?Y37X=GO7ZWK'#WS\1.0=9S     *0?W(7Z)6^_B
M_P ?>6_%X ^.*         "7_'MZ?6CWWO\ 6GRSPH ?<Y
M  %1/)S_ #W$'M3,?7D>$2>4SU=:/@JCHHBVK_[.+U'>L5;"+Q;X
M6/<:7RK3SQ>W^$C&)%\FSQJK^Y_[Z(KEBZI?[3UT+H1,PND
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M ]*_(/W>97Y2,3#!/*$\3*7NI'TBI,NZ+^-%1Q!_3H#4X(=DFP
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M\%4=%$6U?_9Q>H[UBK81>+?        "Q[C2^5:>>+V_PD8Q(ODV>-5?W/\
MWT17+%U2_P!IZZ%T(F872               9P]K?2+RW_=BGULE&NC57ZQ+
MMQM>A:6/<>KI/;$?!C\\0        7\Z&>C3#_;:7^$SF)[:$_5K1_"U'3GE
MY6?J!OJN_.I,89A*F             $>=N?10V=^[SFGR;R47/DGQSM'=2EZ
M?&4#-?BO<N(5'27F%@;$R$P        =#Q'\J^,?&%"_"1M%,O?8:KXK+T#B
MH6KLI3<8CZ-#?4-;!.@               HKYTODHP3XPI)X-EB17)V[,W'B
ML?1F$];.Q=#QA_0&:82P(Y@       !<CP@>E?D'[O,K\I&)A@GE">)E+W4C
MZ14F7=%_&BHX@_IT!J<$.R38              !@/Y;?U%-G/[IBWDYAHAGJ
M5X\7#X1G2F'T_<A?^U#)W$JG_GU97*+&)9@       !MWX(O0!CWC1R7_P D
MB$L]'_$QG&)?SH?.=_V7?W0U7<6W]+>7)C*1K_                  "(F^
M&Y>,^/[5#,&V>64KH[Q7%3&B4)8LP5(_J.;RV1/+=%H1"(_:HKV?LI*98])$
ME#:VWV)2C+U!EM2B;P!XO/N^NM^G.OL(V$W7R QZO,<N:XW:=&YD>XR64HYN
M]QXM^<L=,,=A32]RB>RB/=104>4S-RHRZU->;2RA?JT X7I7S*\=O(!D1^P[
MK;GGV8S%'&M0^N&*)Y LA8HGBAC2VD&*G5C9LCQB-4DR=$4HM,4EMQBI0D)K
M0T\LHJZR^X#HF[G*'H[QX4B*+:O-[?!Y9D$LX^"8X8(W+LC9.EB-.I[D4.C7
M <>L4EDA3&4IMO+]D%1"=!>:4858=<;96P >V:3<AVG?(E!)!D'4/,[/E5IA
MSHC8ITSU9Y-#YK GM>2I-1-LR@LW98[+&+NZJ!5:D5&I.X5]R0_N0\^TDRZT
M#B>'.9#CPSUG*.:_XQSFL>9?/)!-8CBV4N.,,K1C#N9)?CDTTB<Q;#N;I-"V
MC%637R.G$7VWE,[LJHJK;TI+E%*VUJ!)[8+<'"FM,TUXQKD1T?EN2=ILK),0
MX6Q]"HXX3"8R=\H@/>)')#F-IM,5->/<?L*>Y?(GU12Q T)*V7GWTJ87;<!S
MW:?>:&ZD9NTNQ9DJ&R"L.W.S ]X!8<Q(U[:7%,=9A.C5S]BZ'2]M4=5U4F9@
M6I5;<UGI.TL3JTMU5%+"J]I0"<8    (-NGZBT<^Z<?Y37X=GO7ZWK'#WS\1
M.0=9S     *0?W(7Z)6^_B_Q]Y;\7@#XXH         )?\>WI]:/?>_UI\L\
M* 'W.0               !43R<_SW$'M3,?7D>$2>4SU=:/@JCHHBVK_ .SB
M]1WK%6PB\6^        %CW&E\JT\\7M_A(QB1?)L\:J_N?\ OHBN6+JE_M/7
M0NA$S"Z0              #.'M;Z1>6_[L4^MDHUT:J_6)=N-KT+2Q[CU=)[
M8CX,?GB        "_G0ST:8?[;2_PF<Q/;0GZM:/X6HZ<\O*S]0-]5WYU)C#
M,)4P             CSMSZ*&SOW><T^3>2BY\D^.=H[J4O3XR@9K\5[EQ"HZ
M2\PL#8F0F        #H>(_E7QCXPH7X2-HIE[[#5?%9>@<5"U=E*;C$?1H;Z
MAK8)T               %%?.E\E&"?&%)/!LL2*Y.W9FX\5CZ,PGK9V+H>,/
MZ S3"6!',        +D>$#TK\@_=YE?E(Q,,$\H3Q,I>ZD?2*DR[HOXT5'$'
M].@-3@AV2;               ,!_+;^HILY_=,6\G,-$,]2O'BX?",Z4P^G[
MD+_VH9.XE4_\^K*Y18Q+,        -N_!%Z ,>\:.2_^21"6>C_B8SC$OYT/
MG._[+O[H:KN+;^EO+DQE(U_@                 !F_YV'&W*6U/!QI*Y$G
M+H?GWD)2YNGC&00L/+E$2U'9V&3N<;>"TZ4\D^,N%N2*7KBS+[.BTFPZG1V-
M320+B-PIYK1@B L^TFR6/3)BW8"D#>YPE_8\+R#-^0(%)9PXMD+L?(#'(A&)
M5+&IT4U<2B%+@@(+O(25OZYMI=;J5 S+8VV*P7RT?N&=2\Z:ZEEX6:=!L-YB
M39#>LRT8<+;';..<YB,L8(_"\?81?7)-F:08S@+;*#G%6ZNC8G3ITJUR3&$I
M[C4]ZD"3?&\W-6R'[A+FTV&R&D3OTOU'9]6M8<$U>$*9PNQU")E%9]6:W1%0
M?<;<PJ'YZQBH4'&DTH>;8^KB^O84>:48!S.>XYNQG^Y\S%BC$JM/!2^0[B!E
MDAR$I:"S&QO0Y1(E\S@[%DI6@;*$5<9(W$X>(ON4V7D*;ZN"DSM:F&&5, AW
M'D>9(GIGQ$ZH9OU6V2U<4<06XN/=P=V]D\L8V4176&*8:U)KF)YD%V,<Y6*?
MZ8S@Y9QLF3>0U-T5,<U:I4?>2:5=T=>H%@6J&W&K;5LRIY,>4+8;#6MNQ.UL
M-21+0'67,\Y9F"6ZNZ'NS\H,@\BD["K7J$4*R-LHO(J_2)\6W%D$I.S0$K"2
M;%J$@"4G[E2$4FW#QL#DF++3B)WKU(L'[+8@EC-:2N41J88^RW#:TE;69;:<
M76XB$/SO;8?97JEV']I7KEVW67@7-8(R61FG!^&LQIBB4Z;+.*<>9+3D)[%)
M:<DB=Q%GE)11!:VVU98266ZTI;0VE#:6TI2ZG6Z0!U8 <TFV9<48V7I&J?9#
MB4/<EZ/V01H9 ](FQ2J0U.-345DE*3;+S".W(OLZU/4ZUM:?]!^HUR\Q#\54
M3FD-X]D"$9'Y F1\@4J8Y>SI=7EC4I<H^XIW-&0Y$9$<UAR$T]-?>78I*2KB
M3+K*UZ:6&VU_ZT'8J*D6[^EZQPQ17[GI%B8ZCL     *0?W(7Z)6^_B_Q]Y;
M\7@#XXH         )?\ 'MZ?6CWWO]:?+/"@!]SD                5$\G
M/\]Q![4S'UY'A$GE,]76CX*HZ*(MJ_\ LXO4=ZQ5L(O%O@       !8]QI?*
MM//%[?X2,8D7R;/&JO[G_OHBN6+JE_M/70NA$S"Z0              #.'M;
MZ1>6_P"[%/K9*-=&JOUB7;C:]"TL>X]72>V(^#'YX@        OYT,]&F'^V
MTO\ "9S$]M"?JUH_A:CISR\K/U WU7?G4F,,PE3             "/.W/HH;
M._=YS3Y-Y*+GR3XYVCNI2]/C*!FOQ7N7$*CI+S"P-B9"8        .AXC^5?
M&/C"A?A(VBF7OL-5\5EZ!Q4+5V4IN,1]&AOJ&M@G0               45\Z
M7R48)\84D\&RQ(KD[=F;CQ6/HS">MG8NAXP_H#-,)8$<P        N1X0/2O
MR#]WF5^4C$PP3RA/$RE[J1](J3+NB_C14<0?TZ U."'9)L
M P'\MOZBFSG]TQ;R<PT0SU*\>+A\(SI3#Z?N0O\ VH9.XE4_\^K*Y18Q+,
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MUZ+;:4[%55BW?TO6.."(_<](L*'4<P    "D']R%^B5OOXO\?>6_%X ^.*
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M>\:.2_\ DD0EGH_XF,XQ+^=#YSO^R[^Z&J[BV_I;RY,92-?X
M      00Y*=&HSR*Z>91U=?92HQZ]R?^GY1C/**!OO<W3%N5X(^H93 ITW(B
M7!I4J?8QY;K2591*M*<H;E*@FPXJXRE]H$Q8*AES7"(<V3]_;97.VZ*QY#-I
M0S,_].M$DER1H1IY(_M4?JK7U8FUX>2SE!"/MSNY2C+2^TOZO6J![4
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M&)?SH?.=_P!EW]T-5W%M_2WER8RD:_P
M       (-NGZBT<^Z<?Y37X=GO7ZWK'#WS\1.0=9S     *0?W(7Z)6^_B_Q
M]Y;\7@#XXH         )?\>WI]:/?>_UI\L\* 'W.0               !43
MR<_SW$'M3,?7D>$2>4SU=:/@JCHHBVK_ .SB]1WK%6PB\6^        %CW&E
M\JT\\7M_A(QB1?)L\:J_N?\ OHBN6+JE_M/70NA$S"Z0              #.
M'M;Z1>6_[L4^MDHUT:J_6)=N-KT+2Q[CU=)[8CX,?GB        "_G0ST:8?
M[;2_PF<Q/;0GZM:/X6HZ<\O*S]0-]5WYU)C#,)4P             CSMSZ*&
MSOW><T^3>2BY\D^.=H[J4O3XR@9K\5[EQ"HZ2\PL#8F0F        #H>(_E7
MQCXPH7X2-HIE[[#5?%9>@<5"U=E*;C$?1H;ZAK8)T               %%?.
ME\E&"?&%)/!LL2*Y.W9FX\5CZ,PGK9V+H>,/Z S3"6!',        +D>$#TK
M\@_=YE?E(Q,,$\H3Q,I>ZD?2*DR[HOXT5'$'].@-3@AV2;
M ,!_+;^HILY_=,6\G,-$,]2O'BX?",Z4P^G[D+_VH9.XE4_\^K*Y18Q+,
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M\$7H Q[QHY+_ .21"6>C_B8SC$OYT/G._P"R[^Z&J[BV_I;RY,92-?X
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MH_XF,XQ+^=#YSO\ LN_NAJNXMOZ6\N3&4C7^
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M\3&<8E_.A\YW_9=_=#5=Q;?TMY<F,I&O\
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M\YW_ &7?W0U7<6W]+>7)C*1K_
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MF$L".8        7(\('I7Y!^[S*_*1B88)Y0GB92]U(^D5)EW1?QHJ.(/Z=
M:G!#LDV               8#^6W]139S^Z8MY.8:(9ZE>/%P^$9TIA]/W(7_
M +4,G<2J?^?5E<HL8EF        &W?@B] &/>-')?_)(A+/1_P 3&<8E_.A\
MYW_9=_=#5=Q;?TMY<F,I&O\
M @VZ?J+1S[IQ_E-?AV>]?K>L</?/Q$Y!UG,
M          J)Y.?Y[B#VIF/KR/")/*9ZNM'P51T41;5_]G%ZCO6*MA%XM\
M      +'N-+Y5IYXO;_"1C$B^39XU5_<_P#?1%<L75+_ &GKH70B9A=(
M          !G#VM](O+?]V*?6R4:Z-5?K$NW&UZ%I8]QZND]L1\&/SQ
M   !?SH9Z-,/]MI?X3.8GMH3]6M'\+4=.>7E9^H&^J[\ZDQAF$J8
M     1YVY]%#9W[O.:?)O)1<^2?'.T=U*7I\90,U^*]RXA4=)>86!L3(3
M     !T/$?RKXQ\84+\)&T4R]]AJOBLO0.*A:NRE-QB/HT-]0UL$Z
M        "BOG2^2C!/C"DG@V6)%<G;LS<>*Q]&83UL[%T/&'] 9IA+ CF
M     %R/"!Z5^0?N\RORD8F&">4)XF4O=2/I%29=T7\:*CB#^G0&IP0[)-@
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MZ5^0?N\RORD8F&">4)XF4O=2/I%29=T7\:*CB#^G0&IP0[)-@
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MMT_46CGW3C_*:_#L]Z_6]8X>^?B)R#K.8
M       !43R<_P ]Q![4S'UY'A$GE,]76CX*HZ*(MJ_^SB]1WK%6PB\6^
M     %CW&E\JT\\7M_A(QB1?)L\:J_N?^^B*Y8NJ7^T]="Z$3,+I
M       ,X>UOI%Y;_NQ3ZV2C71JK]8EVXVO0M+'N/5TGMB/@Q^>(
M+^=#/1IA_MM+_"9S$]M"?JUH_A:CISR\K/U WU7?G4F,,PE3
M "/.W/HH;._=YS3Y-Y*+GR3XYVCNI2]/C*!FOQ7N7$*CI+S"P-B9"8
M  .AXC^5?&/C"A?A(VBF7OL-5\5EZ!Q4+5V4IN,1]&AOJ&M@G0
M     45\Z7R48)\84D\&RQ(KD[=F;CQ6/HS">MG8NAXP_H#-,)8$<P
M  N1X0/2OR#]WF5^4C$PP3RA/$RE[J1](J3+NB_C14<0?TZ U."'9)L
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MPP3RA/$RE[J1](J3+NB_C14<0?TZ U."'9)L
M                        ,W?- >NG7)?^WHUZ4V6J8C*]S<Q[#.R%0=9:
MA.DFJ<)Q]*HBJ-(,3*;3E2&V:+[B/4I_%=6WIMK?2^P#M'-EL3+G1@PIQ@X
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MRJ*3Z,."E[2GJV<ZU>M;EB5:ANHH3GIJ=>VXFXVM@%R@
M #-W^X$:R\29&XAN0-Q+2TANG'(; 6#+;J<G*OOB>&=C%##%9U,3%1EE.Q0L
MZB&-Y52^TLH:K5)NGU+.O8!9[M_Q5<?N_$TB^1-N];(OFF:0R+UA<9?WN29
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M%3#=;>Q8R@,.Q\RWV)24-MS3#(\W1QNNM1)ZU3H[;D;;96A1?\!=/X;?4I0
M>_   (-NGZBT<^Z<?Y37X=GO7ZWK'#WS\1.0=9S
M              *B>3G^>X@]J9CZ\CPB3RF>KK1\%4=%$6U?_9Q>H[UBK81>
M+?        "Q[C2^5:>>+V_PD8Q(ODV>-5?W/_?1%<L75+_:>NA=")F%T@
M            &</:WTB\M_W8I];)1KHU5^L2[<;7H6ECW'JZ3VQ'P8_/$
M     %_.AGHTP_VVE_A,YB>VA/U:T?PM1TYY>5GZ@;ZKOSJ3&&82I@
M      !'G;GT4-G?N\YI\F\E%SY)\<[1W4I>GQE S7XKW+B%1TEYA8&Q,A,
M       '0\1_*OC'QA0OPD;13+WV&J^*R] XJ%J[*4W&(^C0WU#6P3H
M          **^=+Y*,$^,*2>#98D5R=NS-QXK'T9A/6SL70\8?T!FF$L".8
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M9AKA1"2[OSNZOR6VV^VPM.T.A38G/,NM.I91?;TV=%:F%@:3@
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M!D:2Y=85=W6Q29J+M-K2BFVP :1
M   !!MT_46CGW3C_ "FOP[/>OUO6.'OGXB<@ZSF
M              5$\G/\]Q![4S'UY'A$GE,]76CX*HZ*(MJ_^SB]1WK%6PB\
M6^        %CW&E\JT\\7M_A(QB1?)L\:J_N?^^B*Y8NJ7^T]="Z$3,+I
M            ,X>UOI%Y;_NQ3ZV2C71JK]8EVXVO0M+'N/5TGMB/@Q^>(
M     +^=#/1IA_MM+_"9S$]M"?JUH_A:CISR\K/U WU7?G4F,,PE3
M      "/.W/HH;._=YS3Y-Y*+GR3XYVCNI2]/C*!FOQ7N7$*CI+S"P-B9"8
M       .AXC^5?&/C"A?A(VBF7OL-5\5EZ!Q4+5V4IN,1]&AOJ&M@G0
M          45\Z7R48)\84D\&RQ(KD[=F;CQ6/HS">MG8NAXP_H#-,)8$<P
M       N1X0/2OR#]WF5^4C$PP3RA/$RE[J1](J3+NB_C14<0?TZ U."'9)L
M           #E>9\(8EV(@#CBS-L"C^2<?.KI&GM=%I*FO4MQKS#I&URZ+.I
M=2C2%*9P8I(RI5B<XHRPPLXFVM*]'32H'5               <;P;KWA36F&
MK<?X'QK%\7Q!TEDFG;NS1=%5-8]369.%SI*)6]K#S%#@]2![65I4]6J...N+
M+++I=0LHNRT#L@                                    @VZ?J+1S[I
MQ_E-?AV>]?K>L</?/Q$Y!UG,                                   J
M)Y.?Y[B#VIF/KR/")/*9ZNM'P51T41;5_P#9Q>H[UBK81>+?        "Q[C
M2^5:>>+V_P )&,2+Y-GC57]S_P!]$5RQ=4O]IZZ%T(F872
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M>E?D'[O,K\I&)A@GE">)E+W4CZ14F7=%_&BHX@_IT!J<$.R38
M                                                       $&W3]
M1:.?=./\IK\.SWK];UCA[Y^(G(.LY@
M    %1/)S_/<0>U,Q]>1X1)Y3/5UH^"J.BB+:O\ [.+U'>L5;"+Q;X
M  6/<:7RK3SQ>W^$C&)%\FSQJK^Y_P"^B*Y8NJ7^T]="Z$3,+I
M     ,X>UOI%Y;_NQ3ZV2C71JK]8EVXVO0M+'N/5TGMB/@Q^>(        +^
M=#/1IA_MM+_"9S$]M"?JUH_A:CISR\K/U WU7?G4F,,PE3             "
M/.W/HH;._=YS3Y-Y*+GR3XYVCNI2]/C*!FOQ7N7$*CI+S"P-B9"8
M.AXC^5?&/C"A?A(VBF7OL-5\5EZ!Q4+5V4IN,1]&AOJ&M@G0
M   45\Z7R48)\84D\&RQ(KD[=F;CQ6/HS">MG8NAXP_H#-,)8$<P
MN1X0/2OR#]WF5^4C$PP3RA/$RE[J1](J3+NB_C14<0?TZ U."'9)L
M                                                           "
M#;I^HM'/NG'^4U^'9[U^MZQP]\_$3D'6<P
M        "HGDY_GN(/:F8^O(\(D\IGJZT?!5'11%M7_V<7J.]8JV$7BWP
M     L>XTOE6GGB]O\)&,2+Y-GC57]S_ -]$5RQ=4O\ :>NA=")F%T@
M         &</:WTB\M_W8I];)1KHU5^L2[<;7H6ECW'JZ3VQ'P8_/$
M  %_.AGHTP_VVE_A,YB>VA/U:T?PM1TYY>5GZ@;ZKOSJ3&&82I@
M   !'G;GT4-G?N\YI\F\E%SY)\<[1W4I>GQE S7XKW+B%1TEYA8&Q,A,
M    '0\1_*OC'QA0OPD;13+WV&J^*R] XJ%J[*4W&(^C0WU#6P3H
M       **^=+Y*,$^,*2>#98D5R=NS-QXK'T9A/6SL70\8?T!FF$L".8
M    7(\('I7Y!^[S*_*1B88)Y0GB92]U(^D5)EW1?QHJ.(/Z= :G!#LDV
M
M   !!MT_46CGW3C_ "FOP[/>OUO6.'OGXB<@ZSF
M              5$\G/\]Q![4S'UY'A$GE,]76CX*HZ*(MJ_^SB]1WK%6PB\
M6^        %CW&E\JT\\7M_A(QB1?)L\:J_N?^^B*Y8NJ7^T]="Z$3,+I
M            ,X>UOI%Y;_NQ3ZV2C71JK]8EVXVO0M+'N/5TGMB/@Q^>(
M     +^=#/1IA_MM+_"9S$]M"?JUH_A:CISR\K/U WU7?G4F,,PE3
M      "/.W/HH;._=YS3Y-Y*+GR3XYVCNI2]/C*!FOQ7N7$*CI+S"P-B9"8
M       .AXC^5?&/C"A?A(VBF7OL-5\5EZ!Q4+5V4IN,1]&AOJ&M@G0
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MBJF*+ABU$7#%$7#F8HGI'OXII[P
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MR] XJ%J[*4W&(^C0WU#6P3H
M
M@VZ?J+1S[IQ_E-?AV>]?K>L</?/Q$Y!UG,
M         J)Y.?Y[B#VIF/KR/")/*9ZNM'P51T41;5_]G%ZCO6*MA%XM\
M     +'N-+Y5IYXO;_"1C$B^39XU5_<_]]$5RQ=4O]IZZ%T(F872
M       9P]K?2+RW_=BGULE&NC57ZQ+MQM>A:6/<>KI/;$?!C\\0
M7\Z&>C3#_;:7^$SF)[:$_5K1_"U'3GEY6?J!OJN_.I,89A*F
M $>=N?10V=^[SFGR;R47/DGQSM'=2EZ?&4#-?BO<N(5'27F%@;$R$P
M  =#Q'\J^,?&%"_"1M%,O?8:KXK+T#BH6KLI3<8CZ-#?4-;!.@
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M@
M     0;=/U%HY]TX_P IK\.SWK];UCA[Y^(G(.LY@
M               %1/)S_/<0>U,Q]>1X1)Y3/5UH^"J.BB+:O_LXO4=ZQ5L(
MO%O@       !8]QI?*M//%[?X2,8D7R;/&JO[G_OHBN6+JE_M/70NA$S"Z0
M             #.'M;Z1>6_[L4^MDHUT:J_6)=N-KT+2Q[CU=)[8CX,?GB
M      "_G0ST:8?[;2_PF<Q/;0GZM:/X6HZ<\O*S]0-]5WYU)C#,)4P
M        CSMSZ*&SOW><T^3>2BY\D^.=H[J4O3XR@9K\5[EQ"HZ2\PL#8F0F
M        #H>(_E7QCXPH7X2-HIE[[#5?%9>@<5"U=E*;C$?1H;ZAK8)T
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M#0T
M       "#;I^HM'/NG'^4U^'9[U^MZQP]\_$3D'6<P
M                "HGDY_GN(/:F8^O(\(D\IGJZT?!5'11%M7_V<7J.]8JV
M$7BWP        L>XTOE6GGB]O\)&,2+Y-GC57]S_ -]$5RQ=4O\ :>NA=")F
M%T@              &</:WTB\M_W8I];)1KHU5^L2[<;7H6ECW'JZ3VQ'P8_
M/$        %_.AGHTP_VVE_A,YB>VA/U:T?PM1TYY>5GZ@;ZKOSJ3&&82I@
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MA'#?[H+#&4-SW;'< Q:\\5CE%-5LEYD41I@QXV9WC6P[A)GLEFF4K,21V/9
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M]JO(O3WM&2LC+W/*.2FBXLRPLVMS5/)HXIZWWV67F5+Z]UMMUU;: 6.@
M
M@VZ?J+1S[IQ_E-?AV>]?K>L</?/Q$Y!UG,
M         J)Y.?Y[B#VIF/KR/")/*9ZNM'P51T41;5_]G%ZCO6*MA%XM\
M     +'N-+Y5IYXO;_"1C$B^39XU5_<_]]$5RQ=4O]IZZ%T(F872
M       9P]K?2+RW_=BGULE&NC57ZQ+MQM>A:6/<>KI/;$?!C\\0
M7\Z&>C3#_;:7^$SF)[:$_5K1_"U'3GEY6?J!OJN_.I,89A*F
M $>=N?10V=^[SFGR;R47/DGQSM'=2EZ?&4#-?BO<N(5'27F%@;$R$P
M  =#Q'\J^,?&%"_"1M%,O?8:KXK+T#BH6KLI3<8CZ-#?4-;!.@
M #Q;XRM<D97B.OB,MQ97]K<&5X;SKC+2ES6Z)#D+@C-N*O+-M+4I#[[+JVW6
MW4I=ZE:5]4 5E<-.I69=$- ,7Z@YO4,KK(<%S;.4;BLG8WFCRGE^,7W-D^G.
M.I(JKU"KFI<JC,K))O076VW(K2+2ZTZ:=-0+%YOCK'V3&YN9\CP2&Y :&=^:
MI2TM<WC#)*VYKD[$;>>R2-N0OR%>F1/S,<9=>E6%6VJ$]UU:EWVUK4 >Y #T
MU5CK'RZ=->4%L$AJS);&PK(LRY$51AD43IGC#BIJL<(XURTU#>_M["N5UJ:<
MC*46)S3/XKK*W>J /\N&-\=NTXC^376!0MSR3$VMR8XMD%PBS&LG$:97FEUK
MPT1^6*4)C\S-;M;?=12G3*"RCZ5KU[;ND >GYIUUU]V1CZ")[$X*PWGN*M3A
M[+-<:S3C&$Y2C[:Z]GV/LF@9IRR/K<C<.R_A[8LNTSJ^IT]  ]LQWC+&V((H
MWP3$V/8/B^#M/7]BH;CN)L,)BC9VO14WV/CL:0-C0B[2MM.MV9-O3T>J /%X
MQPQB7"R*4MV),;PO&Z*<SB29,FA$,CS8P6RW(<P56K)1-I)<W)R#'N4/R@NR
MJE:IJ8H,M+LMK=U;+*4 ]0R/JIJ]F*>Q+*N7-;L"93RA 2TY,%R1D?#V/)O/
M844D6F.24J)3"31USD,<+3.)MR@NU&H)I8?=6^G1=6M0!7SNUI+F7>O=K3IH
MR<CBJ#CNU0=K-HY6R5?Z+9=G_;"/JU[-B*$OD1HDN3-^+<7MRHUZ5J%)IECR
M>L-07IJV=4\L"X$
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MMU*UI6E>F@ _H   @VZ?J+1S[IQ_E-?AV>]?K>L</?/Q$Y!UG,
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M4-;!.@
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M0OPD;13+WV&J^*R] XJ%J[*4W&(^C0WU#6P3H
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M_46CGW3C_*:_#L]Z_6]8X>^?B)R#K.8
M     !43R<_SW$'M3,?7D>$2>4SU=:/@JCHHBVK_ .SB]1WK%6PB\6^
M   %CW&E\JT\\7M_A(QB1?)L\:J_N?\ OHBN6+JE_M/70NA$S"Z0
M      #.'M;Z1>6_[L4^MDHUT:J_6)=N-KT+2Q[CU=)[8CX,?GB        "
M_G0ST:8?[;2_PF<Q/;0GZM:/X6HZ<\O*S]0-]5WYU)C#,)4P
M CSMSZ*&SOW><T^3>2BY\D^.=H[J4O3XR@9K\5[EQ"HZ2\PL#8F0F
M #H>(_E7QCXPH7X2-HIE[[#5?%9>@<5"U=E*;C$?1H;ZAK8)T
M
M       !X>0QY@EK"\Q:5L;/)HQ(VM<QR&.2%L1/3"_,KHF,1.;0\M#D0I;W
M1K<49UY1Z<\N\HXJ^MM]M;:UH /Z,;&RQEE:(W&VAKC\=C[6WL; P,;>D:65
MD96E(4@:VAH:T!2="VM;:A3EDITY)=A1)5EMEEM+:4I0#R@       #U-T@4
M&?)7%9X]0R)O$Y@J=_20B9ND=9W"5PY+*TR9%*$T5D2M&<\1Y/)$:(DI?8D.
M)M6%%66G4OMMMI0#VP    $&W3]1:.?=./\ *:_#L]Z_6]8X>^?B)R#K.8
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MFXQ'T:&^H:V"=
M                                                  $&W3]1:.?=
M./\ *:_#L]Z_6]8X>^?B)R#K.8
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M\8^,*%^$C:*9>^PU7Q67H'%0M792FXQ'T:&^H:V"=
M
M                  $&W3]1:.?=./\ *:_#L]Z_6]8X>^?B)R#K.8
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MT:&^H:V"=
M                                              $&W3]1:.?=./\
M*:_#L]Z_6]8X>^?B)R#K.8                                  !XAT
MCS ]W$W/3&T.]R>E]J>YT;42^XBTRMM3+2:JR3:E4,K93K4MZ.GHIT_Z#R5-
MOH*U46L@AF5O,VV-=ACS<-I%PQ_ <7,8_P!DB+ZJ'BOZ"@ON+B?O<9__ "8\
MO\!L?S*D^)C]R<=YB_1;_P"B#^@H+[BXG[W&?_R8?P&Q_,J3XF/W(WF+]%O_
M *(/Z"@ON+B?O<9__)A_ ;'\RI/B8_<C>8OT6_\ H@_H*"^XN)^]QG_\F'\!
ML?S*D^)C]R-YB_1;_P"B#^@H+[BXG[W&?_R8?P&Q_,J3XF/W(WF+]%O_ *(/
MZ"@ON+B?O<9__)A_ ;'\RI/B8_<C>8OT6_\ HAY)LC<=933#V9@96D\TOL33
MFQJ0H#3"NM;?V1AB4@J^\OKVTKU:UK3II2H]%-;;=1/62C@AB>J8*K&-:JIS
M<%5J)N?@.36,:N+41%_ AYH>TY               &</:WTB\M_W8I];)1KH
MU5^L2[<;7H6ECW'JZ3VQ'P8_/$        %_.AGHTP_VVE_A,YB>VA/U:T?P
MM1TYY>5GZ@;ZKOSJ3&&82I@            !'G;GT4-G?N\YI\F\E%SY)\<[
M1W4I>GQE S7XKW+B%1TEYA8&Q,A,        '0\1_*OC'QA0OPD;13+WV&J^
M*R] XJ%J[*4W&(^C0WU#6P3H
M
M @VZ?J+1S[IQ_E-?AV>]?K>L</?/Q$Y!UG,
M                                        SA[6^D7EO^[%/K9*-=&J
MOUB7;C:]"TL>X]72>V(^#'YX@        OYT,]&F'^VTO\)G,3VT)^K6C^%J
M.G/+RL_4#?5=^=28PS"5,             (\[<^BAL[]WG-/DWDHN?)/CG:.
MZE+T^,H&:_%>Y<0J.DO,+ V)D)@        Z'B/Y5\8^,*%^$C:*9>^PU7Q6
M7H'%0M792FXQ'T:&^H:V"=
M                                                           $
M&W3]1:.?=./\IK\.SWK];UCA[Y^(G(.LY@
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MK+T#BH6KLI3<8CZ-#?4-;!.@
M
M"#;I^HM'/NG'^4U^'9[U^MZQP]\_$3D'6<P
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M1_*OC'QA0OPD;13+WV&J^*R] XJ%J[*4W&(^C0WU#6P3H
M
M                      @VZ?J+1S[IQ_E-?AV>]?K>L</?/Q$Y!UG,
M                           "%W)%,WC'''=OMD./&W$/\#TNVDF;&?9?
M4NXEXB^#IT^-AMIE+;JEW%K4-E:7=%>BM.GH %?W$+,\-Z0\!^G&6LDOG](8
M=QUJHVYOR)(T,;?7CV"19"=';*<S>;V"+HGY^<NYGJ9JCE%R5.<:;_&=V=M*
MUMM \/M/S_\ $='-=9BY1[83%&W$BG<3>(W M8\:H%^4YIF>4/[6H2,6.'F
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MP&*/$A:&R23=1&6F]^DA$08UJPATDIT?8RKEJZU$4=<D26U.-I872MP ]J
M           1YVY]%#9W[O.:?)O)1<^2?'.T=U*7I\90,U^*]RXA4=)>86!L
M3(3        !T/$?RKXQ\84+\)&T4R]]AJOBLO0.*A:NRE-QB/HT-]0UL$Z
M
M                                    (-NGZBT<^Z<?Y37X=GO7ZWK'
M#WS\1.0=9S                                YSF'&;%FG$F4L.2B\Z
MR,Y9QS-\9R*]/2RY18Q3R,N<6=[R+3.DNXZUO=3*VTN_AK=T=/J "'G%AK=F
M'4WCRUDU<V(50UZR=A2 N>,Y$LA3P[2:'NK PRR2H(2>W.$B;&ER.)68]]C*
MGIC4I5B4^XQ/9;4HJRM0)+0G5_6C&DK53O'.N^#(!.%QAQRV90G$D BLK6&J
M:'44&JI$Q1] [J##Z*3.O=>=6MW:7=/3UJ]('39?"H=D%@71.?1*,S>+.=ME
MCE&I>PM4E8'"TNZEY=JYF>DJUN5VV7TI6E#"[J4KZH ]-Q=@7!N#DSBCPKAC
M$^($CN98:[)<78ZB&/TSH:53H+-<2(FSM)2TPNG_ (;C:75I_P! ![T;%8P?
M)$LR.CC"=+T+2H8$4J-9V\R2(V)6I+6*V5*^7IZNB=I5+"K33$UAM";S+:75
MMK=2E0!S+)FM6N>:7)$\YCP#A3++NVEEDMSKDS%<%G;D@**K=<44B72EA=52
M4LNZ^ZMMI=UM*5K7H_U '66=F9X\UH&./M3:QLC4E*0M;.SH4K8UMJ)/;2PA
M&@;T11"1&E)LIT6%EV6V6T]2E* #U7'6+,8X?CY\3Q+CF!XNBRE\?).IC6.H
MA'X3'U$DD[B>\260GLT:;FQN-?)"[J3%2Y7<750K4F7&FWWWW5NJ!X>38+PE
M-9U&LHS+#N*Y;DR&%E%0_(LFQ[$GZ=10H@X]025&I<ZM"J0,19*A4:9;:E4%
M4MO,NNIZMU:U KFV9T;RYN)R(:IY-S,NA)6BNDB4W.>.,8I'ET<Y?F#=!2<<
MV0Z;S]AO943,R0W!C%=<M8:E+U2H]X.-[4NY,>866!;:           (:<A6
MX44T%TNV(VXEQ*-<EPSCMS?(\PKE/<B>69 <S4\=QM#3%%IA9Q)<MGSPW-YA
MA?6,**47&6VW5LZ*@5H:"8Z?N./B+S?N?GQP,?-M,NX@R_R'[<3Y_L[H?'W*
MCWCUYR4Q0H\D^TVY*WXXBJ=NCR-F3=*(E<2IJD*M[JK94""G&QPU13:31_63
M.F<N1OD^6YQRUA>"99R8U8ZWVE;<RQ]=D]LNF#$V71VJ!_7QU0GC[BG).3JE
M%QUJHDZEU+;K;K+ -"F=<]X XP]*U.3LSSF568>UKQ;%8BC=Y6^JYUE;(:F-
M,C=$87&['=\5ENF0<M9"<$B9-10K/LO7N2F]2K.**[<\L#+SQIS_ )(=B/W!
M%\QW&R=D;'J(O1)^VL<M*T,NER'&.N<=R?*2,982PC)(7[,IXZ^9*;L<RMNE
M#TO6-:5=8^*U)2@@E4EZ+0-JX RIZC8IEW/5,]H=N]G]@=B8II?#=B<D:\:<
M:EX)R[*\%Q!3#,27H&A=G7+CQC9R997-IU,WM5<I2I%RNM&524J)LO/0WI"B
M@.3:D[E9^T4U/_<%XS)RC/-@8]Q9Y(FS;J!/<SOBS(\T9D4SA\C/AN/9G*G.
MIILR8\1REN;S5!1UUIM"CU)%*)DU4R=.!Z;#82;IWM%P>S%BVSS;*MG-FL99
M6V:Y+LBY4V;R+*L83/7-JP$ER7D:>9/ADNF"K%&,\8Q.6.5Z"$*$[2T)/_LH
MNSMCEB/MK0+9< H<@<L.>8'NKD,B80#CQP)++)9HIA5T)?H;(]H<DM%U2$&Y
M^:V ^Y.HKB]H,I>;BQB46V&*BC:OBXHNTU,0:!S/GZ?U.*Y+PR9\8[C"Y1!^
M8[63'A=2+JISU<(S)$<HL^1F6Q;97M$Y;]'X]1)?3HO+NH9TWVW6V]6X#0\
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MDZ:6_P#HF0_?\N_\H'GTS]_^2E^)3_4>:/)WZ%1\:O\ H/R=-+?_ $3(?O\
MEW_E \^F?O\ \E+\2G^H\T>3OT*CXU?]!^3II;_Z)D/W_+O_ "@>?3/W_P"2
ME^)3_4>:/)WZ%1\:O^AY1BXC-.HZ]LT@;6:?VN+$ZM[R@N.G2XTFU:V*R5J6
MXTJJ6E#"Z'D6]:WI]6GJ#IJ-;<]55/)32R4V]2,<U<(41<'(J+Z/I*=D&E.4
M:>9D\;)]\8Y')^T7FHN*>AZ:%G0Q&9)
M
M        @VZ?J+1S[IQ_E-?AV>]?K>L</?/Q$Y!UG,
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M TK
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M@    0;=/U%HY]TX_P IK\.SWK];UCA[Y^(G(.LY@
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M3?;?2E;:TJ /.
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M?K>L</?/Q$Y!UG,
M                                              #/WSD9AGV3%VI'
M$;@:3+HQEKDVR4XP_*\L83[;'_&NEV.D=DFV5DZ"ZMMY25VDL.*/;45JBEI3
M@C+<TUEUIM;3"P/5^6J-/4+9.(GBRT^RAE[3]EV%VIC&.C'_ %=R$]8GR7$]
M2=;,2O[UE>/0F8,]ZA>WKB&)Q:3[%"LI>FO4I;+UI*BVZ^V\"4VLW#\7K5F^
M#9M-Y0.8?82D&4/"FW$.S.\"K)V$):8[1YV8"[9S TF.XS?)$[/>ZT7HR;UE
MA5CBE(-OM,MLJ7<!Y;;OBE)VES')<YK>3?EEUB2.3*QHSL7:J;EI\)8,C:6,
M,I#<>ZM$,^+9]HW+G:B6Y:YJCEIM3U1AAG399U;+0*?.!O&^;,R;Q;7[3X_W
MWY#=B^-+"2Y_UQUPKMYM/,,WI]F<J)Z-A61LR(FHU'$X>5CF&]S7EL%_L)54
MIO=23:++3DJQ+8!K=?U;J@8GI>Q-%L@?$32XJV9AO<2&BQ[=4R,XYN:+G924
M>F:[7)79835099?812_KW6UI;6@ R*362\M,AYK.*K"^S.V[?#DF2T^;MD\M
M:@Z=N<QA>"<4X>Q)&#%T%8LF3R]R:9SL:LR+,6(]K>*/Z;^G2%UO9-R6B8XZ
M^H%F?+EE7+TIV,XP^-_%&6)Q@=NY LR9N59GRKBR0*8;E1+@K5;&#?E7(4"Q
M_/$?2X01\R*6\ID='1%U' JTKLRKNS-.L, @5I_NXR: Y-YCH^NRGL#LQJ;@
MG:'7/6[0?%LKR-+-A\YY*VXDV)5RW8/5_#LIE[A(IC*G(C++@VEU0&*U)4>2
MT4+55"_^[.- N>T!UESY S<C;2;H3<Z5[C;+VLJR>0B-RMX>,':UP!B-7G03
M7?!C(K4F-B5IB21PJ;(7LNTQ5)9#>>K,/.)M35H! K5"1JH)^XTY4\2-1IE(
MWF_433_8I]0T[2Q$DFV-6AIPV6M3D557IRUCQ'W^RJHTLHNY1W.50SIJ5;=<
M!H:
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M)A@B)^ (W!<>:I*4<#D
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M;T2NME;Z$MLSC#6MI0FZA!MCO;=_'U;;Z@:5
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M2239:64247;2PLHHNREMA99=EM*6VTI2E*4Z* #^@
M
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M-J6IM.TZP L7
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M%+20V++D=,ZI69[VOD6KE=%#' C(WH^17M7%'NC:U%;B[%R(LD15#'H
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M<,3VL1]0UT;6-W[:1T6]R2XM1=O8<FRLD!5#'H
M
M
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M#!-SF>B8[UKTVL>F%1EZT6^:KFO=?EJCN%>DKHU9#4U6VJP0HR-CFLC1B?\
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MHYIFWFH2E2W;4#559*BG;$DE/22X+O2OE27=:CE1V*%Z0R 0K
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MM-F=/1VJDFF=\HN57+,]'5<E75*U&IA3R(^*"!C8H5VT17;:.31F,FFOX
M
M                                          _F<:6G*-/.OH6227>:
M:9=_X;"R[:WWWW?_  MMI6M1^*J(F*\PY,:Y[D8Q,7JN")Z:KS"B+BKU<PYG
MG"V6-H-B->,7Y!GFQNT6;<MLCIEW$D4D\A8XHODA3:W-#4?,F)Q<6UJ(?VIQ
M4%%E7%ETO/KT4]2E1C[*%IH;C037:YTT,E155<LB+)&USD:KL$1-I%5$Q1R_
MC)L\IO4K-N2,X6O3;(-_N5!9,OY:MU#(RAKIX8I)VQ*][WI3R,8]ZQ/B:JKB
MN#?PEPF1<$8GRIB5UP7,(B5\5+PD:4"R(11V?L>)BT+&\MT@;$38XX]=8N],
MJ0AT:B+[BT2E/8<7;<492\DPPNZ]:JWT=91K;YV?_3<B(K6JK-Q%141%8K51
M,43F*F/,7<52)V7\[9HRSFF+.MIJE\)X7/<V>9D54JNDC?$]SV53)HY'*Q[D
M19&.5JJCFX/:UR<DP/HKJYK.Z2AYPSCERC3C,V"L6D9[QDO*\^M7L%ZBU48W
M%)\B3B5IFXL\\NVXR]+8289U;:775I;2E/';LOVBU/?)0Q*QSV[+L7R/Q3TN
M?>[#\6!=6=]:]2M1::FI,WW".HIZ.??HDCI**FV9<-E'JM+30*]415P1ZN1,
M5P1%52@W07$>5=EV'"NC4XB,A8=8M",T91F^<WJ1-QR%-F;(39ER;N^),3ME
M32"+'./MQ[LH=7RPPHPHU/U2J]A?1'=?CK+M%676."P5#'-M-NGD=*KDPWUZ
M2/6.-/3:F*N?Z:;FYSI./7+-66-.JZ\:T66J@GU'SQ9Z.GMT<3T<MOI7T-/'
M75K\%562O1C8:=45%:_%R;:;\B2_SQG*$:;<NCGG[:"R31S$&2=.&K$^'<EH
MH=+)BQ(I2@R CDCY ["(DRO"TM^<%3>J/ZEA!QQ5BPFM]2R%-UU*W<;A3V/.
M:W&[;;:*6A2.-Z-<Y$<CT<K.=15Q7!5YBKNIS$4Q1DC)=YU<Y*T>1M-EIJC-
M=NS:^MKZ1U1!!(Z%U*Z*.IQGDC:L36N8W%7-:Y8WHB.?&B*UAF.0MNN6B<Y\
MF&,IIC7&6"-7$4<PLPSID4,4HH1DZ2EG-LND[4=??5@?IJQ>S:HMO.ZJHIH,
M0]K9;?;=6[\M,]3>LY27&>*2*EIZ1&Q(],'?M';CG)Z"N3;7!=W9V<1J1:;#
MI5R6Z+(]IN5'<<QWO,KI;A+32))#C1PJCX(7I_\ +%3R?)V+*W%CITFV55%3
M#J&D"&7RS8+EKV<:6A4KDDCS73".,K7)+>F*=*:Y059'VFYL-66EE'M#\K<V
MZE#:=))E";:]->BH]E@;--<KS=6-5973[U'CZ.\,5J88^@JJW\&X6UK--:K7
MD/2S3BJE:RWT]F_B-9L.Q5G\6J6ROVT;BJ21-9+N>R3:5,.85\Z5[TMN"^-U
M5KO@R"97F>\<4:<XNN1(LIQM,4*3$TA7RB8/RS*^6)>[-*:/(F:+Q.Y.H+3]
MU'N2U6C*0WDEG'4J+:L68&V_*ZVRWQS/O[&RJ]NPY$C57.59)'*F"(UN"X8J
MY51&X(JF>-8=%:C.O*$;G[.E;:Z31BJEMS*69*N!SJZ)L,$3:*B@8]97233[
M35=L-AC9(Z9'N8P]^G6L63&'@ QCCB'0U^E+^L;\=YRRA"V5$MK+))$)1DRW
M+C\AJW$$U=%#G'VMU0&'EV=102G:[J_ZE=6[TU%IJX].8J6!CGRJC)9&HB[3
MFN?OBIAS<414Q]'!OX"A674C+E=RZ;EF"[5<%-0LDJK=1U$CF[Q#/#1_(8W;
M:KL(R5[)4:JXM<Z9$YCL4[;K_*^$*89 QHAPIC)LR)EJ0/T=:8Y$W?%.<LF/
MT#>'58G(N4R.S(+7)(G 2HN;;>>N7&JB24]B(TXHTVA5+A[[;-D*:IB;01)+
M6.<U&M6.616*J_\ EMHYK-GFJN*(F"JBK@6=GJU\LNTV*XSYQN4E!E:""5\L
M[*VW4<53&QJKA%\E?%/4K,F#8XT8YSED:QS6[:H7[#(I!HS;[5N&P.-.1W9[
M$>N41>U62>0G 6!X_&Y\4B64B^,J1^Q_QU,\E2!X3DEW(?Z+Q_&W U/<4;><
M4LO3WT+-KU2JXOO#KE2YGJZ*V,<M5<J:)&OP79CV<6.>J^ALL:JIZ..&XO,-
MA6F,&1,Q<GW+>:M0*J%N7LAWVY2S4RN;OU9ON]5=/211JJ[7RBJEB:Y%1&K&
MDB*YJ8N2?>2G32+0K6[#FG.P,;>S==)' WJ&N$O>L:OTMQBI<X^>S.CH=DQU
MBZ!S-CLQR%)GL]W07E)NK1:0H.M-35))NNN*J?8<NVN"R7)COX8Z-6JY6*Z/
M%,%7;5J+LN>Y5<FYS45<4P0P;EVFUEUPU"N^K61*B%-0*>NCJ&P1U<<%8C)4
MD8Q*-DSF)+!2PQM@E17X[VZ-BMDVWHD7>,!.W07,>V;YK2OS(Z\:;)#&!YQ
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M+++LMI2VVE*4I2G107JB(B8)S"*#WND<KWJKGN7%57=557FJJ^BJG]!^G$
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MY:]A59@O5PN\K?15*?\ ^G"YWH[+XI(W-]!V"*F*LW+B1>Q$P
M
M
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M
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MN_U']$'G3[I_XZW_ /$1"?@8'FYTG\NH.]D_#CSX<HW[(JKO]1_1!YT^Z?\
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MN_U']$'G3[I_XZW_ /$1"?@8'FYTG\NH.]D_#CSX<HW[(JKO]1_1!YT^Z?\
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MX0?>#UG^RB_]>P< //#V:_Q]Y=]_+#W@#S7:?^6ULZWDX0?>#UG^RB_]>P<
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MX0?>#UG^RB_]>P< //#V:_Q]Y=]_+#W@#S7:?^6ULZWDX0?>#UG^RB_]>P<
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=B.D<B0(JHQ%5RIBF*(6"#"1*X          __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>t1702381_ex23-1img1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 t1702381_ex23-1img1.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ 3 !D P$1  (1 0,1 ?_$ ,H  0 !! ,! 0
M       )!@<*"P$#" (% 0$   8# 0               P4&!P@) @0* 1
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MM$-'R#48F$2!PS=/$TET141CDU4P.0PAN4P&#YAU<?<]ULNL!F?>QEO+E\S
M^?9JZ]4LB?+Z+1MQRIDUK7MQ,D-<W$BJD6JBIP*8B9LW6Y$MV5[A<**@1E9(
MHYKV.VDU<+FM546"O5%@O J*A*_K=^89#0#0#0#0#0#0#0%OLMJ>%BK)JO9Z
M+'US4^MV%^I7)(WUAW#8.SMU)\PMQV"N9QT<Y/LRW$^RLL,SVU4^/T_C6&M\
M:9+7%JV'[D[6Z(_M7]F7_6=:5GY6EH]4\/K7VOZ)Z%)M3/VCN3[9>!>,KRMV
M9"89+.73J,143<F1 B3M("B0$DS]X?$7,.^YQ^C4@N=JF44]LJ4R:YJMCI:O
M&J<"'8IUFSF*Y6KH7B4E0X?3,,BWJ7C3,0CLQLN_BRC%+;=P[VW[[@NV_P V
MK'YZHZQTZ?ADSEY4O4QR\"=@L)O7I*N8E5LY4UWA).ICEX$XD)4L/V2MDROC
M@Y['7RD)<Z^8QC3<6!2E"01$1$1=;  !KO[@:&N9OQRBY\B<C4S#0Q59;T1/
M#-UZ#%G/%MN3LF75K::H5RT$[]F_[Q?P2</VQJ/A>/[4USP/%\#QO7D9X7C]
MSQ/!\3S7<\7P_K=W??;M^37I$V<R,,*Q[2FOGS+>,>SZ)4XX1ALGQA&$88=4
M=$=42H]<"6#0#0#0#0#0#0%K\W_P6R]_*^__ +J2VI?=OFNI^3S/R%*@RE]:
MK9_D*?QS#4T,E$?)M/2)_LR'VR_JB?3K79.1VV?K[Y>Z>CV8CMH[0O?+W2X%
M:41\DMZ1/]I-]HOZM/Z=4]<X[=/<^RI4%G:_HSM"]_["'KC$!T13BOKI_P!1
M)_:+^L6^G5#W9T)CDCPI[!#N:3$EOT+K:>J:49'VPK'UD_\ CD=]HO\ I!/I
MU4VZAW_I^7]/]WIO&M*.O./S15:_U#^X2@[)>Y#;T>WOG_H[?] :W'1_F?Q/
MSC%SE^GO#\Q?UAF"ZH<TM#0#0#0#0$:'5:PQR\SMQCC:5PIN$K2<PHY4J,Z[
MF(?(KG&#L]+CXRRH3C(;(T525417>/6AC-=]E1( _8U0V\&UYBN]B;2Y8FNE
M7%)[7*YLQ92X$:]%3$BMT8E;HCIAJ6!?GJZYJW:9/S^^[;U:675Y86W3I:,?
M3)5IMW/E++=LG(J(J-:_E\$8<)CF?EK_ !#/_L1>_P#[%F_]]U9/T%WR?'IW
MECN>9Q>O?J4_0='_ *67S2H*CTV>OH2VU0]SSS<9:F$M%>-<8E[RWEY1C*U(
MLPR&S1CV+6=G1DV<A" NBJV. D<)G%,P"!A#78I,C;VTJ9:UE9.?2XTQM6K<
MJ*V.E%3'I14UII14T074=*Y[]NINMMJ4M5GI95T6GF;![;,QCF3L#MD]KT2+
M'-F87(Y-+51%34917X!.#OS<0N-A0^8I,+X^(0H?,4A"0!2$*'S    !\FK\
M>AN4OHRA_@2^::^O7)O:_P"FOOEU3[X=R? WA,B42I<2N.B11'O"5/#U#( C
ML ;B!8, WV#7!V2<G/6+[7;U7LR)7-(K-]6]^6F%F:+^B=BNJ??#]=GPKX@Q
MX$!CQAP*S!,# 0&V*J4CW .(B<"^'#%V[PCV_IU ?N_R-,6+[/;57LTTKFGQ
MV^K>^_0_,]^7MUU3[X?J(<1^+399)PWX[86070.55%9+&M1(JDH0=R*)G+$@
M8ARCV@(=H:BTF1LET%5+K:*U6^562GH]CV4\IKV.:L4<UR-145%THJ+%"$_?
M%O8F,67,S)?',<D%1:VH5%3B7PA5'X?L%^1]6>Y[&OJ[SOK'R/L77_*>L/+^
M4\[Y?R'A>:\KZ/O[=[N=F^VJQZ341Q8WXNVI*O6-G_I'2O/5TZ3L\&/I4[%@
MCBPQQQPXM,-4=)=_4 HPX 0$-P$!#](=H: YT T T T!QN&X!N&X@(@&_:(!
MMN(!\NP;Z YT!\@8HB8H&*(EV P (")=_D[P!VAOH#ZT T T T!K3_B?;IU7
M>(>2\8U7+/4OO>2L6\ER99LE8Q;ANM.>.E4HE4I,_7&495;&VH\\"N0U#QML
M13.ZD%#F.=N<QBCX@; 5KQ Z6W5\ZBW1GP-;\(=24U2Q1%0V6G>,^);=O<<?
M>U\E#9/O:<FVR!F.MSPO[7.S\ZV<!'%F&KB,8)JHI +<A5%0 C[Z"'6 Y:\'
MN?.,.,N;,H9&M/'K,&5F&!<HXMR589>S)XPO%EGR4J&NE5)/.9%>I3-3NBZ!
M)5!J9-L^8^8(LF94J"J('I_XD63ZM7!#)>':KE_JP9FSO5N0<?D2XP<#C.(?
M<8X"GLZ7/P3-"'?U?&=G+$3VZ-D2!)<X@<O@&[P")@'0&12]ZK/Y<WPW/#[D
MC9;0\NO)7*G&2@47!;6VRKBR6*Z9DLU>7,6V3R\P[<R<W$T9@"LS)J*G4\8&
MZ34Q@.Z3W @$^$@Y.\D,X=57)++,>?,RY1C7W%C+EG<P]]R7<;3!&L*V1\4'
M-,)04S,.XAN_(,@N":B:!!2*L<I.Z4PAH"W74*G><.5_BG;#B[B]E#+263(C
MD-@Z(QVC%7"R^I*%2(W'>-[)<EW,<5\:+C<<1,$,E(3+44O).&HN 534%4Q3
M@<]6CKF<T^IASP1X'\&LLVS"''24S?#\<Z &.I^1J-DS;:96Y-*,KD&^W*!.
MSLA:9)SBIE8^(;KHLTXHI%72:SDQA3 IKKJ\!KST3[/P8E.'V<>7"V0K51;K
M+9BY$IY'R&W7M&5H&>J_J[U<>"=MX2IMCIO71FT2"BRZK02^84=&*94P&?CT
M?<T<EN0G3:XH9?Y>U^3K_("XX\5<W8)J%"MS-A;Q]BFXFJW66KH-&(0LE>*@
MP82JR(((D%1V*A$TTSE(4"2K0#0#0&O ^.*_BQT[_P"7G(K]Y,2: R'/AJ;;
M6*!T'N+]XN\_%52GU&'SY9+/99YZA&PL# 0^:\FOY27E'[HZ;=HP8,T#J**'
M$"E*41T!KRN)N,9SJ-]<VLI8/AWSNOY;YY6/.QGC2/=%3K.'6&:)#*MBM<L5
M),1BVT92VYSB93N +M1-(/2*$*(&0=\</_&;I\?RQS[^]6,] 49TB\$Y,ZIV
M/J_RHY 5<['AUTC^"MGX^<8*%+)'>U[(W).,Q++2EKR.Y06!-H^6K;UTA*.1
M %")N$8-ON?RSD! A+Z"?4#I/32Y.9YY*6:$>W2V!Q(R)CW"N-8QJ_=/LG9L
MN5]Q8G0Z;]W)*N6L:Y<,%G+Y<@"J1DV5!$IUS))F V!'14Z6N2<)UW,O/;G(
ML%BZE?.YM*6C*<Z_;I>:P73+8D1W$8DKC<AU$861:(%:&ETT![C;R32,2$46
M'?6 UG.,I2W=-CJ?T*;S)6)1I9^'O,"MRV1*XZ9JI2;EMC+)C-[.BR0<%(9?
MUQ"L3N&"O:FX3624()B'*80-S71N2_&;,N%H+/M0S%BBV8.L$&RMD?D16V5O
MV/0C%FQ'J;F5DI)XDS@WL>0XE<H/!0<LEBG36(FH0Q0 J+!7(+"G)N@I94X_
M9+JF7,;.9VQUIE>:1(EF*O)3%2EW4!86\3,(E!E+(1TNR50%PV,JV4,0134.
M7MT!>+0#0#0&O ^.*_BOT[_Y><BOWDQ)H"XG2&Z"%5ZC?2CXW7K*W/WG=3\7
MWASDA>3XST?)<*E@B,& RS;X4?9^E3<#*QC,THM#@^<&72<[OEE%"@41#0&6
M+TYND/P<Z7%<FXWBSC)PSN-M:-V-VR_>Y3VORO;6#94CA&)?659JR;1$ 1TF
M5;U;%-8]@=8I55$CJE*< /-75YZ$V">L+:L)6S,.:,MXJ>8.KUUKL$VQJUIS
MEM,-[M(U^2>N);VHA954JS-6OIE2!$R91*H;O;CML![[X^<%<)\8.$\'P4P^
MT>UO%4)B>PXO&7(1@>T2[FX1$DQMM]FG!&J3)_<+'+3#F2<JF2!(7*O=*0J1
M2$*!"?T_OA4^"_ [DS2N4 9)R[R"M6-"N)/']6RRTHI*=7;L(I!%7LT?7:['
M.).<K1 4/&E74,@V=G(Y HK(HF(!E : @PZIGP^_!?JJ6%KE#)36WX=Y LHM
MK#&S9B)Q$,9NS1,>0B49'9!KTW&R<!<D8IN3PFSDZ;>310 J)78($(F4"(W&
M'P5W#NMS+<<G\P>3&1Z2F\3>.Z-78VD8W9RQDA 2I24D5M<%A(8  #'02;K;
M!]50H]H 967$SB7@7A!@FF\;N-5)+C_$=$+)'@Z^,Q-6!T9]-R+F8G9:2FK"
M_DY:1DYF7>*N%U%%1 5%! A2$ I0 ]'Z : : U8'Q!/K[\:EH_,5_,6]1^W.
M7?PM^NO<1[K_ '6>UC3S/N:\#T'LUX'JOQ?%^\.YY?SGI= 3J_"G?B \;_)7
MX\/R^/=7D+W7^_[W1^X'W@^\B%]8>[GU#_G'U[ZS]=>)Y'[K\3S?F/3>'H#-
4JT T T T T T T T T T T!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>t1702381_ex23-1img2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 t1702381_ex23-1img2.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@ %0*) P$1  (1 0,1 ?_$ *H  0$! 0 # 0$
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M6$R<>*J:?A9<-L+_ &DM[KC79'1&HI8TP>1P6'=FGQSX9@5!>5?CM*/CHK8
MK6.B_P"J(^(;).+:4*B6RT:B.RO'NS)JOK*[>R:R>L]VZGKZ\ ;F7L7S@V G
M:V IEMC61M^[PAHRD:>\"1^D]NV71T)FY$MI^ W#(+_4ES7JKS1^IWZ[QR\P
MB(77D'T_)O%#B\N</\HPAIK:?<GM= '<E,&8HQJE*!V"!: ']7*>V#LZ09N/
M0&2-QQXR6Y8G(BC">)=7JY% 65Y$2UBQJ&=];NCM@TS.>%MMMH!33@#$HIK0
M\/H$HB>3G5;W3"NHZ0U0W<(.D<)B4W#9_&RB"I1>7)R$/@*VKHQT6KH0[C/
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M.=D/-DRYVYA6S!T%37B+TM)SJ<7H<M$?7G3"PX4;\@[S9<%YKN#Z. ;1HNG
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MNP<L<(B&R\6\QF08*)B\N;/,-PU]K[&'!+G0@)X?#)->/2K4.PH-U34,&,;
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M51SI#5#QPZ=.<)B5G#U_+R;I4QGERS^>P1#64PY/:Z .X_P)JG&'I0/;E"@
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M<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4IQ2G%*<4H
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=.*4XI3BE.*4XI3BE.*4XI3BE.*4XI3BE.*5__]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
